"Literature_ID","Literature_Name","Literature_Number","Literature_Author","Literature_Magazine","Literature_Summary","Literature_Image","Literature_Content","Literatrue_NetLink","Literature_AddDate","Literature_UpDate","Literature_UpUser","Literature_BrowseCount","Literature_Score","Literature_KeyWord","Literature_Px","Literature_Demo","Literature_DisId","Literature_EnName","Literature_Date","Literature_Fypdf"
125,"红茶提取物对培养细胞的单纯疱疹-1型病毒感染的影响","10.1186/1472-6882-13-139","Anthony Cantatore, Sade D Randall, Daniel Traum and Sandra D Adams","BMC Complementary and Alternative Medicine","<b><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">Background: </span></b><span style=""font-family:'Tahoma','sans-serif';font-size:14pt;""></span> 
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:'Times New Roman','serif';font-size:14pt;"">&nbsp;&nbsp;&nbsp;&nbsp; The purpose of this investigation was to determine if black tea extract (BTE), consisting primarily of flavanol compounds called theaflavins, could inhibit herpes simplex virus type-1 (HSV-1) infection in cultured A549 (human epithelial) and Vero cells.</span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:宋体;font-size:14pt;"">研究背景：</span></b><span style=""font-family:宋体;font-size:14pt;""> <span></span></span>
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:宋体;font-size:14pt;"">&nbsp;&nbsp;&nbsp; 本文旨在确定红茶提取物（</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">）（主要包括被称为茶黄素的黄烷醇类化合物）是否可以抑制培养的</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">A549</span><span style=""font-family:宋体;font-size:14pt;"">（人类上皮细胞）和</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">Vero</span><span style=""font-family:宋体;font-size:14pt;"">细胞的单纯疱疹</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">1</span><span style=""font-family:宋体;font-size:14pt;"">型病毒感染（</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">HSV-1</span><span style=""font-family:宋体;font-size:14pt;"">）。<span></span></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">Methods:&nbsp;</span></b><span style=""font-family:'Times New Roman','serif';font-size:14pt;""><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The effect of BTE both on A549 and Vero cultured cells and on HSV-1 was assessed by using phase contrast and fluorescent microscopy, and cell viability and proliferation assays. After establishing the maximum non-cytotoxic concentration of BTE, A549 and Vero cells and HSV-1 virions were treated with varying concentrations of BTE, respectively. A549 and Vero cells were infected with HSV-1 with green fluorescent protein (GFP) insert at the UL46 gene. The effect of infectivity was determined by viral DNA extraction followed by PCR, plaque assays, adsorption assays, and electrophoresis of PCR products.<br />
</span><b><span style=""font-family:宋体;font-size:14pt;"">研究方法：</span></b><span style=""font-family:宋体;font-size:14pt;""> <span></span></span>
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:宋体;font-size:14pt;"">&nbsp;&nbsp;&nbsp; 通过相差和荧光显微镜观察，以及细胞活性和增殖试验，评估了</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">对培养的</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">A549</span><span style=""font-family:宋体;font-size:14pt;"">、</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">Vero</span><span style=""font-family:宋体;font-size:14pt;"">细胞以及对</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">HSV-1</span><span style=""font-family:宋体;font-size:14pt;"">病毒的影响。在确立</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">最大非细胞毒性浓度后，用不同浓度的</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">分别处理</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">A549</span><span style=""font-family:宋体;font-size:14pt;"">细胞、</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">Vero</span><span style=""font-family:宋体;font-size:14pt;"">细胞以及</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">HSV-1</span><span style=""font-family:宋体;font-size:14pt;"">病毒。应用绿色荧光蛋白</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">(GFP)</span><span style=""font-family:宋体;font-size:14pt;"">标记的</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">HSV-1</span><span style=""font-family:宋体;font-size:14pt;"">（</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">GFP</span><span style=""font-family:宋体;font-size:14pt;"">嵌入</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">UL46</span><span style=""font-family:宋体;font-size:14pt;"">基因）对</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">A549</span><span style=""font-family:宋体;font-size:14pt;"">和</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">Vero</span><span style=""font-family:宋体;font-size:14pt;"">细胞进行感染。通过</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">PCR</span><span style=""font-family:宋体;font-size:14pt;"">提取的病毒</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">DNA</span><span style=""font-family:宋体;font-size:14pt;"">，斑块检测，吸附测定，以及</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">PCR</span><span style=""font-family:宋体;font-size:14pt;"">产物电泳来确定感染效果。<span></span></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">Results: </span></b><span style=""font-family:'Times New Roman','serif';font-size:14pt;""></span>
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:'Times New Roman','serif';font-size:14pt;"">&nbsp;&nbsp;&nbsp;&nbsp; BTE was not cytotoxic to A549 and Vero cells, as confirmed by cell viability and proliferation assays, in which BTE treated groups paralleled the positive control group. For both cell lines, plaque assays and fluorescent microscopy indicated an inverse relationship between BTE concentration (from 0.14 μM C 1.4 mM) and HSV-1 infectivity. Specifically, PCR and electrophoresis showed a reduction in the viral genome following treatment with BTE. In addition, there was a noticeable decrease in the amount of viral plaques for BTE treated samples in the adsorption assays.</span><span style=""font-family:宋体;font-size:14pt;""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:宋体;font-size:14pt;"">研究结果：</span></b><span style=""font-family:宋体;font-size:14pt;""><br />
</span><span style=""font-family:宋体;font-size:14pt;"">&nbsp;&nbsp;&nbsp; 细胞活性和增殖实验证实了</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">对</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">A549</span><span style=""font-family:宋体;font-size:14pt;"">和</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">Vero</span><span style=""font-family:宋体;font-size:14pt;"">细胞没有细胞毒性，其中</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">处理组与阳性对照组的实验结果相同。对于这两种细胞株，蚀斑试验和荧光显微镜观察表明了</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">浓度（从</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">0.14μM - 1.4 mM</span><span style=""font-family:宋体;font-size:14pt;"">）与</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">HSV-1</span><span style=""font-family:宋体;font-size:14pt;"">感染性呈逆相关。特别地，</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">PCR</span><span style=""font-family:宋体;font-size:14pt;"">和电泳显示通过</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">处理过的病毒的基因组减少。此外，在吸附测定试验中，经过</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">处理的样品中大量病毒斑明显减少。<span></span></span> <br />
<span style=""font-family:'Times New Roman','serif';font-size:14pt;""><b>Conclusions: </b></span><span style=""font-family:宋体;font-size:14pt;""></span>
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:'Times New Roman','serif';font-size:14pt;"">&nbsp;&nbsp;&nbsp;&nbsp; BTE consisting primarily of theaflavins is not cytotoxic and can reduce or block the production of infectious HSV-1 virions in cultured A549 and Vero cells, thus inhibiting the infectivity of the virus by interfering in the attachment, penetration and viral DNA replication of HSV-1 particles. These findings indicate that BTE enriched with theaflavins has the potential to be developed as a safe, therapeutic antiviral agent to prevent the spread of HSV-1.<br />
</span><b><span style=""font-family:宋体;font-size:14pt;"">研究结论：</span></b><span style=""font-family:宋体;font-size:14pt;""> <span></span></span>
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:'Times New Roman','serif';font-size:14pt;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BTE</span><span style=""font-family:宋体;font-size:14pt;"">主要成分茶黄素没有细胞毒性，可以减少或阻止培养的</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">A549</span><span style=""font-family:宋体;font-size:14pt;"">和</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">Vero</span><span style=""font-family:宋体;font-size:14pt;"">细胞里的感染性</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">HSV-1</span><span style=""font-family:宋体;font-size:14pt;"">的复制，因此通过干扰</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">HSV-1</span><span style=""font-family:宋体;font-size:14pt;"">的附着、侵入及其</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">DNA</span><span style=""font-family:宋体;font-size:14pt;"">的复制来抑制病毒的感染。这些结果表明，富含茶黄素的</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">BTE</span><span style=""font-family:宋体;font-size:14pt;"">，很可能开发成为一种防止</span><span style=""font-family:'Times New Roman','serif';font-size:14pt;"">HSV-1</span><span style=""font-family:宋体;font-size:14pt;"">蔓延的、安全的抗病毒治疗剂。<span><br />
<br />
</span></span>
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:'Times New Roman','serif';font-size:14pt;""><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cantatore et al. BMC Complementary and Alternative Medicine ,2013,13:139</span><span style=""font-family:宋体;font-size:14pt;""> </span>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14pt;""></span>
</p>
<b><span style=""font-family:'AdvTT99c4c969','sans-serif';font-size:9pt;""> 
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span><span><span><span style=""font-family:'AdvTTb5929f4c','sans-serif';font-size:9pt;""></span></span></span></span>
</p>
</span></b>","/uploadfiles/image/20131011/20131011155515_8187w.png","/uploadfiles/file/20131011/20131011132858_3541.pdf","http://www.biomedcentral.com/1472-6882/13/139",10/11/2013,10/11/2013,"medicool",46,,"Herpes simplex virus-1, Black tea extract, Theaflavins, Antiviral",0,"65",57,"Effect of black tea extract on herpes simplex virus-1 infection of cultured cells","2013",
133,,"10.1111/j.1525-1470.2011.01542.x","Low LC ; Carton J ; Walker M ; Tudor-Williams G ; Hardman C","Pediatric Dermatology","&nbsp; Genital <strong>herpes</strong> <strong>simplex</strong> <strong>virus</strong> (HSV) is a sexually transmitted <strong>infection</strong> that can be transmitted from mother to child in utero, perinatally, or postnatally. Cutaneous <strong>infection</strong> with HSV commonly presents as vesicles affecting the skin, eyes, or mouth. In our case, we report a well child with cutaneous <strong>hypopigmented</strong> patches at birth that preceded typical blistering.",,"/uploadfiles/file/20131011/20131011155312_9217.pdf",,10/11/2013,10/11/2013,"medicool",44,,,6,"85",57,"Intrauterine Herpes Simplex Virus Infection Presenting with Hypopigmented Lesions","2012",
45,"成年患者的特应性皮炎：临床和流行病学注意事项","r e v a s s o c m e d b r a s . 2 0 1 3;5 9(3):270C275","Marta M. Shimizu等","Assocmedbras","<b><span style=""font-size:16.0pt;font-family:宋体;""></span></b><b><span style=""font-size:16.0pt;""></span></b> 
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;"">Objective</span></b><b><span style=""font-size:14.0pt;""></span></b> 
</p>
<p style=""margin-left:0cm;text-align:justify;text-indent:21.0pt;background:white;vertical-align:baseline;"">
	<span style=""font-size:10.5pt;font-family:&quot;"">Atopic dermatitis (AD) is a <a name=""OLE_LINK45""></a><a name=""OLE_LINK44""></a><span>chronic
inflammatory disease</span> causing intense pruritus, and with typical
clinical features. There are few epidemiological studies concerning AD in
adults, as well as little information about its prognostic. The aim of this
study was to evaluate the <a name=""OLE_LINK47""></a><a name=""OLE_LINK46""></a><span>clinical and epidemiological </span><a name=""OLE_LINK49""></a><a name=""OLE_LINK48""></a><span><span><span>course</span></span></span> of adults with AD.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">研究目的</span></b><b><span style=""font-size:14.0pt;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">特应性皮炎</span><span>(AD)</span><span style=""font-family:宋体;"">是一种伴剧烈瘙痒的慢性炎症性疾病，并有典型临床特征。关于成年</span><span>AD</span><span style=""font-family:宋体;"">患者的流行病学研究及其预后的资料少之又少。本研究旨在对成年</span><span>AD</span><span style=""font-family:宋体;"">患者的临床和流行病学进程进行评估。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;"">Methods</span></b><span style=""font-size:14.0pt;""></span> 
</p>
<p style=""margin-left:0cm;text-align:justify;text-indent:21.0pt;background:white;vertical-align:baseline;"">
	<span style=""font-size:10.5pt;font-family:&quot;"">80 patients aged above 18 years
(mean age&nbsp;=&nbsp;29 years) were selected (30 males and 50 females) and
interviewed about hospitalization, <a name=""OLE_LINK51""></a><a name=""OLE_LINK50""></a><span>systemic corticoid usage</span>, age of AD
onset, and personal and/or familial history of atopy. <a name=""OLE_LINK54""></a><a name=""OLE_LINK53""></a><span>Disease severity</span> was evaluated through the<a name=""OLE_LINK52""></a> Scoring Atopic Dermatitis (SCORAD) tool. Laboratory examination included IgE serum levels and <a name=""OLE_LINK63""></a><a name=""OLE_LINK56""></a><a name=""OLE_LINK55""></a><span><span>eosinophil
blood count</span></span>.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">研究方法</span></b><b><span style=""font-size:14.0pt;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>80</span><span style=""font-family:宋体;"">名（</span><span>30</span><span style=""font-family:宋体;"">名男性和</span><span>50</span><span style=""font-family:宋体;"">名女性）</span><span>18</span><span style=""font-family:宋体;"">岁以上（平均年龄</span><span>=29</span><span style=""font-family:宋体;"">岁）的患者入组，并对他们的住院情况、系统性皮质激素类药物的使用情况、</span><span>AD</span><span style=""font-family:宋体;"">发作的年龄以及个人和或家族史进行了回访。通过“特应性皮炎评分</span><span>(SCORAD)</span><span style=""font-family:宋体;"">”工具评估疾病的严重程度。实验室检查包括血清</span><span>IgE</span><span style=""font-family:宋体;"">水平和<a name=""OLE_LINK65""></a><a name=""OLE_LINK64""></a><span>血嗜酸性粒细胞计数</span>。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;"">Results</span></b><span style=""font-size:14.0pt;""></span> 
</p>
<p style=""margin-left:0cm;text-align:justify;text-indent:21.0pt;background:white;vertical-align:baseline;"">
	<span style=""font-size:10.5pt;font-family:&quot;"">71 out of 80 patients referred
association with respiratory symptoms (18 had asthma, 17 had rhinitis, and 36
had both conditions); nine out of 80 patients denied any respiratory disease.
AD patients were divided in mild (n&nbsp;=&nbsp;25), moderate
(n&nbsp;=&nbsp;30), and severe (n&nbsp;=&nbsp;25); 56% had one or more
hospitalizations due to AD. A positive association was found between IgE serum
levels, eosinophil blood count, and disease severity.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">研究结果</span></b><b><span style=""font-size:14.0pt;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>80</span><span style=""font-family:宋体;"">名特应性皮炎患者中有</span><span>71</span><span style=""font-family:宋体;"">名伴呼吸道症状相关性（</span><span>18</span><span style=""font-family:宋体;"">名患有哮喘，</span><span>17</span><span style=""font-family:宋体;"">名患有鼻炎，</span><span>36</span><span style=""font-family:宋体;"">名两病共患</span><span style=""font-family:宋体;"">）。</span><span style=""font-family:宋体;"">另外</span><span>9</span><span style=""font-family:宋体;"">名患者称没有任何呼吸道疾病。</span><span>AD</span><span style=""font-family:宋体;"">患者被分成轻度</span><span>(n&nbsp;=&nbsp;25)</span><span style=""font-family:宋体;"">、中度</span><span>(n&nbsp;=&nbsp;30)</span><span style=""font-family:宋体;"">和重度</span><span>(n&nbsp;=&nbsp;25)</span><span style=""font-family:宋体;"">。</span><span>56%</span><span style=""font-family:宋体;"">的患者有过</span><span>1</span><span style=""font-family:宋体;"">次或多次因</span><span>AD</span><span style=""font-family:宋体;"">而住院治疗。我们发现</span><span style=""font-family:宋体;"">血清</span><span>IgE</span><span style=""font-family:宋体;"">水平、<a name=""OLE_LINK77""></a><a name=""OLE_LINK76""></a><span>血嗜酸性粒细胞计数</span>与疾病的严重程度呈正相关。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;"">Conclusion</span></b><span style=""font-size:14.0pt;""></span> 
</p>
<p style=""margin-left:0cm;text-align:justify;text-indent:21.0pt;background:white;vertical-align:baseline;"">
	<span style=""font-size:10.5pt;font-family:&quot;"">Adult AD represents a <a name=""OLE_LINK67""></a><a name=""OLE_LINK66""></a><span>clinical
challenge</span> that <a name=""OLE_LINK71""></a><a name=""OLE_LINK70""></a><span>needs to be better characterized</span>,
since it can be misdiagnosed and interferes with the patient's <a name=""OLE_LINK69""></a><a name=""OLE_LINK68""></a><span>social
and personal life</span>. The association of skin and <a name=""OLE_LINK73""></a><a name=""OLE_LINK72""></a><span>respiratory atopic
disease</span> is frequent, and<a name=""OLE_LINK75""></a><a name=""OLE_LINK74""></a><span> laboratory parameters </span>such as
circulating IgE levels and eosinophil blood count may be helpful to assess
disease severity.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">研究结论</span></b><b><span style=""font-size:14.0pt;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">因受患者社会和个人生活的影响，成年患者的</span><span>AD</span><span style=""font-family:宋体;"">容易被误诊，因此它仍是一个临床上的挑战，需要对其临床特征进行更好地描述。皮肤与呼吸道过敏性疾病密切关联；实验室检查诸如血循环的</span><span>IgE</span><span style=""font-family:宋体;"">水平、血嗜酸性粒细胞计数，有助于评估疾病的严重程度。</span> 
</p>","/uploadfiles/image/20130924/20130924103319_9163w.png","/uploadfiles/file/20130924/20130924103332_3807.pdf","http://www.sciencedirect.com/science/article/pii/S0104423013000535",09/24/2013,09/30/2013,"medicool",29,,"Atopic dermatitis; Epidemiology; Scoring Atopic Dermatitis; IgE",0,"65",46,"Atopic dermatitis in adults: clinical and epidemiological considerations","2013",
48,"口服低剂量地塞米松微冲击疗法治疗进行性不稳定性白癜风","10.2310/7750.2013.12053","Amrinder J. Kanwar, Rahul Mahajan, and Davinder Parsad","Canadian Dermatology Association","<p class=""MsoNormal"">
	<span><span><strong>Background:</strong></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span><span><span><span>&nbsp;The course of vitiligo</span></span><span> is <a name=""OLE_LINK60""></a><a name=""OLE_LINK59""></a><span>unpredictable</span>.
If the disease is spreading rapidly, the progression can be controlled with the
use of <a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><a name=""OLE_LINK54""></a><a name=""OLE_LINK53""></a><span><span><span>systemic steroids</span></span></span><span><span> </span></span>daily
or<a name=""OLE_LINK62""></a><a name=""OLE_LINK61""></a><span> in </span><a name=""OLE_LINK56""></a><a name=""OLE_LINK55""></a><a name=""OLE_LINK64""></a><a name=""OLE_LINK63""></a><span><span><span><span><span>pulsed
form</span></span></span></span></span><span><span>.</span></span> <a name=""OLE_LINK66""></a><a name=""OLE_LINK65""></a><span>The present study</span> was planned to assess the efficacy of <a name=""OLE_LINK74""></a><a name=""OLE_LINK73""></a><span>low-dose dexamethasone oral
mini-pulse therapy</span> in progressive unstable vitiligo.<br />
</span></span></span><strong>研究背景：</strong><span style=""font-family:宋体;""><strong><br />
&nbsp;&nbsp;&nbsp; </strong></span>白癜风的病程难以预知。如果病情迅速蔓延，可以通过每日系统性使用类固醇或冲击疗法控制病情发展。本研究旨在评估口服低剂量地塞米松微冲击疗法对进行性不稳定性白癜风的疗效。<br />
<span><span><span> </span></span></span> 
</p>
<p class=""MsoNormal"">
	<span><strong>Materials and Methods:</strong></span><span><br />
&nbsp;&nbsp;&nbsp;&nbsp; In this retrospective study, <a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span>the case records of
patients with vitiligo during the period from January 2006 to December 2010
were studied</span>. Patients who had progressive unstable disease were
included. These patients were<a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span> administered</span> oral dexamethasone 2.5
mg per day on 2 consecutive days after breakfast in a week. The patients were
asked to come for regular follow-up to assess <a name=""OLE_LINK68""></a><a name=""OLE_LINK67""></a><span>the arrest of </span><a name=""OLE_LINK70""></a><a name=""OLE_LINK69""></a><span><span><span>disease
activity</span></span>,</span> <a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span>relapse of disease activity</span>, and
adverse effects.<br />
</span><span style=""font-family:宋体;""><strong>材料和方法：</strong></span><span> </span><span style=""font-family:宋体;""><br />
&nbsp;&nbsp;&nbsp; 在这项回顾性研究中，我们研究了</span><span>2006</span><span style=""font-family:宋体;"">年</span><span>1</span><span style=""font-family:宋体;"">月至</span><span>2010</span><span style=""font-family:宋体;"">年</span><span>12</span><span style=""font-family:宋体;"">月期间白癜风患者的病历。研究对象为进行性不稳定性白癜风的患者。这些患者一周内连续</span><span>2</span><span style=""font-family:宋体;"">天每日早餐后口服地塞米松</span><span>2.5mg</span><span style=""font-family:宋体;"">。要求患者做定期随访，以评估疾病的活动性、复发，以及不良反应。<br />
</span><strong>Results: </strong><br />
<span>&nbsp;&nbsp;&nbsp; A total of 444 patients were analyzed. In 408 (91.8%) patients,
arrest of disease<span>&nbsp; </span>activity was achieved
at a mean duration of 13.2 ± 3.1 weeks. In addition, <a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span>some repigmentation of
the lesions </span>was seen in all patients after a mean of 16.1 ± 5.9
weeks. During the follow-up, <a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span>50 of 408 (12.25%) patients experienced one or
two </span><a name=""OLE_LINK72""></a><a name=""OLE_LINK71""></a><span><span><span>episodes of relapse</span></span></span><span><span> in
disease activity, <a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span>which<span style=""color:red;""> </span>were
treated with reinstitution of low-dose dexamethasone oral mini-pulse therapy</span>. </span></span><a name=""OLE_LINK76""></a><a name=""OLE_LINK75""></a><span>The mean </span><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span><span><span>disease-free survival</span></span> </span>(DFS) until the first relapse was 55.7 ± 26.7 weeks, and the mean
DFS until the second relapse was 43.8 ± 7.2 weeks. Adverse reactions such as
weight gain, lethargy, and <a name=""OLE_LINK78""></a><a name=""OLE_LINK77""></a><span>acneiform eruptions</span> were observed in
41 (9.2%) patients.</span><br />
<span style=""font-family:宋体;""><strong>研究结果：</strong></span><span></span><br />
<span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp; 总共分析了</span><span>444</span><span style=""font-family:宋体;"">名患者，有</span><span>408</span><span style=""font-family:宋体;"">例（占</span><span>91.8</span><span style=""font-family:宋体;"">％）患者的疾病活动性得于平均</span><span>13.2</span><span style=""font-family:宋体;"">±</span><span>3.1</span><span style=""font-family:宋体;"">周得到控制。另外，所有的患者于平均</span><span>16.1</span><span style=""font-family:宋体;"">±</span><span>5.9</span><span style=""font-family:宋体;"">周后有一些皮损部位色素再生。随访期间，</span> <span>408</span><span style=""font-family:宋体;"">名患者中有</span><span>50</span><span style=""font-family:宋体;"">名（</span><span>12.25</span><span style=""font-family:宋体;"">％）疾病活动性反复</span><span>1</span><span style=""font-family:宋体;"">或</span><span>2</span><span style=""font-family:宋体;"">次，通过重新口服低剂量地塞米松微冲击疗法的进行了治疗。平均无病生存期（</span><span>DFS</span><span style=""font-family:宋体;"">）【</span><span style=""font-family:宋体;color:black;background:white;"">无病生存（</span><span style=""color:black;background:white;"">DFS</span><span style=""font-family:宋体;color:black;background:white;"">）：是指</span><span><a href=""http://www.baike.com/wiki/%E4%BB%8E%E9%9A%8F""><span style=""font-family:宋体;color:windowtext;background:white;text-decoration:none;""><span>从随</span></span></a></span><span style=""font-family:宋体;color:black;background:white;"">机化开始至疾病复发或由于疾病进展导致患者死亡的时间】</span><span style=""font-family:宋体;"">到第一次疾病复发为</span><span>55.7</span><span style=""font-family:宋体;"">±</span><span>26.7</span><span style=""font-family:宋体;"">个星期，平均</span><span>DFS</span><span style=""font-family:宋体;"">到第二次复发为</span><span>43.8</span><span style=""font-family:宋体;"">±</span><span>7.2</span><span style=""font-family:宋体;"">周。</span><span>41</span><span style=""font-family:宋体;"">例（占</span><span>9.2</span><span style=""font-family:宋体;"">％）患者出现不良反应，如体重增加、嗜睡、痤疮样皮疹。</span><span></span><br />
<span><strong>Conclusion:</strong></span><span><span><br />
&nbsp;&nbsp;&nbsp; Low-dose oral mini-pulsed examethasone
therapy is a good option for arresting progressive unstable vitiligo with minimal
adverse effects.</span></span><span></span><span></span><br />
<span style=""font-family:宋体;""><strong>研究结论：</strong></span><span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">口服低剂量地塞米松微冲击疗法对于控制进行性不稳定性白癜风是一个很好的选择，并且不良反应较低。</span><span></span> 
</p>
<br />
<span style=""font-family:宋体;""></span><span></span><span></span><span></span><span><strong></strong></span> 
<p>
	<br />
</p>
<span style=""font-size:10.5pt;font-family:宋体;""></span> 
<p>
	<br />
</p>","/uploadfiles/image/20130924/20130924111350_4629w.png","/uploadfiles/file/20130924/20130924111509_4303.pdf",,09/24/2013,09/30/2013,"medicool",51,,,0,"65",28,"Low-Dose Oral Mini-Pulse Dexamethasone Therapy in Progressive Unstable Vitiligo","2013",
75,"甲银屑病的诊断与治疗研究进展","10．3760／cma．j．issn．0412-4030．2013．03．028","陈虹霞  邹先彪","中华皮肤科杂志","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 临床上，甲银屑病容易与甲真菌病相混淆，也是目前最难治的银屑病损害之一。约有10％，78％的银屑病患者伴有指(趾)甲损害，发病无性别差异。甲银屑病与关节型银屑病密切相关，至少70％的银屑病关节炎患者存在甲病损。Lavaroni等发现52例关节型银屑病患者的甲损害率甚至可达86．5％。许多因素可以诱发甲银屑病。TMm等发现，病情中度至重度、病期5年以上、年龄50岁以上、伴关节型银屑病、头皮银屑病或甲皱银屑病的患者更易发生甲损害。<br />
&nbsp; &nbsp; 银屑病甲对患者的心理及生活质量有明显影响Oaonne等制定了第一个用于评价甲银屑病患者生活质量的量表一NPQIO(nail psoriasis quality of life scale)，调查显示，甲银屑病可以影响患者生活的多个方面，诸如影响了手的灵活性、活动受限、对职业影响及产生社会心理障碍(包括焦虑与抑郁)等。Sanchez Regana等对西班牙1500个甲银屑病患者的调查发现，38．8％最近1个月没有去过公共游泳池，43％由于心理压力导致疾病急性发作。另一项对1728例银屑病患者的研究发现，有51．8％患者有指(趾)甲疼痛，58．9％患者日常活动受限。",,"/uploadfiles/file/20130926/20130926160427_0407.pdf",,09/26/2013,09/30/2013,"medicool",56,,,0,"67",26,,"2013",
227,"红癣样花斑癣:病例报道一例"," ","Gorani A ; Oriani A ; Falconi Klein E ; Veraldi S","Mycoses","<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:1.5;""></span><span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp;&nbsp;<span style=""font-size:16px;""> <span style=""line-height:1.5;font-family:Times New Roman;""> A 50-year-old Caucasian man with pityriasis versicolor that was localized almost exclusively in the inguinal folds and was characterized by lesions clinically superimposable on those of erythrasma is described. Due to these clinical characteristics, it is proposed that this variety of pityriasis versicolor is defined as 'erythrasmoid'.</span> <br />
<br />
<span style=""line-height:1.5;""> &nbsp; 患者（男性、50岁、白种人）患有花斑癣，该花斑癣几乎完全位于腹股沟褶上,且以在红癣上出现重叠性的临床皮损为特征。由于这些临床特点，我们称这种多样的花斑癣为“红癣”。</span></span><span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<br />
</p>
<p align=""justify"">
	<br />
</p>","/uploadfiles/image/20131016/20131016155025_2767w.jpg","/uploadfiles/file/20131016/20131016133901_8184.pdf",,10/16/2013,10/16/2013,"medicool",20,,"erythrasmoid pityriasis ；erythrasma",0,"85",4,"Case report. Erythrasmoid pityriasis versicolor","2011",
234,"萎缩性花斑癣病例",,"C. Romano,E. Maritati,A. Ghilardi, C. Miraccoand F. Mancianti","Blackwell Publishing Ltd ? Mycoses,","<p align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A case of pityriasis versicolor atrophicans caused by Malassezia globosa is reported in a 49-year-old woman. Diagnosis was based on direct microscopic examination and culture. Differential diagnosis was performed with respect to other skin diseases manifesting with cutaneous atrophy.
</p>
<p>
	<span></span>&nbsp;
</p>","/uploadfiles/image/20131016/20131016154504_9301w.jpg","/uploadfiles/file/20131016/20131016144212_2507.pdf",,10/16/2013,10/16/2013,"medicool",37,,"Malassezia globosa, pityriasis versicolor.",0,"85",4,"A case of pityriasis versicolor atrophicans","2005",
147,,"10.1258/ijsa.2012.011356","Thurman AR ; Doncel GF","International Journal Of STD & AIDS","&nbsp; Sexual transmission of HIV-1, in the absence of co-factors, is poorly ef?cient. Data support that herpes simplex virus type-2 (HSV-2) may increase a woman’s susceptibility to HIV-1. Potential mechanisms by which HSV-2 serves as an HIV-1 enhancing co-factor include (1) initiation of a clinical or subclinical mucosal in?ammatory response, (2) alteration of innate mucosal immunity and (3) weakening or breaching the protective genital epithelia. No clinical trial has examined prevention of primary HSV-2 infection to eliminate the major morbidities of this recurrent disease and as a strategy to reduce HIV-1 transmission. Topical administration of potent antivirals can achieve local concentrations that are orders of magnitude higher than those obtained with oral administration. This paper reviews major advances in oral and topical pre-exposure prophylaxis of HIV-1 and HSV-2 and, based on these data, hypothesizes that simultaneous prevention of sexual acquisition of HSV-2 and HIV-1 via topical antiretroviral agents will have a synergistic impact on both epidemics.<br />
<br />",,"/uploadfiles/file/20131012/20131012084910_9335.pdf",,10/12/2013,10/12/2013,"medicool",31,,"HIV, herpes simplex virus, genital, HSV, prevention technologies, mucosal in?ammation, mucosal immunity",0,"67",57,"Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention","2012",
77,"1-mm微移植疗法对白癜风的疗效取决于患者年龄、发病部位以及白癜风亚型","10.1111/j.1346-8138.2010.01184.x","Hiroshi KATO, Takuya FURUHASHI, Erika ITO, Natsumi KANEKO, Motoki NAKAMURA, Shoichi WATANABE, Yoichi SHINTANI, Akira MAEDA, Yuji YAMAGUCHI, Akimichi MORITA","Journal of Dermatology","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>Vitiligo vulgaris is a
refractory skin disease. <a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span>Treatment modalities</span> include <a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span>topical
steroids</span>, phototherapy, <a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span><span><span><span><span>suction blister roof </span></span></span></span></span><span><span><span><span>grafts</span></span></span></span><span><span> </span></span>and <a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span>cellular
grafting techniques.</span> Adverse effects may occur, however, and some
cases remain unresponsive to treatment. To evaluate the efficacy of small
(1-mm) punch minigraft therapy in relation to patient age, disease site, disease
duration and vitiligo subtype. </span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">寻常型白癜风是一种难治的皮肤病。治疗方式包括外用类固醇、光疗、吸疱顶移植以及细胞移植术。可能出现副作用，但是，许多病例对治疗没有反应。对与患者年龄、发病部位、病程及白癜风亚型相关的小型打孔微移植疗法的疗效进行评估。</span><span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>We used a <a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span>recently
developed </span>disposable 1.0-mm punch apparatus to perform minigraft
therapy in 20 patients with <a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span>either</span> generalized (n = 4), <a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span>segmental</span> (n = 9) or <a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span>limited</span> (n = 7) vitiligo, and
evaluated the area and rate of <a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span>repigmentation</span> in relation to
patient age, disease site, disease duration and vitiligo subtype. The area of
repigmentation was significantly greater in patients with segmental vitiligo (n
= 9) than in those with generalized vitiligo<a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span>(n = 4)</span>. Repigmentation
covered a broader area and occurred more quickly in patients under 15 years of
age than in those over 20 years of age (n = 9). </span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">我们采用最近研制的任意</span><span>1.0-mm</span><span style=""font-family:宋体;"">打孔设备对</span><span>20</span><span style=""font-family:宋体;"">名患者【或泛发型</span><span>(n = 4)</span><span style=""font-family:宋体;"">、节段型白癜风</span><span>(n = 9)</span><span style=""font-family:宋体;"">或<a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span>限制型白癜风</span></span><span></span><span></span><span>(n = 7)</span><span style=""font-family:宋体;"">】进行微移植疗法，并评估与患者年龄、发病部位、病程及白癜风亚型相关的复色面积与复色率。节段型白癜风患者</span><span>(n = 9)</span><span style=""font-family:宋体;"">的复色面积明显大于泛发型白癜风患者</span><span>(n = 4)</span><span style=""font-family:宋体;"">。</span><span>15</span><span style=""font-family:宋体;"">岁以下的患者比</span><span>20</span><span style=""font-family:宋体;"">岁以上的患者复色更快，面积更广。</span><span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>Disease duration did not
affect the repigmentation rate. <a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span>The results of </span><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span><span><span>the present study</span></span> </span>suggest that 1-mm minigrafts are effective for treating patients
with vitiligo. Better results occurred in patients under 15 years of age,
patients with facial grafts, and patients with segmental and limited subtypes.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">病程对复色率没有影响。本研究的结果表明</span><span>1-mm</span><span style=""font-family:宋体;"">微移植疗法对白癜风患者的治疗有效。</span><span>15</span><span style=""font-family:宋体;"">岁以下、面部移植、以及节段型和限制型白癜风患者的疗效更好。</span><span></span> 
</p>","/uploadfiles/image/20130929/20130929095958_5879w.png","/uploadfiles/file/20130929/20130929100101_6276.pdf",,09/29/2013,09/29/2013,"medicool",54,,"1-mm minigraft, narrow-band ultraviolet B, suction blister roof graft, surgical treatment, vitiligo vulgaris.",0,"66",28,"Efficacy of 1-mm minigrafts in treating vitiligo depends on patient age, disease site and vitiligo subtype","2011",
299,"成人丹毒治疗中肌肉注射青霉素（两种）与静脉注射苄青霉素的比较：随机对照研究","10.1111/j.1468-3083.2004.00938.x","Zeglaoui F ; Dziri C ; Mokhtar I ; Ezzine N ; Kharfi M ; Zghal M ; Fazaa B ; Kamoun MR","Journal Of The European Academy Of Dermatology And Venereology","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">The objective of the
study was to evaluate the ef?cacy of intramuscular penicillin: mixture of
benzyl penicillin and procain penicillin (2 MU×2 times daily) and intravenous
benzyl penicillin (4 MU×6 times daily) in the treatment of hospitalized adult
patients with erysipelas. A prospective randomized unicentric trial was
conducted. In total, 112 patients entered the study; 57 in the intramuscular
group and 55 patients in the intravenous group completed the trial. The failure
rate was 14% for intramuscular group and 20% for the intravenous group (P=0.40).
Local complications such as of the leg abscesses were observed in the two
groups (intravenous 9.1%, intramuscular 7%; P = 0.477). </span></span><a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Of the patients
treated with intravenous benzyl penicillin, 25.5% presented complications related
to </span></span></span></span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">the
route</span></span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> (</span><a name=""OLE_LINK15""></a><a name=""OLE_LINK4""></a><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">venitis</span></span></span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">). </span></span></span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Intramuscular
penicillin should be considered an effective and well-tolerated treatment of
erysipelas in adult patients.</span></span></span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;line-height:1.5;"">该研究旨在评估肌肉注射青霉素――</span><span style=""font-family:宋体;""><span style=""font-size:14px;line-height:1.5;"">苄青霉</span><a name=""OLE_LINK10""></a><span style=""font-size:14px;line-height:1.5;"">素和普鲁卡因青霉素的混合剂（每次</span></span><span style=""font-size:14px;line-height:1.5;"">2MU</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">，一日</span><span style=""font-size:14px;line-height:1.5;"">2</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">次）和静脉注射苄青霉素（每次</span><span style=""font-size:14px;line-height:1.5;"">4MU</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">，一日</span><span style=""font-size:14px;line-height:1.5;"">6</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">次）</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">治疗住院的成人丹毒患者的疗效。我们开展了一项前瞻性随机单中心试验。总计</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">112</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">名患者参加这项研究，其中</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">57</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">名患者分配入肌肉注射组，另外</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">55</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">名患者为静脉注射组，进行试验。肌肉注射组和静脉滴注组的失败率分别为</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">14%</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">和</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">20%</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">（</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">P=0.40</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">）。我们观察到两组中都出现了局部并发症（例如，腿部脓肿），其中静脉滴注组的出现率为</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">9.1%</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">，肌肉注射组的为</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">7%</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">（</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">P = 0.477</span><span style=""font-family:宋体;""><span style=""font-size:14px;line-height:1.5;"">）。</span><a name=""OLE_LINK31""></a><a name=""OLE_LINK30""></a><span style=""font-size:14px;line-height:1.5;"">在采用静脉注射</span></span><span style=""font-size:14px;line-height:1.5;""><span style=""font-size:14px;line-height:1.5;""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">苄青霉素</span></span></span><span style=""font-size:14px;line-height:1.5;""><span style=""font-size:14px;line-height:1.5;""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">治疗（丹毒）后出现并发症的患者中，</span></span></span><span style=""font-size:14px;line-height:1.5;""><span style=""font-size:14px;line-height:1.5;""><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">25.5%</span></span></span><span style=""font-size:14px;line-height:1.5;""><span style=""font-size:14px;line-height:1.5;""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">都与注射途径有关（例如，青霉素对血管内膜刺激会导致静脉炎）</span></span></span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">。研究认为肌肉注射</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">青霉素</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">对于成人丹毒患者来说，</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">是一种有效并耐受良好的疗法。</span> 
</p>
<p class=""MsoNormal"" style=""text-align:center;text-indent:21.0pt;"" align=""center"">
	<span style=""font-size:14px;line-height:1.5;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-align:center;text-indent:18.0pt;"" align=""center"">
	<span style=""font-size:9.0pt;font-family:&quot;""><a><span style=""color:windowtext;text-decoration:none;font-family:Times New Roman;font-size:14px;line-height:1.5;"">Zeglaoui F</span></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> et.al</span></span><span style=""font-size:14px;font-family:Times New Roman;line-height:1.5;"">；</span><span style=""font-size:9.0pt;font-family:&quot;""><a><span style=""color:windowtext;text-decoration:none;font-family:Times New Roman;font-size:14px;line-height:1.5;"">Journal Of
The European Academy Of Dermatology And Venereology</span></a></span><span style=""font-size:14px;font-family:Times New Roman;line-height:1.5;"">；</span><span style=""font-size:14px;font-family:Times New Roman;line-height:1.5;"">2004
Jul; Vol. 18 (4), pp. 426-8.</span> 
</p>","/uploadfiles/image/20131017/20131017164026_4753w.jpg","/uploadfiles/file/20131017/20131017163835_9491.pdf",,10/17/2013,10/17/2013,"medicool",48,,"erysipelas treatment, penicillin",0,"66",70,"Intramuscular bipenicillin vs. intravenous penicillin in the treatment of erysipelas in adults: randomized controlled study","2004",
316,"鸡眼注射疗法的临床研究报告",,"贺治明，谢仁先","中外医学研究","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 本注射疗法是根据外</span><span style=""font-size:14px;"">用药物治疗后复发(只消除了表面的鸡眼组织，而没有清除根部</span><span style=""font-size:14px;"">组织)以及手术切除不彻底(根部没有切除)复发这两种情况，推</span><span style=""font-size:14px;"">测出只有切除根部才能彻底治愈鸡眼，不再复发。皮肤的组织学</span><span style=""font-size:14px;"">也表明，表皮的角质，是由基底层的呈栅状的圆柱状细胞，不断分</span><span style=""font-size:14px;"">裂，最后角化脱落。基于这种理论，利用注射药物的方法，直接将</span><span style=""font-size:14px;"">鸡眼的根部组织杀死破坏，也就是把鸡眼下的表皮的基底层杀死</span><span style=""font-size:14px;"">破坏，从而达到根治鸡眼的目的。</span>",,"/uploadfiles/file/20131024/20131024100121_8423.pdf",,10/24/2013,10/24/2013,"medicool",32,,"鸡眼；注射疗法",0,"85",90,,"2010",
116,,,"Manoj Kumar Tembhre, Vinod Kumar Sharma, Alpana Sharma, Parthaprasad Chattopadhyay, Somesh Gupta","Clinica Chimica Acta","<strong>Background: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vitiligo is a T cell mediated 
autoimmune depigmenting disease. Altered cytokine concentrations have 
been suggested in the pathogenesis of vitiligo. <br />
<strong>Methods: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp; T helper and regulatory T cell cytokines (IL-2, IFN-γ, IL-10, 
IL-13, IL-17 and TGF-β) have been estimated by ELISA and their clinical 
correlation was determined. The study had 3 groups: group I with 80 
vitiligo patients (60 active and 20 stable), group II with 25 narrow 
band ultraviolet B treated vitiligo&nbsp; and group III with 70 healthy 
controls.<br />
<strong>Results:</strong> <br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significant 
difference was found in the serum interleukin (IL)-10, IL-13, IL-17A and
 TGF-β1 concentrations among 3 groups (P b 0.05). In group I, serum 
IL-2, IL-17A concentrations were significantly increased and TGF-β1 
concentrations were decreased in active vitiligo compared to stable 
vitiligo (P b 0.05). Concentrations of IL-2, IL-10 and IL-13 (rho = 
?0.307, rho = ?0.407, rho = ?0.351 and P b 0.05; respectively) were 
negatively- and TGF-β1 concentrationswere positively-correlated (rho = 
0.799, P = 0.001)with disease duration. Interleukin-13 concentrations 
were negatively- and serum TGF-β1 concentrations were 
positively-correlated (rho = ?0.326, rho = 0.244 and P b 0.05; 
respectively) with percentage of body surface area involvement.<br />
<strong>Conclusions: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased concentrations of serum IL-10, IL-13, and IL-17A and 
decreased concentrations of TGF-β1 suggested altered cell-mediated 
immunity that may facilitate the melanocyte cytotoxicity in vitiligo.",,"/uploadfiles/file/20130809/20130809103230_9851.pdf",,09/30/2013,09/30/2013,"medicool",92,,"T helper cells|Regulatory T cells|Cytokines|Narrowband ultraviolet B (NB-UVB)|Active/stable generalized vitiligo",0,"65",28,"T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo","2013",
350,,,"Wall LM ; Smith NP","Clinical And Experimental Dermatology","<p class=""MsoNormal"">
	<span style=""font-family:&quot;""><span>&nbsp; In
an attempt to define better the histopathological changes occurring in the skin
in patients with perniosis, biopsies from twenty-six patients were examined
independently by the two authors. In the majority of cases one of two
characteristic histopathological patterns was seen. The histological
differential diagnosis of perniosis is reviewed.</span></span> 
</p>",,"/uploadfiles/file/20131025/20131025131129_0845.pdf",,10/25/2013,10/25/2013,"medicool",43,,,0,"67",88,"Perniosis: a histopathological review","1981",
364,,"10.1016/j.pdpdt.2012.11.003","Hong-Wei Wang, Ling-Lin Zhang, Xiao-Dong Song,Zheng Huang, Xiu-Li Wang MD, PhD","SciVerse ScienceDirect","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Summary.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp; &nbsp;We report two cases of acute urinary retention (AUR) occurred after intra-urethral aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) in elderly females (&gt;66 years old) with urethral condylomas.</span>",,"/uploadfiles/file/20131101/20131101091751_3652.pdf",,11/01/2013,11/01/2013,"medicool",23,,,0,"85",97,"Acute urinary retention in elderly female patients after photodynamic therapy of urethral condyloma ― Report of two cases","2013",
117,"辣椒素对一例痤疮患者治疗的疗效：新的病理生理学视角","10.1111/j.1468-3083.2009.03513.x","M Simon, G L’Heveder, S Genestet, L Misery","JEADV","&nbsp;&nbsp;&nbsp; We report here the case of a patient with localized acne in an area afflicted with neuralgia that was successfully treated with capsaicin.A 31-year-old woman presented with inflammatory acne lesionsand some comedones on the left cheek, without any underlying telangiectasia. This zone corresponded with an area of painful unilateral trigeminal neuralgia that appeared after violent facial trauma. There were other cutaneous abnormalities in this region, such as oedema and bruising for years. The patient did not apply comedogenic product. The cheek was so painful that the patient never touched it.<br />
&nbsp;<br />
<span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp; 我们报道了一例局部痤疮患者的病例，其病发部位伴有神经痛，使用辣椒素成功治愈。一名</span><span>31</span><span style=""font-family:宋体;"">岁女性患者左脸颊上患有炎症性痤疮皮损以及一些黑头粉刺，没有任何相关性毛细血管扩张症。这一区域与暴力性面部外伤后出现令人痛苦的单侧三叉神经痛的部位相符合。在这一区域中存在其他的皮肤异常，例如多年的水肿和瘀伤。患者并未使用易生黑头粉刺的产品。脸颊如此疼痛，以至于患者从来不触摸它。</span><span></span>","/uploadfiles/image/20130930/20130930162826_3890w.png","/uploadfiles/file/20130930/20130930163021_0336.pdf",,09/30/2013,11/13/2013,"medicool",59,,,0,"85",54,"Efficacy of capsaicin in the treatment of acne in one case: new pathophysiological perspectives","2010","/uploadfiles/kejian/20131113/1113090015_2788.pdf"
115,,,"Sanjeev V. Mulekar , Ahmed Al Issa, Abdullah Al Eisa","burns","<strong>Introduction:</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deep burns often result in 
hypo-pigmentation, referred to as leucoderma which has a similar 
psychosocial impact on the patients as that of vitiligo. Several tissue 
grafting methods have been reported to treat post-burn leucoderma. <br />
<strong>Methods:</strong> <br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A simple method consisting of harvesting a donor skin sample, 
preparation of an epidermal cell suspension and the transplantation of 
the cell suspension on to a dermabraded recipient area, was performed in
 a clean procedure room. No special laboratory set-up was used for the 
cell separation procedure. Patients were treated with 18 sessions of 
excimer laser starting 1 month post-operatively, to hasten the 
repigmentation. <br />
<strong>Observation: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Of the 10 
patients treated with MKTP, 3 were lost to follow-up. The remaining 7 
patients showed repigmentation ranging from 90% to 100% with good color 
matching. <br />
<strong>Conclusion:</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MKTP is an 
effective method to treat post-burn leucoderma. No special precautions 
are required to treat any anatomical site or uneven scarred surface.",,"/uploadfiles/file/20130809/20130809142710_4934.pdf",,09/30/2013,09/30/2013,"medicool",65,,"Post-burn leucoderma|Treatment|Grafting|Melanocyte transplantation|
Surgery|Leucoderma treatment",0,"65",28,"Treatment of post-burn leucoderma with non-cultured melanocyteCkeratinocyte transplantation (MKTP)","2011",
411,"外周过敏原特异性T细胞应答增强对阳性APT反应至关重要","Catharina Johansson a Niklas Ahlborg c, d Anna Andersson a Lena Lundeberg b Maria A. Karlsson b Annika Scheynius a Maria Tengvall Linder a","Catharina Johansson a Niklas Ahlborg c, d Anna Andersson a Lena Lundeberg b Maria A. Karlsson b Annika Scheynius a Maria Tengvall Linder a","Int Arch Allergy Immunol","<p class=""MsoNormal"" align=""justify"">
	<b><span style=""color:#231F20;font-family:&quot;font-size:14px;"">Background:</span></b> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#231F20;font-family:&quot;font-size:14px;"">Atopic eczema </span></span></span></span><span><span><span style=""color:#231F20;font-family:&quot;&quot;;""><span style=""font-size:14px;"">is a chronic </span><span style=""font-size:14px;"">inflammatory skin disease in which several subgroups of cases can be </span><span style=""font-size:14px;"">identified.</span></span></span></span><span style=""color:#231F20;font-family:&quot;&quot;;""><span style=""font-size:14px;""> Atopy patch testing (APT) reveals allergen </span><span style=""font-size:14px;"">sensitization also in atopic eczema patients devoid of detectable allergen- </span><span style=""font-size:14px;"">specific IgE, suggesting the importance of factors other than IgE in the </span><span style=""font-size:14px;"">reaction. Here we investigate the relationship between APT reactions and </span><span><span><span style=""font-size:14px;"">allergen-specific </span><span style=""font-size:14px;"">peripheral</span></span></span><span style=""font-size:14px;""> <span style=""font-size:14px;"">IgE </span></span><span style=""font-size:14px;"">and T cell reactivity in atopic eczema patients.</span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""color:#231F20;font-family:宋体;font-size:14px;"">背景</span></b><span style=""color:#231F20;font-family:宋体;""><span style=""font-size:14px;"">：</span><br />
<span style=""font-size:14px;""></span></span><span style=""color:#313131;font-family:宋体;""><span style=""font-size:14px;"">过敏性湿疹是一种慢性炎症性皮肤病，它是几种能被鉴别的疾病亚群中的其中之一。</span><span style=""font-size:14px;"">斑贴试验</span></span><span></span><span></span><span style=""color:#313131;font-family:&quot;font-size:14px;"">(APT)</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">揭示了过敏原致敏作用在过敏性湿疹患者体内也缺乏可检测的过敏原特异性</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">IgE</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">，提出在反应中除</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">IgE</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">之外的重要因素。这里我们研究</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">APT</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">反应和</span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">过敏原特异性外周</span><span style=""color:#231F20;font-family:&quot;font-size:14px;"">IgE</span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">以及</span><span style=""color:#231F20;font-family:&quot;font-size:14px;"">T</span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">细胞反应在过敏性湿疹患者中</span><span style=""color:#231F20;font-family:宋体;""><span style=""font-size:14px;"">的关系</span><span style=""font-size:14px;"">。</span></span><span style=""color:#231F20;font-family:&quot;&quot;;""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""justify"">
	<b><span style=""color:#231F20;font-family:&quot;font-size:14px;"">Methods:</span></b> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""color:#231F20;font-family:&quot;&quot;;""><span style=""font-size:14px;"">Adult patients </span><span style=""font-size:14px;"">with atopic eczema (n = 64) and healthy controls (n = 24) were analyzed for </span><span style=""font-size:14px;"">reactivity to </span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><i><span style=""color:#231F20;font-family:&quot;font-size:14px;"">Malassezia sympodialis</span></i></span></span></span></span><span></span><span></span><span></span><span><span><span style=""color:#231F20;font-family:&quot;&quot;;""><span style=""font-size:14px;""> extract by APT, measurement of specific </span><span style=""font-size:14px;"">plasma IgE and in vitro determination of the frequency of allergen-reactive </span><span style=""font-size:14px;"">peripheral blood mononuclear cells producing interleukin- 4 and interleukin-5 </span><span style=""font-size:14px;"">using the ELISpot method.</span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""color:#231F20;font-family:宋体;font-size:14px;"">方法</span></b><span style=""color:#231F20;font-family:宋体;font-size:14px;"">：</span><span style=""color:#231F20;font-family:&quot;&quot;;""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""color:#313131;font-family:宋体;font-size:14px;"">通过</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">APT</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">分析过敏性湿疹成人患者组（</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">n=64</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">）和健康对照组（</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">n=24</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">）对合轴马拉色菌提取物的反应，测量特异性血清</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">IgE</span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#313131;font-family:宋体;font-size:14px;"">以及采用酶联免疫斑点</span></span></span><span style=""color:#313131;font-family:宋体;""><span style=""font-size:14px;"">检测法体外测定活性过敏原</span><span style=""font-size:14px;"">外周血单个核细胞</span><span style=""font-size:14px;"">产生白介素</span></span><span style=""color:#313131;font-family:&quot;font-size:14px;"">- 4</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">和白介素</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">-5</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">的频率。</span><span style=""color:#313131;font-family:&quot;&quot;;""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""color:#231F20;font-family:&quot;font-size:14px;"">Results:</span></b> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""color:#231F20;font-family:&quot;&quot;;""><span style=""font-size:14px;"">When combining the results of the APT, IgE </span><span style=""font-size:14px;"">measurements and the ELISpot analyses, reactivity to </span><i><span style=""font-size:14px;"">M. sympodialis</span></i><span style=""font-size:14px;""> was </span><span style=""font-size:14px;"">found in a majority of the atopic eczema patients (69%),whereas the healthy </span><span style=""font-size:14px;"">controls were negative throughout. T cell reactivity to </span><i><span style=""font-size:14px;"">M. </span></i></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><i><span style=""color:#231F20;font-family:&quot;font-size:14px;"">sympodialis</span></i></span></span><span></span><span><span><span style=""color:#231F20;font-family:&quot;&quot;;""><span style=""font-size:14px;""> , manifested by production of both interleukins 4 and 5, was highly </span><span style=""font-size:14px;"">predictive for a positive APT reaction and displayed a strongly positive </span><span style=""font-size:14px;"">correlation with the APT score. In contrast, the allergen-specific IgE levels </span><span style=""font-size:14px;"">did not predict the APT outcome, and no correlation could be found between the </span><span style=""font-size:14px;"">IgE levels and the APT score.</span></span></span></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""color:#231F20;font-family:宋体;font-size:14px;"">结果</span></b><span style=""color:#231F20;font-family:宋体;font-size:14px;"">：</span><span style=""color:#231F20;font-family:&quot;&quot;;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""color:#313131;font-family:宋体;font-size:14px;"">结合</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">APT</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">、</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">IgE</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">测量值和</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">ELISpot</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">分析结果，我们发现大部分过敏性湿疹患者（</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">69%</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">）对合轴马拉色菌有反应，而健康对照组则（对合轴马拉色菌）全都无反应。</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">T</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">细胞对合轴马拉色菌有反应时表现为产生白介素</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">-4</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">和白介素</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">-5</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">，高度预测为阳性</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">APT</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">反应并且与</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">APT</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">值呈现强烈的正相关。相反情况下</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">, </span><span style=""color:#313131;font-family:宋体;font-size:14px;"">特异性过敏原</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">IgE</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">水平则无法预测</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">APT</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">的结果</span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">，并且</span><span style=""color:#231F20;font-family:&quot;font-size:14px;""> <span style=""font-size:14px;"">IgE</span></span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">水平和</span><span style=""color:#231F20;font-family:&quot;font-size:14px;"">APT</span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">值之间并未发现有任何关系。</span><span style=""color:#231F20;font-family:&quot;&quot;;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""color:#231F20;font-family:&quot;font-size:14px;"">Conclusion: </span></b> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#231F20;font-family:&quot;font-size:14px;"">Peripheral allergen-specific </span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#231F20;font-family:&quot;font-size:14px;"">T helper 2 </span></span></span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#231F20;font-family:&quot;font-size:14px;"">cell-mediated reactivity</span></span></span></span></span></span></span><span><span><span><span><span style=""color:#231F20;font-family:&quot;&quot;;""><span style=""font-size:14px;""> appears to be required for a positive APT </span><span style=""font-size:14px;"">reaction to </span><i><span style=""font-size:14px;"">M. sympodialis</span></i></span></span></span></span></span><span><span><span style=""color:#231F20;font-family:&quot;&quot;;""><span style=""font-size:14px;""> .</span><span><span style=""font-size:14px;""> The diagnostic potential of measuring </span><span style=""font-size:14px;"">peripheral allergen-specific T cell responses should be considered in atopic </span><span style=""font-size:14px;"">eczema.</span></span></span></span></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""color:#231F20;font-family:宋体;font-size:14px;"">总结</span></b><span style=""color:#231F20;font-family:宋体;font-size:14px;"">：</span><span style=""color:#231F20;font-family:&quot;&quot;;""></span> 
</p>
<p style=""background:white;text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""color:#231F20;font-family:宋体;""><span style=""font-size:14px;"">外周过敏原特异性</span><span style=""font-size:14px;"">辅助性</span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#231F20;font-family:&quot;font-size:14px;"">T</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#231F20;font-family:宋体;font-size:14px;"">细胞</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#231F20;font-family:&quot;font-size:14px;"">2</span></span></span><span></span><span></span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">（</span><span style=""color:#231F20;font-family:&quot;font-size:14px;"">Th2</span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">）细胞介导反应似乎要求对</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">合轴马拉色菌呈</span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">阳性</span><span style=""color:#231F20;font-family:&quot;font-size:14px;"">APT</span><span style=""color:#231F20;font-family:宋体;font-size:14px;"">反应。因此，</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">通过测量外周过敏原特异性</span><span style=""color:#313131;font-family:&quot;font-size:14px;"">T</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">细胞应答诊断潜在可能性时，应考虑过敏性湿疹。</span> 
</p>","/uploadfiles/image/20131106/20131106170818_3347w.png","/uploadfiles/file/20131106/20131106170809_3647.pdf",,11/06/2013,11/06/2013,"medicool",64,,"Antigen-specific IgE ，Atopic eczema ，Atopic dermatitis ，Atopy patch test，ELISpot，Interleukin-4，Interleukin-5 ，Malassezia",0,"65",64,"Elevated Peripheral Allergen-Specific T Cell Response Is Crucial for a Positive Atopy Patch Test Reaction","2009",
132,,"10.1111/j.1600-0560.2011.01817.x","Boyd AS ; Zwerner JP ; Miller JL","Journal Of Cutaneous Pathology","&nbsp; The clinical and histopathological features of cutaneous <strong>herpes</strong> <strong>simplex</strong> <strong>virus</strong> (HSV) infection have been well described. Genital herpetic infections are largely <strong>induced</strong> by HSV type 2, but 30% of cases can be caused by HSV type 1. Immunocompromised patients are known to exhibit atypical patterns of clinical presentation with variable lesion morphology and anatomic location. A subset of patients may show morphology such as nodules or verrucous lesions. Analogously, some biopsy specimens may show unusual microscopical features, such as a lack of keratinocyte cytopathology, lymphocyte infiltration or vasculopathic changes that are expected irrespective of the patient's immune status. We present the case of a patient carrying a previous diagnosis of pemphigus vulgaris, status posttreatment with methotrexate and prednisone, who developed a perineal ulcer exhibiting significant numbers of plasma cells, many of which were cytologically atypical. This morphology was suggestive of a hematopoietic malignancy. Immunoperoxidase staining for HSV decorated a focal collection of keratinocytes that lacked appreciable viral changes expected of HSV infection.",,"/uploadfiles/file/20131011/20131011154740_0327.pdf",,10/11/2013,10/11/2013,"medicool",43,,"herpes simplex virus, immune compromise, pemphigus vulgaris, plasmacytic atypia",5,"85",57,"Herpes simplex virus-induced plasmacytic atypia","2012",
143,,"10.1111/j.1469-0691.2011.03641.x","Pascual A ; Moessinger A ; Gerber S ; Meylan P","Clinical Microbiology And Infection: The Official Publication Of The European Society Of Clinical Microbiology And Infectious Diseases","A large variation in neonatal herpes incidence is observed in USA and Europe. Better knowledge of neonatal herpes epidemiology is important to inform local prevention strategies. Between 2002 and 2008, the Swiss Paediatric Surveillance Unit reported prospectively proven neonatal herpes simplex virus infections. During the study period seven cases were declared, for an inci- dence of 1.6/100 000 (95% CI 0.64C3.28/100 000) live births. This is one of the lowest incidences of neonatal herpes reported.<br />
<br />",,"/uploadfiles/file/20131011/20131011171030_5134.pdf",,10/11/2013,10/11/2013,"medicool",32,,"Herpes simplex virus, incidence, neonatal herpes, surveillance study, Switzerland",0,"66",57,"Neonatal herpes simplex virus infections in Switzerland: results of a 6-year national prospective surveillance study","2011",
429,"儿童扁平苔藓:100则病例报告","10.1111/j.1365-2230.2009.03613.x","A. J. Kanwar and D. De","Clinical and Experimental Dermatology","<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">Background.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><a name=""OLE_LINK3""></a><a name=""OLE_LINK2""></a><span style=""line-height:2;font-size:14px;"">Lichen planus (LP) is uncommon in
children, and </span><a name=""OLE_LINK22""></a><span style=""line-height:2;font-size:14px;"">there have been few </span><a name=""OLE_LINK37""></a><span style=""line-height:2;font-size:14px;"">large studies on LP in this patient group.</span><a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><span style=""line-height:2;font-size:14px;""> Most of the literature
on childhood LP has appeared as case reports or</span><a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span style=""line-height:2;font-size:14px;""> isolated case series.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">背景：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""line-height:2;font-size:14px;"">扁平苔藓（LP）在儿童中很罕见，在这类患者人群中，很少有关于LP的大规模研究。大多数关于儿童LP的文献已作为病例报告或个别的案例系列出现。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">Methods.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span style=""line-height:2;font-size:14px;"">We report the results of a study
on 100 children with LP, which is, to our knowledge, </span><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span style=""line-height:2;font-size:14px;"">the
largest study to date on this condition.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">方法：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""line-height:2;font-size:14px;"">据我们所知，我们报告一项针对100名LP儿童患者的研究结果，，这是在此条件下，迄今为止最大的研究。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">Results.</span></b> <b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span style=""line-height:2;font-size:14px;"">The mean age of
patients was 8.76 years and mean age at disease onset was 7.6 years. </span><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span style=""line-height:2;font-size:14px;"">T</span><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span style=""line-height:2;font-size:14px;"">he onset
of the disease was most commonly seen on the legs (54% of patients). </span><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span style=""line-height:2;font-size:14px;"">The classic papular lesions
were the commonest morphology seen (42% of patients). </span><a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><a name=""OLE_LINK33""></a><span style=""line-height:2;font-size:14px;"">The oral
mucosa was involved in 17% and nail involvement in 19% of children.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">结果：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""line-height:2;font-size:14px;"">患者的平均年龄为8.76岁，平均发病年龄为7.6岁。此病最常见的发病部位在腿部（占总患者的54％）。经典丘疹性病变是最常见的形态表现（占总患者的42％）。口腔黏膜受累（占17％）、指甲损害（占19％）。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">Conclusion.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK36""></a><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span style=""line-height:2;font-size:14px;"">Vaccination against
hepatitis B has been suggested to be causally related to the onset of LP in
various published studies. </span><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><span style=""line-height:2;font-size:14px;"">However, only 16 of our
patients had been vaccinated against hepatitis B. If there is a causal
relationship, more cases of LP in children may occur in the future, </span><a name=""OLE_LINK35""></a><a name=""OLE_LINK34""></a><span style=""line-height:2;font-size:14px;"">as
vaccination against hepatitis B becomes routine in India.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">结论：</span></b><b></b> 
</p>
<span style=""line-height:2;font-size:14px;"">&nbsp; &nbsp; 在各种已发表的研究报告中表明，B型肝炎疫苗的接种与LP发病是有因果关系的。然而在我们的患者中，仅有16名接种了B型肝炎疫苗。如果存在因果关系，未来可能会有更多的LP儿童患者，因为在印度B型肝炎疫苗，已经普遍接种。</span>","/uploadfiles/image/20131113/20131113150838_7548w.jpg","/uploadfiles/file/20131113/20131113150805_3863.pdf",,11/13/2013,11/13/2013,"medicool",40,,,0,"85",99,"Lichen planus in childhood: report of 100 cases","2009",
431,"亚甲蓝介导光动力疗法治疗口腔扁平苔藓 C 一项临床研究",,"Jayachandran Sadaksharam, K. P. Thanigai Nayaki& Niranzena Panneer Selvam","John Wiley & Sons A/S","<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">Background/Purpose.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><a name=""OLE_LINK3""></a><a name=""OLE_LINK2""></a><span style=""line-height:2;font-size:14px;"">Oral lichen planus is an autoimmune
disorder that has posed a challenge in spite of the several treatment
modalities available. </span><a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span style=""line-height:2;font-size:14px;"">Here, we have proposed
yet another treatment modality, photodynamic therapy, for this condition. </span><a name=""OLE_LINK23""></a><a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><span style=""line-height:2;font-size:14px;"">The aim of the study was to treat patients
having symptomatic oral lichen planus with photodynamic therapy with methylene
blue as photosensitizer.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">背景</span></b><b><span style=""line-height:2;font-size:14px;"">/</span></b><b><span style=""line-height:2;font-size:14px;"">目的：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""line-height:2;font-size:14px;"">口腔扁平苔藓是一种自身免疫性疾病，尽管有一些可用的治疗方法，但对于治疗还是构成了一种挑战。在这种情况下，我们提出了另一种治疗方法――光动力疗法。这项研究的目的是，应用以亚甲蓝作为光敏剂的光动力疗法治疗患有口腔扁平苔藓的患者。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">Methods.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span style=""line-height:2;font-size:14px;"">Twenty patients with
symptomatic oral lichen planus were included in the study. </span><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><span style=""line-height:2;font-size:14px;"">They were treated with 5% methylene blue
mediated photodynamic therapy (light source: Xenon arc lamp, wavelength: 630±5 nm, total dose:120
J/cm2per sitting) in four sessions (1st, 4th, 7th and 15th day). </span><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span style=""line-height:2;font-size:14px;"">Follow-up
was done on second and fourth week after the therapy.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">方法：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""line-height:2;font-size:14px;"">20名伴有口腔扁平苔藓症状的患者纳入研究。他们在四个阶段中（第1，第4，第7和第15天）分别用5％的亚甲蓝介导的光动力疗法（光源：氙弧灯，波长：630±5 nm，总剂量：
120 J/cm2per）进行治疗。在治疗后的第二周和第四周进行随访。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">Results.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span style=""line-height:2;font-size:14px;"">There was significant improvement
in signs and symptoms of the lesion at first and second follow-up visits
(P-value &lt; 0.001).</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">结果：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""line-height:2;font-size:14px;"">在第一次和第二次随访时病变的症状和体征有明显改善（P值&lt;0.001）。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">Conclusion.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK26""></a><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span style=""line-height:2;font-size:14px;"">There was satisfactory
reduction in signs and symptoms of oral lichen planus without any side effects.</span><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a> <a name=""OLE_LINK18""></a><span style=""line-height:2;font-size:14px;"">Thus, methylene blue mediated photodynamic therapy seems
to be a promising alternative for the control of oral lichen planus.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">结论：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""line-height:2;font-size:14px;"">此疗法在减少口腔扁平苔藓的症状和体征上令人满意，并且无任何副作用，。因此，亚甲蓝介导的光动力疗法似乎是一种很有前途的控制口腔扁平苔藓的替代疗法。</span> 
</p>","/uploadfiles/image/20131113/20131113152123_5774w.jpg","/uploadfiles/file/20131113/20131113152051_1761.pdf",,11/13/2013,11/13/2013,"medicool",42,,,0,"66",99,"Treatment of oral lichen planus with methylene blue mediated photodynamic therapy C a clinical study","2012",
113,,,"Amy Chia-Ying Peng, Chien-Hun Huang, Tsy-Sheng Lin, Julia Yu-Yun Lee","Dermatologica Sinica","&nbsp;&nbsp;&nbsp; Severe subcutaneous edema is rare in dermatomyositis (DM). Such patients
 usually have a highly active disease, which requires aggressive 
treatment. To date, there are 14 reported cases of generalized edema 
secondary to adult DM.We described a severe case of DM manifesting 
generalized edema, oropharyngeal dysphagia, and dysarthria. A 
44-year-old female presented with a typical rash of DM, proximal muscle 
weakness, and marked swelling of the limbs and face. The findings in the
 skin biopsy, muscle enzymes, and electromyography were consistent with 
DM. No internal malignancy was detected. After a brief initial response 
to oral dexamethasone, the patient experienced a sudden worsening of 
muscle weakness with dysarthria and an inability to swallow even saliva.
 A magnetic resonance imaging study revealed edema of the subcutaneous 
tissue and muscles. The symptoms improved gradually in 2 months after 
intravenous pulse corticosteroid therapy. Generalized subcutaneous edema
 is a very rare manifestation of DM that can occur as a presenting 
symptom. It appears to be a hallmark of a severe DM that requires prompt
 and aggressive treatment. Additional cases are needed to establish 
guidelines for treatment of this rare variant",,"/uploadfiles/file/20130809/20130809144330_1907.pdf",,09/30/2013,09/30/2013,"medicool",23,,"anasarca|corticosteroids|dermatomyositis|generalized edema|
oropharyngeal dysphagia",0,"85",33,"Severe dermatomyositis with pronounced generalized subcutaneous edema and dysphagia: A rare manifestation of a highly active disease","2013",
112,,,"Yang-Cheng Shih*, Su-Min Tu, Cheng-Chi Chiu","Applied Thermal Engineering","&nbsp;&nbsp;&nbsp; In the past, one main area of focus in the solidification of a liquid 
binary alloy has been the investigation of strategies for the 
elimination or minimization of the presence of “double-diffusive 
convection”, the main cause of poor quality alloys. In particular, 
“freckles” occurring in the solidification process cooled from the 
bottom can result in severe material defects in the final product. The 
objective of this study is to investigate the effect of a periodic 
lid-driven flow on the development of double-diffusive convection during
 solidification from below to aid in the removal or reduction of the 
occurrence of this convection that causes the formation of freckles. A 
hyper-eutectic aqueous ammonium chloride (NH4CleH2O) solution was used 
as the test sample and was contained in an enclosure cooled from the 
bottom to study flow development and heat and mass transport phenomena 
during solidification. Flow visualization using the shadowgraph 
technique and measurements of the temperature distribution, the 
concentration distribution, and the movement of the liquidemush 
interface were conducted during solidification. The experimental results
 revealed that the imposed periodic lid-driven flow had a positive 
effect on the process by suppressing the plumes emanating from the 
channels and reducing the strength of the double-diffusive convection.",,"/uploadfiles/file/20130809/20130809145231_2777.pdf",,09/30/2013,09/30/2013,"medicool",30,,"Binary alloy|Double-diffusive convection|Freckles|Mushy zone|
Shadowgraph technique|Solidification",0,"65",7,"Suppressing freckles during solidification due to periodic motion of top liquid layer","2013",
122,"皮肤暗色丝孢霉病中链格孢菌和短帚霉的相关性",,"V. Anandan, V. Nayak , S. Sundaram, P. Srikanth","Indian J Dermatol Venereol Leprol","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><span><span><span><span>Rare molds </span></span></span></span><span><span><span>are
increasingly emerging</span></span></span><span> <a name=""OLE_LINK10""></a>as a cause of<a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><span> deep and invasive fungal infections</span>. We report here a rare case of
cutaneous phaeohyphomycosis of the lower limbs due to <i>Alternaria alternata </i>associated
with<a name=""OLE_LINK15""></a><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span><span><span style=""color:red;""> </span></span></span><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span><span><span><span><span style=""color:red;"">extra-ungual</span></span></span></span></span><span><span><span><span style=""color:red;""> localization</span></span></span></span> of <i>Scopulariopsis brevicaulis. </i>Diagnosis was made based on repeated,
direct, <a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span><span>microscopic
mycological and histological examinations. </span></span>The study revealed <a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span>hyphae
and fungal cells</span> in a<a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span> granulomatous dermal infiltrate</span>.
Identification of the molds was based on <a name=""OLE_LINK31""></a><a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span><span>macroscopic appearance</span></span> on
culture of samples from the lesions on <a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span><span><span>Sabouraud’s</span></span></span><span><span> dextrose
agar</span></span> and microscopic appearance<a name=""OLE_LINK33""></a><a name=""OLE_LINK32""></a><span> on Lactophenol cotton
blue following </span><a name=""OLE_LINK34""></a><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span><span><span><span>slide culture</span></span></span></span><span><span>.</span></span></span>
</p>
<span></span><span></span> 
<p class=""MsoNormal"" style=""text-align:left;text-indent:21.0pt;"" align=""left"">
	<span style=""font-family:宋体;"">稀有霉菌越来越多的成为引起深度和侵袭性真菌感染的原因。我们报道了一例下肢皮肤暗色丝孢霉病的稀有病例，</span><span> </span><span style=""font-family:宋体;"">由与短帚霉的超爪样定位相关的链格孢菌引起。诊断是在重复、直接、微观真菌学和组织学检查的基础上完成的。本研究揭示肉芽肿性皮肤渗透物中的菌丝和真菌细胞。通过在</span><span>Sabouraud’s</span><span style=""font-family:宋体;"">葡萄糖琼脂上培养皮损处样品的宏观表征，以及在玻片培养下乳酚棉蓝的微观表征对霉菌进行鉴定。</span><span></span>
</p>","/uploadfiles/image/20131010/20131010162205_5202w.png","/uploadfiles/file/20131010/20131010162251_3842.pdf",,10/10/2013,10/10/2013,"medicool",36,,"Alternaria alternata (a), Deep fungal infection, Phaeohyphomycosis, Scopulariopsis brevicaulis",0,"65",20,"An association of Alternaria alternata and Scopulariopsis brevicaulis in cutaneous phaeohyphomycosis","2008",
445,"ZNRD1基因变异预测HIV-1/ADIS的疾病进展――基于台湾地区的汉族人群","10.1371/journal.pone.0067572","Ying-Ju Lin, Yu-Ching Lan, Chien-Hui Hung, Ting-Hsu Lin, Shao-Mei Huang, Chiu-Chu Liao,Cheng-Wen Lin, Chih-Ho Lai, Ni Tien, Xiang Liu, Mao-Wang Ho, Wen-Kuei Chien,Jin-Hua Chen,Jen-Hsien Wang, Fuu-Jen Tsai","Genetic Variants and AIDS Progression","<p align=""justify"">
	<span style=""font-size:16px;""><span style=""font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style=""font-family:Times New Roman;font-size:16px;"">&nbsp;&nbsp; Patients demonstrate notable variations in disease </span></span><span style=""font-family:Times New Roman;font-size:16px;"">progression following human immunodeficiency virus (HIV) infection.We aimed to identifyZNRD1andRNF39genetic variants </span></span><span style=""font-family:Times New Roman;font-size:16px;"">linked to AIDS progression.We conducted a genetic association study in HIV-1-infected Han Chinese </span><span style=""font-family:Times New Roman;font-size:16px;"">patients residing in Taiwan.The clinical characteristics of </span><span style=""font-family:Times New Roman;font-size:16px;"">143 HIV-1-infected patientswere measured, </span><span style=""font-family:Times New Roman;font-size:16px;"">and patients were split into 2 groups:AIDS progression and </span><span style=""font-family:Times New Roman;font-size:16px;"">AIDS non-progression. Genotyping ofZNRD1andRNF39was performed in all </span><span style=""font-family:Times New Roman;font-size:16px;"">participants. We found that patients in the AIDS progression grouphad </span><span style=""font-family:Times New Roman;font-size:16px;"">higher HIV-1 viral loads and lower CD4 cell counts thandid patients </span><span style=""font-family:Times New Roman;font-size:16px;"">inthe AIDS non-progression group. </span><span style=""font-family:Times New Roman;font-size:16px;"">The </span><span style=""font-family:Times New Roman;font-size:16px;"">frequency of the AA genotype ofZNRD1(rs16896970) was lower in the AIDS progression group than in the AIDS non-progression </span><span style=""font-family:Times New Roman;font-size:16px;"">group. Patients with AA genotypeshad lower levels of HIV-1 viral loads and </span><span style=""font-family:Times New Roman;font-size:16px;"">higher levels of CD4 cell countsthan did patients with AG+GG genotypes. AIDS progression in patients with the AA group is </span><span style=""font-family:Times New Roman;font-size:16px;"">significantly different from that in patients with the AG and GG groupsby </span><span style=""font-family:Times New Roman;font-size:16px;"">using Kaplan-Meier survival analysis.The hazard ratio for </span><span style=""font-family:Times New Roman;font-size:16px;"">progression was lower in the AA group than in the AG and GG groups.We </span><span style=""font-family:Times New Roman;font-size:16px;"">identified a SNP that contributes to AIDS progression in HIV-1-infected </span><span style=""font-family:Times New Roman;font-size:16px;"">patients in this population.This SNP had a </span><span style=""font-family:Times New Roman;font-size:16px;"">significant protective influence on AIDS progression,andpolymorphisms </span><span style=""font-family:Times New Roman;font-size:16px;"">of theZNRD1gene mayplay a role in the pathogenesis of HIV-1 </span><span style=""font-family:Times New Roman;font-size:16px;"">infection.</span> 
</p>
<p align=""justify"">
	<span style=""font-size:14px;""><span style=""font-size:16px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;在追踪人类免疫缺陷病毒(HIV)感染的疾病进程中，我们发现患者展现出显著的基因变异。我们的目的是为了鉴别与艾滋病进展相关的ZNRD1和RNF39基因变异体。我们对居住在台湾感染HIV-1的汉族患者进行了基因相</span><span style=""font-size:16px;"">性研究，对143位感染HIV-1患者的临床特征进行检测，并将患者分为2组：艾滋病进展组和艾滋病无进展组。对所有参与者的ZNRD1和RNF39进行基因分型。我们发现，与艾滋病无进展组的患者相比，艾滋病进展组的患者有较高的HIV-1病毒载量和较低的CD4细胞数量。在艾滋病进展组中，ZNRD1(rs16896970)的AA基因型频率比艾滋病无进展组低。与AG+GG基因型的患者相比，AA基因型的患者有较低水平的HIV-1病毒载量和较高水平的CD4细胞数量。通过Kaplan-Meier生存分析发现，AA基因型患者的艾滋病进程与AG+GG基因型患者明显不同。我们鉴别了一个SNP，它能够促进这一人群中感染HIV-1患者的艾滋病进展。这个SNP对艾滋病进展有重大的保护性作用，ZNRD1基因的多态性可能在HIV-1感染的发病机制中发挥作用。</span></span> 
</p>
<br />
<br />","/uploadfiles/image/20131114/20131114161119_0820w.png","/uploadfiles/file/20131114/20131114160546_3490.pdf",,11/14/2013,11/14/2013,"medicool",45,,"ZNRD1 Gene，HIV-1，Cell Counts，Patients with AIDS progression",0,"65",19,"Variants inZNRD1Gene PredictHIV-1/AIDS Disease Progression in a Han Chinese Population in Taiwan ","2013",
110,,,"Gregori Casals, Josep Marcos, ?scar J. Pozo, Paula Aguilera, Carmen Herrero, Jordi To-Figueras","Clinical Biochemistry","<strong>Objective: </strong><br />
&nbsp;&nbsp;&nbsp; Acute intermittent porphyria (AIP) is an autosomal dominant 
disease that results from a deficiency of hydroxymethylbilane synthase, 
the third enzyme of the heme biosynthetic pathway. AIP carriers may 
present acute neurovisceral attacks with hepatic overproduction of 
heme-precursors. In some patients, remission of the acute symptoms leads
 to long-term hepatic metabolic abnormalities. In this study, gas 
chromatographyCmass spectrometry (GC/MS) was used to investigate urinary
 steroid metabolome of AIP patients.<br />
<strong> Design and methods:</strong><br />
&nbsp;&nbsp; Steroid 
profiling in urine was performed in a group of AIP patients with 
biochemically active disease (n = 22) and healthy controls (n = 20). 
Five asymptomatic AIP family carriers were also studied. Commonly used 
ratios for the evaluation of disturbances in the steroid metabolism were
 calculated. <br />
<strong>Results:</strong><br />
&nbsp;&nbsp; We found that etiocholanolone/androsterone and 
tetrahydrocortisol/5α-tetrahydrocortisol (THF/ 5α-THF) metabolic ratios 
were significantly increased in the urine of AIP patients compared to 
controls (2.3 ± 0.3 vs 0.8 ± 0.1; p b 0.001 and 2.9 ± 0.7 vs 0.9 ± 0.1; p
 b 0.01). The (THF + 5α-THF)/tetrahydrocortisone ratio was reduced among
 the AIP patients (p b 0.01). Quantification of the steroid absolute 
concentrations showed that these variations were due to a decrease of 
the 5α metabolites. Other ratios, like cortisol/cortisone and 
6β-hydroxycortisol/cortisol in the free steroid fraction did not show 
differences between patients and controls. All ratios were normal among 
the family carriers. <br />
<strong>Conclusion: </strong><br />
&nbsp;&nbsp;&nbsp; A significant number of AIP patients 
present a basal decrease of steroid 5α-reductase activity in the liver. 
The deficiency may be related to malnutrition and hepatic energy 
misbalance associated with active AIP. Urinary steroid profiling by 
GC/MS may be a valuable tool to assess hepatic metabolome in AIP.",,"/uploadfiles/file/20130809/20130809104434_1867.pdf",,09/30/2013,09/30/2013,"medicool",26,,"Acute porphyria|Steroid metabolism|Liver disease|GC/MS",0,"65",56,"Gas chromatographyCmass spectrometry profiling of steroids in urine of patients with acute intermittent porphyria","2013",
509,"光线性角化病中的肿瘤抑制基因p14ARF、P15INK4b、p16INK4a和p53的基因组不稳定性、突变和表达分析","10.1016/j.canlet.2008.01.042","P. Kanellou a, A. Zaravinos a, M. Zioga b, A. Stratigos b, S. Baritaki a,c, G. Soufla a, O. Zoras d, D.A. Spandidos a,","Cancer Letters","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""></span> 
</p>
<div style=""text-align:justify;"">
	<span style=""text-indent:21pt;font-size:14px;line-height:2;""><span style=""font-family:'Times New Roman';font-size:18px;""><strong>Abstract</strong></span><br />
<span style=""font-family:'Times New Roman';"">&nbsp; &nbsp; &nbsp; Actinic keratosis (AK) is a well-established pre-cancerous skin
lesion that has the potential to progress to squamous cell carcinoma
(SCC).</span></span><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">We investigated the involvement of the CDKN2A, CDKN2B and p53 genes
in AK and in the progression of AK to SCC. Mutational analysis on
exons 1a, 1b and 2 of the CDKN2A locus and exon 1 of the CDKN2B locus as well
as allelic imbalance was performed in 26 AK specimens. </span><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">Expression levels of
the genes p14</span><sup style=""text-indent:21pt;""><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">ARF</span></sup><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">, p15</span><sup style=""text-indent:21pt;""><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4b</span></sup><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">, p16</span><sup style=""text-indent:21pt;""><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4a</span></sup><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';""> and p53
were examined in 16 AKs and 12 SCCs by real-time RT-PCR. </span><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">A
previously described polymorphism of p16</span><sup style=""text-indent:21pt;""><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4a</span></sup><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';""> (Ala148Thr) was
detected at an allelic frequency of 12%. </span><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">Six samples carried novel
mutations at codon 71 of the CDKN2A locus and one sample presented an
additional mutation at codon 65. Two AK samples carried a </span><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">not-previously described </span><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">non-UV type missense mutation at codon 184
(Val184Glu) of exon 1b in the p14</span><sup style=""text-indent:21pt;""><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">ARF</span></sup><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';""> gene. Regarding the CDKN2B
locus a new mutation at codon 50 (Ala50Thr) and another at codon 24 (Arg24Arg),
were detected. Microsatellite instability (MSI) was found in 15% of AKs in at
least one marker, indicating that genetic instability has some implication in
the development of AK. Down-regulation of p16</span><sup style=""text-indent:21pt;""><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4a</span></sup><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';""> and p53 mRNA
levels was noted in SCC compared to AK. TSGs expression levels in sun-exposed
morphologically normal- appearing skin, suggests that abnormal growth stimuli
might exist in these tissues as well. Furthermore, we suggest a possible role
of p15</span><sup style=""text-indent:21pt;""><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4b</span></sup><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">, independently from the intracellular pathway mediated
by p16</span><sup style=""text-indent:21pt;""><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4a</span></sup><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">, and of p14</span><sup style=""text-indent:21pt;""><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">ARF </span></sup><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">in AK development, as well as
in the progression of AK to SCC. </span><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">The deregulation of the expression profiles of
the CDKN2A, CDKN2B and p53 genes may, </span><span style=""text-indent:21pt;font-size:14px;line-height:2;font-family:'Times New Roman';"">independently of
mutations and LOH at 9p21, play a significant role <span style=""line-height:3;"">in AK and
progression of AK to SCC.<br />
<span style=""font-size:18px;""><strong>摘 要</strong></span></span></span> 
</div>
<span style=""font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">&nbsp; &nbsp; &nbsp;光</span><span style=""font-size:14px;line-height:2;"">线性角化病（<span style=""font-family:Times New Roman;"">AK</span>）是一种已经确定的癌前皮肤损伤并且有发展为鳞状细胞癌（<span style=""font-family:Times New Roman;"">SCC</span>）的可能性。我们研究了参与<span style=""font-family:Times New Roman;"">AK</span>和<span style=""font-family:Times New Roman;"">AK</span>发展为<span style=""font-family:Times New Roman;"">SCC</span>过程中的<span style=""font-family:Times New Roman;"">CDKN2A、CDKN2B</span>和<span style=""font-family:Times New Roman;"">p53</span>基因。对<span style=""font-family:Times New Roman;"">26</span>例<span style=""font-family:Times New Roman;"">AK</span>样本中的<span style=""font-family:Times New Roman;"">CDKN2A</span>基因座的外显子<span style=""font-family:Times New Roman;"">1a、1b，CDKN2B</span>基因座的外显子<span style=""font-family:Times New Roman;"">1</span>以及等位基因失衡进行突变分析。通过实时荧光定量<span style=""font-family:Times New Roman;"">RT-PCR</span>方法检测<span style=""font-family:Times New Roman;"">16</span>例<span style=""font-family:Times New Roman;"">AK</span>患者和<span style=""font-family:Times New Roman;"">12</span>例<span style=""font-family:Times New Roman;"">SCC</span>患者的<span style=""font-family:Times New Roman;"">p14</span></span><sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">ARF</span></sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">、 P15</span><sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4b</span></sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">、p16</span><sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4a</span></sup><span style=""font-size:14px;line-height:2;"">和<span style=""font-family:Times New Roman;"">p53</span>基因表达水平。检测到先前描述的<span style=""font-family:Times New Roman;"">p16</span></span><sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4a</span></sup><span style=""font-size:14px;line-height:2;""><span style=""font-family:Times New Roman;"">（Ala148Thr）</span>的多态性，其等位基因频率为<span style=""font-family:Times New Roman;"">12％</span>。六个样品在<span style=""font-family:Times New Roman;"">CDKN2A</span>基因座的密码子<span style=""font-family:Times New Roman;"">71</span>处发生异常突变，一个样品在密码子<span style=""font-family:Times New Roman;"">65</span>处发生额外突变。两个<span style=""font-family:Times New Roman;"">AK</span>样品在<span style=""font-family:Times New Roman;"">p14</span></span><sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">ARF</span></sup><span style=""font-size:14px;line-height:2;"">基因中密码子<span style=""font-family:Times New Roman;"">184（Val184Glu）</span>的外显子<span style=""font-family:Times New Roman;"">1b</span>处有一个非先前描述的的非紫外线型错义突变。我们检测到有关<span style=""font-family:Times New Roman;"">CDKN2B</span>基因座在密码子<span style=""font-family:Times New Roman;"">50（Ala50Thr）</span>和另</span><span style=""font-size:14px;line-height:2;"">一个密码子<span style=""font-family:Times New Roman;"">24（Arg24Arg）</span>处发生新突变。</span><span style=""font-size:14px;line-height:2;"">微卫星不稳定性（<span style=""font-family:Times New Roman;"">MSI</span>）检测发现在<span style=""font-family:Times New Roman;"">15％</span>的<span style=""font-family:Times New Roman;"">AK</span>患者中至少有一个标记，这表明遗传不稳定性对<span style=""font-family:Times New Roman;"">AK</span>的发展过程有一定的影响。与<span style=""font-family:Times New Roman;"">AK</span>相比，<span style=""font-family:Times New Roman;"">SCC</span>中可以观察到<span style=""font-family:Times New Roman;"">p16</span></span><sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4a</span></sup><span style=""font-size:14px;line-height:2;"">和<span style=""font-family:Times New Roman;"">p53</span>的<span style=""font-family:Times New Roman;"">mRNA</span>水平下调。在日光照射下形态学上外观正常皮肤的<span style=""font-family:Times New Roman;"">TSGs</span>表达水平表明，异常的生长刺激可能也存在于这些组织中。此外，我们提出在<span style=""font-family:Times New Roman;"">AK</span>的发展过程以及<span style=""font-family:Times New Roman;"">AK</span>发展为<span style=""font-family:Times New Roman;"">SCC</span>的过程中，<span style=""font-family:Times New Roman;"">p15</span></span><sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4b</span></sup><span style=""font-size:14px;line-height:2;"">可能起作用，独立于由<span style=""font-family:Times New Roman;"">p16</span></span><sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">INK4a</span></sup><span style=""font-size:14px;line-height:2;"">和<span style=""font-family:Times New Roman;"">p14</span></span><sup><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">ARF</span></sup><span style=""font-size:14px;line-height:2;"">介导的细胞内途径。<span style=""font-family:Times New Roman;"">CDKN2A</span>、<span style=""font-family:Times New Roman;"">CDKN2B</span>和<span style=""font-family:Times New Roman;"">p53</span>基因的表达模式异常可能在<span style=""font-family:Times New Roman;"">AK</span>和<span style=""font-family:Times New Roman;"">AK</span>发展为<span style=""font-family:Times New Roman;"">SCC</span>的过程中起着重要作用（与<span style=""font-family:Times New Roman;"">9p21</span>的突变和<span style=""font-family:Times New Roman;"">LOH</span>无关）。</span> 
</div>
</span>","/uploadfiles/image/20131203/20131203145225_6826w.jpg","/uploadfiles/file/20131203/20131203150043_4014.pdf",,12/03/2013,12/03/2013,"medicool",25,,,0,"65",104,"Genomic instability, mutations and expression analysis of the tumour suppressor genes p14ARF, p15INK4b, p16INK4a and p53 in actinic keratosis",,
511,"甲酯氨基酮戊酸局部光动力疗法治疗光线性角化病和减少器官移植受者光损伤：16名患者的病例系列","10.4103/0378-6323.98075","Ariel Hasson, Cristián Navarrete-Dechent, Claudia Nicklas,","Indian Journal of Dermatology","&nbsp;
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-size:14px;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">Background: </span></b></span></a><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">Organ transplant recipients (OTR) are at high risk of developing cutaneous neoplasms</span></span></span></span></a><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">. Topical photodynamic therapy (PDT) has been used for the treatment of actinic keratosis (AK) in OTR. </span></span></span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;""><strong>背景：</strong>器官移植受者（</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">OTR</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">）是病发为皮肤肿瘤的高危人群。局部光动力疗法（</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">PDT</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">）已被用于治疗</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">OTR</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">中的</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">光线性角化病（</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">AK</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">）。</span></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">Aims: </span></b></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">The objective was to evaluate the efficacy of PDT with </span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">methylaminolevulinate (MAL) </span></span></span></span></a><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">in the treatment of facial AK in OTR. As a secondary objective,</span></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""> </span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">we wanted to evaluate the usefulness of topical PDT in the reduction of photodamage in OTR.</span></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><span style=""line-height:150%;font-family:宋体;""><span style=""line-height:2;font-size:14px;""><strong>目的：</strong>研究目的是评</span><span style=""line-height:2;font-size:14px;"">估甲酯氨基酮戊酸（</span></a></span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">MAL</span></span></span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">）</span></span></span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">光动力疗法治疗</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">OTR</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">面部</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">AK</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">的疗效。次要目的是评估局部</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">PDT</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">疗法</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">减少在</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">OTR</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">中光损伤的有效性。</span></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">Methods: </span></b></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;font-size:14px;"">A prospective, single center, single arm study was made. 16 OTR were included. Topical PDT was applied for 1 or 2 cycles depending on the patient’s characteristics. </span><span style=""line-height:2;font-size:14px;"">An evaluation of AK was made at visits pre-treatment, at 12 weeks and at 24 weeks</span></a><span style=""line-height:2;font-size:14px;"">. Photodamage was measured with multispectral image technique (SkinCare</span></span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">?</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">). </span></span></span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;""><strong>方法：</strong>采用一项前瞻性、单中心、单组研究。</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">16</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">位</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">OTR</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">被纳入本项研究。根据患者的特点，应用局部</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">PDT 1</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">或</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">2</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">个周期。在观察治疗前、</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">12</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">周和</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">24</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">周时对</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">AK</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">进行评估。通过多光谱成像技术（</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">SkinCare</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">?</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">）对光损伤进行测量。</span></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">Results: </span></b></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">A complete response rate of 100% was achieved for AK in all patients</span></span></span></span></a><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;font-size:14px;"">; it persisted without change at 12 and 24 weeks of follow-up. 62.5% of patients improved their photodamage as measured by </span><span style=""line-height:2;font-size:14px;"">SkinCare</span></a></span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">?</span></span></span></span></span><span></span><span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;font-size:14px;"">, b</span><span style=""line-height:2;font-size:14px;"">ut </span></a></span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">this result was not statistically significant</span></span></span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;""> (</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><i><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">P </span></i></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">= 0.12). All patients had high level of satisfaction at the end of the therapy. </span></span></span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;""><strong>结果：</strong>所有患者</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">AK</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">的完全缓解率达到</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">100</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">％，并且在随访的</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">12</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">周和</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">24</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">周中该值持续不变。</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">62.5</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">％患者的光损伤（由</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">SkinCare</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">?</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">测量）得到了改善，但这个结果并没有统计学上的显著性（</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">P = 0.12</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:宋体;font-size:14px;"">）。在治疗结束时，所有患者的满意程度较高。</span></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">Conclusions: </span></b></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">MAL-PDT is an effective therapy for the treatment of AK in OTRs. It can reduce photodamage in this group of patients, but these results were </span></span></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">not statistically significant.</span></span></span><span></span><span></span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-family:宋体;font-size:14px;""><strong>结论：</strong></span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">MAL-PDT</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">是一种用于治疗</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">OTR</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">中</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">AK</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">的有效疗法</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">。它可以减少这类患者的光损伤，但这些结果并没有统计学上的显著性。</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span> 
</p>","/uploadfiles/image/20131204/20131204110957_8965w.jpg","/uploadfiles/file/20131204/20131204105321_1795.pdf",,12/04/2013,12/04/2013,"medicool",22,,,0,"85",104,"Topical photodynamic therapy with methylaminolevulinate for the treatment of actinic keratosis and reduction of photodamage in organ transplant recipients: A case-series of 16 patients","2012",
154,,"10.3109/09546630903287460","Tatlican S ; Eren C ; Atacan D ; Dalgic U ; Canpolat F ; Eskioglu F","Journal of Dermatological Treatment","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; </span><span style=""font-family:Times New Roman;""></span><span style=""font-family:Times New Roman;"">A 58-year-old female patient admitted to our out- patient clinic with complaints of painful swelling, erythema, ulcerations, vesicles, and blisters around her right eye for 2 days . Ten years previ- ously she had been given a diagnosis of subacute cutaneous lupus erythematosus (SCLE) and was using topical steroids and sun-care products intermit- tently. The last time she had used topical steroids was 2 months previously. At the time of admission, she was undergoing topical pimecrolimus cream therapy twice daily for 20 days. She had no history of systemic lupus erythematosus (SLE) or any other autoimmune disease, immunosuppressive drug usage, skin or inter- nal malignancy, immune de?ciency syndromes or trauma, which are the known risk factors for the development of herpes zoster . After the clinical diagnosis of herpes zoster, pimecrolimus treatment was stopped and 125 mg brivudine was started once a day. All herpes zoster lesions were cleared after 15 days. No complications, including post-herpetic neuralgia, were observed in the following 6 months.</span>
</p>",,"/uploadfiles/file/20131012/20131012111355_6404.pdf",,10/12/2013,10/12/2013,"medicool",22,,,0,"85",58,"A case of herpes zoster during pimecrolimus use for the treatment of subacute cutaneous lupus erythematosus","2010",
155,,"10.5507/bp.2011.062","Bostikova V ; Salavec M ; Smetana J ; Chlibek R ; Kosina P ; Prasil P ; Plisek S ; Splino M ; Bostik P","Biomedical Papers Of The Medical Faculty Of The University Palack?, Olomouc, Czechoslovakia","<p>
	<strong><span style=""font-family:Times New Roman;"">Aims：</span></strong><span style=""font-family:Times New Roman;"">We report a case of multi-recurrent herpes zoster in a 53-year-old Caucasian woman treated repeatedly at the Faculty Hospital Hradec Kralove, Czech Republic over the years 2009 C 2011.</span>
</p>
<p>
	<strong><span style=""font-family:Times New Roman;"">Methods：</span></strong><span style=""font-family:Times New Roman;""> Specific PCR methods targeting single nucleotide polymorphisms (SNPs) in open reading frames (ORF) 38, 54 and 62 were utilized to determine vaccine or wild type varicella-zoster (VZV) strains followed by SNPs analysis using two amplicons in ORF 22 and/or ORF 21/ORF 50. Additional genotyping in ORF 1, 6, 9 and 28 was subsequently performed due to the unusual results. </span>
</p>
<p>
	<strong><span style=""font-family:Times New Roman;"">Results： </span></strong><span style=""font-family:Times New Roman;"">Three sets of clinical specimens from one patient (from hospital visits 2, 3 and 4) were analyzed and the presence of an unusual wild-type strain of VZV was discovered. The VZV strain isolated from the lesions bears a combination of markers characteristic both for Mosaic 2 (M2) and European 1 (E1) wild-type VZV strains.</span>
</p>
<p>
	<strong><span style=""font-family:Times New Roman;"">Conclusion：</span></strong><span style=""font-family:Times New Roman;"">This is the first report of atypical wild-type VZV strain circulating currently in Czech Republic.</span>
</p>
<br />",,"/uploadfiles/file/20131012/20131012113146_8007.pdf",,10/12/2013,10/12/2013,"medicool",23,,"Herpes zoster/Varicella-zoster virus/Wild-type strain/Czech Republic",0,"85",58,"An unusual case of multi-recurrent herpes zoster (Hz): a case report","2011",
156,,,"Granite EL ; Nwogu SC","Delaware Medical Journal","<span style=""font-family:Times New Roman;"">&nbsp; Herpes Zoster (shingles) is a human infection with varicella (chickenpox) in childhood, or the varicella-zoster virus in adults. The varicella- zoster virus remains latent in the sensory dorsal root and trigeminal ganglia in most individuals. However, in some patients the virus escapes immune surveillance and reactivates a previous infection.1 Herpes zoster manifests itself as vesicu- lar rash in a unilateral dermatomal distribution associated with pain. The eruption is more com- mon in elderly, diabetic and immunocompromised patients. The lesions of zoster are contagious and cause chickenpox in anyone without a prior his- tory of varicella infection or immunization. </span><br />",,"/uploadfiles/file/20131012/20131012114242_8286.pdf",,10/12/2013,10/12/2013,"medicool",28,,,0,"85",58,"Herpes Zoster in Immunocompromised Patients: A Review and Report of Two Cases","2011",
157,,"10.2340/00015555-1290","Mehra T ; Metzler G ; Bauer J ; K?berle M ; Garbe C","Acta Dermato-Venereologica","&nbsp; <span style=""font-family:Times New Roman;"">Wolfs isotopic response is the occurrence of an unrelated cutaneous disorder in an area of healed skin previously affected by another pathology, the most frequent being granulomatous reactions followed by dysimmune reactions and malignancies. Cutaneous graft versus host disease (GVHD) presenting as an isotopic response is very rare. We describe here an unusual manifestation of the aforementioned disorder and review the literature on this topic.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012115812_4811.pdf",,10/12/2013,10/12/2013,"medicool",31,,,0,"85",58,"Isotopic Response of Graft Versus Host Disease Following Herpes Zoster Infection: Case Report and Review of the Literature","2012",
159,,"10.1111/j.1399-3046.2010.01333.x","Cheng FW ; Chan PK ; Lee V ; Leung WK ; Shing MK ; Li CK ; Leung TF","Pediatric Transplantation","<span style=""font-family:Times New Roman;"">&nbsp; We evaluate the recovery of CMI to various herpes viruses by measuring in vitro LPR to speci?c recall antigens. CMI was evaluated by the in vitro LPR of PBMC to speci?c puri?ed HSV-1, VZV, CMV, EBV, HHV-6, -7, -8, antigens. Results were expressed as SI. SI 3 3 was regarded as positive LPR. Serial measurements were taken prospectively from pretransplant till 12-month post-transplant. Thirty-six patients (M = 19; F = 17) with median age 10.5 yr old were recruited. Most transplants were from MSD with PBSC as the stem cell source. Altogether 50% of subjects started to show positive LPR to HSV-1, CMV, and VZV antigens at two-month post-trans- plant, major upsurges were noted until 6-month post-transplant. Subjects showed positive LPR to EBV, HHV-6, HHV-7, and HHV-8 antigens were all along &lt;50% throughout the study period. The antibody status of donor and recipient for HSV-1, CMV, and VZV were associated with the timing of recovery of CMI. Choice of donor and stem cell source were important determinants of eventual LPR to various herpes viruses at 3-month post-transplant. At 12-month post- transplant, there was no statistical di?erence in any parameters in a?ecting LPR to di?erent herpes viruses.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012121125_0560.pdf",,10/12/2013,10/12/2013,"medicool",30,,"lymphoproliferative response ，herpes viruses ，stem cell transplant",0,"65",58,"Lymphoproliferative response to herpes simplex virus type 1, cytomegalovirus, EpsteinCBarr virus, varicella zoster virus, human herpes virus 6, 7, and 8 antigen stimulation in pediatric allogeneic stem cell transplant recipients","2010",
158,,"10.1093/cid/cir079","Brink AA ; van Gelder M ; Wolffs PF ; Bruggeman CA ; van Loo IH","Clinical Infectious Diseases: An Official Publication Of The Infectious Diseases Society Of America","<strong><span style=""font-family:Times New Roman;"">Background. </span></strong><span style=""font-family:Times New Roman;"">Acyclovir resistance of varicella zoster virus (VZV) may arise in stem cell transplant (SCT) recipients with VZV disease and is usually a result of mutations in VZV thymidine kinase (TK), which is the target protein of acyclovir. Early detection of such mutations is necessary to enable timely therapy adaptation, for example, to foscarnet. We aimed to investigate whether TK mutations arise over time, and what sample types might be the most useful for this method. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Methods.</span></strong><span style=""font-family:Times New Roman;""> Spatially and temporally distinct samples from 3 SCT recipients with VZV disease unresponsive to acyclovir treatment were retrospectively investigated for the presence of TK mutations by polymerase chain reaction and sequence analysis. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Results. </span></strong><span style=""font-family:Times New Roman;"">In all 3 patients, a mutation in the VZV TK coding region was found resulting in an amino acid substitution. TK mutations were not only temporally but also spatially compartmentalized. In particular, plasma samples frequently showed wild-type TK sequences, whereas cerebrospinal ?uid or skin vesicle ?uid acquired on the same day contained mutant sequences. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Conclusions.</span></strong><span style=""font-family:Times New Roman;""> This study shows the importance of careful sampling for molecular diagnostics of acyclovir resistance in VZV disease. All affected body sites should be sampled and plasma samples may not be representative for the viral mutation status.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012120522_0278.pdf",,10/12/2013,10/12/2013,"medicool",23,,,0,"65",58,"Compartmentalization of Acyclovir-Resistant Varicella Zoster Virus: Implications for Sampling in Molecular Diagnostics","2011",
571,"瘤内注射5 - 氨基乙酰丙酸光动力疗法治疗病毒疣的新举措","10.3109/09546634.2010.551534","JUNG EUN KIM, SUN JI KIM, JONG IK HWANG, KYUNGJIN LEE, HYUNJEONG PARK & BAIK KEE CHO","Journal of Dermatological Treatment","<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Background: </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Although photodynamic therapy (PDT) using
intralesional injection (ILI) can theoretically enhance the efficacy of the PDT, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the effect of ILI-PDT
on warts has not been reported in the literature so far. </span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">研究背景：尽管,应用瘤内注射（ILI）光动力疗法（PDT）理论上可以提高PDT的疗效，但是至今尚未有ILI-PDT对尖锐湿疣影响的文献报道。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Methods:</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Eight patients with multiple
viral warts were enrolled in the study. PDT was performed </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">after the
incubation for 1 h, followed
by the</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;ILI of aminolevulinic acid (ALA) into the warts.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;The treatment was repeated at 2C3 week intervals. </span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">研究方法：八名多病毒疣患者纳入本次研究。1小时的潜伏期后进行PDT疗法随后在疣的瘤内注射（ILI）氨基乙酰丙酸（ALA）。每隔2 - 3周重复一次治疗。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Results:&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Fifty percent of patients showed good to cure
response. </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Complete remission was observed in two patients. </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">There
was no apparent correlation between the initial severity of warts and the
likelihood of response. </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">No one reported severe adverse reaction.</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">研究结果：百分之五十的患者表现出良好的治疗反馈。在两名患者中观察到症状完全缓解。疣的初始严重程度与其反应可能性之间没有明显的相关性。没有报告显示有严重的不良反应。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Conclusions: </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">The present study suggests that intralesional
administration of ALA </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">might be a safe and effective treatment option
of thick treatment-resistant warts and </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">can
be performed with a shorter incubation period.</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">研究总结：目前的研究表明，瘤内注射ALA可能是对较厚的难治性尖锐湿疣的一种安全，有效的治疗选择，并且它可以在更短的潜伏期内进行治疗。</span><o:p></o:p>
</p>","/uploadfiles/image/20131205/20131205150454_0686w.jpg","/uploadfiles/file/20131205/20131205150509_6218.pdf",,12/05/2013,12/05/2013,"medicool",21,,"intralesional injection, viral warts, 5-aminolevulinic acid, photodynamic therapy",0,"66",107,"New proposal for the treatment of viral warts with intralesional injection of 5-aminolevulinic acid photodynamic therapy","2012",
703,,"10.1016/j.dsi.2012.02.002","Cheng-Han Lee , Yi-Chun Chen, Yung-Tsu Cho , Chia-Ying Chang , Chia-Yu Chu","Dermatologica Sinica","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:2;""><strong>Abstract</strong></span><span style=""font-family:'Times New Roman';font-size:16px;line-height:2;""><strong></strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong></strong></span><span style=""font-size:14px;line-height:2;""><strong>Background/Objective:</strong> Fixed drug eruption (FDE) is a dermatosis characterized by recurrent patches or&nbsp;</span><span style=""font-size:14px;line-height:2;"">plaques at exactly the same sites with each administration of the causative drug. Vesicles or bullae may&nbsp;</span><span style=""font-size:14px;line-height:2;"">sometimes be found, and generalized bullous fixed drug eruption (GBFDE) may be confused with&nbsp;</span><span style=""font-size:14px;line-height:2;"">Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). This study aimed to investigate the&nbsp;</span><span style=""font-size:14px;line-height:2;"">clinical and pathologic features of FDE in Taiwan.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Methods: </strong>A retrospective analysis evaluated patients with FDE in a referral center in Taiwan covering&nbsp;</span><span style=""font-size:14px;line-height:2;"">a period of 11 years. Clinical data, suspected etiologies, and pathology/patch test results were collected.&nbsp;</span><span style=""font-size:14px;line-height:2;"">We also compared the GBFDE cases with SJS/TEN overlap or TEN cases to find differentiating clues.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Results: </strong>There were 39 FDE patients, including nine GBFDE cases. The most frequent causative drugs were&nbsp;</span><span style=""font-size:14px;line-height:2;"">non-steroidal anti-inflammatory drugs (five cases, 12.8%) and antibiotics (four cases, 10.3%). Extremities&nbsp;</span><span style=""font-size:14px;line-height:2;"">other than the hands (71.8%) were the most frequently affected sites, followed by the trunk (51.3%),&nbsp;</span><span style=""font-size:14px;line-height:2;"">mucosa (38.5%), and hands (33.3%). The average age of FDE patients was 52.2 years (median, 56 years;&nbsp;</span><span style=""font-size:14px;line-height:2;"">range, 4e86 years). Patients with GBFDE were significantly older than non-GBFDE patients (69.1  19.7&nbsp;</span><span style=""font-size:14px;line-height:2;"">vs. 47.2  23.6, p ? 0.0124) and the trunk was more likely to be involved in GBFDE cases (88.9% vs. 40.0%,&nbsp;</span><span style=""font-size:14px;line-height:2;"">p ? 0.0197). GBFDE cases also showed tendency to have more mucosal involvement (66.7% vs. 30.0%,&nbsp;</span><span style=""font-size:14px;line-height:2;"">p ? 0.0631). Although similar to SJS/TEN, GBFDE cases had fewer constitutional symptoms, less mucosal&nbsp;</span><span style=""font-size:14px;line-height:2;"">involvement but had previous episodes. Histopathologically, the presence of more than two aggregated&nbsp;</span><span style=""font-size:14px;line-height:2;"">dyskeratotic keratinocytes (fire flag sign) in the epidermis was more frequently observed in SJS/TEN,&nbsp;</span><span style=""font-size:14px;line-height:2;"">whereas GBFDE had superficial and deep dermal infiltration of eosinophils and melanophages.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Conclusion:</strong> FDE is one of the specialized cutaneous drug reactions and GBFDE should be kept in mind and&nbsp;</span><span style=""font-size:14px;line-height:2;"">differentiated from SJS/TEN.</span> 
</div>
</span>",,"/uploadfiles/file/20131218/20131218095213_3659.pdf",,12/18/2013,12/18/2013,"medicool",7,,"generalized bullous fixed drug eruption, fixed drug eruption, Stevens-Johnson syndrome, toxic epidermal necrolysis",0,"65",112,"Fixed-drug eruption: A retrospective study in a single referral center in northern Taiwan","2012",
160,,"10.1111/j.1365-2133.2011.10462.x","Horie C ; Mizukawa Y ; Yamazaki Y ; Shiohara T","The British Journal Of Dermatology","<strong><span style=""font-family:Times New Roman;"">Background </span></strong><span style=""font-family:Times New Roman;"">It is well known that varicella-zoster virus (VZV) exhibits tropism for the epidermis and follicular epithelium, while little attention has been paid to eccrine gland and duct involvement by VZV. The presence of herpetic syringitis in immunocompromised hosts suggested the possibility of eccrine gland and duct involvement by VZV. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Objectives </span></strong><span style=""font-family:Times New Roman;"">To determine whether VZV antigens could be detected in eccrine gland or duct epithelium of herpes zoster (HZ) lesions obtained at various intervals after the onset of a rash, and whether this expression could also be detected in eccrine units from other in?ammatory disease lesions suggestive of VZV infec- tion. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Methods </span></strong><span style=""font-family:Times New Roman;"">We investigated immunohistochemically in vivo localization of VZV glyco- protein E (gE) antigen in HZ lesions and control in?ammatory disease lesions, using the murine monoclonal antibody directed against the VZV gE. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Results </span></strong><span style=""font-family:Times New Roman;"">VZV gE was differentially detected in the epidermis, follicular and eccrine epithelium, and dermal in?ltrating cells in HZ lesions obtained at various inter- vals after onset. The VZV gE was most persistently detected in eccrine units, regardless of the age of individual HZ lesions, compared with keratinocytes and follicular epithelium. The gE expression was also observed in other in?ammatory disease lesions suggestive of VZV infection. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Conclusions </span></strong><span style=""font-family:Times New Roman;"">Immunohistochemical detection of VZV gE in eccrine epithelium can be a subtle clue to the diagnosis of HZ which displays most unusual manifesta- tions, and VZV-related disorders.</span>",,"/uploadfiles/file/20131012/20131012121615_9498.pdf",,10/12/2013,10/12/2013,"medicool",32,,,0,"65",58,"Varicella-zoster virus antigen expression of eccrine gland and duct epithelium in herpes zoster lesions ","2011",
181,"奈比洛尔对白塞氏病患者内皮功能障碍的疗效：一项前瞻性的单组对照试验","10.5152/akd.2013.034","Hasan Akkaya, ?mer ?ahin1, Murat Borlu2, Abdurrahman O?uzhan1, Mustafa Serkan Karaka?","Aves Yayincilik","<strong><span style=""background:white;color:#333333;font-size:10.5pt;"">Objective:<br />
</span></strong><span class=""apple-converted-space""><b><span style=""font-family:'Times New Roman','serif';background:white;color:#333333;font-size:10.5pt;"">&nbsp;&nbsp; &nbsp;</span></b></span><span style=""font-family:'Times New Roman','serif';background:white;color:#333333;font-size:10.5pt;"">Beh?et's<span class=""apple-converted-space"">&nbsp;</span><span>disease</span><span class=""apple-converted-space"">&nbsp;</span>(BD) is a systemic vasculitis, capable of involving all types of vessels. Endothelial dysfunction (ED) has been previously documented in BD. Previous studies showed that nebivolol might improve endothelial functions in endothelial dysfunction. The aim of our study is to assess the effects of nebivolol on endothelial dysfunction in patients with Beh?et's<span class=""apple-converted-space"">&nbsp;</span><span>disease</span>.</span> 
<p>
	<span style=""background:white;color:#333333;font-size:10.5pt;""><strong>&nbsp;研究</strong><span style=""font-family:宋体;""><strong>目的：</strong><br />
&nbsp;&nbsp; 白塞病（<span>BD</span>）是一种系统性血管炎，能累及所有类型的血管。白塞病中出现内皮功能障碍</span><span style=""font-family:宋体;background:white;"">(ED)</span><span style=""font-family:宋体;"">先前已有记录。之前研究显示奈比洛尔可以改善内皮功能障碍的内皮功能。本研究旨在对奈比洛尔用于治疗白塞病患者的内皮功能障碍的疗效进行评定。<br />
<strong><span style=""background:white;color:#333333;font-size:10.5pt;"">Methods:<br />
</span></strong><span class=""apple-converted-space""><span style=""font-family:'Times New Roman','serif';background:white;color:#333333;font-size:10.5pt;"">&nbsp;&nbsp;&nbsp; </span></span><span style=""font-family:'Times New Roman','serif';background:white;color:#333333;font-size:10.5pt;"">This study was designed as prospective single-arm controlled study. We prospectively studied 35 Beh?et's patients who were diagnosed according to the International Study Group criteria. Patients received 5 mg nebivolol per day for 3 months. Endothelial dysfunction was evaluated by brachial artery flow-mediated dilatation (FMD) method using high-resolution vascular ultrasound device at baseline and after for 3-month therapy. The paired samples t test, Wilcoxon test, Pearson, Spearman correlation analyses were used for statistical analysis.<br />
<strong>&nbsp;研究</strong><span style=""font-family:宋体;""><strong>方法：<br />
</strong>&nbsp;&nbsp;&nbsp;&nbsp; 本研究设计为前瞻性单组对照试验。我们前瞻性地研究了<span>35</span>位白塞病患者（根据国际研究组织标准确诊）。受试患者三个月时间内每日服用奈比洛尔<span>5mg</span>。通过采用高分辨率血管超声设备的肱动脉血流介导性舒张法</span><span style=""font-family:宋体;background:white;"">(FMD)</span><span style=""font-family:宋体;"">对治疗初始以及<span>3</span>个月后的内皮功能障碍进行评估。统计分析包括配对样本<span>t</span>检验、威尔科克森检验、以及皮尔森、斯皮尔曼相关性分析。<span></span></span> 
</p>
<p>
	<strong><span style=""background:white;color:#333333;font-size:10.5pt;"">Results:</span></strong><span class=""apple-converted-space""><b><span style=""font-family:'Times New Roman','serif';background:white;color:#333333;font-size:10.5pt;"">&nbsp;<br />
</span></b></span><span style=""font-family:'Times New Roman','serif';background:white;color:#333333;font-size:10.5pt;"">&nbsp;&nbsp;&nbsp; A significant improvement was observed in FMD after therapy period (4.23±1.19 vs 7.95±2.21%, p&amp;lt;0.001). The correlation analysis showed a negative correlation between post-treatment high-sensitive C-reactive protein and FMD (r=-0.435, p=0.009). No adverse effects were observed in treatment period.<br />
<span style=""font-family:宋体;font-size:10.5pt;""><strong>研究结果：</strong><br />
&nbsp;&nbsp;&nbsp; 通过</span><span style=""font-family:宋体;background:white;font-size:10.5pt;"">FMD</span><span style=""font-family:宋体;background:white;color:#333333;font-size:10.5pt;"">的</span><span style=""font-family:宋体;font-size:10.5pt;"">治疗周期结束后，疗效显著</span><span style=""font-family:宋体;background:white;font-size:10.5pt;"">(4.23±1.19 vs 7.95±2.21%, p&amp;lt;0.001)</span><span style=""font-family:宋体;font-size:10.5pt;"">。</span><span style=""font-family:宋体;font-size:10.5pt;"">相关性分析表明预后高敏<span>C</span>反应蛋白和<span>FMD</span>之间呈负相关</span><span style=""font-family:宋体;background:white;font-size:10.5pt;"">(r=-0.435, p=0.009)</span><span style=""font-family:宋体;font-size:10.5pt;"">。在治疗期间没有观察到药物对患者产生副作用。<br />
<span><strong>Conclusion:</strong><span style=""font-family:'Times New Roman','serif';background:white;color:#333333;""><strong>&nbsp;<br />
</strong></span></span><span style=""font-family:'Times New Roman','serif';background:white;color:#333333;"">&nbsp;&nbsp;&nbsp; Nebivolol improved endothelial dysfunction in Beh?et's patients. However, further comprehensive studies are needed to determine the long-term effects of nebivolol.<br />
<span style=""font-family:宋体;""><strong>结论</strong>：<br />
&nbsp;&nbsp;&nbsp;&nbsp;奈比洛尔改善了白塞病患者的内皮功能障碍状况。然而，还需要进一步综合性研究来确定奈比洛尔的长期疗效。<span></span></span> 
</p>
<p>
	<br />
</span><b><span style=""font-size:16pt;""></span></b>&nbsp;
</p>
<p>
	<br />
</span><br />
</span><br />
</span><br />
</span>&nbsp;
</p>
<p>
	<p>
		</span>&nbsp;
	</p>
	<p>
		<br />
	</p>
	<p>
		<span style=""font-family:'Times New Roman','serif';background:white;color:#333333;font-size:10.5pt;"">.</span><span style=""font-family:'Calibri','sans-serif';font-size:10.5pt;""><span style=""font-family:宋体;background:white;color:black;font-size:9pt;""></span></span> 
	</p>","/uploadfiles/image/20131012/20131012141506_2387w.png","/uploadfiles/file/20131012/20131012141524_3971.pdf",,10/12/2013,11/21/2013,"medicool",15,,,0,"66",29,"Effect of nebivolol on endothelial dysfunction in patients with Beh?et's disease; a prospective single-arm controlled study","2013",
729,"硬皮病患者血清和皮肤成纤维细胞中microRNA-92a表达增高","doi:10.1093/rheumatology/kes120","Takaomi Sing, Masatoshi Jinnin, Keitaro Yamane, Norihito Honda, Kastunari Makino, Ikko Kajihara, Takamitsu Makino, Keisuke Sakai, Shinichi Masuguchi, Satoshi Fukushima, and Hironobu Ihn","Advance Access publication","<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-family:'Times New Roman';font-size:16px;line-height:1.5;"">Abstract</span><o:p></o:p></b> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Objectives</span></b><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">microRNAs (miRNAs)
play a part in various cellular activities. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">However, the role of
miRNA </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">in SSc is not
fully understood. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">This study investigated the expression and role
of miR-92a in SSc patients and evaluated the possibility that miR-92a is
involved in the pathogenesis of this disease.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">摘要：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">研究目的：microRNA（miRNAs）在多种细胞活动中发挥作用。然而，在硬皮病中，miRNA的作用尚不完全清楚。本研究探讨了硬皮病患者中miR-92a的表现和作用，评估miR-92a参与该疾病发病机制的可能性。</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Methods.</span></b> <span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Serum samples were obtained from 61 SSc
patients.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">mRNAs were purified from
serum and </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">evels of miR-92a and
miR-135 were measured with quantitative real-time PCR. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">miR-92a
expression in dermal fibroblasts was also determined by quantitative real-time
PCR. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Immunoblotting </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">was
performed to detect MMP-1 protein.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:1.5;"">研究方法：我们从61位硬皮病患者中获得血清样本。从血清中分离纯化mRNA，实时定量PCR检测mRNA及 </span><span lang=""EN-US"" style=""font-size:14px;line-height:1.5;"">miR-135</span><span style=""font-size:14px;line-height:1.5;"">的表达。同时，采用实时定量PCR检测皮肤成纤维细胞中miR-92a的表达。免疫印迹法检测MMP-1蛋白的表达。&nbsp;</span><span style=""line-height:1.5;"">&nbsp; &nbsp;</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Results.</span></b> <span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The
median serum levels of miR-92a, not miR-135, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">were
significantly higher in SSc patients than normal subjects.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The
constitutive up-regulated miR-92a expression was also found in </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cultured dermal fibroblasts from SSc
skin, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">which was decreased by the transfection with siRNA of TGF-b. Furthermore, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the forced overexpression of
miR-92a in normal dermal fibroblasts using miR-92a mimic resulted in the
down-regulation of MMP-1 expression.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:1.5;"">研究结果：血清中的miR-92a，而非miR-135，在硬皮病患者中的表达显著高于正常受试者。从硬皮病患者皮肤组织所获得的皮肤成纤维细胞中发现， </span><span lang=""EN-US"" style=""font-size:14px;line-height:1.5;"">miR-92a</span><span style=""font-size:14px;line-height:1.5;"">的表达也基本上调。TGF-β的siRNA的基因转染后，miR-92a的表达降低。此外，在正常皮肤成纤维细胞模拟miR-92a的表达后，会引起MMP-1的下调。</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Conclusion.</span></b> <span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The increase of miR-92a in SSc may be due to
the stimulation of intrinsic TGF-b activation seen in this disease. There is also a possibility that&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">MMP-1 is the target of miR-92a and
that </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">increased miR-92a expression therefore plays a role in excessive collagen accumulation in SSc via the
down-regulation of MMP-1. </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Clarifying the role
of miRNAs in SSc may result in a better understanding of this disease and the
development of new therapeutic approaches.</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:1.5;"">研究结论：硬皮病中的miR-92a增加可能是由于该疾病中原性TGF-β活刺激引起的。还有一种可能性，miR-92a的作用目标是MMP-1，表达增多的miR-92a通过下调的MMP-1在胶原蛋白过多沉积这一过程中发挥作用。明确miRNA在硬皮病中的作用可能会有助于我们更好的理解该疾病促进新的治疗方法的形成。</span><o:p></o:p>
</p>","/uploadfiles/image/20131219/20131219154121_6160w.jpg","/uploadfiles/file/20131219/20131219154140_1957.pdf",,12/19/2013,12/19/2013,"medicool",5,,"collagen disease, PCR, integrin.",0,"65",114,"microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma","2012",
161,,"10.1111/j.1399-3062.2010.00547.x","Pergam SA ; Forsberg CW ; Boeckh MJ ; Maynard C ; Limaye AP ; Wald A ; Smith NL ; Young BA","Transplant Infectious Disease: An Official Journal Of The Transplantation Society","<strong><span style=""font-family:Times New Roman;"">Background.</span></strong><span style=""font-family:Times New Roman;""> Immunosuppressed patients are at increased risk for herpes zoster (HZ), but incidence in solid organ transplant (SOT) recipients has varied in multiple studies.To assess incidence of HZ, we examined patients who underwent SOTand received follow-up care within the large multicenter US Department of Veteran’s A?airs healthcare system. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Methods.</span></strong><span style=""font-family:Times New Roman;""> Incident cases of HZ were determined using ICD-9 coding from administrative databases. A multivariable Cox proportional hazards model, adjusted fora prioririsk factors, was used to assess demographic factors associated with development of HZ. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Results. </span></strong><span style=""font-family:Times New Roman;"">Among the 1077 eligible SOT recipients, the cohort-speci?c incidence rate of HZ was 22.2 per 1000 patient-years (95% con?dence interval[CI],18.1^27.4).AfricanAmericans(37.6per1000[95%CI,25.0^ 56.6])andhearttransplantsrecipients(40.0per1000[95%CI,23.2^68.9]) had the highest incidence of HZ. Patients transplanted between 2005 and2007hadthelowestincidence(15.3per1000[95%CI,8.2^28.3]).Ina multivariable model, African Americans (hazard ratio [HR] 1.88; 95% CI: 1.12, 3.17) and older transplant recipients (HR 1.13; 95% CI: 1.01,1.27 [per 5-year increment]) had increased relative hazards of HZ. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Conclusions.</span></strong><span style=""font-family:Times New Roman;"">These data demonstrate that HZ is a common infectious complication following SOT. Future studies focused on HZ prevention are needed in this high-risk population.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012121949_7637.pdf",,10/12/2013,10/12/2013,"medicool",21,,"herpes zoster; infection; liver transplantation; kidney transplantation; African American",0,"66",58,"Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients","2011",
736,,"10.1002/art.34573","Min Wang,  Hehuang Xie,  Sheela Shrestha","ARTHRITIS & RHEUMATISM","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Objective.</strong> To determine the effect of methylation&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">alteration in inflamed muscles from children with juve</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">nile dermatomyositis (DM) and other idiopathic inflam</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">matory myopathies (IIMs).</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Methods. </strong>Magnetic resonance imagingCdirected&nbsp;</span><span style=""line-height:1.5;"">diagnostic muscle biopsies yielded samples from 20&nbsp;</span><span style=""line-height:1.5;"">children with juvenile DM, which were used for genome</span><span style=""line-height:1.5;"">wide DNA methylation profiling, as were muscle biopsy</span><span style=""line-height:1.5;"">samples from 4 healthy controls. Bisulfite treatment&nbsp;</span><span style=""line-height:1.5;"">followed by pyrosequencing confirmed methylation sta</span><span style=""line-height:1.5;"">tus in juvenile DM and other IIMs. Immunohistochem</span><span style=""line-height:1.5;"">istry defined localization and expression levels of WT1.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Results.</strong> Comparison of genome-wide DNA meth</span><span style=""line-height:1.5;"">ylation profiling between juvenile DM muscle and nor</span><span style=""line-height:1.5;"">mal control muscle revealed 27 genes with a significant&nbsp;</span><span style=""line-height:1.5;"">methylation difference between the groups. These genes&nbsp;</span><span style=""line-height:1.5;"">were enriched with transcription factors and/or cell&nbsp;</span><span style=""line-height:1.5;"">cycle regulators and were unrelated to duration of&nbsp;</span><span style=""line-height:1.5;"">untreated disease. Six homeobox genes were among&nbsp;</span><span style=""line-height:1.5;"">them; ALX4, HOXC11, HOXD3, and HOXD4 were&nbsp;</span><span style=""line-height:1.5;"">hypomethylated, while EMX2 and HOXB1 were hyper</span><span style=""line-height:1.5;"">methylated. WT1 was significantly hypomethylated in </span><span style=""line-height:1.5;"">juvenile DM (  C0.41, P &lt; 0.001). Bisulfite pyrose</span><span style=""line-height:1.5;"">quencing verification in samples from 56 patients with&nbsp;</span><span style=""line-height:1.5;"">juvenile DM confirmed the methylation alterations of&nbsp;</span><span style=""line-height:1.5;"">these genes. Similar methylation alterations were ob</span><span style=""line-height:1.5;"">served in juvenile polymyositis (n  5) and other IIMs</span><span style=""line-height:1.5;"">(n  9). Concordant with the other findings, WT1&nbsp;</span><span style=""line-height:1.5;"">protein was increased in juvenile DM muscle, with&nbsp;</span><span style=""line-height:1.5;"">average positive staining of 11.6%, but was undetectable&nbsp;</span><span style=""line-height:1.5;"">in normal muscle (P &lt; 0.001).</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Conclusion.</strong> These results suggest that affected&nbsp;</span><span style=""line-height:1.5;"">muscles of children with juvenile DM and IIMs have the&nbsp;</span><span style=""line-height:1.5;"">capacity to be repaired, and that homeobox and WT1&nbsp;</span><span style=""line-height:1.5;"">genes are epigenetically marked to facilitate this repair&nbsp;</span><span style=""line-height:1.5;"">process, potentially suggesting new avenues of therapeu</span><span style=""line-height:1.5;"">tic intervention.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span>
</div>
</span>",,"/uploadfiles/file/20131219/20131219163908_3165.pdf",,12/19/2013,12/19/2013,"medicool",2,,"Inflamed Muscle Biopsy Samples | Juvenile Dermatomyositis |Self-Renewal",0,"65",115,"Methylation Alterations of WT1 and Homeobox Genes in Inflamed Muscle Biopsy Samples From Patients With Untreated Juvenile Dermatomyositis Suggest Self-Renewal Capacity","2012",
739,,"10.1136/ard.2010.137968","Thomas   Schwartz,  Helga   Sanner,    Trygve   Husebye",,"<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Objective </strong>&nbsp; &nbsp;To compare cardiac function in patients&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">with juvenile dermatomyositis (JDM) with matched&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">controls, and examine associations between pathologic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">electrocardiography (ECG), echocardiographic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">abnormalities and disease variables in patients with JDM</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Methods </strong>&nbsp; &nbsp;A total of 59 patients with JDM, examined a&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">median 16.8 years (range 2C38 years) after disease onse&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">were compared with 59 age-matched and sex-matched&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">controls. Echocardiography, including early diastolic&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">transmitral ? ow/early diastolic tissue velocity (E/E’) as a&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">marker for diastolic dysfunction, and 12-channel ECG we&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">performed and analysed blinded to patient information.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Disease activity and damage were assessed by clinical&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">examination at follow-up and chart review. &nbsp;</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Results </strong>&nbsp; &nbsp;E/E’ was elevated (&gt;9.5) in 13 (22%) patients&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">versus 0 controls (p&lt;0.001). In all, 10 patients presente&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with pathological ECG compared to 4 controls (p=0.054&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Previous or current hypertension was found in 12 patien&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">versus 0 controls (p&lt;0.001). Among the patients,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">pathological ECG was found in 6/13 patients with versus&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">4/44 without elevated E/E’ (p=0.002); and systolic bloo&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">pressure was correspondingly 132±24 mm Hg versus </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">112±18 mm Hg in the groups (p=0.012). E/E’ correlate&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">with cumulative organ damage assessed at follow-up &nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(r</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><sub>sp</sub>&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">0.41, p=0.001) and disease activity at 1 year&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">(r</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><sub>sp&nbsp;</sub></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">0.56, p&lt;0.001), which also predicted pathological </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">E/E’ after controlling for age and gender. During disease&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">course, 12% of patients with JDM developed pericarditi</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Conclusion</strong> &nbsp; &nbsp;Only patients with JDM and no controls&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">had subclinical left ventricular diastolic dysfunction; the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patients with elevated E/E’ also had high prevalence of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">pathological ECG and hypertension. High disease activity&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">1-year post diagnosis predicted high E/E’ at follow-up.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The ? ndings suggest that subclinical heart disease is&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">related to the systemic nature of JDM.&nbsp;</span>
</div>",,"/uploadfiles/file/20131219/20131219165406_7221.pdf",,12/19/2013,12/19/2013,"medicool",2,,"a case-control study  | Cardiac dysfunction | JDM",0,"66",115,"Cardiac dysfunction in juvenile dermatomyositis:  a case-control study ","2011",
162,,"10.1186/1471-2407-12-503","Liu YC ; Yang YH ; Hsiao HH ; Yang WC ; Liu TC ; Chang CS ; Yang MY ; Lin PM ; Hsu JF ; Chang PY ; Lin SF","BMC Cancer","<strong><span style=""font-family:Times New Roman;"">Background: </span></strong><span style=""font-family:Times New Roman;"">Infectious agents have been shown to contribute to the development of lymphoid malignancies. The different distribution of lymphoid malignancies in Asian and Western populations suggests possibly different etiologies in Asian populations. Herpes zoster infection, commonly seen in immunocompromised persons, has been reported to be associated with lymphoid malignancies in retrospective caseCcontrol studies from Western populations, but the results are controversial and large-scale prospective studies from Asian populations are lacking. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Methods: </span></strong><span style=""font-family:Times New Roman;"">A nationwide population-based matched-controlled prospective study on Taiwanese patients was performed using the National Health Insurance Research Database from 1996 to 2007. Herpes zoster and malignancies were defined by compatible ICD-9-CM (International Classification of Disease, 9th Revision, Clinical Modification) codes. Patients who had been diagnosed with any malignancies before herpes zoster, with known viral infections including human immunodeficiency virus, and duration from herpes zoster to diagnosis of malignancies less than 6 months were excluded. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Results: </span></strong><span style=""font-family:Times New Roman;"">Of 42,498 patients with herpes zoster prior to the diagnosis of any malignancies, the cumulative incidence for lymphoid malignancies was 0.11% (n = 48), compared with 0.06% (n = 106) in 169,983 age- and gender-matched controls (univariate hazard ratio (HR): 1.82, 95%CI: 1.29-2.55). The most common lymphoid malignancy was non-Hodgkin’s lymphoma (60.4%, n = 29), followed by multiple myeloma (27.1%, n = 13). Risk for developing lymphoid malignancies is significantly higher in herpes zoster patients (log rank P = 0.005). After adjusting for presence of any comorbidities in Charlson comorbidity index, time-dependent covariate for herpes group, and income category using Cox proportional hazard regressions, herpes zoster patients had an increased risk of developing lymphoid malignancies (adjusted HR: 1.68, 95%CI: 1.35-2.42, P = 0.0026), but did not have an increased risk of developing non-lymphoid malignancies (adjusted HR: 1.00, 95%CI: 0.91-1.05, P = 0.872). </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Conclusion: </span></strong><span style=""font-family:Times New Roman;"">Preceding herpes zoster infection is an independent risk marker for subsequent lymphoid malignancies in Taiwanese subjects. Further studies are warranted for pathogenesis exploration and preventive strategies in Asian populations.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012122451_4215.pdf",,10/12/2013,10/12/2013,"medicool",22,,"Herpes zoster, Lymphoma, Leukemia, Epidemiology, Taiwan",0,"66",58,"Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies - A nationwide population-based matched-control study in Taiwan","2012",
163,,"10.1371/journal.pmed.1001420","Langan SM ; Smeeth L ; Margolis DJ ; Thomas SL","Plos Medicine","<span style=""font-family:Times New Roman;""><strong>Background:</strong></span><br />
<span style=""font-family:Times New Roman;"">Herpes zoster is common and has serious consequences, notably post-herpetic neuralgia (PHN). Vaccine efficacy against incident zoster and PHN has been demonstrated in clinical trials, but effectiveness has not been studied in unselected general populations unrestricted by region, full health insurance coverage, or immune status. Our objective was to assess zoster vaccine effectiveness (VE) against incident zoster and PHN in a general population-based setting.</span><br />
<span style=""font-family:Times New Roman;""><strong>Methods and Findings :</strong></span><br />
<span style=""font-family:Times New Roman;"">A cohort study of 766,330 fully eligible individuals aged $65 years was undertaken in a 5% random sample of Medicare who received and did not receive zoster vaccination between 1st January 2007 and 31st December 2009. Incidence rates and hazard ratios for zoster and PHN were determined in vaccinated and unvaccinated individuals. Analyses were adjusted for age, gender, race, low income, immunosuppression, and important comorbidities associated with zoster, and then stratified by immunosuppression status. Adjusted hazard ratios were estimated using time-updated Cox proportional hazards models. Vaccine uptake was low (3.9%) particularly among black people (0.3%) and those with evidence of low income (0.6%). 13,112 US Medicare beneficiaries developed incident zoster; the overall zoster incidence rate was 10.0 (9.8C10.2) per 1,000 person-years in the unvaccinated group and 5.4 (95% CI 4.6C6.4) per 1,000 person-years in vaccinees, giving an adjusted VE against incident zoster of 0.48 (95% CI 0.39C0.56). In immunosuppressed individuals, VE against zoster was 0.37 (95% CI 0.06C0.58). VE against PHN was 0.59 (95% CI 0.21C0.79).</span><br />
<span style=""font-family:Times New Roman;""><strong>Conclusions:</strong></span><br />
<span style=""font-family:Times New Roman;"">Vaccine uptake was low with variation in specific patient groups. In a general population cohort of older individuals, zoster vaccination was associated with reduction in incident zoster, including among those with immunosuppression. Importantly, this study demonstrates that zoster vaccination is associated with a reduction in PHN.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012122716_2989.pdf",,10/12/2013,10/12/2013,"medicool",22,,,0,"66",58,"Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study","2013",
164,,"10.1111/j.1399-3062.2010.00541.x","Oshima K ; Takahashi T ; Mori T ; Matsuyama T ; Usuki K ; Asano-Mori Y ; Nakahara F ; Okamoto S ; Kurokawa M ; Kanda Y","Transplant Infectious Disease: An Official Journal Of The Transplantation Society","<span style=""font-family:Times New Roman;"">&nbsp; Varicella zoster virus (VZV) disease is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). We carried out a trial of 1-year low-dose valacyclovir (VCV) prophylaxis againstVZVdisease to evaluate its e?cacy and safety. Patients received oral acyclovir (ACV) 1000 mg/day until day 35 after HSCT. OralVCV 500 mg/day, 3 times a week, was started on day 36 and continued until1year after HSCT.The development of VZVdisease was monitoreduntil 2 years after HSCT. Atotal of 40 patients with a median age of 43 years were enrolled.VCVwas well tolerated in all but 1 patient who discontinued it on day 224 because of thrombocytopenia of unknown cause. Seven patients developedVZVdisease at a median of 479 days (range 145^651) after HSCT, with a cumulative incidence of 18.5%.Two patients developed breakthrough disease duringVCV prophylaxis.The other 5 patients developedVZVdisease after the discontinuation of VCV, and 3 of these had developed extensive chronic graft-versus-host disease.V|sceral involvement and serious complicationswere completelyeliminated. Allpatients respondedtothe therapeutic dose of VCVorACV. One-year low-doseVCVcan be safely and e?ectively administered for the prevention of VZVdisease after allogeneic HSCT.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012123345_7692.pdf",,10/12/2013,10/12/2013,"medicool",28,,"varicella zoster virus; hematopoietic stem cell transplantation; acyclovir; valacyclovir; prophylaxis",0,"66",58,"One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of theJapan Hematology and Oncology Clinical Study Group","2010",
176,,"10.1111/j.1365-4632.2011.05089.x","Peng Wang, MD, Yan Cheng, MM, Hanjun Yang, MD, and Yuping Ran, MD, PhD","International Journal of Dermatology","<strong><span style=""font-family:Times New Roman;"">Background </span></strong><span style=""font-family:Times New Roman;"">Blue nevi are a group of congenital and acquired dermal melanocytoses characterized by a blue-gray appearance on the skin. The common blue nevus and cellular blue nevus are the most common subtypes. Patch-type blue nevus is rather rare. </span><br />
<strong><span style=""font-family:Times New Roman;"">Observations </span></strong><span style=""font-family:Times New Roman;"">We describe a 77-year-old Chinese male with a 6 ・ 8-cm non-palpable blue patch overlaid by a depigmented patch on the back of the left scalp. Histological examina- tion of the blue-gray patch showed numerous spindled and elongated bipolar dendritic melanocytes in the upper reticular dermis and an absence of epidermal melanocytes. Immunohistochemically, these dendritic melanocytes were positive for S-100 and HMB-45. A diagnosis of a patch-type blue nevus with overlying vitiligo was made after the biopsy. </span><br />
<strong><span style=""font-family:Times New Roman;"">Conclusions </span></strong><span style=""font-family:Times New Roman;"">The patient presents an unusual manifestation of patch-type blue nevi with overlying vitiligo. To the best of our knowledge, these features have not been previously described.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012140718_9399.pdf",,10/12/2013,10/12/2013,"medicool",29,,,0,"85",28,"Acquired patch-type blue nevus with overlying vitiligo: a case report","2012",
165,,"10.1503/cmaj.101137","Yang YW ; Chen YH ; Wang KH ; Wang CY ; Lin HW","CMAJ: Canadian Medical Association Journal","<strong><span style=""font-family:Times New Roman;"">Background: </span></strong><span style=""font-family:Times New Roman;"">Systemic inflammation and dys- regulated immune function in chronic obstructive pulmonary disease (COPD) is hypothesized to predispose patients to devel- opment of herpes zoster. However, the risk of herpes zoster among patients with COPD is undocumented. We therefore aimed to inves- tigate the risk of herpes zoster among patients with COPD.</span><br />
<strong><span style=""font-family:Times New Roman;"">Methods:</span></strong><span style=""font-family:Times New Roman;""> We conducted a cohort study using data from the Taiwan Longitudinal Health Insurance Database. We performed Cox regressions to compare the hazard ratio (HR) of herpes zoster in the COPD cohort and in an age- and sex-matched comparison cohort. We divided the patients with COPD into three groups according to use of steroid medications and performed a further analy- sis to examine the risk of herpes zoster.</span><br />
<strong><span style=""font-family:Times New Roman;"">Results: </span></strong><span style=""font-family:Times New Roman;"">The study included 8486 patients with COPD and 33 944 matched control patients. After adjustment for potential confounding factors, patients with COPD were more likely to have incidents of herpes zoster (adjusted HR 1.68, 95% confidence interval [CI] 1.45C1.95). When compared with the comparison cohort, the adjusted HR of herpes zoster was 1.67 (95% CI 1.43C1.96) for patients with COPD not taking steroid medications. The adjusted HR of herpes zoster was slightly greater for patients with COPD using inhaled corticosteroids only (adjusted HR 2.09, 95% CI 1.38C3.16) and was greatest for patients with COPD using oral steroids (adjusted HR 3.00, 95% CI 2.40C3.75).</span><br />
<strong><span style=""font-family:Times New Roman;"">Interpretation: </span></strong><span style=""font-family:Times New Roman;"">Patients with COPD were at increased risk of herpes zoster relative to the general population. The relative risk of herpes zoster was greatest for patients with COPD using oral steroids.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012123636_5739.pdf",,10/12/2013,10/12/2013,"medicool",38,,,0,"66",58,"Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study","2011",
166,,"10.2340/00015555-1284","Ruocco V ; Sangiuliano S ; Brunetti G ; Ruocco E","Acta Dermato-Venereologica","<span style=""font-family:Times New Roman;"">&nbsp; Neuroepidermal tropism of varicella-zoster virus ac- counts for cutaneous and nerve lesions following herpes zoster. Skin lesions heal in a few weeks and may or may not leave visible scars. Nerve lesions involve peripheral sensory fibres, sometimes causing permanent damage that results in partial denervation of the affected derma- tome. The effects of the nerve injury involve the sensi- bility function, thus causing neuralgia, itch, allodynia, hypo- or anaesthesia, as well as the immune function that is related to neuropeptide release, thus altering immune control in the affected dermatome. The neuro-immune destabilization in the zoster-infected site paves the way for the onset of many and various immunity-related dis- orders along the affected dermatome.</span>",,"/uploadfiles/file/20131012/20131012123928_9230.pdf",,10/12/2013,10/12/2013,"medicool",23,,"herpes zoster, immunocompromised district, post-herpetic itch, post-herpetic neuralgia. Wolf's post-herpetic isotopic response.",0,"67",58,"Beyond Zoster: Sensory and Immune Changes in Zoster-affected Dermatomes: A Review","2012",
167,,"10.1111/j.1365-2141.2012.09233.x","Minarik J ; Pika T ; Bacovsky J ; Langova K ; Scudla V","British Journal Of Haematology","<span style=""font-family:Times New Roman;"">&nbsp; The occurence of herpes zoster is mostly managable, although it might delay or interrupt proper chemotherapy or even become dose-limiting. On the other hand, herpetic infections are easily preventable. Long term administration of acyclovir to all patients receiving bortezomib in clinical trials lead to eradication of this unfavourable condition. Some recent papers have reported successful prevention, even with lower doses of acyclovir </span><span style=""font-family:Times New Roman;"">. To date, however, there has not been a consensus on an appropriate prophylactic dose of acyclovir. </span><br />",,"/uploadfiles/file/20131012/20131012124324_5146.pdf",,10/12/2013,10/12/2013,"medicool",36,,,0,"67",58,"Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients","2012",
168,,"10.2165/10489140-000000000-00000","Sanford M ; Keating GM","Drugs & Aging","<span style=""font-family:Times New Roman;"">&nbsp; Individuals who have been infected with varicella zoster virus (VZV) are at risk for developing herpes zoster and this risk appears to be related to a decline in VZV-specific cell-mediated immunity (CMI). Zostavax (zoster vaccine) is a one- dose, high-potency, live, attenuated VZV vaccine that boosts VZV-specific CMI and this is its presumed mechanism of action. Zoster vaccine is registered in the EU for use in adults aged ?50 years for the prevention of herpes zoster and herpes zoster-related postherpetic neuralgia. </span><br />
<span style=""font-family:Times New Roman;""></span><span style=""font-family:Times New Roman;"">&nbsp; </span><span style=""font-family:Times New Roman;"">In the Shingles Prevention Study, a placebo-controlled trial in adults aged ?60 years (n=38546), zoster vaccine led to a sustained boost of VZV-specific CMI. Over a mean herpes zoster surveillance period of 3.1 years, zoster vaccine reduced the herpes zoster-related burden of illness by 61%, reduced the incidence of herpes zoster by 51% and reduced the incidence of postherpetic neuralgia by 67%. Zoster vaccine recipients who developed herpes zoster had a shorter illness duration and severity than placebo recipients who developed herpes zoster. Zoster vaccine had continuing efficacy in a Shingles Prevention Study sub- population followed for 7 years post-vaccination. Zoster vaccine was generally well tolerated in older adults. While cost-effectiveness estimates in pharmaco- economic analyses varied widely according to vaccine and herpes zoster para- meter cost/benefit estimates, an analysis from a UK perspective found a zoster vaccine immunization programme in adults aged 65 years to be cost effective. In older adults, the zoster vaccine has the potential to significantly reduce the herpes zoster burden of illness by decreasing the incidence of herpes zoster or reducing its severity.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012124708_2502.pdf",,10/12/2013,10/12/2013,"medicool",31,,,0,"67",58,"Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.","2010",
169,,"10.1111/j.1468-3083.2006.02022.x","Xu SX ; Wang HL ; Fan X ; Sun LD ; Yang S ; Wang PG ; Xiao FL ; Gao M ; Cui Y ; Ren YQ ; Du WH ; Quan C ; Zhang XJ","Journal Of The European Academy Of Dermatology And Venereology: JEADV","<strong><span style=""font-family:Times New Roman;"">Background </span></strong><br />
<span style=""font-family:Times New Roman;"">Acne is a chronic in?ammatory disease of the pilosebaceous follicles. Recent studies bring us increasing evidences that hereditary factors play an important but indirect role in acne. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Objective </span></strong><br />
<span style=""font-family:Times New Roman;""></span><span style=""font-family:Times New Roman;"">To investigate the possible role of genetic factors in the pathogenesis of acne vulgaris in Chinese Han ethnic group. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Parients and methods </span></strong><br />
<span style=""font-family:Times New Roman;""></span><span style=""font-family:Times New Roman;"">Volunteers of 975 acne cases and 580 controls were included, contributing 3009 and 1825 ?rst-degree relatives, respectively. One thousand and eighty-?ve ?rst-degree relatives of acne cases were affected with facial acne. This compared with 223 ?rst-degree relatives of non-acne controls. The odds ratio was used to estimate the relative risk for acne vulgaris associated with having an affected ?rst-degree relative. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Results </span></strong><br />
<span style=""font-family:Times New Roman;""></span><span style=""font-family:Times New Roman;"">The risk of acne vulgaris occurring in a relative of a patient with acne vulgaris was signi?cantly greater than for the relative of an unaffected individual (odds ratio 4.05, 95% con?dence interval (CI): 3.45C4.76,&nbsp; P &lt;&nbsp; 0.001). Conclusion Our study suggests that familial factors are important in determining individual susceptibility to acne vulgaris.</span>",,"/uploadfiles/file/20131012/20131012133933_2781.pdf",,10/12/2013,10/12/2013,"medicool",38,,"acne vulgaris, case-control study, familial acne",0,"85",54,"The familial risk of acne vulgaris in Chinese Hans C a case-control study","2007",
170,"与白塞病有关的Budd-Chiari综合征：文献回顾",,"Daniela Carvalho, Fernando Oikawa, Nilce Mitiko Matsuda, Alice Tatsuko Yamada","Sao Paulo Med J.","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>The risk that patients with Beh?et’s disease
may develop various <a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span>thrombotic complications </span>has been
previously described. Although <a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span>vascular complications</span> from <a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span>Budd-Chiari</span> syndrome associated with Beh?et’s disease have been described, the pathogenic
mechanisms are still unknown. Severe vascular complications present in
Budd-Chiari syndrome associated with Beh?et’s disease are very common among<a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span> young male adults</span>. The objective of this study was to review the
literature and present the<a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span> association of Budd-Chiari syndrome with
Beh?et’s disease.<br />
</span></span><span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp; 白塞病患者可能发展为各种血栓性并发症的风险先前已描述过。尽管有过对与白塞病有关的</span><span style=""font-family:宋体;"">Budd-Chiari</span><span style=""font-family:宋体;"">综合症的血管并发症的描述，</span><span style=""font-family:宋体;"">但其发病机制仍然未知。它表现为与白塞病有关的</span><span style=""font-family:宋体;"">Budd-Chiari</span><span style=""font-family:宋体;"">综合症的</span><span style=""font-family:宋体;"">严重型</span><span style=""font-family:宋体;"">血管并发症在</span><span style=""font-family:宋体;"">青年男性患者中非常常见。该研究旨在回顾文献以及呈现白塞病与</span><span style=""font-family:宋体;"">Budd-Chiari</span><span style=""font-family:宋体;"">综合症的相关性。<span></span></span><span><span></span></span>
</p>","/uploadfiles/image/20131012/20131012133913_7469w.png","/uploadfiles/file/20131012/20131012134009_3610.pdf",,10/12/2013,10/12/2013,"medicool",31,,"Budd-Chiari syndrome; Beh?et’s syndrome; Liver; Male; Young adult.",0,"67",29,"Budd-Chiari syndrome in association with Beh?et’s disease：review of the literature","2011",
171,,"10.1177/0009922808315444","Wynnis L. Tom, MD, and Sheila Fallón Friedlander, MD","Clinical pediatrics","<span style=""font-family:Times New Roman;"">&nbsp; Acne vulgaris is a common disorder that affects more than 17 million individuals in the United States. Knowledge of the disease is an important part of clini- cal practice, particularly for the pédiatrie practitioner. Contrary to common belief, acne is not a disease lim- ited to adolescents and young adults but can occur at any stage of life. This article is a case-based review of</span><span style=""font-family:Times New Roman;""> acne during cbikihood and adolescence. Workup is based on age and concurrent physical Findings, whereas tber- apy depends on the t\npe of skin lesions along with patient characteristics and preferences.</span><br />",,"/uploadfiles/file/20131012/20131012134144_0844.pdf",,10/12/2013,10/12/2013,"medicool",50,,"acne vulgaris; neonatal; infantile; mid- childhood or prepubertal; adolescent; acne therapy",0,"85",54,"Acne Through the Ages: Case-Based Ohservations Through Childhood and Adolescence","2008",
172,,"10.2340/00015555-1110","Jensen PR ; Zachariae C ; Hansen P ; Skov L","Acta Dermato-Venereologica","<span style=""font-family:Times New Roman;"">&nbsp; Evidence is increasing that severe psoriasis is an inde- pendent cardiovascular risk factor. Results from case- control studies of endothelial dysfunction, a marker of early atherosclerosis, in patients with moderate-to-severe psoriasis have been conflicting and were conducted with operator-dependent and technically demanding ultra- sound measurement of brachial artery flow-mediated va- sodilation. Therefore, we decided to measure endothelial function and other cardiovascular risk factors in patients with mild-to-moderate psoriasis (n=30) and controls (?=30) using a newer and relatively operator-indepen- dent technique. No difference was detected between the groups with regards to endothelial function. However, despite the patients experiencing rather mild psoriasis they did exhibit higher levels of certain cardiovascular risk factors, including waist circumference, resting heart rate, systolic and diastolic blood pressures, and plasma levels of triglycérides, very-low-density lipoprotein cho- lesterol and glycated glucose, compared with controls. This indicates that even mild-to-moderate psoriasis may be regarded as a systemic inflammatory disease, and that an increased risk of cardiovascular morbidity may be present in these mild-to-moderately affected patients in the long-term. </span><br />",,"/uploadfiles/file/20131012/20131012135306_0396.pdf",,10/12/2013,10/12/2013,"medicool",32,,"psoriasis; endothelial function; atherosclerosis; co-morbidity.",0,"85",26,"Normal Endothelial Function in Patients with Mild-to-Moderate Psoriasis: A Case-control Study","2011",
245,"花斑癣：一例对抗治疗病例","doi: 10.1111/j.1365-4632.2012.05689.x","Josiane Helou, MD，Grace Obeid, MD，Ismael Maatouk, MD","The International Society of Dermatology，Roy Moutran, MD，","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pityriasis versicolor (PV) is a common fungal skin infection </span><span style=""font-family:Times New Roman;font-size:14px;"">affecting young adults worldwide, mainly in tropical </span><span style=""font-family:Times New Roman;font-size:14px;"">climates.1,2 Treatment of PV infection is usually easy and </span><span style=""font-family:Times New Roman;font-size:14px;"">effective3 but is becoming increasingly challenging with </span><span style=""font-family:Times New Roman;font-size:14px;"">the emergence of resistant Malassezia species. Here we </span><span style=""font-family:Times New Roman;font-size:14px;"">present a case of PV, which is resistant to many well conducted </span><span style=""font-family:Times New Roman;font-size:14px;"">antifungal therapies.</span> 
</p>","/uploadfiles/image/20131016/20131016153937_4855w.jpg","/uploadfiles/file/20131016/20131016151419_5248.pdf",,10/16/2013,10/16/2013,"medicool",42,,"Pityriasis versicolor；resistance to treatment；Systemic therapies",0,"66",4,"Pityriasis versicolor: a case of resistance to treatment","2013",
248,"糠疹癣:系统回顾的干预措施",,"Stephanie W. Hu, MD; Michael Bigby, MD","Arch Dermatol.","<p align=""justify"">
	<strong><span style=""font-family:Times New Roman;font-size:14px;"">Objective:</span></strong> <br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;"">To determine the efficacy of topical or systemic </span><span style=""font-family:Times New Roman;font-size:14px;"">agents in the treatment and prevention of pityriasis </span><span style=""font-family:Times New Roman;font-size:14px;"">versicolor.</span><br />
<strong><span style=""font-family:Times New Roman;font-size:14px;"">Design:</span></strong><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;""> Systematic review and meta-analysis.</span><br />
<strong><span style=""font-family:Times New Roman;font-size:14px;"">Data Sources: </span></strong><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;"">The Cochrane Skin Group Specialized&nbsp;</span><span style=""font-family:Times New Roman;font-size:14px;"">Register (to June 2008), Cochrane Central Register of </span><span style=""font-family:Times New Roman;font-size:14px;"">Controlled Trials, MEDLINE (1950 to June 2008),</span><span style=""font-family:Times New Roman;font-size:14px;"">EMBASE (1974 to June 2008), LILACS (to March </span><span style=""font-family:Times New Roman;font-size:14px;"">2009), the gray literature, and sources for registered </span><span style=""font-family:Times New Roman;font-size:14px;"">trials to November 2008. Reference lists of all retrieved </span><span style=""font-family:Times New Roman;font-size:14px;"">trials and review articles were checked for additional </span><span style=""font-family:Times New Roman;font-size:14px;"">trials.</span><br />
<strong><span style=""font-family:Times New Roman;font-size:14px;"">Study Selection:</span></strong><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;""> Controlled trials that examined therapies </span><span style=""font-family:Times New Roman;font-size:14px;"">used in children or adults with a clinical or microscopic </span><span style=""font-family:Times New Roman;font-size:14px;"">diagnosis of pityriasis </span><strong><span style=""font-family:Times New Roman;font-size:14px;"">versicolor</span></strong><strong><span style=""font-family:Times New Roman;font-size:14px;"">Data Extraction: </span></strong><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;"">The primary outcome measure </span><span style=""font-family:Times New Roman;font-size:14px;"">included a negative result from mycological evaluation </span><span style=""font-family:Times New Roman;font-size:14px;"">of participants with direct microscopy using potassium </span><span style=""font-family:Times New Roman;font-size:14px;"">hydroxide smear. The secondary outcome measures </span><span style=""font-family:Times New Roman;font-size:14px;"">were findings from Wood’s light examination </span><span style=""font-family:Times New Roman;font-size:14px;"">and a negative clinical evaluation result, with </span><span style=""font-family:Times New Roman;font-size:14px;"">disappearance </span><span style=""font-family:Times New Roman;font-size:14px;"">of visual signs (except pigmentary defects) </span><span style=""font-family:Times New Roman;font-size:14px;"">and symptoms.</span><br />
<strong><span style=""font-family:Times New Roman;font-size:14px;"">Data Synthesis: </span><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span></strong><span style=""font-family:Times New Roman;font-size:14px;"">Results of treatment and prevention </span><span style=""font-family:Times New Roman;font-size:14px;"">of pityriasis versicolor infection in 8327 participants in </span><span style=""font-family:Times New Roman;font-size:14px;"">93 controlled trials were examined. Overall, trials investigating </span><span style=""font-family:Times New Roman;font-size:14px;"">the efficacy of therapeutic and prophylactic treatments </span><span style=""font-family:Times New Roman;font-size:14px;"">for pityriasis versicolor are poorly reported and </span><span style=""font-family:Times New Roman;font-size:14px;"">may be of low quality. Most trials did not adequately report </span><span style=""font-family:Times New Roman;font-size:14px;"">the methods of randomization, concealment of allocation, </span><span style=""font-family:Times New Roman;font-size:14px;"">and blinding, and many did not use intentionto- </span><span style=""font-family:Times New Roman;font-size:14px;"">treat analysis. Most topical treatments used to treat </span><span style=""font-family:Times New Roman;font-size:14px;"">pityriasis versicolor are effective compared with placebo, </span><span style=""font-family:Times New Roman;font-size:14px;"">with numbers needed to treat of 1 to 3. Data suggest </span><span style=""font-family:Times New Roman;font-size:14px;"">that longer durations of treatment and higher concentrations </span><span style=""font-family:Times New Roman;font-size:14px;"">of active agents produce greater cure rates.</span><span style=""font-family:Times New Roman;font-size:14px;""></span><br />
<strong><span style=""font-family:Times New Roman;font-size:14px;""></span></strong><strong><span style=""font-family:Times New Roman;font-size:14px;"">Conclusions:</span></strong> <br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;"">Most topical and systemic treatments used </span><span style=""font-family:Times New Roman;font-size:14px;"">for pityriasis versicolor are effective compared with placebo. </span><span style=""font-family:Times New Roman;font-size:14px;"">Randomized controlled clinical trials are needed </span><span style=""font-family:Times New Roman;font-size:14px;"">to establish relative efficacy of topical and systemic agents </span><span style=""font-family:Times New Roman;font-size:14px;"">used for treatment and prevention of pityriasis versicolor.</span> 
</p>","/uploadfiles/image/20131016/20131016152637_2657w.jpg","/uploadfiles/file/20131016/20131016151617_0711.pdf",,10/16/2013,10/16/2013,"medicool",38,,"systemic treatments；pityriasis versicolor ；meta-analysis",0,"67",4,"Pityriasis Versicolor：A Systematic Review of Interventions","2010",
173,,"10.1111/j.1365-2133.2010.10031.x","C.L. Martyn-Simmons, R.R. Ranawaka, P. Chowienczyk,* M.A. Crook, M.S. Marber, C.H. Smith and J.N.W.N. Barker","British Journal of Dermatology","<span style=""font-family:Times New Roman;""><strong>Background </strong><br />
There is well-documented evidence that patients with moderate and severe psoriasis have a signi?cantly increased risk of cardiovascular disease (CVD). While this risk can, at least in part, be attributed to the high prevalence of traditional risk factors in the population with psoriasis, some epidemiological evidence suggests it may be independent of these. <br />
<strong></strong><strong>Objectives </strong><br />
This prospective, case-controlled study investigates whether psoriasis is a risk factor for CVD using two, validated, sensitive markers of CVD, endothelial dysfunction and high-sensitivity C-reactive protein (hsCRP). Methods Patients were recruited from a tertiary referral psoriasis clinic and exclusion criteria included established CVD and?or conventional risks for CVD. Preclinical CVD was assessed using ?ow-mediated brachial artery dilatation, which measures endothelial dysfunction, and hsCRP, a serological marker of atherosclerosis. <br />
<strong></strong><strong>Results </strong><br />
Sixty-four patients (22%) out of a total of 285 consecutive patients attend- ing the severe psoriasis clinic were entered into the study. One hundred and sixty-one (56%) were excluded following identi?cation of cardiovascular risk; 39 of the 161 (24%) had at least two cardiovascular risk factors. A further 16 (6%) patients were excluded because of established CVD. No statistically signi?cant difference in endothelial dysfunction was observed between patients with psoria- sis (n = 60) and healthy controls (n = 117) (P =0 ?508). The hsCRP level was, however, signi?cantly elevated in the psoriasis group (2?828 mg L)1, SEM 0 ?219; controls 0?728 mg L)1, SEM 0?142; P &lt;0 ?05). <br />
<strong></strong><strong>Conclusion </strong><br />
This large, investigative study is the ?rst to assess endothelial function in patients with psoriasis after exclusion of traditional risk factors for CVD. These data suggest that psoriasis per se is not a risk factor for CVD and that elevated hsCRP is possibly independent of atheroma risk. There was a high prevalence of traditional risk factors in our population with severe psoriasis.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012135550_7758.pdf",,10/12/2013,10/12/2013,"medicool",30,,"cardiovascular diagnostic techniques, cardiovascular disease, metabolic syndrome, psoriasis",0,"85",26,"A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis","2011",
174,"白塞病患者内脂素水平的研究","10.1007/s10753-011-9328-2","Sezen, Okumus, Pehlivan, Dilli, Tarakcio?lu, Onat","Kluwer Academic/Plenum Publishers","<span style=""font-size:10.5pt;font-family:'Times New Roman','serif';background:white;""><span style=""font-size:10.5pt;font-family:'Times New Roman','serif';background:white;"">&nbsp;&nbsp; The aim of our study is to determine the serum visfatin levels of patients with<span class=""apple-converted-space"">&nbsp; </span><span>Behcet's</span><span class=""apple-converted-space"">&nbsp; </span><span>disease</span><span class=""apple-converted-space"">&nbsp;</span>and to investigate the relationship between visfatin, an adipokine released from adipose tissue, levels and activity of<span class=""apple-converted-space"">&nbsp; </span><span>Behcet's</span><span> </span><span>disease</span>. Fifty-eight patients with<span class=""apple-converted-space"">&nbsp;</span><span>Behcet's</span><span class=""apple-converted-space"">&nbsp;</span><span>disease</span><span class=""apple-converted-space"">&nbsp;</span>were enrolled to the study. Nineteen of the patients were inactive, and 39 of them were active. We enrolled 30 healthy subjects as being control group. Visfatin and tumor necrosis factor alpha (TNF-α) levels were measured with ELISA method. Visfatin levels were significantly lower in patients with<span class=""apple-converted-space"">&nbsp;</span><span>Behcet's</span><span class=""apple-converted-space"">&nbsp;</span><span>disease</span><span class=""apple-converted-space"">&nbsp;</span>whose illnesses were active or inactive than the control group (p?&amp;lt;?0.05). There was no significant difference between the active patient and inactive patient group. The reason for the lower levels of serum visfatin in active and inactive patients' group could be due to pro-inflammatory cytokines such as TNF-α and IL-6 which suppress genetic expression of visfatin in patients with<span class=""apple-converted-space"">&nbsp;</span><span>Behcet's</span><span class=""apple-converted-space"">&nbsp;</span><span>disease</span>, or else<br />
<span style=""font-size:10.5pt;font-family:宋体;"">&nbsp;&nbsp;&nbsp;&nbsp; 本研究旨在确定白塞病患者的血清内脂素水平以及研究内脂素（一种由内脏组织释放的脂肪细胞因子）与白塞病的疾病水平及其活动性之间的关系。本研究纳入</span><span style=""font-size:10.5pt;font-family:'Calibri','sans-serif';"">58</span><span style=""font-size:10.5pt;font-family:宋体;"">位白塞病患者。其中</span><span style=""font-size:10.5pt;font-family:'Calibri','sans-serif';"">19</span><span style=""font-size:10.5pt;font-family:宋体;"">名患者没有疾病活动，另外</span><span style=""font-size:10.5pt;font-family:'Calibri','sans-serif';"">39</span><span style=""font-size:10.5pt;font-family:宋体;"">名患者表现有疾病活动。我们纳入</span><span style=""font-size:10.5pt;font-family:'Calibri','sans-serif';"">30</span><span style=""font-size:10.5pt;font-family:宋体;"">位健康人员作为对照组。应用</span><span style=""font-size:10.5pt;font-family:'Calibri','sans-serif';"">ELISA</span><span style=""font-size:10.5pt;font-family:宋体;"">法测量了内脂素以及肿瘤坏死因子</span><span style=""font-size:10.5pt;font-family:'Calibri','sans-serif';"">―</span><span style=""font-size:10.5pt;font-family:宋体;"">α（</span><span style=""font-size:10.5pt;font-family:'Calibri','sans-serif';"">TNF―</span><span style=""font-size:10.5pt;font-family:宋体;"">α）水平。有疾病活动性或没有疾病活动性的白塞病患者的内脂素水平均明显低于对照组，有疾病活动性的患者组和没有疾病活动性的患者组之间没有明显差异。有和无疾病活动的患者组中较低的血清内脂素水平可能是由于促炎性细胞因子（诸如</span><span style=""font-size:9pt;font-family:'Tahoma','sans-serif';background:white;"">TNF-α</span><span style=""font-size:9pt;font-family:宋体;background:white;"">和</span><span style=""font-size:9pt;font-family:'Tahoma','sans-serif';background:white;"">IL-6</span><span style=""font-size:10.5pt;font-family:宋体;"">）抑制白塞病患者内脂素的基因表达，或者是其他原因。</span><br />
</span></span>","/uploadfiles/image/20131012/20131012142902_1349w.png","/uploadfiles/file/20131012/20131012140147_3613.pdf",,10/12/2013,10/12/2013,"medicool",29,,"Behcet’s disease;  visfatin;  TNF-α.",0,"65",29,"Visfatin levels in Behcet's disease","2012",
309,"胼胝、鸡眼和老茧",,"Dishan Singh,George Bentley, Saul G Trevino","BMJ","<span style=""font-family:Times New Roman;font-size:14px;""><strong><br />
<span style=""line-height:1.5;font-size:14px;"">Summary points:</span></strong></span><span style=""line-height:1.5;font-size:14px;"">&nbsp;</span> 
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">* Corns and calluses arise from hyperkeratosis, a normal physiological response to chronic excessive pressure </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">or friction </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">on the skin</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">* They may </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">be </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">caused by excessive irritation from poorly </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">fitting </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">shoes or by abnormal pressure if there is </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">a </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">deformity </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">of </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">the foot</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">* Treatment should therefore not only provide symptomatic relief (such as by regular paring </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">or</span><span style=""font-family:'Times New Roman','serif';""><span style=""line-height:2;font-size:14px;""> using</span><span style=""line-height:2;font-size:14px;""> keratolytic agents</span></a><span style=""line-height:2;font-size:14px;"">) but should </span></span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">also </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">alleviate </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">the </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">underlying </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">mechanical cause</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">* </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">Most </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">lesions can be </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">managed conservatively by </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">use </span><span style=""font-family:'Times New Roman','serif';""><span style=""line-height:2;font-size:14px;"">of </span><span style=""line-height:2;font-size:14px;"">sensible </span></a></span><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-size:14px;""><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">footwear</span></span></span><span style=""font-family:'Times New Roman','serif';""> </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">(properly </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">fitting </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">shoes with</span><span style=""font-family:'Times New Roman','serif';""> </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">low heels, soft upper, and roomy </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">toebox) </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">and</span><span style=""font-family:'Times New Roman','serif';""> </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">orthoses to </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">redistribute mechanical forces</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">* </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">Surgery </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">is </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">rarely </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">indicated and should be </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">specifi</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">cally aimed </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">at </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">correcting </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">the abnormal </span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">mechanical <span style=""font-size:14px;""><span style=""font-size:14px;"">stresses</span></span></span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;""><span style=""font-size:14px;""></span><br />
<strong><br />
<span style=""line-height:2;font-size:14px;"">要点：</span></strong></span><span style=""font-family:'Times New Roman','serif';font-size:14px;""><br />
<span style=""line-height:2;font-size:14px;"">*</span></span><span style=""line-height:2;font-family:宋体;font-size:14px;"">鸡眼和老茧是由于角化过度引起的，它是长期压力过大或皮肤摩擦的正常生理反应</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';font-size:14px;"">*</span><span style=""font-family:宋体;font-size:14px;"">当足部畸形时，</span><span style=""font-family:宋体;font-size:14px;"">他们可能由不舒适的鞋或异常压力的过度刺激引起</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';font-size:14px;"">*</span><span style=""font-family:宋体;font-size:14px;"">治疗不仅是缓解症状（如定期削除或使用角质溶解剂），而且也应该减轻潜在的机械因素</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';font-size:14px;"">*</span><span style=""font-family:宋体;font-size:14px;"">大多数损伤可以通过使用舒服的鞋类（正确舒适的低跟鞋、柔软的鞋面以及宽敞的脚趾区）和矫形器来进行保守治疗</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';font-size:14px;"">*</span><span style=""font-family:宋体;font-size:14px;"">几乎无需进行</span><span style=""font-family:宋体;font-size:14px;"">手术，并且手术应该是专门针对纠正异常的机械压迫的</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<span style=""font-size:14px;""><br />
</span></span>","/uploadfiles/image/20131025/20131025135659_3077w.jpg","/uploadfiles/file/20131022/20131022134524_5516.pdf",,10/22/2013,10/25/2013,"medicool",28,,"Callosities, corns, and calluses",0,"67",90,"Callosities, corns, and calluses","1996",
328,,"10.2340/00015555-0918","Guadagni M ; Nazzari G","Acta Dermato-Venereologica","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span style=""font-family:&quot;"">Perniosis is a cold-induced vasculopathic disease
characterized by tender, painful, pruritic erythematous, livid papular or
nodular acral lesions, with buUous and ulceronecrotic lesions sometimes present
in severe cases. The most frequently affected areas are the hands, feet, fingers,
nose and ears. The occurrence of acute perniosis (AP) in elderly people is unusual.
Correlation with a wide range of extracutaneous diseases has been reported.
This preliminary study indicates that the sudden appearance of perniosis in an
adult must be evaluated carefully, as it may be a predictive sign of an
associated systemic disease.</span><span style=""font-family:&quot;""></span> 
</p>",,"/uploadfiles/file/20131024/20131024171340_1639.pdf",,10/24/2013,10/24/2013,"medicool",36,,,0,"85",88,"Acute perniosis in elderly people: a predictive sign of systemic disease","2010",
330,"次氯酸钠治疗鸡眼1137例分析","1672―0369(2012)08―0938一02","周晓秋","中国民康医学","<br />
<strong><span style=""line-height:2;font-size:14px;"">目的</span></strong><span style=""line-height:2;font-size:14px;"">：观察次氯酸钠治疗鸡眼的疗效。</span><br />
<strong><span style=""line-height:2;font-size:14px;"">方法</span></strong><span style=""line-height:2;font-size:14px;"">：采用次氯酸纳治疗鸡眼<span style=""font-family:Times New Roman;"">1</span><span style=""font-family:Times New Roman;"">137例。上药2次<span style=""font-family:Times New Roman;"">/</span></span></span><span style=""line-height:2;font-size:14px;""><span style=""font-family:Times New Roman;"">d</span>，并随访。</span><br />
<strong><span style=""line-height:2;font-size:14px;"">结果</span></strong><span style=""line-height:2;font-size:14px;"">：<span style=""font-family:Times New Roman;"">3</span>日内治愈<span style=""font-family:Times New Roman;"">887</span>例，好转<span style=""font-family:Times New Roman;"">237</span>例。在一周内彻底治愈<span style=""font-family:Times New Roman;"">1</span></span><span style=""line-height:2;font-size:14px;""><span style=""font-family:Times New Roman;"">124</span>例，好转<span style=""font-family:Times New Roman;"">11</span>例，无效<span style=""font-family:Times New Roman;"">2</span>例。</span><br />
<strong><span style=""line-height:2;font-size:14px;"">结论</span></strong><span style=""line-height:2;font-size:14px;"">：次氯酸钠治疗鸡眼</span><span style=""line-height:2;font-size:14px;"">疗效确切，可供临床选用。</span>",,"/uploadfiles/file/20131025/20131025084858_3140.pdf",,10/25/2013,10/25/2013,"medicool",24,,"次氯酸钠；鸡眼",0,"66",90,,"2012",
177,"一名35岁白塞氏病患者（女性）伴有右心室炎性假瘤：病例报告一例","DOI: 10.1111/j.1540-8175.2011.01644","Feng Juan Yao, M.D., Donghong Liu, M.D., Ph.D.,Yan Zhang, M.D., Ph.D., and Shengli Yin, M.D., Ph.D.","Wiley Periodicals, Inc","<p align=""justify"">
	&nbsp;<strong><span style=""font-family:'Times New Roman';""></span></strong>
</p>
<p align=""justify"">
	<span style=""font-family:&quot;font-size:10.5pt;""><span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span>Inflammatory pseudotumor is a rare benign neoplasm. It is common in children and has been reported in various locations throughout the body but rarely in the heart. <a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span>Behc?et’s disease is a multisystemic, recurrent, inflammatory disorder</span>. We report a 35-year-old Behc?et’s disease patient with <a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span>pseudotumor of the right ventricle and multiple pulmonary emboli.</span> <a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span>Transthoracic echocardiography showed dilation of right atrium, right ventricle, and</span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span><span><span> a mass in the right ventricle</span></span></span>. <a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span>Multislice computed tomography revealed a large, poorly defined mass infiltrating the groove and multiple pulmonary emboli.</span> <a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span>Surgery was performed with diagnostic and therapeutic intent</span>. <a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span>Following sternotomy,we identified a mass in the anterior wall of right ventricle, the outflow tract, and the inflow tract of right ventricle.</span> <a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span>The histopathologic analysis identified an inflammatory infiltrate composed of lymphocytes, plasma cells, and other inflammatory cells, </span><a name=""OLE_LINK19""></a><span><span>without mitosis</span></span><span><span>.</span></span><br />
&nbsp;<br />
</span></span><span style=""font-family:宋体;font-size:10.5pt;"">&nbsp;&nbsp;&nbsp; 炎性假瘤是一种罕见的良性肿瘤。常见于儿童，据报道该疾病发病位置累及白塞病是一种多系统的<span>, </span>复发性、炎症性疾病我们报道一例<span>35</span>岁伴有右心室假瘤以及多发性肺栓塞的白塞病患者。。经胸超声心动图提示右心房、右心室扩张膨大以及右心室有一肿块。多层螺旋计算机断层扫描显示有一个大的、模糊不清的肿块浸润槽和多个肺动脉栓塞。为了进一步的诊断和治疗进行手术。胸骨切开手术术后，我们发现在右心室前壁、流出道以及右心室流入道有一肿块。病理组织学分析表明有一由淋巴细胞，浆细胞和无丝分裂的其他炎性细胞组成的炎性浸润并且在肿块顶端出现一些血栓。<span></span></span> 
</p>
<p align=""justify"">
	<br />
</p>","/uploadfiles/image/20131012/20131012140048_7988w.jpg","/uploadfiles/file/20131012/20131012140344_2367.pdf",,10/12/2013,10/12/2013,"medicool",39,,"inflammatory pseudotumor;Behc?et’s disease; right ventricle",0,"85",29,"Inflammatory Pseudotumor of the Right Ventricle in a 35-Year-Old Woman with Behcet’s Disease: A Case Report","2012",
178,,"10.1111/j.1468-3083.2011.04131.x","Karelson M ; Silm H ; Salum T ; K?ks S ; Kingo K","Journal Of The European Academy Of Dermatology And Venereology: JEADV","<strong><span style=""font-family:Times New Roman;"">Background </span></strong><span style=""font-family:Times New Roman;"">Most cases of vitiligo are sporadic, but about 10C36% of the patients have positive family history. Objective The aim of our study was to describe differences between familial and sporadic cases of vitiligo. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Methods </span></strong><span style=""font-family:Times New Roman;"">A total of 186 adult vitiligo patients were examined, in 173 of whom the level of thyroid peroxidase antibodies, gastric parietal cell antibodies (PCA), antinuclear antibodies (ANA), anti-adrenal cortex antibodies and rheumatoid factor in blood was measured. All patients were divided in two groups: the cases with positive family history of vitiligo (51) and the sporadic cases (135). </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Results </span></strong><span style=""font-family:Times New Roman;"">The risk of onset of the disease up to 20 years of age was higher in the familial group (P = 0.008). Patients in familial group showed more widespread depigmentation compared with sporadic cases [body surface area (BSA) over 10%: P = 0.004; BSA over 50%: P = 0.001]. In familial group, patients had darker skin phototype (P = 0.045) and the disease had started more often as a vulgar vitiligo (P = 0.008). In sporadic vitiligo group, female gender was a risk factor for more widespread depigmentation (BSA over 10%, P = 0.001). Extensive depigmentation was associated with reported triggering factors and mucosal involvement in both groups and with leukotrichia only in familial group. Widespread depigmentation related to the risk of presence of autoantibodies (P = 0.03) in sporadic cases of vitiligo (especially of PCA: P = 0.04 and ANA: P = 0.0002). </span><strong><span style=""font-family:Times New Roman;"">Conclusions</span></strong><span style=""font-family:Times New Roman;""> In this study, we demonstrated ?rst time that patients with familial vitiligo have a higher risk for vulgar type at the beginning of the disease and female gender increases the risk for more extensive depigmentation in sporadic cases. </span><br />",,"/uploadfiles/file/20131012/20131012140957_2645.pdf",,10/12/2013,10/12/2013,"medicool",35,,,0,"85",28,"Differences between familial and sporadic cases of vitiligo","2012",
179,,"10.2165/11537120-000000000-00000","Parikshit Sharma, Harsha S. Pai, Ganesh S. Pai, Maria Kuruvila and Reshma Kolar","American Journal Of Clinical Dermatology","<strong><span style=""font-family:Times New Roman;"">Background: </span></strong><span style=""font-family:Times New Roman;"">Vitiligo is the most common depigmentary disorder of the skin and hair, resulting from selective destruction of melanocytes. Melasma, a hyperpigmentary disorder, presents as irregular, brown, macular hypermelanosis. A small subset of vitiligo patients paradoxically also have melasma. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Objective: </span></strong><span style=""font-family:Times New Roman;"">To evaluate and compare the response to narrow-band UVB in a group of patients with vitiligo, and another group of patients with vitiligo and coexisting melasma (vitiligo-melasma). </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Methods: </span></strong><span style=""font-family:Times New Roman;"">Patients in both groups were treated with narrow-band UVB and a comparison of the zonal repigmentation was made at 4, 8, and 12 weeks after the initiation of therapy. Results: At the end of 12 weeks, 86% of patients in the vitiligo-melasma group attained &gt;75% pigmentation on the face, whereas this was achieved m only 12,5% of patients in the vitiligo group. Over the limbs, 73% of patients in the vitiligo-melasma group attained 75% or more pigmentation at the end of 12 weeks compared with only 9% in the vitiligo group. On the trunk, only 20% of vitiligo-melasma patients showed &gt;75% pigmentation at 12 weeks compared with 63% of patients in the vitiligo group. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Conclusion: </span></strong><span style=""font-family:Times New Roman;"">Patients having both vitiligo and melasma have a significantly better prognosis for repigmen- tation on the face and hmbs with narrow-band UVB compared with patients with vitiligo alone; the vitiligo- melasma patients achieve repigmentation much earlier and also attain a greater level of repigmentation. Unexpectedly, for truncal lesions, patients with vitiligo alone responded better than those with both con- ditions. Although the vitiligo-melasma group with truncal lesions started repigmenting earlier, the final pigmentation was more extensive in the vitiligo group.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012141409_6106.pdf",,10/12/2013,10/12/2013,"medicool",25,,,0,"66",28,"Response to Narrow-Band UVB - Vitiligo-Melasma versus Vitíligo","2011",
180,,"10.2310/7750.2011.11055","Jakub Sawicki, Sanjay Siddha, and Cheryl Rosen","Journal of Cutaneous Medicine and Surgery","<strong><span style=""font-family:Times New Roman;"">Background: </span></strong><span style=""font-family:Times New Roman;"">Vitiligo, the most common cutaneous depigmentation disorder, has reported associations with other autoimmune diseases. However, literature on the strengths of the associations is conflicting, and no data on the subject exist from a Canadian population. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Objective: </span></strong><span style=""font-family:Times New Roman;"">To determine autoimmune disease associations with vitiligo and which, if any, screening bloodwork is appropriate in vitiligo patients. Methods: A retrospective review of vitiligo patients admitted to the Toronto Western Hospital phototherapy unit was conducted from January 1, 2000, to August 30, 2009. Data regarding patient characteristics, vitiligo clinical features (family history, age at onset, type, extent), associated diseases in the patient and family, and admission bloodwork (hemoglobin, vitamin B12, thyroid-stimulating hormone [TSH], antinuclear antibody) were recorded and compared, using the Fisher exact test where applicable. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Results: </span></strong><span style=""font-family:Times New Roman;"">A total of 300 patient charts were reviewed (average age 41.5 6 15.5 years; 47% male, 53% female). Hypothyroidism was present in 12.0% and pernicious anemia in 1.3% of patients―significant increases over the population prevalence. No other differences in prevalence were seen compared to the general population. TSH was increased in 3.7% of patients without a history of hypothyroidism. Hemoglobin and vitamin B12 were decreased in 0.3% of vitiligo patients without a history of pernicious anemia. </span><br />
<span style=""font-family:Times New Roman;""></span><strong><span style=""font-family:Times New Roman;"">Conclusion: </span></strong><span style=""font-family:Times New Roman;"">We found a significantly higher prevalence of hypothyroidism and pernicious anemia in vitiligo patients.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012141823_3762.pdf",,10/12/2013,10/12/2013,"medicool",32,,,0,"66",28,"Vitiligo and Associated Autoimmune Disease: Retrospective Review of 300 Patients","2012",
182,,"DOI 10.1007/s10165-011-0444-5","Kyoko Honne ? Hitoshi Kohsaka ? Hideki Kaneko ?Yukiko Komano ? Shoichi Nakanishi ?Masanobu Kitagawa ? Nobuyuki Miyasaka","Mod Rheumatol","<p align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients suffering from Behc?et’s disease (BD) with intestinal involvement often have an atypical disease course. The disease in many patients does not fully meet the diagnostic criteria defined by the International Study Group for Behc?et’s Disease, and instead such patients are diagnosed as having an incomplete type of BD according to the criteria of the BD Research Committee of Japan. The patient reported here developed uveitis and gangrene of the extremities as the initial symptoms and was treated with corticosteroid. After 16 years, the gangrene relapsed and multiple deep ulcers suddenly developed in the gastrointestinal tract, with oral ulcer and uveitis. The intestinal perforation was acute, progressive, severe, and extensive. With a diagnosis of incomplete BD with intestinal involvement, she was treated with high-dose glucocorticoid. However, uncontrollable gastrointestinal bleeding led to her death. Histopathological examination revealed that she suffered from intestinal and vascular BD, although gangrene of the extremities has rarely been reported as a manifestation of vascular BD. Thus, the disease course of this patient was characterized by the reappearance of peripheral gangrene after a long interval that preceded the devastating intestinal lesions.
</p>","/uploadfiles/image/20131012/20131012143305_6046w.jpg","/uploadfiles/file/20131012/20131012143632_6793.pdf",,10/12/2013,10/12/2013,"medicool",20,,"Behc?et’s disease ; Gangrene of the extremities ;Intestinal Behc?et’s disease",0,"85",29,"A case of Behc?et’s disease with widespread perforating enteric ulcers preceded by a long history of peripheral gangrene","2011",
183,,"DOI 10.1007/s10165-011-0497-5","Toru Hirano ? Nobuyuki Ohguro ? Satoshi Hohki ? Keisuke Hagihara ?Yoshihito Shima ? Masashi Narazaki ? Atsushi Ogata ? Kazuyuki Yoshizaki ?Atsushi Kumanogoh ? Tadamitsu Kishimoto ? Toshio Tanaka","Mod Rheumatol","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A 47-year-old female patient with Behc?et’s disease had been treated with colchicine, prednisolone, cyclosporine A,and infliximab. Because she relapsed,however, treatment with tocilizumab, a humanized antiinterleukin 6 receptor antibody, was started. This treatment suppressed the patient’s clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity.This experience indicates that tocilizumab may constitute atherapeutic option for refractory Behc?et’s disease.
<p align=""justify"">
	&nbsp;
</p>","/uploadfiles/image/20131012/20131012144240_9492w.jpg","/uploadfiles/file/20131012/20131012144831_2946.pdf",,10/12/2013,10/12/2013,"medicool",35,,"Behc?et’s disease ; IL-6  ;Tocilizumab",0,"85",29,"A case of Behc?et’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab","2012",
197,,"10.2298/VSP1111992T","Tomi?-Luci? A ; Jovanovi? S ; Petronijevi? M ; Veselinovi? M","VOJNOSANITETSKI PREGLED","<strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space""><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Introduction:<span class=""Apple-converted-space""><br />
</span></strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;&nbsp;&nbsp;&nbsp;Behcey'sdisease </span>is multisystemic vasculitis which affects vein and artery blood vessels. Intestinal perforation rarely occurs as clinic manifestation in as little as 1% of patients. The transverse colon is the most infrequent site of perforation. We presented a patient diagnosed with<span class=""Apple-converted-space"">&nbsp;Behcet's disease </span></span><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">who underwent both surgical and conversative treatment due to perforation of the colon.</span><br style=""white-space:normal;text-transform:none;word-spacing:0px;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"" />
<strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Case Report:<span class=""Apple-converted-space"">&nbsp;<br />
&nbsp;&nbsp;&nbsp; </span></strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">A 34-year-old patient was admitted to the hospital with fever, aphthous ulcerations on oral mucosa and genitals and bilateral uveitis. On the basis of clinical symptoms and the International Criteria developed in 1990<span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Behcet's</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">disease</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span>was diagnosed. During the next few days the patient developed erythema nodosum, diarrheic syndrome and acute abdominal symptoms due to perforation of the transverse colon. An emergent laparotomy was undertaken involving resection of a perforated segment of the colon, and bipolar colostomy on the left side of abdomen. Following the surgery the patient was treated except for antibiotics with three successive pulse doses of methylprednisolone (500 mg/daily) and cyclophosphamide (15 mg/kg). The treatment was continued by gradual decrease in the close of the corticosteroid (perorally) and by cyclophosphamide first with monthly doses (5 monthly pulse doses of 15 mg/kg cyclophosphoamide), and then with 3-month doses (totally 6 doses) up to totally 12 g.</span><br style=""white-space:normal;text-transform:none;word-spacing:0px;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"" />
<strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Conclusion:<span class=""Apple-converted-space"">&nbsp;<br />
</span></strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">The therapy with pulse doses of methylprednisolone combined with pulse doses of cyclophosphamide was very effective in the reported case with the complex clinical manifestations leading to resolution of gastrointenstinal, ocular and orogenital lesions.</span></span></strong>",,"/uploadfiles/file/20131012/20131012151443_9802.pdf",,10/12/2013,10/12/2013,"medicool",21,,"behctet syndrome; intestinal perforation; colon;therapeutics; surgical procedures, operative;cyclophosphamide; methylprednisolone",0,"66",29,"Colonic perforation as an unusual manifestation of Behcet's disease","2011",
184,,"10.1111/j.1525-1470.2011.01347.x","Hanan A. Salem, M.D., Magdy El Sohafy, M.D., and Mamdouh Abd El Gawad, M.D.","Pediatric Dermatology","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; A 7-year-old girl suffering from atopic dermatitis developed multiple lesions of Kaposi’s sarcoma, which could not be categorized under any one of the four known types of Kaposi’s sarcoma (classic, human immunode?ciency virus-associated, endemic, or iatrogenic). We propose that atopic dermatitis may cause susceptibility to human herpes virus 8 infection, which is related to the pathogenesis of Kaposi’s sarcoma.</span> 
</p>
<br />
<br />",,"/uploadfiles/file/20131012/20131012145213_2206.pdf",,10/12/2013,10/12/2013,"medicool",20,,,0,"85",46,"Kaposi's sarcoma in an atopic dermatitis patient: a case report and a review of literature","2011",
220,"日本过度角化足癣的发病机理和治疗","10.1046/j.1439-0507.1999.00403.x","Tanuma H","Mycoses","<p class=""MsoNormal"" style=""white-space:normal;text-align:justify;text-indent:10.5pt;"">
	In this paper,&nbsp;<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a>we describe the major characteristics of hyperkeratotic tinea pedis and review therapeutic results obtained in the Department of Dermatology of Kitasato University Hospital and those reported in the literature in Japan and abroad.
</p>
<p class=""MsoNormal"" style=""white-space:normal;text-align:justify;text-indent:10.5pt;"">
	在本文中，我们描述了过度角化足癣的主要特征，并对北里大学医院皮肤科所取得的，以及日本国内和国外的文献中报道过的治疗效果进行评述。
</p>
<div style=""text-align:right;"">
	<span style=""text-indent:10.5pt;""><br />
<br />
<br />
<a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><em>H．Tanuma /Grosse Verlag ,&nbsp;1999 Apr; Vol. 42 (1-2), pp. 21-8.</em></span> 
</div>
<p>
	<br />
</p>","/uploadfiles/image/20131015/20131015172023_3200w.jpg","/uploadfiles/file/20131015/20131015172036_6112.pdf",,10/15/2013,10/16/2013,"medicool",30,,"Tinea pedis, hyperkeratosis, pathogenesis, treatment, Japan.",0,"67",60,"Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan","1999",
233,"连圈状花斑癣：孤立的合轴马拉色菌 - 病例报告",,"Valéria Maria de Souza Framil ， Márcia S.C. Melhem ，Maria Walderez Szeszs ，Elaine Cristina Corneta，Clarisse Zaitz","An Bras Dermatol.","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The authors report a case of pityriasis versicolor circinata whose isolated etiologic agent was Malassezia </span><span style=""font-family:Times New Roman;font-size:14px;"">sympodialis in a 34-year-old woman. The isolation and identification of Malassezia sympodialis were accomplished </span><span style=""font-family:Times New Roman;font-size:14px;"">with modified Dixon's agar, and the molecular method used to confirm the species was polymerase chain reaction </span><span style=""font-family:Times New Roman;font-size:14px;"">and restriction fragment length polymorphism analysis (PCR-RFLP).</span> 
</p>","/uploadfiles/image/20131016/20131016154602_4318w.jpg","/uploadfiles/file/20131016/20131016142553_5673.pdf",,10/16/2013,10/16/2013,"medicool",21,,"Palavras-chave: Evolu??o clínica; Malassezia; Pitiríase",0,"85",4,"Pityriasis versicolor circinata: isolation of Malassezia sympodialis - Case report","2010",
656,,,,"The Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;Celecoxib is a non-steroidal anti-in?ammatory drug</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(NSAID) that relieves pain and in?ammation through&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">inhibition of cyclooxygenase (COX)-2. Celecoxib was&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">?rst used in the USA in 1999&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and is now in common&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">use worldwide due to its lower rate of gastrointestinal irritation compared to non-selective NSAIDs.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">With&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">increased use, there has been an increase in the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">reports of drug eruptions due to celecoxib,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">but only&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">a few cases with diagnosis using tests such as the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patch test, lymphocyte transformation test (LTT) or&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">oral challenge test have been described.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Here, we&nbsp;report a case of erythema multiforme-type drug erup</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tion due to celecoxib that showed a positive patch&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">test.</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp;</span>
</div>
</span>",,"/uploadfiles/file/20131213/20131213093505_3184.pdf",,12/13/2013,12/13/2013,"medicool",11,,"Celecoxib   a positive patch test erythema multiforme-type",0,"65",111,"Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test","2011",
657,"外用0.1％他克莫司软膏治疗复发性大疱性多形性红斑","10.1111/j.1365-2133.2010.10155.x",,,"<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:'Times New Roman';"">&nbsp; &nbsp; Recurrent erythema multiforme, defined as
‘the presence of a symmetrically distributed, fixed eruption, including</span><span style=""font-family:Times New Roman;"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">target lesions, with or without mucous
membrane involvement, occurring on at least three occasions’,</span><span style=""font-size:14px;font-family:'Times New Roman';"">&nbsp;is a condition of substantial morbidity. Herpes simplex virus (HSV) has been implicated
as a causative factor in recurrent erythema multiforme. Continuous antiviral
therapy has been used to suppress recurrent erythema multiforme. Immunosuppressive agents are typically used for patients
who do not respond to antiviral therapy, often with varied and suboptimal
response. </span><span style=""font-size:14px;font-family:'Times New Roman';"">Topical tacrolimus, through its immunomodulatory effect, may
provide an effective alternative to corticosteroids and other immunosuppressive
therapies for recurrent erythema multiforme.</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;"">&nbsp; &nbsp;<span style=""font-family:SimSun;""> 复发性多形红斑是大量发病的一个必要条件，其定义为“呈对称性分布，固定疹，包括靶样病变，有或无粘膜受累，至少发生三次”。单纯疱疹病毒（HSV）与复发性多形性红斑的致病因素有牵连。持续的抗病毒疗法已被用来抑制复发性多形性红斑。免疫抑制剂通常用于对抗病毒治疗无响应的患者，常具有多样性，疗效欠佳。外用他克莫司通过其免疫调节效果可以为治疗复发性多形性红斑提供一种有效的替代皮质类固醇和其他免疫抑制疗法。</span></span><o:p></o:p>
</p>","/uploadfiles/image/20131213/20131213095930_8006w.jpg","/uploadfiles/file/20131213/20131213095938_9126.pdf",,12/13/2013,12/13/2013,"medicool",19,,"Recurrent bullous erythema multiforme | tacrolimus 0.1% ointment | Herpes simplex virus",0,"66",111,"Recurrent bullous erythema multiforme treated with topical tacrolimus 0.1% ointment","2010",
658,,,"Dean Edwards,Eli Boritz,Edward W. Cowen","Elsevier Inc","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Background. </strong>The growth in the use of antiCtumor necrosis factor  (TNF-) agents for treatment of in?ammatory conditions&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">has led to increased recognition of the side effects associated with this class of drugs.</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Case description: </strong>We report a case of a patient who developed erythema multiforme (EM) major with characteristic oral and&nbsp;</span><span style=""line-height:1.5;"">cutaneous lesions following treatment with the anti-TNF- medication in?iximab therapy for Crohn’s disease (CD).</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Clinical implications: </strong>To our knowledge, this is the ?rst reported case of in?iximab-induced EM secondary to the treatment of&nbsp;</span><span style=""line-height:1.5;"">CD. It is important for dental clinicians evaluating patients using anti-TNF- agents to be aware of this possible complication.</span>
</div>
</span>",,"/uploadfiles/file/20131213/20131213100434_9855.pdf",,12/13/2013,12/13/2013,"medicool",6,,"in?iximab | antiCtumor necrosis factor | treatment",0,"66",111,"Erythema multiforme major following treatment with in?iximab","2013",
659,,"10.1093/jjco/hys103","Masaomi Ikeda,Tetsuo Fujita,Sumiyuki Mii","Oxford University Press","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Objective: </strong>Sorafenib is one of the few standard agents for metastatic renal cell carcinoma.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Although sorafenib-induced erythema multiforme is rarely reported, we evaluated the cases&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">of erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Methods:</strong> From November 2006 to November 2011, 36 eligible patients who had been&nbsp;</span><span style=""line-height:1.5;"">treated with sorafenib were enrolled in this study. Patients received sorafenib 200 or 400 mg&nbsp;</span><span style=""line-height:1.5;"">orally, twice daily, at 12 h intervals, on a continuous dosing schedule. All patients who experi</span><span style=""line-height:1.5;"">enced rash or erythema multiforme underwent a skin biopsy, and the histopathological diag</span><span style=""line-height:1.5;"">nosis was con?rmed.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Results:</strong> Twenty-eight patients (78%) experienced a skin reaction of any toxicity grade.&nbsp;</span><span style=""line-height:1.5;"">Hand-foot skin reactions occurred in 17 (47%), erythema multiforme in 9 (25%), rash/</span><span style=""line-height:1.5;"">desquamation in 6 (17%) and alopecia in 9 (25%). Skin biopsy was performed and histo</span><span style=""line-height:1.5;"">pathological diagnosis was con?rmed for all nine patients (25%) who experienced erythema&nbsp;</span><span style=""line-height:1.5;"">multiforme. All nine showed a positive reaction to sorafenib on a subsequent patch test.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Conclusions: </strong>Sorafenib-induced erythema multiforme may not be rare in Japanese patients.&nbsp;</span><span style=""line-height:1.5;"">Patients who once showed erythema multiforme after sorafenib treatment are never to be&nbsp;</span><span style=""line-height:1.5;"">treated with sorafenib again. Patients treated with sorafenib should be monitored carefully,&nbsp;</span><span style=""line-height:1.5;"">with a multidisciplinary approach. Consultation with a dermatologist is critical because some&nbsp;</span><span style=""line-height:1.5;"">cases quickly become severe.</span>
</div>
</span>",,"/uploadfiles/file/20131213/20131213100732_4826.pdf",,12/13/2013,12/13/2013,"medicool",9,,"sorafenib | erythema multiforme | renal cell carcinoma",0,"66",111,"Erythema Multiforme Induced by Sorafenib for Metastatic Renal Cell Carcinoma","2012",
660,,"10.1684/ejd.2009.0677","Kiriko INOUE, Yoko KANO, Hiroaki KAGAWA",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Recent studies by Aurelian and colleagues [1-3] have&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">indicated that the course of herpes virus-associated ery</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">thema multiforme (HAEM) is biphasic, with early virus-</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">specific events and late inflammatory events mediated by&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">cytokines. If so, episodic treatment with antiviral drugs&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">followed by a short-course of systemic corticosteroids&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">would be expected to have a favorable response in&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patients with recurrent HAEM. However, the results of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">our patient indicate that such episodic treatments might&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">paradoxically be associated with an increase in the recur</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">rence and severity of HAEM.</span>
</div>",,"/uploadfiles/file/20131213/20131213101323_0620.pdf",,12/13/2013,12/13/2013,"medicool",10,,"Herpes virus | valacyclovir | systemic corticosteroid | treatment",0,"66",111,"Herpes virus-associated erythema multiforme following valacyclovir and systemic corticosteroid treatment","2009",
670,"由β受体阻滞剂引发的扁平苔癣样药疹---一则病例报道和文献综述",,"Chris Fessa,1 Penny Lim, Steve Kossard, Shawn Richards and Pablo Fernandez Pen?as","Am J Clin Dermatol","<p class=""MsoNormal"" align=""left"">
	<p class=""MsoNormal"" align=""left"">
		<span style=""font-size:16px;font-family:'Times New Roman';"">Abstract</span><o:p></o:p>
	</p>
	<p class=""MsoNormal"" align=""left"">
		<span style=""font-size:14px;font-family:'Times New Roman';"">摘要</span><span lang=""EN-US""><o:p></o:p></span>
	</p>
	<p class=""MsoNormal"">
		<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-size:14px;font-family:'Times New Roman';"">Lichen
planus-like drug eruptions (LDE) can appear similar or identical to idiopathic
lichen planus. </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span style=""font-size:14px;font-family:'Times New Roman';"">We present a
45-year-old man with a widespread, violaceous, papular, </span><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-size:14px;font-family:'Times New Roman';"">generalized exanthema
with histologic features
of a lichenoid reaction, which
subsequently resolved with the cessation of </span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""font-size:14px;font-family:'Times New Roman';"">labetatol.</span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span style=""font-size:14px;font-family:'Times New Roman';""> We found 29 cases of previously reported β-adrenoceptor
antagonist (b-blocker)-associated
LDE. </span><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span style=""font-size:14px;font-family:'Times New Roman';"">This is a relatively
rare complication that may present as classic
lichenoid papules indistinguishable from lichen planus and</span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span style=""font-size:14px;font-family:'Times New Roman';""> has a predilection for the limbs, chest, back,
and oral mucosa.</span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span style=""font-size:14px;font-family:'Times New Roman';""> Histologically, there
is a lichenoid infiltrate often with
eosinophils. </span><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span style=""font-size:14px;font-family:'Times New Roman';"">LDE may be due to drug
cross-reactivity or as a result of a suppressed skin adrenergic system. </span><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span style=""font-size:14px;font-family:'Times New Roman';"">Multiple
potential medications in case studies and the inability to differentiate LDE
from idiopathic lichen planus in cross-sectional
association studies make any conclusive analysis difficult.</span><o:p></o:p>
	</p>
	<p class=""MsoNormal"">
		<span style=""font-size:14px;font-family:'Times New Roman';"">&nbsp; &nbsp; &nbsp; &nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">扁平苔藓样药疹（LDE）可以出现与原发性扁平苔藓类似或相同的特征。我们报道了一名</span><span lang=""EN-US"" style=""font-size:14px;font-family:'Times New Roman';"">45</span><span style=""font-size:14px;font-family:'Times New Roman';"">岁的男性患者，该患者患有广泛分布的、紫罗兰色、丘疹状、具有苔藓样反应组织学特征的全身性皮疹，随后停用拉贝洛尔后症状消失。我们发现先前报道的</span><span lang=""EN-US"" style=""font-size:14px;font-family:'Times New Roman';"">29</span><span style=""font-size:14px;font-family:'Times New Roman';"">例与β</span><span lang=""EN-US"" style=""font-size:14px;font-family:'Times New Roman';"">-</span><span style=""font-size:14px;font-family:'Times New Roman';"">肾上腺素能受体拮抗剂（β</span><span lang=""EN-US"" style=""font-size:14px;font-family:'Times New Roman';"">-</span><span style=""font-size:14px;font-family:'Times New Roman';"">阻断剂）相关的</span><span lang=""EN-US"" style=""font-size:14px;font-family:'Times New Roman';"">LDE</span><span style=""font-size:14px;font-family:'Times New Roman';"">。这是一种比较罕见的并发症，可能表现为与典型的苔藓样丘疹相区别的扁平苔藓样病变，并且好发于四肢、胸部、背部和口腔粘膜。组织学上，常伴有一个嗜酸性粒细胞的苔癣样浸润。</span><span lang=""EN-US"" style=""font-size:14px;font-family:'Times New Roman';"">LDE</span><span style=""font-size:14px;font-family:'Times New Roman';"">可能是由于药物的交叉性反应，或者皮肤肾上腺素能系统受到抑制的结果。在病例研究中的多种潜在药物，以及在横断面研究中无法区分LDE与原发性扁平苔藓，这些使得做出任何结论性的分析变得困难。</span>
	</p>
	<p class=""MsoNormal"">
		<o:p></o:p>
	</p>
<span style=""font-size:14px;font-family:'Times New Roman';""></span>
</p>","/uploadfiles/image/20131217/20131217100552_8792w.png","/uploadfiles/file/20131217/20131217100622_7844.pdf",,12/17/2013,12/17/2013,"medicool",11,,"Lichen Planus-Like Drug Eruptions ,, β-Blockers, Case Report and Literature Review",0,"67",112,"Lichen Planus-Like Drug Eruptions Due to β-Blockers ---A Case Report and Literature Review","2012",
691,,"doi:10.1136/annrheumdis-2011-200742","Florian M P Meier, Klaus W Frommer, Robert Dinser, Ulrich A Walker, Laszlo Czirjak, Christopher P Denton, Yannick Allanore, Oliver Distler, Gabriela Riemekasten, Gabriele Valentini, Ulf Müller-Ladner, EUSTAR Co-authors","Ann Rheum Dis","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:1.5;""><strong>Abstract</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Objectives</strong> Systemic sclerosis (SSc) is a rare&nbsp;</span><span style=""line-height:1.5;"">disease requiring multicentre collaboration to reveal&nbsp;</span><span style=""line-height:1.5;"">comprehensive details of disease-related causes for&nbsp;</span><span style=""line-height:1.5;"">morbidity and mortality.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Methods</strong> The European League Against Rheumatism&nbsp;</span><span style=""line-height:1.5;"">(EULAR) Scleroderma Trials and Research (EUSTAR)&nbsp;</span><span style=""line-height:1.5;"">group initiated a database to prospectively gather key&nbsp;</span><span style=""line-height:1.5;"">data of patients with SSc using a minimal essential&nbsp;</span><span style=""line-height:1.5;"">dataset that was reorganised in 2008 introducing new&nbsp;</span><span style=""line-height:1.5;"">items. Baseline visit data of patients who were registered&nbsp;</span><span style=""line-height:1.5;"">between 2004 and 2011 were analysed using descriptive&nbsp;</span><span style=""line-height:1.5;"">statistics.&nbsp;<br />
<strong></strong></span><span style=""line-height:1.5;""><strong>Results </strong>In June 2011, 7655 patients (2838 with diffuse&nbsp;</span><span style=""line-height:1.5;"">cutaneous (dc) and 4481 with limited cutaneous (lc)&nbsp;</span><span style=""line-height:1.5;"">SSc who fulfilled the American College of Rheumatology&nbsp;</span><span style=""line-height:1.5;"">diagnostic criteria had been registered in 174 centres,&nbsp;</span><span style=""line-height:1.5;"">mainly European. The most prominent hallmarks of&nbsp;</span><span style=""line-height:1.5;"">disease were Raynaud’s phenomenon (96.3%), antinuclear&nbsp;</span><span style=""line-height:1.5;"">antibodies (93.4%) and a typical capillaroscopic pattern&nbsp;</span><span style=""line-height:1.5;"">(90.9%). Scleroderma was more common on fingers and&nbsp;</span><span style=""line-height:1.5;"">hands than on any other part of the skin. Proton pump&nbsp;</span><span style=""line-height:1.5;"">inhibitors (65.2%), calcium channel blockers (52.7%),&nbsp;</span><span style=""line-height:1.5;"">and corticosteroids (45.3%) were most often prescribed.&nbsp;</span><span style=""line-height:1.5;"">Among the immunosuppressant agents, cyclophosphamide&nbsp;</span><span style=""line-height:1.5;"">was used more often in dcSSc than in lcSSc.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Conclusions</strong> The EUSTAR database provides an&nbsp;</span><span style=""line-height:1.5;"">abundance of information on the true clinical face of&nbsp;</span><span style=""line-height:1.5;"">SSc that will be helpful in improving the classification&nbsp;</span><span style=""line-height:1.5;"">of SSc and its subsets and for developing more specific&nbsp;</span><span style=""line-height:1.5;"">therapeutic recommendations.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Introduction</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217155416_4167.pdf",,12/17/2013,12/17/2013,"medicool",8,,"EULAR Scleroderma Trials, Research group database",0,"65",114,"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","2012",
661,"中西医结合治疗多形性红斑临床研究","1672-5654（2013）07（b）-0017-02","王吉松","中国卫生产业","<div style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">&nbsp; &nbsp; 目的 探讨中西医结合治疗多形性红斑临床效果及安全性。方法 选取该院<span style=""font-family:Times New Roman;"">2010</span>年<span style=""font-family:Times New Roman;"">3</span>月―<span style=""font-family:Times New Roman;"">2012</span>年<span style=""font-family:Times New Roman;"">12</span>月收治多形性红</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">斑患者<span style=""font-family:Times New Roman;"">120</span>例，采用随机数字表法分为对照组和中西医结合治疗组，每组各<span style=""font-family:Times New Roman;"">60</span>例；其中对照组患者采用单纯西药治疗；中</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">西医结合治疗组患者在对照组治疗基础上加用当归四逆汤治疗；比较两组患者临床治疗总有效率、复发率、治疗前后临</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">床症状积分及不良反应发生情况等。结果 对照组和中西医结合治疗组患者临床治疗总有效率分别为<span style=""font-family:Times New Roman;"">73.3%</span>，<span style=""font-family:Times New Roman;"">96.7%</span>；中</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">西医结合治疗组患者临床治疗总有效率明显高于对照组，组间比较差异显著（<span style=""font-family:Times New Roman;"">P&lt;0.05</span>）；对照组和中西医结合治疗组患</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">者治疗前临床症状积分组间比较无显著差异（<span style=""font-family:Times New Roman;"">P&gt;0.05</span>);两组患者治疗后临床症状积分较治疗前均显著降低，且中西医</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">结合治疗组患者降低程度明显高于对照组,组间比较差异具有统计学意义（<span style=""font-family:'Times New Roman';"">P&lt;0.05</span>）；中西医结合治疗组患者复发率明</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">显低于对照组，组间比较差异具有统计学意义（<span style=""font-family:Times New Roman;"">P&lt;0.05</span>）。结论与单纯西医治疗相比，中西医结合治疗多形性红斑可有</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">效改善临床症状，降低复发率，且无明显不良反应具有临床使用价值。</span> 
</div>",,"/uploadfiles/file/20131213/20131213102315_9723.pdf",,12/13/2013,12/13/2013,"medicool",10,,"中西医结合| 多形性红斑| 疗效| 安全性",0,"66",111,,"2013",
664,,"10.7860/JCDR/2013/5171.3412","Bharati Patil, SuShmini hegde, ShoBha naiK , raKeSh Sharma",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Erythema multiforme and related disorders comprise a group of mucocutaneous disorders that often compromise the quality of life. The </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">clinical classification of these disorders is variable, thus making definitive diagnosis difficult. Early recognition and prompt management will&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">benefit the patients. This article highlights two such cases of erythema multiforme with detailed literature review on etiopathogenesis, clinical&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">features, and treatment.</span>
</div>",,"/uploadfiles/file/20131213/20131213104113_5286.pdf",,12/13/2013,12/13/2013,"medicool",10,,"Erythema multiforme major | Erythema multiforme minor | Drug associated Erythema Multiforme | Oral Erythema Multiforme",0,"67",111,"Oral Blistering - Report of Two Cases of  Erythema Multiforme & Literature Review ","2013",
662,"多形红斑的临床特点、诊断和治疗：一则适用于执业皮肤科医生的综述",,"Olayemi Sokumbi,and David A. Wetter","international journal of dermatology","<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""line-height:1.5;font-size:14px;font-family:'Times New Roman';"">&nbsp; &nbsp; Erythema multiforme (EM) is an uncommon, immune-mediated
disorder that presents with cutaneous or mucosal lesions or both. In herpes
simplex virus (HSV)Cassociated EM, the ?ndings are thought to result from
cell-mediated immune reaction against viral antigen-positive cells that contain
the HSV DNA polymerase gene (pol ). The target lesion, with concentric
zones of color change, represents the characteristic cutaneous ?nding seen in this
disorder. Although EM can be induced by various factors, HSV infection
continues to be the most common inciting factor. Histopathologic testing and other laboratory investigations may be
used to con?rm the diagnosis of EM and to differentiate it from other clinical imitators.</span><span style=""line-height:1.5;font-size:14px;font-family:'Times New Roman';"">&nbsp;Imitators of EM include urticaria, Stevens-Johnson
syndrome, ?xed drug eruption, bullous pemphigoid, paraneoplastic pemphigus,
Sweet’s syndrome, Rowell’s syndrome, polymorphus light eruption, and cutaneous
small-vessel vasculitis. Because disease
severity and mucosal involvement differ among patients, treatment should be
tailored to each patient, with careful consideration of treatment risk vs
bene?t. Mild cutaneous involvement of EM can be managed primarily with a goal
of achieving symptomatic improvement; however,
patients with HSV-associated recurrent EM and idiopathic recurrent EM require treatment
with antiviral prophylaxis. Inpatient hospitalization may be required
for patients&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">with severe mucosal involvement that
causes poor oral intake and subsequent ?uid and electrolyte imbalance. With
this review, we strive to provide guidance to the practicing dermatologist in
the evaluation and treatment of a patient with EM.</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;"">&nbsp; &nbsp;<span style=""font-family:SimSun;"">多形红斑（<span style=""font-family:Times New Roman;"">EM</span>）是皮肤病变、粘膜病变或两者兼有的一种罕见性免疫介导疾病。在单纯疱疹病毒（<span style=""font-family:Times New Roman;"">HSV</span>）相关的多形红斑中，调查结果认为是由细胞介导的抵抗（含</span></span><span lang=""EN-US"" style=""font-size:14px;font-family:'Times New Roman';"">HSV </span><span style=""font-size:14px;font-family:SimSun;""><span style=""font-family:Times New Roman;"">DNA</span>聚合酶基因（<span style=""font-family:Times New Roman;"">POL</span>）的）病毒抗原阳性细胞的免疫反应造成的。靶样病变，伴有颜色改变的同心圆区，代表着这种疾病中显而易见的皮肤特点。虽然多形红斑可以由各种因素诱导，但单纯疱疹病毒感染仍然是最常见的诱导因素。组织病理学检查和其他的实验室检查可用来确诊多形红斑，并与其他有类似临床表现的疾病进行区分。多形红斑的</span><span style=""font-size:14px;font-family:SimSun;"">类似疾病，包括荨麻疹、<span style=""font-family:Times New Roman;"">Stevens-Johnson</span>综合征、特定的药疹、大疱性类天疱疮、副肿瘤性天疱疮、<span style=""font-family:Times New Roman;"">Sweet</span>综合征，罗威尔氏综合征、多形性日光疹和皮肤小血管炎。由于多形红斑的疾病严重程度和粘膜受累程度在患者中各不相同，因此，治疗应针对每位患者，并仔细考虑治疗方法的风险和效益。轻度皮肤受累的多形红斑主要以实现症状改善这一目标来进行管理；然而，单纯疱疹病毒相关的复发性多形红斑和先天性的复发性多形红斑患者需要采用抗病毒药物预防法进行治疗。由严重粘膜受累引起的进食差、后续流体和电解质紊乱的患者可能需要住院治疗。通过这篇综述，我们力求为那些执业皮肤科医生在诊断和治疗多形红斑患者时提供指导。</span><o:p></o:p>
</p>
<o:p></o:p>
<p style=""text-align:justify;"">
	<br />
</p>","/uploadfiles/image/20131213/20131213103214_1888w.jpg","/uploadfiles/file/20131213/20131213103042_2423.pdf",,12/13/2013,12/13/2013,"medicool",13,,"Clinical features | diagnosis | treatment  review",0,"67",111,"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist","2012",
663,,"10.1159/000319852","Lucía?Pérez-Carmona ，Ingrid?Aguayo-Leiva，Carmen?González-García ，Pedro?Jaén-Olasolo",,"<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp; &nbsp;&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">The quadrivalent human papillomavirus&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(qHPV) vaccine, the first vaccine for use in&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the prevention of cervical cancer and condy</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">loma acuminatum, was approved in June&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">2006. In 2008, the mass media reported sus</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">pected links between the qHPV vaccine and&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">serious adverse events; however, several&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">studies have found that the vaccine is safe&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and the main adverse events are mild local&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">reactions. Erythema multiforme (EM) is an&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">acute self-limited cutaneous or mucocu</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">taneous syndrome characterized by the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">abrupt onset of symmetric target lesions.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">The clinical manifestations and histological&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">features of EM, Stevens-Johnson syndrome&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and toxic epidermal necrolysis show consid</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">erable overlap, and they are classically con</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">sidered to represent a spectrum of skin dis</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">orders. We present a case of EM following&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">qHPV vaccination to review the cutaneous&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">side effects of this vaccine and the possibil</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">ity of more serious side effects with the ad</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">ministration of booster doses.&nbsp;</span>
</div>",,"/uploadfiles/file/20131213/20131213103721_1974.pdf",,12/13/2013,12/13/2013,"medicool",8,,"Erythema multiforme | Human papillomavirus | Immunization",0,"67",111," The Quadrivalent Human Papillomavirus Vaccine:  Erythema Multiforme and Cutaneous Side Effects  after Administration ","2010",
665,,"10.1007/s12070-011-0169-y","Parvinderjit S. Kohli and Jasbir Kaur","Indian J Otolaryngol Head Neck Surg","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Erythema multiforme (EM) is an interesting&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">dermatologic disease which has oral manifestations. EM is&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">clinically characterized by a “minor” form and a “major”&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">form. It presents a diagnostic dilemma because the oral&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">cavity has the ability to produce varied manifestations.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Infections (particularly herpes simplex and mycoplasma&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">pneumonia) and drugs seem to predispose toward the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">development of EM. The range of possible etiologies for&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">oral disease is immense. Therefore, an otolaryngologist or&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">a dentist while treating such patients should have a dif</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">ferential diagnosis for all oral lesions. We report a case of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">erythema multiforme in which alcohol (ethanol) seems to&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">be the precipitating factor and have also reviewed the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">English literature in the present context.</span>
</div>",,"/uploadfiles/file/20131213/20131213104345_7692.pdf",,12/13/2013,12/13/2013,"medicool",18,,"Erythema multiforme |  Mucocutaneous disorders | Drug reactions Ethanol",0,"67",111,"Erythema Multiforme-Oral Variant: Case Report and Review of Literature","2009",
487,"血栓形成伴有亚甲基四氢还原酶纯合子多态性以及同型半胱氨酸水平的升高的白塞氏病独特病例一例",,"Biju Vasudevan, Rajesh Verma, Vijendran Pragasam, Ajay Malik, Ruby Venugopal, Manoj Gopal","Indian Journal of Dermatology","<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">Abstrct<br />
</span></b><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">The article presents a</span><span class=""apple-converted-space"" style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">&nbsp;</span><strong><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">case</span></strong><span class=""apple-converted-space"" style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">study of a 17-year-old male with oral
ulcers of six years duration with around 10 episodes per year.</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">He was evaluated by a hematologist for the leg swelling where Color
Doppler of the left lower limb had affirmed deep vein thrombosis (DVT) along
superficial femoral vein and common femoral vein. </span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">He
was managed with warfarin and low molecular weight heparin (LMWH).</span>
</p>
<span style=""font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<b style=""text-indent:28.1pt;""><span style=""font-size:14px;line-height:2;"">摘要<br />
</span></b><span style=""font-size:14px;line-height:2;text-indent:21pt;"">本文介绍了一个患口腔溃疡六年，每年约发作<span style=""font-family:Times New Roman;"">10</span>次的<span style=""font-family:Times New Roman;"">17</span>岁男性患者的病例。患者被血液学家诊断为腿部肿胀，左下肢彩色多普勒检查证实为沿股浅静脉和股静脉的深静脉血栓形成（<span style=""font-family:Times New Roman;"">DVT</span>）。采用华法林和低分子量肝素（<span style=""font-family:Times New Roman;"">LMWH</span>）进行治疗。</span> 
</div>
</span> 
<p>
	<br />
</p>","/uploadfiles/image/20131126/20131126145645_1076w.jpg","/uploadfiles/file/20131126/20131126145746_6497.pdf",,11/26/2013,11/26/2013,"medicool",44,,,0,"85",29,"A unique case of thrombosis in Beh?et's disease with methylene tetrahydrofolate reductase homozygous polymorphism and raised homocysteine levels","2013","/uploadfiles/kejian/20131126/1126145628_7899.pdf"
490,,"10.1111/j.1600-0536.2012.02014.x","Else N. Kop, Cees J. W. van Ginkel, Heike R ¨ ockmann and Pieter G. M. van der Valk","Department of Dermatology","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp;&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">&nbsp;Although sawdust of tropical woods may be irritating to&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">the skin, eyes, nose, and lungs, and in addition can cause&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">sensit</span><span style=""font-family:'Times New Roman';font-size:14px;""></span><span style=""font-family:'Times New Roman';font-size:14px;"">i</span><span style=""font-family:'Times New Roman';font-size:14px;""></span><span style=""font-family:'Times New Roman';font-size:14px;"">za</span><span style=""font-family:'Times New Roman';font-size:14px;""></span><span style=""font-family:'Times New Roman';font-size:14px;"">tion, relatively few cases of occupational contact</span><span style=""font-family:'Times New Roman';font-size:14px;"">dermatitis caused by tropical woods have been reported</span><span style=""font-family:'Times New Roman';font-size:14px;"">in the medical lite</span><span style=""font-family:'Times New Roman';font-size:14px;"">rat</span><span style=""font-family:'Times New Roman';font-size:14px;""></span><span style=""font-family:'Times New Roman';font-size:14px;"">ure.</span>
</div>",,"/uploadfiles/file/20131128/20131128102333_6343.pdf",,11/28/2013,11/28/2013,"medicool",14,,"airborne contact dermatitis|contact allergy|faveira amargosa| gele kabbes| Leguminosae| occupational|tropical timber|wood dust.",0,"85",103,"A case of occupational airborne allergic contact dermatitis caused by faveira amargosa, a tropical timber","2012",
507,,"10.2478/s11536-011-0106-1","Sonja Prcic, Aleksandra Matic, Milan Matic , Aleksandra Petrovic","Central European Journal of Medicine","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;""> &nbsp; Temporary henna tattoos have recently become increasingly popular, especially among teenagers. Combining henna with other colour</span><span style=""font-family:'Times New Roman';font-size:14px;"">ing agents such as para-phenylenediamine (PPD) may increase its potential for contact sensitization, cross-reaction to related com</span><span style=""font-family:'Times New Roman';font-size:14px;"">pounds, as well as life-long allergy. Several cases of contact dermatitis from temporary tattoos with black henna have been repor ted&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">in the literature. We present our experiences with 4 pediatric cases of allergic contact dermatitis induced by henna tattooing and give </span><span style=""font-family:'Times New Roman';font-size:14px;"">a brief review of the literature. The agent responsible for contact allergy was proven to be PPD in 3 patients, and in one patch testing&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">revealed positive reactions to PPD and benzocaine, as well as to wool alcohols, nickel sulphate and potassium dichromate, to previ</span><span style=""font-family:'Times New Roman';font-size:14px;"">ously used hair dye―all being of clinical relevance.</span> 
</div>",,"/uploadfiles/file/20131129/20131129133837_8230.pdf",,11/29/2013,11/29/2013,"medicool",23,,"Henna tattoo | Contact dermatitis | Para-phenylenediamine",0,"67",103,"Henna tattoo contact dermatitis C a report  f four cases and brief review of the selected  literature","2012",
491,,"10.2478/s11536-011-0106-1","Sonja Prcic, Aleksandra Matic, Milan Matic , Aleksandra Petrovic","Central European Journal of Medicine","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">&nbsp;Temporary henna tattoos have recently become increasingly popular, especially among teenagers. Combining henna with other colour</span><span style=""font-family:'Times New Roman';font-size:14px;"">ing agents such as para-phenylenediamine (PPD) may increase its potential for contact sensitization, cross-reaction to related com</span><span style=""font-family:'Times New Roman';font-size:14px;"">pounds, as well as life-long allergy. Several cases of contact dermatitis from temporary tattoos with black henna have been repor ted&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">in the literature. We present our experiences with 4 pediatric cases of allergic contact dermatitis induced by henna tattooing and give&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">a brief review of the literature. The agent responsible for contact allergy was proven to be PPD in 3 patients, and in one patch testing&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">revealed positive reactions to PPD and benzocaine, as well as to wool alcohols, nickel sulphate and potassium dichromate, to previ</span><span style=""font-family:'Times New Roman';font-size:14px;"">ously used hair dye―all being of clinical relevance.</span>
</div>
<div style=""text-align:justify;"">
	<br />
</div>",,"/uploadfiles/file/20131128/20131128103207_0156.pdf",,11/28/2013,11/28/2013,"medicool",16,,"Henna tattoo|Contact dermatitis| Para-phenylenediamine",0,"85",103,"Henna tattoo contact dermatitis C a report  of four cases and brief review of the selected  literature","2012",
508,"3％双氯芬酸/2.5％透明质酸治疗光线性角化病的作用机制","10.1111/j.1610-0387.2011.07700.x","Adrienne Maltusch, Joachim R?wert-Huber, Carmen Matthies, Susanne Lange-Asschenfeldt","Journal of the German","<b><span style=""font-family:'Times New Roman','serif';"">Background: </span></b> 
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究背景：</span></b><b><span style=""font-family:'Times New Roman','serif';""></span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:'Times New Roman','serif';""></span></b>
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span><span style=""font-family:'Times New Roman','serif';"">The efficacy of topically applied diclofenac 3 % in combination with hyaluronic acid 2.5 % in the treatment of actinic keratoses (AKs) has been demonstrated in several clinical studies</span></span></a><span style=""font-family:'Times New Roman','serif';"">, but the <a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span>exact mode of action is still unclear</span></a>. <a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span>This study evaluates the potential molecular and cellular main modes of action of topically applied diclofenac in the treatment of AKs.</span></a></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp;&nbsp; 在一些临床研究中，局部应用</span><span style=""font-family:'Times New Roman','serif';"">3</span><span style=""font-family:宋体;"">％双氯芬酸联合</span><span style=""font-family:'Times New Roman','serif';"">2.5</span><span style=""font-family:宋体;"">％透明质酸治疗光线性角化病（</span><span style=""font-family:'Times New Roman','serif';"">AKs</span><span style=""font-family:宋体;"">）的疗效已被证实，但具体的作用机制尚未清楚。本研究旨在探讨局部应用双氯芬酸治疗</span><span style=""font-family:'Times New Roman','serif';"">AKs</span><span style=""font-family:宋体;"">的潜在分子和细胞的主要作用机制。</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';""></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:'Times New Roman','serif';"">Patients and methods:</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究对象与方法：</span></b><b><span style=""font-family:'Times New Roman','serif';""></span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:'Times New Roman','serif';""></span></b>
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span><span style=""font-family:'Times New Roman','serif';"">In this prospective study 20 male patients with AKs were treated for 90 days with topically applied diclofenac 3 %/hyaluronic acid 2.5 %.</span></span></a><a name=""OLE_LINK11""></a><span><span style=""font-family:'Times New Roman','serif';""> Before and after treatment, <a name=""OLE_LINK12""></a>skin biopsies</a> were taken from the treatment area and were <a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span>investigated histologically and immunohistochemically as well as compared to healthy skin</span></a>.</span></span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span><span><span style=""font-family:'Times New Roman','serif';""> For this purpose, <a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span>markers for inflammation (COX-2,</span></a><a name=""OLE_LINK36""></a><a name=""OLE_LINK35""></a><span><span><span> CD3</span></span></span></a><span><span>, CD8), apoptosis (p53), cell cycle arrest (p53, p21), proliferation (Ki67), and angiogenesis (CD31) were examined.</span></span></span></span></span> 
</p>
<p style=""text-indent:-97.3pt;margin-left:97.3pt;"" class=""MsoNormal"">
	<span></span><span></span><span></span><span></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp;&nbsp;在这项前瞻性研究中，</span><span style=""font-family:'Times New Roman','serif';"">20</span><span style=""font-family:宋体;"">名</span><span style=""font-family:'Times New Roman','serif';"">AKs</span><span style=""font-family:宋体;"">男性患者局部应用</span><span style=""font-family:'Times New Roman','serif';"">3</span><span style=""font-family:宋体;"">％双氯芬酸</span><span style=""font-family:'Times New Roman','serif';"">/2.5</span><span style=""font-family:宋体;"">％透明质酸进行治疗，疗程为</span><span style=""font-family:'Times New Roman','serif';"">90</span><span style=""font-family:宋体;"">天。在治疗前后，从治疗区的皮肤取样进行活检并进行组织学检查和免疫组化研究，同时与健康的皮肤进行比较。为此，<a name=""OLE_LINK38""></a><a name=""OLE_LINK37""></a><span>对标记的炎症因子（</span></a></span><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span><span><span><span style=""font-family:'Times New Roman','serif';"">COX-2</span></span></span></span></a><span><span><span><span><span style=""font-family:宋体;"">，</span></span></span></span></span><span><span><span><span><span style=""font-family:'Times New Roman','serif';"">CD3</span></span></span></span></span><span><span><span><span><span style=""font-family:宋体;"">，</span></span></span></span></span><span><span><span><span><span style=""font-family:'Times New Roman','serif';"">CD8</span></span></span></span></span><span></span><span></span><span><span><span style=""font-family:宋体;"">），<a name=""OLE_LINK40""></a><a name=""OLE_LINK39""></a><span>细胞凋亡</span></a>（</span></span></span><a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span><span><span><span style=""font-family:'Times New Roman','serif';"">p53</span></span></span></span></a><span></span><span></span><span><span><span style=""font-family:宋体;"">），细胞周期阻滞（</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';"">p53</span></span></span><span><span><span style=""font-family:宋体;"">和</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';"">p21</span></span></span><span><span><span style=""font-family:宋体;"">），细胞增殖（</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';"">Ki67</span></span></span><span><span><span style=""font-family:宋体;"">）和血管生成因子（</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';"">CD31</span></span></span><span><span><span style=""font-family:宋体;"">）进行研究。</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';""></span></span></span> 
</p>
<p style=""text-indent:-97.3pt;margin-left:97.3pt;"" class=""MsoNormal"">
	<span></span><span></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';""></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:'Times New Roman','serif';""><span>&nbsp;</span>Results:</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究结果：</span></b><b><span style=""font-family:'Times New Roman','serif';""></span></b> 
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK17""></a><span style=""font-family:'Times New Roman','serif';"">The immunohistochemical analysis demonstrated a significant decrease in expression of COX-2, CD3 and CD8</span></a><span style=""font-family:'Times New Roman','serif';"">.<a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><span> Furthermore, there was a clear reduction of CD31 expression as a marker for angiogenetic processes</span></a>. <a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span>Additionally,</span></a><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span><span><span> t</span></span></span></a><a name=""OLE_LINK28""></a><span><span><span><span>here was a tendency toward a reduction in markers for proliferation and apoptosis.</span></span></span></span></a></span> 
</p>
<p style=""text-indent:-97.3pt;margin-left:97.3pt;"" class=""MsoNormal"">
	<span></span><span></span><span></span><span></span><span></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp; 免疫组织化学分析证实，</span><span style=""font-family:'Times New Roman','serif';"">COX-2</span><span style=""font-family:宋体;"">、</span><span style=""font-family:'Times New Roman','serif';"">CD3</span><span style=""font-family:宋体;"">和</span><span style=""font-family:'Times New Roman','serif';"">CD8</span><span style=""font-family:宋体;"">的表达显著下降。而且，作为标记血管生成过程的</span><span style=""font-family:'Times New Roman','serif';"">CD31</span><span style=""font-family:宋体;"">表达明显减少。此外，标记增殖及凋亡蛋白有减少的倾向。</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';""></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:'Times New Roman','serif';"">Conclusions:</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究结论：</span></b><b><span style=""font-family:'Times New Roman','serif';""></span></b> 
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK23""></a><a name=""OLE_LINK22""></a><span><i><span style=""font-family:'Times New Roman','serif';""><span>&nbsp;</span></span></i></span></a><span><span><span style=""font-family:'Times New Roman','serif';"">The efficacy of diclofenac 3 %/hyaluronic acid 2.5 % in the treatment of AKs is probably due to anti-inflammatory and anti-angiogenic effects</span></span></span><span style=""font-family:'Times New Roman','serif';"">, <a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><span>potentially associated with anti-proliferative and apoptosis-inducing underlying mechanisms</span></a></span> 
</p>
<p style=""text-indent:-97.3pt;margin-left:97.3pt;"" class=""MsoNormal"">
	<span></span><span></span>
</p>
<p style=""text-indent:-5.25pt;margin-left:5.25pt;"" class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3</span><span style=""font-family:宋体;"">％的双氯芬酸</span><span style=""font-family:'Times New Roman','serif';"">/2.5</span><span style=""font-family:宋体;"">％透明质酸治疗</span><span style=""font-family:'Times New Roman','serif';"">AKs</span><span style=""font-family:宋体;"">的疗效可能是由于其抗炎和抗血管生成作用</span><span style=""font-family:'Times New Roman','serif';"">,</span><span> </span><span style=""font-family:宋体;"">可能与抗细胞增值和诱导细胞凋亡的潜在作用机制有关联。</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>","/uploadfiles/image/20131203/20131203144231_9611w.png","/uploadfiles/file/20131203/20131203144341_1472.pdf",,12/03/2013,12/03/2013,"medicool",22,,"actinic keratosis 、 diclofenac、 immunohistochemistry、 inflammation",0,"66",104,"Modes of action of diclofenac 3 %/hyaluronic acid 2.5 % in the treatment of actinic keratosis","2011",
492,"伤口未愈合型接触性皮炎：病例报告",,"M Leelavathi ,YYLe , H Tohid and AH Hasliza","Asia Pacific Family Medicine","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp;</span><span style=""line-height:1.5;"">&nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">Topical antiseptics are commonly used in the management of minor wounds, burns, and infected skin. These&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">agents are wide</span><span style=""font-family:'Times New Roman';font-size:14px;""></span><span style=""font-family:'Times New Roman';font-size:14px;"">ly used by health professionals and are often self-prescribed by patients as they are easily available&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">over-the-counter. This case illustrates a 73 year old man who presented with a non-healing wound on his right&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">forearm for 4 weeks. The wound started from an insect bite and progressively enlarged with increasing pruritus&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">and burning sensation. Clinically an ill-defined ulcer with surrounding erythema and erosion was noted. There was&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">a yellow crust overlying the center of the ulcer and the periphery was scaly. Further inquiry revealed history of self&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">treatment with a yellow solution to clean his wound for 3 weeks. Patient was provisionally diagnosed to have&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">allergic contact dermatitis secondary to acriflavine. Topical acriflavine was stopped and the ulcer resolved after&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">treatment with non-occlusive saline dressing. Skin patch test which is the gold standard for detection and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">confir</span><span style=""font-family:'Times New Roman';font-size:14px;""></span><span style=""font-family:'Times New Roman';font-size:14px;"">m</span><span style=""font-family:'Times New Roman';font-size:14px;""></span><span style=""font-family:'Times New Roman';font-size:14px;"">a</span><span style=""font-family:'Times New Roman';font-size:14px;""></span><span style=""font-family:'Times New Roman';font-size:14px;"">tion of contact dermatitis showed a positive reaction (2+) to acriflavine. Acriflavine is widely used as a</span><span style=""font-family:'Times New Roman';font-size:14px;"">topical antiseptic agent in this part of the world. Hence, primary care physicians managing a large variety of poorly&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">healing wounds should consider the possibility of contact allergy in recalcitrant cases, not responding to&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">conventional treatment. Patient education is an important aspect of management as this would help curb the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">incidence of future contact allergies.<br />
</span><span style=""line-height:1.5;font-size:14px;""><span style=""font-family:'Times New Roman';"">&nbsp; &nbsp;</span></span><span style=""font-family:SimSun;font-size:14px;"">局部抗菌剂常用于处理轻微创伤、烧伤和皮肤感染。这些药物被医疗卫生人员广泛使用，并且患者通常会自行使用，因为它们很容易无需处方自主购买到。以一位关于73岁男性，他的右前臂有一个连续4周都未愈合伤口为例。他的伤口开始被昆虫叮咬，并逐步扩大，皮肤瘙痒和烧灼感增强。临床发现一些不明原因且周围伴随有红斑和糜烂的溃疡。在溃疡的中心和边缘还覆盖有一层鱼鳞状的黄色痂皮。进一步调查显示，患者有用黄色液体清理伤口的自我治疗史。该患者暂时被诊断为过敏性接触性皮炎继发吖啶黄。停止外敷吖啶黄，并采用非闭塞碱盐敷料治疗后，溃疡得到解决。皮肤斑贴试验是检测和确认接触性皮炎对吖啶黄呈阳性反应（</span><span lang=""EN-US"" style=""font-family:SimSun;font-size:14px;"">2+</span><span style=""font-family:SimSun;font-size:14px;"">）的金标准，在部分国家吖啶黄被广泛用作局部防腐剂。因此，医生在治疗大量各种顽固不愈伤口时，应考虑为顽固的接触性变态反应病例的可能性，而不应采用常规治疗。病人教育是管理的一个重要方面，因为这将有助于控制未来其接触性过敏的发生率。</span> <span style=""font-family:SimSun;font-size:14px;""></span> 
</div>","/uploadfiles/image/20131129/20131129134724_0587w.jpg","/uploadfiles/file/20131128/20131128110813_8906.pdf",,11/28/2013,11/29/2013,"medicool",28,,"non-healing wound|topical antiseptics|allergic contact dermatitis| Patient education",0,"85",103,"Contact dermatitis presenting as non-healing wound: case report","2011",
513,,,"Andrés F. Henao-Martínez\ Guido R. González-FontaP, Steven Johnson'","Biomédica","&nbsp; &nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> Acinetobacterskln and soft tissue infection outside of the traumatic wound setting are rare occurrences.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">The majority of cases occur in the presence of significant comorbilities and by Acinetobacterbaumanii.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Herein a case is reported of community-onset, health-care-associated, non-traumatic cellulitis caused&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">by Acinetobacter, speáes junii-johnsoniimXh bacteremia. This is the first reported case of Acinetobacter&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">junii-jotinsoniiskm and soft tissue infection. Hemorrhagic bullae might be one of the clinical features of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Acinetobacter cellulitis.</span><br />",,"/uploadfiles/file/20131204/20131204112054_1584.pdf",,12/04/2013,12/04/2013,"medicool",13,,,0,"85",106,"A case of community-acquired Acinetobacter junii-johnsonü ceWuWW","2011",
514,,,"Pasquale De Nardo, Maria Letizia Giancola, Salvatore Noto, Elisa Gentilotti, Piero Ghirga, Chiara Tommasi, Rita Bellagamba, Maria Grazia Paglia, Emanuele Nicastri, Andrea Antinori and Angela Corpolongo","BMC Infectious Diseases","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Background.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> In recent years, Nocardia farcinica has been reported to be an increasingly frequent cause of localized&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and disseminated infections in the immunocompromised patient. However, recent literature is limited. We report a&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">case of left thigh phlegmon caused by N. farcinica that occurred in a patient with Leprosy undergoing treatment&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">with prednisone for leprosy reaction.</span><br />",,"/uploadfiles/file/20131204/20131204112459_9212.pdf",,12/04/2013,12/04/2013,"medicool",14,,,0,"85",106,"Left thigh phlegmon caused by Nocardia farcinica identified by 16S rRNA sequencing in a patient with Leprosy: a case report","2013",
493,,"10.1111/j.1600-0536.2012.02083.x","Marie T. Vennegaard, Charlotte M. Bonefeld, Peter H. Hagedorn, Nannie Bangsgaard,",,"<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Background<br />
&nbsp; &nbsp;&nbsp;MicroRNAs are short, endogenous RNAmolecules that can bind to parts&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">of target mRNAs, thus inhibiting their translation and causing accelerated turnover or&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">degradation of transcripts, thereby regulating gene expression. SeveralmicroRNAs have&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">been found to be upregulated in atopic dermatitis and psoriasis, indicating a role in&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">in?ammatory skin diseases. However, there have been no studies on the expression of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">microRNAs in allergic contact dermatitis.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Objectives<br />
&nbsp; &nbsp; &nbsp;To investigate expression of microRNAs in allergic contact dermatitis.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Methods. Lesional and non-lesional skin biopsies were collected from subjects with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">allergic responses to diphenylcyclopropenone (DPCP). Additional samples for pro?ling&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">were collected from an experimental mouse model by use of the strong allergen dini</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tro?uorobenzene. RNAwas puri?ed fromall samples, and locked nucleic acidmicroarray&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">analysis was performed, followed by validation with quantitative polymerase chain&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">reaction (PCR).<br />
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Results<br />
&nbsp; &nbsp; &nbsp; In humans sensitized with DPCP, we found signi?cant upregulation of miR</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">21, miR-142-3p, miR-142-5p and miR-223 in challenged skin. The same microRNAs&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">were signi?cantly upregulated in the skin of mice in a mouse model of contact allergy.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The upregulation of microRNA was con?rmed by quantitative PCR.<br />
</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Conclusion<br />
&nbsp;&nbsp; These are the ?rst results indicating that microRNAs may be involved in</span><span style=""line-height:1.5;"">&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the pathogenesis of allergic contact dermatitis, and they showthatmousemodels are valu</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">able tools for further study of the involvement ofmicroRNAs inallergic contact dermatitis.</span>
</div>",,"/uploadfiles/file/20131128/20131128165708_3941.pdf",,11/28/2013,11/28/2013,"medicool",16,,"allergic contact dermatitis| in?ammation| microRNA| skin",0,"65",103,"Allergic contact dermatitis induces upregulation of identical microRNAs in humans and mice","2012",
494,,"10.1111/j.1600-0625.2011.01323.x","Jette L. Riis, Claus Johansen, Christian Vestergaard, Rikke Bech, Knud Kragballe and Lars Iversen","Original Article","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp; CCL27 and CCL17 are chemokines believed to be&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">involved in the process of establishing the in?ammatory in?ltrate</span> 
</div>
<span style=""font-size:14px;font-family:'Times New Roman';""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">characteristic for the various in?ammatory skin diseases. The skin&nbsp;</span><span style=""line-height:1.5;"">speci?c CCL27 binds the chemokine receptor-10 (CCR10), and&nbsp;</span><span style=""line-height:1.5;"">CCL17 is a chemokine receptor-4 (CCR4) ligand. The purpose of&nbsp;</span><span style=""line-height:1.5;"">our study was to characterize the expression of CCL27 and CCL1&nbsp;</span><span style=""line-height:1.5;"">in the in?ammatory skin diseases: psoriasis, atopic dermatitis&nbsp;</span><span style=""line-height:1.5;"">(AD) and acute allergic contact dermatitis (ACD) induced in&nbsp;</span><span style=""line-height:1.5;"">nickel-sensitive individuals. Surprisingly, our studies revealed a&nbsp;</span><span style=""line-height:1.5;"">markedly decreased CCL27 mRNA and protein expression in&nbsp;</span><span style=""line-height:1.5;"">psoriatic lesions compared with non-lesional psoriatic skin. A&nbsp;</span><span style=""line-height:1.5;"">minor CCL17 mRNA increase was measured in lesional psoriatic&nbsp;</span><span style=""line-height:1.5;"">skin. No alterations were found in AD. In ACD, we found a</span> 
</div>
</span><span style=""font-size:14px;font-family:'Times New Roman';""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">pronounced (90-fold) raise in CCL17 mRNA and a 50-fold&nbsp;</span><span style=""line-height:1.5;"">increase in CCL17 protein compared with normal skin. A kinetic&nbsp;</span><span style=""line-height:1.5;"">ACD study of CCL17 expression showed the highest mean value&nbsp;</span><span style=""line-height:1.5;"">24 h after hapten application. Furthermore, we found the mRNA&nbsp;</span><span style=""line-height:1.5;"">levels of CCR10 and CCR4 paralleling the results of their&nbsp;</span><span style=""line-height:1.5;"">corresponding ligands. Overall, our principal ?ndings were a&nbsp;</span><span style=""line-height:1.5;"">distinct decrease in CCL27 in lesional psoriatic skin and a marked&nbsp;</span><span style=""line-height:1.5;"">upregulation of CCL17 in ACD. These ?ndings underscore the&nbsp;</span><span style=""line-height:1.5;"">differential cutaneous T-cell recruitment in different in?ammatory&nbsp;</span><span style=""line-height:1.5;"">diseases.</span> 
</div>
</span><span style=""font-size:14px;font-family:'Times New Roman';""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span> 
</div>
</span>",,"/uploadfiles/file/20131128/20131128170744_2981.pdf",,11/28/2013,11/28/2013,"medicool",13,,"CCL27| CCL17| CCR10| CCR4| in?ammatory skin diseases",0,"65",103,"Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis","2011",
495,,"10.2340/00015555-1061","Marlene ISAKSSON, Christer HANSSON, Annica INEROT, Carola LID?N,Mihaly MATURA",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Sesquiterpene lactone mix detects contact allergy to&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">these compounds present in the plant family Asteraceae.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">This marker is present in many baseline series. An addi</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">tional marker is Compositae mix, which is not present in&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">many baseline series. To investigate whether this allergen&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">should be inserted into the Swedish baseline series, six&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">dermatology centres representing the Swedish Contact&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Dermatitis Research Group included Compositae mix&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">into their baseline series for L5 years. Of 2,818 patients&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">tested, 31 (1.1%) reacted to Compositae mix and 26</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(0.9%) to Sesquiterpene lactone mix. Active sensitization&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">to Compositae mix was noted in two cases. Only 0.4% of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Asteraceae contact allergy cases would have been missed&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">if Compositae mix had not been tested, a frequency too&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">low to merit its inclusion in the baseline series. Due to&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">obvious geographical differences in frequency of simul</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">taneous allergic reactions to Compositae mix and Sesqui</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">terpene lactone mix, the question as to whether specific&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">baseline series (including Compositae mix or not as a&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">""tail"" substance) should be used in the different centres&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">must be addressed. Another option could be to remove&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Sesquiterpene lactone mix from the baseline series and&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">substitute it with Compositae mix. Key words: sesquiter</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">pene lactone mix; Asteraceae; Compositae mix; baseline&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">series; contact allergy; colophony; fragrance; Myroxylon.</span> 
</div>",,"/uploadfiles/file/20131128/20131128171839_5928.pdf",,11/28/2013,11/28/2013,"medicool",21,,"Multicentre Patch Testing|lactone mix detects|baseline series|allergen",0,"65",103,"Multicentre Patch Testing with Compositae Mix by the Swedish Contact Dermatitis Research Group","2011",
496,,"10.1111/j.1600-0536.2012.02060.x","Sri Awalia Febriana, Frank Jungbauer, Hardyanto Soebono and Pieter-Jan Coenraads",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Background</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	&nbsp; &nbsp;Tannery workers are at considerable risk of developing occupational&nbsp;<span style=""line-height:1.5;"">contact dermatitis. Occupational skin diseases in tanneryworkers in newly industrialized&nbsp;</span><span style=""line-height:1.5;"">countries have been reported, but neither the prevalence of occupational allergic contact&nbsp;</span><span style=""line-height:1.5;"">dermatitis nor the skin-sensitizing agents were speci?cally examined in those studies.&nbsp;<br />
</span><span style=""line-height:1.5;"">Objectives<br />
&nbsp; To assess the prevalence of occupational allergic contact dermatitis in&nbsp;</span><span style=""line-height:1.5;"">Indonesian tanneries, identify the causative allergens, and propose a tannerywork series&nbsp;</span><span style=""line-height:1.5;"">of patch test allergens.<br />
</span><span style=""line-height:1.5;"">Patients/methods<br />
&nbsp;A cross-sectional study in allworkers at two Indonesian tanneries&nbsp;</span><span style=""line-height:1.5;"">was performed to assess the prevalence of occupational contact dermatitis via a&nbsp;</span><span style=""line-height:1.5;"">questionnaire-based interviewand skinexamination.Workerswithoccupational contact&nbsp;</span><span style=""line-height:1.5;"">dermatitis were patch tested to identify the causative allergens.&nbsp;<br />
</span><span style=""line-height:1.5;"">Results<br />
&nbsp;&nbsp;Occupational contactdermatitiswas suspectedin77(16%)of the 472 workers.&nbsp;</span><span style=""line-height:1.5;""></span><span style=""line-height:1.5;"">Thirteen (3%) of these 472workerswere con?rmed to have occupational allergic contact&nbsp;</span><span style=""line-height:1.5;"">dermatitis. Potassium dichromate (9.2%), N,N-diphenylguanidine (5.3%), benzidine</span><span style=""line-height:1.5;"">(3.9%) and sodium metabisul?te (2.6%) were found to be the occupationally relevant&nbsp;</span><span style=""line-height:1.5;"">sensitizers.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Conclusions<br />
&nbsp; &nbsp;The sensitization pattern showed some differences from the data in&nbsp;</span><span style=""line-height:1.5;"">studies reported from other newly industrial countries. We compiled a ‘tannery work&nbsp;</span><span style=""line-height:1.5;"">series’ of allergens for patch testing. A number of these allergens may also be considered&nbsp;</span><span style=""line-height:1.5;"">for patch testing in patients with (leather) shoe dermatitis.</span> 
</div>
</span>",,"/uploadfiles/file/20131128/20131128173324_3172.pdf",,11/28/2013,11/28/2013,"medicool",21,,"occupational allergic contact dermatitis| occupational contact dermatitis|
patch test| tannery workers.",0,"65",103,"Occupational allergic contact dermatitis and patch test results of leather workers at two Indonesian tanneries","2012",
666,,,"Omoregie FO, Ukpebor M & Saheeb BD","West African Journal Of Medicine","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>BACKGROUND:</strong> Mucosal affectation may be a direct cytotoxic&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">or cytostatic effect of methotrexate.</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>OBJECTIVE:</strong> To highlight the diagnostic procedure and&nbsp;</span><span style=""line-height:1.5;"">treatment intervention erythema multiforme complicating&nbsp;</span><span style=""line-height:1.5;"">methotrexate-induced allergic stomatitis.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>CASE REPORT: </strong>The patient was a 60-year-old man suffering&nbsp;</span><span style=""line-height:1.5;"">from stomatitis that rapidly developed into erythema&nbsp;</span><span style=""line-height:1.5;"">multiforme. The patient had been prescribed methotrexate to&nbsp;</span><span style=""line-height:1.5;"">treat rheumatoid arthritis. The patient presented with painful&nbsp;</span><span style=""line-height:1.5;"">ulceration of the vermillion border of the upper and lower lips&nbsp;</span><span style=""line-height:1.5;"">covered with necrotic tissues. We made a tentative diagnosis&nbsp;</span><span style=""line-height:1.5;"">of methotrexate induced allergic stomatitis. On the patient’s&nbsp;</span><span style=""line-height:1.5;"">second visit to the clinic, the lesion had developed into crusted&nbsp;</span><span style=""line-height:1.5;"">and haemorrhagic ulceration with erythematous patches on&nbsp;</span><span style=""line-height:1.5;"">the lips. The patient was now complaining of weakness, fever&nbsp;</span><span style=""line-height:1.5;"">and occasional seizure attack. Examination of the upper and&nbsp;</span><span style=""line-height:1.5;"">lower extremities revealed bilateral bullous eruptions. The&nbsp;</span><span style=""line-height:1.5;"">definitive diagnosis was that of erythema multiforme&nbsp;</span><span style=""line-height:1.5;"">complicating methotrexate induced allergic stomatitis.&nbsp;</span><span style=""line-height:1.5;"">Withdrawal of the methotrexate yielded positive result with&nbsp;</span><span style=""line-height:1.5;"">complete resolution of the lesions after 12 days of drug&nbsp;</span><span style=""line-height:1.5;"">withdrawal.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>CONCLUSION:</strong> Early diagnosis of adverse drug reactions is&nbsp;</span><span style=""line-height:1.5;"">essential for effective treatment, to avoid untoward systemic</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">complications. &nbsp;</span>
</div>
</span>",,"/uploadfiles/file/20131213/20131213104906_5214.pdf",,12/13/2013,12/13/2013,"medicool",17,,"Methotrexate | Allergic Stomatitis | Erythema multiforme | complications.",0,"67",111,"Methotrexate-Induced Erythema Multiforme: A Case Report and Review of the Literature","2011",
667,"一个家庭中的I型点状掌跖角化的两例报告","doi:10.1016/j.foot.2012.03.004","Varadraj V. Pai, N.N. Kikkeri, S.B. Athanikar, T. Sori, Ravikala Rao.","Department of dermatology","<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<b><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Abstract.</span><o:p></o:p></b>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Background: </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Inherited palmoplantar
keratoderma are a rare group of disorder </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">affecting the palm and
sole </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">characterised by hyperkeratosis resulting in
severe disability and deformities.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Objective: </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">To report a rare case of punctate palmoplantar
keratoderma.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Method: </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">A case attending our OPD is reported.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Result: </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Case report.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Conclusion: </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">This case&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">is reported for its unique
presentation and rarity.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">摘要：</span><span lang=""EN-US""><o:p></o:p></span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">研究背景：遗传性掌跖角化病是影响手掌和脚底的一组罕见疾病，角化过度引起的严重残疾和畸形为特征。</span><span lang=""EN-US""><o:p></o:p></span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">研究目的：旨在报道一例罕见的点状掌跖角化病。</span><span lang=""EN-US""><o:p></o:p></span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">研究方法：报道了一例在我们门诊处就诊的病例。</span><span lang=""EN-US""><o:p></o:p></span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">研究结果：病例报告。</span><span lang=""EN-US""><o:p></o:p></span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">研究结论：这一病例因其独特的临床表现和罕见性而被报道。</span><span lang=""EN-US""><o:p></o:p></span>
</p>","/uploadfiles/image/20131213/20131213133739_3484w.jpg","/uploadfiles/file/20131213/20131213133918_9077.pdf",,12/13/2013,12/13/2013,"medicool",18,,"Punctate palmoplantar keratoderma",0,"85",110,"Type I punctate palmoplantar keratoderma (Buschke-Fisher-Brauer disease) in a family―A report of two cases","2012",
668,"掌跖角化病：CO2激光治疗的病例报告文献综述","DOI: 10.1097/SAP.0b013e3182085a8b","Elizabeth A. O’Connor, MD, and William W. Dzwierzynski, MD","Annals of Plastic Surgery ? Volume","<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<b><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">Abstract: </span></b><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">Palmoplantar keratoderma is a heterogeneous group of disorders
affecting keratinization on the palms and soles of the feet. </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">The benign lesions cause pain and </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">limit
function. </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">Treatment
of palmoplantar keratoderma remains problematic and restricted to symptomatic
therapy; </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">no cure exists. </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">Medical treatments and
surgical excision are currently the mainstay of therapy; however, </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">these
treatments have limited success, significant morbidity, and
recurrence is common. </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">We present a case report of
successful treatment with CO2 laser therapy and a review of the literature.</span><o:p></o:p>
</p>
<span style=""font-size:14px;font-family:SimSun;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">摘要：掌跖角化病是影响手掌和脚底角化作用的一组异质性疾病。该疾病的良性病变会引起疼痛并限制身体的部分功能。掌跖角化病的治疗仍然存在问题，并且受对症治疗的限制；尚无痊愈疗法出现。药物治疗和手术切除是目前治疗的主要手段；然而，这些治疗方法的成功率有限，显著的发病率和复发是常见的。我们介绍了一例采用CO2激光治疗成功治疗掌跖角化病的病例报告和一则文献综述。</span>
</div>
</span>","/uploadfiles/image/20131213/20131213134528_6908w.jpg","/uploadfiles/file/20131213/20131213134547_8164.pdf",,12/13/2013,12/13/2013,"medicool",20,,"keratoderma, hyperkeratosis, CO2 laser, palmoplantar keratoderma",0,"67",110,"Palmoplantar Keratoderma Treatment With CO2 Laser Case Report and Review of the Literature","2011",
671,,"10.1111/j.1600-0560.2012.01980.x","Sara C. Shalin Julie Brantley and A. Hafeez Diwan","J Cutan Pathol","<p style=""text-indent:2em;"">
	<span style=""font-size:14px;font-family:'Times New Roman';"">&nbsp;Leuprolide acetate represents a gonadotropin-releasing hormone</span><span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">agonist, used as part of the treatment of prostate cancer. We report an</span><span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">unusual case of disseminated urticarial rash following leuprolide</span><span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">injection in a 67-year-old man that histopathologically and</span><span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">immunohistochemically resembled mycosis-fungoides, including the</span><span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">presence of follicular mucinosis and eosinophils in the follicles. This</span><span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">histopathologic pattern has not been previously described as a drug</span><span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">reaction pattern due to leuprolide, and it underscores the importance of</span><span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">correlation with the clinical impression to arrive at a correct diagnosis.</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';""></span>
</p>",,"/uploadfiles/file/20131217/20131217132626_1163.pdf",,12/17/2013,12/17/2013,"medicool",4,,"atypical lymphocytic proliferation, drug reaction, follicular
mucinosis, leuprolide",0,"67",112,"Follicular mucinosis and mycosis-fungoides-like drug eruption due to leuprolide acetate: a case report and review","2012",
672,,"10.1111/j.1365-2230.2009.03266.x","E. Sendagorta, P. Herranz, M. Feito, P. Ram??rez, R. Feltes, U. Florista?n, A. Marin? o-Enriquez* and M. Casado","Viewpoints in dermatology","<span style=""font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; Imatinib mesylate is a tyrosine kinase inhibitor that targets</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">the BCR-ABL protein, c-KIT and platelet-derived growth</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;"">factor. It is used for the treatment of chronic myeloid</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">leukaemia and gastrointestinal stromal tumour (GIST), a</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">rare tumour involving the gastrointestinal tract.<br />
&nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">A 71-year-old man presented with a cutaneous eruption</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">on the flanks and erosions in the oral mucosa. Nine months</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;"">previously he had been diagnosed with a GIST in the</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">gastric fundus, and had been treated successfully with</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">surgery. He had been started on imatinib 400 mg daily as</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">adjuvant treatment He was not receiving any other</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">treatment. Three months later he developed violaceus</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">scaly pruritic plaques on the flanks and arms (Fig. 1a).</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">Simultaneously, he noticed a burning sensation affecting</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">oral mucosa.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;""></span><br />",,"/uploadfiles/file/20131217/20131217133158_9741.pdf",,12/17/2013,12/17/2013,"medicool",4,,"Lichenoid drug eruption ， imatinib，",0,"67",112,"Lichenoid drug eruption related to imatinib: report of a new case and review of the literature","2009",
674,"外用吡美莫司治疗与西妥昔单抗相关的痤疮样药疹：一项前瞻性随机试验","10.1016/j.jaad.2009.03.046","Alon Scope, MD,a Jocelyn A. Lieb, MD,a Stephen W. Dusza, MPH, Deborah L. Phelan, RN, Patricia L. Myskowski, MD","American Academy of Dermatology","<p class=""MsoNormal"">
	<span style=""font-family:Times New Roman;"">Background:</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:Times New Roman;"">背景：</span>
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-family:Times New Roman;"">Clinical trials addressing the acneiform rash associated
with epidermal growth factor receptor inhibitors are lacking.</span><br />
<span style=""text-indent:4.5pt;font-family:'Times New Roman';"">目前，针对表皮生长因子受体抑制剂相关的痤疮样皮疹的临床试验仍很缺乏。</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:Times New Roman;"">Objective:</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:Times New Roman;"">目的：</span>
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span style=""font-family:Times New Roman;"">We evaluated the ability of topical pimecrolimus to
reduce the severity of cetuximab-related facial rash.</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:Times New Roman;"">我们旨在评估外用吡美莫司在减少与西妥昔单抗相关的面部皮疹严重度上的疗效。</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">Methods:</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">方法：</span> 
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-family:'Times New Roman';"">In all, 24 patients with metastatic colorectal cancer
with cetuximab facial rash received twice daily pimecrolimus application for 5
weeks to half of the face. </span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""font-family:'Times New Roman';"">At baseline, week 2, and week
5, </span><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span style=""font-family:'Times New Roman';"">a dermatologist performed facial lesion counts, </span><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span style=""font-family:'Times New Roman';"">patients
reported perceived severity of rash-related symptoms, and standardized
facial photographs were obtained for</span><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span style=""font-family:'Times New Roman';""> blinded evaluation of
global rash severity.</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">共有24名伴有西妥昔单抗面部皮疹的转移性结直肠癌患者接受吡美莫司治疗，应用于半面脸部，2次/天，持续5周。在治疗前、第二周和第五周，由皮肤科医生进行面部皮损计数，患者报告感知到的皮疹相关症状的严重程度，以及获得标准化面部照片来盲法评估全球皮疹的严重程度。</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">Results:</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">结果：</span> 
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span style=""font-family:'Times New Roman';"">Treatment sides had greater decrease in lesion counts
than observation sides of face at weeks 2 (P&lt; .001) and 5 (P = .02). </span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span style=""font-family:'Times New Roman';"">However, there were no significant differences
in</span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span style=""font-family:'Times New Roman';""> patients’ assessment of symptoms and </span><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span style=""font-family:'Times New Roman';"">in
review of facial photographs for rash severity between treatment and
observation sides.</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">在治疗的第二周（P&lt;.001）和第五周(P = .02)，面部治疗一侧与对照观察一侧相比，皮损数量显著减少。然而，患者评估的症状和检查皮疹严重程度的面部照片在治疗一侧和对照观察一侧之间没有显著性差异。</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">Limitations:</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">局限性：</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">&nbsp;</span><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span style=""font-family:'Times New Roman';"">This
study was not placebo controlled.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:4.5pt;"">
	<span style=""font-family:'Times New Roman';"">这项研究没有空白对照。</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">Conclusions:</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">结论：</span> 
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span style=""font-family:'Times New Roman';"">Pimecrolimus application </span><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span style=""font-family:'Times New Roman';"">did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash.</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';"">对于西妥昔单抗相关的面部皮疹患者，应用吡美莫司治疗在临床上并没有很好疗效。</span> 
</p>","/uploadfiles/image/20131217/20131217134434_5302w.png","/uploadfiles/file/20131217/20131217134456_4483.pdf",,12/17/2013,12/18/2013,"medicool",10,,"acne-like rash; cetuximab; clinical trial; pimecrolimus.",0,"66",112,"A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption","2009",
682,,,"FAHD SAEED, MD AND ANN PARKE, MD","CONNECTICUT MEDICINE","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>ABSTRACT</strong>―Scleroderma renal crisis (SRC) is a&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">rarebut severe complication of systemic sclerosis. SRC&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">usually occurs in the presence of high blood pressure&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">but may be seen in patients witb normal blood pressure.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Normotensive SRCcase shave apoorerprognosis&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and failure to recognize this condition can result in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">a fatal outcome, depriving tbe patient ofthe potential&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">benefits of ACE inhibitors. We present a case of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">diffuse cutaneous systemic sclerosis with early onset&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">normotensive SRC and oliguric acute renal failure.</span> 
</div>",,"/uploadfiles/file/20131217/20131217150414_9402.pdf",,12/17/2013,12/17/2013,"medicool",6,,"Scleroderma Renal Crisis, Progressive Systemic Sclerosis, Case Report",0,"85",114,"Normotensive Scleroderma Renal Crisis in a Patient with Progressive Systemic Sclerosis: Case Report and Review of Literature","2011",
675,,"10.1684/ejd.2010.0980","Nesrine BRAHIMI,Emilie ROUTIER, Nadia RAISON-PEYRON, Anne-Fleur TRONQUOY","Eur J Dermatol 2010","<div style=""text-align:justify;"">
	&nbsp; &nbsp; <span style=""font-family:Times New Roman;"">&nbsp;Fixed drug eruption (FDE) is one of the most typical cutaneous drug&nbsp;adverse reactions. This localized drug-induced reaction is characterized&nbsp;by its relapse at the same sites. Few large series of FDE are&nbsp;reported. The aim of this study was to retrospectively collect and analyse&nbsp;well informed cases observed in a hospital setting. This study&nbsp;involved 17 academic clinical centers. A French nation-wide retrospective&nbsp;multicentric study was carried out on a 3-year-period from&nbsp;2005 to 2007 by collecting data in seventeen departments of dermatology&nbsp;in France. Diagnosis of FDE was based essentially on clinical&nbsp;findings, at times confirmed by pathological data and patch-testing.&nbsp;Records were reviewed for demographics, causative drugs, localization,&nbsp;severity, and patch-tests, when available. Fifty nine cases were&nbsp;analysed. Patients were 59-years-old on average, with a female predilection.&nbsp;The most common drug was paracetamol, followed by the&nbsp;non-steroidal anti inflammatory drugs. The time between drug intake&nbsp;and skin symptoms was, on average, two days. Beside these classical&nbsp;characteristics, some original findings were found including, a frequent&nbsp;non pigmentation course and a sex-dependent pattern of distribution.&nbsp;</span><span style=""font-family:Times New Roman;"">Women often had lesions on the hands and feet, and men on&nbsp;the genitalia. Given the fact that skin pigmentation is an inconstant&nbsp;feature of FDE, its French name (erythème pigmenté fixe) should be&nbsp;reconsidered. The sex-dependent distribution could help our understanding&nbsp;of the pathophysiology of fixed drug eruption.</span>
</div>
<div style=""text-align:justify;"">
</div>",,"/uploadfiles/file/20131217/20131217135156_3854.pdf",,12/17/2013,12/17/2013,"medicool",5,,"cutaneous adverse reaction, fixed drug eruption",0,"66",112,"A three-year-analysis of fixed drug eruptions in hospital settings in France","2010",
684,,"DOI 10.1007/s10165-011-0568-7","Koichi Yanaba ? Yoshihide Asano ? Yayoi Tada ? Makoto Sugaya ? Takafumi Kadono ? Shinichi Sato","Mod Rheumatol","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:1.5;""><strong>Abstract.</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Objective</strong> &nbsp;To determine serum growth differentiation&nbsp;</span><span style=""line-height:1.5;"">factor-15 (GDF-15) levels and their clinical associations in</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">patients with systemic sclerosis (SSc).</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Methods</strong> Serum GDF-15 levels were examined by&nbsp;</span><span style=""line-height:1.5;"">enzyme-linked immunosorbent assay in 61 patients with&nbsp;</span><span style=""line-height:1.5;"">SSc and 24 healthy individuals. In a retrospective longitudinal&nbsp;</span><span style=""line-height:1.5;"">study, sera from 14 patients with SSc were analyzed&nbsp;</span><span style=""line-height:1.5;"">(duration of follow-up 1.2C7.2 years).</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Results</strong> Serum GDF-15 levels were significantly elevated&nbsp;</span><span style=""line-height:1.5;"">in SSc patients (1340 ± 910 pg/ml) compared with healthy</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">individuals (213 ± 79 pg/ml; P\0.001). Among SSc&nbsp;</span><span style=""line-height:1.5;"">patients, patients with diffuse cutaneous SSc (n = 31) had&nbsp;</span><span style=""line-height:1.5;"">higher levels of serum GDF-15 (1609 ± 1069 pg/ml) than&nbsp;</span><span style=""line-height:1.5;"">those with limited cutaneous SSc (n = 30; 1142 ± 646&nbsp;</span><span style=""line-height:1.5;"">pg/ml; P\0.05). SSc patients with high GDF-15 levels&nbsp;</span><span style=""line-height:1.5;"">(C1000 pg/ml) had pulmonary fibrosis, decreased vital&nbsp;</span><span style=""line-height:1.5;"">capacity, and decreased diffusion capacity for carbon&nbsp;</span><span style=""line-height:1.5;"">monoxide more often than those with low GDF-15 levels&nbsp;</span><span style=""line-height:1.5;"">(\1000 pg/ml). GDF-15 levels correlated positively with&nbsp;</span><span style=""line-height:1.5;"">the extent of skin sclerosis and inversely with percentage&nbsp;</span><span style=""line-height:1.5;"">vital capacity and diffusion capacity for carbon monoxide&nbsp;</span><span style=""line-height:1.5;"">in patients with SSc. In a longitudinal study, serum GDF-&nbsp;</span><span style=""line-height:1.5;"">15 levels were generally decreased during the follow-up.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Conclusion</strong> Serum GDF-15 levels were increased in&nbsp;</span><span style=""line-height:1.5;"">patients with SSc and associated with the extent of skin&nbsp;</span><span style=""line-height:1.5;"">sclerosis and the severity of pulmonary fibrosis. These&nbsp;</span><span style=""line-height:1.5;"">results suggest that GDF-15 may play a role in the&nbsp;</span><span style=""line-height:1.5;"">development of cutaneous and pulmonary fibrosis in SSc.&nbsp;</span><span style=""line-height:1.5;"">Measurement of serum GDF-15 may be useful for risk&nbsp;</span><span style=""line-height:1.5;"">stratification in early disease stage.</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217151221_5051.pdf",,12/17/2013,12/17/2013,"medicool",3,,"Systemic sclerosis  Cytokine  ELISA  Pulmonary fibrosis  Growth differentiation factor-15",0,"65",114,"Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity","2012",
676,,,"R Pérez-Calderón, MA Gonzalo-Garijo, I Pérez-Rangel, S Sánchez-Vega, MA Zambonino","J Investig Allergol Clin Immunol","<div style=""text-align:justify;"">
	&nbsp;&nbsp;<span style=""font-family:'Times New Roman';"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';""> Nabumetone is a nonacidic nonsteroidal anti-infl ammatory&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">drug (NSAID) formulated as a pharmacologically inactive</span><span style=""font-family:'Times New Roman';"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">prodrug that becomes active only after absorption, predominantly&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">in the small intestine, and through hepatic conversion to its</span><span style=""font-family:'Times New Roman';"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA).&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">This metabolite is structurally similar to naproxen, and is a&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">potent inhibitor of prostaglandin synthesis, preferentially via&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">the cyclooxygenase-2 (COX-2) pathway [1]. Nabumetone has</span><span style=""font-family:'Times New Roman';"">&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">been recommended as a safe alternative in most patients with&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">hypersensitivity reactions to NSAI</span><span style=""font-family:'Times New Roman';"">Ds [2].</span>
</div>
<br />",,"/uploadfiles/file/20131217/20131217135810_8329.pdf",,12/17/2013,12/17/2013,"medicool",5,,"Cross-reactions. Fixed drug eruption. Nabumetone.Naproxen. Nonsteroidal anti-infl ammatory drugs",0,"66",112,"Fixed Drug Eruption Due to Nabumetone in a Patient With Previous Fixed Drug Eruptions Due to Naproxen","2011",
420,,"10.1177/0961203313492243","DJ Lospinoso, C Fernelius, KD Edhegard, DR Finger and NS Arora",,"&nbsp; &nbsp; <span style=""font-family:'Times New Roman';font-size:14px;"">Lupus erythematosus/lichen planus overlap syndrome is a rare disorder combining the clin</span><span style=""font-family:'Times New Roman';font-size:14px;"">ical, histological and immunopathological features of both lupus erythematosus (LE) and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">lichen planus (LP). Cutaneous lesions mostly affect the distal arms, legs, face and trunk.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">Palmoplantar involvement is felt to be characteristic of this condition. Plaques are often</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">painful, centrally atrophic, bluish-red to hypopigmented in color, large, and scaly. On&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">biopsy of clinically ambiguous lesions, histopathological features of one or both processes&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">can be found, obscuring the diagnosis and complicating prognosis and treatment. Thus, direct&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">immunofluorescence has become an essential tool in helping to diagnose this condition. In this</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">report we describe the unique clinical and immunohistopathological manifestations of lupus&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">erythematosus/lichen planus overlap syndrome along with a successful response to treatment&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">with acitretin.</span><br />",,"/uploadfiles/file/20131112/20131112135718_1043.pdf",,11/12/2013,11/12/2013,"medicool",13,,,0,"66",99,"Lupus erythematosus/lichen planus overlap syndrome: successful treatment with acitretin","2013",
422,,"10.2340/00015555-1249","Peter Holló, Jozsef Szakonyi, Dorottya Ki$$, Hajnaika Jokai, Attila Horváth and Sarolta Kárpáti","Journal Compilation","<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; Lichen planus (LP) is a relatively common inflammatory&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">dermatosis (with a prevalence of approximately 0.5%),&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">characterized by violaceous, polygonal, flat pruritic papu</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">les. It can involve both skin and mucous membranes and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">usually occurs in middle-aged persons. Mild cases usually&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">heal spontaneously, but patients with widespread lesions&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">are sometimes hard to treat. Different treatment modalities&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">are available. Topical anti-inflammatory treatment with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">steroid ointments or calcineurin inhibitors have limited&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">efficacy. Phototherapy, systemic treatment with retinoids,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and depot steroids have been administered with limited</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">success, and systemic ciclosporin is usually effective.</span><br />",,"/uploadfiles/file/20131112/20131112140656_7718.pdf",,11/12/2013,11/12/2013,"medicool",19,,,0,"66",99,"Successful Treatment of Lichen Planus with Adalimumab","2012",
421,,,"Tess McPherson & Susan Cooper","DERMATOLOGIC THERAPY","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Abstract.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp;Lichen sclerosus (LS) and lichen planus (LP) are both immunologically mediated diseases</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">with a preference for the genitalia.The basic principles of management of vulval LS and vulvovaginal LP</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">are the same and involve explanation of the disease, emphasizing the chronic nature of the condition</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and outlining treatment options. The main difference between the two conditions is that LP has a</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">propensity to involve the mucous membranes including the mouth and vagina which are rarely affected</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">in LS. First-line treatment for LS is a super-potent topical corticosteroid ointment which has a high</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">response rate. Erosive vulvovaginal LP is more challenging to treat. Second-line therapies include</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;""><span style=""line-height:2;"">topical calcineurin inhibitors and systemic agents.There is </span><span style=""line-height:2;"">limited evidence for systemic treatments for</span></span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">both conditions. The risk of vulval squamous cell carcinoma (SCC) is increased in both LP and LS, and</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">it is not known how treatment affects this risk.We recommend teaching self-examination and longitu-</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">dinal evaluation.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""></span><br />",,"/uploadfiles/file/20131112/20131112140028_8771.pdf",,11/12/2013,11/12/2013,"medicool",19,,,0,"66",99,"Vulval lichen sclerosus and lichen planus","2010",
423,,,"Pia López-Jornet, Fabio Camacho-Alonso and M. Angeles Rodríguez-Martine","Am J Ciin Dermatoi","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Background.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Oral licheti planus (OLP) is a chronic inflammatory disorder. Recently, a case-control study</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">found that lichen planus was associated with dyslipidemia in a large series of patients. However, no data</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">were presented about lipid values in patients and controls.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Objectives.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">The aim of this study was to investigate the hypothetical association between OLP and dyslipidemia.</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Materials and Methods: The study included a total of 400 patients (200 with OLP and 200 controls with other</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">oral diseases) and investigated the prevalence of dyslipidemia. The variables analyzed were age, sex, tobacco</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and alcohol consumption, clinical form of OLP and lipid profiles.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Results.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp;&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">A 54% prevalence of dyslipidemia was found (58% among the OLP group and 50% in the control</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">group). Statistically significant differences in high-density lipoprotein were found between OLP patients and</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">the control group (p = 0.003). A logistic regression model for presence/absence of cardiovascular risk</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">(Castelli's atherogenic index of &gt;5.1 for men and &gt;4.5 for women) found statistically significant differences</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">for sex and tobacco consumption.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Conclusions.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">The study found a higher atherogenic index amongst OLP patients.</span><br />",,"/uploadfiles/file/20131112/20131112141026_8573.pdf",,11/12/2013,11/12/2013,"medicool",25,,,0,"66",99,"Alterations in Serum Lipid Profile Patterns in Oral Lichen Planus A Cross-Sectional Study","2012",
424,,"10.1111/j.1525-1470.2009.00988.x","Daniela M. Cohen, M.D.,* Dan Ben-Amitai, M.D.,* Meora Feinmesser, M.D.,? and Alex Zvulunov, M.D., M.H.A.*","Pediatric Dermatology","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Abstract.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; Lichen planus pemphigoides is a rare autoimmune blister</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">ing disease that is characterized by evolution of vesico-bullous skin lesions&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">in patients with active lichen planus. We describe a case of lichen planus&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">pemphigoides in a 6-year-old boy and review the clinical and immunopath</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">ologic features of all reported cases of pediatric lichen planus pemphigo</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">ides. The mean age at onset of childhood lichen planus pemphigoides is&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">12 years with a male to female ratio of 3:1 and a mean lag-time between</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">lichen planus and the development of lichen planus pemphigoides of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">7.9 weeks. Vesiculo-bullous lesions were found on the extremities in all&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">patients and there was palmoplantar involvement in about half of the cases.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Direct and indirect immunofluorescence features were similar to those&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">reported in adults. One patient had Western immunoblot data revealing</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">antigens of 180, 230, and 200 kDa. Immunoelectron microscopy in two cases&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">showed localization of immune deposition different from that in bullous&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">pemphigoid. We found that topical corticosteroids or oral dapsone caused&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">resolution of lichen planus pemphigoides without known relapse of blister</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">ing in four cases, suggesting that it might be possible to reserve oral corti</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">costeroids as a second line of therapy in children with lichen planus&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">pemphigoides.</span><br />",,"/uploadfiles/file/20131112/20131112141450_0298.pdf",,11/12/2013,11/12/2013,"medicool",25,,,0,"67",99,"Childhood Lichen Planus Pemphigoides: A Case Report and Review of the Literature","2009",
426,,,"Shilpa S Sawardekar, MD,and Bryan 6 Anderson, MD",,"&nbsp; <span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; Lichen planus (LP) is an inflammatory&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">mucocutaneous condition that character</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">istically results in violaceous-to-purple,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">pruritic, polygonal, flat-topped papules or&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">plaques. It can have a variety of clinical&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">manifestations, and can affect any age group.&nbsp;</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">The eruptions most often affect the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">flexor surfaces of the upper extremities and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">oral mucosa. There are many characteristic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">regions for LP involvement, including the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">skin, oral, and genital mucous membranes,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">commonly termed cutaneous LP, oral LP,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and genital LP, respectively. Often patients&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">have involvement of several of these sites&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">simultaneously. The diagnosis is most&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">commonly ruled in with use of punch biopsy&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and histopathological confirmation.</span>",,"/uploadfiles/file/20131112/20131112142350_8515.pdf",,11/12/2013,11/12/2013,"medicool",37,,,0,"67",99,"Lichen Planus: A Clinical Review","2011",
427,,"10.1111/j.1365-2133.2012.10821.x","G. Lodi, M. Carrozzo,* S. Furness? and K. Thongprasom?","British Journal of Dermatology","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Summary.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; Oral lichen planus (OLP) is a common chronic inflammatory disease associated&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">with cell-mediated immunological dysfunction. Symptomatic OLP is painful and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">complete healing is rare. The aim of this review was to assess the evidence for the</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">efficacy and safety of treatments for symptomatic OLP. The Cochrane Oral Health&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Group Trials Register, the Cochrane Central Register of Controlled Trials (CEN</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">TRAL), MEDLINE and EMBASE were searched in January 2011 to identify all ran</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">domized controlled trials (RCTs) evaluating any intervention for the treatment of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">symptomatic OLP. A total of 28 trials were included in this Cochrane review.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">There was no evidence from three RCTs that topical pimecrolimus is better than&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">placebo in reducing pain from OLP. There was weak evidence from two RCTs that&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">topical aloe vera may be associated with a reduction in pain compared with pla</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">cebo. There was weak and unreliable evidence from two small trials, at high risk&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">of bias, that topical ciclosporin may reduce pain and clinical signs of OLP. There&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">was no evidence (from five trials each evaluating a different steroid and?or calci</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">neurin inhibitor) that there is a difference between treatment with topical corti-</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">costeroids (TCSs) compared with topical calcineurin inhibitors with regard to&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">reducing pain associated with OLP or that any specific steroid therapy is more or&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">less effective at reducing pain. Although TCSs are considered to be the first-line&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">treatment, we did not identify any RCTs that compared TCSs with placebo in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">patients with symptomatic OLP. From the 28 trials included in this systematic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">review, the wide range of interventions compared means there is insufficient evi</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">dence to support the superior effectiveness of any specific treatment.</span><br />",,"/uploadfiles/file/20131112/20131112142641_0634.pdf",,11/12/2013,11/12/2013,"medicool",35,,,0,"67",99,"Interventions for treating oral lichen planus: a systematic review","2012",
433,"关于艾滋病病理学和治疗方案的综述",,"Nadeem Siddiquia, Waquar Ahsana, Priya Ahujaa, M. Shamsher Alama, Anwar Habibb","International Journal of Pharmaceutical Sciences Review and Research","<p class=""MsoNormal"" align=""justify"">
	<span><span style=""font-family:&quot;&quot;;""><span style=""font-size:16px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; People </span><span style=""font-size:16px;"">suffering from HIV have differing needs depending their personal circumstances </span><span style=""font-size:16px;"">and stage of infection</span></span></span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-size:16px;"">. A comprehensive package of care covers the entire </span><span style=""font-size:16px;"">journey from diagnosis to death, </span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-size:16px;"">which with </span><span style=""font-size:16px;"">antiretroviral treatment may span several decades.</span></span></span></span></span></span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-size:16px;""> HIV drugs cannot cure HIV but they can help you stay </span><span style=""font-size:16px;"">healthy by preventing the virus from reproducing.</span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""color:#313131;font-family:宋体;""><span style=""font-size:16px;"">&nbsp;&nbsp; 依据</span><span style=""font-size:16px;"">HIV</span><span style=""font-size:16px;"">患者的个人情况和感染阶段，他们有着不同的需求。伴随抗逆转录病毒治疗的一套涵盖从诊断到死亡整个过程的全面护理方案可能会持续几十年。</span><span style=""font-size:16px;"">HIV</span><span style=""font-size:16px;"">药物不能治愈</span><span style=""font-size:16px;"">HIV,</span><span style=""font-size:16px;"">但它们可以通过阻止病毒的复制来帮助你保持健康。</span><span></span></span> 
</p>
<br />
<br />
<p align=""justify"">
	&nbsp;
</p>","/uploadfiles/image/20131113/20131113154147_1967w.png","/uploadfiles/file/20131113/20131113154004_3457.pdf",,11/13/2013,11/13/2013,"medicool",40,,"HIV, AIDS, Immunity, drug resistance.",0,"67",19,"A REVIEW ON PATHOLOGY OF AIDS AND ITS TREATMENT REGIMENS","2011",
434,,"volume 8 ? number 1 ? 2009","Agnieszka O?dakowska  ?  Sabina Dobosz  ?    Ma?gorzata Szczepaska-Putz  ? Magdalena Marczyska","hiv & aids  r e v i e w","We are presenting the case of a 10-year-old girl with late AIDS diagnosis and a suspicion of invasive aspergillosis with&nbsp;<br />
liver involvement who showed a good response to voriconazole treatment.<br />",,"/uploadfiles/file/20131114/20131114092119_5236.pdf",,11/14/2013,11/14/2013,"medicool",32,,"AIDS | aspergillosis | child",0,"85",19,"A suspicion of aspergillosis in a child   with AIDS C a case report","2009",
436,,"(2009) 13, 285―290","Peritonitis due to Mycobacterium avium complex in patients with AIDS: report of ?ve cases and review of the literature","International Journal of Infectious Diseases","<p style=""text-indent:2em;"">
	Mycobacterium avium complex (MAC) infection is a common complication 
of advanced-stage HIV-1 infection, which often occurs in patients with CD4 
lymphocyte counts of &lt;50 cells/ml. Before the introduction of highly active 
antiretroviral therapy (HAART) and primary prophylaxis, MAC infection in those 
patients at an advanced stage of HIV infection was often associated with 
signi?cant mortality and morbidity.Although the incidence of MAC infection has 
declined sub-stantially in the era of HAART, it continues to occur in patients 
without access to HAART or in patients who develop virological and immunological 
failure to HAART due to drug intolerance or the emergence of antiretroviral 
resistance.<br />
&nbsp; &nbsp; &nbsp;&nbsp;MAC can be isolated from non-sterile sites, such as 
speci-mens of the gastrointestinal and respiratory tracts, which may 
represent colonization or disseminated infection. In disseminated MAC infection, 
the organs most commonly&nbsp;involved are the spleen, lymph nodes, liver, 
intestines,and bone marrow; the lungs, adrenals, stomach, and central nervous 
system are less commonly involved.Although MAC isa well-described pathogen in 
AIDS patients, peritonitis due to&nbsp;MAC  has rarely been described.In this 
report we describe ?ve cases of peritonitis due to MAC and review the 
literature.
</p>
<p style=""text-indent:2em;"">
	<br />
</p>",,"/uploadfiles/file/20131114/20131114101947_2989.pdf",,11/14/2013,11/14/2013,"medicool",22,,"Mycobacterium avium | complex | Peritonitis | AIDS  Non-tuberculous
mycobacteria | Intra-abdominal | infection",0,"85",19,"Peritonitis due to Mycobacterium avium complex in patients with AIDS: report of ?ve cases and review of the literature","2009",
443,,"Biologicals 35 (2007) 367e371","Geetha P. Bansal","International Association for Biologicals","Passive immunization with monoclonal antibodies (MAbs) has been shown to prevent a wide variety of diseases. Currently, there are no MAb&nbsp;products that are licensed for use for immunotherapy or immunoprophylaxis against infection by HIV. However, there are several rational arguments that can be advanced for the use of a passive immunization approaches for counteracting HIV much as for other diseases especially with&nbsp;respect to mother-to-child transmission (MTCT) of HIVand immediate post-exposure situations. Several arguments questioning the feasibility of&nbsp;the approach based on availability of effective drugs, high cost of production and distribution of the MAbs among others, also get raised. It seems&nbsp;that the ?eld now is looking at some promising MAbs as well as several alternate ways to manufacture antibodies and which hopefully may<br />
positively affect cost-related issues. This summary of a workshop held to assess the role of MAbs in the treatment and prevention of HIV/AIDS provides a fairly comprehensive analysis of the usefulness of MAb technology for future HIV/AIDS research.<br />",,"/uploadfiles/file/20131114/20131114155030_4558.pdf",,11/14/2013,11/14/2013,"medicool",23,,"Monoclonal antibodies|Passive immunization|HIV/AIDS prevention|Immunoprophylaxis| Immunotherapeutic| MTCT| MAb",0,"67",19,"A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006 Geetha P. Bansal* Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH, 6700-B Rockledge Drive, Room 5120, Bethesda, MD 20892, US","2007",
437,,"92 (2012) 155C159","Will L. Singleterry, Harold Henderson, Julius M. Cruse","Experimental and Molecular Pathology","<p style=""text-indent:2em;"">
	In this present investigation, ?ow cytometry was utilized to evaluate 13 healthy controls and 31 HIV-1&nbsp;infected patients who had advanced to the AIDS stage of infection (CD4 count below 200 cells/mm3), for&nbsp;the expression of CD161 on CD3+ double negative (DN) (CD3+CD4-CD8-) T cells, CD4+ T cells, CD8+ T&nbsp;cells and γδ T cells. The observed depletion of CD161+ T cells from peripheral circulation was due primarilyto the loss of CD4+CD161+ T cells; as these cells represented 8.67±0.74% of the total healthy control peripheral T cell population, while the CD4+CD161+ T cells of the AIDS group represented only 3.35±0.41%(p=b0.0001) of the total peripheral T cell population. We have also shown here that the&nbsp;DN T cell population was more than doubled in the AIDS group, with the DN T cell population expanding from 3.29±0.45% of<br />
the healthy control peripheral T cell population to 8.64±1.16% (p=0.0001) of the AIDS group peripheral Tcell population. By evaluating the expression of CD161 on the surface of the DN T cells we showed that within&nbsp;the healthy control group, 47.4±4.99% of the DN T cells were positive for the expression of CD161, while only&nbsp;26.4±3.54% (p=0.002) of the AIDS group's DN T cells expressed CD161. Despite CD161 expression being&nbsp;halved on the DN T cells of the AIDS group, when we compared the total peripheral T cell percentage of&nbsp;CD161+ DN T cells between the healthy control group and the AIDS group, there was no statistical difference.Even though only 26.4% DN T cells within the AIDS group were positive for CD161+, the overall DN T cell population had expanded to such an extent that there was no statistical difference between the groups with regard to CD161+ DN T cells as a percentage of the total peripheral T cell population. Furthermore, we showed&nbsp;that within the DN T cell population, there was an approximate 2:1 ratio of γδ to αβ T cells, and this ratio was<br />
maintained in both the healthy control group and the AIDS group.While evaluating γδ T cells we also discovered that CD8+ γδ T cells were expanded from 0.62±.09% of the healthy control peripheral T cell population&nbsp;to 5.01±.88% (p=b0.0001) of the peripheral T cell population of the AIDS group; and that this population of&nbsp;CD8+ γδ T cells underwent the same reduction in percentage of cells expressing CD161+, further demonstrated that the phenomenon of CD161+ percentage reduction and compensatory increase in total cell population was affecting the entire circulating γδ T cell population.
</p>",,"/uploadfiles/file/20131114/20131114142307_7546.pdf",,11/14/2013,11/14/2013,"medicool",12,,"CD161|AIDS|In?ammation|Pro-in?ammatory|Double negative T cell",0,"65",19,"Depletion of pro-in?ammatory CD161+ double negative (CD3+CD4?CD8?) T cells in AIDS patients is ameliorated by expansion of the γδ T cell population",,
438,,"40 (2009) 132e135","Jose ? Manuel Va ?zquez-Guille ?n, a Paola Janeth Garc? ?a-Jacobo, a Pablo Zapata-Benavides, a Adrian G. Rosas-Taraco, b Marco Iva ?n Ordaz-Sa ?nchez, a Paulo Lo ?pez-Guille ?n, c Laura Trejo-A ?vila, a Juan Manuel Alcocer-Gonza ?lez, a Cristina Rodr? ?guez-Padilla, a and Lydia Guadalupe Rivera-Morales a","Archives of Medical Research","<p style=""text-indent:2em;"">
	The main access route for human immunode?ciency virus (HIV) into the lymph nodes is&nbsp;through the mucosa. Once there, dendritic cells (DCs) are the ?rst cells to interact with&nbsp;the virus. Then, DCs can uptake and transport to the lymph nodes, beginning a disseminated infection. Interaction between the virus and DCs is mediated by the receptor&nbsp;DC-SIGN. This study seeks to determine any relationship between HIV-AIDS immunopathology and DC-SIGN expression levels in DCs from typical, rapid, and slow progressors. A DC separation system was implemented using peripheral blood mononuclear cells&nbsp;from infected subjects. The study included 27 patients classi?ed as typical, rapid, and&nbsp;slow progressors according to their clinical and<br />
epidemiological ?les. Finally, quanti?cation of DC-SIGN was achieved by real-time PCR and by applying the Relative Quanti?cation Scheme (DDCt). We isolated DCs from peripheral blood of 27 HIV-infected&nbsp;patients. Nineteen were considered as typical progressors, ?ve as slow progressors, and&nbsp;three as rapid progressors. No signi?cant differences were observed on the expression&nbsp;levels of DC-SIGN among the three groups of patients. Even if there are differences in&nbsp;expression levels among the analyzed patients, we did not ?nd any signi?cant differences&nbsp;in DC-SIGN expression among the three included groups. We therefore cannot conclude&nbsp;that the expression level of the receptor is related with the progression to AIDS.
</p>",,"/uploadfiles/file/20131114/20131114142944_1513.pdf",,11/14/2013,11/14/2013,"medicool",12,,"AIDS| HIV-1| Dendritic cells| DC-SIGN|Progression.",0,"65",19,"Expression of DC-SIGN in Peripheral Blood Dendritic Cells of Patients with Typical, Slow, and Rapid Progression to AIDS","2009",
439,,"17  (2013)  e902Ce906","Bradley  C.  Nelson , Margaret  Z.  Borok , Tafadzwa  O.  Mhlanga,Azure  T.  Makadzange ,Thomas  B.  Campbell","International  Journal  of  Infectious  Diseases","<p style=""text-indent:2em;"">
	AIDS-associated Kaposi  sarcoma (AIDS-KS)  results from co-infection with  
HIV-1 and Kaposi sarcoma-associated  herpes  virus (KSHV)  and  it  is  the  
most  common  AIDS-related  malignancy worldwide.The  high  prevalence  of  
HIV-1/KSHV  co-infection  in Sub-Saharan  Africa  places  30C50%  of  
HIV-1-infected  individuals from  this  region  at  risk  for  development  of  
AIDS-KS.The introduction  of  multi-drug  antiretroviral  therapy  (ART)  
regimens in  developed  countries  has  been  associated  with  a  signi?cant 
decrease  in  the  incidence  of  AIDS-KS11 as  well  as  improved  patient 
survival. Studies  from  North  American  and  European  cohorts  have 
demonstrated  signi?cant  tumor  regression  and  5-year  AIDS-KS survival  
rates  near  90%  after  initiation  of  ART  in  early-stage disease. However,  
similar  outcome  data  for  AIDS-KS  patients from  Sub-Saharan  African  
populations,  where  AIDS-KS  remains  a signi?cant  cause  of  morbidity  and  
mortality  resulting  in  10C14%  of deaths  in  ART  programs,are  lacking.  
Several  recent  ART studies  in  African  AIDS-KS  patients  have  not  shown  
the  same improvements  in  outcomes  as  those  reported  in  studies  from 
developed  nations.
</p>
<p style=""text-indent:2em;"">
	<br />
</p>",,"/uploadfiles/file/20131114/20131114144943_9026.pdf",,11/14/2013,11/14/2013,"medicool",15,,"Kaposi  sarcoma|HIV|AIDS|Antiretroviral  therapy",0,"66",19,"AIDS-associated  Kaposi  sarcoma:  outcomes  after  initiation  of antiretroviral  therapy  at  a  university-af?liated  hospital  in  urban Zimbabwe","2013",
442,,"112 (2010) 178C193","Marwan M. Azar, Sandra A. Springer, Jaimie P. Meyer, Frederick L. Altice","Drug and Alcohol Dependence","<p style=""text-indent:2em;"">
	Background: Alcohol use disorders (AUDs) are highly prevalent and associated 
with non-adherence to antiretroviral therapy, decreased health care utilization 
and poor HIV treatment outcomes among HIV-infected individuals.<br />
Objectives: 
To systematically review studies assessing the impact of AUDs on: (1) medication 
adherence,(2) health care utilization and (3) biological treatment outcomes 
among people living with HIV/AIDS(PLWHA).<br />
&nbsp; &nbsp; &nbsp; Data sources: Six electronic 
databases and Google Scholar were queried for articles published in 
English,French and Spanish from 1988 to 2010. Selected references from primary 
articles were also examined.<br />
&nbsp; &nbsp; &nbsp;&nbsp;Review methods: Selection criteria included: (1) 
AUD and adherence (N= 20); (2) AUD and health services utilization (N= 11); or 
(3) AUD with CD4 count or HIV-1 RNA treatment outcomes (N= 10). Reviews,animal 
studies,non-peer reviewed documents and ongoing studieswithunpublished datawere 
excluded.Studies that did not differentiate HIV+ fromHIV? status and those that 
did not distinguish between drug and alcohol use were also excluded. Data were 
extracted, appraised and summarized.<br />
&nbsp; &nbsp; &nbsp; Data synthesis and conclusions: Our 
?ndings consistently support an association between AUDs and decreased adherence 
to antiretroviral therapy and poor HIV treatment outcomes among HIV-infected 
individuals. Their effect on health care utilization, however, was variable.
</p>",,"/uploadfiles/file/20131114/20131114154046_2035.pdf",,11/14/2013,11/14/2013,"medicool",15,,"HIV/AIDS|Alcohol use disorders|Systematic review|Adherence|Health care utilization",0,"67",19,"A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization","2010",
440,,"12 (2013) 4C  8","Aster  Nila,  Haridana  Indah  Setiawati ,  Retnosari  Andrajati ,  Sjamsuridjal  Djauzi","HIV & AIDS Review","<p style=""text-indent:2em;"">
	Background:  The  use  of  stavudine  in  antiretroviral  regimens  is  
often  associated  with  undesirable  effects such  as  peripheral  neuropathy  
and  lipodystrophy.  This  study  aims  to  overview  the  prevalence  of  
adverse events  of  peripheral  neuropathy  and  lipodystrophy  in  HIV/AIDS  
patients  who  used  stavudine  in  antiretro-viral and factors that in?uence 
the incidence of side effects of stavudine.
</p>
<p style=""text-indent:2em;"">
	Materials and methods: This study was a retrospective cohort study design. 
The intervention groups were  patients  who  used  stavudine  and  control  
groups  were  patients  who  used  zidovudine.  To  determine  the  incidence  
of  peripheral  neuropathy  used  the  Subjective  Peripheral  Neuropathy  
Screen  (SPNS) and  the  incidence  of  lipodystrophy  used  Carr  
Lipodystrophy  Questionnaire  and  patient’s  medical  records 
retrospectively.
</p>
<p style=""text-indent:2em;"">
	Results:  The  prevalence  of  peripheral  neuropathy  was  25.3%  and  
lipodystrophy  40.9%  in  patients  who used <br />
stavudine. Differences 
combination of antiretroviral regimen was factor that signi?cantly in?uence the  
incidence  of  side  effects  of  peripheral  neuropathy  (p  =  0.002).  Age  
(p  =  0.039),  duration  of  stavudine use (p = 0.000), previous <br />
antiretroviral regimen (p = 0.013) and differences combination of 
antiretroviral  regimen  (p  =  0.000)  were  the  factors  most  signi?cantly  
in?uence  the  side  effects  of  lipodystrophy.Stavudine  likely  to  cause  
peripheral  neuropathy  compared  zidovudine  with  relative  risk  (RR)  =  
3.039(95%  CI,  1629C5670)  and  odds  ratio  (OR)  =  3.178  (95%  CI,  
1156C6660).  Stavudine  likely  to  cause  lipodystrophy compared zidovudine 
with relative risk (RR = 1.488 (95% CI) and odds ratio (OR) = 3.353 (95% 
CI,1876C5992).
</p>
<p style=""text-indent:2em;"">
	Conclusions:  The  side  effects  of  peripheral  neuropathy  and  
lipodystrophy  at  the  use  of  antiretroviral regimens stavudine was 
signi?cantly different from antiretroviral regimen zidovudine.
</p>",,"/uploadfiles/file/20131114/20131114150117_7294.pdf",,11/14/2013,11/14/2013,"medicool",13,,"HIV  and  AIDS|Lipodystrophy|Peripheral|neuropathy|Stavudine",0,"66",19,"Evaluation  of  side  effects  events  peripheral  neuropathy  and  lipodystrophy  in patients  with  HIV/AIDS  who  used  stavudine  in  antiretroviral  regimens","2013",
441,,"150 (2013) 639C648","Savina Asiimwe, Maud Kamatenesi-Mugisha,Agnes Namutebi,Anna-Karin Borg-Karlsson,Peace Musiimenta","Journal of Ethnopharmacology","<p style=""text-indent:2em;"">
	Ethnopharmacological relevance: Herbal remedies are a source of therapeutics for 
nearly 80% of the population in Uganda. Poor health facilities and limited 
access to antiretroviral drugs have perpetuated and increased the use of 
traditional medicine especially in rural areas for the treatment of 
opportunistic ailments of HIV/AIDS. To document the traditional uses of 
nutri-medicinal plants in the management of immunocompromised ailments 
associated with HIV/AIDS. To document the parts and growth forms of plants used, 
methods of preparation and administration of the herbal remedies.<br />
&nbsp; &nbsp; &nbsp;&nbsp;Materials and methods: The study was conducted in Mbarara and Isingiro districts 
of western Uganda between December 2010 and May 2011. Ethnobotanical information 
was collected from 64 respondents who were sampled based on recommendations of 
local elders and administrators. Ethnobotanical data on the use of 
nutri-medicinal plants for traditional treatment of HIV/AIDS opportunistic 
ailments were collected by employing semi-structured interviews with selected 
respondents, house hold visits and ?eld observations as described by (Martin, 
1995a). The respondents were mainly traditional medical practitioners who treat 
patients who are already receiving antiretroviral drugs. Fidelity levels of 
plant species and informant consensus factor were determined to show the 
percentage of informants claiming the use of certain plant species for the same 
major purpose and to analyse people's knowledge of plant use.<br />
&nbsp; &nbsp; &nbsp; Results: The study revealed 81 plant species most of which were herbs (49%). 
Leaves (71%) were the most<br />
frequently used parts in remedy preparations which 
were mainly administered orally (85%). The majority of plants (54%) were 
harvested from wild populations. Hibiscus sabdariffa L., Plumeria obtusa L., and 
Abutilon guineense (Shumach.) Baker. F and Exell were the nutri-medicinal plants 
that scored the highest Fidelity level values. The informant's consensus about 
usages of plants ranged from 0.75 to 0.80. Plants that are presumed to be 
effective in treating a certain disease have higher informant consensus factor 
(ICF) values. Family Asteraceae accounted for 18% of the total species recorded. 
Thirteen species (16%) of the plants are edible and provide nutritional 
support.<br />
&nbsp; &nbsp; &nbsp; Conclusion: The study recorded plant species with potential to 
treat ailments associated with immunocompromised people living with HIV/AIDS in 
western Uganda. Such studies can help stimulate con?dence in traditional 
medicine and enhance appreciation of herbal medicine among the people and to 
appreciate the value of the plant resources and therefore enhance conservation 
efforts of the plant species. The high consensus means the majority of 
informants agree on the use of plant species and this re?ects the intercultural 
relevance and the agreement in the use of the nutri-medicinal plants to 
the&nbsp;people. We recommend the documented plants for further 
Ethnopharmacological studies.
</p>",,"/uploadfiles/file/20131114/20131114150845_6842.pdf",,11/14/2013,11/14/2013,"medicool",18,,"Ethnobotanical study|Nutri-medicinal plants|HIV/AIDS|Immunocompromised|Uganda",0,"66",19,"Ethnobotanical study of nutri-medicinal plants used for the management of HIV/AIDS opportunistic ailments among the local communities of western Uganda","2013",
444,,"Biologicals 38 (2010) 511-521","J.L. Excler,C.L. Parks, J. Ackland, H. Rees,I.D. Gust,W.C. Koff","Biologicals","<p style=""text-indent:2em;"">
	In October 2009, The International AIDS Vaccine Initiative (IAVI) convened a satellite symposium entitled&nbsp;‘Replicating Viral Vectors for use in AIDS Vaccines’ at the AIDS Vaccine 2009 Conference in Paris. The&nbsp;purpose of the symposium was to gather together researchers, representatives from regulatory agencies,and vaccine developers to discuss issues related to advancement of replication-competent viral vector-based HIV vaccines into clinical trials. The meeting introduced the rationale for accelerating the development of replicating viral vectors for use as AIDS vaccines. It noted that the EMEA recently<br />
published&nbsp;draft guidelines that are an important ?rst step in providing guidance for advancing live viral vectors into&nbsp;clinical development. Presentations included case studies and development challenges for viral vector-based vaccine candidates. These product development challenges included cell substrates used for&nbsp;vaccine manufacturing, the testing needed to assess vaccine safety, conducting clinical trials with live&nbsp;vectors, and assessment of vaccination risk versus bene?t. More in depth discussion of risk and bene?t&nbsp;highlighted the fact that AIDS vaccine ef?cacy trials must be conducted in the developing world where&nbsp;HIV incidence is greatest and how inequities in global health dramatically in?uence the political and&nbsp;social environment in developing countries.
</p>",,"/uploadfiles/file/20131114/20131114160104_4097.pdf",,11/14/2013,11/14/2013,"medicool",26,,"AIDS Vaccines|Replicating viral vectors|Novel replication-competent viral vectors|Accelerating the development of replicating|viral vectors|
Advancement of HIV vaccines|",0,"67",19,"Replicating viral vectors as HIV vaccines: Summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference","2010",
447,"利用HIV/AIDS临床表现的显著稳定性评估在一个开放性临床试验中复方草药制剂使用情况（PHF）",,"Mangaiarkarasi Asokan, Imtiaz Nisar Lone, Anil Babu Mukthey, Paul Siddhartha Gayathri Mariappa,Praveen Kumar Kotehal, Bhuthiah Satish, Eugene Wilson, Savariraj Sahayam, Gopinath Velayutham,Rajalakshmi Perumal, Karthikeyan Baskaran, Devanathan Rengarajan, Ravichandran Muthusamy,Mariamma Philip, K.C. Ravindra, Jeelan N. Basha, Pushpak Mizar, Gurvinder Kaur, arinder K. Mehra, Tapas K. Kundu, D.K. Subbakrishna, Kadappa Shivappa Satish，daykumar Ranga","INDIAN J MED RES","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">Background &amp; objectives:</span> 
</p>
<p align=""justify"">
	<a></a><a></a><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">The</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">complementary and alternativemedicines(CAM)have not been systematically evaluated for the management of</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">HIV/AIDSpatients.</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">In a prospective,single-site, open-label, non-randomized, controlled, pilot trial,</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">weevaluated a polyherbal formulation (</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">PHF) for itssafety and efficacy in treating subjects with HIV-AIDS.</span> 
</p>
<p align=""justify"">
	<span style=""font-family:SimSun;font-size:14px;"">研究背景和研究目的：</span><br />
<span style=""font-family:SimSun;font-size:14px;""> 补充和替代医疗（</span><a></a><a></a><span style=""font-family:SimSun;font-size:14px;"">CAM）尚未能对HIV/AIDS患者的管理作出系统性评估。在一项前瞻性、独立性、非盲性、非随机性、对照性</span><a></a><a></a><span style=""font-family:SimSun;font-size:14px;"">、先导性试验中，我们在治疗HIV/AIDS受试者的过程中对一种草药复方制剂（PHF）的安全性和有效性进行了评估。</span> 
</p>
<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">Methods:</span> 
</p>
<p align=""justify"">
	<a></a><a></a><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">A total of 32 and 31 subjects were enrolled under the PHF and highlyactive antiretroviral treatment (HAART) arms, respectively, and followed up fora period of 24 months.</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">Plasma viral RNA, CD4 cellcount and</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">blood chemistrywere monitored at 3-month intervals.</span><a></a><a></a><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">Following mid-term safety evaluation, 1</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">2 </span><span style=""font-family:Times New Roman;font-size:14px;"">subjects from the PHF arm were shifted to HAART and were followed separately asPHF-to-HAART arm, for the rest of the period.</span> 
</p>
<p align=""justify"">
	<span style=""font-family:SimSun;font-size:14px;"">研究方法：</span><br />
<span style=""font-family:SimSun;font-size:14px;""> 共有32名和31名受试者被分别登记在PHF组和高活性抗逆转录病毒治疗组（HAART）下，并且对他们进行为期24个月的随访。每隔3个月对血浆病毒RNA、CD4细胞数量和</span><a></a><a></a><span style=""font-family:SimSun;font-size:14px;"">血液生化进行检测。中期安全性评价之后，PHF组的12个受试者被转移到HAART组，至于其余的时间这些患者被作为PHF-to-HAART组单独进行随访。</span><br />
<span style=""font-size:14px;"">&nbsp;<span style=""font-family:Times New Roman;"">Results:</span></span><br />
<a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">The HAART arm was characterized by significant improvements in CD4 cellcount (154.4 cells/ μl/year,P&lt;0.001) and</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;showed a profile of CD4 cell lossat remarkably slower kinetics (14.3 cells/μl/year,P=0.021) and</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">insignificant reduction in the viral load.The PHF and HAART arms</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">didnot differ significantly in the occurrence of AIDS-related illnesses over thestudy period of 24 months. In the PHF-to-HAART arm,</span><a></a><a></a><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">the rates of CD4 countandreduction in viral load were significant and comparable to that of the HAARTgroup.In the PHF arm,</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">at 1 month, asignificant increase in CD4 cell count and a concomitant decrease in viral loadwereseen.</span> 
</p>
<p align=""justify"">
	<span style=""font-family:SimSun;font-size:14px;"">研究结果：</span> 
</p>
<p align=""justify"">
	<span style=""font-family:SimSun;font-size:14px;"">HAART组的特点是显著提高CD4细胞数量(154.4 cells/μl/年, P&lt;0.001)并在3到6个月内降低血浆病毒载量(-0.431+</span><span style=""font-family:SimSun;font-size:14px;"">0.004 log10IU/月, P&lt;0.001)。相反，PHF组在显著减慢的动力学上呈现出CD4细胞减少的概况(14.3 cells/μl/年, P=0.021)，并伴有病毒载量的轻微减少。在超过24个月的研究期间以外，PHF组和HAART组对由艾滋病引起的疾病的发生无显著差异。与HAART组相比，在PHF-to-HAART组中，CD4计数率和病毒载量减少率较显著。在PHF组中，在1个月后可以观察到CD4细胞数量显著增加，病毒载量随之减少。</span> 
</p>
<p align=""justify"">
	<a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">Interpretation &amp; conclusions:</span> 
</p>
<p align=""justify"">
	<a></a><a></a><a></a><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">The PHF</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">appears tohave provided protection by delaying</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">the kinetics of CD4 cell reduction.</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">Given the several study limitations, drawing assertive inferences from the data is challenging.</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">Future studies with a stringent study design</span><a></a><a></a><span style=""font-family:Times New Roman;font-size:14px;"">are warranted toconfirm these findings.</span> 
</p>
<p align=""justify"">
	<span style=""font-family:SimSun;font-size:14px;"">解释和结论：</span> 
</p>
<p align=""justify"">
	<span style=""font-family:SimSun;font-size:14px;"">PHF似乎是通过延迟CD4细胞动力学的下降来提供保护。考虑到一些研究的局限性,从数据独断地推断缩略图是具有挑战性的。利用带有一个严谨研究设计的未来研究来证实这些发现是必要的。</span> 
</p>","/uploadfiles/image/20131115/20131115142400_6728w.png","/uploadfiles/file/20131115/20131115142204_0938.pdf",,11/15/2013,11/15/2013,"medicool",48,,"Chronic immune activation - complementary and alternative medicine - disease progression - HIV-AIDS - human clinical trial -immunomodulation - polyherbal formulation",0,"66",19,"Evident stabilization of the clinical profile in HIV/AIDS as evaluated in an open label clinical trial using a polyherbal formulation","2013",
446,,"10 (2011) 56C60","Karina Pupio Raimundo,Carl V. Asche","HIV & AIDS Review","<p style=""text-indent:2em;"">
	Background: Acquired Immune De?ciency Syndrome (AIDS)―related Kaposi’s 
sarcoma (KS) is a rare aggressive tumor. The bene?ts of drug therapy are 
established by clinical trials but it has been a challenge to draw comparisons 
between the different advanced AIDS-KS pharmacotherapy available. This review 
aims to evaluate the currently approved chemotherapy drugs for the treatment of 
AIDS-related advanced KS as well as the economic burden and impact on the 
quality of life of patients.<br />
&nbsp; &nbsp; &nbsp; Material and methods: Relevant articles were 
identi?ed through a systematic review of the literature via a search of the 
National Center for Biotechnology Information (NCBI) PubMed database and the 
Internet (clinicaltrials.gov) using relevant medical subject heading (MESH) 
terms.<br />
&nbsp; &nbsp; &nbsp; Results: A total of 7 phase II and 4 phase III trials of liposomal 
anthracyclines (liposomal doxorubicin [PLD] and/or liposomal daunorubicin [DNX]) 
were identi?ed. An evaluation of the trials comparing PLD to a competitor showed 
statistical difference p;0.01. DNX phase III trials were also evaluated and 
showed no statistical differences (p = 0.64). For paclitaxel, 6 clinical trials 
were selected (5 phase II and 1 phase III);however heterogeneity was not 
evaluated. 4 cost-effectiveness studies were compared and 3 concluded that PLD 
is more cost-effective than the competitor. 4 quality of life studies were 
analyzed.<br />
&nbsp; &nbsp; &nbsp; Conclusion: AIDS-KS impacts the patient’s life physical, emotional 
and economic well being. In this work we compared studies of liposomal 
anthracyclines, still; further research among all the approved drugs for KS is 
warranted to evaluate ef?cacy as well as its economic burden worldwide.
</p>",,"/uploadfiles/file/20131114/20131114161708_2730.pdf",,11/14/2013,11/14/2013,"medicool",32,,"Kaposi’s sarcoma|Acquired Immune De?ciency Syndrome|(AIDS)|
Liposomes|Quality of life|Health economics",0,"67",19,"A review of the ef?cacy and outcomes studies of currently approved chemotherapy treatments for advanced AIDS-Kaposi’s sarcoma","2011",
448,,"e45267","Rafael Ribeiro Almeida , Daniela Santoro Rosa , Susan Pereira Ribeiro, Vinicius Canato Santana , Esper Georges Kalla ? s , John Sidney , Alessandro Sette, Jorge Kalil ,Edecio Cunha-Neto","Brazilian National Research Council","T-cell based vaccine approaches have emerged to counteract HIV-1/AIDS. Broad, polyfunctional and cytotoxic CD4+<br />
T-cell&nbsp;responses have been associated with control of HIV-1 replication, which supports the inclusion of CD4+&nbsp;T-cell epitopes in&nbsp;vaccines. A successful HIV-1 vaccine should also be designed to overcome viral genetic diversity and be able to confer&nbsp;immunity in a high proportion of immunized individuals from a diverse HLA-bearing population. In this study, we rationally&nbsp;designed a multiepitopic DNA vaccine in order to elicit broad and cross-clade CD4+&nbsp;T-cell responses against highly&nbsp;conserved and promiscuous peptides from the HIV-1 M-group consensus sequence. We identified 27 conserved, multiple&nbsp;HLA-DR-binding peptides in the HIV-1 M-group consensus sequences of Gag, Pol, Nef, Vif, Vpr, Rev and Vpu using the&nbsp;TEPITOPE algorithm. The peptides bound in vitro to an average of 12 out of the 17 tested HLA-DR molecules and also to&nbsp;several molecules such as HLA-DP, -DQ and murine IAb&nbsp;and IAd. Sixteen out of the 27 peptides were recognized by PBMC&nbsp;from patients infected with different HIV-1 variants and 72% of such patients recognized at least 1 peptide. Immunization&nbsp;with a DNA vaccine (HIVBr27) encoding the identified peptides elicited IFN-c secretion against 11 out of the 27 peptides in&nbsp;BALB/c mice; CD4+&nbsp;and CD8+&nbsp;T-cell proliferation was observed against 8 and 6 peptides, respectively. HIVBr27 immunization&nbsp;elicited cross-clade T-cell responses against several HIV-1 peptide variants. Polyfunctional CD4+&nbsp;and CD8+<br />
T cells, able to&nbsp;simultaneously proliferate and produce IFN-c and TNF-a, were also observed. This vaccine concept may cope with HIV-1&nbsp;genetic diversity as well as provide increased population coverage, which are desirable features for an efficacious strategy&nbsp;against HIV-1/AIDS.<br />",,"/uploadfiles/file/20131115/20131115161012_4884.pdf",,11/15/2013,11/15/2013,"medicool",30,,"Cross-Clade CD4+|HIV-1|T-Cell |DNA Vaccine",0,"65",19,"Broad and Cross-Clade CD4+ T-Cell Responses Elicited by a DNA Vaccine Encoding Highly Conserved and Promiscuous HIV-1 M-Group Consensus Peptides","2012",
119,,"10.1111/j.1365-3164.2011.00994.x","Ursula Oberkirchner*, Keith E. Linder and Thierry Olivry","Veterinary Dermatology","&nbsp;&nbsp;&nbsp;Discoid lupus erythematosus (DLE) is a common canine autoimmune disease that usually manifests as a localized ulcerative and scarring nasal dermatitis. We report herein a generalized variant of canine DLE successfully treated with the antimalarial immunomodulator hydroxychloroquine (HCQ). A 9-year-old hairless Chinese crested dog was presented with annular and polycyclic hyperpigmented and scaly skin lesions with central erosions, hypopigmentation&nbsp; and/or scarring on the trunk, neck and lateral extremities. Associated systemic signs were not seen. The clinical diagnosis of generalized DLE was supported by the demonstration of lymphocyte-rich interface dermatitis with epidermal atrophy and dermo-epidermal<br />
deposition of immunoglobulins and activated complement. As for human DLE, treatment was initiated with HCQ at 5 mg/kg once daily along with 2 weeks of 0.1% tacrolimus ointment and restriction of sun exposure. Over the following year, complete remission was maintained with HCQ at 5 mg/kg orally once daily with the exception of three relapses; two occurred during treatment induction and the third arose when the frequency of HCQ administration was reduced to every other day. Disease flares were controlled with 0.1% tacrolimus ointment alternating with 0.1% prednicarbate cream once daily for 5C10 days. Altogether, adverse drug events were not seen with this regimen. In summary, clinically, histologically and immunologically, this dog’s disease mirrored the generalized discoid variant of chronic cutaneous lupus erythematosus of humans. The apparent benefit of HCQ, its safety and low cost warrant future investigations of its use for treatment of canine cutaneous lupus variants.","/uploadfiles/image/20130930/20130930164601_5281w.png","/uploadfiles/file/20130930/20130930164613_3997.pdf",,09/30/2013,10/09/2013,"medicool",58,,,0,"66",3,"Successful treatment of a novel generalized variant of canine discoid lupus erythematosus with oral hydroxychloroquine","2011",
146,,"10.1371/journal.pone.0045749","Guo L ; Wu WJ ; Liu LD ; Wang LC ; Zhang Y ; Wu LQ ; Guan Y ; Li QH","Plos One","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ICP22 is a multifunctional herpes simplex virus 1 (HSV-1) immediate early protein that functions as a general repressor of a subset of cellular and viral promoters in transient expression systems. Although the exact mechanism of repression remains unclear, this protein induces a decrease in RNA polymera-se II Serine 2 (RNAPII Ser-2) phosphorylation, which is critical for transcription elongation. To characterize the mechanism of transcriptional &nbsp;repression &nbsp;by ICP22, we established an in vivo transient expression reporter &nbsp;system. We &nbsp;found &nbsp;that &nbsp;ICP22 &nbsp;inhibits&nbsp; transcription&nbsp; of&nbsp; the&nbsp; HSV-1 a, b &nbsp;and &nbsp;c gene promoters. The viral tegument protein VP16, which plays vital roles in initiation of viral gene expression and viral proliferation, can overcome the inhibitory effect of ICP22 on a-gene transcription. Further immunoprecipitation studies indicated that both ICP22 and VP16 bind to positive transcription elongation factor b (P-TEFb) and form a complex with it in vivo. We&nbsp;extended&nbsp;this&nbsp;to show&nbsp;that&nbsp;P-TEFb regulates transcription of the viral a-gene promoters and aff-ects transcriptional regulation of ICP22 and VP16 on the a-genes. Additionally , ChIP assays&nbsp;demonstrated that ICP22 blocks the recruitment of P-TEFb to the viral promoters, while VP16 reverses this blocking effect by recruiting P-TEFb to the viral a-gene promoters through recognition of the TAATGARAT motif. Taken together, our results suggest that ICP22 interacts with and&nbsp; blocks&nbsp; the recruitment of P-TEFb&nbsp; to &nbsp;viral&nbsp; promoter &nbsp;regions, which&nbsp; inhibits &nbsp;transcription of the viral gene promoters. The transactivator VP16 binds to and induces the recruitment of P-TEFb to viral a-gene promoters, which coun-teracts the transcriptional repression of ICP22 on a- genes by recruiting p-TEFb to the promoter region.<br />
<br />",,"/uploadfiles/file/20131012/20131012084419_3222.pdf",,10/12/2013,10/12/2013,"medicool",26,,,0,"67",57,"Herpes Simplex Virus 1 ICP22 Inhibits the Transcription of Viral Gene Promoters by Binding to and Blocking the Recruitment of P-TEFb","2012",
124,"去骨瓣减压术揭示的单纯疱疹病毒性脑炎一例","10.1007/s00431-007-0566-0","N. Bayram & D. Yilmaz Ciftdogan & B. Karapinar & E. Ozgiray & M. Polat & E. Cagliyan & F. Vardar","European Journal Of Pediatrics","<span><span style=""font-family:'Times New Roman','serif';color:#131413;font-size:12pt;"">&nbsp;&nbsp;&nbsp;&nbsp;A 15-year-old girl was referred to our hospital due to fever, headache, and vomiting of 7 days duration and focal motor convulsion at the day of referral</span></span></a><span style=""font-family:'Times New Roman','serif';color:#131413;font-size:12pt;"">. <span>Her clinical signs </span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#131413;font-size:12pt;"">and cerebral imaging findings were found to be compatible with <span>herpes simplex encephalitis</span></a></span></span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#131413;font-size:12pt;"">.</span></span></span><span style=""font-family:'Times New Roman','serif';color:#131413;font-size:12pt;""> <span>In spite of prompt acyclovir administration, her consciousness deteriorated gradually</span></a>. <span><span>Emergent cranial magnetic resonance imaging</span></span></a> demonstrated a shift of <span>midline intracranial structures</span></a>. Decompressive surgery resulted in partial improvement in the shift of midline intracranial structures and potentially saved the patient’s life. This case report stresses the importance of proper management of increased intracranial pressure in patients with herpes simplex encephalitis.</span> 
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style=""font-family:宋体;color:#131413;font-size:12pt;"">一名</span><span style=""font-family:'AdvTT3713a231','serif';color:#131413;font-size:12pt;"">15</span><span style=""font-family:宋体;color:#131413;font-size:12pt;"">岁患儿（女性），由于持续</span><span style=""font-family:'AdvTT3713a231','serif';color:#131413;font-size:12pt;"">7</span><span style=""font-family:宋体;color:#131413;font-size:12pt;"">天的发热、头痛、和呕吐症状以及在转诊当天出现局灶性运动痉挛，被送往医院。患者的临床症状及脑成像结果符合单纯疱疹病毒性脑炎。尽管立即应用阿昔洛韦进行给药，但患者逐渐失去意识。急诊头颅磁共振成像显示颅内中线结构移位。减压手术使得颅内中线结构移位得到了局部改善，并可能挽救患者的生命。该病例报告强调对单纯疱疹病毒性脑炎患者的颅内压增高实施适当治疗的重要性。<br />
<br />
</span><span style=""font-family:'AdvTT3713a231','serif';color:#131413;font-size:12pt;""></span>
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:'AdvTT3713a231','serif';color:#131413;font-size:12pt;""><span style=""font-family:'Times New Roman','serif';color:#131413;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N. Bayram&nbsp;et al. Eur J Pediatr ,2008,167:821C822</span> 
</p>
</span></span>","/uploadfiles/image/20131011/20131011103942_8610w.png","/uploadfiles/file/20131011/20131011103949_6782.pdf",,10/11/2013,10/11/2013,"medicool",55,,"Herpes simplex encephalitis . Increased intracranial pressure . Decompression",0,"85",57,"A case of herpes simplex encephalitis revealed by decompressive craniectomy","2008",
111,,,"Pilar Toledano, Nicolae Sarbu, Gerard Espinosa, Núria Bargalló, Ricard Cervera","Autoimmunity Reviews","&nbsp;&nbsp;&nbsp; Neuropsychiatric (NP) syndromes are a major cause of morbidity and 
mortality in patients with systemic lupus 25 erythematosus (SLE). The 
aims of this work were to describe the brain abnormalities in a group of
 SLE patients 26 during their first episode of NP manifestations using a
 conventional magnetic resonance imaging (MRI) tech- 27 nique and to 
investigate the possible correlation between these findings and the 
clinical and immunological 28 characteristics of these patients. 29 We 
performed an observational retrospective cross-sectional study that 
included all patients with NP symptoms who underwent MRI at the Hospital
 Clinic of Barcelona between the years 2003 and 2012 because of 
suspecting NP syndromes due to SLE (NPSLE). We studied 43 patients 
inwhich 11 types of NPSLEwere present, being headache themost frequent, 
followed by cerebrovascular disease, epileptic crises and cranial 
neuropathy. A statistically significant association was found 
betweenmyelopathy and lowcomplement (C4) levels (p = 0.035) and disease 
activitymeasured as SLE Disease Activity Index (SLEDAI) N4 (p = 
0.00006). Eighteen (41.9%) patients presentedMRI abnormalities.We found 
an association between myelopathy and the presence of inflammatory 
ormixed (vascular and inflammatory) type lesions (p = 0.003). This 
pattern was also associated with a high SLEDAI score (p = 0.002) and low
 comple- 38 ment (CH50) levels (p = 0.032). We found no relationship 
between MRI changes and age, time of evolution, or the presence of 
antiphospholipid or anti-dsDNA antibodies.  These results suggest 
thatMRI, although it is the imagingmodality of choice in the 
presentmoment, by itself does not establish or exclude the diagnosis of 
NPSLE. In addition, the presence of certain disease activity features 
(SLEDAI and low complement levels) seems to be associated with the 
presence of an inflammatory pattern on MRI.",,"/uploadfiles/file/20130809/20130809151154_4313.pdf",,09/30/2013,09/30/2013,"medicool",41,,"Systemic lupus erythematosus|Neuropsychiatric systemic lupus|
erythematosus|Neuropsychiatric syndromes|Neuroimaging|
Magnetic resonance imaging|White matter lesion",0,"66",3,"Neuropsychiatric systemic lupus erythematosus: Magnetic resonance imaging findings and correlation with clinical and immunological features","2013",
134,,"10.1007/s00430-010-0174-x","D?umer MP ; Schneider B ; Giesen DM ; Aziz S ; Kaiser R ; Kupfer B ; Schneweis KE ; Schneider-Mergener J ; Reineke U ; Matz B ; Eis-Hübinger AM","Medical Microbiology And Immunology","<strong></strong>&nbsp;&nbsp; Monoclonal antibody (MAb) 2c, speci?c for glycoprotein B of herpes simplex virus (HSV), had been shown to mediate clearance of infection from the mucous membranes of mice, thereby completely inhibiting muco- cutaneous in?ammation and lethality, even in mice deple- ted of both CD4? and CD8? cells. Additionally, ganglionic infection was highly restricted. In vitro, MAb 2c exhibits a potent complement-independent neutralising activity against HSV type 1 and 2, completely inhibits the viral cell-to-cell spread as well as the syncytium formation induced by syncytial HSV strains (Eis-Hu ¨binger et al. in Intervirology 32:351C360, 1991; Eis-Hu ¨binger et al. in J Gen Virol 74:379C385, 1993). Here, we describe the mapping of the epitope for MAb 2c. The antibody was found to recognise a discontinuous epitope comprised of<br />
the HSV type 1 glycoprotein B residues 299 to 305 and one or more additional discontinuous regions that can be mimicked by the sequence FEDF. Identi?cation of the epitope was con?rmed by loss of antibody binding to mutated glycoprotein B with replacement of the epitopic key residues, expressed in COS-1 cells. Similarly, MAb 2c was not able to neutralise HSV mutants with altered key residues, and MAb 2c was ineffective in mice inoculated with such mutants. Interestingly, identi?cation and ?ne- mapping of the discontinuous epitope was not achieved by binding studies with truncated glycoprotein B variants expressed in COS cells but by peptide scanning with syn- thetic overlapping peptides and peptide key motif analysis. Reactivity of MAb 2c was immensely increased towards a peptide composed of the glycoprotein B residues 299 to 305, a glycine linker, and a C-terminal FEDF motif. If it could be demonstrated that antibodies of the speci?city and bioactivity of MAb 2c can be induced by the epitope or a peptide mimicking the epitope, strategies for active immunisation might be conceivable.<br />
<br />
<br />",,"/uploadfiles/file/20131011/20131011162700_3792.pdf",,10/11/2013,10/11/2013,"medicool",22,,"Herpes simplex virus  Monoclonal antibody  Glycoprotein B  Epitope mapping  Discontinuous epitope",0,"65",57,"Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity","2010",
109,,,"Sara Gómez-Abecia, María-Josefa Morán-Jiménez, Eva Ruiz-Casares, Nuno Henriques-Gil, Inmaculada García-Pastor, María-Concepción Garrido-Astray, Rafael Enríquez de Salamanca, Manuel Méndez","Gene","&nbsp;&nbsp;&nbsp; Porphyria cutanea tarda (PCT) results from decreased activity of 
uroporphyrinogen decarboxylase (UROD) in the liver. Deficiency in this 
enzyme results in accumulation of highly carboxylated porphyrins 
responsible for the disease. PCT usually occurs in adulthood and is 
characterized by cutaneous photosensitivity, hyperpigmentation, skin 
fragility and hypertrichosis. Familial PCT (F-PCT) occurs in 20C30% of 
patients in whom UROD gene mutations in heterozygosity decrease the 
enzymatic activity to about 50% in all tissues. The rare homozygous form
 of F-PCT (hepatoerythropoietic porphyria) has more severe clinical 
features and onset in childhood. In Spain, F-PCT is molecularly 
heterogeneous and the most frequent UROD mutation is p.G281E. In the 
present study, we searched for the molecular defect causing F-PCT in a 
group of Spanish patients and investigated whether the p.G281E mutation 
in the Spanish population came from a single or various origins. Among 
seventeen F-PCT patients, sixteen UROD mutations were identified, 
including eight novel ones: six missense (p.A23V, p.L78P, p.W180G, 
p.T196I, p.E278G and p.V279M), one frameshift (c.233delT) and one splice
 site mutation (c.774G&gt;C). Prokaryotic expression studies showed the 
detrimental effect for each missense mutation, whereas reverse 
transcription-PCR and sequencing demonstrated that the novel splice site
 mutation caused exon 7 skipping. Moreover, haplotype analysis performed
 in Spanish families with the p.G281E mutation indicated that this 
lesion is associated with at least five haplotype backgrounds. These 
results extend knowledge on the molecular heterogeneity of F-PCT and 
suggest multiple origins of the p.G281E mutation.",,"/uploadfiles/file/20130809/20130809152915_8891.pdf",,09/30/2013,09/30/2013,"medicool",25,,"Porphyria|Uroporphyrinogen decarboxylase|Mutation analysis|
Splicing defect|Prokaryotic expression|Haplotype analysis",0,"65",56,"Familial porphyria cutanea tarda in Spain: Characterization of eight novel mutations in the UROD gene and haplotype analysis of the common p.G281E mutation","2013",
126,"丙型肝炎患者中干扰素诱发的白癜风：一个案例系列",,"Issam Hamadah, MD, Yousef Binamer, MD, Faisal M. Sanai","International Journal of Dermatology","<p class=""MsoNormal"">
	<b><span style=""line-height:125%;font-family:&quot;""><span style=""font-size:16px;line-height:1.5;"">Background</span><span style=""font-size:16px;line-height:1.5;"">&nbsp;&nbsp;&nbsp; </span></span></b><span style=""line-height:125%;font-family:&quot;""><span style=""font-size:16px;line-height:1.5;"">&nbsp;</span><span style=""font-size:16px;line-height:1.5;"">Vitiligo is an
autoimmune disease characterized by depigmented patches and macules. It is
associated with many autoimmune diseases, the most common of which is thyroid
disease. The association between Interferon (IFN) therapy and vitiligo is
rarely reported in the literature, despite its common usage in hepatitis B
viral infection, hepatitis C viral infection (HCV), hematological malignancies
and melanoma. </span></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">Case</span></b><span style=""line-height:125%;font-family:&quot;""> <span style=""font-size:16px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style=""font-size:16px;line-height:1.5;"">We are reporting eight cases of
vitiligo that appeared after treating HCV with IFN. </span></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">Conclusion</span></b><span style=""line-height:125%;font-family:&quot;""> <span style=""font-size:16px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style=""font-size:16px;line-height:1.5;"">Interferon unmasks vitiligo in
susceptible individuals.<br />
</span></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">背景</span></b><b><span style=""line-height:1.5;font-family:&quot;font-size:16px;""><span style=""font-size:16px;line-height:1.5;"">&nbsp;&nbsp;&nbsp; </span></span></b><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">白癜风是一种以</span><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">皮肤上出现浅色或白色斑驳为特征的</span><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">自身免疫性疾病。</span><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">它与许多自身免疫性疾病有关，最常见的是甲状腺疾病。尽管</span><span style=""font-family:&quot;font-size:16px;line-height:1.5;"">INF</span><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">常使用于乙型肝炎病毒感染、丙型肝炎病毒感染（</span><span style=""font-family:&quot;font-size:16px;line-height:1.5;"">HCV</span><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">）、恶性血液病和黑色素瘤中，但是文献中关于干扰素（</span><span style=""font-family:&quot;font-size:16px;line-height:1.5;"">IFN</span><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">）治疗与白癜风之间的关系的报道很少。</span><span style=""font-family:&quot;""></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">案例</span></b><b><span style=""font-family:&quot;font-size:16px;line-height:1.5;""><span style=""font-size:16px;line-height:1.5;"">&nbsp;&nbsp;&nbsp; </span></span></b><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">我们报告了</span><span style=""font-family:&quot;font-size:16px;line-height:1.5;"">8</span><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">例使用</span><span style=""font-family:&quot;font-size:16px;line-height:1.5;"">INF</span><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">治疗</span><span style=""font-family:&quot;font-size:16px;line-height:1.5;"">HCV</span><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">后患者出现白癜风的病例。</span><span style=""font-family:&quot;""></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">结论</span></b><span style=""font-family:&quot;font-size:16px;line-height:1.5;""><span style=""font-size:16px;line-height:1.5;"">&nbsp;&nbsp;&nbsp; </span></span><span style=""font-family:宋体;font-size:16px;line-height:1.5;"">干扰素导致易感个体患白癜风。</span><b><span style=""line-height:125%;font-family:&quot;""></span></b>
</p>","/uploadfiles/image/20131011/20131011140907_2011w.jpg","/uploadfiles/file/20131011/20131011140923_8307.pdf",,10/11/2013,10/11/2013,"medicool",39,,"白癜风；干扰素",0,"85",28,"Interferon-induced vitiligo in hepatitis C patients: a case Series","2009",
144,,,"Miskulin M ; Miskulin I ; Milas J ; Antolovi?-Pozgain A ; Rudan S ; Vuksi? M","School Of Biological Anthropology","The aim ofthe study was to establish the seroprevalence of herpes simplex virus type 2 (HSV-2) among sexually active adults from East Croatia and to evaluate its correlates with demographic and behavioural risk factors. This cross-sec- tional study was conducted from the P' June until the 30""^ September 2005 at the Department of Transfusion Medicine, Osijek University Hospital Center. The study included 423 blood donors composed of 366 (86.5%) men and 57 (13.5%) women. Demographic data and data on the risky sexual behaviour during the lifetime were collected with usage of an anonymous questionnaire consisting of 15 questions. Western blot testing revealed that 3.3% (14/423) subjects were posi- tive for the presence ofIgG antibodies to herpes simplex virus 2, i.e. 10 (2.7%) men and 4 (7.0%) women. A higher HSV-2 seroprevalence was associated with female sex, older age, marital status (with single subjects been under the greater risk), irregular condom use on sexual intercourses with new partners and with higher number (five or more) of sexual partners during lifetime. Among determined risk factors in the study population, only the connection between the HSV-2 positivity and the older age was statistically significant. The study has showed that the demographic rather than the be- havioural risk factors are associated with higher prevalence of HSV-2 antibodies in the observed population.<br />
<br />",,"/uploadfiles/file/20131011/20131011171625_9912.pdf",,10/11/2013,10/11/2013,"medicool",36,,"HSV-2 seroprevalence, blood donors. Western blot testing, HSV-2 antibodies, Croati",0,"66",57,"Prevalence and Risk Factors for Herpes Simplex Virus Type 2 Infections in East Croatia","2011",
114,,,"Silke C. Hofmann, Anneleen Bosma, Leena Bruckner-Tuderman, Milica Vukmanovic-Stejic, Elizabeth C. Jury, David A. Isenberg, Claudia Mauri","Journal of Dermatological Science","<strong>Background:</strong><br />
&nbsp; &nbsp;&nbsp; Systemic lupus erythematosus (SLE)
 is associated with a numerical and functional reduction of peripheral 
blood (PB) invariant natural killer T (iNKT) cells. Limited information 
exists on the role of iNKT cells in the pathogenesis of lupus 
erythematosus. <br />
<strong>Objective: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To 
investigate the frequency and phenotype of iNKT cells in PB and dermal 
infiltrates from patients with SLE, subacute-cutaneous lupus 
erythematosus (SCLE) and discoid lupus erythematosus (DLE). <br />
<strong>Methods: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PB was obtained from 23 SLE, 6 SCLE, and 11 DLE patients, and 
from 30 healthy controls. iNKT cell frequency and CCR4/CCR6 surface 
expression were assessed by flow cytometry. The frequency and phenotype 
of skin infiltrating Va24+Vb11+ iNKT cells were investigated by 
immunofluorescence in lesional biopsies from 20 patients, unaffected 
skin from 3 patients, and from 6 healthy controls. <br />
<strong>Results: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lupus erythematosus patients displayed significantly lower 
percentages of circulating CD3+6B11+ iNKT cells compared to healthy 
controls. Whereas CCR6 expression on iNKT cells was enhanced in active 
SLE patients regardless of cutaneous involvement compared to healthy 
controls, CCR4 was exclusively increased in patients with active 
cutaneous lesions. Furthermore, iNKT cells were significantly enriched 
in lesional skin of SLE and DLE patients, but not in unaffected skin of 
lupus patients. The majority of lesional iNKT cells expressed IFN-g and 
CCR4. <br />
<strong>Conclusion: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The deficiency in 
circulating iNKT cells in cutaneous lupus erythematosus is associated 
with an increase of iNKT cells at the site of cutaneous inflammation. 
These data underscore the importance of analyzing iNKT cells not only in
 PB, but also in the target tissues.",,"/uploadfiles/file/20130809/20130809143926_9239.pdf",,09/30/2013,09/30/2013,"medicool",58,,"Lupus erythematosus|iNKT cells|Immunofluorescence|Flow cytometry|
CCR4",0,"65",3,"Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus","2013",
678,,"10.2340/00015555-0758","Natsuki Kuraishi, Yayoi Nagai, Michiko Hasegawa and Osamu Ishikawa","Acta Derm Venereol","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">Cutaneous adverse effects of imatinib mesylate (Glivec?)</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">are common and various types of skin eruptions have</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">been reported. We report here a 57-year-old man who</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">presented with lichen planus-like lesions on his extremities</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">and palmoplantar hyperkeratosis due to the use of</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">imatinib mesylate for chronic myeloid leukaemia. The</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">skin lesions improved after discontinuation of imatinib</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">mesylate but re-administration of the drug at a lower</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">dose provoked a mild recurrence. He could, however,</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">continue to take the drug at the lower dose and his skin</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">lesions were well-controlled by topical corticosteroid</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""font-size:14px;"">treatment.</span>&nbsp;<span style=""font-size:14px;"">The literature on lichenoid drug eruption due</span>&nbsp;<span style=""font-size:14px;"">to imatinib mesylate is reviewed. Key words: lichenoid</span>&nbsp;<span style=""font-size:14px;"">drug eruption; palmoplantar hyperkeratosis; imatinib</span>&nbsp;<span style=""font-size:14px;"">mesylate.</span>
</div>
</span><span style=""font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""font-size:14px;""></span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217144106_5846.pdf",,12/17/2013,12/17/2013,"medicool",7,,,0,"67",112,"Lichenoid Drug Eruption with Palmoplantar Hyperkeratosis due to Imatinib Mesylate: A Case Report and a Review of the Literature","2010",
679,,,"H. S. K. (50%), Y. J. C. (10%), Y. M. P. (10%), H.-O. K. (10%), J. Y. L. (20%).","the journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Dear Editor,</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Scleroderma is a rare condition in children. Broadly,&nbsp;</span><span style=""line-height:1.5;"">scleroderma can be divided into two major groups:&nbsp;</span><span style=""line-height:1.5;"">localized scleroderma (morphea) and systemic&nbsp;</span><span style=""line-height:1.5;"">sclerosis (SSc). Localized scleroderma has generally&nbsp;</span><span style=""line-height:1.5;""></span><span style=""line-height:1.5;"">been viewed as a skin-limited disease. However,</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">some studies suggest that variants of localized&nbsp;</span><span style=""line-height:1.5;"">scleroderma can have clinically important extracutaneous&nbsp;</span><span style=""line-height:1.5;"">manifestations.1C3 We herein report a case of&nbsp;</span><span style=""line-height:1.5;"">juvenile localized scleroderma with joint sclerosis&nbsp;</span><span style=""line-height:1.5;"">and Sjo¨ gren’s syndrome in a child with precocious</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">puberty.</span> 
</div>
</span><br />",,"/uploadfiles/file/20131217/20131217145242_9698.pdf",,12/17/2013,12/17/2013,"medicool",7,,"juvenile localized scleroderma, Sjo¨ gren’s syndrome, Sjo¨ gren’s syndrome",0,"85",114,"Case of juvenile localized scleroderma with joint sclerosis and Sjo¨ gren’s syndrome in a child with precocious puberty","2011",
680,,,"Robert S. Stern, M.D.","The New England Journal of Medicine","<span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;"">A 50-year-old woman with bipolar depression presents with a widespread pruritic&nbsp;</span><span style=""font-size:14px;"">rash of 1 day’s duration. She is afebrile and otherwise well. She has a history of childhood&nbsp;</span><span style=""font-size:14px;"">eczema and is allergic to sulfonamide antibiotics. Her medications include thyroxine&nbsp;</span><span style=""font-size:14px;"">daily, naproxen intermittently, and lamotrigine, which she began taking&nbsp;</span><span style=""font-size:14px;"">3 weeks earlier. How should this case be evaluated and treated?</span><br />",,"/uploadfiles/file/20131217/20131217144516_5126.pdf",,12/17/2013,12/17/2013,"medicool",5,,,0,"66",112,"Exanthematous Drug Eruptions","2013",
681,,,"David A. Provenzano, MD, Luke Nicholson, Luke Nicholson RN, Evan Lutton, David B. Catalane, MD, and Eileen Mackin, RN","Pain Medicine","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract</strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Objective</strong>. To report a case of scleroderma with&nbsp;</span><span style=""line-height:1.5;"">associated Raynaud’s phenomenon and its successful&nbsp;</span><span style=""line-height:1.5;"">treatment with spinal cord stimulation. To&nbsp;</span><span style=""line-height:1.5;"">demonstrate the use of transcutaneous oxygen&nbsp;</span><span style=""line-height:1.5;"">pressure monitoring to guide the progression from&nbsp;</span><span style=""line-height:1.5;"">trial to implantation and to assess post-implantation&nbsp;</span><span style=""line-height:1.5;"">microcirculatory recovery.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span><span style=""line-height:1.5;"">Design. Case report and literature review.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong></strong></span><span style=""line-height:1.5;""><strong>Patient</strong>. A 51-year-old female with scleroderma,&nbsp;</span><span style=""line-height:1.5;"">associated Raynaud’s phenomenon, and a nonhealing&nbsp;</span><span style=""line-height:1.5;"">3.7-cm lower extremity ischemic ulcer.&nbsp;</span><span style=""line-height:1.5;"">Ankle-brachial indexes demonstrated normal&nbsp;</span><span style=""line-height:1.5;"">macrocirculation, but transcutaneous oxygen pressures&nbsp;</span><span style=""line-height:1.5;"">demonstrated significant microcirculatory&nbsp;</span><span style=""line-height:1.5;"">insufficiency.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span><span style=""line-height:1.5;""><strong>Intervention</strong>. Treatment was a spinal cord stimulator&nbsp;</span><span style=""line-height:1.5;"">implantation after a successful trial. Transcutaneous&nbsp;</span><span style=""line-height:1.5;"">oxygen pressures were interpreted during the&nbsp;</span><span style=""line-height:1.5;"">trial and post-implantation stages.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong></strong></span><span style=""line-height:1.5;""><strong>Results</strong>. Based on a 5-day trial that documented&nbsp;</span><span style=""line-height:1.5;"">improvements in transcutaneous oxygen pressures&nbsp;</span><span style=""line-height:1.5;"">and pain relief, the patient underwent implantation.&nbsp;</span><span style=""line-height:1.5;"">At 4 months, the ischemic ulcer had healed. The&nbsp;</span><span style=""line-height:1.5;"">patient had significant improvement in pain control&nbsp;</span><span style=""line-height:1.5;"">and reduced Raynaud’s phenomenon signs and&nbsp;</span><span style=""line-height:1.5;"">symptoms. At 18 months, the patient continued to&nbsp;</span><span style=""line-height:1.5;"">have improvement with no associated complications.&nbsp;</span><span style=""line-height:1.5;"">A literature review demonstrated only four&nbsp;</span><span style=""line-height:1.5;"">published reports, including a total of 18 patients,&nbsp;</span><span style=""line-height:1.5;"">on spinal cord stimulator treatment for scleroderma&nbsp;</span><span style=""line-height:1.5;"">and associated Raynaud’s phenomenon.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong></strong></span><span style=""line-height:1.5;""><strong>Conclusions</strong>. We report the healing of a greater&nbsp;</span><span style=""line-height:1.5;"">than 3-cm ischemic ulcer in an individual with&nbsp;</span><span style=""line-height:1.5;"">normal macrocirculation but severe microcirculatory&nbsp;</span><span style=""line-height:1.5;"">insufficiency from scleroderma. Improvements&nbsp;</span><span style=""line-height:1.5;"">in microcirculation correlated with wound healing.&nbsp;</span><span style=""line-height:1.5;"">Spinal cord stimulation may be considered for&nbsp;</span><span style=""line-height:1.5;"">select individuals with microcirculatory reserves&nbsp;</span><span style=""line-height:1.5;"">that can be modulated with treatment.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span> 
</div>
</span><br />",,"/uploadfiles/file/20131217/20131217145312_5631.pdf",,12/17/2013,12/17/2013,"medicool",6,,"Spinal Cord Stimulation; Scleroderma; Raynaud’s Phenomenon; Transcutaneous Oxygen Pressure",0,"85",114,"Case Report Spinal Cord Stimulation Utilization to Treat the Microcirculatory Vascular Insufficiency and Ulcers Associated with Scleroderma: A Case Report and Review of the Literature","2011",
683,,"DOI 10.1007/s00296-010-1482-6","Pollyanna d’A? vila Leite ? Joze?lio Freire de Carvalho","Rheumatol Int","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract.</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp; </span><span style=""line-height:1.5;"">The antiphospholipid syndrome (APS) can be&nbsp;</span><span style=""line-height:1.5;"">primary, when it occurs alone, or secondary, when it is&nbsp;</span><span style=""line-height:1.5;"">associated with another autoimmune disease, mainly&nbsp;</span><span style=""line-height:1.5;"">systemic lupus erythematosus and rarely other autoimmune&nbsp;</span><span style=""line-height:1.5;"">diseases. Cases described in literature (Medline 1966 to&nbsp;</span><span style=""line-height:1.5;"">December 2009) associate the presence of antiphospholipid&nbsp;</span><span style=""line-height:1.5;"">antibodies with the presence of APS and systemic sclerosis&nbsp;</span><span style=""line-height:1.5;"">(SS). Currently, however, no cases of the SS variant sine&nbsp;</span><span style=""line-height:1.5;"">scleroderma with APS have been described. In this study,&nbsp;</span><span style=""line-height:1.5;"">the authors describe the case of a patient with APS characterised&nbsp;</span><span style=""line-height:1.5;"">by thrombosis of the retinal veins, in May 2006,&nbsp;</span><span style=""line-height:1.5;"">the presence of lupus anticoagulant and an anticardiolipin&nbsp;</span><span style=""line-height:1.5;"">IgG antibody. In May 2007, this patient developed&nbsp;</span><span style=""line-height:1.5;"">Raynaud’s phenomenon, a lack of oesophageal motility&nbsp;</span><span style=""line-height:1.5;"">and nailfold capillaroscopy with a scleroderma pattern. The&nbsp;</span><span style=""line-height:1.5;"">patient was positive for the anti-centromere antibody but&nbsp;</span><span style=""line-height:1.5;"">lacked any evidence of cutaneous thickening or involvement.&nbsp;</span><span style=""line-height:1.5;"">In summary, the authors describe the first case of a&nbsp;</span><span style=""line-height:1.5;"">patient with APS associated with SS sine scleroderma.</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217150905_8339.pdf",,12/17/2013,12/17/2013,"medicool",6,,"Antiphospholipid syndrome  ,Systemic sclerosis sine scleroderma",0,"85",114,"Systemic sclerosis sine scleroderma associated with antiphospholipid syndrome","2012",
685,,"DOI 10.1007/s10165-011-0553-1","Naohiko Aozasa ? Yoshihide Asano ? Kaname Akamata ? Shinji Noda ? Yuri Masui ? Zenshiro Tamaki ? Yayoi Tada ? Makoto Sugaya ? Takafumi Kadono ? Shinichi Sato","Mod Rheumatol","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract.</strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp; &nbsp;</span><span style=""line-height:1.5;"">We aimed to investigate the clinical significance&nbsp;</span><span style=""line-height:1.5;"">of serum levels of secretory leukocyte protease inhibitor&nbsp;</span><span style=""line-height:1.5;"">(SLPI),which is widely expressed in lung tissues and serves as&nbsp;</span><span style=""line-height:1.5;"">a usefulmarker reflecting the activity of various lung diseases,&nbsp;</span><span style=""line-height:1.5;"">in patients with systemic sclerosis (SSc). Serum SLPI levels&nbsp;</span><span style=""line-height:1.5;"">were measured by a specific enzyme-linked immunosorbent&nbsp;</span><span style=""line-height:1.5;"">assay (ELISA) in 58 SSc patients and 16 healthy controls.&nbsp;</span><span style=""line-height:1.5;"">Serum SLPI levels in diffuse cutaneous SSc and in limited&nbsp;</span><span style=""line-height:1.5;"">cutaneous SSc with interstitial lung disease (ILD) were significantly&nbsp;</span><span style=""line-height:1.5;"">higher than those in healthy controls (43.1 ± 18.4&nbsp;</span><span style=""line-height:1.5;"">vs. 30.9 ± 3.76 ng/ml, p\0.05 and 39.8 ± 10.3 vs.&nbsp;</span><span style=""line-height:1.5;"">30.9 ± 3.76 ng/ml, p\0.01, respectively). The incidences&nbsp;</span><span style=""line-height:1.5;"">of decreased percent diffusing capacity for carbon monoxide&nbsp;</span><span style=""line-height:1.5;"">(%DLco) and decreased percent vital capacity (%VC) were&nbsp;</span><span style=""line-height:1.5;"">significantly greater in SSc patients with elevated SLPI levels&nbsp;</span><span style=""line-height:1.5;"">than in those with normal levels (73 vs. 31%, p\0.01 and 24&nbsp;</span><span style=""line-height:1.5;"">vs. 4%, p\0.05, respectively). Furthermore, serum SLPI&nbsp;</span><span style=""line-height:1.5;"">levels were inversely correlated with %DLco (r = -0.40,&nbsp;</span><span style=""line-height:1.5;"">p\0.01), while they were positively correlated with surfactant&nbsp;</span><span style=""line-height:1.5;"">protein D (r = 0.28, p\0.05). Longitudinal study&nbsp;</span><span style=""line-height:1.5;"">revealed the association of serumSLPI levels with the disease&nbsp;</span><span style=""line-height:1.5;"">activity of SSc-ILD. SLPI serves as a useful serummarker for&nbsp;</span><span style=""line-height:1.5;"">evaluating SSc-ILD.</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217151633_7263.pdf",,12/17/2013,12/17/2013,"medicool",4,,"Interstitial lung disease  Secretory leukocyte protease inhibitor 
Surfactant protein D  Systemic sclerosis",0,"65",114,"Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis","2012",
686,,"doi:10.1038/jid.2012.226","Doanh Le Huu, Takashi Matsushita, Guihua Jin, Yasuhito Hamaguchi, Minoru Hasegawa, Kazuhiko Takehara, and Manabu Fujimoto","Journal of Investigative Dermatology","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp;&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; Systemic sclerosis (scleroderma) is a connective tissue disease characterized by excessive extracellular matrix&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">deposition in the skin and visceral organs. Serum IL-6 levels are reported to be elevated in human scleroderma&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and chronic graft-versus-host disease (cGVHD) patients. IL-6 blockade using anti-IL-6 receptor mAb (anti-IL-6R&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">mAb) results in amelioration of the pathologic symptoms of some autoimmune diseases such as rheumatoid&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">arthritis and juvenile idiopathic arthritis. In this study, we examined the effects of anti-IL-6R mAb on&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">either prevention or treatment of murine sclerodermatous cGVHD (Scl-cGVHD). We found that serum IL-6 levels&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">in Scl-cGVHD mice gradually increased after bone marrow transplantation. Administration of anti-IL-6R&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">mAb attenuated the development of severe Scl-cGVHD and fibrosis and resulted in an increasein&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">CD4?CD25?FoxP3? regulatory T cells. However, treatment of established Scl-cGVHD with anti-IL-6R mAb&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">showed no effects on disease severity. The effects of anti-IL-6R mAb were mostly inhibited by anti-CD25&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">mAb. Together, our results indicate that IL-6 has an important role in the pathogenesis of Scl-cGVHD.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">IL-6 blockade may be an effective approach for preventing Scl-cGVHD and treating cGVHD and scleroderma in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">humans.</span>
</div>",,"/uploadfiles/file/20131217/20131217152227_1917.pdf",,12/17/2013,12/17/2013,"medicool",3,,"Sclerodermatous, Graft-Versus-Host, IL-6 blockade",0,"65",114,"IL-6 Blockade Attenuates the Development of Murine Sclerodermatous Chronic Graft-Versus-Host Disease","2012",
687,,"doi:10.1111/j.1365-2230.2011.04201.x","M. Ozgen, S. S. Koca, A. F. Dagli, B. Gundogdu, B. Ustundag? and A. Isik","Departments of Rheumatology","<div style=""text-align:justify;"">
	<strong style=""line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:16px;line-height:1.5;"">Summary.</span></strong>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong></strong></span><span style=""line-height:1.5;""><strong>Background</strong>. T lymphocytes induce the transformation of fibroblasts into&nbsp;</span><span style=""line-height:1.5;"">myofibroblasts, the main mediators of fibrogenesis. The inosine 5?-monophosphate&nbsp;</span><span style=""line-height:1.5;"">dehydrogenase inhibitor mycophenolate mofetil (MMF) and the anti-CD25 monoclonal&nbsp;</span><span style=""line-height:1.5;"">antibody daclizumab (DCZ) have been reported to suppress the proliferation of T&nbsp;</span><span style=""line-height:1.5;"">lymphocytes.&nbsp;</span><span style=""line-height:1.5;"">Aim. To evaluate the preventive effects of MMF and DCZ in early stages of bleomycin&nbsp;</span><span style=""line-height:1.5;"">(BLM)-induced scleroderma.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Methods</strong>. This study involved five groups of Balb ? c mice (n = 10 per group). Mice in&nbsp;</span><span style=""line-height:1.5;"">four of the groups were injected subcutaneously (SC) with BLM [100 lg ? day in&nbsp;</span><span style=""line-height:1.5;"">100 lL phosphate-buffered saline (PBS)] for 4 weeks; the remaining (control) group&nbsp;</span><span style=""line-height:1.5;"">received only 100 lL PBS. Three of the BLM-treated groups also received either&nbsp;</span><span style=""line-height:1.5;"">intraperitoneal MMF 50 or 150 mg ? kg ? day, or SC DCZ 100 lg ? week. At the end of&nbsp;</span><span style=""line-height:1.5;"">the fourth week, all mice were killed, and blood and tissue samples were obtained for&nbsp;</span><span style=""line-height:1.5;"">further analysis.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Results</strong>. In the BLM-treated group, increases were seen in inflammatory-cell infiltration,&nbsp;</span><span style=""line-height:1.5;"">a-smooth muscle actin-positive (a-SMA+) fibroblastic cell count, tissue&nbsp;</span><span style=""line-height:1.5;"">hydroxyproline content, and dermal thickness. Dermal fibrosis was histopathologically&nbsp;</span><span style=""line-height:1.5;"">prominent. In BLM-treated mice also given MMF or DCZ, inflammatory-cell infiltration,&nbsp;</span><span style=""line-height:1.5;"">tissue hydroxyproline content and dermal thickness were decreased. In the MMF&nbsp;</span><span style=""line-height:1.5;"">groups, decreases were also noted in a-SMA+ fibroblastic cell count.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Conclusion</strong>. In this BLM-induced dermal fibrosis model, MMF and DCZ treatments&nbsp;</span><span style=""line-height:1.5;"">prevented the development of dermal fibrosis. Further studies are needed to evaluate&nbsp;</span><span style=""line-height:1.5;"">whether targeting T lymphocytes is effective in resolving pre-existing fibrosis in human&nbsp;</span><span style=""line-height:1.5;"">scleroderma.</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217153032_1966.pdf",,12/17/2013,12/17/2013,"medicool",6,,"experimental scleroderma, Mycophenolate mofetil, T lymphocytes",0,"65",114,"Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma","2011",
688,,"DOI 10.1007/s00296-011-1963-2","Gehan Ibrahim Abdelrazek Salem ・ Awni Ali Abdulrahman","Rheumatol Int","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract&nbsp;</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""> &nbsp; &nbsp; &nbsp;</span><span style=""line-height:1.5;"">Systemic sclerosis is a clinically heterogeneous,&nbsp;</span><span style=""line-height:1.5;"">systemic disorder which aVects the connective tissue of the&nbsp;</span><span style=""line-height:1.5;"">skin, internal organs, and the walls of blood vessels. It is&nbsp;</span><span style=""line-height:1.5;"">characterized by alterations of the microvasculature, disturbances&nbsp;</span><span style=""line-height:1.5;"">of the immune system and by massive deposition of&nbsp;</span><span style=""line-height:1.5;"">collagen and other matrix substances in the connective tissue.&nbsp;</span><span style=""line-height:1.5;"">This study was done to evaluate the frequency of liver&nbsp;</span><span style=""line-height:1.5;"">disease in patients with scleroderma and, secondarily, to&nbsp;</span><span style=""line-height:1.5;"">study the frequency of infection of hepatitis B and C virus&nbsp;</span><span style=""line-height:1.5;"">in these patients and determine frequency of serum autoantibodies&nbsp;</span><span style=""line-height:1.5;"">in this disease. We studied patients with scleroderma,&nbsp;</span><span style=""line-height:1.5;"">localized or systemic, in the outpatient clinic of&nbsp;</span><span style=""line-height:1.5;"">rheumatology and dermatology departments, at King&nbsp;</span><span style=""line-height:1.5;"">Khalid University Hospital. As for a comparison, healthy&nbsp;</span><span style=""line-height:1.5;"">persons coming to the clinic with the same mean age were&nbsp;</span><span style=""line-height:1.5;"">considered as control group. Forty patients with the diagnosis&nbsp;</span><span style=""line-height:1.5;"">of scleroderma included in this work, 35% had elevated&nbsp;</span><span style=""line-height:1.5;"">gamma-glutamyl-transferase (-GT), 30% had elevated&nbsp;</span><span style=""line-height:1.5;"">alkaline phosphatase (AP) and in 17.5%, the alanineamino-&nbsp;</span><span style=""line-height:1.5;"">transferase (ALT) was above the reference values.&nbsp;</span><span style=""line-height:1.5;"">The ALT had changed to be more in scleroderma patients&nbsp;</span><span style=""line-height:1.5;"">than in controls. Twenty percent (20%) of the patients tested&nbsp;</span><span style=""line-height:1.5;"">positive for anti-smooth muscle antibodies (anti-SMA) and&nbsp;</span><span style=""line-height:1.5;"">only one patient had anti-mitochondrial antibodies (AMA).&nbsp;</span><span style=""line-height:1.5;"">There was no statistical diVerence between the two groups&nbsp;</span><span style=""line-height:1.5;"">regarding antibody testing. Anti-HCV antibodies were&nbsp;</span><span style=""line-height:1.5;"">observed in one patient, and HBsAg was detected in&nbsp;</span><span style=""line-height:1.5;"">another scleroderma patient. There was no patient with&nbsp;</span><span style=""line-height:1.5;"">clinically signiWcant hepatic disease. In this study, although&nbsp;</span><span style=""line-height:1.5;"">changes in liver enzymes in patients with scleroderma were&nbsp;</span><span style=""line-height:1.5;"">not uncommon, there was no scleroderma patient with clinical&nbsp;</span><span style=""line-height:1.5;"">manifestations of liver disease.</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217153407_1026.pdf",,12/17/2013,12/17/2013,"medicool",4,,"Scleroderma ・ Systemic sclerosis ・ Liver disease",0,"66",114,"Evaluation of liver function tests in scleroderma patients","2012",
689,,"doi.org/l 0.101 é/j.mayocp.2013.01.018","Ami A. Shah, MD, MHS, and Frednck M. Wigley, MD","Mayo Clin Proc.","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp; Systemic sclerosis (scleroderma) is unique among the rheumatic diseases because it presents the challenge&nbsp;</span><span style=""line-height:1.5;"">of managing a chronic multisystem autoimmune disease with a widespread obliterative vasculopathy&nbsp;</span><span style=""line-height:1.5;"">of small arteries that is associated with varying degrees of tissue fibrosis. The hallmark of&nbsp;</span><span style=""line-height:1.5;"">scleroderma is clinical heterogeneity with subsets that vary in the degree of disease expression, organ&nbsp;</span><span style=""line-height:1.5;"">involvement, and ultimate prognosis. Thus, the term scleroderma is used to describe patients who have&nbsp;</span><span style=""line-height:1.5;"">common manifestations that link them together, whereas a highly variable clinical course exists that&nbsp;</span><span style=""line-height:1.5;"">spans from mild and subtle findings to aggressive, life-threatening multisystem disease. The physician&nbsp;</span><span style=""line-height:1.5;"">needs to carefully characterize each patient to understand the specific manifestations and level of&nbsp;</span><span style=""line-height:1.5;"">disease activity to decide appropriate treatment. This is particularly important in treating a patient with&nbsp;</span><span style=""line-height:1.5;"">scleroderma because there is no treatment that has been proven to modify the overall disease course,&nbsp;</span><span style=""line-height:1.5;"">although therapy that targets specific organ involvement early before irreversible damage occurs improves&nbsp;</span><span style=""line-height:1.5;"">both quality of life and survival. This review describes our approach as defined by evidence,&nbsp;</span><span style=""line-height:1.5;"">expert opinion, and our experience treating patients. Scleroderma is a multisystem disease with variable&nbsp;</span><span style=""line-height:1.5;"">expression; thus, any treatment plan must be holistic, yet at the same time focus on the dominant&nbsp;</span><span style=""line-height:1.5;"">organ disease. The goal of therapy is to improve quality of life by minimizing specific organ&nbsp;</span><span style=""line-height:1.5;"">involvement and subsequent life-threatening disease. At the same time the many factors that alter daily&nbsp;</span><span style=""line-height:1.5;"">function need to be addressed, including nutrition, pain, deconditioning, musculoskeletal disuse,&nbsp;</span><span style=""line-height:1.5;"">comorbid conditions, and the emotional aspects of the disease, such as fear, depression, and the social&nbsp;</span><span style=""line-height:1.5;"">withdrawal caused by disfigurement.</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217153902_0523.pdf",,12/17/2013,12/17/2013,"medicool",7,,"Treatment, Scleroderma",0,"66",114,"My Approach to the Treatment of Scleroderma","2013",
185,,"10.1007/s10067-010-1650-9","Afshin Borhani Haghighi ， Sirous Sarhadi ，Siamak Farahangiz","Clin Rheumatol","&nbsp; &nbsp;Neurological manifestations present in 5% to 30% of patients with Beh?et’s disease. We studied consecutive patients with relapsingCremitting or progressive neuro-Behcet’s disease who referred from January 2002 to January 2009 to Nemazee Hospital, Shiraz,southern Iran. Sequential MRIs were performed duringclinical relapses in patients with relapsingCremitting course or during relentless progression after first referral ofpatients with progressive course. We reviewed 55 MRIs of 17 patients (ten men and seven women) with age of36.4±8.1 years at the time of first MRI. Nine (53%)<br />
patients had a relapsingCremitting course and eight (47%) had a progressive course. The initial and last follow-up studies had a mean interval of 29.2 months (range, 24 to 84). Of the patients with progressive neuro-Behcet’s disease, 50% had brainstem atrophy and 75% had black holes in their last follow-up MRIs. The respective prevalence rates for those with relapsingCremitting neuro-Behcet’s disease were 0% and 11%. In the total population of patients with neuro-Behcet’s disease, the number of lesions (p=0.002) and MRI burden (p=0.016) had a significant increase in the last follow-up studies in comparison to the initial studies. Incremental pattern in the number of lesions and MRI burdens in patients with parenchymal neuro-Behcet’s disease in our longitudinal study may imply an ongoing pathologic process.
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131012/20131012144011_0953.pdf",,10/12/2013,10/12/2013,"medicool",33,,"Behcet syndrome； Central nervous system； MRI； Neuro-Behcet disease； Neuro-Behcet’s disease",0,"65",29,"MRI findings of neuro-Behcet’s disease","2011",
186,,"DOI 10.1007/s00296-009-1123-0","Taner Babacan ・ Ahmet Mesut Onat ・ Yavuz Pehlivan ・Gazi Comez ・ Ediz Tutar","Rheumatol Int","We herein report a case of 32-year-old woman who developed erythematous, indurated plaques, nodules on her lower back, hips and inguinal areas which had started after immunotherapy on the injection sites. She had a history of recurrent oral aphthous-like ulcers for 2 years and also had abdominal pain for 2 months. Colonoscopy revealed multiple aphthous ulcers on intestine.Diagnosis of lobular panniculitis was conWrmed by histopathological Wnding of the skin biopsy and she was diagnosed as Behcet’s disease. Eruptions due to mesotherapy accepted as hypersensitivity reaction. Before employing this technique,patients should be carefully examined for Behcet’s pathognomonic clinical Wndings.",,"/uploadfiles/file/20131012/20131012145420_4700.pdf",,10/12/2013,10/12/2013,"medicool",21,,"Mesotherapy ・;Behcet’s disease ;Panniculitis",0,"85",29,"A case of the Behcet’s disease diagnosed by the panniculits after mesotherapy","2010",
187,,"10.1111/j.1525-1470.2011.01654.x","Turner PJ ; Kakakios A ; Wong LC ; Wong M ; Campbell DE","Pediatric Dermatology","<span style=""font-family:Times New Roman;"">&nbsp; Severe cases of atopic dermatitis (AD) may require systemic immunosuppression to achieve disease control. Unfortunately, some cases continue to be refractory to management or develop unacceptable adverse effects. There are limited reports of the use of intravenous immunoglobulin (IVIg) in the treatment of severe AD, but results are inconsistent. In a retro- spective study, we report 10 children with severe AD refractory to systemic immunosuppression and maximal topical therapy who were treated using IVIg. The children received monthly IVIg for an average of 24 months. This resulted in a signi?cant improvement in symptoms, with fewer infection- related exacerbations and hospitalizations, allowing systemic immunosup- pression to be tapered. The effect was associated with a signi?cant decrease in serum immunoglobulin E and was sustained after cessation of IVIg in 50% of cases. No signi?cant side effects attributable to the IVIg infusions were noted. In this cohort of children with severe AD and recurrent cutaneous infections, IVIg provided an effective treatment with minimal side effects and signi?cant bene?ts in school attendance and quality of life.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012145953_4526.pdf",,10/12/2013,10/12/2013,"medicool",28,,,0,"85",46,"Intravenous immunoglobulin to treat severe atopic dermatitis in children: a case series","2012",
254,,,"Sadri MF ; Farnaghi F ; Danesh-Pazhooh M ; Shokoohi A","Grosse Verlag","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-size:14px;"">The objective of this study is to define the </span><span style=""font-size:14px;"">frequency</span><span style=""font-size:14px;""> of </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">pedis</span> <span style=""font-size:14px;"">in</span> <span style=""font-size:14px;"">patients</span><span style=""font-size:14px;""> with </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">cruris</span><span style=""font-size:14px;"">. Sixty </span><span style=""font-size:14px;"">patients</span><span style=""font-size:14px;""> (46 males and 14 females) entered our study. Epidermophyton floccosum was the most frequently isolated fungus </span><span style=""font-size:14px;"">in</span> <span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">cruris</span><span style=""font-size:14px;"">. Four </span><span style=""font-size:14px;"">patients</span><span style=""font-size:14px;""> (6.4%) had concurrent </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">pedis</span><span style=""font-size:14px;""> and the only isolate from the foot was Trichophyton mentagrophytes. </span><span style=""font-size:14px;"">In</span><span style=""font-size:14px;""> three of them, the corresponding dermatophyte </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> the groin was E. floccosum.</span>",,"/uploadfiles/file/20131016/20131016154656_8603.pdf",,10/16/2013,10/16/2013,"medicool",33,,"Dermatophytes, dermatophytosis, tinea pedis, tinea cruris, epidemiology, Iran.",0,"67",65,"The frequency of tinea pedis in patients with tinea cruris in Tehran, Iran","2000",
188,,"DOI 10.1007/s00296-009-1123-0","Taner Babacan ・ Ahmet Mesut Onat ・ Yavuz Pehlivan ・Gazi Comez ・ Ediz Tutar","Rheumatol Int","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We herein report a case of 32-year-old woman who developed erythematous, indurated plaques, nodules on her lower back, hips and inguinal areas which had started after immunotherapy on the injection sites. She had a history of recurrent oral aphthous-like ulcers for 2 years and also had abdominal pain for 2 months. Colonoscopy revealed multiple aphthous ulcers on intestine.Diagnosis of lobular panniculitis was conWrmed by histopathological Wnding of the skin biopsy and she was diagnosed as Behcet’s disease. Eruptions due to mesotherapy accepted as hypersensitivity reaction. Before employing this technique,patients should be carefully examined for Behcet’s pathognomonicclinical Wndings.",,"/uploadfiles/file/20131012/20131012150300_0133.pdf",,10/12/2013,10/12/2013,"medicool",28,,"Mesotherapy ・ Behcet’s disease ・ Panniculitis",0,"85",29,"A case of the Behcet’s disease diagnosed by the panniculits after mesotherapy","2010",
189,,"10.1007/s00296-011-2011-y","Ayten Yazici ， Ayse CeXe ， Hakan Savli",,"&nbsp;&nbsp;&nbsp;&nbsp; Investigation of the relation between MEFV gene mutations and clinical Wndings of Beh?et’s disease.Genetic features of 100 patients with Beh?et’s disease (BD) and 100 healthy controls were analyzed. None of the individuals had a family history of FMF in the patient and control group, and none of the individuals in the control group had a family history of BD. MEFV gene analysis was performed in all the patients with BD and healthy controls;twelve diVerent regions were scanned. In the BD group,mutations were detected in more than one region in 27 patients (27%). Twenty-Wve patients had heterozygous and two patients had compound heterozygous mutations (M680I-V726A and M694 V-A744S). The most frequent mutation was M694 V with an allelic frequency of 5%. The allelic frequencies of E148Q, M680I (G/C), and V726A<br />
were 3, 2, and 2%, respectively. The allelic frequencies of P369S, A744S, and K695R were 1, 1, and 0.5%. MEFV gene analysis revealed mutations in 27 (27%) of the individuals in the control group; the allelic frequency was 14%.The most frequent mutation was E148Q that was detected in 16 individuals. One individual was compound heterozygote (E148Q-M694 V). The allelic frequencies of E148Q, M694 V, V726A, and M680I were 8, 3, 1.5, and 0.5%,respectively. The allelic frequencies of K695R and P369S were 0.5 and 0.5%, respectively. The allelic frequency wassimilar in the two groups. There was not a signiWcant relation between the mutations in the BD group and clinical Wndings.",,"/uploadfiles/file/20131012/20131012150339_9338.pdf",,10/12/2013,10/12/2013,"medicool",28,,"Beh?et’s disease ； Familial Mediterranean fever ； MEFV gene ・；Vasculitis",0,"65",29,"The frequency of MEFV gene mutations in behcet’s disease ","2012",
193,,"10.1111/j.1365-2133.2010.09823.x","Pozzi G ; Asero R","The British Journal Of Dermatology","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; Skin photodynamic 
therapy (PDT) is a technique that combines the administration of 
porphyrins or porphyrin pre- cursors and illumination with red or blue 
light at the diseased sites. Photosensitizers show the highest peak of 
absorption at about 405 nm, although a wavelength of about 635 nm is 
preferentially used for irradiation as light in the red part of the 
spectrum shows the best tissue penetration.1 Irradiated photosensitizers
 produce singlet oxygen, a highly reactive acti- vated oxygen species 
and a major cytotoxin. The porphyrin precursor 5-aminolaevulinic acid 
(ALA) or its methyl ester (methyl aminolaevulinate, so far the only 
approved formula- tion in Europe) is applied topically as 
photosensitizer to exclude systemic reactions. Possible light sources 
include lasers as well as incoherent light sources; irradiation with 
incoherent light sources is cheaper and more appropriate for large 
treat- ment areas. PDT appears to exert several favourable features for 
the treatment of localized skin diseases. Clinical conditions such as 
actinic keratoses, nodular and super?cial basal cell car- cinoma, skin 
tumours or precancerous lesions, Bowen disease, nonmalignant conditions 
such as acne vulgaris and leishmania- sis, as well as age-related 
macular degeneration and ageing due to sun exposure have been treated 
with PDT.2,3 The main advantages of PDT in comparison with other 
treatment modal- ities are its excellent cosmetic results and its high 
remission rates
 despite low invasiveness.3 Surprisingly, PDT has not been used in 
atopic dermatitis (AD) so far. In clinical practice patients with severe
 AD might be good candidates to receive a nontoxic treatment instead of 
local tacrolimus or systemic ciclosporin. We report an adult with AD, 
previously showing very severe localized disease, who responded 
favourably to PDT. </span> 
</p>",,"/uploadfiles/file/20131012/20131012151732_4137.pdf",,10/12/2013,10/14/2013,"medicool",33,,"Atopic dermatitis, photodynamic therapy",0,"85",46,"Skin photodynamic therapy in severe localized atopic dermatitis: a case report","2010",
192,,"10.2340/00015555-1415","Schut C ; Weik U ; Tews N ; Gieler U ; Deinzer R ; Kupfer J","Acta Dermato-Venereologica","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; Atopic</span> <span style=""font-family:Times New Roman;"">dermatitis</span><span style=""font-family:Times New Roman;""> leads to, and can be
 triggered by, stress. Psychological interventions have been shown to 
have positive effects on skin status, itch and scratching behaviour. 
However, it has not been analysed whether stress management leads to a 
change in physiological stress level and psychophysiological stress 
reaction under acute stress in this patient group. In this </span><span style=""font-family:Times New Roman;"">study</span><span style=""font-family:Times New Roman;""> 28 patients with </span><span style=""font-family:Times New Roman;"">atopic</span> <span style=""font-family:Times New Roman;"">dermatitis</span><span style=""font-family:Times New Roman;""> were randomized to an experimental group (cognitive behavioural stress 
management) or a control group. The endocrine stress level and skin 
status were measured before and after the stress management programme. A
 public-speaking paradigm was used to induce acute stress. The </span><span style=""font-family:Times New Roman;"">study</span><span style=""font-family:Times New Roman;""> revealed that the experimental group had a tentatively reduced cortisol
 awakening response after the stress management programme. In addition, 
the experimental group remained calmer and showed lower salivary 
cortisol levels under acute stress. Thus, stress management might be a 
useful addition to standard treatment in patients with </span><span style=""font-family:Times New Roman;"">atopic</span> <span style=""font-family:Times New Roman;"">dermatitis</span><span style=""font-family:Times New Roman;"">.</span> 
</p>",,"/uploadfiles/file/20131012/20131012151345_6673.pdf",,10/12/2013,10/12/2013,"medicool",25,,"atopic dermatitis; stress; stress management; cortisol; cortisol awakening response; psyche.",0,"66",46,"Psychophysiological effects of stress management in patients with atopic dermatitis: a randomized controlled trial","2013",
194,,,"Thomas Bryan, MD,Merced, California, USA","Pain Medicine","<strong>Objective. </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To present a case series of patients with refractory Behcet’s disease who presented with myalgia and with signs such as mouth and genital ulcerations and skin lesions and were treated with intravenous amino acids.<br />
<strong></strong><strong>Design and Setting.</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Case series of patients with Behcet’s Disease who presented to a clinical practice devoted to Pain Medicine and Neurology between 2000 and 2009 for treatment of myalgia<br />
<strong></strong><strong></strong><strong>Methods. </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All patients were treated with prednisone 60 mg by mouth daily for exacerbations of their disease. When this failed, eleven patients received intravenous administration of amino acids(Procalamine).<br />
<strong>Results.</strong> <br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ten of eleven patients had a complete resolution of their Behcet’s exacerbation, including myalgia; their painful ulcers became painless and began to heal with the infusion of amino acids for 2C5 days.<br />
<strong></strong><strong>Conclusion.</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Physicians treating myalgia should observe for signs of Behcet’s disease, such as oral and genital ulcerations, and consider intravenous amino acids if steroids are not effective.",,"/uploadfiles/file/20131012/20131012150747_2878.pdf",,10/12/2013,10/12/2013,"medicool",32,,"Behcet’s Syndrome; Myalgia; IV Amino Acids",0,"85",29,"Case Report Behcet’s Disease (Syndrome) with Myalgia and Its Response to Intravenous Amino Acids:A Case Series","2011",
218,"体癣家族的免疫评估","10.1111/j.1468-3083.2007.02572.x","Gazit R; Hershko K; Ingbar A; Schlesinger M; Israel S; Brautbar C; Mandelboim O; Leibovici V","European Academy of Dermatology and Venereology","&nbsp;&nbsp;
<p class=""MsoNormal"">
	<span style=""font-size:14px;""><b><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">Background&nbsp;&nbsp; </span></b></span></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">The mechanisms involved in the immune resistance to fungal infection of the skin are not well understood. We assessed the levels of the various lymphocyte subsets, the HLA haplotypes, the expression of various receptors on natural killer (NK) cells and the serum levels of cytokines, in a family in which four siblings had tinea corporis, while four others were healthy, in order to reveal potential factors of susceptibility to dermatophytes.</span></span></span><span><span><b><span style=""font-family:'Times New Roman','serif';font-size:14pt;""> </span></b></span></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:宋体;font-size:14px;"">背景:</span></b></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">皮肤真菌感染的免疫抵抗机制目前还不是很清楚。为了揭示皮肤癣菌易感性的潜在因素，我们对一个家庭所有成员的淋巴细胞亚群、</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;""> HLA</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">单倍型、自然杀伤（</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">NK</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">）细胞中的各种受体表达以及血清细胞因子水平进行了评估，该家庭中四个兄弟姐妹为体癣患者，另外</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">4</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">个健康正常。</span></span></span><span><span><b><span style=""font-family:'Times New Roman','serif';font-size:14pt;""> <span></span></span></b></span></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">Observations&nbsp;&nbsp; </span></b></span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;""><span style=""font-size:14px;"">Normal numbers of T, B and NK cells were found in the peripheral blood, without significant differences between healthy and infected siblings. The frequency of CD14-positive monocytes was elevated in infected compared with healthy siblings. The proportion of NKG2A</span><sup><span style=""font-size:14px;"">+</span></sup><span style=""font-size:14px;""> NK cells was reduced in the patients compared with healthy siblings (23.8% vs. 33.8%), whereas CXCR3</span><sup><span style=""font-size:14px;"">+</span></sup><span style=""font-size:14px;""> NK cells were increased (41.5% vs. 25.6%, respectively). MHC class I and class II haplotypes were disease independent. Elevated levels of interferon-</span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;color:#231f20;font-size:14px;"">γ</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">, interleukin-8 (IL-8), IL-2 and tumour necrosis factor-</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">α</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;""> (TNF</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">α ) </span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">were observed only in part of the infected siblings. The serum level of TNF-</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">α</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;""><span style=""font-size:14px;""> was strongly correlated with the percentage of CD14</span><sup><span style=""font-size:14px;"">+</span></sup><span style=""font-size:14px;"">monocytes.</span></span></span></span><span><span><b><span style=""font-family:'Times New Roman','serif';font-size:14pt;""> </span></b></span></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:宋体;font-size:14px;"">观察结果:</span></b></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">在健康和感染的兄弟姐妹中，外周血中的</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">T</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">细胞、</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">B</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">细胞和</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">NK</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">细胞数量正常，无显著差异。与健康的兄弟姐妹相比，受感染的兄弟姐妹的</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">CD14</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">阳性单核细胞数升高，</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;"">NKG2A</span><sup><span style=""font-size:14px;"">+</span></sup><span style=""font-size:14px;""> NK</span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">细胞的比例降低（</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">23.8</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">％对</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">33.8</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">％），而</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;"">CXCR3</span><sup><span style=""font-size:14px;"">+</span></sup><span style=""font-size:14px;""> NK</span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">细胞比例增加（分别为</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">41.5</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">％和</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">25.6</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">％）。</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">MHC I</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">类和</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">II</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">类单倍型是独立的疾病。我们只在一部分被感染的兄弟姐妹中观察到</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">γ</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">-</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">干扰素、白介素</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">-8</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">（</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">IL - 8</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">）、</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">IL-2</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">和肿瘤坏死因子</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">-</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">α</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">（</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;""> TNF-</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">α</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">）水平升高。</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">TNF-</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">α</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">的血清水平与</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;"">CD14 </span><sup><span style=""font-size:14px;"">+</span></sup></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">单核细胞的百分比密切相关。</span></span></span><span><span><b><span style=""font-family:'Times New Roman','serif';font-size:14pt;""></span></b></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">Conclusions&nbsp;&nbsp; </span></b></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">We studied here in detail the NK functions of a family of patients suffering from tinea corporis and observed skewed frequencies of specific NK receptors, which imply possible involvement of NK cells in susceptibility tofungal infection.</span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:宋体;font-size:14px;"">结论:</span></b></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">我们详细研究了一个有多名体癣患者家族的</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">NK</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">细胞功能，观察到特定的</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">NK</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">细胞受体水平的变动频率，这意味着真菌感染的易感性可能与</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';font-size:14px;"">NK</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">细胞有关。</span></span></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span><span><span style=""font-family:'Times New Roman','serif';font-size:9pt;""></span></span></span>
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span><span><span style=""font-family:'Times New Roman','serif';font-size:9pt;""></span></span></span>
</p>
<p style=""text-align:right;"" class=""MsoNormal"" align=""right"">
	<span><span><span style=""font-family:'Times New Roman','serif';font-size:7.5pt;"">R Gazit et al. </span></span></span><span><span><span class=""medium-font""><span style=""font-family:'Tahoma','sans-serif';font-size:7.5pt;"">Journal Of The European Academy Of Dermatology And Venereology</span></span></span></span><span><span><i><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:7.5pt;""> (JEADV)</span></i></span></span><span><span><span style=""font-family:CongressSans-Light;color:#231f20;font-size:7.5pt;"">，</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:7.5pt;"">2008,</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:7.5pt;"">22(7)</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:7.5pt;"">, 871C874.</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:9pt;""> </span></span></span>
</p>","/uploadfiles/image/20131015/20131015132341_9598w.jpg","/uploadfiles/file/20131015/20131015132315_6894.pdf",,10/15/2013,10/16/2013,"medicool",46,,"familial tinea corporis | HLA typing|periphera l
blood mononuclear cells | NK cells | cytokines",0,"65",68,"Immunological assessment of familial tinea corporis","2008",
195,,"10.1111/j.1399-3038.2011.01172.x","Jin YY ; Cao RM ; Chen J ; Kaku Y ; Wu J ; Cheng Y ; Shimizu T ; Takase M ; Wu SM ; Chen TX","Pediatric Allergy And Immunology: Official Publication Of The European Society Of Pediatric Allergy And Immunology","<p>
	<strong><span style=""font-family:Times New Roman;"">Objective: </span></strong><span style=""font-family:Times New Roman;"">The allergy-preventing effect of partially hydrolyzed cow's milk formula (phCMF) in infants at high risk of </span><span style=""font-family:Times New Roman;"">atopic</span> <span style=""font-family:Times New Roman;"">dermatitis</span><span style=""font-family:Times New Roman;""> (AD) has been demonstrated in many studies. However, the therapeutic 
potential of phCMF in treating the infants with AD has not been 
reported. We sought to assess such therapeutic efficacy of phCMF in 
infants with mild to moderate AD.</span> 
</p>
<p>
	<strong><span style=""font-family:Times New Roman;"">Methods: </span></strong><span style=""font-family:Times New Roman;"">From 2006
 to 2008, 113 infants &amp;lt;6 months of age with AD were randomized to
 receive either partially hydrolyzed cow's milk formula (phCMF) or 
conventional cow's milk formula (CMF) in a double-blind clinical trial. 
Assessments were made at enrollment and at weeks 4, 8, and 12. The 
severity of AD was assessed using two scoring systems: Standard 
guideline for management (diagnosis, severity scoring, and therapy) of 
AD by the Japanese Dermatological Association Scoring System (JDASS) and
 the SCORing </span><span style=""font-family:Times New Roman;"">Atopic</span> <span style=""font-family:Times New Roman;"">Dermatitis</span><span style=""font-family:Times New Roman;""> (SCORAD). Growth status of the infants was evaluated. Allergy profile 
was assessed by measuring total blood eosinophils (EOS), total/specific 
IgE, Th1/Th2 cytokine profiles, and the percentage of regulatory T 
cells.</span> 
</p>
<p>
	<strong><span style=""font-family:Times New Roman;"">Results: </span></strong><span style=""font-family:Times New Roman;"">After follow-up for 12 wk, 27 infants (23.89%) dropped off </span><span style=""font-family:Times New Roman;"">study</span><span style=""font-family:Times New Roman;"">.
 Analysis was performed on 86 infants by the end of 12-wk observation. 
The AD severity scores were significantly reduced in the phCMF group (n =
 56) compared with CMF group (n = 30) after 12 wk (p &amp;lt; 0.05). The
 severity scores of phCMF group were significantly reduced at weeks 4, 
8, and 12 compared to enrollment (p &amp;lt; 0.05). In contrast, no 
significant improvement was observed for CMF group at any of those time 
points (p &amp;gt; 0.05). The number of AD flare-ups was significantly 
decreased in the phCMF group (p = 0.002). Th1/Th2 ratio in phCMF was 
significantly increased compared with CMF group (p = 0.041). The growth 
rates did not differ significantly between these feeding groups at any 
assessed time point (p &amp;gt; 0.05) and were in the normal range.</span> 
</p>
<p>
	<strong><span style=""font-family:Times New Roman;"">Conclusion: </span></strong><span style=""font-family:Times New Roman;"">This </span><span style=""font-family:Times New Roman;"">study</span><span style=""font-family:Times New Roman;""> suggests a novel therapeutic effect of phCMF in treating infants with 
mild to moderate AD during the first 6 months of their life without 
affecting their nutritional status.</span> 
</p>",,"/uploadfiles/file/20131012/20131012152642_1118.pdf",,10/12/2013,10/12/2013,"medicool",28,,"allergy; atopic dermatitis; infant; partially hydrolyzed formula; SCORing Atopic Dermatitis.",0,"66",46,"Partially hydrolyzed cow's milk formula has a therapeutic effect on the infants with mild to moderate atopic dermatitis: a randomized, double-blind study","2011",
196,,"10.1111/j.1365-2230.2011.04273.x","Park KY ; Jang WS ; Yang GW ; Rho YH ; Kim BJ ; Mun SK ; Kim CW ; Kim MN","Clinical And Experimental Dermatology","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; Because clothing has the longest and most direct contact with human skin, it is important to carefully choose suitable fabrics for atopic patients who have disrupted skin. To evaluate the clinical effectiveness and biophysical properties of a newly developed silver-loaded cellulose fabric with incorporated seaweed, we enrolled 12 subjects with mild to moderate atopic dermatitis into a clinical control study. The subjects wore a two-piece garment (top and leggings), each piece of which was divided into two parts: one side was made of SkinDoctor fabric, and the other of 100% cotton. Treatment ef?cacy was measured with the modi?ed SCORing Atopic Dermatitis (mSCORAD) index, transepidermal water loss (TEWL) and the patients’ subjective impressions. All three of these measures had signi?cantly better scores on the side covered with SkinDoctor. These results suggest that SkinDoctor is a bene?cial fabric that can improve the comfort of patients with AD.</span> 
</p>
<br />",,"/uploadfiles/file/20131012/20131012153157_2480.pdf",,10/12/2013,10/12/2013,"medicool",38,,,0,"66",46,"A pilot study of silver-loaded cellulose fabric with incorporated seaweed for the treatment of atopic dermatitis","2012",
221,"由须毛癣菌变种erinacei引起的手癣一例：韩国第一个分离菌株","10.1111/j.1439-0507.2008.01556.x","Rhee DY, Kim MS, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK, Choi JS.","Journal compilation ? 2008 Blackwell Publishing Ltd","<div style=""text-align:right;"">
	<div style=""text-align:justify;"">
		<p class=""MsoNormal"">
			&nbsp;&nbsp;<a name=""OLE_LINK3""></a><a name=""OLE_LINK2""></a><a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><span style=""font-family:&quot;"">Hedgehogs have recently become </span><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span style=""font-family:&quot;"">popular exotic pets </span><span style=""font-family:&quot;"">in Korea.</span><span style=""font-family:&quot;""> Several diseases may be acquired from these animals
including <a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a>dermatophytosis, Salmonella infections, <a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a>contact
urticaria and<a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a> possibly Mycobacterium infections.
We describe here a 15-year-old girl who developed tinea manuum after keeping a
hedgehog for 4 months. Diagnosis was confirmed by histopathologic and
mycological examination. The causative agent was identified as <i>Trichophyton mentagrophytes </i>var. <i>erinacei</i>,<a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a> a zoophilic
dermatophyte.</span> 
		</p>
		<p class=""MsoNormal"">
			<span style=""font-family:&quot;"">&nbsp; </span><span style=""font-family:宋体;"">在韩国，刺猬最近成为流行且洋气的宠物。接触这些动物可能会患上一些疾病，包括脚气、沙门氏菌感染、接触性荨麻疹及可能的结核分枝杆菌感染。本文中，我们描述了一名<span>15</span>岁女患儿，该患儿在养一只刺猬<span>4</span>个月后患上了手癣。通过组织病理学和真菌学检查得以确诊。病原体被确定为须毛癣菌变种<span>. <i>erinacei</i></span>――一种亲动物性皮肤癣菌。<br />
<br />
<br />
<span></span></span> 
		</p>
		<p class=""MsoNormal"">
			<span style=""font-family:&quot;""></span> 
		</p>
		<p class=""MsoNormal"">
			<span style=""font-family:&quot;""></span> 
		</p>
		<p class=""MsoNormal"">
			<span style=""font-family:&quot;""></span> 
		</p>
		<p class=""MsoNormal"" align=""right"" style=""text-align:right;"">
			<i><span style=""font-size:10px;font-family:'} ';"">Do-Young Rhee et al./Journal compilation </span></i><i><span style=""font-size:10px;font-family:'} ';"">&copy;</span></i><i><span style=""font-size:10px;font-family:'} ';""> 2008 Blackwell Publishing Ltd, 2009 May;52(3):287-90</span></i><i><span style=""font-size:9.0pt;font-family:&quot;""></span></i> 
		</p>
<br />
	</div>
<i><i style=""text-align:right;white-space:normal;""> <br />
<br />
<br />
</i></i> 
</div>
<p>
	<br />
</p>
<div style=""text-align:right;"">
	<br />
</div>
<p>
	<br />
</p>","/uploadfiles/image/20131016/20131016095511_5676w.jpg","/uploadfiles/file/20131016/20131016095604_5921.pdf",,10/16/2013,10/17/2013,"medicool",48,,,0,"85",60,"A case of tinea manuum caused by Trichophyton mentagrophytes var. erinacei: the first isolation in Korea","2009",
282,,"10.1080/09546630500375783","ARCHANA SINGAL, DEEPIKA PANDHI, SUBHAV AGRAWAL & SHUKLA DAS","Journal of Dermatological Treatment","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">Abstract:</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">Localized tinea cruris and tinea corporis can be treated by topical imidazoles (clotrimazole) or newer topical agents like</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">butenafine, a benzylamine derivative with fungicidal activity. The therapeutic efficacy of these two agents was compared in </span><span style=""font-family:Times New Roman;font-size:14px;"">this study. Eighty patients, diagnosed clinically to have tinea cruris or localized tinea corporis and confirmed on KOH </span><span style=""font-family:Times New Roman;font-size:14px;"">examination, were randomly assigned to one of the two treatment groups in a double-blind manner; butenafine once daily </span><span style=""font-family:Times New Roman;font-size:14px;"">for 2 weeks or clotrimazole twice daily for 4 weeks. Follow-up was done at 1, 2, 4 and 8 weeks. Clinical assessment score </span><span style=""font-family:Times New Roman;font-size:14px;"">and KOH examination were performed at each visit. Butenafine recipients exhibited higher clinical cure as compared with </span><span style=""font-family:Times New Roman;font-size:14px;"">clotrimazole recipients at the end of 1 week (26.5% vs 2.9%) as well as higher mycological cure (61.7% vs 17.6%). </span><span style=""font-family:Times New Roman;font-size:14px;"">However, this difference was not statistically significant at 4 and 8 weeks of treatment.</span> 
</p>",,"/uploadfiles/file/20131017/20131017112522_6897.pdf",,10/17/2013,10/17/2013,"medicool",19,,"Tinea cruris, tinea corporis, clotrimazole, butenafine, comparative efficacy",0,"66",68,"Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: A randomized, double-blind trial ","2005",
118,,,"Peng Wang, MD, Yan Cheng, MM, Hanjun Yang, MD, and Yuping Ran, MD, PhD","International Journal of Dermatology","<strong>Background</strong><br />
&nbsp;&nbsp; Blue nevi are a group of congenital and acquired dermal melanocytoses characterized by a blue-gray appearance on the skin. The common blue nevus and cellular blue nevus are the most common subtypes. Patch-type blue nevus is rather rare.<br />
<strong>Observations </strong><br />
&nbsp;&nbsp;&nbsp; We describe a 77-year-old Chinese male with a 6 ・ 8-cm non-palpable blue patch overlaid by a depigmented patch on the back of the left scalp. Histological examination of the blue-gray patch showed numerous spindled and elongated bipolar dendritic melanocytes in the upper reticular dermis and an absence of epidermal melanocytes. Immunohistochemically, these dendritic melanocytes were positive for S-100 and HMB-45. A diagnosis of a patch-type blue nevus with overlying vitiligo was made after the biopsy.<br />
<strong>Conclusions </strong><br />
&nbsp;&nbsp;&nbsp; The patient presents an unusual manifestation of patch-type blue nevi with overlying vitiligo. To the best of our knowledge, these features have not been previously described.","/uploadfiles/image/20130930/20130930163604_1718w.png","/uploadfiles/file/20130930/20130930163830_6717.pdf",,09/30/2013,09/30/2013,"medicool",102,,,0,"85",28,"Acquired patch-type blue nevus with overlying vitiligo: a case report","2012",
55,"对特应性皮炎儿童患者中链球菌感染的回顾","10.1111/j.1525-1470.2010.01377.x 230","Jeffrey L. Sugarman, M.D., Ph.D., Adam L. Hersh, M.D., Ph.D., Tessie Okamura, M.D.,C Renee Howard, M.D.,and Ilona J. Frieden, M.D.","Pediatric Dermatology","<p align=""justify"">
	&nbsp;&nbsp;<span style=""font-size:14px;"">&nbsp; In order to assess the clinical characteristics and impact of group A streptococcal infection in children with atopic dermatitis, a retrospective review was performed in children diagnosed with atopic dermatitis who had a skin culture. Culture results and clinical characteristics of those with group A streptococcus were compared with those with Staphlococcus aureus. Infection with group A streptococcus was present in 16%; infection with Staphlococcus aureus was present in 72%, and 14%had mixed cultures. Patients infected with group A streptococcus were more likely to be febrile, to have facial and periorbital involvement, and to be hospitalized compared with those infected with Staphlococcus aureus alone (p&nbsp;≤ 0.01 for all </span><span style=""font-size:14px;"">comparisons). Bacteremia and cellulitis were significantly more common in those infected with group A streptococcus than in those infected with Staphlococcus aureus. Retrospective design and review of only those patients receiving bacterial cultures may select for greater severity than in the general atopic dermatitis population. Group A streptococcus appears to be a significant skin pathogen infecting children with atopic dermatitis. Children with atopic dermatitis and group A streptococcal infection are more likely to have invasive disease and complications than those infected with Staphlococcus aureus alone.</span><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""line-height:2.5;font-family:宋体;font-size:14px;"">为了评估患有特应性皮炎儿童的</span><span style=""line-height:2.5;font-size:14px;""><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">A</span></span></a><span style=""line-height:2.5;font-size:14px;""><span style=""line-height:2.5;font-size:14px;""><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">链球菌群</span></span></span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">感染的临床特点和影响，我们对被诊断患有特应性皮炎并进行皮肤培养的儿童进行了一项回顾性调查。研究对感染</span><span style=""line-height:2.5;font-size:14px;""><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">A</span></span></a><span style=""line-height:2.5;font-size:14px;""><span style=""line-height:2.5;font-size:14px;""><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">链球菌</span></span></span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">群患者的培养结果和临床特征与感染金黄色葡萄球菌的进行了比较。结果显示，感染</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">A</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">链球菌群的占</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">16%</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">，感染金黄色葡萄球菌的占</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">72%</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">，混合感染的占</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">14%</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">。与感染金黄色葡萄球菌的患者相比，感染</span><span style=""line-height:2.5;font-size:14px;""><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">A</span></span></a><span style=""line-height:2.5;font-size:14px;""><span style=""line-height:2.5;font-size:14px;""><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">链球菌</span></span></span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">群的患者更可能出现发热症状，累及面部及眶周区，需要住院治疗（所有对比组</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">p</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">≤</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">0.01</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">）。此外，感染</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">A</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">链球菌群的患者比感染金黄色葡萄球菌的患者更容易出现菌血症和蜂窝组织炎。针对那些接受细菌培养的患者进行回顾性设计和检查，我们可以筛选出比一般特应性皮炎群体更严重的患者。</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';font-size:14px;"">A</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">链球菌群似乎是感染特应性皮炎儿童患者的一种重要的皮肤病原体。</span><span style=""line-height:2.5;font-family:宋体;background:#fafafa;font-size:14px;"">患有特应性皮炎并感染</span><span style=""line-height:150%;font-family:宋体;font-size:14px;""><span style=""line-height:2.5;"">Ａ链球菌群的儿童与单独感染金黄色葡萄球菌的儿童相比，更有可能发生侵袭性疾病和并发症。</span><br />
<span style=""display:none;"" id=""__kindeditor_bookmark_end_49__""></span><br />
<span style=""font-family:'Times New Roman','serif';font-size:10.5pt;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;Jeffrey L. Sugarman <i>et al. </i>Pediatric Dermatology,<i> </i>2011, 28(3): 230-234.</span></span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span> 
</p>","/uploadfiles/image/20130925/20130925152513_1496w.png","/uploadfiles/file/20130925/20130925152610_6669.pdf",,09/25/2013,10/10/2013,"medicool",51,,,0,"67",46,"A Retrospective Review of Streptococcal Infections in Pediatric Atopic Dermatitis","2010",
223,"一项比较伊曲康唑与氟康唑治疗足癣及手癣的双盲试验",,"E.M. Difonzo , M. Papini , P. Cilli , P. Calandra , E. Panconesi","Journal of the European Academy of Dermatology and Venereology","<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">Background </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">It<b> </b></span><span style=""font-family:&quot;"">has been reported that azole derivatives are useful in the
treatment of <a name=""OLE_LINK6""></a><a name=""OLE_LINK1""></a>dermatophytoses, also in tinea pedis
and tinea manuum.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究背景<span></span></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:宋体;"">据报道，吡咯衍生物在治疗皮肤癣菌病、足癣及手癣上是有效的。<span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;"">&nbsp;</span><b><span style=""font-family:&quot;"">Aim</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-family:&quot;"">The aim of the present multicentre, randomized,
double-blind study</span><span style=""font-family:&quot;""> was to
compare the efficacy and safety of oral itraconazole with fluconazole in the
treatment of tinea pedis and tinea manuum.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究目的<span></span></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:宋体;"">目前，这个多中心，随机，双盲研究旨在比较口服伊曲康唑，氟康唑治疗足癣及手癣的有效性和安全性。</span><span style=""font-size:5.5pt;font-family:宋体;color:#313131;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">Patients and methods </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">In this multicenter, double-blind, comparative study, 37
patients with tinea pedis or tinea manus were randomized to receive treatment
with itraeonazole (100 mg/day) or fluconazole (50 mg/day) for 30 days.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究对象与方法<span></span></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:宋体;"">在这个多中心，双盲，对照研究中，<span>37</span>名足癣或手癣患者随机分配给予伊曲康唑（<span>100</span>毫克<span>/</span>天）或氟康唑（<span>50</span>毫克<span>/</span>天）进行治疗，疗程为<span>30</span>天。<span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;"">&nbsp;</span><b><span style=""font-family:&quot;"">Results</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""font-family:&quot;"">Two patients were not evaluable for efficacy</span><span style=""font-family:&quot;"">. <a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a>Both treatments reduced the number of patients with<a name=""OLE_LINK3""></a><a name=""OLE_LINK2""></a> <a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a>positive
mycological findings, so that
at the end of treatment, 64.7% of patients receiving itraconazole and 61.1% of
those treated with fluconazole had negative results. Both drugs
also resulted in a marked improvement in, or elimination of, all clinical symptoms;
however the improvement appeared to occur more rapidly with itraconazole. The
overall assessment at the end of the 6 week follow-up showed that<a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a> 88.2% of patients treated with itraconazole and 72.2% of those treated with fluconazole <a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a>were cured with negative mycological tests. <a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a>Adverse
events were reported by one patient treated with itraconazole and 5 subjects
receiving fluconazole. The only changes in laboratory parameters were
elevated SGOT and SGPT values in one patient in the fluconazole group, who
dropped out from the study.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究结果</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:宋体;"">两名患者没有参与疗效评估。这两种治疗方法减少了出现阳性真菌患者的数量，因此在治疗结束时，</span><span style=""font-family:&quot;"">64.7</span><span style=""font-family:宋体;"">％接受伊曲康唑和</span><span style=""font-family:&quot;"">61.1</span><span style=""font-family:宋体;"">％氟康唑治疗的患者出现阴性结果。同时这两种药物使全部的临床症状得到了显著改善或消除；然而伊曲康唑对于临床症状的改善似乎更为迅速。</span><span style=""font-family:&quot;"">6</span><span style=""font-family:宋体;"">周随访后的全面评估显示，</span><span style=""font-family:&quot;"">88.2</span><span style=""font-family:宋体;"">％应用伊曲康唑与</span><span style=""font-family:&quot;"">72.2</span><span style=""font-family:宋体;"">％应用氟康唑的患者被治愈，其真菌试验结果为阴性。由</span><span style=""font-family:&quot;"">1</span><span style=""font-family:宋体;"">位接受伊曲康唑的患者和</span><span style=""font-family:&quot;"">5</span><span style=""font-family:宋体;"">位氟康唑的受试者报告了不良反应。实验室参数的唯一改变则是在氟康唑治疗组中的一名患者（退出了本次研究）</span><span style=""font-family:&quot;"">SGOT</span><span style=""font-family:宋体;"">（谷草转氨酶）及</span><span style=""font-family:&quot;"">SGPT</span><span style=""font-family:宋体;"">（谷丙转氨酶）值的升高。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">Discussion </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<a name=""OLE_LINK22""></a><span style=""font-family:&quot;"">The results suggest that itraconazole is at least as
effective as fluconazole in the treatment of tinea pedis and tinea manus,</span><a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span style=""font-family:&quot;""> </span><a name=""OLE_LINK19""></a><span style=""font-family:&quot;"">the </span><a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span style=""font-family:&quot;"">onset</span><span style=""font-family:&quot;""> of improvement in clinical symptoms is more rapid an prolonged </span><span style=""font-family:&quot;"">after cessation of therapy with itraconazole</span><span style=""font-family:&quot;"">, and that
itraconazole appears to be better tolerated.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究结论</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:宋体;"">研究结果表明</span><span style=""font-family:&quot;"">:</span><span style=""font-family:宋体;"">在治疗足癣和手癣上，伊曲康唑与氟康唑的疗效是等同的。在临床症状中，伊曲康唑起效更快，且停止用药后持续时间更长久，同时伊曲康唑显示出了更好的耐受性。<br />
<br />
<br />
</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" align=""right"" style=""text-align:right;"">
	<i><span style=""font-size:9.0pt;font-family:&quot;"">E.M. Difonzo et al.
/J. Eur Acad. Dermatol. Venereoi. 4 (1995) 148-152</span></i><span style=""font-size:9.0pt;font-family:&quot;""></span> 
</p>","/uploadfiles/image/20131016/20131016110747_8285w.jpg","/uploadfiles/file/20131016/20131016110508_9578.pdf",,10/16/2013,10/18/2013,"medicool",33,,"Itraconazole; Fluconazole; Dermatophytosis",0,"65",60,"A double-blind comparison of itraconazole and fluconazole in tinea pedis and tinea manuum","1995",
265,,,"Aste N ; Pau M ; Aste N","Mycoses","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	We report a case of tinea manuum bullosa in a 36-year-old
male, a crop and livestock farmer by trade. The lesion, resembling contact
dermatitis, was located in the palm of the ri^hl hand. We isolated <i>Trichophyton
verrucosum. </i>No other skin lesion was detected. Blood chemistry and
immunology test results were normal. Treatment with terbinatine 250 mg day""'
led to clinical and mycological healing.
</p>",,"/uploadfiles/file/20131016/20131016170226_0786.pdf",,10/16/2013,10/16/2013,"medicool",29,,"Trichophyton verrucosum, tinea manuum bullosa.",0,"85",60,"Tinea manuum bullosa","2005",
280,"外用灰黄霉素治疗体癣的疗效",,"Mohamed A. A. Kassem, Samia Esmat, Eihab R. Bendas1and Mohamed H. M. El-Komy","Blackwell Publishing Ltd ? Mycoses","<p style=""text-indent:21pt;"" class=""MsoNormal"" align=""justify"">
	<span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tinea infections are among the most common dermatological conditions throughout the world. Griseofulvin is a classical oral fungistatic antibiotic, active against</span><i> </i></span><i><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">Epidermophyton floccosum</span></i><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">, </span><i><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">Trichophyton</span></i><span style=""line-height:150%;font-family:'Times New Roman','serif';""> </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">and </span><i><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">Microsporum</span></i><span style=""line-height:150%;font-family:'Times New Roman','serif';""> </span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">species, the causative fungi of tinea corporis. To evaluate the efficacy of topical griseofulvin in the treatment of</span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;""> tinea circinata </span></a><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">using three different vehicles for drug delivery. Sixteen patients with tinea circinata were instructed to apply either griseofulvin gel form in group A or a similar placebo gel for control group; a niosomal gel formulation of griseofulvin for group B or; a liposomal gel formulation of griseofulvin for group C. Patients were evaluated both clinically and mycologically after 3 weeks. </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">Marked improvement was seen for groups A, B and C both clinically and mycologically while no improvement was observed in the placebo group. Mild and transient irritation was reported in four patients. Our results show that topical griseofulvin preparations may be effective and safe in treating tinea circinata and that further large-scale studies may establish the high efficacy of the niosomal gel formulation.</span></a></span> 
</p>
<span></span><span></span> 
<p style=""text-indent:21pt;"" class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2;font-family:宋体;font-size:14px;"">癣感染是世界范围内的最常见的皮肤病。灰黄霉素是一种经典的口服抑菌抗生素，它能有效对抗体癣的致病菌（絮状表皮癣菌、毛癣菌和小孢子菌）。我们采用了三种不同的给药方式来评估在体癣治疗过程中外用灰黄霉素的疗效。</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">16</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">例体癣患者分别使用以下四组制剂，其中</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">A</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">组为灰黄霉素凝胶剂，对照组为类似的安慰剂凝胶剂，</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">B</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">组为灰黄霉素的囊泡凝胶剂，</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">C</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">组为灰黄霉素的脂质体凝胶剂。</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">3</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">周后在临床上和真菌学上对患者进行评估。我们观察到，</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">A</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">组、</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">B</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">组和</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">C</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">组在临床上和真菌学上均有显著改善，而安慰剂组无任何改善。有四名患者称用药后有轻微和短暂的刺激。研究结果表明：外用灰黄霉素制剂治疗体癣可能是有效和安全的，进一步大规模的研究可以确定高效的囊泡凝胶配方。</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span> 
</p>","/uploadfiles/image/20131017/20131017111754_1889w.jpg","/uploadfiles/file/20131017/20131017111451_5750.pdf",,10/17/2013,10/18/2013,"medicool",47,,"griseofulvin | niosomes | tinea corporis |  liposomes | griseofulvin gel | topical griseofulvin.",0,"66",68,"Efficacy of topical griseofulvin in treatment of tinea corporis","2006",
106,,,"E. Darwich,? C. Herrero","Actas Dermosifiliogr","&nbsp;&nbsp;&nbsp; In recent years, important advances have been made in our understanding 
of the genetics of porphyrias, particularly with respect to 
erythropoietic protoporphyria (EPP) and congenital erythropoietic 
porphyria (CEP), 2 forms of erythropoietic porphyria no longer 
considered to be monogenic. The identification of mutations in genes not
 previously associated with these disorders as causative factors or 
modulators of severity has helped to explain the presence of genotypic 
and phenotypic differences between patients carrying the same mutations.
 These advances have also led to the identification of causative genetic
 defects in patients who, based on molecular studies, had no mutations 
in the uroporphyrinogen III synthase gene UROS (in CEP) or in the 
ferrochelatase gene FECH (in EPP). Better understanding and 
characterization of the genetics of porphyrias will allow us to 
determine genotypic and phenotypic correlations and improve the 
molecular classification of these diseases, which will have both 
practical and prognostic implications.<br />",,"/uploadfiles/file/20130809/20130809153639_9283.pdf",,09/30/2013,09/30/2013,"medicool",26,,"Porphyrias|Erythropoietic porphyrias|Erythropoietic protoporphyrias|
Congenital erythropoietic porphyrias",0,"67",56,"New Developments in Erythropoietic Porphyrias","2013",
418,,"10.1111/j.1600-0560.2011.01834.x","Anneli R. Bowen, Lindsay Burt,Kenneth Boucher, Payam Tristani-Firouzi and Scott R. Florell","Journal of  Cutaneous  Pathology","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Background.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Distinguishing keratoacanthoma (KA) and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">hypertrophic lichen planus (LP) histopathologically can be difficult, and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">the challenge is compounded by the tendency of KA to arise in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">association with hypertrophic LP.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Methods.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">In this pilot study, we compared 18 cases each of KA and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">hypertrophic LP for proliferation index (MIB-1), p53 staining and the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">presence of perforating elastic fibers (elastic Verhoeff-van Gieson) to&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">determine the utility of these staining modalities in distinguishing KA&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">from hypertrophic LP.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Results.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Proliferation index in KA compared to hypertrophic LP is&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">88.2 (mean positive MIB-1 cells/×100 field), SD = 56.6 and 47.3,</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">SD = 68.4, respectively. p53 staining in KA compared to hypertrophic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">LP is 251 (mean positive cells/×100 field), SD = 117 and 158,</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">SD = 119, respectively. Fifteen of eighteen (83%) keratoacanthomata&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">demonstrate perforating elastic fibers compared to 1/18 (6%) for&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">hypertrophic LP.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Conclusion.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Proliferation index is not significantly different between&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">KA and hypertrophic LP (p = 0.059). Expression of p53 is increased in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">KA over hypertrophic LP (p = 0.024). The presence of perforating&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">elastic fibers in KA is significantly different from hypertrophic LP&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">(p &lt; 0.0001) and suggests that elastic Verhoeff-van Gieson staining&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">may be of practical benefit in distinguishing KA from hypertrophic LP&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">in difficult cases.</span><br />",,"/uploadfiles/file/20131112/20131112112419_8906.pdf",,11/12/2013,11/12/2013,"medicool",30,,,0,"65",99,"Use of proliferation rate, p53 staining and perforating elastic fibers in distinguishing keratoacanthoma from hypertrophic lichen planus: a pilot study","2012",
145,,"10.1186/1476-511X-9-8","Kuhlmann I ; Minihane AM ; Huebbe P ; Nebel A ; Rimbach G","Lipids In Health And Disease","&nbsp;<span style=""font-family:Times New Roman;""> Apolipoprotein E is a polymorphic and multifunctional protein with numerous roles in lipoprotein metabolism. The three common isoforms apoE2, apoE3 and apoE4 show isoform-specific functional properties including different susceptibilities to diseases. ApoE4 is an accepted risk factor for Alzheimer’s disease and cardiovascular disorders. Recently, associations between apoE4 and infectious diseases have been demonstrated. This review summarises how apoE4 may be involved in the infection incidence and associated pathologies of specific infectious diseases, namely hepatitis C, human immunodeficiency virus disease and herpes simplex. ApoE4 seems to be protective against chronic hepatitis C virus infection and retards fibrosis progression. In con- trast apoE4 enhances the fusion rate of human immunodeficiency virus with target cell membranes, resulting in accelerated cell entry and faster disease progression. Its association with human immunodeficiency virus-associated dementia remains controversial. Regarding herpes simplex virus infection, apoE4 intensifies virus latency and is associated with increased oxidative damage of the central nervous system, and there is some evidence that herpes simplex virus infection in combination with the apoE4 genotype may be associated with an increased risk of Alz- heimer’s disease. In addition to reviewing available data from human trials, evidence derived from a variety of cell culture and animal models are considered in this review in order to provide mechanistic insights into observed association between apoE4 genotype and viral disease infection and pathology.</span><br />
<br />",,"/uploadfiles/file/20131012/20131012084240_1060.pdf",,10/12/2013,10/12/2013,"medicool",20,,,0,"67",57,"Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review","2010",
56,"强脉冲光对印度寻常痤疮患者的效用-一个病例系列",,"Saritha Mohanan, MD, DNB, Basheerahmed Parveen, MD, DD, Priyavathani Annie Malathy, MD, DNB, and Nellainayagam Gomathi, MD, DD","International Journal of Dermatology","<strong></strong> 
<p class=""MsoNormal"">
	<strong><span style=""color:#4D4D4D;"">Background</span></strong><span style=""color:#4D4D4D;""><br />
&nbsp;&nbsp;&nbsp; Intense pulse light (IPL) has become extremely popular in
Indian cosmetology circles. Yet, literature is silent on its effect in<a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span> heavily melanized skin</span>.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;color:#4D4D4D;"">研究背景</span></b><b><span style=""color:#4D4D4D;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;color:#4D4D4D;"">强脉冲光（</span><span style=""color:#4D4D4D;"">IPL</span><span style=""font-family:宋体;color:#4D4D4D;"">）在印度美容圈里已非常普及。但是，文献资料上未提到它在棕黑色皮肤上的应用。</span><span style=""color:#4D4D4D;""><br />
<strong>Objective</strong><br />
&nbsp;&nbsp;&nbsp; A descriptive study to gauge the effect of IPL on acne
vulgaris in Indian patients done in a tertiary care center in south India.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;color:#4D4D4D;"">研究目的</span></b><b><span style=""color:#4D4D4D;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;color:#4D4D4D;"">在印度南部的一家三级保健中心进行了一项评估</span><span style=""color:#4D4D4D;"">IPL</span><span style=""font-family:宋体;color:#4D4D4D;"">对印度寻常痤疮患者疗效的描述性研究。</span><span style=""color:#4D4D4D;""><br />
<strong>Materials and methods</strong><br />
&nbsp;&nbsp; Patients with moderate to severe acne vulgaris were given a
maximum of five sittings of IPL treatment. Lesion counts were performed and
photographs compared before and after treatment.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;color:#4D4D4D;"">材料和方法</span></b><b><span style=""color:#4D4D4D;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;color:#4D4D4D;"">轻度至重度寻常痤疮患者最多进行了</span><span style=""color:#4D4D4D;"">5</span><span style=""font-family:宋体;color:#4D4D4D;"">次</span><span style=""color:#4D4D4D;"">IPL</span><span style=""font-family:宋体;color:#4D4D4D;"">治疗。治疗前后，对皮损计数并对比照片。</span><span style=""color:#4D4D4D;""><br />
<strong>Results </strong><br />
&nbsp;&nbsp; IPL was offered to 10 patients with acne vulgaris. Two patients
dropped out, seven patients had a good response after a mean of 3.4 sittings;
87.5% patients expressed satisfaction with the procedure. No adverse effects
were noted.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;color:#4D4D4D;"">研究结果</span></b><b><span style=""color:#4D4D4D;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;color:#4D4D4D;"">应用</span><span style=""color:#4D4D4D;"">IPL</span><span style=""font-family:宋体;color:#4D4D4D;"">对</span><span style=""color:#4D4D4D;"">10</span><span style=""font-family:宋体;color:#4D4D4D;"">名患者进行治疗。两名患者退出治疗，</span><span style=""color:#4D4D4D;"">7</span><span style=""font-family:宋体;color:#4D4D4D;"">名患者在平均</span><span style=""color:#4D4D4D;"">3.4</span><span style=""font-family:宋体;color:#4D4D4D;"">次会诊后，疗效良好；</span><span style=""color:#4D4D4D;"">87.5%</span><span style=""font-family:宋体;color:#4D4D4D;"">的患者对疗程满意。没有不良反应的记录。</span><span style=""color:#4D4D4D;""><br />
<strong>Conclusion</strong><br />
&nbsp;&nbsp; IPL serves a useful role in the treatment of acne vulgaris and
could reduce treatment costs and pill burden. There is no increased risk of
side effects with IPL on Indian skin with standard care.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;color:#4D4D4D;"">研究结论</span></b><b><span style=""color:#4D4D4D;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""color:#4D4D4D;"">IPL</span><span style=""font-family:宋体;color:#4D4D4D;"">对寻常痤疮的治疗非常有帮助，并且能较少治疗费用以及药物负担。通过对印度皮肤病患者的标准治疗，没有增加副作用的风险。</span><span></span> 
</p>
<br />","/uploadfiles/image/20130925/20130925154500_4053w.png","/uploadfiles/file/20130925/20130925154549_5922.pdf",,09/25/2013,09/30/2013,"medicool",109,,,0,"66",54,"Use of intense pulse light for acne vulgaris in Indian skinC a case series ","2012",
52,"Distinct SPINK5 and IL-31 polymorphisms are associated with atopic eczema and non-atopic hand dermatitis in Taiwanese nursing population","10.1111/j.1600-0625.2011.01374.x","Cheng-Che E. Lan, Hung-Pin Tu, Ching-Shuang Wu, Ying-Chin Ko, Hsin-Su Yu, Yi-Wei Lu, Wan-Chen Li, Yin-Chun Chen and Gwo-Shing Chen","Experimental Dermatology","&nbsp;&nbsp;&nbsp;<span style=""font-size:14px;""> The term ‘hand dermatitis’ describes inflammatory skin condition localized to the hands. Nurses working at hospital settings are prone to develop hand dermatitis. The current study aimed to evaluate whether certain genetic polymorphisms were associated with the development of atopic eczema or non-atopic hand dermatitis in Taiwanese population. Nurses of Kaohsiung Medical University Hospital were recruited. Atopic eczema, non-atopic hand dermatitis and normal control groups were identified. The serine protease inhibitor Kazal type 5 (SPINK5), filaggrin and interleukin-31 (IL-31) gene variants were compared between the diseased and control groups. Our results showed that rs2303070 T allele of SPINK5 (assuming recessive model; OR = 3.58, 95% CI 1.63C7.84; P = 0.0014) and rs7977932 G allele of IL-31 (assuming recessive model; OR = 18.25, 95% CI = 3.27C101.94; P = 0.0009) were associated with increased risks of developing atopic eczema, while rs6892205 G allele of SPINK5 (assuming dominant model; OR = 3.79, 95% CI 1.55C9.28; P = 0.0036) was associated with the development of non-atopic hand dermatitis. In summary, our results showed that distinct SPINK5 and IL-31 gene variants were associated with the development of atopic eczema and non-atopic hand dermatitis. The barrier function, particularly those regulated by SPINK5, may play an important role in the development of both </span><span style=""font-size:14px;"">atopic eczema and non-atopic hand dermatitis.</span>",,"/uploadfiles/file/20130925/20130925150204_2168.pdf",,09/25/2013,09/30/2013,"medicool",46,,"atopic eczema C interleukin 31 C non-atopic hand dermatitis serine protease inhibitor Kazal type 5",0,"65",46,,"2011",
46,"一项小儿银屑病与特应性皮炎的对比研究：对银屑病-皮炎重叠病情的深入了解","10.1111/j.1440-0960.2012.00878.x","Shivam Kapila, Esther Hong and Gayle Fischer","Australasian Journal of Dermatology","<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14.0pt;"">Background and Objectives: </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>Psoriasis (Pso) in
children may be confused clinically with atopic dermatitis (AD) and, indeed,
the two conditions may co-exist. The aim of this study was to determine
historical and clinical features that are different in paediatric Pso and AD
and to describe children who have features of both: psoriasis-dermatitis
overlap (PD).</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">研究背景和目的：</span></b><b><span style=""font-size:14.0pt;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">临床上，小儿银屑病（</span><span>Pso</span><span style=""font-family:宋体;"">）可能跟特应性皮炎（</span><a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><span><span>AD</span></span><span></span><span></span><span style=""font-family:宋体;"">）混淆，并且实际上这两种皮肤病可能并存。本研究旨在确定<a name=""OLE_LINK56""></a><a name=""OLE_LINK55""></a><span>儿童</span></span><span><span><span>Pso</span></span></span><span><span><span style=""font-family:宋体;"">和</span></span></span><span><span><span>AD</span></span></span><span></span><span></span><span style=""font-family:宋体;"">的病史以及临床特征的差异性，同时对含有这两种皮肤病（银屑病</span><span>-</span><span style=""font-family:宋体;"">皮炎重叠症）特征的患儿进行描述。</span><span></span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14.0pt;"">Methods: </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>Children with features
of psoriasis or eczema, or both, who were referred to paediatric outpatients
and/or private rooms were evaluated. Data were collected from 170 <a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span>consecutive
children aged less than 12 years</span> between July 2011 and November
2011. Participants were classified by <a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span>described criteria </span>as
having <a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span>Pso (<i>n </i></span></span><span><span><span>= </span></span></span><span><span><span>64), AD (<i>n </i></span></span></span><span><span><span>= </span></span></span><span><span><span>62) or PD (<i>n </i></span></span></span><span><span><span>= </span></span></span><span><span><span>44)</span></span></span><span>.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">研究方法：</span></b><b><span style=""font-size:14.0pt;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">对到儿科门诊和</span><span>/</span><span style=""font-family:宋体;"">或私人诊室就诊的银屑病或湿疹，或两病共患的临床特征患儿进行评定。在</span><span>2011</span><span style=""font-family:宋体;"">年</span><span>7</span><span style=""font-family:宋体;"">月到</span><span>11</span><span style=""font-family:宋体;"">月之间，收集</span><span>170</span><span style=""font-family:宋体;"">名不超过</span><span>12</span><span style=""font-family:宋体;"">岁的连续性患儿的资料。通过根据患有</span><span>Pso (<i>n </i></span><span>= </span><span>64), AD (<i>n </i></span><span>= </span><span>62) or PD (<i>n </i></span><span>= </span><span>44)</span><span style=""font-family:宋体;"">的描述标准对患儿进行分类。</span><span></span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14.0pt;"">Results: </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;"">Only 9.4% of children
with Pso were correctly diagnosed by the <a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span>referring doctor</span>.
Children with Pso relative to AD were more likely to have had a history of <a name=""OLE_LINK22""></a><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><span><span><span><span>scaly scalp</span></span></span></span><span><span><span> and<a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span> nappy rash</span></span></span></span> in infancy, a family history of psoriasis,<a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span> </span><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span><span><span>current
scalp and periauricular rashes</span></span></span>, <a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span>defined, patchy plaque
morphology and papulosquamous rashes </span>not typical of adult psoriasis on <a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span><span><span>extensor elbows </span></span></span><span><span>and
knees.</span></span> Children with <a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span>PD</span> had features of both but <a name=""OLE_LINK36""></a><a name=""OLE_LINK35""></a><span>present</span>ed
most often as <a name=""OLE_LINK38""></a><a name=""OLE_LINK37""></a><span>typical paediatric psoriasis</span> combined with <a name=""OLE_LINK40""></a><a name=""OLE_LINK39""></a><span>flexural eczema</span>. Children with Pso
and PD responded well to <a name=""OLE_LINK42""></a><a name=""OLE_LINK41""></a><span>specific treatment strategies</span> for
psoriasis, including <a name=""OLE_LINK44""></a><a name=""OLE_LINK43""></a><span>potent topical corticosteroids</span> (TCS), <a name=""OLE_LINK46""></a><a name=""OLE_LINK45""></a><span>calcipotriol and phototherapy</span>. Both Pso and PD tended to
require more potent TCS than AD to <a name=""OLE_LINK48""></a><a name=""OLE_LINK47""></a><span>achieve disease suppression</span>.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">研究结果：</span></b><b><span style=""font-size:14.0pt;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">仅</span><span style=""font-family:&quot;"">9.4% </span><span style=""font-family:宋体;"">的</span><span style=""font-family:&quot;"">Pso</span><span style=""font-family:宋体;"">患儿，其主诊医生诊断正确。与</span><span style=""font-family:&quot;"">AD</span><span style=""font-family:宋体;"">相关的</span><span style=""font-family:&quot;"">Pso</span><span style=""font-family:宋体;"">患儿在婴儿时期更多的有头皮鳞屑和尿布疹病史、银屑病家族史，以及当前的头皮和耳部皮疹，界限清楚的片状斑块和丘疹鳞屑性皮疹而无成人肘部伸侧和膝部银屑病的典型特征。</span><span style=""font-family:&quot;"">PD</span><span style=""font-family:宋体;"">患儿含有以上两种疾病的特征，但是最常表现为典型小儿银屑病伴屈侧部位的湿疹。通过银屑病的特定治疗措施，包括强效外用皮质类固醇（</span><a name=""OLE_LINK50""></a><a name=""OLE_LINK49""></a><span><span style=""font-family:&quot;"">TCS</span></span><span></span><span></span><span style=""font-family:宋体;"">）、卡泊三醇治疗和光疗，</span><span style=""font-family:&quot;"">Pso</span><span style=""font-family:宋体;"">和</span><span style=""font-family:&quot;"">PD</span><span style=""font-family:宋体;"">患儿都有良好的效果。为了达到抑制疾病的效果，</span><span style=""font-family:&quot;"">Pso</span><span style=""font-family:宋体;"">和</span><span style=""font-family:&quot;"">PD</span><span style=""font-family:宋体;"">患儿比</span><span style=""font-family:&quot;"">AD</span><span style=""font-family:宋体;"">患儿趋向于需要更强效的</span><span style=""font-family:&quot;"">TCS</span><span style=""font-family:宋体;"">。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14.0pt;"">Conclusion: </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>We found that Pso and <a name=""OLE_LINK52""></a><a name=""OLE_LINK51""></a><span>PD</span> in children both differ clinically from AD and have identified <a name=""OLE_LINK54""></a><a name=""OLE_LINK53""></a><span>historical
and clinical features </span>that characterise childhood Pso.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">结论：</span></b><b><span style=""font-size:14.0pt;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">我们发现儿童</span><span>Pso</span><span style=""font-family:宋体;"">和</span><span>PD</span><span style=""font-family:宋体;"">均不同于</span><span>AD</span><span style=""font-family:宋体;"">，并且确定了儿童</span><span>Pso</span><span style=""font-family:宋体;"">的病史和临床特征。</span><span></span> 
</p>","/uploadfiles/image/20130924/20130924104557_5628w.png","/uploadfiles/file/20130924/20130924104651_0709.pdf","http://web.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=2&sid=7c047e28-303f-490d-bc0a-ebd6d96986bd%40",09/24/2013,09/30/2013,"medicool",40,,"atopic dermatitis, childhood, diagnosis, paediatric, psoriasiform dermatitis, psoriasis.",0,"66",26,"A comparative study of childhood psoriasis and atopic dermatitis and greater understanding of the overlapping condition, psoriasis-dermatitis","2012",
47,"全基因组DNA的甲基化分析发现系统性红斑狼疮的患者干扰素基因持续性低甲基化以及CD4+T细胞群主要转化",,"Devin M. Absher1, Xinrui Li, Lindsay L. Waite, Andrew Gibson, Kevin Roberts, Jeffrey Edberg, W. Winn Chatham, Robert P. Kimberly","genetics","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span><span style=""font-family:&quot;"">Systemic lupus erythematosus (SLE) is an autoimmune
disease with</span></span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span><span><span><span style=""font-family:&quot;""> known </span></span></span></span><a name=""OLE_LINK72""></a><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span><span><span><span><span><span><span style=""font-family:&quot;"">genetic</span></span></span></span></span></span></span><span><span><span style=""font-family:&quot;"">, epigenetic, and environmental risk <a name=""OLE_LINK73""></a><a name=""OLE_LINK71""></a><a name=""OLE_LINK70""></a><span><span>factor</span></span>s</span></span></span><span style=""font-family:&quot;"">. <a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span>To assess the role of DNA methylation in SLE, </span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span><span><span>we
collected CD4</span></span></span></span><span><span><span><span><sup><span style=""font-family:&quot;"">+</span></sup></span></span></span></span><span><span><span><span><span style=""font-family:&quot;""> </span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;"">T-cells, CD19</span></span></span></span></span><span><span><span><span><sup><span style=""font-family:&quot;"">+</span></sup></span></span></span></span><span><span><span><span><span style=""font-family:&quot;""> </span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;"">B-cells, and CD14</span></span></span></span></span><span><span><span><span><sup><span style=""font-family:&quot;"">+</span></sup></span></span></span></span><span><span><span><span><span style=""font-family:&quot;""> </span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;"">monocytes from 49 SLE patients and 58 controls</span></span></span></span></span><span><span><span style=""font-family:&quot;"">, <a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span>and performed genome-wide DNA methylation
analysis with</span><a name=""OLE_LINK23""></a><a name=""OLE_LINK22""></a><span><span><span><i> </i></span></span></span><a name=""OLE_LINK74""></a><a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span><span><span><span><span><span><span><span><span>Illumina</span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span> Methylation450 microarrays</span></span></span></span></span></span></span><span><span><span><span>.</span></span> </span></span></span></span></span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><a name=""OLE_LINK28""></a><span><span><span><span><span><span><span><span style=""font-family:&quot;""></span></span></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span><span><span><span><span><span style=""font-family:宋体;"">系统性红斑狼疮（</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">SLE</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">）是一种与已知遗传因素、表观因素和环境危险因素有关的自身免疫性疾病。为了评估</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">SLE</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">中</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">DNA</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">甲基化的作用，我们收集了</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">49</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">例</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">SLE</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">患者和</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">58</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">名对照组的</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">CD4 <sup>+</sup> T</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">细胞、</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">CD19<sup>+</sup> B</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">细胞和</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">CD14<sup>+</sup></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">单核细胞，并应用</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">Illumina</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">甲基化</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">450</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">基因芯片对全基因组</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;"">DNA</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:宋体;"">甲基化进行分析。</span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;""></span></span></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span><span><span><span><span><span><span><span style=""font-family:&quot;"">&nbsp;</span></span></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span><span><span><span><span><span style=""font-family:&quot;"">We
identified <a name=""OLE_LINK78""></a><a name=""OLE_LINK77""></a><span>166</span><a name=""OLE_LINK76""></a><a name=""OLE_LINK75""></a><span><span><span> CpGs</span></span> </span>in
B-cells</span></span></span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">, 97 CpGs in
monocytes, and 1,033 <a name=""OLE_LINK80""></a><a name=""OLE_LINK79""></a><span>CpGs</span> in T-cells with <a name=""OLE_LINK82""></a><a name=""OLE_LINK81""></a><span>highly
significant changes</span> in DNA methylation levels (p</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">&lt;</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">1×10</span></span></span></span></span></span><span><span><span><span><span><sup><span style=""font-family:&quot;"">-8</span></sup></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">) among SLE
patients.</span></span></span></span></span></span><a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span><span><span><span><span style=""font-family:&quot;""> Common to
all three cell-types were widespread and severe hypomethylation<a name=""OLE_LINK36""></a><a name=""OLE_LINK35""></a><span> events </span>near genes involved in interferon signaling (type I). </span></span></span></span></span><a name=""OLE_LINK43""></a><a name=""OLE_LINK38""></a><a name=""OLE_LINK37""></a><span><span><span><span><span><span style=""font-family:&quot;""></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span><span><span><span style=""font-family:宋体;"">在</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">SLE</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">患者中，我们发现</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">B</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">细胞中有</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">166</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">个</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;""> CpGs</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">，单核细胞中有</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">97</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">个</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">CpGs</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">和</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">T-</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">细胞中有</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">1033</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">个</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">CpGs</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">，</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">SLE</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">患者中这些细胞的</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">DNA</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">甲基化水平有高度显著的差异</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">(p</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">&lt;</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">1×10</span></span></span></span></span></span><span><span><span><span><span><sup><span style=""font-family:&quot;"">-8</span></sup></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">)</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">。三种类型的细胞分布广泛，并且在基因上发生严重地低甲基化涉及干扰素转导信号（</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;"">I</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:宋体;"">型）。</span></span></span></span></span></span><span><span><span><span><span><span style=""font-family:&quot;""></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span><span><span><span><span><span style=""font-family:&quot;"">&nbsp;</span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span><span><span><span style=""font-family:&quot;"">These
interferon-related changes were apparent in patients collected during <a name=""OLE_LINK86""></a><a name=""OLE_LINK85""></a><span>active
and quiescent stages</span> of the disease, suggesting that <a name=""OLE_LINK40""></a><a name=""OLE_LINK39""></a><a name=""OLE_LINK42""></a><a name=""OLE_LINK41""></a><a name=""OLE_LINK88""></a><a name=""OLE_LINK87""></a><span><span><span><span><span>epigenetically</span></span></span></span></span><span><span><span><span>-mediated </span></span></span></span><span><span>hypersensitivity to interferon persists beyond
acute stages of the disease</span></span> and is independent of circulating
interferon levels.</span></span></span></span></span></span><span><span><span style=""font-family:&quot;""> This interferon hypersensitivity was apparent in memory, <a name=""OLE_LINK47""></a><a name=""OLE_LINK46""></a><a name=""OLE_LINK90""></a><a name=""OLE_LINK89""></a><span><span><span>naive</span></span></span><span><span> </span></span>and
regulatory T-cells,<a name=""OLE_LINK49""></a><a name=""OLE_LINK48""></a><span> suggesting that this epigenetic state in lupus
patients is established in </span><a name=""OLE_LINK92""></a><a name=""OLE_LINK91""></a><span><span><span>progenitor cell populations</span></span></span>.<a name=""OLE_LINK53""></a><a name=""OLE_LINK52""></a><span> </span><a name=""OLE_LINK58""></a><a name=""OLE_LINK57""></a><span><span><span></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span><span><span><span><span style=""font-family:宋体;"">在疾病的活动期和静止期，患者的干扰素相关变化较明显，这表明表观遗传介导的干扰素超敏反应持续超出该病的急性期，并且不依赖于循环干扰素水平。这种干扰素超敏反应在记忆性、先天性和调节性</span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;"">T</span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:宋体;"">细胞中较明显，提示红斑狼疮患者的这种表观遗传发生于前体细胞群。</span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;""></span></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span><span><span><span><span><span><span style=""font-family:&quot;"">&nbsp;</span></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span><span><span><span><span style=""font-family:&quot;"">We also identified a widespread, but<a name=""OLE_LINK94""></a><a name=""OLE_LINK93""></a><span> </span><a name=""OLE_LINK51""></a><a name=""OLE_LINK50""></a><span><span><span>lower
amplitude shift</span></span></span> in methylation in CD4</span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;"">+</span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;"">T-cells (</span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;"">&gt;</span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;"">16,000 CpGs at FDR</span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;"">&lt;</span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;"">1%) near genes involved in cell division and <a name=""OLE_LINK56""></a><a name=""OLE_LINK55""></a><a name=""OLE_LINK54""></a><span><span>MAPK</span></span> signaling.</span></span></span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;""> </span></span></span><a name=""OLE_LINK64""></a><a name=""OLE_LINK63""></a></span></span><span><span><span><span><span style=""font-family:&quot;"">These <a name=""OLE_LINK96""></a><a name=""OLE_LINK95""></a><span>cell
type-specific</span></span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;""> effects </span></span></span></span></span><span><span><span style=""font-family:&quot;"">are consistent with disease-specific changes <a name=""OLE_LINK66""></a><a name=""OLE_LINK65""></a><span>in
the composition of the CD4</span></span></span></span><span><span><span><span><span style=""font-family:&quot;"">+ </span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;"">population </span></span></span></span></span><span><span><span style=""font-family:&quot;"">and suggest that shifts in the proportion of CD4</span></span></span><span><span><span style=""font-family:&quot;"">+ </span></span></span><span><span><span style=""font-family:&quot;"">subtypes can be monitored at CpGs with subtype-specific
DNA methylation patterns.</span></span></span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">我们还发现在</span><span style=""font-family:&quot;"">CD4<sup>+</sup>T</span><span style=""font-family:宋体;"">细胞中，与细胞分裂和</span><span style=""font-family:&quot;"">MAPK</span><span style=""font-family:宋体;"">信号转导相关基因附近有低幅度的甲基化转移</span><span style=""font-family:&quot;"">(</span><span style=""font-family:&quot;"">&gt;</span><span style=""font-family:&quot;"">16,000 CpGs
at FDR</span><span style=""font-family:&quot;"">&lt;</span><span style=""font-family:&quot;"">1%)</span><span style=""font-family:宋体;"">。这些细胞类型特异性的结果是与由与疾病特异性的</span><span style=""font-family:&quot;"">CD4<sup>+</sup></span><span style=""font-family:宋体;"">细胞群构成变化相一致的，表明</span><span style=""font-family:&quot;"">CD4<sup>+</sup></span><span style=""font-family:宋体;"">亚型比例的改变可以被亚型特异性</span><span style=""font-family:&quot;"">DNA</span><span style=""font-family:宋体;"">甲基化模式的</span><span style=""font-family:&quot;"">CpGs</span><span style=""font-family:宋体;"">监测。</span><span style=""font-family:&quot;""></span> 
</p>","/uploadfiles/image/20130924/20130924110052_9108w.png","/uploadfiles/file/20130924/20130924110148_1193.pdf",,09/24/2013,09/30/2013,"medicool",54,,,0,"65",3,"Genome-Wide DNA Methylation Analysis of Systemic Lupus Erythematosus Reveals Persistent Hypomethylation of Interferon Genes and Compositional Changes to CD4+ T-cell Populations","2013",
92,,,"aJOSHUA A. ZEICHNER, MD; bVARSHA BHATT, PhD; bRADHAKRISHNAN PILLAI, PhD",,"&nbsp;&nbsp; Fixed combination therapy in acne is standard of care, and benzoyl peroxide is a common component of a number of<br />
fixed-dose combination products available today. Given that benzoyl peroxide can cause concentration-dependent<br />
irritation, newer combinations have been developed utilizing lower concentrations (2.5%) in their formulation. These<br />
formulations have been shown to provide better tolerability than products with higher benzoyl peroxide concentrations,<br />
while offering comparable efficacy. In vitro skin permeation studies can be used to determine the relative availability of<br />
benzoyl peroxide from different dosage forms. In this in vitro percutaneous absorption study, the authors compared<br />
three fixed combinations, two with 2.5% benzoyl peroxide and one with 5% benzoyl peroxide. Both 2.5% benzoyl<br />
peroxide products (1.2% clindamycin phosphate and 2.5% benzoyl peroxide, and 0.1% adapalene and 2.5% benzoyl<br />
peroxide) had similar benzoyl peroxide delivery profiles in terms of efficiency of deposition and total benzoyl peroxide<br />
tissue permeation. Although 1.2% clindamycin phosphate and 2.5% benzoyl peroxide delivered the same amount of<br />
benzoyl peroxide into the receptor fluid as 1.2% clindamycin phosphate and 5% benzoyl peroxide, it was statistically<br />
more efficient in terms of percent applied dose (P=0.002). This suggests a more advanced formulation, as it contains only<br />
half the concentration of benzoyl peroxide. All three products showed similar delivery characteristics in terms of the<br />
amount of benzoyl peroxide depositing into the dermis.",,"/uploadfiles/file/20130909/20130909153708_8020.pdf",,09/30/2013,09/30/2013,"medicool",47,,,0,"66",54,"In Vitro Percutaneous Absorption of Benzoyl Peroxide from Three Fixed Combination Acne Formulations","2013",
49,"掺铒钇铝石榴石点阵式换肤激光对面部痤疮疤痕治疗的有效性和安全性",,"Balakrishnan Nirmal, Sathish B. Pai, Handattu Sripathi, Raghavendra Rao, Smitha Prabhu, Mohan H. Kudur, Sudhir U. K. Nayak","Indian Journal of Dermatology","<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:12.0pt;font-family:宋体;"">Background:<br />
</span></b> 
</p>
<p class=""MsoNormal"" style=""text-align:left;text-indent:12.0pt;"" align=""left"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span><span style=""font-size:12.0pt;font-family:宋体;"">Treatment of acne scars
with </span></span><a name=""OLE_LINK52""></a><a name=""OLE_LINK49""></a><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span><span><span><span><span><span style=""font-size:12.0pt;font-family:宋体;"">ablative fractional laser resurfacing</span></span></span></span></span></span><span><span><span style=""font-size:12.0pt;font-family:宋体;""> has given good improvement</span></span></span><span style=""font-size:12.0pt;font-family:宋体;"">. But, data on Indian skin
are limited. A study comparing <a name=""OLE_LINK54""></a><a name=""OLE_LINK53""></a><span>qualitative, quantitative, and subjective
assessments</span> is also lacking.<br />
</span><b><span style=""font-size:12.0pt;font-family:宋体;"">研究背景：<span></span></span></b><span style=""font-size:12.0pt;font-family:宋体;""> </span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;text-indent:24.0pt;"" align=""left"">
	<span style=""font-size:12.0pt;font-family:宋体;"">应用剥脱性点阵式激光换肤术对痤疮瘢痕的治疗已经得到很好地改进，但是有关印度患者的相应数据却很有限，而且，缺乏一项对定性，定量和主观评估进行比较的研究。<br />
</span><b><span style=""font-size:12.0pt;font-family:宋体;"">Aim: </span></b><span style=""font-size:12.0pt;font-family:宋体;""><span> </span></span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;text-indent:12.0pt;"" align=""left"">
	<span style=""font-size:12.0pt;font-family:宋体;"">Our aim was to assess the
improvement of facial acne scars with Erbium-doped Yttrium Aluminium Garnet
(Er:YAG) 2940 nm fractional laser resurfacing and its adverse effects in 25
patients at <a name=""OLE_LINK56""></a><a name=""OLE_LINK55""></a><span>a tertiary care teaching hospital</span>.<br />
</span><b><span style=""font-size:12.0pt;font-family:宋体;"">研究目的：<span></span></span></b><span style=""font-size:12.0pt;font-family:宋体;""> </span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;text-indent:24.0pt;"" align=""left"">
	<span style=""font-size:12.0pt;font-family:宋体;"">我们旨在评估<span>25</span>名来自三级医疗教学医院的患者<span>,</span>在应用掺铒钇铝石榴石（<span>Er</span>：<span>YAG</span>）<span>2940nm</span>点阵激光换肤术后<span>,</span>面部痤疮瘢痕的改善情况及其不良反应。<br />
</span><b><span style=""font-size:12.0pt;font-family:宋体;"">Methods: </span></b><span style=""font-size:12.0pt;font-family:宋体;""><span> </span></span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;text-indent:12.0pt;"" align=""left"">
	<a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span><span style=""font-size:12.0pt;font-family:宋体;"">All 25 patients received
four treatment sessions with Er:YAG fractional laser</span></span><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span><span><span><span style=""font-size:12.0pt;font-family:宋体;""> </span></span></span></span><a name=""OLE_LINK58""></a><a name=""OLE_LINK57""></a><span><span><span><span><span><span style=""font-size:12.0pt;font-family:宋体;"">at 1-month </span></span></span></span></span></span><span style=""font-size:12.0pt;font-family:宋体;"">interval. The laser parameters were kept constant for each of the four sittings
in all patients. <a name=""OLE_LINK43""></a><a name=""OLE_LINK42""></a><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span><span><span>Qualitative
and quantitative assessments were done using Goodman and Barron grading</span></span></span><span><span>. </span></span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span>Subjective
assessment in percentage of improvement was also documented 1 month after each
session</span>. <a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span><span><span>Photographs
were taken before each treatment session and 1 month after the final session</span></span></span><span><span>.</span></span> <a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span><span><span>Two unbiased dermatologists
performed independent clinical assessments by comparing the photographs</span></span></span><span><span>. <a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span>The
kappa statistics was used to monitor the agreement between the dermatologists
and patients</span></span></span>.<br />
</span><b><span style=""font-size:12.0pt;font-family:宋体;"">研究方法：<span></span></span></b><span style=""font-size:12.0pt;font-family:宋体;""> </span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:12.0pt;font-family:宋体;"">应用<span>Er</span>：<span>YAG</span>点阵激光对<span>25</span>名患者进行了<span>4</span>次治疗，每<span></span>次间隔<span>1</span>个月。所有患者每次</span><span style=""font-size:12.0pt;font-family:宋体;"">治疗的激光参数保持不变。使用古德曼和巴伦（<span>Goodman and</span> Barron</span><span style=""font-size:12.0pt;font-family:宋体;"">）分级进行定性和定量评估。每次治疗后<span>1</span>个月，按照改善百分比记录主观评估。每次治疗前以及最后<span>1</span>次治疗后<span>1</span>个月进行拍照。由两名公正的皮肤科医生通过对比照片，进行独立的临床评估。采用<span>Kappa</span>统计分析皮肤科医生评估结果和病人的评估结果。<br />
</span><b><span style=""font-size:12.0pt;font-family:宋体;"">Results: <br />
</span></b><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span><span style=""font-size:12.0pt;font-family:宋体;"">Most patients (96%) showed
at </span></span><a name=""OLE_LINK62""></a><a name=""OLE_LINK61""></a><span><span><span><span style=""font-size:12.0pt;font-family:宋体;"">least fair improvement</span></span></span></span><span><span><span style=""font-size:12.0pt;font-family:宋体;"">. <a name=""OLE_LINK60""></a><a name=""OLE_LINK59""></a><span>Rolling and superficial
box scars </span>showed higher significant improvement when compared with
ice pick and <a name=""OLE_LINK64""></a><a name=""OLE_LINK63""></a><span>deep box scars</span>. Patient</span></span></span><span><span><span style=""font-size:12.0pt;font-family:宋体;"">’<span>s
satisfaction of improvement was higher when compared to physician</span>’<span>s observations. No serious adverse effects were noted with
exacerbation of acne lesions forming the majority.<br />
</span></span></span></span><b><span style=""font-size:12.0pt;font-family:宋体;"">研究结果：<span></span></span></b><span><span><span style=""font-size:12.0pt;font-family:宋体;""><span> </span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;text-indent:24.0pt;"" align=""left"">
	<span style=""font-size:12.0pt;font-family:宋体;"">大多数患者（<span>96</span>％）都得到了明显的改善。与冰锥状瘢痕和凹陷性瘢痕相比萎缩性浅疤痕改善较明显。与医生的观测数据相比，病人对改善后的满意度较高。没有观察到大面积痤疮皮损加剧的严重不良反应。<br />
</span><b><span style=""font-size:12.0pt;font-family:宋体;"">Conclusion: </span></b><span style=""font-size:12.0pt;font-family:宋体;""><span> </span></span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<span><span><span><span><span><span style=""font-size:12.0pt;font-family:宋体;"">Ablative fractional</span><span><span style=""font-size:12.0pt;font-family:宋体;""> photothermolysis</span></span></span></span></span></span></span><span><span><span><span><span style=""font-size:12.0pt;font-family:宋体;""> </span></span></span></span></span><span><span><span style=""font-size:12.0pt;font-family:宋体;"">is both effective and safe
treatment for atrophic acne scars in Indian skin. <a name=""OLE_LINK39""></a><a name=""OLE_LINK38""></a><a name=""OLE_LINK37""></a><span><span>Precise evaluation of acne scar treatment can
be done by taking </span></span><a name=""OLE_LINK68""></a><a name=""OLE_LINK67""></a><span><span><span><span>consistent</span></span></span></span><span><span><span> digital photographs</span></span></span></span></span></span><span style=""font-size:12.0pt;font-family:宋体;"">.<br />
</span><b><span style=""font-size:12.0pt;font-family:宋体;"">研究结论：<span></span></span></b><span style=""font-size:12.0pt;font-family:宋体;""> </span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;text-indent:24.0pt;"" align=""left"">
	<span style=""font-size:12.0pt;font-family:宋体;"">剥脱性点阵式光热作用治疗印度患者皮肤的萎缩性痤疮瘢痕，既有效又安全。通过拍取一致的数码照片可以对痤疮瘢痕的治疗进行准确的评估。<span></span></span> 
</p>
<p>
	<br />
</p>
<p>
	<br />
</p>
<span style=""font-size:12.0pt;font-family:宋体;""></span><b><span style=""font-size:12.0pt;font-family:宋体;""></span></b><span style=""font-size:12.0pt;font-family:宋体;""><span></span></span><span style=""font-size:12.0pt;font-family:宋体;""></span> 
<p>
	<br />
</p>
<span><span><span><span><span><span style=""font-size:12.0pt;font-family:宋体;""></span></span></span></span></span></span><span></span><span></span><span></span><span></span><span></span><span></span><b><span style=""font-size:12.0pt;font-family:宋体;""></span></b> 
<p>
	<br />
</p>
<p>
	<br />
</p>
<p>
	<br />
</p>
<p>
	<br />
</p>
<p>
	<br />
</p>","/uploadfiles/image/20130930/20130930123117_1516w.jpg","/uploadfiles/file/20130924/20130924134128_2053.pdf","http://web.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=3&sid=0dc62955-00dd-40e5-8612-a0884aefe576%40",09/24/2013,09/30/2013,"medicool",139,,"Acne scars, fractional laser, photographs",0,"65",54,"Efficacy and safety of Erbium-doped Yttrium Aluminium Garnet fractional resurfacing laser for treatment of facial acne scars","2013",
50,"白菜型油菜和油菜对特应性皮炎患儿的致敏作用：一项病例对照研究","10.1111/j.1399-3038.2007.00666.x","Sanna Poikonen, Tuija J. Puumalainen, Hannu Kautiainen, Timo Palosuo, Timo Reunala1 and Kristiina Turjanmaa","Pediatr Allergy Immunol","<p class=""MsoNormal"">
	<a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span><span style=""font-family:&quot;""><span>&nbsp;</span><span>Turnip rape and oilseed rape
2S albumins are new allergens in children with atopic dermatitis suspected for
food allergy.</span></span></span><span style=""font-family:&quot;""> We recently found that <a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span>11% (206/1887) of these
children had a positive skin prick test to seeds of oilseed rape (</span></span><span><span><span style=""font-family:&quot;"">Brassica napus</span></span></span><span><span><span style=""font-family:&quot;"">) and/or turnip rape (</span></span></span><span><span><span style=""font-family:&quot;"">Brassica rapa</span></span></span><span><span><span style=""font-family:&quot;"">).</span></span></span> 
</p>
<span></span><span></span> 
<p class=""MsoNormal"">
	<span style=""font-family:宋体;""><span>&nbsp; </span></span><span style=""font-family:宋体;"">白菜型油菜和油菜<span>2S</span>白蛋白被怀疑是特应性皮炎患儿食物过敏的新过敏原。最近我们发现<span>11</span>％（<span>206/1887</span>）的患儿在对油菜（欧洲油菜）和（或）白菜型油菜（</span><span style=""font-family:宋体;"">芜菁</span><span style=""font-family:宋体;"">）种子的皮肤点刺试验中呈现出阳性。<span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""><span>&nbsp; </span>In the present case-control study we examined
how the children with atopic dermatitis sensitized to turnip rape and oilseed
rape had been breast-fed and whether they had some common sensitization pattern
to certain foods or pollens. A total of 64 children with atopic dermatitis and
a positive skin prick test to turnip rape and/or oilseed rape (</span><span style=""font-size:10.0pt;font-family:&quot;"">≥</span><span style=""font-family:&quot;"">5 mm) were examined.
Sixty-four age- and sex-matched children with atopic dermatitis but negative
skin prick tests to turnip rape and oilseed rape served as case controls. </span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""><span>&nbsp; </span></span><span style=""font-family:宋体;"">在本病例对照研究中，我们调查了对白菜型油菜和油菜过敏的特应性皮炎患儿是如何一直用母乳喂养的，以及他们是否对某些食物或花粉有普遍的致敏模式。共对</span><span style=""font-family:&quot;"">64</span><span style=""font-family:宋体;"">名对球茎甘蓝和</span><span style=""font-family:宋体;"">（</span><span style=""font-family:宋体;"">或）油菜（</span><span style=""font-size:10.0pt;font-family:&quot;"">≥</span><span style=""font-family:&quot;"">5 </span><span style=""font-family:&quot;"">mm</span><span style=""font-family:宋体;"">）的皮肤点刺试验呈阳性的特应性皮炎患儿进行了调查，病例对照为</span><span style=""font-family:&quot;"">64</span><span style=""font-family:宋体;"">名年龄和</span><span style=""font-family:宋体;"">性别与其匹配的</span><span style=""font-family:宋体;"">特应性皮炎患儿，但是对球茎甘蓝和油菜的皮肤点刺试验结果为阴性。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""><span>&nbsp; </span>The turnip rape and/or oilseed rape
sensitized children with atopic dermatitis had significantly more often
positive skin prick tests reactions and IgE antibodies to various foods (cow’s
milk, egg, wheat, mustard; p &lt; 0.01) and pollens (birch, timothy, mugwort; p
&lt; 0.01) than the control children.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:宋体;"">与对照组患儿相比，对白菜型油菜和</span><span style=""font-family:宋体;"">（</span><span style=""font-family:宋体;"">或）油菜过敏的特应性皮炎患儿的皮肤点刺试验反应明显更经常呈阳性，且对各种食物（牛奶、鸡蛋、小麦、芥末；</span><span style=""font-family:&quot;"">p&lt;0.01</span><span style=""font-family:宋体;"">）和花粉（桦树、梯牧草、艾蒿；</span><span style=""font-family:&quot;"">p &lt;0.01</span><span style=""font-family:宋体;"">）均有</span><span style=""font-family:&quot;"">IgE</span><span style=""font-family:宋体;"">（免疫球蛋白</span><span style=""font-family:&quot;"">E</span><span style=""font-family:宋体;"">）</span><span style=""font-family:宋体;"">抗体。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""><span>&nbsp; </span>They had been exclusively breast-fed for a
longer period (median 4 months; p &lt; 0.05) and had more often associated
asthma (36%) and allergic rhinitis (44%). Children with atopic dermatitis
sensitized to oilseed rape and turnip rape had high frequency of associated
sensitizations to all foods and pollens tested showing that oilseed plant
sensitization affects especially atopic children who have been sensitized to
multiple allergens.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:宋体;"">他们被专门用母乳喂养了一长段时间（平均为</span><span style=""font-family:&quot;"">4</span><span style=""font-family:宋体;"">个月，</span><span style=""font-family:&quot;"">P &lt;0.05</span><span style=""font-family:宋体;"">），且更经常患哮喘（</span><span style=""font-family:&quot;"">36</span><span style=""font-family:宋体;"">％）和过敏性鼻炎（</span><span style=""font-family:&quot;"">44</span><span style=""font-family:宋体;"">％）。研究发现对油菜和白菜型油菜过敏的特应性皮炎患儿在所有食物和花粉的过敏测试中相应的致敏频率高，这表明油料作物使特异性患儿致敏，尤其是有多种过敏原过敏的患儿。<br />
<br />
<br />
<br />
	<p class=""MsoNormal"" align=""right"" style=""margin-right:18.0pt;text-align:right;background:white;"">
		<i>Poikonen S.et.al.</i><i> Pediatr Allergy Immunol 2008: 19: 408C411</i><i><o:p></o:p></i>
	</p>
</span><span style=""font-family:&quot;""></span> 
</p>
<br />","/uploadfiles/image/20130930/20130930165345_9409w.png","/uploadfiles/file/20130925/20130925143123_7099.pdf",,09/25/2013,10/16/2013,"medicool",45,,"atopic dermatitis; food allergy; oilseed rape; turnip rape",0,"66",46,"Sensitization to turnip rape and oilseed rape in children with atopic dermatitis: a case control study","2008",
51,"特应性皮炎患者中的卡波西氏肉瘤：一例病例报告和文献综述","10.1111/j.1525-1470.2011.01347.x","Hanan A. Salem, M.D., Magdy El Sohafy, M.D., and Mamdouh Abd El Gawad, M.D.","Pediatric Dermatology","<p align=""justify"">
	&nbsp;<span style=""font-size:14px;"">&nbsp;&nbsp; A 7-year-old girl suffering from atopic dermatitis developed multiple lesions of Kaposi’s sarcoma, which could not be categorized under any one of the four known types of Kaposi’s sarcoma (classic, human immunodeficiency virus-associated, endemic, or iatrogenic). We propose that atopic dermatitis may cause susceptibility to human herpes virus 8 infection, which is related to the pathogenesis of Kaposi’s sarcoma.</span><span style=""font-size:14px;"">&nbsp;</span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:2.5;font-family:宋体;font-size:14px;"">患者，女，七岁，从特应性皮炎发展成</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">多重皮损的卡波西氏（</span><span style=""line-height:2.5;font-family:'Tahoma','sans-serif';font-size:14px;"">Kaposi’s</span><span style=""font-family:宋体;""><span style=""line-height:2.5;font-size:14px;"">）肉瘤，</span><span style=""line-height:2.5;font-size:14px;"">这不能归类到四种已知的卡波西氏肉瘤类</span></a><span style=""line-height:2.5;font-size:14px;"">型（</span></span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">经典型、人类免疫缺陷病毒相关型、地方型，或医源型</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">）中的任何一类。我们认为，特应性皮炎可能会导致患者容易感染与卡波西氏肉瘤发病机制有关的人类疱疹病毒</span><span style=""line-height:2.5;font-family:'Tahoma','sans-serif';font-size:14px;"">8</span><span style=""line-height:2.5;font-family:宋体;font-size:14px;"">。 <br />
<br />
&nbsp;
</p>
<p style=""text-align:right;text-indent:21pt;"" class=""MsoNormal"" align=""right"">
	<span style=""font-family:'Times New Roman','serif';"">Hanan A.Salem <i>et al</i>. Pediatric Dermatology, 2011, 28(5): 547-549.</span>
</p>
</span>","/uploadfiles/image/20130930/20130930165042_2818w.png","/uploadfiles/file/20130925/20130925144841_7045.pdf",,09/25/2013,10/11/2013,"medicool",45,,,0,"85",46,"Kaposi’s Sarcoma in an Atopic Dermatitis Patient: A Case Report and a Review of Literature","2011",
203,,"DOI 10.1007/s10067-011-1726-1","Afshin Borhani Haghighi . Anahid Safari .Mohammad Ali Nazarinia .Zahra Habibagahi Saeedeh Shenavandeh.","Clin Rheumatol","<p align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This study aims to report the therapeutic effects of anti-tumor necrotic factor antibody, infliximab, for treatment of neuro-Behcet""s disease (NBD) and to review the literature. We described four patients (all male, median age 40 years old) who fulfilled the International Study Group criteria for Behcet""s disease (BD) and presented with neurological complication. Demographic and clinical characteristics of the patients, dose, therapeutic effects, and adverse drug reaction (ADR) of infliximab were reported. Two patients had secondary progressive, one relapsing progressive, and one primary progressive course (median duration of BD and<br />
NBD 11 and 2 years, respectively). Two patients each received infliximab with 3 and 5 mg/kg infusions, respectively. The patients received infliximab for median of 22 weeks. Clinical responses were unsatisfactory for two patients on 3 mg/kg regimen; and good in two patients on 5 mg/kg and monthly intravenous 500C1,000 mg cyclophosphamide. Varicella zoster infection was seen as a major ADR in one patient. Our results with infliximab were not as promising as the previous reports. Infliximab, 5 mg/kg per dose with adjuvant immunosuppressive therapy, is probably more effective than other regimens.
</p>",,"/uploadfiles/file/20131012/20131012160515_2995.pdf",,10/12/2013,10/12/2013,"medicool",31,,"Anti-tumor necrotic factor antibody.Behcet syndrome . Behcet""s disease . Infliximab .Neuro-Behcet""s disease",0,"67",29,"Infliximab for patients with neuro-Behcet's disease:case series and literature review","2011",
73,,"10.1111/j.1365-2133.2010.10031.x","C.L. Martyn-Simmons, R.R. Ranawaka, P. Chowienczyk, M.A. Crook, M.S. Marber, C.H. Smith and J.N.W.N. Barker","British Journal of Dermatology","<strong>Background </strong><br />
&nbsp;&nbsp;&nbsp; There is well-documented evidence that patients with moderate and severe psoriasis have a significantly increased risk of cardiovascular disease (CVD). While this risk can, at least in part, be attributed to the high prevalence of traditional risk factors in the population with psoriasis, some epidemiological evidence suggests it may be independent of these.<br />
<strong>Objectives</strong><br />
&nbsp;&nbsp; This prospective, case-controlled study investigates whether psoriasis is a risk factor for CVD using two, validated, sensitive markers of CVD, endothelial dysfunction and high-sensitivity C-reactive protein (hsCRP).<br />
<strong>Methods</strong><br />
&nbsp;&nbsp; Patients were recruited from a tertiary referral psoriasis clinic and exclusion criteria included established CVD and ?or conventional risks for CVD. Preclinical CVD was assessed using flow-mediated brachial artery dilatation, which measures<br />
endothelial dysfunction, and hsCRP, a serological marker of atherosclerosis.<br />
<strong>Results </strong><br />
&nbsp;&nbsp; Sixty-four patients (22%) out of a total of 285 consecutive patients attending the severe psoriasis clinic were entered into the study. One hundred and sixty-one (56%) were excluded following identification of cardiovascular risk; 39 of the 161 (24%) had at least two cardiovascular risk factors. A further 16 (6%) patients were excluded because of established CVD. No statistically significant difference in endothelial dysfunction was observed between patients with psoriasis(n = 60) and healthy controls (n = 117) (P = 0?508). The hsCRP level was, however, significantly elevated in the psoriasis group (2?828 mg L)1, SEM 0?219; controls 0?728 mg L)1, SEM 0?142; P &lt; 0?05).<br />
<strong>Conclusion</strong><br />
&nbsp;&nbsp; This large, investigative study is the first to assess endothelial function in patients with psoriasis after exclusion of traditional risk factors for CVD. These data suggest that psoriasis per se is not a risk factor for CVD and that elevated<br />
hsCRP is possibly independent of atheroma risk. There was a high prevalence of traditional risk factors in our population with severe psoriasis.",,"/uploadfiles/file/20130926/20130926110748_1582.pdf",,09/26/2013,11/01/2013,"medicool",23,,"cardiovascular diagnostic techniques, cardiovascular disease, metabolic syndrome, psoriasis",0,"66",26,"A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis","2010",
74,"当前的治疗选择以及最新进展",,"Veronika Dvorakova MRCPI and Trevor Markham MD, FRCPI","Prescriber","<span style=""font-family:宋体;""></span><span></span><span style=""font-size:9.0pt;font-family:宋体;""></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>Management of psoriasis is based
on <a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span>a
stepwise approach </span>that includes <a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span>a wide variety of </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span>treatment
options</span>. Our <a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span>Drug review</span> focuses on<a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span> key points and recent advances</span> in the management of psoriasis,
followed by a review of the<a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span> prescription data and sources of further
information.</span></span> 
</p>
<span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">银屑病的治疗依据阶梯式方法，包括各种各样的治疗方案。我们的药品审评集中于银屑病治疗的关键点和最新进展，随后对处方资料和进一步的信息来源作一综述。</span><span></span> 
</p>
<br />","/uploadfiles/image/20130926/20130926141445_9507w.png","/uploadfiles/file/20130926/20130926140919_0833.pdf",,09/26/2013,10/10/2013,"medicool",52,,,0,"67",26,"Psoriasis: current treatment options and recent advances","2013",
83,,"10.1111/j.1365-2133.2012.10868.x","A. Lallas, A. Kyrgidis, T.G. Tzellos, Z. Apalla, E. Karakyriou, A. Karatolias, I. Lefaki, E. Sotiriou, D. Ioannides, G. Argenziano and I. Zalaudek","British Journal of Dermatology","<strong>Background </strong><br />
&nbsp;&nbsp;&nbsp; Dermoscopy is useful in evaluating skin tumours, but its applicability extends also to the field of inflammatory skin disorders. Plaque psoriasis (PP), dermatitis, lichen planus (LP) and pityriasis rosea (PR) are common inflammatory skin diseases, but little is currently known about their dermoscopic features.<br />
<strong>Objectives </strong><br />
&nbsp;&nbsp;&nbsp; To determine and compare the dermoscopic patterns associated with PP, dermatitis, LP and PR and to assess the validity of certain dermoscopic criteria in the diagnosis of PP.<br />
<strong>Methods </strong><br />
&nbsp;&nbsp;&nbsp; Patients with PP, dermatitis, LP and PR were prospectively enrolled. The single most recently developed lesion was examined dermoscopically and histopathologically. Variables included vascular morphology, vascular arrangement, background colour, scale colour, scale distribution and presence of Wickham striae. Univariate and adjusted odds ratios were calculated. Discriminant functions were used to plot receiver-operator characteristic curves.<br />
<strong>Results </strong><br />
&nbsp;&nbsp;&nbsp; Eighty-three patients with PP and 86 patients with either dermatitis, LP or PR were included in the study. Dotted vessels in a regular arrangement over a light red background and white scales were highly predictive for the diagnosis of<br />
PP, whereas dermatitis more commonly showed yellow scales and dotted vessels in a patchy arrangement. PR was characterized by yellowish background, dotted vessels and peripheral scales; whitish lines (Wickham striae) were seen exclusively in LP.<br />
<strong>Conclusions</strong><br />
&nbsp;&nbsp; PP, LP, PR and dermatitis show specific dermoscopic patterns that may aid their clinical diagnosis. Certain combinations of dermoscopic features can reliably predict the diagnosis of PP.",,"/uploadfiles/file/20130929/20130929170026_2970.pdf",,09/29/2013,11/01/2013,"medicool",15,,,0,"66",26,"Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea","2012",
85,,,"Golandam Khayef, Julia Young, Bonny Burns-Whitmore and Thomas Spalding","Lipids in Health and Disease","<span id=""lb_con""><strong>Background:</strong><br />
&nbsp; &nbsp;&nbsp; Given that acne is a rare 
condition in societies with higher consumption of omega-3 (n-3) relative to 
omega-6 (n-6) fatty acids, supplementation with n-3 may suppress inflammatory 
cytokine production and thereby reduce acne severity.<br />
<strong>Methods: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13 individuals with inflammatory acne were given three grams 
of fish oil containing 930 mg of EPA to their unchanged diet and existing acne 
remedies for 12 weeks. Acne was assessed using an overall severity grading 
scale, total inflammatory lesion counts, and 
colorimetry.<br />
<strong>Findings:</strong><br />
&nbsp; &nbsp;&nbsp; There was no significant 
change in acne grading and inflammatory counts at week 12 compared to baseline. 
However, there was a broad range of response to the intervention on an 
individual basis. The results showed that acne severity improved in 8 
individuals, worsened in 4, and remained unchanged in 1. Interestingly, among 
the individuals who showed improvement, 7 were classified as having moderate to 
severe acne at baseline, while 3 of the 4 whose acne deteriorated were 
classified as having mild acne.<br />
<strong>Conclusion:</strong><br />
&nbsp; &nbsp;&nbsp; There is 
some evidence that fish oil supplementation is associated with an improvement in 
overall acne severity, especially for individuals with moderate to severe acne. 
Divergent responses to fish oil in our pilot study indicates that dietary and 
supplemental lipids are worthy of further investigation in acne.<br />
</span>",,"/uploadfiles/file/20130911/20130911095308_6613.pdf",,09/30/2013,09/30/2013,"medicool",28,,"Acne Vulgaris, Fish Oil, Inflammation, n-3 Fatty Acid, Omega 3 Fatty Acid, EPA",0,"66",54,"Effects of fish oil supplementation on inflammatory acne","2012",
90,,,"Alena Borovaya, MD, Olga Olisova, MD, PhD, Thomas Ruzicka, MD, and Miklos Sardy, MD, PhD","International Journal of Dermatology","&nbsp;&nbsp; &nbsp; Cosmetic defects in acne may provoke a wide range of mental disorders (depressive, social-phobic, etc.). Isotretinoin is a very effective acne treatment; hence, it usually resolves the associated mental disorders. However, more available data show the possible association of taking isotretinoin and the onset of a depressive syndrome that includes frank depression and even suicidal ideation. The frequency of depressive disorders during isotretinoin treatment varies from 1% to 11% in different studies, and it is unclear whether this is a consequence of isotretinoin therapy. Since it crosses the blood-brain barrier, isotretinoin affects the expression of a broad spectrum of genes in the limbic structures, thus affecting the function of the dopaminergic, serotonergic, and noradrenergic neurons involved in the regulation of mood and emotion. It was suggested that isotretinoin in high concentrations inhibits hippocampal neurogenesis and induces apoptosis of hippocampal cells. However, some studies do not confirm this pathogenic role, and isotretinoin was even reported to have a therapeutic effect in acne-associated depression. In this review, we highlight epidemiological data, the underlying molecular pathogenesis, and the aspects of prevention concerning retinoid-induced depression in acne from the practical point of view of a dermatologist.",,"/uploadfiles/file/20130909/20130909155545_2804.pdf",,09/30/2013,09/30/2013,"medicool",47,,,0,"67",54,"Does isotretinoin therapy of acne cure or cause depression?","2013",
121,"斑替枝孢霉引发一名免疫功能正常者的皮肤暗色丝孢霉病","10.1111/j.1365-2230.2007.02461.x","C. Y. Neoh, S. H. Tan and P. Perera","Clinical dermatology","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>We report the case of a
56-year-old Chinese woman with phaeohyphomycosis. She presented with a 4-year
history of a <a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><span>recurring erythematous plague</span> initially diagnosed as <a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><span>chromoblastomycosis</span> on <a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span>histopathological
examination</span>. Surgical excision was performed when the lesion
recurred despite<a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span> intial treatment response to itraconazole</span>.
Tissue cultures of the surgical specimen grew <a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span>Cladophialophora bantiana</span>.
Treatment with<a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span> terbinafine</span> post surgery was
instituted with no recurrence of the lesion to date. Cutaneous
phaeohyphomycosis caused by Cladophialophora bantiana is rare and this case highlights<span style=""color:red;""> </span>the<a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span> </span><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><span><span><span>clinical presentation</span></span></span>, <a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span>laboratory
findings</span> and treatment of this infection.</span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">我们报道了患有皮肤暗色丝孢霉病的中国</span><span>56</span><span style=""font-family:宋体;"">岁女性患者一例。她有</span><span>4</span><span style=""font-family:宋体;"">年复发性红斑的病史，最初经由病理组织学检查被诊断为患有色霉菌病。尽管初始治疗对伊曲康唑有反应，但当皮损复发时，对皮损进行了手术切除。手术标本的组织培养为斑替枝孢霉。术后使用特比萘芬进行治疗，至今皮损未复发。由斑替枝孢霉引发的皮肤暗色丝孢霉病非常罕见，这一病例强调了这种感染的临床表现、实验结果及其治疗。</span><span></span>
</p>","/uploadfiles/image/20131010/20131010161750_3505w.png","/uploadfiles/file/20131010/20131010161837_3846.pdf",,10/10/2013,10/10/2013,"medicool",41,,,0,"85",20,"Cutaneous phaeohyphomycosis due to Cladophialophora bantiana in an immunocompetent patient","2007",
105,,,"Sahar S. Ganeb, Hanan H. Sabry, Mohammed M. El-Assal, Howyda M. Kamal, Ayser A. Fayed, Islam M. El-Shazly","The Egyptian Rheumatologist","<strong>Aim of the work: </strong><br />
This study aimed to investigate 
serum levels of vascular endothelial growth factor (VEGF) and to measure
 common carotid intima media thickness (cc-IMT) in Egyptian patients 
with Behc? et’s disease (BD) to evaluate their relations to disease 
activity and different clinical manifestations.<br />
<strong> Patients and methods: </strong><br />
Seventy patients with BD and 70 healthy controls participated in this 
study. Behc? et’s disease patients were subjected to detailed history 
taking, thorough clinical examination, disease activity assessment using
 the BD Current Activity Form (BDCAF) and laboratory investigation. 
Vascular endothelial growth factor levels were measured using ELISA. The
 carotid arteries were assessed for cc-IMT and plaques with a carotid 
high-resolution B-mode ultrasound.",,"/uploadfiles/file/20130812/20130812143128_3172.pdf",,09/30/2013,09/30/2013,"medicool",24,,"Behc? et’s disease|Vascular endothelial growth factor|B-mode ultrasonography|Disease activity",0,"65",29,"Vascular endothelial growth factor and subclinical atherosclerosis by carotid ultrasonography in Egyptian patients with Behc? et’s disease ","2013",
130,,"10.1186/1743-422X-9-224","Hajime Tomita1, Fumihide Ogawa1, Sayaka Kuwatsuka1, Fumi Toriyama2, Shinichirou Yasumoto3, Shimeru Kamihira4 and Atsushi Utani1*","Virology Journal","&nbsp; We report the development and treatment of eczema herpeticum in a 51-year-old male suffering from adult T-cell leukemia (ATL). Lesions of eczema herpeticum coexisted with the skin lesions of ATL. Treatment of eczema herpeticum resulted in a concomitant improvement in the symptoms of ATL, including a reduction in the size of the ATL plaques, for over 2 months before relapse.<br />
<br />",,"/uploadfiles/file/20131011/20131011153648_6379.pdf",,10/11/2013,10/11/2013,"medicool",37,,"Adult T-cell leukemia virus type 1, Herpes simplex, Eczema herpeticum",3,"85",57,"Attenuation of an adult T-cell leukemia skin lesion after treatment of a concomitant herpes simplex infection: a case study","2012",
89,,"10.4103/0378-6323.95450","Niti Khunger, Chandan Kumar","Indian Journal of Dermatology","<span id=""lb_con""><strong>Background: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Although acne is usually recognized as an adolescent skin disorder, the prevalence of adults with acne is increasing. There is surprisingly a paucity of data on the prevalence and clinical features of postadolescent acne in the adult Indian population.<br />
<strong>Aims: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The clinical and epidemiological data of adult acne were evaluated with a view to establishing possible contributing etiological factors and observing whether clinical features differ from adolescent acne. <br />
<strong>Methods:</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp; Patients over the age of 25 years presenting with acne in a tertiary care hospital were included in the study. A detailed history and examination was carried out, with a stress on aggravating factors. Hormonal imbalances were investigated in females with alopecia, obesity, hirsutism and menstrual irregularity. Severity of acne and complications like scarring and psychological stress were included.<br />
<strong>Results: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Out of 280 patients included in the study 82.1% were women and 17.9% were men. The mean age of the patients was 30.5 years. Persistent acne was observed in 73.2%, while it was late onset in 26.8%. Majority of the patients had inflammatory papular acne (55%), whereas comedonal acne was the least common (6%). Most common predominant site of involvement was cheek (81%), followed by chin (67%), and mandibular area (58.3%). Family history&nbsp; of acne was present in 38.6%. Premenstrual flare was seen in 11.7% of female patients, obesity in 6.4%, hirsutism in 5.7% and alopecia in 1.8%, but raised laboratory markers of hyperandrogenism were observed in only 3.08%. Scarring was observed in a majority of patients (76.4%) and psychological stress in 52.8% patients.<br />
<strong>Conclusion:</strong> <br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adult acne is predominant in women, and as compared to adolescent acne is more inflammatory, with involvement of the cheeks and lower half of the face, while comedones are rare. Facial scarring occurs in a majority and stress is common, which emphasizes that adult acne should not be neglected.</span>",,"/uploadfiles/file/20130911/20130911094403_3779.pdf",,09/30/2013,09/30/2013,"medicool",34,,"Acne, adult, inflammatory, women",0,"66",54,"A clinico?epidemiological study of adult acne: Is it different from adolescent acne?","2012",
91,,"10.1111/phpp.12059","Gui-Lan Yang, Min Zhao, Jia-Mei Wang, Chun-Feng He, Yang Luo, Hai-Yan Liu, Jian Gao, Chao-Qin Long & Jing-Rui Bai","Photodermatology, Photoimmunology & Photomedicine","<span id=""lb_con""><strong>Background</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acne conglobata is hardly curable and easily leads to scar formation after treatment using traditional methods.<br />
<strong>Aim</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To develop a novel way to treat acne conglobata.<br />
<strong>Methods</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seventy-five patients with facial acne conglobata were included in this clinical study and divided into either a treatment group (n = 35) to receive photodynamic therapy (PDT) with topical 5% 5-aminolevulinic acid and red light once every 10 days for a month or a control group (n = 40) to receive a Chinese herbal medicine mask plus red light once per week for the same duration. Patients in both groups were given oral viaminate capsules, doxycycline, zinc gluconate, and topical metronidazole. Efficacy was evaluated with respect to symptom score, cure rate, and response rate up to 2 weeks following the final treatment, and time points for assessment included baseline (D0), the visit before each treatment (D10 and D20 for the treatment group, and D7, D14, and D21 for the control group), and 2 weeks after treatment (D34 for the treatment group and D35 for the control group). Safety was assessed by recording adverse effects.<br />
<strong>Results</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with PDT significantly improved acne lesions and reduced scar formation. The treatment group had a significantly lower symptom score, a higher cure rate, and response rate than the control group. No systemic side effects occurred.<br />
<strong>Conclusion</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The treatment of acne conglobata with PDT is associated with a high cure rate, short treatment period, few side effects, and reduced scar formation. To the best of our knowledge, this is the first report on the treatment of acne<br />
conglobata with PDT.</span>",,"/uploadfiles/file/20130909/20130909154559_0626.pdf",,09/30/2013,09/30/2013,"medicool",34,,"acne conglobata; Chinese herbal; medicine mask; photodynamic therapy; red light",0,"66",54,"Short-term clinical effects of photodynamic therapy with topical 5-aminolevulinic acid for facial acne conglobata: an open, prospective, parallel-arm trial","2013",
93,,,"Li Ma1, Lei-Hong Xiang, Bo Yu, Rui Yin, Lei Chen, Yan Wu, Zhi-Jian Tan, Yong-Bin Liu, Hong-Qing Tian, Hui-Zhong Li, Tong Lin, Xiu-Li Wang, Yuan-Hong Li, Wei-Zheng Wang, Hui-Lan Yang, Wei Lai",,"<span id=""lb_con""><strong>Objectives: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To investigate the efficacy and safety of low-concentration 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in the treatment of different severity of acne vulgaris and optimize the treatment regimen. <br />
<strong>Methods: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A self-controlled multicenter clinical trial was carried out in 15 centers throughout China. A total of 397 acne patients of grade II to IV received 3- or 4-session PDT treatment. 5% ALA gel was applied topically to acne lesions for 1h incubation. The lesions were irradiated by a LED light of 633nm at dose levels of 96-120J/cm2. Clinical assessment was conducted before and after every treatment up to 8 weeks.<br />
<strong>Results: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The effective rate overall and of grade II, III and IV are 82.1%, 71.6%, 79.6% and 88.2% separately. The effective rate rises significantly proportionally to the severity of acne (P＜0.01). No significant differences are found in the efficacy between patients received 3- or 4-session PDT treatments (P＞0.05). The count of inflammatory and non-inflammatory acne lesions gradually decrease after each treatment (P＜0.01) and during the 8-week follow up (P＜0.01 or P＜0.05). Maximum efficacy is obtained at 8 weeks after the treatment completion. <br />
<strong>Conclusions: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A low-dose topical ALA-PDT regimen using 5% ALA, 1h incubation and red light source of 3 treatment sessions is suggested as optimal scheme for the treatment of different severity of acne vulgaris in Chinese patients. Superior efficacy is found in severe cystic acne of grade IV with mild side effects.</span>",,"/uploadfiles/file/20130809/20130809140451_7302.pdf",,09/30/2013,09/30/2013,"medicool",48,,"acne vulgaris|severity|aminolevulinic acid|photodynamic therapy",0,"66",54,"Low-dose topical 5-aminolevulinic acid photodynamic therapy in the treatment of different severity of acne vulgaris","2013",
102,,"10.1007/s00296-010-1368-7","Tomonori Taniguchi ? Hideki Maejima ? Akira Watarai ? Ryoichi Aki ? Kensei Katsuoka",,"&nbsp; Diffuse idiopathic skeletal hyperostosis (DISH) is difficult to distinguish from various forms of inflammatory arthritis, including psoriatic arthritis (PsA), rheumatoid arthritis, and ankylosing spondylitis. A 67-year-old Japanese male had been treated for psoriasis vulgaris for 13 years. Numbness of his right arm and lower limbs and spinal stiffening had developed 7 years prior to his initial evaluation at our facility. He noticed pain mainly while exercising. There were symmetrical marginal syndesmophytes in the spine, from the thoracic vertebrae to the upper lumbar vertebrae, on radiological examinations. We<br />
therefore suspected DISH. Furthermore, ossifications of the posterior and anterior longitudinal ligaments were noted in<br />
the cervical spine. Laboratory examinations revealed a normal peripheral white blood cell count, serum C-reactive protein, and erythrocyte sedimentation rate, and he was negative for rheumatoid factor. We detected human leukocyte antigen B39 but not B27. All distal interphalangeal joints were swollen but without pain. X-ray imaging showed narrowing of the joint space, and the consolidation of the joint was recognized, but there was no new juxtaarticular bone formation. Based on clinical and radiological findings, we concluded that he had DISH and not PsA. DISH was indicated by marked radiological features of the<br />
axial skeleton, particularly the thoracic spine, but may also have involved the peripheral joints. DISH is one of the entheseal disorders, and 10% of Japanese middle-aged and elderly men have DISH. Therefore, the differentiation of DISH from PsA is necessary in psoriasis patients with spinal involvement.",,"/uploadfiles/file/20130906/20130906150735_1480.pdf",,09/30/2013,09/30/2013,"medicool",24,,"DISH  PsA  OPLL  Entheseal disorder",0,"85",26,"A case of psoriasis vulgaris with diffuse idiopathic skeletal hyperostosis involved with ossifications of posterior and anterior longitudinal ligament","2012",
101,,,"Siaw C Liew, Esha Das-Gupta, Shew F Wong, Nagarajah Lee, Najeeb Safdar and Adawiyah Jamil","Nutrition Journal","<span id=""lb_con""><strong>Background: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The methylenetetrahydrofolate reductase (MTHFR) enzyme catalyzes the reduction of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate and methyl donors. The methyl donors are required for the conversion of homocysteine to methionine. Mutation of MTHFR 677 C &gt; T disrupts its thermostability therefore leads to defective enzyme activities and dysregulation of homocysteine levels.<br />
<strong>Methods: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This case-control study (n = 367) was conducted to investigate the correlation of the MTHFR gene polymorphism [NM_005957] and psoriasis vulgaris amongst the Malaysian population. Overnight fasting blood samples were collected from a subgroup of consented psoriasis vulgaris patients and matched controls (n = 84) for the quantification of homocysteine, vitamin B12 and folic acid levels.<br />
<strong>Results: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There was no significant increase of the MTHFR 677 C &gt; T mutation in patients with psoriasis vulgaris compared with controls (c2 = 0.733, p = 0.392). No significant association between homocysteine levels and MTHFR gene polymorphism in cases and controls were observed (F = 0.91, df = 3, 80, p = 0.44). However, homocysteine levels in cases were negatively correlated with vitamin B12 (r = -0.173) and folic acid (r = -0.345) levels. Vitamin B12 and folic acid levels in cases were also negatively correlated (r = -0.164).<br />
<strong>Conclusions: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Our results indicate that there was no significant association between the MTHFR gene polymorphism and psoriasis vulgaris in the Malaysian population. There was no significant increase of the plasma homocysteine level in the psoriasis patients compared to the controls.</span>",,"/uploadfiles/file/20130906/20130906150343_5656.pdf",,09/30/2013,09/30/2013,"medicool",34,,,0,"65",26,"Association of Methylentetraydrofolate Reductase (MTHFR) 677 C > T gene polymorphism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a case-control study","2012",
104,,,"Sanjay Singh, Shri Nivash, Baldeep K. Mann",,"<span id=""lb_con""><strong>Background:</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psoriasis is a multifactorial disease. Genetic and environmental factors, which determine the disease epidemiology and clinical spectrum, are heterogeneous in different populations. A few case-control studies from other countries have shown an association between psoriasis and migratory glossitis (MG). The characteristics of the association (e.g. relationship with gender, severity of psoriasis, early- versus late-onset psoriasis, etc.) have not been clearly defined. <br />
<strong>Aim: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To investigate the association of psoriasis and MG by conducting a matched case-control study in India.<br />
<strong> Methods: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The study was conducted on 600 patients with psoriasis and 800 age- and sex-matched controls. Patients were examined for oral lesions and psoriasis severity was assessed by overall severity index (OSI) and psoriasis area and severity index (PASI). We compared the proportions of patients and controls with oral lesions, proportions of male and female patients who had MG, psoriasis severity scores of patients with or without MG, and proportions of early- and late-onset psoriasis patients who had MG.<br />
<strong>Results: </strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signifi cantly, more patients had oral lesions than controls (P=0.0013). There was a strong association between<br />
psoriasis and MG (P&lt;0.0001). MG and fi ssured tongue (FT) occurring in the same patient were also strongly associated with psoriasis (P=0.0003). There was a weak association of psoriasis with FT (P=0.0456). Signifi cantly, higher proportion of male patients had MG compared to female patients (P=0.0246). Patients with MG had more severe psoriasis compared to those without the tongue lesions (P&lt;0.0001). Similar proportions of patients with type 1 and type 2 psoriasis had<br />
MG (P=0.7268).<br />
<strong>Conclusions:</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp; The results suggest that MG is a rare manifestation of psoriasis which occurs more commonly in male patients and in those with severe disease, and that it occurs with equal frequency in early- and late-onset psoriasis. It will be interesting to follow those patients who have MG, but not psoriasis, to see whether they develop psoriasis phenotype in future.</span> 
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20130906/20130906170840_8452.pdf",,09/30/2013,09/30/2013,"medicool",41,,"Case-control study, geographical tongue, India, migratory glossitis, psoriasis",0,"66",26,"Matched case-control study to examine association of psoriasis and migratory glossitis in India","2013",
135,,"10.1111/j.1442-9071.2011.02668.x","Duan F ; Ni S ; Nie Y ; Huang Q ; Wu K","Clinical & Experimental Ophthalmology","Background: This study sought to inhibit herpes simplex virus type 1 replication using small interfer- ing RNA which targeting infected-cell polypeptide 4 genes to mediate transcription of early and late viral genes in herpes simplex virus type 1 lytic (produc- tive) infection in retina epithelial cells.<br />
Methods: After pre- or post-infecting with herpes simplex virus type 1, small interfering RNAs were transfected into retina epithelial cells. The antiviral effects of small interfering RNA were evaluated by Western blot, plaque assays, indirect immuno?uo- rescence and reverse transcription polymerase chain reaction. The viral titre was detected by the 50% tissue culture infective dose method.<br />
Results: Small interfering RNA decreased infected-cell polypeptide 4 expression in retina epithelial cells that were infected with herpes simplex virus type 1 before oraftersmallinterferingRNAtransfection.Compared with herpes simplex virus type 1 infection alone or transfection with negative control small interfering RNA, the viral titre and the retina epithelial cell cytopathic effect were signi?cantly decreased in retina epithelial cells transfected with infected-cell polypeptide 4-targeting small interfering RNA (50 and 100 nM) (P &lt; 0.05). The small interfering RNA<br />
effectively silenced herpes simplex virus type 1 infected-cell polypeptide 4 expression on both mRNA and the protein levels <br />
(P&lt; 0.05). The inhibition of infected-cellpolypeptide4-targetingsmallinterfering RNA on infected-cell polypeptide 4 protein expres- sion was also veri?ed by Western blot in herpes simplexvirustype1infectedhumancorneaepithelial cell, human trabecular meshwork cells and Vero cells.<br />
Conclusions: Infected-cell polypeptide 4-targeting small interfering RNA can inhibit herpes simplex virus type 1 replication in retina epithelial cells, pro- viding a foundation for development of RNA inter- ference as an antiviral therapy.<br />
<br />",,"/uploadfiles/file/20131011/20131011162626_6676.pdf",,10/11/2013,10/11/2013,"medicool",25,,,0,"65",57,"Small interfering RNA targeting for infected-cell polypeptide 4 inhibits herpes simplex virus type 1 replication in retinal pigment epithelial cells.","2011",
136,"单纯疱疹病毒性淋巴结炎：病例报告及文献回顾",,"Mallory D. Witt,Mauro S. Torno, Nora Sun, and Tomiko Stein","Clinical Infectious Diseases","<p>
	<span><span><span style=""font-family:'Minion-Regular','serif';font-size:14pt;""></a><span><span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp; Herpes simplex virus (HSV) is a well-known cause of gingivostomatitis, herpes labialis, genital ulcers, and encephalitis.</span></span></a><span style=""font-family:'Times New Roman','serif';""> <span><span><span><span><span><span>Lymphadenopathy</span></span></span></span></span></span></a><span><span><span><span><span> in HSV infection may occur in association with disseminated infection with multiorgan involvement</span></span></span></span></span><span><span><span>, <span>as </span></a></a><span><span><span><span><span>generalized lymphadenopathy</span></span></span></span></span></a><span><span> associated with an <span>erythematous rash </span></a>with no other organ involvement</span></span>, <span>or rarely as generalized or </span></a><span><span><span><span><span>regional lymphadenopathy</span></span></span></span></span></a><span><span><span><span> </span></span></span></span><span><span>with or without associated <span>regional </span></a><span><span><span>skin rash</span></span></span></a><span><span> </span></span>and <span>no other evidence of disease</span></a>. </span></span></span></span></span><span>The following case report describes a patient with common variable immunodeficiency (CVID), natural killer (NK) cell deficiency, and </span><span><span><span>massive cervical lymphadenopathy</span></span></span></a><span><span> in response to infection with HSV.<br />
<span style=""font-family:宋体;""><span style=""font-family:宋体;font-size:16pt;""><br />
&nbsp;&nbsp;&nbsp; 众所周知，单纯疱疹病毒（</span><span style=""font-family:'Times New Roman','serif';font-size:16pt;"">HSV</span><span style=""font-family:宋体;font-size:16pt;"">）能引起龈口炎、唇疱疹、生殖器溃疡、和脑炎。</span><span style=""font-family:宋体;font-size:16pt;"">由<span>HSV</span>感染所致的淋巴结肿大的发生可能与累及多器官的播散性感染有关，如伴有皮肤某处红斑而无其他器官累及的全身性淋巴结肿大，或者很罕见的，全身性或局部淋巴结肿大伴或不伴相应局部皮疹，且没有其他相关症状。</span><span style=""font-family:宋体;font-size:16pt;"">下面的病例报告描述了一位患有常见变异型免疫缺陷症（</span><span style=""font-family:'Times New Roman','serif';font-size:16pt;"">CVID</span><span style=""font-family:宋体;font-size:16pt;"">）、自然杀伤（</span><span style=""font-family:'Times New Roman','serif';font-size:16pt;"">NK</span><span style=""font-family:宋体;font-size:16pt;"">）细胞缺乏症以及对</span><span style=""font-family:'Times New Roman','serif';font-size:16pt;"">HSV</span><span style=""font-family:宋体;font-size:16pt;"">的感染有反应的颈部大规模的淋巴结肿大的患者。</span></span><span style=""font-family:'Times New Roman','serif';""><br />
<br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</p>
<p class=""MsoNormal"">
	<b><b><span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mallory D. Witt et al. Clinical Infectious Diseases <span>&nbsp;</span>,2002, <span>&nbsp;</span>34:1C6</span></b><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"">
	</b><span style=""font-family:'Times New Roman','serif';""></span>&nbsp;
</p>
<p>
	</span><span style=""font-family:'Times New Roman','serif';""></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';""></span>
</p>
</span></span></span></span></span></span>","/uploadfiles/image/20131011/20131011162852_7618w.png","/uploadfiles/file/20131011/20131011162928_5951.pdf",,10/11/2013,10/14/2013,"medicool",44,,"Herpes Simplex Virus Lymphadenitis,Case Report ,Review",0,"67",57,"Herpes Simplex Virus Lymphadenitis: Case Report and Review of the Literature","2002",
140,,"10.1179/016164110X12644252260556","Zhou Y ; Lu ZN ; Guo YJ ; Mei YW","Neurological Research","<strong>Background and purpose:</strong> The prognosis of herpes simplex encephalitis (HSE) remains poor despite available antiviral treatment. Matrix metalloproteinase-9 (MMP-9) is currently considered to play a major role in promoting cerebrovascular complications which contribute to the high mortality and morbidity of HSE. We hypothesize that temporally knockdown MMP-9 expression in early phase of HSE might be an effective treatment strategy. <br />
<strong>Methods: </strong>The animal models of herpes simplex encephalitis were established by intracerebrally inoculated herpes simplex virus type 1 (HSV-1) in mice. Mice were inoculated intracerebrally with MMP-9 targeting siRNA (MMP-9 siRNA). MMP-9 expression was assessed by RT-PCR and western blot analysis at 3 and 7 days after HSV-1 infected. The bloodCbrain barrier (BBB) permeability was quantitated by Evans blue dye extravasations and brain water content. Immunohistochemistry method was adopted to analyse the expression of AQP4 protein. Quantitative real-time PCR analysis was used to detect cytokines expression. Neurological score was quantified using an established neurological scale at 7 days after HSE. <br />
<strong>Results: </strong>Using synthetic small interfering RNA, we found a single intracerebral injection of siRNA targeting murine MMP-9 mRNA (MMP-9 siRNA) silenced MMP-9 expression and reduced it to normal level at day 7 post-infection. The improvement in neurological function and increased cumulative survival reflected the functional consequence of this therapy. MMP-9 knockdown mice also displayed less uptake of Evans blue and reduced brain water content compared with control siRNA-treated group. Also the HSV-1-induced up- regulation of proinflammatory cytokines was significantly diminished in MMP-9 siRNA-treated mice. In addition, aquaporin-4 expression in perivascular decreased in MMP-9 siRNA-treated mice and might contribute to the protection of bloodCbrain barrier. <br />
<strong>Discussion:</strong> This compelling evidence suggests that MMP-9 is a key pathogenic factor within HSE, and local injection of synthetic siRNA in the brain could knock down MMP-9 expression in acute phase of HSE, reduce brain edema and improves mice neurological function and increase cumulative survival.<br />
<br />",,"/uploadfiles/file/20131011/20131011171141_8367.pdf",,10/11/2013,10/11/2013,"medicool",26,,"BloodCbrain barrier, Gene silencing, Herpes simplex encephalitis, Matrix metalloproteinase-9, RNAi",0,"66",57,"Favorable effects of MMP-9 knockdown in murine herpes simplex encephalitis using small interfering RNA","2010",
141,,"10.3349/ymj.2012.53.2.401","Il Dong Kim, Ho Sun Chang, and Kyung Jin Hwang","Yonsei Medical Journal","<strong>Purpose:</strong> This study determined the seroprevalence of herpes virus 2 in gravidas and the differences between herpes virus 2-infected and healthy gravidas. The need to screen gravidas for herpes virus 2 was also evaluated.<br />
<strong>Materials and Methods: </strong>A retrospective analysis involving 500 gravidas who underwent herpes virus 2 serologic testing and delivery in our hospital between January 2009 and August 2010 was performed. All patients in the study group were classified as her- pes simplex virus 2 (HSV2) positive, and all cases were analyzed with respect to the clinical course of the pregnancy, pregnancy outcome, obstetric complications, and neonatal outcomes. SPSS software (version 14.0) was used for statistical anal- ysis. A chi-square test and Student’s t-test were used for statistical analysis. <br />
<strong>Results: </strong>In the current study, the herpes virus 2 seroprevalence rate in gravidas was 17%. There was no significant difference in the rates of preterm delivery, prema- ture rupture of membranes, preterm labor, and intrauterine growth restriction be- tween the herpes virus 2-infected gravidas and the healthy control group. The rates of spontaneous abortion and sexually transmitted disease were higher in the herpes virus 2 infection group than the healthy control group.<br />
<strong>Conclusion: </strong>After educat- ing gravidas on genital herpes and, if gravidas thereafter consent to herpes virus 2 screening, the risk of neonatal herpes virus 2 infections can be reduced. In addi- tion, examination of gravidas for sexually transmitted diseases would increase as would appropriate treatment",,"/uploadfiles/file/20131011/20131011171209_6360.pdf",,10/11/2013,10/11/2013,"medicool",25,,"Herpes virus 2, seroprevalence, pregnancy, sexually transmitted disease",0,"66",57,"Herpes Simplex Virus 2 Infection Rate and Necessity  of Screening during Pregnancy: A Clinical and  Seroepidemiologic Study","2012",
142,,"10.1186/1471-2334-12-356","Poissy J ; Champenois K ; Dewilde A ; Melliez H ; Georges H ; Senneville E ; Yazdanpanah Y","BMC Infectious Diseases","<strong>Background: </strong>Herpes simplex encephalitis (HSE) often leads to severe disability or death. Factors usually associated with outcome include Simplified Acute Physiology Score, age and delay of initiation of acyclovir treatment. Our aim was to determine the impact of Herpes simplex virus (HSV) load in cerebrospinal fluid (CSF) upon HSE outcome. <br />
<strong>Methods:</strong> We retrospectively determined HSV load in the CSF of 43 patients with confirmed HSE, hospitalized in northern France from 1998 to 2005, using CSF samples collected the day of hospital admission and stored at ?20°C. We analyzed the association between HSV load and mortality/morbidity by the Glasgow Outcome Scale. Fisher’s exact test and Wilcoxon’s test were used for statistical analysis.<br />
<strong>Results: </strong>The M/F sex ratio was 1.7 and median patient age was 61 years. Median HSV load in CSF was 2.0 log copies/μL (IQR 25-75=1.2-2.6). The mortality rate was 32.6% six months after HSE diagnosis. Higher age was associated with mortality (p=0.03). Longer delay in acyclovir initiation tended to be associated with higher mortality but did not reach statistical significance (p=0.08). Severe disability and death due to HSV were associated with a higher Knaus score (p=0.004), later acyclovir initiation (p=0.006), older age (p=0.04) and presence of red blood cells in CSF (p=0.05). HSV load in CSF was neither associated with mortality (p=1.00) nor with morbidity (p=0.90). <br />
<strong>Conclusion: </strong>In this study, HSV load in CSF was not found to be associated with poor outcome in patients with HSE. These data do not support measurement of HSV load at admission in patients with HSE.<br />
<br />",,"/uploadfiles/file/20131011/20131011171257_0913.pdf",,10/11/2013,10/11/2013,"medicool",23,,"Herpes virus, Prognosis, Neurological/brain, Viral load",0,"66",57,"Impact of Herpes simplex virus load and red blood cells in cerebrospinal fluid upon herpes simplex meningo-encephalitis outcome","2012",
150,"复式双侧分布的慢性带状疱疹","10.2340/00015555-1206","Castronovo C ; Nikkels AF","Acta Dermato-Venereologica","<b><span style=""font-size:16.0pt;font-family:宋体;""></span></b><b><span style=""font-size:16.0pt;""></span></b><span></span><b><span style=""font-size:14.0pt;font-family:&quot;""></span></b> 
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">ABSTRACT</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">摘要</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;""><span style=""font-family:Times New Roman;"">Although varicella
zoster virus latency has been demonstrated in several sensory ganglia, herpes
zoster usually effects only one single, either left or right, dermatome in half
of the body. In immunocompromised patients, more than one </span><a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><span style=""font-family:Times New Roman;"">contiguous unilateral
dermatome</span><span style=""font-family:Times New Roman;""> may be involved. Bilateral non-contiguous herpes zoster,
also termed herpes zoster duplex, is rarely reported. Chronic varicella zoster
virus skin infection is another rare entity encountered in HIV-infected and
immunocompromised patients, often associated with </span><a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><span style=""font-family:Times New Roman;"">aciclovir resistance</span><span style=""font-family:Times New Roman;"">.
We describe here a patient with chronic lymphocytic leukaemia, who presented
simultaneously non-contiguous bilateral and chronic herpes zoster lasting for
more than 2 months, with resistance to aciclovir. To our knowledge, this is the
first report of chronic herpes zoster duplex bilateralis. Physicians should be
aware of and recognize these atypical manifestations of varicella zoster virus.</span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">虽然研究已证明水痘</span><span style=""font-family:Times New Roman;"">-</span><span style=""font-family:宋体;""><span style=""font-family:Times New Roman;"">带状疱疹病毒潜伏在几个感觉神经节中，但是带状疱疹通常只影响身体的一半皮区，非左即右。对免疫功能低下的患者而言，可能涉及不止一个连续单边皮区。关于</span><a name=""OLE_LINK10""></a><span style=""font-family:Times New Roman;"">双侧不连续的带状疱疹（也称之为复式带状疱疹）的报道也很少。在</span></span><span style=""font-family:Times New Roman;"">HIV</span><span style=""font-family:Times New Roman;"">感染者和免疫功能低下的患者中出现慢性水痘</span><span style=""font-family:Times New Roman;"">-</span><span style=""font-family:Times New Roman;"">带状疱疹病毒性皮肤感染是另一种罕见现象，这种现象的出现常与阿昔洛韦耐药有关。我们在这里描述了一位慢性淋巴细胞性白血病患者，这名患者同时患有双侧不连续的慢性型带状疱疹</span><span style=""font-family:Times New Roman;"">2</span><span style=""font-family:Times New Roman;"">个月以上，并且对阿昔洛韦有耐药性。据我们所知，这是第一例关于复式双侧分布的慢性带状疱疹的报道。医师应知道并认识水痘</span><span style=""font-family:Times New Roman;"">-</span><span style=""font-family:Times New Roman;"">带状疱疹病毒的这些非典型临床表现。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-align:right;"" align=""right"">
	<span style=""font-size:9pt;font-family:Times New Roman;"">&nbsp;</span>&nbsp; <span style=""font-size:9pt;font-family:Times New Roman;""></span>
</p>
<p class=""MsoNormal"" style=""text-align:right;"" align=""right"">
	<span><a><span style=""font-size:9pt;font-family:Times New Roman;"">Castronovo C</span></a></span><span style=""font-size:9.0pt;font-family:&quot;color:black;""> </span><span style=""font-size:9pt;font-family:Times New Roman;"">et.al ; Acta Denn Venereol ; 2012
Mar; Vol. 92 (2), pp. 148-51</span> 
</p>","/uploadfiles/image/20131012/20131012101438_2257w.jpg","/uploadfiles/file/20131012/20131012101431_0185.pdf",,10/12/2013,10/12/2013,"medicool",32,,"herpes zoster; varicella zoster virus; immuno- suppression.",0,"85",58,"Chronic Herpes Zoster Duplex Bilateralis","2012",
151,"带状疱疹患者水泡液中辅助性T细胞1/2的细胞因子谱及其临床意义的研究","10.1111/j.1346-8138.2011.01289.x","Zhang M ; Wu N ; Yang L ; Zhang J ; Sun X ; Zhong S ; Ma X ; Wang Y","Journal of Dermatology","<b><span style=""font-size:16.0pt;font-family:宋体;""></span></b><b><span style=""font-size:16.0pt;""></span></b><b><span style=""font-size:14pt;font-family:Times New Roman;"">ABSTRACT</span></b> 
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">摘要</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;""><span style=""font-family:Times New Roman;"">Herpes zoster (HZ) is
a Varicella zoster virus infection disease. Previous studies have presumed the
connection between development of HZ and involvement of cellular immunity in
peripheral blood. However, whether cellular immunity plays a role in the local
skin lesion has not been addressed. To explore the levels of </span><a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span style=""font-family:Times New Roman;"">T-helper cell Th1?Th2
type cytokine pro?les </span><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-family:Times New Roman;""><span style=""font-family:Times New Roman;""><span style=""font-family:Times New Roman;"">in the blister ?uid of the skin lesions</span></span></span><span style=""font-family:Times New Roman;""> from the patients with HZ and its role in pathogenesis, we used the cytometric
bead array kit to compare the levels of cytokines (interleukin [IL]-2, tumor
necrosis factor [TNF]- </span></span><span style=""font-family:Times New Roman;"">α</span><span style=""font-family:Times New Roman;"">, IL-10 and IL-4) in
blister ?uid from 46 patients with those from the suction blister ?uids from 20
volunteers without any infectious disease (the control group). The results
indicated that the levels of Th1 cytokinesIL-2 and TNF-a in the blister ?uid
from the patients’ skin lesions were signi?cantly lower than those from the
control group, whereas the levels of Th2 cytokines IL-10 and IL-4 were
signi?cantly higher than those in the control group. Moreover, signi?cant
variation of the levels of Th1?Th2 cytokines (IL-2, TNF-a, IL-10 and IL-4) in
the blister ?uid from the HZ patients’ lesions was also observed among
different stages of the disease. It is concluded that a cytokine imbalance was
present in the local lesions of patients with HZ during disease development.
Our data suggested that the Th immunity was associated with disease activity,
which may play an important role in the pathogenesis of HZ.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">带状疱疹（</span><span style=""font-family:Times New Roman;"">HZ</span><span style=""font-family:Times New Roman;"">）是一种由水痘</span><span style=""font-family:Times New Roman;"">-</span><span style=""font-family:Times New Roman;"">带状疱疹病毒感染引起的疾病。以往的研究认为</span><span style=""font-family:Times New Roman;"">HZ</span><span style=""font-family:Times New Roman;"">的发展与外周血细胞免疫的参与之间存在联系。然而，细胞免疫在局部皮肤损伤中是否发挥作用这一问题还尚未解决。为探索带状疱疹患者皮损处水泡液中辅助性</span><span style=""font-family:Times New Roman;"">T</span><span style=""font-family:Times New Roman;"">细胞</span><span style=""font-family:Times New Roman;"">Th1/Th2</span><span style=""font-family:Times New Roman;"">型细胞因子水平及其在发病机制中发挥的作用，我们使用流式微珠阵列盒对来自</span><span style=""font-family:Times New Roman;"">46</span><span style=""font-family:Times New Roman;"">例患者水泡液中以及</span><span style=""font-family:Times New Roman;"">20</span><span style=""font-family:Times New Roman;"">名无任何传染病的志愿者（对照组）负压吸疱液中的细胞因子（白介素</span><span style=""font-family:Times New Roman;"">[IL]-2</span><span style=""font-family:Times New Roman;"">，肿瘤坏死因子</span><span style=""font-family:Times New Roman;"">[TNF]-</span><span style=""font-family:Times New Roman;"">α，</span><span style=""font-family:Times New Roman;"">IL-10</span><span style=""font-family:Times New Roman;"">和</span><span style=""font-family:Times New Roman;"">IL-4</span><span style=""font-family:Times New Roman;"">）水平进行了比较。研究结果表明，患者皮损处水泡液中的</span><span style=""font-family:Times New Roman;"">Th1</span><span style=""font-family:Times New Roman;"">型细胞因子</span><span style=""font-family:Times New Roman;"">IL-2</span><span style=""font-family:Times New Roman;"">和</span><span style=""font-family:Times New Roman;"">TNF-</span><span style=""font-family:Times New Roman;"">α的水平显著低于对照组，但是</span><span style=""font-family:Times New Roman;"">Th2</span><span style=""font-family:Times New Roman;"">型细胞因子</span><span style=""font-family:Times New Roman;"">IL-10</span><span style=""font-family:Times New Roman;"">和</span><span style=""font-family:Times New Roman;"">IL-4</span><span style=""font-family:Times New Roman;"">的水平却显著高于对照组。此外，我们也观察到在疾病的不同阶段</span><span style=""font-family:Times New Roman;"">HZ</span><span style=""font-family:Times New Roman;"">患者损伤处泡液中</span><span style=""font-family:Times New Roman;"">Th1?Th2</span><span style=""font-family:Times New Roman;"">型细胞因子（</span><span style=""font-family:Times New Roman;"">IL-2, TNF-a, IL-10</span><span style=""font-family:Times New Roman;"">和</span><span style=""font-family:Times New Roman;"">IL-4)</span><span style=""font-family:Times New Roman;"">）水平存在显著差异。从而得出结论，在</span><span style=""font-family:Times New Roman;"">HZ</span><span style=""font-family:Times New Roman;"">病情发展过程中，患者的局部病变组织存在细胞因子失衡。我们的数据表明，辅助</span><span style=""font-family:Times New Roman;"">T</span><span style=""font-family:Times New Roman;"">细胞免疫与疾病活动相关，并且可能在</span><span style=""font-family:Times New Roman;"">HZ</span><span style=""font-family:Times New Roman;"">的发病机制中发挥重要作用。</span><span style=""font-family:&quot;""></span><span style=""font-family:Times New Roman;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:Times New Roman;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-align:right;"" align=""right"">
	<span><a><span style=""font-size:9pt;font-family:Times New Roman;"">Zhang M</span></a></span><span style=""font-size:9.0pt;font-family:&quot;color:black;""> </span><span style=""font-size:9pt;font-family:Times New Roman;"">et.al ; Journal of Dermatology ; 2011
Dec; Vol. 38 (12), pp</span> 
</p>","/uploadfiles/image/20131012/20131012101925_9370w.jpg","/uploadfiles/file/20131012/20131012101920_4926.pdf",,10/12/2013,10/12/2013,"medicool",46,,"blister ?uid, cell-mediated immunity, cytokine, cytometric bead array, herpes zoster.",0,"65",58,"Study on the T-helper cell 1?2 cytokine pro?le in blister ?uid of patients with herpes zoster and its clinical signi?cance","2011",
148,,"10.1258/ijsa.2012.011433","Bastien S ; Mason-Jones AJ ; De Koker P ; Mmbaga EJ ; Ross DA ; Mathews C","International Journal Of STD & AIDS","&nbsp; Biological markers are needed in order to provide objective measures to validate self-reported sexual behaviour and interpret prevention trial data. In this review, we evaluated herpes simplex type 2 virus (HSV-2), one of the most prevalent sexually transmitted infections in sub-Saharan Africa as a biological marker of sexual debut. Based on our ?ndings, we do not recommend using HSV-2 as a biomarker for sexual debut due to its low transmission probabilities and the fact that HSV-2 prevalence is not 100% among potential sexual partners. We recommend that the validation of alternative biological measures should be prioritized, and included in future studies and trials of interventions to reduce sexual health risk.<br />
<br />",,"/uploadfiles/file/20131012/20131012085314_6372.pdf",,10/12/2013,10/12/2013,"medicool",43,,"sexually transmitted infections, STI, herpes simplex type 2, HSV-2, seroprevalence, genital herpes, biological marker, sexual debut, Africa",0,"67",57,"Herpes simplex virus type 2 infection as a biomarker for sexual debut among young people in sub-Saharan Africa: a literature review","2012",
149,,"10.1111/j.1365-2249.2011.04502.x","Laing KJ ; Dong L ; Sidney J ; Sette A ; Koelle DM","Clinical And Experimental Immunology","&nbsp;Herpes&nbsp;virus&nbsp;infections are chronic and co-exist with acquired immune responses that generally prevent severe damage to the host, while allowing periodic&nbsp; shedding&nbsp; of&nbsp; virus&nbsp; and&nbsp; maintenance&nbsp; of its transmission in the community. Herpes simplex viruses type 1 and 2 (HSV-1, HSV-2) are typical in this regard and&nbsp; are &nbsp;representative&nbsp;of the&nbsp; viral subfamily Alphaherpesviri- nae, which has a tropism for neuronal and epithelial cells. This review will emphasize recent progress &nbsp;in&nbsp; decoding&nbsp; the&nbsp; physiologically&nbsp; important&nbsp; CD8+ and CD4+ T &nbsp;cell &nbsp;responses &nbsp;to &nbsp;HSV in humans. The expanding data set is discussed in the context of the search for an effective HSV vaccine as therapy for existing infections and to prevent new infections.<br />
<br />",,"/uploadfiles/file/20131012/20131012085522_7446.pdf",,10/12/2013,10/12/2013,"medicool",42,,"antigen, epitope, herpes simplex virus, lymphocyte, vaccine",0,"67",57,"Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses","2012",
79,"Potential Role of Neurogenic Inflammatory Factors in the Pathogenesis of Vitiligo","10.2310/7750.2011.11068","Richard Yu, Yuanshen Huang, Xuejun Zhang, and Youwen Zhou","Canadian Dermatology Association","<strong><span style=""font-size:14px;"">Background: </span></strong><br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;"">Vitiligo is a highly complex multifactorial condition of the skin that has an unclear mechanism of pathogenesis.</span><br />
<strong><span style=""font-size:14px;"">Objective:</span></strong><br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;""> &nbsp;&nbsp;</span><span style=""font-size:14px;""> This review summarizes the role of various neurogenic inflammatory factors significantly upregulated in vitiligo.</span><br />
<strong><span style=""font-size:14px;"">Methods: </span></strong><br />
<span style=""font-size:14px;"">&nbsp;&nbsp; &nbsp; A literature review was conducted of all pertinent data regarding neuropeptides that are altered in vitiligo and their possible role in the destruction of melanocytes.</span><br />
<strong><span style=""font-size:14px;"">Results:</span></strong><br />
<span style=""font-size:14px;""> &nbsp;&nbsp; The close associations between the skin, immune system, and nervous system, along with specific changes demonstrated in vitiligo patients, support a pathogenic mechanism of vitiligo that involves neuroimmunologic factors, the release of which can be governed by mental stress.</span><br />
<strong><span style=""font-size:14px;"">Conclusion:</span></strong><br />
<span style=""font-size:14px;""> &nbsp;&nbsp; Neuropeptides and nerve growth factors are critical regulators of emotional response and may precipitate the onset and development of vitiligo in certain predisposed individuals. More studies are required to investigate whether a direct link exists between genetics, mental stress, and neurogenic factors in vitiligo.</span>",,"/uploadfiles/file/20130929/20130929133524_5678.pdf",,09/29/2013,09/29/2013,"medicool",46,,,0,"67",28,,"2012",
78,"银屑病与白癜风的共患","10.2310/7750.2011.11028","Michael Sawchuk, Frank Spano, Wei Jing Loo, and Lyn Guenther","Canadian Dermatology Association","<p class=""MsoNormal"">
	<b><span>Background: </span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>Psoriasis and vitiligo
are both autoimmune diseases with <a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span>an </span><a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span><span><span>increased incidence</span></span></span><span><span> noted in <a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span><span>genetic
relatives</span></span>.</span></span> They share similar <a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span>trigger
factors </span>and have been observed to coexist in individuals.</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究背景：</span></b><b><span></span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">银屑病与白癜风都是自身免疫性疾病，在遗传关系亲属上表现有发病率的增加。二者有相似的引发因素，并且已观察到同一个体同时患有这两种皮肤病。</span><span></span>
</p>
<p class=""MsoNormal"">
	<b><span>Objective: </span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>The purpose was to
review the literature on the coexistence of psoriasis and vitiligo and to
determine if <a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span>there is a higher than </span><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><span><span><span>expected
prevalence</span></span></span><span><span> of psoriasis in patients with vitiligo</span></span> and vice versa.</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究目的：</span></b><b><span></span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">本研究旨在对<a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span>有关银屑病和白癜风两病共患的</span>文献资料进行回顾，并确定是否白癜风患者的银屑病患病率比预期的要高，反之亦然。</span><span></span>
</p>
<p class=""MsoNormal"">
	<b><span>Methods:</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>A literature review was
conducted using Medline, EMBASE, and the <a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span>Cochrane Library</span> from 1968 to 2010. All articles that included reports of individuals with both
psoriasis and vitiligo in the English language were documented.</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究方法：</span></b><b><span></span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">利用</span><span>Medline</span><span style=""font-family:宋体;"">、</span><span>EMBASE</span><span style=""font-family:宋体;"">和</span><span>Cochrane
Library1968</span><span style=""font-family:宋体;"">到</span><span>2010</span><span style=""font-family:宋体;"">年间的文献进行文献综述。所有包括银屑病和白癜风两病共患的患者的英文文章都为该综述提供材料。</span><span></span>
</p>
<p class=""MsoNormal"">
	<b><span>Results:</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>We identified 338
articles, among which 35 case reports and 7 case series were mentioned. For
each case series, the prevalence of psoriasis in patients with vitiligo, or
vice versa, falls within <a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span>the prevalence range of the </span><a name=""OLE_LINK23""></a><a name=""OLE_LINK22""></a><span><span><span>background
population</span></span> </span>on which the study was based.</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究结果：</span></b><b><span></span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">我们鉴定了</span><span>338</span><span style=""font-family:宋体;"">篇文章，其中提到了</span><span>35</span><span style=""font-family:宋体;"">篇病例报道和</span><span>7</span><span style=""font-family:宋体;"">篇病例系列。对于每一病例系列，白癜风患者的银屑病患病率，<a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span>或银屑病者的白癜风患病率</span>，在本研究所依据的背景人口的患病率范围内下降。</span><span></span>
</p>
<p class=""MsoNormal"">
	<b><span>Conclusion:</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span>An increase in the <a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><span>expected
prevalence</span> of psoriasis in individuals with vitiligo, or vice versa,
was not found in our study, suggesting that the coexistence of the two diseases
appears to be due to chance alone. <a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span><span>Large epidemiologic studies</span></span> are required to
address with certainty whether psoriasis is more common in individuals with
vitiligo and vice versa.</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究结论：</span></b><b><span></span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">本研究未发现白癜风患者的银屑病预期患病率的增加，反之亦然，表明两病共患仅是偶然发生。需要进行大量的流行病学研究以确定是否银屑病在白癜风患者中较常见，反之亦然。</span><span></span>
</p>","/uploadfiles/image/20130929/20130929112352_3268w.png","/uploadfiles/file/20130929/20130929112434_3532.pdf",,09/29/2013,09/29/2013,"medicool",49,,,0,"67",28,"The Coexistence of Psoriasis and Vitiligo: A review","2011",
82,"白癜风表皮黑素细胞超微结构及小眼畸形相关转录因子转录调控研究","10．3760／cma．j．issn．0412―4030．2010．07．01","王平  洪为松  章莉 洪健  郑俊惠  许爱娥","中华皮肤科杂志","<strong>目的</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 研究白癜风黑素细胞超微结构和小眼畸形相关转录因子(MITF)及其转录调控的酪氨酸酶相关蛋白(TRP)与白癜风临床类型与病程的相关性。<br />
<strong>方法</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 选择不同病程的寻常型白癜风(VV)12例和节段型白癜风(sv)8例，分别取白斑区、白斑边缘正常肤色区和远离白斑正常肤色区的表皮片，经组织学确定其表皮的完整性。透射电镜观察1O例患者(vv 6例，sv 4例)不同区表皮黑素细胞的超微结构特点。对所有20例远离白斑正常肤色区的表皮片黑素细胞进行培养，应用免疫印迹方法检测MITF及其转录调控的酪氨酸酶(TYR)、酪氨酸酶相关蛋白1(TYRP1)和酪氨酸酶相关蛋白2(TYRP2)的表达水平。<br />
<strong>结果</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp; 白癜风表皮黑素细胞超微结构病理改变：10例中7例白斑区表皮内未见黑素细胞，1例短病程和2例长病程VV分别可见少量黑素体显著减少或缺失的黑素细胞；白斑边缘正常肤色区，6例VV中，3例病程小于15个月者可见黑素细胞超微结构异常，而4例SV中仅1例异常；远离白斑正常肤色区，l0例黑素细胞超微结构均正常。白癜风表皮黑素细胞MITF及其转录调控TRP的表达：vv的MITF表达下调与TYR、TYRP1、TYRP2的表达下调一致；SV存在MITF显著表达下调，而 ITYR、TYRP1、TYRP2几均正常表达。<br />
<strong>结论</strong><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vV和SV可能存在不同的表皮黑素细胞超微结构病理改变和MITF转录调控机制。",,"/uploadfiles/file/20130929/20130929140404_8297.pdf",,09/29/2013,09/30/2013,"medicool",26,,"白癜风；黑素细胞；黑色素小体；小眼畸形相关转录因子",0,"65",28,,"2010",
127,"印度系统性红斑狼疮患者中皮肤型红斑狼疮病面积和严重度指数的研究",,"P Salphale, D Danda, L Chandrashekar","Lupus","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK4""></a><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">The Cutaneous
Lupus Erythematosus Disease Area and Severity Index (CLASI) is a newly
described tool used to assess the activity of and damage caused by cutaneous
lupus erythematosus (CLE). There is a paucity of data on CLASI from the Indian
subcontinent. We sought to determine the applicability of CLASI in specific
lesions of CLE in patients with systemic lupus erythematosus (SLE) attending a
tertiary care hospital in India. In this prospective, cross-sectional study, 93
patients of SLE with cutaneous lesions were recruited. CLASI activity and
damage scores of lupus erythematosus (LE)-specific skin lesions were done in 75
patients with SLE. The mean CLASI activity score was 15.4</span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">±</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">9.4
(range 0C30) and the mean damage score was 6.87</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">±</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;""> 7.75
(range 0C30). Higher mean CLASI activity scores were seen in patients with a
combination of acute, subacute and chronic CLE and in those with widespread
lesions. Patients with longstanding disease and long duration of skin lesions had
higher damage scores. This study shows that CLASI is an effective tool to
assess cutaneous activity of LE-specific lesions, and the damage caused by
them, in Indian patients.</span></span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">皮肤型红斑狼疮病面积和严重度指数（</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLASI</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">）是一种用来评价皮肤型红斑狼疮（</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLE</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">）引起的活动性和损毁的新的工具。印度在</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLASI</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">的数据上很缺乏。我们试图确定系统性红斑狼疮（</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">SLE</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">）患者中的</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLE</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">患者的特殊病灶处的</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLASI</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">的适用性，这些患者均来自印度三甲医院。在这项前瞻性的横向研究中，招募了</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">93</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">名</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">SLE</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">皮损患者。我们对</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">75</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">名</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">SLE</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">患者进行了红斑狼疮（</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">LE</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">）特应性皮肤损害的</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLASI</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">损毁评分和活动性评分。平均</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLASI</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">活动性分数为</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">15.4</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">±</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">9.4</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">（范围</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">0-30</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">），平均损毁分数为</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">6.87</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">±</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;""> 7.75</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">（范围</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">0-30</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">）。其中，</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">SLE</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">患者中伴有急性、亚急性、慢性</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLE</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">的患者和病变范围广的患者的平均</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLASI</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">活动分数更高；有长期疾病和皮损时间长的患者的</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLASI</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">损毁分数更高。研究表明：</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">CLASI</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">是一个用来评价印度患者中</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:&quot;font-size:16px;"">LE</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""line-height:1.5;font-family:宋体;font-size:16px;"">特应性病变的皮肤活动和损毁的有用工具。</span></span><span></span><span style=""line-height:125%;font-family:&quot;""></span>
</p>","/uploadfiles/image/20131011/20131011152109_8751w.jpg","/uploadfiles/file/20131011/20131011152131_5903.pdf",,10/11/2013,10/11/2013,"medicool",54,,"activity; CLASI; cutaneous lupus; damage; systemic lupus erythematosus",0,"66",3,"The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus","2011",
128,,"10.1007/s13365-012-0110-5","Maria Teresa Ferrò & Diego Franciotta & Alessandro Prelle & Arabella Bestetti & Paola Cinque","Journal Of Neurovirology","&nbsp; Several herpes viruses, including herpes simplex virus type 1 and 2 (HSV-1/2), varicella zoster virus (VZV), <br />
EpsteinCBarr virus, and human herpesvirus-6 (HHV-6), have been suggested to be implicated in the pathogenesis of<br />
multiple sclerosis (MS)(Gilden 2005). We report a case of acute MS preceded by herpes zoster, temporarily associated with intrathecal reactivation of HSV-1 and HHV-6.<br />
<br />",,"/uploadfiles/file/20131011/20131011152804_5862.pdf",,10/11/2013,10/12/2013,"medicool",35,,,2,"85",57,"Active intrathecal herpes simplex virus type 1 (HSV-1) and human herpesvirus-6 (HHV-6) infection at onset of multiple sclerosis","2012",
129,"外用二十二烷醇10％霜治疗口唇单纯疱疹的临床疗效:一项多中心，随机，安慰剂对照试验","10.1067/mjd.2001.116215","Stephen L. Sacks, MD, FRPCP,Ronald A. Thisted, PhD, Terry M. Jones, MD","American Academy of Dermatology","<b><span style=""font-family:'Times New Roman','serif';"">Background:</span></b> 
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span><span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp; Recurrent herpes simplex labialis (HSL) occurs in 20% to 40% of the US population.</span></span></a><span><span><span><span><span style=""font-family:'Times New Roman','serif';"">Although the disease is self-limiting in persons with <span><span>a healthy immune response</span></span></a></span></span></span></span></span><span><span><span style=""font-family:'Times New Roman','serif';"">, <span>patients seek treatment </span></a>because of <span>the discomfort and visibility </span></a>of a recurrent lesion.
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:宋体;"">研究背景：</span></b><b><span style=""font-family:'Times New Roman','serif';""></span></b> 
</p>
</span></span></span><span></span><span></span> 
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20</span><span style=""font-family:宋体;"">％至</span><span style=""font-family:'Times New Roman','serif';"">40</span><span style=""font-family:宋体;"">％的美国人患有复发性口唇单纯疱疹（</span><span style=""font-family:'Times New Roman','serif';"">HSL</span><span style=""font-family:宋体;"">）。尽管具有健全免疫应答反映的患者对该疾病能进行自我限制，但是由于复发皮损的不适和可见,患者仍然求医。</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:'Times New Roman','serif';"">Objective:</span></b> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><i><span style=""font-family:'Times New Roman','serif';""><span>&nbsp;&nbsp;&nbsp;&nbsp; </span></span></i></b><span><span style=""font-family:'Times New Roman','serif';"">Our purpose was to determine whether docosanol 10% cream (docosanol) is efficacious compared with placebo for the </span></span></a><span><span><span><span style=""font-family:'Times New Roman','serif';"">topical treatment</span></span></span></span></a><span><span><span style=""font-family:'Times New Roman','serif';""> of episodes of acute HSL.
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:宋体;"">研究目的:</span></b><b><span style=""font-family:'Times New Roman','serif';""></span></b> 
</p>
</span></span></span><span></span><span></span> 
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp; 本研究旨在确定</span><span style=""font-family:'Times New Roman','serif';"">10</span><span style=""font-family:宋体;"">％二十二烷醇霜（二十二烷醇）与安慰剂对急性</span><span style=""font-family:'Times New Roman','serif';"">HSL</span><span style=""font-family:宋体;"">发作的局部治疗相比，是否有效。</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:'Times New Roman','serif';"">Methods: </span></b>
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span><span style=""font-family:'Times New Roman','serif';""><span style=""font-family:Tahoma;"">&nbsp;&nbsp;&nbsp; </span>Two identical double-blind, placebo-controlled studies were conducted at a total of 21 sites.</span></span></a><span style=""font-family:'Times New Roman','serif';""> <span>Otherwise healthy adults, with documented histories of HSL, were randomized to receive either docosanol or polyethylene glycol placebo and initiated therapy in the</span></a><span><span><span> prodrome</span></span></span></a><span><span> or <span>erythema stage of an </span></a><span><span><span>episode</span></span></span></a>.</span></span> <span>Treatment was administered 5 times daily until healing occurred.
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:宋体;"">研究方法：</span></b><b><span style=""font-family:'Times New Roman','serif';""></span></b> 
</p>
</span></a></span> 
<p style=""text-align:left;text-indent:5.25pt;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:宋体;"">&nbsp;&nbsp; 在</span><span style=""font-family:'Times New Roman','serif';"">21</span><span style=""font-family:宋体;"">个地方进行两个完全相同的双盲性、安慰剂对照试验研究。此外健康的成人，以及记录有</span><span style=""font-family:'Times New Roman','serif';"">HSL</span><span style=""font-family:宋体;"">病史的患者，被随机分组接受二十二醇或者聚乙二醇安慰剂，并且在前驱症状或发作性症状的红斑期开始治疗。每日给予</span><span style=""font-family:'Times New Roman','serif';"">5</span><span style=""font-family:宋体;"">次治疗直到康复。</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:'Times New Roman','serif';""><span>&nbsp;</span>Results:</span></b> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span><span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp;&nbsp; The median time to healing in the 370 docosanol-treated patients was 4.1 days, 18 hours shorter than observed in the 367 placebo-treated patients (<i>P </i>= .008; 95% </span></span></a><span><span><span><span style=""font-family:'Times New Roman','serif';"">confidence interval</span></span></span></span></a><span><span><span style=""font-family:'Times New Roman','serif';""> [CI]: 2, 22). </span></span></span><span><span><span><span><span style=""font-family:'Times New Roman','serif';"">The docosanol group also exhibited reduced times from <span>treatment initiation </span></a>to (1) cessation of pain and all other symptoms (itching, burning, and/or tingling; <i>P </i>= .002; 95% CI: 3, 16.5)</span></span></span></span></span><span><span><span style=""font-family:'Times New Roman','serif';"">; (2) complete healing of <span>classic lesions</span></a> (<i>P </i>= .023; 95% CI: 1, 24.5); and (3) cessation of the ulcer or <span><span><span>soft crust stage</span></span></span></a><span><span> </span></span>of classic lesions (<i>P </i>&lt; .001; 95% CI: 8, 25)</span></span></span><span style=""font-family:'Times New Roman','serif';"">.<span style=""color:red;""> </span><span><span><span><span>Aborted episodes</span></span></span></span></a><span><span> were experienced by 40% of the docosanol recipients versus 34% of placebo recipients (<i>P </i>= .109; 95% CI for odds ratio: 0.95, 1.73). Adverse experiences with docosanol were mild and similar to those with placebo.<br />
<br />
<span style=""font-family:宋体;""><strong>研究结果：</strong></span></span></span></span> 
</p>
<span></span><span></span> 
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp;&nbsp;接受二十二烷醇治疗的</span><span style=""font-family:'Times New Roman','serif';"">370</span><span style=""font-family:宋体;"">名患者，平均康复时间为</span><span style=""font-family:'Times New Roman','serif';"">4.1</span><span style=""font-family:宋体;"">天，与</span><span style=""font-family:'Times New Roman','serif';"">367</span><span style=""font-family:宋体;"">例接受安慰剂治疗的患者相比减少</span><span style=""font-family:'Times New Roman','serif';"">18</span><span style=""font-family:宋体;"">小时（</span><span style=""font-family:'Times New Roman','serif';"">P =.008; 95</span><span style=""font-family:宋体;"">％置信区间</span><span style=""font-family:'Times New Roman','serif';"">[CI]</span><span style=""font-family:宋体;"">：</span><span style=""font-family:'Times New Roman','serif';"">2</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">22</span><span style=""font-family:宋体;"">）。从治疗起始到（</span><span style=""font-family:'Times New Roman','serif';"">1</span><span style=""font-family:宋体;"">）疼痛和所有其他症状的消失（瘙痒，灼痛，和</span><span style=""font-family:'Times New Roman','serif';"">/</span><span style=""font-family:宋体;"">或刺痛，</span><span style=""font-family:'Times New Roman','serif';"">P = 0.002</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">95</span><span style=""font-family:宋体;"">％</span><span style=""font-family:'Times New Roman','serif';"">CI</span><span style=""font-family:宋体;"">：</span><span style=""font-family:'Times New Roman','serif';"">16.5</span><span style=""font-family:宋体;"">）；（</span><span style=""font-family:'Times New Roman','serif';"">2</span><span style=""font-family:宋体;"">）典型皮损的完全康复（</span><span style=""font-family:'Times New Roman','serif';"">P =.023;95</span><span style=""font-family:宋体;"">％</span><span style=""font-family:'Times New Roman','serif';"">CI</span><span style=""font-family:宋体;"">：</span><span style=""font-family:'Times New Roman','serif';"">1</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">24.5</span><span style=""font-family:宋体;"">）；以及（</span><span style=""font-family:'Times New Roman','serif';"">3</span><span style=""font-family:宋体;"">）溃疡消失或典型皮损的软壳阶段（</span><span style=""font-family:'Times New Roman','serif';"">P &lt;0.001</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">95</span><span style=""font-family:宋体;"">％</span><span style=""font-family:'Times New Roman','serif';"">CI</span><span style=""font-family:宋体;"">：</span><span style=""font-family:'Times New Roman','serif';"">8</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">25</span><span style=""font-family:宋体;"">），二十二烷醇组还显示出了治疗次数的减少。二十二烷醇组中有</span><span style=""font-family:'Times New Roman','serif';"">40</span><span style=""font-family:宋体;"">％患者的疾病，安慰剂组中有</span><span style=""font-family:'Times New Roman','serif';"">34%</span><span style=""font-family:宋体;"">的患者。（</span><span style=""font-family:'Times New Roman','serif';"">P =0.109</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">95</span><span style=""font-family:宋体;"">％</span><span style=""font-family:'Times New Roman','serif';"">CI</span><span style=""font-family:宋体;"">：</span><span style=""font-family:'Times New Roman','serif';"">0.95</span><span style=""font-family:宋体;"">，比值比</span><span style=""font-family:'Times New Roman','serif';"">1.73</span><span style=""font-family:宋体;"">）。二十二醇组有轻微的不良反应，与安慰剂组相似。</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<b><span style=""font-family:'Times New Roman','serif';"">Conclusion:</span></b> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span><span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp;&nbsp; Docosanol applied 5 times daily is safe and effective in the treatment of recurrent HSL. </span></span></a><span><span><span><span style=""font-family:'Times New Roman','serif';"">Differences in healing time compared favorably with those reported for the only treatment of HSL</span></span></span></span></a><span><span><span style=""font-family:'Times New Roman','serif';""> that has been approved by the Food and Drug Administration.<br />
<br />
<span style=""font-family:宋体;""><strong>研究结论：</strong></span></span></span></span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp; 应用二十二烷醇（每日</span><span style=""font-family:'Times New Roman','serif';"">5</span><span style=""font-family:宋体;"">次）对复发性</span><span style=""font-family:'Times New Roman','serif';"">HSL</span><span style=""font-family:宋体;"">的治疗是安全和有效的。其康复时间与报道过的唯一的</span><span style=""font-family:'Times New Roman','serif';"">HSL</span><span style=""font-family:宋体;"">疗法（已通过美国食品和药物管理局批准）相比，毫不逊色。<br />
<br />
<br />
<br />
&nbsp;&nbsp;<br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</p>
&nbsp;
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href=""http://www.sciencedirect.com.libproxy.tulane.edu:2048/science/article/pii/S019096220130676X""><span style=""color:windowtext;text-decoration:none;"">Stephen L</span></a> et al.<a href=""http://www.sciencedirect.com.libproxy.tulane.edu:2048/science/journal/01909622""><span style=""color:windowtext;text-decoration:none;"">Journal of the American Academy of Dermatology</span></a>,2001,45:222-30.</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';""></span>&nbsp;
</p>
</span>","/uploadfiles/image/20131011/20131011152224_8488w.png","/uploadfiles/file/20131011/20131011152353_6286.pdf",,10/11/2013,10/11/2013,"medicool",53,,"Clinical efficacy , topical docosanol 10% cream , herpes simplex labialis,multicenter, randomized, placebo-controlled trial",0,"66",57,"Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial","2001",
81,"Understanding and Assessing Potential Serious Adverse Events: A Practical Approach to Understanding the Benefits and Harm of Psoriasis Treatments","10.2310/7750.2012.12046","Kim Papp, Lyn Guenther, Neil Shear, Carin Binder, Jerry Tan, Charles Lynde, Wayne Gulliver, and Paul Stang","Canadian Dermatology Association","<strong><span style=""font-size:14px;"">Background: </span></strong><br />
<span style=""font-size:14px;""> &nbsp;&nbsp;&nbsp; Any therapeutic intervention carries with it the potential for benefit and harm. Generally, benefit is far more common than risk; however, risk aversion drives many of the treatment decisions made by patients and their physicians.</span><br />
<strong><span style=""font-size:14px;"">Objective:</span></strong><br />
<span style=""font-size:14px;""> &nbsp;&nbsp; To provide guidelines to help clinicians improve their understanding of causality and the interpretation of harm.</span><br />
<strong><span style=""font-size:14px;"">Methods: </span></strong><br />
<span style=""font-size:14px;""> &nbsp; &nbsp; A group of dermatologists involved in data safety monitoring boards, clinical trial investigators, and a clinical epidemiologist identified the need for practical advice on how to understand and explain causality and harm and combined to share their knowledge.</span><br />
<strong><span style=""font-size:14px;"">Results: </span></strong><br />
<span style=""font-size:14px;""> &nbsp; &nbsp; An explanation of how data are collected and the environment that shapes the data seen by clinicians is presented. The</span><span style=""font-size:14px;""> article spans an overview of the regulatory environment that informs trial design for regulatory approval to a description of types of designs that inform safety and techniques, such as the rule of three, to provide guidance to clinicians in interpreting the data.</span><br />
<strong><span style=""font-size:14px;"">Conclusion:</span></strong><br />
<span style=""font-size:14px;""> &nbsp;&nbsp; Communicating the potential for harm to patients is critical. Placing the potential for rare and serious risks into perspective for the patient is as important as discussing the potential benefits of medication.</span>",,"/uploadfiles/file/20130929/20130929135456_9723.pdf",,09/29/2013,09/29/2013,"medicool",34,,,0,"65",28,,"2013",
53,"Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis","10.1111/j.1399-3038.2009.00851.x","Fujisawa T, Nagao M, Hiraguchi Y, Katsumata H, Nishimori H, Iguchi K, Kato Y, Higashiura M, Ogawauchi I, Tamaki K.","Pediatr Allergy Immunol","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp; Elevated blood levels of thymus and activation-regulated chemokine (TARC)/CCL17 have been observed in atopic dermatitis (AD) and may serve as a new biomarker for AD. However, the normal levels, especially in children, have not been well determined. We sought to establish an efficient enzyme-linked immunosorbent assay (ELISA) with a wide range of detection that would be suitable for measurement of serum TARC/CCL17 and to determine the normal ranges of this chemokine in different age groups and its diagnostic usefulness for AD. A sensitive specific ELISA for TARC/CCL17, which we previously reported, was modified to accommodate the wide range of TARC/CCL17 values often found in sera. Twenty-seven children with AD under 6 yr of age and 25 age-matched normal non-atopic controls, and 18 patients with AD and 27 controls who were 6 yr and older were enrolled. The severity of AD was evaluated using the SCORAD index. The serum levels of TARC/ CCL17 were measured with the ELISA, and the serum levels of IP-10/ CXCL10 were also measured. With the novel ELISA system, the assayable range of TARC/CCL17 was 14C8000 pg/ml, and the coefficient</span><span style=""font-size:14px;""> of variation at various concentrations ranged from 2.3% to 5.0%. The serum levels of TARC/CCL17 in normal individuals were significantly higher in young children, especially in the age group of 0C1 yr. The cut-off values of TARC/CCL17 for the diagnosis of AD were 1431 pg/ml for 0C1 yr group, 803 pg/ml for 2C5 yr group and 510 pg/ml for the 6 yr and older group, with high sensitivity and specificity of 0.83 and 0.93, 0.83 and 0.92, 0.85 and 0.96, respectively. The magnitude of</span><span style=""font-size:14px;"">the decrease in the SCORAD index after treatment with topical steroids correlated significantly with the decrease in serum TARC/CCL17. There was no difference in the serum levels of IP-10/CXCL10 between AD and the controls. The TARC/CCL17:IP-10/CXCL10 ratio tended to be higher in the control children aged 0C1 yr than in those aged 2C5 yr. The serum level of TARC/CCL17 reflects the severity and therapeutic response in AD. The high normal levels in infants should</span><br />
<span style=""font-size:14px;"">be taken into account when assaying TARC/CCL17.</span>",,"/uploadfiles/file/20130925/20130925151122_6197.pdf",,09/25/2013,10/14/2013,"medicool",35,,"Atopic dermatitis; Infants; TARC/CCL17; IP-10/CXCL10; Th1/Th2 balance",0,"65",46,,"2009",
54,"醋酸氢化可的松单独用药或联合莫匹罗星治疗两岁以下婴幼儿特应性皮炎―一项随机双盲试验",,"F. CANPOLAT, M. ERKO?O?LU*, H. TEZER**, C.N. KOCABA?*, B. KANDI","European Review for Medical and Pharmacological Sciences","<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">BACKGROUND:</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:15.5pt;"">
	<b><span style=""font-family:&quot;""><span>&nbsp;</span></span></b><span style=""font-family:&quot;"">The skin of patients with
atopic dermatitis (AD) is heavily colonized with <i>Staphylococcus (S.) aureus</i>,
even at uninvolved sites. Toxins secreted by the majority of <i>S. aureus </i>on
the skin behave as superantigens and can directly influence the disease
activity, although clinical signs of bacterial superinfection might be absent. </span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究背景：</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:20.6pt;"">
	<span style=""font-family:宋体;"">特应性皮炎（</span><span style=""font-family:&quot;"">AD</span><span style=""font-family:宋体;"">）患者在皮损甚至非皮损处金黄色葡萄球菌（</span><span style=""font-family:&quot;"">S.</span><span style=""font-family:宋体;"">）的定植率很高。皮损处大多数金黄色葡萄球菌分泌的毒素表现为超抗原，并可以直接影响该疾病活动，尽管可能没有出现<a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span>细菌二重感染</span>的临床症状。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">OBJECTIVES: </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:20.6pt;"">
	<span style=""font-family:&quot;"">This study was conducted to
compare the efficacy of hydrocortisone cream, combined with mupirocin or alone
with <a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span>emmolient ointment</span> for the treatment of mild to moderate
AD in infants between six months and two years of age. </span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究目的：</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:20.45pt;"">
	<span style=""font-family:宋体;"">本研究旨在对氢化可的松乳膏联用莫匹罗星或单独用药治疗</span><span style=""font-family:宋体;color:#313131;"">六个月到两岁之间患</span><span style=""font-family:宋体;"">轻</span><span style=""font-family:宋体;color:#313131;"">度至中度</span><span style=""font-family:&quot;color:#313131;"">AD</span><span style=""font-family:宋体;color:#313131;"">的婴儿的疗效与</span><span style=""font-family:宋体;"">与</span><span style=""font-family:&quot;color:#313131;"">emmolient</span><span style=""font-family:宋体;color:#313131;"">软膏进行比较。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">&nbsp;</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">MATERIALS AND METHODS:</span></b><span style=""font-family:&quot;""> </span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;"">A total of 83 patients with
mild to moderate AD were randomized to receive hydrocortisone, hydrocortisone+
mupirocin or emmolient ointment twice daily in one week and followed-up for 8
weeks, in a blind study. Efficacy evaluation made by SCORAD and eczema area and
severity index (EASI) at baseline, day 7, and weeks 2, 4, and 8. Possible
adverse events were recorded to evaluate safety.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">材料和方法：</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:20.6pt;"">
	<span style=""font-family:宋体;"">在双</span><span style=""font-family:宋体;color:#313131;"">盲研究中，随机对</span><span style=""font-family:&quot;color:#313131;"">83</span><span style=""font-family:宋体;color:#313131;"">名轻度至中度</span><span style=""font-family:&quot;color:#313131;"">AD</span><span style=""font-family:宋体;color:#313131;"">患者施用氢化可的松、氢化可的松</span><span style=""font-family:&quot;color:#313131;"">+</span><span style=""font-family:宋体;color:#313131;"">莫匹罗星软及</span><span style=""font-family:&quot;color:#313131;"">emmolient</span><span style=""font-family:宋体;color:#313131;"">软膏，每天两次，持续一周，随访</span><span style=""font-family:&quot;color:#313131;"">8</span><span style=""font-family:宋体;color:#313131;"">周。采用</span><span style=""font-family:&quot;color:#313131;"">SCORAD</span><span style=""font-family:宋体;color:#313131;"">评分法（特应性皮炎评分指数）和</span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span><span style=""font-family:&quot;color:#313131;"">EASI</span></span><span><span><span style=""font-family:宋体;color:#313131;"">（<a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span>湿疹面积及严重度指数</span></span></span></span><span style=""font-family:宋体;color:#313131;"">）为对第七天，第</span><span style=""font-family:&quot;color:#313131;"">2</span><span style=""font-family:宋体;color:#313131;"">、</span><span style=""font-family:&quot;color:#313131;"">4</span><span style=""font-family:宋体;color:#313131;"">、</span><span style=""font-family:&quot;color:#313131;"">8</span><span style=""font-family:宋体;color:#313131;"">周进行疗效评价。记录可能产生的不良反应来评估药物的安全性。</span><span style=""font-family:&quot;color:#313131;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;color:#313131;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">RESULTS: </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:20.6pt;"">
	<span style=""font-family:&quot;"">At the end of study, 65% (17 of
26) of the patients were treated successfully with hydrocortisone ointment
based on SCORAD and EASI scores. Also there was a significant improvement in
patients combined with mupirocin ointment [74% (20 of 27)]. The percent
improvement from baseline in EASI scores was also significantly greater in
hydrocortisone and combined group compared with emmolient-treated patients
(36%) (<i>p </i>= 0.0187, <i>p </i>= 0.012 respectively).</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究结果：</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:20.6pt;"">
	<span style=""font-family:宋体;color:#313131;"">研究最后，根据</span><span style=""font-family:&quot;color:#313131;"">SCORAD</span><span style=""font-family:宋体;color:#313131;"">和</span><span style=""font-family:&quot;color:#313131;"">EASI</span><span style=""font-family:宋体;color:#313131;"">的评分，使用氢化可的松软膏的患者中</span><span style=""font-family:&quot;color:#313131;"">65%(17/26)</span><span style=""font-family:宋体;color:#313131;"">成功治愈。使用氢化可的松软膏与莫匹罗星软膏联合用药的患者也疗效显著</span><span style=""font-family:&quot;color:#313131;"">[74%(20/27)]</span><span style=""font-family:宋体;color:#313131;"">。在</span><span style=""font-family:&quot;color:#313131;"">EASI</span><span style=""font-family:宋体;color:#313131;"">评分上，氢化可的松与联合用药组对</span><span style=""font-family:&quot;color:#313131;"">AD</span><span style=""font-family:宋体;color:#313131;"">的改善百分率显著高于</span><span style=""font-family:&quot;color:#313131;"">emmolient</span><span style=""font-family:宋体;color:#313131;"">软膏</span><span style=""font-family:&quot;color:#313131;"">(36%)</span><span style=""font-family:宋体;color:#313131;"">的</span><span style=""font-family:&quot;color:#313131;"">(</span><span style=""font-family:宋体;color:#313131;"">分别为</span><span style=""font-family:&quot;color:#313131;"">p = 0.0187,p =
0.012)</span><span style=""font-family:宋体;color:#313131;"">。</span><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">&nbsp;</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">CONCLUSIONS: <a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span></span></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:20.6pt;"">
	<span><span><span style=""font-family:&quot;"">Monotherapy with hydrocortisone ointment is the main treatment in infants
with mild to moderate AD and combination with mupirocin is safe and effective
often needed because of possible <i>Staphylococcus </i>carriage.</span></span></span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究结论</span></b><span style=""font-family:宋体;"">：</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">婴幼儿在患轻度至中度</span><span style=""font-family:&quot;"">AD</span><span style=""font-family:宋体;"">时，单独使用氢化可的松软膏是主要的治疗方法，联合莫匹罗星用药是安全和有效的，且这种联合用药往往是必要的，因为可能存在葡萄球菌。<br />
<br />
<br />
<br />
<br />
</span> 
</p>
<div style=""text-align:right;"">
	<span style=""text-indent:21pt;""><span style=""font-family:'Times New Roman';""><em>F. CANPOLAT</em></span><span style=""font-family:'Times New Roman';""></span><span style=""font-family:'Times New Roman';""></span></span><span style=""text-indent:21pt;""><span style=""font-family:'Times New Roman';""></span><span style=""color:#131413;font-family:'Times New Roman', serif;line-height:40px;white-space:normal;""><span style=""font-family:'Times New Roman';""><em>&nbsp;</em></span><span style=""font-family:'Times New Roman';""><em>et al.</em></span><span class=""journal-title-abbr""><span style=""font-family:'Times New Roman';""><em>Eur. Rev. Med. Pharmacol. Sci.</em></span><span style=""font-family:'Times New Roman';""><em>2012; 16: 1989-1993</em></span></span></span></span> 
</div>
<p>
	<br />
</p>
<br />","/uploadfiles/image/20130925/20130925153518_6179w.png","/uploadfiles/file/20130925/20130925151951_7578.pdf",,09/25/2013,10/16/2013,"medicool",31,,"Atopic dermatitis, Infants, Hydrocortisone ointment, Mupirocin, Staphylococcus.",0,"65",46,"Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age C a randomized double blind pilot trial","2012",
70,"红斑狼疮研究进展","10．3760／cma．J．issn．0412―4030．201 1．01．00","陆前进  曾凡 钦崔勇  张学军","中华皮肤科杂志","&nbsp;&nbsp;&nbsp; 红斑狼疮(LE)是一种多器官、多系统受累，严重危害人类健康的自身免疫性疾病。其病因及发病机制尚不清楚，临床表现多样，尚无根治办法。现对其研究进展及热点研究方向作如下综述。",,"/uploadfiles/file/20130926/20130926101536_1719.pdf",,09/26/2013,09/30/2013,"medicool",36,,,0,"67",3,,"2011",
139,,"10.1007/s13365-011-0065-y","Nancy M. Sawtell & Steven J. Triezenberg & Richard L. Thompson","Journal of NeuroVirology","&nbsp; Development of novel prevention and treatment strategies for herpes simplex virus (HSV) mediated diseases is dependent upon an accurate understanding of the central molecular events underlying the regulation of latency and reactivation. We have recently shown that the transactivation function of the virion protein VP16 is a critical determinant in the exit from latency in vivo. HSV-1 strain SJO2 carries a single serine to alanine substitution at position 375 in VP16 which disrupts its interaction with its essential co-activator Oct-1. Here we report that SJO2 is severely impaired in its ability to exit latency in vivo. This result reinforces our prior observations with VP16 transactivation mutant, in1814, in which VP16 interaction with Oct-1 is also disrupted and solidifies the importance of the VP16COct-1 interaction in the early steps in HSV-1 reactivation.",,"/uploadfiles/file/20131011/20131011164204_3540.pdf",,10/11/2013,10/11/2013,"medicool",39,,"Herpes simplex virus . VP16 . Latency. Reactivation . Exit from latency. Phosphorylation . Transactivation . Mouse model",0,"65",57,"VP16 serine 375 is a critical determinant of herpes simplex virus exit from latency in vivo","2011",
57,,"10.1111/j.1365-2133.2012.10897.x","A.C. Jahns,1 B. Lundskog, R. Ganceviciene, R.H. Palmer, . Golovleva, C.C. Zouboulis, A. McDowell, S. Patrick6 and O.A. Alexeyev","British Journal of Dermatology","<strong><span style=""font-size:14px;"">Background</span></strong><br />
<span style=""font-size:14px;""> &nbsp;&nbsp; Acne vulgaris is a disorder of the sebaceous follicles. Propionibacterium acnes can be involved in inflammatory acne.</span><br />
<strong><span style=""font-size:14px;"">Objectives </span></strong><br />
<span style=""font-size:14px;"">&nbsp;&nbsp; This caseCcontrol study aimed at investigating the occurrence and localization of P. acnes in facial biopsies in acne and to characterize the P. acnes phylotype in skin compartments.</span><br />
<strong><span style=""font-size:14px;"">Methods </span></strong><br />
<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp; Specific monoclonal and polyclonal antibodies were applied to skin biopsies of 38 patients with acne and matching controls to localize and characterize P. acnes and to determine expression of co-haemolysin CAMP factor, a putative</span><span style=""font-size:14px;""> virulence determinant.</span><br />
<strong><span style=""font-size:14px;"">Results</span></strong><br />
<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp; Follicular P. acnes was demonstrated in 18 (47%) samples from patients with acne and eight (21%) control samples [odds ratio (OR) 3?37, 95% confidence interval (CI) 1?23C9?23; P = 0?017]. In 14 (37%) samples from patients</span><br />
<span style=""font-size:14px;"">with acne, P. acnes was visualized in large macrocolonies ?biofilms in sebaceous follicles compared with only five (13%) control samples (OR 3?85, 95% CI 1?22C12?14; P = 0?021). Macrocolonies ?biofilms consisting of mixed P. acnes</span><br />
<span style=""font-size:14px;"">phylotypes expressing CAMP1 were detected in both case and control samples. Only four samples tested positive for the presence of Staphylococcus spp. and fungi were not observed.</span><br />
<strong><span style=""font-size:14px;"">Conclusions </span></strong><br />
<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp; We have for the first time visualized different P. acnes phylotypes in macrocolonies ?biofilms in sebaceous follicles of skin biopsies. Our results support the hypothesis that P. acnes can play a role in the pathogenesis of acne as acne samples showed a higher prevalence of follicular P. acnes colonization, both in terms of follicles containing P. acnes and the greater numbers of bacteria in macrocolonies?biofilms than in control samples.</span>",,"/uploadfiles/file/20130925/20130925155131_2172.pdf",,09/25/2013,10/08/2013,"medicool",26,,,0,"66",54,"An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a caseCcontrol study","2012",
87,"反常性痤疮的治疗进展",,"付思祺范金财","中华整形外科杂志","反常性痤疮(Acne Inversa，AI)，以往称为化脓性汗腺炎、毛囊闭锁三联征，是一种特殊的皮肤化脓性炎性反应，以反复发生皮肤脓肿、窦道及瘢痕形成为特征性表现。该病病因仍不明，发病有家族聚集性，遗传方式符合常染色体显性遗传。晚期患者多以瘢痕、挛缩等就诊于整形外科",,"/uploadfiles/file/20130909/20130909151121_6849.pdf",,09/30/2013,09/30/2013,"medicool",56,,,0,"67",54,,"2013",
58,,"10.1111/j.1468-3083.2006.02022.x","SX Xu, HL Wang, X Fan,LD Sun,S Yang,?PG Wang,FL Xiao, M Gao, Y Cui, YQ Ren, WH Du, C Quan, XJ Zhang","JEADV  ISSN","<strong>Background</strong><br />
&nbsp;&nbsp;&nbsp; Acne is a chronic inflammatory disease of the pilosebaceous follicles. Recent studies bring us increasing evidences that hereditary factors play an important but indirect role in acne.<br />
<strong>Objective</strong><br />
&nbsp;&nbsp;&nbsp; To investigate the possible role of genetic factors in the pathogenesis of acne vulgaris in Chinese Han ethnic group.<br />
Parients and methods Volunteers of 975 acne cases and 580 controls were included, contributing 3009 and 1825 first-degree relatives, respectively. One thousand and eighty-five first-degree relatives of acne cases were affected with facial acne. This compared with 223 first-degree relatives of non-acne controls. The odds ratio was used to estimate the relative risk for acne vulgaris associated with having an affected first-degree relative.<br />
<strong>Results</strong><br />
&nbsp;&nbsp;&nbsp; The risk of acne vulgaris occurring in a relative of a patient with acne vulgaris was significantly greater than for the relative of an unaffected individual (odds ratio 4.05, 95% confidence interval (CI): 3.45C4.76,P &lt;0.001).<br />
<strong>Conclusion</strong><br />
&nbsp;&nbsp;&nbsp; Our study suggests that familial factors are important in determining individual susceptibility to acne vulgaris.",,"/uploadfiles/file/20130925/20130925155708_6770.pdf",,09/25/2013,10/08/2013,"medicool",22,,"acne vulgaris, case-control study, familial acne",0,"66",54,"The familial risk of acne vulgaris in Chinese HansCa case-control study","2006",
60,,"10.2340/00015555-1358","Bodo C. MELNIK","Acta Derm Venereol","&nbsp;&nbsp;&nbsp; Recent evidence underlines the role of Western diet in the pathogenesis of acne. Acne is absent in populations consuming Palaeolithic diets with low glycaemic load and no consumption of milk or dairy products. Two randomized controlled studies, one of which is presented in this issue of Ada Dermato-Venereologica, have provided evidence for the beneficial therapeutic effects of low glycaemic load diets in acne. Epidemiological evidence confirms that milk consumption has an acne-promoting or acne-aggravating effect. Recent progress in understanding the nutrient-sensitive kinase mammalian target of rapamycin complex 1 (mTORCl) allows a new view of nutrient signalling in acne by both high glycaemic load and increased insulin-, IGF-1-, and leucine signalling due to milk protein consumption. Acne should be regarded as an mTORCl-driven disease of civilization, like obesity, type 2 diabetes and cancer induced by Western diet. Early dietary counselling of teenage acne patients is thus a great opportunity for dermatology, which will not only help to improve acne but may reduce the long-term adverse effects of Western diet on more serious mTORCldriven diseases of civilization.",,"/uploadfiles/file/20130925/20130925161732_4367.pdf",,09/25/2013,09/30/2013,"medicool",40,,"acne; diet; glycaemic load; milk; mTORC",0,"65",54,"Diet in Acne: Further Evidence for the Role of Nutrient Signallizing in Acne Pathogenesis","2012",
449,,"141: 338C356","W. L. Lin, J. E. Fincke, L. R. Sharer, D. S. Monos,  S. Lu,J. Gaughan, C. D. Platsoucas and E. L. Oleszak","Clinical and Experimental Immunology","We have recently described the presence of perivascular CD3+ &nbsp;CD45RO+T&nbsp;cells in?ltrating the brains of children with AIDS. To determine whether these&nbsp;in?ltrates contain oligoclonal populations of T cells, we ampli?ed by PCR b-chain T-cell receptor (TCR) transcripts from autopsy brains of four paediatric&nbsp;patients with AIDS. The ampli?ed transcripts were cloned and sequenced.&nbsp;Sequence analysis of the &nbsp;b b b b-chain TCR transcripts from all four patients&nbsp;revealed multiple identical copies of TCR b b b b-chain transcripts, suggesting the&nbsp;presence of oligoclonal populations of T-cells. These TCR transcripts were&nbsp;novel. The presence of oligoclonal populations of T cells in the brains of these&nbsp;four paediatric patients with AIDS suggests that these T cells have undergone&nbsp;antigen-driven proliferation and clonal expansion very likely &nbsp;in situ, in the<br />
brains of these AIDS patients, in response to viral or self-antigens. Although&nbsp;the speci?city of the clonally expanded b-chain TCR transcripts remains to be&nbsp;elucidated, none of the b-chain TCR transcripts identi?ed in this study were&nbsp;identical to those speci?c for HIV-1 antigens that are currently reported in the&nbsp;GENBANK/EMBL databases. Certain common CDR3 motifs were observed&nbsp;in brain-in?ltrating T cells within and between certain patients. Large proportions (24 of 61; 39%) of b-chain TCR clones from one patient (NP95-73)&nbsp;and 2 of 27 (7%) of another patient (NP95-184-O) exhibited substantial&nbsp;CDR3 homology to myelin basic protein (MBP)-speci?c TCR derived from&nbsp;normal donors or TCR expressed in the brain of patients with multiple sclerosis (MS) or with viral encephalitis. These two patients (NP95-73 and NP95-184-O) also shared HLA class II with the normal donors and the MS patients&nbsp;who expressed these homologous TCR. Pathologic examination at autopsy of&nbsp;the brains revealed the presence of myelin pallor only in patient NP95-73. T-cell clones identi?ed in the brain of patients NP95-73 and NP95-184-O may&nbsp;recognize MBP or another CNS self antigen and this recognition may be&nbsp;restricted by either DRB1*15 or DQB1*0602 speci?cities.<br />
<br />",,"/uploadfiles/file/20131115/20131115163430_1862.pdf",,11/15/2013,11/15/2013,"medicool",25,,"NS, paediatric AIDS, T-cell receptor (TCR)",0,"65",19,"Oligoclonal T cells are infiltrating the brains of children with AIDS:  sequence analysis reveals high proportions of identical b b b b-chain T-cell  receptor transcripts","2005",
474,,"10.1002/lsm.22105","Maria Cla?udia Almeida Issa, MD, PhD,1","Lasers in Surgery and Medicine","<span style=""font-family:Times New Roman;"">Background: <br />
&nbsp; Striae distensae (SD) treatment still </span><span style=""font-family:Times New Roman;"">remains a therapeutic challenge to dermatologists. Ablative </span><span style=""font-family:Times New Roman;"">fractional laser and radiofrequency (RF) enhance </span><span style=""font-family:Times New Roman;"">skin-drug permeability for SD treatment.<br />
</span><br />
<span style=""font-family:Times New Roman;"">Objective: <br />
&nbsp; To clinically evaluate the efficacy and safety </span><span style=""font-family:Times New Roman;"">as well as patient’s satisfaction in relation to a method </span><span style=""font-family:Times New Roman;"">using ablative fractional RF associated with retinoic acid </span><span style=""font-family:Times New Roman;"">0.05% cream and an acoustic pressure wave ultrasound </span><span style=""font-family:Times New Roman;"">(US) in patients with alba-type SD on the breast.<br />
</span><br />
<span style=""font-family:Times New Roman;"">Methods and Materials:<br />
&nbsp;&nbsp; Eight patients with alba-type </span><span style=""font-family:Times New Roman;"">SD on the breast were treated with three step procedure: </span><span style=""font-family:Times New Roman;"">(1) fractional ablative RF for skin perforation; (2) topical </span><span style=""font-family:Times New Roman;"">application of retinoic acid 0.05% on the perforated skin; </span><span style=""font-family:Times New Roman;"">and (3) US was applied to enhance the retinoic acid penetration </span><span style=""font-family:Times New Roman;"">into the skin. Other eight patients with alba-type </span><span style=""font-family:Times New Roman;"">SD on the abdominal area were submitted to RF treatment </span><span style=""font-family:Times New Roman;"">isolated without retinoic acid or US. Three of them </span><span style=""font-family:Times New Roman;"">were submitted to skin biopsies.<br />
</span><br />
<span style=""font-family:Times New Roman;"">Results: <br />
&nbsp; Three patients with SD on the breast area </span><span style=""font-family:Times New Roman;"">improved from ‘‘severe’’ to ‘‘moderate;’’ two patients </span><span style=""font-family:Times New Roman;"">improved from ‘‘severe’’ to ‘‘mild;’’ two patients from</span><span style=""font-family:Times New Roman;"">‘‘moderate’’ to ‘‘mild;’’ one patient from ‘‘marked’’ to</span><span style=""font-family:Times New Roman;"">‘‘mild.’’ Clinical assessment demonstrated significant </span><span style=""font-family:Times New Roman;"">improvement in the appearance of SD in all patients </span><span style=""font-family:Times New Roman;"">treated with RF associated with retinoic acid 0.05% cream </span><span style=""font-family:Times New Roman;"">and US (P ? 0.008), with low incidence of side effects and </span><span style=""font-family:Times New Roman;"">high level of patient’s satisfaction. Among the patients </span><span style=""font-family:Times New Roman;"">treated only with RF, two patients improved from</span><span style=""font-family:Times New Roman;"">‘‘severe’’ to ‘‘marked;’’ one patient from ‘‘marked’’ to </span><span style=""font-family:Times New Roman;"">‘‘moderate;’’ and one patient improved from ‘‘marked’’ to </span><span style=""font-family:Times New Roman;"">‘‘mild.’’ Four patients did not show any sort of improvement. </span><span style=""font-family:Times New Roman;"">Clinical assessment demonstrated no significant </span><span style=""font-family:Times New Roman;"">improvement in the appearance of SD treated with RF</span><br />
<span style=""font-family:Times New Roman;"">isolated with low incidence of side effects, but low-level of </span><span style=""font-family:Times New Roman;"">patient’s satisfaction.</span><br />
<span style=""font-family:Times New Roman;""><br />
Conclusion: <br />
&nbsp; &nbsp;Ablative fractional RF and acoustic pressure </span><span style=""font-family:Times New Roman;"">US associated with retinoic acid 0.05% cream is safe </span><span style=""font-family:Times New Roman;"">and effective for alba-type SD treatment</span>",,"/uploadfiles/file/20131122/20131122114241_4537.pdf",,11/22/2013,11/22/2013,"medicool",21,,,0,"66",102,"Transepidermal Retinoic Acid Delivery Using Ablative Fractional Radiofrequency Associated With Acoustic Pressure Ultrasound for Stretch Marks Treatment","2012",
450,,,"Jennifer P. Chou1 , Christina M. Ramirez2 , Jennifer E. Wu1 , Rita B. Effros3 *","Novel Biomarkers of Senescent T Cells in HIV/AIDS","Clinical evaluation of immune reconstitution and health status during HIV-1 infection and anti-retroviral therapy (ART) is<br />
largely based on CD4+ T cell counts and viral load, measures that fail to take into account the CD8+ T cell subset, known to<br />
show features of accelerated aging in HIV disease. Here, we compare adenosine deaminase (ADA), glucose uptake receptor<br />
1 (GLUT1), and leucine-rich repeat neuronal 3 (LRRN3) to CD38 expression and telomerase activity, two strong predictors of<br />
HIV disease progression. Our analysis revealed that reduced ADA, telomerase activity and LRRN3 gene expression were<br />
significantly associated with high CD38 and HLA-DR in CD8+ T cells, with % ADA+ cells being the most robust predictor of<br />
CD8+ T cell activation. Our results suggest that ADA, LRRN3 and telomerase activity in CD8+ T cells may serve as novel,<br />
clinically relevant biomarkers of immune status in HIV-1 infection, specifically by demonstrating the degree to which CD8+ T<br />
cells have progressed to the end stage of replicative senescence. Since chronological aging itself leads to the accumulation<br />
of senescent CD8+ T cells, the prolonged survival and resultant increased age of the HIV+ population may synergize with<br />
the chronic immune activation to exacerbate both immune decline and age-associated pathologies. The identification and<br />
future validation of these new biomarkers may lead to fresh immune-based HIV treatments.<br />",,"/uploadfiles/file/20131115/20131115171447_5352.pdf",,11/15/2013,11/15/2013,"medicool",43,,"CD8+| T Cells|HIV|AIDS|anti-retrovira",0,"65",19,"Accelerated Aging in HIV/AIDS: Novel Biomarkers of Senescent Human CD8+ T Cells","2013",
452,,,"Yan Li  , Jin-Kou Zhao, Ming Wang , Zhi-Gang Han , Wei-Ping Cai , Bo-Jian Zheng , Hui-Fang Xu","Virology Journal","Background: Immunoassays composed of screening and confirmation are the established algorithm to confirm<br />
HIV infection in China, with a Western blot result as the final diagnosis.<br />
Case presentation: In this report, three late-stage AIDS patients were initially tested HIV antibody positive using<br />
multiple screening kits, but tested indeterminate using Western blot. HIV infection diagnosis was confirmed based<br />
on nucleic acid assays, clinic manifestations and epidemiological history. Case A was identified positive at 30<br />
months, using Western blot, Case B at 8 months, and case C remained indeterminate until he died of Kaposi’s<br />
sarcoma 4 months after HAART.<br />
Conclusion: The report indicates that current antibody-based testing algorithms may miss late-stage AIDS patients<br />
and therefore miss the opportunity for preventing these cases from further transmission. The report also implies<br />
that viral load assays is not easy to be universely applicated in developing country like China although it is helpful<br />
in diagnosing complicated cases of HIV infection, so the counselling before and after testing is imperative to the<br />
diagnosis of HIV infection and risk behavior survey on the examinee should be as detailed as possible.<br />",,"/uploadfiles/file/20131118/20131118100220_4553.pdf",,11/18/2013,11/18/2013,"medicool",36,,"immunoassay algorithm|antibody-based|AIDS",0,"85",19,"Current antibody-based immunoassay algorithm failed to confirm three late-stage AIDS cases in China: case report","2010",
451,,,"Juan Garc? ?a-Arriaza, Pilar Arna ?ez , Carmen E. Go ?mez , Carlos O ? scar S. Sorzano, Mariano Esteban","MVA and Immunomodulatory Genes on IFN Signaling","Poxvirus vector Modified Vaccinia Virus Ankara (MVA) expressing HIV-1 Env, Gag, Pol and Nef antigens from clade B (termed&nbsp;MVA-B) is a promising HIV/AIDS vaccine candidate, as confirmed from results obtained in a prophylactic phase I clinical trialin humans. To improve the immunogenicity elicited by MVA-B, we have generated and characterized the innate immune&nbsp;sensing and the in vivo immunogenicity profile of a vector with a double deletion in two vaccinia virus (VACV) genes (C6L&nbsp;and K7R) coding for inhibitors of interferon (IFN) signaling pathways. The innate immune signals elicited by MVA-B deletion&nbsp;mutants (MVA-B DC6L and MVA-B DC6L/K7R) in human macrophages and monocyte-derived dendritic cells (moDCs)&nbsp;showed an up-regulation of the expression of IFN-b, IFN-a/b-inducible genes, TNF-a, and other cytokines and chemokines. A&nbsp;DNA prime/MVA boost immunization protocol in mice revealed that these MVA-B deletion mutants were able to improve&nbsp;the magnitude and quality of HIV-1-specific CD4+&nbsp;and CD8+&nbsp;T cell adaptive and memory immune responses, which were&nbsp;mostly mediated by CD8+&nbsp;T cells of an effector phenotype, with MVA-B DC6L/K7R being the most immunogenic virus&nbsp;recombinant. CD4+&nbsp;T cell responses were mainly directed against Env, while GPN-specific CD8+<br />
T cell responses were&nbsp;induced preferentially by the MVA-B deletion mutants. Furthermore, antibody levels to Env in the memory phase were&nbsp;slightly enhanced by the MVA-B deletion mutants compared to the parental MVA-B. These findings revealed that double&nbsp;deletion of VACV genes that act blocking intracellularly the IFN signaling pathway confers an immunological benefit,&nbsp;inducing innate immune responses and increases in the magnitude, quality and durability of the HIV-1-specific T cell&nbsp;immune responses. Our observations highlighted the immunomodulatory role of the VACV genes C6L and K7R, and that&nbsp;targeting common pathways, like IRF3/IFN-b signaling, could be a general strategy to improve the immunogenicity of&nbsp;poxvirus-based vaccine candidates.<br />",,"/uploadfiles/file/20131115/20131115172718_1773.pdf",,11/15/2013,11/15/2013,"medicool",36,,"Poxvirus| HIV Vaccine| Immune|CD8+
T cell|CD4+",0,"65",19,"Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways","2013",
483,,"10.1007/s00347-008-1748-5","A. Gericke ・ S. Pitz ・ I. Strempel ・ W. Sekundo","Ophthalmologe","<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ein 41-j?hriger Patient stellte sich aufgrund einer persistierenden Bindehauthyper?mie am linken Auge vor. Seit der Kindheit waren eine schwere Neurodermitis und rezidivierende Keratokonjunktivitiden bekannt. Des Weiteren sei er starker Raucher (20 Packungsjahre).</span> 
</p>",,"/uploadfiles/file/20131122/20131122140232_8644.pdf",,11/22/2013,11/22/2013,"medicool",36,,,0,"85",77,"Bilaterale konjunktivale Plattenepithelneoplasie bei Neurodermitis","2008",
453,,,"Alexandra A. Lambert , Arezki Azzi ., Sheng-Xiang Lin , Genevie `ve Allaire , Karianne P. St-Gelais, Michel J. Tremblay, Caroline Gilbert",,"The HIV-1 pandemic continues to expand while no effective vaccine or cure is yet available. Existing therapies have<br />
managed to limit mortality and control viral proliferation, but are associated with side effects, do not cure the disease and<br />
are subject to development of resistance. Finding new therapeutic targets and drugs is therefore crucial. We have previously<br />
shown that the dendritic cell immunoreceptor (DCIR), a C-type lectin receptor expressed on dendritic cells (DCs), acts as an<br />
attachment factor for HIV-1 to DCs and contributes to HIV-1 transmission to CD4+&nbsp;T lymphocytes (CD4TL). Directly involved<br />
in HIV-1 infection, DCIR is expressed in apoptotic or infected CD4TL and promotes trans-infection to bystander cells. Here<br />
we report the 3D modelling of the extracellular domain of DCIR. Based on this structure, two surface accessible pockets<br />
containing the carbohydrate recognition domain and the EPS binding motif, respectively, were targeted for screening of<br />
chemicals that will disrupt normal interaction with HIV-1 particle. Preliminary screening using Raji-CD4-DCIR cells allowed<br />
identification of two inhibitors that decreased HIV-1 attachment and propagation. The impact of these inhibitors on&nbsp;infection of DCs and CD4TL was evaluated as well. The results of this study thus identify novel molecules capable of&nbsp;blocking HIV-1 transmission by DCs and CD4TL.<br />",,"/uploadfiles/file/20131118/20131118100743_9531.pdf",,11/18/2013,11/18/2013,"medicool",33,,"Dendritic CelAnti-
AIDS Drugl|DCIR/HIV|CD4TL",0,"66",19,"Dendritic Cell Immunoreceptor Is a New Target for Anti- AIDS Drug Development: Identification of DCIR/HIV-1 Inhibitors","2013",
455,"白癜风与食管腺癌共患",,"Ali Asilian, Iman Momeni, Parastou Khosravani","International Journal of Preventive Medicine","<p class=""MsoNormal"">
	<b><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">ABSTRACT </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Vitiligo is a
disease that results in depigmented areas in the skin. It may develop at any
age but the average age at onset is 20 years.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Association of
vitiligo and melanoma has been commonly reported, but
malignancies other than melanoma have been rarely associated with vitiligo. We
report a 73?year?old patient with new onset vitiligo who developed esophageal
adenocarcinoma in the following years.</span> 
</p>
<p class=""MsoNormal"" align=""left"">
	<b><span style=""font-size:14px;line-height:2;"">摘要</span></b><b></b> 
</p>
<span style=""font-size:14px;line-height:2;"">白癜风是引起皮肤色素脱失的一种疾病。白癜风可在任何年龄发病，但其平均发病年龄为</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">20</span><span style=""font-size:14px;line-height:2;"">岁左右。白癜风和黑色素瘤的关系已被广泛报道，但除黑色素瘤以外的其他恶性肿瘤却很少与白癜风有关联。我们报道了一例新发白癜风的</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">73</span><span style=""font-size:14px;line-height:2;"">岁患者，该患者在随后几年患食管腺癌。</span>","/uploadfiles/image/20131119/20131119100531_2622w.jpg","/uploadfiles/file/20131119/20131119100817_5429.pdf",,11/19/2013,11/19/2013,"medicool",51,,"Esophageal adenocarcinoma, vitiligo, thyrosinase, malignant
melanoma",0,"85",28,"Vitiligo Associated with Esophageal Adenocarcinoma","2013","/uploadfiles/kejian/20131119/1119101056_7568.pdf"
454,,,"Iart Luca Shytaj , Barbara Chirullo, Wendeline Wagner , Maria G Ferrari , Rossella Sgarbanti , Alessandro Della Corte, Celia LaBranche, Lucia Lopalco , Anna Teresa Palamara , David Montefiori , Mark G Lewis , Enrico Garaci and Andrea Savarino","BioMed Central","Background: HIV infection persists despite antiretroviral treatment (ART) and is reignited as soon as therapies are&nbsp;suspended. This vicious cycle is fueled by the persistence of viral reservoirs that are invulnerable to standard ART&nbsp;protocols, and thus therapeutic agents able to target these reservoirs are needed. One such agent, auranofin, has&nbsp;recently been shown to decrease the memory T-cell reservoir in chronically SIVmac251-infected macaques.&nbsp;Moreover, auranofin could synergize with a fully suppressive ART protocol and induce a drug-free post-therapy&nbsp;containment of viremia.<br />
Results: We administered buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis currently in clinical&nbsp;trials for cancer, in combination with auranofin to chronically SIVmac251-infected macaques under highly-intensified ART (H-iART). The ART/auranofin/BSO therapeutic protocol was followed, after therapy suspension, by a&nbsp;significant decrease of viral RNA and DNA in peripheral blood as compared to pre-therapy levels. Drug-free post-therapy control of the infection was achieved in animals with pre-therapy viral loads ranging from values&nbsp;comparable to average human set points to levels largely higher. This control was dependent on the presence&nbsp;CD8+&nbsp;cells and associated with enhanced levels of cell-mediated immune responses.<br />
Conclusions: The level of post-therapy viral set point reduction achieved in this study is the largest reported so far&nbsp;in chronically SIVmac251-infected macaques and may represent a promising strategy to improve over the current&nbsp;“ART for life” plight.<br />",,"/uploadfiles/file/20131118/20131118104904_7474.pdf",,11/18/2013,11/18/2013,"medicool",38,,"Functional cure of HIV/AIDS|Viral reservoirs| Eradication research|Antireservoir therapy|Auranofin| Buthionine sulfoximine|SIVmac251 infection|Macaque AIDS model",0,"66",19,"Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS","2013",
457,"复方氟米松软膏治疗神经性皮炎的随机开放试验","10．3760／cma．j ．issn．0412― 4030．2010．02．038","陈连军 马莉 黄雯 陈向东  温海 章伟 郑捷 杨勤萍 徐金华","中华皮肤科杂志","<span style=""line-height:2;font-size:14px;"">&nbsp; &nbsp; 神经性皮炎是一种常见的慢性皮肤病，以剧烈瘙痒和皮</span><span style=""line-height:2;font-size:14px;"">肤局限性苔藓样变为特点</span><span style=""white-space:normal;line-height:2;font-size:14px;"">，</span><span style=""line-height:2;font-size:14px;"">外用糖皮质激素是主要的治疗手</span><span style=""line-height:2;font-size:14px;"">段。复方氟米松软膏是含 0． 02％匹伐酸氟米松及 3％水杨酸</span><span style=""line-height:2;font-size:14px;"">的糖皮质激素复方制剂， 为全面评价其治疗神经眭皮炎的临</span><span style=""line-height:2;font-size:14px;"">床疗效， 我们进行随机</span><span style=""white-space:normal;line-height:2;font-size:14px;"">、</span><span style=""line-height:2;font-size:14px;"">开放、 复方卤米松乳膏作为阳性药物</span><span style=""line-height:2;font-size:14px;"">对照的多中心平行临床试验 。</span><br />","/uploadfiles/image/20131119/20131119162329_6616w.jpg","/uploadfiles/file/20131119/20131119162413_9969.pdf",,11/19/2013,11/19/2013,"medicool",36,,,0,"65",77,,"2010",
458,"采用贝伐单抗治疗一个14岁复发性胶质母细胞瘤男性患者时由皮质类固醇引起的腹部皮纹开裂","10.1177/0883073811428007","Helen Wheeler, Jason Black, Suzanne Webb and Han Shen","Journal of Child Neurology","<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids have been the mainstay for management of </span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">cerebral </span><span style=""font-size:14px;"">edema caused by leaky angiogenic vessels</span></span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;&quot;;""> <span style=""font-size:14px;"">associated with high-grade brain tumors </span><span style=""font-size:14px;"">since </span><span style=""font-size:14px;"">the early 1960s</span></span></span></span></span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;font-size:14px;"">.</span></span></span></span></span><span><span><span style=""font-family:&quot;&quot;;""> <span><span><span><span style=""font-size:14px;"">Chronic </span><span style=""font-size:14px;"">corticosteroid use can cause iatrogenic Cushing syndrome</span></span></span></span><span><span><span style=""font-size:14px;"">, which </span><span style=""font-size:14px;"">is associated with weight gain and abdominal striae (striae distensae)</span></span></span><span style=""font-size:14px;"">. </span><span><span style=""font-size:14px;"">The </span><span style=""font-size:14px;"">antiCvascular endothelial growth factor therapy, bevacizumab, has recently been </span><span style=""font-size:14px;"">introduced for the management of recurrent glioblastoma. </span></span><span><span style=""font-size:14px;"">Vascular </span><span style=""font-size:14px;"">endothelial growth factor plays multiple roles in wound healing, including </span><span style=""font-size:14px;"">promoting angiogenesis, acting as a chemo-attractant for inflammatory cells, </span><span style=""font-size:14px;"">and stimulating collagen production</span></span><span style=""font-size:14px;"">. We report the first pediatric </span><span style=""font-size:14px;"">case of </span><span style=""font-size:14px;"">a 14-year-old boy with corticosteroid-induced abdominal striae </span><span><span><span><span style=""font-size:14px;"">who developed ulceration and dehiscence of the </span><span style=""font-size:14px;"">striae following the introduction of bevacizumab therapy</span></span></span></span><span style=""font-size:14px;"">. </span><span><span style=""font-size:14px;"">The </span><span style=""font-size:14px;"">combination of high-dose corticosteroids and antiCvascular endothelial growth </span><span style=""font-size:14px;"">factor therapy may cause significant complications, especially in </span></span><span><span style=""font-size:14px;""><span style=""font-size:14px;"">children </span></span><span style=""font-size:14px;"">who are susceptible to abdominal striae</span></span><span style=""font-size:14px;""> and therefore should be </span><span style=""font-size:14px;"">avoided.</span><br />
<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></span><span style=""color:#313131;font-family:宋体;""><span style=""font-size:14px;"">自二十世纪</span><span style=""font-size:14px;"">60</span><span style=""font-size:14px;"">年代早期以来，</span></span><span style=""font-family:宋体;""><span style=""font-size:14px;"">皮质类固醇一直是由新生血管渗漏引起脑水肿的（与高分级脑肿瘤相关的）主要管理手段。长期使用皮质类固醇会导致医源性库欣综合征，它与体重增加和腹部皮纹（萎缩纹）有关。作为复发性胶质母细胞瘤的管理手段，抗血管内皮生长因子治疗法（贝伐单抗）在最近被引进。血管内皮生长因子在伤口愈合时起着多重作用，包括促进血管新生，作为炎性细胞的一个化学诱体，以及促进胶原蛋白生成。我们报道了首例由于皮质类固醇引起腹部皮纹的</span><span style=""font-size:14px;"">14</span><span style=""font-size:14px;"">岁男性儿科病例，随着贝伐单抗疗法的应用，患者出现了溃疡和皮纹开裂。高剂量皮质类固醇和抗血管内皮生长因子治疗方法相结合时，可能会导致显著并发症，尤其是易患腹部皮纹的儿童，因此应加以避免。</span><span style=""display:none;"" id=""__kindeditor_bookmark_end_54__""></span><span></span></span> 
</p>
<br />
<br />","/uploadfiles/image/20131121/20131121131536_8849w.png","/uploadfiles/file/20131121/20131121131608_5530.pdf",,11/21/2013,11/21/2013,"medicool",25,,"striae, bevacizumab, antiCvascular endothelial growth factor, corticosteroids, glioblastoma",0,"85",102,"Dehiscence of Corticosteroid-Induced Abdominal Striae in a 14-Year-Old Boy Treated With Bevacizumab for Recurrent Glioblastoma","2012",
460,"针刺疗法治疗萎缩纹：一项初步研究","10.1111/j.1524-4725.2012.02552.x","KUI YOUNG PARK, MD, PHD,HYUN KYU KIM, MD,SUNG EUN KIM, MD","the American Society for Dermatologic Surgery","<p align=""justify"">
	<span style=""font-size:14px;""><b><span style=""font-family:&quot;&quot;;font-size:14px;"">BACKGROUND：</span></b></span><span><span><span style=""font-family:&quot;&quot;;""> <br />
<span style=""font-size:14px;"">Striae distensae are dermal scars characterized by flattening and atrophy of the epidermis</span><span style=""font-size:14px;"">. Although many treatment modalities have been attempted with variable results,</span><span style=""font-size:14px;""> there is no criterion standard treatment modality for striae distensae.</span></span></span></span> <br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:宋体;font-size:14px;"">研究背景：</span></b></span></span><span><span><b><span style=""font-family:&quot;&quot;;""></span></b></span></span><span style=""font-size:14px;"">&nbsp;</span><br />
<span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">萎缩纹是以表皮压扁和萎缩为特征的皮肤疤痕。尽管许多治疗方法已经被试用并得到了不同的结果，但目前并无萎缩纹的标准治疗方法。</span></span></span><span><span><span style=""font-family:&quot;&quot;;""></span></span></span><span style=""font-size:14px;"">&nbsp;</span><br />
<b><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">OBJECTIVES：</span><br />
</span></b><span style=""font-family:&quot;&quot;;font-size:14px;""> To evaluate the effectiveness and safety of a disk microneedle therapy system (DTS) in the treatment of striae distensae.</span><span style=""font-size:14px;"">&nbsp;&nbsp;</span><br />
<strong></strong><strong><span style=""font-size:14px;"">研</span></strong><span style=""font-family:宋体;font-size:14px;""><strong>究目的：</strong></span><strong><span style=""font-size:14px;"">&nbsp;</span></strong><br />
<span style=""font-family:宋体;""><span style=""font-size:14px;"">旨在评估萎缩纹治疗中</span><span style=""font-size:14px;"">磁盘微针治疗系统</span></span><span></span><span></span><span style=""font-family:&quot;&quot;;font-size:14px;"">(DTS)</span><span style=""font-family:宋体;font-size:14px;"">的有效性和安全性。</span><span style=""font-family:&quot;&quot;;""></span><span style=""font-size:14px;"">&nbsp;</span><br />
<span><b><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">MATERIALS&nbsp;AND METHOD</span><br />
</span></b></span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">Sixteen Korean volunteers with</span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""> striae distensae alba or rubra</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""> were enrolled.</span></span><span style=""font-size:14px;""> Patients received three treatments using a DTS at 4-week intervals. </span><span><span style=""font-size:14px;"">Clinical response to treatment was assessed by comparing pre-and post-treatment clinical photographs, skin biopsies, and</span><br />
<span style=""font-size:14px;""> patient satisfaction scores.</span></span> <span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">Clinical improvement</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""> was assessed using the quartile grading scale.</span></span></span><span style=""font-size:14px;"">&nbsp;</span><br />
<b><span style=""font-family:宋体;font-size:14px;"">材料和方法</span></b><span style=""font-family:宋体;font-size:14px;"">：</span><span style=""font-family:&quot;&quot;;""></span><span style=""font-size:14px;"">&nbsp;</span><br />
<span style=""font-family:&quot;&quot;;""><span style=""font-family:Tahoma;font-size:14px;"">1</span><span style=""font-size:14px;"">6</span></span><span style=""font-family:宋体;font-size:14px;"">名患红色或白色萎缩纹的韩国志愿者参加试验。采用</span><span style=""font-family:&quot;&quot;;font-size:14px;"">DTS</span><span style=""font-family:宋体;font-size:14px;"">对患者进行了</span><span style=""font-family:&quot;&quot;;font-size:14px;"">3</span><span style=""font-family:宋体;font-size:14px;"">次治疗（每隔</span><span style=""font-family:&quot;&quot;;font-size:14px;"">4</span><span style=""font-family:宋体;font-size:14px;"">周）。通过比较治疗前和治疗后的临床照片、皮肤活组织切片检查和病人满意度得分，我们对治疗的临床结果进行评估。采用四分分级量表对临床效果进行评估。</span><span style=""font-family:&quot;&quot;;""></span><span style=""font-size:14px;"">&nbsp;</span><br />
<span style=""font-size:14px;"">&nbsp;</span><b><span style=""font-family:&quot;&quot;;font-size:14px;"">RESULTS</span></b><span style=""font-family:&quot;&quot;;""> <br />
<span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">Marked to excellent improvement was noted in seven (43.8%) patients, with minimal to moderate improvement in the remaining nine</span></span></span><span><span><span style=""font-size:14px;"">. </span><span style=""font-size:14px;"">Patient satisfaction scores showed that six (37.5%) patients were highly satisfied</span><span style=""font-size:14px;"">, eight (50.0%) were somewhat satisfied, and two (12.5%) were unsatisfied.</span><span><span style=""font-size:14px;"">There were no significant side effects except mild pain, erythema, and spotty bleeding.</span><br />
</span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:宋体;font-size:14px;"">结果：</span></b></span></span><span><span><b><span style=""font-family:&quot;&quot;;""></span></b></span></span><span style=""font-size:14px;"">&nbsp;</span><br />
<span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">结果显示其中</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">7</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">位</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">(43.8%)</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">患者得到显著改善，剩下</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">9</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">例有轻微改善。患者满意度得分显示，</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">6</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">位（</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">37.5%</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">）患者非常满意，</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">8</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">位患者（</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">50%</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">）基本满意，</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">2</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">位患者（</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">12.5%</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">）不满意。除轻微疼痛、红斑和点状出血外无明显副作用.</span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:&quot;&quot;;font-size:14px;"">CONCLUSION</span></b><span style=""font-family:&quot;&quot;;""> <br />
<span style=""font-size:14px;""></span><span><span style=""font-size:14px;"">Disk microneedle therapy system (DTS) can be </span><span style=""font-size:14px;"">effectively and safely used in the treatment of striae distensae.</span></span></span> 
</p>
<p align=""justify"">
	<b><span style=""font-family:宋体;font-size:14px;"">结论：</span></b><b><span style=""font-family:&quot;&quot;;""></span></b><span style=""font-size:14px;"">&nbsp;</span><span style=""font-size:14px;"">&nbsp;</span><br />
<span style=""font-family:宋体;font-size:14px;"">磁盘微针治疗系统（</span><span style=""font-family:&quot;font-size:10.5pt;font-size:14px;"">DTS</span><span style=""font-family:宋体;font-size:14px;"">）可以安全有效地用于萎缩纹治疗。</span>
</p>","/uploadfiles/image/20131121/20131121135828_3622w.png","/uploadfiles/file/20131121/20131121135904_4919.pdf",,11/21/2013,11/21/2013,"medicool",24,,,0,"65",102,"Treatment of Striae Distensae Using Needling Therapy:A Pilot Study","2012",
462,"外用封包疗 法治疗神经性皮炎 32 例疗效观察","1000~ 817( 2007)l1-1054- 01","陈大鸣","中国学校卫生","<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; 神经性皮炎是一种皮肤神经功能障碍的慢性皮肤病 ， 临床</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">上十分常见。据相关文献报道， 此病约占皮肤科初诊病例的</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">2.1％ 7.7％，多发于颈项、肘部、眉 窝 、骶部等处?。开始为</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">瘙痒，继为扁平丘疹，皮肤逐渐增厚，</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">形成苔藓样变损害。自觉</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">夜间阵发性剧痒，患者常因此失眠，且情绪烦躁 ，从而影响正常</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">的学习和生活。笔者根据多年的临床经验，应用自创的封包疗</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">法外用治疗神性皮炎共32例，疗效满意，现报道如下。 &nbsp;</span><br />","/uploadfiles/image/20131121/20131121141245_0221w.jpg","/uploadfiles/file/20131121/20131121141440_3687.pdf",,11/21/2013,11/21/2013,"medicool",17,,,0,"85",77,,"2007",
463,"分段式微针射频和点阵二氧化碳激光器联合改善韩国患者的萎缩纹","10.1111/dsu.12268","HAN-WONRYU,MD, SUNG-AEKIM,MD,PHD,HYE RA JUNG,MDYOUNG-WOOKRYOO,MD,PHD","the American Society for Dermatologic Surgery","<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><strong>BACKGROUND</strong><br />
</span><span style=""font-size:14px;"">Striae distensae are dermal scars with flattening and atrophy of the epidermis.</span> 
</p>
<p style=""text-align:left;vertical-align:baseline;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><strong>背景</strong></span><span style=""font-size:14px;""> <strong>&nbsp;&nbsp;</strong></span> 
</p>
<p style=""text-align:left;vertical-align:baseline;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;"">萎缩纹是指表皮层扁平萎缩的皮肤疤痕。</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><strong>OBJECTIVE</strong></span><br />
<span style=""font-size:14px;"">T</span><span style=""font-size:14px;"">o </span><span style=""font-size:14px;"">evaluate the efficacy and safety of </span><span style=""font-size:14px;"">combination therapy</span><span style=""font-size:14px;""> with fractionated microneedle radiofrequency (RF) and fractional carbon dioxide </span><span style=""font-size:14px;"">(CO</span><span style=""font-size:14px;"">2</span><span style=""font-size:14px;"">) </span><span style=""font-size:14px;"">laser in the treatment of striae distensae.</span> 
</p>
<p style=""text-align:left;vertical-align:baseline;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><strong>研究目的</strong></span><span style=""font-size:14px;""><strong>&nbsp;</strong>&nbsp; </span> 
</p>
<p style=""text-align:left;vertical-align:baseline;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;"">旨在评估分段式微针射频</span><span style=""font-size:14px;"">(RF)</span><span style=""font-size:14px;"">和点阵二氧化碳</span><span style=""font-size:14px;"">(CO</span><span style=""font-size:14px;"">2</span><span style=""font-size:14px;"">)</span><span style=""font-size:14px;"">激光器联合治疗萎缩纹的有效性和安全性。</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><strong>MATERIALS AND METHODS</strong></span> <br />
<span style=""font-size:14px;"">Thirty patients (30 female; mean age 33, range 21</span><span style=""font-size:14px;"">C</span><span style=""font-size:14px;"">51, </span><span style=""font-size:14px;"">Fitzpatrick</span><span style=""font-size:14px;""> skin type IV)with </span><span style=""font-size:14px;"">moderate to severe striae distensae were enrolled in this study. Patients were </span><span style=""font-size:14px;"">divided into three groups: fractional CO</span><span style=""font-size:14px;"">2 </span><span style=""font-size:14px;"">laser only (</span><span style=""font-size:14px;"">n </span><span style=""font-size:14px;"">= </span><span style=""font-size:14px;"">10), microneedle RF only (</span><span style=""font-size:14px;"">n </span><span style=""font-size:14px;"">= </span><span style=""font-size:14px;"">10), and combination (</span><span style=""font-size:14px;"">n </span><span style=""font-size:14px;"">= </span><span style=""font-size:14px;"">10).</span> 
</p>
<p style=""text-align:left;vertical-align:baseline;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><strong>材料和方法</strong></span><span style=""font-size:14px;""><strong>&nbsp; </strong></span> 
</p>
<p style=""text-align:left;vertical-align:baseline;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;"">三十例患有中度至重度萎缩纹的患者被纳入此项研究（</span><span style=""font-size:14px;"">30</span><span style=""font-size:14px;"">例女性，平均年龄</span><span style=""font-size:14px;"">33</span><span style=""font-size:14px;"">岁，年龄范围在</span><span style=""font-size:14px;"">21</span><span style=""font-size:14px;"">到</span><span style=""font-size:14px;"">51</span><span style=""font-size:14px;"">之间，</span><span style=""font-size:14px;"">Fitzpatrick</span><span style=""font-size:14px;"">皮肤类型</span><span style=""font-size:14px;"">IV</span><span style=""font-size:14px;"">）。患者被分为三组：仅用点阵</span><span style=""font-size:14px;"">CO</span><span style=""font-size:14px;"">2</span><span style=""font-size:14px;"">激光组（</span><span style=""font-size:14px;"">N = 10</span><span style=""font-size:14px;"">），仅用微针</span><span style=""font-size:14px;"">RF</span><span style=""font-size:14px;"">组（</span><span style=""font-size:14px;"">N = 10</span><span style=""font-size:14px;"">），以及联合治疗组（</span><span style=""font-size:14px;"">N</span><span style=""font-size:14px;"">= 10</span><span style=""font-size:14px;"">）。</span> 
</p>
<p style=""text-align:left;vertical-align:baseline;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><strong>RESULTS</strong></span><br />
<span style=""font-size:14px;"">Improvement was evaluated using a visual analogue scale </span><span style=""font-size:14px;"">(range 1</span><span style=""font-size:14px;"">C</span><span style=""font-size:14px;"">4). Mean clinical improvement score of the dermatologist was 2.2 in the fractional CO</span><span style=""font-size:14px;"">2 </span><span style=""font-size:14px;"">laser</span><span style=""font-size:14px;"">C</span><span style=""font-size:14px;"">treated group, 1.8 in the microneedle RF</span><span style=""font-size:14px;"">C</span><span style=""font-size:14px;"">treated group, and 3.4 in the combination group. Through skin biopsy, we observed thickened epidermis and a </span><span style=""font-size:14px;"">clear </span><span style=""font-size:14px;"">increase </span><span style=""font-size:14px;"">in the number of collagen fibers in the microneedle RF</span><span style=""font-size:14px;"">C </span><span style=""font-size:14px;"">and fractional CO</span><span style=""font-size:14px;"">2 </span><span style=""font-size:14px;"">combination</span><span style=""font-size:14px;"">C</span><span style=""font-size:14px;"">treated sites. Consistent with these results, greater expression of transforming growth factor-</span><span style=""font-size:14px;"">b</span><span style=""font-size:14px;"">1 and stratifin was observed in treated sites.</span> 
</p>
<p style=""text-align:left;vertical-align:baseline;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><strong>结果</strong></span><span style=""font-size:14px;"">&nbsp; </span> 
</p>
<p style=""text-align:left;vertical-align:baseline;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;"">采用视觉模拟评分完善评估（范围</span><span style=""font-size:14px;"">1―4</span><span style=""font-size:14px;"">），皮肤科医生给出的点阵</span><span style=""font-size:14px;"">CO</span><span style=""font-size:14px;"">2</span><span style=""font-size:14px;"">激光治疗组的平均治疗效果得分为</span><span style=""font-size:14px;"">2.2</span><span style=""font-size:14px;"">，微针</span><span style=""font-size:14px;"">RF</span><span style=""font-size:14px;"">治疗组为</span><span style=""font-size:14px;"">1.8</span><span style=""font-size:14px;"">，联合治疗组为</span><span style=""font-size:14px;"">3.4</span><span style=""font-size:14px;"">。通过皮肤活检，我们观察到在微针射频和点阵</span><span style=""font-size:14px;"">CO</span><span style=""font-size:14px;"">2</span><span style=""font-size:14px;"">结合治疗位点处表皮增厚、胶原纤维数明显增加。与这些结果相一致，治疗位点处可以观察到细胞转化因子</span><span style=""font-size:14px;"">-β1</span><span style=""font-size:14px;"">与人分层蛋白的大量表达。</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><strong>CONCLUSION</strong></span><br />
<span style=""font-size:14px;"">Combination therapy of fractionated microneedle RF and fractional CO</span><span style=""font-size:14px;"">2 </span><span style=""font-size:14px;"">laser is a safe treatment </span><span style=""font-size:14px;"">protocol with a positive therapeutic effect on striae distensae.</span><br />
<span style=""font-size:14px;""><strong>结论</strong></span><span style=""font-size:14px;"">&nbsp;</span><br />
<span style=""font-size:14px;"">分段式微针射频和点阵二氧化碳激光器的联合治疗是一项对萎缩纹有积极疗效的安全治疗方案。</span>&nbsp;
</p>","/uploadfiles/image/20131121/20131121154642_9968w.jpg","/uploadfiles/file/20131121/20131121152252_8175.pdf",,11/21/2013,11/21/2013,"medicool",29,,"Striae Distensae ，fractional CO2 laser，microneedle RF",0,"66",102,"Clinical Improvement of Striae Distensae in Korean Patients Using a Combination of Fractionated Microneedle Radiofrequency and Fractional Carbon Dioxide Laser","2013",
459,"激光和光治疗萎缩纹","10.1007/s10103-013-1342-1","J. A. Savas & J. A. Ledon & K. Franca & K. Nouri","Springer-Verlag London","<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#131413;font-family:&quot;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Striae distensae (SD) or </span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#131413;font-family:&quot;font-size:14px;"">“</span></span></span></span></span><span><span><span><span><span style=""color:#131413;font-family:&quot;font-size:10pt;""><span style=""font-size:14px;"">stretch </span><span style=""font-size:14px;"">marks</span></span></span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#131413;font-family:&quot;font-size:14px;"">” </span></span></span></span></span><span><span><span><span><span style=""color:#131413;font-family:&quot;font-size:10pt;""><span style=""font-size:14px;"">are a common </span><span style=""font-size:14px;"">and well-recognized dermatologic entity affecting patients of all ages, genders, </span><span style=""font-size:14px;"">and ethnicities</span></span></span></span></span></span><span><span><span style=""color:#131413;font-family:&quot;font-size:10pt;""><span style=""font-size:14px;"">. </span><span style=""font-size:14px;""><span style=""font-size:14px;"">The treatment of SD has long been </span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">plagued</span></span></span></span><span><span><span><span style=""font-size:14px;""> by disappointing outcomes and remains a </span><span style=""font-size:14px;"">frustrating entity for both physicians and patients.</span></span></span></span> <span><span style=""font-size:14px;"">While </span><span style=""font-size:14px;"">striae may become less conspicuous over time, they rarely resolve without </span><span style=""font-size:14px;"">intervention.</span></span> <span><span style=""font-size:14px;"">Inspired by the success of lasers for the </span><span style=""font-size:14px;"">treatment of scars and rhytides, these devices have been applied to the </span><span style=""font-size:14px;"">treatment of SD in the hopes of achieving similar efficacy.</span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""color:#131413;font-family:宋体;font-size:14px;"">&nbsp;&nbsp;&nbsp;萎缩纹</span><span style=""color:#131413;font-family:&quot;font-size:14px;"">(SD)</span><span style=""color:#131413;font-family:宋体;font-size:14px;"">或</span><span style=""color:#131413;font-family:&quot;font-size:14px;"">“</span><span style=""color:#131413;font-family:宋体;font-size:14px;"">妊娠纹</span><span style=""color:#131413;font-family:&quot;font-size:14px;"">”</span><span style=""color:#131413;font-family:宋体;font-size:14px;"">是一种常见和公认的皮肤病实体，它影响所有年龄、性别和种族的患者。</span><span style=""color:#131413;font-family:&quot;font-size:14px;"">SD</span><span style=""color:#131413;font-family:宋体;font-size:14px;"">的治疗长期以来一直被令人失望的结果困扰着，因此对于医生和患者来说仍然是一种令人沮丧的皮肤病实体。虽然皮纹可能随着时间的推移变得不那么显眼，但它们在没有介入治疗的情况下很少消退。受激光成功治疗疤痕和皱纹的启发，这些设备已被用于治疗</span><span style=""color:#131413;font-family:&quot;font-size:14px;"">SD</span><span style=""color:#131413;font-family:宋体;font-size:14px;"">以期望获得类似的疗效。</span><span style=""color:#131413;font-family:&quot;font-size:10pt;""></span> 
</p>
<br />
<br />","/uploadfiles/image/20131121/20131121132420_1098w.png","/uploadfiles/file/20131121/20131121132541_1676.pdf",,11/21/2013,11/21/2013,"medicool",32,,"Laser . Treatment . Striae distensae .Striae rubra . Striae alba . Stretch marks",0,"67",102,"Lasers and lights for the treatment of striae distensae","2013",
461,"医学共振音乐疗法对银屑病和神经性皮炎的影响――一项试验研究",,"ILYA LAZAROFF , RAPHAEL SHIMAHONI",,"<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Abstract.</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><span style=""font-size:14px;line-height:2;"">Stress
medicine has shown that emotional disharmony can be a substantial factor for
skin diseases.</span><a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a> <a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span style=""font-size:14px;line-height:2;"">The </span><a name=""OLE_LINK26""></a><span style=""font-size:14px;line-height:2;"">harmonization of the emotional status and </span><a name=""OLE_LINK27""></a><span style=""font-size:14px;line-height:2;"">a corresponding
reduction of stress hormones by the Medical Resonance Therapy Music as
shown in other studies (1,2,3,4) inspired us to investigate its benefits for
patients with psoriasis vulgaris and neurodermatitis.</span><a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a> <a name=""OLE_LINK29""></a><a name=""OLE_LINK28""></a><span style=""font-size:14px;line-height:2;"">Over a period of 14
days we measured the parameters of the bloods pressure, heart rate, stimulus to
scratch and the degree of sickness in two, </span><a name=""OLE_LINK31""></a><a name=""OLE_LINK30""></a><span style=""font-size:14px;line-height:2;"">respectively four
groups of 68 patients in total: two experimental groups and two
control groups. </span><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span style=""font-size:14px;line-height:2;"">All
patients received the normal treatment of our hospital, the experimental groups
were additional treated with 3×30 minutes of MRT-Music per day, while the
controls were asked to somehow relax during this time. </span><a name=""OLE_LINK32""></a><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span style=""font-size:14px;line-height:2;"">In the
experimental groups the measurements showed a reduction of blood pressure and
the heart rate and revealed </span><a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span style=""font-size:14px;line-height:2;"">an enhanced </span><a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span style=""font-size:14px;line-height:2;"">reduction of the stimulus to
scratch and an enhanced reduction in the
degree of sickness. </span><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span style=""font-size:14px;line-height:2;"">Interestingly
the effects of MRT-Music were stronger with the psoriasis patients than with
the neurodermatitis patients. </span><a name=""OLE_LINK37""></a><a name=""OLE_LINK36""></a><a name=""OLE_LINK35""></a><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><span style=""font-size:14px;line-height:2;"">The
results of this pilot study convinced us to offer the treatment with the
Medical Resonance Therapy Music to all our patients.</span><br />
<span style=""font-size:14px;line-height:2;""></span><b style=""text-indent:21pt;line-height:1.5;""><span style=""font-size:14px;line-height:2;"">概要：</span></b>
	<p class=""MsoNormal"">
		<b></b>
	</p>
	<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
		<span style=""font-size:14px;line-height:2;"">应力医学已经表明，感情不和谐可能是导致皮肤疾病的主要因素。在其他研究中（1,2,3,4）显示，通过医学共振音乐疗法，促使了情感状态融洽，应激激素相应的减少，这启发我们去研究它对治疗寻常型银屑病和神经性皮炎患者的益处。试验分为四组共有68名患者：两个实验组和两个对照组，14天后，我们在两组中测量血压、心率、刺激划伤和患病程度的参数。所有患者都接受了我们医院的常规治疗，实验组每天额外接受MRT-Music（医学共振音乐）治疗3次，每次30分钟，而对照组要求在这段时间内以某种方式保持放松。实验组的测量结果表明血压和心率降低，有效减少刺激划伤以及和降低疾病的严重程度。有趣的是，医学共振音乐疗法对银屑病患者的作用效果强于神经性皮炎患者。这项试验研究结果使我们确信医学共振音乐疗法适用于我们所有的患者。</span>
	</p>
</p>","/uploadfiles/image/20131121/20131121140327_0716w.jpg","/uploadfiles/file/20131121/20131121140403_9344.pdf",,11/21/2013,11/21/2013,"medicool",17,,,0,"66",77,"Effects of Medical Resonance Therapy Music on Patients with Psoriasis and Neurodermatitis―A Pilot Study",,
59,"痤疮分析、分级和计算评估方法概述","10.1111/j.1600-0846.2011.00542.x","Roshaslinie Ramli, Aamir Saeed Malik, Ahmad Fadzil Mohamad Hani and Adawiyah Jamil","Skin Research and Technology","<strong> 
<p class=""MsoNormal"">
	<strong><span style=""color:#4D4D4D;"">Objectives: </span></strong><span style=""color:#4D4D4D;""><br />
&nbsp;&nbsp;&nbsp; To review and identify the issues for acne vulgaris grading
and computational assessment methods. To determine the future direction for <a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span>addressing
the identified issues.</span></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;color:#4D4D4D;"">研究目的</span></b><b><span style=""color:#4D4D4D;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;color:#4D4D4D;"">对寻常痤疮分级以及其计算评估方法的回顾和鉴定。为解决已认定的问题确定未来走向。</span><span style=""color:#4D4D4D;""><br />
<strong>Methods:</strong><br />
&nbsp;&nbsp; There are two main methods of assessment for acne severity
grading, namely, lesion counting and comparison of patient with a <a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span>photographic
standard</span>. For the computational assessment method, the emphasis is
on computational imaging techniques.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;color:#4D4D4D;"">研究方法</span></b><b><span style=""color:#4D4D4D;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;color:#4D4D4D;"">对于痤疮严重程度的分级，存在两个主要的评估方法，即皮损计数和采用摄影标准对患者的对比。就计算评估方法而言，重点是计算成像技术。</span><span style=""color:#4D4D4D;""><br />
<strong>Results:</strong><br />
&nbsp;&nbsp;&nbsp; Current acne grading methods are very time consuming and
tedious. Generally, they rely on approximation for counting lesions and hence
the assessment is quite subjective, with both inter and intra-observer
variability. It is important to accurately assess acne grade to evaluate its
severity as this influences treatment selection and assessment of response to
therapy. This will further help in better disease management and more
efficacious treatment.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;color:#4D4D4D;"">研究结果</span></b><span style=""color:#4D4D4D;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;color:#4D4D4D;"">当前的痤疮分级方法很费时且冗长。通常，这些方法都依据对皮损的近似计数，因此评估相当主观，内部和外部观察员都具有可变性。对评估痤疮严重程度的分级的准确评价很重要，因为它影响治疗选择以及影响对疗效的评定。这将进一步有助于更好的疾病管理和更有效的治疗。</span><span style=""color:#4D4D4D;""><br />
<strong>Conclusion: </strong><br />
&nbsp;&nbsp;&nbsp; Semi-automated or automated methods based on computational
imaging techniques should be devised for acne grade assessment.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;color:#4D4D4D;"">研究结论</span></b><b><span style=""color:#4D4D4D;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;color:#4D4D4D;"">依据计算成像技术的半自动</span><span style=""color:#4D4D4D;"">/</span><span style=""font-family:宋体;color:#4D4D4D;"">自动方法应当被设计应用于痤疮分级评估。</span><span style=""color:#4D4D4D;""></span> 
</p>
</strong>","/uploadfiles/image/20130925/20130925160615_3019w.png","/uploadfiles/file/20130925/20130925160822_7385.pdf",,09/25/2013,10/08/2013,"medicool",82,,"acne vulgaris ；acne types ； acne lesions；acne grading ； acne treatment； acne therapy ； acne imaging methods",0,"67",54,"Acne analysis, grading and computational assessment methods: an overview","2011",
64,"线状皮肤型红斑狼疮六例","10．3760／cma．j．issn．0412-4030．2010．06．","罗燕 李晓建 黄琼","中华皮肤科杂志","<strong>目的</strong><br />
&nbsp;&nbsp;&nbsp; 探讨线状皮肤型红斑狼疮(LCLE)临床和组织病理学特点。<br />
<strong>方法</strong><br />
&nbsp;&nbsp;&nbsp; 回顾分析6例LCLE的临床和病理学特点。<br />
<strong>结果</strong><br />
&nbsp;&nbsp;&nbsp; LCLE多单侧发病，表现为带状或线状分布的暗红斑，伴毛细血管增生扩张，部分黏着性鳞屑。组织病理学诊断依据为真皮浅、深丛细血管周围及毛囊、皮脂腺、汗腺周围有致密团块状淋巴细胞浸润，部分病例可见表皮角化不全，毛囊角栓，基底细胞液化变性，类似盘状红斑狼疮组织像。治疗以氯喹为首选，对于皮疹范围较广泛，且组织病理改变见淋巴细胞浸润达真皮深部甚至皮下脂肪小叶处的患者，给予小剂量糖皮质激素治疗疗效明显。<br />
<strong>结论</strong><br />
&nbsp;&nbsp;&nbsp; LCLE诊断需要结合临床和组织病理。","/uploadfiles/image/20130925/20130925165459_2463w.png","/uploadfiles/file/20130925/20130925165504_4255.pdf",,09/25/2013,09/30/2013,"medicool",56,,"红斑狼疮，皮肤；皮肤表现；病理学",0,"85",3,,"2010",
100,,"10.2340/00015555-1110","Peter JENSEN, Claus ZACHARIAE, Peter R. HANSEN and Lone SKOV","Acta Derm Venereol","&nbsp;&nbsp;&nbsp; Evidence is increasing that severe psoriasis is an independent cardiovascular risk factor. Results from casecontrol studies of endothelial dysfunction, a marker of early atherosclerosis, in patients with moderate-to-severe psoriasis have been conflicting and were conducted with operator-dependent and technically demanding ultrasound measurement of brachial artery flow-mediated vasodilation. Therefore, we decided to measure endothelial function and other cardiovascular risk factors in patients with mild-to-moderate psoriasis (n=30) and controls (?=30) using a newer and relatively operator-independent technique. No difference was detected between the groups with regards to endothelial function. However, despite the patients experiencing rather mild psoriasis they did exhibit higher levels of certain cardiovascular risk factors, including waist circumference, resting heart rate, systolic and diastolic blood pressures, and plasma levels of triglycérides, very-low-density lipoprotein cholesterol and glycated glucose, compared with controls. This indicates that even mild-to-moderate psoriasis may<br />
be regarded as a systemic inflammatory disease, and that an increased risk of cardiovascular morbidity may be present in these mild-to-moderately affected patients in the long-term.",,"/uploadfiles/file/20130906/20130906151549_5441.pdf",,09/30/2013,10/08/2013,"medicool",29,,"psoriasis; endothelial function; atherosclerosis; co-morbidity",0,"66",26,"Normal Endothelial Function in Patients with Mild-to-Moderate Psoriasis: A Case-control Study","2011",
61,,"10.1111/j.1365-2133.2011.10598.x","C.W. Choi, J.W. Choi,K.C. Park and S.W. Youn","British Journal of Dermatology","<strong>Background </strong><br />
&nbsp;&nbsp;&nbsp; The ultraviolet (UV)-induced red fluorescence of patients with acne has been considered to be caused by Propionibacterium acnes.<br />
<strong>Objectives</strong><br />
&nbsp;&nbsp; To study the correlation of the facial red fluorescence with the casual sebum level and the number of acne lesions and to investigate the difference in clinical features, according to both distribution and proportion of fluorescence.<br />
<strong>Methods</strong><br />
&nbsp;&nbsp;&nbsp; A total of 878 patients clinically diagnosed with acne vulgaris were included. Inflammatory and noninflammatory acne lesions were counted separately. UV fluorescent photography and casual sebum level measurements were performed. UV-induced fluorescence patterns were classified according to the facial distribution. The proportions of UV-induced red fluorescence were calculated.<br />
<strong>Results</strong><br />
&nbsp;&nbsp;&nbsp; We identified six different fluorescence distribution patterns in the T-zone(the forehead, nose and chin) and three different patterns in the U-zone (both cheeks). The proportion of fluorescence in the U-zone showed a positive correlation<br />
with the casual sebum level and the number of acne lesions. In the T-zone, the fluorescence proportion correlated with the casual sebum level, but not with the number of acne lesions. As the patients’ age and the age at onset increased, the distribution of fluorescence changed from the upper part of the T-zone to the lower part, and to the centre of the face in the U-zone.<br />
<strong>Conclusions</strong><br />
&nbsp;&nbsp; Our results support the hypothesis that the origin of facial red fluorescence is sebum. In patients with acne, analyses of the pattern and proportion of UV-induced red fluorescence can be useful for evaluating the sebum secretion and selecting efficient treatment modalities.",,"/uploadfiles/file/20130925/20130925163600_5379.pdf",,09/25/2013,10/14/2013,"medicool",32,,,0,"65",54,"Ultraviolet-induced red fluorescence of patients with acne reflects regional casual sebum level and acne lesion distribution: qualitative and quantitative analyses of facial fluorescence","2011",
153,"带状疱疹及其疫苗接种的临床综述","10.2146/ajhp090118","Adams EN ; Parnapy S ; Bautista P","American Journal Of Health-System Pharmacy: AJHP: Official Journal Of The American Society Of Health-System Pharmacists","<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Purpose</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">目的</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">Herpes zoster, herpes
zoster vaccine, and the cost-effectiveness of the vaccine are reviewed. </span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">旨在对带状疱疹、带状疱疹疫苗及其成本效益进行综述。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Summary</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">概要</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">Herpes zoster
infection is estimated to affect one in three people during their lifetime. Two
thirds of people who develop this disease are over age 60 years. Postherpetic
neuralgia (PHN) is the most common complication of herpes zoster, occurring in
10C18% of patients. The associated chronic pain can be very debilitating,
affecting patients’ quality of life. The pain may last for months or years and
is difficult to treat, leading to increased health care costs and morbidity. To
prevent herpes zoster, a live attenuated vaccine was developed and approved for
marketing in 2006 for individuals age ≥60 years. The safety and efficacy of the
vaccine were evaluated in the Shingles Prevention Study in 38,546 adults age
≥60 years. Compared with placebo, administration of the vaccine resulted in a
51.3% reduction in the incidence of herpes zoster and a 66.5% reduction in the
incidence of PHN (p &lt; 0.001 for both comparisons). A single dose of the
vaccine is approximately $162 and is not covered by all insurance plans.
Several studies evaluated the cost-effectiveness of the vaccine, which was
found to be most beneficial in individuals age 70 years or older. The use of
the vaccine appears to reduce health care costs and protect the public health. </span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">估计三分之一的人会在其一生中感染带状疱疹的病毒，而三分之二的人会在</span><span style=""font-family:Times New Roman;"">60</span><span style=""font-family:Times New Roman;"">岁以后患带状疱疹。带状疱疹后神经痛（</span><span style=""font-family:Times New Roman;"">PHN</span><span style=""font-family:Times New Roman;"">）是带状疱疹最常见的并发症，出现于</span><span style=""font-family:Times New Roman;"">10C18%</span><span style=""font-family:Times New Roman;"">患者中。伴随的慢性疼痛会使患者非常虚弱，并影响其生活质量。疼痛可能会持续数月或数年且难以治疗，从而导致卫生保健费用和发病率的增加。为了预防带状疱疹，我们研制出减毒活疫苗，并且该疫苗在</span><span style=""font-family:Times New Roman;"">2006</span><span style=""font-family:Times New Roman;"">年被批准销售（适用年龄年龄</span><span style=""font-family:Times New Roman;"">≥</span><span style=""font-family:Times New Roman;"">60</span><span style=""font-family:Times New Roman;"">岁）。该疫苗的安全性和有效性的评估是通过带状疱疹预防研究项目中</span><span style=""font-family:Times New Roman;"">38,546</span><span style=""font-family:Times New Roman;"">名</span><span style=""font-family:Times New Roman;"">60</span><span style=""font-family:Times New Roman;"">岁以上的成年人进行的。与空白对照组相比，接种疫苗可使带状疱疹的发病率下降</span><span style=""font-family:Times New Roman;"">51.3%</span><span style=""font-family:Times New Roman;"">（</span><span style=""font-family:Times New Roman;"">p&lt;0.001</span><span style=""font-family:Times New Roman;"">），</span><span style=""font-family:Times New Roman;"">PHN</span><span style=""font-family:Times New Roman;"">的发病率下降</span><span style=""font-family:Times New Roman;"">66.5%</span><span style=""font-family:Times New Roman;"">（</span><span style=""font-family:Times New Roman;"">p&lt;0.001</span><span style=""font-family:Times New Roman;"">）。单剂量的疫苗大约是</span><span style=""font-family:Times New Roman;"">$162</span><span style=""font-family:Times New Roman;"">且并未被所有保险计划所涵盖。一些研究项目对疫苗的成本效益进行评估，发现</span><span style=""font-family:Times New Roman;"">70</span><span style=""font-family:Times New Roman;"">岁以上的老年人最受益。疫苗的使用可降低医疗成本，保护公众健康。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Conclusion</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">结论</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;""><span style=""font-family:Times New Roman;"">The herpes zoster
vaccine is effective in preventing herpes zoster and decreasing the incidence
of complications. However, </span><a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span style=""font-family:Times New Roman;"">insurance coverage</span><span style=""font-family:Times New Roman;""> may hinder
eligible patients from receiving the vaccination.</span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">带状疱疹疫苗能有效预防带状疱疹并降低其并发症的发生率。然而，医疗保险覆盖面可能会阻碍符合条件的患者接受疫苗接种。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-align:right;"" align=""right"">
	<span style=""font-size:9pt;font-family:Times New Roman;"">&nbsp;</span> <span style=""font-size:9pt;font-family:Times New Roman;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-align:right;"" align=""right"">
	<span><a><span style=""font-size:9pt;font-family:Times New Roman;"">Adams
EN</span></a></span><span style=""font-size:9pt;font-family:Times New Roman;""> et.al; </span><span><a><span style=""font-size:9pt;font-family:Times New Roman;"">American Journal
Of Health-System Pharmacy</span></a></span><span style=""font-size:9pt;font-family:Times New Roman;"">; 2010 May 1; Vol. 67 (9), pp.
724-7</span> 
</p>","/uploadfiles/image/20131012/20131012103109_5451w.jpg","/uploadfiles/file/20131012/20131012103055_5207.pdf",,10/12/2013,10/12/2013,"medicool",46,,,0,"67",58,"Herpes zoster and vaccination：a clinical review","2010",
62,,"10.1155/2010/858176","Monica Ottaviani, Emanuela Camera, andMauro Picardo",,"&nbsp;&nbsp;&nbsp; Multiple factors are involved in acne pathogenesis, and sebum secretion is one of the main ones. The role sebum plays in acne development has not been completely elucidated yet; however, increasing amounts of data seem to confirm the presence of alterations in sebum from acne patients. Altered ratio between saturated and unsaturated fatty acids has been indicated as an important feature to be considered in addition to the altered amount of specific fatty acids such as linoleic acid. Furthermore, particular attention has been focused on squalene peroxide that seems to be able to induce an inflammatory response beyond cytotoxicity and comedones formation. Moreover, recent data suggest that lipid mediators are able to interfere with sebocytes differentiation and sebogenesis through the activation of pathways related to peroxisome proliferators-activated receptors. Understanding the factors and mechanisms that regulate sebum production is needed in order to identify novel therapeutic strategies for acne treatment.",,"/uploadfiles/file/20130925/20130925164146_6089.pdf",,09/25/2013,10/08/2013,"medicool",27,,,0,"67",54,"Lipid Mediators in Acne","2010",
65,"冻疮样红斑狼疮-文献综述","10.1007/s10067-008-0942-9","C. M. Hedrich & B. Fiebig & F. H. Hauck & S. Sallmann & G. Hahn & C. Pfeiffer & G. Heubner & M. Gahr","Clin Rheumatol","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""line-height:1.5;font-family:&quot;font-size:16px;"">Chilblain lupus erythematosus
(CHLE) is a rare, chronic form of cutaneous lupus erythematosus. Sporadic cases
and two families with autosomal dominant-inherited CHLE have been reported. In familial
CHLE, two missense mutations in TREX1 encoding the 3′C5′ repair exonuclease 1
were described in affected individuals. The pathogenesis of sporadic CHLE
remains unknown. Up to 20% of patients develop systemic lupus erythematosus
(SLE). An association with anorexia is discussed. In many cases, there is good
response to symptomatic therapy. SLE therapeutics have good effects on
SLE-typical symptoms but not on chilblains themselves. This article reviews the
clinical presentation, pathogenesis, diagnosis and treatment of CHLE. As an
index patient with unique features, we report a 13-year-old boy developing CHLE
after anorexia nervosa. Sequencing of TREX1 was normal. With psychotherapeutic
support for anorexia and after antibiotic therapy, topical steroids, physical
warming and calcium channel blockers, the patient experienced significant
relief.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:20.0pt;"">
	<span style=""font-size:16px;line-height:1.5;font-family:宋体;"">冻疮红斑性狼疮（</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;""> CHLE </span><span style=""font-size:10.0pt;line-height:125%;font-family:宋体;""><span style=""font-size:16px;line-height:1.5;"">）是一种罕见的、慢性皮肤型红斑狼疮。本文报道了一些散发病例和两个</span><a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span style=""font-size:16px;line-height:1.5;"">患常染色体显性遗传</span></span><span style=""font-size:16px;line-height:1.5;""><span style=""font-size:16px;line-height:1.5;""><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">CHLE</span></span></span><span></span><span></span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">病的家庭。在家族性</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">CHLE</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">中，患者体内有两个在</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">TREX1</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">中编码为</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">3'-5'</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">修复核酸外切酶</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">1</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">的错义突变。目前散发的</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">CHLE</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">的发病机制尚不清楚。高达</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">20</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">％的</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">CHLE</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">患者最后发展为系统性红斑狼疮（</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">SLE</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">）。我们对</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">CHLE</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">与厌食的关系进行了讨论。在多数情况下，对症治疗疗效好。系统性红斑狼疮治疗方法对</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">SLE</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">的典型症状有很好的疗效，但对</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">CHLE</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">的治疗效果不佳。本文综述了</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">CHLE</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">的临床表现、发病机制、诊断和治疗。我们对一名</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">13</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">岁的男孩在患神经性厌食症后发展为</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">CHLE</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">进行了报告，并作为特色的指示病例。该患者的</span><span style=""font-size:16px;line-height:1.5;font-family:&quot;"">TREX1</span><span style=""font-size:16px;line-height:1.5;font-family:宋体;"">排序是正常的。通过心理治疗神经性厌食症及抗生素治疗、外用类固醇、物理暖机和使用钙通道阻滞剂后，患者情况得到明显缓解。</span><span style=""font-family:&quot;""></span> 
</p>
<br />
<span style=""font-size:14px;""></span>","/uploadfiles/image/20130925/20130925165922_9179w.png","/uploadfiles/file/20130925/20130925170159_4954.pdf",,09/25/2013,10/11/2013,"medicool",52,,"Chilblain lupus erythematosus . Cutaneous lupus erythematosus . Lupus therapy . Phalangeal vasoconstriction . Raynaud’s syndrome",0,"67",3,"Chilblain lupus erythematosus―a review of literature","2008",
131,,"10.3109/00365548.2011.633551","Damsgaard J ; Marinovskij E ; Leutscher PD","Scandinavian Journal Of Infectious Diseases","&nbsp;The authors report discrepant ? ndings between proton magnetic resonance spectroscopy and conventional magnetic reso- nance imaging in a 67-y-old woman with herpes simplex virus type 1 encephalitis. The sparse amount of literature on proton magnetic resonance spectroscopy in patients with herpes simplex type 1 encephalitis is discussed. &nbsp;<br />
<br />",,"/uploadfiles/file/20131011/20131011154524_0784.pdf",,10/11/2013,10/11/2013,"medicool",42,,"Herpes simplex encephalitis  ,   magnetic resonance spectroscopy  ,   magnetic resonance imaging  ,   herpes simplex virus type 1",4,"85",57," Discrepant ? ndings between proton magnetic resonance spectroscopy and magnetic resonance imaging in an immunocompetent patient with herpes simplex virus type 1 encephalitis  ","2012",
66,"Neonatal Lupus Erythematosus in Identical Twins, Showing Transient Bullous Lesions","10.1111/j.1525-1470.2010.01197.x","Kimiko Nakajima, M.D., Hiroshi Wakiguchi, M.D., Hajime Kodama, M.D., and Shigetoshi Sano, M.D.","Pediatric Dermatology","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp; One of identical twin girlswasbornwithulcersonher leg,and shortly after birth developed a flaccid blister on the leg. Subepidermal blister with vacuolar degeneration of basal cell layer and the heavy infiltration of mononuclear cells in the upper dermis were observed in the blister lesion. She also had generalized livedo. Her identical twin sister did not exhibit ulcers</span><span style=""font-size:14px;""> or blisters, but was born with milia on her limbs. Their mother was found to have lupus erythematosus with positive anti-Ro ?SSA antibodies and developed Sjo¨gren syndrome. We emphasize neonatal blistering and congenital milia unique manifestations of neonatal lupus erythematosus.</span>",,"/uploadfiles/file/20130926/20130926093656_3854.pdf",,09/26/2013,09/30/2013,"medicool",30,,,0,"85",3,,"2010",
67,"Lupus Erythematosus Panniculitis in Children: Report of Three Cases and Review of Previously Reported Cases","10.1111/j.1525-1470.2011.01544.x","Joshua S. Weingartner, M.D., Daniel C. Zedek, M.D., Craig N. Burkhart, M.D., and Dean S. Morrell M.D.","Pediatric Dermatology","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp; Lupus erythematosus panniculitis (LEP) is a rare finding in children, with only 12 fully reported prior cases in the English literature. We describe three cases of LEP in children younger than 18 and compare them to previous cases reported in the literature. We examine laboratory tests performed, biopsy results, age at onset and diagnosis, presence or absence</span><span style=""font-size:14px;""> of systemic symptoms, and outcomes after treatment. It is unknown what the risk is of these patients developing future systemic lupus erythematosus. We also discuss the relevance of subcutaneous panniculitis-like T-cell lymphoma, because the clinical and pathologic pictures are similar in presentation.</span>",,"/uploadfiles/file/20130926/20130926094314_4989.pdf",,09/26/2013,09/30/2013,"medicool",45,,,0,"85",3,,"2011",
68,"Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates","10.1177/0961203310370048","G Obermoser, RD Sontheimer and B Zelger","Lupus","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp; The skin is the second most frequently affected organ system in lupus erythematosus. Although only very rarely life threatening C an example is lupus erythematosus-associated toxic epidermal necrolysis C skin disease contributes disproportionally to disease burden in terms of personal and psychosocial wellbeing, vocational disability, and hence in medical</span><span style=""font-size:14px;""> and social costs. Since several manifestations are closely associated with the presence and activity of systemic lupus erythematosus, prompt and accurate diagnosis of cutaneous lupus erythematosus is essential. This review aims to cover common, rare, and atypical manifestations of lupus erythematosus-associated skin disease with a detailed discussion of</span><span style=""font-size:14px;""> histopathological correlates. Cutaneous lupus erythematosus covers a wide morphological spectrum well beyond acute, subacute and chronic cutaneous lupus erythematosus, which are commonly classified as lupus-specific skin disease. Other uncommon or less well-known manifestations include lupus erythematosus tumidus, lupus profundus, chilblain lupus, mucosal</span><span style=""font-size:14px;""> lupus erythematosus, and bullous lupus erythematosus. Vascular manifestations include leukocytoclastic and urticarial vasculitis, livedoid vasculopathy and livedo reticularis/ racemosa. Finally, we discuss rare presentations such as lupus erythematosus-related erythema exsudativum multiforme (Rowell syndrome), Kikuchi-Fujimoto disease, extravascular necrotizing palisaded granulomatous dermatitis (Winkelmann granuloma), and neutrophilic urticarial dermatosis.</span>",,"/uploadfiles/file/20130926/20130926095414_5049.pdf",,09/26/2013,09/30/2013,"medicool",45,,"Cutaneous lupus erythematosus; SLE; SCLE; DLE; CCLE; ACLE; lupus
erythematosus tumidus; vasculitis; livedo; livedoid vasculopathy; livedoid vasculitis; pathology; antiphospholipid syndrome",0,"67",3,,"2010",
152,"大型管理式医疗队列中成人接种带状疱疹疫苗的安全性:一项疫苗安全数据链的研究","10.1111/j.1365-2796.2011.02474.x","Tseng HF ; Liu A ; Sy L ; Marcy SM ; Fireman B ; Weintraub E ; Baggs J ; Weinmann S ; Baxter R ; Nordin J ; Daley MF ; Jackson L ; Jacobsen SJ","Journal Of Internal Medicine","<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Objectives</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">目的</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;""><span style=""font-family:Times New Roman;"">The aim of this study was
to examine a large cohort of adults who received the zoster vaccine for
evidence of an increased risk of prespeci?ed adverse events </span><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-family:Times New Roman;"">requiring medical attention</span><span style=""font-family:Times New Roman;"">.</span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">这项研究的目的是调查一个大型接种带状疱疹疫苗的成人队列，以此作为预先设定的需要医疗护理的不良事件风险增加的证据</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Design</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">设计</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;""><span style=""font-family:Times New Roman;"">Two self-comparison
approaches, including a </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span style=""font-family:Times New Roman;"">case-centred approach</span><span style=""font-family:Times New Roman;""> and a
self-controlled case series(SCCS)analysis were used.</span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">采用了两种自我比较的方法：以案例为中心的方法和自身对照的案例系列研究（</span><span style=""font-family:Times New Roman;"">SCCS</span><span style=""font-family:Times New Roman;"">）方法。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Setting</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">背景</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">Eight managed-care
organizations participating in the Vaccine Safety Datalink project in the
United States.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">八个管理式医疗保健组织都参与了美国的疫苗安全数据链项目。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Subjects</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">主体</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">A total of 193 083
adults aged 50 and older receiving a zoster vaccine from 1 January 2007 to 31
December 2008 were included.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">在</span><span style=""font-family:Times New Roman;"">2007</span><span style=""font-family:Times New Roman;"">年</span><span style=""font-family:Times New Roman;"">1</span><span style=""font-family:Times New Roman;"">月</span><span style=""font-family:Times New Roman;"">1</span><span style=""font-family:Times New Roman;"">日到</span><span style=""font-family:Times New Roman;"">2008</span><span style=""font-family:Times New Roman;"">年</span><span style=""font-family:Times New Roman;"">12</span><span style=""font-family:Times New Roman;"">月</span><span style=""font-family:Times New Roman;"">31</span><span style=""font-family:Times New Roman;"">日期间接种带状疱疹疫苗的</span><span style=""font-family:Times New Roman;"">193083</span><span style=""font-family:Times New Roman;"">名</span><span style=""font-family:Times New Roman;"">50</span><span style=""font-family:Times New Roman;"">岁以上的成人。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Main outcome
measures</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">主要观察指标</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;""><span style=""font-family:Times New Roman;"">Prespeci?ed adverse
events were identi?ed by aggregated</span><i><span style=""font-family:Times New Roman;""> International Classi?cation of Diseases, Ninth Revision</span></i><span style=""font-family:Times New Roman;""> (ICD-9) codes in
auto-mated health plan datasets.</span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">预先设定的不良反应由自动配对的健康计划数据集中国际疾病分类第九版（</span><span style=""font-family:Times New Roman;"">ICD-9</span><span style=""font-family:Times New Roman;"">）的聚合编码确定。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Results</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">结果</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;""><span style=""font-family:Times New Roman;"">The risk of allergic
reaction was signi?cantly increased within 1C7 days of vaccination [relative
risk = 2.13, 95% con?dence interval (CI): 1.87C2.40 by case-centred method and
relative rate =2.32, 95%</span><span style=""font-family:Times New Roman;"">&nbsp; </span><span style=""font-family:Times New Roman;"">CI: 1.85C2.91
by SCCS].</span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">过敏反应风险在接种疫苗后的</span><span style=""font-family:Times New Roman;"">1-7</span><span style=""font-family:Times New Roman;"">天内显著增加。</span><span style=""font-family:Times New Roman;"">[</span><span style=""font-family:Times New Roman;"">通过案例集中方法得出相对风险</span><span style=""font-family:Times New Roman;"">=2.13</span><span style=""font-family:Times New Roman;"">，</span><span style=""font-family:Times New Roman;"">95% </span><span style=""font-family:Times New Roman;"">置信区间（</span><span style=""font-family:Times New Roman;"">CI</span><span style=""font-family:Times New Roman;"">）：</span><span style=""font-family:Times New Roman;"">1.87-2.40</span><span style=""font-family:Times New Roman;"">，</span><span style=""font-family:Times New Roman;"">SCCS</span><span style=""font-family:Times New Roman;"">得出相对风险</span><span style=""font-family:Times New Roman;"">=2.32</span><span style=""font-family:Times New Roman;"">，</span><span style=""font-family:Times New Roman;"">95% CI</span><span style=""font-family:Times New Roman;"">：</span><span style=""font-family:Times New Roman;"">1.85-2.91]</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">No increased risk was
found for the following adverse event groupings: cerebrovascular events;
cardiovascular events; meningitis; encephalitis; and encephalopathy; and Ramsay-Hunt
syndrome and Bell’s palsy.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">下面不良事件组中未发现风险增加：脑血管事件，心血管事件，脑膜炎，脑炎，脑病，以及</span><span style=""font-family:Times New Roman;"">Ramsay-Hunt</span><span style=""font-family:Times New Roman;"">综合征和贝尔氏麻痹症。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:Times New Roman;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Conclusions</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:Times New Roman;"">结论</span></b><b><span style=""font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">The results of this
study support the ?ndings from the pre licensure clinical trials, providing
reassurance that the zoster vaccine is generally safe and well-tolerated with a
small increased risk of allergic reactions in1C7 days after vaccination.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">这项研究结果支持了之前的临床试验发现，并提供保证。带状疱疹疫苗通常是安全的并且耐受良好，在接种疫苗后的</span><span style=""font-family:Times New Roman;"">1-7</span><span style=""font-family:Times New Roman;"">天内出现过敏反应的风险小量会有小幅度增加。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;"">&nbsp;</span><span style=""font-family:Times New Roman;"">&nbsp; </span><span style=""font-family:&quot;""></span>
</p>
<p class=""MsoNormal"" style=""text-align:right;"" align=""right"">
	<span><a><span style=""font-size:9pt;font-family:Times New Roman;"">Tseng
HF</span></a></span><span style=""font-size:9pt;font-family:Times New Roman;""> et.al; </span><span><a><span style=""font-size:9pt;font-family:Times New Roman;"">Journal Of Internal Medicine</span></a></span><span style=""font-size:9pt;font-family:Times New Roman;""> ;
2012 May; Vol. 271 (5), pp</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>","/uploadfiles/image/20131012/20131012102659_4454w.jpg","/uploadfiles/file/20131012/20131012102504_6136.pdf",,10/12/2013,10/12/2013,"medicool",38,,"adult vaccination, case-centered method, herpes zoster vaccine, self-controlled case series, varicellazostervirus.",0,"66",58,"Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study","2012",
69,"Cutaneous Hypertrophic Lupus Erythematosus","10.5858/arpa.2013-0241-CR","David P. Arps, MD; Rajiv M. Patel, MD","Arch Pathol Lab Med","&nbsp;<span style=""font-size:14px;"">&nbsp;&nbsp; Hypertrophic lupus erythematosus (HLE) is rare variant of chronic cutaneous lupus characterized histologically by irregular epidermal hyperplasia associated with features of classic chronic cutaneous lupus, including interface changes. Lesions frequently demonstrate reactive squamous atypia of the basal layer and may show histopathologic overlap with other more common cutaneous atypical squamoproliferative lesions. Typical histologic features of cutaneous lupus, such as follicular plugging, angiocentric lymphocytic inflammation, and dermal mucin, are very helpful clues to the diagnosis of hypertrophic</span><span style=""font-size:14px;""> lupus erythematosus. Recently, immunohistochemistry for CD123 used to detect increased plasmacytoid dendrocytes</span><span style=""font-size:14px;""> in hypertrophic lupus erythematosus has proven to be diagnostically useful. A high index of suspicion for hypertrophic lupus erythematosus is essential to avoid overdiagnosis of squamous neoplasia, particularly in limited cutaneous biopsies in the absence of adequate clinical information.</span>",,"/uploadfiles/file/20130926/20130926100520_7664.pdf",,09/26/2013,09/30/2013,"medicool",38,,,0,"65",3,,"2013",
76,"银屑病患者的MiR-21上调并抑制T细胞凋亡","10.1111/j.1600-0625.2012.01462.x","Florian Meisgen, Ning Xu, Tianling Wei, Peter C. Janson, Susanna Obad, Oliver Broom, Nikoletta Nagy, Sakari Kauppinen, Lajos Keme?ny, Mona Stahle, Andor Pivarcsi and Eniko¨ Sonkoly","Experimental Dermatology","<span style=""font-size:14px;""></span><span style=""font-size:14px;""> 
<p class=""MsoNormal"" style=""text-indent:14.25pt;"">
	<span>MicroRNAs are short non-coding RNAs that
regulate gene expression. Previously, <a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span>in a </span><a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span><span><span><span>genome-wide
screen</span></span></span></span>, we found deregulation of microRNA
expression in psoriasis skin. MicroRNA-21 (miR-21) is one of the microRNAs
significantly up-regulated in psoriasis skin lesions. To identify the cell type
responsible for the increased miR-21 level, we compared expression of miR-21 in
epidermal cells and dermal T cells between psoriasis and healthy skin and found
elevated levels of miR-21 in psoriasis in both cell types.<a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span> In cultured T cells</span>, <a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span>expression
of miR-21 increased markedly upon activation.</span> To explore the
function of miR-21 in <a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span>primary human T helper cells</span>, we
inhibited miR-21 using a<a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span> tiny </span><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><span><span><span>seed-targeting LNA-anti-miR</span></span></span>. <a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span>Specific
inhibition </span>of <a name=""OLE_LINK23""></a><a name=""OLE_LINK22""></a><span>miR-21</span> increased the<a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><span> apoptosis rate </span>of<a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span> activated T cells</span>. Our results
suggest that miR-21 suppresses apoptosis in activated T cells, and thus,
overexpression of miR-21 may contribute to <a name=""OLE_LINK29""></a><a name=""OLE_LINK28""></a><span>T cellCderived</span><a name=""OLE_LINK31""></a><a name=""OLE_LINK30""></a><span> psoriatic skin inflammation</span>.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:14.25pt;"">
	<span>MicroRNAs</span><span style=""font-family:宋体;"">是短的非编码</span><span>RNAs</span><span style=""font-family:宋体;"">，起调控基因表达的作用。先前的研究中，通过全基因组扫描，我们发现银屑病患者皮肤中</span><span>microRNA</span><span style=""font-family:宋体;"">表达异常。</span><span>MicroRNA-21 (miR-21)</span><span style=""font-family:宋体;"">是银屑病皮损处表达明显上调的</span><span>microRNAs</span><span style=""font-family:宋体;"">之一。为了鉴定</span><span>miR-21</span><span style=""font-family:宋体;"">水平升高的细胞类型，我们对银屑病患者与健康对照组皮肤的表皮细胞和真皮中</span><span>T</span><span style=""font-family:宋体;"">细胞</span><span>miR-21</span><span style=""font-family:宋体;"">的表达进行了比较，发现银屑病患者的这两类细胞中</span><span>miR-21</span><span style=""font-family:宋体;"">水平均升高。在培养的</span><span>T</span><span style=""font-family:宋体;"">细胞中，通过激活用，</span><span>miR-21</span><span style=""font-family:宋体;"">的表达明显增加。我们利用</span><span>seed-targeting LNA-anti-miR</span><span style=""font-family:宋体;"">抑制</span><span>miR-21</span><span style=""font-family:宋体;"">来研究人类主要辅助性</span><span>T</span><span style=""font-family:宋体;"">细胞中</span><span>miR-21</span><span style=""font-family:宋体;"">的功能。</span><span>miR-21</span><span style=""font-family:宋体;"">的特异性抑制增加了活化</span><span>T</span><span style=""font-family:宋体;"">细胞的细胞凋亡率。实验结果表明活化</span><span>T</span><span style=""font-family:宋体;"">细胞中</span><span>miR-21</span><span style=""font-family:宋体;"">抑制细胞凋亡，</span><span>miR-21</span><span style=""font-family:宋体;"">的过度表达可促成</span><span>T</span><span style=""font-family:宋体;"">细胞衍生的银屑病皮肤炎症。</span><span></span> 
</p>
<br />
</span>","/uploadfiles/image/20130926/20130926165056_9340w.png","/uploadfiles/file/20130926/20130926164826_6589.pdf",,09/26/2013,10/10/2013,"medicool",52,,"chronic inflammation； inflammatory skin disease；
microRNA； skin；T cells",0,"65",26,"MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis","2012",
138,,"10.1172/JCI60893","Reinert LS ; Harder L ; Holm CK ; Iversen MB ; Horan KA ; Dagn?s-Hansen F ; Ulh?i BP ; Holm TH ; Mogensen TH ; Owens T ; Nyengaard JR ; Thomsen AR ; Paludan SR","The Journal Of Clinical Investigation","&nbsp; Herpes simplex viruses (HSVs) are highly prevalent neurotropic viruses. While they can replicate lytically in cells of the epithelial lineage, causing lesions on mucocutaneous surfaces, HSVs also establish latent infections in neurons, which act as reservoirs of virus for subsequent reactivation events. Immunological control of HSV 
involves activation of innate immune pattern-recognition receptors such 
as TLR3, which detects double-stranded RNA and induces type I IFN 
expression. Humans with defects in the TLR3/IFN pathway have an elevated susceptibility to HSV infections of the CNS. However, it is not known what cell type mediates the role of TLR3 in the immunological control of HSV, and it is not known whether TLR3 sensing occurs prior to or after CNS entry. Here, we show that in mice TLR3 provides early control of HSV-2 infection immediately after entry into the CNS by mediating type I IFN responses in astrocytes. Tlr3-/- mice were hypersusceptible to HSV-2 infection in the CNS after vaginal inoculation. HSV-2 exhibited broader neurotropism in Tlr3-/- mice than it did in WT mice, with astrocytes being most abundantly infected. Tlr3-/- mice did not exhibit a global defect in innate immune responses to HSV, but astrocytes were defective in HSV-induced type I IFN production. Thus, TLR3 acts in astrocytes to sense HSV-2 infection immediately after entry into the CNS, possibly preventing HSV from spreading beyond the neurons mediating entry into the CNS",,"/uploadfiles/file/20131011/20131011163730_8387.pdf",,10/11/2013,10/11/2013,"medicool",48,,,0,"65",57,"TLR3 deficiency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS  infection in mice","2012",
71,"Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice","10.1172/JCI65907","Michael Look, Eric Stern, Qin A. Wang, Leah D. DiPlacido,Michael Kashgarian,Joe Craft, and Tarek M. Fahmy","The Journal of Clinical Investigation.","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp; The ability to selectively inactivate immune cells with immunosuppressants is a much sought-after modality for the treatment of systemic lupus erythematosus and autoimmunity in general. Here, we designed and tested a novel nanogel drug delivery vehicle for the immunosuppressant mycophenolic acid (MPA). Treatment with MPA-loaded nanogels increased the median survival time (MST) of lupus-prone NZB/W F1 mice by 3 months with prophylactic use (MST was 50 weeks versus 38 weeks without treatment), and by 2 months when administered after the development of severe renal damage (MST after proteinuria onset was 12.5 weeks versus 4 weeks without treatment). Equivalent and greater doses of MPA administered in buffer were not efficacious. Nanogels had enhanced biodistribution to organs and association with immune cells. CD4-targeted nanogels yielded similar therapeutic results compared with nontargeted formulations, with protection from glomerulonephritis</span><span style=""font-size:14px;""> and decreases in IFN-γCpositive CD4 T cells. DCs that internalized nanogels helped mediate immunosuppression, as they had reduced production of inflammatory cytokines such as IFN-γ and IL-12. Our results demonstrate efficacy of nanogel-based lupus therapy and implicate a mechanism by which immunosuppression is enhanced, in part, by the targeting of antigen-presenting cells.</span>",,"/uploadfiles/file/20130926/20130926102144_4886.pdf",,09/26/2013,09/30/2013,"medicool",49,,,0,"65",3,,"2013",
80,"白癜风表皮微环境研究进展",,"陈惠英，许爱娥","中国皮肤性病学杂志","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 白癜风是一种由于黑素细胞受损而致色素脱失的获得性皮肤病，其病因及发病机制迄今尚未完全阐明，本文着重从皮损处存在氧化应激、神经、免疫、细胞因子等变化的相关研究报道，阐述白癜风患者皮损微环境变化的错综复杂性，为进一步研究白癜风的发病与治疗提供思路。",,"/uploadfiles/file/20130929/20130929135038_1054.pdf",,09/29/2013,09/29/2013,"medicool",37,,"白癜风；微环境",0,"67",28,,"2008",
72,"一例伴随与后部和前纵韧带骨化有关的弥漫性特发性骨质增生症的寻常型银屑病","10.1007/s00296-010-1368-7","Tomonori Taniguchi ? Hideki Maejima ? Akira Watarai ? Ryoichi Aki ? Kensei Katsuoka","Rheumatol Int","<span style=""font-size:14px;""></span><span style=""font-size:14px;""> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK74""></a><a name=""OLE_LINK73""></a><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span><span><span><span>Diffuse idiopathic skeletal hyperostosis</span></span></span></span><span><span><span> (DISH) is difficult to
distinguish from <a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span>various forms of inflammatory arthritis</span>,
including <a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span>psoriatic arthritis</span> (PsA), rheumatoid arthritis, and <a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span>ankylosing
spondylitis</span>. </span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span style=""font-family:宋体;"">弥漫性特发性骨质增生症（</span></span></span><span><span><span>DISH</span></span></span><span><span><span style=""font-family:宋体;"">）与各种类型的炎症性关节炎（包括银屑病关节炎、风湿性关节炎及强直性脊柱炎）很难区分。</span></span></span><span><span><span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span>A 67-year-old Japanese male had
been treated for psoriasis vulgaris for 13 years. Numbness of his right arm and
lower limbs and <a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span>spinal stiffening</span> had developed 7
years prior to his <a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span>initial evaluation</span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span><span><span> at our facility</span></span></span>. <a name=""OLE_LINK19""></a>He noticed pain mainly while exercising. There were <a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span>symmetrical
marginal syndesmophytes</span> in the spine, from the thoracic vertebrae to
the <a name=""OLE_LINK23""></a><a name=""OLE_LINK22""></a><span>upper lumbar vertebrae</span>, on <a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><span>radiological
examinations</span>. </span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span style=""font-family:宋体;"">一名</span></span></span><span><span><span>67</span></span></span><span><span><span style=""font-family:宋体;"">岁的日本男性寻常型银屑病患者已进行了</span></span></span><span><span><span>13</span></span></span><span><span><span style=""font-family:宋体;"">年的治疗。在他来我们部门的首次评估之前，患右臂、下肢麻木及脊髓硬化已</span></span></span><span><span><span>7</span></span></span><span><span><span style=""font-family:宋体;"">年。运动时，他感觉的主要是疼痛。放射学检查发现从胸椎到上腰椎的脊柱中有对称边缘骨赘。</span></span></span><span><span><span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span>We therefore suspected DISH.
Furthermore, <a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span>ossifications of the posterior and anterior
longitudinal ligaments </span>were noted in the cervical spine. <a name=""OLE_LINK29""></a><a name=""OLE_LINK28""></a><span>Laboratory
examinations revealed a normal peripheral white blood cell count</span>, <a name=""OLE_LINK31""></a><a name=""OLE_LINK30""></a><span>serum
C-reactive protein</span>, and<a name=""OLE_LINK33""></a><a name=""OLE_LINK32""></a><span> erythrocyte sedimentation rate</span>, and<a name=""OLE_LINK35""></a><a name=""OLE_LINK34""></a><span> he was negative for rheumatoid factor.</span> <a name=""OLE_LINK39""></a><a name=""OLE_LINK38""></a><span>We detected </span><a name=""OLE_LINK37""></a><a name=""OLE_LINK36""></a><span><span><span>human
leukocyte antigen B39</span></span></span><span><span> but not B27.</span></span> <a name=""OLE_LINK43""></a><a name=""OLE_LINK42""></a><span>All </span><a name=""OLE_LINK41""></a><a name=""OLE_LINK40""></a><span><span><span>distal
interphalangeal joints</span></span></span> were swollen but without pain. <a name=""OLE_LINK47""></a><a name=""OLE_LINK46""></a><a name=""OLE_LINK45""></a><a name=""OLE_LINK44""></a><span><span><span>X-ray imaging</span></span></span><span><span> showed narrowing
of the joint space, </span></span>and <a name=""OLE_LINK49""></a><a name=""OLE_LINK48""></a><span>the consolidation of
the joint<span style=""color:red;""> </span>was recognized, </span>but there
was no new<a name=""OLE_LINK51""></a><a name=""OLE_LINK50""></a><span> </span><a name=""OLE_LINK54""></a><a name=""OLE_LINK53""></a><a name=""OLE_LINK52""></a><span><span><span><span>juxta articular</span></span></span></span><span><span> bone</span></span> formation. </span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span style=""font-family:宋体;"">因此怀疑患有弥漫性特发性骨质增生症（</span></span></span><span><span><span>DISH</span></span></span><span><span><span style=""font-family:宋体;"">）。此外，注意到颈椎中的后部和前纵韧带骨化。实验室检查发现外周血白细胞计数、血清</span></span></span><span><span><span>C-</span></span></span><span><span><span style=""font-family:宋体;"">反应蛋白以及红细胞沉降率正常，并且他的类风湿因子呈阴性。我们检查了人类白细胞抗原</span></span></span><span><span><span>B39</span></span></span><span><span><span style=""font-family:宋体;"">。所有远端指间关节肿胀但并不疼痛。</span></span></span><span><span><span>X</span></span></span><span><span><span style=""font-family:宋体;"">射线成像显示关节间隙变窄，同时识别到关节固化，但是没有生成新的近关节骨。</span></span></span><span><span><span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span>Based on <a name=""OLE_LINK56""></a><a name=""OLE_LINK55""></a><span>clinical and
radiological findings</span>, we concluded that he had DISH and not PsA. <a name=""OLE_LINK58""></a><a name=""OLE_LINK57""></a><span>DISH
was indicated by</span><a name=""OLE_LINK60""></a><a name=""OLE_LINK59""></a><span><span><span> marked radiological features</span></span></span><span><span> of <a name=""OLE_LINK64""></a><a name=""OLE_LINK63""></a><span>the </span><a name=""OLE_LINK62""></a><a name=""OLE_LINK61""></a><span><span><span>axial skeleton</span></span></span>, </span></span>particularly
the thoracic spine, but may also have involved the peripheral joints. DISH is
one of the <a name=""OLE_LINK66""></a><a name=""OLE_LINK65""></a><span>entheseal disorders</span>, and 10% of
Japanese <a name=""OLE_LINK68""></a><a name=""OLE_LINK67""></a><span>middle-aged and elderly men</span> have DISH. Therefore, <a name=""OLE_LINK72""></a><a name=""OLE_LINK71""></a><span>the
differentiation of DISH from PsA </span>is necessary in psoriasis patients
with <a name=""OLE_LINK70""></a><a name=""OLE_LINK69""></a><span>spinal involvement</span>.</span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span style=""font-family:宋体;"">基于临床和影像学结果，我们推断他患有弥漫性特发性骨质增生症（</span></span></span><span><span><span>DISH</span></span></span><span><span><span style=""font-family:宋体;"">），并非银屑病关节炎。明显轴向骨骼的放射学特征表明其患有</span></span></span><span><span><span>DISH</span></span></span><span><span><span style=""font-family:宋体;"">。</span></span></span><span><span><span>DISH</span></span></span><span><span><span style=""font-family:宋体;"">是一种</span></span></span><span><span><span>entheseal</span></span></span><span><span><span style=""font-family:宋体;"">障碍，日本</span></span></span><span><span><span>10%</span></span></span><span><span><span style=""font-family:宋体;"">的中老年男性患有</span></span></span><span><span><span>DISH</span></span></span><span><span><span style=""font-family:宋体;"">。因此，在脊柱受损的银屑病患者中，区分</span></span></span><span><span><span>DISH</span></span></span><span><span><span style=""font-family:宋体;"">与</span></span></span><span><span><span>PsA</span></span></span><span><span><span style=""font-family:宋体;"">是必要的。</span></span></span><span></span><span></span><span></span> 
</p>
<br />
</span>","/uploadfiles/image/20130930/20130930162245_7780w.png","/uploadfiles/file/20130926/20130926104846_1426.pdf",,09/26/2013,10/10/2013,"medicool",70,,"DISH  PsA  OPLL  Entheseal disorder",0,"85",26,"A case of psoriasis vulgaris with diffuse idiopathic skeletal hyperostosis involved with ossifications of posterior and anterior longitudinal ligament","2012",
137,,"10.1007/s10753-010-9246-8","Guo YJ ; Li W ; Li XF ; Zhao L ; Zhang SL ; Zhou Y ; Dong JH ; Mei YW","Kluwer Academic/Plenum Publishers","&nbsp; Our study showed that S-methylisothiourea (SMT) had anti-in?ammatory effects in treating herpes simplex encephalitis in mice, and SMT also induced apoptosis of herpes simplex virus (HSV-1)-infected microglial cells. Both animal and cell models were employed in this study. Both models included the following ?ve groups: a normal control group, a virus group (HSV-1 infected), an SMT group (HSV-1-infected+SMT (0.1 mg/10 g)), a dexamethasone group (HSV-1 infected+dexamethasone (2 μg/10 g)), and an APS group (HSV-1-infected+APS (0.8 mg/10 g)). ELISA was used to measure tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-10, and Greiss method was used for measuring nitric oxide (NO) secretion. HE staining was performed for detecting changes in mice brain. Flow cytometry assay for caspase-3, caspase-8, caspase-9, and caspase-12 expressions was also carried out to assess apoptosis. Expressions of TNF-α, IL-1β, and NO were signi?cantly elevated after stimulation of microglial cells with HSV-1. Following SMT intervention, TNF-α, IL-1β, and NO levels were signi?cantly decreased. The in?ammatory changes in HSV-1-infected murine brain tissues were also reduced. SMT induction of apoptosis of HSV- stimulated microglia seemed to be through three pathways: the death receptor, mitochondrially gated, and endoplasmic reticulum. SMT can reduce HSV-induced in?ammatory insult to the brain. Its mechanism of action is most probably due to the induction of microglial cell apoptosis.<br />
<br />",,"/uploadfiles/file/20131011/20131011163033_9904.pdf",,10/11/2013,10/11/2013,"medicool",28,,"S-methylisothiourea; herpes simplex virus; encephalitis; apoptosis; microglia.",0,"65",57,"S-Methylisothiourea Induces Apoptosis of Herpes Simplex Virus-1-Infected Microglial Cells","2011",
198,,"10.2500/aap.2012.33.3569","DaVeiga SP","Allergy And Asthma Proceedings: The Official Journal Of Regional And State Allergy Societies","<p align=""justify"">
	<span style=""font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; Atopic dermatitis (AD) is a common skin condition with significant associated social and financial burden. AD affects adults and children with worldwide prevalence rates of 1C20%. International study of epidemiology and geographic variability in prevalence of AD has been conducted in three phases with 1,000,000 subjects in the third phase study. Prevalence continues to vary and has changed in different regions of the world. Nigeria, the United Kingdom and New Zealand had been areas of the highest prevalence; Latin America has emerged as a region of relatively high prevalence in follow up data. The prevalence of AD seems to have reached a plateau around 20% in countries with the highest prevalence, suggesting that AD may not be on a continued rise but that a finite number of individuals may be susceptible to the condition. Risk factors associated with increased prevalence include higher socioeconomic status, higher level of family education, smaller family size and urban environment. Research indicates that food allergy and atopic sensitization to environmental allergens may not be directly causal of the condition and that a non-atopic form of the condition exists. 60% of patients will experience remission. The number of patients who will progress through the atopic march to develop asthma and allergic rhinitis depends on the underlying features of their condition. </span> 
</p>",,"/uploadfiles/file/20131012/20131012153700_7153.pdf",,10/12/2013,10/12/2013,"medicool",33,,,0,"67",46,"Epidemiology of atopic dermatitis: a review","2012",
201,,"DOI 10.1007/s00415-011-5968-2","Afshin Borhani-Haghighi ? Anahid Safari","J Neurol","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aguiar de Sousa et al. nicely described different aspects of cerebral venous sinus thrombosis (CVST) in Behcet’s disease (BD) [1] but there are some issues to be discussed further.",,"/uploadfiles/file/20131012/20131012155425_3711.pdf",,10/12/2013,10/12/2013,"medicool",20,,"Behcet’s disease;cerebral venous thrombosis",0,"67",29,"Comment on ‘‘cerebral venous thrombosis in Behcet’s disease:a systematic review’’","2011",
202,,,"Kayatas K ; Karatoprak C ; Cebeci F ; Dayan A ; Ozkan S ; Pehlevan SM ; Kartal I ; Demirtunc R","European Review For Medical And Pharmacological Sciences","<strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Background:<span class=""Apple-converted-space"">&nbsp;<br />
</span></strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">A relapsing systemic inflammatory process is a well-known feature of<span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Behcet's</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">disease</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">. Because systemic inflammation and dyslipidemia are involved in the pathogenesis of atherosclerosis,<span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Behcet's</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">disease</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span>may play a part in the development of atherosclerosis. Lipid profile in<span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Behcet's</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">disease</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span>and the development of atherosclerosis remain to be controversial. In order to learn more about this relationship, our study compared blood lipid levels in healthy controls to those in patients with<span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Behcet's</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">disease</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span>during both their active and inactive stages.</span><br style=""white-space:normal;text-transform:none;word-spacing:0px;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"" />
<strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Patients and Methods:<span class=""Apple-converted-space"">&nbsp;</span></strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Between December 2010 and March 2012, this prospective, observational study was designed to evaluate three groups The study included 91<span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Behcet's</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span>patients (36 in active and 55 in inactive period) and 61 healthy control subjects matched for age, gender, and body mass index. Data from lipid profiles included total cholesterol, triglyceride, low-density lipoprotein, and high-density lipoprotein. Acute phase reactants were also recorded, including high sensitive C-reactive protein and erythrocyte sedimentation rate levels.</span><br style=""white-space:normal;text-transform:none;word-spacing:0px;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"" />
<strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Results:<span class=""Apple-converted-space"">&nbsp;</span></strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Total cholesterol, low density lipoprotein, and high density lipoprotein cholesterol levels of patients in active stage were significantly lower than those in inactive stage, while total cholesterol and low density lipoprotein levels were lower in the control group (p &amp;lt; 0.05).</span><br style=""white-space:normal;text-transform:none;word-spacing:0px;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"" />
<strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Conclusions:<span class=""Apple-converted-space"">&nbsp;</span></strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Patients with<span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">Behcet's</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">disease</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span>in the active period may be less susceptible to atherogenic events as compared with the controls and those in the inactive period of the<span class=""Apple-converted-space"">&nbsp;</span></span><strong style=""font-size:12px;border-top:0px;font-family:Tahoma, Verdana, Arial, sans-serif;border-right:0px;font-variant:normal;vertical-align:baseline;white-space:normal;border-bottom:0px;text-transform:none;word-spacing:0px;color:#333333;outline-width:0px;padding-bottom:0px;font-style:normal;padding-top:0px;outline-style:none;padding-left:0px;margin:0px;border-left:0px;orphans:2;widows:2;letter-spacing:normal;outline-color:invert;line-height:16px;padding-right:0px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">disease</strong><span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">.</span>",,"/uploadfiles/file/20131012/20131012160509_6991.pdf",,10/12/2013,10/12/2013,"medicool",23,,"Behcet disease, Atherosclerosis, Activation, Lipid profile",0,"66",29,"Presence of low lipid levels in patients with Behcet' s disease as a protector against atherosclerosis","2013",
207,"mackenziei（原名Ramichloridium mackenziei）引起的脑暗色丝孢霉病：分类更新和文献回顾","10.3109/13693780903383914","SAAD J. TAJ-ALDEEN, MUNA ALMASLAMANI, ABDULLATIF ALKHAL, ISSAM AL BOZOM, ANNA M. ROMANELLI, BRIAN L. WICKES, ANNETTE W. FOTHERGILL & DEANNA A. SUTTON","Medical Mycology","<p class=""MsoNormal"" style=""text-indent:15.75pt;"">
	<span style=""font-family:&quot;"">Cerebral
phaeohyphomycosis caused by<a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span><i> Rhinocladiella
mackenziei </i></span>(formerly <i>Ramichloridium
mackenziei</i>) is extremely rare, and geographically limited to the Middle
East. The fungus exclusively targets the brain and <a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span>infections have a grave
prognosis.</span> Eighteen cases have been reported in the literature from
1983 to 2004 with almost 100% mortality. Our patient presented in February 2008
with a brain abscess while receiving chemotherapy for carcinoma of the breast.
Diagnosis was by<a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span> craniotomy and aspiration of the brain abscess</span>.<a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span> Direct microscopy</span> showed <a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span>dematiaceous fungal
hyphae</span>.<i> R. mackenziei</i> was
recovered in culture and this identification was confirmed by molecular
analysis. Examination of his to pathological sections of tissue from the brain
biopsy revealed <a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span>moniliform hyphae characteristic </span>for
phaeohyphomycosis. The patient failed to respond to antifungal therapy with
amphotericin B and voriconazole or amphotericin B and posaconazole and<a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span> finally expired 64 days after diagnosis. </span>In vitro antifungal
susceptibility testing showed this isolate to be resistant to amphotericin B
while susceptible to itraconazole, voriconazole, and posaconazole. Previously
published antifungal susceptibility data indicate that although strains show <a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span>variable
susceptibility</span> to amphotericin B, the organism is generally
refractory to treatment with this agent. Similar outcomes are seen with the
azole agents used alone or in combination with other drugs. Although no specific
risk factors have been identified, the majority of cases have occurred in
immunocompromised individuals. <i>R.
mackenziei</i> is a highly virulent agent of serious cerebral
phaeohyphomycosis, and should be considered in the differential diagnosis of
central nervous system disease in the Middle East.<br />
</span> 
</p>
<p class=""MsoNormal"" style=""text-align:left;text-indent:21.0pt;"" align=""left"">
	<span style=""font-family:宋体;"">由</span><i><span style=""font-family:&quot;"">Rhinocladiella mackenziei</span></i><span style=""font-family:宋体;"">（原名</span><i><span style=""font-family:&quot;"">Ramichloridium
mackenziei</span></i><i><span style=""font-family:宋体;"">）</span></i><span style=""font-family:宋体;"">引起的脑<a name=""OLE_LINK36""></a><a name=""OLE_LINK35""></a><span>暗色丝孢霉病</span>十分罕见，并且从地理学上来看，仅限于中东地区。这种真菌专门攻击脑，且感染有严重的预后。从</span><span>1983</span><span style=""font-family:宋体;"">年到</span><span>2004</span><span style=""font-family:宋体;"">年已有</span><span>18</span><span style=""font-family:宋体;"">个病历记录在案，几乎</span><span>100%</span><span style=""font-family:宋体;"">的死亡率。一名患者在</span><span>2008</span><span style=""font-family:宋体;"">年</span><span>2</span><span style=""font-family:宋体;"">月因乳腺癌而接受化疗时出现脑脓肿。通过脑脓肿的开颅手术和抽吸术进行的诊断。直接镜检显示培养皿中<a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span>存在暗色真菌菌丝</span></span><span><span><i><span style=""font-family:&quot;"">R. mackenziei</span></i></span></span><span><span><span style=""font-family:宋体;"">的复苏</span></span></span><span></span><span></span><span style=""font-family:宋体;"">，且此结论通过分子分析进行了证实。对他的脑活检组织的病理学切片检查显示为念珠菌感染特征的暗色丝孢霉病。患者用两性霉素</span><span>B</span><span style=""font-family:宋体;"">和福利康唑或两性霉素</span><span>B</span><span style=""font-family:宋体;"">和<a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span>泊沙康唑</span>进行抗菌治疗最终在治疗</span><span>64</span><span style=""font-family:宋体;"">天后药物对疾病失去治疗效果，宣告治疗失败。在体外进行抗真菌药物敏感性实验表明这种分离菌可耐受两性霉素</span><span>B</span><span style=""font-family:宋体;"">，但是对伊曲康唑、福利康唑和泊沙康唑敏感。先前发表的有关抗菌敏感性的资料表明，尽管不同的菌株对两性霉素</span><span>B</span><span style=""font-family:宋体;"">的敏感性不同，但是菌株通常对该药物的治疗有耐性。</span><span style=""font-family:宋体;"">类似的结论在唑类药物单独使用或和其他药物联合使用时也得到体现。尽管未鉴定到特殊的危险因素，但大部分病例都是在免疫功能不全的患者。</span><i><span style=""font-family:&quot;"">R. mackenziei</span></i><span style=""font-family:宋体;"">是一种引起脑暗色丝孢霉病的非常严重的恶性真菌，并且关于中东地区的中枢神经系统疾病的鉴别诊断，应当考虑该菌。</span><span style=""font-family:宋体;""></span> 
</p>
<p>
	<br />
</p>","/uploadfiles/image/20131012/20131012163713_3229w.png","/uploadfiles/file/20131012/20131012163836_2058.pdf",,10/12/2013,10/12/2013,"medicool",38,,"Rhinocladiella mackenziei, cerebral phaeohyphomycosis",0,"67",20,"Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): a taxonomic update and review of the literature","2010",
199,,"10.1111/j.1525-1470.2010.01377.x","Sugarman JL ; Hersh AL ; Okamura T ; Howard R ; Frieden IJ","Pediatric Dermatology","<p align=""justify"">
	<span style=""font-family:Times New Roman;"">&nbsp;&nbsp; &nbsp; In order to assess the clinical characteristics and impact of group A streptococcal infection in children with </span><span style=""font-family:Times New Roman;"">atopic</span> <span style=""font-family:Times New Roman;"">dermatitis</span><span style=""font-family:Times New Roman;"">, a retrospective </span><span style=""font-family:Times New Roman;"">review</span><span style=""font-family:Times New Roman;""> was performed in children diagnosed with </span><span style=""font-family:Times New Roman;"">atopic</span> <span style=""font-family:Times New Roman;"">dermatitis</span><span style=""font-family:Times New Roman;""> who had a skin culture. Culture results and clinical characteristics of
 those with group A streptococcus were compared with those with 
Staphlococcus aureus. Infection with group A streptococcus was present 
in 16%; infection with Staphlococcus aureus was present in 72%, and 14% 
had mixed cultures. Patients infected with group A streptococcus were 
more likely to be febrile, to have facial and periorbital involvement, 
and to be hospitalized compared with those infected with Staphlococcus 
aureus alone (p ≤ 0.01 for all comparisons). Bacteremia and cellulitis 
were significantly more common in those infected with group A 
streptococcus than in those infected with Staphlococcus aureus. 
Retrospective design and </span><span style=""font-family:Times New Roman;"">review</span><span style=""font-family:Times New Roman;""> of only those patients receiving bacterial cultures may select for greater severity than in the general </span><span style=""font-family:Times New Roman;"">atopic</span> <span style=""font-family:Times New Roman;"">dermatitis</span><span style=""font-family:Times New Roman;""> population. Group A streptococcus appears to be a significant skin pathogen infecting children with </span><span style=""font-family:Times New Roman;"">atopic</span> <span style=""font-family:Times New Roman;"">dermatitis</span><span style=""font-family:Times New Roman;"">. Children with </span><span style=""font-family:Times New Roman;"">atopic</span> <span style=""font-family:Times New Roman;"">dermatitis</span><span style=""font-family:Times New Roman;""> and group A streptococcal infection are more likely to have invasive 
disease and complications than those infected with Staphlococcus aureus 
alone.</span> 
</p>",,"/uploadfiles/file/20131012/20131012154241_3887.pdf",,10/12/2013,10/12/2013,"medicool",29,,,0,"67",46,"A retrospective review of streptococcal infections in pediatric atopic dermatitis","2011",
238,,"DOI: 10.3315/10 jdcr.2007.1.1003","Vijay Z aw ar, Antonio Ch uh , Sudh ir Sank ale ch a","J D e rm atol Case Rep","<p align=""justify"">
	<span style=""font-family:Times New Roman;""><span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; W e&nbsp;&nbsp; re port&nbsp; a&nbsp; re trospe ctive&nbsp;&nbsp; case -control&nbsp; study&nbsp; to&nbsp; inve stigate&nbsp;whether the&nbsp;rotundiform&nbsp; variant of pityriasis ve rsicolor (PV) is </span><span style=""font-size:14px;"">significantly associate d w ith&nbsp;&nbsp; the&nbsp;first&nbsp; e pisode s&nbsp; of&nbsp; PV.&nbsp; O ur&nbsp; se tting&nbsp; w as&nbsp; a&nbsp; de rm atology&nbsp; clinic&nbsp; run&nbsp; by&nbsp; a&nbsp; consultant de rm atologist. W e&nbsp; re trie ve d m e dical re cords of all patie nts w ith&nbsp; PV&nbsp;be tw e e n April 1, 2002 and March&nbsp; 31, 2005. W e&nbsp; ide ntifie d patie nts w ith&nbsp; le sions form ing close d round circle s. W e&nbsp; e xclude d patie nts w ith&nbsp; unce rtain diagnosis or diagnosis not substantiate d by W ood’s ligh t e xam ination or sk in scrapings for potassium&nbsp;&nbsp; h ydroxide&nbsp;&nbsp; e xam ination. For&nbsp; e ach&nbsp;&nbsp; patie nt,&nbsp; w e&nbsp;&nbsp; re trie ve d&nbsp; th e&nbsp;&nbsp; m e dical re cord of th e&nbsp; ne xt patie nt of th e&nbsp; sam e&nbsp; se x and sim ilar age&nbsp; (±&nbsp; th re e&nbsp; ye ars) w ith&nbsp; docum e nte d non-rotundiform&nbsp; PV and diagnosis substantiate d by inve stigations as th</span></span><span style=""font-family:Times New Roman;font-size:14px;""> e&nbsp; control subje ct.</span><span style=""font-family:Times New Roman;font-size:14px;"">80 patie nts w e re&nbsp; diagnose d as h aving PV during th e&nbsp; re cord re trie val pe riod. 18 </span><span style=""font-family:Times New Roman;font-size:14px;"">h ad clinical de scriptions or clinical ph otograph s docum e nting rotundiform&nbsp; PV. </span><span style=""font-family:Times New Roman;font-size:14px;"">Five&nbsp; w e re&nbsp; e xclude d ow ing to unce rtain diagnosis, uncle ar clinical de scriptions, </span><span style=""font-family:Times New Roman;font-size:14px;"">or&nbsp; diagnose s&nbsp; unsubstantiate d&nbsp; by&nbsp; e xam ination&nbsp; unde r&nbsp; W ood’s&nbsp; ligh t&nbsp; or&nbsp; sk in </span><span style=""font-family:Times New Roman;font-size:14px;"">scrapings&nbsp; for&nbsp; potassium&nbsp;&nbsp; h ydroxide&nbsp;&nbsp; e xam ination.&nbsp; 13&nbsp; h ad&nbsp; de finite&nbsp;&nbsp; diagnosis&nbsp; of </span><span style=""font-family:Times New Roman;font-size:14px;"">rotundiform&nbsp; PV. Te n agre e d to atte nd clinic. Th e&nbsp; re sponse&nbsp; rate&nbsp; w as 76.9 %. Te n </span><span style=""font-family:Times New Roman;font-size:14px;"">age -and-se x&nbsp; pair-m atch e d&nbsp; control&nbsp; subje cts&nbsp; w ith&nbsp;&nbsp; non-rotundiform&nbsp;&nbsp; PV&nbsp; w e re&nbsp; </span><span style=""font-family:Times New Roman;font-size:14px;"">re cruite d.&nbsp; Nine&nbsp;&nbsp; patie nts&nbsp; w ith&nbsp;&nbsp; rotundiform&nbsp;&nbsp; PV&nbsp; and&nbsp; tw o&nbsp; controls&nbsp; w ith&nbsp;&nbsp; nonrotundiform</span><span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;PV h ad th e ir e pisode&nbsp; of PV re pre s e nting th e ir first e pisode&nbsp; of PV (p </span><span style=""font-family:Times New Roman;font-size:14px;"">= 0.01; O R = 36.0, 9 5% CI: 2.2 - 866.9 ). W e&nbsp; conclude&nbsp; th at rotundiform&nbsp; PV is </span><span style=""font-family:Times New Roman;font-size:14px;"">significantly associate d w ith&nbsp; th e&nbsp; first e pisode&nbsp; of PV. Th is ph e nom e non m igh t be&nbsp; </span><span style=""font-family:Times New Roman;font-size:14px;"">analogous to th e&nbsp; h e rald patch&nbsp; be ing th e&nbsp; prim ary le sion in pityriasis rose a.</span> 
</p>
<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;</span> 
</p>","/uploadfiles/image/20131016/20131016154325_0119w.jpg","/uploadfiles/file/20131016/20131016145150_2941.pdf",,10/16/2013,10/16/2013,"medicool",23,,"H yph ae , Malasse zia furfur, itraconazole , potassium  h ydroxide  pre paration, W ood's ligh t, ye ast",0,"66",4,"Rotundiform m orph ology during th e firs t e pis ode of pityriasis  ve rs icolor C a re tros pe ctive cas e -control s tudy on a dis tinct clinical pre s e ntation","2007",
200,,"DOI 10.1007/s00415-010-5885-9","D. Aguiar de Sousa ? T. Mestre ? J. M. Ferro","J Neurol (","<p align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Behc?et’s disease (BD) is a chronic inflammatory multisystem disorder which can involve the central nervous system (CNS). Cerebral venous thrombosis (CVT) is one of its major neurological manifestations. We aimed to review the epidemiologic and clinical features of CVT in patients with BD, as well as the available data on therapeutic interventions and prognosis. Systematic review of all observational studies of BD patients was done. Search strategy included electronic searches of MEDLINE (1966- August 2009). Occurrence of CVT in BD and Neuro-Behc?et patients, occurrence of CVT as the inaugural manifestation of BD, clinical and neuro-imaging characteristics of CVT, prothrombotic evaluation, treatment options and prognosis were extracted. A meta-analysis of available results was performed when feasible. Twenty-three studies were included, with 290 cases of CVT in patients with BD. The incidence of CVT per 1,000 person-years was 3 (95%CI: 1C8), being higher in retrospective studies (3.2, 95%CI: 1C10) than in prospective studies (2.7, 95% CI: 1C13).Among patients with neurologic involvement, the incidence rate was 15.1/1,000 person-years. The onset was progressive in 77% of the patients. Intracranial hypertension syndrome was a frequent presentation of CVT in BD.The most frequent sites of occlusion were the superior sagittal and the transverse sinus. Most of the studies did not evaluate the prevalence of prothrombotic disorders. Treated CVT was associated with a good prognosis. CVT is a frequent neurological manifestation of BD. When treated,BD-associated CVT bears a good prognosis. There is insufficient information regarding the role of concomitant prothrombotic disorders and specific treatments.
</p>","/uploadfiles/image/20131012/20131012154227_4735w.jpg","/uploadfiles/file/20131012/20131012154149_7682.pdf",,10/12/2013,10/12/2013,"medicool",28,,"Cerebral venous thrombosis ;Behc?et’s disease;  Neuro-Behc?et syndrome",0,"67",29,"Cerebral venous thrombosis in Behc?et’s disease: a systematic review","2011",
204,,"DOI 10.1007/s00380-006-0973-6","Heart Vessels",,"<p align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A 26-year-old woman with intermittent fever was admitted to our hospital, and gradually developed facial edema. Examinations including computed tomography, transesophageal echocardiography, digital subtraction angiography,and pulmonary perfusion scintigraphy revealed intracardiac thrombus, superior vena cava syndrome, and pulmonary embolism. Clinical fi ndings and laboratory data led us to make a diagnosis of Beh?et’s disease. Combination of intracardiac thrombus, superior vena cava syndrome, and pulmonary embolism are rare complications in Beh?et’s disease. Beh?et’s disease should be considered in the differential diagnosis of intracardiac mass of the right heart, and early diagnosis and treatment are essential for the management of Beh?et’s disease especially with largevessel manifestations. In addition to a case report, we review the literature and report the characteristics of intracardiac thrombus in Beh?et’s disease.
</p>",,"/uploadfiles/file/20131012/20131012162403_0723.pdf",,10/12/2013,10/12/2013,"medicool",26,,,0,"67",29,"Intracardiac thrombus, superior vena cava syndrome, and pulmonary embolism in a patient with Beh?et’s disease: a case report and literature review","2007",
206,,"DOI 10.1007/s00296-008-0578-8","Y. K. Hong ・ W. H. Yoo","Rheumatol Int","<p align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Massive gastrointestinal bleeding is a very rare manifestation of gastrointestinal Beh?et’s disease, mainly from the gastrointestinal mucosal lesions. We report herein the case of a 50-year-old man with intestinal Beh?et’s disease who suVered massive hemorrhage from ruptured arterial aneurysm. Colonoscopy demonstrated large amount of fresh blood in the entire colon, but we were not able to localize bleeding focus anywhere in the colon. Angiography was performed and it revealed that a small aneurysm on the right ileocolic artery with apparent extravasation of contrast material. A guiding catheter was inserted to a right ileocolic artery and superselective arterial embolization using microcoils was successful. Following this procedure, the gastrointestinal bleeding gradually subsided and completely stopped within a few days. He is now treating with prednisolone and sulfasalazine without recurrent bleeding until now.
</p>
<p>
	&nbsp;
</p>","/uploadfiles/image/20131012/20131012163423_0330w.jpg","/uploadfiles/file/20131012/20131012163141_1827.pdf",,10/12/2013,10/12/2013,"medicool",33,,"Beh?et’s disease ; Gastrointestinal bleeding ;Arterial aneurysm",0,"67",29,"Massive gastrointestinal bleeding due to the rupture of arterial aneurysm in Beh?et’s disease: case report and literature review","2008",
205,"由ExophialaXenobiotica引发皮下暗色丝孢霉病的非霍奇金淋巴瘤患者",,"YUMI AOYAMA*, MASAYO NOMURA, SHINYA YAMANAKA, YOKO OGAWA & YASUO KITAJIMA","Medical Mycology February","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span><span>Phaeohyphomycosis
is a rare fungal infection that is more commonly associated with immunocompromised
patients.</span></span><span> <a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span>We present a case in which a 77-year-old woman
with non-Hodgkin lymphoma developed subcutaneous phaeohyphomycosis caused by
Exophiala xenobiotica.</span> <a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span>E. xenobiotica is a dematiaceous hyphomycete
that was recently identified as a segregant of the E. </span><a name=""OLE_LINK23""></a><a name=""OLE_LINK22""></a><span><span><span>jeanselmei</span></span></span><span><span> complex. </span></span><a name=""OLE_LINK18""></a>The patient was successfully treated with
local excision of the lesions and post-surgical oral itraconazole. <a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span><span>The
latter was administered with the aim of </span></span><a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span><span><span><span>preventing systemic dissemination in this immunocompromised patient.<br />
	<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
		<span style=""font-family:宋体;color:#313131;"">暗色丝孢霉病</span><span style=""font-family:宋体;"">是一种罕见的真菌感染性疾病，</span><span style=""font-family:宋体;color:#313131;"">在免疫功能低下的患者中较为常见。</span><span style=""font-family:宋体;"">我们报导一例<span>77</span>岁（女性）伴有</span><span style=""font-family:宋体;"">非霍奇金淋巴瘤<a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span>由</span></span><span><span><span>E</span></span></span><span><span><span>xoph</span></span></span><span><span><span>ialaXenobiotica</span></span></span><span></span><span></span><span style=""font-family:宋体;color:#313131;"">引发的皮下暗色丝孢霉病的患者<span>E. xenobiotica</span>是一种暗色丝孢菌，近来被认为是</span><span style=""font-family:&quot;color:#313131;""></span><span style=""font-family:宋体;color:#313131;""> 甄氏外瓶霉复合体的一种分离体。通过局部切除病变皮损以及</span><span style=""font-family:宋体;"">术后口服伊曲康唑，患者被成功治愈。应用后者（口服伊曲康唑）的目的是为了防止在免疫功能低下的患者中出现全身性的播散。</span><span style=""font-family:宋体;color:#313131;""></span>
	</p>
<br />
</span></span></span></span></span>
</p>","/uploadfiles/image/20131012/20131012162958_0197w.png","/uploadfiles/file/20131012/20131012163050_1238.pdf",,10/12/2013,10/12/2013,"medicool",30,,"phaeohyphomycosis, Exophiala xenobiotica, Exophiala jeanselmei",0,"66",20,"Subcutaneous phaeohyphomycosis caused by Exophiala xenobiotica in a non-Hodgkin lymphoma patient","2009",
208,,"10.1080/13693780701861470","D. A. SUTTON, B. L. WICKES, E. H. THOMPSON, M. G. RINALDI, R. M. ROLAND, M. C. LIBAL, K. RUSSELL & S. GORDON","Medical Mycology","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; Phialemonium curvatum, frequently misidentified as an Acremonium species, is reported here as a new agent of pulmonary phaeohyphomycosis in a Standard Poodle dog, and added as a new species in the genus to cause mycoses in canines. In vitro susceptibility data, for both human and animal isolates, suggests resistance to amphotericin B and susceptibility to the triazole agents itraconazole, voriconazole, and posaconazole.</span> 
</p>
<br />",,"/uploadfiles/file/20131012/20131012164712_7539.pdf",,10/12/2013,10/14/2013,"medicool",28,,"Phialemonium curvatum, canine, systemic phaeohyphomycosis",0,"65",20,"Pulmonary Phialemonium curvatum phaeohyphomycosis in a Standard Poodle dog","2008",
209,,"10.3109/13693780903471081","SOPHIA KOO, MICHAEL KLOMPAS & FRANCISCO M. MARTY","Medical Mycology","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; We report a case of Fonsecaea monophora cerebral phaeohyphomycosis successfully treated with surgical excision and voriconazole monotherapy in a patient receiving main- tenance immunosuppression therapy for 8 years after cadaveric renal transplantation. She presented with a severe frontal headache in the absence of any constitutional or neurologic symptoms. Brain magnetic resonance imaging showed an irregular 3.1  3.4 cm ring-enhancing lesion in her left frontal lobe. The patient underwent craniotomy and resection of her mass, with intraoperative spillage of some of her abscess contents into her lateral ventricle. Histopathology of her resected mass showed necrotic fragments of brain parenchyma with granulomatous infl ammation and numerous pigmented fungal forms. A mold, recovered from cultures inoculated with portions of her brain resec- tion specimen, was later defi nitively identifi ed as Fonsecaea monophora. Initial serum (1→3) β-D-glucan (BG) levels exceeded 500 pg/ml. The patient received voriconazole, which she tolerated well, without recurrent headaches or abscess formation noted on serial brain imaging. Her BG declined to 31 pg/ml one year following her abscess resection. She discontinued antifungal therapy after an 18-month treatment course, and has remained free of any clinical or radiographic evidence of recurrent abscess&nbsp; formation three years later.</span> 
</p>
<br />",,"/uploadfiles/file/20131012/20131012164958_6914.pdf",,10/12/2013,10/14/2013,"medicool",29,,"Fonsecaea monophora, cerebral phaeohyphomycosis, beta-glucan, voriconazole",0,"65",20,"Fonsecaea monophora cerebral phaeohyphomycosis: case report of successful surgical excision and voriconazole treatment and review","2010",
215,"暗色丝孢霉病的治疗进展","10.3760/cma.j.issn.1673-4173.2009.02.02","桑红 邓德权 谢其 美 何威","国际皮肤性病学杂志","<p>
	&nbsp;&nbsp; 暗色丝孢霉病是 由一大组条件致病性暗色真菌 引起 的浅表组织及皮肤 、角膜 、皮下组织甚至系统 性感染 ，其病原菌在寄生组织内主要以暗色分 隔菌 丝为特征 ，还可见有发芽或不发芽 的酵母样细胞 。 暗色丝孢霉病的病原真菌种类繁多，包含 50余属 100余种暗色真菌，较重要的致疴I生暗色真菌包括 链格孢 、离蠕孢 、斑替枝孢霉 、旁孢霉 、外瓶霉 、裴 氏 着色霉 、马杜拉分支菌属 、瓶霉菌属 、足放 线病菌 属、柱霉属、皮炎瓶霉属等。
</p>
<p>
	&nbsp; 根据致病性暗色真菌侵犯部位 的不同 ，可将暗 色丝孢霉病分为 5种临床类型：浅表型暗色丝孢霉 病 、暗色真菌性角膜炎 、皮肤和皮下组织 暗色丝孢 霉病 、暗色丝孢霉所致的甲真菌病 、系统性暗色丝 孢霉病。暗色丝孢霉病患者常需长期 、大量服用抗 真菌药物 ，但疗效往往欠佳。对于皮肤 、鼻窦 、脑 的 某些局限性损害 ，可考虑在使用抗真菌药物的基础 上进行手术治疗。但已有一些关于暗色丝孢霉病复 发、在治疗中病情仍有进展或患者对抗真菌药物治 疗抵抗的报道 。新的抗真菌药物的开发和联合治疗 可能改善暗色丝孢霉病的疗效。
</p>
<br />",,"/uploadfiles/file/20131012/20131012171214_9585.pdf",,10/12/2013,10/14/2013,"medicool",47,,,0,"67",20,,"2009",
216,,"10.3349/ymj.2013.54.5.1084","Park JJ ; Kim WH ; Cheon JH",,"<span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beh?et's<span class=""Apple-converted-space"">&nbsp;</span></span>disease<span style=""font-size:12px;font-family:Tahoma, Verdana, Arial, sans-serif;font-variant:normal;white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font-style:normal;orphans:2;widows:2;display:inline !important;letter-spacing:normal;line-height:16px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span>(BD) is a multisystem inflammatory disorder that presents as recurrent oral and genital ulcers in conjunction with other dermatological and ocular manifestations. The prevalence of BD is higher in Middle and East Asia than in Western countries. Intestinal BD is a specific subtype of BD, characterized by intestinal ulcers and associated gastrointestinal symptoms. Similar to inflammatory bowel<span class=""Apple-converted-space"">&nbsp;</span></span>disease<span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">, intestinal BD exhibits a fluctuating</span>disease<span style=""white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font:12px/16px Tahoma, Verdana, Arial, sans-serif;orphans:2;widows:2;display:inline !important;letter-spacing:normal;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span>course with repeated episodes of relapse and remission that necessitate adequate maintenance therapy after achievement of clinical remission. Medical treatment of intestinal BD is largely empirical since well-controlled studies have been difficult to perform due to the heterogeneity and rarity of the<span class=""Apple-converted-space"">&nbsp;</span></span>disease<span style=""font-size:12px;font-family:Tahoma, Verdana, Arial, sans-serif;font-variant:normal;white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font-style:normal;orphans:2;widows:2;display:inline !important;letter-spacing:normal;line-height:16px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">. To date, 5-aminosalicylic acid, systemic corticosteroids, and immunosuppressants have been used anecdotally to treat intestinal BD. The clinical course of intestinal BD shows considerable variability, and the exact point at which more potent agents such as immunosuppressants should be used has not yet been elucidated. Given the difficulty in predicting which patients will experience complicated<span class=""Apple-converted-space"">&nbsp;</span></span>disease<span style=""font-size:12px;font-family:Tahoma, Verdana, Arial, sans-serif;font-variant:normal;white-space:normal;text-transform:none;word-spacing:0px;float:none;color:#333333;font-style:normal;orphans:2;widows:2;display:inline !important;letter-spacing:normal;line-height:16px;background-color:#ffffff;text-indent:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span class=""Apple-converted-space"">&nbsp;</span>courses and the fact that these drugs are related with certain risk resulting from immunosuppression, proper identification of prognostic factors in intestinal BD may allow physicians to implement tailored medical therapy and individualized patient monitoring based on risk stratification. In this review, the impact of baseline characteristics on the long-term course of intestinal BD, prognostic factors during various medical therapies, and outcome predictors related to surgery will be discussed.</span>",,"/uploadfiles/file/20131012/20131012171947_0005.pdf",,10/12/2013,10/14/2013,"medicool",46,,"intestinal Beh?et’s disease, prognostic factors, medical treatment, 
surgical treatment",0,"66",29,"Outcome predictors for intestinal Beh?et's disease","2013",
210,,"10.1080/13693780600895181","S. A. MARQUES, R. M. P. CAMARGO, R. C. SUMMERBELL, G.S. DE HOOG, P. ISHIOKA,","Medical Mycology","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; A 49-year-old renally transplanted man, under a five-year course of immunosup- pressive therapy with prednisone and cyclosporine A, experienced a subcutaneous phaeohyphomycosis caused by Phaeoacremonium parasiticum. The clinical pre- sentation consisted of impressive, large, inflammatory and draining cystic tumors on the left foot that had been present for one year. A significant improvement was obtained with itraconazole plus intralesional injection with amphotericin B. Drug interaction was observed between itraconazole and cyclosporine A causing a severe hypertensive crisis and requiring a temporary sharp reduction in cyclosporine administration. Subcutaneous phaeohyphomycosis caused by P. parasiticum is uncommon among major organ transplant patients but several cases have previously been published and some patterns are emerging, e.g., limbs are generally involved but no known traumatic event has preceded lesion development. The identification of the case isolate was confirmed using a recently published online system based in part on b-tubulin sequence comparison.</span> 
</p>",,"/uploadfiles/file/20131012/20131012165501_3787.pdf",,10/12/2013,10/14/2013,"medicool",23,,"subcutaneous phaeohyphomycosis, Phaeoacremonium parasiticum, kidney transplant, immunosuppressive therapy",0,"85",20,"Subcutaneous phaeohyphomycosis caused by Phaeoacremonium parasiticum in a renal transplant patient","2006",
211,,"10.1111/j.1751-0813.2006.00068.x","IM SWIFT, A GRIFFIN and MA SHIPSTONE","Australian Veterinary Journal","<p>
	<span style=""font-family:Times New Roman;"">&nbsp;</span><span style=""font-family:Times New Roman;""> A 7-year-old castrated male Whippet developed deep ulcerative skin lesions whilst receiving immunosuppressive doses of prednisolone and cyclosporine for the treatment of immune- mediated haemolytic anaemia. The lesions were determined to be a phaeohyphomycosis, caused by&nbsp; Curvularia lunata . The dog was treated with a combination of systemic antifungals and weaning off immunosuppressants and made a complete recovery. To the authors’ knowledge, this is the ?rst case report of the successful treatment of disseminated cutaneous phaeohyphomycosis in a dog.</span><span style=""font-family:Times New Roman;""></span> 
</p>",,"/uploadfiles/file/20131012/20131012165706_2881.pdf",,10/12/2013,10/14/2013,"medicool",26,,"amphotericin B, cutaneous phaeohyphomycosis, dermatology, fungus",0,"85",20,"Successful treatment of disseminated cutaneous phaeohyphomycosis in a dog","2006",
212,,,"Sean M. Hussey, MD; Rita Gander, PhD; Paul Southern, MD; Mai P. Hoang, MD","Arch Pathol Lab Med","<p>
	&nbsp; <span style=""font-family:Times New Roman;"">Primary subcutaneous phaeohyphomycosis can rarely be caused by Cladophialophora bantiana , and we present the histologic and culture ?ndings of such a case. A 32-year- old African American woman with systemic lupus erythe- matosus presented with a 2-year history of multiple, re- current, tender, and ulcerated skin nodules with purulent drainage on her upper back. Histologic sections of the ex- cision demonstrated features of phaeohyphomycosis. Cul- ture ?ndings were characteristic of C bantiana . Of interest, at age 10 she had sustained traumatic implantation of wood splinters into this area during a tornado, yet clinical symptoms of a subcutaneous infection did not manifest un- til she developed lupus erythematosus at age 27. Our case highlights the role of trauma and immunosuppression in the pathogenesis of subcutaneous phaeohyphomycosis.</span> 
</p>",,"/uploadfiles/file/20131012/20131012170035_8589.pdf",,10/12/2013,10/14/2013,"medicool",38,,,0,"66",20,"Subcutaneous Phaeohyphomycosis Caused by Cladophialophora bantiana","2005",
222,"短期口服伊曲康唑治疗体癣和股癣",,"Sanmano B ; Hiruma M ; Mizoguchi M ; Ogawa H","Blackwell Publishing","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-family:'Times New Roman','serif';background:white;color:black;""><span style=""font-size:16px;"">The present study was designed to determine the lowest dose of orally administered itraconazole and the shortest duration of therapy necessary for treatment of</span><span class=""apple-converted-space"" style=""font-size:16px;"">&nbsp;</span><span style=""font-size:16px;"">tinea</span><span class=""apple-converted-space"" style=""font-size:16px;"">&nbsp;</span><span style=""font-size:16px;"">corporis and</span><span class=""apple-converted-space"" style=""font-size:16px;"">&nbsp;</span><span style=""font-size:16px;"">tinea</span><span class=""apple-converted-space"" style=""font-size:16px;"">&nbsp;</span><span style=""font-size:16px;"">cruris</span><span style=""font-size:16px;"">. For all patients, the itraconazole dose was 100 mg twice a day immediately after meals. Twenty-eight patients received itraconazole on days 1 and 8, 12 patients received itraconazole on days 1 and 2, and five patients received itraconazole only on day 1. Clinical and mycological evaluations were performed at baseline and on day 14. Based on the clinical and mycological responses, treatment efficacy was classified as excellent, good, fair, or poor. ""Excellent"" and ""good"" responses made up 86% of the first group, 100% of the second group, and 20% of the third group. A comparison of efficacy ratings of the three regimens showed that the patients who received a single 200-mg dose had a significantly inferior outcome compared with the other two groups. We conclude that an abbreviated oral regimen of itraconazole for treatment of</span><span class=""apple-converted-space"" style=""font-size:16px;"">&nbsp;</span><span style=""font-size:16px;"">tinea</span><span class=""apple-converted-space"" style=""font-size:16px;"">&nbsp;</span><span style=""font-size:16px;"">corporis and</span><span class=""apple-converted-space"" style=""font-size:16px;"">&nbsp;</span><span style=""font-size:16px;"">tinea</span><span class=""apple-converted-space"" style=""font-size:16px;"">&nbsp;</span><span style=""font-size:16px;"">cruris</span><span class=""apple-converted-space"" style=""font-size:16px;"">&nbsp;</span><span style=""font-size:16px;"">r</span><span style=""font-size:16px;"">equires a total dose of at least 400 mg to induce a favorable outcome.</span><br />
<span style=""font-size:16px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">本研究旨在确定对于体癣和股癣治疗，口服伊曲康唑的最低用药量及进行必要治疗的最短时限。所有患者饭后立即服用伊曲康唑，一天两次</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">,</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">每次</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">100mg</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">。</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">28</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">名患者在第</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">1</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">天和第</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">8</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">天服用伊曲康唑，</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">12</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">名患者在第</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">1</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">天和第</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">2</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">天服用（伊曲康唑），</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">5</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">名患者仅在第</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">1</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">天服用（伊曲康唑）。在用药初始和第</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">14</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">天，进行临床与真菌学评估。根据临床和真菌学反应，疗效被分为优秀、良好、一般、较差（四个等级）。“优秀”和“良好”反应占第一组的</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">86%</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">，第二组的</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">100%</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">，第三组的</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">20%</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">。对这</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">3</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">种方案的疗效评级进行比较，表明接受单一</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">200mg</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">治疗剂量患者的疗效明显低于其他两组。我们推断：通过小剂量口服伊曲康唑来治疗体癣和股癣，其总用药量至少要达到</span><span style=""font-size:16px;font-family:'Times New Roman','serif';background:white;color:black;"">400mg</span><span style=""font-size:16px;font-family:宋体;background:white;color:black;"">才能产生良好的效果。</span><span style=""font-family:'Times New Roman','serif';background:white;color:black;""></span><br />
</span>","/uploadfiles/image/20131016/20131016101828_5813w.png","/uploadfiles/file/20131016/20131016101858_3929.pdf",,10/16/2013,10/16/2013,"medicool",43,,"Tinea corporis, tinea cruris, antimycotic chemotherapy, itraconazole, basal dose",0,"66",65,"Abbreviated oral itraconazole therapy for tinea corporis and tinea cruris","2003",
258,,,"Peter Mayser, Inga Rieche","XuJ et al., Proc Natl Acad Sci USA","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The clinical phenomena of pityriasis versicolor (PV), a common Malassezia-associated </span><span style=""font-family:Times New Roman;font-size:14px;"">skin disease, such as hyperpigmentation, depigmentation and fluorescence of the </span><span style=""font-family:Times New Roman;font-size:14px;"">lesions may at least partly be explained by the generation of Trp-derived indole </span><span style=""font-family:Times New Roman;font-size:14px;"">pigment through the action of transaminase 1 (TAM 1). Cycloserine, a TAM inhibitor, </span><span style=""font-family:Times New Roman;font-size:14px;"">was able to completely inhibit pigment production in M. furfur in vitro in a dosedependent </span><span style=""font-family:Times New Roman;font-size:14px;"">manner. Application of a 0.2-mol l)1 aqueous cycloserine solution b.i.d. for </span><span style=""font-family:Times New Roman;font-size:14px;"">5 days in three patients with hyperpigmented PV resulted in complete healing within </span><span style=""font-family:Times New Roman;font-size:14px;"">3C5 days without side-effects. Topically applied TA inhibitors may therefore </span><span style=""font-family:Times New Roman;font-size:14px;"">represent a new therapeutic principle for prophylaxis and therapy of PV, thus </span><span style=""font-family:Times New Roman;font-size:14px;"">underlining the importance of the TAM pathway for the pathogenesis of the disease.</span> 
</p>","/uploadfiles/image/20131016/20131016162050_5579w.jpg","/uploadfiles/file/20131016/20131016162009_6234.pdf",,10/16/2013,10/16/2013,"medicool",19,,"Patients and methods;Malassezia-associated;pityriasis versicolor",0,"65",4,"Rapid reversal of hyperpigmentation in pityriasis versicolor upon short-term topical cycloserine application","2009",
213,,"10.1080/13693780802172017","Mani RS ; Chickabasaviah YT ; Nagarathna S ; Chandramuki A ; Shivprakash MR ; Vijayan J ; Prashantha DK ; Vasudevan PS ; Natarajan A ; Kovoor J","Medical Mycology","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; We report a case of cerebral phaeohyphomycosis caused by Scytalidium dimidiatum (synanamorph Nattrassia mangiferae) in a young, apparently immunocompetent Indian male. Etiological diagnosis was made by recovery of the fungus in culture and histopathological examination. The infection proved fatal despite aggressive antifungal therapy.</span> 
</p>
<br />",,"/uploadfiles/file/20131012/20131012170421_8097.pdf",,10/12/2013,10/14/2013,"medicool",42,,"Scytalidium dimidiatum, Scytalidium dimidiatum cerebral abscess, cerebral phaeohyphomycosis",0,"66",20,"Cerebral phaeohyphomycosis caused by Scytalidium dimidiatum : a case report from IndiaCerebral phaeohyphomycosis caused by Scytalidium dimidiatum : a case report from India","2008",
217,"由变种毛癣菌引起股癣的异常表现一例","10.1111/j.1346-8138.2008.00517.x","Khosravi AR ; Mansouri P ; Naraghi Z ; Shokri H ; Ziglari T","Journal of Dermatology","<span style=""font-size:10.5pt;font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp;&nbsp; Tinea cruris is a subacute or chronic dermatophytosis. This report describes a 30-year-old man presenting with a history of bullous erythematous along with itching of his crural regions. On the basis of clinical findings, the lesions were diagnosed as contact dermatitis and pustular psoriasis, so he was treated by local and systemic corticosteroids but pustular lesions were progressed on the affected sites. By using mycological and histological examinations, dermatophytosis caused by Trichophyton mentagrophytes var. mentagrophytes was confirmed.The patient was successfully treated with itraconazole and local antifungal treatments.<br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
<p class=""MsoNormal"" style=""text-align:left;text-indent:21pt;"" align=""left"">
	<span style=""font-family:宋体;"">股癣是一种亚急性或慢性皮肤真菌病。报告描述了一位</span><span style=""font-family:'Times New Roman','serif';"">30</span><span style=""font-family:宋体;"">岁的男性患者，该患者表现有伴随脚部瘙痒的大疱性红斑病史。基于临床研究结果，该皮损被诊断为接触性皮炎和脓疱性银屑病，因此对他实施局部和系统性皮质类固醇的治疗，但脓疱皮损在感染部位仍发展。通过真菌学和组织学检查，确诊了该皮肤真菌病是由变种毛癣菌感染所引起。使用伊曲康唑以及进行局部抗真菌治疗，成功治愈了该患者。</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
</span>","/uploadfiles/image/20131015/20131015112700_6675w.png","/uploadfiles/file/20131015/20131015112732_2108.pdf",,10/15/2013,10/16/2013,"medicool",39,,"tinea cruris, trichophyton mentagrophytes, itraconazole.",0,"65",65,"Unusual presentation of tinea cruris due to Trichophyton mentagrophytes var. mentagrophytes","2008",
228,"美国花斑癣的治疗","DOI: 10.1080/09546630410032421","LA Mellen, J Vallee, SR Feldman ，AB Fleischer, Jr","Journal of Dermatological Treatment","<p class=""MsoNormal"" align=""justify"">
	<a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span style=""font-size:14px;""><b><span style=""font-size:14px;"">BACKGROUND: </span></b></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span><span><span style=""font-size:14px;"">Pityriasis versicolor is a common chronic superficial </span><span style=""font-size:14px;"">fungal infection of the skin.</span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><b><span style=""font-family:宋体;""><span style=""font-size:14px;"">研究背景：</span><br />
<span style=""font-size:14px;""></span></span></b></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">花斑癣是</span></span></span><span><span><span style=""color:#313131;font-family:宋体;""><span style=""font-size:14px;"">一种常见的慢性浅表性真菌感染疾病。</span><br />
<span style=""font-size:14px;""></span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:&quot;font-size:14px;"">OBJECTIVE: </span></b></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">The purpose of this study is to determine the frequency </span><span style=""font-size:14px;"">of visits for pityriasis versicolor and to assess how it is currently being </span><span style=""font-size:14px;"">treated.</span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><b><span style=""font-family:宋体;""><span style=""font-size:14px;"">研究目的：</span><br />
<span style=""font-size:14px;""></span></span></b></span></span><span><span><span style=""font-family:宋体;""><span style=""font-size:14px;"">本研究旨在确定花斑癣患者的就诊次数以及评估目前如何治疗。</span><span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:&quot;font-size:14px;"">METHODS: </span></b></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:14px;"">Data from the National Ambulatory Medical Care survey </span><span style=""font-family:Times New Roman;font-size:14px;"">were used from the years 1990C1999.</span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><b><span style=""font-family:宋体;""><span style=""font-size:14px;"">研究方法：</span><span></span></span></b></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><span style=""font-family:宋体;""><span style=""font-size:14px;"">本研究采用从</span><span style=""font-size:14px;"">1990</span><span style=""font-size:14px;"">年至</span><span style=""font-size:14px;"">1999</span><span style=""font-size:14px;"">年期间，全国非卧床病人医疗护理调查数据。</span><span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><b><span style=""font-family:&quot;font-size:14px;"">RESULTS:</span></b></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span><span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">There were 2.9 </span><span style=""font-size:14px;"">million visits per year in which pityriasis (tinea) versicolor was listed as a </span><span style=""font-size:14px;"">diagnosis;</span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-family:&quot;&quot;;""> <a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span><span><span><span style=""font-size:14px;"">this </span><span style=""font-size:14px;"">corresponds to a visit rate of 110 visits per 100 000 persons per year</span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;"">.</span></span></span></span></span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;&quot;;""> <a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span><span style=""font-size:14px;"">Visit rates varied among racial and ethnic </span><span style=""font-size:14px;"">groups, with the highest visit rates for black people and American </span><span style=""font-size:14px;"">Indians/Eskimos.</span></span> <a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span><span style=""font-size:14px;"">A total of 76% of the medications listed at </span><span style=""font-size:14px;"">visits for pityriasis versicolor are FDA approved for the condition</span></span><span style=""font-size:14px;"">; </span><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span><span style=""font-size:14px;"">however, </span><span style=""font-size:14px;"">many treatments that were prescribed were not.</span></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><span><span><b><span style=""font-family:宋体;""><span style=""font-size:14px;"">研究结果：</span><br />
<span style=""font-size:14px;""></span></span></b></span></span></span></span><span><span><span><span><span style=""font-family:宋体;""><span style=""font-size:14px;"">每年有</span><span style=""font-size:14px;"">290</span><span style=""font-size:14px;"">万花斑癣（癣）就诊者被列入诊断，</span></span></span></span></span></span><span><span><span><span><span class=""shorttext""><span style=""color:#222222;font-family:宋体;""><span style=""font-size:14px;"">这相当于每年每</span><span style=""font-size:14px;"">100</span><span style=""font-size:14px;"">万人中有</span><span style=""font-size:14px;"">110</span><span style=""font-size:14px;"">人的就诊率。在种族和族裔群体之间就诊率有所不同，</span></span></span></span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""color:#313131;font-family:宋体;font-size:14px;"">其中</span></span></span></span></span><span><span><span><span><span class=""shorttext""><span style=""color:#222222;font-family:宋体;""><span style=""font-size:14px;"">就诊率最高为黑人和美洲印第安人</span><span style=""font-size:14px;"">/</span><span style=""font-size:14px;"">爱斯基摩人。</span></span></span></span></span></span></span><span><span><span><span><span style=""color:#313131;font-family:宋体;""><span style=""font-size:14px;"">共有</span><span style=""font-size:14px;"">76%</span><span style=""font-size:14px;"">的治疗花斑癣的上市药物已被</span><span style=""font-size:14px;"">FDA</span><span style=""font-size:14px;"">批准；然而，还有许多治疗处方没有被批准。</span><span></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><b><span style=""font-family:Times New Roman;font-size:14px;"">CONCLUSIONS:</span></b></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:14px;"">Given that as many as one-quarter of treatments </span><span style=""font-family:Times New Roman;font-size:14px;"">prescribed for this easily treatable condition are inappropriate, </span></span></span><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><a name=""OLE_LINK32""></a><span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;</span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">continued education of medical practitioners</span></span></span></span></span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""> concerning appropriate treatment options is needed.</span></span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""color:#313131;font-family:宋体;""><span style=""font-size:14px;"">研究总结：</span><span></span></span></b> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;"" class=""shorttext""><span style=""color:#222222;font-family:宋体;font-size:14px;"">鉴于多达四分之一的治疗处方（对于这种很容易治疗的问题）的不恰当性执业医师的继续深造对于治疗方案的恰当选择是必要的。</span></span><span style=""color:#313131;font-family:宋体;""></span> 
</p>
<p align=""justify"">
	<br />
</p>
<span style=""display:none;"" id=""__kindeditor_bookmark_end_3__""></span>","/uploadfiles/image/20131016/20131016154912_3309w.jpg","/uploadfiles/file/20131016/20131016135553_4490.pdf",,10/16/2013,10/16/2013,"medicool",14,,"Fungal infection ；Health care delivery ；Skin",0,"66",4,"Treatment of pityriasis versicolor in the United States","2004",
229,"花斑癣及马拉色氏霉菌属物种微评","DOI 10.1007/s11046-006-0081-2","N. Morishita1 ， Y. Sei，Miu Skin Clinic， 1-26-14 Kamata,，Ohta-ku, Tokyo ，144-0052, Japan","Mycopathologia","<p align=""justify"">
	&nbsp;&nbsp;&nbsp; <a name=""OLE_LINK3""></a><span style=""font-family:Times New Roman;font-size:14px;"">Recently 11 </span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Malassezia </span></span><span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:14px;"">species were isolated. </span><a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><span><span style=""font-family:Times New Roman;font-size:14px;"">Attention has focused on </span><span style=""font-family:Times New Roman;font-size:14px;"">the relationship between </span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Malassezia </span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">species and </span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Malassezia </span></span></span></span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:14px;"">related disease.</span><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span> </span></span></span></span><a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a></span><span><span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:14px;"">The causal fungus of </span><span style=""font-family:Times New Roman;font-size:14px;"">Pityriasis versicolor</span></span></span></span></span></span></span><span><span><span><span style=""font-family:&quot;&quot;;""> <a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span style=""font-family:Times New Roman;font-size:14px;"">is </span></span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">M. globosa</span></span></span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">.</span></span></span></span></span></span><span><span style=""font-family:&quot;&quot;;""> <a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span style=""font-family:Times New Roman;font-size:14px;"">The conditions</span></span></span><span><span><span><span style=""font-family:&quot;&quot;;""> </span></span></span></span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:14px;"">of mycelial form </span><span style=""font-family:Times New Roman;font-size:14px;"">induction are not clear for </span></span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">M. globosa</span></span></span></span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:14px;"">.</span><br />
<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span></span></span><span style=""font-family:宋体;""><span style=""font-size:14px;"">近来 </span><span style=""font-size:14px;"">11</span><span style=""font-size:14px;"">种</span></span><span style=""color:#313131;font-family:宋体;font-size:14px;"">马拉色氏霉菌被分离</span><span style=""font-family:宋体;font-size:14px;"">。焦点集中到</span><span style=""color:#313131;font-family:宋体;""><span style=""font-size:14px;"">马拉色氏霉菌与马拉色氏霉菌相关疾病之间的关系。球形马拉色菌<span style=""font-family:Times New Roman;"">（</span></span><span style=""font-family:Times New Roman;font-size:14px;"">M.</span></span><span style=""font-family:Times New Roman;font-size:14px;"">globosa</span><span style=""font-family:Times New Roman;font-size:14px;"">）</span><span style=""color:#313131;font-family:宋体;font-size:14px;"">是</span><span style=""font-family:宋体;font-size:14px;"">引起</span><a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span style=""font-size:14px;""><span style=""color:#313131;font-family:宋体;font-size:14px;"">花斑癣真菌的原因</span></span><span></span><span></span><span style=""font-family:宋体;font-size:14px;"">。</span><span style=""color:#313131;font-family:Times New Roman;font-size:14px;"">M.</span><span style=""font-family:Times New Roman;font-size:14px;"">globosa</span><span style=""font-family:宋体;""><span style=""font-size:14px;"">（球形马拉色菌）菌丝体形成的诱导条件尚不清楚。</span><span></span></span><span style=""font-size:14px;"">&nbsp;</span> 
</p>","/uploadfiles/image/20131016/20131016154800_6020w.jpg","/uploadfiles/file/20131016/20131016140006_0134.pdf",,10/16/2013,10/16/2013,"medicool",18,,"Malassezia, Malassezia globosa, mycelial form, nested PCR, Pityriasis versicolor",0,"67",4,"Microreview of Pityriasis versicolor and Malassezia species","2006",
214,,"10.3109/13693780903383914","Taj-Aldeen SJ ; Almaslamani M ; Alkhalf A ; Al Bozom I ; Romanelli AM ; Wickes BL ; Fothergill AW ; Sutton DA","Medical Mycology","<p>
	<span style=""font-family:Times New Roman;"">&nbsp; </span><span style=""font-family:Times New Roman;"">Cerebral phaeohyphomycosis caused by Rhinocladiella mackenziei (formerly Ramichlo- ridium mackenziei) is extremely rare, and geographically limited to the Middle East. The fungus exclusively targets the brain and infections have a grave prognosis. Eighteen cases have been reported in the literature from 1983 to 2004 with almost 100% mortality. Our patient presented in February 2008 with a brain abscess while receiving chemotherapy for carcinoma of the breast. Diagnosis was by craniotomy and aspiration of the brain abscess. Direct microscopy showed dematiaceous fungal hyphae. R. mackenziei was recovered in culture and this identifi cation was confi rmed by molecular analysis. Examination of his- topathological sections of tissue from the brain biopsy revealed moniliform hyphae char- acteristic for phaeohyphomycosis. The patient failed to respond to antifungal therapy with amphotericin B and voriconazole or amphotericin B and posaconazole and fi nally expired 64 days after diagnosis. In vitro antifungal susceptibility testing showed this isolate to be resistant to amphotericin B while susceptible to itraconazole, voriconazole, and posaco- nazole. Previously published antifungal susceptibility data indicate that although strains show variable susceptibility to amphotericin B, the organism is generally refractory to treatment with this agent. Similar outcomes are seen with the azole agents used alone or in combination with other drugs. Although no specifi c risk factors have been identifi ed, the majority of cases have occurred in immunocompromised individuals. R. mackenziei is a highly virulent agent of serious cerebral phaeohyphomycosis, and should be considered in the differential diagnosis of central nervous system disease in the Middle East.</span><span style=""font-family:Times New Roman;""></span> 
</p>
<br />",,"/uploadfiles/file/20131012/20131012170851_5498.pdf",,10/12/2013,10/14/2013,"medicool",45,,"Rhinocladiella mackenziei, cerebral phaeohyphomycosis",0,"67",20,"Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei):  a taxonomic update and review of the literature","2010",
226,,,"Cohen AD ; Wolak A ; Alkan M ; Shalev R ; Vardy DA","International Journal Of Dermatology","<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;color:#231F20;"">Background </span></b><span style=""font-family:&quot;color:#231F20;"">Tinea pedis is a common infection in
soldiers. However, prevalence and risk factors for tinea pedis in soldiers were
investigated in only a few studies.<b></b></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;color:#231F20;"">Objectives </span></b><span style=""font-family:&quot;color:#231F20;"">To investigate the prevalence and risk
factors for tinea pedis in Israeli soldiers.<b></b></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;color:#231F20;"">Methods </span></b><span style=""font-family:&quot;color:#231F20;"">A cross-sectional study including
interviews, clinical skin examination and mycological tests was performed in
Israeli soldiers. The presence of tinea pedis was assessed using the Athlete’s
Foot Severity Index (AFSI), a scoring system that was developed in order to evaluate
the presence and severity of tinea pedis. In soldiers with clinical evidence of
tinea pedis (AFSI &gt; 1), scrapings were taken for direct microscopic
examination (20% KOH preparation) and fungal culture. Statistical analyses were
performed using chi-square or Fisher’s exact test for dichotomous variables (as
needed), or <i>t</i>-tests for continuous variables. Logistic regression was used
for multivariate analyses of dichotomous variables.<b></b></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;color:#231F20;"">Results </span></b><span style=""font-family:&quot;color:#231F20;"">Two hundred and twenty-three soldiers were
included in the study: 205 men (91.9%)<b> </b>and 18 women (8.1%). Mean age was
19.6 years (SD 1.0 year). Clinical point prevalence was<b> </b>60.1%.
Mycological point prevalence was 27.3%. Further analyses were performed using
the<b> </b>clinical point prevalence. Univariate analyses demonstrated that the
prevalence of tinea pedis<b> </b>varied with the setting of military training
(basic training: 70.3%, advanced infantry training:<b> </b>81.5%, armor
commander training: 56.4% and armor officer training: 34.8%) and was<b> </b>associated
with male gender, frequency of sock changes and the length of military service.<b> </b>A multivariate analysis demonstrated that tinea pedis was associated with
the setting of the<b> </b>military training (OR 1.6, 95% CI 1.2C2.1) and male
gender (OR 4.3, 95% CI 1.4C13.8);<b> </b>however, there was no association with
hygiene measures (e.g. frequency of changing socks<b> </b>or sleeping with
socks) or the length of military service.<b></b></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;color:#231F20;"">Conclusion </span></b><span style=""font-family:&quot;color:#231F20;"">Tinea pedis is highly prevalent in Israeli
soldiers. Association of tinea pedis with<b> </b>the setting of military
training suggests that contagious spread may be an important risk factor. We
suggest that environmental interventions should be planned to in order to
decrease the<b> </b>morbidity of tinea pedis among soldiers.<b></b></span>
</p>",,"/uploadfiles/file/20131016/20131016132335_3484.pdf",,10/16/2013,10/16/2013,"medicool",22,,,0,"65",60,"Prevalence and risk factors for tinea pedis in Israeli soldiers","2005",
225,,,"Tausch I ; Decroix J ; Gwiezdzinski Z ; Urbanowski S ; Baran E ; Ziarkiewicz M ; Levy G ; Del Palacio A","International Journal Of Dermatology","<p class=""MsoNormal"" align=""left"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">A total of 304 patients with a clinical diagnosis of
palmar-type tinea pedis or manus and a positive mycologic examination were
recruited into this double-blind, randomized, multicenter, phase III study.
Patients were randomized to receive either oral itraconazole 200 mg twice daily
(in the morning and evening) for 7 days, followed by placebo for 7 days (n = 153),
or placebo in the morning and oral terbinafine 250 mg in the evening for 14
days (n = 151).</span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">At the first visit and 1, 2, and 6 weeks after the start
of the study, signs and symptoms were assessed clinically, and scales were
taken for mycologic assessments (microscopy and culture). At weeks 1, 2, and 6,
the effectiveness of therapy was evaluated globally and given a rating of
healed (absence of signs and symptoms), marked improvement ( ≥ 50% clinical
improvement), considerable residual lesions ( &lt; 50% clinical improvement),
no change, or worsened. The primary efficacy parameter was the mycologic cure
rate at the follow-up end-point (week 6). </span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">The tolerability of the study medications was assessed at
weeks 1 and 2. Adverse events were recorded at weeks 1, 2, and 6. Routine
hematologic and biochemical tests were performed at the start of the study and
after 1 week of treatment.</span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">No significant differences were seen in the baseline
patient characteristics between the two groups. The rate of mycologic cure
(negative microscopy and culture test result) was 79% in the itraconazole group
and 80% in the terbinafine group at the follow-up end-point. The analysis of
the 90% confidence interval for the difference between the treatment groups (C7.1,
5.4) and the outcome of the Blackwelder test (for two one-sided tests, P = 0.013
and P = 0.029) showed the two treatments to be equivalent.</span>
</p>",,"/uploadfiles/file/20131016/20131016121316_1650.pdf",,10/16/2013,10/16/2013,"medicool",22,,,0,"65",60,"Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus","1998",
251,,"DOI 10.1007/s00105-012-2380-5","P.A. Mayser ・ J. Preuss","Der Hautarzt","<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pityriasis versicolor (PV) ist eine der h?ufigsten erregerbedingten Hauterkrankungen sowie weltweit die h?ufigste Dermatose, die mit Pigmentverschiebungen der Haut einhergeht. In den gem??igten Breitengraden findet sich PV bei ca. 1% der Bev?lkerung mit erh?hter Inzidenz w?hrend der Sommermonate, in den Tropen ist sie bei bis zu 50% der dermatologischen Patienten zu finden.</span>","/uploadfiles/image/20131016/20131016153619_4588w.jpg","/uploadfiles/file/20131016/20131016153553_7655.pdf",,10/16/2013,10/16/2013,"medicool",36,,,0,"67",4,"Pityriasis versicolor：Aktuelles zu einer alten Erkrankung","2012",
249,"治疗股癣的最佳方案",,"Nadalo D ; Montoya C ; Hunter-Smith D","Quadrant HealthCom","<p class=""MsoNormal"" style=""text-indent:26.25pt;"">
	<span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;"">After clinical diagnosis and microscopic confirmation, </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">cruris</span><span style=""font-size:14px;""> is best treated with a topical allylamine or an azole antifungal (strength of recommendation: A, based on multiple randomized controlled trials [RCTs]). Differences in current comparison data are insufficient to stratify the 2 groups of topical antifungals. Determining which group to use depends on patient compliance, medication accessibility, and cost. The fungicidal allylamines (naftifine and terbinafine) and butenafine (allylamine derivative) are a more costly group of topical </span><span style=""font-size:14px;"">tinea</span><span style=""font-size:14px;""> treatments, yet they are more convenient as they allow for a shorter duration of treatment compared with fungistatic azoles (clotrimazole, econazole, ketoconazole, oxiconazole, miconazole, and sulconazole).&nbsp;
</p>
<p class=""MsoNormal"" style=""text-align:left;text-indent:26.25pt;"" align=""left"">
	<span style=""font-family:宋体;"">经临床诊断和微观确诊后，股癣的最佳治疗方法是用烯丙胺或唑类抗真菌药物进行局部治疗（建议用量：</span><span style=""font-family:'Times New Roman','serif';"">A</span><span style=""font-family:宋体;"">，基于多个随机对照实验【</span><span style=""font-family:'Times New Roman','serif';"">RCTs</span><span style=""font-family:宋体;"">】）</span><span style=""font-family:'Times New Roman','serif';"">.</span><span style=""font-family:宋体;"">将现有的数据进行比较得到的差异不足以区分这两组的抗真菌效果。哪个组用哪种药取决于患者的遵医行为，药物敏感性以及治疗所需要的花费（都是影响因素）。虽然杀真菌性烯丙胺类药物（萘替芬和特比萘芬）和布替奈芬类药物（烯丙胺类）在局部癣治疗上花费较高，但是它们更方便，因为与抑菌性唑类药物相比，这组药物的疗程较短。</span><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
</span></span>","/uploadfiles/image/20131016/20131016153027_5533w.png","/uploadfiles/file/20131016/20131016152701_9294.pdf",,10/16/2013,10/16/2013,"medicool",35,,,0,"67",65,"What is the best way to treat tinea cruris","2006",
230,"Case Report. Pityriasis versicolor mimicking Pityriasis rotunda",,"Nicola Aste, Monica Pau, Natalia Aste and P. Biggio","MYCOSES","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pityriasis versicolor is a common </span><span style=""font-family:Times New Roman;font-size:14px;"">dermatomycosis, occurring throughout the world,</span><span style=""font-family:Times New Roman;font-size:14px;"">characterized by irregular, slightly scaly patches, </span><span style=""font-family:Times New Roman;font-size:14px;"">varying in color from red/light brown to white. </span><span style=""font-family:Times New Roman;font-size:14px;"">Pityriasis rotunda, on the other hand, is an </span><span style=""font-family:Times New Roman;font-size:14px;"">uncommon disease, reported in specific ethnic </span><span style=""font-family:Times New Roman;font-size:14px;"">groups, and characterized by perfectly round or </span><span style=""font-family:Times New Roman;font-size:14px;"">oval&nbsp;atches of varying color, with a scaly surface. </span><span style=""font-family:Times New Roman;font-size:14px;"">The histologic pattern is that of ichthyosis </span><span style=""font-family:Times New Roman;font-size:14px;"">vulgaris. We report here the case of a male </span><span style=""font-family:Times New Roman;font-size:14px;"">patient, aged 31, from Sardinia (Italy), affected </span><span style=""font-family:Times New Roman;font-size:14px;"">by Pityriasis versicolor mimicking Pityriasis </span><span style=""font-family:Times New Roman;font-size:14px;"">rotunda. Mycological examination allowed us to </span><span style=""font-family:Times New Roman;font-size:14px;"">formulate the correct diagnosis, and ensuing treatment </span><span style=""font-family:Times New Roman;font-size:14px;"">with antifungal drugs was entirely successful. </span><span style=""font-family:Times New Roman;font-size:14px;"">The authors, while pointing out the rarity of </span><span style=""font-family:Times New Roman;font-size:14px;"">this case, stress the possibility that Pityriasis versicolor </span><span style=""font-family:Times New Roman;font-size:14px;"">mimics Pityriasis rotunda and vice-versa, </span><span style=""font-family:Times New Roman;font-size:14px;"">especially in those countries in which the two diseases </span><span style=""font-family:Times New Roman;font-size:14px;"">are endemic. More widespread recourse to </span><span style=""font-family:Times New Roman;font-size:14px;"">microscopic examination can help avoid the risk </span><span style=""font-family:Times New Roman;font-size:14px;"">of mistaken diagnosis and consequent incorrect </span><span style=""font-family:Times New Roman;font-size:14px;"">treatment.</span> 
</p>","/uploadfiles/image/20131016/20131016154655_6123w.jpg","/uploadfiles/file/20131016/20131016141650_1560.pdf",,10/16/2013,10/16/2013,"medicool",21,,"Malassezia, Pityriasis versicolor, Pityriasis rotunda",0,"85",4,"病例报告：形如圆形糠疹的花斑癣","2002",
231,,,"Faergemann J ; M?rk NJ ; Haglund A ; Odeg?rd T","Blackwell Scientific Publications","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In</span> <span style=""font-size:14px;"">a</span> <span style=""font-size:14px;"">double</span><span style=""font-size:14px;"">-</span><span style=""font-size:14px;"">blind</span><span style=""font-size:14px;"">, parallel group </span><span style=""font-size:14px;"">study</span><span style=""font-size:14px;""> we compared </span><span style=""font-size:14px;"">fluconazole</span><span style=""font-size:14px;""> 150 mg once weekly with </span><span style=""font-size:14px;"">griseofulvin</span><span style=""font-size:14px;""> 500 mg once daily for 4-6 weeks </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> the </span><span style=""font-size:14px;"">treatment</span><span style=""font-size:14px;""> of </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">corporis</span><span style=""font-size:14px;""> or </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">cruris</span><span style=""font-size:14px;"">. Eighty-four of 114 patients (74%) (39% after 3 weeks) were clinically cured </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> the </span><span style=""font-size:14px;"">fluconazole</span><span style=""font-size:14px;""> group compared with 72 of 116 (62%) (39% after 3 weeks) </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> the </span><span style=""font-size:14px;"">griseofulvin</span><span style=""font-size:14px;""> group (P = 0.06). </span><span style=""font-size:14px;"">In</span><span style=""font-size:14px;""> the </span><span style=""font-size:14px;"">fluconazole</span><span style=""font-size:14px;""> group 78% were mycological cured compared with 80% </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> the </span><span style=""font-size:14px;"">griseofulvin</span><span style=""font-size:14px;""> group. </span><span style=""font-size:14px;"">In</span><span style=""font-size:14px;""> the </span><span style=""font-size:14px;"">fluconazole</span><span style=""font-size:14px;""> group nine patients (7.5%) had </span><span style=""font-size:14px;"">treatment</span><span style=""font-size:14px;""> related adverse events and </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> the </span><span style=""font-size:14px;"">griseofulvin</span><span style=""font-size:14px;""> group 15 patients (12.5%) had adverse events. </span><span style=""font-size:14px;"">Fluconazole</span><span style=""font-size:14px;""> 150 mg once weekly for 6 weeks is both clinically and mycologically effective </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> the </span><span style=""font-size:14px;"">treatment</span><span style=""font-size:14px;""> of </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">corporis</span><span style=""font-size:14px;""> and </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">cruris</span><span style=""font-size:14px;""> and few side-effects were reported.</span>",,"/uploadfiles/file/20131016/20131016141957_7151.pdf",,10/16/2013,10/16/2013,"medicool",20,,,0,"66",65,"A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris","1997",
232,,,"Ledezma E ; López JC ; Marin P ; Romero H ; Ferrara G ; De Sousa L ; Jorquera A ; Apitz Castro R","Editio Cantor","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ajoene</span><span style=""font-size:14px;""> (CAS 92284-99-6), an organic trisulphur originally isolated from garlic, has an antimycotic activity which has been widely demonstrated both </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> vitro and </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> vivo. The objective of this work was to compare the safety and effectiveness of </span><span style=""font-size:14px;"">ajoene</span><span style=""font-size:14px;""> (0.6%, gel) with terbinafine (CAS 91161-71-6) (1%, cream) for the </span><span style=""font-size:14px;"">treatment</span><span style=""font-size:14px;""> of </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">corporis</span><span style=""font-size:14px;""> and </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">cruris</span><span style=""font-size:14px;"">. The patients selected were 60 soldiers with clinical and mycological diagnosis of either dermatophytosis. They were distributed at random </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> two </span><span style=""font-size:14px;"">treatment</span><span style=""font-size:14px;""> groups, one treated with </span><span style=""font-size:14px;"">ajoene</span><span style=""font-size:14px;""> at 0.6% and the other with terbinafine at 1%. All patients were evaluated clinically and mycologically 30 and 60 days after completion of the </span><span style=""font-size:14px;"">treatment</span><span style=""font-size:14px;"">, which was considered effective when clinical signs and symptoms had disappeared and the mycological cultures were negative. Thirty days after </span><span style=""font-size:14px;"">treatment</span><span style=""font-size:14px;"">, the percent healing rate was 77 and 75 for the groups treated with </span><span style=""font-size:14px;"">ajoene</span><span style=""font-size:14px;""> and terbinafine, respectively. Sixty days after </span><span style=""font-size:14px;"">treatment</span><span style=""font-size:14px;"">, the healing rate 73% and 71% for the groups treated with </span><span style=""font-size:14px;"">ajoene</span><span style=""font-size:14px;""> and terbinafine, respectively. These results and those obtained </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> previous studies confirm that </span><span style=""font-size:14px;"">ajoene</span><span style=""font-size:14px;""> is a new agent for the topic </span><span style=""font-size:14px;"">treatment</span><span style=""font-size:14px;""> of superficial mycoses, and for the first time show the therapeutic usefulness of an inhibitor of phospholipids biosynthesis </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> eukaryotes.</span>",,"/uploadfiles/file/20131016/20131016143057_4091.pdf",,10/16/2013,10/16/2013,"medicool",19,,"Ajoene, antimycotic activity, clinical studies ,CAS 91161-71-6 ,CAS 92284-99-6 , Ter-binafine , Tinea corporis , Tinea cruris",0,"66",65,"Ajoene in the topical short-term treatment of tinea cruris and tinea corporis in humans. Randomized comparative study with terbinafine","1999",
235,,,"Nozickova M ; Koudelkova V ; Kulikova Z ; Malina L ; Urbanowski S ; Silny W","Blackwell Science","<div style=""font-size:10px;font-family:sans-serif;left:261px;top:478px;transform:scale(0.938066, 1);transform-origin:0% 0% 0px;"" dir=""ltr"" data-canvas-width=""428.9150013856888"" data-font-name=""Helvetica"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two hundred and forty five patients with dermatophytoses and cutaneous candidosis were </span><span style=""font-size:14px;"">enrolled in the study; 122 were randomized to the once-weekly regimen and 123 to the </span><span style=""font-size:14px;"">once-daily regimen. Subjects included both men and women; the average age was </span><span style=""font-size:14px;"">42 years. There were no statistically significant differences between the two groups with </span><span style=""font-size:14px;"">regard to age, sex, race, and body weight distributions.</span>
</div>",,"/uploadfiles/file/20131016/20131016143826_6587.pdf",,10/16/2013,10/16/2013,"medicool",35,,,0,"66",65,"A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis.","1998",
250,"口服特比萘芬治疗过度角化型足癣的有效性及药代动力学研究","10.1111/j.1439-0507.2007.01438.x","Kikuchi I ; Tanuma H ; Morimoto K ; Kawana S","Mycoses","<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp; To study and establish an optimal administration method
of oral antifungal, terbinafine (TBF), for hyperkeratotic type tinea pedis,
from the pharmacokinetic point of view, 20 patients with hyperkeratotic type
tinea pedis were given TBF 125 mg once daily for 4 weeks and observed over time
for improvement in dermatological symptoms and mycological efficacy. </span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp; </span><span style=""font-family:宋体;"">从药代动力学角度来看，为了研究及建立一个口服特比萘芬（</span><span style=""font-family:&quot;"">TBF</span><span style=""font-family:宋体;"">）抗真菌药治疗过度角化型足癣的最佳给药方式，我们选取了</span><span style=""font-family:&quot;"">20</span><span style=""font-family:宋体;"">例过度角化型足癣患者，给予</span><span style=""font-family:&quot;"">TBF125 mg</span><span style=""font-family:宋体;"">，每日一次，连续</span><span style=""font-family:&quot;"">4</span><span style=""font-family:宋体;"">周，随着给药时间的推移，观察患者皮肤症的改善及真菌学疗效。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a>&nbsp;Targeting five of the patients, TBF
concentration in the stratum corneum was measured using the liquid
chromatography </span><span style=""font-family:&quot;"">? </span><span style=""font-family:&quot;"">tandem mass
spectrometry (LC-MS </span><span style=""font-family:&quot;"">? </span><span style=""font-family:&quot;"">MS) method. TBF was
detected in the stratum corneum of the sole 1 week after beginning the
treatment in some cases and reached its peak 1 week after the completion of the
treatment with a concentration of 247.8 ng g</span><sup><span style=""font-family:&quot;"">-</span></sup><sup><span style=""font-family:&quot;"">1</span></sup><span style=""font-family:&quot;"">, <a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a>which
was approximately more than 50 times higher than its minimal inhibitory
concentration against dermatophytes. </span><span style=""font-family:宋体;""><br />
</span>&nbsp;&nbsp;<span style=""font-family:宋体;"">以五名患者为目标通过液质联用色谱（</span><span style=""font-family:&quot;"">LC-MS/ MS</span><span style=""font-family:宋体;"">）测定角质层中</span><span style=""font-family:&quot;"">TBF</span><span style=""font-family:宋体;"">的血药浓度。开始治疗一周后，一些患者的角质层中</span><span style=""font-family:&quot;"">TBF</span><span style=""font-family:宋体;"">的血药浓度出现波谷，并在治疗结束一周后血药浓度达到</span><span style=""font-family:&quot;"">247.8 ng g</span><sup><span style=""font-family:&quot;"">-</span></sup><sup><span style=""font-family:&quot;"">1</span></sup><span style=""font-family:宋体;"">的峰值，这一浓度比最低抑菌浓度大约高出了</span><span style=""font-family:&quot;"">50</span><span style=""font-family:宋体;"">倍。</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp; TBF was not
detected at 8 weeks post-treatment, although its concentration was 50.73 ng g</span><sup><span style=""font-family:&quot;"">-1</span></sup><span style=""font-family:&quot;""> at 6 weeks post-treatment. Its effectiveness rate
(effective + markedly effective) was 95% (19 </span><span style=""font-family:&quot;"">? </span><span style=""font-family:&quot;"">20) with no adverse reactions, including abnormal changes
in the laboratory test values, in any patient. These results suggest that TBF
is a useful drug to treat hyperkeratotic tinea pedis from the pharmacokinetic
point of view.</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp; </span><span style=""font-family:宋体;"">尽管在治疗</span><span style=""font-family:&quot;"">6</span><span style=""font-family:宋体;"">周后</span><span style=""font-family:&quot;"">TBF</span><span style=""font-family:宋体;"">血药浓度为</span><span style=""font-family:&quot;"">50.73ng g</span><sup><span style=""font-family:&quot;"">-1</span></sup><span style=""font-family:AdvPSSPS-AS;"">，</span><span style=""font-family:宋体;"">但</span><span style=""font-family:&quot;"">8</span><span style=""font-family:宋体;"">周后未检测到</span><span style=""font-family:&quot;"">TBF</span><span style=""font-family:宋体;"">。其有效率（有效</span><span style=""font-family:&quot;"">+</span><span style=""font-family:宋体;"">显效）达到</span><span style=""font-family:&quot;"">95</span><span style=""font-family:宋体;"">％（</span><span style=""font-family:&quot;"">19/20</span><span style=""font-family:宋体;"">），并且无不良反应，包括任一患者实验室测试值的异常变化。从药动学观点来看，研究结果表明，</span><span style=""font-family:&quot;"">TBF</span><span style=""font-family:宋体;"">是一种有效治疗过度角化型足癣的药物。<br />
<br />
<br />
</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:9.0pt;font-family:&quot;color:#333333;""></span> 
</p>
<p class=""MsoNormal"" align=""right"" style=""text-align:right;"">
	<i><span style=""font-size:9.0pt;font-family:&quot;"">Izumi Kikuchi et al./ Journal compilation </span></i><i><span style=""font-size:9.0pt;font-family:&quot;"">&copy;</span></i><i><span style=""font-size:9.0pt;font-family:&quot;""> </span></i><i><span style=""font-size:9.0pt;font-family:&quot;"">2007 Blackwell
Publishing Ltd </span></i><i><span style=""font-size:9.0pt;font-family:&quot;"">? </span></i><i><span style=""font-size:9.0pt;font-family:&quot;"">Mycoses 51, 7C13</span></i> 
</p>","/uploadfiles/image/20131016/20131016151749_6572w.jpg","/uploadfiles/file/20131016/20131016151823_9461.pdf",,10/16/2013,10/22/2013,"medicool",31,,"tinea pedis, antimycotic chemotherapy, terbinafine concentration, stratum corneum.",0,"66",60,"Usefulness and pharmacokinetic study of oral terbinafine for hyperkeratotic type tinea pedis","2008",
308,"长途骑自行车穿越蒙古的冻疮患者","10.1111/j.1708-8305.2011.00574.x","Neal AJ ; Jarman AM ; Bennett TG","Journal Of Travel Medicine","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">We report a case
of severe perniosis in a long-distance cyclist. <a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a>This case demonstrates
the importance of identifying those at risk of cold-related injuries <a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a>who are
about to embark on extensive travel in cold environments.</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	我们报道了一例长途骑自行车的严重冻疮患者。本病例表明了鉴别那些即将在寒冷环境下开展广泛旅程的有受寒冷伤害风险的患者的重要性。
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:宋体;color:#222222;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:宋体;color:#222222;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" align=""right"" style=""text-align:right;text-indent:9.0pt;"">
	<i><span style=""font-size:9.0pt;font-family:&quot;"">Andrew J. Neal et al./</span></i><i><span style=""font-size:9.0pt;font-family:&quot;""> Journal of
Travel Medicine 2012; Volume 19 (Issue 1): 66C68</span></i><i><span style=""font-size:9.0pt;font-family:&quot;""></span></i> 
</p>","/uploadfiles/image/20131021/20131021171927_8796w.jpg","/uploadfiles/file/20131021/20131021171618_9945.pdf",,10/21/2013,10/25/2013,"medicool",34,,,0,"85",88,"Perniosis in a Long-Distance Cyclist Crossing Mongolia","2012",
236,,"10.1111/j.1365-4632.2011.05204.x","Martin SJ ; Duvic M","International Journal Of Dermatology","<p class=""MsoNormal"">
	<b>Background</b> Mycosis fungoides (MF) and the Se?zary syndrome (SS) are
non-Hodgkin’s lymphomas that present with cutaneous lesions. Se?zary syndrome
is characterized by blood involvement, exfoliative eryrthroderma, lymphadenopathy,
pruritus, keratoderma, and immunosuppression. This study was to estimate the
prevalence of palmoplantar keratoderma and tinea pedis in Se?zary syndrome and
to analyze the effectiveness of anti-fungal treatment.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Methods</b> We conducted a retrospective review of 1562
prospectively collected patients at the MD Anderson Cancer Center Cutaneous
Lymphoma Clinic over sixteen years. All patients’ palms and soles were
evaluated for clinical evidence of keratoderma (hyperkeratosis) and for
dermatophytosis (tinea pedis or unguum) by examining scales under 10% potassium
hydroxide by light microscopy for hyphae.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Results</b> Of 138 Se?zary syndrome patients (88 men, 50 women,
median age at diagnosis 64 years), 85 (61.6%) had palmoplantar keratoderma; 45
of the 85 Se?zary syndrome patients (52.9%) also had coexisting tinea pedis.
Only 14 (10.1%) had tinea pedis without keratoderma. Treatment for tinea pedis
resulted in microscopy cure of keratoderma in 12 of 45 (26.7%) patients and
clinical improvement.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Conclusions </b>The prevalence of palmoplantar keratoderma in Se?zary
syndrome is 61.6%, with co-existing tinea pedis found in 52.9%. Palmoplantar
keratoderma with tinea pedis showed clinical improvement with fungicidal
therapy suggesting that tinea often contributes to the pathogenesis and
severity of Se?zary syndrome-related keratoderma.<o:p></o:p>
</p>",,"/uploadfiles/file/20131016/20131016144409_6097.pdf",,10/16/2013,10/16/2013,"medicool",35,,,0,"65",60,"Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Se?zary syndrome","2012",
237,,"10.1080/09546630500375783","Singal A ; Pandhi D ; Agrawal S ; Das S","Informa Healthcare","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Localized </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">cruris</span><span style=""font-size:14px;""> and </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">corporis</span><span style=""font-size:14px;""> can be treated by </span><span style=""font-size:14px;"">topical</span><span style=""font-size:14px;""> imidazoles (</span><span style=""font-size:14px;"">clotrimazole</span><span style=""font-size:14px;"">) or newer </span><span style=""font-size:14px;"">topical</span><span style=""font-size:14px;""> agents like </span><span style=""font-size:14px;"">butenafine</span><span style=""font-size:14px;"">, </span><span style=""font-size:14px;"">a</span><span style=""font-size:14px;""> benzylamine derivative with fungicidal activity. The therapeutic </span><span style=""font-size:14px;"">efficacy</span><span style=""font-size:14px;""> of these two agents was compared </span><span style=""font-size:14px;"">in</span><span style=""font-size:14px;""> this study. Eighty patients, diagnosed clinically to have </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">cruris</span><span style=""font-size:14px;""> or localized </span><span style=""font-size:14px;"">tinea</span> <span style=""font-size:14px;"">corporis</span><span style=""font-size:14px;""> and confirmed on KOH examination, were randomly assigned to one of the two treatment groups </span><span style=""font-size:14px;"">in</span> <span style=""font-size:14px;"">a</span> <span style=""font-size:14px;"">double</span><span style=""font-size:14px;"">-</span><span style=""font-size:14px;"">blind</span><span style=""font-size:14px;""> manner; </span><span style=""font-size:14px;"">butenafine</span><span style=""font-size:14px;""> once daily for 2 weeks or </span><span style=""font-size:14px;"">clotrimazole</span><span style=""font-size:14px;""> twice daily for 4 weeks. Follow-up was done at </span><span style=""font-size:14px;"">1</span><span style=""font-size:14px;"">, 2, 4 and 8 weeks. Clinical assessment score and KOH examination were performed at each visit. </span><span style=""font-size:14px;"">Butenafine</span><span style=""font-size:14px;""> recipients exhibited higher clinical cure as compared with </span><span style=""font-size:14px;"">clotrimazole</span><span style=""font-size:14px;""> recipients at the end of </span><span style=""font-size:14px;"">1</span><span style=""font-size:14px;""> week (26.5% vs 2.9%) as well as higher mycological cure (61.7% vs 17.6%). However, this difference was not statistically significant at 4 and 8 weeks of treatment.</span>",,"/uploadfiles/file/20131016/20131016144916_6026.pdf",,10/16/2013,10/16/2013,"medicool",36,,"Tinea cruris, tinea corporis, clotrimazole, butenafine, comparative efficacy",0,"66",65,"Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial","2005",
239,,,"Lee HJ ; Ha SJ ; Ha JH ; Cho BK ; Kim JW","Society for the Publication of Acta Dermato-Venereologica","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A 66-year-old man presented with a 5-month history of tinea </span><span style=""font-size:14px;"">cruris. Physical examination revealed round, marginate, eryth</span><span style=""font-size:14px;"">ematous scaling patches on the buttocks and groin. He had </span><span style=""font-size:14px;"">no history of animal contact or other underlying disease.</span><span style=""font-size:14px;"">Direct mycologic examination of skin scrapes in 20% KOH </span><span style=""font-size:14px;"">showed a large number of branching hyphae of regular width.</span><span style=""font-size:14px;"">Cultures in Sabouraud dextrose agar showed growths of two </span><span style=""font-size:14px;"">dermatophytes, M. canis and T. mentagrophytes var. mentagro</span><span style=""font-size:14px;"">phytes. Culture in potato dextrose agar with chloramphenicol </span><span style=""font-size:14px;"">with orwithout cycloheximide showed growths ofT. mentagro</span><span style=""font-size:14px;"">phytes and M. canis. The patient was treated with isoconazole </span><span style=""font-size:14px;"">cream for 2 weeks and showed clinical cure.</span>",,"/uploadfiles/file/20131016/20131016150111_2711.pdf",,10/16/2013,10/16/2013,"medicool",24,,,0,"85",65,"Tinea cruris due to combined infections of Trichophyton mentagrophytes and Microsporum canis. A case report","2001",
240,"采用5 - 氨基酮戊酸光动力疗法成功治疗花斑癣","143(3):413-415.","William H. Eaglstein, MD","American Medical Association，You Chan Kim, MD, PhD，Young Jin Kim, MD","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pityriasis versicolor is a common chronic superficial </span><span style=""font-family:Times New Roman;font-size:14px;"">fungal infection caused by the organism Malassezia </span><span style=""font-family:Times New Roman;font-size:14px;"">furfur. Although many conventional treatments </span><span style=""font-family:Times New Roman;font-size:14px;"">have been shown to be successful in treating </span><span style=""font-family:Times New Roman;font-size:14px;"">pityriasis versicolor, therapy of long-term duration may </span><span style=""font-family:Times New Roman;font-size:14px;"">be needed in many cases, and recurrence is not uncommon. </span><span style=""font-family:Times New Roman;font-size:14px;"">In vitro experimental investigations have demonstrated </span><span style=""font-family:Times New Roman;font-size:14px;"">that several fungal strains can be effectively inactivated </span><span style=""font-family:Times New Roman;font-size:14px;"">by irradiation with visible light wavelengths in</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">the presence of photosensitizer.1-3 However, to our knowledge, </span><span style=""font-family:Times New Roman;font-size:14px;"">there have been no clinical trials of photodynamic</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">therapy (PDT) against pityriasis versicolor.</span> 
</p>","/uploadfiles/image/20131016/20131016154209_0086w.jpg","/uploadfiles/file/20131016/20131016145738_7675.pdf",,10/16/2013,10/16/2013,"medicool",24,,"pityriasis versicolor；Photodynamic Therapy",0,"85",4,"Successful Treatment of Pityriasis Versicolor With 5-Aminolevulinic Acid Photodynamic Therapy","2007",
241,,"0.1016/j.riam.2009.03.006","Pérez-González M ; Torres-Rodríguez JM ; Martínez-Roig A ; Segura S ; Griera G ; Trivi?o L ; Pasarín M","Revista Iberoamericana De Micología","<p class=""MsoNormal"">
	<b>Objective:</b> To evaluate the prevalence of tinea capitis, tinea pedis, and tinea unguium in children from several
schools of Barcelona city.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Methods:</b> During the period of 2003C2004, a prospective
cross-sectional study was carried out in 1,305 children (9% immigrant
population) between the ages 3 and 15 in 17 schools in Barcelona. A systematic examination
of the feet, (including nails and scalp), was performed to identify lesions
compatible with tinea. Cultures of scalp and feet samples were done and
analysis of environmental samples was performed for dermatophyte isolation.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Results:</b> Dermatophytes were isolated in 2.9% of the samples with a
prevalence of 2.5% in feet, 0.23% in scalp, and 0.15% in nails of the feet. The
predominant etiologic agents in feet were Trichophyton mentagrophytes in 45.7% of the cases
and Trichophyton rubrum
in 31.4%. In the
nails, T. rubrum and Trichophyton tonsurans were isolated, while T. mentagrophytes (2 cases) and Trichophyton
violaceum (1 case) were identified in scalp samples. Forty-five per cent of
dermatophytes were isolated from healthy feet, the majority of cases in
children 13C15 years old (po0.05). Microsporum gypseum was the only agent
identified in the environmental samples, and was also found in one of the cases
of tinea pedis.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Conclusion:</b> The results of this study demonstrate a low prevalence of
tinea capitis and tinea unguium in school children of
Barcelona. On the contrary, high prevalence of dermatophytes in feet was found.
It highlights the high prevalence of healthy carriers of dermatophytes in feet.<o:p></o:p>
</p>",,"/uploadfiles/file/20131016/20131016144512_6650.pdf",,10/16/2013,10/16/2013,"medicool",31,,"Tinea capitis, Tinea pedis, Tinea unguium, Barcelona, Epidemiology, Etiology, School children",0,"65",60,"Prevalence of tinea pedis, tinea unguium of toenails and tinea capitis in school children from Barcelona","2009",
242,,"10.1111/j.1439-0507.2008.01614.x","Onsun N ; Pirmit S ; Ummetoglu O","Grosse Verlag","<span style=""font-size:16px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style=""font-size:14px;"">Tinea cruris is a common superficial fungal infection of </span></span><span style=""font-size:14px;"">the skin and it affects approximately 7C15% of all </span><span style=""font-size:14px;"">patients attending dermatology clinics in Turkey.1,2.</span><span style=""font-size:14px;"">This case is a fairly typical patient that responded well to </span><span style=""font-size:14px;"">topical treatment with a combined anti-fungal and </span><span style=""font-size:14px;"">corticosteroid cream.</span>",,"/uploadfiles/file/20131016/20131016150510_6223.pdf",,10/16/2013,10/16/2013,"medicool",22,,"Tinea cruris, isoconazole, corticosteroid.",0,"85",65,"Successful therapy of tinea cruris with topical isoconazole in combination with a corticosteroid","2008",
244,,"10.1111/j.1439-0507.2008.01611.x","Jürgens J","Grosse Verlag","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In South Africa, tinea is the fifth most common </span><span style=""font-size:14px;"">cutaneous manifestation of HIV and AIDS, with other </span><span style=""font-size:14px;"">opportunistic fungal infections such as candidiasis being </span><span style=""font-size:14px;"">the 11th most frequent cause of skin complaints in </span><span style=""font-size:14px;"">immunocompromised patients.1The overall incidence </span><span style=""font-size:14px;"">of tinea in Sub-Saharan Africa was reportedly 78 </span><span style=""font-size:14px;"">million in 2005.</span>",,"/uploadfiles/file/20131016/20131016151030_4072.pdf",,10/16/2013,10/16/2013,"medicool",31,,"Tinea cruris, isoconazole, corticosteroid",0,"85",65,"Tinea cruris treated with a combined topical therapy containing isoconazole and a corticosteroid","2008",
246,,,"Bakos L, Bonamigo RR, Pisani AC, Mariante JC, Mallmann R.","Journal of the American Academy of Dermatology","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Superficial fungal infections are common in pa</span><span style=""font-size:14px;"">tients with HIV infection. These infections may be </span><span style=""font-size:14px;"">widespread or have an </span><span style=""font-size:14px;"">unusual form or stmctureJ&nbsp; </span><span style=""font-size:14px;"">Scutula are yellow cup-shaped crusts classically&nbsp; </span><span style=""font-size:14px;"">present in favus of the scalp. 2 To our </span><span style=""font-size:14px;"">knowledge,</span><span style=""font-size:14px;"">their presence on glabrous skin in a patient with&nbsp; </span><span style=""font-size:14px;"">AIDS has not been reported previously.</span>",,"/uploadfiles/file/20131016/20131016151905_4889.pdf",,10/16/2013,10/16/2013,"medicool",36,,,0,"85",65,"Scutular favus-like tinea cruris et pedis in a patient with AIDS","1996",
243,,,"Egberto Santos Carmo，Fillipe de Oliveira Pereira，Neuza Maria Cavalcante，Carla Wanderley Gayoso，Edeltrudes de Oliveira Lima","Anais Brasileiros de Dermatologia","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BACKGROUND: Pityriasis versicolor is a fungal infection caused by Malassezia spp. that has frequent </span><span style=""font-family:Times New Roman;font-size:14px;"">relapses. OBJECTIVES: The main objective of this research was to perform phase I and II clinical studies, using formulations </span><span style=""font-family:Times New Roman;font-size:14px;"">containing essential oil of Cymbopogon citratus in patients with pityriasis versicolor. METHODS: Phase </span><span style=""font-family:Times New Roman;font-size:14px;"">I study included twenty volunteers to ascertain the safety of the formulations. In phase II, 47 volunteers randomly </span><span style=""font-family:Times New Roman;font-size:14px;"">received essential oil formulations at 1.25 μL/mL concentration, for forty days. The shampoo should be </span><span style=""font-family:Times New Roman;font-size:14px;"">applied three times a week and the cream twice a day. A control group in phase II, consisting of 29 volunteers, </span><span style=""font-family:Times New Roman;font-size:14px;"">received the same formulations but with 2% ketoconazole as the active ingredient. RESULTS: No significant </span><span style=""font-family:Times New Roman;font-size:14px;"">adverse events were observed in volunteers during Phase I. In Phase II, 30 (63.83%) volunteers using essential oil </span><span style=""font-family:Times New Roman;font-size:14px;"">and 18 (62.07%) using ketoconazole remained until the end of the study. We observed a predominance of lesions </span><span style=""font-family:Times New Roman;font-size:14px;"">in disseminated form, with M. sympodialis detected as the predominant agent identified in cultures. After 40 days </span><span style=""font-family:Times New Roman;font-size:14px;"">of treatment, the rate of mycological cure was 60% (p &lt;0.05) for the group treated with essential oil of C. citratus </span><span style=""font-family:Times New Roman;font-size:14px;"">and over 80% (p &lt;0.05) for the group treated with ketoconazole formulations. CONCLUSIONS: Notwithstanding the </span><span style=""font-family:Times New Roman;font-size:14px;"">safety and antifungal effects observed in this study after application of formulations containing the essential oil </span><span style=""font-family:Times New Roman;font-size:14px;"">of C. citratus, further studies with larger populations should be performed to confirm the actual potential of these </span><span style=""font-family:Times New Roman;font-size:14px;"">formulations in the treatment of patients with Pityriasis versicolor.</span> 
</p>","/uploadfiles/image/20131016/20131016154102_1313w.jpg","/uploadfiles/file/20131016/20131016150739_9613.pdf",,10/16/2013,10/16/2013,"medicool",36,,"Antifungal agents; Infection; Malassezia; Mycoses; Tinea versicolor",0,"66",4,"Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf -therapeutic pilot study","2013",
247,"由猴发癣菌引发的体癣-伊朗首例","10.1080/13693780802368938","ALI ZAREI MAHMOUDABADI & REZA YAGHOOBI","Medical Mycology December","<p style=""text-indent:21pt;"" class=""MsoNormal"" align=""justify"">
	<span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;""><br />
<span style=""font-family:Tahoma;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>A 25-year-old man was examined for tinea corporis. Microscopic examination of direct 10% KOH mount of skin scraping revealed the presence of hyaline, septate, branching hyphae. Cultures inoculated with portions of skin scrapings yielded, after two weeks Trichophyton simii. The identification of the fungus was based on colony morphology on mycobiotic agar and microscopic characteristics on</span><span style=""font-size:14px;""> slide cultures</span></a><span style=""font-size:14px;"">. Microscopic features of T. simii were cylindrical, 3-7 celled, thin-walled macroconidia. In older culture, macroconidia converted into chlamydospores, which is an important characteristic of T. simii.</span></span> 
</p>
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<span style=""font-family:宋体;font-size:14px;"">对一位</span><span style=""font-family:'Times New Roman','serif';font-size:14px;"">25</span><span style=""font-family:宋体;font-size:14px;"">岁的男子进行了体癣检查。在该患者的皮肤刮取物上直接滴加</span><span style=""font-family:'Times New Roman','serif';font-size:14px;"">10</span><span style=""font-family:宋体;font-size:14px;"">％的</span><span style=""font-family:'Times New Roman','serif';font-size:14px;"">KOH</span><span style=""font-family:宋体;font-size:14px;"">制片，镜检结果显示有透明的分支状有隔菌丝存在。取部分皮肤碎屑接种培养，两个星期后有猴发癣菌出现。真菌的鉴定是以真菌琼脂上的菌落形态和载玻片上的微观特征为基础的。猴发癣菌的微观特征是有</span><span style=""font-family:'Times New Roman','serif';font-size:14px;"">3-7</span><span style=""font-family:宋体;font-size:14px;"">个分隔的圆柱形的、薄壁大分生孢子。猴发癣菌有一个重要的特性，即在经过较长时间培养后，大分生孢子转化形成厚膜孢子。</span> 
</p>","/uploadfiles/image/20131016/20131016152117_4652w.jpg","/uploadfiles/file/20131016/20131016152057_2007.pdf",,10/16/2013,10/18/2013,"medicool",31,,"Trichophyton simii | tinea corporis | dermatophyte | Iran",0,"85",68,"Tinea corporis due to Trichophyton simii -a first case from Iran","2008",
252,,"10.1016/S0733-8635(03)00031-7","Aditya K. Gupta, MD, PhD, FRCP(C), Maria Chaudhry, HBScb,","Dermatol Clin","<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tinea infections are among the most common </span><span style=""font-size:14px;"">dermatologic conditions throughout the world. Skin </span><span style=""font-size:14px;"">ringworm infections, such as tinea corporis and tinea </span><span style=""font-size:14px;"">cruris, are primarily caused by the dermatophytes </span><span style=""font-size:14px;"">Trichophyton rubrum, Trichophyton mentagrophytes,</span><span style=""font-size:14px;"">and Microsporum canis. Tinea nigra is an infection of </span><span style=""font-size:14px;"">the palms or soles, which may be associated with</span><br />
<span style=""font-size:14px;"">travel to endemic regions (eg, Southeast United </span><span style=""font-size:14px;"">States and Central America). Black or white nodules </span><span style=""font-size:14px;"">found along the shaft of the hair may be infections </span><span style=""font-size:14px;"">with Piedraia hortae, or Trichosporon species, better </span><span style=""font-size:14px;"">known as ‘‘black piedra’’ or ‘‘white piedra.’’ To </span><span style=""font-size:14px;"">avoid a misdiagnosis, identification of dermatophyte </span><span style=""font-size:14px;"">infections requires both a fungal culture on Sabour</span><span style=""font-size:14px;"">aud’s </span><span style=""font-size:14px;"">agar media, and a mycologic examination, </span><span style=""font-size:14px;"">consisting of a 10% to 15% KOH preparation, from </span><span style=""font-size:14px;"">skin scrapings. Topical </span><span style=""font-size:14px;"">antifungals may be sufficient </span><span style=""font-size:14px;"">for treatment of tinea corporis and cruris and tinea </span><span style=""font-size:14px;"">nigra, and the shaving of hair infected by piedra may </span><span style=""font-size:14px;"">also be beneficial. Systemic therapy, however, may </span><span style=""font-size:14px;"">be required when the infected areas are large, mac</span><span style=""font-size:14px;"">erated with a secondary infection, or in immunocom</span><span style=""font-size:14px;"">promised individuals. Preventative measures of tinea </span><span style=""font-size:14px;"">infections include </span><span style=""font-size:14px;"">practicing good personal hygiene; </span><span style=""font-size:14px;"">keeping the skin dry and cool at all times; and </span><span style=""font-size:14px;"">avoiding sharing towels, clothing, or hair accessories </span><span style=""font-size:14px;"">with infected individuals.</span>",,"/uploadfiles/file/20131016/20131016153746_0545.pdf",,10/16/2013,10/16/2013,"medicool",31,,,0,"67",65,"Tinea corporis, tinea cruris, tinea nigra, and piedra","2003",
253,,,"Morimoto K ; Tanuma H ; Kikuchi I ; Kusunoki T ; Kawana S","Mycoses","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	In the present study, the authors administered 100 mg
itraconazole (ITCZ) twice daily for a period of 1 week to six patients with
hyperkeratotic type tinea pedis, and examined its efficacy, safety profile, and
usefulness. ITCZ concentration in stratum corneum was also measured to examine
the mobility of the drug into the affected site of planta pedis. ITCZ
concentration in the stratum corneum of the affected part was first detected at
1 week after the completion of administration, gradually increased over time,
and peaked at 3 weeks, with the sum of ITCZ and hydroxyitraconazole (OH-ITCZ) amounting
to 163.7 ng g<sup>-</sup><sup>1</sup> on a average. It then gradually decreased to a total sum
of 10.3 ng g<sup>-</sup><sup>1</sup> on average at 8 weeks following the completion of
administration. When compared with the geometric mean minimum inhibitory
concentration (MIC) of ITCZ against fresh clinical isolates of dermatophytes (Trichophyton
rubrum) (0.06 lg ml<sup>-</sup><sup>1</sup>), the stratum corneum ITCZ concentration in this study
was 2.1-fold of the geometric mean MIC at 2 weeks following the completion of administration,
and 2.4-fold at 4 weeks. Although ITCZ does not produce therapeutic effectiveness
(fungistasis) during the period of administration, it starts appearing at 2
weeks after the completion of administration, and after it peaks out at 3C4 weeks,
clinical symptoms started improving. These results suggest that satisfying
effects can be achieved in a short-term oral ITCZ at a dose of 100 mg twice
daily for a period of 1 week in cases of hyperkeratotic type tinea pedis.
</p>",,"/uploadfiles/file/20131016/20131016153744_5725.pdf",,10/16/2013,10/16/2013,"medicool",22,,"Tinea pedis, antimycotic chemotherapy, itraconazole, pharmacokinetics, stratum corneum.",0,"66",60,"Pharmacokinetic investigation of oral itraconazole in stratumcorneum level of tinea pedis","2004",
255,,,"Aditya K. Gupta, MD, PhD, FRCP(C), Roma Batra, PhD, MSc, MPhil,Robyn Bluhm, HBS, MA, BA, Jan Faergemann, MD, PhD","Dermatol Clin","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pityriasis versicolor (tinea versicolor) is a common </span><span style=""font-family:Times New Roman;font-size:14px;"">superficial fungal infection of the skin. The prevalence </span><span style=""font-family:Times New Roman;font-size:14px;"">of the disorder varies with the seasons; cases of </span><span style=""font-family:Times New Roman;font-size:14px;"">pityriasis versicolor are more common in the warmer </span><span style=""font-family:Times New Roman;font-size:14px;"">months and in tropical climates. In Scandinavia,</span><span style=""font-family:Times New Roman;font-size:14px;"">approximately 1% of the population has been reported </span><span style=""font-family:Times New Roman;font-size:14px;"">to be affected by pityriasis versicolor [1C3], whereas </span><span style=""font-family:Times New Roman;font-size:14px;"">rates as high as 50% have been reported in some </span><span style=""font-family:Times New Roman;font-size:14px;"">tropical countries [4,5]. The lesions are also more </span><span style=""font-family:Times New Roman;font-size:14px;"">extensive in tropical climates compared with temperate </span><span style=""font-family:Times New Roman;font-size:14px;"">climates [6]. Although studies have reported that </span><span style=""font-family:Times New Roman;font-size:14px;"">pityriasis versicolor is more common in one sex or the </span><span style=""font-family:Times New Roman;font-size:14px;"">other [1,7C9], the overall consensus is that persons of </span><span style=""font-family:Times New Roman;font-size:14px;"">either sex are equally likely to develop this infection.</span>
</p>",,"/uploadfiles/file/20131016/20131016160140_7578.pdf",,10/16/2013,10/16/2013,"medicool",30,,"Pityriasis versicolor;Clinical presentation;Topical therapies",0,"67",4,"Pityriasis versicolor","2003",
256,,"10.1111/j.1468-3083.2005.01396.x","Mistik S ; Ferahbas A ; Koc AN ; Ayangil D ; Ozturk A","Journal Of The European Academy Of Dermatology And Venereology: JEADV","<p class=""MsoNormal"">
	<b>Objectives </b>The aim of
this study has been to evaluate patients with tinea pedis<b> </b>for their
demographic data and attitudes affecting the treatment of disease, and<b> </b>to
compare the<b> </b><i>in vitro </i>activity of 10 antifungal agents and to
relate them to<i> </i>their<i> in vivo </i>activity.<b><o:p></o:p></b> 
</p>
<p class=""MsoNormal"">
	<b>Methods </b>Patients
with positive mycological examination were enrolled in<b> </b>the study, and a
questionnaire comprised of 22 questions was administered.<b> </b>A mycological
culture was carried out for each specimen. The antifungal<b> </b>susceptibility
of the subcultured species was determined for griseofulvin,<b> </b>terbinafine,
ciclopiroxolamine, fluconazole, ketoconazole, itraconazole,<b> </b>bifonazole,
sulconazole, oxiconazole and miconazole with microdilution.<b><o:p></o:p></b> 
</p>
<p class=""MsoNormal"">
	<b>Results </b>Mycological
cultures were carried out from 59 patients and there<b> </b>were 35 positive
cultures (59.3%). The dermatophytes were<b> </b><i>Trichophyton</i><b> </b><i>rubrum</i><b> </b>( <i>n</i> = 25) and <i>Trichophyton mentagrophytes</i> ( <i>n</i> = 3).
The yeasts were <i>Candida albicans</i> ( <i>n</i> = 7), <i>Candida glabrata</i> ( <i>n</i> = 1) and <i>Trichosporon</i> ( <i>n</i> = 2). In the minimum
inhibitory concentration (MIC) study, the mean ± standard error of the mean
(SEM) MICs of the antifungals for <i>T. rubrum </i>were as follows:<b> </b>terbinafine
0.01<b> </b>±<b> </b>0.003, oxiconazole 0.16<b> </b>±<b> </b>0.05, sulkonazole
0.31 ±<b> </b>0.05,<b> </b>miconazole 0.45<b> </b>±<b> </b>0.15, itraconazole
0.74<b> </b>±<b> </b>0.01, ketokonazole 1.03<b> </b>±<b> </b>0.17,<b> </b>ciclopiroxolamine
1.30<b> </b>±<b> </b>0.12, bifonazole 1.94<b> </b>±<b> </b>0.51, griseofulvin
4.87<b> </b>± 0.61,<b> </b>and fluconazole 17.91<b> </b>±<b> </b>3.67<b> </b>μg/mL.<b><o:p></o:p></b> 
</p>
<p class=""MsoNormal"">
	<b>Conclusion </b>Our study
supports that azoles could be used as first-line treatment,<b> </b>as
oxiconazole is very effective for both dermatophytes and <i>C. albicans</i>.<b> </b>Correlation between<b> </b><i>in vitro </i>results and clinical outcomes of
cases of<b> </b>dermatophytes is still to be established and interpretive
breakpoints defined, in<b> </b>order to increase the quality of patient care in
tinea pedis.<b><o:p></o:p></b> 
</p>",,"/uploadfiles/file/20131016/20131016160859_6178.pdf",,10/16/2013,10/16/2013,"medicool",22,,"antifungal susceptibility, azoles, terbinafine, tinea pedis",0,"66",60,"What defines the quality of patient care in tinea pedis?","2006",
257,,,"Anna Lyakhovitsky1, MD, Avner Shemer2, MD, and Boaz Amichai3, MD","International Journal of Dermatology","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;""><strong>Background</strong></span><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;""> Pityriasis versicolor (PV) is a common superficial fungal infection of the skin </span><span style=""font-family:Times New Roman;font-size:14px;"">caused by Malassezia species. The clinical significance of each of these species is not fully </span><span style=""font-family:Times New Roman;font-size:14px;"">understood. M. furfur has long been identified as the causative agent of PV. Several recent </span><span style=""font-family:Times New Roman;font-size:14px;"">studies suggest that M. globosa is most frequently associated with PV.</span> 
</p>
<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;""><strong>Objectives</strong></span><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;""> The aim of this study was to examine the prevalence of Malassezia species in </span><span style=""font-family:Times New Roman;font-size:14px;"">affected and unaffected skin in Israeli patients with PV using a polymerase chain reaction </span><span style=""font-family:Times New Roman;font-size:14px;"">(PCR)-based culture-independent method.</span><br />
<span style=""font-family:Times New Roman;font-size:14px;""><strong>Methods </strong></span><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;"">Samples were taken from affected skin of 75 patients with PV (35 females and </span><span style=""font-family:Times New Roman;font-size:14px;"">40 males, age range 18C65 years) who visited our outpatient clinic and from unaffected</span><span style=""font-family:Times New Roman;font-size:14px;"">skin in 26 patients for direct microscopy and detection of Malassezia species using a PCRbased </span><span style=""font-family:Times New Roman;font-size:14px;"">method.</span><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;""><strong>Results </strong></span><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;"">The major Malassezia species in PV was M. globosa, found in 97.3% (73 of 75) </span><span style=""font-family:Times New Roman;font-size:14px;"">of samples from affected skin and 80.8% (21 of 26) samples of unaffected skin. M. restricta </span><span style=""font-family:Times New Roman;font-size:14px;"">was associated with M. globosa in 1.3% (one of 75) of patients. No cases of M. furfur were </span><span style=""font-family:Times New Roman;font-size:14px;"">detected in this study. There was no difference in the distribution of Malassezia species </span><span style=""font-family:Times New Roman;font-size:14px;"">between affected and unaffected skin.</span><br />
<span style=""font-family:Times New Roman;font-size:14px;""><strong>Conclusion</strong></span><br />
<span style=""font-family:Times New Roman;font-size:14px;""></span><span style=""font-family:Times New Roman;font-size:14px;""> Based on the PCR test, we have shown that M. globosa is probably most </span><span style=""font-family:Times New Roman;font-size:14px;"">frequently associated with PV.</span> 
</p>",,"/uploadfiles/file/20131016/20131016161324_1007.pdf",,10/16/2013,10/16/2013,"medicool",21,,"sample collection;Affected skin;plityriasis versicolor",0,"65",4,"Molecular analysis of Malassezia species isolated from Israeli patients with pityriasis versicolor ","2013",
259,,"10.1080/09546630701247971","James IG ; Loria-Kanza Y ; Jones TC","The Journal Of Dermatological Treatment","<p class=""MsoNormal"">
	<b>Background:</b> In the treatment of tinea pedis, current terbinafine
formulations are applied once or twice daily for 7 days. A terbinafine emulsion
gel formulation has been developed to provide a 5-day treatment course for
tinea pedis. <o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Objective: </b>To determine the lowest effective concentration of
terbinafine (1% or 3%) emulsion gel applied once daily for 5 days for the treatment
of tinea pedis. <o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Methods:</b> This double-blind, placebo-controlled study evaluated
the efficacy of 1% and 3% terbinafine gel for 5 days in 84 outpatients with
tinea pedis. The primary efficacy endpoint was the percentage of patients with
effective treatment (negative microscopy and culture with only mild
erythema/desquamation/pruritus [total score≤2]) at study endpoint (last
post-baseline observation up to and including week 6). <o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Results: </b>Efficacy rates with terbinafine 1% and 3% emulsion gel
were significantly higher than with placebo (86% and 68% vs 11%, respectively; p&lt;0.001). Similarly, mycological cure rates were
significantly greater with terbinafine 1% and 3% gel (97% and 89%,
respectively) than with placebo (22%; p&lt;0.001).<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Conclusions: </b>Terbinafine 1% emulsion gel used once daily for 5 days
was the lowest effective concentration, and was significantly superior to
placebo. Both concentrations were effective and safe, providing convenient, short-duration
treatment of tinea pedis.<o:p></o:p>
</p>",,"/uploadfiles/file/20131016/20131016162656_7685.pdf",,10/16/2013,10/16/2013,"medicool",29,,"Dermatophyte, emulsion gel, terbinafine, tinea pedis",0,"66",60,"Short-duration topical treatment of tinea pedis using terbinafine emulsion gel: Results of a dose-ranging clinical trial","2007",
287,"体癣的非典型性临床表现",,"Mirjana Ziemer, Florian Seyfarth, Peter Elsner and Uta-Christina Hipler","Blackwell Publishing Ltd ? Mycoses","<p align=""justify"">
	<span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""font-family:Tahoma;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />
&nbsp;&nbsp;&nbsp;&nbsp; <span style=""line-height:2;"">&nbsp;</span></span><span style=""line-height:2;font-size:14px;"">Tinea corporis classically presents as an erythematous annular plaque with a scaly, centrifugally advancing border. However, sometimes vesicles and pustules are observed. Occasionally, even frank bullae appear secondary to severe inflammation. Diagnostic difficulties arise when atypical manifestations mimic other inflammatory skin diseases, including atopic or seborrheic dermatitis, subacute cutaneous lupus erythematosus, or vesicular diseases. We report five cases of atypical tinea corporis, where the initial clinical diagnosis was different from dermatophytosis. The differential diagnoses and the diagnostic difficulties related to atypical manifestations of fungal infections are discussed. Moreover, our cases emphasise the importance of conventional histological examination, which enables a fast, correct diagnosis.</span><span style=""line-height:2;"">&nbsp;</span><span style=""line-height:1.5;font-family:宋体;""><span style=""line-height:2;"">&nbsp;</span>
</p>
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<span style=""line-height:2;font-family:宋体;font-size:14px;"">体癣的典型表现为鳞屑性环状红斑，呈离心状向边界扩展，但有时可观察到囊泡和脓疱，偶尔甚至在出现严重的炎症后继发明显的大疱。当体癣的非典型临床表现与其他皮肤炎症性疾病（包括特应性或脂溢性皮炎、亚急性皮肤红斑狼疮或水泡性疾病）的临床表现类似时，诊断出现困难。我们报道了</span><span style=""line-height:2;font-family:'Times New Roman','serif';font-size:14px;"">5</span><span style=""line-height:2;font-family:宋体;font-size:14px;"">例最初的临床诊断与皮肤真菌病不同的非典型体癣病例，对有关真菌感染的非典型表现的鉴别诊断和诊断困难进行了讨论。此外，我们的病例强调了对能够进行快速、正确诊断的传统组织学检查的重要性。</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span> 
</p>
</span></span>","/uploadfiles/image/20131017/20131017142441_9506w.jpg","/uploadfiles/file/20131017/20131017142153_8915.pdf",,10/17/2013,10/18/2013,"medicool",37,,"tinea corporis | atypical | vesicular | fulminant | inconspicuous",0,"67",68,"Atypical manifestations of tinea corporis","2007",
310,,,"Denise B. Freeman","American family physician","&nbsp;
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">&nbsp;&nbsp;<span style=""line-height:2;"">&nbsp; The formation of corns and calluses can be caused by mechanical stress from faulty footgear (the wearing of poorly fitting shoes), abnormal foot mechanics (deformity of the foot exerting abnormal pressure), and high level of activity. Corns and calluses result from hyperkeratosis, a normal physiologic response of the skin to chronic excessive pressure or friction. Treatment should provide symptomatic relief and alleviate the underlying mechanical forces. Most lesions will usually disappear following the removal of the causative mechanical force. Most lesions can be managed conservatively by the use of properly fitting shoes and padding to redistribute mechanical force. Surgery is only indicated if conservative measures fail and should be aimed at correcting the abnormal mechanical stresses.</span></span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span> 
</p>",,"/uploadfiles/file/20131022/20131022140621_4302.pdf",,10/22/2013,10/22/2013,"medicool",29,,,0,"67",90,"Corns and calluses resulting from mechanical hyperkeratosis","2002",
260,,"DOI: 10.1111/j.1365-2133.2007.07888.x","D.S. KIM,M.R. ROH,J.H. LE E,K.H. LE E","Journal Compilation","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SIR, the efficacy of pramiconazole (R126638) has recently </span><span style=""font-family:Times New Roman;font-size:14px;"">been tested in a first series of patients with pityriasis versicolor.</span><span style=""font-family:Times New Roman;font-size:14px;"">This chronic superficial fungal disease is usually located </span><span style=""font-family:Times New Roman;font-size:14px;"">on the upper trunk, neck or upper arms. Under the influence </span><span style=""font-family:Times New Roman;font-size:14px;"">of predisposing factors Malassezia changes in pityriasis versicolor </span><span style=""font-family:Times New Roman;font-size:14px;"">from blastospores into hyphae.1 Pramiconazole is a broadspectrum </span><span style=""font-family:Times New Roman;font-size:14px;"">antifungal belonging to the class of triazoles. In vitro </span><span style=""font-family:Times New Roman;font-size:14px;"">and in vivo data have demonstrated activity against several dermatophytes </span><span style=""font-family:Times New Roman;font-size:14px;"">and Malassezia spp.2</span><span style=""font-family:Times New Roman;font-size:14px;"">C</span><span style=""font-family:Times New Roman;font-size:14px;"">4 The aim of the present study </span><span style=""font-family:Times New Roman;font-size:14px;"">was to evaluate the effects of a single dose of 200 mg of </span><span style=""font-family:Times New Roman;font-size:14px;"">pramiconazole given orally during three consecutive days in a </span><span style=""font-family:Times New Roman;font-size:14px;"">group of 19 patients with pityriasis versicolor.</span>
</p>","/uploadfiles/image/20131016/20131016163359_9972w.jpg","/uploadfiles/file/20131016/20131016163350_8712.pdf",,10/16/2013,10/16/2013,"medicool",35,,"treatment with pramiconazole;pityriasis versicolor;",0,"65",4,"The efficacy of oral treatment with pramiconazole in pityriasis versicolor: a phase II a trial","2007",
318,"足部摩擦水疱的形成：基于实验室的水疱产生模型的发展","10.1111/j.1600-0846.2012.00669.x","Farina Hashmi1, Barry S Richards1, Saeed Forghany1,2, Anna L Hatton1,3 and Christopher J Nester1","Skin Research and Technology","<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:&quot;&quot;;font-size:14px;"">Background/Purpose</span></b><span style=""font-family:&quot;&quot;;font-size:14px;"">:</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">Friction blisters on the foot are a debilitating pathology</span></span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;""> that have an impact on activities of daily living and can severely impair function. </span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span style=""font-size:14px;"">The purpose of this study was to test the hypotheses that d</span><a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">igital infrared thermographic </span></span></span><span><span><span style=""font-size:14px;"">imaging will reveal: 1) </span><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span style=""font-size:14px;"">a correlation between load application to the skin and the creation of blisters</span><span style=""font-size:14px;"">, and 2) a correlation between thermographic readings and </span><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">contact thermometric temperatures.</span></span></span><span><span></span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span><b><span style=""font-family:宋体;""><span style=""font-size:14px;"">研究背景</span><span style=""font-size:14px;"">/</span><span style=""font-size:14px;"">目的：</span><br />
<span style=""font-size:14px;""> &nbsp;&nbsp;&nbsp;</span></span></b></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">足部摩擦水疱是一种另人虚弱的病理疾病，它影响患者的日常活动并严重损害运动功能。</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">这项研究的目的是检验数字红外热成像揭示的假设：</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">1</span></span></span><span><span><span style=""font-family:宋体;""><span style=""font-size:14px;"">）对皮肤施加负荷与产生水疱的相关性，</span><span style=""font-size:14px;"">2</span><span style=""font-size:14px;"">）热成像读数与接触测温的相关性。</span><span></span></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:&quot;&quot;;font-size:14px;"">Methods</span></b><span style=""font-family:&quot;&quot;;font-size:14px;"">: </span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">Apparatus was developed to cause the formation of heel blisters through controlled load application (70 kPa)</span></span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">. </span><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span style=""font-size:14px;"">One foot of each of the 30 healthy volunteers </span><span style=""font-size:14px;"">(21 men and 9 women), with an age range of 31 </span></span><span style=""font-family:&quot;&quot;;font-size:14px;"">± </span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">8 years, was subjected to load until a blister formed, after which load application ceased and temperature measurements were taken </span><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span style=""font-size:14px;"">at set times during the following 5.5 h. </span><span style=""font-size:14px;"">Temperature measurements were also taken using a contact thermometer.</span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:宋体;""><span style=""font-size:14px;"">研究方法：</span><span></span></span></b> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;""><span style=""font-size:14px;"">&nbsp; 通过控制施加负荷的压力（</span><span style=""font-size:14px;"">70kpa</span><span style=""font-size:14px;"">）引起脚后跟水疱的形成，，我们选取了</span><span style=""font-size:14px;"">30</span><span style=""font-size:14px;"">名健康的志愿者</span></span><span class=""shorttext""><span style=""color:#222222;font-family:宋体;""><span style=""font-size:14px;"">（</span><span style=""font-size:14px;"">21</span><span style=""font-size:14px;"">名男性和</span><span style=""font-size:14px;"">9</span><span style=""font-size:14px;"">名女性，年龄范围在</span></span></span><span style=""font-family:宋体;font-size:14px;"">31</span><span style=""font-family:宋体;""><span style=""font-size:14px;"">±</span><span style=""font-size:14px;"">8</span><span style=""font-size:14px;"">岁之间</span></span><span style=""font-size:14px;"" class=""shorttext""><span style=""color:#222222;font-family:宋体;font-size:14px;"">），每位志愿者的一只脚承受一定的压力，直到水疱的形成，停止施加荷载后，在接下来的</span></span><span style=""font-family:宋体;font-size:14px;"">5.5</span><span style=""font-family:宋体;""><span style=""font-size:14px;"">个小时内，进行温度 的测定。。采用接触式温度计进行温度测量。</span><span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:&quot;&quot;;font-size:14px;"">Results</span></b><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">: </span><br />
<span style=""font-size:14px;""> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">The majority of the participants (77%) blistered within 18 min of load application. </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">All the blisters created showed significant increases in local temperature compared to </span></span></span></span></span><a name=""OLE_LINK35""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">baseline during blister creation (P </span></span></span></span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">&lt; </span></span></span></span></span></span></span></span><span><span><span><span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">0.001) and 30 min </span><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span style=""font-size:14px;"">post-blister</span><span style=""font-size:14px;""> creation (P </span></span></span></span></span></span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">&lt; </span></span></span></span></span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">0.001)</span></span></span></span></span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:&quot;&quot;;font-size:14px;"">.</span></span></span></span></span><span><span><span style=""font-family:&quot;&quot;;""> </span></span></span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">There was a strong correlation between</span><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span style=""font-size:14px;""> contact thermometry </span><span style=""font-size:14px;"">and </span><a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span style=""font-size:14px;"">thermographic temperature data</span><span style=""font-size:14px;"">(r </span></span><span style=""font-family:&quot;&quot;;font-size:14px;"">&gt; </span><span style=""font-family:&quot;&quot;;font-size:14px;"">8)</span><b><span style=""font-family:宋体;""> </span></b> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:宋体;""><span style=""font-size:14px;"">研究结果：</span><span></span></span></b> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;""><span style=""font-size:14px;"">&nbsp; 大多数的参与者</span><span style=""font-size:14px;"">(77%</span><span style=""font-size:14px;"">），加载负荷</span><span style=""font-size:14px;"">18</span><span style=""font-size:14px;"">分钟形成水疱。在水疱形成初期和</span><span style=""font-size:14px;"">30min</span><span style=""font-size:14px;"">后水疱形成过程中，与基线比，所有出现的水疱在局部温度下显著增加（</span><span style=""font-size:14px;"">p</span><span style=""font-size:14px;"">＜</span><span style=""font-size:14px;"">0.001</span><span style=""font-size:14px;"">）接触测温和红外测温数据（</span><span style=""font-size:14px;"">r&gt;8</span><span style=""font-size:14px;"">）之间有很强的相关性。</span></span><span style=""font-family:&quot;&quot;;font-size:14px;"">.</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:&quot;&quot;;font-size:14px;"">Conclusion</span></b><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">: </span><br />
<span style=""font-size:14px;""> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span style=""font-family:&quot;&quot;;""><span style=""font-size:14px;"">These results suggest that </span><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span style=""font-size:14px;"">thermographic images </span><span style=""font-size:14px;"">may prove useful for the remote assessment of traumatically damaged foot skin.</span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:宋体;""><span style=""font-size:14px;"">研究总结：</span><span></span></span></b> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:14px;"" class=""shorttext""><span style=""color:#222222;font-family:宋体;font-size:14px;"">&nbsp; 结果表明，热成像图像用来远程评估足部受损肌肤可能是有用的。</span></span> 
</p>","/uploadfiles/image/20131024/20131024124123_5968w.jpg","/uploadfiles/file/20131024/20131024124246_9321.pdf",,10/24/2013,10/24/2013,"medicool",45,,"skin C inflammation C thermography C perfusion",0,"65",94,"The formation of friction blisters on the foot: the development of a laboratory-based blister creation model","2013",
320,"水杨酸膏药与“常规的”手术刀清创术治疗鸡眼的效果对比：一项随机对照试验",,"Lisa J Farndon, Wesley Vernon, Stephen J Walters, Simon Dixon, Mike Bradburn, Michael Concannon","JOURNAL OF FOOT AND ANKLE RESEARCH","<p style=""text-align:center;"" class=""MsoNormal"" align=""center"">
	&nbsp;
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';"">Abstract</span></b></span></a> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2;""><span style=""line-height:2;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';"">Background: </span></b></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;"">Corns are a common foot problem and surveys have indicated that between 14-48% of people suffer from them. Many of these will seek podiatry treatment, however there is little evidence to indicate which current treatments provide long term resolution. This study compared ‘usual’ treatment (enucleation with a scalpel) with the application of 40% salicylic acid plasters to corns to investigate which is the most effective in terms of clinical, economic and </span><span style=""line-height:2;"">patient-centred </span></a><span style=""line-height:2;"">outcomes.</span></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2;""><span style=""line-height:2;""><b><span style=""line-height:2;font-family:宋体;"">背景：</span></b></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">鸡眼是一种常见的足部问题，调查表明，</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">14-48</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">％的人患有鸡眼。许多患者想要寻求足部治疗，然而，很少有证据表明目前的治疗能够长期解决问题。本项研究比较了“常规的”的治疗法（手术刀去除术）和使用</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">40</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">％水杨酸膏药治疗鸡眼的疗效，依据临床、经济和以病人为中心的结果，调查两种方法中哪一种方法最有效。</span></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2;""><span style=""line-height:2;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';"">Methods: </span></b></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;"">A parallel-group randomised controlled trial was carried out in two centres where adults who presented with one or more corns and who met the inclusion criteria were allocated to either ‘usual’ scalpel debridement or corn plaster treatment. All participants had measurements of corn size, pain using a 100 mm visual analogue scale (VAS) and health-related quality of life </span><span style=""line-height:2;"">(EQ-5D) </span></a><span style=""line-height:2;"">measures by an independent podiatrist, blind to treatment allocation </span><span style=""line-height:2;"">at baseline, 3, 6, 9 and 12 months</span></a><span style=""line-height:2;"">.</span></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2;""><span style=""line-height:2;""><b><span style=""line-height:2;font-family:宋体;"">方法：</span></b></span></span><span><span><span style=""line-height:150%;font-family:宋体;""><span style=""line-height:2;"">平行组随机对照试验在两个小组中进行，患有一个或多个鸡眼并且符合入选标准的成年人被随机分配到“常规的”手术刀清创术或鸡眼膏药治疗两组中的任意一组。</span><span style=""line-height:2;"">由一个独立的足科医生随机分配治疗，在</span></a></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">0</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">、</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">3</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">、</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">6</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">、</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">9 </span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">和</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">12</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">个月时采用</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">100</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">毫米的视觉模拟评分法（</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">VAS</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）和健康相关的生活质量（</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">EQ -5D</span></span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）措施对所有参与者的鸡眼大小和疼痛程度进行测量。</span></span></span></span></span><span><span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""> </span></span></span></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span></span>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2;""><span style=""line-height:2;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';"">Results:</span></b></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;""> 202 participants were randomised to receive scalpel debridement or corn plaster treatment (101 in each group). At 3 months 34% (32/95) of corns had completely resolved in the corn plaster group compared with 21% (20/94) in the scalpel group (p = 0.044), and 83% (79/95) had reduced in size in the corn plaster group compared with 56% (53/94) in the scalpel group (p &lt; 0.001). At 12 months, </span><span style=""line-height:2;"">time to corn recurrence was longer </span></a><span style=""line-height:2;"">in the corn plaster group (p &lt; 0.001). Pain from the corns was significantly lower in the corn plaster group at 3 months (p &lt; 0.001) and EQ-5D scores changed (improved), from baseline, by 0.09 (SD ±0.31) and 0.01 (SD ±0.25) points in the corn plaster and scalpel groups respectively (p = 0.056). By month 12, EQ-5D scores had changed by 0.12 and ?0.05 in the corn plaster and scalpel groups respectively (p = 0.005). The EQ-5D, VAS scores and the four domains of the Foot Disability Scale were similar in both groups at 3 and 12 months. The economic analysis indicated that corn plasters were a cost effective intervention.</span></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2;""><span style=""line-height:2;""><b><span style=""line-height:2;font-family:宋体;"">结果</span></b></span></span><span style=""line-height:2;""><span style=""line-height:2;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';"">: </span></b></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">202</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">名参与者被随机分配接受手术刀清创术治疗或鸡眼膏药治疗（每组</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">101</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">人）。</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">3</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">个月时，与手术刀组</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">21</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">％（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">20/94</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）的治愈率相比，鸡眼膏治疗组中</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">34</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">％（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">32/ 95</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）的患者鸡眼被彻底治愈（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">p = 0.044</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）；在鸡眼膏治疗组中，</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">83</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">％（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">79/ 95</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）患者的鸡眼尺寸减小，而手术刀组中为</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';""> <span style=""line-height:2;"">56</span></span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">％（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">53/ 94 </span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">P &lt; 0.001</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）。</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">12</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">个月时，鸡眼膏组的鸡眼复发时间延长（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">P &lt; 0.001</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）。</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">3</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">个月时，鸡眼膏治疗组的鸡眼疼痛程度明显降低（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">P &lt; 0.001</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">），</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">EQ-5D</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">分数改变，鸡眼膏组和手术刀组分别比治疗前提高了</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">0.09</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">分（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">SD</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">±</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">0.31</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）和</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">0.01</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">分（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">SD </span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">±</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">0.25</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">P = 0.056 </span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）。</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">12</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">个月时，鸡眼膏组的</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">EQ -5D</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">分数提高了</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">0.12</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">分，手术组的降低了</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">0.05</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">分（</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">P = 0.005</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">）。在两组中，</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">EQ - 5D</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">、</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">VAS</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">评分和足残疾量表的四个区域在</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">3</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">个月和</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">12</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">个月时是相似的。经济学分析表明，鸡眼膏药是一个经济实惠的治疗方法。</span></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2;""><span style=""line-height:2;""><b><span style=""line-height:2;font-family:'Times New Roman','serif';"">Conclusions:</span></b></span></span><span><span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;""> The use of corn plasters was associated with a higher proportion of resolved corns, a prolonged time to corn recurrence, less pain and reduced corn size over the first 6 months in comparison with ‘usual’ scalpel treatment and this intervention was </span><span style=""line-height:2;"">cost effective</span></a><span style=""line-height:2;"">. Used under supervision of a podiatrist on appropriate patients, corn plasters offer an effective alternative to scalpel debridement.</span></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2;""><span style=""line-height:2;""><b><span style=""line-height:2;font-family:宋体;"">结论：</span></b></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">治疗</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:'Times New Roman','serif';"">6</span></span></span><span style=""line-height:2;""><span style=""line-height:2;""><span style=""line-height:2;font-family:宋体;"">个月后，与“常规的”的手术刀治疗方法相比，使用鸡眼膏治愈鸡眼的比例较高、鸡眼复发时间延长、痛苦较少、鸡眼尺寸减小，而且更加经济实惠。在足科医生的监督下使用鸡眼膏给特定的患者提供了一个有效的可以替代手术刀清创术的治疗方法。</span></span></span><span></span><span></span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span> 
</p>
<p>
	&nbsp;
</p>","/uploadfiles/image/20131024/20131024134329_0393w.jpg","/uploadfiles/file/20131024/20131024134128_3419.pdf",,10/24/2013,10/24/2013,"medicool",32,,"Foot, Pain, Podiatry, Callosities, Debridement",0,"66",90,"The effectiveness of salicylic acid plasters compared with ‘usual’ scalpel debridement of corns: a randomised controlled trial","2013",
261,,,"Dermatology Department and Shiraz University of Medical Science, Pharmacology Toxicology Department andShiraz University of Medical Science and Shiraz University of Medical Science, Shiraz, Iran","Journal of Dermatological Treatment.","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Background: Tinea versicolor is a superficial fungal infection of the skin caused by Malassezia yeasts. Tinea versicolor is a </span><span style=""font-family:Times New Roman;font-size:14px;"">common disease and has a high rate of recurrence. Methods: This is a prospective, double-blind, randomized, </span><span style=""font-family:Times New Roman;font-size:14px;"">placebo-controlled clinical trial in Faghihi Hospital Dermatology Department. Participants were older than 10 years with </span><span style=""font-family:Times New Roman;font-size:14px;"">a clinical diagnosis of tinea versicolor and positive KOH preparation, and were divided in two groups: active and control </span><span style=""font-family:Times New Roman;font-size:14px;"">(32 individuals in each). They were randomized to receive either nitric oxide (NO)-liberating cream as the active group and </span><span style=""font-family:Times New Roman;font-size:14px;"">placebo as a control. Creams were applied twice daily on the affected sites for 10 days. Results: Sixty-four patients were </span><span style=""font-family:Times New Roman;font-size:14px;"">entered into the study (31 male and 33 female). No significant difference was found between the two groups in terms of </span><span style=""font-family:Times New Roman;font-size:14px;"">severity, age and sex distribution. There was significant improvement with acidified nitrite cream in the active group after </span><span style=""font-family:Times New Roman;font-size:14px;"">10 days (p = 0.000). Conclusion: NO is an important cytotoxic effector in immune defense against fungi that are too large </span><span style=""font-family:Times New Roman;font-size:14px;"">to phagocyte. This study shows the efficacy of an exogenous NO-releasing cream in treating tinea versicolor</span><span style=""font-family:Times New Roman;font-size:14px;"">.</span>
</p>",,"/uploadfiles/file/20131016/20131016163708_4612.pdf",,10/16/2013,10/16/2013,"medicool",31,,"efficacy, nitric oxide, pityriasis versicolor",0,"65",4,"Efficacy of nitric oxide-liberating cream on pityriasis versicolor","2010",
274,"脂溢性皮炎及花斑癣患者糠秕马拉色菌的细胞介导免疫",,"I.-M. Bergbrant, B. Andersson* and J. Faergemann","Experimental dermatology","<p class=""MsoNormal"" align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a name=""OLE_LINK10""></a><a name=""OLE_LINK16""></a><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span><span><span><span><span><span style=""font-size:9.5pt;""><span style=""font-family:Times New Roman;font-size:14px;"">The lymphocyte transformation response to </span><i><span style=""font-family:Times New Roman;font-size:14px;"">Malassezia furfur</span></i><span style=""font-family:Times New Roman;font-size:14px;"">, </span><i><span style=""font-family:Times New Roman;font-size:14px;"">Candida albicans</span></i><span style=""font-family:Times New Roman;font-size:14px;"">, phytohaemagglutinin, </span></span></span></span></span></span></span><a name=""OLE_LINK12""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">concanavlin A </span></span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-size:9.5pt;""><span style=""font-family:Times New Roman;font-size:14px;"">and tuberculin purified protein derivative of </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span><span style=""font-family:Times New Roman;font-size:14px;"">12 </span><span style=""font-family:Times New Roman;font-size:14px;"">patients with pityriasis versicolor,</span></span></span></span></span></span></span></span></span><span><span><span><span><span><span><span style=""font-size:9.5pt;""><span style=""font-family:Times New Roman;font-size:14px;""> 15 patients with seborrhoeic dermatitis and matched </span><span style=""font-family:Times New Roman;font-size:14px;"">controls,</span></span></span></span></span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""> was studied</span></span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">.</span></span></span><span style=""font-size:9.5pt;""><span style=""font-family:Times New Roman;font-size:14px;""> Patients </span><span style=""font-family:Times New Roman;font-size:14px;"">with pityriasis </span><span style=""font-family:Times New Roman;font-size:14px;"">versicolor showed a significantly lower response to </span><i><span style=""font-family:Times New Roman;font-size:14px;"">M. </span><span style=""font-family:Times New Roman;font-size:14px;"">f</span><span style=""font-family:Times New Roman;font-size:14px;"">urfur </span></i><span style=""font-family:Times New Roman;font-size:14px;"">than patients with seborrhoeic dermatitis and controls.</span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span style=""font-size:14px;""><span style=""font-size:14px;"">本文研究了</span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">12</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">名花斑癣患者、</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">15</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">名脂溢性皮炎患者及对照组的淋巴细胞，在糠秕马拉色菌、白色念珠菌、植物血凝素、</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">ConA</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">以及结核菌素纯蛋白衍生物的刺激下的淋巴细胞转化反应。</span></span></span><span style=""font-size:14px;"">与脂溢性皮炎以及对照组的患者相比，花斑癣患者</span><span class=""shorttext""><span style=""color:#222222;""><span style=""font-size:14px;"">对糠秕马拉色菌反应明显降低。</span><span style=""display:none;"" id=""__kindeditor_bookmark_end_13__""></span></span></span><span style=""font-family:&quot;&quot;;""></span> 
</p>
<br />
<br />","/uploadfiles/image/20131017/20131017103628_0905w.jpg","/uploadfiles/file/20131017/20131017103657_7306.pdf",,10/17/2013,10/17/2013,"medicool",35,,,0,"65",4,"Cell-mediated immunity to Malassezia furfur in patients with seborrhoeic dermatitis and pityriasis versicolor ","2000",
275,,,"Claudia Cafarchia, Diana Romito, Gioia Capelli, Jacques Guillot and Domenico Otranto","European Society of Veterinary Dermatology","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">Abstract:</span><br />
<span style=""font-family:Times New Roman;font-size:14px;""><em>Microsporum canis </em></span><span style=""font-family:Times New Roman;font-size:14px;"">has been frequently isolated from </span><span style=""font-family:Times New Roman;font-size:14px;"">human cases of tinea capitis and tinea corporis. The </span><span style=""font-family:Times New Roman;font-size:14px;"">infection may be acquired from infected animals with </span><span style=""font-family:Times New Roman;font-size:14px;"">cutaneous lesions but also from asymptomatic carriers </span><span style=""font-family:Times New Roman;font-size:14px;"">or from the environment. As asymptomatic </span><span style=""font-family:Times New Roman;font-size:14px;""><em>M. </em></span><span style=""font-family:Times New Roman;font-size:14px;""><em>canis </em></span><span style=""font-family:Times New Roman;font-size:14px;"">carriers are considered to be a critical factor in </span><span style=""font-family:Times New Roman;font-size:14px;"">the epidemiology of dermatophytosis in humans, this </span><span style=""font-family:Times New Roman;font-size:14px;"">study investigated the relationship between the presence </span><span style=""font-family:Times New Roman;font-size:14px;"">of dermatophytes on the hair coats of dogs and </span><span style=""font-family:Times New Roman;font-size:14px;"">cats without cutaneous lesions and the occurrence of </span><span style=""font-family:Times New Roman;font-size:14px;"">the disease in their respective owners. A total of 136 </span><span style=""font-family:Times New Roman;font-size:14px;"">dogs and 248 cats were sampled from January 1999 to</span><span style=""font-family:Times New Roman;font-size:14px;"">January 2005. Seventy-eight animals (22 dogs and 56 </span><span style=""font-family:Times New Roman;font-size:14px;"">cats) belonged to individuals affected by tinea corporis </span><span style=""font-family:Times New Roman;font-size:14px;""> caused by</span><span style=""font-family:Times New Roman;font-size:14px;""><em>M. canis </em></span><span style=""font-family:Times New Roman;font-size:14px;"">and 306 (114 dogs and 192 cats) to </span><span style=""font-family:Times New Roman;font-size:14px;"">individuals without dermatophytosis. Age, sex, breed, </span><span style=""font-family:Times New Roman;font-size:14px;"">habitat and season were recorded for each animal and </span><span style=""font-family:Times New Roman;font-size:14px;"">examined as potential risk factors. Dermatophytes </span><span style=""font-family:Times New Roman;font-size:14px;"">were isolated from 20.5% of the dogs and 28.2% of </span><span style=""font-family:Times New Roman;font-size:14px;"">the cats. </span><span style=""font-family:Times New Roman;font-size:14px;""><em>Microsporum canis </em></span><span style=""font-family:Times New Roman;font-size:14px;"">was isolated from 36.4% </span><span style=""font-family:Times New Roman;font-size:14px;"">of dogs cohabiting with owners diagnosed with tinea </span><span style=""font-family:Times New Roman;font-size:14px;"">corporis but it was never isolated from dogs whose </span><span style=""font-family:Times New Roman;font-size:14px;"">owners had no lesions. By contrast, </span><span style=""font-family:Times New Roman;font-size:14px;""><em>M. canis </em></span><span style=""font-family:Times New Roman;font-size:14px;"">was </span><span style=""font-family:Times New Roman;font-size:14px;"">isolated from 53.6% of cats cohabiting with owners </span><span style=""font-family:Times New Roman;font-size:14px;"">diagnosed with tinea corporis and from 14.6% of </span><span style=""font-family:Times New Roman;font-size:14px;"">cats whose owners had no signs of the disease. These </span><span style=""font-family:Times New Roman;font-size:14px;"">results clearly indicate that both cats and dogs should </span><span style=""font-family:Times New Roman;font-size:14px;"">be considered as a major source of pathogenic dermatophytes </span><span style=""font-family:Times New Roman;font-size:14px;"">for humans even when they do not present </span><span style=""font-family:Times New Roman;font-size:14px;"">clinical signs of dermatophytosis.</span>
</p>",,"/uploadfiles/file/20131017/20131017103752_6895.pdf",,10/17/2013,10/17/2013,"medicool",18,,,0,"65",68,"Isolation of Microsporum canis from the hair coat of pet dogs and cats belonging to owners diagnosed with M. canis tinea corporis","2006",
276,,"10.1002/14651858.CD003584.pub2.","Bell-Syer SE, Khan SM, Torgerson DJ.","Cochrane Database Syst Rev.","<p class=""MsoNormal"" style=""margin-left:0cm;background:white;"">
	<b>BACKGROUND: </b>About 15% of the world population have fungal infections of the feet
(tinea pedis or athlete's foot). There are many clinical presentations of tinea
pedis, and most commonly, tinea pedis is seen between the toes (interdigital)
and on the soles, heels, and sides of the foot (plantar). Plantar tinea pedis
is known as moccasin foot. Once acquired, the infection can spread to other
sites including the nails, which can be a source of re-infection. Oral therapy
is usually used for chronic conditions or when topical treatment has failed.<b></b>
</p>
<p class=""MsoNormal"" style=""margin-left:0cm;background:white;"">
	<b>OBJECTIVES: </b>To assess the effects of oral treatments for fungal infections of the skin
of the foot (tinea pedis).<b></b>
</p>
<p class=""MsoNormal"" style=""margin-left:0cm;background:white;"">
	<b>SEARCH METHODS: </b>For this update we searched the following databases to
July 2012: the Cochrane Skin Group Specialised Register, CENTRAL in The
Cochrane Library, MEDLINE (from 1946), EMBASE (from 1974), and CINAHL (from
1981). We checked the bibliographies of retrieved trials for further references
to relevant trials, and we searched online trials registers.<b></b>
</p>
<p class=""MsoNormal"" style=""margin-left:0cm;background:white;"">
	<b>SELECTION CRITERIA: </b>Randomised controlled trials of oral treatments in
participants who have a clinically diagnosed tinea pedis, confirmed by
microscopy and growth of dermatophytes (fungi) in culture.<b></b>
</p>
<p class=""MsoNormal"" style=""margin-left:0cm;background:white;"">
	<b>DATA COLLECTION AND ANALYSIS: </b>Two review authors
independently undertook study selection, 'Risk of bias' assessment, and data
extraction.<b></b>
</p>
<p class=""MsoNormal"" style=""margin-left:0cm;background:white;"">
	<b>MAIN RESULTS: </b>We included 15 trials, involving 1438 participants. The 2 trials (71
participants) comparing terbinafine and griseofulvin produced a pooled risk
ratio (RR) of 2.26 (95% confidence interval (CI) 1.49 to 3.44) in favour of
terbinafine's ability to cure infection. No significant difference was detected
between terbinafine and itraconazole, fluconazole and itraconazole, fluconazole
and ketoconazole, or between griseofulvin and ketoconazole, although the trials
were generally small. Two trials showed that terbinafine and itraconazole were
effective compared with placebo: terbinafine (31 participants, RR 24.54, 95% CI
1.57 to 384.32) and itraconazole (72 participants, RR 6.67, 95% CI 2.17 to
20.48). All drugs reported adverse effects, with gastrointestinal effects most
commonly reported. Ten of the trials were published over 15 years ago, and this
is reflected by the poor reporting of information from which to make a clear
'Risk of bias' assessment. Only one trial was at low risk of bias overall. The
majority of the remaining trials were judged as 'unclear' risk of bias because
of the lack of clear statements with respect to methods of generating the
randomisation sequence and allocation concealment. More trials achieved
blinding of participants and personnel than blinding of the outcome assessors,
which was again poorly reported.<b></b>
</p>
<p class=""MsoNormal"" style=""margin-left:0cm;background:white;"">
	<b>AUTHORS' CONCLUSIONS: </b>The evidence suggests that terbinafine is more effective
than griseofulvin, and terbinafine and itraconazole are more effective than no
treatment. In order to produce more reliable data, a rigorous evaluation of
different drug therapies needs to be undertaken with larger sample sizes to
ensure they are large enough to show any real difference when two treatments
are being compared. It is also important to continue to follow up and collect
data, preferably for six months after the end of the intervention period, to
establish whether or not the infection recurred.<b></b>
</p>",,"/uploadfiles/file/20131017/20131017104500_4110.pdf",,10/17/2013,10/17/2013,"medicool",33,,,0,"67",60,"Oral treatments for fungal infections of the skin of the foot","2012",
262,,"10.1111/j.1468-3083.2008.02783.x","Sotiriou E ; Koussidou T ; Patsatsi A ; Apalla Z ; Ioannides D","Journal Of The European Academy Of Dermatology And Venereology: JEADV","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	As standard
drug treatments are prolonged and expensive and drug-resistant strains are
becoming more frequent, the search for new therapeutic approaches is emerging.
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	Photodynamic
treatment (PDT) has proven itself, in worldwide studies, to be an effective
tool for skin tumours as well as for inflammatory and infectious skin diseases.
Experimental findings of <i>in vitro </i>studies have shown that dermatophytes can be effectively
photosensitized after topical application of 5- aminolevulinic acid (ALA).<sup>1C4 </sup>Based on these findings, we recruited 10 patients with tinea pedis of
interdigital type in order to evaluate the therapeutic effect of PDT on the
disease. Written informed consent was provided by all patients. Patients’ mean
age was 46.5 years (range, 28C62 years). Mycological examination that was
performed before treatment initiation included direct microscopic examination
plus culture in Sabouraud dextrose agar medium at 28 °C for 3 weeks. Direct
examination showed fungal elements in all patients, whereas cultures revealed <i>Trichophyton</i> <i>rubrum </i>in four cases
and <i>Trichophyton mentagrophytes </i>var. interdigitales in six cases.
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	All patients
underwent the following therapeutic procedure: 20% 5-aminolevulinic acid (MEDAC
GmBh, Hamburg, Germany) was applied topically to the involved area and sealed
with an occlusive dressing. Lesions were treated 3 h after ALA application with
red light (570C670 nm) by a non-coherent light source (Waldmann PDT 1200, Waldmann-Medizin-Technik,
Villingen-Schwenningen, Germany) at a light dose of 50 J/cm<sup>2</sup> and a
fluence rate of 50 mW/cm<sup>2</sup>. Endpoint of the study was either clinical
and mycological cure or a total of three treatments at 2-week intervals.
Clinical cure was defined as no clinically evident lesions and mycological cure
as negative direct microscopic examination.
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	Treatment was
well tolerated. All patients reported a burning sensation during irradiation,
but none of them asked to interrupt the procedure. Erythema was observed in all
patients up to 1 week after therapy, but swelling or blistering did not
develop.
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	Clinical and
mycological evaluations were performed at baseline, 1 week following each
treatment and 2 months after the last treatment.
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	Seven days
after the first treatment, direct microscopic examination was negative in one
patient. The remaining nine patients received two additional treatments that
lead to the clinical and mycological cure in five of them. However, only three
patients had a persistent healing at the last follow-up visit after 8 weeks. In
all other patients, cultures revealed the same species isolated before ALAPDT. Patient
characteristics and results are summarized in Table 1.
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	There are
numerous possible reasons for these unsatisfactory results. Although ALA is <i>in vitro </i>sufficiently
metabolized into <i>PpI</i>X, <i>in vivo </i>conditions such as humidity and temperature could lead to
its deficient biosynthesis.
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	The delivery of
ALA cream or of the light might not be uniform because of the irregular shape
of the interdigital spaces.
</p>",,"/uploadfiles/file/20131016/20131016164536_8505.pdf",,10/16/2013,10/16/2013,"medicool",32,,,0,"66",60,"5-Aminolevulinic acidphotodynamic treatment for dermatophytic tinea pedis of interdigital type: a small clinical study","2009",
263,,"DOI: 10.1111/j.1525-1470.2012.01753.x","William W. Huang, M.D., M.P.H.","Pediatric Dermatology","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tinea versicolor is a commonly encountered </span><span style=""font-family:Times New Roman;font-size:14px;"">superficial fungal infection often presenting on the </span><span style=""font-family:Times New Roman;font-size:14px;"">chest and back wit hyperpigmented or hypopigmented </span><span style=""font-family:Times New Roman;font-size:14px;"">scaly macules and patches. We report an unusual and </span><span style=""font-family:Times New Roman;font-size:14px;"">rare presentation of tinea versicolor affecting only the </span><span style=""font-family:Times New Roman;font-size:14px;"">eyelids.</span> 
</p>","/uploadfiles/image/20131016/20131016165046_2614w.jpg","/uploadfiles/file/20131016/20131016165034_4366.pdf",,10/16/2013,10/16/2013,"medicool",38,,"Tinea versicolor;pityriasis versicolor;",0,"85",4,"A CASE OF TINEA VERSICOLOR OF THE EYELIDS","2012",
267,,"10.1111/j.1365-2230.2009.03458.x","Zhan P ; Ge YP ; Lu XL ; She XD ; Li ZH ; Liu WD","Clinical And Experimental Dermatology","<p class=""MsoNormal"">
	<b>Background. </b>Two feetCone hand syndrome (bilateral plantar tinea pedis
with coexistent unilateral tinea manuum) is commonly seen in dermatology
clinics, but the cause of the unilateral hand involvement remains unresolved.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Aims.</b> To investigate the unilateral hand involvement in this
syndrome.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Methods.</b> This was a caseCcontrol study. The experimental group
comprised 113 patients with bilateral tinea pedis and unilateral tinea manuum
and the control group comprised 44 patients with tinea pedis only, without tinea
manuum. Clinical data were recorded and pathogens were identified by fungal
examination. The predominant pathogen, Trichophyton rubrum, was genotyped by
PCR amplification of tandem repeat elements from the ribosomal DNA
nontranscribed spacer region.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Results. </b>Scratching habits were significantly different between
the groups, and there was a significant relationship between tinea manuum and
the hand reportedly used to scratch the feet. In analysis of isolates from the
feet and the involved hand, 94.5% of pairs were of the same species, and 80% of
pairs had the same genotypes.<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<b>Conclusions.</b> Contact between hands and feet probably results in the
transmission of dermatophytes from the feet to the scratching hand.<o:p></o:p>
</p>",,"/uploadfiles/file/20131017/20131017092500_5634.pdf",,10/17/2013,10/17/2013,"medicool",36,,"Case-Control Studies ; China ; Disease Transmission, Infectious ; Female ; Hand Dermatoses/microbiology ; Humans ; Male ; Risk Factors ; Syndrome ; Time Factors ; Trichophyton/genetics",0,"85",60,"A caseCcontrol analysis and laboratory study of the two feetCone hand syndrome in two dermatology hospitals in China","2010",
264,,"10.1080/09603123.2010.484861","Kiraz N ; Metintas S ; Oz Y ; Koc F ; Koku Aksu EA ; Kalyoncu C ; Kasifoglu N ; Cetin E ; Arikan I","International Journal Of Environmental Health Research","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	The aim of this study
was to determine the frequency of tinea pedis and manuum (dermatophyte
infections of the hands and feet) in adults in rural areas of Turkey, the risk
factors and self-administered treatment options. A total of 2,574 people living
in a rural area were enrolled in the study. Participants were asked demographic
data, hygienic habits in a questionnaire. KOH preparations and culture were
performed from suspicious lesions. Medical and alternative therapy methods and
former dermatophytosis diagnosis history were taken from the respondents with
suspicious lesions. Microbiological samples were taken from 285 (11.1%)
participants. Culture was positive in 109 (4.2%) of those. The most common
agent was Trichophyton rubrum. The predisposing factors were found as age older than
40, male gender and obesity. Forty-nine (44.9%) of patients had taken a medical
therapy, 56 (51.4%) had performed non-medical methods (cologne, Lawsonia inermis-Henna and softener
creams). Patient’s education about the treatment compliance is important.
</p>",,"/uploadfiles/file/20131016/20131016165313_9313.pdf",,10/16/2013,10/16/2013,"medicool",22,,"Microbiology; prevalence; therapy; tinea pedis; tinea manuum",0,"85",60,"The prevalence of tinea pedis and tinea manuum in adults in rural areas in Turkey","2010",
266,,,"Ogasawara Y ; Hiruma M ; Muto M ; Ogawa H","Mycoses","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	An epidemiological investigation was conducted to
determine the prevalence and circumstances of untreated, unsuspected tinea
pedis and tinea unguium, morbid conditions that could be termed occult athlete’s
foot, in patients visiting a dermatology clinic in Tokyo, Japan, for the first
time, for other complaints. All subjects completed a questionnaire covering comprehensive
anamnestic details, and were examined for disposition of toes, presence of
signs suggestive of tinea pedis, other diseases of the foot, score of clinical
signs and symptoms, potassium hydroxide (KOH) test, severity score, and
mycological culture. The results showed that the prevalence of occult athlete’s
foot was 25%, and that 59% of those cases were complicated by tinea unguium.
The characteristics of patients with occult athlete’s foot included a higher
proportion of men and a tendency toward a low clinical score together with a
high severity score. In the patient background, a strong correlation was
observed between a positive KOH test result and characteristics such as age,
disposition of toes, and predisposing disease.
</p>",,"/uploadfiles/file/20131016/20131016171308_1758.pdf",,10/16/2013,10/16/2013,"medicool",37,,"Trichophyton mentagrophytes, tinea pedis, tinea unguium, occult athlete’s foot.",0,"85",60,"Clinical and mycological study of occult tinea pedis and tinea unguium in dermatological patients from Tokyo","2003",
268,"Perniosis-like tinea corporis caused by Trichophyton verrucosum in cold-exposed individuals",,"M. Placzek, M. E. van den Heuvel, M. J. Flaig and H. C. Korting","Blackwell Publishing Ltd ? Mycoses","<p align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-family:Times New Roman;font-size:14px;"">Trichophyton verrucosum is a zoophilic infectious agent causing 98% of the </span><span style=""font-family:Times New Roman;font-size:14px;"">dermatophytic infections of cattle. Transmission to humans has, until recently, been </span><span style=""font-family:Times New Roman;font-size:14px;"">rare. One reason for an increase of infection in humans and animals seems to be the </span><span style=""font-family:Times New Roman;font-size:14px;"">decrease in immunisation of cattle. We report on three cases of pertinent human </span><span style=""font-family:Times New Roman;font-size:14px;"">infections with disseminated, sharply defined, bluish red, partly oedematous nodules </span><span style=""font-family:Times New Roman;font-size:14px;"">and plaques in particular not only on the thighs, but also on the trunk and arms. Two </span><span style=""font-family:Times New Roman;font-size:14px;"">of our patients work with farm animals. The third one works as an assistant in a </span><span style=""font-family:Times New Roman;font-size:14px;"">butcher shop, but lives on a cow farm. All three patients are often exposed to the cold. </span><span style=""font-family:Times New Roman;font-size:14px;"">In all three cases T. verrucosum was detected by culture. Tinea corporis was </span><span style=""font-family:Times New Roman;font-size:14px;"">histologically confirmed in two patients. Based on the microbiological results, we </span><span style=""font-family:Times New Roman;font-size:14px;"">began a combined systemic and local antimycotic therapy with fluconazole </span><span style=""font-family:Times New Roman;font-size:14px;"">50 mg day)1 in two patients, itraconazole 100 mg day)1 in one patient p.o. </span><span style=""font-family:Times New Roman;font-size:14px;"">combined with topical ciclopiroxolamine. All patients were cured. Dermatophytosis </span><span style=""font-family:Times New Roman;font-size:14px;"">caused by T. verrucosum can, under certain circumstances, such as frequent exposure </span><span style=""font-family:Times New Roman;font-size:14px;"">to cold or a long-term corticosteroid therapy, mimic the characteristic clinical picture </span><span style=""font-family:Times New Roman;font-size:14px;"">of perniosis, as we demonstrate here.</span> 
</p>",,"/uploadfiles/file/20131017/20131017094216_2804.pdf",,10/17/2013,10/17/2013,"medicool",22,,"perniosis, Trichophyton verrucosum, dermatophytes.",0,"85",68,,"2006",
312,"鸡眼防治的研究进展","1008―5149(2012)05一O111―02","安立国，谭晓波","内蒙古民族大学学报","<span style=""font-family:SimSun;font-size:14px;"">摘要:</span>&nbsp;<br />
<span style=""font-family:SimSun;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style=""font-family:SimSun;font-size:14px;"">鸡眼是一种常见的皮肤病，不易根治，患病人数较多，给患者的生活带来很多不便。本文对该病的发&nbsp;&nbsp; </span><span style=""font-family:SimSun;font-size:14px;"">病原因及危害、症状、预防和治疗进行了比较全面的综述。</span>",,"/uploadfiles/file/20131022/20131022145418_6369.pdf",,10/22/2013,10/22/2013,"medicool",46,,"鸡眼；防治；综述",0,"67",90,,"2012",
324,,,"De Silva BD ; McLaren K ; Doherty VR","Clinical And Experimental Dermatology","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">Reports of equestrian perniosis are rare in the
literature and in the cases previously described there have been no abnormal
laboratory investigations. We describe two patients with equestrian perniosis
who had persistently elevated titres of cold agglutinins. We discuss the
relationship of these cold agglutinins to the pathogenesis of perniosis and
other related skin disorders.</span>
</p>",,"/uploadfiles/file/20131024/20131024161007_6264.pdf",,10/24/2013,10/24/2013,"medicool",26,,,0,"85",88,"Equestrian perniosis associated with cold agglutinins: a novel finding","2000",
269,,"10.1111/j.1439-0507.2009.01736.x","Debby Budihardja, Viviane Freund and Peter Mayser","Blackwell Verlag GmbH ? Mycoses","<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;<span style=""font-family:Times New Roman;"">&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;"">Superficial fungal infections are expected to be more prevalent in renal transplant </span></span><span style=""font-family:Times New Roman;font-size:14px;"">recipients because of graft-preserving immunosuppressive therapy. Here we report the </span><span style=""font-family:Times New Roman;font-size:14px;"">case of a 45-year-old patient with widespread erosive tinea corporis transmitted by </span><span style=""font-family:Times New Roman;font-size:14px;"">domestic animals. Sequencing of the internal transcribed spacer region identified </span><span style=""font-family:Times New Roman;font-size:14px;"">Arthroderma benhamiae (teleomorph of Trichophyton mentagrophytes) in the patient, her </span><span style=""font-family:Times New Roman;font-size:14px;"">husband and her domestic animals. A combination therapy with systemic terbinafine </span><span style=""font-family:Times New Roman;font-size:14px;"">hydrochloride and topically applied ciclopiroxolamine was successful.</span> 
</p>",,"/uploadfiles/file/20131017/20131017094929_2280.pdf",,10/17/2013,10/17/2013,"medicool",20,,,0,"85",68,"Widespread erosive tinea corporis by Arthroderma benhamiae in a renal transplant recipient: case report","2009",
270,,,"Cohen AD ; Wolak A ; Alkan M ; Shalev R ; Vardy DA","Mycoses","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	We developed a simple scoring system to evaluate the severity of tinea
pedis (Athlete's foot severity score, AFSS). The AFSS consists of a clinical evaluation, using a three-point
scale, of erythema and scaling in the plantar and interdigital spaces of the
feet, and counts of interdigital spaces involved. Each<b> </b>foot is<b> </b>evaluated
separately. The validity of the AFSS was assessed in 224 soldiers of the Israel
Defense Force using mycological cultures as the main outcome measure and
subjective assessment of pruritus as the secondary outcome measure. Mycological
examinations were performed in 106 patients who had clinical evidence of tinea
pedis. AFSS was significantly associated with culture results
(P&amp;lt;0.0001), as well as with the presence of pruritus (P=0.002), and
pruritus scores (P=0.025). We conclude the AFSS is valid for the clinical
evaluation of tinea pedis severity in military settings. The application of AFSS to civilian
morbidity should be subjected to further evaluation.&nbsp;
</p>",,"/uploadfiles/file/20131017/20131017095246_0067.pdf",,10/17/2013,10/17/2013,"medicool",23,,"Athlete’s foot, clinical evaluation, severity score.",0,"67",60,"AFSS: athlete's foot severity score. A proposal and validation","2002",
297,"A群链球菌引起的丹毒可激活接触系统，并诱导肝素结合蛋白的释放","10.1038/jid.2009.437","Linder A ; Johansson L ; Thulin P ; Hertzén E ; M?rgelin M ; Christensson B ; Bj?rck L ; Norrby-Teglund A ; Akesson P","Journal of Investigative Dermatology","<span style=""font-size:9.0pt;""></span>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Bacterial skin
infections, such as erysipelas or cellulitis, a</span></span><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">re characterized by
fever and a painful erythematous rash</span></span></span></span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">. Despite the high
prevalence of these infections, little is known about the underlying pathogenic
mechanisms. This is partly due to the fact that</span><a name=""OLE_LINK9""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> a bacterial
diagnosis is often difficult to attain.</span><span style=""color:red;""> </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">To
gain insight into the pathogenesis of erysipelas, we investigated the samples
obtained from infected and non-infected areas of skin from 12 patients with
erysipelas. Bacterial cultures, </span><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">detection of specific streptococcal antibodies
in convalescent sera</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">, and immunohistochemical analyses of biopsies
indicated group A streptococcal etiology in 11 of the 12 patients. Also,
electron micrographs of erythematous skin confirmed the presence of group A
streptococcal cells and showed </span><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">a limited solubilization of the
surface-attached M protein</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">. Degradation of high-molecular-weight
kininogen and upregulation of the bradykinin-1 receptor in inflamed tissues
indicated </span><a name=""OLE_LINK15""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">activation of </span><a name=""OLE_LINK14""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">the contact system</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> in 11 patients.
Analyses of release of the vasoactive heparin-binding protein (HBP) showed
increased levels in the infected as compared with the non-infected areas. The
results suggest that group A streptococci induce contact activation and HBP
release during skin infection, which likely contribute to the symptoms seen in
erysipelas: fever, pain, erythema, and edema.</span></span></span></span><span style=""font-family:&quot;""></span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;line-height:1.5;"">细菌性皮肤感染（如丹毒或蜂窝组织炎）的临床特征是发热、红斑且疼痛。尽管这些感染有高患病率，但是人们对它们的潜在致病机制知之甚少。部分原因是一次细菌诊断常常难以达到鉴别的目的。为了更深入了解丹毒的发病机制，我们研究了</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">12</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">名丹毒患者的感染和未感染区域的皮肤样品。经过细菌培养、</span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">恢复期血清中的特异性链球菌抗体检测及活检标本的免疫组化分析，结果表明</span><span style=""font-size:14px;line-height:1.5;"">12</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">例患者的感染区域中有</span><span style=""font-size:14px;line-height:1.5;"">11</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">例存在</span><span style=""font-size:14px;line-height:1.5;"">A</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">组链球菌。此外，皮肤红斑的电子显微图也确定了</span><span style=""font-size:14px;line-height:1.5;"">A</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">组链球菌细胞的存在，并显示出表面附着的</span><span style=""font-size:14px;line-height:1.5;"">M</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">蛋白有有限的增溶作用。发炎组织中高分子激肽原的降解和缓激肽</span><span style=""font-size:14px;line-height:1.5;"">-1</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">受体的上调表明</span><span style=""font-size:14px;line-height:1.5;"">11</span></span><span class=""shorttext""><span style=""font-family:宋体;""><span style=""font-size:14px;line-height:1.5;"">名患者的接触系统都已激活。</span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span style=""font-size:14px;line-height:1.5;"">释放血管活性的肝素结合蛋白</span><span style=""font-size:14px;line-height:1.5;"">（</span></span><span style=""font-size:14px;line-height:1.5;"">HBP</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">）的分析显示，与未感染区相比，感染区的</span><span style=""font-size:14px;line-height:1.5;"">HBP</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">水平增加。研究结果表明，在皮肤感染期间，</span><span style=""font-size:14px;line-height:1.5;"">A</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">组链球菌会诱发接触系统的激活和</span><span style=""font-size:14px;line-height:1.5;"">HBP</span></span><span class=""shorttext""><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">的释放，这有可能导致丹毒患者出现发热、疼痛、红斑和水肿的症状。</span><span></span></span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;"">&nbsp;</span>
</p>
<p class=""MsoNormal"" style=""text-align:center;"" align=""center"">
	<span style=""font-size:9pt;font-family:Times New Roman;"">Adam Linder et.al</span><span style=""font-size:9pt;font-family:Times New Roman;"">；</span><span style=""font-size:9.0pt;""><a><span style=""color:windowtext;text-decoration:none;font-family:Times New Roman;"">The Journal
Of Investigative Dermatology</span></a></span><span style=""font-size:9pt;font-family:Times New Roman;"">；</span><span style=""font-size:9pt;font-family:Times New Roman;"">2010 May; Vol. 130 (5), pp. 1365-72.</span><span style=""font-size:9.0pt;font-family:&quot;""></span>
</p>
<br />","/uploadfiles/image/20131017/20131017160423_4535w.jpg","/uploadfiles/file/20131017/20131017160454_7939.pdf",,10/17/2013,10/17/2013,"medicool",25,,,0,"65",70,"Erysipelas caused by group A streptococcus activates the contact system and induces the release of heparin-binding protein","2010",
271,,"1806-4841.20131854","Camila Fernanda Novak Pinheiro de Freitas, Fabiane Mulinari-Brenner, Hanae Rafaela Fontana, Arthur Conelian Gentili, Mariana Hammerschmidt","An Bras Dermatol","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;""><strong>Abstract: </strong>Ichthyoses are a common group of keratinization disorders. A non-inflammatory generalized persistent </span><span style=""font-family:Times New Roman;font-size:14px;"">skin desquamation is observed. It is characterized by increased cell turnover, thickening of the stratum </span><span style=""font-family:Times New Roman;font-size:14px;"">corneum and functional changes of sebaceous and sweat glands. All of these favor fungal proliferation. </span><span style=""font-family:Times New Roman;font-size:14px;"">Dermatophytes may infect skin, hair and nails causing ringworm or tinea. They have the ability to obtain nutrients </span><span style=""font-family:Times New Roman;font-size:14px;"">from keratinized material. One of its most prevalent genera is Trichophyton rubrum. Although tineas and </span><span style=""font-family:Times New Roman;font-size:14px;"">ichthyoses are quite common, the association of the two entities is rarely reported in the literature. Three cases of </span><span style=""font-family:Times New Roman;font-size:14px;"">ichthyosis associated with widespread infection by <em>T. rubrum </em>are presented. Resistance to several antifungal </span><span style=""font-family:Times New Roman;font-size:14px;"">treatments was responsible for worsening of ichthyosis signs and symptoms.</span> 
</p>",,"/uploadfiles/file/20131017/20131017100252_3486.pdf",,10/17/2013,10/17/2013,"medicool",33,,"Dermatomycoses; Ichthyosis; Therapeutics; Tinea",0,"85",68,"Ichthyosis associated with widespread tinea corporis: report of three cases","2013",
284,,,"Jaco Jürgens","Blackwell Publishing Ltd ? Mycoses","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">Trichophyton species are the most common cause of </span><span style=""font-family:Times New Roman;font-size:14px;"">tinea in South Africa. A study performed in children </span><span style=""font-family:Times New Roman;font-size:14px;"">living in Kwa-Zulu ? Natal, the most populous province </span><span style=""font-family:Times New Roman;font-size:14px;"">in South Africa, showed that 90% of cases of tinea </span><span style=""font-family:Times New Roman;font-size:14px;"">capitis were due to <em>T. violaceum</em>.</span><span style=""font-family:Times New Roman;font-size:14px;""> The 1000 children </span><span style=""font-family:Times New Roman;font-size:14px;"">included in this trial were aged from 1 to 11 years, were </span><span style=""font-family:Times New Roman;font-size:14px;"">from a poor socio-economic background and were of </span><span style=""font-family:Times New Roman;font-size:14px;"">African descent.</span> 
</p>",,"/uploadfiles/file/20131017/20131017112838_7040.pdf",,10/17/2013,10/17/2013,"medicool",36,,"Tinea corporis, isoconazole, corticosteroid",0,"66",68,"Tinea corporis treated with a combined topical therapy containing isoconazole and a corticosteroid","2008",
272,"Tinea corporis caused by Microsporum gallinae: First clinical case in Japan",,"Hitona MIYASATO, Sayaka YAMAGUCHI, Kiyohito TAIRA, Atsushi HOSOKAWA,1 Susumu KAYO, Ayako SANO, Hiroshi UEZATO,Kenzo TAKAHASHI",,"<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;""><strong>Abstract:</strong></span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">We report herein a case of tinea corporis caused by </span><em><span style=""font-family:Times New Roman;font-size:14px;"">Microsporum gallinae </span></em><span style=""font-family:Times New Roman;font-size:14px;"">in a 96-year-old, otherwise healthy </span><span style=""font-family:Times New Roman;font-size:14px;"">Japanese man. The patient had a long working history as a breeder of fighting cocks, and he suffered from two </span><span style=""font-family:Times New Roman;font-size:14px;"">erythematous macules after being bitten by a cock. </span><em><span style=""font-family:Times New Roman;font-size:14px;"">M. gallinae </span></em><span style=""font-family:Times New Roman;font-size:14px;"">was identified as the infectious agent based on the </span><span style=""font-family:Times New Roman;font-size:14px;"">morphology of isolates cultured on slides and analysis of DNA sequences of the internal transcribed spacers (ITS) </span><span style=""font-family:Times New Roman;font-size:14px;"">from ribosomal DNA from cultured isolates. The patient was successfully treated with antifungal ointments. To our </span><span style=""font-family:Times New Roman;font-size:14px;"">knowledge, this is the first case of </span><em><span style=""font-family:Times New Roman;font-size:14px;"">M. gallinae </span></em><span style=""font-family:Times New Roman;font-size:14px;"">infection in a human reported in Japan.</span>
</p>",,"/uploadfiles/file/20131017/20131017101420_6218.pdf",,10/17/2013,10/17/2013,"medicool",37,,"internal transcribed spacer, Microsporum gallinae, polymerase chain reaction, sequencing",0,"85",68,,"2010",
300,,"10.1177/0003319709351257","Pereira de Godoy JM ; Galacini Massari P ; Yoshino Rosinha M ; Marinelli Brand?o R ; Foroni Casas AL","Angiology","<span style=""line-height:1.5;"">&nbsp;&nbsp;</span><span style=""font-size:14px;font-family:Times New Roman;line-height:1.5;"">&nbsp;&nbsp;&nbsp; The aim of this study was to evaluate the epidemiological data and the main comorbidities of patients with erysipelas admitted to a tertiary hospital. All patients admitted due to erysipelas during the period from 1999 to 2008 were included in a prospective and cross-sectional study. The Fisher exact test and logistic regression were used for statistical analysis. A total of 428 individuals were hospitalized with 41 rehospitalizations; 51.17% of the patients were women, the mean age was 58.6 years. The main comorbidities were hypertension (51.6%), diabetes mellitus (41.6%), chronic venous insufficiency (36.2%), other cardiovascular diseases (33.2%) including angina, peripheral arterial insufficiency, acute myocardial infarction, and strokes, obesity (12.1%), chronic renal failure (6.8%), neoplasms (4.9%), cirrhosis (4.9%), chronic lymphedema (4.2%), and leg ulcers (2.6%). Erysipelas is a seasonal dis- ease that affects adults and the elderly people, has a repetitive nature, and is associated with comorbidities.</span><br />
<br />",,"/uploadfiles/file/20131017/20131017170503_4703.pdf",,10/17/2013,10/17/2013,"medicool",23,,"erysipelas, comorbidities, epidemiology, chronic venous",0,"66",70,"Epidemiological Data and Comorbidities of 428 Patients Hospitalized With Erysipelas","2010",
273,,,"Bell-Syer SE ; Hart R ; Crawford F ; Torgerson DJ ; Young P ; Tyrrell W ; Williams H ; Russell I","The Journal Of Dermatological Treatment","<p class=""MsoNormal"">
	<strong>Objective: </strong>To synthesize the evidence for the effectiveness and
cost-effectiveness of oral treatments for fungal infections of the skin of
the feet.<br />
<strong>Design: </strong>Systematic review.<br />
<strong>Interventions:</strong> Oraltreatments for fungal infections.<br />
<strong>Methods: </strong>Ten electronic databases, four journals and the
bibliographies of all review papers identified were searched. The authors also
wrote to international pharmaceutical companies and all podiatry schools in the
UK. The studies selected were randomized trials of clinically diagnosed fungal skin infections<b></b>of the foot that confirmed cure by
culture and microscopy. Two reviewers independently selected trials and
abstracted data using a structured tool including 12 recognized quality
criteria.<br />
<strong>Results: </strong>Of 26 trials identified, 12 met the inclusion
criteria and evaluated five different treatments. Single
placebo-controlled trials showed that terbinafine and itraconazole were both
effective. Two trials showed that terbinafine cures 50% more patients than
griseofulvin. Four trials compared terbinafine with itraconazole, one showed
that terbinafine given for 2 weeks had a better cure rate than 2 weeks of
itraconazole, but the other three showed that it was no better than 4 weeks of
itraconazole.<br />
<strong>Conclusions: </strong>There is significant evidence that terbinafine is
more effective than griseofulvin, though more costly. There is weak evidence
that terbinafine may be more cost-effective than itraconazole. Firm
recommendations about the choice between terbinafine and the azoles need
further research.<b><o:p></o:p></b>
</p>",,"/uploadfiles/file/20131017/20131017103040_0383.pdf",,10/17/2013,10/17/2013,"medicool",22,,"Oral therapy ― Systematic review ― Tinea pedis",0,"67",60,"A systematic review of oral treatments for fungal infections of the skin of the feet","2001",
277,,"10.1038/sj.jid.5700788","Jens-Michael Jensen, Stephan Pfeiffer, Tatsuya Akaki, Jens-Michael Schro¨der, Michael Kleine, Claudia Neumann, Ehrhardt Proksch and Jochen Brasch","Journal of Investigative Dermatology","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tinea corporis is a superficial mycotic infection resulting in substantial epidermal changes. We determined skin </span><span style=""font-family:Times New Roman;font-size:14px;"">barrier function, epidermal differentiation, and human-b-defensin 2 (hBD-2) protein expression in 10 patients </span><span style=""font-family:Times New Roman;font-size:14px;"">with tinea corporis caused by <em>Trichophyton rubrum</em> (<em>T. rubrum</em>). We found disturbed skin barrier function as </span><span style=""font-family:Times New Roman;font-size:14px;"">shown by a significant increase in transepidermal water loss (TEWL) and specific ultrastructural changes </span><span style=""font-family:Times New Roman;font-size:14px;"">including disturbed formation of extracellular lipid bilayers, lamellar body extrusion, and deposit of clotted </span><span style=""font-family:Times New Roman;font-size:14px;"">material at the stratum granulosum/stratum corneum interface. Epidermal proliferation in tinea increased </span><span style=""font-family:Times New Roman;font-size:14px;"">several fold and accordingly, proliferation and inflammation-associated keratins K6, K16, and K17 were </span><span style=""font-family:Times New Roman;font-size:14px;"">expressed. Expression of basal keratins K5 and K14 increased, whereas differentiation-associated K10 was </span><span style=""font-family:Times New Roman;font-size:14px;"">reduced. Reduction of the cornified envelope proteins involucrin, loricrin, and the S100 protein filaggrin was </span><span style=""font-family:Times New Roman;font-size:14px;"">also seen. Reduced filaggrin expression correlated with reduced skin hydration; protein breakdown products of </span><span style=""font-family:Times New Roman;font-size:14px;"">filaggrin have been shown to be important for water binding. Surprisingly, we found pronounced epidermal </span><span style=""font-family:Times New Roman;font-size:14px;"">protein expression of hBD-2, which may be related to disturbed epidermal differentiation and inflammation. </span><span style=""font-family:Times New Roman;font-size:14px;"">hBD-2 showed a weak, although significant, antifungal activity against <em>T. rubrum</em> in the turbidimetric assay and </span><span style=""font-family:Times New Roman;font-size:14px;"">the immunohistological staining was somewhat less pronounced in areas directly underneath fungal hyphae in </span><span style=""font-family:Times New Roman;font-size:14px;"">the stratum corneum. Together, we describe profound changes in skin barrier structure and function, epidermal </span><span style=""font-family:Times New Roman;font-size:14px;"">proliferation, and differentiation including pronounced protein expression of hBD-2 in tinea corporis.</span>
</p>",,"/uploadfiles/file/20131017/20131017104916_2047.pdf",,10/17/2013,10/17/2013,"medicool",21,,,0,"65",68,"Barrier Function, Epidermal Differentiation, and Human β-Defensin 2 Expression in Tinea Corporis","2007",
278,,"10.1111/j.1439-0507.2011.02014.x","Takehiko Kaneko, Michiyo Kaneko and Koichi Makimura","Blackwell Verlag GmbH ? Mycoses","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;""><strong>Introduction: </strong></span><span style=""font-family:Times New Roman;font-size:14px;"">Microsporum canis has been sometimes isolated from </span><span style=""font-family:Times New Roman;font-size:14px;"">patients with tinea capitis and ? or corporis. The infection </span><span style=""font-family:Times New Roman;font-size:14px;"">may be acquired not only from dermatophyte-infected </span><span style=""font-family:Times New Roman;font-size:14px;"">animals with cutaneous lesions but also from asymptomatic </span><span style=""font-family:Times New Roman;font-size:14px;"">carriers. In recent years, the molecular biological </span><span style=""font-family:Times New Roman;font-size:14px;"">analysis of these dermatophytes has achieved rapid </span><span style=""font-family:Times New Roman;font-size:14px;"">development. The mutual phylogenetic relationships of </span><span style=""font-family:Times New Roman;font-size:14px;"">dermatophytes of the genera Trichophyton, Microsporum </span><span style=""font-family:Times New Roman;font-size:14px;"">and Epidermophyton have been demonstrated by using </span><span style=""font-family:Times New Roman;font-size:14px;"">internal transcribed spacer 1 (ITS1) of ribosomal DNA </span><span style=""font-family:Times New Roman;font-size:14px;"">sequences (Makimura K et al. J Clin Microbiol 1999; 37: </span><span style=""font-family:Times New Roman;font-size:14px;"">920C4). Furthermore, the cluster analysis of ITS1 has </span><span style=""font-family:Times New Roman;font-size:14px;"">gradually elucidated human and animal pathogenic </span><span style=""font-family:Times New Roman;font-size:14px;"">Microsporum species and their teleomorphic states, </span><span style=""font-family:Times New Roman;font-size:14px;"">Arthroderma species including Arthroderma otae-related </span><span style=""font-family:Times New Roman;font-size:14px;"">species (Makimura K et al. Microbiol Immunol 2001; 45: </span><span style=""font-family:Times New Roman;font-size:14px;"">209C16). However, this search strategy using clinical </span><span style=""font-family:Times New Roman;font-size:14px;"">isolates has not yet been fully verified. Therefore, we </span><span style=""font-family:Times New Roman;font-size:14px;"">used M. canis (isolated from a patient with tinea </span><span style=""font-family:Times New Roman;font-size:14px;"">corporis; she had been infected from her cat reared as </span><span style=""font-family:Times New Roman;font-size:14px;"">a companion animal) in an attempt to elucidate not only </span><span style=""font-family:Times New Roman;font-size:14px;"">its morphological but also molecular features.</span>
</p>",,"/uploadfiles/file/20131017/20131017105840_4733.pdf",,10/17/2013,10/17/2013,"medicool",38,,,0,"65",68,"Cluster analysis of Microsporum canis isolated from a patient with tinea corporis and an infected cat based on the DNA sequences of nuclear ribosomal internal transcribed spacer 1 ","2011",
286,"中医药治疗手足癣的研究进展","1000-3649 (2011)08―0044-04","刘静 蔡希","Journal of Sichuan of Traditional Chinese Medicine","<div style=""text-align:justify;"">
	&nbsp; 目的：总结近十年来中医药对手足癣的治疗，包括中药浸泡、中药外涂、中西医结合治疗及其他一些疗法，提出了一些问题，为今后临床治疗手足癣的进一步研究与发展提供一个参考依据。结论：中医药治疗手足癣主要采用中药浸泡法，尤其是醋泡法，均取得了较好的疗效，但目前仍存在一些不足和待改进之处。<br />
<br />
</div>",,"/uploadfiles/file/20131017/20131017132416_5198.pdf",,10/17/2013,10/17/2013,"medicool",42,,"手足癣 中药浸泡 中药外涂 中西医结合 综述",0,"67",60,,"2011",
279,,,"Florian Seyfarth,1 Mirjana Ziemer, Yvonne Gra¨ ser,  Peter Elsner  and Uta-Christina Hipler","Blackwell Publishing Ltd ? Mycoses","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;""><strong>Summary:</strong> From the epidemiological point of view, </span><em><span style=""font-family:Times New Roman;font-size:14px;"">Trichophyton rubrum </span></em><span style=""font-family:Times New Roman;font-size:14px;"">is the most important </span><span style=""font-family:Times New Roman;font-size:14px;"">dermatophyte in the Western world. Mostly, the lesions of fungal infections of the skin </span><span style=""font-family:Times New Roman;font-size:14px;"">are restricted and circumscribed. Immunodeficiency, diabetes or treatment with </span><span style=""font-family:Times New Roman;font-size:14px;"">steroids, however, favour widespread disease involving the entire integument. In the </span><span style=""font-family:Times New Roman;font-size:14px;"">present study, we describe a patient without immunodeficiency or diabetes presenting </span><span style=""font-family:Times New Roman;font-size:14px;"">with widespread tinea corporis caused by </span><em><span style=""font-family:Times New Roman;font-size:14px;"">T. rubrum</span></em><span style=""font-family:Times New Roman;font-size:14px;"">. The fungal isolate showed atypical </span><span style=""font-family:Times New Roman;font-size:14px;"">morphological features. Moreover, the typical metabolic features (negative urease test, </span><span style=""font-family:Times New Roman;font-size:14px;"">production of red pigment on potato dextrose agar) were expressed with delay after </span><span style=""font-family:Times New Roman;font-size:14px;"">6 weeks of cultivation. Thus, sequencing of the internal transcribed spacer of the </span><span style=""font-family:Times New Roman;font-size:14px;"">ribosomal DNA was applied to identify the fungal isolate and led us to the correct </span><span style=""font-family:Times New Roman;font-size:14px;"">diagnosis, before conventional mycological methods were successful.</span>
</p>",,"/uploadfiles/file/20131017/20131017110440_1319.pdf",,10/17/2013,10/17/2013,"medicool",45,,"tinea corporis, trichophyton rubrum, PCR, internal transcribed spacer",0,"65",68,"Widespread tinea corporis caused by Trichophyton rubrum with non-typical cultural characteristics C diagnosis via PCR","2007",
289,"小儿体癣的临床特点及治疗",,"刘大华","中国临床医生","<p align=""justify"">
	<span style=""font-family:SimSun;font-size:14px;"">&nbsp;&nbsp; 体癣又称为金钱癣，也有人叫做圆癣，主要是</span><span style=""font-family:SimSun;font-size:14px;"">外形像过去流通使用的铜钱故有此之称。体癣是发</span><span style=""font-family:SimSun;font-size:14px;"">生在人体平滑皮肤上的癣菌感染。所谓平滑皮肤，是</span><span style=""font-family:SimSun;font-size:14px;"">指除头皮、胡须部、掌跖、腹股沟以及毛发和指(趾)甲</span><span style=""font-family:SimSun;font-size:14px;"">以外的皮肤。在人体平滑皮肤上，寄生着一些致病性</span><span style=""font-family:SimSun;font-size:14px;"">真菌，由它们感染皮肤引起的癣，统称为体癣。</span> 
</p>",,"/uploadfiles/file/20131017/20131017144511_2015.pdf",,10/17/2013,10/17/2013,"medicool",19,,,0,"67",68,,"2005",
292,"复发性丹毒：47例",,"Leclerc S ; Teixeira A ; Mahé E ; Descamps V ; Crickx B ; Chosidow O","Dermatology","<b><span style=""font-size:16.0pt;font-family:宋体;""></span></b><b><span style=""font-size:16.0pt;font-family:&quot;""></span></b><span style=""font-family:&quot;""></span><b><span style=""font-size:14pt;font-family:Times New Roman;"">Background: </span></b> 
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:SimSun;"">背景：</span></b><b><span style=""font-size:14.0pt;font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrence
is a common complication of erysipelas (cellulitis). </span></span></span> 
</p>
<span></span><span></span><span></span> 
<p class=""MsoNormal"">
	<span style=""font-family:宋体;font-size:14px;"">&nbsp;&nbsp;&nbsp; 复发性丹毒（复发性蜂窝组织炎）是丹毒（蜂窝组织炎）的一种常见并发症。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Objectives: </span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:SimSun;"">目的</span></b><b><span style=""font-size:14.0pt;font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">To
describe the characteristics of patients with </span></span><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">recurrent erysipelas</span></span></span></span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;""> and thereby, identify
potential risk factors and evaluate prophylaxis efficacy.</span><span style=""font-family:Times New Roman;font-size:14px;"">&nbsp; </span></span></span></span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;font-size:14px;"">&nbsp;&nbsp;&nbsp; 旨在描述复发性丹毒患者的症状体征，以此确定潜在的风险因素，并评估预防功效。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Methods: </span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">方法：</span></b><b><span style=""font-size:14.0pt;font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Data
were retrospectively recorded from the files of 47 patients admitted to
hospital between 1995 and 2003 for erysipelas recurrence. Studied variables
included: general condition, </span></span><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">regional and local factors</span></span></span></span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;"">, e.g. </span><a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span style=""font-family:Times New Roman;font-size:14px;"">broken
cutaneous barrier</span><span style=""font-family:Times New Roman;font-size:14px;"">. Patient characteristics were used to construct
tree-based models according to the classification and regression tree
methodology. </span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;</span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;font-size:14px;"">&nbsp;&nbsp;&nbsp; 我们对</span><span style=""font-family:&quot;font-size:14px;"">1995</span><span style=""font-family:宋体;font-size:14px;"">至</span><span style=""font-family:&quot;font-size:14px;"">2003</span><span style=""font-family:宋体;font-size:14px;"">年间</span><span style=""font-family:&quot;font-size:14px;"">47</span><span style=""font-family:宋体;font-size:14px;"">例丹毒复发入院的患者的档案数据进行回顾性记录。研究的变量包括：一般条件、区域和因素（例如，破损的皮肤屏障）。根据分类和回归树方法，我们利用患者的特点来构建树状模型。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Results:</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">结果：</span></b><b><span style=""font-size:14.0pt;font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Our
patients suffered a mean of 4.1 recurrences. Cutaneous barrier disruption was
observed in 81%, mainly intertrigo (60%). Antibiotic prophylaxis was taken by
68% of the patients for 30.6 months. After 1 and 2 years, 84 and 72% of the patients,
respectively, were recurrence-free. </span></span> 
</p>
<span></span><span></span> 
<p class=""MsoNormal"">
	<span style=""font-family:宋体;font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">&nbsp;&nbsp;&nbsp; </span>参与研究的丹毒患者平均复发</span><span style=""font-family:&quot;font-size:14px;"">4.1</span><span style=""font-family:宋体;font-size:14px;"">次。我们观察到</span><span style=""font-family:&quot;font-size:14px;"">81%</span><span style=""font-family:宋体;font-size:14px;"">的患者出现皮肤屏障破坏，其中主要是擦烂（占</span><span style=""font-family:&quot;font-size:14px;"">60%</span><span style=""font-family:宋体;font-size:14px;"">）。</span><span style=""font-family:&quot;font-size:14px;"">68%</span><span style=""font-family:宋体;font-size:14px;"">的患者在采取了</span><span style=""font-family:&quot;font-size:14px;"">30.6</span><span style=""font-family:宋体;font-size:14px;"">个月的抗生素预防后，</span><span style=""font-family:&quot;font-size:14px;"">1</span><span style=""font-family:宋体;font-size:14px;"">年后内</span><span style=""font-family:&quot;font-size:14px;"">84%</span><span style=""font-family:宋体;font-size:14px;"">患者没有复发，</span><span style=""font-family:&quot;font-size:14px;"">2</span><span style=""font-family:宋体;font-size:14px;"">年内</span><span style=""font-family:&quot;font-size:14px;"">72%</span><span style=""font-family:宋体;font-size:14px;"">的患者无复发。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14pt;font-family:Times New Roman;"">Conclusion: </span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14.0pt;font-family:宋体;"">结论：</span></b><b><span style=""font-size:14.0pt;font-family:&quot;""></span></b> 
</p>
<p class=""MsoNormal"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Our
results showed that erysipelas recurrence has the same risk factors as single
episodes and underlines the potential benefit of oral or parenteral antibiotic
prophylaxis to prevent recurrences.</span></span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;font-size:14px;"">&nbsp;&nbsp;&nbsp; 研究结果表明丹毒复发与单次发作的风险因素相同，且复发性丹毒也突显了采用口服或注射抗生素预防其复发的潜在利益。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-align:center;"" align=""center"">
	<span style=""font-size:9.0pt;font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-align:center;"" align=""center"">
	<span style=""font-size:9.0pt;font-family:&quot;""><a><span style=""color:windowtext;text-decoration:none;font-family:Times New Roman;"">Leclerc S</span></a><span style=""font-family:Times New Roman;""> et.al</span></span><span style=""font-size:9pt;font-family:Times New Roman;"">；</span><span style=""font-size:9.0pt;font-family:&quot;""><a><span style=""color:windowtext;text-decoration:none;font-family:Times New Roman;"">Dermatology</span></a><span style=""font-family:Times New Roman;"">2007; Vol. 214
(1), pp. 52-7.</span></span> 
</p>","/uploadfiles/image/20131017/20131017150756_1103w.jpg","/uploadfiles/file/20131017/20131017150746_3759.pdf",,10/17/2013,10/17/2013,"medicool",38,,"Antibiotic prophylaxis；Erysipelas；Cellulitis",0,"85",70,"Recurrent Erysipelas: 47 Cases","2007",
301,,"10.1111/j.1365-2133.2008.08503.x","Damstra RJ ; van Steensel MA ; Boomsma JH ; Nelemans P ; Veraart JC","The British Journal Of Dermatology","<p>
	<strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp; Background: </span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Erysipelas</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> is </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">a</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> common skin infection that is usually caused by beta-haemolytic group </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">A</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> streptococci. After having had </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">erysipelas</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> in an extremity, </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">a</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> significant percentage of </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">patients</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> develops persistent swelling or suffers from recurrent </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">erysipelas</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">. We hypothesize that in cases of </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">erysipelas</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> without </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">a</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> clear precipitating agent, </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">subclinical</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> pre-existing congenital or acquired disturbances in the function of the
 lymphatic system are present. The persistent swelling after </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">erysipelas</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> is then most likely caused by </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">lymphoedema</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">.</span> 
</p>
<p>
	<strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Objectives:</span></strong> <span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">We designed </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">a</span> <span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">study</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> to examine if </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">erysipelas</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> of unknown origin is associated with </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">a</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> pre-existent insufficiency of the lymphatic system. If our hypothesis is correct, </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">patients</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> with </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">erysipelas</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> of unknown cause without previously evident </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">lymphoedema</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> should have evidence of disturbed lymphatic transport in the unaffected extremity.</span> 
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Methods: </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">A</span> <span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">prospective</span> <span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">study</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">, in which lymphoscintigraphy of both legs was performed in </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">patients</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> 4 months after presenting with an episode of </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">erysipelas</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> only in one </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">leg</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">. No patient had any known risk factor for </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">erysipelas</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">, such as diabetes mellitus, chronic venous insufficiency or clinical signs of </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">lymphoedema</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">. Lymphoscintigraphy was performed in </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">40</span> <span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">patients</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> by subcutaneous injection of Tc-99m-labelled human serum albumin in the first web space of both feet. After 30 and 120 min, </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">quantitative</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> and qualitative scans were performed using </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">a</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> computerized gamma camera. During the lymphoscintigraphy, the </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">patients</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> performed </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">a</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> standardized exercise programme. Lymph drainage was quantified as the 
percentage uptake of Tc-99m-labelled human serum albumin in the groin 
nodes at 2 h after injection. Groin uptake of &amp;lt; 15% is 
pathological; uptake between 15-20% is defined as borderline, and uptake
 of &amp;gt; 20% as normal.</span> 
</p>
<p>
	<strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Results: </span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">The mean +/- SD
 percentage uptake in the groin nodes in the affected limbs was 9.6 +/- 
8.5% vs. 12.1% +/- 8.9% in the nonaffected limbs. The mean paired 
difference in uptake between the nonaffected vs. affected side was 2.5% 
(95% confidence interval 1.1-3.9%). This indicates that lymphatic 
drainage in the nonaffected limb was only slightly better than in the 
affected limb despite the infectious event in the latter. Of 33 </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">patients</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> with objective impairment of lymph drainage in the affected limb, 26 
(79%) also had impaired lymph drainage in the nonaffected limb. 
Agreement in qualitative measurements between affected and nonaffected </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">leg</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> was less pronounced: 21 </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">patients</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> had abnormal qualitative results in the affected </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">leg</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> of whom nine also had impairment of the nonaffected </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">leg</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> (43%).</span> 
</p>
<p>
	<strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp; Conclusions:</span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> Erysipelas is often presumed to be purely infectious in origin, with a high rate of recurrence and a risk of persistent swelling due to secondary lymphoedema. In this study, we show that patients presenting with a first episode of erysipelas often have signs of pre-existing lymphatic impairment in the other, clinically nonaffected, leg. This means that subclinical lymphatic dysfunction of both legs may be an important predisposing factor. Therefore, we recommend that treatment of erysipelas should focus not only on the infection but also on the lymphological aspects, and long-standing treatment for lymphoedema is essential in order to prevent recurrence of erysipelas and aggravation of the pre-existing lymphatic impairment. Our study may change the clinical and therapeutic approach to erysipelas as well as our understanding of its aetiology.</span> 
</p>",,"/uploadfiles/file/20131017/20131017171214_4210.pdf",,10/17/2013,10/17/2013,"medicool",23,,"aetiology, cellulitis, erysipelas, lymphoedema, primary lymphoedema, quantitative lymphoscintigraphy",0,"66",70,"Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg ","2008",
281,,,"B. Sanmano, M. Hiruma, M. Mizoguchi and H. Ogawa","Blackwell Publishing Ltd ? Mycoses","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;""><strong>Summary: </strong>The present study was designed to determine the lowest dose of orally administered </span><span style=""font-family:Times New Roman;font-size:14px;"">itraconazole and the shortest duration of therapy necessary for treatment of tinea </span><span style=""font-family:Times New Roman;font-size:14px;"">corporis and tinea cruris. For all patients, the itraconazole dose was 100 mg twice a day </span><span style=""font-family:Times New Roman;font-size:14px;"">immediately after meals. Twenty-eight patients received itraconazole on days 1 and 8, 12</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">patients received itraconazole on days 1 and 2, and five patients received itraconazole </span><span style=""font-family:Times New Roman;font-size:14px;"">only on day 1. Clinical and mycological evaluations were performed at baseline and on </span><span style=""font-family:Times New Roman;font-size:14px;"">day 14. Based on the clinical and mycological responses, treatment efficacy was classified </span><span style=""font-family:Times New Roman;font-size:14px;"">as excellent, good, fair, or poor. ‘Excellent’ and ‘good’ responses made up 86% of the first </span><span style=""font-family:Times New Roman;font-size:14px;"">group, 100% of the second group, and 20% of the third group. A comparison of efficacy </span><span style=""font-family:Times New Roman;font-size:14px;"">ratings of the three regimens showed that the patients who received a single 200-mg dose </span><span style=""font-family:Times New Roman;font-size:14px;"">had a significantly inferior outcome compared with the other two groups. We conclude </span><span style=""font-family:Times New Roman;font-size:14px;"">that an abbreviated oral regimen of itraconazole for treatment of tinea corporis and tinea </span><span style=""font-family:Times New Roman;font-size:14px;"">cruris requires a total dose of at least 400 mg to induce a favorable outcome.</span>
</p>",,"/uploadfiles/file/20131017/20131017112034_1360.pdf",,10/17/2013,10/17/2013,"medicool",20,,"Tinea corporis, tinea cruris, antimycotic chemotherapy, itraconazole, basal dose",0,"66",68,"Abbreviated oral itraconazole therapy for tinea corporis and tinea cruris","2003",
317,"手术治疗鸡眼临床疗效观察","1002―1310．2012．03．036","胡瑚，刘秀红","皮肤病与性病","<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 鸡眼是长期摩擦受压后局部皮肤角质层逐渐增厚所致，</span><span style=""font-size:14px;"">形成由同心角质层环绕的尖端向组织内的圆锥状致密角质结</span><span style=""font-size:14px;"">构。其坚硬的顶端抵压刺激神经末梢．引起局部疼痛。从而影</span><span style=""font-size:14px;"">响患者生活质量。多发生于穿着紧鞋靴，长期行路或足部畸</span><span style=""font-size:14px;"">形者</span><span style=""font-size:14px;"">。治疗鸡眼方法较多，如小针刀、微波治疗、采用解除</span><span style=""font-size:14px;"">挤压和软化角质等姑息疗法，只能暂时部分缓解病情，不能彻</span><span style=""font-size:14px;"">底解决病痛，只有完全去除增生的角质才能根治鸡眼。</span> 
</p>",,"/uploadfiles/file/20131024/20131024103117_2650.pdf",,10/24/2013,10/24/2013,"medicool",52,,,0,"85",90,,"2012",
283,"有异常表观的伴大疱性皮损的股癣一例","10.2310/7750.2013.1300","Vinay K ; Mahajan R ; Sawatkar GU ; Kanwar AJ ; Kumar M","Journal Of Cutaneous Medicine And Surgery","&nbsp;<span style=""font-size:14px;font-family:'Times New Roman','serif';"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Superficial dermatophytic infections are one of the most common dermatologie conditions worldwide. Tinea cruris is a superficial dermatophytic infection affecting the groin, genitalia, pubic area, and perineum. Herein we report, for the first time, an unusual presentation of tinea cruris with a bullous lesion.</span> 
<p class=""MsoNormal"" style=""text-indent:26.25pt;"">
	<span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;"">A 35-year-old male, an entrepreneur by occupation, presented to the outpatient department with the complaint of an itchy rash in the groin for 3 weeks. There was no history of trauma, insect bite, exposure to pets and farm animals, or use of any topical medication prior to or after the onset of rash. There were no other skin lesions or itching in other body parts. He was otherwise in good health and had no systemic comorbidities.</span><br />
<span style=""font-size:14px;"">&nbsp;</span>
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-size:14px;font-family:宋体;"">浅表皮肤真菌感染性疾病是全球范围内最常见的皮肤病之一。股癣是一种发生于腹股沟、外阴、阴部和会阴处的浅表性真菌感染疾病。这里我们首次报道有异常表观的伴大疱性股癣一例。</span><span style=""font-family:'Times New Roman','serif';""></span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.75pt;"">
	<span style=""font-size:14px;font-family:宋体;"">患者为一名</span><span style=""font-size:14px;font-family:'Times New Roman','serif';"">35</span><span style=""font-size:14px;font-family:宋体;"">岁的男性，是一名职业企业管理经理人，由于三周的腹股沟部瘙痒性皮疹来就诊。在皮疹发作前后，没有受到过创伤、蚊虫叮咬、也没有接触过宠物和家畜，或者没有使用过任何外用药物。身体其他部位没有出现皮损或瘙痒。否则患者身体健康，无全身合并症。</span><span style=""font-family:'Times New Roman','serif';""></span>
</p>
</span>","/uploadfiles/image/20131017/20131017112757_2547w.png","/uploadfiles/file/20131017/20131017112837_8304.pdf",,10/17/2013,10/17/2013,"medicool",37,,,0,"85",65,"An unusual presentation of tinea cruris with bullous lesions","2013",
304,"丹毒与蜂窝组织炎成人住院患者的临床和流行病学特征","10.1007/s10096-012-1549-2","Perelló-Alzamora MR ; Santos-Duran JC ; Sánchez-Barba M ; Ca?ueto J ; Marcos M ; Unamuno P","European Journal Of Clinical Microbiology & Infectious Diseases","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK2""></a><span style=""font-family:Times New Roman;font-size:14px;"">The
purpose of this investigation was to analyze the clinical and epidemiological
aspects of all cases of erysipelas and infectious cellulitis admitted to a
tertiary hospital during a period of five years. </span><a name=""OLE_LINK17""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">All
patients admitted with the main diagnosis of erysipelas or cellulitis to the </span></span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;"">Department
of Dermatology of the author’s institution from January 2005 to May 2010 were
included. Seventy patients were identified and their medical records were </span><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-family:Times New Roman;font-size:14px;"">retrospectively
review</span><span style=""font-family:Times New Roman;font-size:14px;"">ed so as to record the epidemiological and clinical data. </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span style=""font-family:Times New Roman;font-size:14px;"">Univariate
and multivariable analyses</span><span style=""font-family:Times New Roman;font-size:14px;""> were performed to analyze variables that </span><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><span style=""font-family:Times New Roman;font-size:14px;"">predicted
longer length of stay</span><span style=""font-family:Times New Roman;font-size:14px;"">. The frequency of cellulitis in the lower
limbs was higher in men and patients older than 65 years. Moderate/ severe
cellulitis in patients with</span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span> </span><a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">basal comorbidity</span></span> </span><span style=""font-family:Times New Roman;font-size:14px;"">followed by a</span><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-family:Times New Roman;font-size:14px;""> poor response</span><span style=""font-family:Times New Roman;font-size:14px;""> to oral antibiotic
therapy for 48h were the most common reasons for admission. </span><a name=""OLE_LINK26""></a><a name=""OLE_LINK23""></a><a name=""OLE_LINK22""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">At arrival</span></span><span style=""font-family:Times New Roman;font-size:14px;"">, </span><a name=""OLE_LINK24""></a><span style=""font-family:Times New Roman;font-size:14px;"">four patients had abscessed areas. Fourteen patients
developed </span><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span style=""font-family:Times New Roman;font-size:14px;"">local complications</span><span style=""font-family:Times New Roman;font-size:14px;""> and </span><a name=""OLE_LINK25""></a><span style=""font-family:Times New Roman;font-size:14px;"">18 cases
developed general in hospital complications. Most patients improved or were
healed with intravenous </span><a name=""OLE_LINK27""></a><span style=""font-family:Times New Roman;font-size:14px;"">amoxicillinCclavulanate 1 gC 200
mg/8 h. Intravenous amoxicillinCclavulanate 1gC 200 mg/8 h may be a good
choice for empiric treatment </span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span style=""font-family:Times New Roman;font-size:14px;"">in our setting</span><span style=""font-family:Times New Roman;font-size:14px;"">. The development of </span><a name=""OLE_LINK33""></a><a name=""OLE_LINK32""></a><span style=""font-family:Times New Roman;font-size:14px;"">in-hospital
complications</span><span style=""font-family:Times New Roman;font-size:14px;""> and the need for </span><a name=""OLE_LINK29""></a><a name=""OLE_LINK28""></a><span style=""font-family:Times New Roman;font-size:14px;"">changing </span><a name=""OLE_LINK35""></a><a name=""OLE_LINK34""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">empiric
antibiotic therapy</span></span></span><span style=""font-family:Times New Roman;font-size:14px;""> were significant and </span><a name=""OLE_LINK37""></a><a name=""OLE_LINK36""></a><span style=""font-family:Times New Roman;font-size:14px;"">independent
variables</span><span style=""font-family:Times New Roman;font-size:14px;""> associated with</span><a name=""OLE_LINK39""></a><a name=""OLE_LINK38""></a><a name=""OLE_LINK31""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""> longer l</span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">ength of
stay</span></span><span style=""font-family:Times New Roman;font-size:14px;"">.</span><span style=""color:red;""> </span></span></span> 
</p>
<p>
	<span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;"">本次调查旨在对一个三级医院五年期间纳入的丹毒和传染性蜂窝组织炎的所有病例，就临床和流行病学方面进行分析。调查纳入了</span><span style=""font-size:14px;"">2005</span><span style=""font-family:宋体;font-size:14px;"">年</span><span style=""font-size:14px;"">1</span><span style=""font-family:宋体;font-size:14px;"">月到</span><span style=""font-size:14px;"">2010</span><span style=""font-family:宋体;font-size:14px;"">年</span><span style=""font-size:14px;"">5</span><span style=""font-family:宋体;font-size:14px;"">月期间，所有到作者所在机构的皮肤病科室的（主要诊断为丹毒或蜂窝组织炎）患者。我们鉴定了</span><span style=""font-size:14px;"">70</span><span style=""font-family:宋体;font-size:14px;"">例患者，并且对其病历进行回顾性审查，以便于记录流行病学和临床数据。通过单变量和多变量分析法，对预测住院时间的变量进行分析。下肢蜂窝组织炎在男性和</span><span style=""font-size:14px;"">65</span><span style=""font-family:宋体;font-size:14px;"">岁以上患者中的发病率较高。伴有基础合并症的中度</span><span style=""font-size:14px;"">/</span><span style=""font-family:宋体;""><span style=""font-size:14px;"">重度蜂窝组织炎患者</span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span style=""font-size:14px;"">口服抗生素治疗</span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">48</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">小时</span></span></span><span style=""font-family:宋体;font-size:14px;"">后的反应不佳，这是入院的最常见原因。就医时，</span><span style=""font-size:14px;"">4</span><span style=""font-family:宋体;font-size:14px;"">例患者身上出现脓肿区域。</span><span style=""font-size:14px;"">14</span><span style=""font-family:宋体;font-size:14px;"">例患者发展为局部并发症，</span><span style=""font-size:14px;"">18</span><span style=""font-family:宋体;font-size:14px;"">例患者在住院时发展为一般并发症。多数患者病状有所改善或通过静脉注射阿莫西林</span><span style=""font-size:14px;"">-</span><span style=""font-family:宋体;font-size:14px;"">克拉维酸</span><a name=""OLE_LINK30""></a><span style=""font-size:14px;"">1g</span><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">（</span></span><span style=""font-size:14px;""><span style=""font-family:&quot;font-size:14px;"">200
mg/8 h</span></span><span style=""font-size:14px;""><span style=""font-family:宋体;font-size:14px;"">）</span></span><span style=""font-family:宋体;font-size:14px;"">得以治愈。在我们设想的经验疗法中静脉注射阿莫西林</span><span style=""font-size:14px;"">-</span><span style=""font-family:宋体;font-size:14px;"">克拉维酸</span><span style=""font-size:14px;"">1g</span><span style=""font-family:宋体;font-size:14px;"">（</span><span style=""font-family:&quot;font-size:14px;"">200 mg/8 h</span><span style=""font-family:宋体;font-size:14px;"">）是一个不错的选择。住院并发症的发展和对改变经验性抗生素治疗的需要都是有意义的，并且都是与较长住院时间有关的独立变量。</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-align:center;text-indent:18.0pt;"" align=""center"">
	<span style=""font-size:9.0pt;font-family:&quot;""><a><span style=""color:windowtext;text-decoration:none;font-family:Times New Roman;font-size:12px;"">Perelló-Alzamora MR</span></a><span style=""font-family:Times New Roman;font-size:12px;""> et.al</span></span><span style=""font-size:12px;font-family:Times New Roman;"">；</span><span style=""font-size:9.0pt;font-family:&quot;""><a><span style=""color:windowtext;text-decoration:none;""><span style=""font-family:Times New Roman;font-size:12px;"">European
Journal Of </span><strong><span style=""font-weight:normal;font-family:Times New Roman;font-size:12px;"">Clinical</span></strong><b> </b><span style=""font-family:Times New Roman;font-size:12px;"">Microbiology &amp; Infectious Diseases</span></span></a></span><span style=""font-size:12px;font-family:Times New Roman;"">；</span><span style=""font-size:12px;font-family:Times New Roman;"">2012
Sep</span><span style=""font-size:12px;font-family:Times New Roman;"">；</span><span style=""font-size:12px;font-family:Times New Roman;"">Vol.
31 (9)</span><span style=""font-size:12px;font-family:Times New Roman;"">；</span><span style=""font-size:12px;font-family:Times New Roman;"">pp.
2147-52.</span> 
</p>","/uploadfiles/image/20131018/20131018090235_2980w.jpg","/uploadfiles/file/20131018/20131018090217_4203.pdf",,10/18/2013,10/18/2013,"medicool",55,,,0,"67",70,"Clinical and epidemiological characteristics of adult patients hospitalized for erysipelas and cellulitis","2012",
307,"红斑狼疮皮损处白介素-17的表达与干扰素-α表达有关","10.1111/j.1365-2230.2010.03996.x","S. H. Oh, H. J. Roh, J. E. Kwon*, S. H. Lee, J. Y. Kim, H. J. Choi? and B. J. Lim*","CED","<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">Background</span></b><span style=""font-family:&quot;"">. <br />
</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""><span></span><span></span>&nbsp;&nbsp;&nbsp;&nbsp; Type I interferon
(IFN) has been reported to have an important role in the development of <span><span>cutaneous</span></span><span> lupus erythematosus (CLE) and systemic lupus
erythematosus (SLE). <span><span><span>A new </span></span></span><span><span><span><span><span>subset</span></span></span></span></span><span><span><span><span> of </span></span>CD4+
T cells,<span> T helper (Th)17 cells</span>, also plays a role in <span>the
development of autoimmunity</span>.</span></span></span></span> 
</p>
<span></span><span></span> 
<p class=""MsoNormal"">
	<span><b><span style=""font-family:宋体;"">研究背景</span></b></span><span><span style=""font-family:宋体;"">：</span></span><span><span style=""font-family:&quot;""></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span style=""font-family:宋体;"">据报道</span></span><span><span style=""font-family:&quot;"">I</span></span><span><span style=""font-family:宋体;"">型干扰素（</span></span><span><span style=""font-family:&quot;"">IFN</span></span><span><span style=""font-family:宋体;"">）在皮肤型红斑狼疮（</span></span><span><span style=""font-family:&quot;"">CLE</span></span><span><span style=""font-family:宋体;"">）和系统性红斑狼疮（</span></span><span><span style=""font-family:&quot;"">SLE</span></span><span><span style=""font-family:宋体;"">）的发展中具有重要的作用。</span></span><span><span style=""font-family:&quot;"">CD4+T</span></span><span><span style=""font-family:宋体;"">细胞的一个新的亚型――</span></span><span><span style=""font-family:&quot;"">T</span></span><span><span style=""font-family:宋体;"">辅助（</span></span><span><span style=""font-family:&quot;"">Th</span></span><span><span style=""font-family:宋体;"">）</span></span><span><span style=""font-family:&quot;"">17</span></span><span><span style=""font-family:宋体;"">细胞，也在自身免疫性疾病的发展中发挥作用。</span></span><span><span style=""font-family:&quot;""></span></span> 
</p>
<p class=""MsoNormal"">
	<span><span style=""font-family:&quot;"">&nbsp;</span></span> 
</p>
<span></span> 
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">Aim</span></b><span style=""font-family:&quot;"">. <span><span><span></span></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:15.75pt;"">
	<span><span><span><span><span style=""font-family:&quot;"">To
investigate expression of </span></span></span></span></span><span><span><span style=""font-family:&quot;"">interleukin
(IL)-17 and IFN-a in different CLE<span> subset</span>s, and their associations
with the pathogenesis of LE.</span></span></span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究目的</span></b><span style=""font-family:宋体;"">：</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">为了调查白介素（</span><span style=""font-family:&quot;"">IL</span><span style=""font-family:宋体;"">）</span><span style=""font-family:&quot;"">-17</span><span style=""font-family:宋体;"">和</span><span style=""font-family:&quot;"">IFN-a</span><span style=""font-family:宋体;"">在不同</span><span style=""font-family:&quot;"">CLE</span><span style=""font-family:宋体;"">亚型中的表达情况，以及与</span><span style=""font-family:&quot;"">LE</span><span style=""font-family:宋体;"">发病机理的联系。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">Methods</span></b><span style=""font-family:&quot;"">.</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""><span>&nbsp;</span><span><span>&nbsp;&nbsp; </span>Skin tissue samples from 33 cases, including </span><span><span><span>chronic discoid LE</span></span></span><span><span> (n=24),<span> acute (A)CLE</span> (n=4), subacute CLE (n=1) and <span>lupus panniculitis</span> (n=4) were collected for immunohistochemistry. Expression of<span> IL-6, IL-17A, IFN-a,
IFN-c</span>, <span>myxovirus protein</span> (Mx)A and <span>transforming
growth factor </span>(TGF)-b was assessed in these samples.</span></span></span> 
</p>
<p class=""MsoNormal"">
	<span><span><b><span style=""font-family:宋体;"">研究方法</span></b></span></span><span><span><span style=""font-family:宋体;"">：</span></span></span><span><span><span style=""font-family:&quot;""></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span style=""font-family:宋体;"">从</span></span></span><span><span><span style=""font-family:&quot;"">33</span></span></span><span><span><span style=""font-family:宋体;"">个病例（包括</span></span></span><span><span><span style=""font-family:&quot;"">24</span></span></span><span><span><span style=""font-family:宋体;"">例慢性盘状</span></span></span><span><span><span style=""font-family:&quot;"">LE</span></span></span><span><span><span style=""font-family:宋体;"">、</span></span></span><span><span><span style=""font-family:&quot;"">4</span></span></span><span><span><span style=""font-family:宋体;"">例急性</span></span></span><span><span><span style=""font-family:&quot;"">CLE</span></span></span><span><span><span style=""font-family:宋体;"">、</span></span></span><span><span><span style=""font-family:&quot;"">1</span></span></span><span><span><span style=""font-family:宋体;"">例亚急性</span></span></span><span><span><span style=""font-family:&quot;"">CLE</span></span></span><span><span><span style=""font-family:宋体;"">和</span></span></span><span><span><span style=""font-family:&quot;"">4</span></span></span><span><span><span style=""font-family:宋体;"">例狼疮性脂膜炎）上收集皮肤组织样品进行免疫组织化学研究。对这些样品中的</span></span></span><span><span><span style=""font-family:&quot;"">IL-6</span></span></span><span><span><span style=""font-family:宋体;"">、</span></span></span><span><span><span style=""font-family:&quot;"">IL-17A</span></span></span><span><span><span style=""font-family:宋体;"">、</span></span></span><span><span><span style=""font-family:&quot;""> <span>IFN-a</span></span></span></span><span><span><span style=""font-family:宋体;"">、</span></span></span><span><span><span style=""font-family:&quot;"">IFN-c</span></span></span><span><span><span style=""font-family:宋体;"">、粘病毒蛋白</span></span></span><span><span><span style=""font-family:&quot;"">(Mx)A</span></span></span><span><span><span style=""font-family:宋体;"">以及转化生长因子</span></span></span><span><span><span style=""font-family:&quot;"">(TGF)-b</span></span></span><span><span><span style=""font-family:宋体;"">的表达进行评估。</span></span></span><span><span><span style=""font-family:&quot;""></span></span></span> 
</p>
<p class=""MsoNormal"">
	<span><span><span style=""font-family:&quot;"">&nbsp;</span></span></span> 
</p>
<span></span><span></span> 
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">Results</span></b><span style=""font-family:&quot;"">.</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""><span></span><span><span>&nbsp;&nbsp;&nbsp; </span></span><span><span><span>All LE specimens had staining
for IL-6 and TGF-b in the </span></span></span><span><span><span><span><span>infiltrated </span></span></span></span></span><span><span><span><span><span><span><span>inflammatory</span></span></span></span></span></span></span><span><span><span><span><span><span> cells</span></span>. </span></span></span></span><span><span>IL-17A staining was seen in 84.8% of specimens,
and IFN-a or MxA was seen in 93.9%. TGF-b expression in ACLE was significantly
greater than that in both chronic cutaneous (CC)LE and in lupus panniculitis(P=
0.02 for both). Expression of L- 17A was positively associated with expression
of IFN-a and MxA (Spearman’s q = 0.56 and 0.39, respectively). In addition, <span>the </span><span><span><span>Cutaneous Lupus Erythematosus Disease Area </span></span></span><span><span>and
Severity Index</span></span> (CLASI) correlated <span>positively </span>with
expression of IFN-a and MxA (q = 0.40 for both), whereas there was no
correlation with IL-17A expression.</span></span></span> 
</p>
<p class=""MsoNormal"">
	<span><span><b><span style=""font-family:宋体;"">研究结果</span></b></span></span><span><span><span style=""font-family:宋体;"">：</span></span></span><span><span><span style=""font-family:&quot;""></span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span style=""font-family:宋体;"">所有</span></span></span><span><span><span style=""font-family:&quot;"">LE</span></span></span><span><span><span style=""font-family:宋体;"">样本中浸润性炎症细胞中的</span></span></span><span><span><span style=""font-family:&quot;"">IL-6 </span></span></span><span><span><span style=""font-family:宋体;"">和</span></span></span><span><span><span style=""font-family:&quot;""> TGF-b</span></span></span><span><span><span style=""font-family:宋体;"">都染色。观察到</span></span></span><span><span><span style=""font-family:&quot;"">84.8%</span></span></span><span><span><span style=""font-family:宋体;"">的样本中有</span></span></span><span><span><span style=""font-family:&quot;"">IL-17A</span></span></span><span><span><span style=""font-family:宋体;"">的染色，以及</span></span></span><span><span><span style=""font-family:&quot;"">93.9%</span></span></span><span><span><span style=""font-family:宋体;"">的样本中有</span></span></span><span><span><span style=""font-family:&quot;"">IFN-a </span></span></span><span><span><span style=""font-family:宋体;"">或</span></span></span><span><span><span style=""font-family:&quot;"">MxA</span></span></span><span><span><span style=""font-family:宋体;"">的染色。</span></span></span><span><span><span style=""font-family:&quot;"">ACLE</span></span></span><span><span><span style=""font-family:宋体;"">中</span></span></span><span><span><span style=""font-family:&quot;"">TGF-b</span></span></span><span><span><span style=""font-family:宋体;"">的表达显著高于慢性皮肤型（</span></span></span><span><span><span style=""font-family:&quot;"">CC</span></span></span><span><span><span style=""font-family:宋体;"">）</span></span></span><span><span><span style=""font-family:&quot;"">LE</span></span></span><span><span><span style=""font-family:宋体;"">和狼疮脂膜炎（</span></span></span><span><span><span style=""font-family:&quot;"">P=
0.02</span></span></span><span><span><span style=""font-family:宋体;"">）中的表达。</span></span></span><span><span><span style=""font-family:&quot;"">L-
17A</span></span></span><span><span><span style=""font-family:宋体;"">的表达确实和</span></span></span><span><span><span style=""font-family:&quot;"">IFN-a </span></span></span><span><span><span style=""font-family:宋体;"">、</span></span></span><span><span><span style=""font-family:&quot;"">MxA
(Spearman’s q = 0.56 </span></span></span><span><span><span style=""font-family:宋体;"">和</span></span></span><span><span><span style=""font-family:&quot;"">0.39, </span></span></span><span><span><span style=""font-family:宋体;"">分别</span></span></span><span><span><span style=""font-family:&quot;"">)</span></span></span><span><span><span style=""font-family:宋体;"">的表达有关。此外，皮肤型红斑狼疮发病面积和严重指数（</span></span></span><span><span><span style=""font-family:&quot;"">CLASI</span></span></span><span><span><span style=""font-family:宋体;"">）确实和</span></span></span><span><span><span style=""font-family:&quot;"">IFN-a</span></span></span><span><span><span style=""font-family:宋体;"">、</span></span></span><span><span><span style=""font-family:&quot;""> MxA (</span></span></span><span><span><span style=""font-family:宋体;"">两者</span></span></span><span><span><span style=""font-family:&quot;"">q
= 0.40 )</span></span></span><span><span><span style=""font-family:宋体;"">的表达相关，而和</span></span></span><span><span><span style=""font-family:&quot;"">IL-17A</span></span></span><span><span><span style=""font-family:宋体;"">的表达无关。</span></span></span><span></span><span></span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:&quot;"">Conclusions</span></b><span style=""font-family:&quot;"">. <span></span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span><span><span style=""font-family:&quot;"">Two
major cytokines, <span>IL-17A and IFN-a</span>, may play roles in
the <span>pathogenesis </span>of CLE. Their patterns of expression
positively <span>correlate</span>d with each other.</span></span></span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-family:宋体;"">研究结论</span></b><span style=""font-family:宋体;"">：</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;"">两个主要的细胞因子：</span><span style=""font-family:&quot;"">IL-17A </span><span style=""font-family:宋体;"">和</span><span style=""font-family:&quot;""> <span>IFN-a</span></span><span><span><span style=""font-family:宋体;"">可能在</span></span></span><span><span><span style=""font-family:&quot;"">CLE</span></span></span><span><span><span style=""font-family:宋体;"">的发病机制中发挥作用。其表达模式确实互相关联。</span></span></span><span><span><span style=""font-family:&quot;""></span></span></span> 
</p>","/uploadfiles/image/20131018/20131018152008_0042w.jpg","/uploadfiles/file/20131018/20131018152020_8430.pdf",,10/18/2013,10/18/2013,"medicool",60,,"cutaneous lupus erythematosus丨interleukin (IL)-17丨IFN-a",0,"65",3,"Expression of interleukin-17 is correlated with interferon-αexpression in cutaneous lesions of lupus erythematosus","2010",
313,"维生素D3不能有效治疗慢性冻疮","10.1111/j.1742-1241.2008.01912.x","Souwer IH ; Lagro-Janssen AL","International Journal Of Clinical Practice","<p class=""MsoNormal"">
	<b><span>Background: </span></b><span>Chronic chilblains is a common disease causing major restrictions
in</span><span> </span><span>daily
life, nevertheless little is known about effective treatment. In a literature</span><span> </span><span>search,
we found thin evidence of three interventions: fluocinolone cream, nifedipine</span><span> </span><span>and
vitamin D3. </span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp;<b>&nbsp;</b></span><b><span style=""font-family:宋体;"">研究</span></b><b><span style=""font-family:&quot;"">背景：</span></b><span style=""font-family:&quot;"">慢性冻疮是一种常见疾病，给我们的日常生活带来了严重困扰，然而我们对冻疮的有效疗法却知之甚少。通过文献检索，我们未发现这三种干预措施（<span class=""shorttext"">氟轻松乳膏</span>，硝苯地平和维生素<span lang=""EN-US"">D3</span>）能有效治疗痤疮的证据。</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp; </span><b><span>Objective: </span></b><span>We have conducted a study to assess
the effect</span><span> </span><span>of
oral administration of 2000 IU vitamin D3 per day on patients suffering from</span><span> </span><span>chronic
chilblains.</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp;<b>&nbsp;</b></span><b><span style=""font-family:宋体;"">研究</span></b><b><span style=""font-family:&quot;"">目的：</span></b><span style=""font-family:&quot;"">我们开展了一项研究旨在评估慢性冻疮患者口服维生素<span lang=""EN-US"">D3 2000
IU/</span>天的疗效。</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp; </span><b><span>Methods:</span></b><span> </span><span>The study was based on a
self-controlled design. The</span><span> </span><span>study population consisted of patients with a confirmed diagnosis.
Outcome measurement</span><span> </span><span>was
the change in severity of the complaints and disability. We checked</span><span> </span><span>for
interference by temperature and other confounders.</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp; </span><b><span style=""font-family:宋体;"">研究</span></b><b><span style=""font-family:&quot;"">方法：</span></b><span style=""font-family:&quot;"">本研究采用自身对照实验的方法。研究对象主要为确诊患者。结果指标可揭示疾病严重程度和残疾程度的改变。研究过程中，我们排除了温度和其他<a name=""OLE_LINK71""></a><a name=""OLE_LINK70""></a>混淆因素的干扰。</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp;<b>&nbsp;</b></span><b><span>Limitations:</span></b><span> </span><span>The size of</span><span> </span><span>the cohort (n = 33) was a limitation. </span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp; </span><b><span style=""font-family:宋体;"">研究（限制）因素</span></b><b><span style=""font-family:&quot;"">：</span></b><span style=""font-family:&quot;"">有限的队列组人数（<span lang=""EN-US"">n =33</span>）。</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp; </span><b><span>Results:</span></b><span> </span><span>After correction for confounding</span><span> </span><span>factors,
19% of the subjects reported fewer complaints and 6% fewer disability, in</span><span> </span><span>both the
placebo and vitamin D3 treatment groups.</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp; </span><b><span style=""font-family:宋体;"">研究</span></b><b><span style=""font-family:&quot;"">结果：</span></b><span style=""font-family:&quot;"">干扰因素排除后，本研究项目（空白对照组和维生素<span lang=""EN-US"">D3</span>治疗组）<span lang=""EN-US"">19</span>％的患者报告疾病严重程度减轻，<span lang=""EN-US"">6%</span>患者残疾程度减轻。</span><span></span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp;<b>&nbsp;</b></span><b><span>Conclusion: </span></b><span>Oral administration</span><span> </span><span>of 2000 IU vitamin D3 per day is not better than placebo in the
treatment of</span><span> </span><span>patients
with chronic chilblains.</span> 
</p>
<p class=""MsoNormal"">
	<span>&nbsp; </span><b><span style=""font-family:宋体;"">研究</span></b><b><span style=""font-family:&quot;"">结论：</span></b><span style=""font-family:&quot;"">
	<p class=""MsoNormal"" style=""display:inline !important;"">
		与空白对照组相比，口服维生素<span lang=""EN-US"">D3 2000
IU/</span>天 在治疗慢性痤疮患者时无优越性。<br />
<br />
<br />
		<div style=""text-align:right;"">
			<p class=""MsoNormal"" style=""display:inline !important;"">
			</p>
<i style=""text-align:right;"">
			<p class=""MsoNormal"" align=""right"" style=""display:inline !important;"">
				<i>I. H. Souwer et al./</i> <i>International Journal Of Clinical
Practice, February 2009, 63, 2, 282C286</i>
			</p>
</i>
		</div>
	</p>
</span><span style=""font-family:&quot;"">
	<p class=""MsoNormal"" style=""display:inline !important;"">
	</p>
</span>
</p>","/uploadfiles/image/20131023/20131023130718_8385w.jpg","/uploadfiles/file/20131023/20131023130122_6275.pdf",,10/23/2013,10/24/2013,"medicool",41,,,0,"66",88,"Vitamin D3 is not effective in the treatment of chronic chilblains","2009",
285,,"1175-0561/07/0006-0371/","Claudia Borelli, Gunther Kl¨ovekorn, Thomas-Matthias Ernst, Rolf-Hasso B¨odeker, Hans Christian Korting","Am J Clin Dermatol","<p align=""justify"">
	<strong><span style=""font-family:Times New Roman;font-size:14px;"">Background:</span></strong><span style=""font-family:Times New Roman;font-size:14px;""> Based on the results of numerous preclinical and clinical studies, sertaconazole can be considered </span><span style=""font-family:Times New Roman;font-size:14px;"">a safe and effective drug for the treatment of fungal skin infections.</span><br />
<strong><span style=""font-family:Times New Roman;font-size:14px;"">Objective: </span></strong><span style=""font-family:Times New Roman;font-size:14px;"">The objective of the study was to compare the efficacy of a solution containing 2% sertaconazole </span><span style=""font-family:Times New Roman;font-size:14px;"">with the well established 2% sertaconazole cream formulation in patients with tinea corporis, tinea pedis </span><span style=""font-family:Times New Roman;font-size:14px;"">interdigitalis, or a corresponding candidosis.</span><br />
<strong><span style=""font-family:Times New Roman;font-size:14px;"">Methods: </span></strong><span style=""font-family:Times New Roman;font-size:14px;"">This was a prospective, open-label, randomized, controlled, parallel-group, multicenter, noninferiority </span><span style=""font-family:Times New Roman;font-size:14px;"">therapy study. Patients received either sertaconazole solution or cream twice daily for 28 days. The full </span><span style=""font-family:Times New Roman;font-size:14px;"">analysis set comprised 160 patients in the solution group and 153 patients in the cream group. The primary </span><span style=""font-family:Times New Roman;font-size:14px;"">efficacy parameter was a combination of culture test result and total clinical score. Efficacy was defined by </span><span style=""font-family:Times New Roman;font-size:14px;"">eradication of the pathogen and reduction of the total clinical score between pretreatment and the final visit.</span><br />
<strong><span style=""font-family:Times New Roman;font-size:14px;"">Results:</span></strong><span style=""font-family:Times New Roman;font-size:14px;""> Efficacy was documented in 90.6% of patients using the solution and 88.9% of those using the cream</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">(full analysis set). No adverse events occurred.</span><br />
<strong><span style=""font-family:Times New Roman;font-size:14px;"">Conclusion: </span></strong><span style=""font-family:Times New Roman;font-size:14px;"">Solution and cream formulations of 2% sertaconazole applied for 28 days were associated with </span><span style=""font-family:Times New Roman;font-size:14px;"">comparable efficacy and safety in the treatment of fungal skin infections.</span> 
</p>",,"/uploadfiles/file/20131017/20131017113228_2740.pdf",,10/17/2013,10/17/2013,"medicool",33,,,0,"66",68,"Comparative Study of 2% Sertaconazole Solution and Cream Formulations in Patients with Tinea Corporis, Tinea Pedis Interdigitalis, or a Corresponding Candidosis ","2007",
288,"中医药外治法治疗体癣手足癣研究进展","1672-2779（2011）-12-0168-02","郑媛, 刘文舟","中国中医药现代远程教育","<p align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-family:SimSun;font-size:14px;"">体癣、手足癣均为浅部真菌病。发生在光滑皮肤的</span><span style=""font-family:SimSun;font-size:14px;"">浅表癣菌感染总称体癣，邻近生殖器和肛门的体癣又称</span><span style=""font-family:SimSun;font-size:14px;"">为股癣；指（趾）间及掌、跖面皮肤的浅部真菌感染称</span><span style=""font-family:SimSun;font-size:14px;"">手、足癣，临床上均为常见病及多发病。此类疾病治疗</span><span style=""font-family:SimSun;font-size:14px;"">虽不甚困难，但每因反复发作，缠绵难愈。中医认为“体</span><span style=""font-family:SimSun;font-size:14px;"">癣”乃系肥胖痰湿之体，外受风、湿、热、虫侵袭皮肤</span><span style=""font-family:SimSun;font-size:14px;"">所致；“足癣”则多因湿毒蕴阻肌肤致浸渍糜烂，病久湿</span><span style=""font-family:SimSun;font-size:14px;"">热化燥伤及气血，肌肤失养，则干燥、脱屑、皲裂等。</span><span style=""font-family:SimSun;font-size:14px;"">数年来，中医药在治疗体癣、手足癣等浅部真菌病方面</span><span style=""font-family:SimSun;font-size:14px;"">多有报道，治法屡有创新，且疗效肯定，故做一总结，</span><span style=""font-family:SimSun;font-size:14px;"">以利临床。中医药治疗不外内服外用，而癣类疾病则以</span><span style=""font-family:SimSun;font-size:14px;"">外治为多，常用有酊剂、醋剂、膏剂、水溶剂、散剂等，</span><span style=""font-family:SimSun;font-size:14px;"">偶见纸剂。</span> 
</p>",,"/uploadfiles/file/20131017/20131017143816_3968.pdf",,10/17/2013,10/17/2013,"medicool",23,,"体癣；手足癣；中医药外治法；文献综述",0,"67",68,,"2011",
290,"体、股癣与药物治疗","1001―0408(2o05)13―1039―02","龙振华，张石革","中国药房","<p align=""justify"">
	<span style=""font-family:SimSun;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style=""font-family:;font-size:14px;"">体癣(<span style=""font-family:Times New Roman;"">Tinea </span><span style=""font-family:Times New Roman;"">coproris)因其形状呈圆形而</span>极似古钱币，故</span><span style=""font-family:;font-size:14px;"">又称为钱癣或环癣，为发生于面、胸、腹、臀、腿部或头皮的浅部</span><span style=""font-family:;font-size:14px;"">真菌感染(发生于股部或腿根部的体癣又称为股癣)。体癣多见</span><span style=""font-family:;font-size:14px;"">于温暖而潮湿的季节，冬季消退后夏季可复发，以肥胖的男性</span><span style=""font-family:;font-size:14px;"">或多汗者高发。一般由其自身的手、足、甲癣蔓延形成，也与真</span><span style=""font-family:;font-size:14px;"">菌及病兽(如猫、犬)接触、不良卫生习惯和机体抵抗力弱有</span><span style=""font-family:;font-size:14px;"">关。另外，长期服用肾上腺皮质激素者、糖尿病患者、有慢性消</span><span style=""font-family:;font-size:14px;"">耗性疾病者也易罹患。</span> 
</p>",,"/uploadfiles/file/20131017/20131017145029_9101.pdf",,10/17/2013,10/17/2013,"medicool",31,,,0,"67",68,,"2005",
367,,,"Votyakov V.I., Amvrosieva T.V., Vladyko G.V., Andreeva O.T.,",,"<span style=""font-size:14px;font-family:Times New Roman;"">Trental is a well-known cardiovascular spasmolytic drug, used for arterial and arteriovenous blood circulation distur- bances.</span>",,"/uploadfiles/file/20131101/20131101093151_2395.pdf",,11/01/2013,11/01/2013,"medicool",19,,,0,"65",97,"Trental as a Wide-spectrum Inhibitor of Virus Activity ",,
291,"中药治疗体癣刍议",,"陈江，栗波","中国中医药咨讯","<p align=""justify"">
	<span style=""font-family:SimSun;font-size:14px;"">&nbsp;&nbsp; 癣是皮科的常见病。在民问有“大夫不治癣，治癣就丢脸”</span><span style=""font-family:SimSun;font-size:14px;"">的说法，说明癣症的难治。在癣症中，临床以体癣和股癣最为</span><span style=""font-family:SimSun;font-size:14px;"">常见，股癣是体癣的一种特殊类型，因其发生在人体的股部而</span><span style=""font-family:SimSun;""><span style=""font-size:14px;"">单独提出。现代医学所说体癣是指发生于除头皮、毛发、掌</span><span style=""font-size:14px;"">、</span></span><span style=""font-family:SimSun;font-size:14px;"">指(趾)甲以外的皮肤上的一种皮肤真菌感染；股癣则指发生</span><span style=""font-family:SimSun;font-size:14px;"">于腹股沟、会阴和肛门周围的皮肤癣菌感染。该病主要通过直</span><span style=""font-family:SimSun;font-size:14px;"">接接触患者以及患有癣体癣的家畜如狗、猫，或问接接触被患</span><span style=""font-family:SimSun;font-size:14px;"">者污染的衣物而引起；也可由自身感染(先患有手、足、甲癣</span><span style=""font-family:SimSun;font-size:14px;"">等)而发生；长期应用糖皮质激素，或发生糖尿病、慢性消耗</span><span style=""font-family:SimSun;font-size:14px;"">性疾病者，也易发生体癣或股癣。体癣一般好发于面、颈、腰</span><span style=""font-family:SimSun;font-size:14px;"">腹、臀及四肢等皮肤处，临床表现为红斑、丘疹或水疱，由中</span><span style=""font-family:SimSun;font-size:14px;"">心逐渐向周围等距离扩展蔓延，形成环形或多环形。中央炎症</span><span style=""font-family:SimSun;font-size:14px;"">减轻，伴脱屑或色素沉着，也就是说，患部中央有自愈倾向，</span><span style=""font-family:SimSun;font-size:14px;"">日久成为环形。环的边缘稍微比邻近正常皮肤高起，该处炎症</span><span style=""font-family:SimSun;font-size:14px;"">表现较明显，主要以较密集的小丘疹形成环状、上有水疱或鳞</span><span style=""font-family:SimSun;font-size:14px;"">屑附着。</span>
</p>",,"/uploadfiles/file/20131017/20131017145145_7574.pdf",,10/17/2013,10/17/2013,"medicool",32,,"癣；真菌感染；中医中药；抗真菌",0,"67",68,,"2011",
294,,,"Modesto Dos Santos V, de Carvalho Santos S, Robério de Melo Nogueira P, Mendon?a Ferreira Borges N.","Acta Dermatovenerol Alp Panonica Adriat","<span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 
Blistering erysipelas has been reported only rarely and may be 
under-diagnosed. Very often, pati- ents presenting with erysipelas are 
treated by non-dermatologist primary physicians. The current growth in 
the elderly population may increase the economic burden resulting from 
this disease. Therefore, case reports highlighting possible misdiagnoses
 of erysipelas can contribute to greater awareness among primary care 
professionals and lead to earlier diagnosis and prompt treatment. This 
description seeks to emphasize the main risk factors and predisposing 
factors, in addition to some atypical features and current challenges 
involved in the differential diagnosis for erysipelas.</span><br />
</span>",,"/uploadfiles/file/20131017/20131017153501_3836.pdf",,10/17/2013,10/17/2013,"medicool",20,,"blistering disease, elderly, erysipelas, skin infections",0,"85",70,"Erysipelas in the elderly: Are the concerns and economic burden increasing? Apropos of a case","2011",
315,"火针治疗鸡眼42例疗效观察","1671-0126(2012)05-0044-02","王雅萍，刘远东","山西职业医学院院学报","<p align=""justify"">
	<br />
<span style=""font-size:14px;"">目的：探讨火针治疗鸡眼的疗效。<br />
方法：患处局部常规消毒，使用单头或多头火针，酒精灯上烧至红</span><span style=""font-size:14px;"">白迅速焯刺，针后消毒，无菌纱布包扎。<br />
结果：本组<span style=""font-family:Times New Roman;"">42</span>例，治愈<span style=""font-family:Times New Roman;"">37</span>例，好转<span style=""font-family:Times New Roman;"">5</span>例，总有效率<span style=""font-family:Times New Roman;"">100％</span>。<br />
结论：火针治疗</span><span style=""font-size:14px;"">鸡眼经济实惠，操作简单，治愈率高，复发率低。</span> 
</p>",,"/uploadfiles/file/20131024/20131024095538_1113.pdf",,10/24/2013,10/24/2013,"medicool",41,,"火针；消毒；鸡眼",0,"85",90,,"2012",
293,,,"Hoffmann CW ; Bilkei G","Reprod Dom Anim","<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic infections with Erysipelothrix rhusiopathiae are usually 
associated with skin lesions, vegetative endocarditis and arthritis, but
 they can also cause </span><span style=""font-size:14px;font-family:Times New Roman;"">reproductive</span><span style=""font-size:14px;font-family:Times New Roman;""> symptoms such as abortion, increased stillbirths, and smaller litter size. In </span><span style=""font-size:14px;font-family:Times New Roman;"">a</span><span style=""font-size:14px;font-family:Times New Roman;""> large Hungarian breeding unit that had ceased to vaccinate the sows against </span><span style=""font-size:14px;font-family:Times New Roman;"">erysipelas</span><span style=""font-size:14px;font-family:Times New Roman;"">,
 an increased incidence of pre- and post-partal vulval discharge, 
increased weaning-to-oestrus intervals, decreased farrowing rates, and 
reductions in total number of pigets born and live-born litter size were
 reported. Anterior vaginal swabs were obtained from 64 sows shortly 
before parturition and they all yielded heavy growths of E. 
rhusiopathiae. </span><span style=""font-size:14px;font-family:Times New Roman;"">A</span><span style=""font-size:14px;font-family:Times New Roman;""> vaccination programme with </span><span style=""font-size:14px;font-family:Times New Roman;"">a</span><span style=""font-size:14px;font-family:Times New Roman;""> killed vaccine was reinstated and subsequently the incidence of vulval 
discharge and weaning-to-oestrus intervals were decreased and total born
 and live-born litter size were increased. In the absence of </span><span style=""font-size:14px;font-family:Times New Roman;"">a</span><span style=""font-size:14px;font-family:Times New Roman;""> control group definitive conclusions can not be made regarding the effect of vaccination against E. rhusiopathiae on </span><span style=""font-size:14px;font-family:Times New Roman;"">sow</span><span style=""font-size:14px;font-family:Times New Roman;""> fertility. However, it is not unreasonable to suggest that the aetiology of the reduced </span><span style=""font-size:14px;font-family:Times New Roman;"">sow</span><span style=""font-size:14px;font-family:Times New Roman;""> fertility in the present herd did involve E. rhusiopathiae and that 
appropriate vaccinations subsequently protected the sows from the 
disease.</span>",,"/uploadfiles/file/20131017/20131017151343_9285.pdf",,10/17/2013,10/17/2013,"medicool",21,,,0,"85",70,"Case Study: Chronic Erysipelas of the Sow-a Subclinical Manifestation of Reproductive Problems","2002",
295,,"10.1111/j.1365-2230.2008.02771.x","C. Bachmeyer, E. Begon*, P. Martres? and L. Blum*","Clinical and Experimental Dermatology","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-family:Times New Roman;font-size:14px;"">On physical examination, her temperature was 39 C with chills. A painful erythematous plaque was present on the right buttock and an intertigo of the gluteal fold with disrupted cutaneous barrier was seen . No lymphadenopathy was palpable. The remainder of the physical examination was otherwise unremarkable and a gynaecological examination gave normal results. </span><br />",,"/uploadfiles/file/20131017/20131017154031_8078.pdf",,10/17/2013,10/17/2013,"medicool",30,,,0,"85",70,"Relapsing erysipelas of the buttock due to Streptococcus agalactiae in an immunocompetent woman","2009",
296,"针刺释放淋巴液配伍抗感染治疗下肢淋巴水肿并发急性丹毒 31例临床观察","1000―7377(2010)09―1215―02","洪伟；聂会勇；杨成林","陕西医学杂志","<p style=""text-indent:15.0pt;"">
	<span style=""font-size:7.5pt;""><span style=""font-family:SimSun;font-size:14px;"">目的</span><span style=""font-family:SimSun;font-size:14px;"">:</span><span style=""font-family:SimSun;font-size:14px;"">探讨针刺释放淋巴液配伍抗感染治疗下肢淋巴水肿并发急性丹毒的疗效</span><span style=""font-family:SimSun;font-size:14px;"">.</span></span> 
</p>
<p style=""text-indent:15.0pt;"">
	<span style=""font-size:7.5pt;font-family:&quot;""></span><span style=""font-size:7.5pt;""><span style=""font-family:SimSun;font-size:14px;"">方法</span><span style=""font-family:SimSun;font-size:14px;"">:</span><span style=""font-family:SimSun;font-size:14px;"">将</span><span style=""font-family:SimSun;font-size:14px;"">60</span><span style=""font-family:SimSun;font-size:14px;"">例</span><span style=""font-family:SimSun;font-size:14px;"">(60</span><span style=""font-family:SimSun;font-size:14px;"">条肢体</span><span style=""font-family:SimSun;font-size:14px;"">)</span><span style=""font-family:SimSun;font-size:14px;"">下肢淋巴水肿并发急性丹毒患者随机分为两组</span><span style=""font-family:SimSun;font-size:14px;"">:</span><span style=""font-family:SimSun;font-size:14px;"">治疗 组除常规抗感染外</span><span style=""font-family:SimSun;font-size:14px;"">,</span><span style=""font-family:SimSun;font-size:14px;"">对患者局部肿胀部位行针刺释放淋巴液</span><span style=""font-family:SimSun;font-size:14px;"">;</span><span style=""font-family:SimSun;font-size:14px;"">对照组常规抗感染和外敷硫酸镁</span><span style=""font-family:SimSun;font-size:14px;"">.</span><span style=""font-family:SimSun;font-size:14px;"">比较两组疗效</span><span style=""font-family:SimSun;font-size:14px;"">,</span><span style=""font-family:SimSun;font-size:14px;"">肢体肿胀减轻程度和红肿消退情况</span><span style=""font-family:SimSun;font-size:14px;"">.</span></span> 
</p>
<p style=""text-indent:15.0pt;"">
	<span style=""font-size:7.5pt;font-family:&quot;""></span><span style=""font-size:7.5pt;""><span style=""font-family:SimSun;font-size:14px;"">结果</span><span style=""font-family:SimSun;font-size:14px;"">:</span><span style=""font-family:SimSun;font-size:14px;"">治疗</span><span style=""font-family:SimSun;font-size:14px;""> 3</span><span style=""font-family:SimSun;font-size:14px;"">～</span><span style=""font-family:SimSun;font-size:14px;"">7d</span><span style=""font-family:SimSun;font-size:14px;"">后</span><span style=""font-family:SimSun;font-size:14px;"">,</span><span style=""font-family:SimSun;font-size:14px;"">治疗组患肢周径减轻较对照组明显</span><span style=""font-family:SimSun;font-size:14px;"">;</span><span style=""font-family:SimSun;font-size:14px;"">患肢红肿改善较对照组明显</span><span style=""font-family:SimSun;font-size:14px;"">;</span><span style=""font-family:SimSun;font-size:14px;"">总体疗效优于对照组</span><span style=""font-family:SimSun;font-size:14px;"">(P</span><span style=""font-family:SimSun;font-size:14px;"">＜</span><span style=""font-family:SimSun;font-size:14px;"">0.05).</span></span> 
</p>
<p style=""text-indent:15.0pt;"">
	<span style=""font-size:7.5pt;font-family:&quot;""></span><span style=""font-size:7.5pt;""><span style=""font-family:SimSun;font-size:14px;"">结论</span><span style=""font-family:SimSun;font-size:14px;"">:</span><span style=""font-family:SimSun;font-size:14px;"">针刺释放淋巴液配伍抗感染治疗下肢 淋巴水肿并发急性丹毒疗效较好</span><span style=""font-family:SimSun;font-size:14px;"">.</span></span> 
</p>
<br />",,"/uploadfiles/file/20131017/20131017154812_0398.pdf",,10/17/2013,10/17/2013,"medicool",34,,"淋巴水肿/并发症 ；丹毒/病因学； 丹毒/治疗；腿",0,"85",70,,"2010",
298,,"10.1371/journal.pone.0056225","Hannula-Jouppi K ; Massinen S ; Siljander T ; M?kel? S ; Kivinen K ; Leinonen R ; Jiao H ; Aitos P ; Karppelin M ; Vuopio J ; Syrj?nen J ; Kere J","PLoS One","<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<b><span style=""font-family:Times New Roman;font-size:14px;"">Background: </span></b><span style=""font-family:Times New Roman;font-size:14px;"">Bacterial
non-necrotizing erysipelas and cellulitis are often recurring, diffusely spreading
infections of the skin and subcutaneous tissues caused most commonly by
streptococci. Host genetic factors influence infection susceptibility but no
extensive studies on the genetic determinants of human erysipelas exist.</span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<b><span style=""font-family:Times New Roman;font-size:14px;"">Methods: </span></b><span style=""font-family:Times New Roman;font-size:14px;"">We
performed genome-wide linkage with the 10,000 variant Human Mapping Array
(HMA10K) array on 52 Finnish families with multiple erysipelas cases followed
by microsatellite fine mapping of suggestive linkage peaks. A scan with the
HMA250K array was subsequently performed with a subset of cases and controls.</span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<b><span style=""font-family:Times New Roman;font-size:14px;"">Results: </span></b><span style=""font-family:Times New Roman;font-size:14px;"">Significant
linkage was found at 9q34 (nonparametric multipoint linkage score (NPLall)
3.84, p=0.026), which is syntenic to a quantitative trait locus for
susceptibility to group A streptococci infections on chromosome 2 in mouse.
Sequencing of candidate genes in the 9q34 region did not conclusively associate
any to erysipelas/cellulitis susceptibility. Suggestive linkage (NPLall.3.0)
was found at three loci: 3q22-24, 21q22, and 22q13. A subsequent denser genome scan
with the HMA250K array supported the 3q22 locus, in which several SNPs in the
promoter of AGTR1 (Angiotensin II receptor type I) suggestively associated with
erysipelas/cellulitis susceptibility.</span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<b><span style=""font-family:Times New Roman;font-size:14px;"">Conclusions: </span></b><span style=""font-family:Times New Roman;font-size:14px;"">Specific
host genetic factors may cause erysipelas/cellulitis susceptibility in humans.</span>
</p>",,"/uploadfiles/file/20131017/20131017161130_2546.pdf",,10/17/2013,10/17/2013,"medicool",35,,,0,"65",70,"Genetic susceptibility to non-necrotizing erysipelas/cellulitis","2013",
302,,"10.1159/000252824","Zaghdoudi I ; Rezgui M ; Zouaoui W ; Marhbene T ; Jendoubi A ; El Fatimi R ; Borsali-Falfoul N ; Daghfous MH ; Jerbi Z","Pathophysiology Of Haemostasis And Thrombosis","<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp; The treatment of lower limb erysipelas is based on anti- streptococcal antibiotherapy. The indication of adjuvant an- ticoagulant therapy is not clear because of the lack of data about the incidence of deep venous thrombosis (DVT) in these patients. We performed a prospective study using a colour Doppler vein exploration combined with ultrasonog- raphy within the first 48 h, with evaluation of clinical prob- ability of DVT according to the Wells score to assess the inci- dence of DVT in patients with erysipelas of the lower limb. Of 30 patients studied, 3 DVT were diagnosed: 2 distal DVT (posterior tibial vein) and 1 proximal DVT (superficial femo- ral vein) in patients having a clinical score&nbsp; 63 . Pulmonary embolism was diagnosed in 2 cases. The incidence of DVT&nbsp; i n our study was 10%.&nbsp;&nbsp; DVT should be considered in patients with erysipelas of the lower limb having a high pretest clinical probability. </span>
</p>",,"/uploadfiles/file/20131017/20131017171738_7456.pdf",,10/17/2013,10/17/2013,"medicool",37,,"Lower limb erysipelas；Anticoagulation ；Deep venous thrombosis",0,"66",70,"Incidence of Deep Venous Thrombosis in Patients with Erysipelas of the Leg: Prospective Study of 30 Cases in an Emergency Department ","2008",
303,,"10.1111/j.1365-2230.2010.03978.x","K. Krasagakis, G. Samonis, A. Valachis, P. Maniatakis, G. Evangelou and A. Tosca","Clinical and Experimental Dermatology","<p>
	<strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Background.</span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> Local complications of erysipelas include haemorrhagic, bullous, abscessing and necrotic lesions. The risk factors predisposing patients to local complications are not fully known. </span> 
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Aim. </span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">To examine local complications of erysipelas and to identify possible risk factors predisposing to their appearance. </span><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Methods.</span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> Medical records from all patients hospitalized with complications of erysipelas (purpura, bullae, abscesses and necrosis), admitted to the University Hospital of Heraklion between 1994 and 2002, were retrospectively studied. Clinical and laboratory data were compared with those from patients with erysipelas without local complications. </span> 
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Results.</span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> In total, 145 patients were analysed, of whom 46 had local disease complications. Using bivariate analysis, the factors signi?cantly associated with disease complications were found to be age ? 51 years, obesity, longer duration of local symptoms, and fever on admission. During hospitalization, increased C-reactive protein level, isolation of pathogens, longer duration of fever and ? or presence of leucocytosis, absence of response to initial antibiotic therapy, and longer length of hospitalization were also associated with complications in the bivariate analysis. However, in the multivariate analysis, obesity (OR 4.489, 95% </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">CI 1.719C11.725, P = 0.002) was the only independent factor associated with complicated erysipelas. </span> 
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span></strong><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Conclusions. </span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">This study found obesity to be an independent risk factor for local complications, of erysipelas. Hence, obese patients with erysipelas are prone to com- plications, and should be carefully evaluated because of the potential severity of disease and the increased risk of failure of empirical antimicrobial therapy.</span> 
</p>
<br />",,"/uploadfiles/file/20131018/20131018085342_8534.pdf",,10/18/2013,10/18/2013,"medicool",59,,,0,"66",70,"Local complications of erysipelas: a study of associated risk factors","2010",
305,,,"Krasagakis K ; Valachis A ; Maniatakis P ; Krüger-Krasagakis S ; Samonis G ; Tosca AD","International Journal Of Dermatology","<p>
	<strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Background </span></strong>
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erysipelas is a super?cial form of cellulitis affecting the upper dermis and super?cial lymphatics. The widespread use of antibiotics may affect clinical ?ndings and response to therapy of infectious disorders. The purpose of the study was to investigate the epidemiological, clinical, and laboratory features of erysipelas and to compare the results of treatment with penicillin vs. other antibiotic regimens. </span>
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Methods </span></strong>
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">All charts of erysipelas patients treated at the University Hospital of Heraklion, Crete, Greece from 1994 to 2002 were retrospectively studied. </span>
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Results </span></strong>
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median age of the 99 patients was 54.5 years; 59% were females. The most frequent site involved was the lower extremity (76%), followed by the face (17%) and upper extremity (6%). In 61 patients (62%), a possible entry portal was identi?ed. The most common manifestation of erysipelas was local symptoms and signs (pain, erythema, and swelling) in all patients, together with elevated erythrocyte sedimentation rate (ESR) (60%). Fever was present in 25% of patients. The most commonly used antibiotic was intravenous penicillin G (64%). In the penicillin group, mean duration of fever after treatment initiation was shorter than in the nonpenicillin group (1.7 vs. 4.5 days, P = 0.002). Both treatment failures and recurrences were the same between the two groups. </span>
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Discussion </span></strong>
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">The diagnosis of erysipelas can be based on careful examination for local signs and symptoms. The role of ESR in primary diagnosis needs further investigation. Penicillin seems to preserve its fundamental role in the treatment of disease.</span>
</p>
<br />",,"/uploadfiles/file/20131018/20131018091528_8877.pdf",,10/18/2013,10/18/2013,"medicool",46,,,0,"67",70,"Analysis of epidemiology, clinical features and management of erysipelas ","2010",
306,,"10.1111/j.1610-0387.2008.06866.x","Reich-Schupke S ; Kreuter A ; Altmeyer P ; Stücker M","Journal Der Deutschen Dermatologischen Gesellschaft = Journal Of The German Society Of Dermatology","<p>
	<strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Background: </span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Patients with an advanced chronic venous insufficiency (CVI) often show inflammatory changes of their legs. Often erysipelas is diagnosed and systemic antibiotic therapy initiated. Frequently this approach is not successful. <strong>Patients and </strong></span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> <strong>Methods:</strong></span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">During the last 6 months 5 patients with an outside diag- nosis of erysipelas presented to our clinic. All had a painful erythema of the medial part of one or both calves and all failed numerous antibiotic regimens. </span>
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Results:</span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> In all patients a sharply demarcated, tender indurated erythema of the medial part of one or both calves was seen. Inguinal lymphadenopathy, fever and other systemic signs and symptoms were absent. In 4 of 5 patients normal laboratory inflammatory parameters were normal. We diagnosed hypodermitis in all. They were treated with compression therapy and topical corticosteroids. In addition, their underlying CVI was addressed. </span>
</p>
<p>
	<span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""></span><strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Conclusions: </span></strong><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Dermatosclerosis is often seen in patients with advanced CVI. An acute inflammatory phase (hypodermitis) and a chronic phase of the disease can be differentiated. The acute hypodermitis can imitate erysipelas clinically, with systemic signs and symptoms, as well as laboratory evidence of inflamma- tion generally being absent.</span>
</p>
<br />",,"/uploadfiles/file/20131018/20131018092203_5840.pdf",,10/18/2013,10/18/2013,"medicool",47,,"hypodermitis；liposclerosis；lipodermatosclerosis；chronic venous insufficiency ；erysipelas",0,"67",70,"Wrong diagnosis erysipelas: hypodermitis-case series and review of literature","2009",
311,,,,,"<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;font-size:14px;"">Corns and calluses develop in </span><span style=""font-family:Times New Roman;font-size:14px;"">the same way, but the result is different. </span><span style=""font-family:Times New Roman;font-size:14px;"">Calluses usually develop on </span><span style=""font-family:Times New Roman;font-size:14px;"">the heel or bottom of the foot and </span><span style=""font-family:Times New Roman;font-size:14px;"">rarely hurt. They often appear as a </span><span style=""font-family:Times New Roman;font-size:14px;"">thick, rough layer of skin and can </span><span style=""font-family:Times New Roman;font-size:14px;"">be an inch or more in diameter.</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;font-size:14px;"">Corns are smaller ― usually </span><span style=""font-family:Times New Roman;font-size:14px;"">about a quarter-inch to a half-inch </span><span style=""font-family:Times New Roman;font-size:14px;"">in diameter ― and have a hard center. </span><span style=""font-family:Times New Roman;font-size:14px;"">They typically develop on the </span><span style=""font-family:Times New Roman;font-size:14px;"">tops and sides of toes. Corns can be </span><span style=""font-family:Times New Roman;font-size:14px;"">painful when pushed and may cause </span><span style=""font-family:Times New Roman;font-size:14px;"">a dull ache.</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;font-size:14px;"">In addition to being caused by </span><span style=""font-family:Times New Roman;font-size:14px;"">ill-fitting shoes, corns and calluses </span><span style=""font-family:Times New Roman;font-size:14px;"">may also develop if you have some </span><span style=""font-family:Times New Roman;font-size:14px;"">type of a foot deformity, such as a </span><span style=""font-family:Times New Roman;font-size:14px;"">bunion or hammertoe, which caus</span><span style=""font-family:Times New Roman;font-size:14px;"">es a bone protrusion from your foot </span><span style=""font-family:Times New Roman;font-size:14px;"">to rub on the inside of your shoe.</span> 
</p>",,"/uploadfiles/file/20131022/20131022145029_1137.pdf",,10/22/2013,10/22/2013,"medicool",35,,"corns, calluses",0,"67",90,"Corns and calluses","2008",
321,,,"St Clair NE ; Kim CC ; Semrin G ; Woodward AL ; Liang MG ; Glickman JN ; Leichtner AM ; Binstadt BA","Pediatric Dermatology","<span style=""font-size:10.5pt;font-family:&quot;"">&nbsp; Chilblains, or pernio, are cutaneous lesions
that may accompany systemic illnesses including states of malnutrition and
autoimmune diseases. We report an adolescent girl in whom chilblains were the
chief presenting sign of celiac disease. A gluten-free diet led to weight gain
and resolution of the chilblains. We speculate that in this patient, weight
loss due to celiac disease contributed to the development of chilblains.</span><br />",,"/uploadfiles/file/20131024/20131024135851_4845.pdf",,10/24/2013,10/24/2013,"medicool",18,,,0,"85",88,"Celiac Disease Presenting with Chilblains in an Adolescent Girl","2006",
314,"病例报告：正电子发射计算机断层扫描和计算机断层扫描偶然发现鸡眼","10.1111/j.1346-8138.2008.00454.x","Teruki DAINICHI, Yutaka HONMA, Takashi HASHIMOTO, Masutaka FURUE","Journal of Dermatology","<span style=""font-size:14px;"">&nbsp;</span> 
<p class=""MsoNormal"">
	<b><span style=""line-height:2.5;font-family:Times New Roman;color:#231f20;font-size:14px;"">ABSTRACT</span></b><span style=""line-height:2.5;font-size:14px;""> :</span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:150%;font-family:'Times New Roman','serif';color:#231f20;""><span style=""line-height:2.5;font-family:Times New Roman;font-size:14px;"">This is the first report showing that positron emission tomography with computed tomography (PET/CT) can detect clavus. A 37-year-old woman diagnosed with </span><span style=""line-height:2.5;font-family:Times New Roman;font-size:14px;"">epithelioid sarcoma </span></a><span style=""line-height:2.5;font-family:Times New Roman;font-size:14px;"">on her left inguinal region was investigated by whole-body PET/CT. The imaging showed some 18F-fluorodeoxyglucose uptake at the right lateral foot. There had been a clavus in exactly the same region. Every dermatologist, radiologist and oncologist needs to know about this finding for making an accurate diagnosis.</span></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2.5;font-family:宋体;color:#231f20;font-size:14px;"">摘要：</span></b><b><span style=""line-height:150%;font-family:'Times New Roman','serif';color:#231f20;""></span></b> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:2.5;font-family:宋体;color:#231f20;font-size:14px;"">这是第一例关于正电子发射计算机断层扫描和计算机断层扫描（</span><span style=""line-height:2.5;font-family:Times New Roman;color:#231f20;font-size:14px;"">PET/ CT</span><span style=""line-height:2.5;font-family:宋体;color:#231f20;font-size:14px;"">）可检测鸡眼的报道。我们对一个被诊断为上皮样肉瘤（在其左腹股沟区）的</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">37</span><span style=""line-height:2.5;font-family:宋体;color:#231f20;font-size:14px;"">岁女性患者进行了全身</span><span style=""line-height:2.5;font-family:Times New Roman;color:#231f20;font-size:14px;"">PET / CT</span><span style=""line-height:2.5;font-family:宋体;color:#231f20;font-size:14px;"">检查。成像显示右外侧脚有一些</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">18F-</span><span style=""line-height:2.5;font-family:宋体;color:#231f20;font-size:14px;"">氟脱氧葡萄糖（</span><span style=""line-height:2.5;font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">18F-FDG</span><span style=""line-height:2.5;font-family:宋体;color:#231f20;font-size:14px;"">）的摄取，而在这个区域恰好曾经有过鸡眼。每个皮肤科医生、放射科医生和肿瘤科医生都需要了解这一发现以便作出正确的诊断。</span><span style=""line-height:150%;font-family:'Times New Roman','serif';color:#231f20;""></span> 
</p>","/uploadfiles/image/20131023/20131023143453_0682w.jpg","/uploadfiles/file/20131023/20131023143350_6369.pdf",,10/23/2013,10/23/2013,"medicool",63,,"clavus, diagnosis, positron emission tomography with computed tomography (PET/CT)",0,"85",90,"Case Report: Clavus detected incidentally by positron emission tomography with computed tomography","2008",
319,"水疱与顺势疗法:病例报告及鉴别诊断","doi:10.1016/j.homp.2011.02.014","Gheorghe Jurj ；Silvia Waisse","Homeopathy","<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blisters are skin lesions characterized by accumulation </span><span style=""font-size:14px;"">of fluid between the layers of the skin. </span><a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span><span style=""font-size:14px;"">Their severity varies </span><span style=""font-size:14px;"">from the common blisters caused by </span></span><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span><span><span><span style=""font-size:14px;"">friction to severe autoimmune and </span><span style=""font-size:14px;"">congenital bullous disorders</span></span></span></span><span><span><span style=""font-size:14px;"">, </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span><span style=""font-size:14px;"">some of them currently </span><span style=""font-size:14px;"">without treatment in conventional medicine or requiring drugs with potentially </span><span style=""font-size:14px;"">severe side-effects</span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;"">.</span></span> <a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span><span style=""font-size:14px;"">This article reports </span><span style=""font-size:14px;"">cases of blistering diseases successfully treated with homeopathic medicines, which </span><span style=""font-size:14px;"">represent an alternative for the treatment of such disorders.</span></span></span>
</p>
<p align=""justify"">
	<span class=""shorttext""><span style=""color:#222222;font-family:宋体;font-size:14px;"">&nbsp; 水疱是一种皮肤损伤，以皮肤层间液体累积为特征。其严重程度与由严重摩擦的自身免疫性疾病和先天性大疱性疾病所引起的常见水疱不同），目前，他们中的一些没有应用常规疗法进行治疗或者一些治疗的药物具有潜在的，很严重的副作用。</span><span style=""color:#222222;font-family:宋体;font-size:14px;"">本文报告了应用顺势疗法成功治疗水疱的病例，这为治疗这类疾病提供了另一种选择。</span></span>
</p>","/uploadfiles/image/20131024/20131024124704_2702w.jpg","/uploadfiles/file/20131024/20131024124655_3937.pdf",,10/24/2013,10/24/2013,"medicool",32,,"Homeopathy; Blisters; Pemphigus vulgaris; Atopic dermatitis;Bullous lupus; Toxic blisters; Bullous pemphigoid; Ranunculaceae",0,"85",94,"Blisters and homeopathy: case reports and differential diagnosis","2011",
347,,,"White KP ; Rothe MJ ; Milanese A ; Grant-Kels JM","Pediatric Dermatology","<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp; Several dennatologic
abnormalities have been described in anorexia nervosa, but only rare
associations have been made with perniosis. We recently saw two teenage girls
and one woman wtth anorexia nervosa who had symptoms of perniosis. We suggest
that altered thermoreguiation and a hyperreactive peripherai vascuiar response
to coid in anorexia nervosa may predispose these patients to perniosis.</span>
</p>",,"/uploadfiles/file/20131025/20131025120944_3744.pdf",,10/25/2013,10/25/2013,"medicool",38,,,0,"85",88,"Perniosis in association with anorexia nervosa","1994",
349,,,"Bielan B","Dermatology Nursing / Dermatology Nurses' Association","<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp; The “What’s Your Assessment?”
series includes a short case presentation and differential diagnosis. It is
followed by a discussion of the disease or condition and the rationale used in
each step of the assessment.</span>
</p>",,"/uploadfiles/file/20131025/20131025130705_6780.pdf",,10/25/2013,10/25/2013,"medicool",38,,,0,"67",88,"What's your assessment? Pernio","2006",
322,,"10.1016/j.wem.2009.12.023","Raza N ; Habib A ; Razvi SK ; Dar NR","Wilderness & Environmental Medicine","<p class=""MsoNormal"" style=""text-indent:10.35pt;"">
	<b><span style=""font-family:&quot;"">Objectives.</span></b><span style=""font-family:&quot;"">―To study
constitutional and behavioral risk factors for chilblains in patients at
Abbottabad and Sialkot, Pakistan.</span>
</p>
<p class=""MsoNormal"" style=""text-indent:10.35pt;"">
	<b><span style=""font-family:&quot;"">Methods.</span></b><span style=""font-family:&quot;"">―One hundred
patients and matched controls completed a single-page, close-ended questionnaire
which included demographic data and questions related to possible
constitutional and behavioral risk factors for chilblains. Computer program
SPSS-10 was used to manage and analyze the data. Risk factors were identified
statistically by determining odds ratios and 95% confidence intervals using
multivariate analysis.</span>
</p>
<p class=""MsoNormal"" style=""text-indent:10.35pt;"">
	<b><span style=""font-family:&quot;"">Results.</span></b><span style=""font-family:&quot;""> ―There<b> </b>were an equal number of
male and female respondents in each group. Age of the patients and controls
ranged from 2 to 80 years with a mean of 24.51 ± 16.02. Twenty-six patients and
3 controls had a positive family history for chilblains (odds ratio = 9.33); 42
patients and 14 controls reported a history of constipation (odds ratio =
2.69); 32 patients and 8 controls had a history of either numbness or tingling
of fingers or toes (odds ratio = 2.93); 55 patients and 45 controls led
sedentary lifestyles (odds ratio = 1.27); 85 patients and 58 controls consumed
a low number of cups of tea daily (odds ratio! = 3.20); 65 patients and 29
controls frequently washed their hands and/or feet (odds ratio = 4.93); and 56
patients and 33 controls had occasional sun exposure during winter months (odds
ratio = 2.08).</span>
</p>
<p class=""MsoNormal"" style=""text-indent:10.35pt;"">
	<b><span style=""font-family:&quot;"">Conclusion.</span></b><span style=""font-family:&quot;"">―Significant
risk factors for the development of chilblains for people at Abbottabad and Sialkot
included a history of chilblains in first-degree relatives, numbness and
tingling sensations of fingers or toes, frequent hand or feet washing, and
lower tea consumption during winter months.</span>
</p>",,"/uploadfiles/file/20131024/20131024141436_9086.pdf",,10/24/2013,10/24/2013,"medicool",24,,"chilblains, Pakistan, perniosis, cold inujury",0,"66",88,"Constitutional and Behavioral Risk Factors for Chilblains: A Case-Control Study From Pakistan","2010",
358,"与HPV 16/18相关的膀胱尖锐湿疣:首例国际报道和文献综述",,"MChrisofos MD, A Skolarikos MD, A Lazaris MD, S Bogris MD","International Journal of STD & AIDS","<p style=""text-indent:21pt;"" class=""MsoNormal"" align=""justify"">
	<a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span><span style=""line-height:150%;font-family:&quot;&quot;;""><span style=""line-height:1.5;font-size:14px;"">Condyloma acuminatum is an </span><span style=""line-height:1.5;font-size:14px;"">anogenital lesion caused by human papillomavirus (HPV) infection, a common </span><span style=""line-height:1.5;font-size:14px;"">sexually transmitted disease. It usually affects the external genitalia while </span><span style=""line-height:1.5;font-size:14px;"">urethral and/or bladder involvement is rare. HPV types are classified into three </span><span style=""line-height:1.5;font-size:14px;"">categories depending on their oncogenic potential: low risk (type 6, 11, 42, </span><span style=""line-height:1.5;font-size:14px;"">43, 44, 59, 66, 68, 70), intermediate risk (type 30, 31, 33, 34, 35, 39, 40, </span><span style=""line-height:1.5;font-size:14px;"">49, 51, 52, 53, 57, 58, 63, 64) and high risk (type 16, 18, 45, 56). High-risk </span><span style=""line-height:1.5;font-size:14px;"">and intermediate-risk HPV-DNA types, together with other co-factors still to be </span><span style=""line-height:1.5;font-size:14px;"">defined, are responsible for over 90% of the cases of anogenital pre-malignant </span><span style=""line-height:1.5;font-size:14px;"">and malignant tumours. We report a unique case of a urinary bladder condyloma </span><span style=""line-height:1.5;font-size:14px;"">acuminatum positive for HPV 16/18 DNA, presented as the primary and </span></span></span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">only </span></span></span></span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">site</span></span></span></span></span></span><span><span><span><span><span style=""line-height:150%;font-family:&quot;&quot;;""> </span></span></span></span></span><span><span><span style=""line-height:150%;font-family:&quot;&quot;;""><span style=""line-height:1.5;font-size:14px;"">of the disease in an </span><span style=""line-height:1.5;font-size:14px;"">immunocompetent patient. We review the treatment and follow-up strategies of </span><span style=""line-height:1.5;font-size:14px;"">this rare lesion.</span></span></span></span> 
</p>
<p align=""justify"">
	<span style=""line-height:1.5;font-family:宋体;font-size:14px;"">&nbsp; 尖锐湿疣是一种由人类乳头瘤病毒</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">(HPV)</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">感染所致的肛门生殖器损害，是一种常见的性传播疾病。它通常影响外生殖器，很少累及尿道和</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">/</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">或膀胱部位。人类乳头瘤病毒依据其致癌潜力可分为三类：低风险</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">(6</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">11、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">42</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">43</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">44</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">59</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">66</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">68</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">70</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">型</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">)</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">，</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">中风险</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">(30</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">31</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">33</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">34</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">35</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">39</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">40</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">49</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">51</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">52</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">53</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">57</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">58</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">63</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">64</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">型</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">)</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">和高风险</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">(16</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">18</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">45</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">、</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">56</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">型</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">)</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">。高风险和中风险的</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">HPV-DNA</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">与其他辅助因子一起被认为是造成</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">90%</span><span style=""font-family:宋体;font-size:10.5pt;""><span style=""line-height:1.5;font-size:14px;"">以上的肛门和生殖器</span><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""line-height:1.5;font-size:14px;"">癌前病变</span><span style=""line-height:1.5;font-size:14px;"">和恶性肿瘤的原因。我们报告了一例</span></span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">HPV16/18 DNA</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">呈阳性的膀胱尖锐湿疣的特殊病例</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">，</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">膀胱为该疾病在该患者（具有免疫能力）身上首要和唯一的位点。我们对这例罕见病变的治疗和随访策略进行了回顾。</span> 
</p>
<p align=""justify"">
	&nbsp;
</p>
<span style=""display:none;"" id=""__kindeditor_bookmark_end_17__""></span>","/uploadfiles/image/20131031/20131031085846_3514w.png","/uploadfiles/file/20131031/20131031090013_7584.pdf",,10/31/2013,10/31/2013,"medicool",45,,"condyloma acuminatum, HPV, bladder, carcinogenesis",0,"67",97,"HPV 16/18-associated condyloma acuminatum of the urinary bladder: first international report and review of literature","2004",
323,,"10.1111/j.1524-4725.2012.02461.x","Ayli EE ; Ingraffea A ; Weinman M ; Gloster HM Jr","Dermatologic Surgery: Official Publication For American Society For Dermatologic Surgery [Et Al.]","<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">Chilblains (perniosis) is a skin disease that primarily
affects young to middle-aged white women and presents as tender, erythematous, acrally
distributed macules and papules in response to nonfreezing cold temperatures.
Histologically, lesions are characterized by a superficial and deep perivascular
and perieccrine lymphocytic infiltrate with variable amounts of papillary
dermal edema. Chilblains can be idiopathic or associated with systemic disease
(most commonly lupus erythematosus). 1 Although various types of exposure to cold
can induce chilblains, we describe the first case of chilblains occurring in a
Mohs histotechnician as a result of exposure of the hands to cold temperatures
while sectioning tissue within a cryostat.</span>
</p>",,"/uploadfiles/file/20131024/20131024143517_0172.pdf",,10/24/2013,10/24/2013,"medicool",27,,,0,"85",88,"Chilblains in a Mohs Histotechnician","2012",
339,"胼胝、鸡眼与皮肤硬结",,"Singh D, Bentley G, Trevino SG","EDUCATION & DEBATE","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-size:16px;""><span style=""font-size:16px;font-family:'Times New Roman','serif';"">Inappropriate shoes, abnormal foot mechanics, and high levels of activity produce pressure and friction that lead to corns and calluses.</span></span></a><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;font-family:'Times New Roman','serif';""> Most lesions can be managed conservatively by proper footwear, orthoses, and, if necessary, regular paring. </span></span></span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:16px;"">The lesions usually disappear when the causative mechanical forces are removed. </span><span style=""font-size:14px;""><span style=""font-size:16px;"">Surgery is rarely indicated and should be specifically aimed at correcting the abnormal mechanical stresses.</span><br />
<span style=""font-size:16px;"">&nbsp;</span> 
<p class=""MsoNormal"">
	<span style=""font-family:宋体;""><span style=""font-size:16px;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:16px;"">由于不舒适的鞋子、足部力学异常、高水平运动产生的压力及摩擦，导致鸡眼和胼胝的形成。大多数的皮损可以通过，穿舒适的鞋，使用矫正器，如有必要可以定期去皮来进行适当的治疗。损伤通常在致病的机械力移除后消失。该疾病很少进行手术治疗，而是应专门针对性的矫正异常的机械压力。</span></span><span style=""font-family:'Times New Roman','serif';""></span>
</p>
</span></a></span>","/uploadfiles/image/20131025/20131025101928_8084w.png","/uploadfiles/file/20131025/20131025102237_2255.pdf",,10/25/2013,10/25/2013,"medicool",38,,,0,"67",93,"Callosities, corns, and calluses","1996",
357,"免疫刺激减少肛门尖锐湿疣术后复发:一项前瞻性随机对照试验","10.1111/j.1463-1318.2009.01960.x","M. Mistrangelo*, S. M. Mistrangelo*, S. Cornaglia?, M. Pizzio*, R. Rimonda*, G. Gavello*, I. Dal Conte? and A. Mussa?","Original article","<span style=""font-size:14px;"">&nbsp;<b><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">Aim.<br />
</span></b><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human papillomavirus is the most common cause of sexually transmitted disease. It is associated with immunosuppression and shows a marked tendency to recur. We investigated a natural immunostimulant aimed to reduce recurrence.</span><span style=""font-size:14pt;font-family:'Tahoma','sans-serif';line-height:150%;""> </span> 
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">目的</span></b><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">：<span><br />
&nbsp;&nbsp;</span>人乳头瘤病毒是引起性传播疾病最常见的原因。它与免疫抑制相关，并有明显的复发趋势。为了减少其复发，我们研究了一种天然免疫刺激剂的疗效。 <span></span></span>
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">Method.<br />
</span></b><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A randomized controlled study was carried out including 261 patients allocated to surgical excision alone (control group; n = 122) and surgical excision plus postoperative immunostimulation for 30 days with a natural product (STET; study group; n = 139). Patients with HIV positivity were excluded. All patients gave fully informed consent.</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;""> </span>
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">方法：<span>&nbsp;<br />
</span></span></b><b><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">对</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">261</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">名患者进行了一项随机对照研究，所有患者被随机分配到单纯手术切除治疗（对照组，</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">n= 122</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">）和手术切除加术后天然产品免疫刺激</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">30</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">天（</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">STET;</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">研究组，</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">n= 139</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">）这两组中。</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">HIV</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">阳性的患者被排除在外。所有患者给予了充分的知情同意。 <span></span></span>
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">Results.</span></b><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;""><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patients were followed for 6 months after surgery. Recurrence occurred in 7.2% (10 ? 139) in the study group and in 27.1% (33 ? 122) in the control group (P &lt; 0.0001). There were no significant differences in the sex, sexual orientation, number of lesions, time to diagnosis and treatment or localization of lesions in the two groups.</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;""> </span>
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">结果：<span><br />
</span></span></b><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">&nbsp;&nbsp;</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">对患者在术后进行为期</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">6</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">个月的随访。研究组的复发率为</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">7.2%(10 ? 139)</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">，对照组的复发率为</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">27.1%(33 ? 122) </span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">（</span><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">P &lt; 0.0001</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">）。这两组在性、性取向、疣体的数量、诊断和治疗的时间以及疣体的位置上无显著差异。 <span></span></span>
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">Conclusions.<br />
</span></b><span style=""font-size:14pt;font-family:'Times New Roman','serif';line-height:150%;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immunostimulation using a natural product significantly reduced the incidence of recurrence of anal condylomata in patients undergoing surgical excision.</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;""> </span>
</p>
<p class=""MsoNormal"" style=""text-align:left;"" align=""left"">
	<b><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">结论：<span><br />
</span></span></b><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">&nbsp;&nbsp;</span><span style=""font-size:14pt;font-family:宋体;line-height:150%;"">患者手术切除后使用天然产品免疫刺激显著降低了肛门尖锐湿疣的复发率。 <span></span></span>
</p>
<p class=""MsoNormal"" style=""text-indent:28pt;"">
	<span style=""font-size:14pt;line-height:150%;""></span>
</p>
</span>","/uploadfiles/image/20131030/20131030140052_6599w.jpg","/uploadfiles/file/20131031/20131031100311_3206.pdf",,10/30/2013,11/01/2013,"medicool",35,,,0,"65",97,"Immunostimulation to reduce recurrence after surgery for anal condyloma acuminata: a prospective randomized controlled trial","2009",
363,,"10.1016/j.ijscr.2013.08.020","Giuseppe Pietro Mingolla?, Oscar Potì, Giuseppe Carbotta, Claudio Marra, Gianluca Borgia, Donato De Giorgi","International  Journal of  Surgery  Case  Reports","<span style=""font-size:14px;font-family:Times New Roman;"">INTRODUCTION: Giant anal condyloma also called BuschkeCL?wenstein tumor is a rare sexually transmit-ted disease involving anogenital region with potential malignant degeneration into invasive squamous carcinoma. Complete surgical excision is the treatment of choice and often wide wounds are necessary to reach clear margins and prevent recurrence.</span>",,"/uploadfiles/file/20131101/20131101090500_2090.pdf",,11/01/2013,11/01/2013,"medicool",24,,,0,"85",97,"International Journal of Surgery Case Reports","2013",
325,,"10.1111/j.1346-8138.2010.01172.x","Haruka MINATO,1 Norito ISHII,2 Shunpei FUKUDA,2 Tomoko WAKASA,Ken’ichi WAKASA, Ryosuke SOGAME, Takashi HASHIMOTO,Yuji HORIGUCHI","Journal of Dermatology","<p align=""justify"">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An otherwise healthy 31-year-old man presented with multiple, vesicular, subepidermal blistering on the head, face, chest and oral cavity, leaving shallow scar formation, typical of BrunstingCPerry type pemphigoid. Direct immunofluorescence showed linear deposition of immunoglobulin (Ig)G and C3 along the basement membrane zone (BMZ), and indirect showed anti-BMZ autoantibodies (IgG, &gt;40・) reactingwith the dermal side under the salt-split study. Immunofluorescence staining for type IV collagen and laminins, as well as routine electron microscopy, demonstrated that the cleavage level of the blister was intra-lamina lucida. The immunoperoxidase method applied to lesional skin demonstrated IgG deposits along the lamina densa. The post-embedding immunogold method demonstrated that the autoantibodies against BMZ reacted with the lamina densa and the dermis just beneath it. Immunoblot studies demonstrated that the autoantibodies reacted with the 290-kD polypeptide (suggesting type VII collagen) when dermal extract was used as the substrate. The patient was treated with combination therapy consisting of 30 mg prednisolone, 900 mg nicotinamide and 750 mg tetracycline, and the number of newly forming blisters decreased. We concluded that BrunstingCPerry type pemphigoid, a rare autoimmune blistering disease, includes cases showing characteristics of epidermolysis bullosa acquisita as well as bullous pemphigoid. This case showed discrepancy between the blistering level (intra-lamina lucida) and location of antigen (lamina densa and sub-lamina densa areas).
</p>","/uploadfiles/image/20131024/20131024144633_4343w.jpg","/uploadfiles/file/20131024/20131024144838_0474.pdf",,10/24/2013,10/24/2013,"medicool",46,,"BrunstingCPerry type pemphigoid, epidermolysis bullosa acquisita, type VII collagen.",0,"85",94,"Heterogeneity of BrunstingCPerry type pemphigoid:A case showing blister formation at the lamina lucida,immune deposition beneath the lamina densa and autoantibodies against the 290-kD polypeptide along the lamina densa","2011",
351,,"10.1016/j.jpeds.2010.08.035","Lim KB, Tawng DK, Lokino ES, Raveendran R, Tay GT.","J Pediatr","<span style=""font-size:16px;"">&nbsp;&nbsp;&nbsp; Talar callosity in children--what, who, why?</span>",,"/uploadfiles/file/20131025/20131025133032_6133.pdf",,10/25/2013,10/25/2013,"medicool",51,,,0,"67",93,"Talar callosity in children--what, who, why","2011",
326,,,"T. VOGT, MD, S. BRUNNBERG, MD, U. HOHENLEUTNER, MD, AND M. LANDTHALER, MD, HAVE INDICATED NO SIGNIFICANT INTEREST WITH COMMERCIAL SUPPORTERS.","Dermatol Surg","<p align=""justify"">
	<span style=""font-size:14px;""><strong>BACKGROUND.</strong></span><br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;""> A 66-year-old woman presented to our outpatient </span><span style=""font-size:14px;"">clinic with a 32.5-cm tense, hemorrhagic-appearing </span><span style=""font-size:14px;"">bulla on her forefoot. Histopathology and immunohistochemistry </span><span style=""font-size:14px;"">confirmed a transtumoralCtransepidermal blister formation </span><span style=""font-size:14px;"">within an advanced acrolentiginous malignant melanoma</span><span style=""font-size:14px;"">(MM).</span><br />
<span style=""font-size:14px;""> <strong>OBJECTIVE&nbsp;</strong>&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</span><br />
<span style=""font-size:14px;"">To study bullous malignant melanoma.</span><span style=""font-size:14px;"">&nbsp;<br />
<strong></strong><strong>METHODS.</strong></span><br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;""> Blistering in MMs represents a rare but clinicall</span><span style=""font-size:14px;"">&nbsp;important pitfall in clinical differential diagnosis. The blisters </span><span style=""font-size:14px;"">are typically due to the disruption of the cohesion between </span><span style=""font-size:14px;"">neoplastic cells and keratinocytes, but physical friction may also </span><span style=""font-size:14px;"">contribute.</span><br />
<span style=""font-size:14px;""> <strong>RESULTS</strong><strong>. </strong></span><br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;"">Hemorrhagic blistering is, in many cases, a relatively </span><span style=""font-size:14px;"">insignificant finding in which frictional forces are imposed.</span><br />
<span style=""font-size:14px;""> <strong>CONCLUSION</strong><strong>. </strong></span><br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;"">The case reported here underscores that in rare </span><span style=""font-size:14px;"">cases MMs, particularly if acrally located, can be complicated </span><span style=""font-size:14px;"">by hemorrhagic blistering. Because of the life-threatening </span><span style=""font-size:14px;"">consequences, one should be aware of this rare differential </span><span style=""font-size:14px;"">diagnosis<strong>.</strong></span>
</p>","/uploadfiles/image/20131024/20131024150004_2458w.jpg","/uploadfiles/file/20131024/20131024150027_0374.pdf",,10/24/2013,10/24/2013,"medicool",41,,"Friction Blister，Bullous Malignant Melanoma",0,"85",94,"Bullous Malignant Melanoma: An Unusual Differential Diagnosis of a Hemorrhagic Friction Blister","2003",
327,,"10.1093/jb/mvh182","Yasushi Hanakawa,John R. Stanley","The Japanese Biochemical Society","<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Many children suffer from the bacterial skin diseases bullous impetigo and staphylococcal </span><span style=""font-size:14px;"">scalded skin syndrome (SSSS). Staphylococcus aureus, which produces exfoliative </span><span style=""font-size:14px;"">toxins (ETs), causes these diseases. Recently, it was proven that ETs cleave the </span><span style=""font-size:14px;"">cell adhesion molecule desmoglein (Dsg) 1, which plays an important role in maintaining </span><span style=""font-size:14px;"">the proper structure and barrier function of the epidermis. Surprisingly, Dsg1 </span><span style=""font-size:14px;"">is also the antibody target in the autoimmune disease pemphigus foliaceus. Skin biopsies </span><span style=""font-size:14px;"">from pemphigus foliaceus patients show the same pathology as those from bullous </span><span style=""font-size:14px;"">impetigo and SSSS patients. The crystal structure of ET suggests that it is a serine </span><span style=""font-size:14px;"">protease with an inactive catalytic site, which may become activated when ET </span><span style=""font-size:14px;"">binds a specific receptor. This receptor binding is thought to cause a change in conformation </span><span style=""font-size:14px;"">that exposes the catalytic site. It has recently been shown that Dsg1 specifically </span><span style=""font-size:14px;"">binds and activates ET, which in turn cleaves the bound Dsg1 at only one peptide </span><span style=""font-size:14px;"">bond. This process is absolutely dependent on the calcium-dependent </span><span style=""font-size:14px;"">conformation of Dsg1. These data suggest that ETs have a very high specificity for </span><span style=""font-size:14px;"">human Dsg1, and that S. aureus uses ETs to disrupt the barrier of the human epidermis </span><span style=""font-size:14px;"">in order to survive and proliferate on the human body.</span>
</p>",,"/uploadfiles/file/20131024/20131024151023_0833.pdf",,10/24/2013,10/24/2013,"medicool",39,,"desmoglein, exfoliative toxin, pemphigus foliaceus, serine protease, staphylococcal scalded skin syndrome",0,"67",94,"Mechanisms of Blister Formation by Staphylococcal Toxins","2004",
690,,,"Betul Sozeri, MD; Nesrin Gulez, MD; Guzide Aksu, MD; Necil Kutukculer, MD; Taner Akal?n, MD; Gulsen Kandiloglu, MD","Archives of Environmental & Occupational Health,","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>ABSTRACT.</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""> &nbsp; &nbsp;</span><span style=""line-height:1.5;"">The authors report 2 children with generalized cutaneous sclerosis exposed to pesticides&nbsp;</span><span style=""line-height:1.5;"">containing malathion and diniconazole. Treatment with immunosuppressives resulted in partial&nbsp;</span><span style=""line-height:1.5;"">improvement in the cutaneous signs, particularly over the face, trunk, and proximal limbs. The considerable&nbsp;</span><span style=""line-height:1.5;"">exposure to chemicals related with the initiation of symptoms and absence of organ involvement&nbsp;</span><span style=""line-height:1.5;"">suggested a diagnosis of chemically induced scleroderma-like disorder. Although autoantibodies were&nbsp;</span><span style=""line-height:1.5;"">negative, previously reported relevant associations of anti-kinetochore and anti-topoisomerase function</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">of active ingredients―diniconazole and phosphorodithioate―and solvents of these pesticides&nbsp;</span><span style=""line-height:1.5;"">are also discussed. Careful follow-up for systemic involvement is warranted, since these agents may&nbsp;</span><span style=""line-height:1.5;"">have triggered systemic scleroderma in these patients. Elimination of chemical exposure of children&nbsp;</span><span style=""line-height:1.5;"">is stressed.</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217154929_3450.pdf",,12/17/2013,12/17/2013,"medicool",5,,"anti-kinetochore, anti-topoisomerase, children, dichlorophenyl, dimethyl ethyl, diniconazole, malathion, pesticide, phosphorodithioate, scleroderma",0,"66",114,"Pesticide-Induced Scleroderma and Early Intensive Immunosuppressive Treatment","2012",
692,,"DOI 10.1007/s00296-010-1697-6","Gerald Trang ? Russell Steele ? Murray Baron ? Marie Hudson","Rheumatol Int","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract</strong><br />
&nbsp; &nbsp; &nbsp;Scleroderma renal crisis (SRC) has been associated&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with the use of corticosteroids (CS) in retrospective&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">studies. Using an evidence-based approach, we undertook a&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">systematic review of the literature to identify prospective&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">studies in which scleroderma patients were administered&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">CS to ascertain the risk of SRC in those patients. A comprehensive&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">search was conducted using Medline, EMBASE,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the Cochrane Library, and Web of Science. All&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">original prospective clinical studies were eligible if they&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">enrolled SSc patients newly treated with CS. Selected&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">studies were reviewed, and data extraction was systematically&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">performed for the dose and duration of the CS&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">intervention as well as the occurrence of SRC. Twenty-six&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">studies with a total of 500 SSc patients commencing new&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">CS therapy were included in the systematic review. Ten&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">definite cases of SRC, equivalent to a rate of 2%, were&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">identified. In the subset of early diffuse patients, the rate of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">SRC was 4%. All 10 definite cases of SRC occurred in&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patients who received medium- to high-dose CS therapy.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Seven cases occurred in the setting of stem cell transplant.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">CS are associated with SRC, although this may be due to&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">confounding by disease severity and/or co-intervention.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Great caution must continue to be exerted when initiating&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">such therapy, especially in high doses and in the early&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">diffuse subset of SSc patients</span>
</div>",,"/uploadfiles/file/20131217/20131217155805_0507.pdf",,12/17/2013,12/17/2013,"medicool",8,,"Systemic sclerosis  Scleroderma renal crisis  Corticosteroids  Systematic review",0,"67",114,"Corticosteroids and the risk of scleroderma renal crisis: a systematic review","2012",
693,,"DOI 10.1007/s00296-011-1967-y","Hadi Poormoghim ? Maziar Moradi Lakeh ? Mastoureh Mohammadipour ? Faezeh Sodagari ? Neda Toofaninjed","Rheumatol Int","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract&nbsp;</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""> &nbsp; &nbsp;&nbsp;</span><span style=""line-height:1.5;"">To assess the effectiveness of cyclophosphamide&nbsp;</span><span style=""line-height:1.5;"">in the management of scleroderma-related interstitial&nbsp;</span><span style=""line-height:1.5;"">lung disease (ILD). In this systematic review study, the&nbsp;</span><span style=""line-height:1.5;"">primary outcome measures were change in forced vital&nbsp;</span><span style=""line-height:1.5;"">capacity (FVC) and diffusing capacity of the lung for&nbsp;</span><span style=""line-height:1.5;"">carbon monoxide (DLCO) of the patients after 6 and&nbsp;</span><span style=""line-height:1.5;"">12 months. To assess the effect of cyclophosphamide on&nbsp;</span><span style=""line-height:1.5;"">early stage of ILD, alveolitis, in SSc patients, we selected&nbsp;</span><span style=""line-height:1.5;"">the studies that used the BAL findings or HRCT or recent&nbsp;</span><span style=""line-height:1.5;"">deterioration of PFT with minimal chest X-ray finding in&nbsp;</span><span style=""line-height:1.5;"">early stage of disease as diagnosis of alveolitis. A sensitive&nbsp;</span><span style=""line-height:1.5;"">systematic search strategy was used to find all relevant&nbsp;</span><span style=""line-height:1.5;"">studies. Finally, 17 trials were included in the analysis that&nbsp;</span><span style=""line-height:1.5;"">was performed using STATA. (Version 8) and Review&nbsp;</span><span style=""line-height:1.5;"">Manager (version 4.1; MetaView version 4.1) softwares.&nbsp;</span><span style=""line-height:1.5;"">Results from 10 studies were pooled for the outcome variable&nbsp;</span><span style=""line-height:1.5;"">of FVC after 12 months. The summary WMD (random&nbsp;</span><span style=""line-height:1.5;"">effects) was 2.45 (95% CI, 0.760C4.149 P = 0.005),&nbsp;</span><span style=""line-height:1.5;"">which means that cyclophosphamide was able to prevent&nbsp;</span><span style=""line-height:1.5;"">deterioration of FVC after 12 months. In pooled data of 13&nbsp;</span><span style=""line-height:1.5;"">studies, about DLCO after 12 months WMD (random&nbsp;</span><span style=""line-height:1.5;"">effects) was 2.003 2.96 (95% CI, -0.228 to 6.159&nbsp;</span><span style=""line-height:1.5;"">P = 0.069), which means that cyclophosphamide was not</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">able to prevent deterioration of DLCO after 12 months. If&nbsp;</span><span style=""line-height:1.5;"">we considered clinically sensible improvement as absolute</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">value C10% in DLCO and VC, then result of treatment&nbsp;</span><span style=""line-height:1.5;"">with cyclophosphamide treatment in scleroderma patients&nbsp;</span><span style=""line-height:1.5;"">with ILD was not significant.</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217160045_9962.pdf",,12/17/2013,12/17/2013,"medicool",5,,"Cyclophosphamide  Interstitial lung disease 
Systemic sclerosis  Systematic review  Meta-analysis",0,"67",114,"Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis","2012",
694,,"DOI 10.1007/s11926-011-0220-8","Jennifer Nashel & Virginia Steen","Curr Rheumatol Rep","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract&nbsp;</strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""> &nbsp; &nbsp;&nbsp;</span><span style=""line-height:1.5;"">Scleroderma is a rare systemic autoimmune&nbsp;</span><span style=""line-height:1.5;"">disease with multiple organ manifestations, including skin&nbsp;</span><span style=""line-height:1.5;"">fibrosis. The groups of disorders classified as scleroderma&nbsp;</span><span style=""line-height:1.5;"">mimics share the common thread of skin thickening but are&nbsp;</span><span style=""line-height:1.5;"">otherwise quite incongruous in terms of underlying disease&nbsp;</span><span style=""line-height:1.5;"">process and other organ involvement. This article reviews&nbsp;</span><span style=""line-height:1.5;"">the clinical presentation, etiology, and treatment options&nbsp;</span><span style=""line-height:1.5;"">available for scleroderma mimics, including morphea,&nbsp;</span><span style=""line-height:1.5;"">scleredema, diabetic cheiroarthropathy, scleromyxedema,&nbsp;</span><span style=""line-height:1.5;"">nephrogenic systemic fibrosis, and eosinophilic fasciitis.&nbsp;</span><span style=""line-height:1.5;"">Through greater understanding of these diseases and the&nbsp;</span><span style=""line-height:1.5;"">associated extradermal implications, we hope to facilitate&nbsp;</span><span style=""line-height:1.5;"">recognition of scleroderma and its mimics.</span> 
</div>
</span>",,"/uploadfiles/file/20131217/20131217161036_3480.pdf",,12/17/2013,12/17/2013,"medicool",6,,"Scleroderma mimics . Morphea . Localized
scleroderma . Scleredema . Scleredema of Buschke .
Scleredema adultorum . Scleredema diabeticorum . Diabetic
cheiroarthropathy. Limited joint mobility syndrome .
Scleromyxedema . Lichen myxedematosus . Nephrogenic
systemic fibrosis . Eosinophilic fasciitis",0,"67",114,"Scleroderma Mimics","2012",
695,,"doi:10.1111/j.1445-5994.2011.02706.x","P. J. Roberts-Thomson and J. G. Walker","Internal medicine journal","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract</strong></span>
</div>
<span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp; &nbsp;We review the aetiology of scleroderma from an epidemiological perspective examining&nbsp;</span><span style=""line-height:1.5;"">genetic, environmental and stochastic risk factors. The presence of familial clustering&nbsp;</span><span style=""line-height:1.5;"">(but with low twin concordance) suggests a genetic contribution, and this has been&nbsp;</span><span style=""line-height:1.5;"">confirmed with recent candidate gene and genome-wide association screening demonstrating&nbsp;</span><span style=""line-height:1.5;"">both major histocompatibility complex and non-major histocompatibility&nbsp;</span><span style=""line-height:1.5;"">complex genetic linkage. In contrast, environmental associations are weak or inconsistent.&nbsp;</span><span style=""line-height:1.5;"">An examination of the age-adjusted incidence curve of scleroderma is consistent&nbsp;</span><span style=""line-height:1.5;"">with a stochastic process involving five to eight random events. In pathogenesis, scleroderma</span>
</div>
</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">is best considered as an autoimmune disorder where genetic and environmental&nbsp;</span><span style=""line-height:1.5;"">factors are both important variables, but random events are also likely to play a&nbsp;</span><span style=""line-height:1.5;"">pivotal role. We suggest that these random events might result in acquired somatic</span>
</div>
</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">mutations or epigenetic alterations involving genes coding for immune receptors,&nbsp;</span><span style=""line-height:1.5;"">tolerogenic gates or proteins involved in immune regulation, inflammation and/or&nbsp;</span><span style=""line-height:1.5;"">repair that, over time, might summate to form a requisite cassette (of genetic changes),&nbsp;</span><span style=""line-height:1.5;"">which allows the initiation and progression of the autoimmune process.</span>
</div>
</span>",,"/uploadfiles/file/20131217/20131217161309_6183.pdf",,12/17/2013,12/17/2013,"medicool",5,,"systemic sclerosis, aetiopathogenesis, autoimmunity, random, stochastic.",0,"67",114,"Stochastic processes in the aetiopathogenesis of scleroderma","2011",
696,"非甾体类抗炎药引起的全身固定性药疹两例","10.1177/0960327111412804","SG Bilgili, O Calka, AS Karadag, N Akdeniz and M Kosem","Human and Experimental Toxicology","<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><br />
Abstract</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Fixed
drug eruption (FDE) is a drug-induced cutaneous reaction that occurs at the
same site with each exposure to a specific medication and usually manifests as
round or oval, sharply demarcated erythematous or edematous plaques. The exact mechanism
is unknown. The most common causative agent is co-trimoxazole. Other major categories
of causative agents of FDE include antibiotics, antiepileptics, and
nonsteroidal anti-inflammatory drugs (NSAIDs). FDE usually causes localized eruptions
and very rarely generalized lesions. We report two cases of developing
generalized FDEs after exposure to diclofenac and naproxen.</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">摘要</span> 
</p>
<span style=""font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">固定性药疹（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">FDE</span><span style=""font-size:14px;line-height:2;"">）是一种由药物引起的皮肤反应性疾病。患者每次接触到一个特定的药物后都会在同一部位发作，通常表现为圆形或椭圆形、边界清楚的红斑或水肿性斑块。固定性药疹的确切机制尚不清楚。最常见的致病药物是复方新诺明。固定性药疹（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">FDE</span><span style=""font-size:14px;line-height:2;"">）</span><span style=""font-size:14px;line-height:2;"">致病药物的种类主要包括：抗生素、抗癫痫药和非甾体类抗炎药（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">NSAIDs</span><span style=""font-size:14px;line-height:2;"">）。固定性药疹（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">FDE</span><span style=""font-size:14px;line-height:2;"">）通常引起局部发疹，很少累及全身病变。我们报道了两例接触双氯芬酸和萘普生后发展为全身固定性药疹的病例。</span> 
</div>
</span>","/uploadfiles/image/20131218/20131218090023_2976w.jpg","/uploadfiles/file/20131218/20131218090109_8325.pdf",,12/18/2013,12/18/2013,"medicool",11,,"fixed drug eruption; generalized; naproxen; nonsteroidal anti-inflammatory drug; diclofenac",0,"85",112,"Nonsteroidal anti-inflammatory drugs-induced generalized fixed drug eruption: two cases","2011",
701,"严重药疹中miR -18a -5p的上调促进表皮坏死松解",,"Asako Ichihara,  Zhongzhi Wang, Masatoshi Jinnin,  Yuki Izuno, Naoki Shimozono, Keitaro Yamane, Akihiko Fujisawa,Chikako Moriya, Satoshi Fukushima, Yuji Inoue,  and Hironobu Ihn,","American Academy of Allergy, Asthma & Immunology","<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><br />
Background: </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Toxic
epidermal necrolysis (TEN) is a severe drug induced cutaneous reaction. Although
one of the primary histologic features of TEN is</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp;keratinocyte apoptosis,
its exact mechanism remains unknown.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">背景：中毒性表皮坏死松解症（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">TEN</span><span style=""font-size:14px;line-height:2;"">）是一种严重的药物性皮肤反应性疾病。虽然中毒性表皮坏死松解症（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">TEN</span><span style=""font-size:14px;line-height:2;"">）的主要组织学特征之一是角质形成细胞的凋亡，但其确切机制尚不清楚。</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Objectives: We
investigated the role of microRNAs (</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miRNAs) in the pathogenesis of
severe drug eruptions and evaluated the possibility that miRNA can be a disease
marker.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">目标：我们调查研究了</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">microRNAs（miRNAs）</span><span style=""font-size:14px;line-height:2;"">在严重药疹发病机制中的作用，评估了</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miRNA</span><span style=""font-size:14px;line-height:2;"">成为一个疾病标志的可能性。</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Methods: miRNAs were
extracted from tissues and sera of patients. PCR array analyses were performed
to identify pathogenic miRNAs. The results were confirmed with quantitative
real-time PCR, in situ hybridization, transient transfection of small interfering RNAs or miRNA
mimics into cultured keratinocytes, flow cytometry, immunoblotting, luciferase
assay, and immunohistochemistry.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">方法：从患者的组织和血清中提取</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miRNAs</span><span style=""font-size:14px;line-height:2;"">。采用</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">PCR</span><span style=""font-size:14px;line-height:2;"">阵列分析来识别致病</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miRNA</span><span style=""font-size:14px;line-height:2;"">。通过实时定量</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">PCR</span><span style=""font-size:14px;line-height:2;"">、原位杂交、</span><span style=""font-size:14px;line-height:2;"">瞬时转染小分子干扰</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">RNA</span><span style=""font-size:14px;line-height:2;"">或进入培养的角质形成细胞中的</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miRNA</span><span style=""font-size:14px;line-height:2;"">模拟物、流式细胞术、免疫印迹、荧光素酶测定法和免疫组织化学证实结果。</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Results: PCR array
analysis and real-time PCR using tissue miRNAs demonstrated that the miR-18a-5p
level was increased in the skin of patients with TEN</span><i> </i><i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">in vivo</span></i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">. Transfection of the </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miR-18a-
5p mimic into keratinocytes in vitro resulted in increased
apoptotic cell numbers and caspase-9 activity, which were also increased in the
skin of patients with TEN. The miR-18a-5p mimic also downregulated the
expression of B-cell lymphoma/leukemia-2-like protein 10 (</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCL2L10), </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">an anti-intrinsic
apoptotic molecule. A luciferase assay with the </span><i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCL2L10</span></i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 3’ untranslated region showed </span><i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCL2L10</span></i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> is directly targeted by miR-18a-5p. The protein and mRNA expressions of
BCL2L10 were decreased in the skin of patients with TEN. Transfection with </span><i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCL2L10</span></i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> small interfering RNA induced keratinocyte
apoptosis and caspase activity. Furthermore, serum miR-18a-5p levels tended to
be increased in patients with TEN and were correlated with areas of skin
erythema or erosion in patients with drug eruptions.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">结果：</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">PCR</span><span style=""font-size:14px;line-height:2;"">阵列分析和实时</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">PCR</span><span style=""font-size:14px;line-height:2;"">技术利用组织的</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miRNA</span><span style=""font-size:14px;line-height:2;"">证明了中毒性表皮坏死松解症（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">TEN</span><span style=""font-size:14px;line-height:2;"">）患者皮肤中</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miR -18a - 5p</span><span style=""font-size:14px;line-height:2;"">水平增加。在体外转染到角质形成细胞内的</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miR-18a-5p</span><span style=""font-size:14px;line-height:2;"">模拟物导致细胞凋亡数和</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">caspase-9</span><span style=""font-size:14px;line-height:2;"">活性增加，这些在中毒性表皮坏死松解症（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">TEN</span><span style=""font-size:14px;line-height:2;"">）患者的皮肤中也增加了。</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miR-18A-5p</span><span style=""font-size:14px;line-height:2;"">的模拟物也抑制了一种抗内在凋亡分子（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">B-cell lymphoma/leukemia-2-like protein 10（BCL2L10））</span><span style=""font-size:14px;line-height:2;"">的表达。</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCL2L10 3'</span><span style=""font-size:14px;line-height:2;"">非编码区的荧光素酶检测结果显示</span><i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCL2L10</span></i><span style=""font-size:14px;line-height:2;"">是</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miR-18a-5p</span><span style=""font-size:14px;line-height:2;"">的直接目标。在中毒性表皮坏死松解症（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">TEN</span><span style=""font-size:14px;line-height:2;"">）患者的皮肤中，</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCL2L10</span><span style=""font-size:14px;line-height:2;"">的蛋白及</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">mRNA</span><span style=""font-size:14px;line-height:2;"">表达下降。含</span><i><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCL2L10</span></i><span style=""font-size:14px;line-height:2;"">小分子干扰RNA的转染诱导角质形成细胞凋亡和半胱天冬酶活性。此外，血清中的</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miR-18a-5p</span><span style=""font-size:14px;line-height:2;"">水平在中毒性表皮坏死松解症（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">TEN</span><span style=""font-size:14px;line-height:2;"">）患者中呈增加趋势，并且与药疹患者的皮肤红斑区或糜烂区有关。</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Conclusions: Our
results indicated that downregulated BCL2L10 caused by </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miR-18a-5p
overexpression mediates intrinsic keratinocyte apoptosis in patients
with TEN. Serum miR-18a-5p levels can be a useful disease marker for drug eruptions.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">结论：我们的研究结果表明，在中毒性表皮坏死松解症（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">TEN</span><span style=""font-size:14px;line-height:2;"">）患者中，由于</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miR-18a-5p</span><span style=""font-size:14px;line-height:2;"">的过度表达介导内在角质形成细胞凋亡导致</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCL2L10</span><span style=""font-size:14px;line-height:2;"">基因下调。血清中的</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">miR-18a-5p</span><span style=""font-size:14px;line-height:2;"">水平可以作为鉴别药疹的一个有</span><span style=""font-size:14px;line-height:2;"">效疾病标志。</span> 
</p>","/uploadfiles/image/20131218/20131218093629_8918w.jpg","/uploadfiles/file/20131218/20131218093901_3525.pdf",,12/18/2013,12/18/2013,"medicool",10,,"MicroRNA, apoptosis, drug eruption, keratinocyte, serum",0,"65",112,"Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions","2013",
702,,,"Denise Lage, Priscila Bianchini Juliano1, Konradin Metze, Elemir Macedo de Souza,  and Maria Let??cia Cintra,","International Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:3;""><strong>Abstract</strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Introduction</strong>&nbsp; Lichenoid drug eruption (LDE) shares similar features with lichen planus&nbsp;</span><span style=""font-size:14px;line-height:2;"">(LP), that could reflect the same pathogenesis. In LP, an autoimmune attack is accepted&nbsp;</span><span style=""font-size:14px;line-height:2;"">and cytotoxic T-lymphocytes (CD8+) predominate, especially in late lesions. Apoptosis of&nbsp;</span><span style=""font-size:14px;line-height:2;"">keratinocytes may be mediated by CD8+ T and NK cells in two distinct ways: by the&nbsp;</span><span style=""font-size:14px;line-height:2;"">release of cytotoxic molecules such as perforin and granzyme B or by the Fas/FasL system.&nbsp;</span><span style=""font-size:14px;line-height:2;"">The immunological mechanisms involved in LDE are not yet fully established.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Objectives</strong>&nbsp; Investigate immunohistological features in LP and LDE to add clues to better&nbsp;</span><span style=""font-size:14px;line-height:2;"">understand their pathogenesis.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Material and methods &nbsp;</strong>Twenty-two patients fulfilled all clinical, laboratory, histopathological,&nbsp;</span><span style=""font-size:14px;line-height:2;"">and follow-up features of lichen planus (n = 16) and lichenoid drug eruption (n = 6).&nbsp;</span><span style=""font-size:14px;line-height:2;"">Classic histological features favoring LP or LDE were evaluated by two observers. HAM56,&nbsp;</span><span style=""font-size:14px;line-height:2;"">MAC387, UCHL-1, OPD4, CD8, Granzyme B, Perforin, and ICAM-1 antibodies were used&nbsp;</span><span style=""font-size:14px;line-height:2;"">to decorate the immune infiltrate. Results were analyzed through Pearson correlation,&nbsp;</span><span style=""font-size:14px;line-height:2;"">Student’s t-test, and linear discriminant analysis.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Results</strong>&nbsp; A higher number of necrotic keratinocytes as well as plasma cells and eosinophils&nbsp;</span><span style=""font-size:14px;line-height:2;"">within inflammatory cells were associated with LDE diagnosis. Only in LDE, a correlation&nbsp;</span><span style=""font-size:14px;line-height:2;"">was found between the number of T and CD8+ cells and between the number of granzyme&nbsp;</span><span style=""font-size:14px;line-height:2;"">B+ cells and apoptotic keratinocytes.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Conclusion</strong>&nbsp; Our findings suggest a more important role of CD8+ granzyme B-containing&nbsp;</span><span style=""font-size:14px;line-height:2;"">cells in LDE group, being its synthesis associated with more intense apoptosis. So, LP and&nbsp;</span><span style=""font-size:14px;line-height:2;"">LDE may have a somewhat distinct pathogenesis.</span> 
</div>
</span>",,"/uploadfiles/file/20131218/20131218094633_2853.pdf",,12/18/2013,12/18/2013,"medicool",6,,,0,"65",112,"Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study","2012",
697,,"10.1177/0960327112440112","SG Bilgili, AS Karadag, R Karadag, G Bulut and O Calka","Human and Experimental Toxicology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:2;""><strong><span style=""line-height:3;""></span><span style=""line-height:3;"">Abstract</span></strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">Fixed drug eruption (FDE) usually develops after oral administration and is described as a cutaneous reaction&nbsp;</span><span style=""font-size:14px;line-height:2;"">recurring at the same location each time the drug is taken. Olopatadine is both a H1 histamine receptor&nbsp;</span><span style=""font-size:14px;line-height:2;"">antagonist and a mast cell stabilizer, indicated for the treatment of allergic conjunctivitis. Here, we report a&nbsp;</span><span style=""font-size:14px;line-height:2;"">14-year-old male patient who developed FDE localised on the lateral side of periorbital rim bilaterally, whilst&nbsp;</span><span style=""font-size:14px;line-height:2;"">applying olopatadine 0.1% ophthalmic solution for the treatment of allergic conjunctivitis. As far as we know, FDE&nbsp;</span><span style=""font-size:14px;line-height:2;"">due to olopatadine has not been previously reported in the literature. Wedeem it appropriate to report this case&nbsp;</span><span style=""font-size:14px;line-height:2;"">because FDE that results from the application of topical drugs is a rare event in the literature.</span> 
</div>
</span>",,"/uploadfiles/file/20131218/20131218090758_6936.pdf",,12/18/2013,12/18/2013,"medicool",4,,"fixed drug eruption, topically, olopatadine, antihistaminic drug",0,"85",112,"Fixed drug eruption induced by topical olopatadine ophthalmic solution","2012",
711,,,"Clive Grattan","Royal College of Physicians","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">Urticaria has been recognised as an illness since the time of Hippocrates. It is a common disease with an estimated lifetime prevalence of 20%.1 The term is derived from the stinging nettle, Urtica dioica. Indeed, the lay term for urticaria is nettle rash. At one end of the clinical spectrum, urticaria can be brief, mild and no more than a nuisance. When severe, acute urticaria may merge with life-threatening anaphylaxis. Chronic urticaria may cause severe quality of life impairment comparable to ischaemic heart disease.</span> 
</div>",,"/uploadfiles/file/20131219/20131219093518_2283.pdf",,12/19/2013,12/19/2013,"medicool",3,,,0,"66",113,"The urticarias: pathophysiology and management","2012",
698,,,"Keiko TANAKA, Youichi OGAWA, Shinji SHIMADA","Japanese Dermatological Association","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:3;""><strong>Abstract</strong></span> 
</div>
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;"">Sitagliptin is a newly developed oral hypoglycemic drug, classified&nbsp;</span><span style=""font-size:14px;line-height:2;"">as a dipeptidyl peptidase (DPP)-IV inhibitor for patients with&nbsp;</span><span style=""font-size:14px;line-height:2;"">type 2 diabetes. Sitagliptin was approved by the US Food and&nbsp;</span><span style=""font-size:14px;line-height:2;"">Drug Administration and in Japan in 2006 and 2009, respectively.&nbsp;</span><span style=""font-size:14px;line-height:2;"">As for glucose regulation, incretins, including glucagonslike&nbsp;</span><span style=""font-size:14px;line-height:2;"">peptide 1 (GLP-1) and glucose-dependent insulinotropic&nbsp;</span><span style=""font-size:14px;line-height:2;"">peptide (GIP), play an important role.1 These incretins were&nbsp;</span><span style=""font-size:14px;line-height:2;"">secreted from the gastrointestinal tract and act on the pancreatic&nbsp;</span><span style=""font-size:14px;line-height:2;"">b-cells to stimulate insulin release in response to the rise in&nbsp;</span><span style=""font-size:14px;line-height:2;"">glucose. It has been reported that in type 2 diabetic patients,&nbsp;</span><span style=""font-size:14px;line-height:2;"">GLP-1 levels were decreased.2 Thus, treatment with exogenous&nbsp;</span><span style=""font-size:14px;line-height:2;"">GLP-1 improved glycemic control in type 2 diabetic patients,&nbsp;</span><span style=""font-size:14px;line-height:2;"">however incretins were rapidly inactivated via DPP-IV (CD26), a&nbsp;</span><span style=""font-size:14px;line-height:2;"">cell-surface protease. In this regard, it was impractical to use&nbsp;</span><span style=""font-size:14px;line-height:2;"">GLP-1 in a clinical setting. On the other hand, sitagliptin is an&nbsp;</span><span style=""font-size:14px;line-height:2;"">inhibitor for DPP-IV, which means that sitagliptin is an enhancer&nbsp;</span><span style=""font-size:14px;line-height:2;"">of incretins including GLP-1.</span> 
</div>
</span>",,"/uploadfiles/file/20131218/20131218091244_9853.pdf",,12/18/2013,12/18/2013,"medicool",4,,,0,"85",112,"Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor","2012",
699,,"10.1177/0960327111400105","Hikmet Akyazi, Davut Baltaci, Sevdegul Mungan and Ismail Hamdi Kara","Human and Experimental Toxicology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:3;""><strong>Abstract</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">Naproxen is a non-steroidal anti-inflammatory drug (NSAID) widely used for symptomatic relief of arthritis&nbsp;</span><span style=""font-size:14px;line-height:2;"">and other painful disorders, such as dysmenorrheal. Pruritus is the most common side effect of naproxen.&nbsp;</span><span style=""font-size:14px;line-height:2;"">Fixed drug eruption (FDE) due to naproxen is a rarely reported side-effect. No previous report has declared&nbsp;</span><span style=""font-size:14px;line-height:2;"">cross-reactivity between naproxen and other propionic acid derivatives. A 28-year-old man, presented with&nbsp;</span><span style=""font-size:14px;line-height:2;"">edematous and erythematous patchy lesion along with pruritus and inflammation on lip, have been suffering&nbsp;</span><span style=""font-size:14px;line-height:2;"">since 3 hours. It started after taking naproxen 550 mg for headache. On detailed inquiry, he defined similar&nbsp;</span><span style=""font-size:14px;line-height:2;"">symptom which recurred after whenever he took naproxen. Based on clinical and histopathological findings,&nbsp;</span><span style=""font-size:14px;line-height:2;"">it is evaluated as naproxen-induced FDE. We have tested cross-reactivity between naproxen and other propionic&nbsp;</span><span style=""font-size:14px;line-height:2;"">acid derivatives, and then we obtained negative result for oral provocation test with flurbiprofen. Here,&nbsp;</span><span style=""font-size:14px;line-height:2;"">we present a case of naproxen-induced FDE of 28-year-old man, by overviewing literatures.</span>
</div>
</span>",,"/uploadfiles/file/20131218/20131218092159_9719.pdf",,12/18/2013,12/18/2013,"medicool",6,,"fixed drug eruption, naproxen, cross-reactivity",0,"85",112,"Naproxen-induced fixed drug eruption: A case report","2011",
700,,"10.1111/j.1610-0387.2011.07621.x","Alessandra Handisurya1, Katharina Barbara Moritz, Elisabeth Riedl, Christina Reinisch, Georg Stingl, Stefan W?hrl","JDDG","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:3;""><strong>Summary</strong></span> 
</div>
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Background: </strong>Fixed drug eruption is a fairly common drug-induced hypersensitivity&nbsp;</span><span style=""font-size:14px;line-height:2;"">reaction of the skin and the mucous membranes, which is characterized&nbsp;</span><span style=""font-size:14px;line-height:2;"">by the re-occurrence of the lesion(s) exactly on the previously involved sites&nbsp;</span><span style=""font-size:14px;line-height:2;"">after repeated administration. The pathogenetic mechanisms of this site-specificity&nbsp;</span><span style=""font-size:14px;line-height:2;"">are not fully elucidated.</span> 
</div>
</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Patients and Methods: </strong>We report on three cases of fixed drug eruption, including&nbsp;</span><span style=""font-size:14px;line-height:2;"">a non-pigmenting generalized bullous fixed drug eruption, caused by&nbsp;</span><span style=""font-size:14px;line-height:2;"">mefenamic acid in its pure form.</span> 
</div>
</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Results and Conclusion:</strong> Provocation tests with the assumed causative drug represent&nbsp;</span><span style=""font-size:14px;line-height:2;"">the gold standard for establishing the diagnosis and for identifying the&nbsp;</span><span style=""font-size:14px;line-height:2;"">culprit. Advantages and pitfalls of topical and systemic provocation tests as</span> 
</div>
</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">diagnostic approaches are discussed.</span> 
</div>
</span>",,"/uploadfiles/file/20131218/20131218092846_0562.pdf",,12/18/2013,12/18/2013,"medicool",6,,,0,"85",112,"Fixed drug eruption caused by mefenamic acid: a case series and diagnostic algorithms","2011",
704,,,"Toshiharu Fujiyamaa1, Chika Kawakamib1, Kazunari Sugitab, Rieko Kubo-Kabashimab, Yu Sawadab, Ryosuke Hinob, Motonobu Nakamurab, Takatoshi Shimauchia, Taisuke Itoa, Kenji Kabashimac, Hideo Hashizumed, Yoshiki Tokuraa*","Journal of Dermatological Science","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:3;""><strong>Abstract</strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;"">T cell-mediated hypersensitivity is the most frequent type of&nbsp;</span><span style=""font-size:14px;line-height:2;"">drug eruptions &nbsp;and includes maculopapular eruption (MPE),&nbsp;</span><span style=""font-size:14px;line-height:2;"">erythema multiforme (EM), StevensCJohnson syndrome (SJS), toxic&nbsp;</span><span style=""font-size:14px;line-height:2;"">epidermal necrolysis (TEN), and drug-induced hypersensitivity&nbsp;</span><span style=""font-size:14px;line-height:2;"">syndrome (DIHS). SJS and TEN, and some of EM are characterized&nbsp;</span><span style=""font-size:14px;line-height:2;"">by cytotoxic T (Tc) cell attack toward epidermal keratinocytes with&nbsp;</span><span style=""font-size:14px;line-height:2;"">granulysin and FasCFas ligand , and DIHS is associated with&nbsp;</span><span style=""font-size:14px;line-height:2;"">reactivation of human herpesvirus 6 (HHV6) . Upon occurrence&nbsp;</span><span style=""font-size:14px;line-height:2;"">of these eruptions, the populations of circulating T cells may be</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">polarized . Interleukin (IL)-17A-producing Th17 cell is a CD4+ T&nbsp;</span><span style=""font-size:14px;line-height:2;"">helper subset, and dysregulated Th17 responses mediate psoriasis,&nbsp;</span><span style=""font-size:14px;line-height:2;"">allergic diseases, and others . Drug eruption merits Th17&nbsp;</span><span style=""font-size:14px;line-height:2;"">investigation to see the biased relationship between Th17 cells and&nbsp;</span><span style=""font-size:14px;line-height:2;"">the other T cell subsets &nbsp;and the host-defensive role of Th17 cells&nbsp;</span><span style=""font-size:14px;line-height:2;"">in DIHS. We investigated circulating and skin-infiltrating Th17&nbsp;</span><span style=""font-size:14px;line-height:2;"">cells in drug eruptions.</span> 
</div>
</span><br />",,"/uploadfiles/file/20131218/20131218095637_6148.pdf",,12/18/2013,12/18/2013,"medicool",7,,,0,"65",112,"Increased frequencies of Th17 cells in drug eruptions","2014",
705,,,"Tetsuo Shiohara","Dermatologica Sinica","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong><span style=""font-size:16px;line-height:3;"">Abstract</span></strong><br />
The role of viral infections in the development of drug allergy has recently received increasing attention.&nbsp;Evidence is accumulating that immune responses to drugs can be profoundly influenced by herpesvirus&nbsp;infection that occurs before, concurrent with, or subsequent to drug administration. The current advances&nbsp;in our understanding of the role of viral infections in drug eruptions have been sparked by recent&nbsp;studies on human herpesvirus 6 (HHV-6) reactivation in severe systemic hypersensitivity reactions to&nbsp;drugs, eventually referred to as drug-induced hypersensitivity syndrome (DiHS)/drug reaction with&nbsp;eosinophilia with systemic symptoms (DRESS). It becomes clear that HHV-6 is not the only herpes virus&nbsp;reactivated during the course of DiHS and other herpes viruses are also reactivated in sequence as shown&nbsp;in graft-versus-host disease (GVHD), which can explain frequent deterioration or several flare-ups of&nbsp;clinical symptoms occurring after withdrawal of the causative drug in DiHS. Here we describe how&nbsp;sequential reactivations of herpesviruses occur during the course of DiHS and discuss how the reactivation&nbsp;events could influence the initiation and maintenance of drug-specific immune responses,&nbsp;resulting in severe immunopathology.</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong></strong></span><span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;""></span> 
</div>
</span>",,"/uploadfiles/file/20131218/20131218100733_3775.pdf",,12/18/2013,12/18/2013,"medicool",6,,"autoimmunity, drug-induced hypersensitivity syndrome, Epstein-Barr virus
herpes viruses, regulatory T cells",0,"65",112,"The role of viral infection in the development of severe drug eruptions","2013",
725,"血清类胰蛋白酶的效用作为慢性自发性荨麻疹的一个标志物",,"Roxana Siles', Meng Xu^ and Fred H.","Journal Compilation","<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">Chronic spontaneous
urticaria (CsU) is defined as </span><span style=""font-size:16px;font-family:Times New Roman;"">recurrent episodes
of spontaneous pruritic wheal and flare skin lesions that occur daily</span><span style=""font-size:16px;font-family:Times New Roman;"">, or on most days of the week, forat least 6 weeks</span> <span style=""font-size:16px;font-family:Times New Roman;"">(1).</span><span style=""font-size:16px;font-family:Times New Roman;"">CsU is
characterized by an unpredictable clinical course with varying degrees of
frequency and severity</span><span style=""font-size:16px;font-family:Times New Roman;"">. </span><span style=""font-size:16px;font-family:Times New Roman;"">Mast cell activation may play a role in the pathogenesis
of chronic urticaria as mast cells release avariety of mediators</span><span style=""font-size:16px;font-family:Times New Roman;"">,
including histamine and tryptase</span><span style=""font-size:16px;font-family:Times New Roman;""> (2)</span><span style=""font-size:16px;font-family:Times New Roman;""></span><span style=""font-size:16px;font-family:Times New Roman;"">Elevated tryptase levels can be identified in
the setting of mast cell degranulation</span> <span style=""font-size:16px;font-family:Times New Roman;"">(</span><span style=""font-size:16px;font-family:Times New Roman;"">i.e. </span><span style=""font-size:16px;font-family:Times New Roman;"">IgE -mediated</span><span style=""font-size:16px;font-family:Times New Roman;""> reactions, such as anaphylaxis</span><span style=""font-size:16px;font-family:Times New Roman;"">)
and/or </span><span style=""font-size:16px;font-family:Times New Roman;"">increased mast cell burden(i.e. mastocytosis) </span><span style=""font-size:16px;font-family:Times New Roman;"">(3,4).</span><span style=""font-size:16px;font-family:Times New Roman;"">Elevated
total serum tryptase(tST) has been demonstrated in a subset of patients</span><span style=""font-size:16px;font-family:Times New Roman;""> with
CsU compared with controls</span> <span style=""font-size:16px;font-family:Times New Roman;"">(5-7). </span><span style=""font-size:16px;font-family:Times New Roman;"">The
aim of this study was to identify clinical features of a subset of patients
with CsU and</span> <span style=""font-size:16px;font-family:Times New Roman;"">elevated tST compared with those
with normal tST</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;font-family:SimSun;"">&nbsp;</span> 
</p>
<div align=""justify"">
</div>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;font-family:SimSun;"">慢性自发性荨麻疹被定义为反复发作的自发性瘙痒风团和耀斑皮损，在每天或一周的大半部分时间发病，持续时间最少六周。</span><span style=""font-size:16px;font-family:SimSun;"">CsU</span><span style=""font-size:16px;font-family:SimSun;"">以一个发病频率和严重程度不同的无法预测的临床过程为特征。由于肥大细胞释放多种介质，包括组胺和类胰蛋白酶，因此肥大细胞的活性在慢性荨麻疹的发病机制起着重要的作用。在肥大细胞脱颗粒的环境下，可以确定类胰蛋白酶水平的升高（即</span><span style=""font-size:16px;font-family:SimSun;"">IgE</span><span style=""font-size:16px;font-family:SimSun;"">介导的反应，如过敏反应）和</span><span style=""font-size:16px;font-family:SimSun;"">/</span><span style=""font-size:16px;font-family:SimSun;"">或肥大细胞负荷的增加（如肥大细胞增多症）。与对照组相比，在</span><span style=""font-size:16px;font-family:SimSun;"">CsU</span><span style=""font-size:16px;font-family:SimSun;"">患者的一个子群体中证实了总血清类胰蛋白酶（</span><span style=""font-size:16px;font-family:SimSun;"">tST</span><span style=""font-size:16px;font-family:SimSun;"">）的升高。本研究的目的确定</span><span style=""font-size:16px;font-family:SimSun;"">CsU</span><span style=""font-size:16px;font-family:SimSun;"">患者中的一个子群体患者的临床特征以及与</span><span style=""font-size:16px;font-family:SimSun;"">tST</span><span style=""font-size:16px;font-family:SimSun;"">（</span><span style=""font-size:16px;font-family:SimSun;"">总血清类胰蛋白酶）正常的人群比较升高的</span><span style=""font-size:16px;font-family:SimSun;"">tST</span><span style=""font-size:16px;font-family:SimSun;"">值。</span><span style=""font-family:&quot;""></span> 
</p>","/uploadfiles/image/20131220/20131220093242_3870w.png","/uploadfiles/file/20131219/20131219140357_8926.pdf",,12/19/2013,12/20/2013,"medicool",3,,"Chronic spontaneous urticaria,tryptase,retrospective study",0,"65",113,"The Utility of Serum Tryptase as a Marker in Chronic Spontaneous Urticaria","2013",
727,"阿托伐他汀联合抗组胺药与抗组胺药加安慰剂治疗慢性特发性荨麻疹疗效的比较：一项临床对照试验",,"Fakhrozaman Pezeshkpoor1, Reza Farid Hosseini2, Houshang Rafatpanah3, Behzad Shakerian2, Farahzad Jabbari4, Mohammad Reza Zandkarimi2, Hadis Yousefzadeh5, Homa Sadri 4, Abdolazim Bahrami2, and Mohammad Ali Zamani3","Iran J Allergy Asthma Immunol","<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-family:Times New Roman;font-size:16px;"">Chronic Idiopathic
Urticaria is defined as recurrent hives occurring for at least 6 weeks</span></span><span style=""font-family:TTE22BF5A8t00;""><span style=""font-size:16px;font-family:Times New Roman;"">.In the majority of
cases, there is no identifiable underlying etiology despite extensive evaluation. </span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">A
subset of these patients is classified as having autoimmune urticaria </span></span></span><span><span><span style=""font-size:16px;font-family:Times New Roman;"">defined
by</span><span style=""font-size:16px;font-family:Times New Roman;""> the presence of a functional IgG antibody </span><span style=""font-size:16px;font-family:Times New Roman;"">to the</span></span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-family:Times New Roman;font-size:16px;"">α</span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-family:Times New Roman;font-size:16px;"">subunit of the high-affinity IgE receptor(FceRIa) </span></span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-family:Times New Roman;font-size:16px;"">or to IgE</span></span></span><span style=""font-family:Times New Roman;font-size:16px;"">. The aim of this stud</span><span style=""font-family:TTE22BF5A8t00;""><span style=""font-size:16px;font-family:Times New Roman;"">y was to evaluate the
effects of the drug </span><span style=""font-size:16px;font-family:Times New Roman;"">atorvastatinin</span><span style=""font-size:16px;font-family:Times New Roman;""> patients with
chronic urticaria compared to the placebo.</span></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"" align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">慢性特发性荨麻疹被定义为反复发作的荨麻疹其症状至少持续</span><span style=""font-family:Times New Roman;font-size:16px;"">6</span><span style=""font-family:Times New Roman;font-size:16px;"">周。在大多数情况下，尽管对其有广泛的研究评论，但是并没有证实其潜在的病因。这些患者中的一个子群体被划分为患有自身免疫性荨麻疹，通过α亚基高亲和力</span><span style=""font-family:Times New Roman;font-size:16px;"">IgE</span><span style=""font-family:Times New Roman;font-size:16px;"">受体（</span><span style=""font-family:Times New Roman;font-size:16px;"">FceRIa</span><span style=""font-family:Times New Roman;font-size:16px;"">）或</span><span style=""font-family:Times New Roman;font-size:16px;"">IgE</span><span style=""font-family:Times New Roman;font-size:16px;"">受体功能性</span><span style=""font-family:Times New Roman;font-size:16px;"">IgG</span><span style=""font-family:Times New Roman;font-size:16px;"">抗体的存在来鉴别。本文旨在评估阿托伐他汀与安慰剂对照相比治疗慢性荨麻疹的疗效。</span><span style=""font-family:TTE22BF5A8t00;""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:TTE22BF5A8t00;""><span style=""font-size:16px;font-family:Times New Roman;"">In this single-blind
study, 50 patients suffering from chronic urticaria (15-45 years old)were
selected and divided into two groups by simple randomization method. The first
groupwas treated with atorvastatin and antihistamines and the second group
(control group) wastreated with placebo and antihistamines for 3 months.
Urticaria severity was measured by score index, before and after the treatment
course: </span><span style=""font-size:16px;font-family:Times New Roman;"">ASST (Autologous serum skin test) was performed for all patients
and sera were collected to measure cytokines.</span></span> 
</p>
<div align=""justify"">
	<span></span><span></span> 
</div>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">在这项单盲研究中，选入</span><span style=""font-family:Times New Roman;font-size:16px;"">50</span><span style=""font-family:Times New Roman;font-size:16px;"">名慢性荨麻疹（年龄在</span><span style=""font-family:Times New Roman;font-size:16px;"">15-45</span><span style=""font-family:Times New Roman;font-size:16px;"">岁）的患者，通过简单的随机方法划分为两个组。第一个小组给予阿托伐他汀联合抗组胺药物进行治疗，第二个小组（对照小组）用安慰剂联合抗组胺治疗，疗程为</span><span style=""font-family:Times New Roman;font-size:16px;"">3</span><span style=""font-family:Times New Roman;font-size:16px;"">个月。通过评分指数来测量荨麻疹的严重程度，在疗程前后，对所有患者进行</span><span style=""font-family:Times New Roman;font-size:16px;"">ASST</span><span style=""font-family:Times New Roman;font-size:16px;"">（自体血清皮肤实验），并且收集患者的血清测量细胞因子。</span><span style=""font-family:TTE22BF5A8t00;""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-family:Times New Roman;font-size:16px;"">In cases, IL-5
decreased and IL-10 increased after treatment compared to the time point before
treatment (</span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-family:Times New Roman;font-size:16px;"">p</span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-family:Times New Roman;font-size:16px;"">&lt;0.05)</span></span></span><span style=""font-family:Times New Roman;font-size:16px;"">. All patients with severe urticaria according our scoring, had positive
ASST.</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">在这些病例中，与治疗前的时间点</span><span style=""font-family:Times New Roman;font-size:16px;"">(</span><span style=""font-family:Times New Roman;font-size:16px;"">p</span><span style=""font-family:Times New Roman;font-size:16px;"">&lt;0.05)</span><span style=""font-family:Times New Roman;font-size:16px;"">相比，治疗后</span><span style=""font-family:Times New Roman;font-size:16px;"">IL-5</span><span style=""font-family:Times New Roman;font-size:16px;"">水平下降、</span><span style=""font-family:Times New Roman;font-size:16px;"">IL-10</span><span style=""font-family:Times New Roman;font-size:16px;"">水平升高。根据我们计算出的得分，所有患有严重荨麻疹的患者，在自</span><span style=""font-family:Times New Roman;font-size:16px;"">ASST</span><span style=""font-family:Times New Roman;font-size:16px;"">实验中显示阳性结果。</span><span style=""font-family:TTE22BF5A8t00;""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-family:Times New Roman;font-size:16px;"">The patients with
severe urticaria identified by urticaria score and ASST positivity </span></span></span></span><span><span><span style=""font-family:TTE22BF5A8t00;""><span style=""font-size:16px;font-family:Times New Roman;"">had chronic idiopathic
urticaria. </span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">By
prescribing the Atorvastatin plus antihistamines in severe and resistant forms
of urticaria</span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">,</span></span> <span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">the use of more toxic medications </span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">like cytotoxic
drugs may be avoided.</span></span></span></span></span> 
</p>
<div align=""justify"">
	<span></span><span></span><span></span><span></span> 
</div>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">通过荨麻疹评分和患有慢性特发性荨麻疹患者在</span><span style=""font-family:Times New Roman;font-size:16px;"">ASST</span><span style=""font-family:Times New Roman;font-size:16px;"">实验中显示出的阳性结果，来鉴定严重的荨麻疹患者。对于严重并耐药的荨麻疹，通过对阿托伐他汀和抗组胺药给予适当的剂量，能够避免使用毒性更大的药物，像细胞毒性药物。</span><span style=""font-family:TTE22BF5A8t00;""></span> 
</p>","/uploadfiles/image/20131219/20131219152736_4838w.png","/uploadfiles/file/20131219/20131219152712_9746.pdf",,12/19/2013,12/20/2013,"medicool",3,,"Atorvastatin; Chronic Idiopathic Urticaria; Cytokines",0,"66",113,"Efficacy of Atorvastatin and Antihistamines in Comparison with Antihistamines plus Placebo in the Treatment of Chronic Idiopathic Urticaria: A Controlled Clinical Trial","2012",
706,"硬皮病中的脑静脉窦血栓形成一则病例报告",,"Maryam Poursadegh Fard and Sina Karami Magham","Department of Neurology","<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Abstract- </span><o:p></o:p></b>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp; Scleroderma or systemic sclerosis is a multisystem
disease due to excessive collagen deposition in different organs and
autoimmunity by production of autoantibodies. According to previous reports, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">brain is rarely affected
in scleroderma, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">however recent studies show central nervous
system can be affect not only as a complication of </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">systemic
involvement (hypertension, renal failure) but also as a
primary manifestation.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">In scleroderma, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">thrombus
formation in central nervous system and peripheral systems is uncommon may be
due to endothelial cells damage which causes to release antithrombotic factors.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">We discuss a scleroderma patient </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">with high titter of </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">anticardiolipin antibody who </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">developed to cerebral
sinus thrombosis and cerebellum infarction. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Then we review literature for both primary
brain involvement and thrombotic event in systemic sclerosis.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">&nbsp; &nbsp;硬皮病或系统性硬化症是由于过多的胶原蛋白沉积在不同的器官以及自身抗体产生的自身免疫所引起的一种多系统性疾病。据以往报道，大脑在硬皮病中很少受到影响，然而最新研究显示，中枢神经系统受影响不仅仅是全身受累的并发症（高血压、肾功能衰竭），而且还作为一种主要的临床表现形式。在硬皮病中，中枢神经系统和外围系统中血栓形成是很少见的，这或许是由于内皮细胞损伤引起抗血栓药释放的原因。我们讨论了一例伴有抗心磷脂抗体的硬皮病患者，患者后来发展为脑静脉窦血栓形成和小脑梗死。随后，我们对系统性硬化症中同时伴有原发性脑部受累和血栓形成两种症状的相关文献进行了回顾复习。</span><span lang=""EN-US""><o:p></o:p></span>
</p>","/uploadfiles/image/20131218/20131218161614_2476w.jpg","/uploadfiles/file/20131218/20131218161630_4560.pdf",,12/18/2013,12/18/2013,"medicool",7,,"Scleroderma, systemic; Cerebral sinus thrombosis; Cerebellum infarction",0,"85",114,"Cerebral Sinus Thrombosis in Scleroderma: A Case Report","2012",
708,,,"Nami Shrestha Palikhe, Hye Jung Sin, Seung Hyun Kim, Hyun Jung Sin, Eui Kyung Hwang, Young Min Ye and Hae-Sim Park","Journal of Human Genetics","<span style=""font-size:16px;font-family:'Times New Roman';"">Aspirin ingestion can induce a wide range of clinically recognized&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">allergic reactions, including aspirin-exacerbated respiratory disease&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">(AERD), acetyl salicylic acid (ASA)-intolerant urticaria, chronic&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">rhinitis and anaphylaxis.</span><br />",,"/uploadfiles/file/20131218/20131218164539_5467.pdf",,12/18/2013,12/18/2013,"medicool",4,,"aspirin; mast cell; polymorphism; PTGER4; urticaria",0,"65",113,"Genetic variability of prostaglandin E2 receptor subtype EP4 gene in aspirin-intolerant chronic urticaria","2012",
709,,,"Cedric Lenormand, MD, PhD Dan Lipsker, MD, PhD","Annals of Internal Medicine","<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Background: Delayed-pressure urticaria is a rare form of physical&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">urticaria that can be a highly incapacitating and treatment-refractory&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">chronic condition (1). H|-antihistamines are ineffective, even at high&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">doses, and various treatment options, including corticosteroids, nonsteroidal&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">anti-inflammatory drugs, montelukast, colchicine, dapsone,&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">intravenous immunoglobulin, and omalizumab, have been proposed&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">with mitigated success. We report 2 cases of severe refractory&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">delayed-pressure urticaria that had responded spectacularly to the&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">interleukin-1-receptor antagonist anakinra.</span>
</div>",,"/uploadfiles/file/20131218/20131218164908_9146.pdf",,12/18/2013,12/18/2013,"medicool",5,,,0,"65",113,"Efficiency of lnterleukin-1 Blockade in Refractory Delayed-Pressure Urticaria","2012",
710,,"10.1111/j.1365-2222.2011.03795.x","K. R¨ossing1, N. Novak2, S. Mommert1, F. Pfab3,4,5, M. Gehring1, B. Wedi1,4,5, A. Kapp1 and U. Raap1","Clinical & Experimental Allergy","<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Background Chronic spontaneous urticaria is triggered by many direct and indirect&nbsp;aggravating factors including autoreactive/autoimmune mechanisms, infections, nonallergic&nbsp;and pseudoallergic intolerance reactions. However, the role of neuroimmune&nbsp;mechanisms in chronic spontaneous urticaria so far is unclear.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Objective Thus, we wanted to address the regulation of the neurotrophin brain-derived&nbsp;neurotrophic factor (BDNF) in serum and inflammatory skin of patients with chronic&nbsp;spontaneous urticaria in comparison to subjects with healthy skin.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Methods Fifty adult patients with chronic spontaneous urticaria and 23 skin-healthy subjects&nbsp;were studied. Chronic spontaneous urticaria was defined as recurrent weals for more than 6&nbsp;weeks. Autologous serum skin test was performed in all patients with chronic spontaneous&nbsp;urticaria and BDNF serum levels were analysed by enzyme immunoassay in all subjects.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Furthermore, skin biopsies were taken from weals of eight patients with chronic spontaneous&nbsp;urticaria as well as from healthy skin of eight controls to evaluate the expression of BDNF and&nbsp;its receptors including tyrosine kinase (trk) B and pan-neurotrophin receptor p75NTR by&nbsp;immunohistochemistry.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Results BDNF serum levels were detectable in all subjects studied. However, BDNF levels were&nbsp;significantly higher in patients with chronic spontaneous urticaria compared to non-atopic&nbsp;skin-healthy controls (Po0.001). Furthermore, epidermal and dermal expression of BDNF and&nbsp;epidermal expression of p75NTR was significantly higher in patients with chronic spontaneous&nbsp;urticaria compared with controls (Po0.05C0.001). There was no difference with regard to the&nbsp;expression of trkB between chronic spontaneous urticaria and controls and no difference in&nbsp;BDNF serum levels between autologous serum skin test-positive (n = 23) and -negative&nbsp;(n = 27) patients with chronic spontaneous urticaria.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Conclusions and Clinical Relevance This study shows that BDNF is increased in serum and&nbsp;diseased skin of patients with chronic spontaneous urticaria, suggesting a role for&nbsp;neurotrophins in the pathophysiology of this chronic inflammatory skin disease. Further&nbsp;studies are needed to address the functional role of BDNF on key target effector cells in&nbsp;chronic spontaneous urticaria to establish new therapeutic implications.</span> 
</div>
<span style=""font-size:16px;font-family:'Times New Roman';""></span><br />","/uploadfiles/image/20131220/20131220090232_5186w.png","/uploadfiles/file/20131218/20131218165259_3270.pdf",,12/18/2013,12/20/2013,"medicool",4,,"brain-derived neurotrophic factor, chronic spontaneous urticaria, eosinophils,neurotrophins, skin inflammation",0,"65",113,"Brain-derived neurotrophic factor is increased in serum and skin levels of patients with chronic spontaneous urticaria","2011",
712,,"10.1111/j.1346-8138.2011.01473.x","Suna BU¨ YU¨ KO¨ ZTU¨ RK,1 Asl? GELINCIK,1 Mustafa DEMIRTU¨ RK,1 Emek KOCATURK,2 Bahattin C? OLAKOG? LU,1 Murat DAL","Journal of Dermatology","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">Treatment of chronic urticaria consists of antihistamines as the first-line treatment. For more severe symptoms, combinations can be necessary as well as dose augmentations. The recent guidelines suggest the possibility of using omalizumab in resistant cases, but this therapy is still investigational. We treated two patients with idiopathic recurrent angioedema and 12 patients with chronic spontaneous urticaria (CSU) with omalizumab, who had not benefited from the recommended first-line, second-line and third-line treatments. To evaluate the efficacy of the omalizumab treatment, urticaria activity scores (UAS) and chronic urticaria quality of life (CU-Q2oL) scores were measured at baseline, and at the end of the first and sixth month of the therapy. The dosage and intervals of omalizumab therapy were determined according to the rules suggested for severe asthma treatment. CU-Q2oL scores and UAS displayed significant improvements in all 14 patients. None of the patients reported any adverse effect during the treatment until the submission of this data. Our results show that omalizumab apparently improves CU-Q2oL as well as UAS in treatment-resistant CSU in a real life setting.</span>
</div>",,"/uploadfiles/file/20131219/20131219093801_4826.pdf",,12/19/2013,12/19/2013,"medicool",3,,"angioedema, chronic urticaria, hives, omalizumab, quality of life",0,"66",113,"Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: A real life survey","2012",
718,,"10.1111/j.1365-2230.2011.04127.x","N. M. Zuel-Fakkar, D. M. Abdel Hameed* and O. M. Hassanin","Clinical and Experimental Dermatology","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">Blastocystis hominis is a common intestinal parasite, with a prevalence in developing countries of up to 50%. The aim of this study was to investigate the association of this parasite with urticaria by determining the genotypic isotypes in the Egyptian population. In total, 54 patients with urticaria and 50 controls were enrolled in the study. Stool samples were examined and assessed by PCR. The parasite was detected in a significantly higher number (P &lt; 0.001) of the patient group than the control group. There was no significant difference between the patients with acute and those with chronic urticaria (P = 0.2). The amoeboid form was found in 60.6% of Blastocystispositive patients with urticaria, but in none of the healthy controls. Subtype 3 was the only isolate found in both the patient and control groups. We recommend treatment for Blastocystis-positive patients with urticaria in developing countries. The prevalence is much lower (around 10%) in developed countries, where treatment should only be considered in the absence of other possible causes of urticaria.</span> 
</div>",,"/uploadfiles/file/20131219/20131219100917_1519.pdf",,12/19/2013,12/19/2013,"medicool",6,,,0,"85",113,"Study of Blastocystis hominis isolates in urticaria: a caseCcontrol study","2011",
713,,,"Young-Min YE', Hyun-Jung m<P, Eui-Kyung HWANG', Young-Hee NAM^, Joo-Hee KIM"", Yoo-Seob SHIN' and Hae-Sim PARK'","Acta Derm Venereol","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">A systemic pro-inflammatory and pro-coagulating state occurs in subjects who have both chronic urticaria and metabolic syndrome. To investigate the prevalence and clinical impact of metabolic syndrome in Korean patients with chronic urticaria, a hospital-based cross-sectional study of 131 patients was performed. Metabolic syndrome was assessed by the criteria of the National Cholesterol Education Program's Adult Treatment Panel m. Urticaria disease activity was assessed by total urticaria activity score (range 0-15). Thirty-nine patients (29.8%) had metabolic syndrome compared to 17.8% in a matched control group (p=0.001). Patients with chronic urticaria and metabolic syndrome were older, had a higher mean urticaria activity score and serum levels of eosinophil cationic protein, tumour necrosis factor-a, and complements, and showed a higher rate of negative autologous serum skin tests compared with those without metabolic syndrome. Logistic regression analysis indicated</span><span style=""font-size:16px;font-family:Times New Roman;""> that an urticaria activity score of &gt;13 (p = 0.025) and the presence of metabolic syndrome (p=0.036) were independent predictors of uncontrolled chronic urticaria. We conclude that patients with severe and uncontrolled chronic urticaria should be evaluated for metabolic syndrome in order to reduce cardiovascular risk and improve chronic urticaria outcomes.</span>
</div>",,"/uploadfiles/file/20131219/20131219094310_6595.pdf",,12/19/2013,12/19/2013,"medicool",3,,"chronic urticaria; metabolic syndrome; urticaria activity score; inflammation.",0,"66",113,"Co-existence of Chronic Urticaria and Metabolic Syndrome: Clinical Implications","2013",
714,,"10.1111/j.1365-2230.2011.04281.x","V. Samarasinghe and A. M. Marsland","Clinical and Experimental Dermatology","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">Chronic spontaneous urticaria is a common condition, with a lifetime prevalence of 0.5C1.0%. It has a significant effect on quality of life, comparable to having triple-vessel coronary artery disease. Warfarin and nicoumalone are synthetic derivatives of the plant toxin coumarin. We report the first case of successful response to both warfarin and nicoumalone in the same patient, thereby demonstrating a class action of synthetic coumarins in the disease. Complete response with both coumarins occurred once an INR above 2.0 was achieved, and was maintained during a 12-month followup. The mechanism of action of coumarins on urticaria is not known, but may be related to decrease in thrombin production or to interference of activation of other inflammatory proteins produced during the coagulation process. Side-effects of anticoagulation can be catastrophic, and coumarin treatment currently remains reserved for restricted severe recalcitrant cases only.</span> 
</div>",,"/uploadfiles/file/20131219/20131219095104_5727.pdf",,12/19/2013,12/19/2013,"medicool",4,,,0,"66",113,"Class action of oral coumarins in the treatment of a patient with chronic spontaneous urticaria and delayed-pressure urticaria","2012",
715,,,"Hrishikesh Belani, MPH; Lianne Gensler, MD; Urmila Bajpai, MD, PhD; Eric Meinhardt, MD; Jonathan Graf, MD; Laura Pincus, MD; Kieron S. Leslie, DTM&H, FRCP","American Medical Association","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">Predominantly neutrophilic infiltrates are seen in a subset of patients with urticaria. The lesions tend to be less itchy and poorly responsive to standard therapy, including antihistamines. We describe 2 patients having neutrophilic urticaria with systemic inflammation (NUSI) without known connective tissue disorder or malignancy. We propose the term NUSI to help classify a previously undefined multisystemic inflammatory entity likely mediated by interleukin 1 (IL-1).</span> 
</div>",,"/uploadfiles/file/20131219/20131219095311_8066.pdf",,12/19/2013,12/19/2013,"medicool",4,,,0,"85",113,"Neutrophilic Urticaria With Systemic Inflammation","2013",
717,,,"Giovanna Vitaliti*, Ignazio Morselli, Valeria Di Stefano, Angela Lanzafame, Mario La Rosa and Salvatore Leonardi","Vitaliti et al. Italian Journal of Pediatrics","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">Background: Among legumes, lentils seem to be the most common legume implicated in pediatric allergic reactions in the Mediterranean area and India, and usually they start early in life, below 4 years of age.</span><br />
<span style=""font-size:16px;font-family:Times New Roman;""> Case report: A 22 -month-old child was admitted to our Pediatric Department for anaphylaxis and urticaria. At the age of 9 months she presented a first episode of angioedema and laryngeal obstruction, due to a second assumption of lentils in her diet. At admission we performed routine analyses that were all in the normal range, except for the dosage of specific IgE, that revealed a positive result for lentils. Prick tests too were positive for lentils, while they were all negative for other main food allergens. The child also performed a prick by prick that gave the same positive result (with a wheal of 8 mm of diameter). The child had not previously eaten lentils and other legumes, but her pathological anamnesis highlighted that the allergic reaction appeared soon after the inhalation of cooking lentil vapours when the child entered the kitchen Therefore a diagnosis of lentils vapours allergy was made.</span><br />
<span style=""font-size:16px;font-family:Times New Roman;""> Conclusions: Our case shows the peculiarity of a very early onset. In literature there are no data on episodes of anaphylaxis in so young children, considering that our child was already on lentils exclusion diet. Therefore a diet of exclusion does not absolutely preserve patients from allergic reactions, that can develop also after their cooking steams inhalation.</span>
</div>",,"/uploadfiles/file/20131219/20131219100530_0311.pdf",,12/19/2013,12/19/2013,"medicool",4,,"Papillonacae family, Lentils, Food, Allergy, Inhalation, Vapours, Child, Anaphylaxis, Urticaria, Asthma",0,"85",113,"Urticaria and anaphilaxis in a child after inhalation of lentils vapours: a case report and literature review","2012",
719,,,"Martin K. Church1,2, Karsten Weller1, Philippe Stock3 & Marcus Maurer","Pediatric Allergy and Immunology","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">While there is increasing information about the pathogenesis and treatment of chronic spontaneous urticaria (csU) in adults, there is little published information about csU in children. Consequently, most of the recommendations contained in current guidelines for the prevention and treatment of csU in infants and children is based on extrapolation of data obtained in adults. To rectify this, this review points out critical gaps in our knowledge and suggests strategies which may help us to improve our understanding of this condition. How common is csU in children? What do we know about its clinical presentation and the presence of useful biomarkers? What are its common underlying causes? What is the course of csU in children? How does csU affect the everyday life of children? What treatment options are available for children? To answer these questions, two separate types of information are required. The first is information about the prevalence of the condition in the community at large and how csU affects the everyday life of both the childpatient and the parent or carer. Because most csU cases in infants and children do not come to specialists but are treated by general practitioners or by parents using over-the-counter medications, these questions may be answered only by general population surveys or schools programmes. The second is clinical information including family history and disease presentation, the presence of biomarkers and comorbidities, objective measures of severity, frequency and duration of exacerbations, the response to therapy and the time to remission. Targeted questionnaires need to be developed and validated for these investigations. This has already begun in Germany with the establishment of the CU-KID Netzwerk (Email address: cu-kid@charite.de), the aim of which is to identify clinical centres and colleagues who treat children with urticaria and to initiate the information gathering described above.</span>
</div>",,"/uploadfiles/file/20131219/20131219102330_1614.pdf",,12/19/2013,12/19/2013,"medicool",3,,"biomarkers; children; Chronic spontaneous urticaria; quality of life; questionnaires;therapy.",0,"67",113,"Chronic spontaneous urticaria in children: Itching for insight","2010",
720,,"10.1007/s11882-012-0269-0","Marina Abajian & Agnieszka M?ynek & Marcus Maurer","Curr Allergy Asthma Rep","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">The physical urticarias are a heterogeneous subgroup of chronic urticarias in which wheals can be reproducibly induced by different specific physical stimuli such as cold, heat, pressure, vibration, or sunlight. Physical urticarias comprise up to 25 % of chronic urticarias and occur more frequently in young adults. Symptoms, i.e. wheal and flare responses or angioedema, are usually limited to the skin areas exposed to the eliciting stimulus. However, generalised urticaria with variable extracutaneous manifestations can also occur. Some patients may also present with more than one physical urticaria. Skin lesions in physical</span><span style=""font-size:16px;font-family:Times New Roman;""> urticaria result from mast cell activation and mediator release. The mechanisms by which physical stimuli activate skin mast cells are not fully understood. Because of this, trigger avoidance and symptomatic treatment are key therapeutic concepts for physical urticarias. Identification of the inducing physical trigger, including its individual thresholds, is necessary for an effective therapy. Here, we have summarized clinical features, diagnostic workup and therapy options for physical urticarias.</span>
</div>",,"/uploadfiles/file/20131219/20131219102821_9755.pdf",,12/19/2013,12/19/2013,"medicool",3,,"Physical urticaria . Urticaria factitia .Symptomatic dermographism . Delayed pressure urticaria",0,"67",113,"Physical Urticaria","2012",
721,,"10.1007/s11882-012-0270-7",,"Curr Allergy Asthma Rep","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">Chronic urticaria is defined as case of spontaneous wheals and/or angioedema persisting for a period of at least six weeks. The disease has an average duration of three to five years and is strongly associated with a decrease of quality of life and performance. Current international guidelines recommend the use of non-sedating antihistamines as the first choice in therapy and updosing these up to fourfold in cases of non-response. Alternative treatments for the afflicted who do not respond</span><span style=""font-size:16px;font-family:Times New Roman;""> to antihistamine-treatment are also available but are not approved for use on urticaria.</span>
</div>",,"/uploadfiles/file/20131219/20131219112830_5270.pdf",,12/19/2013,12/19/2013,"medicool",5,,"Urticaria . Chronic urticaria . Wheal .
Angioedema . Antihistamine . Omalizumab . Diagnosis .
Classification . Treatment",0,"67",113,"Chronic Urticaria","2012",
723,,,"Tara F. Carr, M.D., and Carol A. Saltoun, M.D.","Division of AllergyCImmunology","<div align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">Urticaria, also known as hives, may affect up to 20% of the population at some time in their lives. Urticaria is characterized</span><br />
<span style=""font-size:16px;font-family:Times New Roman;"">by extreme pruritus and described as erythematous, raised, circumscribed lesions with central pallor that blanch with pressure.</span><br />
<span style=""font-size:16px;font-family:Times New Roman;"">The pathogenesis of urticaria involves mast cell activation, with subsequent release of histamine and other vasoactive mediators, leading to increased vascular permeability of postcapillary venules and development of edema, erythema, and pruritus. Urticaria is closely associated with angioedema in 40% of individuals; 10% of patients experience angioedema without</span><span style=""font-size:16px;font-family:Times New Roman;""> urticaria. Urticarial lesions often are generalized with multiple lesions in no specific distribution; angioedema tends to be</span><span style=""font-size:16px;font-family:Times New Roman;""> localized, commonly affecting the face (periorbital and perioral regions), tongue, uvula, soft palate or larynx, extremities, and</span><br />
<span style=""font-size:16px;font-family:Times New Roman;"">genitalia. Urticaria is subdivided into acute and chronic urticaria based on duration of symptoms. Acute urticaria lasts 6</span><span style=""font-size:16px;font-family:Times New Roman;""> weeks and an identifiable cause may be discovered such as food products, medications (aspirin, nonsteroidal anti-inflammatory</span><span style=""font-size:16px;font-family:Times New Roman;""> drugs, and antibiotics), or insect stings. Urticaria lasting 6 weeks is designated as chronic urticaria, and an etiology is seldom</span><span style=""font-size:16px;font-family:Times New Roman;""> identified and thus considered idiopathic. Chronic urticaria may have an autoimmune basis. There is a well-documented</span><span style=""font-size:16px;font-family:Times New Roman;""> association between autoimmune hypothyroidism (Hashimoto’s disease) and urticaria and angioedema with higher incidence of</span><span style=""font-size:16px;font-family:Times New Roman;""> antithyroid (antithyroglobulin and antiperoxidase) antibodies in these usually euthyroid patients. Furthermore, studies have</span><span style=""font-size:16px;font-family:Times New Roman;""> revealed a circulating IgG antibody directed against the IgE receptor (FCRI) or IgE in 40C60% of patients with chronic</span><span style=""font-size:16px;font-family:Times New Roman;""> urticaria. Histamine 1Creceptor antagonists (antihistamines) are initial therapy.</span>
</div>",,"/uploadfiles/file/20131219/20131219134838_7546.pdf",,12/19/2013,12/19/2013,"medicool",3,,,0,"67",113,"Urticaria and angioedema","2012",
724,"多形性荨麻疹-一则病例报告","10.1111/j.1525-1470.2011.01311.x","Lesley Starnes, M.D., Tejesh Patel, M.D., and Robert B. Skinner, M.D.","Pediatric Dermatology","<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;"">The term ‘‘urticaria multiforme’’
has recently been proposed to replace </span><span style=""font-size:16px;font-family:Times New Roman;"">acute annular urticaria</span><span style=""font-size:16px;font-family:Times New Roman;"">and refers
to a benign cutaneous hypersensitivity reaction characterized by </span><span style=""font-size:16px;font-family:Times New Roman;"">the
acute onset of large, polycyclic, and annular wheals with ecchymotic centers</span><span style=""font-size:16px;font-family:Times New Roman;"">.</span><span style=""font-size:16px;font-family:Times New Roman;""> It is associated
with acral and facial angioedema, dermatographism, </span><span style=""font-size:16px;font-family:Times New Roman;"">favorable response to
antihistamines, and a self-limited course.</span><span style=""font-size:16px;font-family:Times New Roman;""> It is most often
mistaken for erythema multiforme and occasionally for serum sickness-like
reaction. </span><span style=""font-size:16px;font-family:Times New Roman;"">We report a
case of urticaria multiforme in a 4-month-old infant, followed by a review of
the literature.</span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;"">&nbsp;最近提出了用“多形性荨麻疹”这个术语取代“急性环状荨麻疹”这个词汇。多形性荨麻疹指的是一种以急性爆发的大型的、多环的、中心具有瘀斑的环形风团为特征的良性皮肤过敏性反应。它与肢端和面部血管性水肿、皮肤划痕症有关，对于抗组胺药有良好的反应和自限性过程。它经常被误诊为多形性红斑，有时为血清病样反应。我们报告了一例</span><span style=""font-size:16px;"">4</span><span style=""font-size:16px;"">个月大的多形性荨麻疹的患儿的病例和综述。</span>
</p>","/uploadfiles/image/20131219/20131219135650_4674w.png","/uploadfiles/file/20131219/20131219135642_5894.pdf",,12/19/2013,12/19/2013,"medicool",6,,"Acute annular urticaria,Urticaria Multiforme",0,"85",113,"Urticaria Multiforme―A Case Report","2011",
726,,"10.1007/s00296-010-1763-0","Tokunori Ikeda , En Kimura , Teruyuki Hirano , Makoto Uchino",,"<p class=""MsoNormal"" style=""text-align:justify;text-indent:15.75pt;"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">We
report the case of a 66-year-old woman who developed progressive proximal muscle
weakness and papillary thyroid cancer. After a thyroidectomy, she was treated
with intravenous methylprednisolone pulse therapy and oral prednisolone
followed by tacrolimus therapy. However, her clinical symptoms and
laboratory data did not improve suf?ciently. Therefore, we administered intravenous
immunoglobulin. As a result, she regained substantial muscle strength along
with complete normalization of serum muscle enzymes and showed no evidence of
recurrence of papillary thyroid cancer or exacerbation of dermatomyositis (DM). Although there is
controversy as to whether papillary thyroid cancer is involved in DM, the results
of this study support a connection between these two conditions.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;text-indent:15.75pt;"">
	<br />
</p>",,"/uploadfiles/file/20131219/20131219150000_3693.pdf",,12/19/2013,12/19/2013,"medicool",2,,"Dermatomyositis | Papillary thyroid cancer | IFN-a  Plasmacytoid dendritic cells",0,"85",115,"The association between dermatomyositis and papillary thyroid cancer: a case report","2012",
728,"视网膜霜枝样血管炎，推测可能与皮肌炎有关","10.3109/09273948.2010.531895","Mee Yon Lee, , Hans H. Kim , and Kyu Seop Kim","Ocular Immunology & Inflammation","<p class=""MsoNormal"">
	<span style=""font-size:14px;font-family:'Times New Roman';"">
	<p class=""MsoNormal"">
		<strong>Purpose:</strong> To report the first case of frosted branch angiitis associated with
dermatomyositis in a Korean woman.<o:p></o:p>
	</p>
	<p class=""MsoNormal"">
		<span style=""font-family:SimSun;"">目的：旨在报道首例患有与皮肌炎相关的</span><span style=""font-family:SimSun;"">视网膜霜枝样血管炎的韩国女性患者病例。</span>
	</p>
	<p class=""MsoNormal"">
		Methods:
Case report.<o:p></o:p>
	</p>
	<p class=""MsoNormal"">
		<span style=""font-family:SimSun;"">方法：病例报告。</span>
	</p>
	<p class=""MsoNormal"">
		<strong>Results: </strong>A 42-year-old woman with history of dermatomyositits presented with unilateral
decreased visual acuity. Fundus examination showed findings consistent with frosted
branch angiits. After 1 month of oral prednisolone, the patient made
significant visual recovery with near complete resolution of vascular
sheathing.<o:p></o:p>
	</p>
	<p class=""MsoNormal"">
		<span style=""font-family:SimSun;"">结果：一位<span style=""font-family:Times New Roman;"">42</span>岁有皮肌炎病史的女性出现单侧视力下降的情况。眼底检查显示结果符合视网膜霜枝样血管炎。口服泼尼松一个月后，随着血管套几乎完全消退，患者视力得到了显著的恢复。</span><o:p></o:p>
	</p>
	<p class=""MsoNormal"">
		<strong>Conclusions: </strong>To the best of the authors’ knowledge, this is the first case of frosted branch
angiitis associated with dermatomyositis. Dermatomyositis should be considered
in the differential diagnosis of patients presenting with frosted branch
angiitis.<o:p></o:p>
	</p>
	<p class=""MsoNormal"">
		<span style=""font-family:SimSun;"">结论：就作者的知识面而言，这是首例与皮肌炎相关的视网膜霜枝样血管炎病例。对于出现视网膜霜枝样血管炎患者，皮肌炎应考虑作为鉴别诊断。</span><o:p></o:p>
	</p>
</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;""></span><o:p></o:p>
</p>","/uploadfiles/image/20131219/20131219154454_2444w.jpg","/uploadfiles/file/20131219/20131219154328_8031.pdf",,12/19/2013,12/20/2013,"medicool",5,,"dermatomyositis| frosted branch angiitis| macula edema| panuveitis| vascular sheathing",0,"85",115,"Frosted Branch angiitis, presumably Related to Dermatomyositis","2011",
730,,"10.1007/s10165-011-0502-z","Yuko Matsuki ,Hiroyuki Yamashita ,Yuko Takahashi ,Toshikazu Kano",,"<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp;&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">The clinical course of diffuse alveolar damage</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(DAD) was studied in six consecutive cases of dermato</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">myositis (DM) based on our hospital records over 8 years.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Three patients had severe myopathy at presentation, and&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the other three patients showed clinically amyopathic DM&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(CADM). Interstitial pneumonia in all patients developed&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">shortly after they manifested DM. DAD in ?ve deceased&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patients, which was proven pathologically, did not respond&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">to steroid therapy combined with cyclosporine or tacroli</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">mus. Of these, two patients began receiving combination&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">therapy before suffering respiratory symptoms, and one of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">them had elevated serum Krebs von der Lungen-6 (KL-6)&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">levels before visible abnormalities appeared on a plain&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">chest X-ray. Only one patient with CADM survived; this&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patient received intravenously administered pulse cyclo</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">phosphamide (IVCY) therapy intravenously for DAD from&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the early stage. Delayed adjunctive IVCY was ineffective&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">for progressed DAD in the remaining ?ve patients. Ele</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">vated serum ferritin levels were observed in all four&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patients examined and might have predicted the lethal&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">DAD, as in a previous report. In conclusion, promptly&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">beginning IVCY therapy may be bene?cial for patients&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with DM and interstitial pneumonia who show elevated&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">serum levels of ferritin or KL-6 with minimal pulmonary&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">abnormalities.</span>
</div>",,"/uploadfiles/file/20131219/20131219155604_2812.pdf",,12/19/2013,12/19/2013,"medicool",3,,"Interstitial pneumonia | Dermatomyositis | Amyopathic dermatomyositis | Diffuse alveolar damage",0,"85",115,"Diffuse alveolar damage in patients with dermatomyositis: a six-case series","2012",
731,,,"Ahmad Nofal&Eman Salah El-Din","International Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Background </strong>Hydroxyurea-induced dermatomyositis is a rare adverse reaction of long-term&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">hydroxyurea therapy. It has been reported under different names; however, the exact clas</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">si?cation and nomenclature of this eruption have been the subject of much debate, and a&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">more precise term is still awaiting. Herein, we review the different aspects of this reaction&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and suggest a new term that might help to minimize the confusion about its nomenclature.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Materials and methods</strong> We describe a 68-year-old woman who had been on long-term&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">hydroxyurea therapy for the treatment of chronic myeloid leukemia for nine years. She&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">presented with typical dermatomyositis-like lesions and many of the other mucocutaneous&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">adverse effects of hydroxyurea.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Results</strong> Skin examination revealed typical Gottron’s papules on the dorsa of the hands,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">atrophy, xerosis, acquired ichthyosis, photosensitivity, cutaneous, oral and nail hyperpig</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">mentation, acral erythema, palmoplantar keratoderma, actinic keratoses, and leg ulcers.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">There was no clinical or laboratory evidence of proximal muscle weakness. Cessation of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">hydroxyurea was associated with remarkable improvement of the skin lesions.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Conclusion</strong> Hydroxyurea-induced dermatomyositis is a rare drug-induced dermatomyositis&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">characterized by skin lesions identical to classic dermatomyositis without clinical or labora</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tory evidence of myositis. We propose that the term hydroxyurea-induced amyopathic der</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">matomyositis that adequately describes the ?ndings reported in this subset of patients&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">would be more precise and speci?c.</span>
</div>",,"/uploadfiles/file/20131219/20131219160408_2252.pdf",,12/19/2013,12/19/2013,"medicool",2,,"amyopathic dermatomyositis | dermatomyositis-like | drug-induced dermatomyositis",0,"85",115,"Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption?","2012",
732,,"10.1007/s00296-008-0822-2","Hui-Jung Kim ,Yun-Kyung Hong , Wan-Hee Yoo","Rheumatol Int","&nbsp; &nbsp; <span style=""font-family:'Times New Roman';font-size:14px;"">&nbsp;We report a rare case of patient with dermato</span><span style=""font-family:'Times New Roman';font-size:14px;"">myositis (DM) who developed spontaneous pneumomedi</span><span style=""font-family:'Times New Roman';font-size:14px;"">astinum (PnM) and subcutaneous emphysema. She was&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">successfully treated with oral prednisolone and cyclospor</span><span style=""font-family:'Times New Roman';font-size:14px;"">ine A (CsA). We reviewed the cases of PnM in patients&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">with DM treated with CsA. A review of four previously&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">reported cases revealed that treatment with systemic gluco</span><span style=""font-family:'Times New Roman';font-size:14px;"">corticoid and CsA was eVective for the DM and PnM. We&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">indicate that initial and early treatment of the patients with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">DM and PnM with CsA enabled rapid tapering of the dose&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">of glucocorticoid and improved the disease.</span><br />",,"/uploadfiles/file/20131219/20131219160910_2886.pdf",,12/19/2013,12/19/2013,"medicool",2,,"Cyclosporine A | Dermatomyositis | Pneumomediastinum",0,"85",115,"Dermatomyositis, complicated with pneumomediastinum,  successfully treated with cyclosporine A: a case report  and review of literature","2009",
733,"在皮肌炎和多发性肌炎中TLR2、TLR4和TLR9的表达","10.1007/s10067-009-1316-7","Geun-Tae Kim,  Mi-La Cho , Young-Eun Park & Wan Hee Yoo",,"<p>
	<span style=""font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp;&nbsp;The aim
of this study was to investigate the expressions of Toll-like receptor (TLR) 2,
TLR4, TLR9, and their correlations with the expression of cytokines that are
associated with activation of CD4+T cells and inflammation
including interferon γ (IFNγ), interleukin 4 (IL4), interleukin 17 (IL17), and
tumor necrosis factor α (TNFα) in muscle tissues of patients with
dermatomyositis(DM) and polymyositis (PM). The expressions of
TLR2, TLR4, TLR9, IFNγ, IL4, IL17, and TNFα were measured by real-time reverse
transcriptionCpolymerase chain reaction in muscle tissues from 14 patients with
DM and PM (nine patients with DM, five patients with PM) and three controls. The
expressions of TLR2, TLR4, and TLR9 were also localized with
immunohistochemistry. The
expression levels of TLR2, TLR4, TLR9, IFNγ, IL4, IL17, and TNFα&nbsp;were
significantly high in patients with DM and PM compared with those in the
controls, and the expression levels of TLR4 and TLR9 had significant positive
correlations with the expressions of IFNγ, IL4, IL17, and TNFα. Immunohistochemistry
showed that TLR2, TLR4, and TLR9 were expressed by infiltrating cells of
perimysium in DM, whereas they were expressed by infiltrating cells of endomysium
in PM. These results suggest that the involvement of TLR4 and TLR9 in
immunopathogenesis of DM and PM might be connected with activation of CD4+T
cells.</span> 
</p>
<div style=""text-align:justify;"">
	&nbsp; &nbsp; <span style=""font-family:SimSun;font-size:14px;"">&nbsp;</span><span style=""font-family:SimSun;font-size:14px;"">这项研究的目的是探讨在患有皮肌炎（<span style=""font-family:Times New Roman;"">DM</span>）和多发性肌炎（<span style=""font-family:Times New Roman;"">PM</span>）的肌肉组织中<span style=""font-family:Times New Roman;"">toll</span>样受体（<span style=""font-family:Times New Roman;"">TLR</span>）<span style=""font-family:Times New Roman;"">2、TLR4、TLR9</span>的表达，以及它们与有关<span style=""font-family:Times New Roman;"">CD4+T</span>细胞的活化和炎症发作的细胞因子表达的相关性，包括的<span style=""font-family:Times New Roman;"">γ</span>干扰素(<span style=""font-family:Times New Roman;"">IFNγ</span>)、白介素<span style=""font-family:Times New Roman;"">4(IL4)</span>、白介素<span style=""font-family:Times New Roman;"">17(IL17)</span>和肿瘤坏死因子<span style=""font-family:Times New Roman;"">α(TNFα)</span>。<span style=""font-family:Times New Roman;"">14</span>例皮肌炎和多发性肌炎患者（<span style=""font-family:Times New Roman;"">9</span>例皮肌炎患者，<span style=""font-family:Times New Roman;"">5</span>例多发性肌炎）和三例对照者肌肉组织中的<span style=""font-family:Times New Roman;"">TLR2、TLR4、TLR9、IFNγ、IL4、IL17</span>和<span style=""font-family:Times New Roman;"">TNFα</span>的表达采用实时逆转录聚合酶链式反应进行测量。皮肌炎和多发性肌炎患者的<span style=""font-family:Times New Roman;"">TLR2、TLR4、TLR9、IFNγ、IL4、IL17</span>和<span style=""font-family:Times New Roman;"">TNFα</span>的表达水平显著高于那些对照者，并且<span style=""font-family:Times New Roman;"">TLR4</span>和<span style=""font-family:Times New Roman;"">TLR9</span>的表达水平与<span style=""font-family:Times New Roman;"">IFNγ、IL4、IL17</span>和<span style=""font-family:Times New Roman;"">TNF-α</span>的表达呈显著正相关。免疫组化显示皮肌炎中<span style=""font-family:Times New Roman;"">TLR2、TLR4</span>和<span style=""font-family:Times New Roman;"">TLR9</span>通过浸润的肌束膜细胞进行表达，而在多发性肌炎中则通过浸润的肌内膜细胞进行表达。这些结果表明，在皮肌炎和多发性肌炎的免疫发病机制中，<span style=""font-family:Times New Roman;"">TLR4</span>和<span style=""font-family:Times New Roman;"">TLR9</span>的参与可能与活化的<span style=""font-family:Times New Roman;"">CD4+T</span>细胞有关。</span> 
</div>
<p>
	<br />
</p>","/uploadfiles/image/20131219/20131219162700_0917w.jpg","/uploadfiles/file/20131219/20131219161621_7073.pdf",,12/19/2013,12/19/2013,"medicool",8,,"Dermatomyositis | Polymyositis | Toll-like receptors",0,"65",115,"Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis","2010",
735,,"10.2340/00015555-1459","Yuka OSHIKAWA, Masatoshi JINNIN, Takamitsu MARINO","Journal Compilation","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; &nbsp; Expression of microRNA (miRNA) in the skin in derma</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tomyositis has not previously been studied in detail. In&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">this study, we performed miRNA array analysis using&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">miRNAs purified from dermatomyositis-involved skin&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and normal skin, and found that several miRNAs were&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">up- or down-regulated iu dermatomyositis skin. Among&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">them, we focused on mLR-7, one of the most down-regu-</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">lated miRNAs in dermatomyositis skin. Total miRNAs&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">were purified from serum, and hsa-miR-7 levels were&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">measured with quantitative real-time PCR using the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">specific primer. Serum levels of miR-7 were significantly&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">decreased in patients with dermatomyositis compared&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with normal subjects or patients with other autoimmune&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">diseases. Thus, serum miR-7 levels might be a possible&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">diagnostic marker for dermatomyositis. Clarifying the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">up- or down-stream events of down-regulated miR-7 in&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patients with dermatomyositis may lead to further un</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">derstanding of the disease and a new therapeutic ap</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">proach.</span>
</div>",,"/uploadfiles/file/20131219/20131219163431_2445.pdf",,12/19/2013,12/19/2013,"medicool",2,,"autoimmune diseases| polymerase chain reaction | polymyositis.",0,"65",115,"Decreased miR-7 Expression in the Skin and Sera of Patients with Dermatomyositis","2013",
740,,,"Yasuhiro Shimojima, Wataru Ishii, Masayuki Matsuda",,"<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Background:</strong> To investigate whether or not coadministration of tacrolimus (TAC) with prednisolone (PSL) can</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (PM/DM).</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Methods:</strong> We reviewed medical records of 32 PM/DM patients who had been admitted to our hospital, and</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">abstracted those who had received TAC in addition to oral PSL for treatment. The clinical usefulness of TAC in</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">PM/DM was objectively evaluated focusing upon the manual muscle strength test (MMT) score, serum creatine</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">kinase (CK) and tapering of PSL.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Results: </strong>Nine patients with PM and 6 with DM were enrolled in this study. TAC was added because of difficulty in</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">reduction of PSL in 12 patients and recurrence with corticosteroid-induced complications in the remaining 3. Both</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">PM and DM patients showed significant increases in the MMT score and significant decreases in serum CK 1 to</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">3 months after starting TAC compared with before. Skin symptoms in a clinically amyopathic DM patient also</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">improved 1 month after starting TAC. The daily dosage of PSL could be significantly reduced in both PM and DM</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">after starting TAC compared with before. No serious adverse events ascribable to TAC occurred in any patients.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Conclusion: </strong>Additional use of TAC with PSL may safely promote improvement of PM/DM and also accelerate</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">tapering of the latter.</span>
</div>",,"/uploadfiles/file/20131219/20131219165858_7702.pdf",,12/19/2013,12/19/2013,"medicool",2,,"Dermatomyositis| Polymyositis| Tacrolimus",0,"66",115,"Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/ dermatomyositis: a retrospective study","2012",
741,,"10.1111/j.1365-2230.2011.04188.x","T. Hornung, A. Ko, T. Tu ¨ ting, T. Bieber & J. Wenzel",,"<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; &nbsp; A limited number of case series has indicated that methotrexate (MTX) might be a&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">useful drug in the treatment of dermatomyositis (DM), a rare autoimmune disease&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">involving the skin and muscles. However, these earlier studies mainly focused on the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">ef?cacy of MTX on DM muscular symptoms. To analyse the ef?cacy of MTX on skin&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">lesions in DM, the records of 34 patients with DM seen between 2004 and 2009 were&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">retrospectively analysed, and the DM skin disease activity at different time points was&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">determined, with speci?c focus on cutaneous features using the validated Cutaneous&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Dermatomyositis Activity Index (CDASI) score. The lesional in?ammation was scored&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">in primary skin biopsies. Additionally, we performed a systematic review of the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">available literature. In our series, 11 patients with DM received MTX, and in 8 of them,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">MTX led to a signi?cant reduction of the DM skin lesions. CDASI scores decreased from&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">15.7 to 6.4 (P &lt; 0.01) within 2C3 months, supporting the effectiveness of MTX in skin&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">disease in DM. The lymphocytic in?ltrate in primary skin lesions of MTX responders&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">was signi?cantly more pronounced than that in nonresponders. These results indicate&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">that MTX might be an effective drug to treat the cutaneous symptoms of DM, as&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">measured by the validated CDASI. Interestingly, MTX responders histologically&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">presented a signi?cantly stronger lesional lymphocytic in?ammatory in?ltrate than&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">did nonresponders. These ?ndings suggest that the functional inhibition of lymphocyte&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">migration in the skin might be an important mechanism of MTX in the treatment of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">DM.</span> 
</div>",,"/uploadfiles/file/20131219/20131219170424_0620.pdf",,12/19/2013,12/19/2013,"medicool",2,,"methotrexate|  DM muscular symptoms | a systematic review",0,"66",115,"Ef?cacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions","2011",
743,"皮肌炎的发病机制：细胞因子和干扰素的作用","10.1007/s11926-011-0166-x","Lily Kao , Lorinda Chung & David F. Fiorentino","Curr Rheumatol Rep","<p class=""MsoNormal"" style=""text-align:justify;text-indent:15.75pt;"">
	<span style=""font-size:14px;font-family:'Times New Roman';"">Dermatomyositis is a
systemic autoimmune disease that primarily affects skeletal muscle, skin, and the
lungs. Dermatomyositis is characterized by autoantibodies, tissue inflammation,
parenchymal cell damage and death, and vasculopathy. This review focuses on
recent advances&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">regarding
the role of cytokines and interferon in the pathogenesis of the disease.
Evidence for the role of a particular cytokine is based on data showing </span><span style=""font-size:14px;font-family:'Times New Roman';"">dysregulated levels in tissue and/or blood; correlation with histopathologic or clinical
markers of disease activity; and, rarely, clinical efficacy of targeted
cytokine inhibitors. Many of the recent advances pertain to elucidation of the
role of interferons in both muscle and skin disease in dermatomyositis.
Although a great deal of progress has been made regarding the role of interferon
in the disease, many critical questions remain unanswered.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;"">&nbsp; &nbsp;皮肌炎是一种全身性自身免疫性疾病，主要影响骨骼肌、皮肤和肺部。皮肌炎以自身抗体、组织炎症、薄壁细胞损伤和死亡、以及血管病变为特征。本文主要讲述疾病的发病机制中关于细胞因子和干扰素作用的最新进展。特定细胞因子作用的证据是基于显示组织和/或血液失调水平的数据；与疾病活动相关的组织病理学或临床指标；以及罕见的以细胞因子抑制剂为目标的临床疗效。许多最新进展阐明了干扰素在皮肌炎相关的肌肉和皮肤疾病中的作用。虽然该疾病中有关干扰素的作用已经获得了很大的进展，但许多关键问题仍未解决。</span> 
</p>","/uploadfiles/image/20131219/20131219172124_1010w.jpg","/uploadfiles/file/20131219/20131219171440_3255.pdf",,12/19/2013,12/19/2013,"medicool",7,,"Dermatomyositis | Interferon | Cytokine | Interface dermatitis",0,"67",115,"Pathogenesis of Dermatomyositis: Role of Cytokines and Interferon","2011",
744,,"10.1007/s11926-011-0167-9","Michelle Batthish & Brian M. Feldman","Springer Science+Business Media","<p class=""MsoNormal"" style=""text-indent:15.75pt;"">
	<div style=""text-align:justify;"">
		<span style=""text-indent:15.75pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Juvenile dermatomyositis (JDM) is a rare, often&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;text-indent:15.75pt;"">chronic autoimmune disease with onset during childhood. It&nbsp;</span><span style=""text-indent:15.75pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">is characterized by weakness in proximal muscles and&nbsp;</span><span style=""text-indent:15.75pt;font-family:'Times New Roman';font-size:14px;line-height:1.5;"">pathognomonic skin rashes. Although the etiology remains&nbsp;</span><span style=""text-indent:15.75pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">unclear, it has been proposed that JDM is caused by a&nbsp;</span><span style=""text-indent:15.75pt;font-family:'Times New Roman';font-size:14px;line-height:1.5;"">vasculopathy within the muscle tissue and multiple other&nbsp;</span><span style=""text-indent:15.75pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">organ systems of genetically susceptible individuals, possi</span><span style=""text-indent:15.75pt;font-family:'Times New Roman';font-size:14px;line-height:1.5;"">bly in response to environmental triggers. The goals of&nbsp;</span><span style=""text-indent:15.75pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">treatment include control of the underlying inflammatory&nbsp;</span><span style=""text-indent:15.75pt;font-family:'Times New Roman';font-size:14px;line-height:1.5;"">myositis and prevention and/or treatment of complications&nbsp;</span><span style=""text-indent:15.75pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(eg, contractures and calcinosis). Delayed treatment may&nbsp;</span><span style=""text-indent:15.75pt;font-family:'Times New Roman';font-size:14px;line-height:1.5;"">lead to poorer outcome in terms of disease course and&nbsp;</span><span style=""text-indent:15.75pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">calcinosis. The course in JDM is variable. Monocyclic&nbsp;</span><span style=""text-indent:15.75pt;font-family:'Times New Roman';font-size:14px;line-height:1.5;"">disease occurs in about one third of patients. These patients&nbsp;</span><span style=""text-indent:15.75pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">have a good response to standard therapy. Early recognition&nbsp;</span><span style=""text-indent:15.75pt;font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and aggressive immunosuppressive treatment result in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;text-indent:15.75pt;"">improved prognosis.</span>
	</div>
</p>
<p class=""MsoNormal"">
	<br />
</p>",,"/uploadfiles/file/20131219/20131219172344_8912.pdf",,12/19/2013,12/19/2013,"medicool",6,,"Keywords Juvenile dermatomyositis | Epidemiology | Pathogenesis | Clinical features | Treatment . Outcome measures | Clinical course",0,"67",115,"Juvenile Dermatomyositis","2011",
745,,"10.1007/s00296-009-0890-y","Nikolay Tzaribachev , C. Well , J. Schedel & M. Horger","Rheumatol Int","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp; Juvenile Dermatomyositis (JDM) is a rare auto</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">immune disease in childhood. Distinction between muscle&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">inXammation and a residual state can be diYcult especially&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">under immunosuppressive therapy and in active disease&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">without correlating muscle enzyme tests or functional mus</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cle scores. Our goal is to demonstrate the beneWt of whole-</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">body magnetic resonance imaging (MRI) as a diagnostic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">modality in the detection and management of JDM. One&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">patient with JDM was monitored using clinical examina</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tion, muscle enzyme tests, muscle scores and whole-body&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">MRI. During immunosuppression, the patient presented&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">several times to our department without clear correlation&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">between clinical picture, muscle enzyme tests and muscle&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">scores. Whole-body MRI proved reliable in assessing the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">true state of the disease, thus providing invaluable informa</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tion in the management of the inXammatory myopathy.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">This is of utmost importance for the therapeutic optimiza</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tion in order to prevent further damage especially in&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">children with active but subclinical disease.</span>
</div>",,"/uploadfiles/file/20131219/20131219172728_8608.pdf",,12/19/2013,12/19/2013,"medicool",5,,"diagnostic tool | juvenile dermatomyositis | case report  | review",0,"67",115,"Whole-body MRI: a helpful diagnostic tool for juvenile  dermatomyositis case report and review of the literature","2009",
746,,"10.1007/s00296-009-1231-x","Matthew B. Carroll , Robert Holmes","Rheumatol Int","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;Since the 1980s, a host of autoimmune phe</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">nomena and rheumatologic illnesses have been linked to&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">infection with the human immunodeWciency virus (HIV).</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Given the broad eVects of this virus on both the humoral&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and cell-mediated arms of the immune system, illnesses&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">such as polymyositis and Reiter’s syndrome appear to be&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">more prevalent in HIV-infected individuals and occur in the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">absence of well-described predispositions. The activities of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">some rheumatologic illnesses exhibit an inverse relation</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">ship with the course of HIV infection, such as rheumatoid&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">arthritis, which becomes more quiescent with advancing&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">disease. Dermatomyositis is a rheumatologic illness that&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">very infrequently occurs and during our review of literature&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">only three other cases were reported. We present the case of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">a Caucasian male in his mid-20s who presented with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">acquired immunodeWciency syndrome and subsequently&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">developed dermatomyositis. In this review, we highlight&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the current relationship between HIV infection and autoim</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">munity, the possible ways HIV infection may foster an&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">environment favorable for the development of dermatomy</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">ositis, and review the previously reported cases of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">individuals with HIV infection who developed dermatomy</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">ositis. The complex issues of how to treat individuals with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">HIV and dermatomyositis is also discussed.</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span>
</div>
</span>",,"/uploadfiles/file/20131219/20131219173014_4083.pdf",,12/19/2013,12/19/2013,"medicool",6,,"Dermatomyositis | Human immunodeWciency  virus | AIDS ・ Immune reconstitution inXammatory syndrome",0,"67",115,"Dermatomyositis and HIV infection: case report and review  of the literature","2011",
749,"系统性硬化症",,"Dr Michael Hughes, Professor Ariane Herrick","British Journal of Hospital Medicine","<p class=""MsoNormal"" style=""text-align:justify;text-indent:15.75pt;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Systemic sclerosis,
often referred to as ‘scleroderma’, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">is a highly heterogeneous
connective tissue disease. Although uncommon, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">it affects many organ
systems and so is a major cause of morbidity and mortality in those affected. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">A
range of clinicians may be involved in the care of patients with systemic
sclerosis.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The
clinical spectrum of disease, including the significance of Raynaud’s
phenomenon and overlap with other autoimmune disorders, will be discussed.
Relevant investigations (including immunological tests), advances in treatment and
future </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">targeted molecular therapies will be explored. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">This article gives an overview for the general physician: </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">more
detailed discussions can be found in recent review articles cited below.</span>
</p>
<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; 系统性硬化症，通常也被称为“硬皮病”，是一种高度异质性结缔组织病。虽然不常见，但却影响很多器官系统，因此也是影响死亡率和发病率的主要原因。一些临床医生可能参与了系统性硬化症患者的护理。我们将讨论该疾病的临床表现，包括雷诺现象的意义以及与其他自身免疫性疾病的重叠。有关调查（包括免疫测试）将探索该疾病的治疗进展和未来的分子靶向疗法。本文为广大医生提供了一则概述：更详细的讨论将在下面引用的最近一篇综述文章中找到。</span>
</div>
</span>","/uploadfiles/image/20131220/20131220094349_4285w.jpg","/uploadfiles/file/20131220/20131220094414_3574.pdf",,12/20/2013,12/20/2013,"medicool",7,,"review, systemic sclerosis, molecular therapies",0,"67",114,"Systemic sclerosis","2012",
497,"接触性皮炎的实验模型：评估 Wistar大鼠经游离氯倍他索和纳米胶囊氯倍他索处理后的氧化概况","10.1179/1351000212Y.0000000024","Jeandre Augusto dos Santos Jaques, Jo?o Felipe Peres Rezer, Jader Betsch Ruchel , Viviane do Carmo Gon?alves Souza",,"<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Objective:</span><span style=""font-family:'Times New Roman';""> </span> 
</p>
<p class=""MsoNormal"" align=""left"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp;An
experimental animal model of contact dermatitis (CD) was used to investigate
the effects of free and nanoencapsulated clobetasol propionate on the skin and
on the oxidative profile of liver tissue.</span><span style=""font-family:'Times New Roman';font-size:14px;""></span><o:p></o:p>
</p>
<span style=""font-size:14px;""><span style=""font-family:'Times New Roman';""></span> 
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;line-height:1.5;"">目的：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;""><span style=""line-height:1.5;"">&nbsp; &nbsp;&nbsp;利用接触性皮炎（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">CD</span><span style=""line-height:1.5;"">）的实验动物模型研究游离氯倍他索丙酸酯和纳米胶囊氯倍他索丙酸酯对皮肤和肝组织的氧化概况。</span><br />
</span> 
</p>
<span style=""font-family:'Times New Roman';""></span></span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">Methods:</span><span style=""font-size:14px;""> 
<p class=""MsoNormal"" align=""left"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';""><span style=""line-height:1.5;"">&nbsp; &nbsp;Female Wistar rats were divided into six groups, each containing eight
rats. The first group, control(C), was sensitized with solid vaseline. Group 2,
(CD), was sensitized with 5% NiSO4. Groups 3 and 4 were sensitized with 5%
NiSO4 and treated with free (FC) and nanoencapsulated (NC) clobetasol (0.42
mg/g), respectively, daily for 5 days. Group 5 was treated with
nanoencapsulated clobetasol (0.42 mg/g) on days 1, 3, and 5 (C135) and group 6
received a hydrogel containing empty nanoparticles (NP) daily for 5 days.
Thiobarbituric acid reactive substances (TBARS), carbonyl levels, non-protein
sulfhydryl groups (NPSH) and catalase activity were measured in liver
homogenates.</span><br />
</span><span style=""font-family:SimSun;line-height:1.5;"">方法：</span><span style=""font-family:'Times New Roman';""><br />
</span> 
</p>
<p class=""MsoNormal"" align=""left"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;""><span style=""line-height:1.5;"">&nbsp; &nbsp;雌性</span><span style=""font-family:'Times New Roman';line-height:1.5;"">Wistar</span><span style=""line-height:1.5;"">大鼠被随机分为</span><span style=""font-family:'Times New Roman';line-height:1.5;"">6</span><span style=""line-height:1.5;"">组，每组含</span><span style=""font-family:'Times New Roman';line-height:1.5;"">8</span><span style=""line-height:1.5;"">只大鼠。第</span><span style=""font-family:'Times New Roman';line-height:1.5;"">1</span><span style=""line-height:1.5;"">组，对照组（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">C</span><span style=""line-height:1.5;"">），用固体凡士林采用</span><span style=""font-family:'Times New Roman';line-height:1.5;"">5％NiSO4</span><span style=""line-height:1.5;"">致敏，随后分别胶囊氯倍他索（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">NC</span><span style=""line-height:1.5;"">）（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">0.42mg/g</span><span style=""line-height:1.5;"">）用游离氯倍他索（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">FC</span><span style=""line-height:1.5;"">）（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">0.42mg/g</span><span style=""line-height:1.5;"">）和纳米致敏。第</span><span style=""font-family:'Times New Roman';line-height:1.5;"">2</span><span style=""line-height:1.5;"">组（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">CD</span><span style=""line-height:1.5;"">），用</span><span style=""font-family:'Times New Roman';line-height:1.5;"">5％NiSO4</span></span><span style=""font-family:SimSun;""><span style=""line-height:1.5;"">致敏。第3组和第4组均进行处理，为期5天。第5组在第1、3、5天（C135）用纳米胶囊氯倍他索（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">0.42 mg/g</span><span style=""line-height:1.5;"">）进行处理，第6组用含空白纳米粒子（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">NP</span><span style=""line-height:1.5;"">）的水凝胶处理</span><span style=""font-family:'Times New Roman';line-height:1.5;"">5</span><span style=""line-height:1.5;"">天。在肝匀浆中测量硫代巴比妥酸反应物（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">TBARS</span><span style=""line-height:1.5;"">）、羰基水平、非蛋白巯基团（</span><span style=""font-family:'Times New Roman';line-height:1.5;"">NPSH</span><span style=""line-height:1.5;"">）和过氧化氢酶的活性。</span><br />
</span> 
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';line-height:1.5;"">Results: </span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:Times New Roman;""><span style=""line-height:1.5;"">&nbsp; &nbsp; &nbsp;A significant increase was observed in the levels of TBARS, NPSH, and
catalase activity for the groups CD and NP.</span><br />
</span> 
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""line-height:1.5;"">结果：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp; &nbsp; 观察发现</span><span style=""font-family:'Times New Roman';line-height:1.5;"">CD</span><span style=""line-height:1.5;"">组和NP组中的TBARS、NPSH水平和过氧化氢酶活性显著增加。</span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';line-height:1.5;"">Discussion: </span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:Times New Roman;""><span style=""line-height:1.5;"">&nbsp; &nbsp;Our results suggest that both NiSO4 sensitization and NP administration
induced oxidation of cellular lipids and activated the antioxidant enzyme
catalase to protect from this damage. These results also indicated that daily
treatment with the free and nanoencapsulated clobetasol, as well as treatment
with the nanoencapsulated clobetasol every other day, were able to prevent
these redox alterations and protect against histological damage.</span><br />
</span> 
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">讨论：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">&nbsp; &nbsp;结果表明，NiSO4的致敏作用和NP的使用均可以诱导细胞脂质的氧化反应并激活抗氧化酶过氧化氢酶从而保护其免受损坏。这些结果还表明，每天用游离氯倍他索和氯倍他索纳米胶囊处理，以及隔天用氯倍他索纳米胶囊处理，都能够阻止这些氧化还原变化并保护其免受组织损伤。</span> 
</p>
</span><o:p></o:p>
<p>
	<br />
</p>
<p>
	<br />
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">&nbsp;</span> 
</p>
<o:p></o:p>
<p>
	<br />
</p>
<p>
	<br />
</p>
<br />
<o:p></o:p>
<p>
	<br />
</p>
<br />
<span style=""font-family:'Times New Roman';line-height:1.5;""></span><br />
<span style=""font-family:'Times New Roman';font-size:14px;""> </span> 
<p>
	<br />
</p>
<p class=""MsoNormal"" style=""text-align:left;"">
	<o:p></o:p>
</p>
<span style=""font-family:SimSun;line-height:1.5;""> 
<p class=""MsoNormal"">
	&nbsp;
</p>
</span>","/uploadfiles/image/20131129/20131129091637_2542w.gif","/uploadfiles/file/20131129/20131129093921_8198.pdf",,11/29/2013,11/29/2013,"medicool",26,,"Clobetasol|Contact dermatitis| Nanostructured | Oxidative stress",0,"65",103,"An experimental model of contact dermatitis: Evaluation of the oxidative profile of Wistar rats treated with free and nanoencapsulated clobetasol","2012",
500,,,"Sandra Lawton","art &science skin care focus","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; This article provides an overview of the issues involved in the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">assessment and management of patients presenting with contact&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">dermatitis. It describes the different types of contact dermatitis,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">outlines possible triggers and highlights treatment strategies</span> 
</div>",,"/uploadfiles/file/20131129/20131129102729_6656.pdf",,11/29/2013,11/29/2013,"medicool",10,,"Contact dermatitis| Dermatology| Patch testing|Skin disorders",0,"66",103,"Contact dermatitis: types, triggers and treatment strategies","2009",
517,"扁桃体周围脓肿和蜂窝织炎，以及它们与链球菌感染的阳性抗原检测试验之间的关系","10.3109/00365548.2010.490236","STEFAN RISBERG , PETER ENGFELDT  & SVANTE HUGOSSON","Scandinavian Journal of Infectious Diseases","<p class=""MsoNormal"" align=""center"" style=""text-align:center;"">
	<b><span style=""font-size:14px;line-height:2;"">Abstract </span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK3""></a><a name=""OLE_LINK2""></a><a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><span style=""font-size:14px;line-height:2;"">The microbiological cause of
peritonsillar abscess and the role of group A β-haemolytic Streptococcus (GAS)
are unclear. </span><a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span style=""font-size:14px;line-height:2;"">We
performed a retrospective study at the ear, nose and throat clinic (ENT) of ?rebro
University Hospital, Sweden, and included 376 events of peritonsillitis between
2002 and 2004. </span><a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><a name=""OLE_LINK29""></a><a name=""OLE_LINK28""></a><span style=""font-size:14px;line-height:2;"">We
determined if the patients had visited a primary health-care centre (PHCC)
within 30 days prior to inclusion. </span><a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><a name=""OLE_LINK31""></a><a name=""OLE_LINK30""></a><span style=""font-size:14px;line-height:2;"">The
results of the rapid antigen detection test for GAS (Strep A) </span><a name=""OLE_LINK33""></a><a name=""OLE_LINK32""></a><span style=""font-size:14px;line-height:2;"">taken
at the PHCC were compared with the occurrence of peritonsillar
abscess (PTA) and peritonsillar cellulitis (PTC). </span><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><a name=""OLE_LINK35""></a><a name=""OLE_LINK34""></a><span style=""font-size:14px;line-height:2;"">A
Strep A test was performed in 61% (229/376) of the events studied. </span><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span style=""font-size:14px;line-height:2;"">Strep
A was positive in 22% of PTA events and in 35% of PTC events ( p=0.036).</span><a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span style=""font-size:14px;line-height:2;""> Of 48,000 Strep A tests taken in primary healthcare, mainly for sore throat,
22% were positive. </span><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span style=""font-size:14px;line-height:2;"">We
examined the relationship between age, the incidence of PTA, and positive Strep
A tests. </span><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><a name=""OLE_LINK36""></a><span style=""font-size:14px;line-height:2;"">We also determined if
there was a monthly correlation between number of positive Strep A tests and
number of PTA events. </span><a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span style=""font-size:14px;line-height:2;"">We found no significant
correlations. In conclusion, </span><a name=""OLE_LINK38""></a><a name=""OLE_LINK37""></a><span style=""font-size:14px;line-height:2;"">our findings indicate that GAS does not play a
major role in the development of PTA/PTC.</span>
</p>
<p class=""MsoNormal"" align=""center"" style=""text-align:center;"">
	<b><span style=""font-size:14px;line-height:2;"">摘要</span></b><b></b>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp;&nbsp; 扁桃体周围脓肿的微生物病因和A群β-溶血性链球菌（GAS）的作用尚不清楚。我们在瑞典厄勒布鲁大学医院耳、鼻、喉诊所（ENT）进行了一项回顾性研究，纳入了2002年至2004年间376例扁桃体周炎患者。我们确定了患者是否在前30天去过初级卫生保健中心（PHCC）就诊。将在PHCC处采取的GAS（A型链球菌）快速抗原检测试验的结果与扁桃体周围脓肿（PTA）和扁桃体蜂窝织炎（PTC）中出现的进行比较。在61％(229/376)患者中进行A型链球菌检验研究。A型链球菌在22％的PTA和35％的PTC患者（P = 0.036）中呈阳性。在初级卫生保健中心进行的48,000例A型链球菌检测（主要针对咽喉肿痛）中，， </span><span style=""font-size:14px;line-height:2;"">22</span><span style=""font-size:14px;line-height:2;"">％的患者呈阳性。我们研究了年龄、PTA的发病率，以及A型链球菌测试呈阳性之间的关系。我们还确定了A型链球菌检测呈阳性的数量是否与PTA患者数量呈月月相关。我们发现没有显著的相关性。总之，研究结果表明，GAS不会对PTA/ PTC的病发起到关键的作用。</span>
</p>","/uploadfiles/image/20131204/20131204134112_6820w.jpg","/uploadfiles/file/20131204/20131204134132_8840.pdf",,12/04/2013,12/04/2013,"medicool",17,,,0,"65",106,"Peritonsillar abscess and cellulitis and their relation to a positive antigen detection test for streptococcal infection","2010",
518,,,"Lubing Zhu, MD, PhD, Dongyan Hu, MD, Qiang Wang, MD, Jun Hou, MD, and Ming Li, MD, PhD","The International Society of Dermatology","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Case report</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; A 77-year-old man was referred to us for three episodes&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">of an eruption in the last six months.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp;Six months ago,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">there were mildly pruritic plaques distributed throughout&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">the lateral aspect of the right thigh with vesicles and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">bullae&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">on&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">surface.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""></span><br />",,"/uploadfiles/file/20131204/20131204134414_0479.pdf",,12/04/2013,12/04/2013,"medicool",15,,,0,"65",106,"Diffuse polymorphic eosinophilic cellulitis in a patient with metallic alloy implants: a possible association?","2011",
498,"组胺H4受体拮抗剂与H1受体拮抗剂治疗小鼠过敏性接触性皮炎的优势","10.1111/j.1600-0625.2012.01559.x","Ayuko Matsushita , Masahiro Seike , Haruka Okawa , Yayoi Kadawaki  and Hiroshi Ohtsu",,"<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	&nbsp; <span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Histamine facilitates
development of eczematous lesions in chronic allergic contact dermatitis. In addition to the wellknown corticosteroid treatments, H1 receptor
(H1R) antagonists also have been used. This study observed effects of histamine
H4 receptor (H4R) antagonist usage with H1R antagonist in a murine chronic
allergic contact dermatitis model, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">developed by repeated percutaneous challenge to
the dorsal skin with 2,4,6-trinitro-1-chlorobenzene (TNCB). </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The
H1R antagonist olopatadine hydrochloride and/or the H4R antagonist JNJ7777120
was then administered. Combination therapy was more effective than&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">H1R
antagonist monotherapy. </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Serum IgE and levels of interleukin (IL)-4,
IL-5 and IL-6 (Th2 cytokines) in eczematous lesions decreased with combined
therapy. </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Combined therapy with H1R and H4R antagonists
counteracts the disadvantages of each as monotherapeutic agents and&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';""><span style=""font-size:14px;line-height:1.5;"">potentially represents a new strategy for the treatment of chronic allergic
contact dermatitis.</span><br />
</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:SimSun;""><span style=""font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp; 组胺可以促进慢性过敏性接触性皮炎湿疹样病变的产生。除了应用公认的皮质类固醇治疗以外，H1受体（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">H1R</span><span style=""font-size:14px;line-height:1.5;"">）拮抗剂也已经开始使用。本研究旨在观察使用组胺</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">H4</span><span style=""font-size:14px;line-height:1.5;"">受体（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">H4R</span><span style=""font-size:14px;line-height:1.5;"">）拮抗剂与H1R拮抗剂对小鼠慢性变应性接触性皮炎模型的影响，使用</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">2</span><span style=""font-size:14px;line-height:1.5;"">,</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">4</span><span style=""font-size:14px;line-height:1.5;"">,</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">6-</span><span style=""font-size:14px;line-height:1.5;"">三硝基</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">-1-</span><span style=""font-size:14px;line-height:1.5;"">氯苯（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">TNCB</span><span style=""font-size:14px;line-height:1.5;"">）对背部皮肤进行反复的经皮刺激。然后给予</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">H1R</span><span style=""font-size:14px;line-height:1.5;"">拮抗剂盐酸奥洛他定及（或）</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">H4R</span><span style=""font-size:14px;line-height:1.5;"">拮抗物</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">JNJ7777120</span><span style=""font-size:14px;line-height:1.5;"">。与H1R拮抗剂单药治疗相比联合治疗更有效。经过联合治疗在湿疹性病变中血清</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">IgE</span><span style=""font-size:14px;line-height:1.5;"">和白细胞介素（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">IL</span><span style=""font-size:14px;line-height:1.5;"">）</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">-4</span><span style=""font-size:14px;line-height:1.5;"">，白细胞介素</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">-5</span><span style=""font-size:14px;line-height:1.5;"">和白细胞介素</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">-6</span><span style=""font-size:14px;line-height:1.5;"">（</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Th2</span><span style=""font-size:14px;line-height:1.5;"">细胞因子）的水平降低。</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">H1R</span><span style=""font-size:14px;line-height:1.5;"">和</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">H4R</span><span style=""font-size:14px;line-height:1.5;"">拮抗剂的联合疗法中和了每种药物单一疗法的缺点，并可能为慢性过敏性接触性皮炎的治疗提供新的对策。</span></span> 
</p>
<span style=""font-family:SimSun;""></span> 
<p>
	<br />
</p>
<p class=""MsoNormal"" align=""left"">
	<o:p></o:p>
</p>","/uploadfiles/image/20131129/20131129101035_7263w.gif","/uploadfiles/file/20131129/20131129101050_9831.pdf",,11/29/2013,11/29/2013,"medicool",27,,"chronic allergic contact dermatitis | H1 receptor antagonist|
H4 receptor antagonist",0,"66",103,"Advantages of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis","2012",
523,,,"Tim Garrett,Yvonne Harbort, Mary Trebble and Toni Docherty","EMA","<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Objective.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; Cellulitis is a common presentation to the ED and a significant cause of hospitalization that&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">can be managed in hospital-in-the-home programmes. Current clinical-practice guidelines&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">recommend once or twice-daily i.v. antibiotics; however, there is an absence of data&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">describing the impact of these guidelines in real-world practice-based settings. This study&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">aims to describe the safety and effectiveness of home-based cellulitis treatment according&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">to an online treatment algorithm.</span><br />",,"/uploadfiles/file/20131204/20131204142337_4677.pdf",,12/04/2013,12/04/2013,"medicool",9,,,0,"66",106,"Once or twice-daily, algorithm-based intravenous cephazolin for home-based cellulitis treatmentemm_1553 383","2012",
526,,"10.1016/j.ajo.2013.01.031","NEELAM PUSHKER, LALIT KUMAR TEJWANI, MANDEEP S. BAJAJ, SAURBHI KHURANA, THIRUMURTHY VELPANDIAN, AND MAHESH CHANDRA","ELSEVIER INC.","<span style=""line-height:1.5;"">&nbsp; &nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> A cute orbital cellulitis attributable to bacterial infection is associated with diffuse&nbsp;</span></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">edema of the orbital tissues with infiltration&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">by inflammatory cells. It is a potentially sight- and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">life-threatening condition. Permanent visual loss has&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">been reported in 11% to 26% of cases.1C3This results&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">from panophthalmitis or compressive optic neuropathy&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">attributable to raised intraorbital pressure or toxic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">optic neuritis or due to exposure keratopathy following&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">proptosis.</span><br />",,"/uploadfiles/file/20131204/20131204143434_5408.pdf",,12/04/2013,12/04/2013,"medicool",9,,,0,"66",106,"Role of Oral Corticosteroids in Orbital Cellulitis","2013",
499,,"10.1111/j.1600-0536.2011.01896.x","Melisa Yi Zhi Lau, Melanie Claire Matheson, John Anthony Burgess","Occupational Dermatology Research and Education Centre","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Background</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span><span style=""line-height:1.5;"">&nbsp; &nbsp; Few studies have investigated how occupational contact dermatitis and&nbsp;</span><span style=""line-height:1.5;"">its severity affect patients’ quality of life (QoL).</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Objectives<br />
&nbsp; &nbsp;To investigate the impact of occupational contact dermatitis and its severity&nbsp;</span><span style=""line-height:1.5;"">on patients’ QoL, and to examine the association between different QoL measures.<br />
</span><span style=""line-height:1.5;"">Method<br />
&nbsp;&nbsp;Patientspreviouslydiagnosedwithoccupational contactdermatitis completed&nbsp;</span><span style=""line-height:1.5;"">the Short FormHealthSurvey (SF-36) andDermatology LifeQuality Index (DLQI).Disease&nbsp;</span><span style=""line-height:1.5;"">severity was rated both by the patient and by the physician.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Results<br />
&nbsp; &nbsp;Of a possible 725, a total of 119 patients (16.4%) were included in the study,&nbsp;</span><span style=""line-height:1.5;"">and, at follow-up, just over 21%had normal skin and 18.3%had progressed to persistent&nbsp;</span><span style=""line-height:1.5;"">dermatitis. The SF-36median physical component summary score was 52 [interquartile&nbsp;</span><span style=""line-height:1.5;"">range (IQR): 43C56] and the mental component summary median score was 51 (IQR:</span><span style=""line-height:1.5;"">44C57). The correlation between patient-rated and physician-rated disease severity&nbsp;</span><span style=""line-height:1.5;"">was moderate (r = 0.708, p&lt; 0.00001). The correlation between the disease severity&nbsp;</span><span style=""line-height:1.5;"">measures and DLQI was moderate, whereas the SF-36 correlated poorly with both the&nbsp;</span><span style=""line-height:1.5;"">DLQI and disease severitymeasures.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Conclusions<br />
&nbsp; &nbsp;&nbsp;QoL was generally reduced in this group of patients with occupational&nbsp;</span><span style=""line-height:1.5;"">contact dermatitis, with some correlation between severity and DLQI. The DLQI was&nbsp;</span><span style=""line-height:1.5;"">a more sensitive measurement of QoL than the SF-36 in this patient population.&nbsp;</span><span style=""line-height:1.5;"">Incorporating disease severity ratingwith aQoL questionnaire is valuable in occupational&nbsp;</span><span style=""line-height:1.5;"">contact dermatitis and is recommended.</span>
</div>
</span>",,"/uploadfiles/file/20131129/20131129101713_3554.pdf",,11/29/2013,11/29/2013,"medicool",12,,"allergic| dermatology life quality index| hand eczema|irritant| SF-36| skin
disease| worker.",0,"66",103,"Disease severity and quality of life in a follow-up study of patients with occupational contact dermatitis","2011",
502,,"10.1111/j.1398-9995.2009.02240.x","M. Seike, K. Furuya , M. Omura , K. Hamada-Watanabe , A. Matsushita & H. Ohtsu",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Background: <br />
&nbsp; &nbsp; The present study observed effects of the histamine H4 receptor on&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">chronic allergic contact dermatitis induced by repeated challenge in mice.</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Methods:<br />
&nbsp; &nbsp; &nbsp;Acute contact dermatitis was induced by single epicutaneous challenge of&nbsp;</span><span style=""line-height:1.5;"">2,4,6-trinitro-1-chlorobenzene (TNCB) to the ear. Chronic allergic contact dermatitis&nbsp;</span><span style=""line-height:1.5;"">was developed by repeated epicutaneous challenge using TNCB on the dorsal back&nbsp;</span><span style=""line-height:1.5;"">skin. H4 receptor antagonist JNJ7777120 was administered to wild-type mice, while&nbsp;</span><span style=""line-height:1.5;"">H4 receptor agonist 4-methylhistamine was administered to histidine decarboxylase&nbsp;</span><span style=""line-height:1.5;"">(HDC) ()/)) mice that synthesized no histamine.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Results: <br />
&nbsp; &nbsp;&nbsp;HDC ()/)) mice did not differ phenotypically from HDC (+/+) mice,&nbsp;</span><span style=""line-height:1.5;"">and H4 receptor antagonist/agonist did not have clinical effects in terms of acute&nbsp;</span><span style=""line-height:1.5;"">contact dermatitis reactions. H4 receptor antagonist ameliorated skin eczematous&nbsp;</span><span style=""line-height:1.5;"">lesions induced by repeated TNCB challenge in HDC (+/+) mice. On the contrary,&nbsp;</span><span style=""line-height:1.5;"">H4 receptor agonist exacerbated skin lesions exclusively in HDC ()/)) mice. Appli</span><span style=""line-height:1.5;"">cation of H4 receptor agonist induced migration of mast cells and eosinophils in&nbsp;</span><span style=""line-height:1.5;"">skin lesions, and H4 receptor antagonist suppressed these changes. H4 receptor was&nbsp;</span><span style=""line-height:1.5;"">immunohistochemically detected on mast cells in eczematous lesions. Levels of inter</span><span style=""line-height:1.5;"">leukin (IL)-4, -5, and -6 in lesions were decreased, whereas levels of interferon-c and&nbsp;</span><span style=""line-height:1.5;"">IL-12 were increased by H4 receptor antagonistic activity. Serum Immunoglobulin E&nbsp;</span><span style=""line-height:1.5;"">levels rapidly increased with repeated challenge, but decreased with H4 receptor&nbsp;</span><span style=""line-height:1.5;"">antagonist.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Conclusion: <br />
&nbsp; &nbsp; &nbsp;Because chronic allergic contact dermatitis is developed by H4 receptor&nbsp;</span><span style=""line-height:1.5;"">stimulation, H4 receptor antagonists might represent new candidate drugs for treat</span><span style=""line-height:1.5;"">ing chronic allergic contact dermatitis.</span> 
</div>
</span>",,"/uploadfiles/file/20131129/20131129104400_4390.pdf",,11/29/2013,11/29/2013,"medicool",20,,"chronic allergic contact dermatitis|cytokine,histamine| H4 receptor| mast cell.",0,"66",103,"Histamine H4 receptor antagonist ameliorates chronic allergic contact dermatitis induced by repeated challenge","2010",
503,"中老年人接触性皮炎一则文献综述","1175.O5ól/10/CX)06.O373/$49.95/0","Amy V. Prakash and Mark D.P. Davis","Prakash & Davis","<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; <span style=""line-height:1.5;font-size:14px;font-family:'Times New Roman';"">&nbsp;Contact dermatitis is a
significant health problem affecting the elderly. Impaired epidermal barrier
function and delayed cutaneous recovery after insult enhances susceptibility to
both irritants and allergens</span></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Exposure to more numerous
potential sensitizers and for greater durations influences the rate of allergic
contact dermatitis in this population. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Medical co-morbidities,
including stasis dermatitis and venous ulcérations, further exacerbate this
clinical picture. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">However, while these factors tend to increase
the degree of sensitization in the elderly, waning immunity can actually
decrease such a propensity.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">This
interplay of both intrinsic and extrinsic factors makes a generalization on</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;trends
for contact dermatitis in older adults challenging. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The
literature has varying reports on the overall incidence of allergic contact
dermatitis with advancing age. Nevertheless, it does clearly show that
sensitivity to topical medicaments increases with age. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Irritant
contact dermatitis studies are more consistent, with less reactivity (to
irritants) in older compared with younger skin. Diagnosis of both irritant
and allergic contact dermatitis is based on a thorough history, complete skin
examination, and comprehensive patch testing. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The mainstay of therapy
is avoidance of the offending chemical substances and the use of topical along
with systemic therapies, depending on the severity of the condition.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;""><span style=""font-family:SimSun;font-size:14px;"">接触性皮炎是影响老年人的一个重要健康问题。表皮屏障功能受损及皮肤恢复性缓慢，使其对刺激物和过敏原两者的敏感度增加。接触到更多暴露的潜在致敏物，且长时间持续影响将影响到这部分患过敏性接触性皮炎人群的比例。医疗共病，包括淤积性皮炎、静脉溃疡等医学并发症，将进一步加剧这种临床表现。然而，尽管这些因素往往会增加中老年人的过敏程度、但实际上减弱免疫力可以减少这种倾向。在内外因素的相互作用下，这是对老年人接触性皮炎挑战性泛化趋势的一个概括。文献已报告了随着年龄增长过敏性接触性皮炎的总发病率的报告。不过，这也清楚地显示，外用药物敏感性随着年龄的增加而增加。与刺激性接触性皮炎的研究较一致，中老年皮肤与年轻皮肤相比较只需用更少的反应性（刺激物）。无论是刺激性还是过敏性接触性皮炎，完成皮肤检查和全面的斑贴测试的诊断依据是在一个完整的病史中进行的。治疗主要是避免使用有问题的化学物质，另外采用局部使用还是全身治疗，这取决于疾病的严重程度。</span></span> 
</p>","/uploadfiles/image/20131129/20131129113014_0458w.gif","/uploadfiles/file/20131129/20131129113029_5679.pdf",,11/29/2013,11/29/2013,"medicool",37,,"Older Adults|potential sensitizers |both intrinsic and extrinsic factors |he severity of the condition",0,"67",103,"Contact Dermatitis in Older Adults A Review of the Literature","2010",
504,,"10.1111/j.1600-0536.2012.02135.x","Juan Garc? ?a-Gav? ?n, Joana Parente and An Goossens",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Background<br />
&nbsp; &nbsp;Sul?tes, preservatives and antioxidants used in the cosmetic,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">pharmaceutical and food industry are contact allergens whose relevance seems to&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">be dif?cult to establish.</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Objectives<br />
&nbsp; &nbsp;To perform a retrospective study on patients patch tested with a sul?te.&nbsp;<br />
</span><span style=""line-height:1.5;"">Materials andmethods<br />
&nbsp; &nbsp; Between 1990 and 2010, 2763 patients were patch tested&nbsp;</span><span style=""line-height:1.5;"">with sodium metabisul?te. The reactions were considered to be relevant if there was a&nbsp;</span><span style=""line-height:1.5;"">clear relationship between the dermatitis and sul?te exposure.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Results<br />
&nbsp; &nbsp;One hundred and twenty-four (4.5%) of 2763 patients patch tested positively&nbsp;</span><span style=""line-height:1.5;"">to sodium metabisul?te. The most frequent localizations of the lesions were the face&nbsp;</span><span style=""line-height:1.5;"">(40.3%) and the hands (24.2%). Six patients also reported systemic symptoms. Thirteen&nbsp;</span><span style=""line-height:1.5;"">cases (10.5%) were occupational, 10 of them presenting with hand eczema. Sodium&nbsp;</span><span style=""line-height:1.5;"">metabisul?te was the single allergen found in 76 cases (61.3%). The reactions were&nbsp;</span><span style=""line-height:1.5;"">considered to be relevant in 80 cases (64.5%), of which 11 were occupational.&nbsp;<br />
</span><span style=""line-height:1.5;"">Conclusions<br />
&nbsp; &nbsp;Allergic contact dermatitis caused by sul?tes is frequent and often&nbsp;</span><span style=""line-height:1.5;"">relevant. One should be aware of possible relevant sources of exposure, particularly in&nbsp;</span><span style=""line-height:1.5;"">occupational settings such as hairdressing and the food industry, and in pharmaceutical&nbsp;</span><span style=""line-height:1.5;"">and cosmetic products. Patch testing with sodium metabisul?te, which seems to be the&nbsp;</span><span style=""line-height:1.5;"">best indicator for sul?te contact allergy, is also useful in cases of immediate reactions to&nbsp;</span><span style=""line-height:1.5;"">sul?te-containing products.</span>
</div>
</span>",,"/uploadfiles/file/20131129/20131129113426_3919.pdf",,11/29/2013,11/29/2013,"medicool",25,,"allergic contact dermatitis| antioxidants| preservatives| sodium bisul?te|
sodium metabisul?te| sodium sul?te| sul?tes.",0,"67",103,"Allergic contact dermatitis caused by sodium metabisul?te: a challenging allergen. A case series and literature review","2012",
505,,"10.1111/j.1600-0536.2010.01860.x","Nikolaos G. Bonitsis, Athina Tatsioni , Konstantinos Bassioukas and John P. A. Ioannidis",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">Background<br />
&nbsp; Multiple studies have evaluated diverse allergens in paediatric popu</span><span style=""font-family:'Times New Roman';font-size:14px;"">lations. Consensus is still lacking on which allergens are most commonly implicated in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">allergic contact dermatitis.</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span>Objectives<br />
&nbsp; &nbsp; To evaluate the proportion of positive reactions for allergens tested in&nbsp;</span><span>children and to identify allergens with positive reactions in at least 1% of them.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span>Methods<br />
&nbsp; This was a systematic review of studies in PubMed (1966C2010)&nbsp;</span><span>investigating allergens in at least 100 enrolled children. Proportions of positive reactions&nbsp;</span><span>for each allergen were combined with random effects models across studies.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span>Results<br />
&nbsp; &nbsp; We included49 studieswith available data on 170 allergens. Each study tested&nbsp;</span><span>a median of two allergens. Among the 94 allergensevaluatedbyatleasttwostudies,58&nbsp;</span><span>had estimates of positive reactions of at least 1%by randomeffects calculations, and for 21&nbsp;</span><span>of themthe 95%con?dence interval ensured that the proportion of positive reactionswas&nbsp;</span><span>at least 1%. The top ?ve allergens tested by at least two studies included nickel sulfate,</span><span>ammonium persulfate, gold sodium thiosulfate, thimerosal, and toluene-2,5-diamine&nbsp;</span><span>(p-toluenediamine). For most allergens, the proportion of positive reactions was higher&nbsp;</span><span>in studies published after 1995 than in earlier studies (p = 0.0065).</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span>Conclusions<br />
&nbsp; Thismeta-analysis offers guidance onwhichallergens aremost prevalent&nbsp;</span><span>in the paediatric populationandshouldhave priorityfor inclusioninstandardizedallergen</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span>series.</span> 
</div>
</span>",,"/uploadfiles/file/20131129/20131129113858_6436.pdf",,11/29/2013,11/29/2013,"medicool",28,,"allergens|allergic contact dermatitis| children| meta-analysis| patch
testing",0,"67",103,"Allergens responsible for allergic contact dermatitis among children: a systematic review and meta-analysis","2011",
506,,"10.1111/j.1600-0536.2011.01963.x","Anne Birgitte Simonsen, Mette Deleuran, Jeanne Duus Johansen and Mette Sommerlund",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; <span style=""line-height:1.5;"">&nbsp;Allergic contact dermatitis (ACD) in children was previously considered to be a rare&nbsp;</span></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">occurrence. However, the growing number of case reports and cross-sectional studies&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">through the past three decades indicate that ACD is, in fact, a highly relevant diagnosis in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">children. Furthermore, the frequency of ACD in children seems to be increasing. In 1999,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">a review of the literature reported prevalence rates of 14.5C70% in selected paediatric&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">populations. The current paper reviews the studies on the prevalence of positive patch&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">test reactions and ACD in the paediatric population during the past decade, and provides&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">an overviewof themain ?ndings.We found reported sensitization rates of 26.6C95.6% in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">selected groups of children.The associated relevancewas51.7C100%.Themost common&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">allergens were nickel, cobalt, thimerosal, and fragrance. Tailored patch testing increases&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the rate of relevant patch test reactions. Children with atopic dermatitis are as frequently&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">sensitized as children with no history of atopic dermatitis, and there are no differences&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">associatedwith sex. Children and adults can be testedwith equal concentrations of patch&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">test allergens. Our ?ndingsmay support the notion that the prevalence ofACD in children&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">is increasing over time or indicate an increased awareness.</span> 
</div>",,"/uploadfiles/file/20131129/20131129114642_4792.pdf",,11/29/2013,11/29/2013,"medicool",25,,"allergic contact dermatitis| children|patch test | prevalence| selected",0,"67",103,"Contact allergy and allergic contact dermatitis in children C a review of current data","2011",
515,,"10.1007/s10165-011-0459-y","Makoto Hirao?Akihide Nampei?Kenrin Shi? Hideki Yoshikawa?Norihiro Nishimoto? Jun Hashimoto","Mod Rheumatol","<strong><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Abstract</span></strong><br />
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">&nbsp; &nbsp; Two cases of subcutaneous soft tissue infection&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">in 30 RA patients treated with tocilizumab are reported. In&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">both patients, local redness, swelling, and heat were&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">observed around the affected site. WBC spikes and such&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">local findings were suggested to be clinically useful for the&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">early detection of low-grade subcutaneous infection in RA&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">patients whose disease is tightly controlled with toc</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">ilizumab. Of note, the C-reactive protein (CRP) level and&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">temperature lacked clinical utility for such detection.</span><br />",,"/uploadfiles/file/20131204/20131204112711_6167.pdf",,12/04/2013,12/04/2013,"medicool",23,,,0,"85",106,"Diagnostic features of mild cellulitis phlegmon in patients with rheumatoid arthritis treated with tocilizumab: a report of two cases","2011",
520,,,,"ndian Journal of Dermatology, Venereology, and Leprology","<span style=""line-height:1.5;"">&nbsp; &nbsp; <span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">A 40?years?old man presented with recurrent, slightly&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">itchy, red?colored eruptions over trunk for 2 months.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">He had received multiple antibiotics for the eruptions&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">without any improvement. He denied history of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Raynaud’s phenomenon, dysphagia, fever, joint&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">pains, malaise, photosensitivity, oral ulcerations,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">weight loss and anorexia. He also denied any drug&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">intake, vaccinations, and arthropod bites. Physical&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">examination revealed multiple erythematous?tumid,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">non?tender, non?calor plaques over abdomen, back&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and proximal arms.</span><br />
</span><br />",,"/uploadfiles/file/20131204/20131204135452_7130.pdf",,12/04/2013,12/04/2013,"medicool",22,,,0,"65",106,"Idiopathic bullous eosinophilic  cellulitis (Wells syndrome)  responsive to topical tacrolimus  and antihistamine combination","2012",
516,,"10.1007/s00296-009-1281-0","Dulgeroglu Deniz?Umay Ebru?Bal Ajda? Tetik Menevse Gulsum?Tatlican Semih?Cakci Aytul","Rheumatol Int","<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Abstract</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">&nbsp; &nbsp; Tumor necrosis factor-alpha (TNF-a) antago</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">nists are employed increasingly during recent years in&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">patients with active rheumatoid arthritis who do not&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">respond to disease-modifying anti-rheumatic drugs. Con</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">traindications such as infections, auto-antibody formation&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">and hypersensitive reactions can be observed during the&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">treatment with TNF-a antagonist drugs. Our case was a&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">52-year-old woman, followed by several centers for a&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">period of 21 years with a seropositive, erosive and nodular&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">RA diagnosis. Anti TNF-a treatment was commenced due&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">to the failure to control the disease. During the treatment, a&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">serious cellulite developed, which required hospitalization&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">and surgical debridement as well as intravenous antibiotics&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">treatment. Through the present case, we aimed to draw&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">attention to the skin infection during the use of etanercept&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">in a patient with RA.</span><br />",,"/uploadfiles/file/20131204/20131204112929_8953.pdf",,12/04/2013,12/04/2013,"medicool",23,,,0,"85",106,"A case of cellulitis causing tissue defect during etanercept therapy","2012",
522,"口服氟氯西林和青霉素与单独服用氟氯西林治疗急诊门诊蜂窝织炎疗效的比较：随机对照试验的研究方案",,"Michael Quirke, Abel Wakai, Peadar Gilligan and Ronan O’Sullivan","BioMed Central","<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Abstract</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">概要</span></b><b></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Background.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><a name=""OLE_LINK36""></a><a name=""OLE_LINK35""></a><span style=""font-size:14px;line-height:2;"">Oral flucloxacillin, either alone
or in combination with phenoxymethylpenicillin, is a commonly prescribed
antibiotic for the treatment of cellulitis, particularly in Ireland and the United
Kingdom. </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><a name=""OLE_LINK37""></a><span style=""font-size:14px;line-height:2;"">This study aims to establish the non-inferiority
of oral monotherapy (flucloxacillin alone) to dual therapy (flucloxacillin and phenoxymethylpenicillin)
for the outpatient treatment of cellulitis in adults.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">背景：</span></b><b></b> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp;&nbsp; 口服氟氯西林，无论是单独服用或与青霉素联合使用，都是治疗蜂窝织炎常用的抗生素处方，尤其是在爱尔兰和英国。本文旨在对门诊处治疗的成人蜂窝组织炎患者，建立口服单药治疗（单独服用氟氯西林）与联合疗法（氟氯西林和青霉素）之间的非劣效性研究。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Methods/design. </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><a name=""OLE_LINK39""></a><a name=""OLE_LINK38""></a><span style=""font-size:14px;line-height:2;"">This study is a multicentre, randomised,
double-blind, placebo-controlled trial of adults who present to the emergency
department (ED) with cellulitis that is deemed
treatable on an outpatient basis with oral antibiotics. </span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><a name=""OLE_LINK41""></a><a name=""OLE_LINK40""></a><span style=""font-size:14px;line-height:2;"">After
fulfilling specified inclusion and exclusion criteria, informed consent will be
taken. </span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span style=""font-size:14px;line-height:2;"">Patients will be given
a treatment pack containing 7 days of treatment with flucloxacillin 500 mg four
times daily and placebo or flucloxacillin 500 mg four times daily and
phenoxymethylpenicillin 500 mg four times daily. </span><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><a name=""OLE_LINK45""></a><a name=""OLE_LINK44""></a><span style=""font-size:14px;line-height:2;"">The
primary outcome measure under study is the proportion of patients in each group
in which there is greater than or equal to a 50% reduction in the area of
diameter of infection from the area measured at enrolment at the
end-of-treatment visit (7 to 10 days).</span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><a name=""OLE_LINK47""></a><a name=""OLE_LINK46""></a><span style=""font-size:14px;line-height:2;""> Secondary endpoints include </span><a name=""OLE_LINK52""></a><a name=""OLE_LINK51""></a><span style=""font-size:14px;line-height:2;"">a health-related quality of life measurement as
rated by the SF-36 score and </span><a name=""OLE_LINK54""></a><a name=""OLE_LINK53""></a><span style=""font-size:14px;line-height:2;"">the Extremity Soft
Tissue Infection Score (</span><a name=""OLE_LINK56""></a><a name=""OLE_LINK55""></a><span style=""font-size:14px;line-height:2;"">not validated), </span><a name=""OLE_LINK58""></a><a name=""OLE_LINK57""></a><span style=""font-size:14px;line-height:2;"">compliance and adverse
events.</span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a> <a name=""OLE_LINK60""></a><a name=""OLE_LINK59""></a><span style=""font-size:14px;line-height:2;"">Patients
will be followed up by telephone call at 3 days, end-of-treatment visit (EOT)
at 7 to 10 days and test-of-cure (TOC) visit at 30 days. </span><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span style=""font-size:14px;line-height:2;"">To
achieve 90% power, a sample size of 172 patients per treatment arm is needed.</span><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a> <a name=""OLE_LINK62""></a><a name=""OLE_LINK61""></a><span style=""font-size:14px;line-height:2;"">This assumes a
treatment success rate of 85% with oral flucloxacillin and phenoxymethylpenicillin,
an equivalence threshold Δ = 12.5% and an</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">α
= 0.025. </span><a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><a name=""OLE_LINK64""></a><a name=""OLE_LINK63""></a><span style=""font-size:14px;line-height:2;"">Non-inferiority
will be assessed using a one-sided confidence interval on the difference of
proportions between the two groups. </span><a name=""OLE_LINK65""></a><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span style=""font-size:14px;line-height:2;"">Standard
analysis including per-protocol and </span><a name=""OLE_LINK67""></a><a name=""OLE_LINK66""></a><span style=""font-size:14px;line-height:2;"">intention-to-treat will
be performed.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">方法</span></b><b><span style=""font-size:14px;line-height:2;"">/</span></b><b><span style=""font-size:14px;line-height:2;"">设计：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:14px;line-height:2;"">本文对曾经在门诊处口服抗生素治疗现转诊到急诊处的蜂窝织炎成年患者进行了一项多中心、随机的、双盲对照试验。在完成规定的入选和排除标准后，发放患者知情同意书。患者将被给予氟氯西林（500mg/次，4次/天，共7天），安慰剂或氟氯西林（500mg/次，4次/天），和青霉素（500mg/次，4次/天）进行治疗。主要研究结果依据各组患者的比例哪一组大于或等于在感染区域上减少了50%（观察治疗结束时登记人数的测量区域）。次要结果包括通过SF-36得分评定的健康相关的生活质量、下肢软组织感染评分（未经验证）、合规性以及不良反应。患者将在第3天进行电话随访，在治疗结束后（EOT）第7?10天随访，第30天进行治愈测试的（TOC）随访。为了获得90％的治愈率，需要对172名治疗组样本进行研究。综上所述，我们可以近似得出：口服氟氯西林和青霉素联合治疗的成功率是85％，等值的阈值是Δ=12.5％和α=0.025。非劣效性的评估将采用（在两组之间比例差异基础上的）单侧置信区间的方法。使用两组之间比例差异的单侧置信区间评估非劣效性。将要进行标准分析包括合方案集和意向性治疗。<br />
</span> 
</p>
<div style=""white-space:nowrap;"">
	<b style=""line-height:1.5;""><span style=""font-size:14px;line-height:2;"">Discussion.</span></b>
</div>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span style=""font-size:14px;line-height:2;"">This trial aims to
establish the non-inferiority of flucloxacillin monotherapy to dual therapy in
the treatment of </span><a name=""OLE_LINK69""></a><a name=""OLE_LINK68""></a><span style=""font-size:14px;line-height:2;"">uncomplicated
cellulitis among ED patients. </span><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span style=""font-size:14px;line-height:2;"">In
doing so,</span><a name=""OLE_LINK73""></a><a name=""OLE_LINK72""></a> <a name=""OLE_LINK75""></a><a name=""OLE_LINK74""></a><span style=""font-size:14px;line-height:2;"">t</span><a name=""OLE_LINK71""></a><a name=""OLE_LINK70""></a><span style=""font-size:14px;line-height:2;"">his trial will bridge a
knowledge gap in this understudied and common condition and will
be relevant to clinicians across several different disciplines.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">讨论：</span></b><b></b> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp;&nbsp; 本试验旨在对急诊科处治疗的简单蜂窝组织炎患者，建立氟氯西林单药治疗与联合疗法之间的非劣效性研究。。与此同时，该试验将弥补深入研究与常见疾病相关知识方面的缺口，并与一些不同学科的临床医生有关。</span> 
</p>","/uploadfiles/image/20131204/20131204141740_8354w.jpg","/uploadfiles/file/20131204/20131204141720_8206.pdf",,12/04/2013,12/12/2013,"medicool",10,,,0,"66",106,"Oral flucloxacillin and phenoxymethylpenicillin versus flucloxacillin alone for the emergency department outpatient treatment of cellulitis study protocol for a randomised controlled trial","2013",
536,,"10.1111/j.1464-5491.2009.02722.x","I. R. Bristow and M. C. Spruce","DIABETIC Medicine","<strong><span style=""font-size:14px;font-family:'Times New Roman';"">Aims.</span></strong><br />
<span style=""font-size:14px;font-family:'Times New Roman';"">&nbsp; &nbsp; To review the current evidence for the presence of fungal foot infection (tinea pedis and toenail onychomycosis) as a risk</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">factor for the development of cellulitis within the lower limb, particularly for those individuals with diabetes.</span><br />",,"/uploadfiles/file/20131204/20131204145455_5082.pdf",,12/04/2013,12/04/2013,"medicool",20,,,0,"67",106,"Fungal foot infection, cellulitis and diabetes: a review","2009",
519,,"10.2340/00015555-1499","Sumangali Chandra Prasad and Anette Bygum","Ada Derm Venereo","&nbsp; &nbsp; <span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Keratitis-ichthyosis-deafness (KID) syndrome is a con</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">genital disorder, which is associated with mutations in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">the GJB2 gene encoding connexin 26 or in the closely&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">related connexin 30 gene, GJB6. To date, approximately&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">100 cases have been described, mainly sporadic, but auto</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">somal dominant inheritance has been reported in a small&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">number of families. The syndrome is characterized by&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">profound sensorineural hearing loss accompanied by vas</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">cularizing keratitis and erythrokeratoderma-like skin le</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">sions. Palmoplantar hyperkeratosis, alopecia, dystrophic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">nails, and increased susceptibility to bacterial, viral and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">fungal infections and squamous cell carcinoma are other&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">common features of this syndrome (1,2). Treatment of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">patients with KID syndrome is difficult and often disap</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">pointing. Systemic retinoids, acitretin or isotretinoin have&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">been used in patients with KID syndrome with variable&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">success (3-6). We report here a case of KID syndrome&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">where dissecting cellulitis of the scalp was treated suc</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">cessfully with alitretinoin.</span><br />",,"/uploadfiles/file/20131204/20131204134747_4251.pdf",,12/04/2013,12/04/2013,"medicool",13,,,0,"65",106,"Successful Treatment with Alitretinoin of Dissecting Cellulitis of the Scalp in Keratitis-Ichthyosis- Deafness Syndrome","2013",
559,,"10.1186/1471-2407-13-58","Liesbeth Hameetman,Suzan Commandeur,Jan Nico Bouwes Bavinck,Hermina C Wisgerhof,Frank R de Gruijl,Rein Willemze,Leon Mullenders,Cornelis P Tensen,and Harry Vrieling","Department of Dermatology","<span style=""font-family:'Times New Roman';font-size:16px;""><strong>Abstract.</strong></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong><br />
</strong></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Background</strong>: The risk of developing cutaneous squamous cell carcinoma (SCC) is markedly increased in organ</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">transplant recipients (OTRs) compared to the normal population. Next to sun exposure, the immunosuppressive</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">regimen is an important risk factor for the development of SCC in OTRs. Various gene mutations (e.g. TP53) and</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">genetic alterations (e.g. loss of CDKN2A, amplification of RAS) have been found in SCCs. The aim of this</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">genome-wide study was to identify pathways and genomic alterations that are consistently involved in the</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">formation of SCCs and their precursor lesions, actinic keratoses (AKs).</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Methods</strong>: To perform the analysis in an isogenic background, RNA and DNA were isolated from SCC, AK and</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">normal (unexposed) epidermis (NS) from each of 13 OTRs. Samples were subjected to genome-wide expression</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">analysis and genome SNP analysis using Illumina’s HumanWG-6 BeadChips and Infinium II HumanHap550</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Genotyping BeadChips, respectively. mRNA expression results were verified by quantitative PCR.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Results</strong>: Hierarchical cluster analysis of mRNA expression profiles showed SCC, AK and NS samples to separate into</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">three distinct groups. Several thousand genes were differentially expressed between epidermis, AK and SCC; most</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">upregulated in SCCs were hyperproliferation related genes and stress markers, such as keratin 6 (KRT6), KRT16 and</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">KRT17. Matching to oncogenic pathways revealed activation of downstream targets of RAS and cMYC in SCCs and</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">of NFκB and TNF already in AKs. In contrast to what has been reported previously, genome-wide SNP analysis</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">showed very few copy number variations in AKs and SCCs, and these variations had no apparent relationship with</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">observed changes in mRNA expression profiles.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Conclusion</strong>: Vast differences in gene expression profiles exist between SCC, AK and NS from immunosuppressed</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">OTRs. Moreover, several pathways activated in SCCs were already activated in AKs, confirming the assumption that</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">AKs are the precursor lesions of SCCs. Since the drastic changes in gene expression appeared unlinked to specific</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">genomic gains or losses, the causal events driving SCC development require further investigation. Other molecular</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">mechanisms, such as DNA methylation or miRNA alterations, may affect gene expression in SCCs of OTRs. Further</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">study is required to identify the mechanisms of early activation of NFκB and TNF, and to establish whether these</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">pathways offer a feasible target for preventive intervention among OTRs.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Keywords</strong>: Cutaneous squamous cell carcinoma, Non-melanoma skin cancer, Actinic keratosis, Organ transplant</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">recipient, Gene expression, Genomic profiling</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""></span><br />",,"/uploadfiles/file/20131205/20131205091221_7574.pdf",,12/05/2013,12/06/2013,"medicool",11,,"Cutaneous squamous cell carcinoma, Non-melanoma skin cancer, Actinic keratosis, Organ transplant,recipient, Gene expression, Genomic profiling",0,"66",104,"Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients","2013",
521,,,"Carlo Tascini, MD, Enrico Tagliaferri, MD, Gian M. Rossolini, UP, Elisabetta Mantengoli, UP, Gianfranco Mirarchi, MD, Alessandro Leonildi, Res Biol, Marina Polidori, MD, and Francesco Menichetti, CMD","The International Society of Dermatology","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Introduction</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; PantonCValentine leukocidin (PVL) is a pore-forming cyto</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">toxin produced by Staphylococcus aureus inducing leuko</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">cyte destruction and tissue necrosis.1Although produced&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">by &lt;5% of S. aureus strains, the toxin is detected in large&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">percentages of isolates that cause necrotic skin lesions2C8&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and severe necrotizing pneumonia.2,4Although commonly&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">associated with community-acquired methicillin-resistant&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">S. aureus (CA-MRSA),9several outbreaks caused by meth</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">icillin-susceptible strains have also been reported.</span><br />",,"/uploadfiles/file/20131204/20131204135708_7297.pdf",,12/04/2013,12/04/2013,"medicool",21,,,0,"65",106,"Cellulitis caused by a methicillin-sensitive Staphylococcus aureus isolate harboring Panton-Valentine toxin in an American soldier returning from Iraq ","2011",
555,,"10.1111/j.1525-1470.2011.01315.x","Segna KG, Koch LH , Williams JV","Wiley Country of Publication","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; &nbsp;Pseudomonas aeruginosa is common&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">cause of folliculitis following contact with contaminated&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">water. We report a case of pseudomonal folliculitis that&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">occurred after swimming in a children’s pool ?lled with&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">water from a well.</span>
</div>",,"/uploadfiles/file/20131204/20131204164534_9266.pdf",,12/04/2013,12/04/2013,"medicool",22,,"Pseudomonas aeruginosa|pseudomonal folliculitis|children’s pool",0,"85",105,"“Hot tub”folliculitis from a nonchlorinated children’s pool","2011",
524,,,"Laura KUZNETSOV, Christina M. REITMAIER-WEBER^ Thomas RUZICKA^ and Alexander V. KUZNETSOV""","Acta Derm Venereol","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There has been little research into awareness of human </span><span style=""font-family:Times New Roman;font-size:16px;"">papillomavirus (HPV) among dermatological outpatients, </span><span style=""font-family:Times New Roman;font-size:16px;"">despite the fact that management of HPV infection </span><span style=""font-family:Times New Roman;font-size:16px;"">causing genttoanal warts/cancer is part of the </span><span style=""font-family:Times New Roman;font-size:16px;"">routine practice of dermato-venereologists. The aim </span><span style=""font-family:Times New Roman;font-size:16px;"">of this study was to explore awareness of HPV among </span><span style=""font-family:Times New Roman;font-size:16px;"">dermatological outpatients. A self-administered questionnaire </span><span style=""font-family:Times New Roman;font-size:16px;"">was distributed to 360 consecutive attendees </span><span style=""font-family:Times New Roman;font-size:16px;"">of a Munich dermatological outpatient clinic in November </span><span style=""font-family:Times New Roman;font-size:16px;"">2009. Of the total number of questionnaires, 77.2% </span><span style=""font-family:Times New Roman;font-size:16px;"">were returned, and 69.7% (?=251, 51.8% females) were </span><span style=""font-family:Times New Roman;font-size:16px;"">included in the analysis. 39.4% of the respondents had </span><span style=""font-family:Times New Roman;font-size:16px;"">heard of HPV infection, and 23.9% of vaccination. Of </span><span style=""font-family:Times New Roman;font-size:16px;"">those who had heard of HPV, 81.8% knew that HPV risk </span><span style=""font-family:Times New Roman;font-size:16px;"">is associated with non-use of condoms, number of sexual </span><span style=""font-family:Times New Roman;font-size:16px;"">partners (77.8%), smoking (8.1%), and that HPV causes </span><span style=""font-family:Times New Roman;font-size:16px;"">genital warts (65.7%), anal warts (39.4%) and cervical </span><span style=""font-family:Times New Roman;font-size:16px;"">cancer (57.6%). HPV ignorance (never having heard of </span><span style=""font-family:Times New Roman;font-size:16px;"">HPV) was predicted by being male (adjusted odds ratio= </span><span style=""font-family:Times New Roman;font-size:16px;"">2.23,95% confidence interval= 1.32-3.80) and being </span><span style=""font-family:Times New Roman;font-size:16px;"">a parent (adjusted odds ratio=2.11, 95% confidence interval </span><span style=""font-family:Times New Roman;font-size:16px;"">=1.24-3.59). We conclude that dermatological outpatients </span><span style=""font-family:Times New Roman;font-size:16px;"">have insufficient knowledge of HPV, its sequelae </span><span style=""font-family:Times New Roman;font-size:16px;"">and prevention.</span> 
</p>",,"/uploadfiles/file/20131204/20131204142609_3651.pdf",,12/04/2013,12/04/2013,"medicool",9,,"human papillomavirus; genitoanal region; cancer; warts; dermatology outpatients;knowledge.",0,"66",107,"Awareness of Human Papillomavims Infection, Genitoanal Warts and Cancer in a Dermatological Outpatient Clinic Setting","2013",
525,"Prevalence of Anogenital Warts Among Participants in Private Health Plans in the United States, 2003C2010: Potential Impact of Human Papillomavirus Vaccination","0.2105/AJPH.2012.301182","Elaine W. Flagg, PhD, MS, Robert Schwartz, BS, and Hillard Weinstock, MD, MPH","American Journal of Public Health","<p align=""justify"">
	<span style=""font-size:16px;""><span style=""font-family:Times New Roman;"">Objectives. </span><br />
<span style=""font-family:Times New Roman;""></span><span style=""font-family:Times New Roman;"">We estimated anogenital wart prevalence from 2003 to 2010 by </span></span><span style=""font-family:Times New Roman;font-size:16px;"">gender and age group in a large US cohort with private insurance to detect </span><span style=""font-family:Times New Roman;font-size:16px;"">potential decreases among people most likely to be affected by human </span><span style=""font-family:Times New Roman;font-size:16px;"">papillomavirus (HPV) vaccination.</span><br />
<span style=""font-size:16px;""><span style=""font-family:Times New Roman;"">Methods. </span><br />
<span style=""font-family:Times New Roman;""></span><span style=""font-family:Times New Roman;"">We restricted health care claims to those from individuals aged 10 to </span></span><span style=""font-family:Times New Roman;font-size:16px;"">39 yearswith continuous insurance within a given year.We derived anogenital wart </span><span style=""font-family:Times New Roman;font-size:16px;"">diagnoses from a diagnosis of condyloma acuminata, or either a less specific viral </span><span style=""font-family:Times New Roman;font-size:16px;"">wart diagnosis or genital wart medication combined with either a benign anogenital </span><span style=""font-family:Times New Roman;font-size:16px;"">neoplasm or destruction or excision of a noncervical anogenital lesion.</span><br />
<span style=""font-size:16px;""><span style=""font-family:Times New Roman;"">Results. </span><br />
<span style=""font-family:Times New Roman;""></span><span style=""font-family:Times New Roman;"">Prevalence increased slightly in 2003 to 2006, then significantly </span></span><span style=""font-family:Times New Roman;font-size:16px;"">declined in 2007 to 2010 among girls aged 15 to 19 years; increased in 2003 to </span><span style=""font-family:Times New Roman;font-size:16px;"">2007, remained level through 2009, and declined in 2010 among women aged 20 </span><span style=""font-family:Times New Roman;font-size:16px;"">to 24 years; and increased through 2009 but not in 2010 for women aged 25 to 39 </span><span style=""font-family:Times New Roman;font-size:16px;"">years. For males aged 15 to 39 years, prevalence for each 5-year age group </span><span style=""font-family:Times New Roman;font-size:16px;"">increased in 2003 to 2009, but no increases were observed for 2010.</span><br />
<span style=""font-size:16px;""><span style=""font-family:Times New Roman;"">Conclusions. </span><br />
<span style=""font-family:Times New Roman;""></span><span style=""font-family:Times New Roman;"">These data indicate reductions in anogenital warts among US </span></span><span style=""font-family:Times New Roman;font-size:16px;"">females aged 15 to 24 years, the age group most likely to be affected by </span><span style=""font-family:Times New Roman;font-size:16px;"">introduction of the HPV vaccine.</span> 
</p>",,"/uploadfiles/file/20131204/20131204143522_0429.pdf",,12/04/2013,12/04/2013,"medicool",10,,,0,"66",107,,"2013",
527,,"10.1007/s00228-012-1240-7","Matthew S. Davies & Munro B. Robertson & Stewart H. A. Brown & Bethan Saunders & W. Stephen Waring","Eur J Clin Pharmacol","<strong><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Abstract.</span></strong><br />
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">&nbsp; &nbsp; Purpose Clinical guidelines concerning treatment of infec</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">tion are incorporated into prescribing formularies and anti</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">microbial stewardship policies. The extent to which these&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">influence prescribing is uncertain. In this study, we sought&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">to examine antimicrobial prescribing patterns in patients&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">with cellulitis.</span><br />",,"/uploadfiles/file/20131204/20131204143804_3456.pdf",,12/04/2013,12/04/2013,"medicool",10,,,0,"66",106,"Variability of antimicrobial prescribing in patients with acute cellulitis","2012",
566,,"10.1111/j.1745-7599.2011.00686.x","Christopher Englert, NP-MS (Nurse Practitioner/Owner Englert Dermatology),& Brittney Hughes, MPAS, PA-C (Physician Assistant)","Christopher Englert, NP-MS, North Baltimore Dermatology LLC","<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract.</strong></span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Purpose: To describe key points in the diagnosis and treatment of and patient</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">education for actinic keratosis.</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Data sources: Selected review of scientific literature.</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Conclusions: Actinic keratosis is a common skin lesion seen in primary care</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">that results from exposure to ultraviolet light. Accurate and timely diagnosis is</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">essential to prevent progression to squamous cell carcinoma.</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Implications for practice: Nurse practitioners can make a positive impact on</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">patients’ health by promoting treatment adherence and follow-up in primary</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">care.</span><br />
<br />",,"/uploadfiles/file/20131205/20131205094338_5655.pdf",,12/05/2013,12/06/2013,"medicool",20,,"Clinical practice guidelines; dermatology;,nurse practitioners; prevention",0,"67",104,"A review of actinic keratosis for the nurse practitioner: Diagnosis, treatment, and clinical pearls","2010",
528,,,"Claus ZACHARIAE', Carsten SAND^ Jesper MELCHIOR HANSEN^, Seren SCHWARTZ S0RENSEN\ Karen KOCH^ John","Acta Derm Venereol","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">There are no published clinical studies evaluating the impact </span><span style=""font-family:Times New Roman;font-size:16px;"">of warts on qualify of life after transplantation. The </span><span style=""font-family:Times New Roman;font-size:16px;"">aim of this study was to determine the frequency of selfreported </span><span style=""font-family:Times New Roman;font-size:16px;"">skin warts and skin cancer and their impact on </span><span style=""font-family:Times New Roman;font-size:16px;"">quality of life in kidney transplanted patients, as measured </span><span style=""font-family:Times New Roman;font-size:16px;"">with the Dermatology Life Quality Index (DLQI). Of </span><span style=""font-family:Times New Roman;font-size:16px;"">740 patients with a functioning renal allograft and were </span><span style=""font-family:Times New Roman;font-size:16px;"">free of dialysis who were surveyed, 568 returned the </span><span style=""font-family:Times New Roman;font-size:16px;"">questionnaires. Patients were asked about general health </span><span style=""font-family:Times New Roman;font-size:16px;"">issues, with a focus on transplantation history, cutaneous </span><span style=""font-family:Times New Roman;font-size:16px;"">warts and whether they had ever had cutaneous cancer. </span><span style=""font-family:Times New Roman;font-size:16px;"">A total of 285 (52%) patients replied that they had warts, </span><span style=""font-family:Times New Roman;font-size:16px;"">and these increased with time since last transplantation, </span><span style=""font-family:Times New Roman;font-size:16px;"">with a/7-value &lt; 0.0001. A total of 101 patients (18%) reported </span><span style=""font-family:Times New Roman;font-size:16px;"">that they had ever had skin cancer. The median </span><span style=""font-family:Times New Roman;font-size:16px;"">DLQI was 0 for patients not having warts, 1 for patient </span><span style=""font-family:Times New Roman;font-size:16px;"">with warts, and 2 for patients having warts and skin cancer. </span><span style=""font-family:Times New Roman;font-size:16px;"">In conclusion, renal transplant recipients experience </span><span style=""font-family:Times New Roman;font-size:16px;"">increasing numbers of warts and skin cancer over time, </span><span style=""font-family:Times New Roman;font-size:16px;"">and having skin cancer impairs patients' quality of life to </span><span style=""font-family:Times New Roman;font-size:16px;"">a greater degree than warts.</span>
</p>",,"/uploadfiles/file/20131204/20131204143824_8284.pdf",,12/04/2013,12/04/2013,"medicool",10,,"transplantation;warts; skin cancer; DLQI.",0,"66",107,"Warts in a Cohort of Danish Kidney Transplanted Patients: Impact on Quality of Life","2012",
529,,,,"BMJ","&nbsp; &nbsp;<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> In their clinical review of the management and&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">treatment of cellulitis Phoenix and colleagues&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">recommend different treatment on the basis of&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">streptococcal and staphylococcal infection.&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">However, clinically distinguishing between&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">streptococcal and staphylococcal cellulitis is&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">often impossible, so such recommendation&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">is not helpful in clinical practice.</span><br />",,"/uploadfiles/file/20131204/20131204144051_6871.pdf",,12/04/2013,12/04/2013,"medicool",18,,,0,"66",106,"Treat all cases of cellulitis with anti-staphylococcal antibiotics","2012",
530,,"10.1111/j.1524-4725.2011.02049.x","CHAD D. HOUSEWRIGHT, MD,ERICA RENSVOLD, BS,JAMES TIDWELL, MD,DENNIS LYNCH, MD,yAND DAVID F. BUTLER, MD, FAAD","DERMATOLOGIC SURGERY","&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; A 25-year-old African-American man presented&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">with a 3-year history of recurrent pustules,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">sinus tracts, and scarring of the scalp and sinus tract&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">formation in the axillae. He was diagnosed with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">dissecting cellulitis of the scalp an dhidradenitis&nbsp;</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">suppurativa.</span><br />",,"/uploadfiles/file/20131204/20131204144243_5549.pdf",,12/04/2013,12/04/2013,"medicool",21,,,0,"66",106,"Excisional Surgery (Scalpectomy) for Dissecting Cellulitis of the Scalp","2011",
570,"跖疣治疗中斑蝥素-足叶草毒素-水杨酸疗法VS冷冻疗法：一项随机前瞻性研究","10.1111/j.1468-3083.2011.04186.x","N. Kac? ar, L. Tas? l? , S. Korkmaz, S? Ergin, B.S? . Erdog an","Journal of the European Academy of Dermatology and Venereology","<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Backg</span><span style=""line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">round.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""></span></span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Plantar warts are refractory to any form of treatment. High cure rates
have been reported with a topical proprietary formulation consisting of 1%
cantharidin, 5% podophyllotoxin and 30% salicylic acid (CPS). However,
no data exists comparing the efficacy of this formulation with another
treatment. Cryotherapy is a method that is also widely used in the treatment of
plantar warts. Likewise, there is no evidence that it is more effective than
any topical treatment.</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">研究背景：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">采用任何形式的治疗都难以治愈跖疣。已有报道称采用一种含1％斑蝥素、5％足叶草毒素和30％的水杨酸（CPS）的外用专有制剂可以获得高治愈率。但是，目前还没有比较这种制剂与其他治疗方法疗效的的数据。冷冻疗法也是一种被广泛用于治疗跖疣的方法。同样，没有证据表明它比任何局部治疗更有效。<br />
</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Objective</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">We aim to compare the efficacy of topical CPS and
cryotherapy in the treatment of plantar warts.</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">研究目的：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">我们的目地是比较外用CPS和冷冻疗法治疗跖疣的疗效。<br />
</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Methods</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Patients with plantar warts were consecutively treated
with either cryotherapy or </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">topical CPS. Both treatments were performed every 2 weeks for up to
five sessions. In patients without complete clearance, the therapy was switched
to the other treatment option.</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">研究方法：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">跖疣患者采用冷冻疗法或外用CPS连续治疗。这两种治疗方法均持续五个疗程，每2周为1个疗程。在没有完全清除的患者身上，原先的疗法又被切换到其他治疗方法。<br />
</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Results</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Twenty-six patients with a total of 134 warts were
included. Fourteen patients were completely cleared of their warts with topical
CPS, whereas only in five of 12 patients (41.7%) warts were completely cleared
with cryotherapy (P = 0.001). In seven patients without complete clearance, the
therapy was switched to CPS. Four of these patients missed the follow-up. While
the two of the remaining three patients were cleared of their warts, one
patient’s warts still failed to clear.</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">研究结果：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">26位患者（共含134个疣）被纳入本项研究。采用CPS局部治疗的14例患者身上的疣被彻底清除，而采用冷冻治疗法的十二例患者中只有五例患者身上的疣（41.7％）被完全清除（P = 0.001）。7例未完全清除的患者，其治疗方法被切换到CPS。其中四位患者错过随访。而剩下三位患者中两位身上的疣被清除，另一位患者的疣仍未能清除。<br />
</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Conclusion</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Topical CPS is more effective
than cryotherapy in the treatment of plantar warts.</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">研究总结：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">对于跖疣的治疗，外用CPS比冷冻疗法更有效。</span><o:p></o:p>
</p>","/uploadfiles/image/20131205/20131205145445_0903w.jpg","/uploadfiles/file/20131205/20131205145507_3047.pdf",,12/05/2013,12/05/2013,"medicool",21,,"Plantar warts，either cryotherapy， topical CPS",0,"65",107,"CantharidinCpodophylotoxinCsalicylic acid versus cryotherapy in the treatment of plantar warts: a randomized prospective study","2011",
531,,,"Azizjalali M1,2, Ghaffarpour GH1*, Mousavifard B1","IRAN. J. MICROBIOL.","<p align=""justify"">
	<span style=""font-size:12px;""><span style=""font-family:Times New Roman;font-size:16px;"">Background and Objective: </span><br />
<span style=""font-family:Times New Roman;font-size:16px;""></span><span style=""font-family:Times New Roman;font-size:16px;"">Genital warts, due to specific types of the human papillomavirus, have long been regarded as </span></span><span style=""font-family:Times New Roman;font-size:16px;"">one of the most important causes of cervical cancer and one of the most common cause of Sexually Transmited Diseases </span><span style=""font-family:Times New Roman;font-size:16px;"">(STDs). Over the years, it has been the focus of several studies in order to find the best effective approach to eradicate </span><span style=""font-family:Times New Roman;font-size:16px;"">the virus, however there are still controversies regarding this matter. We compared efficacy of the two physical ablative </span><span style=""font-family:Times New Roman;font-size:16px;"">therapies; Liquid Nitrogen and CO2 laser.</span><br />
<span style=""font-size:12px;""><span style=""font-family:Times New Roman;font-size:16px;"">Material and Methods: O</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""></span><span style=""font-family:Times New Roman;font-size:16px;"">ne hundred and sixty patients, with external genital warts, were divided into two groups. Each </span></span><span style=""font-family:Times New Roman;font-size:16px;"">group consisted of 80 patients treated with CO2-laser or cryotherapy. Clearance and recurrence rates were evaluated for 3 </span><span style=""font-family:Times New Roman;font-size:16px;"">months.</span><br />
<span style=""font-size:12px;""><span style=""font-family:Times New Roman;font-size:16px;"">Results: </span><br />
<span style=""font-family:Times New Roman;font-size:16px;""></span><span style=""font-family:Times New Roman;font-size:16px;"">C</span><span style=""font-family:Times New Roman;font-size:16px;""></span><span style=""font-family:Times New Roman;font-size:16px;"">omplete clearance was achieved in 76 lesions (95%) treated by CO2-laser and 37 lesions (46.2%) treated by </span></span><span style=""font-family:Times New Roman;font-size:16px;"">cryotherapy which was significantly different (p &lt; 0.001). In the CO2-laser group, lesions required only one treatment to clear </span><span style=""font-family:Times New Roman;font-size:16px;"">while in the cryotherapy group, lesions required two (12%) even up to three (12.2%) treatments for some patients to clear </span><span style=""font-family:Times New Roman;font-size:16px;"">completely. Laser therapy was associated with less recurrence rate compared to cryotherapy (0.05% Vs 0.18%).</span><br />
<span style=""font-size:12px;""><span style=""font-family:Times New Roman;font-size:16px;"">Conclusion: </span><br />
<span style=""font-family:Times New Roman;font-size:16px;""></span><span style=""font-family:Times New Roman;font-size:16px;"">Generally, the efficacy of CO2 laser treatment of external genital warts was approximately two fold greater than </span></span><span style=""font-family:Times New Roman;font-size:16px;"">cryotherapy and it was associated with lower recurrence rate.</span> 
</p>",,"/uploadfiles/file/20131204/20131204144418_6371.pdf",,12/04/2013,12/04/2013,"medicool",15,,"Genital warts, Human Papillomavirus, CO2 laser, cryotherapy",0,"66",107,"CO2 Laser therapy versus cryotherapy in treatment of genital warts; a Randomized Controlled Trial (RCT)","2012",
532,,,"Baring, D.E.C. & Hilmi, O.J.","Clinical Otolaryngology","&nbsp; &nbsp; <span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Sepsis in and around the eye is a common problem&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">which can lead to devastating morbidity or mortality&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">from uncontrolled disease, with blindness or intracranial&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">infection being well documented.1,2The purpose of this&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">paper is to review the literature surrounding this prob</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">lem, establish current UK practice and discuss the areas&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">of controversy and their related evidence.</span><br />",,"/uploadfiles/file/20131204/20131204145056_7341.pdf",,12/04/2013,12/04/2013,"medicool",9,,,0,"67",106,"An evidence based review of Periorbital Cellulitis","2011",
534,,"10.3109/15569527.2011.554482","Zehra A?iran Serdar,Seniha ?enbayrak Ak?ay, Asuman ?nan, and ?zgür Da?l?","Cutaneous and Ocular Toxicology","<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Abstract.</strong></span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; Background and design: Cellulitis is a common soft tissue infection and the severity of disease vary from mild to life &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">threatening. The aim of the present retrospective study was to evaluate age, sex, site of infection, microbiological &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">spectrum and the risk factors of cellulitis in hospitalized patients.</span><br />",,"/uploadfiles/file/20131204/20131204145325_1528.pdf",,12/04/2013,12/04/2013,"medicool",8,,,0,"67",106,"Evaluation of microbiological spectrum and risk factors of  cellulitis in hospitalized patients","2011",
533,,,"Marion Pi?eros1*, Gustavo Hernández-Suárez1?, Liliana Orjuela1?, Juan Carlos Vargas2? and Gonzalo Pérez","Pi?eros et al. BMC Public Health","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Background: Information on HPV knowledge in patients with genital warts is scarse as is the information on </span><span style=""font-family:Times New Roman;font-size:16px;"">factors related to the impact on self-esteem and sex life among them.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Methods: We conducted a cross-sectional study in adult patients with a clinical diagnosis of genital warts (GW) </span><span style=""font-family:Times New Roman;font-size:16px;"">attending a major private out-patient clinic in Bogotá, Colombia. Patients underwent biopsy for pathological </span><span style=""font-family:Times New Roman;font-size:16px;"">diagnosis, HPV-DNA testing and completed a questionnaire assessing HPV knowledge, and the consequences of </span><span style=""font-family:Times New Roman;font-size:16px;"">GW on self-esteem and sexual life. Differences in proportions were assessed with a chi2 test.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Results: 106 men and 155 women had pathologic confirmation of GW. 51% of subjects had heard of HPV before </span><span style=""font-family:Times New Roman;font-size:16px;"">consultation coming mainly from the media (82%). Less than half of the participants knew that HPV could be </span><span style=""font-family:Times New Roman;font-size:16px;"">transmitted through non-penetrant sexual intercourse and only two thirds acknowledged HPV vaccine as a </span><span style=""font-family:Times New Roman;font-size:16px;"">preventive measure against HPV infection. Impact on self-esteem was higher among women than men (90.3% vs </span><span style=""font-family:Times New Roman;font-size:16px;"">60.4%, [p &lt; 0.01]). In men, factors related to a higher impact on sexual life were HPV awareness and age; in women </span><span style=""font-family:Times New Roman;font-size:16px;"">they were higher education and anatomic location; external GW had a higher impact on sexual life in women </span><span style=""font-family:Times New Roman;font-size:16px;"">(83% vs. 66%; [p = 0.05]).</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Conclusions: We found a low awareness of HPV and low knowledge on the vaccine as a preventive measure for </span><span style=""font-family:Times New Roman;font-size:16px;"">associated diseases even in patients suffering from genital warts, highlighting the need for communication and </span><span style=""font-family:Times New Roman;font-size:16px;"">education on HPV. Greater impact on self-esteem in women might reflect higher health consciousness among Latin </span><span style=""font-family:Times New Roman;font-size:16px;"">American women.</span>
</p>",,"/uploadfiles/file/20131204/20131204144845_4755.pdf",,12/04/2013,12/04/2013,"medicool",9,,"Genital warts, HPV, Psychosexual impact, Patients, Colombia",0,"65",107,"HPV knowledge and impact of genital warts on self esteem and sexual life in Colombian patients","2013",
535,,,"Paolo Broganelli, Antonella Chiaretta, Barbara Fragnelli & Maria Grazia Bernengo","Dermatologic Therapy","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Cidofovir is a nucleoside analog of deoxycytidine with a strong activity against a broad </span><span style=""font-family:Times New Roman;font-size:16px;"">spectrum of DNA viruses, including human papillomavirus. The first objective was to evaluate efficacy </span><span style=""font-family:Times New Roman;font-size:16px;"">of cidofovir for the treatment of cutaneous viral warts, recalcitrant after conventional therapies or </span><span style=""font-family:Times New Roman;font-size:16px;"">where the surgery approach is difficult for their location or extension. Second, the present authors </span><span style=""font-family:Times New Roman;font-size:16px;"">propose to point out possible local and systemic side effects consequent to treatment. Two-hundred </span><span style=""font-family:Times New Roman;font-size:16px;"">eighty patients affected by recalcitrant cutaneous viral warts, were treated with intralesional cidofovir </span><span style=""font-family:Times New Roman;font-size:16px;"">15 mg/mL once a month. The present authors stated that candidates were those who had made before </span><span style=""font-family:Times New Roman;font-size:16px;"">at least two other treatments reported in the guideline for management of cutaneous viral warts. In 276 </span><span style=""font-family:Times New Roman;font-size:16px;"">cases, warts completely cleared: 158 of those have a follow-up period longer than 12 months and 118 </span><span style=""font-family:Times New Roman;font-size:16px;"">have a follow-up of 6 months. On the average, 3,2 injections were enough to solve the problem. Local </span><span style=""font-family:Times New Roman;font-size:16px;"">side effects consisted of pain and burning sensation during the injections; itching, erythema, and </span><span style=""font-family:Times New Roman;font-size:16px;"">post-inflammatory hyperpigmentation were observed. No cases of systemic side effects were noted. </span><span style=""font-family:Times New Roman;font-size:16px;"">The treatment was well tolerated, and the warts were completely cleared without relapses. Intralesional </span><span style=""font-family:Times New Roman;font-size:16px;"">cidofovir is emerging as an effective therapeutic alternative for warts that are unresponsive to conventional</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">treatments.</span>
</p>",,"/uploadfiles/file/20131204/20131204145351_5793.pdf",,12/04/2013,12/04/2013,"medicool",8,,"cidofovir, intralesional, viral warts",0,"65",107,"Intralesional cidofovir for the treatment of multiple and recalcitrant cutaneous viral warts","2012",
553,"棘层松解型光线性角化病一例","J Diagn Ther Dermato-Venereol ,Aug.2012.Vol.19,No.14","米向斌 刘真喜 邱贤文",,"<strong><span style=""font-size:14px;"">摘要：</span></strong><br />
&nbsp;<span style=""font-size:14px;line-height:1.5;font-family:SimSun;""> 报告1例棘层松解型光线性角化病。患者男，80岁，因左颞部皮肤斑块伴疼痛一年余就诊。皮肤组织病理检查示：表皮增生，角化过度，</span><span style=""white-space:normal;""><span style=""font-size:14px;line-height:1.5;font-family:SimSun;"">棘层松解，基底层不典型细胞向真皮上部生长，免疫组化检查示：CK(+)、P63(+)，ki67约20%（+）。诊断为</span><span style=""white-space:normal;font-size:14px;line-height:1.5;font-family:SimSun;"">棘层松解型光线性角化病。</span></span>",,"/uploadfiles/file/20131204/20131204154804_4658.pdf",,12/04/2013,12/05/2013,"medicool",21,,"光线性角化病，病理，免疫组化",0,"85",104,,"2012",
537,,"10.1186/1471-2334-13-186","Ines Schneider1, Mandy D Lehmann, Vlada Kogosov, Eggert Stockfleth and Ingo Nindl","BioMed Central","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:2;""><strong>Abstract</strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Background: </strong>Cutaneous human papillomavirus (HPV) infections seem to be associated with the onset of actinic</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">keratosis (AK). This study compares the presence of cutaneous HPV types in eyebrow hairs to those in tissues of</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">normal skin and skin lesions of 75 immunocompetent AK patients.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Methods: </strong>Biopsies from AK lesions, normal skin and plucked eyebrow hairs were collected from each patient. DNA from&nbsp;</span><span style=""font-size:14px;line-height:2;"">these specimens was tested for the presence of 28 cutaneous HPV (betaPV and gammaPV) by a PCR based method.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Results: </strong>The highest number of HPV prevalence was detected in 84% of the eyebrow hairs (63/75, median 6 types)&nbsp;</span><span style=""font-size:14px;line-height:2;"">compared to 47% of AK lesions (35/75, median 3 types) (p&lt; 0.001) and 37% of normal skin (28/75, median 4 types)&nbsp;</span><span style=""font-size:14px;line-height:2;"">(p&lt; 0.001), respectively. A total of 228 HPV infections were found in eyebrow hairs compared to only 92 HPV infections&nbsp;</span><span style=""font-size:14px;line-height:2;"">in AK and 69 in normal skin. In all three specimens HPV20, HPV23 and/or HPV37 were the most prevalent types. The&nbsp;</span><span style=""font-size:14px;line-height:2;"">highest number of multiple types of HPV positive specimens was found in 76% of the eyebrow hairs compared to 60%&nbsp;</span><span style=""font-size:14px;line-height:2;"">in AK and 57% in normal skin. The concordance of at least one HPV type in virus positive specimens was 81%&nbsp;</span><span style=""font-size:14px;line-height:2;"">(three specimens) and 88-93% of all three combinations with two specimens.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""><strong>Conclusions: </strong>Thus, eyebrow hairs revealed the highest number of cutaneous HPV infections, are easy to collect and are&nbsp;</span><span style=""font-size:14px;line-height:2;"">an appropriate screening tool in order to identify a possible association of HPV and AK.</span> 
</div>
</span>",,"/uploadfiles/file/20131204/20131204150101_8748.pdf",,12/04/2013,12/04/2013,"medicool",19,,,0,"65",104,"Eyebrow hairs from actinic keratosis patients harbor the highest number of cutaneous human papillomaviruses","2013",
538,,"10.1007/s10156-010-0072-6","Jennifer H. Han?Josephine C. Nguyen? Shuko Harada?Larry M. Baddour? Paul H. Edelstein","Springer","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Abstract.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; Legionella spp. rarely cause soft tissue infec</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">tions, with only a few cases reported and usually in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">the setting of immunocompromise. We report a case of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">L. pneumophila cellulitis, without pneumonia, in a 65-year-</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">old immunocompromised woman. The patient had a&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">history of interstitial lung disease and idiopathic throm</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">bocytopenic purpura, for which she was receiving high-</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">dose corticosteroids, and had recently experienced an&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">episode of L. pneumophila cellulitis of the lower extremity,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">which responded to an extended course of levofloxacin.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">She was initially transferred to this institution for definitive</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">workup of presumed B cell lymphoma and, during her&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">hospital course, suffered a relapse of L. pneumophila-</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">associated cellulitis that responded promptly to azithro</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">mycin. More unusual organisms such as Legionella spp.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">should be considered in the etiology of cellulitis, particu</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">larly in the setting of immunocompromise, in cases that are&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">refractory to conventional antibiotics routinely adminis</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">tered for skin and soft tissue infections.</span><br />",,"/uploadfiles/file/20131204/20131204150342_0247.pdf",,12/04/2013,12/04/2013,"medicool",18,,,0,"67",106,"Relapsing Legionella pneumophila cellulitis: a case report and review of the literature","2010",
541,,"10.5146/tjpath.2012.01110","?Iker KARAGECE YAL?IN\ Selda SECK?N","Turkish Journal of Pathology","<span style=""font-size:16px;font-family:'Times New Roman';""><strong>ABSTRACT&nbsp;</strong></span><br />
<div style=""text-align:justify;"">
	<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Objective: </span></strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">The aim of this study was to investigate p53 and COX-2&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">expressions in basal cell carcinoma, squamous cell carcinoma and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">actinic kératoses, and to determine a possible relationship.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Material and Method: </strong></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">50 basal cell carcinoma, 45 squamous cell&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">carcinoma and 45 actinic keratosis cases were evaluated. The type of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">tumor in basal cell carcinoma and tumor differentiation in squamous&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">cell carcinoma were noted and the paraffin block that best represented&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">the tumor was chosen. Immunostaining by p53 and COX-2 was&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">performed on sections of the paraffin blocks.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> <strong>Results:&nbsp;</strong></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">p53 expression was observed in 98% of basal cell carcinoma,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">88.9% of squamous cell carcinoma and all actinic keratosis cases. p53&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">expression was also noted in non-dysplastic appearing epithelium in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">actinic keratosis cases. COX-2 expression was seen in 90, 100 and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">88.9% of the basal cell carcinoma, squamous cell carcinoma and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">actinic keratosis groups, respectively. Skin appendages, inflammatory&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">cells and vascular structures were also stained by COX-2 besides&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">tumor tissue. COX-2 expression increased by the p53 expression&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">increase in basal cell carcinoma and squamous cell carcinoma. p53&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and COX-2 expressions were not related in terms of tumor type in the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">BCC and were not related in terms of differentiation in SCC.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> <strong>Conclusion:&nbsp;</strong></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">The existence of p53 expression in actinic keratosis&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">cases has supported the idea that p53 plays a role in the early steps of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">carcinogenesis in skin cancers. The fact that the expression of COX-2&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">increases in line with the increase of p53 expression in basal cell&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">carcinoma and squamous cell carcinoma cases indicates that COX-2&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">expression may be affected by p53.</span> 
</div>",,"/uploadfiles/file/20131204/20131204151137_0611.pdf",,12/04/2013,12/04/2013,"medicool",11,,"Basal cell carcinoma, Squamous cell carcinoma. Actinic
keratosis, p53, Cyclooxygenase 2",0,"65",104,"The Expression of p53 and COX-2 ín Basal Cell Carcinoma, Squamous Cell Carcinoma and Actinic Keratosis Cases","2012",
574,,,"Chunqing Lin1, Joseph TF Lau1,2*, King-Man Ho3, Man-Chun Lau1, Hi-Yi Tsui1, Kuen-Kong Lo3","Lin et al. BMC Infectious Diseases","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Background: The objective of this study is to estimate the incidence of genital warts in Hong Kong and explore a </span><span style=""font-family:Times New Roman;font-size:16px;"">way to establish a surveillance system for genital warts among the Hong Kong general population.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Methods: A total of 170 private doctors and all doctors working in the 5 local Social Hygiene Clinics (SHC) </span><span style=""font-family:Times New Roman;font-size:16px;"">participated in this study. During the 14-day data collection period (January 5 through18, 2009), the participating </span><span style=""font-family:Times New Roman;font-size:16px;"">doctors filled out a log-form on a daily basis to record the number of patients with genital warts. The total </span><span style=""font-family:Times New Roman;font-size:16px;"">number of new cases of genital warts presented to private and public doctors in Hong Kong was projected using </span><span style=""font-family:Times New Roman;font-size:16px;"">the stratification sampling method.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Results: A total of 721 (0.94%) adults presented with genital warts to the participating doctors during the twoweek </span><span style=""font-family:Times New Roman;font-size:16px;"">study period, amongst them 73 (10.1%) were new cases. The projected number of new cases of genital warts </span><span style=""font-family:Times New Roman;font-size:16px;"">among Hong Kong adults was 442 (297 male and 144 female) during the study period. The incidence of genital </span><span style=""font-family:Times New Roman;font-size:16px;"">warts in Hong Kong was estimated to be 203.7 per 100,000 person-years (respectively 292.2 and 124.9 per 100,000 </span><span style=""font-family:Times New Roman;font-size:16px;"">person-years for males and females).</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Conclusions: The incidence of genital warts is high among adults in Hong Kong. The study demonstrates the </span><span style=""font-family:Times New Roman;font-size:16px;"">importance of collecting surveillance data from both private and public sectors. </span> 
</p>",,"/uploadfiles/file/20131206/20131206092440_4217.pdf",,12/06/2013,12/06/2013,"medicool",16,,"human papillomavirus,Recruitment procedure,sexually transmitted diseases",0,"67",107,"Incidence of genital warts among the Hong Kong general adult population","2010",
540,,,"Matthew G Hawkins1?, David M Winder1?, Siolian L R Ball1, Katie Vaughan1, Christopher Sonnex2,Margaret A Stanley1, Jane C Sterling1,3 and Peter K C Goon1,2","Hawkins et al. Virology Journal","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Background: <br />
The low-risk human papillomavirus types 6 and 11 are responsible for approximately 90% of </span><span style=""font-family:Times New Roman;font-size:16px;"">anogenital wart cases, with approximately 190,000 new and recurrent cases reported in the UK in 2010. The UK has </span><span style=""font-family:Times New Roman;font-size:16px;"">recently selected the quadrivalent HPV vaccine, which conveys protection against both HPV6 and HPV 11, as part of </span><span style=""font-family:Times New Roman;font-size:16px;"">its immunisation programme for 2012 and it is expected that this will reduce disease burden in the UK. The aims of </span><span style=""font-family:Times New Roman;font-size:16px;"">the study were to evaluate current strategies used for the monitoring of HPV infection in genital warts and to </span><span style=""font-family:Times New Roman;font-size:16px;"">assess the suitability of laser-capture microdissection (LCM) as a technique to improve the understanding of the </span><span style=""font-family:Times New Roman;font-size:16px;"">natural history of HPV types associated with genital wart lesions.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Methods: <br />
DNA and RNA were extracted from whole wart, surface swabs and LCM sections from 23 patients. HPV </span><span style=""font-family:Times New Roman;font-size:16px;"">types present were determined using the Linear Array HPV Genotyping Test (Roche), with HPV DNA viral load and </span><span style=""font-family:Times New Roman;font-size:16px;"">mRNA expression investigated using qPCR and qRT-PCR, respectively.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Results: <br />
Results indicated that swabbing the surface of warts does not accurately reflect potential causative HPV </span><span style=""font-family:Times New Roman;font-size:16px;"">types present within a wart lesion, multiple HPV types being present on the surface of the wart that are absent in </span><span style=""font-family:Times New Roman;font-size:16px;"">the lower layers of tissue isolated by LCM. Although it was shown that HPV DNA viral load does not directly </span><span style=""font-family:Times New Roman;font-size:16px;"">correlate with HPV mRNA load, the presence of both DNA and mRNA from a single HPV type suggested a causative </span><span style=""font-family:Times New Roman;font-size:16px;"">role in lesion development in 8/12 (66.6%) of patients analysed, with dual infections seen in 4/12 (33.3%) cases. HPV </span><span style=""font-family:Times New Roman;font-size:16px;"">6 and HPV 11 were present in more than 90% of the lesions examined.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Conclusions: <br />
Surface swabbing of warts does not necessarily reflect the causative HPV types. HPV type specific </span><span style=""font-family:Times New Roman;font-size:16px;"">DNA and mRNA loads do not correlate. HPV 6 and 11 were likely to be causally involved in over 90% of the lesions. </span><span style=""font-family:Times New Roman;font-size:16px;"">Dual infections were also found, and further studies are required to determine the biological and clinical nature of </span><span style=""font-family:Times New Roman;font-size:16px;"">dual/multiple infections and to establish the relationship of multiple HPV types within a single lesion.</span> 
</p>",,"/uploadfiles/file/20131204/20131204145958_3359.pdf",,12/04/2013,12/04/2013,"medicool",9,,"HPV types, Warts, Laser-capture and microdissection, Quantitative PCR, DNA, mRNA",0,"65",107,"Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata","2013",
542,,"10.1111/j.1468-3083.2010.03906.x","N. Tomson,?,* J. Sterling,? I. Ahmed,§ J. Hague,C J. Berth-Jones",,"<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Background <br />
Cutaneous warts are common and caused by a number of different types of human papillomaviruses</span><span style=""font-family:Times New Roman;font-size:16px;"">(HPVs).</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Objective <br />
The aim of this study was to investigate the HPV types causing common warts and to determine any </span><span style=""font-family:Times New Roman;font-size:16px;"">association between the HPV type and the duration of warts and response to cryotherapy.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Methods Eighty wart samples from 76 immunocompetent patients were taken from warts by paring prior to </span><span style=""font-family:Times New Roman;font-size:16px;"">cryotherapy and analysed by in situ hybridization (ISH) with HPV probes specific to HPV 1, 2, 3, 4, 7, 10 and 57 and </span><span style=""font-family:Times New Roman;font-size:16px;"">PCR analysis using degenerate cutaneous HPV primers with subsequent DNA sequencing. Each patient’s details, </span><span style=""font-family:Times New Roman;font-size:16px;"">including site, duration and response of the wart to cryotherapy were recorded. Cryotherapy was performed at 2 </span><span style=""font-family:Times New Roman;font-size:16px;"">week intervals for a maximum of 12 weeks.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Results <br />
An HPV type was identified in 65 samples. The majority of warts (58 samples) were typed as HPV </span><span style=""font-family:Times New Roman;font-size:16px;"">2 ? 27 ? 57 by ISH and ? or PCR. Three of the 18 samples that were HPV negative with ISH were HPV positive by PCR. </span><span style=""font-family:Times New Roman;font-size:16px;"">Response to treatment did not correlate with HPV type, duration or location. In the 21 wart parings taken from </span><span style=""font-family:Times New Roman;font-size:16px;"">patients aged 16 and under, response to treatment did not correlate with HPV type but warts of shorter duration </span><span style=""font-family:Times New Roman;font-size:16px;"">were more likely to resolve with cryotherapy treatment than longer standing lesions.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Conclusion <br />
This study demonstrates that HPV type can be determined from wart parings. HPV-2 related viruses </span><span style=""font-family:Times New Roman;font-size:16px;"">are the prevalent HPV types causing common warts on the hands and feet in this population.</span>
</p>",,"/uploadfiles/file/20131204/20131204151304_6241.pdf",,12/04/2013,12/04/2013,"medicool",14,,"cryotherapy, DNA probes, HPV, PCR, warts",0,"65",107,"Human papillomavirus typing of warts and response to cryotherapy","2010",
543,,"org/10.1155/2013/102698","Laura Held, Thomas Kurt Eigentler, Ulrike Leiter, Claus Garbe, and Mark-Jürgen Berneburg",,"<span style=""font-size:14px;font-family:'Times New Roman';""><strong>Background.<br />
&nbsp; &nbsp; </strong><span style=""line-height:1.5;"">Therapy for actinic keratoses includes photodynamic therapy (PDT) and imiquimod 5% cream. e sequential</span><br />
<span style=""line-height:1.5;"">use of both could result in better clinical outcomes. Objectives. To enhance efficacy of therapies while improving tolerability,&nbsp;</span><span style=""line-height:1.5;"">convenience, and patient adherence with a scheme combining two concomitant or sequential AK treatments. Methods. All patients&nbsp;</span><span style=""line-height:1.5;"">underwent one session of conventional PDT. Two weeks aer, the PDT imiquimod 5% cream was applied to the treatment area&nbsp;</span><span style=""line-height:1.5;"">once daily for three days per week. One course continued for four weeks followed by a clinical evaluation and decision about further&nbsp;</span><span style=""line-height:1.5;"">treatment. Patients who had not cleared all of their AK lesions in the treatment area in course 1 participated in a second 4-week&nbsp;</span><span style=""line-height:1.5;"">course of treatment. Limitations. Small size of population. Results. ree participants were enrolled. Two patients showed complete&nbsp;</span><span style=""line-height:1.5;"">clinical clearance of AKs. e effect was also noted aer long-term followup, at months seven and eleven. No subject discontinued&nbsp;</span><span style=""line-height:1.5;"">for an adverse event. ere were severe local skin reactions in two participants which were severe erythema, scaling, and crusting.&nbsp;</span><span style=""line-height:1.5;"">One patient showed no response to the therapy. Conclusions. Photodynamic therapy followed by imiquimod was well tolerated and&nbsp;</span><span style=""line-height:1.5;"">improved reduction of actinic keratoses. is initial proof-of-concept should be studied in larger clinical trials.</span><br />
<span style=""line-height:1.5;""></span></span>",,"/uploadfiles/file/20131204/20131204151532_5747.pdf",,12/04/2013,12/04/2013,"medicool",17,,,0,"85",104,"Methodology Report Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases","2013",
545,,"10.1186/1471-2407-13-58","Liesbeth Hameetman, Suzan Commandeur, Jan Nico Bouwes Bavinck, Hermina C Wisgerhof, Frank R de Gruijl, Rein Willemze, Leon Mullenders, Cornelis P Tensen and Harry Vrieling","BioMed Central","<span style=""font-size:16px;font-family:'Times New Roman';""><strong>Abstract</strong></span><br />
<div style=""text-align:justify;"">
	<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Background: </span></strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">The risk of developing cutaneous squamous cell carcinoma (SCC) is markedly increased in organ&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">transplant recipients (OTRs) compared to the normal population. Next to sun exposure, the immunosuppressive&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">regimen is an important risk factor for the development of SCC in OTRs. Various gene mutations (e.g. TP53) and&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">genetic alterations (e.g. loss of CDKN2A, amplification of RAS) have been found in SCCs. The aim of this&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">genome-wide study was to identify pathways and genomic alterations that are consistently involved in the&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">formation of SCCs and their precursor lesions, actinic keratoses (AKs).</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Methods: </strong></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">To perform the analysis in an isogenic background, RNA and DNA were isolated from SCC, AK and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">normal (unexposed) epidermis (NS) from each of 13 OTRs. Samples were subjected to genome-wide expression&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">analysis and genome SNP analysis using Illumina’s HumanWG-6 BeadChips and Infinium II HumanHap550&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Genotyping BeadChips, respectively. mRNA expression results were verified by quantitative PCR.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Results: </strong></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Hierarchical cluster analysis of mRNA expression profiles showed SCC, AK and NS samples to separate into</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">three distinct groups. Several thousand genes were differentially expressed between epidermis, AK and SCC; most&nbsp;</span><span style=""font-size:14px;line-height:2;"">upregulated in SCCs were hyperproliferation related genes and stress markers, such as keratin 6 (KRT6), KRT16 and&nbsp;</span><span style=""font-size:14px;line-height:2;"">KRT17. Matching to oncogenic pathways revealed activation of downstream targets of RAS and cMYC in SCCs and&nbsp;</span><span style=""font-size:14px;line-height:2;"">of NFκB and TNF already in AKs. In contrast to what has been reported previously, genome-wide SNP analysis&nbsp;</span><span style=""font-size:14px;line-height:2;"">showed very few copy number variations in AKs and SCCs, and these variations had no apparent relationship with&nbsp;</span><span style=""font-size:14px;line-height:2;"">observed changes in mRNA expression profiles.</span> 
</div>
</span> 
<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Conclusion:&nbsp;</strong></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Vast differences in gene expression profiles exist between SCC, AK and NS from immunosuppressed&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">OTRs. Moreover, several pathways activated in SCCs were already activated in AKs, confirming the assumption that&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">AKs are the precursor lesions of SCCs. Since the drastic changes in gene expression appeared unlinked to specific&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">genomic gains or losses, the causal events driving SCC development require further investigation. Other molecular&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">mechanisms, such as DNA methylation or miRNA alterations, may affect gene expression in SCCs of OTRs. Further&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">study is required to identify the mechanisms of early activation of NFκB and TNF, and to establish whether these&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">pathways offer a feasible target for preventive intervention among OTRs.</span> 
</div>",,"/uploadfiles/file/20131204/20131204152044_5597.pdf",,12/04/2013,12/04/2013,"medicool",13,,,0,"65",104,"Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients","2013",
546,"夫西地酸乳膏治疗头皮细菌性毛囊炎临床观察",,"顾小平 ，陈英姿，朱亚刚","安徽医药","<div style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">&nbsp; &nbsp; &nbsp;为了了解夫西地酸乳膏治疗细菌感染性皮肤病的疗效和&nbsp;</span><span style=""font-family:SimSun;font-size:14px;"">安全性， 我们于2 0 0 9年 1月 ～2 0 0 9年 l 1 月应用夫西地酸乳</span><span style=""font-family:SimSun;font-size:14px;"">膏( 商品名： 奥络， 香港澳美制药厂有限公司) 治疗头皮细菌&nbsp;</span><span style=""font-family:SimSun;font-size:14px;"">性毛囊炎50例 ， 并以莫匹罗星软膏 ( 商品名：百多邦 &nbsp;天津中</span><span><span style=""font-family:SimSun;font-size:14px;"">美史克公司) 作为观察对照， 结果报道如下。</span></span><span style=""line-height:1.5;""> &nbsp;</span>
</div>",,"/uploadfiles/file/20131204/20131204152020_6916.pdf",,12/04/2013,12/04/2013,"medicool",12,,"夫西地酸乳膏| 德囊炎|头皮",0,"66",105,,"2011",
544,"外用抗菌离子膜治疗细菌性毛囊炎的临床研究","1 0 0 9―8 9 6 8 ( 2 0 0 6) 0 4― 0 2 8 5― 0 3","许庆芳， 黄怀球 ，赖 维， 陈 剑 ，苏向阳，龚子鉴","岭南皮肤性病科杂态","<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;text-align:justify;"">Objective：</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;To evaluate the efficacy and safety of antibacterial spray in the
topical treatment of bacterial folliculitis．</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Methods：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; 28 cases of bacterial folliculitis had been collected in the study．Antibacterial&nbsp;&nbsp; spray was applied topically to the affected areas
twice a day for 2 weeks．The efficacy was evaluated by scores of&nbsp;&nbsp; clinical signs and symptoms and the clearance
rate of bacteria．</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Results：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; After two weeks，the scores of clinical signs and symptoms decreased significantly(P&lt;0．0 5)，the&nbsp;&nbsp; clearance rate of bacteria was 68．75％．The clinical cured
rate and efficacy rate were 53．57％ </span><span lang=""EN-US"" style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and 92</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">．86％ respectively．while the total
cure rate and efficacy rate were 46．43％ </span><span lang=""EN-US"" style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and 75</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">．0％．N0 side effect
was observed．</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Conclusion：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; It is a safe and efficient to apply antibacterial spray topically
in treating bacterial folliculitis．<br />
</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">目的：<br />
&nbsp;&nbsp;观察外用抗菌离子膜治疗细菌性毛囊炎的临床疗效。</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;""><span style=""font-size:14px;"">方法： <br />
&nbsp;&nbsp;从门诊筛选符合入选标准</span><span style=""font-family:'Times New Roman';font-size:14px;"">28</span><span style=""font-size:14px;"">例细菌性毛囊炎患者，予抗菌离子膜外喷，每日</span><span style=""font-family:'Times New Roman';font-size:14px;"">2</span><span style=""font-size:14px;"">次，疗程</span><span style=""font-family:'Times New Roman';font-size:14px;"">2</span><span style=""font-size:14px;"">周，观察临床症状、体征和治疗前后病原学指标的变化。</span></span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;""><span style=""font-size:14px;"">结果：<br />
&nbsp;治疗2周后，临床症状和体征评分及脓疱数较治疗前明显下降(</span><span style=""font-family:'Times New Roman';font-size:14px;"">P&lt;0．05</span><span style=""font-size:14px;"">)；细菌清除率达</span><span style=""font-family:'Times New Roman';font-size:14px;"">82．14％</span><span style=""font-size:14px;"">；临床疗效痊愈率、有效率分别为</span><span style=""font-family:'Times New Roman';font-size:14px;"">53．57％</span><span style=""font-size:14px;"">、</span><span style=""font-family:'Times New Roman';font-size:14px;"">92．86％</span><span style=""font-size:14px;"">；总体疗效痊愈率、有效率分别为</span><span style=""font-family:'Times New Roman';font-size:14px;"">46．43％</span><span style=""font-size:14px;"">、</span><span style=""font-family:'Times New Roman';font-size:14px;"">75．0％</span><span style=""font-size:14px;"">。</span></span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;""><span style=""font-size:14px;"">结论：外用抗菌离子膜是一安全有效的非抗菌素抗菌剂，能有效地治疗细菌性毛囊炎 。&nbsp;</span><span style=""font-size:14px;"">&nbsp;</span></span><o:p></o:p>
</p>
<span style=""font-family:SimSun;""></span><o:p></o:p>
<p>
	<br />
</p>
<span style=""font-family:SimSun;font-size:14px;line-height:1.5;""></span> 
<p>
	<br />
</p>","/uploadfiles/image/20131204/20131204144023_1078w.jpg","/uploadfiles/file/20131204/20131204144035_7907.pdf",,12/04/2013,12/04/2013,"medicool",21,,"Folliculitis| Bacterial | Antibacterial apray",0,"66",105,"Topical antimicrobial treatment of bacterial folliculitis caustic clinical research","2006",
581,,,,,"<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp;We report a case of a young man with&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">perforating folliculitis and cystic ?brosis with complica</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">tions including chronic obstructive pulmonary disease,</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">insulin dependent diabetes mellitus, and liver cirrhosis.</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">We demonstrate increased TGF-b1 immunohistochemi</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">cal staining in the perforating folliculitis lesions of our&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patient and discuss the possible associations between&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cystic ?brosis and perforating folliculitis.</span> 
</div>",,"/uploadfiles/file/20131206/20131206164938_8546.pdf",,12/06/2013,12/06/2013,"medicool",13,,"perforating folliculitis| cystic ?brosis|the perforating folliculitis lesions",0,"85",105,"PERFORATING FOLLICULITIS IN A PATIENT WITH CYSTIC FIBROSIS","2010",
582,,,,,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp;The common clinical presentations of molluscum contagiosum</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(MC) are well known to dermatologists. However, folliculitis due&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">to MC is infrequently reported. Herein, we report a 6-year-old gir&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">presenting with multiple discrete skin-coloured to whitish shiny&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">papules on the face for months. Biopsy of the lesion revealed&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">multiple molluscum bodies within the follicular epithelium with&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">sparing of the interfollicular epithelium. Molluscum folliculitis&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(MF) was diagnosed. We review the literature and discuss the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">differences between MF and ordinary MC.</span> 
</div>",,"/uploadfiles/file/20131206/20131206165113_3283.pdf",,12/06/2013,12/06/2013,"medicool",17,,"molluscum contagiosum|folliculitis |papules",0,"85",105,"Paediatric molluscum folliculitis:  a diagnosis to keep in mind","2009",
547,,,,"International Journal of Dermatology","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Viral warts is a very common pediatric complaint, occurring </span><span style=""font-family:Times New Roman;font-size:16px;"">in 5C10% of children.1 Although, many warts in </span><span style=""font-family:Times New Roman;font-size:16px;"">children may resolve spontaneously without treatment, </span><span style=""font-family:Times New Roman;font-size:16px;"">patients frequently request treatment to alleviate the </span><span style=""font-family:Times New Roman;font-size:16px;"">patients’ physical and psychological discomfort and to </span><span style=""font-family:Times New Roman;font-size:16px;"">prevent the spread of the infection. A variety of therapies </span><span style=""font-family:Times New Roman;font-size:16px;"">have been studied for treatment of warts, but none of </span><span style=""font-family:Times New Roman;font-size:16px;"">hese is uniformly effective in the elimination of the </span><span style=""font-family:Times New Roman;font-size:16px;"">lesions. These include cryotherapy, carbon dioxide laser, </span><span style=""font-family:Times New Roman;font-size:16px;"">podophyllin resin, salicylic acid, cimetidine, phenol, tape </span><span style=""font-family:Times New Roman;font-size:16px;"">occlusion, excision, and no treatment.2 Cryotherapy with </span><span style=""font-family:Times New Roman;font-size:16px;"">liquid nitrogen is one of the most effective and established </span><span style=""font-family:Times New Roman;font-size:16px;"">treatments, but the optimum method for delivery of liquid </span><span style=""font-family:Times New Roman;font-size:16px;"">nitrogen is uncertain. The most widely used method is </span><span style=""font-family:Times New Roman;font-size:16px;"">either a cryo-spray or a cotton-tipped applicator. By using</span><span style=""font-family:Times New Roman;font-size:16px;"">melamine foam (Magic Eraser sponge) instead of cotton </span><span style=""font-family:Times New Roman;font-size:16px;"">wool, we could treat various types of wart more readily </span><span style=""font-family:Times New Roman;font-size:16px;"">and quickly.</span>
</p>
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131204/20131204152133_6374.pdf",,12/04/2013,12/04/2013,"medicool",12,,,0,"85",107,"Cryotherapy using melamine foam of warts C An easy and rapid new trial method instead of cotton-tipped applicator: a case series of 13 patients","2011",
548,"蒲地蓝消炎口服液联合莫匹罗星乳膏治疗细菌性毛囊炎70例 疗效观察","1672-8351（2013）06-0050-02","郑小景","北方药学","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:SimSun;font-size:14px;"">目的：观察蒲地蓝消炎口服液联合莫匹罗星乳膏治疗细菌性毛囊炎疗效。<br />
方法：将200例细菌性毛囊炎患者分为3组，治</span><span style=""line-height:1.5;font-family:SimSun;font-size:14px;"">疗组口服蒲地蓝消炎口服液，同时外用莫匹罗星软膏。对照1组单纯口服蒲地蓝消炎口服液；对照2组单纯外用莫匹罗星软膏。</span><span style=""line-height:1.5;font-family:SimSun;font-size:14px;"">观察3组疗效。<br />
结果：治疗组有效率97.1%明显优于对照1组61.5%和对照2组70.8%，差异具有显著性。2对照组比较差异不</span><span style=""line-height:1.5;font-family:SimSun;font-size:14px;"">具显著性。<br />
结论：蒲地蓝消炎口服液联合莫匹罗星乳膏治疗细菌性毛囊炎疗效好，安全性高。</span> 
</div>",,"/uploadfiles/file/20131204/20131204152622_9399.pdf",,12/04/2013,12/04/2013,"medicool",11,,"蒲地蓝消炎口服液| 莫匹罗星乳膏| 细菌性毛囊炎",0,"66",105,,"2013",
549,"日光性弹性组织变性综合征合并光线性角化病一例","Chin J Dermatol,April 2013,Vol.46,No.4","孙怡 王振华 王玉坤","中华皮肤科杂志","&nbsp; &nbsp;患者，女，60岁，因左面部角化性斑块及粉刺4年于2010年11月来我院就诊。患者20年前于左侧颧部起豆粒大褐色斑疹，自用黄瓜摩擦局部约半月，皮疹颜色变淡，但有扩大局势。",,"/uploadfiles/file/20131204/20131204152222_9647.pdf",,12/04/2013,12/05/2013,"medicool",12,,"皮疹，皮损，囊肿",0,"85",104,,"2013",
550,"局部热疗成功清除面部常见疣：两例病例报告",,"Yan Ma, Wei Huo, Yu-Xiao Hong, Hong-Duo Chen &Xing-Hua Gao","Dermatologic Therapy","<p class=""MsoNormal"" align=""justify"">
	<span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:16px;"">Facial </span><span style=""font-family:Times New Roman;font-size:16px;"">common wart is a disfiguring condition caused by human papilloma virus </span><span style=""font-family:Times New Roman;font-size:16px;"">infection. </span></span></span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:16px;"">Choices </span><span style=""font-family:Times New Roman;font-size:16px;"">to treat facial warts should be cautious, in consideration of adverse cosmetic </span><span style=""font-family:Times New Roman;font-size:16px;"">consequences</span></span></span></span></span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-family:Times New Roman;font-size:16px;"">. </span><span><span style=""font-family:Times New Roman;font-size:16px;"">Two </span><span style=""font-family:Times New Roman;font-size:16px;"">cases of facial common warts were treated by local hyperthermia at 44°C for 30 </span><span style=""font-family:Times New Roman;font-size:16px;"">minutes, once a day for three consecutive days (the first session), and </span><span style=""font-family:Times New Roman;font-size:16px;"">similarly treated a week later for more 2 days (second session)</span></span><span style=""font-family:Times New Roman;font-size:16px;"">.</span><span><span style=""font-family:Times New Roman;font-size:16px;"">The </span><span style=""font-family:Times New Roman;font-size:16px;"">warts completely disappeared in 10 and 12weeks, respectively in the two </span><span style=""font-family:Times New Roman;font-size:16px;"">patients</span></span><span style=""font-family:Times New Roman;font-size:16px;"">. </span><span><span style=""font-family:Times New Roman;font-size:16px;"">Adverse effect was tolerable burning sensation </span><span style=""font-family:Times New Roman;font-size:16px;"">in the two patients and a temporary heat-induced blistering in one of them. </span></span><span><span style=""font-family:Times New Roman;font-size:16px;"">This </span><span style=""font-family:Times New Roman;font-size:16px;"">pioneer trial suggested that mild hyperthermia is a safe and effective method </span><span style=""font-family:Times New Roman;font-size:16px;"">in treating facial common warts.</span></span></span></span></span><span><span><span style=""font-family:&quot;&quot;;""></span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">面部寻常疣是由人类乳头状瘤病毒感染造成的容貌变形。考虑到化妆品的不良后果，我们应当谨慎选择面部疣的治疗方法。本文介绍了采用局部热疗法治疗面部寻常疣的两例病例，患者在</span><span style=""font-family:Times New Roman;font-size:16px;"">44</span><span style=""font-family:Times New Roman;font-size:16px;"">℃下处理</span><span style=""font-family:Times New Roman;font-size:16px;"">30</span><span style=""font-family:Times New Roman;font-size:16px;"">分钟，每天一次，连续三天（第一期），一个星期后接受相似的疗法再处理两天（第二期）。两位患者身上的疣分别在</span><span style=""font-family:Times New Roman;font-size:16px;"">10</span><span style=""font-family:Times New Roman;font-size:16px;"">周和</span><span style=""font-family:Times New Roman;font-size:16px;"">12</span><span style=""font-family:Times New Roman;font-size:16px;"">周时完全消失。该疗法的副作用是治疗时出现可以忍受的灼热感，以及其中一位患者出现了因热引起的暂时性起泡。这种先锋性试验表明，温和型热疗法是治疗面部寻常疣的一种安全有效的方法。</span><span style=""font-family:&quot;&quot;;""></span> 
</p>
<br />
<br />","/uploadfiles/image/20131204/20131204153356_9007w.png","/uploadfiles/file/20131204/20131204153326_2934.pdf",,12/04/2013,12/04/2013,"medicool",15,,"common wart, facial, hyperthermia",0,"85",107,"Successful clearance of facial common warts by local hyperthermia: report of two cases","2012",
551,,"10.1038/modpathol.2011.39","Seong Hui Ra, Xinmin Li and Scott Binder","Modern Pathology","<div style=""text-align:justify;"">
	<strong style=""font-family:'Times New Roman';font-size:16px;line-height:2;"">Abstract</strong> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">&nbsp; &nbsp; &nbsp; </span><span style=""font-size:14px;line-height:2;"">Actinic keratosis is widely believed to be a neoplastic lesion and a precursor to invasive squamous cell&nbsp;</span><span style=""font-size:14px;line-height:2;"">carcinoma. However, there has been some debate as to whether actinic keratosis is in fact actually squamous&nbsp;</span><span style=""font-size:14px;line-height:2;"">cell carcinoma and should be treated as such. As the clinical management and prognosis of patients is widely&nbsp;</span><span style=""font-size:14px;line-height:2;"">held to be different for each of these lesions, our goal was to identify unique gene signatures using DNA&nbsp;</span><span style=""font-size:14px;line-height:2;"">microarrays to discriminate among normal skin, actinic keratosis, and squamous cell carcinoma, and examine&nbsp;</span><span style=""font-size:14px;line-height:2;"">the molecular pathways of carcinogenesis involved in the progression from normal skin to squamous cell&nbsp;</span><span style=""font-size:14px;line-height:2;"">carcinoma. Formalin-fixed and paraffin-embedded blocks of skin: five normal skins (pooled), six actinic&nbsp;</span><span style=""font-size:14px;line-height:2;"">keratoses, and six squamous cell carcinomas were retrieved. The RNA was extracted and amplified. The labeled&nbsp;</span><span style=""font-size:14px;line-height:2;"">targets were hybridized to the Affymetrix human U133plus2.0 array and the acquisition and initial quantification&nbsp;</span><span style=""font-size:14px;line-height:2;"">of array images were performed using the GCOS (Affymetrix). The subsequent data analyses were performed&nbsp;</span><span style=""font-size:14px;line-height:2;"">using DNA-Chip Analyzer and Partek Genomic Suite 6.4. Significant differential gene expression (42 fold&nbsp;</span><span style=""font-size:14px;line-height:2;"">change, Po0.05) was seen with 382 differentially expressed genes between squamous cell carcinoma and&nbsp;</span><span style=""font-size:14px;line-height:2;"">normal skin, 423 differentially expressed genes between actinic keratosis and normal skin, and 9 differentially&nbsp;</span><span style=""font-size:14px;line-height:2;"">expressed genes between actinic keratosis and squamous cell carcinoma. The differentially expressed genes&nbsp;</span><span style=""font-size:14px;line-height:2;"">offer the possibility of using DNA microarrays as a molecular diagnostic tool to distinguish between normal&nbsp;</span><span style=""font-size:14px;line-height:2;"">skin, actinic keratosis, and squamous cell carcinoma. In addition, the differentially expressed genes and their&nbsp;</span><span style=""font-size:14px;line-height:2;"">molecular pathways could be potentially used as prognostic markers or targets for future therapeutic&nbsp;</span><span style=""font-size:14px;line-height:2;"">innovations.</span> 
</div>
</span>",,"/uploadfiles/file/20131204/20131204153453_8876.pdf",,12/04/2013,12/04/2013,"medicool",15,,,0,"65",104,"Molecular discrimination of cutaneous squamous cell carcinoma from actinic keratosis and normal skin","2011",
552,,,"Harshila Patel1*, Monika Wagner1, Puneet Singhal2 and Smita Kothari2","Patel et al. BMC Infectious Diseases","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Background: Anogenital warts (AGWs) are a common, highly infectious disease caused by the human </span><span style=""font-family:Times New Roman;font-size:16px;"">papillomavirus (HPV), whose high recurrence rates contribute to direct medical costs, productivity loss and </span><span style=""font-family:Times New Roman;font-size:16px;"">increased psychosocial impact. Because of the lack of a systematic review of the epidemiology of AGWs in the </span><span style=""font-family:Times New Roman;font-size:16px;"">literature, this study reviewed the published medical literature on the incidence and prevalence of AGWs. </span><span style=""font-family:Times New Roman;font-size:16px;"">Methods: A comprehensive literature search was performed on the worldwide incidence and prevalence of AGWs </span><span style=""font-family:Times New Roman;font-size:16px;"">between 2001 and 2012 using the PubMed and EMBASE databases. An additional screening of abstracts from </span><span style=""font-family:Times New Roman;font-size:16px;"">relevant sexual health and infectious disease conferences from 2009 to 2011 was also conducted. Only original </span><span style=""font-family:Times New Roman;font-size:16px;"">studies with general adult populations (i.e., at least including ages 20 through 40 years) were included.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Results: The overall (females and males combined) reported annual incidence of any AGWs (including new and </span><span style=""font-family:Times New Roman;font-size:16px;"">recurrent) ranged from 160 to 289 per 100,000, with a median of 194.5 per 100,000. New AGW incidence rates </span><span style=""font-family:Times New Roman;font-size:16px;"">among males ranged from 103 to 168 per 100,000, with a median of 137 per 100,000 and among females from 76 </span><span style=""font-family:Times New Roman;font-size:16px;"">to 191 per 100,000, with a median of 120.5 per 100,000 per annum. The reported incidence of recurrent AGWs was </span><span style=""font-family:Times New Roman;font-size:16px;"">as high as 110 per 100,000 among females and 163 per 100,000 among males. Incidence peaked before 24 years of </span><span style=""font-family:Times New Roman;font-size:16px;"">age in females and between 25 and 29 years of age among males. The overall prevalence of AGWs based on </span><span style=""font-family:Times New Roman;font-size:16px;"">retrospective administrative databases or medical chart reviews or prospectively collected physician reports ranged </span><span style=""font-family:Times New Roman;font-size:16px;"">from 0.13% to 0.56%, whereas it ranged from 0.2% to 5.1% based on genital examinations.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Conclusions: The literature suggests that AGWs are widespread and the prevalence depends on study </span><span style=""font-family:Times New Roman;font-size:16px;"">methodology as suggested by higher rates reported from routine genital examinations versus those from treatment </span><span style=""font-family:Times New Roman;font-size:16px;"">records. However, there remains a need for more population-based studies from certain regions including Africa, </span><span style=""font-family:Times New Roman;font-size:16px;"">Latin America and Southern Asia to further elucidate the global epidemiology of this disease.</span> 
</p>",,"/uploadfiles/file/20131204/20131204154042_3454.pdf",,12/04/2013,12/04/2013,"medicool",15,,"Anogenital warts, Condylomata acuminate, Epidemiology, Prevalence, Incidence",0,"67",107,"Systematic review of the incidence and prevalence of genital warts","2013",
554,,"org/10.1016/j.jaad.2012.09.053","Brian Berman, MD, PhD, and Clay J. Cockerell, MD Miami, Florida, and Dallas, Texas","the American Academy of Dermatology","&nbsp; &nbsp; <span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">Actinic keratoses are proliferations of transformed neoplastic keratinocytes in the epidermis that are the&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">result of cumulative ultraviolet (UV) radiation from sun exposure. They are commonly found on sites of&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">sun-exposed skin such as the face, balding scalp, and back of the hand. Although UV exposure does exert&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">certain beneficial effects on the skin, excessive exposure to UV radiation induces multiple cascades of&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">molecular signaling events at the cellular level that produce inflammation, immunosuppression, failure of&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">apoptosis, and aberrant differentiation. Cumulatively, these actions result in mutagenesis and, ultimately,&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">carcinogenesis. This article provides a brief overview of the key mediators that are implicated in the&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">pathobiology of actinic keratosis. Three evolutionary possibilities exist for these keratoses in the absence of&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">treatment: (1) spontaneous remission, which can be common; (2) remaining stable, without further&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">progression; or (3) transformation to invasive squamous cell carcinoma, which may metastasize. Because&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">the effects of UVradiation on the skin are complex, it is not yet fully clear how all of the mediators of actinic&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">keratosis progression are interrelated. Nonetheless, some represent potential therapeutic targets, because it&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">is clear that directing therapy to the effects of UV radiation at a number of different levels could interrupt&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">and possibly reverse the mechanisms leading to malignant transformation. ( J Am Acad Dermatol&nbsp;</span><span style=""font-size:14px;line-height:1.5;font-family:'Times New Roman';"">2013;68:S10-9.)</span><br />",,"/uploadfiles/file/20131204/20131204155900_3377.pdf",,12/04/2013,12/05/2013,"medicool",16,,"actinic keratosis; apoptosis; immunosuppression; keratinocyte carcinogenesis",0,"65",104,"Pathobiology of actinic keratosis: Ultraviolet-dependent keratinocyte proliferation","2012",
557,,,"Fabiano O. Poswara,, Carlos A.C. Fraga, Lucyana C. Farias, John D. Feltenberger, Vitória P.D. Cruz, Sérgio H.S. Santos, Christine M. Silveira , Alfredo M.B. de Paula, André L.S. Guimar?es","journal homepage: www.elsevier.com/locate/prp","<span style=""font-family:'Times New Roman';font-size:14px;""><strong>Abstract.</strong></span><br />
&nbsp; &nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The expression of metalloproteinases and their inhibitors has been related to different invasive and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">metastatic potentials in cancer. This study aims to investigate the immunohistochemical expression of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">TIMP-3 and MMP-9 in samples of basal cell carcinoma (BCC), squamous cell carcinoma of the skin (SCC),&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and actinic keratosis (AK). Immunohistochemistry was performed to evaluate the expression of TIMP-3&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and MMP-9 in samples of BCC (n = 22), SCC (n = 10), and AK (n = 15). Ten fields of both tumor parenchyma&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and tumor stroma were photographed and counted in image software. The ratio of positive cells to total&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cells was used to quantify the staining. A higher expression of MMP-9 was found in tumor stroma of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">SCC compared to BCC and AK. No significant differences in TIMP-3 expression were observed among&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the groups. Considering the well-described differences between these neoplasms, these results provide&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">additional evidence of the role of MMP-9 in tumor invasiveness of keratinocyte-derived tumors.</span><br />",,"/uploadfiles/file/20131205/20131205085512_0776.pdf",,12/05/2013,12/05/2013,"medicool",15,,"Basal cell carcinoma,Squamous cell carcinoma,Actinic keratosis,Tissue inhibitor of metalloproteinase 3,Matrix metalloproteinase-9",0,"65",104,"Immunohistochemical analysis of TIMP-3 and MMP-9 in actinic keratosis, squamous cell carcinoma of the skin, and basal cell carcinoma","2013",
558,,"10.1371/journal.ppat.1002125.g004","Daniele Viarisio,Karin Mueller-Decker,Ulrich Kloz,Birgit Aengeneyndt,Annette Kopp-Schneider,Hermann-Josef Gro¨ ne,Tarik Gheit,Christa Flechtenmacher,Lutz Gissmann,Massimo Tommasino",,"<span style=""font-family:'Times New Roman';font-size:14px;""><strong>Abstract.</strong></span>&nbsp; &nbsp; <span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;<br />
&nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Cutaneous beta human papillomavirus (HPV) types appear to be involved in the development of non-melanoma skin cancer</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">(NMSC); however, it is not entirely clear whether they play a direct role. We have previously shown that E6 and E7&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">oncoproteins from the beta HPV type 38 display transforming activities in several experimental models. To evaluate the</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">possible contribution of HPV38 in a proliferative tissue compartment during carcinogenesis, we generated a new transgenic</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">mouse model (Tg) where HPV38 E6 and E7 are expressed in the undifferentiated basal layer of epithelia under the control of</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the Keratin 14 (K14) promoter. Viral oncogene expression led to increased cellular proliferation in the epidermis of the Tg&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">animals in comparison to the wild-type littermates. Although no spontaneous formation of tumours was observed during</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the lifespan of the K14 HPV38 E6/E7-Tg mice, they were highly susceptible to 7,12-dimethylbenz(a)anthracene (DMBA)/12-0-</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tetradecanoylphorbol-13-acetate (TPA) two-stage chemical carcinogenesis. In addition, when animals were exposed to</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">ultraviolet light (UV) irradiation, we observed that accumulation of p21WAF1 and cell-cycle arrest were significantly alleviated</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">in the skin of Tg mice as compared to wild-type controls. Most importantly, chronic UV irradiation of Tg mice induced the</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">development of actinic keratosis-like lesions, which are considered in humans as precursors of squamous cell carcinomas&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">(SCC), and subsequently of SCC in a significant proportion of the animals. In contrast, wild-type animals subjected to&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">identical treatments did not develop any type of skin lesions. Thus, the oncoproteins E6 and E7 from beta HPV38&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">significantly contribute to SCC development in the skin rendering keratinocytes more susceptible to UV-induced&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">carcinogenesis.</span><br />",,"/uploadfiles/file/20131205/20131205090105_7302.pdf",,12/05/2013,12/05/2013,"medicool",16,,"Actinic Keratosis-Like Lesions,Squamous Cell Carcinoma",0,"65",104,"E6 and E7 from Beta Hpv38 Cooperate with Ultraviolet Light in the Development of Actinic Keratosis-Like Lesions and Squamous Cell Carcinoma in Mice","2011",
560,,"org/10.1016/j.jaad.2012.09.050","George Martin, MD,and Neil Swanson,MD,Maui, Hawaii, and Portland, Oregon","the American Academy of Dermatology","<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp; Actinic keratosis (AK) is a common ultraviolet lighteinduced skin lesion found on sun-exposed skin areas&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">generally in older, fair-skinned people. It is part of a disease continuum observed in photodamaged skin&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">that may lead to invasive squamous cell carcinoma. The presence of AK is associated with an increased risk&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">of all skin cancers, as it is visible evidence of the carcinogenic effects of cumulative ultraviolet exposure.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">AKs are treated with lesion- and field-directed methods. Field-directed methods treat both the visible and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">subclinical lesions present in photodamaged skin, but treatment regimens are often lengthy and associated&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">with poor tolerability because of vigorous local inflammatory reactions. Ingenol mebutate gel was recently</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">approved by the Food and Drug Administration for topical treatment of AK. It induces cell death&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">preferentially in transformed keratinocytes and promotes an inflammatory response that kills remaining&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tumor cells. In human studies, ingenol mebutate achieved high clearance rates of AK on the trunk or&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">extremities and face or scalp after once-daily application for 2 or 3 consecutive daily treatments, when&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">measured by complete or partial clearance of lesions. The localized inflammatory skin responses were&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">generally mild to moderate and resolved in approximately 2 weeks on the face or scalp and 4 weeks on the</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">trunk or extremities. ( J Am Acad Dermatol 2013;68:S39-48.)</span><br />",,"/uploadfiles/file/20131205/20131205091650_1247.pdf",,12/05/2013,12/05/2013,"medicool",11,,"actinic keratosis; field cancerization; field therapy; ingenol mebutate; local skin response.",0,"66",104,"Clinical findings using ingenol mebutate gel to treat actinic keratoses","2013",
561,,"org/10.1016/j.jaad.2012.10.001","Darrell S. Rigel, MD,and Linda F. Stein Gold, MD,New York, New York, and Detroit, Michigan","the American Academy of Dermatology","<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Chronic, long-term sun exposure results in genetic changes in epidermal keratinocytes and the development</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">of various skin lesions ranging from actinic keratosis (AK) to skin cancer. AK lesions may first appear</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">as rough, scaly spots on sun-exposed skin, and, although most individual AK lesions do not become</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">invasive cancers, the majority of invasive squamous cell carcinomas originate from AK. Genetic analysis</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">demonstrates that ultraviolet radiationeinduced mutations and changes in gene expression are present in</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">squamous cell carcinoma, AK, and clinically normal-appearing perilesional sun-exposed skin, which</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">supports the progressive nature of keratinocyte transformation. The presence of certain clinical features,</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> such as large size, ulceration, or bleeding, suggests an increased risk of disease progression. The risk is also</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">increased by evidence of extensive solar damage, advanced age, and immunosuppression. Early diagnosis</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and consideration for treatment are indicated to clear actinically damaged sites and diminish the risk of</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">invasive squamous cell carcinoma. ( J Am Acad Dermatol 2013;68:S20-7.)</span><br />",,"/uploadfiles/file/20131205/20131205092138_4912.pdf",,12/05/2013,12/05/2013,"medicool",9,,"actinic keratosis; field cancerization; genetic mutations; immunosuppression; p53; risk factors",0,"66",104,"The importance of early diagnosis and treatment of actinic keratosis","2013",
565,,"org/10.1016/j.jaad.2012.10.050","Hye Jin Chung, MD,Kelly L. McGuigan, MD,Katie L. Osley, MD,Kate Zendell, MD,and Jason B. Lee, MD,Philadelphia, Pennsylvania, and Annapolis, Maryland","the American Academy of Dermatology","<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;""><strong>Background</strong>: The lack of well-established diagnostic criteria for pigmented solar (actinic) keratosis (PSK)</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">along with its poorly understood etiopathogenesis has contributed to underrecognition.</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">Objective: The clinical, dermatoscopic, and histopathologic features of PSK and the cause of the</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">pigmentation are elucidated.</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;""><strong>Methods</strong>: In all, 167 histologic specimens, 22 clinical images, and 17 dermatoscopic images of PSK were</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">reviewed. In 38 cases, Melan-Aestained sections were available for analysis.</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;""><strong>Results</strong>: The majority of the lesions were located on the head and neck (84%). A separate pigmented</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">lesion was adjacent to or admixed within PSK in 138 (83%) of the cases indicating that PSK represents a</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">collision between a nonpigmented solar keratosis and a pigmented lesion. Solar lentigo (72%) was the most</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">commonly associated pigmented lesion followed by seborrheic keratosis and melanoma. PSK was</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">suspected clinically in 17% of the cases. There were no significant differences in the quality and quantity of</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">the melanocytes between pigmented and nonpigmented solar keratosis.</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;""><strong>Limitations</strong>: This was a single-center retrospective study. The sample sizes were small for the clinical and</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">dermatoscopic images and Melan-A stains.</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;""><strong>Conclusion</strong>: In the majority of the cases, a collision between a nonpigmented solar keratosis and a</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">separate coexistent pigmented lesion, primarily a solar lentigo, accounts for the pigmentation in PSK rather</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">than from any fundamental changes in the quantity or quality of the melanocytes. The collision</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">phenomenon accounts for the spectrum of the clinical and dermatoscopic features observed in PSK and</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">its underrecognition. ( J Am Acad Dermatol 2013;68:647-53.)</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;""><strong>Key words</strong>: collision tumor; Melan-A; melanoma; pigmented actinic keratosis; pigmented solar keratosis;</span><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">solar lentigo; spreading pigmented actinic keratosis.</span><br />",,"/uploadfiles/file/20131205/20131205093941_5231.pdf",,12/05/2013,12/06/2013,"medicool",13,,"collision tumor; Melan-A; melanoma; pigmented actinic keratosis; pigmented solar keratosis;
solar lentigo; spreading pigmented actinic keratosis.",0,"67",104,"Pigmented solar (actinic) keratosis: An underrecognized collision lesion","2012",
568,"在印度一家三级医院回顾九年间眶膈前和眶蜂窝织炎以及社区获得性耐甲氧西林金黄色葡萄球菌的出现","10.4103/0301-4738.86309","Datt  a G Pandian, Ramesh K Babu, A Chaitra, A Anjali, Vasudev A Rao, Renuka Srinivasan","Indian?Journal?of?Ophthalmology","<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Context. </span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><a name=""OLE_LINK43""></a><a name=""OLE_LINK42""></a><span style=""font-size:14px;line-height:2;"">Preseptal cellulitis is the
commonest orbital disease which frequently needs to be differentiated from
orbital cellulitis. </span><a name=""OLE_LINK44""></a><a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span style=""font-size:14px;line-height:2;"">Prompt diagnosis and treatment with appropriate
antibiotics can prevent </span><a name=""OLE_LINK46""></a><a name=""OLE_LINK45""></a><span style=""font-size:14px;line-height:2;"">vision loss and</span><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span style=""font-size:14px;line-height:2;""> life-threatening complications of
orbital cellulitis.</span>
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><b><span style=""font-size:14px;line-height:2;"">环境：</span></b><b></b>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp;&nbsp; 眶膈前蜂窝织炎是最常见的眼眶疾病，经常需要与眼眶蜂窝织炎相鉴别。及时的诊断和应用适当的抗生素治疗可以防止视力减退和危及生命的眼眶蜂窝织炎并发症的发生。</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Aims.</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><a name=""OLE_LINK48""></a><a name=""OLE_LINK47""></a><span style=""font-size:14px;line-height:2;"">To describe the clinical profile
of cases with preseptal and orbital cellulitis admitted to a tertiary care hospital </span><a name=""OLE_LINK50""></a><a name=""OLE_LINK49""></a><span style=""font-size:14px;line-height:2;"">during
a period of nine years. </span><a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span style=""font-size:14px;line-height:2;"">The</span><a name=""OLE_LINK52""></a><a name=""OLE_LINK51""></a><span style=""font-size:14px;line-height:2;""> causative organisms and the clinical outcome were analyzed.</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">目的：</span></b><b></b>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp;&nbsp; 为了描述在九年期间中，一家三级医院纳入的眶膈前和眶蜂窝织炎病例的临床特点。对致病微生物及临床结果进行分析。</span>
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK53""></a><b><span style=""font-size:14px;line-height:2;"">Settings
and Design.</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><a name=""OLE_LINK55""></a><a name=""OLE_LINK54""></a><span style=""font-size:14px;line-height:2;"">Retrospective descriptive case
study done in a tertiary care hospital in South India.</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">地点与试验设计：</span></b><b></b>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp;&nbsp; 在南印度的一家三级医院进行一项回顾性描述的病例研究。</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Material and
Methods.</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span style=""font-size:14px;line-height:2;"">The in-patient records
of patients with preseptal and orbital cellulitis were reviewed from 1998 to
2006.</span><a name=""OLE_LINK57""></a><a name=""OLE_LINK56""></a> <a name=""OLE_LINK23""></a><a name=""OLE_LINK22""></a><a name=""OLE_LINK59""></a><a name=""OLE_LINK58""></a><span style=""font-size:14px;line-height:2;"">The
factors reviewed included </span><a name=""OLE_LINK60""></a><span style=""font-size:14px;line-height:2;"">ocular findings </span><a name=""OLE_LINK63""></a><span style=""font-size:14px;line-height:2;"">aiding in the distinction of </span><a name=""OLE_LINK62""></a><a name=""OLE_LINK61""></a><span style=""font-size:14px;line-height:2;"">the two
clinical conditions,
the duration of symptoms, the duration of hospital stay, microbiological
culture report of pus or wound swab, blood culture, drugs used for treatment,
the response to therapy and complications.</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">材料与方法：</span></b><b></b>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp;&nbsp; 对1998至2006年间的眶膈前和眶蜂窝织炎患者的住院记录进行审查。审查的因素包括眼部特征有利于区分两种疾病的临床症状、症状的持续时间、住院时间、脓液或创面拭子的微生物培养报告、血液培养、用于治疗的药物、对治疗和并发症的反应。</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Statistical
Analysis Used.</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:14px;line-height:2;"">Descriptive analysis.</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">统计分析方法：</span></b><b></b>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp;&nbsp; 描述性分析。</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Results.</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><span style=""font-size:14px;line-height:2;"">One hundred and ten
cases, 77 patients with preseptal cellulitis and 33 patients with orbital
cellulitis were reviewed.</span><a name=""OLE_LINK65""></a><a name=""OLE_LINK64""></a> <a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span style=""font-size:14px;line-height:2;"">Five
percent of children and 21% of adults presented with cutaneous anthrax
contributing to preseptal cellulitis. </span><a name=""OLE_LINK29""></a><a name=""OLE_LINK28""></a><span style=""font-size:14px;line-height:2;"">Thirty-nine
percent cases with orbital cellulitis were caused by methicillin-resistant
Staphylococcus aureus (MRSA).</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">结果：</span></b><b></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:14px;line-height:2;"">对110例其中77例眶膈前蜂窝织炎和33例眼眶蜂窝织炎进行审查。5%的儿童和21％的成人表现为皮肤炭疽引发的眶膈前蜂窝织炎。39%的眼眶蜂窝织炎病例由耐甲氧西林金黄色葡萄球菌（MRSA）引起。</span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Conclusions.</span></b>
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK31""></a><a name=""OLE_LINK30""></a><span style=""font-size:14px;line-height:2;"">This study has helped
in identifying organisms which cause orbital infections, especially community-acquired
MRSA. </span><a name=""OLE_LINK66""></a><a name=""OLE_LINK33""></a><a name=""OLE_LINK32""></a><span style=""font-size:14px;line-height:2;"">It
indicates the need for modifying our empirical antimicrobial therapy,
especially in orbital cellulitis.</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">结论：</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp;&nbsp; 这项研究有助于鉴定引起眼眶感染的生物，尤其是社区获得性MRSA。它表明我们需要修改经验性抗菌疗法，尤其对眼眶蜂窝织炎的治疗。</span>
</p>","/uploadfiles/image/20131205/20131205094814_5456w.jpg","/uploadfiles/file/20131205/20131205094732_4411.pdf",,12/05/2013,12/05/2013,"medicool",23,,,0,"67",106,"Nine years’ review on preseptal and orbital cellulitis and emergence of communityCacquired methicillin-resistant staphylococus aureus in a tertiary hospital in India","2011",
562,,"org/10.1016/j.pdpdt.2012.12.003","Hong Cai, Yi-Xia Wang, Ping Sun, Zhi-Yong Yang, Rong Tian,Xiao-Yong Liu, Qiang Li, Li Qiao, Wei Liu PhD","Department of Dermatology","<span style=""font-family:'Times New Roman';font-size:16px;""><strong>Summary.</strong></span><span style=""font-family:'Times New Roman';font-size:16px;""><strong></strong></span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Background</strong>: Photodynamic therapy (PDT) is a promising treatment modality for skin malignan-cies. Aminolevulinic acid (ALA)-PDT for the treatment of actinic keratosis (AK) has been wellstudied in Europe and North America. However, there have only been a few clinical studies thathave evaluated ALA-PDT for the treatment of AK in Chinese patients.<br />
<strong>Objective</strong>: The objective of our study was to determine the therapeutic response of Chinesepatients with AK lesions to photodynamic therapy (PDT), and the histologic changes associatedwith PDT.<br />
<strong></strong><strong>Methods</strong>: Forty-two patients with a total of 56 AK lesions on the face were enrolled in this study.After the application of 20% ALA under occlusion for 5 h, the lesions were illuminated by diodelaser ( = 630 nm; intensity 100 mW/cm2) for 30 min. All patients were reviewed at intervalsof at least 2 weeks. One month after therapy, response to PDT was evaluated and treatmentrepeated if necessary.<br />
<strong></strong><strong>Results</strong>: At 1 month after PDT, a complete response was achieved in 85.71% of treated lesions.The remaining lesions received one or two additional PDT treatments, and were eventuallycleared. Clinically, there was no significant scarring or pigmentary changes after therapy.<br />
<strong>Conclusions</strong>: In this small study, PDT using topical ALA was demonstrated to be a safe andeffective therapy for AK lesions with excellent cosmetic outcome. It is a promising treatmentthat merits further study in China.&copy; 2013 Elsevier B.V. All rights reserved.</span><br />",,"/uploadfiles/file/20131205/20131205092756_0119.pdf",,12/05/2013,12/06/2013,"medicool",13,,"Photodynamictherapy;Aminolevulinic acid;Actinic keratosis.",0,"66",104,"Photodynamic therapy for facial actinickeratosis: A clinical and histological study inChinese patients","2013",
563,,"Acta Derm Venereol 2013; 93: 433^37","Christina B. HALLDIN,Helena GONZALEZ,Ann-Marie WENNBERG,and Margret LEPP","Journal Compilation","<p>
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Photodynamic therapy (PDT) is a well-known, effective&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">method for treating extensive areas of multiple actinic<br />
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">kératoses in the face and scalp. The main side-effect of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">PDT is the pain experienced during treatment. The objective<br />
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">of this study was to explore and describe patients'&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">experiences of PDT. The study used individual interviews,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and analysis was carried out using phenomenography.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The patients had all been treated with PDT for&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">actinic kératoses on the face and scalp, and experienced&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">PDT with and without nerve blocks. The results are presented&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">in 3 themes and 10 categories. Most patients reported&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">that the nerve blocks given prior to PDT altered&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">their experience of pain. Alternative options are needed<br />
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">to reduce pain during PDT based on patients' needs and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">body site. This study adds a patient perspective highlighting<br />
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">patients' own voices as a qualitative complement to&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">statistical analysis using the visual analogue scale. Key&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">words: actinic kératoses; interviews; nerve blocks; pain;&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">phenomenography; photodynamic therapy.</span> 
</p>",,"/uploadfiles/file/20131205/20131205093229_0591.pdf",,12/05/2013,12/06/2013,"medicool",15,,"actinic kératoses; interviews; nerve blocks; pain;
phenomenography; photodynamic therapy.",0,"66",104,"Patients' Experiences of Pain and Pain Relief During Photodynamic Therapy on Actinic Kératoses: An Interview Study","2013",
564,,"10.1016/j.jaad.2009.07.026","Elizabeth E. Uhlenhake, BS, Omar P. Sangueza, MD, Andrew D. Lee, MD, and Joseph L. Jorizzo, MD Winston-Salem, North Carolina","Department of Dermatology","<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Introduction: Spreading pigmented actinic keratosis (SPAK) is a common, but uncommonly reported or</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">appreciated, variant of classic actinic keratosis (AK). It can mimic different pigmented lesions, which may</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">be benign (eg, solar lentigo) or malignant (eg, lentigo maligna).</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Objective</strong>: We sought to review current data and identify areas needing further research to establish</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">diagnostic guidelines for SPAK and to increase awareness of this common entity.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Methods</strong>: A literature search was performed in both PubMed and MEDLINE databases using the search terms</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">‘‘spreading pigmented actinic keratosis,’’ ‘‘pigmented solar keratosis,’’ ‘‘pigmented actinic,’’ and ‘‘pigmented</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">solar.’’ Each article was retrieved, reviewed, and summarized.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Results</strong>: SPAK is a rarely reported lesion that can be difficult to distinguish from other benign and malignant</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">pigmented lesions, including seborrheic keratosis,melanoma in situ (lentigomaligna type), and lentigomaligna</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">melanoma. Locatedmainly onsun-exposed areas and with a size greater than 1.5cm, the lesion typically spreads</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">laterally. Pathologically, the lesion resembles classic AK with increased basal melanization. The malignancy</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">potential has not yet been elucidated but destructive therapies such as cryotherapy are recommended.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Limitations: Reports not yet published or not included in the comprehensive databases we used may exist</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">that were not analyzed.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Conclusions</strong>: SPAK can be associated with adjacent melanoma in situ; therefore, its diagnosis merits</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">increased suspicion for coexisting melanoma. ( J Am Acad Dermatol 2010;63:499-506.)</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Key words</strong>: actinic keratosis; atypical junctional melanocytic proliferation; lentigo maligna; spreading</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">pigmented actinic keratosis; squamous cell carcinoma.</span><br />",,"/uploadfiles/file/20131205/20131205093535_7603.pdf",,12/05/2013,12/06/2013,"medicool",14,,"actinic keratosis; atypical junctional melanocytic proliferation; lentigo maligna; spreading
pigmented actinic keratosis; squamous cell carcinoma.",0,"67",104,"Spreading pigmented actinic keratosis: A review","2010",
329,"手术治疗鸡眼临床疗效观察","1673―7210(2011)09(b)一146―02","曹浩财，李文绮",,"<p align=""justify"">
	<span style=""font-family:Times New Roman;""><span style=""line-height:2;font-size:14px;""><br />
<strong>Oblective</strong>：To explore the CO</span><sub><span style=""line-height:2;font-size:14px;"">2 </span></sub><span style=""line-height:2;font-size:14px;"">laser new treatment and effective for com．</span></span><br />
<span style=""font-family:Times New Roman;""><span style=""font-size:14px;""><span style=""line-height:2;font-size:14px;""><strong>目的</strong>：探讨C0</span><sub><span style=""line-height:2;font-size:14px;"">2</span></sub><span style=""line-height:2;font-size:14px;"">激光治疗鸡眼的新治疗方法及其效果。</span></span><br />
<span style=""line-height:2;font-size:14px;""><strong>Methods</strong>：120 patients had been </span></span><span style=""font-family:Times New Roman;""><span style=""line-height:2;font-size:14px;"">treated by the CO</span><sub><span style=""line-height:2;font-size:14px;"">2</span></sub><span style=""line-height:2;font-size:14px;""> laser direct vaporizing in traditional method．104 patients had been treated in new method，that firsfly </span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""line-height:2;font-size:14px;"">the pathologic tissue of the corn was cleared away by surgical scissors，lastly the remnant tissue was vaporized by the C0</span><sub><span style=""line-height:2;font-size:14px;"">2</span></sub> </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">laser．</span><br />
<span style=""font-family:Times New Roman;""><span style=""line-height:2;font-size:14px;""><strong>方法</strong>：120例患者用CO</span><span style=""line-height:2;font-size:14px;""><sub>2</sub></span><span style=""line-height:2;font-size:14px;"">激光传统方法直接气化治疗(旧疗法组)；104例患者用新方法治疗(新疗法组)，即先用手术剪清除鸡眼病变组织，最后激光气化残余部分。</span><br />
<span style=""line-height:2;font-size:14px;""><strong>Results</strong>：The efective rate of traditional method group was 94.1％(113／120)，the new method group was 97.1％ (101／104)．</span></span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">By x tests，the diference was no significant(x =1.136，P&gt;0.05)．Wound diameter of the traditional method group was </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">(1.32+0.68)em，the healing time of the traditional method group was (6.96~0.86)days；wound diameter of the new method </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">group was(0．65+0．35)em，the healing time of the new method group was(2.77+0.27)days．By analysis of t tests，wound </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">diameter and the healing time between the two groups both had significant diference =2.03，P&lt;0.05；t=3.42，P&lt;0.05)．</span><br />
<span style=""font-family:Times New Roman;""><span style=""line-height:2;font-size:14px;""><strong>结果</strong>：旧疗法治愈88例，好转25例，有效率为94.1％(113／120)；新疗法治愈85例，好转16例，有效率为97.1％(101／104)，</span><span style=""line-height:2;font-size:14px;"">经x</span><span style=""line-height:2;font-size:14px;""><sup>2</sup></span><span style=""font-size:14px;""><span style=""line-height:2;font-size:14px;"">检验</span><span style=""line-height:2;font-size:14px;"">，两组有效率比较无显著性差异(x</span></span><span style=""line-height:2;font-size:14px;""><sup>2</sup></span><span style=""line-height:2;font-size:14px;"">=1.136，P&gt;0.05)。旧疗法伤口直径(1.32~0.68)cm，好转时间(6.96~0.86)d；</span><span style=""line-height:2;font-size:14px;"">新疗法伤口直径(0.65~0.35)cm，好转时间(2.77+0.27)d。两组伤口直径经t检验，有显著性差异(t=2.03，P&lt;0.05)；两</span><span style=""line-height:2;font-size:14px;"">组术后伤口好转时间经t检验，亦有显著性差异(t=3.42，P&lt;0.05)。</span><br />
<span style=""line-height:2;font-size:14px;""><strong>Conclusion</strong>：The new method group is better than the traditional method group．The new method of CO</span><sub><span style=""line-height:2;font-size:14px;"">2</span></sub><span style=""line-height:2;font-size:14px;""> laser treatment for </span></span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><span style=""line-height:2;font-size:14px;"">corn is a simple and practical technique with less side effect．</span></span><span style=""font-family:Times New Roman;""><br />
<span style=""line-height:2;font-size:14px;""><strong>结论</strong>：新方法治疗组优于传统方法治疗组。CO</span><sub><span style=""line-height:2;font-size:14px;"">2</span></sub><span style=""line-height:2;font-size:14px;"">激</span><span style=""line-height:2;font-size:14px;"">光治疗鸡眼新方法是一种治疗鸡眼简单实用、副作用少的方法。</span></span> 
</p>",,"/uploadfiles/file/20131024/20131024173149_4514.pdf",,10/24/2013,10/25/2013,"medicool",25,,"激光；鸡眼；新疗法",0,"66",90,"Study on the laser new treatment in corn","2011",
341,"距骨胼胝――一种未被认知的常见病",,"Verbov JL ; Monk CJ","Blackwell Scientific Publications","&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-family:'Times New Roman','serif';""><span style=""font-size:16px;"">An ankle </span><span style=""font-size:16px;"">callosity</span><span style=""font-size:16px;""> overlying the talus is defined and described in three patients and the lesion is considered common but often unrecognized. The aetiology is discussed.<br />
&nbsp;
<p class=""MsoNormal"" style=""text-indent:15.75pt;"">
	<span style=""font-family:宋体;"">对三名距骨上覆有踝关节胼胝的患者进行确诊和描述，该疾病的皮损病变是常见的，但很少被人认知。本文对该疾病的病因进行了讨论。</span><span style=""font-family:'Times New Roman','serif';""></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:9pt;font-family:'Times New Roman','serif';""></span>
</p>
</span></span>","/uploadfiles/image/20131025/20131025103901_4936w.png","/uploadfiles/file/20131025/20131025103917_8268.pdf",,10/25/2013,10/25/2013,"medicool",39,,,0,"85",93,"Talar callosity--a little-recognized common entity","2004",
346,"先天性甲肥厚症 l 型一家系调查","1000-4963(2007)03-0153― 03","马慧军，赵广，韩德奎 ，刘雯，李东光 ，史 飞","临床皮肤科杂志","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-size:16px;"">报告先天性甲肥厚症一家系，</span><span style=""font-size:16px;"">4代</span><span style=""font-size:16px;"">17人中有</span><span style=""font-size:16px;"">8人患病，</span><span style=""font-size:16px;"">8例患者均于出生后不久即有甲变色，</span><span style=""font-size:16px;"">继而甲增厚，</span><span style=""font-size:16px;"">2― 4 岁时出现</span><span style=""font-size:16px;"">掌跖角化，</span><span style=""font-size:16px;"">局部摩擦后可发生水疱和糜烂。 部分患者有舌苔白腻， 所有患者均未见胎生齿及脂囊瘤。 先证者双肘膝关节毛囊角化性</span><span style=""font-size:16px;"">丘疹</span><span style=""font-size:16px;"">。</span><span style=""font-size:16px;"">足趾及跖部灶性胼胝样角化过度， 20 甲营养不良。该家系中有 2 例患者 2 岁时因突发急性呼吸困难抢救无效而死亡。&nbsp;</span>",,"/uploadfiles/file/20131025/20131025111044_1198.pdf",,10/25/2013,10/25/2013,"medicool",37,,"甲肥厚， 先天性；调查， 家系",0,"65",93,,"2007",
331,,,"Farzaneh Dehghani, Ahmad Merat, Mohammad Reza Panjehshahin, Farhad Handjani","International Journal of Dermatology","<p align=""justify"">
	<span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp; Warts and corns are among the commonest conditions found </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">in dermatologic clinics and different approaches are employed </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">for their treatment. The present study was undertaken to </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">investigate the healing effect of both aqueous and lipid extracts </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">of garlic on warts and corns. Inclusion criteria for enrolling </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">patients in this study were: no treatment for warts in the previous </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">2 months prior to the initiation of the study, failure to </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">respond to conventional treatments in the past, and willingness </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">to participate in the study. Twenty-eight patients with </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">2C96 warts, nine patients with 1C2 corns and a control group </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">consisting of five patients with 7C35 warts were included in </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">the study after obtaining a written informed consent. Patients </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">were of both genders and aged between 5 and 62 years.</span> 
</p>",,"/uploadfiles/file/20131025/20131025085404_6830.pdf",,10/25/2013,10/25/2013,"medicool",30,,,0,"66",90,"Healing effect of garlic extract on warts and corns","2005",
354,"对风湿性关节炎患者疼痛的前脚跖部胼胝进行清创术：CARROT随机对照试验","10.1007/s10067-012-2134-x. Epub 2012 Dec 18","Siddle HJ, Redmond AC, Waxman R, Dagg AR, Alcacer-Pitarch B, Wilkins RA, Helliwell PS","Clin Rheumatol","<span style=""font-family:'Times New Roman','serif';""><span style=""font-family:Tahoma;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;"">The objective of this study was to evaluate the </span><span style=""font-size:14px;"">long-term benefits</span></a><span style=""font-size:14px;""> of </span><span style=""font-size:14px;"">sharp scalpel debridement</span></a><span style=""font-size:14px;""> of painful forefoot plantar callosities in rheumatoid arthritis (RA). </span><span style=""font-size:14px;"">The null hypothesis: sharp scalpel debridement would offer no additional long-term advantage in terms of pain and function.</span></a><span style=""font-size:14px;""> Sixty-five people with RA were randomised to receive regular sharp scalpel debridement of painful forefoot plantar callosities in conjunction with a combined therapeutic approach or a combined therapeutic approach alone. T</span><span style=""font-size:14px;"">he primary outcome measure was change at 18 months in participant-reported forefoot plantar pain measured by a 100-mm visual analogue scale (VAS).</span></a> <span style=""font-size:14px;"">Secondary outcome measures were recorded at baseline and study exit and included revised Foot Function Index, Health Assessment Questionnaire, Foot Impact Scale and gait parameters.</span></a><span style=""font-size:14px;""> At 18 months, </span><span style=""font-size:14px;"">there were no differences between groups for the primary outcome VAS-measured forefoot plantar pain (left foot (F = 0.23, p = 0.635), right foot (F = 2.14, p = 0.148))</span></a><span style=""font-size:14px;"">. </span><span style=""font-size:14px;"">Within-group changes were highly significant (treatment arm, difference = 16.9 (95 % confidence interval (CI) 9.4, 24.4), t = 4.6, p &lt; 0.0001; control arm, difference = 17.5 (95 % CI 9.4, 25.5), t = 4.4, p &lt; 0.0001). </span></a><span style=""font-size:14px;"">There was little change in scores of overall function and foot impact in either group and there were no significant changes in gait parameters noted. </span></a><span style=""font-size:14px;"">The long-term effects of sharp scalpel debridement of painful forefoot plantar callosities in people with RA, when used in conjunction with a combined therapeutic approach, produced no additional benefit over the combined therapeutic approach alone. <br />
&nbsp;
<p class=""MsoNormal"">
	<span style=""font-family:宋体;"">&nbsp;&nbsp;&nbsp; 本研究旨在评估对类风湿关节炎（</span><span style=""font-family:'Times New Roman','serif';"">RA</span><span style=""font-family:宋体;"">）患者疼痛的前掌足底胼胝进行外科手术清创的长远益处。零假设：就其所产生的痛苦和作用而言，外科手术清创没有提供额外的长期益处。从</span><span style=""font-family:'Times New Roman','serif';"">65</span><span style=""font-family:宋体;"">名类风湿关节炎伴有令人不适的前脚掌足底胼胝的患者中随机选取一部分定期接受外科手术清创同时使用联合治疗，剩下的仅接受联合治疗。关于参与者前脚跖疼痛（通过一个</span><span style=""font-family:'Times New Roman','serif';"">100</span><span style=""font-family:宋体;"">毫米的视觉模拟评分法测定）的主要结果测定在</span><span style=""font-family:'Times New Roman','serif';"">18</span><span style=""font-family:宋体;"">个月内发生变化。次要结果测定在研究初始和结束后进行记录，包括修订的足部功能指数，健康评估问卷，足部冲击量表和步态参数。在</span><span style=""font-family:'Times New Roman','serif';"">18</span><span style=""font-family:宋体;"">个月左右，两组之间的</span><span style=""font-family:'Times New Roman','serif';"">VAS</span><span style=""font-family:宋体;"">测测定前脚跖疼痛（左脚（</span><span style=""font-family:'Times New Roman','serif';"">F=0.23</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">P= 0.635</span><span style=""font-family:宋体;"">），右脚（</span><span style=""font-family:'Times New Roman','serif';"">F =2.14</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">P= 0.148</span><span style=""font-family:宋体;"">）的结果无显著差异。组内变化非常显著（治疗组，差异</span><span style=""font-family:'Times New Roman','serif';"">=16.9</span><span style=""font-family:宋体;"">（</span><span style=""font-family:'Times New Roman','serif';"">95</span><span style=""font-family:宋体;"">％可信区间（</span><span style=""font-family:'Times New Roman','serif';"">CI</span><span style=""font-family:宋体;"">）</span><span style=""font-family:'Times New Roman','serif';"">9.4</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">24.4</span><span style=""font-family:宋体;"">），</span><span style=""font-family:'Times New Roman','serif';"">T= 4.6</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">P &lt;0.0001;</span><span style=""font-family:宋体;"">对照组，差异</span><span style=""font-family:'Times New Roman','serif';"">=17.5</span><span style=""font-family:宋体;"">（</span><span style=""font-family:'Times New Roman','serif';"">95</span><span style=""font-family:宋体;"">％</span><span style=""font-family:'Times New Roman','serif';"">CI</span><span style=""font-family:宋体;"">为</span><span style=""font-family:'Times New Roman','serif';"">9.4</span><span style=""font-family:宋体;"">％，</span><span style=""font-family:'Times New Roman','serif';"">25.5</span><span style=""font-family:宋体;"">）</span><span style=""font-family:'Times New Roman','serif';"">T =4.4</span><span style=""font-family:宋体;"">，</span><span style=""font-family:'Times New Roman','serif';"">P &lt;0.0001</span><span style=""font-family:宋体;"">）。两组在整体功能和足部治疗效果上的分数变化不大，且步态参数并没有显着变化。外科手术清创与联合治疗方法相结合治疗类风湿关节炎患者的前脚跖部胼胝，其长期效果与仅用联合方法治疗相比没有优势。</span><span style=""font-family:'Times New Roman','serif';""></span>
</p>
</span></a></span><span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-family:'Times New Roman','serif';""></span>
</p>","/uploadfiles/image/20131025/20131025161014_5713w.png","/uploadfiles/file/20131025/20131025161114_9590.pdf",,10/25/2013,10/25/2013,"medicool",64,,"Callusdebridement.Forefootpain.Metatarsophalangealjoint.Plantarcallosities.Rheumatoid arthritis",0,"66",93,"Debridement of painful forefoot plantar callosities in rheumatoid arthritis: the CARROT randomised controlled trial","2012",
332,,,"R.SWAIN","Clinical and Experimental Dermatology","<span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp; A Corn (Clavus) is a hyperkeratotic response to friction or pressure, usually present over bony </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">prominences of the foot, occasionally of the fingers. Corns cause exquisite pain due to pressure </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">on nerve endings and can become infected with subsequent cellulitis (Wilkinson, 1979).</span><br />
<span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp; Conventional treatments for corns include removal of the cause where possible, topical </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">applications of keratolytic agents and surgical excision or enucleation. I wish to report here a </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">new treatment for corns which I tried on myself and found to be dramatically effective.</span>",,"/uploadfiles/file/20131025/20131025085749_9474.pdf",,10/25/2013,10/25/2013,"medicool",38,,,0,"66",90,"Topical 5-fluorouracil for corns―an effective","1986",
333,,,"Weston WL ; Morelli JG","Pediatric Dermatology","<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:11.0pt;font-family:&quot;"">&nbsp;</span><strong><span style=""color:#333333;font-weight:normal;font-family:'Times New Roman';"">Childhood</span></strong><b><span style=""font-family:&quot;color:#333333;""> </span></b><strong><span style=""color:#333333;font-weight:normal;font-family:'Times New Roman';"">pernio</span></strong><b><span style=""font-family:&quot;color:#333333;""> </span></b><span style=""font-family:&quot;color:#333333;"">is an uncommon condition described
mainly through isolated case reports. We examined the cutaneous spectrum,
clinical associations, presence of cryoproteins, and evolution of the condition
in children, and performed a retrospective case series evaluation of children
with <strong><span style=""font-weight:normal;"">pernio</span></strong> seen at a single ambulatory care university center over a 10-year period. Cases
were drawn from a population of 3.2 million. Follow-up was at least 3 years. We
found four boys and four girls with<b> </b><strong><span style=""font-weight:normal;"">pernio</span></strong>. Distribution
of skin lesions was on the fingers, toes, and ears. Four children had
cryoglobulins or cold agglutinins, two had a positive rheumatoid factor, and
none had a positive ANA or ANA profile. All eight cleared within 3 months and
did not recur over at least a 3-year period. We concluded that <strong><span style=""font-weight:normal;"">childhood</span></strong><b> </b><strong><span style=""font-weight:normal;"">pernio</span></strong> is uncommon and may be
associated with the presence of cryoproteins.</span><span style=""font-family:&quot;""></span>
</p>",,"/uploadfiles/file/20131025/20131025090043_1077.pdf",,10/25/2013,10/25/2013,"medicool",21,,,0,"66",88,"Childhood pernio and cryoproteins","2000",
361,"由临床发起的，口服泛昔洛韦2次/日治疗复发性生殖器疱疹：一项随机，双盲，对照试验",,"Sacks SL ; Aoki FY ; Martel AY ; Shafran SD ; Lassonde M","Clinical Infectious Diseases: An Official Publication Of The Infectious Diseases Society Of America","<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-family:Times New Roman;font-size:14px;""><b><span style=""font-family:Times New Roman;font-size:14px;"">Background. </span></b></span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;"">Famciclovir,
the oral prodrug of penciclovir, is effective for the treatment of recurrent
genital herpes. </span><a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">This
randomized, clinic-initiated, double-blind trial compared the therapeutic
ef?cacy and safety of treatment with famciclovir </span></span></span><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">at
dosages of 125 mg, 250 mg, and 500 mg twice daily for 5 days</span></span></span></span></span><span><span><span><span><span style=""font-family:Times New Roman;font-size:14px;""> with
placebo in </span><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span style=""font-family:Times New Roman;font-size:14px;"">immunocompetent adults</span><span style=""font-family:Times New Roman;font-size:14px;""> with a
recurrent episode of genital herpes. </span></span></span></span></span></span></span></span>
</p>
<span></span><span></span><span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;"">研究背景：泛昔洛韦（喷昔洛韦口服前体药物）能有效治疗复发性生殖器疱疹。这项随机的、由临床发起的、双盲实验旨在研究，应用泛昔洛韦（剂量为</span><span style=""font-size:14px;"">125mg</span><span style=""font-family:宋体;font-size:14px;"">、</span><span style=""font-size:14px;"">250mg</span><span style=""font-family:宋体;font-size:14px;"">、</span><span style=""font-size:14px;"">500mg</span><span style=""font-family:宋体;font-size:14px;"">，</span><span style=""font-size:14px;"">2</span><span style=""font-family:宋体;font-size:14px;"">次</span><span style=""font-size:14px;"">/</span><span style=""font-family:宋体;font-size:14px;"">日，持续治疗</span><span style=""font-size:14px;"">5</span><span style=""font-family:宋体;font-size:14px;"">日）与安慰剂对照相比，治疗伴有复发性生殖器疱疹的免疫功能正常患者的有效性与安全性。</span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span style=""font-family:Times New Roman;font-size:14px;""><b><span style=""font-family:Times New Roman;font-size:14px;"">Methods.</span></b></span><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span><span><span><span style=""font-family:&quot;""> </span></span></span></span><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Ef?cacy and
tolerability were assessed in 308 patients with lesions present for no more
than 6.5 h at the time of the ?rst dose.</span></span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;""> <a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span style=""font-family:Times New Roman;font-size:14px;"">Two assessments per day
were performed to increase the precision of </span><a name=""OLE_LINK11""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">the
determination of</span></span><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""> study
end points</span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">. </span></span></span></span></span></span></span>
</p>
<span></span><span></span><span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;"">研究方法：对首次给予剂量在不超过</span><span style=""font-family:&quot;font-size:14px;"">6.5h</span><span style=""font-family:宋体;font-size:14px;"">内出现皮损的</span><span style=""font-family:&quot;font-size:14px;"">308</span><span style=""font-family:宋体;font-size:14px;"">例患者进行</span><span style=""font-family:宋体;font-size:14px;"">有效性</span><span style=""font-family:宋体;font-size:14px;"">和耐受性的评估。每日进行</span><span style=""font-family:&quot;font-size:14px;"">2</span><span style=""font-family:宋体;font-size:14px;"">次评估来确定研究终点的精准度。</span><span style=""font-family:&quot;""></span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-family:Times New Roman;font-size:14px;""><b><span style=""font-family:Times New Roman;font-size:14px;"">Results. </span></b></span><a name=""OLE_LINK36""></a><a name=""OLE_LINK35""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">All
doses of famciclovir were signi?cantly more effective than placebo in </span></span></span></span><a name=""OLE_LINK38""></a><a name=""OLE_LINK37""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">reducing the time to </span></span></span></span></span></span><a name=""OLE_LINK39""></a><a name=""OLE_LINK14""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">cessation of viral
shedding</span></span></span></span></span></span></span></span><span><span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;"">, complete lesion
healing, and loss of all lesion-associated symptoms, particularly </span><a name=""OLE_LINK41""></a><a name=""OLE_LINK40""></a><span style=""font-family:Times New Roman;font-size:14px;"">lesion
tenderness</span><span style=""font-family:Times New Roman;font-size:14px;"">, pain, and itching.</span></span></span></span></span></span><span><span><span style=""font-family:&quot;""> <a name=""OLE_LINK43""></a><a name=""OLE_LINK42""></a><span style=""font-family:Times New Roman;font-size:14px;"">Patients receiving
treatment with famciclovir were signi?cantly less likely to experience new
lesions than were patients receiving placebo</span><span style=""font-family:Times New Roman;font-size:14px;"">. All doses of
famciclovir were tolerated as well as placebo was. </span><a name=""OLE_LINK45""></a><a name=""OLE_LINK44""></a><span style=""font-family:Times New Roman;font-size:14px;"">There was no difference
in ef?cacy or tolerability among the different doses of famciclovir</span><span style=""font-family:Times New Roman;font-size:14px;"">;
the lowest effective dose was 125 mg twice per day. </span></span></span></span>
</p>
<span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;""><span style=""font-size:14px;"">研究结果：与安慰剂对照相比，服用泛昔洛</span><a name=""OLE_LINK15""></a><span style=""font-size:14px;"">韦能更显著有效缩短病毒停止排出时间、皮损愈合、以及所有皮损相关症状，特别是病变压痛、疼痛和瘙痒的消失。接受泛昔洛韦治疗的患者发生新的皮损病变的可能性明显小于安慰剂对照组。每种</span></span><span style=""font-family:宋体;font-size:14px;"">剂量的泛昔洛韦所表现出的耐受性同安慰剂对照组一致。不同剂量的泛昔洛韦其疗效或耐受性之间没有显着差异；最低有效剂量为</span><span style=""font-size:14px;"">125</span><span style=""font-family:宋体;font-size:14px;"">毫克（</span><span style=""font-size:14px;"">2</span><span style=""font-family:宋体;font-size:14px;"">次</span><span style=""font-size:14px;"">/</span><span style=""font-family:宋体;font-size:14px;"">日）。</span>
</p>
<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<b><span style=""font-family:Times New Roman;font-size:14px;"">Conclusions.</span></b><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;""> In immunocompetent
adults with recurrent genital herpes, a 5-day course of famciclovir at a dosage
of 125 mg, 250 mg, or 500 mg twice per day was signi?cantly more effective than
was placebo </span><a name=""OLE_LINK49""></a><a name=""OLE_LINK48""></a><span style=""font-family:Times New Roman;font-size:14px;"">in reducing the duration of viral shedding and
symptoms and in accelerating lesion healing</span><span style=""font-family:Times New Roman;font-size:14px;"">. </span><a name=""OLE_LINK47""></a><a name=""OLE_LINK46""></a><span style=""font-family:Times New Roman;font-size:14px;"">These results support
the use of treatment with famciclovir at a dosage of 125 mg for 5 days as an
effective, well-tolerated treatment for episodes of recurrent genital herpes.</span></span>
</p>
<span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;"">研究结论：对患有复发性生殖器疱疹的免疫功能正常的患者应用</span><span style=""font-family:宋体;font-size:14px;"">泛昔洛韦（</span><span style=""font-family:宋体;font-size:14px;"">剂量为</span><span style=""font-family:&quot;font-size:14px;"">125mg</span><span style=""font-family:宋体;font-size:14px;"">、</span><span style=""font-family:&quot;font-size:14px;"">250mg</span><span style=""font-family:宋体;font-size:14px;"">、</span><span style=""font-family:&quot;font-size:14px;"">500mg</span><span style=""font-family:宋体;font-size:14px;"">（</span><span style=""font-family:&quot;font-size:14px;"">2</span><span style=""font-family:宋体;font-size:14px;"">次</span><span style=""font-family:&quot;font-size:14px;"">/</span><span style=""font-family:宋体;font-size:14px;"">日，连续</span><span style=""font-family:&quot;font-size:14px;"">5</span><span style=""font-family:宋体;font-size:14px;"">日）进行治疗，其疗效与安慰剂对照组相比，在减少病毒排出以及症状持续时间，加速皮损愈合方面，</span><span style=""font-family:宋体;font-size:14px;"">泛昔洛韦显示出了</span><span style=""font-family:宋体;font-size:14px;"">更好的疗效。这些实验结果表明应用</span><span style=""font-family:宋体;font-size:14px;"">泛昔洛韦</span><span style=""font-family:宋体;font-size:14px;"">（</span><span style=""font-family:&quot;font-size:14px;"">125mg/</span><span style=""font-family:宋体;font-size:14px;"">剂量，持续</span><span style=""font-family:&quot;font-size:14px;"">5</span><span style=""font-family:宋体;font-size:14px;"">日）</span><span style=""font-family:宋体;font-size:14px;"">治疗复发性生殖器疱疹发作是有效的并且耐受性良好。</span><span style=""font-family:&quot;""></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;</span>
</p>
<p class=""MsoNormal"" style=""text-align:center;"" align=""center"">
	<span style=""font-size:9pt;font-family:Times New Roman;"">Stephen L. Sacks
et.al</span><span style=""font-size:9pt;font-family:Times New Roman;"">；</span><span><a><span style=""font-size:9pt;font-family:Times New Roman;"">Clinical
Infectious Diseases: An Official Publication Of The Infectious Diseases Society
Of America</span></a></span><span style=""font-size:9pt;font-family:Times New Roman;"">；</span><span style=""font-size:9pt;font-family:Times New Roman;"">2005 Oct 15</span><span style=""font-size:9pt;font-family:Times New Roman;"">；</span><span style=""font-size:9pt;font-family:Times New Roman;"">Vol. 41 (8), pp.
1097-104.</span>
</p>","/uploadfiles/image/20131031/20131031143621_4426w.jpg","/uploadfiles/file/20131031/20131031143634_0318.pdf",,10/31/2013,10/31/2013,"medicool",67,,,0,"66",96,"Clinic-Initiated, Twice-Daily Oral Famciclovir for Treatment of Recurrent Genital Herpes: A Randomized, Double-Blind, Controlled Trial","2005",
334,,"10.1080/13814780701471068","Souwer IH ; Robins LJ ; Lagro-Janssen AL","The European Journal Of General Practice","<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp; Chronic chilblains is generally considered by doctors to
be a slightly inconvenient and harmless condition. We observed that a large
number of our patients showed unexpectedly severe complaints, with a distinct
impact on daily life. Adequate information about the clinical picture is
available (1_6), but we did not find any publications about how patients feel
about their symptoms, nor about the measures they take to cope with them.
Therefore, the aim of our study was to gain better insight by interviewing
patients on two issues: 1) how do patients experience chronic chilblains, and
what are their views on the condition? 2) How do patients cope with the
disease, and what are their needs?</span>
</p>",,"/uploadfiles/file/20131025/20131025091850_3672.pdf",,10/25/2013,10/25/2013,"medicool",35,,,0,"66",88,"Chilblains from the patient's perspective","2007",
335,,,"Benchikhi H ; Roujeau JC ; Levent M ; Gouault-Heilmann M ; Revuz J ; Cosnes A","Acta Dermato-Venereologica","<p class=""MsoNormal"">
	<span style=""font-family:&quot;color:#333333;"">&nbsp; Hereditary protein C and S deficiencies are risk factors for
thrombosis. They are associated with purpura fulminans and coumarin-induced
skin necrosis. Recently, necrotic livedo of the extremities, severe <strong><span style=""font-weight:normal;"">chilblains</span></strong><b> </b>and severe frostbite have been
observed in protein C or S deficient patients. Our study was designed to
evaluate the prevalence of cold-induced acral manifestations in patients with
protein C or S deficiency. One-hundred-and-six patients with protein C or S
deficiency and controls matched for sex and age were studied by questionnaire.
Data included any history of acral manifestation possibly related to cold
exposure, i.e. <strong><span style=""font-weight:normal;"">chilblains</span></strong>, <strong><span style=""font-weight:normal;"">Raynaud</span></strong><b> </b><strong><span style=""font-weight:normal;"">phenomenon</span></strong>,
acrocyanosis and possible associated factors. Assessment of the diagnosis by a
dermatologist was recorded. No difference was found in the prevalence of acral
manifestations between patients and controls. This study suggests that protein
C and S deficiencies are not risk factors for cold-induced acral
manifestations.</span><span style=""font-family:&quot;""></span>
</p>",,"/uploadfiles/file/20131025/20131025092538_0271.pdf",,10/25/2013,10/25/2013,"medicool",30,,,0,"66",88,"Chilblains and Raynaud phenomenon are usually not a sign of hereditary protein C and S deficiencies","1998",
356,"类维生素A联合γ-干扰素成功治疗巨大型尖锐湿疣","10.1258/ijsa.2011.011331","Y P Tian, L Yao, P Malla, Y Song and S S Li","International Journal of STD & AIDS","<p class=""MsoNormal"" style=""text-align:center;"" align=""center"">
	<b><span style=""font-size:16pt;font-family:宋体;color:#313131;""></span></b><b><span style=""font-size:16pt;font-family:宋体;""></span></b>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Summary:</span></b><span style=""font-family:'Times New Roman','serif';""> <a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span style=""font-size:14px;"">Giant condyloma acuminatum, or </span></a><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">BuschkeCL?wenstein</span></span></span></a><span><span><span style=""font-size:14px;""> tumour, is </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span style=""font-size:14px;"">a unique variant of </span></a><a name=""OLE_LINK36""></a><a name=""OLE_LINK35""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">anogenital warts</span></span></span></a><span style=""font-size:14px;"">. </span></span></span><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-size:14px;"">It is characterized by </span></a><a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">locally aggressive behaviour </span></span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;"">but rarely metastasizes.</span></span> <a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""font-size:14px;"">Many treatment strategies such as radical surgery, radiation and chemotherapy have been used to treat it but their efficacy is often poor and the recurrence rates are high. </span></a><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span style=""font-size:14px;""><span style=""font-size:14px;"">We report a case of 16- year-old girl who was treated with oral</span></span></a><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""> retinoid </span></span></span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">combined with intramuscular interferon-</span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;font-family:宋体;"">γ</span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">.</span></span></span></span><span style=""font-family:'Times New Roman','serif';""> <a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span style=""font-size:14px;"">All lesions cleared within three months.</span></a> <a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span style=""font-size:14px;""><span style=""font-size:14px;"">During a </span></span></a><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">follow-up period </span></span></span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">of more than two years, no recurrence has developed.</span></span></span> <a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span style=""font-size:14px;"">This relatively painless, non-scarring treatment may</span></a><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""> represent </span></span></span></a><span><span><span style=""font-size:14px;"">a novel </span><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><span style=""font-size:14px;"">therapeutic option</span></a><span style=""font-size:14px;"">.</span></span></span></span> 
</p>
<span></span><span></span> 
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman','serif';""></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;font-family:宋体;"">摘要</span></b><span style=""font-size:14px;font-family:宋体;"">：巨大型尖锐湿疣（或</span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;"">BuschkeCL</span><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span style=""font-size:14px;"">?</span></a><span style=""font-size:14px;"">wenstein</span></span><span style=""font-family:宋体;""><span style=""font-size:14px;"">肿瘤）是肛门生殖器疣的一种独特变体，其特点是局部性侵略感染，但极少发生转移。许多治疗方法已被用于治疗该疾病，如根治性手术、放射治疗和化学治疗，但往往疗效不佳、复发率高。我们报道了一例口服类维生素</span><span style=""font-size:14px;"">A</span><span style=""font-size:14px;"">结合肌肉注射γ</span><span style=""font-size:14px;"">-</span><span style=""font-size:14px;"">干扰素治疗</span><span style=""font-size:14px;"">16</span><span style=""font-size:14px;"">岁女患者的的病例。该患者所有的病变在三个月内均被清除，在两年多的随访期内，无复发。这种相对无痛、无疤的治疗方法可能提供了一种新的治疗选择。</span></span> 
</p>","/uploadfiles/image/20131029/20131029145424_4530w.jpg","/uploadfiles/file/20131031/20131031100758_4859.pdf",,10/29/2013,11/01/2013,"medicool",56,,,0,"66",97,"Successful treatment of giant condyloma acuminatum with combination retinoid and interferon-g therapy","2012",
359,"利用中心实验数据监控不列颠哥伦比亚省单纯疱疹-1型和-2型病毒的感染趋势以及生殖器疱疹的病因变化",,"Gilbert M ; Li X ; Petric M ; Krajden M ; Isaac-Renton JL ; Ogilvie G ; Rekart ML","Canadian Journal Of Public Health","<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span style=""font-family:Times New Roman;font-size:14px;""><b><span style=""font-family:Times New Roman;font-size:14px;"">Objectives: </span></b></span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;"">Understanding
the regional epidemiology of genital Herpes Simplex Virus (</span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span style=""font-family:Times New Roman;font-size:14px;"">HSV</span><span style=""font-family:Times New Roman;font-size:14px;"">)
infections is important for clinical and public health practice, </span><a name=""OLE_LINK33""></a><a name=""OLE_LINK32""></a><span style=""font-family:Times New Roman;font-size:14px;"">due
to the increasing availability of type-specific serologic testing in Canada and </span><a name=""OLE_LINK35""></a><a name=""OLE_LINK34""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">the contribution of genital HSV-2 infection to
ongoing HIV transmission.</span></span> </span><a name=""OLE_LINK37""></a><a name=""OLE_LINK36""></a><span style=""font-family:Times New Roman;font-size:14px;"">We used </span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">centralized
laboratory data</span></span></span><span><span><span style=""font-family:Times New Roman;font-size:14px;""> to describe trends in </span><a name=""OLE_LINK39""></a><a name=""OLE_LINK38""></a><span style=""font-family:Times New Roman;font-size:14px;"">viral identifications
of </span><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">genital HSV</span></span></span></span></span><span><span> </span></span><span style=""font-family:Times New Roman;font-size:14px;"">in
BC and assess the utility of these data for </span><a name=""OLE_LINK41""></a><a name=""OLE_LINK40""></a><span style=""font-family:Times New Roman;font-size:14px;"">ongoing population
surveillance.</span></span></span></span> 
</p>
<span></span><span></span><span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;"">研究目的：因为在加拿大特定类型的血清学检测日渐普及且生殖器疱疹病毒</span><span style=""font-family:&quot;font-size:14px;"">HSV-2</span><span style=""font-family:宋体;font-size:14px;"">感染导致了</span><span style=""font-family:&quot;font-size:14px;"">HIV</span><span style=""font-family:宋体;font-size:14px;"">持续传播，所以了解生殖器单纯疱疹病毒（</span><span style=""font-family:&quot;font-size:14px;"">HSV</span><span style=""font-family:宋体;font-size:14px;"">）感染的区域流行病学，对临床研究和公共卫生实践具有重要意义。我们利用中心实验室数据来描述</span><span style=""font-size:14px;"" class=""shorttext""><span style=""font-size:14px;"">BC</span></span><span style=""font-size:14px;"" class=""shorttext""><span style=""font-family:宋体;font-size:14px;"">省</span></span><span style=""font-family:宋体;font-size:14px;"">生殖器疱疹</span><span style=""font-family:宋体;font-size:14px;"">病毒鉴定的发展趋势，并评估这些数据对于持续人口监测的效用。</span><span style=""font-family:&quot;""></span><span style=""font-family:&quot;font-size:14px;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<b><span style=""font-family:Times New Roman;font-size:14px;"">Methods: </span></b><a name=""OLE_LINK43""></a><a name=""OLE_LINK42""></a><a name=""OLE_LINK45""></a><a name=""OLE_LINK44""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Records of viral
identifications</span></span></span></span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;""> (1997-2005) were</span><a name=""OLE_LINK47""></a><a name=""OLE_LINK46""></a><span style=""font-family:Times New Roman;font-size:14px;""> extracted from</span> <a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span style=""font-family:Times New Roman;font-size:14px;"">the Provincial Public
Health Microbiology &amp; Reference Laboratory database</span></span></span></span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;"">. </span><a name=""OLE_LINK49""></a><a name=""OLE_LINK48""></a><span style=""font-family:Times New Roman;font-size:14px;"">Classification as
genital or other site was based on </span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">documented specimen site</span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">.</span></span> <a name=""OLE_LINK51""></a><a name=""OLE_LINK50""></a><span style=""font-family:Times New Roman;font-size:14px;"">We
conducted a descriptive analysis of trends over time, and calculated odds of
HSV-1 infection among individuals with genital herpes.</span></span> 
</p>
<span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;"">研究方法：我们对摘录自省公共卫生微生物学以及参考实验室数据库中（</span><span style=""font-family:&quot;font-size:14px;"">1997-2005</span><span style=""font-family:宋体;font-size:14px;"">年间）的病毒鉴定记录进行研究。生殖器疱疹或其他部位疱疹的分类都基于所记录的标本部位。随着时间的推移，我们对发展趋势进行了描述性分析，并计算出在生殖器疱疹个体中感染</span><span style=""font-family:&quot;font-size:14px;"">HSV-1</span><span style=""font-family:宋体;font-size:14px;"">的几率。</span><span style=""font-family:&quot;""></span><span style=""font-family:&quot;font-size:14px;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<a name=""OLE_LINK3""></a><b><span style=""font-family:Times New Roman;font-size:14px;"">Results: </span></b><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;"">Of
48,183 viral identifications, 56.8% were genital, 10.0% were peri-oral and 9.1%
cutaneous; site was unknown for 22.9%. Among genital identifications, </span><a name=""OLE_LINK53""></a><a name=""OLE_LINK52""></a><span style=""font-family:Times New Roman;font-size:14px;"">HSV-1
infection was more likely in females, </span><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">younger age groups</span></span></span><span><span><span style=""font-family:Times New Roman;font-size:14px;"">, and </span><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span style=""font-family:Times New Roman;font-size:14px;"">later
time periods</span><span style=""font-family:Times New Roman;font-size:14px;"">.</span></span></span><span style=""font-family:Times New Roman;font-size:14px;""> The proportion of genital herpes due to
HSV-1 increased over time from 31.4% to 42.8% in BC.</span></span></span> 
</p>
<span></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;"">研究结果：在</span><span style=""font-family:&quot;font-size:14px;"">48,183</span><span style=""font-family:宋体;font-size:14px;"">例病毒鉴定中，</span><span style=""font-family:&quot;font-size:14px;"">56.8%</span><span style=""font-family:宋体;font-size:14px;"">感染部位在生殖器、</span><span style=""font-family:&quot;font-size:14px;"">10.0%</span><span style=""font-family:宋体;font-size:14px;"">在口周、</span><span style=""font-family:&quot;font-size:14px;"">9.1%</span><span style=""font-family:宋体;font-size:14px;"">在皮肤；其他未知部位占</span><span style=""font-family:&quot;font-size:14px;"">22.9%</span><span style=""font-family:宋体;font-size:14px;"">。在生殖器鉴定中，</span><span style=""font-family:&quot;font-size:14px;"">HSV-1</span><span style=""font-family:宋体;font-size:14px;"">感染更可能出现于女性，年轻群体以及随后周期。在</span><span style=""font-family:&quot;font-size:14px;"">BC</span><span style=""font-family:宋体;font-size:14px;"">省，随着时间的推移由于</span><span style=""font-family:&quot;font-size:14px;"">HSV-1</span><span style=""font-family:宋体;font-size:14px;"">感染所致的生殖器疱疹所占比例从</span><span style=""font-family:&quot;font-size:14px;"">31.4%</span><span style=""font-family:宋体;font-size:14px;"">上升至</span><span style=""font-family:&quot;font-size:14px;"">42.8%</span><span style=""font-family:宋体;font-size:14px;"">。</span><span style=""font-family:&quot;""></span><span style=""font-family:&quot;font-size:14px;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.1pt;"">
	<a name=""OLE_LINK5""></a><a name=""OLE_LINK4""></a><span style=""font-family:Times New Roman;font-size:14px;""><b><span style=""font-family:Times New Roman;font-size:14px;"">Conclusions: </span></b></span><a name=""OLE_LINK54""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Our
analysis of </span></span></span><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">population-level
laboratory data</span></span></span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""> demonstrates</span></span></span></span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;""> that the proportion
of genital herpes due to HSV-1 is increasing over time in BC, particularly
among women and younger age groups; </span><a name=""OLE_LINK56""></a><a name=""OLE_LINK55""></a><span style=""font-family:Times New Roman;font-size:14px;"">this has implications
for clinical practice including the interpretation of type-specific serology.</span> <a name=""OLE_LINK58""></a><a name=""OLE_LINK57""></a><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">Provincial viral
identification data</span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""> are useful for monitoring the distribution of
genital HSV-1 and HSV-2 infections over time</span></span><span style=""font-family:Times New Roman;font-size:14px;"">. </span><a name=""OLE_LINK60""></a><a name=""OLE_LINK59""></a><span style=""font-family:Times New Roman;font-size:14px;"">Improving clinical
documentation of specimen site would </span><a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">improve the utility of these
data</span></span></span><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">.</span></span></span></span></span> 
</p>
<span></span><span></span><span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;"">研究结论：人口水平实验室数据的分析表明：在</span><span style=""font-family:&quot;font-size:14px;"">BC</span><span style=""font-family:宋体;font-size:14px;"">省，由于</span><span style=""font-family:&quot;font-size:14px;"">HSV-1</span><span style=""font-family:宋体;font-size:14px;"">感染所致生殖器疱疹比例随着时间的推移而增加，特别是在女性和年轻群体中；这对临床实践包括对特定类型的血清学阐释都产生影响。省病毒识别数据可有效监测（随着时间的推移）生殖器疱疹</span><span style=""font-family:&quot;font-size:14px;"">HSV-1</span><span style=""font-family:宋体;font-size:14px;"">和</span><span style=""font-family:&quot;font-size:14px;"">HSV-2</span><span style=""font-family:宋体;font-size:14px;"">感染的分布情况。完善临床标本部位的）记录，可提高这些数据的有效性。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-align:center;text-indent:18.0pt;"" align=""center"">
	<span style=""font-size:12px;font-family:Times New Roman;"">Mark Gilbert, MD et.al;Canadian Public Health
Association, 2011;Vol.102(3);pp.225-29.</span> 
</p>","/uploadfiles/image/20131031/20131031141516_8108w.jpg","/uploadfiles/file/20131031/20131031141530_2580.pdf",,10/31/2013,10/31/2013,"medicool",38,,"Herpes simplex; herpes simplex, genital; epidemiology; Canada",0,"65",96,"Using Centralized Laboratory Data to Monitor Trends in Herpes Simplex Virus Type 1 and 2 Infection in British Columbia and the Changing Etiology of Genital Herpes","2011",
336,"针刺结合艾条灸治疗鸡眼58例","1006―4931(2012)Z1一O239-02","郭新荣，马小卫","中国药业","<strong><span style=""font-size:14px;""><br />
<span style=""line-height:2;"">目的：</span></span></strong><span style=""line-height:2;font-size:14px;"">观察针刺结合艾条灸治疗鸡眼的效果。</span><br />
<strong><span style=""line-height:2;font-size:14px;"">方法：</span></strong><span style=""font-size:14px;""><span style=""line-height:2;"">采用针刺结合艾条灸治疗鸡眼患者</span><span style=""line-height:2;font-family:Times New Roman;"">58</span><span style=""line-height:2;"">例。</span></span><br />
<strong><span style=""line-height:2;font-size:14px;"">结果：</span></strong><span style=""font-size:14px;""><span style=""line-height:2;"">治愈</span><span style=""line-height:2;font-family:Times New Roman;"">48</span><span style=""line-height:2;"">例，好转</span><span style=""line-height:2;font-family:Times New Roman;"">5</span><span style=""line-height:2;"">例，未</span></span><span style=""font-size:14px;""><span style=""line-height:2;"">愈</span><span style=""line-height:2;font-family:Times New Roman;"">5</span><span style=""line-height:2;"">例．总有效率为</span><span style=""line-height:2;font-family:Times New Roman;"">91.</span></span><span style=""font-size:14px;""><span style=""line-height:2;font-family:Times New Roman;"">4％</span><span style=""line-height:2;"">。</span></span><br />
<strong><span style=""line-height:2;font-size:14px;"">结论：</span></strong><span style=""line-height:2;font-size:14px;"">针刺结合艾条灸治疗鸡眼是一种较好的治疗方法，对正常人体组织无创伤、痛苦很小、操作简便，</span><span style=""font-size:14px;""><span style=""line-height:2;"">并可</span><span style=""line-height:2;"">自行操作，治疗后可自由活动，不影响个人的卫生生活习惯，值得临床大力推广应用。</span></span>",,"/uploadfiles/file/20131025/20131025093104_5981.pdf",,10/25/2013,10/25/2013,"medicool",33,,"鸡眼；针刺；艾条灸",0,"85",90,,"2012",
337,"欧洲足部疾病的高患病率：跟腱项目的结果",,"T. Burzykowski,1 G. Molenberghs, D. Abeck, E. Haneke, R. Hay, A. Katsambas, D. Roseeuw, P. van de Kerkhof, R. van Aelst and G. Marynissen","Blackwell Publishing Ltd ? Mycoses","<span><span style=""line-height:150%;font-family:'Times New Roman','serif';""> 
<p class=""MsoNormal"" align=""justify"">
	<br />
<span style=""line-height:1.5;font-size:14px;"">Objective</span></span><span style=""line-height:2;font-family:宋体;font-size:14px;"">：</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:2;font-size:14px;"">To provide an insight into the </span><span style=""line-height:2;font-size:14px;"">prevalence</span></a><span style=""line-height:2;font-size:14px;""> of foot disease in Europe, and to include an assessment of the prevalence of predisposing factors and their correlation with foot disease.</span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:150%;font-family:宋体;""><span style=""line-height:1.5;font-size:14px;"">目的：</span><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-size:14px;"">旨在对欧洲足部疾病患病率进行深入调查，评估足部疾病的诱发因素及其与该疾病的关系</span></span></a><span style=""line-height:1.5;font-size:14px;"">。</span></span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">Design</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">：</span></span><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;""><span style=""line-height:1.5;font-size:14px;"">Large population-based survey</span></span></span></a><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;""><span style=""line-height:1.5;font-size:14px;""> conducted in 16 European countries. </span></span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">设计：研究以大量人群为基础，在</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">16</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">个欧洲国家内展开调查。</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">Setting</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">：</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:1.5;font-size:14px;"">The project consisted of two parts (study </span><span style=""line-height:1.5;font-size:14px;"">I </span></a><span style=""line-height:1.5;font-size:14px;"">and study II), in which all patients presenting to general practitioners and dermatologists over a defined time period were invited to participate. </span></span></span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">环境：该项目包括两个部分（研究</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">I</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">和研究</span></span><span style=""line-height:1.5;font-size:14px;""><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;""><span style=""line-height:1.5;font-size:14px;"">II</span></span></span></a><span></span><span></span><span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">），所有患者的都是由全科医生和皮肤科医生在一个规定的时间内邀请参加。</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">Patients</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">：</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""> </span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">In study I, 70497 patients presenting to dermatologists or general practitioners were recruited, and in study II 19 588 patients presenting to dermatologists were recruited. </span></span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">患者：在研究</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">I</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">中，皮肤科医生或全科医生招募到了</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">70497</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">名患者；在研究</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">II</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">中，</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">19588</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">名患者被皮肤科医生招募。</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">Main outcome measure</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">：</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">The feet of all participants were examined for signs of foot disease. The assessors also recorded relevant details such as the age and sex of patients, and the presence of predisposing factors for foot disease. In addition, patients in study II were offered a free mycological examination of the toenails and skin on the feet. </span></span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">主要观察指标：对所有参与者的双脚进行了足病迹象的检查。评估人员还记录了相关的详细信息，如患者的年龄、性别和足部疾病存在的诱发因素。此外，研究</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">II</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">中的患者还进行了一项免费的脚趾甲和脚部皮肤的真菌学检查。</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">Results</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">：</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""><span style=""line-height:1.5;font-size:14px;"">In study I, 57.0% of patients had at least one foot disease. In study </span><span style=""line-height:1.5;font-size:14px;"">II</span></a><span style=""line-height:1.5;font-size:14px;"">, 61.3% had at least one foot disease. The proportions of patients with fungal foot disease and non-fungal foot disease in study I were 34.9% and 38.4%, respectively, and in study II were 40.6% and 41.7%, respectively. Orthopedic conditions and metatarsal corns were the most frequently reported non-fungal foot diseases, and onychomycosis and tinea pedis were the most frequently observed fungal infections.</span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">结果：患有至少一种足部疾病的患者在研究</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">I</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">中的比例为</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">57.0</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">％，在研究</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">II</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">中占</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">61.3</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">％。在研究</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">I</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">中，患有真菌性足部疾病和非真菌性足部疾病的患者比例分别为</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">34.9</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">％和</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">38.4</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">％，而研究</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">II</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">中则分别为</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">40.6</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">％和</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">41.7</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">％。骨科疾病和跖骨鸡眼是最常报道的非真菌性足部疾病，而甲癣和脚癣是最常见的真菌感染性疾病。</span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">Conclusions</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">：</span><span style=""line-height:1.5;font-family:'Times New Roman','serif';font-size:14px;"">This large-scale survey suggests that the prevalence of fungal and nonfungal foot disease is higher than previously estimated.</span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""line-height:1.5;font-family:宋体;font-size:14px;""><span style=""line-height:1.5;font-size:14px;"">结论：大规模的调查表明，真菌性和非真菌性足部疾病的患病率比之前估计的高。</span></span><span style=""line-height:150%;font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"">
	&nbsp;
</p>","/uploadfiles/image/20131025/20131025094826_9919w.jpg","/uploadfiles/file/20131025/20131025094749_6142.pdf",,10/25/2013,10/25/2013,"medicool",30,,,0,"65",90,"High prevalence of foot diseases in Europe: results of the Achilles","2003",
338,,,"Emel Krkek, M.D., Mukadder Kogak, M.D., Onder Bo/dogan, M.D., Pinar Atasoy, M.D., Ahu Birol, M.D.","Pediatric Dermatology","<p align=""justify"">
	<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong>Abstract: </strong>Acrokeratoelastoidosis and focal acral hyperkeratosis share </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">similar clinical features and identical histologic epidermal alterations.These </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">disorders are distinguished solely on the basis of the absence of elastorrhexis </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">in the latter. We present a case of focal acral hyperkeratosis in a 9-yearold </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">girl.The lesions consisted of translucent polygonal papules clustered on </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">the thenar regions of the palms and over the metacarpophalangeal and </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">interphalangeal joints. Histopathologic examination revealed orthohyperkeratosis </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">within focal clavus-like depressions of the epidermis and prominent </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">hypergranulosis. There was no evidence of alterations in elastic tissue. The </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">clinicopathologic distinction between focal acral hyperkeratosis and </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">acrokeratoelastoidosis is blurred. There is enough evidence to consider the </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">former as a histologic variant of Costa acrokeratoetastoidosis syndrome, </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">and a better nomenclature for this disorder would be acrokeratoelastoidosis </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">without elastorrhexis.""</span>
</p>",,"/uploadfiles/file/20131025/20131025101638_8773.pdf",,10/25/2013,10/25/2013,"medicool",20,,,0,"65",90,"Focal Acral Hyperkeratosis: A Rare Cutaneous Disorder within the Spectrum of Costa Acrokeratoelastoidosis ","2004",
342,"一项减少皮肤剪切及摩擦的新技术：在野外环境下水疱护理启示",,"Adrian A. Polliack, PhD; Samuel Scheinberg, MD","Wilderness and Environmental Medicine","<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:'font-size:14px;color:#231f20;"">Objective.</span></b><span style=""font-family:';color:#231f20;""><span style=""font-size:14px;"">―</span><a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span style=""font-size:14px;"">It is well known that physical trauma to skin caused by repetitive friction is a primary component of blister formation</span><span style=""font-size:14px;"">. Although friction blisters in a wilderness setting particularly occur on the feet and ankles, they often form on the hands and fingers during such activities as white-water rafting, kayaking, and canoeing. These blisters are often incapacitating and can have disabling consequences. This article describes laboratory and clinical experiments testing the efficacy of a new bandage technology in reducing shear and friction forces on the skin.</span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;color:#231f20;""><span style=""font-size:14px;""><strong>研究目的：</strong></span><span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;color:#231f20;font-size:14px;"">众所周知，由于反复摩擦</span><span style=""font-family:宋体;color:#313131;font-size:14px;"">导致的皮肤损伤是形成水疱的主要因素。</span><span style=""font-family:宋体;font-size:14px;"">虽然在野外环境中，双足和踝关节的位置特别容易出现摩擦水疱，但是当我们进行</span><span style=""font-family:宋体;color:#313131;font-size:14px;"">白水漂流</span><span style=""font-family:'font-size:14px;color:#313131;"">, </span><span style=""font-family:宋体;color:#313131;font-size:14px;"">皮划艇或独木舟这类运动时，它们也经常出现在双手和手指处。这些水泡往往导致我们失去了运动能力，甚至可能带来严重的后果。本文旨在介绍，一项新的绷带技术对于减少皮肤剪切和摩擦在实验室及临床上的有效性。</span><span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:'font-size:14px;color:#231f20;"">Methods.</span></b><span style=""font-family:';color:#231f20;""><span style=""font-size:14px;"">―A custom-made apparatus was used in a laboratory setting to measure and compare the surface coefficient of friction of 11 bandages. In addition, a controlled clinical study was conducted on 15 healthy, able-bodied female subjects (mean age 35 years), where </span><a name=""OLE_LINK7""></a><span style=""font-size:14px;"">the same apparatus was used to measure the coefficient of friction of the skin over the medial tibial cortex. </span></span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;color:#231f20;""><span style=""font-size:14px;""><strong>研究方法：</strong></span><span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;color:#231f20;""><span style=""font-size:14px;"">通过使用专门定制的仪器对实验室环境进行检测，比较</span><span style=""font-size:14px;"">11</span><span style=""font-size:14px;"">个绷带的表面摩擦系数。</span></span><span style=""font-family:宋体;""><span style=""font-size:14px;"">此外，对</span><span style=""font-size:14px;"">15</span><span style=""font-size:14px;"">名身体健全的受试者（女性，平均年龄</span><span style=""font-size:14px;"">35</span><span style=""font-size:14px;"">岁</span></span><span style=""font-family:宋体;font-size:14px;"">）进行临床对照研究，使用相同的仪器，测量胫骨内侧皮质皮肤的摩擦系数</span><span style=""font-family:宋体;color:#313131;font-size:14px;"">。</span><span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<b><span style=""font-family:'font-size:14px;color:#231f20;"">Results.</span></b><span style=""font-family:';color:#231f20;""><span style=""font-size:14px;"">―</span><a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span style=""font-size:14px;"">This laboratory study demonstrated the new device to have the lowest surface coefficient of friction of any bandage tested </span><span style=""font-size:14px;"">(0.57). For example, </span><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span style=""font-size:14px;"">the common product Moleskin was 21% higher (0.67), with all other products testing at least 64% higher</span><span style=""font-size:14px;""> (</span></span><span style=""font-family:';color:#231f20;""><span style=""font-size:14px;"">0.94). In the clinical study, the new technology device reduced the coefficient of friction on the skin by 31% (0.225 vs 0.327), and </span><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span style=""font-size:14px;"">this difference was statistically significant </span><span style=""font-size:14px;"">(</span></span><i><span style=""font-family:'font-size:14px;color:#231f20;"">P &lt;</span></i><span style=""font-family:';color:#231f20;""><span style=""font-size:14px;"">0.01).</span><br />
</span><span style=""font-family:宋体;color:#313131;font-size:14px;""><strong>研究结果</strong></span><span style=""font-family:'font-size:14px;color:#313131;""><strong>:</strong></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;color:#313131;font-size:14px;"">实验室研究表明，这种新型的设备在任何绷带测试中都具有最低的表面摩擦系数的（</span><span style=""font-family:'font-size:14px;color:#313131;"">0.57</span><span style=""font-family:宋体;color:#313131;font-size:14px;"">）。例如</span><span style=""font-family:'font-size:14px;color:#313131;"">,</span><span style=""font-family:宋体;color:#313131;font-size:14px;"">这种普通的斜纹棉布要比其高出</span><span style=""font-family:'font-size:14px;color:#313131;"">21%(0.67),</span><span style=""font-family:宋体;color:#313131;font-size:14px;"">其他产品测试结果至少比其高出</span><span style=""font-family:'font-size:14px;color:#313131;"">64%(0.94)</span><span style=""font-family:宋体;color:#313131;font-size:14px;"">。在临床研究中</span><span style=""font-family:'font-size:14px;color:#313131;"">,</span><span style=""font-family:宋体;color:#313131;font-size:14px;"">这项新技术设备使皮肤表面摩擦系数减少到</span><span style=""font-family:'font-size:14px;color:#313131;"">31%(0.225 vs 0.327),</span><span style=""font-family:宋体;color:#313131;font-size:14px;"">并且这种差异有统计学意义</span><span style=""font-family:'font-size:14px;color:#313131;"">(P &lt; 0.01)</span><span style=""font-family:宋体;color:#313131;""><span style=""font-size:14px;"">。</span><br />
</span><b><span style=""font-family:'font-size:14px;color:#231f20;"">Conclusions.</span></b><span style=""font-family:';color:#231f20;""><span style=""font-size:14px;"">―</span><a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span><span><span><span style=""font-size:14px;"">A bandage containing a new </span><span style=""font-size:14px;"">technology</span></span></span></span><span><span><span style=""font-size:14px;""> demonstrated the lowest surface coefficient of </span><span style=""font-size:14px;"">friction of any bandage tested. In addition, clinical tests performed with the </span><span style=""font-size:14px;"">same bandage demonstrated significant reduction of the coefficient of friction </span><span style=""font-size:14px;"">on the skin.</span><br />
<span style=""font-size:14px;""><strong></strong></span></span></span></span><span style=""font-family:宋体;color:#313131;font-size:14px;""><strong>研究结论：</strong></span><span style=""font-family:';color:#313131;""></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;color:#313131;font-size:14px;"">包含新技术的绷带，在任何绷带测试中都显示出了最低的表面摩擦系数。此外，在临床试验中采用相同的绷带，显著降低了皮肤的摩擦系数。</span> 
</p>","/uploadfiles/image/20131025/20131025104331_2493w.jpg","/uploadfiles/file/20131025/20131025104235_7288.pdf",,10/25/2013,10/25/2013,"medicool",54,,"blisters, skin friction, skin breakdown, coefficient of friction, shear",0,"66",94,"A New Technology for Reducing Shear and Friction Forces on the Skin: Implications for Blister Care in the Wilderness Setting","2006",
340,"足底角化过度：一项关于胼胝与正常足底皮肤的研究",,"Thomas SE ; Dykes PJ ; Marks R","Nature Publishing Group","<span style=""font-family:'Times New Roman','serif';""><span style=""font-family:Tahoma;"">&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;"">Although </span><span style=""font-size:14px;"">callosities</span> <span style=""font-size:14px;"">of the</span> <span style=""font-size:14px;"">plantar</span> <span style=""font-size:14px;"">skin</span><span style=""font-size:14px;""> are common and often disabling, little is known of their pathology or the reasons for their persistence.</span><span> </span></a><span><span><span><span style=""font-size:14px;"">In this </span><span style=""font-size:14px;"">study</span> <span style=""font-size:14px;"">plantar</span><span style=""font-size:14px;""> epidermal structure and cell renewal were investigated in patients with </span><span style=""font-size:14px;"">callosities</span><span style=""font-size:14px;""> and </span><span style=""font-size:14px;"">normal</span><span style=""font-size:14px;"">, age-, sex- and site-matched control subjects. </span></span></span></span></a><span style=""font-size:14px;"">Tritiated thymidine autoradiographic labeling indices were increased in the calluses but the dansyl chloride fluorescence clearance time was prolonged, reflecting the increased thickness of the stratum corneum.</span></a> <span style=""font-size:14px;"">The number of corneocytes that could be removed from the surface of </span><span style=""font-size:14px;"">callosities</span><span style=""font-size:14px;""> by </span><span style=""font-size:14px;"">a</span> <span style=""font-size:14px;"">standardized stimulus was considerably increased compared to controls but after adhesive tape stripping no such increase was observed.</span></a> <span><span style=""font-size:14px;"">The density of corneocytes as measured on Percoll gradients was decreased in corneocytes from callus compared to </span><span style=""font-size:14px;"">normal</span> <span style=""font-size:14px;"">plantar</span> <span style=""font-size:14px;"">skin</span><span style=""font-size:14px;"">, and their volume was increased. </span></span></a><span><span style=""font-size:14px;"">These observations suggest that there are differences in epidermal differentiation due to an increased rate of epidermal cell production in </span><span style=""font-size:14px;"">plantar</span> <span style=""font-size:14px;"">skin</span><span style=""font-size:14px;""> affected by callosity.<br />
&nbsp;
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-family:宋体;"">尽管足底胼胝十分常见，并且常常导致患者活动功能障碍，但是很少有人知道其病理学原理及持久存在的原因。本文对胼胝患者以及正常人（年龄、性别和所在地均与之匹配的对照组）的足底表皮结构和细胞再生进行研究。</span><span style=""font-family:宋体;"">在胼胝患者中氚标记的胸腺嘧啶自显影标记指数增加，而</span><span style=""font-family:宋体;"">丹磺酰氯荧光消除时间延长，这反应出角质层厚度增加。</span><span style=""font-family:宋体;"">通过标准化的刺激，从胼胝表面移除的角质细胞数量与对照组相比明显增加，但当粘合带剥离后，没有观察到数量的增加。通过</span><span style=""font-family:'Times New Roman','serif';"">Percoll</span><span style=""font-family:宋体;"">梯度离心分离测得胼胝患者角质细胞的密度与正常足底皮肤相比有所减少，并且它们的体积增加。这些观察表明，由于受到胼胝影响，足底皮肤的表皮细胞生长速度增加导致了表皮分化的差异。</span><span style=""font-family:'Times New Roman','serif';""></span>
</p>
</span></span></span>","/uploadfiles/image/20131025/20131025103300_1970w.png","/uploadfiles/file/20131025/20131025103320_5706.pdf",,10/25/2013,10/25/2013,"medicool",32,,,0,"65",93,"Plantar hyperkeratosis: a study of callosities and normal plantar skin","2006",
343,,,"Hisashi Wakita, Kenji Nishimura, and Masahiro Takigawa","J Invest Dermatol","<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""> 
<p align=""justify"">
	<br />
The composition of molecular species of free long-chain </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">bases (FLCB) isolated from stratum corneum of various </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">human skin conditions was analyzed by the high-performance </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">liquid chromatographic and fast atom bombardment </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">mass spectrometric methods. FLCB with carbon length </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">ranging from 16 to 20 comprised about 0.3% of total lipids in </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">stratum corneum of normal and pathologic skin conditions. </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">Major FLCB included sphinganines and sphingenines with </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">18 to 20 carbons and some phytosphingosines such as t l7:1, </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">t l 8 : l , tl8:0, t20:l, and t 20:0. Compared with stratum </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">corneum of normal lower legs, molar percentages of FLCB </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">having 18 carbons and those with 20 carbons were slightly </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">higher and lower, respectively, in normal plantar epidermis, </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">showing site-related differences in normal skin. Psoriatic </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">scales and hyperkeratotic stratum corneum from clavus and </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">plantar keratoderma contained increased levels of FLCB with </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">18 carbons and decreased levels of FLCB with 20 carbons. </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">These findings may reflect abnormal keratinization in hyperkeratotic </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">skin conditions.<span style=""display:none;"" id=""__kindeditor_bookmark_end_13__""></span></span> 
</p>",,"/uploadfiles/file/20131025/20131025105048_6429.pdf",,10/25/2013,10/25/2013,"medicool",28,,,0,"65",90,"Composition of Free Long-Chain (Sphingoid) Bases in Stratum Corneum of Normal and Pathologic Human Skin Conditions ","1992",
344,,"10.1111/j.1365-2230.2007.02421.x","H. B. Menz, G. V. Zammit and S. E. Munteanu","Plantar pressure and calluses","<p align=""justify"">
	<br />
<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong>Background:</strong></span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">Mechanically induced hyperkeratotic lesions (corns and calluses) are </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">among the most common foot problems in older people. However, their aetiology is not </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">well understood.</span><br />
<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong>Aim:</strong> To compare the magnitude of pressures generated under the foot when walking </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">in older people with and without plantar calluses.</span><br />
<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong>Methods: </strong>Peak plantar pressure measurements were obtained from 292 participants </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">(99 men and 193 women) aged 62C96 years (mean ± SD 77.6 ± 6.9) recruited from </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">a retirement village and a university health sciences clinic. Comparisons were then </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">made between callused and noncallused regions of the foot.</span><br />
<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong>Results: </strong>In total, 151 participants (52%) had at least one plantar callus. Those with </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">plantar calluses were more likely to be female, have moderate to severe hallux valgus, </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">and at least one lesser toe deformity. Regional peak plantar pressures were significantly </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">higher in people with calluses under the second metatarsophalangeal joint </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">(2.34 ± 0.46 vs. 2.12 ± 0.51 kg ? cm2, P ? 0.001), the third to fifth </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">metatarsophalangeal joints (1.71 ± 0.46 vs. 1.50 ± 0.51 kg ? cm2, P ? 0.009) and </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">the hallux (1.40 ± 0.34 vs. 1.23 ± 0.47 kg ? cm2, P ? 0.007) compared with people </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">without calluses under these sites.</span><br />
<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong>Conclusion:</strong> Plantar pressures are significantly higher under callused regions of the </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">foot in older people. Raised pressure may play a role in the development of plantar </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">calluses by accelerating the turnover rate of keratinocytes in the epidermis. Future </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">studies should focus on evaluating the efficacy of pressure-relieving interventions in </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">the prevention and treatment of keratotic disorders in older people.</span> 
</p>",,"/uploadfiles/file/20131025/20131025105610_3310.pdf",,10/25/2013,10/25/2013,"medicool",31,,,0,"65",90,"Plantar pressures are higher under callused regions of the foot in older people","2007",
345,,"10.1111/j.1748-5827.2009.00892.x","M. J. GUILLIARD, I. SEGBOER AND D. H. SHEARER","Journal of Small Animal Practice","<p align=""justify"">
	<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong><br />
OBJECTIVES: </strong>To describe the signalment and response to surgical </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">treatment, and to propose aetiopathogenetic mechanisms for the </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">development of paw pad corns in dogs.</span><br />
<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong>METHODS: </strong>A combined retrospective and prospective study was </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">conducted on 30 dogs that presented with paw pad corns. The age, </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">breed and gender of the dogs, together with anatomical positions </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">of the corns were recorded. Surgical treatments involved either </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">excision (n=27) or distal digital ostectomy (n=3). The minimum </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">follow-up period was one year.</span><br />
<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong>RESULTS: </strong>The age at presentation was from two to 15 years. All the </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">breeds in this study were either greyhounds or sighthounds. Males </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">were over-represented. Ninety percent of the corns were found in </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">the digital pads of digits three and four, and 90% were found in </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">the thoracic limbs. The evidence suggests a mechanical aetiology </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">or foreign body penetration. Long-term response to surgical excision </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">resulted in a recurrence rate of more than 50% (n=27). Distal </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">digital ostectomy gave good results in selective cases (n=3).</span><br />
<span style=""line-height:2;font-family:Times New Roman;font-size:14px;""><strong>CLINICAL SIGNIFICANCE:</strong> Corns can cause severe chronic lameness in </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">greyhounds and related breeds. Long-term response to surgical </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">treatments is disappointing but it is recommended as an initial </span><span style=""line-height:2;font-family:Times New Roman;font-size:14px;"">treatment as it can be curative.</span>
</p>",,"/uploadfiles/file/20131025/20131025110829_4915.pdf",,10/25/2013,10/25/2013,"medicool",26,,,0,"65",90,"Corns in dogs; signalment, possible aetiology and response to surgical treatment","2010",
348,"冻疮与抗磷脂抗体：四例病例报道及文献回顾","10.1111/j.1365-2133.2010.09829.x","Lutz V ; Cribier B ; Lipsker D","The British Journal Of Dermatology","<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp; MADAM, Chilblains are skin lesions resulting from
abnormal response to cold temperature and </span><span style=""font-family:&quot;"">?</span><span style=""font-family:&quot;"">or humid climate. They manifest as erythematous or
purplish, infiltrated papules or plaques localized on fingers, toes, ears and
nose. In the majority of cases they are idiopathic, but they can be associated with
some diseases. </span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp;&nbsp;女士，冻疮是在低温（潮湿）气候下出现异常反应而引起的皮肤损伤。皮损常表现为紫红色、浸润丘疹或斑块，主要集中于手指，脚趾，耳朵以及鼻子这几个部位。在大多数情况下，冻疮具有原发性，但也可能与某些疾病相关。</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">Chilblain lupus erythematosus is a form of chronic
cutaneous lupus erythematosus which is difficult to distinguish clinically from
idiopathic chilblain. We report four patients in whom chilblains were
associated with antiphospholipid antibodies.<br />
&nbsp;</span><span style=""font-family:'} ';text-indent:10.5pt;"">冻疮样红斑狼疮是盘状红斑狼疮的一种表现形式，而在临床上它与特发性冻疮难以区分。我们报道的四例冻疮患者出现冻疮的原因可能都与抗磷脂抗体有关。</span><span style=""font-family:&quot;"">
	<p class=""MsoNormal"">
		<o:p></o:p>
	</p>
</span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:10.5pt;"">
	<span style=""font-family:&quot;"">This association is probably underestimated, as it is not
recommended in most textbooks to search for antiphospholipid antibodies in the
initial exploration of chilblains. We discuss the relevance of this finding. </span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;"">&nbsp; 然而这种关联（冻疮的出现与抗磷脂抗体水平有关）可能不受重视，因为在冻疮的初始探索中，不推荐在大多数教科书中查找抗磷脂抗体的相关资料。我们围绕这一发现的相关性展开讨论。&nbsp; <br />
</span><span style=""font-family:宋体;""><br />
<br />
</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" align=""right"" style=""text-align:right;"">
	<span><a href=""file://C:/Users/Administrator/Desktop/%E5%86%BB%E7%96%AE/%E7%9B%B8%E5%85%B3%E6%96%87%E7%8C%AE/%E7%BB%BC%E8%BF%B0/%E4%BD%99%E5%A8%9F%E8%AF%91%EF%BC%9A%E5%86%BB%E7%96%AE%EF%BC%88%E7%BB%BC%E8%BF%B0%EF%BC%89.docx""><i><span style=""font-size:9.0pt;font-family:&quot;"">Lutz V</span></i></a></span><i><span style=""font-size:9.0pt;font-family:&quot;""> et al./ </span></i><span><a href=""file://C:/Users/Administrator/Desktop/%E5%86%BB%E7%96%AE/%E7%9B%B8%E5%85%B3%E6%96%87%E7%8C%AE/%E7%BB%BC%E8%BF%B0/%E4%BD%99%E5%A8%9F%E8%AF%91%EF%BC%9A%E5%86%BB%E7%96%AE%EF%BC%88%E7%BB%BC%E8%BF%B0%EF%BC%89.docx""><i><span style=""font-size:9.0pt;font-family:&quot;"">The
British Journal Of Dermatology</span></i></a></span><i><span style=""font-size:9.0pt;font-family:&quot;"">,
2010 Sep; Vol. 163 (3), pp. 645-6</span></i><i><span style=""font-family:&quot;""></span></i> 
</p>","/uploadfiles/image/20131025/20131025130021_6841w.jpg","/uploadfiles/file/20131025/20131025125947_7697.pdf",,10/25/2013,10/25/2013,"medicool",55,,"antiphospholipid antibodies, antiphospholipid syndrome, chilblain",0,"67",88,"Chilblains and antiphospholipid antibodies: report of four cases and review of the literature","2010",
352,,"10.1093/rheumatology/keh435","Davys HJ, Turner DE, Helliwell PS, Conaghan PG, Emery P, Woodburn J","Rheumatology (Oxford)","<div>
	<h4>
		<span style=""font-size:12px;"">OBJECTIVE:</span>
	</h4>
	<p>
		<span style=""font-size:12px;"">&nbsp; To compare forefoot pain, pressure and function before and after normal and sham callus treatment in </span><span class=""highlight"" style=""font-size:12px;"">rheumatoid arthritis</span><span style=""font-size:12px;""> (RA). Patients and</span>
	</p>
	<h4>
		<span style=""font-size:12px;"">METHODS:</span>
	</h4>
	<p>
		<span style=""font-size:12px;"">&nbsp; Thirty-eight RA patients were randomly assigned to normal (NCT group) or sham (SCT) scalpel </span><span class=""highlight"" style=""font-size:12px;"">debridement</span><span style=""font-size:12px;"">. The sham procedure comprised blunt-edged scalpel paring of the callus which delivered a physical stimulus but left the hyperkeratotic tissue intact, the procedure being partially obscured from the patient. Forefoot pain was assessed using a 100 mm visual analogue scale (VAS), pressure using a high-resolution foot pressure scanner and function using the spatial-temporal gait parameters measured on an instrumented walkway. Radiographic scores of joint erosion were obtained for metatarsophalangeal (MTP) joints with and without overlying </span><span class=""highlight"" style=""font-size:12px;"">callosities</span><span style=""font-size:12px;"">. The trial consisted of a randomized sham-controlled phase evaluating the immediate same-day treatment effect and an unblinded 4-week follow-up phase.</span>
	</p>
	<h4>
		<span style=""font-size:12px;"">RESULTS:</span>
	</h4>
	<p>
		<span style=""font-size:12px;"">&nbsp; During the sham-controlled phase, forefoot pain improved in both groups by only 3 points on a VAS and no statistically significant between-group difference was found (P = 0.48). When data were pooled during the unblinded phase, the improvement in forefoot pain reached a peak after 2 days and gradually lessened over the next 28 days. Following </span><span class=""highlight"" style=""font-size:12px;"">debridement</span><span style=""font-size:12px;"">, peak pressures at the callus sites decreased in the NCT group and increased in the SCT group, but there was no statistically significant between-group difference (P = 0.16). The area of and duration of contact of the callus site on the ground remained unchanged following treatment in both groups. Following </span><span class=""highlight"" style=""font-size:12px;"">debridement</span><span style=""font-size:12px;"">, walking speed was increased, the stride-length was longer and the double-support time shorter in both groups; however, between-group differences did not reach levels of statistical significance. MTP joints with overlying callus were significantly more eroded than those without (P = 0.02).</span>
	</p>
	<h4>
		<span style=""font-size:12px;"">CONCLUSIONS:</span>
	</h4>
	<p>
		<span style=""font-size:12px;"">&nbsp; Treatment of painful </span><span class=""highlight"" style=""font-size:12px;"">plantar</span> <span class=""highlight"" style=""font-size:12px;"">callosities</span><span style=""font-size:12px;""> in RA using scalpel </span><span class=""highlight"" style=""font-size:12px;"">debridement</span><span style=""font-size:12px;""> lessened forefoot pain but the effect was no greater than sham treatment. Localized pressure or gait function was not significantly improved following treatment.</span>
	</p>
</div>",,"/uploadfiles/file/20131025/20131025152134_3866.pdf",,10/25/2013,10/25/2013,"medicool",53,,"Plantar callosities, Callus debridement, Forefoot pain, Metatarsophalangeal joint, Gait parameters",0,"85",93,"Debridement of plantar callosities in rheumatoid arthritis: a randomized controlled trial","2005",
353,,"10.1111/j.1600-0625.2005.00367.x","Sitaru C, Zillikens D","Experimental Dermatology","<p class=""MsoNormal"" align=""justify"">
	<a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-size:14px;"">Autoimmune diseases are </span><span style=""font-size:14px;"">characterized by defined self-antigens, organ specificity, autoreactive T cells </span><span style=""font-size:14px;"">and/or autoantibodies that can transfer disease. Autoimmune blistering diseases </span><span style=""font-size:14px;"">are organspecific autoimmune diseases associated with an immune response </span><span style=""font-size:14px;"">directed to structural proteins mediating cellCcell and cellCmatrix adhesion in </span><span style=""font-size:14px;"">the skin. While both autoreactive T and B cells have been detected and </span><span style=""font-size:14px;"">characterized in patients with autoimmune blistering diseases, current evidence </span><span style=""font-size:14px;"">generally supports a pathogenic role of autoantibodies for blister formation. </span><span style=""font-size:14px;"">The immunopathology associated with blisters induced by autoantibodies relies </span><span style=""font-size:14px;"">on several mechanisms of action. Autoantibodies from patients with pemphigus </span><span style=""font-size:14px;"">diseases can exert a direct effect just by binding to their target mediated by </span><span style=""font-size:14px;"">steric hindrance and/or by triggering the transduction of a signal to the cell. </span><span style=""font-size:14px;"">In most subepidermal autoimmune blistering conditions, in addition to the </span><span style=""font-size:14px;"">binding to their target antigen, autoantibodies need to interact with factors </span><span style=""font-size:14px;"">of the innate immune system, including the complement system and inflammatory </span><span style=""font-size:14px;"">cells, in order to induce blisters. Generally, decisive progress has been made </span><span style=""font-size:14px;"">in the characterization of the mechanisms of blister formation in autoimmune </span><span style=""font-size:14px;"">skin diseases. However, various aspects, including the exact contribution of </span><span style=""font-size:14px;"">steric hindrance and signal transduction for pemphigus IgG-induced acantholysis </span><span style=""font-size:14px;"">or the fine tuning of the inflammatory cascade triggered by autoantibodies in </span><span style=""font-size:14px;"">some subepidermal blistering diseases, still need to be addressed. </span><span style=""font-size:14px;"">Understanding the mechanisms by which autoantibodies induce blisters should </span><span style=""font-size:14px;"">facilitate the development of more specific therapeutic strategies of </span><span style=""font-size:14px;"">autoimmune blistering diseases.</span></span></span>
</p>
<br />
<br />","/uploadfiles/image/20131025/20131025151757_7490w.jpg","/uploadfiles/file/20131025/20131025151745_2846.pdf",,10/25/2013,10/25/2013,"medicool",64,,"adhesion molecule , complement ,leucocytes , signal transduction , steric
hindrance",0,"67",94,"Mechanisms of blister induction by autoantibodies","2005",
355,,"10.1111/j.1600-0846.2007.00230.x","Malcolm Xing, Ning Pan, Wen Zhong and Howard Maibach","Skin Research and Technology","<p align=""justify"">
	<strong><span style=""font-size:14px;"">Background/purpose</span></strong><strong><span style=""font-size:14px;"">: </span></strong><span style=""font-size:14px;"">Friction blisters, a common injury in </span><span style=""font-size:14px;"">sports and military operations, can adversely effect or even </span><span style=""font-size:14px;"">halt performance. Given its frequency and hazardous nature, </span><span style=""font-size:14px;"">recent research efforts appear limited. Blistering can be </span><span style=""font-size:14px;"">treated as a delamination phenomenon; similar issues in </span><span style=""font-size:14px;"">materials science have been extensively investigated in </span><span style=""font-size:14px;"">theory and experiment. An obstacle in studying blistering </span><span style=""font-size:14px;"">is the difficulty of conducting experiment on humans and </span><span style=""font-size:14px;"">animals. Computer modeling thus becomes a preferred tool.</span><br />
<strong><span style=""font-size:14px;""></span></strong><strong><span style=""font-size:14px;"">Method:</span></strong><span style=""font-size:14px;""> This paper used a dynamic non-linear finite-element </span><span style=""font-size:14px;"">model with a blister-characterized structure and contact </span><span style=""font-size:14px;"">algorithm for outer materials and blister roof to </span><span style=""font-size:14px;"">investigate the effects on deformation and stress of an </span><span style=""font-size:14px;"">existing blister by changing the friction coefficient and </span><span style=""font-size:14px;"">elastic modulus of the material in contact with the blister.</span><br />
<strong><span style=""font-size:14px;""></span></strong><strong><span style=""font-size:14px;"">Results:</span></strong><span style=""font-size:14px;""> Through the dynamics mode and harmonic frequency </span><span style=""font-size:14px;"">approach, we demonstrated that the loading frequency </span><span style=""font-size:14px;"">leads to dramatic changes of displacement and </span><span style=""font-size:14px;"">stress in spite of otherwise similar loading. Our simulations </span><span style=""font-size:14px;"">show that an increased friction coefficient does not necessarily </span><span style=""font-size:14px;"">result in an increase in either the stress on the hot spot </span><span style=""font-size:14px;"">or blister deformation; local maximum friction stress and </span><span style=""font-size:14px;"">Von Mises stress exist for some friction coefficients over the </span><span style=""font-size:14px;"">wide range examined here. In addition, the stiffness of </span><span style=""font-size:14px;"">contact material on blistering is also investigated, and no </span><span style=""font-size:14px;"">significant effects on deformation and Von Mises stress are </span><span style=""font-size:14px;"">found, again at the range used. The model and method </span><span style=""font-size:14px;"">provided</span><span style=""font-size:14px;"">&nbsp;here may be useful for evaluating loading environments </span><span style=""font-size:14px;"">and contact materials in reducing blistering incidents.</span><br />
<strong><span style=""font-size:14px;""></span></strong><strong><span style=""font-size:14px;"">Conclusion:</span></strong><span style=""font-size:14px;""> The coupling finite-element model can predict </span><span style=""font-size:14px;"">the effects of friction coefficient and contacting materials&amp;apos </span><span style=""font-size:14px;"">stiffness on blister deformation and hot spot stress.</span><span style=""font-size:14px;""></span>
</p>",,"/uploadfiles/file/20131025/20131025164055_1406.pdf",,10/25/2013,10/25/2013,"medicool",65,,"friction ,blisters , bullae , models , man",0,"67",94,"Skin friction blistering: computer model","2007",
360,"非典型生殖器疱疹：5例病例报告","10.1080/00365540310017276","Uusküla A ; Raukas E","Scandinavian Journal Of Infectious Diseases","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Manifestations of human genital
herpes virus (HSV) infection are not limited to the typical cluster of genital
lesions</span></span></span></span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">. </span><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">Here
we present 5 case histories suggestive to clinically atypical genital herpes
(HSV detected with the polymerase chain reaction) collected in 2001 from a
private outpatient clinic specializing in dermatological and venereal diseases.</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> The clinical presentations included</span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> mucopurulent cervicitis</span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">,
haemorrhagic cystitis, recurrent urethritis, and </span><a name=""OLE_LINK11""></a><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;"">lower hack</span></span><span style=""font-family:Times New Roman;font-size:14px;line-height:1.5;""> pain.</span></span></span></span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:宋体;font-size:14px;line-height:1.5;"">人类生殖器疱疹病毒（</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">HSV</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">）感染的临床表现并不仅限于典型的生殖器病灶群。我们报道了</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">5</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">例于</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">2001</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">年在专门从事皮肤病及性病诊疗的一个私人门诊处就诊的，临床非典型生殖器疱疹（聚合酶链式反应检测到的</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">HSV</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">）的患者。</span><span style=""font-family:&quot;font-size:14px;line-height:1.5;"">HSV</span><span style=""font-family:宋体;font-size:14px;line-height:1.5;"">的临床表现包括：粘液脓性宫颈炎、出血性膀胱炎、复发性尿道炎以及下腰疼痛。</span><span style=""font-family:&quot;""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-align:center;"" align=""center"">
	<span style=""font-size:9.0pt;font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"" style=""text-align:center;"" align=""center"">
	<span><a><span style=""font-size:9pt;font-family:Times New Roman;"">Uusküla A</span></a></span><span style=""font-size:9pt;font-family:Times New Roman;""> et.al;</span><span><a><span style=""font-size:9pt;font-family:Times New Roman;"">Scandinavian
Journal Of Infectious Diseases</span></a></span><span style=""font-size:9pt;font-family:Times New Roman;""> ;2004; Vol. 36
(1), pp. 37-9.</span><span style=""font-size:9.0pt;font-family:&quot;""></span> 
</p>","/uploadfiles/image/20131031/20131031142259_7104w.jpg","/uploadfiles/file/20131031/20131031142310_8176.pdf",,10/31/2013,10/31/2013,"medicool",56,,,0,"85",96,"Atypical Genital Herpes: Report of Five Cases","2004",
362,"外科手术成功治愈尖锐湿疣（外阴和乳房处有多个巨大疣体）一例",,"LiangZhao MD, Fang Fang MD , Fiona Carey MRCP，Qian-Qiu Wang MD","International Journal of STD & AID","<p class=""MsoNormal"">
	<span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-size:14px;"">We report a case of a 24-year-old female patient </span><a name=""OLE_LINK2""></a><a name=""OLE_LINK1""></a><span><span style=""font-size:14px;"">with </span><span style=""font-size:14px;"">a history of giant and multiple lesions of condylomata acuminata </span></span><span style=""font-size:14px;"">on </span><span style=""font-size:14px;"">the vulva and breasts which were treated by surgical excision.</span></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:宋体;font-size:14px;"">我们报道了一例通过手术切除治愈</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:14px;"">24</span><span style=""font-family:宋体;font-size:14px;"">岁女性尖锐湿疣患者的病例，该患者长期患有尖锐湿疣，外阴和乳房处有多个巨大疣体。</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""></span>
</p>
<br />
<br />","/uploadfiles/image/20131031/20131031163400_6110w.png","/uploadfiles/file/20131031/20131031163206_6684.pdf",,10/31/2013,10/31/2013,"medicool",70,,"condyloma acuminatum, giant, surgical operation",0,"85",97,"A case of condyloma acuminata with giant and multiple lesions on the vulva and breast: successfully treated with surgical operations","2005",
365,,,"JOSEPH COPULSKY, M.D. E. DOUGLAS WHITEHEAD, M.D. LAZARUS A.ORKIN, M.D.",,"<strong><span style=""font-size:14px;font-family:Times New Roman;"">ABSTRACT</span></strong><span style=""font-size:14px;font-family:Times New Roman;"">.</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; The occurrence of condyloma acuminata of the urethral meatus is extremely rare in </span><span style=""font-size:14px;font-family:Times New Roman;"">children. This is the second case in the literature of this type of lesion in a child less thanfive years of age. </span><span style=""font-size:14px;font-family:Times New Roman;"">This is considered a benign lesion which is best managed by excision and fulguration of its base.</span>",,"/uploadfiles/file/20131101/20131101092045_1651.pdf",,11/01/2013,11/01/2013,"medicool",30,,,0,"85",97,"CONDYLOMA ACUMINATA IN A THREE-YEAR-OLD BOY ",,
366,,"10.1016/j.ijid.2009.11.031","Vincenzo Nucci, Daniele Torchia, Pietro Cappugi","International Journal of Infectious Diseases","<span style=""font-size:14px;font-family:Times New Roman;""><strong>S</strong><strong>U</strong><strong>M</strong><strong>M</strong><strong>A</strong><strong>R</strong><strong>Y.</strong></span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp; Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is an emerging technique for the </span><span style=""font-size:14px;font-family:Times New Roman;"">treatment of genital human papillomavirus (HPV)-induced benign and premalignant lesions. We report </span><span style=""font-size:14px;font-family:Times New Roman;"">herein a case series of anogenital CA successfully treated with ALA-PDT and review the literature </span><span style=""font-size:14px;font-family:Times New Roman;"">available to date on this topic. Thirteen out of 14 cases of anogenital condylomata acuminata were </span><span style=""font-size:14px;font-family:Times New Roman;"">successfullytreatedwith topicalPDT.Weconcludethat PDTcan be considered ahighly effective and safe </span><span style=""font-size:14px;font-family:Times New Roman;"">treatment option for anogenital condylomata acuminata. Also, considering the available literature, the </span><span style=""font-size:14px;font-family:Times New Roman;"">best results are likely to be achieved with a 16C20% gel formulation of 5-ALA and a red light dose of 100 C </span><span style=""font-size:14px;font-family:Times New Roman;"">150 J/cm2.</span>",,"/uploadfiles/file/20131101/20131101092727_9578.pdf",,11/01/2013,11/01/2013,"medicool",23,,,0,"85",97,"Treatment of anogenital condylomata acuminata with topical photodynamic","2010",
368,,"10.1016/j.jaad.2013.04.036","Viktoryia Kazlouskaya, MD, PhD,Elina Shustef, DO,Sherihan H. Allam, MD,Karan Lal, BS,and Dirk Elston, MD","DERMATOPATHOLOGY","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background</span></strong><span style=""font-size:14px;font-family:Times New Roman;"">.</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">The histopathological and clinical overlapping features between condyloma acuminata and</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">bowenoid papulosis can present a diagnostic challenge and we sought to determine if immunochemistry</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">can be helpful in this setting.</span>",,"/uploadfiles/file/20131101/20131101093923_5779.pdf",,11/01/2013,11/01/2013,"medicool",17,,,0,"66",97,"Expression of p16 protein in lesional and perilesional condyloma acuminata and bowenoid papulosis:Clinical significance and diagnostic implications","2013",
376,,,"S. Aslam, K. Carroll, B. Naz, A. Alao",,"<span style=""font-size:14px;font-family:Times New Roman;"">We report the first case of valacyclovir-induced psychosis with symptoms of mania in an adolescent female with no psychiatric </span><span style=""font-size:14px;font-family:Times New Roman;"">history.</span>",,"/uploadfiles/file/20131101/20131101103525_2122.pdf",,11/01/2013,11/01/2013,"medicool",26,,,0,"85",96,"VALACYCLOVIR-ASSOCIATED PSYCHOSIS AND MANIC SYMPTOMS IN AN ADOLESCENT FEMALE WITH GENITAL HERPES SIMPLEX: A CASE REPORT ",,
369,,"10.1016/j.antiviral.2010.08.012","Li-li Zhu, Xing-Hua Gao, Ruiqun Qi, Yuxiao Hong, Xiaodong Li, Xiaoqin Wang,Uwesu Omari Mchepange, Li Zhang, Huachen Wei, Hong-Duo Chen","Antiviral Research","<span style=""font-size:14px;font-family:Times New Roman;""><strong>Abstract.</strong></span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">Local hyperthermia has been successfully used in the treatment of viral warts by mechanisms that have</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">largely remained unclear.</span> 
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131101/20131101094417_4200.pdf",,11/01/2013,11/01/2013,"medicool",29,,,0,"66",97,"Local hyperthermia could induce antiviral activity by endogenous interferon-dependent pathway in condyloma acuminata","2010",
370,,,"Johnnie Wright, Jr., MD, Jeffrey Hines, MD","Elsevier Science","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">All papillomaviruses consist of 55</span><span style=""font-size:14px;font-family:Times New Roman;"">nm, non-enveloped virions with a </span><span style=""font-size:14px;font-family:Times New Roman;"">double-stranded DNA genome of </span><span style=""font-size:14px;font-family:Times New Roman;"">approximately 8,000 base pairs </span><span style=""font-size:14px;font-family:Times New Roman;"">within an icosahedral capsid. The </span><span style=""font-size:14px;font-family:Times New Roman;"">papillomavirus genome has three </span><span style=""font-size:14px;font-family:Times New Roman;"">functional regions defined as the </span><span style=""font-size:14px;font-family:Times New Roman;"">early, late, and control regions. The </span><span style=""font-size:14px;font-family:Times New Roman;"">early region consists of approxi- </span><span style=""font-size:14px;font-family:Times New Roman;"">mately 4,500 base pairs and con- </span><span style=""font-size:14px;font-family:Times New Roman;"">tains eight open reading frames </span><span style=""font-size:14px;font-family:Times New Roman;"">(ORF) or genes.</span>",,"/uploadfiles/file/20131101/20131101100125_0874.pdf",,11/01/2013,11/01/2013,"medicool",30,,,0,"66",97,"CONDYLOMA ACUMINATA:TREATMENT STRATEGIES FOR THE PRIMARY CARE PROVIDER","2000",
371,,"10.1016/j.jpag.2006.01.049","Hanoch Levavi, MD, Yael Perez-Davidi, MD and Gad Sabah, MD","Elsevier","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Abstract.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">Purpose: To describe a case of bilateral labial </span><span style=""font-size:14px;font-family:Times New Roman;"">edema in an adolescent patient and review the literature </span><span style=""font-size:14px;font-family:Times New Roman;"">on this rare occurrence.</span>",,"/uploadfiles/file/20131101/20131101100435_8757.pdf",,11/01/2013,11/01/2013,"medicool",34,,,0,"67",97,"Labial Edema Following Treatment of Condyloma Acuminata with CO2Laser in an Adolescent:A Case Report and Literature Review","2006",
430,"基质金属蛋白酶9（MMP-9）在皮肤扁平苔藓和硬化性苔藓中表达的不同",,"ILZE LEGUSA', VALERIE GROMA^","Papers on Anthropology","<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Abstract.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK22""></a><a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-size:14px;line-height:2;"">Lichen
planus is a mucocutaneous inflammatory disease of unknown etiology. </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><a name=""OLE_LINK23""></a><span style=""font-size:14px;line-height:2;"">Hyperkeratosis, </span><a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><span style=""font-size:14px;line-height:2;"">focal
hypergranulosis, damage to the basal cell layer, and band-like
infiltrate are </span><a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span style=""font-size:14px;line-height:2;"">hallmarks of LP skin. </span><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><a name=""OLE_LINK29""></a><a name=""OLE_LINK28""></a><span style=""font-size:14px;line-height:2;"">Lichen
sclerosus is a lymphocyte-mediated dermatosis that has a predilection for the
genital skin in both sexes. </span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><a name=""OLE_LINK31""></a><a name=""OLE_LINK30""></a><span style=""font-size:14px;line-height:2;"">Both
pathologies are sharing a number of common characteristics. </span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><a name=""OLE_LINK33""></a><a name=""OLE_LINK32""></a><a name=""OLE_LINK35""></a><a name=""OLE_LINK34""></a><span style=""font-size:14px;line-height:2;"">Previous studies have reported on
involvement of matrix metalloproteinases and their capability of digesting
extracellular matrix and basement membrane components. </span><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><a name=""OLE_LINK37""></a><a name=""OLE_LINK36""></a><span style=""font-size:14px;line-height:2;"">We
report on the clinical examination of 11 lichen planus patients and 5 lichen
sclerosus patients and the morphological evaluation of their skin biopsy samples</span><a name=""OLE_LINK39""></a><a name=""OLE_LINK38""></a><span style=""font-size:14px;line-height:2;"">.</span><a name=""OLE_LINK15""></a><span style=""font-size:14px;line-height:2;""> Clinical
and routine light microscopy findings correlate with the literature data. </span><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><span style=""font-size:14px;line-height:2;"">By contrast, </span><a name=""OLE_LINK41""></a><a name=""OLE_LINK40""></a><span style=""font-size:14px;line-height:2;"">the expression
of MMP-9 was greatly varying among clinical types of cutaneous lichen ruber planus.</span><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><span style=""font-size:14px;line-height:2;""> There was similarity in the MMP-9 expression observed between lichen planus </span><a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span style=""font-size:14px;line-height:2;"">pemphigoides and lichen
sclerosus.</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;</span><b style=""line-height:1.5;""><span style=""font-size:14px;line-height:2;"">摘要：</span></b> 
</p>
<p class=""MsoNormal"">
	<b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:14px;line-height:2;"">扁平苔藓是一种皮肤粘膜的炎症性疾病，目前病因不明。角化过度、局灶性增生、基底细胞层受损以及带状浸润是LP皮肤的特点。硬化性苔藓是一种淋巴细胞介导的皮肤病，好发于两性的生殖器皮肤。这两种病症具有一些共同的特点。以往研究已经报道了基质金属蛋白酶的参与及其消化细胞外基质和基底膜成分的能力。我们报告了经临床检查的</span><span style=""font-size:14px;line-height:2;"">11</span><span style=""font-size:14px;line-height:2;"">名扁平苔藓和</span><span style=""font-size:14px;line-height:2;"">5</span><span style=""font-size:14px;line-height:2;"">名硬化性苔藓的患者，对他们皮肤活检标本进行形态学评估。临床和常规光学显微镜所发现的与文献资料一致。与此相比，</span><span style=""font-size:14px;line-height:2;"">MMP-9</span><span style=""font-size:14px;line-height:2;"">在临床类型的皮肤扁平红苔藓上的表达有很大的差别。观察到的类天疱疮样扁平苔藓和硬化性苔藓在</span><span style=""font-size:14px;line-height:2;"">MMP-9</span><span style=""font-size:14px;line-height:2;"">上的表达相似。</span> 
</p>","/uploadfiles/image/20131113/20131113151731_2929w.jpg","/uploadfiles/file/20131113/20131113151658_6889.pdf",,11/13/2013,11/13/2013,"medicool",28,,,0,"65",99,"Matrix metalloproteinase 9 (MMP-9) is differently expressed in cutaneous lichen planus and lichen sclerosus","2012",
372,,"10.1016/j.asjsur.2012.06.013","Farouk Safi, Omar Bekdache, Suhail Al-Salam, Mouied Alashari,Taha Mazen, Haytham El-Salhat","Elsevier Taiwan LLC","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Summary.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">Giant condyloma acuminatum (GCA), originally described by Buschke and Loe-</span><span style=""font-size:14px;font-family:Times New Roman;"">wenstein in 1925 as a lesion of the penis, is more rarely seen in the anorectum and is char-</span><span style=""font-size:14px;font-family:Times New Roman;"">acterized by clinical malignancy in the face of histologic benignity; however, malignant </span><span style=""font-size:14px;font-family:Times New Roman;"">transformation to frankly invasive squamous-cell carcinoma has been described in about </span><span style=""font-size:14px;font-family:Times New Roman;"">one-third of patients.</span>",,"/uploadfiles/file/20131101/20131101100843_0270.pdf",,11/01/2013,11/01/2013,"medicool",31,,,0,"67",97,"Management of peri-anal giant condyloma acuminatumd ――A case report and literature review","2013",
373,,"10.1016/j.jaad.2008.08.031",,"J AM ACAD DERMATOL","<span style=""font-size:14px;font-family:Times New Roman;"">TotheEditor:Vestibularpapillaeofthevulvaarevery </span><span style=""font-size:14px;font-family:Times New Roman;"">small asymptomatic filiform or soft, frond-like pro</span><span style=""font-size:14px;font-family:Times New Roman;"">jections on the vestibular epithelium or the inner </span><span style=""font-size:14px;font-family:Times New Roman;"">aspect of the labia minora.1,2This normal variant has </span><span style=""font-size:14px;font-family:Times New Roman;"">a smooth surface and similar color to the adjacent </span><span style=""font-size:14px;font-family:Times New Roman;"">mucosa.2Although common, the condition may be </span><span style=""font-size:14px;font-family:Times New Roman;"">unfamiliar to clinicians and may be misdiagnosed as </span><span style=""font-size:14px;font-family:Times New Roman;"">condyloma acuminata.3</span>",,"/uploadfiles/file/20131101/20131101102100_0035.pdf",,11/01/2013,11/01/2013,"medicool",27,,,0,"65",97,"The use of dermatoscopy to differentiate vestibular papillae, a normal variant of the female external genitalia, from condyloma acuminata","2008",
392,"益生菌治疗湿疹:系统综述","10.1111/j.1365-2222.2009.03305.x","R. J. Boyle, F. J. Bath-Hextall, J. Leonardi-Bee, D. F. Murrell and M. L-K Tang","The Cochrane Collaboration","<span style=""font-size:14px;""><b><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Background .</span></b></span></a> 
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span><span><span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Probiotics have been proposed as a treatment for eczema, but the results of intervention trials have been mixed. </span></span></a></span></span><span><span><span style=""font-family:'Times New Roman','serif';""></span></span></span>
</p>
<span></span><span></span> 
<p class=""MsoNormal"">
	<b><span style=""font-size:16pt;font-family:宋体;""><span style=""font-size:14px;"">研究背景</span><span style=""font-size:14px;"">:</span></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-family:宋体;""><span style=""font-size:14px;"">益生菌已被提议作为一种治疗湿疹的方法，但其干预试验的结果喜忧参半。</span><span></span></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Objective .</span></b><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">To evaluate the efficacy of probiotics for treating eczema by performing a systematic review of randomized-controlled trials (RCTs).</span></span></span></span></a><span><span><span style=""font-family:'Times New Roman','serif';""> </span></span></span>
</p>
<span></span><span></span> 
<p class=""MsoNormal"">
	<b><span style=""font-size:16pt;font-family:宋体;""><span style=""font-size:14px;"">研究目的</span><span style=""font-size:14px;"">:</span></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-family:宋体;""><span style=""font-size:14px;"">本文旨在通过一项随机对照试验</span><span style=""font-size:14px;"">(RCTs)</span><span style=""font-size:14px;"">的系统性回顾</span><span style=""font-size:14px;"">,</span><span style=""font-size:14px;"">来评估应用益生菌治疗湿疹的有效性。</span><span></span></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Design . </span></b><span style=""font-family:'Times New Roman','serif';""></span>
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">We searched the </span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Cochrane Skin Group </span></span></span></span></span></span></span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Specialised Register</span></span></span></span></span></span></span></span></span></span></a><span><span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;"">, </span><span style=""font-size:14px;"">Cochrane Central Register of Controlled Trials</span></a><span style=""font-size:14px;"">, MEDLINE, EMBASE, PsycINFO, AMED, LILACS, </span><span style=""font-size:14px;""><span style=""font-size:14px;"">ISI Web of Science</span></span></a><span style=""font-size:14px;"">, </span><span style=""font-size:14px;"">the reference lists of articles</span></a><span style=""font-size:14px;"">, </span><span style=""font-size:14px;"">ongoing clinical trial registers and conference proceedings</span></a><span style=""font-size:14px;"">. </span></span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">RCTs of live orally ingested microorganisms for the treatment of eczema were eligible for inclusion.</span></span></span></span></span><span><span><span style=""font-family:'Times New Roman','serif';""> </span></span></span>
</p>
<span></span><span></span> 
<p class=""MsoNormal"">
	<b><span style=""font-size:16pt;font-family:宋体;""><span style=""font-size:14px;"">研究设计：</span><span></span></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-size:14px;font-family:宋体;"">我们查阅了</span><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Cochrane Skin Group Specialised Register</span><span style=""font-size:14px;font-family:宋体;"">、</span><span style=""font-size:14px;font-family:'Times New Roman','serif';""> <span style=""font-size:14px;"">Cochrane</span></span><span style=""font-size:14px;font-family:宋体;"">临床试验对照数据库、</span><span style=""font-size:14px;font-family:'Times New Roman','serif';"">MEDLINE</span><span style=""font-size:14px;font-family:宋体;"">、</span><span style=""font-size:14px;font-family:'Times New Roman','serif';"">EMBASE</span><span style=""font-size:14px;font-family:宋体;"">、</span><span style=""font-size:14px;font-family:'Times New Roman','serif';"">PsycINFO</span><span style=""font-size:14px;font-family:宋体;"">、</span><span style=""font-size:14px;font-family:'Times New Roman','serif';"">AMED</span><span style=""font-size:14px;font-family:宋体;"">、</span><span style=""font-size:14px;font-family:'Times New Roman','serif';"">LILACS</span><span style=""font-size:14px;font-family:宋体;"">、</span><span style=""font-size:14px;font-family:'Times New Roman','serif';"">ISI</span><span style=""font-size:14px;font-family:宋体;"">科学网，文章参考文献目录、</span><span style=""font-family:宋体;""><span style=""font-size:14px;"">正在进行的临床试验登记簿及会议论文。在随机对照试验（</span><span style=""font-size:14px;"">RCTs</span><span style=""font-size:14px;"">）中，入选了口服摄入活微生物治湿疹的方法。</span><span></span></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Results</span></b><span style=""font-family:'Times New Roman','serif';""> </span><b><span style=""font-size:14px;font-family:'Times New Roman','serif';"">.</span></b><span style=""font-family:'Times New Roman','serif';""></span> 
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Twelve trials (781 participants) were identified</span></span></span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">. </span></span></span><span><span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;"">Meta-analysis of data from five of these trials showed that there was no significant reduction in eczema symptoms with probiotic treatment compared with placebo (</span><span style=""font-size:14px;"">mean difference-0.90 points on a 20-point visual analogue scale; 95% confidence interval -2.84, 1.04</span></a><span style=""font-size:14px;"">).</span></span></span></span><span style=""font-family:'Times New Roman','serif';""> <span style=""font-size:14px;""><span style=""font-size:14px;"">Meta-analysis of data from seven trials showed no significant difference in investigator rated eczema severity between probiotic and placebo treatments. </span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;"">Subgroup analysis by eczema severity or </span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">presence of atopy</span></span></span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""> did not identify a specific population in which probiotic treatment was effective.</span></span></span> <span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">There was significant heterogeneity between studies</span></span></span></a><span><span><span style=""font-size:14px;"">; however, the results of three studies that used the same probiotic strain were concordant.</span><span> </span></a></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">The adverse events search identified case reports of sepsis and bowel ischaemia caused by probiotics</span></span></span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;"">. </span></span></span>
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:16pt;font-family:宋体;""><span style=""font-size:14px;"">研究结果：</span><span></span></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-family:宋体;""><span style=""font-size:14px;"">对</span><span style=""font-size:14px;"">12</span><span style=""font-size:14px;"">项试验（</span><span style=""font-size:14px;"">781</span><span style=""font-size:14px;"">名参与者）进行鉴定。其中五项试验的数据经过荟萃分析表明，与安慰剂对照组相比益生菌疗法并没有显著减轻湿疹的症状（在</span><span style=""font-size:14px;"">20</span><span style=""font-size:14px;"">分的视觉模拟评分时平均差为</span><span style=""font-size:14px;"">0.90</span><span style=""font-size:14px;"">分；</span><span style=""font-size:14px;"">95</span><span style=""font-size:14px;"">％置信区间为</span><span style=""font-size:14px;"">-2.84</span><span style=""font-size:14px;"">，</span><span style=""font-size:14px;"">1.04</span><span style=""font-size:14px;"">）。其中七项试验的数据经过荟萃分析显示对于研究者评定湿疹严重程度益生菌疗法和安慰剂疗法没有显著的差异。根据湿疹严重程度或特应性反应的存在进行亚组分析，在益生菌疗法中没有鉴定出某种特殊群体对于治疗是有效的。研究之间存在着显著的异质性，然而，使用相同的益生菌菌株进行的三组试验的研究结果是一致的。不良反应在已确认的由益生菌引起败血症和肠道缺血的病例报告中发现。</span><span></span></span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Conclusions .</span></b><span style=""font-family:'Times New Roman','serif';""> </span>
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-size:14px;""><span style=""font-size:14px;font-family:'Times New Roman','serif';"">Currently, probiotics cannot be recommended for treating eczema.</span></span></a><span style=""font-family:'Times New Roman','serif';""> <span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">The heterogeneity between studies may be attributable to probiotic strain-specific effects</span></span></span></a><span><span><span style=""font-size:14px;"">,</span><span style=""font-size:14px;""> which means that novel probiotic strains may still have a role in eczema management.</span></a></span></span></span> 
</p>
<span></span><span></span><span></span><span></span> 
<p class=""MsoNormal"">
	<b><span style=""font-size:16pt;font-family:宋体;""><span style=""font-size:14px;"">研究结论：</span><span></span></span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-size:14px;font-family:宋体;"">目前，益生菌不能被推荐用于治疗湿疹。研究之间的异质性可能归因于益生菌菌株特异性影响，这意味着新的益生菌菌株对湿疹治疗可能还是有一定的作用。</span> 
</p>","/uploadfiles/image/20131105/20131105141429_8383w.jpg","/uploadfiles/file/20131105/20131105141706_4781.pdf",,11/05/2013,11/05/2013,"medicool",40,,,0,"67",64,"Probiotics for the treatment of eczema: a systematic review","2009",
375,,,"Yasuhito Hamaguchi, MD, PhD, Manabu Fujimoto, MD, Yuri Enokido, MD,Takamasa Wayaku, MD, PhD, Kenzo Kaji, MD, PhD, Takeshi Echigo, MD, PhD and Kazuhiko Takehara, MD, PhD","International Journal of Dermatology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Abstract.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">Background Drug-induced hypersensitivity syndrome (DIHS/DRESS) is a severe adverse </span><span style=""font-size:14px;font-family:Times New Roman;"">systemic reaction. Reactivation of human herpesvirus (HHV) family members other than </span><span style=""font-size:14px;font-family:Times New Roman;"">HHV-6 has been reported in patients with DIHS. Reactivation of HHV family members is </span><span style=""font-size:14px;font-family:Times New Roman;"">generally characterized by increased serum antibody titers against the virus. By contrast, </span><span style=""font-size:14px;font-family:Times New Roman;"">clinical symptoms caused by viral reactivation are relatively rare.</span>",,"/uploadfiles/file/20131101/20131101103248_0731.pdf",,11/01/2013,11/01/2013,"medicool",29,,,0,"85",96,"Intractable genital ulcers from herpes simplex virusreactivation in drug-induced hypersensitivity syndrome caused by allopurinol","2010",
394,,,"Yoshihiro Miyake*, Keiko Tanaka and Masashi Arakawa","RESEARCH ARTICLE","<span style=""font-size:14px;font-family:Times New Roman;""><strong>Background.</strong></span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; In Japan, atopic eczema is a major public health pro</span><span style=""font-size:14px;font-family:Times New Roman;"">blem not only among children but also among adults.</span><span style=""font-size:14px;font-family:Times New Roman;"">One study has reported atopic eczema prevalence values </span><span style=""font-size:14px;font-family:Times New Roman;"">of 10.9% and 7.8% among Japanese women in their 20s </span><span style=""font-size:14px;font-family:Times New Roman;"">and 30s, respectively [1]. The role of genetic and envir</span><span style=""font-size:14px;font-family:Times New Roman;"">onmental risk factors in the development of atopic </span><span style=""font-size:14px;font-family:Times New Roman;"">eczema has gained interest.</span>",,"/uploadfiles/file/20131105/20131105144857_7155.pdf",,11/05/2013,11/05/2013,"medicool",16,,,0,"85",64,"IL13 genetic polymorphisms, smoking, and eczema in women: a case-control study in Japan","2011",
403,,,"Christian J. Apfelbacher, Ulrich Funke, Magda Radulescu and Thomas L. Diepgen","Contact Dermatitis","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">Hand eczema is often a result of the interplay of exogenous and endogenous risk factors. </span><span style=""font-size:14px;font-family:Times New Roman;"">Epidemiological studies demonstrating the interrelationship between these factors are lacking.</span>",,"/uploadfiles/file/20131105/20131105153524_9724.pdf",,11/05/2013,11/05/2013,"medicool",23,,,0,"66",64,"Determinants of current hand eczema: results from caseCcontrol studies nested in the PACO follow-up study (PACO II)","2010",
377,,"2011;102(3):225-29.","Mark Gilbert, MD,Xuan Li, MSc,Martin Petric, PhD,Mel Krajden, MD,Judith L. Isaac-Renton, MD,Gina Ogilvie, MD,Michael L. Rekart, MD","Canadian Public Health Association","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Objectives</span></strong><span style=""font-size:14px;font-family:Times New Roman;"">.</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">Understanding the regional epidemiology of genital Herpes Simplex Virus (HSV) infections is important for clinical and public health </span><span style=""font-size:14px;font-family:Times New Roman;"">practice, due to the increasing availability of type-specific serologic testing in Canada and the contribution of genital HSV-2 infection to ongoing HIV </span><span style=""font-size:14px;font-family:Times New Roman;"">transmission. We used centralized laboratory data to describe trends in viral </span><span style=""font-size:14px;font-family:Times New Roman;"">identifications of genital HSV in BC and assess the utility of these data for </span><span style=""font-size:14px;font-family:Times New Roman;"">ongoing population surveillance.</span>",,"/uploadfiles/file/20131101/20131101103956_4966.pdf",,11/01/2013,11/01/2013,"medicool",23,,,0,"65",97,"Using Centralized Laboratory Data to Monitor Trends in Herpes Simplex Virus Type 1 and 2 Infection in British Columbia and the Changing Etiology of Genital Herpes","2011",
378,,,"Bulbulgul Aumakhan, Andrew Hardick, Thomas C Quinn, Oliver Laeyendecker, Stephen J Gange,Chris Beyrer, Christopher Cox, Kathryn Anastos, Mardge Cohen, Ruth M Greenblatt, Daniel J Merenstein,Howard Minkoff, Marek Nowicki, Charlotte A Gaydos",,"<strong><span style=""font-size:14px;font-family:Times New Roman;"">Objective:.</span><br />
</strong><span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">To evaluate the utility of a single quantitative PCR (qPCR) measurement of HSV (HSV-1&amp;2) DNA in</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">cervicovaginal lavage (CVL) specimens collected from women with predominantly chronic HSV-2 infection in</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">assessing genital HSV shedding and the clinical course of genital herpes (GH) within a cohort with semiannual</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">schedule of follow up and collection of specimens.</span>",,"/uploadfiles/file/20131101/20131101104809_1455.pdf",,11/01/2013,11/01/2013,"medicool",17,,,0,"65",96,"Genital herpes evaluation by quantitative TaqMan PCR: correlating single detection and quantity of HSV-2 DNA in cervicovaginal lavage fluids with cross-sectional and longitudinal clinical data","2010",
382,"泛昔洛韦：治疗带状疱疹、生殖器疱疹和口唇疱疹的 疗效综述",,"Dene Simpson and Katherine A. Lyseng-Williamson","Adis, Springer International","<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">Famciclovir (Famvir) is the oral prodrug of penciclovir,</span></span><a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span><span><span style=""font-family:';""><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""> an agent that has demonstrated antiviral activity against </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""> simplex viruses,</span></span></span></span><span style=""font-family:';""><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""> type 1 (HSV-1) and 2 (HSV-2) [which cause orolabial and/or </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">genital herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""> simplex], and against varicella zoster virus (VZV) [a reactivation of which leads to </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">herpes </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">zoster]. </span></span>
</p>
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:宋体;font-size:14px;"">泛昔洛韦（泛昔洛韦片）是喷昔洛韦口服前体药物，且经研究证明该药物对单纯疱疹病毒</span><span style=""line-height:1.5;font-size:14px;"">1</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">型（</span><span style=""line-height:1.5;font-size:14px;"">HSV-1</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">）和</span><span style=""line-height:1.5;font-size:14px;"">2</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">型（</span><span style=""line-height:1.5;font-size:14px;"">HSV-2</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">）</span><span style=""line-height:1.5;font-size:14px;"">[</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">可引起口唇、生殖器疱疹</span><span style=""line-height:1.5;font-size:14px;"">]</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">以及水痘带状疱疹病毒（</span><span style=""line-height:1.5;font-size:14px;"">VZV</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">）</span><span style=""line-height:1.5;font-size:14px;"">[</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">该病毒激活可导致带状疱疹</span><span style=""line-height:1.5;font-size:14px;"">] </span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">有抗病毒活性。</span> 
</p>
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<a name=""OLE_LINK3""></a><a name=""OLE_LINK2""></a><span><span style=""font-family:';""><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">Famciclovir has efficacy similar to that of aciclovir (in immunocompetent or immunocompromised patients) or valaciclovir (in immunocompetent patients) in the treatment of </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""> zoster, and efficacy similar to aciclovir in the treatment of first or recurrent episodes of </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">genital herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""> (in immunocompetent or immunocompromised patients). Famciclovir also has efficacy in the suppression of recurrent episodes of </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">genital herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">, and in the treatment o</span></span></span><a name=""_GoBack""></a><span><span><span style=""font-family:';""><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">f orolabial </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">, in immunocompetent patients.</span></span></span></span><span style=""font-family:';""></span> 
</p>
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:宋体;font-size:14px;"">泛昔洛韦与阿昔洛韦</span><span style=""font-family:'font-size:14px;line-height:1.5;font-size:14px;"">(</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">治疗免疫功能正常或免疫功能低下的患者</span><span style=""font-family:'font-size:14px;line-height:1.5;font-size:14px;"">)</span><span style=""line-height:1.5;font-family:宋体;font-size:14px;"">或伐昔洛韦（治疗免疫功能正常的患者）在治疗带状疱疹方面有相似的疗效，并与阿昔洛韦在治疗首发或复发性生殖器疱疹（治疗免疫功能正常或免疫功能低下的患者）方面的疗效也同样相似。对于免疫功能正常的患者，泛昔洛韦对于抑制复发性生殖器疱疹和治疗口唇疱疹同样有效。</span><span style=""font-family:';""></span> 
</p>
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span><span style=""font-family:';""><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">As such, famciclovir is a well tolerated first-line option for the treatment of </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""> zoster and the treatment and suppression of </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">genital herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">, and is approved for the treatment of recurrent orolabial </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">.</span></span></span><span style=""font-family:';""><a name=""OLE_LINK17""></a><a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;color:;font-size:14px;"">Convenient </span></span></span></span></span></span></span></span><a name=""OLE_LINK4""></a><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;color:;font-size:14px;"">patient-initiated</span></span></span></span></span></span></span></span></span><span><span><span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;background-color:#ffffff;font-family:Times New Roman;color:;font-size:14px;""> single-day</span></span></span></span> </span></span></span></span></span></span><span style=""font-family:';""><span><span><span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;""></span></span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">(for recurrent </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">genital herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">) and single-dose (for orolabial </span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">herpes</span><span style=""line-height:1.5;font-family:Times New Roman;font-size:14px;"">) dosage regimens may contribute to treatment compliance, patient acceptability and subsequent treatment outcomes.</span></span></span></span></span> 
</p>
<span></span><span></span><span></span> 
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<span style=""font-family:宋体;""><span style=""line-height:1.5;""><span style=""font-size:14px;"">因此，对于带状疱疹的治疗以及生殖器疱疹的抑制，泛昔洛韦是一种耐受性良好的首选药物，并已被批准用于治疗复发性口唇疱疹。</span><span style=""font-family:宋体;color:#4d4d4d;font-size:14px;"">该药物可以采用非常方便的单天（对于复发性生殖器疱疹）和单剂量（对于口唇疱疹）给药方案，这可能有助于提高患者的依从性、可接受性以及后续的治疗效果。</span>
</p>
</span></span> 
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<span style=""font-family:'line-height:1.5;font-size:14px;"">&nbsp;</span> 
</p>
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<span style=""font-family:';font-size:14px;"">&nbsp;</span> 
</p>
<p style=""text-align:center;text-indent:18pt;"" class=""MsoNormal"" align=""center"">
	<span style=""font-family:Times New Roman;font-size:14px;"">Dene Simpson et.al</span><span style=""font-family:Times New Roman;font-size:14px;"">；</span><span style=""font-family:Times New Roman;font-size:14px;"">Adis Data Information BV. All rights reserved</span><span style=""font-family:Times New Roman;font-size:14px;"">；</span><span style=""font-family:Times New Roman;font-size:14px;"">2006; Vol. 66 (18), pp. 2397-416.</span><span style=""font-family:';font-size:9pt;""></span> 
</p>","/uploadfiles/image/20131101/20131101110250_4847w.jpg","/uploadfiles/file/20131101/20131101110326_8483.pdf",,11/01/2013,11/28/2013,"medicool",18,,,0,"67",96,"Famciclovir: a reviewof its use in herpes zoster and genitaland orolabial herpes","2006",
379,,,"Lisa K. Gilbert, PhD; Brooke A. Levandowski, PhD, MPA;Craig M. Roberts, PA-C, MS","JOURNAL OF AMERICAN COLLEGE HEALTH","<strong>Abstract.<br />
&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;Objectives and Participants: In the United States, genital herpes (GH) prevalence is 10.6% among 20- to 29-year-olds and about 90% of seropositive persons do not know their status.This study investigated individual characteristics associated with GH screening and diagnosis in sexually active young adults aged 18 to 24.",,"/uploadfiles/file/20131101/20131101105151_6955.pdf",,11/01/2013,11/01/2013,"medicool",37,,,0,"65",96,"Characteristics Associated With Genital Herpes Testing Among Young Adults: Assessing Factors From Two National Data Sets","2010",
380,,,"Natalie EDMISTON, Maree O’SULLIVAN, Deryck CHARTERS, John CHUAH and Lucinda PALLIS","Australian and New Zealand Journal of Obstetrics and Gynaecology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Abstract.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">A descriptive survey of knowledge of genital herpes and attitudes to testing was conducted among antenatal clinic</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">attendees at the Gold Coast Hospital, Australia. The study subjects showed a good knowledge of genital herpes, to</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">a level that appears sufficient for an informed choice regarding herpes serology testing to be made. A preference for</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">testing for genital herpes was suggested. Although serological testing is not routinely required, the results of the study</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">indicate that discussion of genital herpes should be considered in the antenatal clinic setting.</span>",,"/uploadfiles/file/20131101/20131101105532_1551.pdf",,11/01/2013,11/01/2013,"medicool",33,,,0,"65",96,"Study of knowledge of genital herpes infection and attitudes to testing for genital herpes among antenatal clinic attendees","2003",
425,,"10.1111/j.1365-2133.2012.10882.x","J.S. Wee,P.J. Shirlaw,S.J. Challacombe and J.F. Setterfield","British Journal of Dermatology","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Background.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Ulcerative lichen planus is an uncommon and severe subtype of lichen&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">planus primarily affecting the oral mucosal surfaces. It may be associated with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">significant morbidity and often requires immunosuppressive therapy to achieve&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">disease control. There have been no previous reports in which objective outcome&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">measures have been used to assess the efficacy of mycophenolate mofetil (MMF)&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">in severe ulcerative lichen planus.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Objective.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">To evaluate the clinical responses of patients with severe ulcerative oral&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">lichen planus who were treated with MMF at a tertiary oral medicine?dermato</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">logy centre.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Methods.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">This was a retrospective review of oral disease severity scores performed in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">10 patients with recalcitrant ulcerative oral lichen planus (vulvovaginalCgingival,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">n = 8; penogingival, n = 1; oral, n = 1) before and after treatment with MMF&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">therapy. The results were analysed using the Wilcoxon matched pairs signed-rank&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">test.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Results.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; The mean duration of MMF treatment was 3?7 (SD ± 2?4) years with a mean&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">follow-up of 4?2 (SD ± 2?7) years. The mean baseline oral disease severity scores&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">(39?1 ± 11?9) improved by 40% after 12C15 months (24?3 ± 11?9, n = 8,</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">P = 0?01) and by 43% after 21C24 months of MMF treatment (22?2 ± 10?4,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">n = 9, P = 0?01). Of the 10 patients, six achieved remission, one had well-con</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">trolled disease and three had partially controlled disease. Two patients who&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">achieved remission successfully discontinued treatment. MMF was well tolerated&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">in all patients.</span><br />
<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Conclusion.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Our case series demonstrates the efficacy and favourable side-effect pro-&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">file of MMF in the treatment of severe ulcerative lichen planus.</span><br />",,"/uploadfiles/file/20131112/20131112141925_8851.pdf",,11/12/2013,11/12/2013,"medicool",34,,,0,"67",99,"Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients","2012",
381,,"10.1155/2012/149135","Aziz Alami Chentoufi and Lbachir Ben Mohamed","Hindawi Publishing Corporation","<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; Herpes simplex viruses type 1 and type 2 (HSV-1 and HSV-2) are amongst the most common human infectious viral pathogens </span><span style=""font-size:14px;font-family:Times New Roman;"">capable of causing serious clinical diseases at every stage of life, from fatal disseminated disease in newborns to cold sores genital </span><span style=""font-size:14px;font-family:Times New Roman;"">ulcerations and blinding eye disease.</span>",,"/uploadfiles/file/20131101/20131101110124_0761.pdf",,11/01/2013,11/01/2013,"medicool",19,,,0,"66",96,"Mucosal Herpes Immunityand Immunopathology to Ocular and Genital Herpes Simplex Virus Infections","2012",
395,,,"Biflie Kell and Fiona Hawkins","Paediatric Nursing","&nbsp;&nbsp;&nbsp; <span style=""font-size:14px;font-family:Times New Roman;"">Collaboration, partnership and interagency working are </span><span style=""font-size:14px;font-family:Times New Roman;"">terms frequently employed to highlight the need for </span><span style=""font-size:14px;font-family:Times New Roman;"">providers of services and families to work tcêther to meet </span><span style=""font-size:14px;font-family:Times New Roman;"">tlie needs ofthe individual child. Lack of teamwork and </span><span style=""font-size:14px;font-family:Times New Roman;"">communication, rather than individual error or incom</span><span style=""font-size:14px;font-family:Times New Roman;"">petence, often results in poor services (Hall and EUinian </span><span style=""font-size:14px;font-family:Times New Roman;"">2004). Over the last decade there has been a shift from </span><span style=""font-size:14px;font-family:Times New Roman;"">national health services being oi^nised around the needs </span><span style=""font-size:14px;font-family:Times New Roman;"">of professionals to being organised around those of tlie </span><span style=""font-size:14px;font-family:Times New Roman;"">individual patient/client (DH 2003). Government policy </span><span style=""font-size:14px;font-family:Times New Roman;"">is now directed at providers and service users working </span><span style=""font-size:14px;font-family:Times New Roman;"">effectively together.</span>",,"/uploadfiles/file/20131105/20131105145410_4961.pdf",,11/05/2013,11/05/2013,"medicool",25,,,0,"85",64,"Collaboration in eczema care: a case study","2005",
385,,,"Kapil Goyal, Radha Kanta Ratho, A. J. Kanwar, Baijayantimala Mishra, Mini P. Singh","Indian Journal of Dermatology, Venereology, and Leprology","<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genital herpes is a significant public health disease&nbsp;</span><span style=""font-size:14px;font-family:Times New Roman;"">worldwide. Clinical diagnosis of genital herpes&nbsp;</span><span style=""font-size:14px;font-family:Times New Roman;"">simplex virus (HSV)</span><span style=""font-size:14px;font-family:Times New Roman;"">infection is insensitive and </span><span style=""font-size:14px;font-family:Times New Roman;"">non-specific and requires laboratory confirmation.</span>",,"/uploadfiles/file/20131101/20131101134045_2861.pdf",,11/01/2013,11/01/2013,"medicool",26,,,0,"66",96,"Role of polymerase chain reaction in detection genital herpes","2013",
387,,,"Edward W.Hook,MD","VENTANX","&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-size:14px;font-family:Times New Roman;"">The diagnosis of genital herpes infection is a </span><span style=""font-size:14px;font-family:Times New Roman;"">cause of dismay for many people. However, </span><span style=""font-size:14px;font-family:Times New Roman;"">recent advances in herpes virus diagnosis and </span><span style=""font-size:14px;font-family:Times New Roman;"">management provide tools for both more accurate </span><span style=""font-size:14px;font-family:Times New Roman;"">diagnosis and for management to help patients with </span><span style=""font-size:14px;font-family:Times New Roman;"">this all-too-common and often rtiisdiagnosed sexu</span><span style=""font-size:14px;font-family:Times New Roman;"">ally transmitted disease, which also has particular </span><span style=""font-size:14px;font-family:Times New Roman;"">implications for women.</span>",,"/uploadfiles/file/20131101/20131101134719_3116.pdf",,11/01/2013,11/01/2013,"medicool",46,,,0,"66",96,"A new look at genital herpes:the critical role of the laboratory in diagnosis and management","2012",
388,,"10.1258/ijsa.2007.007304.","David Goldmeier MD FRCP*, Lucy Garvey MRCP* and Simon Barton MD FRCP?","International Journal of STD & AIDS","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Summary</span></strong><span style=""font-size:14px;font-family:Times New Roman;"">.</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">It is a commonly expressed expert view that stress is associated with frequent recurrences of genital herpes (GH) but </span><span style=""font-size:14px;font-family:Times New Roman;"">the evidence for this is poor and it is often asserted that stress is the result of GH rather than any other cause. We have reviewed the </span><span style=""font-size:14px;font-family:Times New Roman;"">recent literature on this topic, restricting evidence to only prospective studies. We have further combined and integrated this evidence </span><span style=""font-size:14px;font-family:Times New Roman;"">with both human and animal work in the psychoneuroimmunological field to come up with suggestive evidence that recurrence rates </span><span style=""font-size:14px;font-family:Times New Roman;"">of GH are indeed associated with antecedent chronic stress/depression, </span><span style=""font-size:14px;font-family:Times New Roman;"">whatever might be the cause. We further discuss the </span><span style=""font-size:14px;font-family:Times New Roman;"">psychoneuroimmunological underpinning of the systemic features of the recurrent GH prodrome. Recommendations about holistic </span><span style=""font-size:14px;font-family:Times New Roman;"">management of recurrent GH that include both pharmacological and psychological therapies are given.</span>",,"/uploadfiles/file/20131101/20131101135002_9091.pdf",,11/01/2013,11/01/2013,"medicool",37,,,0,"67",96,"Does chronic stress lead to increased rates of recurrences of genital herpes C a review of the psychoneuroimmunological evidence?","2008",
384,,"10.2340/00015555-1033","Marius DOMEIKA', Karen BABAYAhP, Rashad ISMAILOV?ryna SHIMANSKAYA"", Krasimira CHUDOMIROVA^ Tatjana BRILENE*, Oleg KVLIVIDZE', Judith DEAK', Gulsum ASKAROVA', Galina MAMAJEVA'"", Vesta KUCINSKIENB"", Natalia FRIGO'?levtina SAVICHEVA'\ Tatiana KRASNOSELSKICH'"", Gennadiy MAVROV"", Olim KASYMOV'*, Olga IZVEKOVA"",Magnus UNEMO'* and Ronald CAMPBELL BALLARD""","Acta Derm Venereol","<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This paper reports survey-based data on the diagnosis </span><span style=""font-size:14px;font-family:Times New Roman;"">and management of genital herpes simplex virus (HSV) </span><span style=""font-size:14px;font-family:Times New Roman;"">infection in 14 countries of the Eastern European Net-</span><span style=""font-size:14px;font-family:Times New Roman;"">work for Sexual and Reproductive Health (EE SRH). </span><span style=""font-size:14px;font-family:Times New Roman;"">Only 43% of the countries could provide the number of </span><span style=""font-size:14px;font-family:Times New Roman;"">genital HSV cases recorded at national level. Eighty-six </span><span style=""font-size:14px;font-family:Times New Roman;"">percent of countries employed </span><span style=""font-size:14px;font-family:Times New Roman;"">syndromic management </span><span style=""font-size:14px;font-family:Times New Roman;"">in cases of genital ulcer disease. Most countries perfor- </span><span style=""font-size:14px;font-family:Times New Roman;"">med type-specific and/or non-type-specific enzyme im</span><span style=""font-size:14px;font-family:Times New Roman;"">munoassays to detect HSV antibodies. Non-type-specific </span><span style=""font-size:14px;font-family:Times New Roman;"">serology for diagnostic purposes should be actively dis</span><span style=""font-size:14px;font-family:Times New Roman;"">couraged. Direct detection methods for HSV, such as </span><span style=""font-size:14px;font-family:Times New Roman;"">PCR, antigen detection and culture, are available in </span><span style=""font-size:14px;font-family:Times New Roman;"">the region, but their usage was extremely low. Their use </span><span style=""font-size:14px;font-family:Times New Roman;"">in Eastern European countries should be actively pro</span><span style=""font-size:14px;font-family:Times New Roman;"">moted. The availability of laboratory services must be </span><span style=""font-size:14px;font-family:Times New Roman;"">improved, and countries in the region should implement </span><span style=""font-size:14px;font-family:Times New Roman;"">consensus recommendations for the laboratory diagno</span><span style=""font-size:14px;font-family:Times New Roman;"">sis of genital HSV infections in order to improve clinical </span><span style=""font-size:14px;font-family:Times New Roman;"">practice.</span>",,"/uploadfiles/file/20131101/20131101133525_1579.pdf",,11/01/2013,11/01/2013,"medicool",15,,,0,"66",96,"Survey of Diagnostic Services for Genital Herpes in Fourteen Countries in Eastern Europe","2011",
389,,,"JOHN G. BEAUMAN, MAJ, MC, USA, F.vans U.S. Army Hospitai Fort Carson, Colorado","American Family Physicia","&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-size:14px;font-family:Times New Roman;"">Genital herpes simplex virus infection is a recurrent, lifelong disease with no cure. The strongest </span><span style=""font-size:14px;font-family:Times New Roman;"">predictor for infection </span><span style=""font-size:14px;font-family:Times New Roman;"">is a person's number of lifetime sex partners. The natural history includes </span><span style=""font-size:14px;font-family:Times New Roman;"">first-episode mucocutaneous infection, </span><span style=""font-size:14px;font-family:Times New Roman;"">establishment of latency in the dorsal root ganglion, </span><span style=""font-size:14px;font-family:Times New Roman;"">and subsequent reactivation.</span>",,"/uploadfiles/file/20131101/20131101135319_7190.pdf",,11/01/2013,11/01/2013,"medicool",41,,,0,"67",96,"Genital Herpes: A Review","2005",
390,,,"R.L. Miller, M.A. Tomai, C.J. Harrison, D.I. Bernstein","International Immunopharmacology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Abstract</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">In this review, we discuss the ongoing development of a new treatment option for genital herpes (GH), the disease caused by </span><span style=""font-size:14px;font-family:Times New Roman;"">herpes simplex virus (HSV) types I and II. Following infection, the virus establishes a latent infection in peripheral neurons, </span><span style=""font-size:14px;font-family:Times New Roman;"">which periodically activates to cause recurrent skin lesions or asymptomatic shedding in the anogenital area.</span>",,"/uploadfiles/file/20131101/20131101135717_8690.pdf",,11/01/2013,11/01/2013,"medicool",47,,,0,"67",96,"Immunomodulation as a treatment strategy for genital herpes: review of the evidence","2002",
391,,"10.1016/j.it.2013.08.001","Haina Shin and Akiko Iwasaki","Trends in Immunology","&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;</span><span style=""font-size:14px;font-family:Times New Roman;"">Genital herpes is an incurable, chronic disease that </span><span style=""font-size:14px;font-family:Times New Roman;"">affects millions of people worldwide. Not only does </span><span style=""font-size:14px;font-family:Times New Roman;"">genital herpes cause painful, recurrent symptoms, it is </span><span style=""font-size:14px;font-family:Times New Roman;"">also a significant risk factor for the acquisition of other </span><span style=""font-size:14px;font-family:Times New Roman;"">sexually transmitted infections such as HIV-1. Antiviral </span><span style=""font-size:14px;font-family:Times New Roman;"">drugs are used to treat herpes simplex virus (HSV) </span><span style=""font-size:14px;font-family:Times New Roman;"">infection, but they cannot stop viral shedding and trans</span><span style=""font-size:14px;font-family:Times New Roman;"">mission. Thus, developing a vaccine that can prevent or </span><span style=""font-size:14px;font-family:Times New Roman;"">clear infection will be crucial in limiting the spread of </span><span style=""font-size:14px;font-family:Times New Roman;"">disease. In this review we outline recent studies that </span><span style=""font-size:14px;font-family:Times New Roman;"">improve our understanding of host responses against </span><span style=""font-size:14px;font-family:Times New Roman;"">HSV infection, discuss past clinical vaccine trials, and </span><span style=""font-size:14px;font-family:Times New Roman;"">highlight new strategies for vaccine design against gen</span><span style=""font-size:14px;font-family:Times New Roman;"">ital herpes.</span>",,"/uploadfiles/file/20131101/20131101140021_5594.pdf",,11/01/2013,11/01/2013,"medicool",47,,,0,"67",96,"Generating protective immunity against genital herpes","2013",
393,,"10.1111/j.1365-2230.2010.04006.x","J. English, R. Graham-Brown,* A. de Sica Chapman? and A. B. Alexandroff*","Clinical dermatology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Summary</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; Chronic hand eczema (CHE) is a debilitating and distressing disease for patients, the </span><span style=""font-size:14px;font-family:Times New Roman;"">physical symptoms of which are compounded by psychosocial problems. Alitretinoin is </span><span style=""font-size:14px;font-family:Times New Roman;"">an endogenously occurring physiological vitamin A derivative (retinoid) that possesses </span><span style=""font-size:14px;font-family:Times New Roman;"">strong anti-inflammatory and immunomodulatory activity. It is currently the only</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">licensed product for severe CHE unresponsive to treatment with potent topical </span><span style=""font-size:14px;font-family:Times New Roman;"">corticosteroids, and has been proven to be highly effective in clinical trials with two-</span><span style=""font-size:14px;font-family:Times New Roman;"">thirds of patients who responded to treatment remaining in remission at 6 months. </span><span style=""font-size:14px;font-family:Times New Roman;"">For those that did relapse, a second study showed they could be successfully retreated </span><span style=""font-size:14px;font-family:Times New Roman;"">with a further 3C6 month course of alitretinoin. Seven case studies of alitretinoin have </span><span style=""font-size:14px;font-family:Times New Roman;"">been provided by consultant dermatologists showing its use in normal UK clinical </span><span style=""font-size:14px;font-family:Times New Roman;"">practice. The cases chosen demonstrate the efficacy of alitretinoin across several</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">different subtypes of CHE, and the positive effects the treatment brought to patients’</span><span style=""font-size:14px;font-family:Times New Roman;"">quality of life.</span>",,"/uploadfiles/file/20131105/20131105143904_1189.pdf",,11/05/2013,11/05/2013,"medicool",18,,,0,"85",64,"Everyday clinical experience of alitretinoin in the treatment of severe chronic hand eczema: seven case studies","2010",
432,"由于β-受体阻滞剂导致的扁平苔藓样药疹一则病例报告和文献综述",,"Chris Fessa} Penny Lim} Steve Kossard} Shawn Richards'^ and Pablo Fernandez Pe?a","Am J Ciln Dermafoi","<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">Abstract.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:18.0pt;"">
	<a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><a name=""OLE_LINK27""></a><a name=""OLE_LINK26""></a><span style=""line-height:2;font-size:14px;"">Lichen
planus-like drug eruptions (LDE) can appear similar or identical to</span><a name=""OLE_LINK25""></a><a name=""OLE_LINK24""></a><span style=""line-height:2;font-size:14px;""> idiopathic lichen planus. </span><a name=""OLE_LINK35""></a><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><a name=""OLE_LINK58""></a><a name=""OLE_LINK57""></a><a name=""OLE_LINK34""></a><a name=""OLE_LINK31""></a><a name=""OLE_LINK30""></a><span style=""line-height:2;font-size:14px;"">We
present a 45-year-old man with a widespread, violaceous, papular, </span><a name=""OLE_LINK33""></a><a name=""OLE_LINK32""></a><span style=""line-height:2;font-size:14px;"">generalized
exanthema with histology features of a lichenoid reaction, </span><a name=""OLE_LINK37""></a><a name=""OLE_LINK36""></a><span style=""line-height:2;font-size:14px;"">which subsequently
resolved with the cessation of labetatol. </span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><a name=""OLE_LINK39""></a><a name=""OLE_LINK38""></a><span style=""line-height:2;font-size:14px;"">We found 29 cases of </span><a name=""OLE_LINK41""></a><a name=""OLE_LINK40""></a><span style=""line-height:2;font-size:14px;"">previously
reported </span><a name=""OLE_LINK42""></a><span style=""line-height:2;font-size:14px;"">?-adrenoceptor </span><a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span style=""line-height:2;font-size:14px;"">antagonist (?-blocker)-associated LDE. </span><a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><a name=""OLE_LINK43""></a><span style=""line-height:2;font-size:14px;"">This is a
relatively rare complication that may present as</span><a name=""OLE_LINK45""></a><a name=""OLE_LINK44""></a><span style=""line-height:2;font-size:14px;""> classic lichenoid papules indistinguishable from lichen planus and has a
predilection for the limbs, chest, back, and oral mucosa.</span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span style=""line-height:2;font-size:14px;""> Histologically, </span><a name=""OLE_LINK47""></a><a name=""OLE_LINK46""></a><span style=""line-height:2;font-size:14px;"">there is a </span><a name=""OLE_LINK49""></a><a name=""OLE_LINK48""></a><span style=""line-height:2;font-size:14px;"">lichenoid
infiltrate often with eosinophils.</span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a> <a name=""OLE_LINK50""></a><span style=""line-height:2;font-size:14px;"">LDE may be due to drug cross-reactivity or </span><a name=""OLE_LINK52""></a><a name=""OLE_LINK51""></a><span style=""line-height:2;font-size:14px;"">as a result of a suppressed skin adrenergic
system. </span><a name=""OLE_LINK54""></a><a name=""OLE_LINK53""></a><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span style=""line-height:2;font-size:14px;"">Multiple potential medications in case studies
and the inability to differentiate LDE from idiopathic lichen planus in </span><a name=""OLE_LINK56""></a><a name=""OLE_LINK55""></a><span style=""line-height:2;font-size:14px;"">cross-sectional
association studies make any
conclusive analysis difficult.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""line-height:2;font-size:14px;"">摘要：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:18.0pt;"">
	<span style=""line-height:2;font-size:14px;"">扁平苔藓样药疹（LDE）可能会出现相似或相同的特发性扁平苔藓。我们报道了一例45岁男性患者，伴有分布广泛的、紫红色、全身性丘疹性皮疹苔藓样反应的组织学特点。，后来通过停用拉贝洛尔症状消失。我们发现先前报道的29例与β-肾上腺素受体拮抗剂（β-受体阻滞剂）相关的LDE（扁平苔癣样药疹）。这是一种比较罕见的并发症，可能会出现区别于扁平苔藓的经典苔藓样丘疹，好发于四肢、胸部、背部、和口腔黏膜等处。组织学上，经常伴有嗜酸性粒细胞的青苔状浸润。LDE的出现可能是由于药物的交叉反应性的结果，或者是皮肤肾上腺素能系统被抑制的原因。案例研究中的多种潜在药物以及在横断面研究中无法区分LDE与特发性扁平苔藓之间的不同，使做出任何结论性的分析变得困难。</span> 
</p>","/uploadfiles/image/20131113/20131113152435_0833w.jpg","/uploadfiles/file/20131113/20131113152457_4849.pdf",,11/13/2013,11/13/2013,"medicool",39,,,0,"67",99,"Lichen Planus-Like Drug Eruptions Due to ?-Blockers A Case Report and Literature Review","2012",
396,,"10.1111/j.1440-0960.2010.00634.x","Hugh Roberts and David Orchard","Australasian Journal of Dermatology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Abstract.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">We present a case series of 25 paediatric patients with </span><span style=""font-size:14px;font-family:Times New Roman;"">refractory discoid eczema treated with methotrexate.</span><span style=""font-size:14px;font-family:Times New Roman;"">Patients were commenced on either 5 mg or 10 mg </span><span style=""font-size:14px;font-family:Times New Roman;"">of methotrexate per week. Sixteen patients (64%) </span><span style=""font-size:14px;font-family:Times New Roman;"">completely cleared their eczema after an average of </span><span style=""font-size:14px;font-family:Times New Roman;"">10.5 months of methotrexate therapy. A further three </span><span style=""font-size:14px;font-family:Times New Roman;"">patients (12%) have responded well and are almost </span><span style=""font-size:14px;font-family:Times New Roman;"">clear at the time of writing. Methotrexate was well </span><span style=""font-size:14px;font-family:Times New Roman;"">tolerated by the majority of patients and no serious</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">adverse events were observed. Methotrexate should </span><span style=""font-size:14px;font-family:Times New Roman;"">beconsideredinmoderatetoseverepaediatricdiscoid </span><span style=""font-size:14px;font-family:Times New Roman;"">eczema that has failed to respond to conventional </span><span style=""font-size:14px;font-family:Times New Roman;"">therapies.</span>",,"/uploadfiles/file/20131105/20131105145608_5103.pdf",,11/05/2013,11/05/2013,"medicool",25,,,0,"85",64,"Methotrexate is a safe and effective treatment for paediatric discoid (nummular) eczema: A case series of 25 children","2010",
397,,"10.1503/cmaj.121036","Kachiu C. Lee MD MPH, Barry Ladizinski MD","CMAJ","&nbsp;&nbsp;&nbsp; <span style=""font-size:14px;font-family:Times New Roman;"">A </span><span style=""font-size:14px;font-family:Times New Roman;"">57-year-old man with chronic inflam</span><span style=""font-size:14px;font-family:Times New Roman;"">matory demyelinating polyneuropathy </span><span style=""font-size:14px;font-family:Times New Roman;"">had a pruritic rash on his palms 2 days </span><span style=""font-size:14px;font-family:Times New Roman;"">following his first treatment with intravenous </span><span style=""font-size:14px;font-family:Times New Roman;"">immunoglobulin. He had no known drug aller</span><span style=""font-size:14px;font-family:Times New Roman;"">gies or history of rashes caused by drugs. He </span><span style=""font-size:14px;font-family:Times New Roman;"">was not aware of contact with new substances, </span><span style=""font-size:14px;font-family:Times New Roman;"">and, aside from the intravenous immunoglobu</span><span style=""font-size:14px;font-family:Times New Roman;"">lin, he had not received any new medications.</span>",,"/uploadfiles/file/20131105/20131105150003_8211.pdf",,11/05/2013,11/05/2013,"medicool",16,,,0,"65",64,"Dyshidrotic eczema following intravenous immunoglobulin treatment","2013",
398,,,"Ali H Ziyab, Gwyneth A Davies, Susan Ewart, Julian M Hopkin, Eric M Schauberger, Marsha Wills-Karp, John W Holloway, Syed Hasan Arshad, Hongmei Zhang and Wilfried Karmaus*","BMC Medical Genetics","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">Eczema is a prevalent skin disease that is mainly characterized by systemic deviation of immune </span><span style=""font-size:14px;font-family:Times New Roman;"">response and defective epidermal barrier. Th2 cytokines, such as IL-13 and transcription factor STAT6 are key </span><span style=""font-size:14px;font-family:Times New Roman;"">elements in the inflammatory response that characterize allergic disorders, including eczema. Previous genetic </span><span style=""font-size:14px;font-family:Times New Roman;"">association studies showed inconsistent results for the association of single nucleotide polymorphisms (SNPs) with </span><span style=""font-size:14px;font-family:Times New Roman;"">eczema. Our aim was to investigate whether SNPs in IL13 and STAT6 genes, which share a biological pathway, have </span><span style=""font-size:14px;font-family:Times New Roman;"">an interactive effect on eczema risk.</span>",,"/uploadfiles/file/20131105/20131105150638_5642.pdf",,11/05/2013,11/05/2013,"medicool",16,,,0,"65",64,"Interactive effect of STAT6 and IL13 gene polymorphisms on eczema status: results from a longitudinal and a cross-sectional study","2013",
399,,"10.1111/j.1399-3038.2010.01077.x","Aida Semic-Jusufagic*, Philippe Gevaert*, Claus Bachert, Clare Murray, Angela Simpson and Adnan Custovic","Pediatr Allergy Immunol","<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; Eosinophils are involved in the pathogenesis of </span><span style=""font-size:14px;font-family:Times New Roman;"">allergic disease, and increasing blood and tissue </span><span style=""font-size:14px;font-family:Times New Roman;"">eosinophilia is related to the presence and </span><span style=""font-size:14px;font-family:Times New Roman;"">severity of symptoms (1, 2). Eosinophil precur</span><span style=""font-size:14px;font-family:Times New Roman;"">sors in the bone marrow are differentiated and </span><span style=""font-size:14px;font-family:Times New Roman;"">activated under the influence of several cyto</span><span style=""font-size:14px;font-family:Times New Roman;"">kines, mainly IL-3, IL-5 and GM-CSF. Eosin</span><span style=""font-size:14px;font-family:Times New Roman;"">ophil proliferation, homing and local survival in </span><span style=""font-size:14px;font-family:Times New Roman;"">peripheral tissues depend on IL-5 stimulation.</span>",,"/uploadfiles/file/20131105/20131105151338_5481.pdf",,11/05/2013,11/05/2013,"medicool",23,,,0,"65",64,"Increased serum-soluble interleukin-5 receptor alpha level precedes the development of eczema in children","2010",
400,,"10.1111/j.1468-3083.2011.04128.x","M. Lode ?n* K. Wire ?n,K.T. Smerud,N. Meland,H. H?nna ?s,G. M?rk,CC. Lu ¨tzow-Holm, J. Funk,B. Meding","JEADV","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background.</span><br />
</strong><span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;Hand eczema is a common and persistent disease with a relapsing course. Clinical data suggest that</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">once daily treatment with corticosteroids is just as effective as twice daily treatment.</span>",,"/uploadfiles/file/20131105/20131105152026_9412.pdf",,11/05/2013,11/05/2013,"medicool",24,,,0,"65",64,"The effect of a corticosteroid cream and a barrier-strengthening moisturizer in hand eczema. A double-blind, randomized, prospective, parallel group clinical trial","2011",
406,,"10.1111/j.1365-2133.2010.09689.x","M.E. Schram, A.M. Tedja, R. Spijker,* J.D. Bos, H.C. Williams? and Ph.I. Spuls","British Journal of Dermatology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background.</span><br />
</strong><span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;Eczema affects approximately 10% of all schoolchildren in the western </span><span style=""font-size:14px;font-family:Times New Roman;"">world and has shown an increase over the past decades in ‘developing’ countries.</span><span style=""font-size:14px;font-family:Times New Roman;"">Numerous factors have been suggested that might contribute to the increasing</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">prevalence of eczema. A plausible explanation is the role of environmental fac</span><span style=""font-size:14px;font-family:Times New Roman;"">tors. As part of the ‘hygiene hypothesis’ it has been thought that eczema is more </span><span style=""font-size:14px;font-family:Times New Roman;"">common in urban than in rural communities, but such a notion has never been</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">assessed systematically.</span>",,"/uploadfiles/file/20131105/20131105160026_3814.pdf",,11/05/2013,11/05/2013,"medicool",21,,,0,"67",64,"Is there a rural?urban gradient in the prevalence of eczema? A systematic review","2010",
401,,,"Ryan P Kopp, Jonathan L Silberstein and Ithaar H Derweesh*","BMC Urology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">By combining trocar sites and extraction incision, Laparo-endoscopic Single-site Surgery (LESS) may </span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">provide less morbidity than traditional laparoscopy. Concerns continue about LESS for locally advanced tumors. We </span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">present our experience with LESS-radical nephrectomy with renal vein thrombectomy (LESS-RN-RVT)</span>",,"/uploadfiles/file/20131105/20131105152409_0076.pdf",,11/05/2013,11/05/2013,"medicool",15,,,0,"66",64,"Laparo-endoscopic single-site (LESS) radical nephrectomy with renal vein thrombectomy: initial report","2010",
407,,"10.1111/j.1365-2133.2010.09743.x","F.J. Bath-Hextall, A.J. Birnie,* J.C. Ravenscroft? and H.C. Williams","British Journal of Dermatology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background.</span><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span></strong><span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;An association between the bacterium Staphylococcus aureus and atopic </span><span style=""font-size:14px;font-family:Times New Roman;"">eczema has been recognized for many years. Although few would dispute the </span><span style=""font-size:14px;font-family:Times New Roman;"">benefit of systemic antibiotics in people with overtly clinically infected eczema,</span><span style=""font-size:14px;font-family:Times New Roman;"">the clinical role of S. aureus in causing inflammatory flares in clinically uninfected </span><span style=""font-size:14px;font-family:Times New Roman;"">eczema is less clear.</span>",,"/uploadfiles/file/20131105/20131105160407_5742.pdf",,11/05/2013,11/05/2013,"medicool",55,,,0,"67",64,"Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review","2010",
402,,"10.2500/aap.2013.34.3625","Chian-Yin Shen, M.D. Ming-Chih Lin, M.D., Heng-Kuei Lin, M.D. Ching-Heng Lin, Ph.D.Lin-Shien Fu, M.D.?nd Yun-Chin Fu, M.D., Ph.D.","Allergy and Asthma Proceedings","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Abstract.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">Although ""atopic march"" is a popular concept, the relationship between eczema and subsequent asthma is far from clear.</span><span style=""font-size:14px;font-family:Times New Roman;"">However, some cohort studies have shown the possibility of two different allergic phenotypes in those who present with early </span><span style=""font-size:14px;font-family:Times New Roman;"">eczema in terms of their persistency. We checked the cohort data from 308,849 children born in 2000 in Taiwan, to evaluate </span><span style=""font-size:14px;font-family:Times New Roman;"">the different courses of eczema and their relationships to subsequent asthma and allergic rhinitis (AR) at age 7 years.</span>",,"/uploadfiles/file/20131105/20131105153003_6742.pdf",,11/05/2013,11/05/2013,"medicool",18,,,0,"66",64,"The natural course of eczema from birth to age 7 years and the association with asthma and allergic rhinitis: A population-based birth cohort study","2013",
405,,"10.1111/j.1365-2133.2012.10994.x","E. Ernst","British Journal of Dermatology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;Homeopathy is often advocated for patients with eczema.</span><span style=""font-size:14px;font-family:Times New Roman;"">Objectives This article systematically reviews the evidence from controlled clinical </span><span style=""font-size:14px;font-family:Times New Roman;"">trials of any type of homeopathic treatment for any type of eczema.</span>",,"/uploadfiles/file/20131105/20131105154839_2166.pdf",,11/05/2013,11/05/2013,"medicool",22,,,0,"67",64,"Homeopathy for eczema: a systematic review of controlled clinical trials","2012",
567,,"10.2310/7750.2012.11131",,"Journal of Cutaneous Medicine and Surgery","<strong><span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">To the Editor:</span></strong><br />
<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">&nbsp; &nbsp; We present the case of a 72-year-old woman who</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">developed an acute inflammation of her actinic keratosis</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">while on oral capecitabine chemotherapy for rectal</span>&nbsp;<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">adenocarcinoma.</span>",,"/uploadfiles/file/20131205/20131205094734_1259.pdf",,12/05/2013,12/06/2013,"medicool",23,,"Inflammation,photodermatosis",0,"67",104,"Capecitabine-Induced Inflammation of Actinic Keratosis: Case Report and Literature Review","2012",
595,,,"Ilko Bakardzhiev, MD, PhD","International Journal of Dermatology","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">Editor,</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">Disseminated superficial actinic porokeratosis (DSAP) is </span><span style=""font-family:Times New Roman;font-size:14px;"">the most common type of porokeratosis. It is related to </span><span style=""font-family:Times New Roman;font-size:14px;"">sun exposure and an autosomal dominant inheritance pattern </span><span style=""font-family:Times New Roman;font-size:14px;"">is recognized. No ideal treatment of this clonal disorder </span><span style=""font-family:Times New Roman;font-size:14px;"">of keratinization exists.1 We describe a patient in </span><span style=""font-family:Times New Roman;font-size:14px;"">whom the complete resolution of lesions was achieved </span><span style=""font-family:Times New Roman;font-size:14px;"">with topical treatment with the vitamin D3 analog calcipotriol. </span><span style=""font-family:Times New Roman;font-size:14px;"">Thus we add more evidence on the efficacy of </span><span style=""font-family:Times New Roman;font-size:14px;"">calcipotriol to the literature.</span>
</p>
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131209/20131209164658_4497.pdf",,12/09/2013,12/09/2013,"medicool",16,,"treatment, disseminated superficial actinic porokeratosis , calcipotriol",0,"66",108,"Successful treatment of disseminated superficial actinic porokeratosis with calcipotriol","2012",
569,,"10.1111/j.1468-3083.2010.03796.x","TG Tzellos,? C Sardeli,? A Lallas,? G Papazisis,? M Chourdakis,? D Kouvelas?","Journal of the European Academy of Dermatology and Venereology","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Background External anogenital warts (EGWs) are non-malignant skin tumours caused by human papillomavirus. </span><span style=""font-family:Times New Roman;font-size:16px;"">They are one of the fastest growing sexually transmitted diseases. Current treatments are unsatisfactory. Green tea </span><span style=""font-family:Times New Roman;font-size:16px;"">sinecatechin Polyphenon E ointment is a botanical extract from green tea leaves exhibiting anti-oxidant, anti-viral </span><span style=""font-family:Times New Roman;font-size:16px;"">and anti-tumour properties.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Objective The aim of this study was to integrate valid information and provide basis for rational decision making </span><span style=""font-family:Times New Roman;font-size:16px;"">regarding efficacy and safety of green tea extracts in the treatment of EGWs.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Methods A systematic search in electronic databases was conducted using specific key terms. Main search was </span><span style=""font-family:Times New Roman;font-size:16px;"">performed independently by two reviewers. The accumulated relevant literature was subsequently systematically </span><span style=""font-family:Times New Roman;font-size:16px;"">reviewed and a meta-analysis was conducted.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Results Three randomized, double-blind, placebo-controlled studies evaluating efficacy and safety of Polyphenon </span><span style=""font-family:Times New Roman;font-size:16px;"">E 15% and 10% in the treatment of warts were included in the systematic review and meta-analysis. A total of 660 </span><span style=""font-family:Times New Roman;font-size:16px;"">men and 587 women were enrolled. Regarding primary outcome, both Polyphenon E 15% and 10% demonstrated </span><span style=""font-family:Times New Roman;font-size:16px;"">significantly higher likelihood of complete clearance of baseline and baseline and new warts compared with controls. </span><span style=""font-family:Times New Roman;font-size:16px;"">No significant heterogeneity was detected. Recurrence rates were very low. Commonest local skin sign was </span><span style=""font-family:Times New Roman;font-size:16px;"">erythema and local skin symptom was itching.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;"">Conclusions Efficacy of Polyphenon 15% and 10%, at least for the primary endpoint, is clearly indicated. </span><span style=""font-family:Times New Roman;font-size:16px;"">Polyphenon E treatment exhibits very low recurrence rates and appears to have a rather favourable safety and </span><span style=""font-family:Times New Roman;font-size:16px;"">tolerability profile. Recommendations for future studies should include evaluation of the efficacy of green tea </span><span style=""font-family:Times New Roman;font-size:16px;"">catechins in the treatment of internal anogenital warts and direct comparison with its principal comparator, </span><span style=""font-family:Times New Roman;font-size:16px;"">imiquimod.</span>
</p>
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131205/20131205105220_5920.pdf",,12/05/2013,12/05/2013,"medicool",20,,"catechins, condylomata acuminata, genital warts, green tea, polyphenon E",0,"67",107,"Efficacy, safety and tolerability of green tea catechins in the treatment of external anogenital warts: a systematic review and meta-analysis ","2010",
573,,"org/10.1155/2013/102698","Laura Held，Thomas Kurt Eigentler，Ulrike Leiter，Claus Garbe，and Mark-Jürgen Berneburg.",,"<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Background. Therapy for actinic keratoses includes photodynamic therapy (PDT) and imiquimod 5% cream. e sequential</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">use of both could result in better clinical outcomes. Objectives. To enhance efficacy of therapies while improving tolerability,</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">convenience, and patient adherence with a scheme combining two concomitant or sequential AK treatments.&nbsp;Methods. All patients</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">underwent one session of conventional PDT. Two weeks aer, the PDT imiquimod 5% cream was applied to the treatment area</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">once daily for three days per week. One course continued for four weeks followed by a clinical evaluation and decision about further</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">treatment. Patients who had not cleared all of their AK lesions in the treatment area in course 1 participated in a second 4-week</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">course of treatment. Limitations. Small size of population. Results. ree participants were enrolled. Two patients showed complete</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">clinical clearance of AKs. e effect was also noted aer long-term followup, at months seven and eleven. No subject discontinued</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">for an adverse event. ere were severe local skin reactions in two participants which were severe erythema, scaling, and crusting.</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">One patient showed no response to the therapy. Conclusions. Photodynamic therapy followed by imiquimod was well tolerated and</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">improved reduction of actinic keratoses. is initial proof-of-concept should be studied in larger clinical trials.</span><br />",,"/uploadfiles/file/20131205/20131205154729_6183.pdf",,12/05/2013,12/05/2013,"medicool",25,,"Photodynamic therapy,AK treatments,clinical evaluation",0,"85",104,"Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases","2013",
577,"阿拉伯浴场的假单胞菌毛囊炎",,"Molina-Leyva, Alejandro,Ruiz-Ruigomez, Maria","Dermatology Online Journal, UC Davis","<p class=""MsoNormal"" style=""text-align:justify;text-indent:18pt;"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">A
35-year-old man </span><span style=""font-family:'Times New Roman';font-size:14px;"">presented with a
painful cutaneous skin eruption that was localized on the upper trunk. He
stated that the previous weekend he had attended an Arabian bath. The physical
examination revealed multiple hair follicle-centered papulopustules surrounded
by </span><span style=""font-family:'Times New Roman';font-size:14px;"">an
erythematous halo. A clinical diagnosis of pseudomonas folliculitis
was made and treatment was prescribed. Afterwards Pseudomonas aeruginosa was isolated
from a pustule culture. Pseudomonas folliculitis is a bacterial infection of
the hair follicles. The most common reservoirs include facilities with hot
water and complex piping systems that are difficult to clean, such as hot tubs
and bathtubs. Despite adequate or high chlorine levels, Pseudomonas aeruginosa
can grow within a biofilm.<br />
&nbsp; &nbsp;</span><span style=""text-indent:24pt;font-family:SimSun;line-height:1.5;font-size:14px;"">一位35岁男子的上躯干出现了疼痛性皮疹。他说上周末他参加了一个阿拉伯沐浴。体检时发现多个以毛囊为中心的由红晕包围的丘疹。假单胞菌毛囊炎的临床诊断被制定并且需要按规定进行治疗。事后从脓包培养物中分离出了绿脓杆菌。绿脓杆菌毛囊炎是细菌感染毛囊的一种。最常见的储藏场所包括很难清理的热水设施和复杂的管道系统，如热水浴池和浴缸。尽管具备充足的或较高的氯含量，绿脓杆菌也可以在生物膜内生长。</span><span style=""font-family:'Times New Roman';""><br />
<span style=""font-family:SimSun;font-size:14px;""></span></span> 
</p>","/uploadfiles/image/20131206/20131206131555_6008w.jpg","/uploadfiles/file/20131206/20131206131323_1574.pdf",,12/06/2013,12/06/2013,"medicool",25,,"Pseudomonas folliculitis|erythematous halo|hot tubs and bathtubs|biofilm",0,"85",105,"Pseudomonas folliculitis in arabian baths","2013",
579,"表皮生长因子受体抑制剂引发的毛囊炎、在管理和发病率中四环素的预防和治疗功效（依据表皮生长因子受体抑制剂管理类型）：一个系统性的文献综述",,"JEAN-BAPTISTE BACHET,  LUCIE PEUVREL,  CLAUDE BACHMEYER,",,"<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">Introduction.
Folliculitis is the most common side effect of epidermal growth factor receptor
(EGFR) inhibitors (EGFRIs). It is often apparent, altering patients’ quality of</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">life
and possibly impacting compliance. Variations&nbsp;in terms of the
treatment-related incidence and intensity have not been fully elucidated.
Tetracyclines have been recommended for the prophylaxis and treatment of
folliculitis but their efficacy is yet to be established.</span><span style=""text-align:center;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp;</span>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">引言</span><o:p></o:p>
</p>
<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">&nbsp; 毛囊炎是表皮生长因子受体（<span style=""font-family:Times New Roman;"">EGFR</span>）抑制剂（<span style=""font-family:Times New Roman;"">EGFRIs</span>）最常见的副作用。它往往显著地改变了患者的生活质量并可能影响其依从性。但从治疗相关的发病率和强度的角度来讲的变化尚未完全阐明。尽管四环素已被建议用于预防和治疗毛囊炎，但其功效仍有待确定。</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">Materials
and　Methods.　We carried
out two systematic literature reviews. The first assessed the preventive and
curative efficacy of tetracyclines. The second assessed the incidence of grade
3C4 folliculitis in the main clinical studies published.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">材料和方法</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">&nbsp; &nbsp;我们进行了两次系统性文献回顾。第一次对四环素的预防和治疗效果进行了评估。第二次对已发表的主要临床研究中<span style=""font-family:Times New Roman;"">3-4</span>级毛囊炎的发病率进行了评估。</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">Results.
In four randomized studies, </span><span style=""font-family:'Times New Roman';font-size:14px;"">preventive tetracycline treatment
was associated with a significantly lower incidence of</span><span style=""font-family:'Times New Roman';font-size:14px;"">grade
2C3 folliculitis and a better quality of life in three of the four studies.
In curative terms, tetracycline efficacy was not evaluated in any randomized
study, but an improvement in grade&gt;2 folliculitis was reported in case
series.　The
frequency and severity of folliculitis seem　to be greater
with the antibodies than with the tyrosine kinase inhibitors. Analysis restricted
to lung cancer studies showed a statistically greater incidence in terms of
grade 3C4 folliculitis with cetuximab (9%) and erlotinib (8%) than with
gefitinib (2%) (p&lt;.0001).</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">结果</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">&nbsp; 在<span style=""font-family:Times New Roman;"">4</span>项随机性研究中，预防药四环素的治疗与<span style=""font-family:Times New Roman;"">2-3</span>级毛囊炎的发病率显著下降以及其中４项研究中的3项获得了较高的生活质量有关。在治疗方面，任何随机研究中四环素的疗效均不能被评价，但在病例系列中超过2级的毛囊炎得到改善这一情况已被报道。与使用酪氨酸激酶抑制剂的毛囊炎相比，使用抗体的毛囊炎的发病次数和严重程度似乎更大。仅限于肺癌的分析研究表明，就<span style=""font-family:Times New Roman;"">3-4</span>级的毛囊炎而言，使用西妥昔单抗（9％）和厄洛替尼（<span style=""font-family:Times New Roman;"">8％</span>）比用吉非替尼（<span style=""font-family:Times New Roman;"">2％</span>）（<span style=""font-family:Times New Roman;"">P
&lt;0.0001</span>）的发病率更高。</span><o:p></o:p>
</p>","/uploadfiles/image/20131206/20131206160538_1287w.jpg","/uploadfiles/file/20131206/20131206160930_6939.pdf",,12/06/2013,12/06/2013,"medicool",19,,"Folliculitis | EGFR inhibitors |Systematic review |Cycline |Cancer",0,"67",105,"Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review","2012",
580,,"10.1159/000258050","Carine Michot, Bernard Guillot, Olivier Dereure",,"<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp;&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp; Lenalidomide is a thalidomide-related immunomodulating&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">molecule with anti-tumoral and anti-angiogenic properties. It is&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">currently used in multiple myeloma, myelodysplastic syndromes&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and systemic amyloidosis either in monotherapy or in combina</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">tion with dexamethasone &nbsp; [1] . Cutaneous side effects have been&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">reported, as with thalidomide, the large majority being low-grade&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">maculopapular rashes. Conversely, the occurrence of acneiform&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">eruptions very much alike anti-epidermal growth factor receptor&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(EGFR)-related skin complications have been far more rarely re</span><span style=""line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;"">ported. Here, we report a new case illustrating this unusual side&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">effect and underscoring that it is not specific to anti-EGFR&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;"">agents. &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;""></span></span>
</div>",,"/uploadfiles/file/20131206/20131206164445_3089.pdf",,12/06/2013,12/06/2013,"medicool",9,,"Lenalidomide|Acneiform rash|Folliculitis",0,"85",105," Lenalidomide-Induced Acute Acneiform Folliculitis of the Head and Neck: Not Only the Anti-EGF Receptor Agents ","2009",
583,,,"Esther Casta?o-Suárez, Alberto Romero-Maté, Dolores Arias-Palomo & Jesús Borbujo","BRIEF COMMUNICATION","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp; Folliculitis decalvans is a chronic form of deep folliculitis that occurs on the scalp as patches&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">of scarring alopecia at the expanding margins of which are follicular pustules.Treatment of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">folliculitis decalvans is extremely dif?cult with a resultant poor prognosis. Photodynamic&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">therapy has been reported to be effective in disorders as acne or folliculitis.We report one&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patient with folliculitis decalvans who was successfully treated with photodynamic therapy.</span> 
</div>",,"/uploadfiles/file/20131206/20131206165730_9894.pdf",,12/06/2013,12/06/2013,"medicool",13,,"folliculitis decalvans| photodynamic therapy| treatment",0,"66",105,"Photodynamic therapy for the treatment of folliculitis decalvans","2011",
589,,,"J. Scott Weese, DVM, DVSc a, Anthony A. Yu, DVM, MS",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;Bacterial, dermatophilosis, and superficial ringworm infections are common skin diseases</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	noted in equine dermatology.The ability to recognize and accurately diagnose the skin condition is key to selecting an
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	appropriate and successful treatment regimen.Addressing underlying etiology, environmental management, and infection control play a&nbsp;crucial role in preventing relapse of clinical signs.
</div>
</span>",,"/uploadfiles/file/20131206/20131206173017_3572.pdf",,12/06/2013,12/06/2013,"medicool",20,,"Staphylococcus|  Methicillin-resistant Staphylococcus aureus  |Dermatophilus| Rainrot  Dermatophytosis | Ringworm",0,"67",105,"Infectious Folliculitis and Dermatophytosis",,
606,"掌跖角化病病发假性箍趾病一例","1000-4963（2012）07-0432-01","余晖，段岚桦，蔡念宁，王萍","临床皮肤科杂志","<div style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;""><strong>病例摘要：</strong></span> 
</div>
<span style=""font-family:SimSun;font-size:14px;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""> &nbsp; 患者女，32岁。因掌跖角化过度30年，双手指远端指间关节环形缩窄9年于2011年4月14日来北京市中医医院皮肤科就诊。患者自30年前无明显诱因双掌跖皮开始粗糙，逐渐增厚、变硬，并累及指、趾。9年前无明显诱因左手小指远端指间关节横纹处出现线状缩窄，逐渐发展成环状缩窄，手指末节肥大，伴有间歇性疼痛。病情逐渐发展，双手食指、中指、无名指的末端指间关节出现相似情况，未曾系统诊治。患者出生时无皮损，出生时即伴有听力障碍。父母均健在，非近亲结婚。父母、兄弟均无指趾缩窄情况。</span> 
</div>
</span>",,"/uploadfiles/file/20131211/20131211093945_0990.pdf",,12/11/2013,12/11/2013,"medicool",11,,"掌跖角化病，阿洪病，假性",0,"85",110,,"2012",
585,,"10.1016/j.jaad.2006.08.021","Alan L. Levy, MD, Gregory Simpson, MD, and Robert B. Skinner","the American Academy of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp; Bacterial folliculitis is an infection of the su</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">per?cial portion of the pilosebaceous unit.</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">A furuncle or boil represents the evolution of</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the infection to the deeper portion of the hair follicle.</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Although there are many causes, Staphylococcus&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">aureus has become the primary culprit underlying</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">these skin infections.</span><span style=""font-size:9px;line-height:1.5;font-family:'Times New Roman';"">1</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Although S aureus is a com</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">mon asymptomatic colonizer of many body areas,</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">including the nares, axilla, perineum, and vagina,</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-size:9px;"">2-3</span><span style=""line-height:1.5;"">microtears in the epidermis provide a portal of entry&nbsp;</span><span style=""line-height:1.5;"">of S aureus into deeper tissues, resulting in folliculitis,</span><span style=""line-height:1.5;"">furunculosis, carbuncles, abscesses, and cellulitis.</span><span style=""line-height:1.5;"">Clinically, folliculitis presents as an eruption of&nbsp;</span><span style=""line-height:1.5;"">erythematous papules or pustules with surrounding&nbsp;</span><span style=""line-height:1.5;"">erythema centered on hair follicles. A furuncle&nbsp;</span><span style=""line-height:1.5;"">appears as a tender, ?rm, erythematous, often ?uc</span><span style=""line-height:1.5;"">tuant nodule with central purulence that may spon</span><span style=""line-height:1.5;"">taneously drain. A ?nding that is often seen in images&nbsp;</span><span style=""line-height:1.5;"">of these lesions but infrequently discussed is the&nbsp;</span><span style=""line-height:1.5;"">presence of a rim of desquamation surrounding the&nbsp;</span><span style=""line-height:1.5;"">infected hair follicle (Fig 1). There may be one or,</span><span style=""line-height:1.5;"">less commonly, multiple circles of desquamation&nbsp;</span><span style=""line-height:1.5;"">arranged in a lamellar fashion around the infected&nbsp;</span><span style=""line-height:1.5;"">hair follicle</span> 
</div>
</span>",,"/uploadfiles/file/20131206/20131206170707_4416.pdf",,12/06/2013,12/06/2013,"medicool",12,,"The diagnosis of folliculitis|Staphylococcus aureus| Bacterial folliculitis",0,"65",105,"Medical Pearl: Circle of desquamation―A clue to the diagnosis of folliculitis and furunculosis caused by Staphylococcus aureus","2006",
586,,,"Jin Woong Lee,Hye In Lee,Myeung Nam Kim,",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;Malassezia folliculitis, formerly called ‘‘Pityrosporum&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">folliculitis,’’ was ?rst described in 1969 by Weary et al.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">It is an infection of the hair follicle presumably caused&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">by yeasts, Malassezia furfur (previously called ‘‘Pityro</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">sporum ovale’’) and other strains of Malassezia species.</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">It usually responds well to oral antifungal agents.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">But&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">recurrence is common, and the appearance of drug resis</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">tant strains is becoming more frequent as a result of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">prolonged oral medications. Moreover, oral antifungal&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">agents have adverse effects such as hepatotoxicity, drug&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">reactions, and gastrointestinal discomfort. Because of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">these problems related to poor compliance of oral medi</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">cation, some patients require topical therapy without&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">systemic medication. But the ef?cacy of topical treat</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">ment is usually disappointing. Because of these therapeu</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">tic weaknesses, there remains an ongoing need for&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">alternative treatments for recalcitrant Malassezia follicu</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">litis. Herein we report a case of a 41-year-old man with&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Malassezia folliculitis successfully treated with a topical&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">photodynamic therapy (PDT) with methyl aminolevulin</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">ate (MAL), as a new therapeutic option for recalcitrant&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Malassezia folliculitis.</span>
</div>
<br />",,"/uploadfiles/file/20131206/20131206171411_4504.pdf",,12/06/2013,12/06/2013,"medicool",12,,"Pityrosporum folliculitis |Topical photodynamic therapy | Malassezia folliculitis",0,"65",105,"Topical photodynamic therapy with methyl aminolevulinate may be an alternative therapeutic option for the recalcitrant Malassezia folliculitis","2011",
587,,,,"British Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; &nbsp; &nbsp;Tufted folliculitis is an uncommon folliculitis of the scalp that resolves with patches of scarring&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">alopecia within which multiple hair tufts emerge from dilated follicular ori?ces. The clinicohistolo</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">gical data from a group of 15 patients with tufted folliculitis were reviewed and compared with those&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">of seven patients with folliculitis decalvans, ?ve with acne keloidalis nuchae, four with dissecting&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cellulitis of the scalp, three with kerion celsi and 20 with follicular lichen planus. It was found that&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tufted folliculitis could be differentiated from folliculitis decalvans only by ?nding several hair tufts&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">scattered within patches of scarring alopecia. Histologically, a single tuft consisted of peculiar&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">clustering of adjacent follicular units opening at the bottom of an epidermal depression. Conversely,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the presence of keloidal plaques in acne keloidalis nuchae, coalescing nodules discharging purulent&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">material in dissecting cellulitis of the scalp, erythematous plaques covered by pustules replete with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">fungal elements in kerion celsi, and the absence of follicular pustules in follicular lichen planus&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">distinguished these diseases from tufted folliculitis. On the basis of these ?ndings, it is suggested that&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tufted folliculitis should be considered as a distinctive clinicohistological variant of folliculitis&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">decalvans. Tufting of hair is caused by clustering of adjacent follicular units due to a ?brosing&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">process and to retention of telogen hairs within the involved follicular units.</span> 
</div>",,"/uploadfiles/file/20131206/20131206171949_4873.pdf",,12/06/2013,12/06/2013,"medicool",22,,"Tufted folliculitis|folliculitis decalvans|reviewe",0,"65",105,"Tufted folliculitis of the scalp: a distinctive clinicohistological variant of folliculitis decalvans","1998",
588,,"10.1111/j.1610-0387.2011.07716.x","Patrick A. Oberholzer,Dermatologische Klinik,Universit?t Bern","Journal of the German","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;A 61-year-old man presented with&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">adenocarcinoma of the distal descending&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">colon and extensive lymphatic metasta</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">sis. Following an initial left hemicolec</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">tomy and para-aortic lymphadenectomy,</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">he received chemotherapy with FOL-</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">FOX/bevacizumab. FOLFOX is a triple&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">combination therapy consisting of FO-</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Linic acid, 5-Fluorouracil, and OXalipla</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">tin. In addition, he also was given bevaci</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">zumab, which inhibits binding of VEGF</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(vascular endothelial growth factor) to its&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">receptors VEGFR1 and VEGFR2. The&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">disease continued to progress despite tre</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">atment. The patient was switched to the&nbsp;less toxic drug FOLFIRI (with IRInote</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">can instead of OXaliplatin). There was&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">renewed progression of disease including&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">skin metastases which were confirmed by&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">a biopsy. Pubic and bilateral inguinal&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">palliative percutaneous radiotherapy&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(total 30 Gy) was performed. Along with&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">prior lymphadenectomy, therapy led to&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">chronic lymphedema and blockage of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">venous drainage in both legs and subse</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">quently to development of ulcers on the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">lower legs, the medial aspects of the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">thighs, and the scrotum.</span> 
</div>
<br />",,"/uploadfiles/file/20131206/20131206172454_1871.pdf",,12/06/2013,12/06/2013,"medicool",21,,"Cetuximab-associated folliculitis| Treatment schedule|papules and pustules",0,"65",105,"Cetuximab-associated folliculitis predominantly affecting the lower limbs","2011",
590,,,"Paul Bloom","The Veterinary Journal","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;Superficial bacterial folliculitis (SBF) is more common in the dog than other&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">mammalian species. Until recently, a successful outcome in cases of canine SBF was possible&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">by administering a potentiated amoxicillin, a first generation cephalosporin or a potentiated&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">sulfonamide. Unfortunately, this predictable susceptibility has changed, because methicillin&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">resistant Staphylococcus pseudintermedius (MRSP) and Staphylococcus aureus (MRSA) are&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">becoming more prevalent in canine SBF cases. The increasing frequency of multidrug&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">resistance complicates the selection of antimicrobial therapy. Antimicrobial agents that were&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">once rarely used in cases of canine SBF, such as amikacin, rifampicin and chloramphenicol,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">are becoming the drugs of choice, based on bacterial culture and susceptibility testing.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Furthermore, changes in antimicrobial susceptibility have helped to re-emphasize the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">importance of a multimodal approach to treatment of the disease, including topical therapy.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Due to the increasing frequency of identification of highly resistant Staphylococcus spp.,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">topical antimicrobial therapy, including the use of diluted sodium hypochlorite (bleach), is&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">becoming necessary to successfully treat some cases of canine SBF. Other important&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">antiseptics that can be used include chlorhexidine, benzoyl peroxide, ethyl lactate, triclosan&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and boric acid/acetic acid. This review discusses the diagnostic and therapeutic management&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">of canine SBF, with a special emphasis on treating methicillin resistant staphylococcal&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">infections.&nbsp;</span> 
</div>
<br />",,"/uploadfiles/file/20131206/20131206173642_4907.pdf",,12/06/2013,12/06/2013,"medicool",24,,"Staphylococcus|Pyoderma|Canine|Methicillin| Antimicrobial resistance",0,"67",105,"Canine superficial bacterial folliculitis: Current understanding of its etiology, diagnosis and treatment","2013",
591,,,"NINA OTBERG, HOON  KANG, ABDULLATEEF A. ALZOLIBANI & JERRY SHAPIRO",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;Folliculitis decalvans is a rare in?ammatory scalp disorder. The present paper gives a&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">practical approach to diagnosis and patient management and reviews possible pathogenetic factors&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and treatment options. Folliculitis decalvans is classi?ed as primary neutrophilic cicatricial alopecia&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and predominantly occurs in middle-aged adults.&nbsp;Staphylococcus aureus</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;and a de?cient host&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">immune response seem to play an important role in the development of this dis?guring scalp&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">disease. Lesions occur mainly in the vertex and occipital area. Clinically, the lesions present with&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">follicular pustules, lack of ostia, diffuse and perifollicular erythema, follicular tufting, and, oftentimes,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">hemorrhagic crusts and erosions. Histology displays a mainly neutrophilic in?ammatory in?ltrate in early&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">lesions and additionally lymphocytes and plasma cells in advanced lesions. Treatment is focused on the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">eradication of&nbsp;S. aureus</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;anti-in?ammatory agents.</span> 
</div>",,"/uploadfiles/file/20131206/20131206173944_0282.pdf",,12/06/2013,12/06/2013,"medicool",18,,"cicatricial alopecia| folliculitis decalvans| neutrophilic| Staphylococcus aureus|tufted",0,"0",105,"Folliculitis decalvans","2008",
592,,,"Jacob O. Levitt, MD, FAAD, Brieze R. Keeley, BA,","J AM ACAD DERMATOL","<p>
	<span style=""font-family:Times New Roman;font-size:14px;"">To the Editor: <br />
&nbsp;&nbsp;&nbsp;&nbsp; We present 2 cases of porokeratosis of </span><span style=""font-family:Times New Roman;font-size:14px;"">Mibelli treated successfully with 1 application of a </span><span style=""font-family:Times New Roman;font-size:14px;"">thin film of cantharidin to the circumference of the </span><span style=""font-family:Times New Roman;font-size:14px;"">entire lesion. </span><span style=""font-family:Times New Roman;font-size:14px;"">Patient 1 was a 76-year-old man with psoriasis. </span><span style=""font-family:Times New Roman;font-size:14px;"">He presented with a 17-year history of a porokeratosis </span><span style=""font-family:Times New Roman;font-size:14px;"">of Mibelli (Fig 1, A) on the right shin. The </span><span style=""font-family:Times New Roman;font-size:14px;"">lesion failed photodynamic therapy (blue light, </span><span style=""font-family:Times New Roman;font-size:14px;"">16.5 minutes and aminolevulinic acid, 3 hours) </span><span style=""font-family:Times New Roman;font-size:14px;"">2 years before the current therapy.</span>
</p>",,"/uploadfiles/file/20131209/20131209163359_8835.pdf",,12/09/2013,12/09/2013,"medicool",12,,,0,"66",108,"Treatment of porokeratosis of Mibelli with cantharidin","2013",
594,,,"Reiko Noborio, M.D., Ph.D","Japanese Dermatological Association","<p>
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;</span><span style=""font-family:Times New Roman;font-size:14px;"">Dear Editor,</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp; An 83-year-old woman visited our hospital for the treatment </span><span style=""font-family:Times New Roman;font-size:14px;"">of several ring-shaped superficial keratotic papules on her face </span><span style=""font-family:Times New Roman;font-size:14px;"">and forearm, which she had developed 20 years previously </span><span style=""font-family:Times New Roman;font-size:14px;"">(Figs 1a,2a). The patient was clinically diagnosed with disseminated </span><span style=""font-family:Times New Roman;font-size:14px;"">superficial actinic porokeratosis (DSAP) and the diagnosis </span><span style=""font-family:Times New Roman;font-size:14px;"">was confirmed histopathologically. The patient requested treatment </span><span style=""font-family:Times New Roman;font-size:14px;"">for the facial DSAP for cosmetic reasons.</span>
</p>",,"/uploadfiles/file/20131209/20131209164300_9861.pdf",,12/09/2013,12/09/2013,"medicool",16,,"treatment, disseminated superficial actinic porokeratosis",0,"66",108,"Split-face trial of CO2 laser-induced ring abrasion and high-dose tacalcitol in the treatment of disseminated superficial actinic porokeratosis","2012",
593,,,,,"<span style=""font-family:Times New Roman;font-size:14px;"">To the Editor:</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">Porokeratosis is a skin keratinization disorder that gives </span><span style=""font-family:Times New Roman;font-size:14px;"">rise to a number of clinical variants; the underlying disorder </span><span style=""font-family:Times New Roman;font-size:14px;"">can be acquired or hereditary. Clinically, it presents </span><span style=""font-family:Times New Roman;font-size:14px;"">as a macule or annular plaque characterized by a central </span><span style=""font-family:Times New Roman;font-size:14px;"">atrophic patch surrounded by a clearly defined hyperkeratotic </span><span style=""font-family:Times New Roman;font-size:14px;"">border. Histology shows a compact parakeratotic </span><span style=""font-family:Times New Roman;font-size:14px;"">column known as a cornoid lamella. The various clinical </span><span style=""font-family:Times New Roman;font-size:14px;"">forms of the disease are defined by the number and distribution </span><span style=""font-family:Times New Roman;font-size:14px;"">of the lesions: porokeratosis of Mibelli, disseminated </span><span style=""font-family:Times New Roman;font-size:14px;"">superficial actinic porokeratosis, linear porokeratosis, porokeratosis </span><span style=""font-family:Times New Roman;font-size:14px;"">palmaris et plantaris disseminata, and punctate </span><span style=""font-family:Times New Roman;font-size:14px;"">porokeratosis. Although the lesions are benign, some of their </span><span style=""font-family:Times New Roman;font-size:14px;"">characteristics are associated with a greater risk of malignant </span><span style=""font-family:Times New Roman;font-size:14px;"">transformation, hence the importance of deciding how </span><span style=""font-family:Times New Roman;font-size:14px;"">to approach these lesions and knowing the different therapeutic </span><span style=""font-family:Times New Roman;font-size:14px;"">options available.</span> 
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131209/20131209163944_5037.pdf",,12/09/2013,12/09/2013,"medicool",11,,,0,"66",108,"Porokeratosis of Mibelli: A New Indication for Photodynamic Therapy","2013",
596,"与烟雾综合征相关的系统性红斑狼疮：一则病例报告和文献综述","10.1177/0961203313485828","R Wang, Y Xu, R Lv and J Chen","Lupus","<span><span style=""font-family:'Times New Roman','serif';"">&nbsp;&nbsp; Moyamoya syndrome (MMS) is a rare, chronic progressive cerebrovascular occlusive disease that is characterized by </span></span></a><a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><span><span><span><span style=""font-family:'Times New Roman','serif';"">a stenosis or occlusion of the bilateral internal carotid arteries</span></span></span></span></a><span><span><span style=""font-family:'Times New Roman','serif';"">.</span></span></span><span style=""font-family:'Times New Roman','serif';""> <a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span>We report a case of a 24-year-old woman with nephrotic syndrome whose biopsy showed membranous nephropathy</span></a>.<a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><span> Ten months after the diagnosis </span></a><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span><span><span>she suffered sudden right hemiplegia and </span></span></span></a><a name=""OLE_LINK123""></a><a name=""OLE_LINK122""></a><span><span><span><span><span>seizure</span></span></span></span></span></a><span><span>.</span></span> <a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a><span>She was diagnosed with MMS by angiogram seven months ago and received decompressive craniotomy. </span></a><a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><span><span><span>The patient was admitted to our hospital and a diagnosis</span></span> of systemic lupus erythematosus (SLE) was made.</span></a> <a name=""OLE_LINK22""></a><a name=""OLE_LINK21""></a><span>Glucocorticoids and tacrolimus were used to control the symptoms of SLE</span></a>. Following one month of immunosuppressant treatment, the patient died of brain hemorrhage. <a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span>This case alongside another six reviewed cases shows that </span></a><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span><span><span><span><span>an underlying cerebrovascular lesion of moyamoya</span></span></span></span></span></a><span><span><span><span> in the vessels of patients with SLE <a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><span>is susceptible to cerebrovascular accidents.<br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></span></span></span><span style=""font-family:宋体;"">烟雾综合征（<span>MMS</span>）是一种罕见的慢性渐进性脑血管闭塞性疾病，以双侧颈内动脉狭窄或闭塞为特征。我们报道了一例<span>24</span>岁伴有肾病综合征的女性患者，其活检显示为膜性肾病。确诊十个月后，患者突发右侧偏瘫和癫痫。七个月前，患者通过血管造影诊断出患有<span>MMS</span>并接受了<a name=""OLE_LINK125""></a><a name=""OLE_LINK124""></a><span>去骨瓣减压术</span></a>的治疗。患者被送到我们医院并被诊断为系统性红斑狼疮（<span>SLE</span>）。应用糖皮质激素和他克莫司来控制<span>SLE</span>的症状。免疫抑制治疗一个月后，患者死于脑出血。这则病例与其他六例回顾性病例表明，<span> SLE</span>患者的血管中有一种潜在的烟雾性脑血管病变，容易发生脑血管意外。<span></span></span> 
<p style=""text-indent:21pt;"" class=""MsoNormal"">
	<span style=""font-family:宋体;""></span>
</p>","/uploadfiles/image/20131209/20131209171017_7098w.png","/uploadfiles/file/20131209/20131209171128_6743.pdf",,12/09/2013,12/09/2013,"medicool",25,,"Systemic lupus erythematosus; moyamoya syndrome; nephrotic syndrome; cerebral vascular hemorrhage; internal carotid artery occlusion",0,"85",3,"Systemic lupus erythematosus associated with moyamoya syndrome: a case report and literature review","2013","/uploadfiles/kejian/20131209/1209171239_9352.pdf"
597,"汗孔角化症：外用5％咪喹莫特乳膏后症状消退和缓解","10.1111/j.1440-0960.2010.00712.x","Branislava Gajic, Kenneth Tang and Margot Whitfeld","Australasian Journal of Dermatology","<b><span style=""font-family:'Times New Roman','serif';font-size:12pt;""><span style=""font-family:Times New Roman;font-size:14px;"">ABSTRACT</span> 
<p class=""MsoNormal"">
	<a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span style=""font-family:Times New Roman;font-size:14px;""><span style=""font-family:Times New Roman;font-size:14px;"">An 82-year-old woman presented with a longstanding, slowly enlarging annular lesion on the medial aspect of the ankle</span></span></a><span style=""font-family:'Times New Roman','serif';font-size:12pt;""><span style=""font-family:Times New Roman;font-size:14px;"">. </span><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-family:Times New Roman;font-size:14px;"">Histology confirmed the clinical diagnosis of Porokeratosis of Mibelli</span></a><span style=""font-family:Times New Roman;font-size:14px;"">. </span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""font-family:Times New Roman;font-size:14px;"">The lesion slowly involuted and resolved over 26 weeks of 5% imiquimod cream applied topically </span></a><span style=""font-family:Times New Roman;font-size:14px;"">and has not recurred during a 36 month follow-up period.</span></span>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:Times New Roman;font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 一名</span><span style=""font-family:Times New Roman;font-size:14px;"">82</span><span style=""font-family:Times New Roman;font-size:14px;"">岁的女性患者，其脚踝内侧部位出现了一个长期、缓慢扩大的环形病变。组织病理学证实其临床诊断为汗孔角化症。局部应用</span><span style=""font-family:Times New Roman;font-size:14px;"">5</span><span style=""font-family:Times New Roman;font-size:14px;"">％咪喹莫特乳膏</span><span style=""font-family:Times New Roman;font-size:14px;"">26</span><span style=""font-family:Times New Roman;font-size:14px;"">周后，皮损部位渐渐缓解和消退，并且在</span><span style=""font-family:Times New Roman;font-size:14px;"">36</span><span style=""font-family:Times New Roman;font-size:14px;"">个月的随访期内无复发。</span>
</p>
</span></b>","/uploadfiles/image/20131210/20131210112417_3679w.png","/uploadfiles/file/20131210/20131210112451_3135.pdf",,12/10/2013,12/10/2013,"medicool",20,,"imiquimod, involution, porokeratosis, treatment.",0,"66",108,"Porokeratosis of Mibelli: Involution and resolution with 5% imiquimod cream","2011",
404,,"10.2340/00015555-1522","Kerstin BINGEFORS, Ake SVENSSON, Dag ISACSON and Magnus LINDBERG","Acta Derm Venereol","&nbsp;&nbsp;&nbsp; <span style=""font-size:14px;font-family:Times New Roman;"">Atopie dermatitis and its co-morbidity with asthma and </span><span style=""font-size:14px;font-family:Times New Roman;"">allergy is well described in younger age groups. However, </span><span style=""font-size:14px;font-family:Times New Roman;"">population-based studies on adults with atopie dermati</span><span style=""font-size:14px;font-family:Times New Roman;"">tis in childhood are sparse.</span>",,"/uploadfiles/file/20131105/20131105154056_0518.pdf",,11/05/2013,11/05/2013,"medicool",29,,,0,"66",64,"Self-reported Lifetime Prevalence of Atopie Dermatitis and Comorbidity with Asthma and Eczema in Adulthood: A Population-based Cross-sectional Survey","2013",
408,,"10.1111/j.1365-2133.2010.10030.x","J. Schmitt, L. von Kobyletzki,* A?. Svensson and C. Apfelbacher","British Journal of Dermatology","<strong><span style=""font-size:14px;font-family:Times New Roman;"">Background.</span></strong><br />
<span style=""font-size:14px;font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp;&nbsp; </span><span style=""font-size:14px;font-family:Times New Roman;"">Long-term low-level topical anti-inflammatory therapy has been </span><span style=""font-size:14px;font-family:Times New Roman;"">suggested as a new paradigm in the treatment of atopic eczema (AE).</span>",,"/uploadfiles/file/20131105/20131105160711_9666.pdf",,11/05/2013,11/05/2013,"medicool",44,,,0,"67",64,"Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials","2011",
409,"口服他克莫司治疗成人严重的全身过敏性湿疹疗效不佳：一则简短的回顾性病例","10.1111/j.1440-0960.2011.00789.x","Frederick J Lee,Brad S Frankum and Constance H Katelaris","Australasian Journal of Dermatology","<b><span style=""font-size:14px;font-family:Times New Roman;color:black;"">Abstract.</span></b> 
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;font-family:Times New Roman;color:black;"">摘要</span></b><b><span style=""font-size:14px;font-family:Times New Roman;color:black;"">:</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;"">We report a small, but novel case series</span></span></span></span></span></span></span><span><span><span><span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;font-family:Times New Roman;""> of </span><span style=""font-size:14px;font-family:Times New Roman;"">four adults with severe generalized atopic eczema (AE) not responsive to several other immunomodulatory therapies</span></span></span></span></span></span><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;"">, who were treated with oral tacrolimus(5 mg twice-daily). </span></span></span><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;"">Three of the four patients failed therapy with systemic tacrolimus</span></span></span></span></span></span></span><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;"">, despite two of these showing an initial clinical response</span></span></span></span></span><span><span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;font-family:Times New Roman;"">; </span><span style=""font-size:14px;font-family:Times New Roman;"">the fourth patient remains on tacrolimus monotherapy with good control of skin disease</span><span style=""font-size:14px;font-family:Times New Roman;"">. </span></span></span></span><span><span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;font-family:Times New Roman;"">Although oral tacrolimus was well-tolerated in this small group of adults, </span><span style=""font-size:14px;font-family:Times New Roman;"">the clinical efficacy in this series for severe AE was poor.</span> </span></span></span><span><span><span style=""font-family:'Times New Roman','serif';""><span style=""font-size:14px;font-family:Times New Roman;"">T</span><span style=""font-size:14px;font-family:Times New Roman;"">acrolimus may yet have a role in </span><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;""><span style=""font-size:14px;font-family:Times New Roman;"">less severe disease</span></span></span><span><span><span style=""font-size:14px;font-family:Times New Roman;"">, </span><span style=""font-size:14px;font-family:Times New Roman;"">but larger prospective studies are required to qualify its place as a treatment option in AE.</span></span></span></span></span></span> 
</p>
<span></span><span></span><span></span><span></span><span></span><span></span> 
<p class=""MsoNormal"" style=""text-indent:21pt;"">
	<span style=""font-size:14px;font-family:Times New Roman;""> </span>
</p>
<div>
	&nbsp; &nbsp; 我们报告了4例常见但却很有特点的病例系列，他们都接受了口服他克莫司的治疗（5mg&nbsp;2/日）。这些成年患者有严重的全身过敏性湿疹(AE)&nbsp;，对其他免疫调节疗法无效。<span style=""text-indent:21pt;"">尽管两名患者表现出了初始的临床反应，但是其中的三名全身应用他克莫司治疗的患者显示治疗失败；第四位患者仍使用他克莫司单一治疗，皮肤疾病得到了良好地控制。尽管在这个成人小组中口服他克莫司表现出了良好的耐受性，但对于严重的</span><span style=""text-indent:21pt;"">AE</span><span style=""text-indent:21pt;"">患者，临床疗效较差。他克莫司可能在症状较轻的疾病上启作用，但还需要大量的前瞻性研究来证实它可以作为一种治疗</span><span style=""text-indent:21pt;"">AE</span><span style=""text-indent:21pt;"">的方法。</span> 
</div>
<p>
	<br />
</p>","/uploadfiles/image/20131105/20131105163316_6181w.jpg","/uploadfiles/file/20131105/20131105163240_6600.pdf",,11/05/2013,11/13/2013,"medicool",40,,,0,"85",64,"Poor efficacy of oral tacrolimus in the treatment of severe generalized atopic eczema in adults: A small retrospective case","2012",
417,,"10.1111/j.1468-3083.2011.04306.x","K. Danielsson,?,* M. Ebrahimi,?Y.B. Wahlin,?K. Nylander,?L. Boldrup?","JEADV","<strong><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Background.</span></strong><br />
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">&nbsp; &nbsp; </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Oral lichen planus (OLP) is a chronic inflammatory disease for which the pathogenesis is not fully&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">understood. OLP has autoimmune features and auto immunity has been suggested as a potential cause, whereas&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">WHO has classified OLP as a premalignant condition. Association between chronic inflammation and cancer is&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">known and chronic inflammation is one of the characteristics of OLP. A protein connected to inflammation and&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">suggested to be involved in cancer development is cyclooxygenase-2 (COX-2) which can be inhibited by microRNA-</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">26b (miR-26b).</span><br />
<strong><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Objective. </span></strong><br />
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> &nbsp; &nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">The aim was to map levels of COX-2 and miR-26b in OLP lesions to see if there was any correlation&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">between expression of COX-2 and its regulator miR-26b in OLP.</span><br />
<strong><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Methods. </span></strong><br />
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">&nbsp; &nbsp;&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""></span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">In biopsies from 20 OLP patients and 20 age and gender-matched controls laser- micro dissection of&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">epithelium was performed. Quantitative RT-PCR, immunohistochemistry and Western blot were used in the analysis.</span><br />
<strong><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Results.</span></strong> <br />
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> &nbsp; &nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Levels of COX-2 mRNA were significantly higher while levels of miR-26b were significantly lower in OLP&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">lesions compared to controls. Using immunohistochemistry normal oral mucosa samples did not show any&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">expression of COX-2 while OLP samples expressed the protein. No COX-2 protein was detectable with Western&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">blot.</span><br />
<strong><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Conclusion. </span></strong><br />
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">&nbsp; &nbsp; </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">Increased expression of COX-2 and decreased expression of miR-26b in OLP suggests both to play a&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">role in OLP. COX-2 has been connected to both malignant development and autoimmunity but as malignant&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">development of OLP is quite rare we suggest that the increased levels of COX-2 seen here support an autoimmune&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;"">cause of the disease.</span><br />",,"/uploadfiles/file/20131112/20131112112005_8130.pdf",,11/12/2013,11/12/2013,"medicool",29,,,0,"65",99,"Increased levels of COX-2 in oral lichen planus supports an autoimmune cause of the disease","2011",
410,"甲氨蝶呤-一种安全有效的儿科圆盘状（钱币状）湿疹疗法:一个25位儿童患者的病例系列","10.1111/j.1440-0960.2010.00634.x","Hugh Roberts and David Orchard","Australasian Journal of Dermatology","<p style=""text-indent:21pt;"" class=""MsoNormal"" align=""justify"">
	<span><span style=""line-height:150%;font-family:&quot;&quot;;""><span style=""font-size:14px;"">We present a case series of 25 </span><span style=""font-size:14px;"">paediatric patients with refractory discoid eczema treated with methotrexate. </span><span style=""font-size:14px;"">Patients were commenced on either 5 mg or 10 mg of methotrexate per week. </span><span style=""font-size:14px;"">Sixteen patients (64%) completely cleared their eczema after an average of 10.5 </span><span style=""font-size:14px;"">months of methotrexate therapy. A further three patients (12%) have responded </span><span style=""font-size:14px;"">well and are almost clear at the time of writing. Methotrexate was well </span><span style=""font-size:14px;"">tolerated by the majority of patients and no serious adverse events were </span><span style=""font-size:14px;"">observed. Methotrexate should be considered in moderate to severe paediatric </span><span style=""font-size:14px;"">discoid eczema that has failed to respond to conventional therapies.</span></span></span> 
</p>
<p style=""text-indent:21pt;"" class=""MsoNormal"" align=""justify"">
	<span style=""color:#313131;line-height:150%;font-family:宋体;font-size:14px;"">我们报道了用甲氨蝶呤治疗患有顽固性钱币状湿疹的</span><span style=""color:#313131;line-height:150%;font-family:&quot;font-size:14px;"">25</span><span style=""color:#313131;line-height:150%;font-family:宋体;font-size:14px;"">位儿科患者的病例系列。患者每周开始服用</span><span style=""color:#313131;line-height:150%;font-family:&quot;font-size:14px;"">5</span><span style=""color:#313131;line-height:150%;font-family:宋体;font-size:14px;"">毫克或</span><span style=""color:#313131;line-height:150%;font-family:&quot;font-size:14px;"">10</span><span style=""color:#313131;line-height:150%;font-family:宋体;font-size:14px;"">毫克的甲氨蝶呤。在甲氨蝶呤治疗平均</span><span style=""color:#313131;line-height:150%;font-family:&quot;font-size:14px;"">10.5</span><span style=""color:#313131;line-height:150%;font-family:宋体;font-size:14px;"">个月后，</span><span style=""color:#313131;line-height:150%;font-family:&quot;font-size:14px;"">16</span><span style=""color:#313131;line-height:150%;font-family:宋体;font-size:14px;"">位</span><span style=""color:#313131;line-height:150%;font-family:&quot;font-size:14px;"">(64%)</span><span style=""color:#313131;line-height:150%;font-family:宋体;font-size:14px;"">患者的湿疹被完全清除。另有</span><span style=""color:#313131;line-height:150%;font-family:&quot;font-size:14px;"">3</span><span style=""color:#313131;line-height:150%;font-family:宋体;font-size:14px;"">位</span><span style=""color:#313131;line-height:150%;font-family:&quot;font-size:14px;"">(12%)</span><span style=""color:#313131;line-height:150%;font-family:宋体;font-size:14px;"">患者反应良好，并且在撰写本文时几乎痊愈。大部分患者对于甲氨蝶呤的耐受性良好且无严重的副反应。甲氨蝶呤应被考虑运用到对于常规疗法无效的中度到重度的儿科钱币状湿疹。</span> 
</p>
<br />
<br />","/uploadfiles/image/20131106/20131106135457_5772w.png","/uploadfiles/file/20131106/20131106135427_9527.pdf",,11/06/2013,11/06/2013,"medicool",61,,"Methotrexate, paediatric, discoid,eczema.",0,"66",64,"Methotrexate is a safe and effective treatment for paediatric discoid (nummular) eczema: A case series of 25 childrena","2010",
412,,"10.1111/j.1468-3083.2011.04288.x","S. Goettmann,?,* I. Zaraa,?I. Moulonguet§","JEADV","<strong style=""font-family:'Times New Roman';line-height:1.5;""><span style=""font-size:14px;line-height:2;"">Background.</span></strong><br />
<span style=""font-family:'Times New Roman';line-height:2;font-size:14px;"">&nbsp; &nbsp; &nbsp;Lichen planus limited to the nail is uncommon, and information about its long-term prognosis is</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">lacking.</span><br />
<strong style=""font-family:'Times New Roman';""><span style=""font-size:14px;line-height:2;"">Objectives.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> We attempted to review the epidemiological, clinical and histological features, the response to</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">treatment and the follow-up of a large series of patients with nail lichen planus (NLP).</span><br />
<strong style=""font-family:'Times New Roman';""><span style=""font-size:14px;line-height:2;"">Methods.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> We searched for the records of all patients with a clinical and histopathological diagnosis of isolated NLP</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">apart from January 1997 to December 2008. The patients presented during this period and followed until December</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">2009 in the consultation for nail disorder were reviewed in detail.</span><br />
<strong style=""font-family:'Times New Roman';""><span style=""font-size:14px;line-height:2;"">Results.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp;&nbsp;</span><span style=""font-family:'Times New Roman';""><span style=""font-size:14px;line-height:1.5;""></span></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> Data on 67 patients were collected, with an average age of 47 years (6C78 years). A male preponderance</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">was observed (64%). The mean duration of the disease was about 38 months. Fingernails were the site of</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">involvement in 94% of cases. Matrix involvement was observed in 91% of cases. A total of 120 specimen’s biopsy</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">were taken and was contributory in 90% of cases. Two specimens biopsy were practiced in 70.15% of patients.</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Systemic corticosteroids were used in 46 patients, and associated in 20 cases to intralesional corticosteroids.</span><br />
<strong style=""font-family:'Times New Roman';""><span style=""font-size:14px;line-height:2;"">Conclusions.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Our findings indicate that if NLP is correctly diagnosed and appropriately treated. Nail biopsy is</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">proven to be a relatively simple, safe and useful procedure with a minimal scarring risk. Long-term observation</span><span style=""line-height:2;"">&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">indicates that the prognosis of NLP is poor with high rate of relapses, with permanent damage to the nail unit.</span><br />",,"/uploadfiles/file/20131112/20131112104707_1679.pdf",,11/12/2013,11/12/2013,"medicool",18,,,0,"85",99,"Nail lichen planus: epidemiological, clinical, pathological,therapeutic and prognosis study of 67 cases","2011",
428,"一名患有组织胞浆菌真菌血症的艾滋病患者的罕见病例",,"VP Baradkar, U Tendolkar, S Baveja, S Kamath","Department of Microbiology","<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disseminatedcases of histoplasmosis inacquired immunedeficiency syndrome (AIDS)are rarelyreported from IndiaMost of these casesreport isolation ofthis fungus fromthe bone marrow,lymphnode aspirate,spleenicaspirate, and biopsies.Wereport isolation ofHistoplasmacapsulatumfromthe blood of an AIDS patient.A 30-year-old malefrom Utter Pradesh was admitted with fever, loss of appetite, and nausea sincetwo months.Few intracellular andextracellular budding cells were observed on bone marrow examination on the fifthday of admission.Diagnosis was confirmed by blood cultures takenon the 11th day of admission.Amphotericin B wasstarted, but the patient’s condition deteriorated and he died.</span> 
</p>
<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;播散性组织胞浆菌病在获得性免疫缺乏综合症（艾滋病）患者中的病例在印度很少被报道。大部分病例报道的是从骨髓、淋巴结穿刺、脾穿刺和活检中分离的这种真菌。我们报告了从艾滋病患者血液中分离出的荚膜组织胞浆菌。一名来自北方邦的30岁男性承认两个月以来有发热、食欲不振、恶心的症状。入院第五天时，骨髓检查发现几乎没有胞内和胞外出芽的细胞。入院第11天时取血通过血液培养确诊。两性霉素B开始起作用，但病人病情恶化并死亡。</span> 
</p>
<p align=""justify"">
	<br />
</p>","/uploadfiles/image/20131113/20131113095052_8069w.png","/uploadfiles/file/20131113/20131113095018_6273.pdf",,11/13/2013,11/13/2013,"medicool",49,,"Acquired immune defi ciency syndrome, blood culture,Histoplasma capsulatum, histoplasmosis",0,"85",19,"A rare case of Histoplasma fungemia in an AIDS patient","2011",
435,,,"Ryoji  Yoshidaa,  Hideki  Nakayamaa,?,  Nozomu  Takahashi a,  Masashi  Nagataa,  Takuya  Tanakaa, Masafumi Nakamotoa, Hideto Satob, Toshikazu Miyakawac , Hiroaki Mitsuyac , Masanori Shinoharaa","Journal  of  Oral  and  Maxillofacial  Surgery, Medicine,  and  Pathology","<p style=""text-indent:2em;"">
	Kaposi’s sarcoma (KS) is one of the most common diseases seen in patients 
presenting with acquired immunode?ciency syndrome (AIDS); however, it is rare 
in Japan. We herein report a case of AIDS- associated KS of the tongue, which 
was initially misdiagnosed as recurrent hemangioma according to the initial 
histopathological diagnosis. The patient is a 42-year-old male who had been 
suffering from a painful vascular neoplasm-like mass on the dorsum of the 
tongue. The patient did not complain of any other distinct symptoms and a 
debulking operation was planned based on the clinical diagnosis of hemangioma. 
However, preoperative blood tests revealed the presence of syphilis and the 
human immunode?ciency virus and the patient was therefore diagnosed to have 
full-blown AIDS. Therefore, the patient’s oral lesion was then instead suspected 
to be oral KS (OKS). A histopathological examination of the tongue biopsy 
specimen showed the typical ?ndings of KS. Combination active antiretroviral 
therapy (cART) combined with liposomal doxorubicin was administered and the 
patient achieved a complete remission (CR). In conclusion, clinicians including oral surgeons, should take OKS into account in the diagnosis of vascular 
neoplasm-like masses of the tongue in adults since this complication may occur 
as a result of AIDS.
</p>",,"/uploadfiles/file/20131114/20131114100039_9481.pdf",,11/14/2013,11/14/2013,"medicool",30,,"Kaposi’s  sarcoma  (KS)|AIDS|Tongue|Vascular  neoplasm-like  mass
|Combination  active  antiretroviral  therapy(cART)",0,"85",19,"A case of AIDS-associated oral Kaposi’s sarcoma of the tongue","2012",
413,,,"Itaru Dekio, Shingo Matsuki, Minao Furumura, Eishin Morita& Akimichi Morita","B R I E F C O M M U N I C A T I O N","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Summary</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Actinic lichen planus (ALP) is a rare variant of lichen planus in which lichen planus develops&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">on the light-exposed areas of the skin. ALP is reported to occur in the African, Middle Eastern,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and Indian populations, with very few cases reported in Caucasians. Here, we report a case of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">ALP in a Japanese man; to the best of our knowledge, this is the first reported occurence of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">ALP in the East Asian population. A 52-year-old Japanese man developed recurrent painful&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">annular erythema on the face and hands. Histopathological examination of his skin biopsy&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">revealed lichenoid-type infiltrates of lymphocytes and histiocytes. We established a diagnosis&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">of ALP on the basis of the distribution of eruptions only on the sunlight-exposed areas and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">histological findings. Oral administration of systemic steroids proved effective in improving&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">his condition. Lichen planus is known to be induced by an irritant (Koebner phenomenon);&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">we believe that our patient is genetically susceptible to sunlight exposure and that sunlight&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">acted as an irritant stimulating the development of ALP.</span><br />",,"/uploadfiles/file/20131112/20131112105545_0108.pdf",,11/12/2013,11/12/2013,"medicool",23,,,0,"85",99,"Actinic lichen planus in a Japanese man: first case in the East Asian population","2010",
456,"医院外用中药制剂治疗神经性皮炎概况","1008-0805 (2006)08―1578-03","艾东方","时珍国医国药","&nbsp; &nbsp;<span style=""line-height:2;font-size:14px;""> 神经性皮炎又称慢性单纯性苔藓 ， 属中医""牛皮癣"""" 摄领</span><span style=""line-height:2;font-size:14px;"">疮 ” 等病证范畴。本病发病原因不明确 ， 一般认为是多种因素引</span><span style=""line-height:2;font-size:14px;"">起的神经功能失调和机体组织改变所致。中医认为本病多为湿</span><span style=""line-height:2;font-size:14px;"">热毒邪蕴于肌肤，阻滞经络 ， t3久生风化燥，肌肤失养所致。临床</span><span style=""line-height:2;font-size:14px;"">多用皮质激素制剂治疗，但效果不理想，复发率高，药物副作用</span><span style=""line-height:2;font-size:14px;"">大。近年来研究发现，一些医院外用中药制剂治疗神经性皮炎有</span><span style=""line-height:2;font-size:14px;"">较好疗效。本文结合相关文献综述如下。</span><br />","/uploadfiles/image/20131119/20131119161618_1025w.jpg","/uploadfiles/file/20131119/20131119161903_1819.pdf",,11/19/2013,11/19/2013,"medicool",25,,,0,"67",77,,"2006",
414,,"10.1111/j.1468-3083.2011.03983.x","S. Arias-Santiago,?,* A. Buend? á-Eisman,?J. Aneiros-Ferna ?ndez,?M.S. Giro ?n-Prieto,§M.T. Gutie ?rrez-Salmero ?n,?V. Garc? á-Mellado,§A. Cutando,CR. Naranjo-Sintes?","JEADV","<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Background.</strong></span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Cardiovascular risk factors have been assessed with some skin diseases such as alopecia and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">psoriasis. Recently, a caseCcontrol study found that lichen planus (LP) was associated with dyslipidaemia in a large&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">series of patients. However, no data were presented about lipid values in patients and controls.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Objective.</strong></span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">The objective of this caseCcontrol study was to evaluate lipid levels in men and women with lichen&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">planus and in healthy controls, excluding lichenoid drug eruption and treatment for LP such as systemic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">corticosteroids, retinoid acid or methotrexate.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Patients and methods This caseCcontrol study included 160 patients, 80 with LP (40 men and 40 women) and 80&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">controls consecutively admitted to the outpatient clinic in Dermatology department of San Cecilio Hospital, Granada, Spain.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Results.&nbsp;</strong></span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Patients with LP presented higher significant triglycerides values (145.9 vs. 101.5 mg?dL P = 0.0007), total&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">cholesterol values (197.7 vs. 178.4 mg?dL P = 0.001), LDL-C values (120.8 vs. 100.9 mg?dL P &lt; 0.0001) and lower&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">HDL-C values (55.3 vs. 61.9 mg?dL P = 0.004) vs. controls. Adjusted OR for dyslipidaemia in patients with LP was&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">3.03 (95% confidence interval: 1.49C6.17, P = 0.002).</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Conclusion.</strong></span><br />
<span style=""line-height:1.5;font-family:'Times New Roman';""><span style=""font-size:14px;line-height:2;"">&nbsp; &nbsp;&nbsp;</span><span style=""font-size:14px;line-height:2;"">The results obtained in this study indicate an association between LP and dyslipidaemia. Lipid levels&nbsp;</span></span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">screening in men or women with LP may be useful to detect individuals at risk and start preventive treatment&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">against the development of cardiovascular disease.</span><br />",,"/uploadfiles/file/20131112/20131112105849_3563.pdf",,11/12/2013,11/12/2013,"medicool",26,,,0,"85",99,"Lipid levels in patients with lichen planus: a caseCcontrol study","2011",
415,,"10.1111/j.1442-2050.2010.01120.x","F. Donnellan, M. P. Swan, G. R. May, G. Kandel, N. E. Marcon, P. P. Kortan","Diseases of the Esophagus","<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">SUMMARY. </span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Esophageal lichen planus is a rare condition, and although the majority of cases occur in conjunction&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">with lichen planus at other sites, the endoscopic features are often misinterpreted resulting in a delay in diagnosis.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">We report a series of five patients presenting to our unit between 2005 and 2009. All five patients were female and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">presented with dysphagia. Endoscopy demonstrated proximal esophageal stricturing in four patients. Character</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">istic histological findings were found in four patients. Lichen planus was diagnosed at other sites, and preceded&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">gastrointestinal symptoms, in all patients; five had oral involvement, two had genital involvement, and one had&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">dermal involvement. All patients received proton pump inhibitor therapy without demonstrable benefit. Adminis</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">tration of oral fluticasone proprionate resulted in symptomatic improvement in three patients.</span><br />",,"/uploadfiles/file/20131112/20131112110338_3156.pdf",,11/12/2013,11/12/2013,"medicool",31,,,0,"85",99,"Fluticasone propionate for treatment of esophageal lichen planus. A case series","2010",
416,,"10.1038/jid.2011.369","Annelinde Terlou, Lindy A.M. Santegoets, Willem. van der Meijden, Claudia Heijmans-Antonissen, Sigrid M.A. Swagemakers, Peter J. van der Spek, Patricia C. Ewing, Marc van Beurden, Theo J.M. Helmerhorst and Leen J. Blok","The Society for Investigative Dermatology","<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>Introduction.</strong></span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; Vulvar lichen sclerosus (LS) and lichen planus (LP) are both&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">chronic inflammatory skin disorders that have a negative&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">impact on the quality of life and may proceed to malignant&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">disease (McPherson and Cooper, 2010).</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; LS can affect any part of the skin, but it is most frequently&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">seen in the anogenital area. Although it can occur at all ages,</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">even among children, LS is most common in the fifth to sixth&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">decade of life (Powell and Wojnarowska, 1999; Tasker and</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Wojnarowska, 2003). Women with vulvar LS often present&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">with severe pruritus and soreness of the vulvar and perianal</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">area (Powell and Wojnarowska, 1999; Tasker and Wojnar</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">owska, 2003; Val and Almeida, 2005). Typically, lesions&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">appear as a figure-of-eight pattern around the vulva and anus,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">with white atrophic lesions or hyperkeratosis. In advanced&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">stages, there is destruction of the vulvar anatomy, character</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">ized by resorption of the labia minora, narrowing of the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">introitus, and a buried clitoris (Powell and Wojnarowska,</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">1999).</span><br />",,"/uploadfiles/file/20131112/20131112111703_2614.pdf",,11/12/2013,11/12/2013,"medicool",23,,,0,"65",99,"An Autoimmune Phenotype in Vulvar Lichen Sclerosus and Lichen Planus: A Th1 Response and High Levels of MicroRNA-155","2012",
512,"儿科眶周蜂窝织炎：117例临床特征及治疗","10.2310/7070.2011.100180","Sami Pierre Moubayed, MD, Thien-Tuong Vi Vu, MD, Caroline Quach, MD, MSc, FRCPC, and Sam J. Daniel, MD, MSc, FRCSC","Journal of Otolaryngology-Head & Neck Surgery","<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">ABSTRACT</span></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">摘要</span></b><b></b> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Objective.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><a name=""OLE_LINK26""></a><a name=""OLE_LINK25""></a><span style=""font-size:14px;line-height:2;"">Since the advent of the
Haemophilus influenzae type B vaccine,</span><a name=""OLE_LINK51""></a><a name=""OLE_LINK50""></a><span style=""font-size:14px;line-height:2;""> no North American
case series has described periorbital cellulitis extensively </span><a name=""OLE_LINK53""></a><a name=""OLE_LINK52""></a><span style=""font-size:14px;line-height:2;"">as
the main focus in the otolaryngology literature has been the management of
orbital abscesses. </span><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><a name=""OLE_LINK55""></a><a name=""OLE_LINK54""></a><span style=""font-size:14px;line-height:2;"">The
aim of this study was to describe the epidemiology, </span><a name=""OLE_LINK57""></a><a name=""OLE_LINK56""></a><span style=""font-size:14px;line-height:2;"">underlying causes,
clinical presentation, and medical management of periorbital cellulitis.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">目的</span></b><b><span style=""font-size:14px;line-height:2;"">:</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:14px;line-height:2;"">自从B型流感嗜血疫苗问世，北美国家没有广泛报道眶周蜂窝织炎的案例系列，因为耳鼻喉科文献的主要焦点已经集中在对眼眶脓肿的治疗。本研究旨在描述其流行病学，内在原因，临床表现，及对眶周蜂窝织炎的药物治疗。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Study Design.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK28""></a><a name=""OLE_LINK27""></a><span style=""font-size:14px;line-height:2;"">Retrospective
observational case series.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">研究设计：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:14px;line-height:2;"">回顾性观察性研究病例系列。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Setting. </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK30""></a><a name=""OLE_LINK29""></a><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-size:14px;line-height:2;"">Montreal Children’s Hospital,
McGill University Health Centre, a tertiary pediatric referral center in
Montreal, Quebec. </span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">研究地点：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:14px;line-height:2;"">Montreal儿童医院，McGill大学健康中心，Montreal. Quebec三级儿科转诊中心。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Subjects and
Methods. </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><a name=""OLE_LINK32""></a><a name=""OLE_LINK31""></a><a name=""OLE_LINK36""></a><a name=""OLE_LINK35""></a><span style=""font-size:14px;line-height:2;"">The
medical charts of all pediatric
patients hospitalized from January 2000 to August 2006 with a </span><a name=""OLE_LINK34""></a><a name=""OLE_LINK33""></a><span style=""font-size:14px;line-height:2;"">discharge
ICD-9 code indicating a diagnosis of periorbital cellulitis without
abscess were reviewed. </span><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span style=""font-size:14px;line-height:2;"">One hundred seventeen
cases were identified.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">研究对象和方法：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:14px;line-height:2;"">对从2000年1月到2006年8月，其带有ICD-9出院诊断编码诊断为无脓肿的眶周蜂窝织炎的所有住院儿童患者的病例进行审查。117例被鉴定。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Results. </span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK14""></a><a name=""OLE_LINK13""></a><a name=""OLE_LINK38""></a><a name=""OLE_LINK37""></a><span style=""font-size:14px;line-height:2;"">Periorbital cellulitis in the
pediatric population affects mainly preschool-aged patients (mean age 4.1±4.2 years [SD]) and is
more frequent among males than females (1.3:1). </span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span style=""font-size:14px;line-height:2;"">The
most common predisposing conditions are sinusitis (24.8%), trauma (23.1%), and </span><a name=""OLE_LINK40""></a><a name=""OLE_LINK39""></a><span style=""font-size:14px;line-height:2;"">ocular
conditions (13.7%).</span><a name=""OLE_LINK18""></a><a name=""OLE_LINK17""></a> <a name=""OLE_LINK42""></a><a name=""OLE_LINK41""></a><a name=""OLE_LINK44""></a><a name=""OLE_LINK43""></a><span style=""font-size:14px;line-height:2;"">All
patients were successfully managed with intravenous antibiotics for a mean
period of 3.4±2.6 days and oral antibiotics
for 8.1±4.4 days and recovered
fully without complications.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">结果：</span></b><b></b> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:14px;line-height:2;"">&nbsp;&nbsp; 儿科眶周蜂窝织炎主要影响学龄前的患者（平均年龄4.1±4.2岁[SD]），男性患者发病概率比女性患者（1.3:1）更频繁。最常见的诱发条件鼻窦炎（24.8％）、创伤（23.1％）以及眼部病症（13.7％）。所有患者应用静脉注射抗生素均成功治愈，平均周期为3.4±2.6天，口服抗生素平均周期为8.1±4.4天，完全康复无并发症。</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">Conclusion.</span></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<a name=""OLE_LINK20""></a><a name=""OLE_LINK19""></a><a name=""OLE_LINK46""></a><a name=""OLE_LINK45""></a><span style=""font-size:14px;line-height:2;"">Our results are consistent with
the literature on the subject and show that </span><a name=""OLE_LINK47""></a><span style=""font-size:14px;line-height:2;"">timely identification of periorbital cellulitis cases and
appropriate medical management result in </span><a name=""OLE_LINK49""></a><a name=""OLE_LINK48""></a><span style=""font-size:14px;line-height:2;"">resolution of the condition without complications.</span> 
</p>
<p class=""MsoNormal"">
	<b><span style=""font-size:14px;line-height:2;"">结论：</span></b><b></b> 
</p>
<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<span style=""font-size:14px;line-height:2;"">我们的研究结果与关于这一问题的文献记载的一致，结果表明及时鉴定眶周蜂窝织炎病例以及和采用适当的药物治疗，有利于病情缓解，消除并发症。</span> 
</p>","/uploadfiles/image/20131204/20131204111609_4735w.jpg","/uploadfiles/file/20131204/20131204111700_9380.pdf",,12/04/2013,12/04/2013,"medicool",20,,,0,"85",106,"Periorbital Cellulitis in the Pediatric Population: Clinical Features and Management of 117 Cases","2011",
419,,,"Manar M. El-Sholkamy; Nagwa Osman; Heba Ahmad Farag and Noha Ayman Ghallab1","Nature and Science","<strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Abstract.</span></strong><br />
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Oral Lichen Planus (OLP), is a chronic, inflammatory disease of immunological disorder. The most &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">important complication of OLP is the development of oral squamous cell carcinoma (OSCC). Survivin is an &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">inhibitor of apoptosis gene and encourages the continued proliferation and survival of tumors. The aim of this study &nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">was to detect the level of Survivin as a molecular indicator of malignancy in control, reticulo-papular and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">bollous-erosive OLP patients using immunohistochemistry. Materials and Methods: 25 subjects participated in this&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">study,10 reticulo-papular, 5 bollousCerosive OLP patients and 10 healthy controls. All subjects were non-smokers&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">and systemically free to standardize their medical condition. All patients and controls were subjected to biopsy&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">procedures from the buccal mucosa for histopathological examination &nbsp;and immunostained with Survivin using the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Ultra Vision System. Results: This study showed a highly significant difference (P&lt;0.001), in mean Survivin optical&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">density between the control group and OLP groups. The highest values were observed in the bullous-erosive group.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Mean Survivin area % was nearly 30 % in the reticulo-papular group, 90% in the bollous-erosive group, but only&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">around 10% in the control group. Conclusion: Survivin levels are higher in OLP than in healthy tissue and highest in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">bullous-erosive forms of OLP compared to the reticulo-papular form. Bullous-erosive forms of OLP are hence more&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">liable to turn malignant than reticulo-papular forms. Diagnosis of OLP patients histopathologically together with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">molecular profiling and localization of their Survivin levels, can be therefore used as an early biomarker for&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">malignant transformation, before the appearance of tissue abnormalities.&nbsp;</span><br />",,"/uploadfiles/file/20131112/20131112112757_3862.pdf",,11/12/2013,11/12/2013,"medicool",28,,,0,"65",99,"Immunohistochemical analyses of Survivin expression in patients with Oral Lichen Planus ","2012",
598,"播散性浅表性光线性汗孔角化症：治疗综述","10.3109/09546634.2010.495381","HADAS SKUPSKY, JONATHAN SKUPSKY & GARY GOLDENBERG","Journal of Dermatological Treatment","<span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">Abstract</span> 
<p class=""MsoNormal"">
	<span style=""font-family:宋体;color:#231f20;font-size:14px;"">摘要：</span><span style=""font-family:'Times New Roman','serif';color:#231f20;""></span>
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">Disseminated super</span></span></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">fi</span></span></span><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">cial actinic porokeratosis (DSAP) is a chronic disorder of keratinization characterized by numerous papules and plaques distributed over sun-exposed sites</span></span></span><span style=""font-family:'Times New Roman','serif';color:#231f20;""><span style=""font-size:14px;"">.</span><a name=""OLE_LINK13""></a> </a><a name=""OLE_LINK14""></a><a name=""OLE_LINK6""></a><a name=""OLE_LINK5""></a><span><span><span style=""font-size:14px;"">Treatments are poorly standardized</span><span style=""font-size:14px;""> and </span></span></span></a><a name=""OLE_LINK8""></a><a name=""OLE_LINK7""></a><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;""><span style=""font-size:14px;"">several investigational therapies have demonstrated limited success in treating DSAP</span></span></span></span></a><span style=""font-size:14px;"">. </span><a name=""OLE_LINK10""></a><a name=""OLE_LINK9""></a><span style=""font-size:14px;"">To our knowledge, there have been no systematic reviews of the literature regarding the treatment of this disease</span></a><span style=""font-size:14px;"">. Herein, we review recent studies pertaining to the treatment of DSAP and</span><a name=""OLE_LINK16""></a><a name=""OLE_LINK15""></a><span> </span></a><a name=""OLE_LINK12""></a><a name=""OLE_LINK11""></a><span><span style=""font-size:14px;""><span style=""font-size:14px;"">evaluate the level of evidence for each of these therapeutic modalities</span></span><span style=""font-size:14px;"">.</span></span></a></span>
</p>
<p class=""MsoNormal"">
	<span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;""></span></span></span>
</p>
<span></span><span></span> 
<p class=""MsoNormal"">
	<span style=""font-family:宋体;color:#231f20;font-size:14px;"">&nbsp;&nbsp;&nbsp; 播散性浅表性光线性汗孔角化症（</span><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">DSAP</span><span style=""font-family:宋体;color:#231f20;font-size:14px;"">）是一种角质化的慢性疾病，以分散在日光暴露部位的大量的丘疹和斑块为特征。治疗缺乏标准化，一些临床试验的疗法已经证实对于</span><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">DSAP</span><span style=""font-family:宋体;color:#231f20;font-size:14px;"">的治疗效果甚微。据我们所知，目前还没有关于治疗这种疾病的系统性综述文献。在此，我们回顾了近来关于</span><span style=""font-family:'Times New Roman','serif';color:#231f20;font-size:14px;"">DSAP</span><span style=""font-family:宋体;color:#231f20;font-size:14px;"">治疗的研究，评估每种治疗方法的等级。</span><span style=""font-family:'Times New Roman','serif';color:#231f20;""></span>
</p>","/uploadfiles/image/20131210/20131210113043_8273w.png","/uploadfiles/file/20131210/20131210113053_2809.pdf",,12/10/2013,12/10/2013,"medicool",23,,"DSAP, photodynamic therapy, porokeratosis",0,"67",108,"Disseminated superficial actinic porokeratosis: A treatment review","2012",
599,,,"Eliane Chouery , Claire Guissart , Hala Mégarbané , Bernard Aral , Charbel Nassif","European Journal of Medical Genetics","<p align=""justify"">
	<span style=""font-family:Times New Roman;""><span style=""font-size:16px;"">A&nbsp;</span><span style=""font-size:16px;"">b s t r a c t</span></span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">CDAGS syndrome is an autosomal recessive syndrome characterized by craniosynostosis, large open </span><span style=""font-family:Times New Roman;font-size:14px;"">fontanelles, hearing loss, anal anomalies, genitourinary malformations and porokeratosis. To our </span><span style=""font-family:Times New Roman;font-size:14px;"">knowledge, only four families from different geographic regions and ethnic backgrounds have been </span><span style=""font-family:Times New Roman;font-size:14px;"">reported until now and no molecular defect has been identified. Here we report two sisters presenting </span><span style=""font-family:Times New Roman;font-size:14px;"">with craniosynostosis, microcephaly, short downslanting palpebral fissures, sparse hair, eyelashes, and </span><span style=""font-family:Times New Roman;font-size:14px;"">eyebrows and porokeratosis that appeared at the age of one month. The youngest sister had an </span><span style=""font-family:Times New Roman;font-size:14px;"">imperforate anus with rectoperineal fistula. Array-CGH did not reveal any pathological CNV. Molecular </span><span style=""font-family:Times New Roman;font-size:14px;"">analysis of the c16orf57, RECQL4 and MCM5 genes was normal.</span> 
</p>
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131210/20131210131620_9953.pdf",,12/10/2013,12/10/2013,"medicool",16,,"CDAGS、 Craniosynostosis 、Porokeratosis Abnormal placement of anus",0,"67",108,"Craniosynostosis, anal anomalies, and porokeratosis (CDAGS syndrome): Case report and literature review","2013",
601,,"10.1111/j.1468-3083.2011.04275.x","P. Sertznig,V. von Felbert, M. Megahed","Journal of the European Academy of Dermatology and Venereology","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:14px;"">Abstract</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">Porokeratosis represents a group of disorders of epidermal keratinization which are characterized by the </span><span style=""font-family:Times New Roman;font-size:14px;"">histopathological feature of the cornoid lamella, a column of tightly fitted parakeratotic cells. The aetiology of </span><span style=""font-family:Times New Roman;font-size:14px;"">porokeratosis is still unclear. This review summarizes the currently available data on the pathophysiology of this </span><span style=""font-family:Times New Roman;font-size:14px;"">condition and discusses the clinical variants and the currently available therapies.</span> 
</p>",,"/uploadfiles/file/20131210/20131210133650_7142.pdf",,12/10/2013,12/10/2013,"medicool",16,,,0,"67",108,"Porokeratosis: present concepts","2011",
621,"汗孔角化症家庭中EMILIN2基因的复制",,"Corrado Occella, Dario Bleidl, Paolo Nozza, Samantha Mascelli, Alessandro Raso, Giorgio Gimelli, Stefania Gimelli, Elisa Tassano","PLOS ONE","<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">Abstract</span></b> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;text-indent:21.75pt;"">
	<span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">Porokeratosis is a
rare disease of epidermal keratinization characterized by the histopathological
feature of the cornoid lamella, a column of tightly fitted </span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">parakeratocytic cells, whose etiology is still unclear. Porokeratosis of Mibelli is a subtype
of porokeratosis presenting a single plaque or a small number of plaques of
variable size located unilaterally on limbs. It frequently appears in childhood
and occurs with a higher incidence in males. Cytogenetic analyses were
performed in all members of the family on lesioned and uninvolved skin. </span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">An
array-CGH analysis was also performed utilizing the </span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">Human Genome CGH Microarray
Kit G3 400 with 5.3 KB overall median probe spacing.</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">&nbsp;Gene expression was performed on skin fibroblasts. In this study, we
describe a Caucasian healthy 4-year-old child and his father showing features
of porokeratosis of Mibelli. Array-CGH analysis revealed an interstitial 429.5
Kb duplication of chromosome 18p11.32-p11.3 containing four genes, namely: </span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">SMCHD1</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">, </span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">, </span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">LPIN2</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">, and </span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">MYOM1</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';""> both in patient and
his father. </span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2 </span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">resulted overexpressed
on skin fibroblasts. Also other members of this family, without evident signs
of porokeratosis, carried the same duplication. Among these genes, we focused
our attention on </span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">elastin microfibril interfacer 2 (</span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">) gene. Apoptosis plays a
fundamental role in maintaining epidermal homeostasis, balancing keratinocytes
proliferation, and forming the stratum corneum. </span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';""> is known to trigger
the apoptosis of different cell lines negatively affecting cell survival. It is
expressed in the skin. We could speculate that the duplication and
overexpression of </span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';""> cause an abnormal apoptosis of epidermal keratinocytes and alter the
process of keratinization, even if other </span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">epigenetic and genetic factors could also be involved. Our results could contribute to a
better understanding of the pathogenesis of porokeratosis of Mibelli.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-size:14px;line-height:2;"">摘要</span></b> 
</p>
<span style=""font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">&nbsp; &nbsp; 汗孔角化症是一种罕见的表皮角质化疾病，以组织病理学上存在角质样板层为特征，由紧紧排列的角化不全细胞组成的一个细胞柱，其病因学目前仍不清楚。汗孔角化症是汗孔角化病的一个亚型，其临床表现为位于单侧四肢的单个斑块或少数大小不一的斑块。通常在幼年期发病，在男性中发病率较高。我们对家庭所有成员的皮损处及未受累皮肤处进行了细胞遗传学分析。我们还利用整体探针间距中间值为<span style=""font-family:Times New Roman;"">5.3
KB</span>的</span><span style=""font-size:14px;line-height:2;"">人类基因组微阵列<span style=""font-family:Times New Roman;"">CGH</span>试剂盒的<span style=""font-family:Times New Roman;"">G3
400</span>进行</span><span style=""font-size:14px;line-height:2;"">微阵列比较基因组杂交（<span style=""font-family:Times New Roman;"">array-CGH</span>）分析。</span><span style=""font-size:14px;line-height:2;"">在皮肤成纤维细胞上进行基因表达。在这项研究中，我们描述了具有汗孔角化症特征的一个<span style=""font-family:Times New Roman;"">4</span>岁健康的白人小孩和他父亲。微阵列比较基因组杂交（<span style=""font-family:Times New Roman;"">array-CGH</span>）分析显示</span><span style=""font-size:14px;line-height:2;"">患者和他父亲两者的染色体<span style=""font-family:Times New Roman;"">18p11.32
- p11.3</span>上的一个间隙<span style=""font-family:Times New Roman;"">429.5
KB</span>的重叠包含四个基因，即：</span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">SMCHD1</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">，</span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">，</span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">LPIN2</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">和</span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">MYOM1</span></i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">。</span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2</span></i><span style=""font-size:14px;line-height:2;"">导致了皮肤成纤维细胞过度表达。并且，这个家庭的其他成员并无汗孔角化症的明显迹象，均携带相同的副本。在这些基因中，我们的注意力集中在弹性蛋白微原纤维界面因子<span style=""font-family:Times New Roman;"">2（</span></span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2</span></i><span style=""font-size:14px;line-height:2;""><span style=""font-family:Times New Roman;"">）</span>基因。细胞凋亡在维持表皮稳态、平衡角质细胞增殖和形成角质层中起基础性作用。我们已知</span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2</span></i><span style=""font-size:14px;line-height:2;"">可以触发不同细胞系的细胞凋亡，对细胞存活起消极影响。它在皮肤中表达。我们可以推测，</span><i><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">EMILIN2</span></i><span style=""font-size:14px;line-height:2;"">的复制和过表达能够导致表皮角质形成细胞的异常凋亡并改变角化作用过程，即使可能还涉及其它的表观因素和遗传因素。我们的研究结果可能有助于更好地理解汗孔角化症的发病机制。</span> 
</div>
</span>","/uploadfiles/image/20131211/20131211162851_5393w.jpg","/uploadfiles/file/20131211/20131211162934_5330.pdf",,12/11/2013,12/11/2013,"medicool",13,,,0,"65",108,"Duplication Including the EMILIN2 Gene in a Family with Porokeratosis of Mibelli","2013",
600,,"10.1111/j.1365-2133.2006.07295.x","T-J. Chen, Y-C. Chou, C-H. Chen, T-T. Kuo* and H-S. Hong","British Association of Dermatologists","<span style=""font-family:Times New Roman;font-size:14px;"">Background：<br />
Porokeratosis (PK) is an uncommon disorder of epidermal keratinization </span><span style=""font-family:Times New Roman;font-size:14px;"">with a unique clinical appearance, unknown aetiology, and an unpredictable </span><span style=""font-family:Times New Roman;font-size:14px;"">outcome. Genital PK (defined as localized PK confined to the genital area in this </span><span style=""font-family:Times New Roman;font-size:14px;"">study) is extremely rare and is not well documented.</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">Objectives ：<br />
To evaluate the clinical manifestations, histopathology, clinical course </span><span style=""font-family:Times New Roman;font-size:14px;"">and treatment response for genital PK.</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">Methods ：<br />
We reviewed the clinicohistological data from 10 patients with genital PK </span><span style=""font-family:Times New Roman;font-size:14px;"">seen at Chang Gung Memorial Hospital from 1990 to 2005.</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">Results ：<br />
Seven patients had lesions only in the genital area, and three patients had </span><span style=""font-family:Times New Roman;font-size:14px;"">genital and adjacent areas involved. All patients were male and the mean age at </span><span style=""font-family:Times New Roman;font-size:14px;"">initial diagnosis was 46?0 years (range 36C59). All but one patient presented </span><span style=""font-family:Times New Roman;font-size:14px;"">with pruritic lesions. Three patients (30%) had diabetes mellitus. No malignant </span><span style=""font-family:Times New Roman;font-size:14px;"">transformation was observed. Surgical excision was the most effective treatment </span><span style=""font-family:Times New Roman;font-size:14px;"">if it could be performed.</span><br />
<span style=""font-family:Times New Roman;font-size:14px;"">Conclusions:<br />
Genital PK appeared more frequently in the Asian population than in </span><span style=""font-family:Times New Roman;font-size:14px;"">reports from western countries. Genital PK presented mostly as pruritic lesions in </span><span style=""font-family:Times New Roman;font-size:14px;"">Taiwan, with a wide age distribution. Long-term follow-up might be needed.</span> 
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131210/20131210132337_6088.pdf",,12/10/2013,12/10/2013,"medicool",17,,"genital porokeratosis",0,"67",108,"Genital porokeratosis: a series of 10 patients and review of the literature","2006",
602,,"doi:10.1016/j.foot.2012.03.004","Varadraj V. Pai,  N.N. Kikkeri,  S.B. Athanikar,  T. Sori,  Ravikala Rao","Elsevier Ltd.","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;""><strong>Abstract.</strong></span>
</div>
<span style=""font-family:'Times New Roman';line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-size:14px;"">Background: Inherited palmoplantar keratoderma are a rare group of disorder affecting the palm and sole&nbsp;</span><span style=""line-height:1.5;""><span style=""font-size:14px;"">characterised by hyperkeratosis resulting in severe disability and deformities.&nbsp;</span><br />
<span style=""font-size:14px;""></span></span><span style=""line-height:1.5;""><span style=""font-size:14px;"">Objective: To report a rare case of punctate palmoplantar keratoderma.&nbsp;</span><br />
<span style=""font-size:14px;""></span></span><span style=""line-height:1.5;""><span style=""font-size:14px;"">Method: A case attending our OPD is reported.&nbsp;</span><br />
<span style=""font-size:14px;""></span></span><span style=""line-height:1.5;font-size:14px;"">Result: Case report.</span>
</div>
</span><span style=""font-family:'Times New Roman';line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-size:14px;"">Conclusion: This case is reported for its unique presentation and rarity</span>
</div>
</span>",,"/uploadfiles/file/20131211/20131211090116_5133.pdf",,12/11/2013,12/11/2013,"medicool",6,,"Punctate palmoplantar keratoderma",0,"85",110,"Type I punctate palmoplantar keratoderma (Buschke-Fisher-Brauer disease) in a family―A report of two cases","2012",
612,,"DOI: 10.4103/0378-6323.74987","Dr. Sreedhar K. Krishna, Faculty of Medicine, South Kensington Campus, Imperial College, Exhibition Road, SW7 2AZ, London","Indian Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Sir,</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp;I read Joshi’s comprehensive review of the use of&nbsp;</span><span style=""line-height:1.5;"">moulage in dermatology with interest.[1] While moulage&nbsp;</span><span style=""line-height:1.5;"">has undoubtedly been in steady decline as a teaching&nbsp;</span><span style=""line-height:1.5;"">aid, I believe that it still has a significant role to play.&nbsp;</span><span style=""line-height:1.5;"">Skin lesions are largely three-dimensional structures,&nbsp;</span><span style=""line-height:1.5;"">with subtle details often only apparent at a specific&nbsp;</span><span style=""line-height:1.5;"">angle. While technology has advanced, the ability&nbsp;</span><span style=""line-height:1.5;"">to appreciate details of a high-resolution, twodimensional&nbsp;</span><span style=""line-height:1.5;"">photo does not always correlate to the</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">real-world clinical diagnostic ability.</span>
</div>
</span>",,"/uploadfiles/file/20131211/20131211103200_2677.pdf",,12/11/2013,12/11/2013,"medicool",7,,"palmoplantar hyperkeratotic, treatment, PHLP",0,"66",110,"The successful treatment of palmoplantar hyperkeratotic lichen planus with enoxaparin","2011",
603,,"doi: 10.1111/j.1440-0960.2011.00817.x","David Lim, Marius Rademaker, David Gardner and Amanda Oakley.","Australasian Journal of Dermatology","<span style=""font-family:'Times New Roman';font-size:14px;""><strong>ABSTRACT.</strong></span><br />
<span style=""font-family:'Times New Roman';font-size:14px;"">Acquired palmoplantar keratoderma (PPK) is a rare</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">group of conditions with a number of aetiologies,</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">including adverse reactions to drugs. Herein, we</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">report a case of acquired PPK in association with</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">influenza vaccination, confirmed by rechallenge.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;"">Key words: eczema craquelé, ichthyosis.</span><br />",,"/uploadfiles/file/20131211/20131211091046_9595.pdf",,12/11/2013,12/11/2013,"medicool",8,,"eczema craquelé, ichthyosis.",0,"85",110,"Palmoplantar keratoderma: An adverse reaction to influenza vaccination","2011",
618,"表皮松解性掌跖角化病研究进展","1006・2084(2011)05-0707-0","陈军，康晓静","医学综述2011年3月第17卷第5期","<div style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;""><strong>摘要：</strong></span>
</div>
<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""> &nbsp;&nbsp;</span><span style=""line-height:1.5;"">表皮松解性掌跖角化病(EPPK)是一种常染色体显性遗传性皮肤病，随着国内外家系报道&nbsp;</span><span style=""line-height:1.5;"">的不断增多，对该病有了新的认识。药物卡培他滨可能是其致病因素，临床中部分EPPK患者并发</span><span style=""line-height:1.5;"">指节垫，现总结了近几年所发现的导致表皮松解性掌跖角化症的7种不同的角蛋白1、9基因突变类</span><span style=""line-height:1.5;"">型，此外异维A酸在本病中的治疗作用尚需进一步确认。现就EPPK 的致病因素、分子遗传学研究、</span><span style=""line-height:1.5;"">临床表现及治疗予以综述。</span>
</div>
</span>",,"/uploadfiles/file/20131211/20131211111739_3829.pdf",,12/11/2013,12/11/2013,"medicool",16,,"掌跖角化病；基因突变；指节垫；对症治疗",0,"67",110,,"2011",
630,,"10.1007/s00105-012-2441-9","E. Uche-Holub1, 2 ・ M. Ritter3 ・ D. Helbig1 ・ H. Stege3 ・ J. Frank1, 2","Verlag Berlin Heidelberg","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;"">Ein 45-j?hriger Patient pr?sentierte sich mit Hautver?nderungen, die im 13. Lebensjahr erstmals aufgetreten seien. Damals sei eine operative Behandlung erfolgt, nach der er mehrere Jahre lang beschwerdefrei gewesen sei. Nach einer Exazerbation vor 4 Monaten erfolgte die aktuelle Vorstellung mit dem Wunsch einer vollst?ndigen operativen Abtragung der ?sthetisch st?renden L?sionen. Die Eigen- und Familienanamnese waren negativ.</span>
</div>",,"/uploadfiles/file/20131212/20131212094554_7446.pdf",,12/12/2013,12/12/2013,"medicool",7,,,0,"65",109,"Segmentale Typ-1-Manifestation des Morbus Darier","2012",
604,,,"Masahiro HAYASHI, Hajime NAKANO, Daisuke SAWAMURA, Tamio SUZUKI","the journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp;&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;Epidermolytic palmoplantar keratoderma (EPPK)&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(Online Mendelian Inheritance in Man 144200) is an&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">autosomal dominant inherited genodermatosis first&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">described by Vo¨ rner1 in 1901. Its clinical features are&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">well-demarcated thickening of the palms and the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">soles with a yellowish discoloration and an erythematous&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">border. The gene responsible for EPPK is&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the keratin 9 gene (KRT 9),2 which is exclusively&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">expressed in the suprabasal keratinocytes of the palmoplantar&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">epidermis.3 Keratin 9 (K9) is member of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the keratin interfilament superfamily and is essential&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">for maintaining the cytoskeleton of epithelial cells.4&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Mutant K9 weakens the cytoskeleton and excessive&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">hyperkeratosis occurs in response to mechanical friction.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">5,6 Knuckle pads or knuckle pad-like keratosis&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">may be seen in some patients with EPPK.7C12 Though&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">mechanical friction and? or a KRT 9 mutation are suggested&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">as its cause, its pathogenesis remains uncertain.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Here, we report a Japanese patient with EPPK&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with knuckle pads and a unique distribution of keratotic&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">erythema.</span>
</div>
<div style=""text-align:justify;"">
	<br />
</div>",,"/uploadfiles/file/20131211/20131211092356_4613.pdf",,12/11/2013,12/11/2013,"medicool",7,,"Epidermolytic palmoplantar keratoderma, knuckle",0,"85",110,"Case of epidermolytic palmoplantar keratoderma with knuckle pads","2011",
605,,,"Satoshi NAKAMIZO, Norito KATOH, Yoshiki MIYACHI, Kenji KABASHIMA.","Journal of Dermatology","<span style=""font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; &nbsp;Nagashima-type palmoplantar keratosis (PPK) is characterized by</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">transgressive and non-progressive PPKwith an autosomal recessive</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">trait. Nagashima-type PPKwas first described in a report from Japan</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">in 1977.1 Since then,more than 20 cases have been reported,2C4 but</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">clinical manifestations on the nails in Nagashima-type PPK have</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">never been described in the published work. In this report, we present</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">a possible case of Nagashima-type PPK with nail deformity.</span><br />",,"/uploadfiles/file/20131211/20131211093245_0370.pdf",,12/11/2013,12/11/2013,"medicool",11,,"Nagashima-type palmoplantar keratosis, Bilateral palmoplantar hyperkeratotic",0,"85",110,"Atypical nail dystrophy in a possible case of Nagashima-type palmoplantar keratosis","2012",
615,,"DOI: 10.1097/SAP.0b013e3182085a8b","Elizabeth A. O’Connor, MD, and William W. Dzwierzynski, MD","Annals of Plastic Surgery","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract</strong>: <br />
&nbsp; &nbsp; Palmoplantar keratoderma is a heterogeneous group of disorders&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">affecting keratinization on the palms and soles of the feet. The benign lesions&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">cause pain and limit function. Treatment of palmoplantar keratoderma&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">remains problematic and restricted to symptomatic therapy; no cure exists.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Medical treatments and surgical excision are currently the mainstay of</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">therapy; however, these treatments have limited success, significant morbidity,&nbsp;</span><span style=""line-height:1.5;"">and recurrence is common. We present a case report of successful&nbsp;</span><span style=""line-height:1.5;"">treatment with CO2 laser therapy and a review of the literature.</span>
</div>
</span>",,"/uploadfiles/file/20131211/20131211104642_1684.pdf",,12/11/2013,12/11/2013,"medicool",13,,"keratoderma, hyperkeratosis, CO2 laser, palmoplantar keratoderma",0,"67",110,"Palmoplantar Keratoderma Treatment With CO2 Laser Case Report and Review of the Literature","2011",
607,,"doi.org/10.1016/j.ajhg.2013.06.008.","Diana C. Blaydon，Lisbet K. Lind，Vincent Plagnol，Kenneth J. Linton，Francis J.D. Smith，Neil J. Wilson，W.H. Irwin McLean，Colin S. Munro，Andrew P. South，Irene M. Leigh，Edel A. O’Toole，Anita Lundstro¨m，and David P. Kelsell.","The American Journal of Human Genetics","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Autosomal-dominant diffuse nonepidermolytic palmoplantar keratoderma is characterized by the adoption of a white, spongy appearance&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">of affected areas upon exposure to water. After exome sequencing, missense mutations were identified in AQP5, encoding waterchannel&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">protein aquaporin-5 (AQP5). Protein-structure analysis indicates that these AQP5 variants have the potential to elicit an effect&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">on normal channel regulation. Immunofluorescence data reveal the presence of AQP5 at the plasma membrane in the stratum granulosum&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">of both normal and affected palmar epidermis, indicating that the altered AQP5 proteins are trafficked in the normal manner.We&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">demonstrate here a role for AQP5 in the palmoplantar epidermis and propose that the altered AQP5 proteins retain the ability to form&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">open channels in the cell membrane and conduct water.</span>
</div>",,"/uploadfiles/file/20131211/20131211100553_0733.pdf",,12/11/2013,12/11/2013,"medicool",7,,"nonepidermolytic palmoplantar keratoderma, AQP5, Water-Channel Protein",0,"65",110,"Mutations in AQP5, Encoding a Water-Channel Protein, Cause Autosomal-Dominant Diffuse Nonepidermolytic Palmoplantar Keratoderma","2013",
608,,"DOI: 10.1111/j.1365-2133.2011.10317.x","N. UMEGAKI, H. NAKANO, K. TAMA I, Y. MI TSUHAS H I, E AKASAKA, D. SAWAMURA, I . KATAYAMA.","British Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Epidermolytic palmoplantar keratoderma, Vo¨rner type (EPPK,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">OMIM 144200) is an autosomal dominantly inherited skin&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">disease caused by mutations in the keratin 9 gene (KRT9) and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">rarely in the keratin 1 gene. This condition is characterized by&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">diffuse yellow thickening of the skin of the palms and soles,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">sharply offset by erythematous margins. Histopathologically,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">EPPK presents the characteristic features of epidermolytic&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">hyperkeratosis. This report concerns two Japanese EPPK&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">families with associated characteristic cutaneous manifestations:&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">knuckle pad-like lesions associated with a novel nonsense&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">KRT9 mutation and digital mutilation caused by a&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">recurrent KRT9 mutation.</span>
</div>",,"/uploadfiles/file/20131211/20131211101103_6231.pdf",,12/11/2013,12/11/2013,"medicool",8,,"Epidermolytic palmoplantar keratoderma, KRT9 mutation, Histopathology",0,"65",110,"Vo¨rner type palmoplantar keratoderma: novel KRT9 mutation associated with knuckle padlike lesions and recurrent mutation causing digital mutilation","2011",
609,,"DOI 10.1111/j.1365-2133.2011.10552.x","E. Akasaka, H. Nakano, A. Nakano, Y. Toyomaki, N. Takiyoshi, D. Rokunohe, Y. Nishikawa, A. Korekawa, Y. Matsuzaki, Y. Mitsuhashi","British Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;The palmoplantar keratodermas (PPKs) are a large group of genodermatoses comprising&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">nearly 60 genetically distinct diseases.They are characterized by hyperkeratosis&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">on the palms and soles with or&nbsp;without&nbsp;extrapalmoplantar&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">hyperkeratotic lesions. Focal PPK is one of the hallmarks of pachyonychia congenita,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">a rare autosomal dominant disorder resulting from mutations in the keratin&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">genes KRT6A, KRT6B, KRT16 or KRT17. Recently, in-frame deletion mutations&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">of KRT6C have been identified in three families with focal PPK with slight or no&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">nail changes. We report here a novel KRT6C mutation identified in a Japanese&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">family with PPK with phenotypic heterogeneity, presenting with not only focal&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">but also diffuse hyperkeratosis. The proband had diffuse hyperkeratosis on the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">soles and small focal hyperkeratoses on the palms, while the two other affected&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">individuals showed focal hyperkeratoses on the soles. All three patients were heterozygotes&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">for c.1414G&gt;A in KRT6C, predicted to result in p.Glu472Lys. These&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">findings strongly suggest that screening of patients with nonepidermolytic diffuse&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">PPK, in whom the pathogenic mutations are yet to be determined, might identify&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">mutations in KRT6C.</span>
</div>",,"/uploadfiles/file/20131211/20131211101451_1963.pdf",,12/11/2013,12/11/2013,"medicool",14,,"keratin 6c mutation, palmoplantar keratoderma, hyperkeratosis",0,"65",110,"Diffuse and focal palmoplantar keratoderma can be caused by a keratin 6c mutation","2011",
610,,"doi:10.1038/jid.2012.6","Juliane C. Lessard, and Pierre A. Coulombe","Journal of Investigative Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Keratin 16 (KRT16 in human, Krt16 in mouse), a type I intermediate filament protein, is constitutively expressed&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">in epithelial appendages and is induced in the epidermis upon wounding and other stressors. Mutations&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">altering the coding sequence of KRT16 cause pachyonychia congenita (PC), a rare autosomal dominant disorder&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">characterized by hypertrophic nail dystrophy, oral leukokeratosis, and palmoplantar keratoderma (PPK). PPK&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">associated with PC is extremely painful and compromises patient mobility, making it the most debilitating PC&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">symptom. In this study, we show that, although inherited in a recessive manner, the inactivation of Krt16 in mice&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">consistently causes oral lesions as well as PPK-like hyperkeratotic calluses on Krt16/ front and hind paws,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">which severely compromise the animals’ ability to walk. Our findings call into question the view that PC-related&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">PPK arises exclusively as a gain-of-function on account of dominantly acting mutated keratins, and highlight the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">key role of modifiers in the clinical heterogeneity of PC symptoms.</span>
</div>",,"/uploadfiles/file/20131211/20131211102258_5255.pdf",,12/11/2013,12/11/2013,"medicool",10,,"Keratin 16CNull Mice, Palmoplantar Keratoderma, pachyonychia congenita",0,"65",110,"Keratin 16CNull Mice Develop Palmoplantar Keratoderma, a Hallmark Feature of Pachyonychia Congenita and Related Disorders","2012",
611,,"doi:10.1111/j.1365-2230.2008.03136.x","M. Ferran, E. Bussaglia, X. Matias-Guiu? and R. M. Pujol","Journal compilation","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Palmoplantar punctate keratoses may be the main cutaneous sign of various diseases&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(porokeratosis punctata palmaris et plantaris, keratosis punctata of the palmar creases,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">familial punctate palmoplantar keratoderma) or represent a secondary feature&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">[Cowden’s syndrome (CS) and Darier’s disease]. In CS, such keratoses usually appear&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">during the second and third decades of life, together with other mucocutaneous&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">features. We present the case of a 3-year-old girl with palmoplantar punctate keratoses&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">in whom diagnosis of new-onset CS was suspected only after the development of other&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">cutaneous lesions. Genetic analysis confirmed the diagnosis. This case highlights the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">necessity to consider CS in the differential diagnosis when palmoplantar punctate&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">keratoses are found, even in paediatric patients. A prompt diagnosis is important in</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">order to monitor the development of possible underlying associated neoplasms.</span>
</div>
</span>",,"/uploadfiles/file/20131211/20131211102721_8696.pdf",,12/11/2013,12/11/2013,"medicool",9,,"Palmoplantar punctate keratoses, Cowden’s syndrome, PTEN
hamartomaCtumour syndrome",0,"66",110,"Bilateral and symmetrical palmoplantar punctate keratoses in childhood: a possible clinical clue for an early diagnosis of PTEN hamartomaCtumour syndrome","2009",
613,,"DOI: 10.1111/j.1610-0387.2010.07579.x","Stefan Rapprich, Manfred Hagedorn","journal of the German","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Introduction.</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp; &nbsp;Keratosis palmoplantaris papulosa&nbsp;</span><span style=""line-height:1.5;"">(Buschke-Fischer-Brauer disease) [1C4]&nbsp;</span><span style=""line-height:1.5;"">is a form of keratosis that is inherited in an</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">autosomal dominant pattern and manifests&nbsp;</span><span style=""line-height:1.5;"">only on the palms of the hands and&nbsp;</span><span style=""line-height:1.5;"">soles of the feet. Onset occurs between</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">ages 20 and 40 years. The gene locus is&nbsp;</span><span style=""line-height:1.5;"">on chromosome 15q22.2C15q22.31 [2].&nbsp;</span><span style=""line-height:1.5;"">The disease has a progressive course, initially&nbsp;</span><span style=""line-height:1.5;"">presenting with solitary papules&nbsp;</span><span style=""line-height:1.5;"">and later with thickening of the skin that&nbsp;</span><span style=""line-height:1.5;"">can impair or even prevent walking.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Therapy options include chemical or&nbsp;</span><span style=""line-height:1.5;"">mechanical keratolysis as well as systemic&nbsp;</span><span style=""line-height:1.5;"">acitretin [5C6]. The effects of these therapy&nbsp;</span><span style=""line-height:1.5;"">forms are only transient, however. There&nbsp;</span><span style=""line-height:1.5;"">are reports in the literature of surgical&nbsp;</span><span style=""line-height:1.5;"">approaches consisting of excision and&nbsp;</span><span style=""line-height:1.5;"">skin grafting [7C10]. In September 2005&nbsp;</span><span style=""line-height:1.5;"">we performed skin transplantation on&nbsp;</span><span style=""line-height:1.5;"">the plantar aspects of both feet of one</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">patient in combination with vacuumassisted&nbsp;</span><span style=""line-height:1.5;"">closure. The results of the procedure&nbsp;</span><span style=""line-height:1.5;"">and 3-year follow-up observation&nbsp;</span><span style=""line-height:1.5;"">are presented in the following.</span>
</div>
</span>",,"/uploadfiles/file/20131211/20131211103722_2991.pdf",,12/11/2013,12/11/2013,"medicool",9,,"palmoplantar keratoderma, Surgical treatment, skin grafting",0,"66",110,"Surgical treatment of severe palmoplantar keratoderma","2011",
614,,,"Stephanie J. Martin, MD, and Madeleine Duvic, MD","International Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract.</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Background</strong>. Mycosis fungoides (MF) and the Se?zary syndrome (SS) are non-Hodgkin’s&nbsp;</span><span style=""line-height:1.5;"">lymphomas that present with cutaneous lesions. Se?zary syndrome is characterized by&nbsp;</span><span style=""line-height:1.5;"">blood involvement, exfoliative eryrthroderma, lymphadenopathy, pruritus, keratoderma, and&nbsp;</span><span style=""line-height:1.5;"">immunosuppression. This study was to estimate the prevalence of palmoplantar keratoderma&nbsp;</span><span style=""line-height:1.5;"">and tinea pedis in Se?zary syndrome and to analyze the effectiveness of anti-fungal&nbsp;</span><span style=""line-height:1.5;"">treatment.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Methods</strong>. We conducted a retrospective review of 1562 prospectively collected patients at&nbsp;</span><span style=""line-height:1.5;"">the MD Anderson Cancer Center Cutaneous Lymphoma Clinic over sixteen years. All&nbsp;</span><span style=""line-height:1.5;"">patients’ palms and soles were evaluated for clinical evidence of keratoderma (hyperkeratosis)&nbsp;</span><span style=""line-height:1.5;"">and for dermatophytosis (tinea pedis or unguum) by examining scales under 10%&nbsp;</span><span style=""line-height:1.5;"">potassium hydroxide by light microscopy for hyphae.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Results</strong>. Of 138 Se?zary syndrome patients (88 men, 50 women, median age at diagnosis&nbsp;</span><span style=""line-height:1.5;"">64 years), 85 (61.6%) had palmoplantar keratoderma; 45 of the 85 Se?zary syndrome&nbsp;</span><span style=""line-height:1.5;"">patients (52.9%) also had coexisting tinea pedis. Only 14 (10.1%) had tinea pedis without&nbsp;</span><span style=""line-height:1.5;"">keratoderma. Treatment for tinea pedis resulted in microscopy cure of keratoderma in 12&nbsp;</span><span style=""line-height:1.5;"">of 45 (26.7%) patients and clinical improvement.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Conclusions</strong>. The prevalence of palmoplantar keratoderma in Se?zary syndrome is 61.6%,&nbsp;</span><span style=""line-height:1.5;"">with co-existing tinea pedis found in 52.9%. Palmoplantar keratoderma with tinea pedis&nbsp;</span><span style=""line-height:1.5;"">showed clinical improvement with fungicidal therapy suggesting that tinea often contributes&nbsp;</span><span style=""line-height:1.5;"">to the pathogenesis and severity of Se?zary syndrome-related keratoderma.</span>
</div>
</span>",,"/uploadfiles/file/20131211/20131211104214_0976.pdf",,12/11/2013,12/11/2013,"medicool",9,,"Mycosis fungoides, palmoplantar keratoderma, tinea pedis",0,"66",110,"Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Se?zary syndrome","2012",
616,,"DOI: 10.1159/000264607","J. Kanitakis, V. Lora, B. Balme, J. Roby","Deparment of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Abstract.</strong></span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp; &nbsp; Circumscribed palmoplantar hypokeratosis&nbsp;</span><span style=""line-height:1.5;"">(CPH) is a recently described dermatosis of&nbsp;</span><span style=""line-height:1.5;"">unknown origin, of which 46 cases have&nbsp;</span><span style=""line-height:1.5;"">been published so far. CPH affects predominantly&nbsp;</span><span style=""line-height:1.5;"">adult women. It presents clinically&nbsp;</span><span style=""line-height:1.5;"">with a sharply circumscribed annular erythematous&nbsp;</span><span style=""line-height:1.5;"">depressed plaque rimmed by&nbsp;</span><span style=""line-height:1.5;"">a slightly hyperkeratotic border, localized&nbsp;</span><span style=""line-height:1.5;"">usually over the thenar or hypothenar eminences&nbsp;</span><span style=""line-height:1.5;"">of the palm, less commonly on the&nbsp;</span><span style=""line-height:1.5;"">soles. Histopathologically, it is characterized&nbsp;</span><span style=""line-height:1.5;"">by an abrupt decrease in the horny layer&nbsp;</span><span style=""line-height:1.5;"">thickness, forming a sharp stair between&nbsp;</span><span style=""line-height:1.5;"">normal and involved skin. We report herein&nbsp;</span><span style=""line-height:1.5;"">a new patient with CPH who presented an&nbsp;</span><span style=""line-height:1.5;"">associated aspect of actinic keratosis, a hitherto&nbsp;</span><span style=""line-height:1.5;"">unreported finding. This case suggests&nbsp;</span><span style=""line-height:1.5;"">that CPH can undergo malignant transformation,&nbsp;</span><span style=""line-height:1.5;"">probably as a result of actinic damage.&nbsp;</span><span style=""line-height:1.5;"">On this occasion, a complete literature&nbsp;</span><span style=""line-height:1.5;"">review of CPH is presented.</span>
</div>
</span>",,"/uploadfiles/file/20131211/20131211110952_5833.pdf",,12/11/2013,12/11/2013,"medicool",11,,"Circumscribed palmar hypokeratosis  Actinic keratosis  p53  Ki67",0,"67",110,"Premalignant Circumscribed Palmar Hypokeratosis: A New Form of Circumscribed Palmar Hypokeratosis? Case Report and Literature Review","2010",
617,,"doi: 10.2340/00015555-0758","Natsuki Kuraishi, Yayoi Nagai, Michiko Hasegawa and Osamu Ishikawa","Journal Compilation","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Cutaneous adverse effects of imatinib mesylate (Glivec?)&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">are common and various types of skin eruptions have&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">been reported. We report here a 57-year-old man who&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">presented with lichen planus-like lesions on his extremities&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and palmoplantar hyperkeratosis due to the use of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">imatinib mesylate for chronic myeloid leukaemia. The&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">skin lesions improved after discontinuation of imatinib&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">mesylate but re-administration of the drug at a lower&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">dose provoked a mild recurrence. He could, however,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">continue to take the drug at the lower dose and his skin&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">lesions were well-controlled by topical corticosteroid&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">treatment.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">The literature on lichenoid drug eruption due&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">to imatinib mesylate is reviewed. Key words: lichenoid&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">drug eruption; palmoplantar hyperkeratosis; imatinib&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">mesylate.</span>
</div>",,"/uploadfiles/file/20131211/20131211111454_6622.pdf",,12/11/2013,12/11/2013,"medicool",12,,"lichenoid drug eruption; palmoplantar hyperkeratosis; imatinib mesylate.",0,"67",110,"Lichenoid Drug Eruption with Palmoplantar Hyperkeratosis due to Imatinib Mesylate: A Case Report and a Review of the Literature","2010",
619,"残毁性掌跖角化病的致病基因的研究进展",,"黄乐天 吕呈  任萍萍","中国实用医药2010年5月第5卷第14期","<div style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">【摘要】</span>
</div>
<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""> &nbsp; &nbsp;</span><span style=""line-height:1.5;"">残毁性掌跖角化病(vohwinkel syndrome)是一种罕见的常染色体显性遗传病。现已发现2</span><span style=""line-height:1.5;"">个残毁性掌跖角化病的相关位点：① 定位于染色体13ql1一q12上，接近连接蛋白26基因编码区(GJB2)；</span><span style=""line-height:1.5;"">② 定位于染色体lq21上，接近兜甲蛋白基因编码区(LOR)。研究表明，GJB2基因或者LOR基因的突变</span><span style=""line-height:1.5;"">与残毁性掌跖角化病的发生有很大的联系，本文对该病的致病基因的研究进展进行了综述。</span>
</div>
</span>",,"/uploadfiles/file/20131211/20131211112005_5084.pdf",,12/11/2013,12/11/2013,"medicool",14,,"残毁性掌跖角化病；致病基因；连接蛋白26；兜甲蛋白",0,"67",110,,"2010",
623,,,"Katia Giuliodori*, Anna Campanati*, Giulia Ganzetti*, Luca Conocchiari*, Ivana Cataldi, Oriana Simonetti, Mirella Giangiacomi?, Annamaria Offidani","Dermatologic Therapy","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><strong>ABSTRACT: <br />
&nbsp; &nbsp;</strong>Porokeratosis of Mibelli is an uncommon chronic disorder of epidermal keratinization&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">that should be treated because it can undergo malignant change into epithelial tumors on the lesions.&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">At the moment, it represents a therapeutic challenge for dermatologists because of the lack of standardized&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">guidelines about the treatment. Herein, we report a case of classic porokeratosis of Mibelli&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">treated with photodynamic therapy successfully.</span>
</div>",,"/uploadfiles/file/20131211/20131211171336_7096.pdf",,12/11/2013,12/11/2013,"medicool",12,,"photodynamic therapy, porokeratosis",0,"85",108,"The successful off-label use of photodynamic therapy for classic porokeratosis of Mibelli: case report","2011",
642,,,"Zheng-Hua Zhang, Zhi-Min Wang, Meredith E. Crosby, Ke-Fei Kang, Jing Luan, Wei Huang, Lei-Hong Xiang and Zhi-Zhong Zheng","J Cutan Pathol","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:2;""><strong><br />
Background:&nbsp;</strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;"">Porokeratosis (PK) is a heterogeneous group of&nbsp;</span><span style=""font-size:14px;line-height:2;"">keratinization disorders that exhibit similarities with psoriasis at both</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">the clinical and molecular levels.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:16px;line-height:2;""><strong>Methods:&nbsp;</strong></span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;"">The transcript levels of keratin (KRT) 6A, 16, 17,&nbsp;</span><span style=""font-size:14px;line-height:2;"">S100A7, A8, A9, p53 and three candidate genes (i.e. SART3, SSH1&nbsp;</span><span style=""font-size:14px;line-height:2;"">and ARPC3) were reassessed in pairwise lesional and uninvolved skin&nbsp;</span><span style=""font-size:14px;line-height:2;"">from nine patients with PK by real-time quantitative polymerase&nbsp;</span><span style=""font-size:14px;line-height:2;"">chain reaction (RTQCPCR).</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:16px;line-height:2;""><strong>Results:&nbsp;</strong></span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;"">The results of RTQCPCR confirmed that KRT6A, 16,&nbsp;</span><span style=""font-size:14px;line-height:2;"">S100A7, A8 and A9 (p = 0.008) were mostly up-regulated in the&nbsp;</span><span style=""font-size:14px;line-height:2;"">lesional skin when compared with uninvolved skin. Different from the&nbsp;</span><span style=""font-size:14px;line-height:2;"">microarray data, there was no significant difference observed in&nbsp;</span><span style=""font-size:14px;line-height:2;"">KRT17 expression patterns between lesional and normal-appearing&nbsp;</span><span style=""font-size:14px;line-height:2;"">skin (p = 0.066). No statistical difference was observed in p53 and&nbsp;</span><span style=""font-size:14px;line-height:2;"">three candidate genes’ expression patterns between lesional and&nbsp;</span><span style=""font-size:14px;line-height:2;"">uninvolved skin.</span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:16px;line-height:2;""><strong>Conclusions:</strong></span> 
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">In the present study, 9 of the 10 gene expression&nbsp;</span><span style=""font-size:14px;line-height:2;"">measured by RTQCPCR in PK were statistically comparable to&nbsp;</span><span style=""font-size:14px;line-height:2;"">microarray data. KRT6A was identified as specific biomarker for&nbsp;</span><span style=""font-size:14px;line-height:2;"">porokeratotic keratinocytes, as it was the most significantly&nbsp;</span><span style=""font-size:14px;line-height:2;"">up-regulated gene in the nine patient samples.</span> 
</div>
</span><br />",,"/uploadfiles/file/20131212/20131212135756_7092.pdf",,12/12/2013,12/12/2013,"medicool",10,,,0,"65",108,"Reassessment of microarray expression data of porokeratosis by quantitative real-time polymerase chain reaction","2010",
646,"对bath PUVA治疗后获得良好疗效的慢性掌跖病患者进行回顾性长期随访","DOI: 10.1111/j.1610-0387.2012.07975.x","Agnes Bretterklieber, Franz J. Legat, Peter Wolf, Angelika Hofer","journal of the German","<p class=""MsoNormal"" align=""left"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;line-height:1.5;font-size:14px;""><strong>Summary.</strong></span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Background: Numerous studies have confirmed the
short-term effectiveness </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">of </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> 8-methoxypsoralen bath PUVA therapy
in patients with chronic palmoplantar dermatoses; however, little is known
about long-term results.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">研究背景：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">大量研究已证实水浴8-</span><span class=""web-item2"" style=""font-family:SimSun;font-size:14px;line-height:1.5;"">甲氧基补骨脂素（</span><span class=""web-item2"" style=""font-family:SimSun;font-size:14px;line-height:1.5;"">8-</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">Mop）加PUVA疗法在慢性掌跖皮肤病患者中有良好的短期疗效，但是我们对该方法的长期疗效还知之甚少。<br />
</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Patients and
methods: In this retrospective study we examined the
long-term results in 79 patients (mean age: 48 years) with chronic palmoplantar
dermatoses who were treated with bath PUVA three times a week over an 8-year period. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">A
good clinical response (a reduction of more than 50 % of the skin lesions)
occurred </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">after a mean of 23 treatments and a mean cumulative UVA dose of 39
J/cm2 in 51 patients </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">(65 %).</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;In 2007 a questionnaire was sent to these 51
patients to assess the long-term outcome.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">患者和研究方法：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">在这项回顾性的研究中，我们调查了79名慢性掌跖皮肤病患者（平均年龄：48岁）的长期疗效，他们在过去8年时间里采用bath
PUVA疗法每周治疗三次。在51例患者(65
%)平均治疗23次，平均累积的UVA剂量为39</span><span class=""apple-converted-space"" style=""font-family:SimSun;font-size:14px;line-height:1.5;"">&nbsp;</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">J/cm</span><sup><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">2</span></sup><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">时获得了一个良好的临床反应（皮肤减少量大于50%）。我们通过2007年发放给这51例患者的一则问卷调查评估得出这项长期疗效。</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<br />
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Results: With bath PUVA treatment, the best results
were found in patients with</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp;hyperkeratotic eczema (17/22; 77 %
good clinical response) followed by patients with palmoplantar psoriasis
(26/41; 63 %) and patients with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">dyshidrotic eczema</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> (8/16;
50 %).</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">研究结果：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">Bath PUVA疗法在角化性湿疹患者中可以获得最好的临床结果（17/22；77%获得良好的临床反应），其次是掌跖牛皮`的患者(26/41；63 %)和汗疱疹患者(8/16；50 %)。</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<br />
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Thirty-four patients (67 %) answered the
questionnaire after a mean follow-up interval of 4.3 years (10C87 months).
Among these patients, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">36 % reported an improved course of disease
after PUVA therapy with reduced frequency and/or intensity of the skin rash,
&nbsp;&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and 29 % of patients
reported continued complete clearance. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">79 % of our patients
reported a long-term reduction in the use of </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">topical corticosteroids during
the follow-up period (mean: 4.3 years). In addition, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">67
% of patients reported a lasting improvement in quality of life.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">34位患者（67%）在平均4.3年（10―87个月）的随访期后对问卷调查作出了回复。在这些患者当中，36%的患者报道在PUVA疗法后皮疹频率和/或强度降低，疾病病程得到改善，29%的患者报道皮疹获得了持续彻底的清除。而我们患者中的79%在随访期间（平均4.3年）使用外用皮质类固醇时皮疹得到了长期减少。此外，67%的患者称他们的生活质量得到了持续改进。</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<br />
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Conclusions: </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">These data show that bath PUVA may have a
long-term, beneficial influence on the course of disease in a majority of
patients with recalcitrant chronic palmoplantar dermatoses.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">研究结论：</span><o:p></o:p>
</p>
<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">这些数据显示，在大多数患有顽固性慢性掌跖病患者的疾病进程中，bath PUVA疗法可能有着长期积极的疗效。</span>
</div>
</span>","/uploadfiles/image/20131212/20131212142711_2754w.jpg","/uploadfiles/file/20131212/20131212142732_6631.pdf",,12/12/2013,12/12/2013,"medicool",13,,"dyshidrotic eczema, PUVA therapy, 8-methoxypsoralen,  psoriasis, hyperkeratosis palmaris et plantaris, smoking",0,"66",110,"Retrospective long-term follow-up in patients with chronic palmoplantar dermatoses after good response to bath PUVA therapy","2012",
620,"伴有皮肤淀粉样蛋白沉积的角化过度型汗孔角化症","10.1111/j.1346-8138.2010.00803.x",,"Journal of Dermatology","<p class=""MsoNormal"" style=""text-align:justify;line-height:150%;"">
	<b><span style=""font-family:'Times New Roman';font-size:16px;line-height:2;"">ABSTRACT</span><o:p></o:p></b> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;line-height:150%;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">We report a case of hyperkeratotic variant of
porokeratosis Mibelli with dermal amyloid deposits. A 66-year-old man presented
with multiple brownish keratotic lesions on the lower extremities, a verrucous
nodule on the third toe of the left foot and brownish verrucous plaques on the
buttocks for several years. Histopathological examination of the hyperkeratotic
plaque in the right gluteal region revealed extreme hyperkeratosis and </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">cornoid
lamella. In the papillary dermis, </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">there were prominent&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">eosinophilic
amorphous materials which
were positive to Dylon staining. Treatment with oral etretinate
resulted in a remission of the skin lesions in this case.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;line-height:150%;"">
	<b><span style=""font-size:16px;line-height:2;"">摘要</span></b><b><o:p></o:p></b> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;line-height:150%;"">
	<span style=""font-size:14px;line-height:2;"">我们报道了一例伴有皮肤淀粉样蛋白沉积的</span><span style=""font-size:14px;line-height:2;"">角化过度型汗孔角化症病例。一名</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">66</span><span style=""font-size:14px;line-height:2;"">岁的男性患者，在过去的几年中下肢有多个褐色角化性病变，左脚的第三脚趾有一个疣状结节，臀部有褐色疣状斑块。对右臀部区域的角化斑块进行病理组织学检查，结果显示为极度角化过度和</span><span style=""font-size:14px;line-height:2;"">角质样板层。在乳头状突起的真皮层，见显著嗜伊红物质沉积，</span><span style=""font-size:14px;line-height:2;"">对</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Dylon</span><span style=""font-size:14px;line-height:2;"">染色呈阳性。在该病例中，口服阿维A酯进行治疗后皮损得到了缓解。</span><o:p></o:p>
</p>","/uploadfiles/image/20131211/20131211160159_4637w.jpg","/uploadfiles/file/20131211/20131211160123_8176.pdf",,12/11/2013,12/11/2013,"medicool",14,,"cornoid lamella, dermal amyloid deposit, hyperkeratotic variant, oral etretinate, porokeratosis",0,"85",108,"Hyperkeratotic variant of porokeratosis Mibelli with dermal amyloid deposits","2010",
622,,"10.1016/j.jaad.2008.12.049","Rudolf Happle, MD","American Academy of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><span style=""font-size:16px;""><strong>Abstract</strong></span><br />
&nbsp; &nbsp; In autosomal dominant skin disorders, a pronounced mosaic involvement may sometimes be found to be&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">superimposed on the ordinary nonsegmental lesions. Such ‘‘type 2 segmental manifestation’’ reflects loss of&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">heterozygosity occurring at an early developmental stage, giving rise to a cell clone that lacks the&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">corresponding wild-type allele. Here, this genetic concept is applied to an unusual case of plaque-type&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">porokeratosis of Mibelli (PM) as published in 1893 by Vittorio Mibelli in the International Atlas of Rare Skin&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">Diseases. The right forearm and hand of the 21-year-old patient showed a pronounced linear porokeratosis&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">that had developed since the age of 2 years. Moreover, nonsegmental lesions of PM involved both hands&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">and forearms as well as the face and the neck, having first been noticed at the age of 7 years. Two siblings&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">and the father were likewise affected with PM. Hence, Mibelli’s case from 1893 meets all of the criteria of a&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">type 2 segmental manifestation of an autosomal dominant skin disorder. Recognizing such cases of&nbsp;</span><span style=""font-size:14px;line-height:2;font-family:'Times New Roman';"">superimposed segmental involvement may help elucidate the molecular basis of PM.</span> 
</div>",,"/uploadfiles/file/20131211/20131211171152_9382.pdf",,12/11/2013,12/11/2013,"medicool",12,,,0,"85",108,"Mibelli revisited: A case of type 2 segmental porokeratosis from 1893","2009",
626,"一位英国血统的棘状秃发性毛囊角化症患者中的MBTPS2突变","10.1111/j.1365-2230.2011.04288.x","K. Fong, E. K. Wedgeworth,* J. E. Lai-Cheong, I. Tosi, J. E. Mellerio,* A. M. Powell* and J. A. McGrath","Clinical and Experimental Dermatology","<br />
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;""><span style=""font-family:Times New Roman;font-size:16px;""><span style=""font-family:Times New Roman;font-size:16px;""><span style=""font-family:Times New Roman;font-size:16px;"">Keratosis follicularis spinulosa decalvans </span></span></span></span><span><span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-family:Times New Roman;font-size:16px;"">(KFSD; OMIM 308800) is an</span><span style=""font-family:Times New Roman;font-size:16px;""> X-linked disorder </span><span><span style=""font-family:Times New Roman;font-size:16px;"">characterized </span><span style=""font-family:Times New Roman;font-size:16px;"">by widespread hyperkeratotic follicular papules (including keratosis </span><span style=""font-family:Times New Roman;font-size:16px;"">pilaris-like lesions), facial erythema, hypotrichosis and scarring alopecia</span></span><span style=""font-family:Times New Roman;font-size:16px;"">.</span></span></span></span><span><span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-family:Times New Roman;font-size:16px;""> KFSD results from </span><span style=""font-family:Times New Roman;font-size:16px;"">mutations in the MBTPS2 gene.</span></span></span></span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""> <span><span><span><span style=""font-family:Times New Roman;font-size:16px;"">Mutations </span><span style=""font-family:Times New Roman;font-size:16px;"">in this gene also underlie ichthyosis follicularis, alopecia and photophobia </span><span style=""font-family:Times New Roman;font-size:16px;"">syndrome</span></span></span></span><span style=""font-family:Times New Roman;font-size:16px;""><span style=""font-family:Times New Roman;font-size:16px;"">.</span></span> <span><span style=""font-family:Times New Roman;font-size:16px;"">We report a British </span><span style=""font-family:Times New Roman;font-size:16px;"">pedigree with KFSD resulting from the mutation p.Asn508Ser.</span></span> <span><span style=""font-family:Times New Roman;font-size:16px;"">This </span><span style=""font-family:Times New Roman;font-size:16px;"">particular mutation has been reported in three other pedigrees with KFSD </span><span style=""font-family:Times New Roman;font-size:16px;"">(Dutch, American, British) and is the only pathogenic mutation reported in this </span><span style=""font-family:Times New Roman;font-size:16px;"">disorder to date. </span></span><span><span style=""font-family:Times New Roman;font-size:16px;"">However, the same mutation has also been </span><span style=""font-family:Times New Roman;font-size:16px;"">reported in a Chinese pedigree with IFAP syndrome, highlighting the clinical </span><span style=""font-family:Times New Roman;font-size:16px;"">heterogeneity and overlapping molecular pathology of these two disorders. </span><span style=""display:none;"" id=""__kindeditor_bookmark_end_12__""></span></span></span>
</p>
<span style=""font-family:宋体;font-size:16px;"">棘状秃发性毛囊角化症（</span><span style=""font-family:&quot;&quot;;font-size:16px;"">KFSD; OMIM308800</span><span style=""font-family:宋体;font-size:16px;"">）是一种</span><span style=""font-family:&quot;&quot;;font-size:16px;"">X</span><span style=""font-family:宋体;font-size:16px;"">染色体紊乱性疾病，以广泛的毛囊角化性丘疹（包括毛发角化病样病变）、面部红斑、毛发稀疏和瘢痕性秃发为特征。</span><span style=""font-family:&quot;&quot;;font-size:16px;"">KFSD</span><span style=""font-family:宋体;font-size:16px;"">是由</span><span style=""font-family:&quot;&quot;;font-size:16px;"">MBTPS2</span><span style=""font-family:宋体;font-size:16px;"">的基因突变引起。这种基因突变也存在于毛囊性鱼鳞病，脱发症和畏光综合征中。我们报道了一位由于</span><span style=""font-family:&quot;&quot;;font-size:16px;"">p.Asn508Ser</span><span style=""font-family:宋体;font-size:16px;"">突变导致的棘状秃发性毛囊角化症的具有英国血统的患者。这种特殊的突变，在其他三名患有</span><span style=""font-family:&quot;&quot;;font-size:16px;"">KFSD</span><span style=""font-family:宋体;font-size:16px;"">疾病的（荷兰，美国，英国）血统患者中已有报道，并且迄今为止这是这种疾病报道中的唯一的致病突变。然而，相同的突变也在患有</span><span style=""font-family:&quot;&quot;;font-size:16px;"">IFAP</span><span style=""font-family:宋体;font-size:16px;"">综合症中国血统患者中被报道，在这两种疾病中具有突出临床异质性和重叠的分子病理学特征。</span><span style=""font-family:&quot;&quot;;""></span>&nbsp;<br />
<br />","/uploadfiles/image/20131212/20131212085807_7560w.png","/uploadfiles/file/20131212/20131212085822_7632.pdf",,12/12/2013,12/12/2013,"medicool",11,,"temperature regulation,keratosis follicularis,keratosis pilaris",0,"65",109,"MBTPS2 mutation in a British pedigree with keratosis follicularis spinulosa decalvans","2012",
624,,"10.4103/0378-6323.55418","Sudip Kumar Ghosh, Debabrata Bandyopadhyay, Gobinda Chatterjee, Arghya Prasun Ghosh","Indian J Dermatol Venereol Leprol","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:2;""><strong>Abstract:</strong></span> 
</div>
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-size:14px;line-height:2;"">Coexistence of lichen planus (LP) with a number of&nbsp;</span><span style=""font-size:14px;line-height:2;"">dermatological disorders is well documented. We&nbsp;</span><span style=""font-size:14px;line-height:2;"">are reporting here a case of co-localization of lichen&nbsp;</span><span style=""font-size:14px;line-height:2;"">planus with porokeratosis of Mibelli in a 40-year-old&nbsp;</span><span style=""font-size:14px;line-height:2;"">man who presented with some itchy bluish-black&nbsp;</span><span style=""font-size:14px;line-height:2;"">lesions on the dorsum of his feet for one year. The&nbsp;</span><span style=""font-size:14px;line-height:2;"">patient recalled having some brownish, circular,&nbsp;</span><span style=""font-size:14px;line-height:2;"">asymptomatic spots on his feet since childhood. He&nbsp;</span><span style=""font-size:14px;line-height:2;"">noticed that over the last few months the spots had&nbsp;</span><span style=""font-size:14px;line-height:2;"">been gradually increasing in size and became elevated&nbsp;</span><span style=""font-size:14px;line-height:2;"">and itchy. In addition, a few pigmented, itchy, small&nbsp;</span><span style=""font-size:14px;line-height:2;"">elevations appeared in the vicinity of the preexisting&nbsp;</span><span style=""font-size:14px;line-height:2;"">lesion on the right foot. There was no family history&nbsp;</span><span style=""font-size:14px;line-height:2;"">of similar lesions and no history of any drug intake&nbsp;</span><span style=""font-size:14px;line-height:2;"">prior to the exacerbation of eruptions.</span> 
</div>
</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""></span> 
</div>
</span>",,"/uploadfiles/file/20131211/20131211172027_2555.pdf",,12/11/2013,12/11/2013,"medicool",12,,,0,"85",108,"Co-localization of lichen planus and porokeratosis of Mibelli","2009",
625,,"10.4103/0378-6323.77467","Sankha Koley, Jyotirindranath Sarkar, Sanjiv Choudhary, Suparna Dhara, Manoj Choudhury, Swagata Bhattacharya","Indian Journal of Dermatology, Venereology, and Leprology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">Abstract:</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""> &nbsp; &nbsp;</span><span style=""font-size:14px;line-height:2;"">Porokeratosis (PK) is a rare genodermatosis of abnormal&nbsp;</span><span style=""font-size:14px;line-height:2;"">epidermal keratinization. The etiology is unknown&nbsp;</span><span style=""font-size:14px;line-height:2;"">with varying presentation and an unpredictable&nbsp;</span><span style=""font-size:14px;line-height:2;"">outcome. Coexistence of the different variants of PK is&nbsp;</span><span style=""font-size:14px;line-height:2;"">seldom noted. Disseminated lesions of PK of Mibelli are&nbsp;</span><span style=""font-size:14px;line-height:2;"">considered to be very rare.[1] Hypertrophic verrucous&nbsp;</span><span style=""font-size:14px;line-height:2;"">type of PK may present in two ways: the whole&nbsp;</span><span style=""font-size:14px;line-height:2;"">surface may be hyperkeratotic or the hypertrophy&nbsp;</span><span style=""font-size:14px;line-height:2;"">may be localized only to periphery. We report two&nbsp;</span><span style=""font-size:14px;line-height:2;"">different presentations of hypertrophic verrucous PK&nbsp;</span><span style=""font-size:14px;line-height:2;"">in association with disseminated chronic plaque type&nbsp;</span><span style=""font-size:14px;line-height:2;"">in the same patient.</span> 
</div>
</span>",,"/uploadfiles/file/20131211/20131211172236_7046.pdf",,12/11/2013,12/11/2013,"medicool",11,,,0,"85",108,"Different morphological variants of hypertrophic porokeratosis and disseminated lesions of porokeratosis of Mibelli: A rare co-existence","2011",
633,,,"Gupta Lalit, MD, Garg Anubhav, MD, Khare Ashok Kumar, MD, and Mittal Asit, MD","International Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Erythromelanosis follicularis faciei et colli (EFFC) is a&nbsp;condition probably related to keratosis pilaris (KP),&nbsp;seen primarily in adolescents and young adults, most&nbsp;commonly in males.1 It comprises the triad of welldemarcated&nbsp;erythema, hyperpigmentation, and follicular&nbsp;plugging on the cheeks and neck.2 Kitamura et al. (1960)&nbsp;originally described this entity in six young Japanese&nbsp;males and named it ‘‘erythromelanosis follicularis&nbsp;faciei’’.3 In 1966, Mishima and Reuder described this&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">entity in four middle-aged Caucasian males with neck&nbsp;involvement and added the term ‘‘et colli’’ to the name of&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">the disease.4 EFFC is a rare condition. Thirty-three cases&nbsp;had been reported around the world till 2001.5 As per&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">another report (2007),6 less than 50 patients were&nbsp;reported in the literature. Their report included an additional&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">five cases. This case is being reported on account&nbsp;of rarity of this entity, association with extensive KP, and&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">familial occurrence.</span>
</div>",,"/uploadfiles/file/20131212/20131212100624_0267.pdf",,12/12/2013,12/12/2013,"medicool",8,,,0,"85",109,"Familial erythromelanosis follicularis faciei et colli with extensive keratosis pilaris","2012",
627,"在一名女性患者中的棘状秃发性毛囊角化病","10.4103/0378-6323.79708","Fiona F. Sequeira, Elizabeth Jayaseelan","Indian Journal of Dermatology","<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;""><span style=""font-family:&quot;font-size:16px;"">Keratosis follicularis spinulosa decalvans (KFSD), is a</span></span><span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-size:16px;""> rare follicular syndrome associated with widespread </span><span style=""font-size:16px;"">keratosis pilaris and progressive scarring alopecia</span></span></span></span></span><span><span><span style=""font-family:&quot;&quot;;""><span style=""font-size:16px;"">.</span><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;"">This </span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;"">genodermatoses</span></span></span></span></span><span><span><span><span><span style=""font-size:16px;""> often </span><span style=""font-size:16px;"">starts at infancy or early childhood with an X-linked mode of inheritance</span></span></span></span></span><span style=""font-size:16px;"">.</span>&nbsp;<span><span style=""font-size:16px;"">Males are predominantly affected and females frequently show no disease or only </span><span style=""font-size:16px;"">a mild form</span></span><span style=""font-size:16px;"">. </span><span><span style=""font-size:16px;"">We describe this not so common entity of KFSD in </span><span style=""font-size:16px;"">a nine year old female child</span></span></span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-family:&quot;font-size:16px;"">.</span></span></span> 
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;font-size:16px;"">棘状秃发性毛囊角化病是一种与广泛的毛囊角化病和渐进性瘢痕脱发相关的罕见的毛囊综合征。这种遗传性皮肤病往往好发于婴儿期或儿童早期伴随有</span><span style=""font-family:&quot;font-size:16px;"">x--</span><span style=""font-family:宋体;font-size:16px;"">连锁遗传模式。男性受其主要影响，女性常常显示为无症状或者症状较轻。我们报道了一位</span><span style=""font-family:&quot;font-size:16px;"">9</span><span style=""font-family:宋体;font-size:16px;"">岁</span><span style=""font-family:&quot;font-size:16px;"">KFSD</span><span style=""font-family:宋体;font-size:16px;"">综合征患儿（女性）不太常见的病例。</span><span style=""font-family:&quot;&quot;;""></span> 
</p>
<br />
<br />","/uploadfiles/image/20131212/20131212090627_5340w.png","/uploadfiles/file/20131212/20131212090620_7012.pdf",,12/12/2013,12/12/2013,"medicool",13,,"Keratosis follicularis spinulosa decalvans, female, child",0,"85",109,"Keratosis follicularis spinulosa decalvans in a female","2011",
628,"口服阿利维A酸治疗毛囊角化病","10.1111/ced.12078 Summary","V. Letul,T. Herzinger, T. Ruzicka and S. Molin","Department of Dermatology and Allergy","<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Darier disease (DD) is an autosomal dominant skin
disease.</span><i>&nbsp;</i><span style=""font-size:16px;font-family:'Times New Roman';"">Treatment is often
difficult and unsatisfactory because of the chronic nature of the condition and</span><span style=""font-size:16px;font-family:'Times New Roman';"">&nbsp;the
irritant potential of various therapeutic agents.</span><span style=""font-size:16px;font-family:'Times New Roman';"">S</span><span style=""font-size:16px;font-family:'Times New Roman';"">ystemic
vitamin </span><span style=""font-size:16px;font-family:'Times New Roman';"">A
derivatives such as acitretin and isotretinoin are the treatment of choice, but </span><span style=""font-size:16px;font-family:'Times New Roman';"">their use
is often limited by class-specific side-effects. </span><span style=""font-size:16px;font-family:'Times New Roman';"">Alitretinoin
(9-cis-retinoic acid), has antiproliferative and anti-inflammatory potential,
and is licensed for the systemic treatment of chronic hand eczema in a number
of countries. </span><span style=""font-size:16px;font-family:'Times New Roman';"">Unlike acitretin, alitrenoin requires
contraception in women of childbearing age to be extended for only 1 month
after the end of treatment. </span><span style=""font-size:16px;font-family:'Times New Roman';"">There is evidence that alitretinoin might be a well-tolerated
alternative for the systemic treatment of various retinoid-responsive skin
diseases. </span><span style=""font-size:16px;font-family:'Times New Roman';"">We present two cases of
women with refractory DD successfully treated with alitretinoin without marked
side-effects, who both obtained near-complete remission of their skin lesions.</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-size:16px;"">毛囊角化病（DD）是一种常染色体显性遗传性皮肤病。因为该疾病是一种慢性病症以及各种药物潜在刺激,因此治疗常常是困难的并且疗效难以令人满意。系统性维生素A衍生物如维生素A酸和异维A酸是首选的治疗药物，但它们的使用往往受到特定类的副作用限制。阿利维A酸（9 - 顺式 - 视黄酸），具有抗增殖和抗炎的作用，并且在许多国家中，被许可用于慢性手部湿疹的系统治疗。与维生素Ａ酸不同的是，阿利维A酸要求避孕的育龄妇女在治疗结束后，再延长1个月的治疗。有证据表明，阿利维A酸可能是系统治疗各种维生素A酸反应性皮肤疾病的耐受性良好的替代药物。我们报道了两例应用阿利维A酸成功治愈的难治性DD患者，并且没有出现明显副作用，患者皮损处几乎完全缓解。</span>
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>","/uploadfiles/image/20131212/20131212091759_3952w.png","/uploadfiles/file/20131212/20131212091838_4733.pdf",,12/12/2013,12/12/2013,"medicool",12,,"mucosal membranes,therapeutic regimen,Darier disease,therapeutic agents",0,"66",109,"Treatment of Darier disease with oral alitretinoin","2012",
629,"毛囊角化病：皮肤内受损钙稳态的疾病模型","10.1016/j.bbamcr.2010.12.006","Magali Savignac a,b, Anissa Edir c,d, Marina Simon c,d, Alain Hovnanian c,d,e,?","Biochimica et Biophysica Acta","<p class=""MsoNormal"" align=""justify"">
	<span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-size:16px;"">The importance of extracellular calcium in epidermal </span><span style=""font-size:16px;"">differentiation and </span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">intra-epidermal cohesion</span></span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;""> has been recognized for many years.</span></span></span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""> <span style=""font-size:16px;""><span style=""font-size:16px;"">Darier disease (DD) was the </span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">fi</span></span></span></span><span><span><span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-size:16px;"">rst genetic skin disease caused by </span><span><span style=""font-size:16px;"">abnormal epidermal </span><span style=""font-size:16px;"">calcium homeostasis</span></span><span style=""font-size:16px;""> to be identi</span></span></span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">fi</span></span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">ed.</span></span></span></span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""> <span style=""font-size:16px;"">DD is characterized by </span><span><span><span><span style=""font-size:16px;"">loss of </span><span style=""font-size:16px;"">cell-to-cell adhesion</span></span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;""> and abnormal keratinization.</span></span> <span><span><span><span style=""font-size:16px;"">DD is caused by genetic </span><span style=""font-size:16px;"">defects in ATP2A2 encoding the sarco/endoplasmic reticulum Ca2+-ATPase isoform </span><span style=""font-size:16px;"">2 (SERCA2)</span></span></span></span><span><span><span style=""font-size:16px;"">. </span><span><span style=""font-size:16px;"">SERCA2 is a calcium pump of the endoplasmic </span><span style=""font-size:16px;"">reticulum (ER) transporting Ca2+ from the cytosol to the lumen of ER</span></span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;"">.</span></span><span><span><span><span><span><span style=""font-size:16px;"">ATP2A2 </span><span style=""font-size:16px;"">mutations lead to loss of Ca2+ transport by SERCA2 resulting in decreased ER </span><span style=""font-size:16px;"">Ca2+ concentration in Darier keratinocytes</span></span></span></span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;"">.</span></span><span><span style=""color:#31849B;font-size:16px;"">H</span><span style=""font-size:16px;"">ere, we </span><span style=""font-size:16px;"">review the role of SERCA2 pumps and calcium in normal epidermis, and we discuss </span><span style=""font-size:16px;"">the consequences of ATP2A2 mutations on </span></span><span style=""font-size:16px;""><span style=""font-size:16px;""><span style=""font-size:16px;"">Ca2+ signaling</span></span></span><span style=""font-size:16px;""><span style=""font-size:16px;""> in DD. </span></span></span>
</p>
<p class=""MsoNormal"" align=""justify"">
	<span style=""font-family:宋体;font-size:16px;"">细胞外钙的表皮分化和内表皮凝聚的重要性已被公认了很多年。毛囊角化病（</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">DD</span><span style=""font-family:宋体;font-size:16px;"">）是第一种被认定的由于异常表皮钙稳态导致的遗传性皮肤病。</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">DD</span><span style=""font-family:宋体;font-size:16px;"">以细胞</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;""> - </span><span style=""font-family:宋体;font-size:16px;"">细胞粘附流失和角质化异常为特征。</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">DD</span><span style=""font-family:宋体;font-size:16px;"">是由</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">ATP2A2</span><span style=""font-family:宋体;font-size:16px;"">编码肌浆</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">/</span><span style=""font-family:宋体;font-size:16px;"">内质网</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-size:16px;"">Ca</span><sub><span style=""font-size:16px;"">2</span></sub><span style=""font-size:16px;"">+-ATP</span></span><span style=""font-family:宋体;font-size:16px;"">酶异构体</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">2</span><span style=""font-family:宋体;font-size:16px;"">（</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">SERCA2</span><span style=""font-family:宋体;font-size:16px;"">）遗传缺陷引起的.</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">SERCA2</span><span style=""font-family:宋体;font-size:16px;"">是一种内质网（</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">ER</span><span style=""font-family:宋体;font-size:16px;"">）钙泵，从细胞质基质到</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">ER</span><span style=""font-family:宋体;font-size:16px;"">的内腔输送</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-size:16px;"">Ca</span><sub><span style=""font-size:16px;"">2</span></sub><span style=""font-size:16px;""> +</span></span><span style=""font-family:宋体;font-size:16px;"">。</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">ATP2A2</span><span style=""font-family:宋体;font-size:16px;"">基因突变导致通过</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">SERCA2</span><span style=""font-family:宋体;font-size:16px;"">运输的</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">Ca2 +</span><span style=""font-family:宋体;font-size:16px;"">的流失，从而降低毛囊角化角质细胞中</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-size:16px;"">ER Ca</span><sub><span style=""font-size:16px;"">2</span></sub><span style=""font-size:16px;""> +</span></span><span style=""font-family:宋体;font-size:16px;"">的浓度。这里，我们回顾了</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">SERCA2</span><span style=""font-family:宋体;font-size:16px;"">泵和钙在正常表皮中的作用，同时我们讨论的</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">ATP2A2</span><span style=""font-family:宋体;font-size:16px;"">基因突变的对</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;font-size:16px;"">DD</span><span style=""font-family:宋体;font-size:16px;"">患者</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""><span style=""font-size:16px;"">Ca</span><sub><span style=""font-size:16px;"">2</span></sub><span style=""font-size:16px;"">+</span></span><span style=""font-family:宋体;font-size:16px;"">信号传导的影响。</span><span style=""font-family:&quot;Times New Roman&quot;,&quot;serif&quot;;""></span>
</p>
<br />
<br />","/uploadfiles/image/20131212/20131212093529_5423w.png","/uploadfiles/file/20131212/20131212093646_3880.pdf",,12/12/2013,12/12/2013,"medicool",13,,"extracellular calcium,autosomal dominant,autosomal dominant",0,"67",109,"Darier disease : A disease model of impaired calcium homeostasis in the skin","2010",
631,,,"Bing-Jun Shi1, PhD, Mei Xue1, MPhil, Gui-Shu Zhong2, Prof., Yang Jiang1, MPhil, De-Yu Chen2, Prof., Jie Feng3, Prof., Jing Hao1, Prof., and Qing-Chun Diao1","International Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Background Darier’s disease (DD) is a rare, inherited skin disorder characterized by warty&nbsp;papules and plaques over the seborrheic area, such as central trunk, flexures, scalp, and&nbsp;forehead. Mutations in ATP2A2 gene encoding the enzyme sarco/endoplasmic reticulum&nbsp;Ca2+ATPase type 2 are responsible for the disease. Here we report two Chinese families&nbsp;</span><span style=""font-family:'Times New Roman';font-size:16px;"">affected by DD with two ATP2A2 mutations.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Materials and methods DNA was extracted from the peripheral blood samples and&nbsp;then subjected to polymerase chain reaction amplification and direct automated DNA&nbsp;sequencing.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Results A heterozygous G to T transition in the first nucleotide of intron 7&nbsp;(c.630 + 1G &gt; T) and G to A transversion at nucleotide 2898 in exon 20 of the ATP2A2&nbsp;gene were identified in two pedigrees, respectively. The former mutation in the splice site&nbsp;is a novel mutation and is thought to lead to aberrant splicing and premature protein&nbsp;</span><span style=""font-family:'Times New Roman';font-size:16px;"">truncation. The latter has already been described, which leads to premature termination&nbsp;</span><span style=""font-family:'Times New Roman';font-size:16px;"">codons (PTC) (W966X).</span>
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Conclusion The results will contribute to the expanding database of ATP2A2 mutations in&nbsp;patients with DD and be useful for inherited counseling and prenatal examination for&nbsp;affected families.</span>
</div>
<div style=""text-align:justify;"">
	<br />
</div>",,"/uploadfiles/file/20131212/20131212095244_1205.pdf",,12/12/2013,12/12/2013,"medicool",11,,"Physical examination,Direct sequence,Darier’s disease,psychiatric
symptoms,general population",0,"65",109,"The ATP2A2 gene in patients with Darier’s disease: one novel splicing mutation","2012",
632,,"10.1111/j.1365-2230.2011.04288.x","K. Fong, E. K. Wedgeworth,* J. E. Lai-Cheong, I. Tosi, J. E. Mellerio,* A. M. Powell* and J. A. McGrath","Clinical and Experimental Dermatology","<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Keratosis follicularis spinulosa decalvans (KFSD; OMIM 308800) is an X-linked&nbsp;disorder characterized by widespread hyperkeratotic follicular papules (including&nbsp;keratosis pilaris-like lesions), facial erythema, hypotrichosis and scarring alopecia.&nbsp;KFSD results from mutations in the MBTPS2 gene. Mutations in this gene also underlie&nbsp;ichthyosis follicularis, alopecia and photophobia syndrome. We report a British&nbsp;pedigree with KFSD resulting from the mutation p.Asn508Ser. This particular&nbsp;mutation has been reported in three other pedigrees with KFSD (Dutch, American,&nbsp;British) and is the only pathogenic mutation reported in this disorder to date. However,&nbsp;the same mutation has also been reported in a Chinese pedigree with IFAP syndrome,&nbsp;highlighting the clinical heterogeneity and overlapping molecular pathology of these&nbsp;two disorders.</span>
</div>",,"/uploadfiles/file/20131212/20131212100056_5666.pdf",,12/12/2013,12/12/2013,"medicool",12,,"perifollicular accentuation,follicular hyperkeratosis,Keratosis follicularis,Extracutaneous features",0,"65",109,"MBTPS2 mutation in a British pedigree with keratosis follicularis spinulosa decalvans","2011",
636,,"10.1111/j.1365-2230.2008.02962.x","Y. Nomura, M. Abe, K. Natsuga, R. Moriuchi, H. Kawasaki, M. Mayuzumi, A. Yasuoka* and H. Shimizu","Clinical and Experimental Dermatology","<span style=""font-size:16px;font-family:'Times New Roman';"">Keratosis follicularis squamosa (KFS), first described by&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">Dohi and Momose in 1903,1 is characterized by small,&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">scattered, scaly lesions up to 10 mm in diameter with tiny&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">pigmented keratotic plugs in the centre. We describe a case&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">of KFS that involved extraordinarily large areas of the&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">body.</span><br />",,"/uploadfiles/file/20131212/20131212103300_5648.pdf",,12/12/2013,12/12/2013,"medicool",13,,,0,"85",109,"Widespread keratosis follicularis squamosa","2009",
634,,"10.4103/0378-6323.74992","Yan Lu, Mei-Hua Zhang, Wen-Yuan Zhu","Indian Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;"">Keratosis follicular squamosa (KFS), first reported by&nbsp;Dohi and Momose[1] in 1903, is a separate clinical entity&nbsp;from keratosis follicularis, Darier’s disease. It appears&nbsp;clinically as scaly patches, 3C10 mm in diameter, with&nbsp;brownish follicular plugs in the center. The margins&nbsp;of the patches, slightly raised from the underlying&nbsp;epidermis, are seen like “lotus leaves on the water”.</span><span style=""font-family:'Times New Roman';font-size:16px;"">The most commonly affected sites are the abdomen,&nbsp;thighs, buttocks and waist.[2] Here we describe a rare&nbsp;case of KFS which occurred on the face and resembled&nbsp;atrophic acne scarring in clinical features, and it is the&nbsp;first report of facial case with unique manifestation to&nbsp;our knowledge, and furthermore, we achieved satisfyingtherapeutic results with pimecrolimus cream 1%.</span> 
</div>",,"/uploadfiles/file/20131212/20131212101331_5455.pdf",,12/12/2013,12/12/2013,"medicool",9,,,0,"85",109,"A case of facial keratosis follicularis squamosa resembling atrophic acne scarring, successfully treated with topical pimecrolimus","2011",
635,,,"S Eisman,? RM Ngwanya,? K Pillay,? NP Khumalo*?","European Academy of Dermatology and Venereology","<span style=""font-size:16px;font-family:'Times New Roman';"">A 10-year-old girl born of non-consanguineous parents, presented&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">with a 3-year history of patchy alopecia. She also had life-long dry&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">skin, delayed milestones and difficulty at school. Except for&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">paternal severe atopic eczema, there was no family history of note.</span><br />",,"/uploadfiles/file/20131212/20131212102040_0783.pdf",,12/12/2013,12/12/2013,"medicool",15,,,0,"85",109,"Whorled follicular keratosis, scarring alopecia in ichthyosis follicularis atrichia with photophobia syndrome","2009",
637,,,"WJ Lee, GH Park, MW Lee,* JH Choi, KC Moon, JK Koh","European Academy of Dermatology and Venereology","<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Dermatomyositis is characterized by inflammatory myopathy&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">and variable cutaneous manifestations. To date, however, there</span>&nbsp;<span style=""font-size:16px;font-family:'Times New Roman';"">have been no reports of keratosis follicularis associated with&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">dermatomyositis. We describe here a patient showing both of</span>&nbsp;<span style=""font-size:16px;font-family:'Times New Roman';"">these conditions.</span>
</div>",,"/uploadfiles/file/20131212/20131212105217_0104.pdf",,12/12/2013,12/12/2013,"medicool",12,,,0,"66",109,"Keratosis follicularis and dermatomyositis: Is there a common pathogenesis?","2009",
641,,"10.4103/0378-6323.55427","Nilendu Sarma, Anup Kumar Boler1, Sneha Ranjan Bhattacharya","Net Case","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:2;""><strong>ABSTRACT</strong></span><span style=""font-family:'Times New Roman';font-size:16px;line-height:2;""><strong></strong></span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;"">Porokeratosis is a disorder of keratinization showing a well-de? ned lesion with a hyperkeratotic&nbsp;</span><span style=""font-size:14px;line-height:2;"">ridge on the border that contains the coronoid lamella. We report familial (autosomal dominant&nbsp;</span><span style=""font-size:14px;line-height:2;"">with reduced penetrance) disseminated plaque type (Mibelli?s type) porokeratosis in a father&nbsp;</span><span style=""font-size:14px;line-height:2;"">and son. In the father, there were multiple horns and a large squamous cell carcinoma in&nbsp;</span><span style=""font-size:14px;line-height:2;"">a large lesion over the perianal region that reached up to the squamo-columnar junction of&nbsp;</span><span style=""font-size:14px;line-height:2;"">the anal mucosa and even invaded the anal sphincteric muscles. Disseminated lesions of&nbsp;</span><span style=""font-size:14px;line-height:2;"">the Mibelli?s type, development of horns, and malignancy in this unusual location have not&nbsp;</span><span style=""font-size:14px;line-height:2;"">been previously reported.</span> 
</div>
</span>",,"/uploadfiles/file/20131212/20131212135200_0457.pdf",,12/12/2013,12/12/2013,"medicool",9,,"Porokeratosis of Mibelli, Anus, Familial, Horns, Squamous cell carcinoma",0,"65",108,"Familial disseminated plaque type porokeratosis with multiple horns and squamous cell carcinoma involving anal skin","2009",
638,,"10.1111/j.1365-2133.2011.10789.x","M. Kamijo,*C. Nishiyama,* A. Takagi,N. Nakano,* M. Hara,* S. Ikeda,K. Okumura* and H. Ogawa","British Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Background ATP2A2 encoding the sarcoplasmic ?endoplasmic reticulum Ca2+-&nbsp;ATPase2 (SERCA2) is a Darier disease (DD)-related gene. Ultraviolet (UV) B&nbsp;irradiation downregulates ATP2A2 ?SERCA2 expression in keratinocytes, whereas&nbsp;cyclooxygenase-2 (COX-2) expression is dramatically upregulated by UVB.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Objectives To analyse the involvement of COX-2 in ATP2A2 ?SERCA2 expression.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Methods Keratinocytes were transfected with COX-2 siRNA or treated with COX-2&nbsp;inhibitor, celecoxib, to evaluate the effect of COX-2 on ATP2A2 ?SERCA2 expression.</span><span style=""font-family:'Times New Roman';font-size:16px;"">Quantitative real-time polymerase chain reaction, Western blotting analysis&nbsp;and reporter assay were used to determine the amount of mRNA, protein level&nbsp;and transcription activity, respectively.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Results COX-2 knockdown by siRNA resulted in upregulation of ATP2A2 transcription.&nbsp;Treatment by celecoxib rescued UVB-mediated suppression of the ATP2A2&nbsp;transcription and SERCA2 protein expression. Simple addition of prostaglandin&nbsp;(PG) E2, which is a product of COX-2 enzyme, reduced the amounts of ATP2A2&nbsp;mRNA and SERCA2 protein in keratinocytes.</span>
</div>
<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">Conclusions UVB downregulates ATP2A2 ?SERCA2 expression via induction of COX-2&nbsp;expression and subsequent increase of PGE2 production in keratinocytes. Considering&nbsp;that DD is caused by the decreased function of SERCA2 due to the reduced&nbsp;expression of the ATP2A2 gene, this finding shows the possibility that COX-2&nbsp;inhibition may be useful to prevent and ?or treat DD.</span>
</div>",,"/uploadfiles/file/20131212/20131212105957_8976.pdf",,12/12/2013,12/12/2013,"medicool",15,,,0,"66",109,"Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2?SERCA2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease","2011",
655,,"10.1111/j.1346-8138.2012.01532.x","Shinsaku IWAI,Hirohiko SUEKI,Hideaki WATANABE","Journal of Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; The early clinical presentations of StevensCJohnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are similar to&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">that of erythema multiforme major (EMM). Cytotoxic molecules, especially granulysin, are expressed in the skin lesions of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">SJS?TEN and cause extensive keratinocyte death. It is postulated that the function of regulatory T cells (Treg) in SJS?TEN&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">is inadequate. This study examined whether an immunohistological examination of cytotoxic molecules and the immuno</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">phenotype of Treg is useful for discriminating SJS from EMM in the early period. Over the past 9 years, the lesional skin&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">of 14 patients with SJS?TEN and 16 patients with EMM was biopsied. Double immuno?uorescence labeling of CD8 and&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">granulysin, perforin, or granzyme B was performed, and immunohistochemical analyses of granulysin, perforin, granzyme&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">B, CD1a, CD3, CD4, CD8, CD68 and Foxp3 were conducted using a highly sensitive indirect immunoperoxidase technique.</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">The number of cells positive for each antibody per ?ve high-power ?elds was counted. The proportions of granulysin+</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cells ?CD8</span><sup><span style=""font-family:'Times New Roman';font-size:14px;"">+</span></sup><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cells (P = 0.012) and perforin</span><sup><span style=""font-family:'Times New Roman';font-size:14px;"">+</span></sup><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cells ?CD8</span><sup><span style=""font-family:'Times New Roman';font-size:14px;"">+</span></sup><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cells (P = 0.037) in SJS?TEN were signi?cantly higher than in EMM.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">The number of Foxp3</span><sup><span style=""font-family:'Times New Roman';font-size:14px;"">+</span></sup><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cells ??ve high-power ?elds in SJS?TEN was signi?cantly lower than in EMM (P =0.004).Similarly,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the number of CD4</span><sup><span style=""font-family:'Times New Roman';font-size:14px;"">+</span></sup><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">cells ??ve high-power ?elds in SJS?TEN was signi?cantly lower than in EMM (P = 0.0017). These data&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">suggest that these panels of antibodies for labeling cytotoxic molecules, CD4 and Treg are useful for discriminating early&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">SJS?TEN and EMM with a skin biopsy.</span>
</div>",,"/uploadfiles/file/20131213/20131213093046_1083.pdf",,12/13/2013,12/13/2013,"medicool",9,,"cytotoxic molecules | Foxp3 | granulysin | perforin | regulatory T cells",0,"65",111,"Distinguishing between erythema multiforme major and StevensCJohnson syndrome? toxic epidermal necrolysis immunopathologically","2012",
639,,"10.1111/dsu.12299","VALERIE PALLURE, MD,* NICOLAS DUPIN, PHD,? BERNARD GUILLOT, PHD","the American Society for Dermatologic Surgery","<span style=""font-size:16px;font-family:'Times New Roman';"">BACKGROUND Wide-excision surgery is required in Darier-Ferrand dermatofibrosarcoma protuberans, but&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">there is no consensus regarding the lateral margins.</span><br />
<span style=""font-size:16px;font-family:'Times New Roman';""> MATERIALS AND METHODS We performed a systematic review based on a MEDLINE search of articles,&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">published from 1994 to 2009 to determine the optimal procedure to avoid recurrences and treatment&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">morbidity.</span><br />
<span style=""font-size:16px;font-family:'Times New Roman';""> RESULTS The analyzed articles included five meta-analyses of retrospective studies; three prospective,&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">nonrandomized studies; and 35 retrospective studies.</span><br />
<span style=""font-size:16px;font-family:'Times New Roman';""> DISCUSSION Positive deep margins may lead to a recurrence independent of lateral margin status. Despite&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">an absence of formal evidence, wide excision with 3-cm margins appears to result in significantly less risk of a&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">recurrence than surgery using &lt;3-cm margins. Negative histologic margins appear to be the best criterion to&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">decrease recurrence. Despite a lack of strong data, there was a marked tendency of Mohs micrographic&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">surgery (MMS) to produce better results than conventional surgery. If MMS is unavailable, surgery using 3-cm&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">lateral margins and a disease-free anatomic zone deep into the lesion is proposed. Slow Mohs could be a safe&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">alternative to MMS when the latter technique is not available. Patients should be followed for a minimum of&nbsp;</span><span style=""font-size:16px;font-family:'Times New Roman';"">10 years and preferably indefinitely.</span><br />",,"/uploadfiles/file/20131212/20131212110333_2872.pdf",,12/12/2013,12/12/2013,"medicool",15,,,0,"67",109,"Surgical Treatment of DarierCFerrand Dermatofibrosarcoma: A Systematic Review","2013",
640,,"10.3109/09546634.2012.660518","PICHAI SAELIM, MARISA PONGPRUTTHIPAN, SUWIMON POOTONGKAM, VORAPICHA JARIYASETHAVONG & PRAVIT ASAWANONDA","Department of Medicine","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;"">Background: Keratosis pilaris (KP) is a very common disorder; yet, very few treatment options are available. Objectives: To&nbsp;</span><span style=""font-family:'Times New Roman';font-size:16px;"">evaluate the efficacy of long-pulsed 1064-nm Nd:YAG laser for the treatment of KP. Materials and methods: Eighteen patients&nbsp;</span><span style=""font-family:'Times New Roman';font-size:16px;"">with untreated KP on the upper outer arms were enrolled in a randomized clinical trial. One arm was treated with longpulsed&nbsp;</span><span style=""font-family:'Times New Roman';font-size:16px;"">1064-nm Nd:YAG laser at 30 msec pulse width and fluence of 34 J/cm2, while the contralateral arm served as control.</span><span style=""font-family:'Times New Roman';font-size:16px;"">Patients received three consecutive treatments at 4-week intervals. Three blinded dermatologists assessed digital photographs&nbsp;</span><span style=""font-family:'Times New Roman';font-size:16px;"">using a quartile grading system to separately rate global improvement, erythema and the number of keratotic papules. <br />
Results:&nbsp;</span><span style=""font-family:'Times New Roman';font-size:16px;"">Seventeen patients completed the study. There were statistically significant improvements in global assessment, erythema and&nbsp;the number of keratotic papules at 4 weeks after the last treatment (p &lt; 0.05). All patients also stated that their lesions improved&nbsp;and were satisfied with the laser treatment. <br />
Conclusion: Long-pulsed 1064-nm Nd:YAG laser has been shown to improve KP&nbsp;in Thai patients compared with control after three treatment sessions.</span> 
</div>",,"/uploadfiles/file/20131212/20131212133857_7512.pdf",,12/12/2013,12/12/2013,"medicool",10,,"keratosis pilaris, Nd:YAG laser, hair follicle",0,"66",109,"Long-pulsed 1064-nm Nd:YAG laser significantly improves keratosis pilaris: a randomized, evaluator-blind study","2013",
643,,"10.1111/j.1365-2230.2010.03844.x","S. Wei,*?? T. D. Zhang,* Y. Zhou,? X. B. Zhang,? H. L. Zhu,? J. Li,? Z. M. Huang,? L. Deng* and X. J. Zhang§","Clinical and Experimental Dermatology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""><span style=""font-size:16px;""><strong>Summary</strong></span>&nbsp;</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;""></span><span style=""font-size:14px;line-height:2;"">Disseminated superficial porokeratosis (DSP) is an autosomal dominant epidermal&nbsp;</span><span style=""font-size:14px;line-height:2;"">keratinization disorder. The genetic basis for DSP has not been clearly elucidated. We&nbsp;</span><span style=""font-size:14px;line-height:2;"">previously mapped the locus for DSP to a large region (5.7 Mb) at 18p11.3 in a fourgeneration&nbsp;</span><span style=""font-size:14px;line-height:2;"">Chinese family with DSP, but no gene responsible for porokeratosis has&nbsp;</span><span style=""font-size:14px;line-height:2;"">been identified to date. To narrow the critical region for DSP, thereby facilitating the&nbsp;</span><span style=""font-size:14px;line-height:2;"">identification of this disease gene and possibly leading to an understanding of the&nbsp;</span><span style=""font-size:14px;line-height:2;"">pathogenesis of porokeratosis, genotyping was performed on the same Chinese family&nbsp;</span><span style=""font-size:14px;line-height:2;"">with DSP using nine heterozygous single-nucleotide polymorphism markers at&nbsp;</span><span style=""font-size:14px;line-height:2;"">18p11.3. We found the locus of DSP to be located within a 2.7 Mb region between&nbsp;</span><span style=""font-size:14px;line-height:2;"">markers rs58085394 and rs238533. Our study provides a map location for isolation of&nbsp;</span><span style=""font-size:14px;line-height:2;"">a gene causing DSP.</span> 
</div>
</span>",,"/uploadfiles/file/20131212/20131212140058_7927.pdf",,12/12/2013,12/12/2013,"medicool",12,,,0,"65",108,"Fine mapping of the disseminated superficial porokeratosis locus to a 2.7 Mb region at 18p11.3","2010",
644,,"10.1111/j.1365-2230.2012.04380.x","H. M. Cao, Z. Y. Wang,* G. W. Zhang,? C. F. Liu,? C. M. Pan, S. X. Zhao, Z. Y. Song, H. D. Song and L. Zhang*",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:16px;line-height:2;""><strong>Summary</strong></span> 
</div>
<span style=""font-size:14px;font-family:'Times New Roman';line-height:2;""> 
<div style=""text-align:justify;"">
	<span style=""font-size:14px;line-height:2;"">Porokeratosis is a rare disorder of epidermal keratinization that is characterized by the&nbsp;</span><span style=""font-size:14px;line-height:2;"">presence of a border called the cornoid lamella. Disseminated superficial porokeratosis&nbsp;</span><span style=""font-size:14px;line-height:2;"">(DSP) is a subtype of porokeratosis, which is inherited as an autosomal trait. The first&nbsp;</span><span style=""font-size:14px;line-height:2;"">locus for DSP was localized to chromosome 18p11.3, but no causative gene has yet&nbsp;</span><span style=""font-size:14px;line-height:2;"">been identified. In this study, we recruited and analysed a large six-generation Chinese&nbsp;</span><span style=""font-size:14px;line-height:2;"">family with autosomal dominant DSP. The genome-wide screening identified a&nbsp;</span><span style=""font-size:14px;line-height:2;"">maximum two-point LOD score of 3.06 at θ = 0.00 with the microsatellite marker&nbsp;</span><span style=""font-size:14px;line-height:2;"">D12S78. Fine mapping and haplotype analysis defined a critical region of 38 Mb&nbsp;</span><span style=""font-size:14px;line-height:2;"">between D12S326 and D12S79 on chromosome 12q21.2C24.21, which is a probable&nbsp;</span><span style=""font-size:14px;line-height:2;"">second locus identified for DSP (DSP2). We sequenced 50 candidate genes in this&nbsp;</span><span style=""font-size:14px;line-height:2;"">region, but no causative mutation was found. This study provides a map location for&nbsp;</span><span style=""font-size:14px;line-height:2;"">isolation of a gene causing DSP.</span> 
</div>
</span>",,"/uploadfiles/file/20131212/20131212140347_1170.pdf",,12/12/2013,12/12/2013,"medicool",14,,,0,"65",108,"Identification of a locus (DSP2) for disseminated superficial porokeratosis at chromosome 12q21.2C24.21",,
645,"在一个患有点状掌跖角化病的中国大家族中利用外显子测序技术鉴别COL14A1的突变","doi:10.1136/jmedgenet-2012-100868","Bi-Rong Guo, Xin Zhang, Gang Chen, Jian-Guo Zhang, Liang-Dan Sun. Wei-dong Du, Qing Zhang, Yong Cui, Jun Zhu, Xian-Fa Tang, Ruo Xiao, Yuan Liu, Min Li, Hua-Yang Tang, Xu Yang, Hui Cheng, Ming Li, Min Gao, Ping Li, Jian-Bo Wang, Feng-Ping Xu, Xian-Bo Zuo, Xiao-Dong Zheng, Xiao-Guang Zhang, Lin Yang, Jian-Jun Liu, Jun Wang, Sen Yang, Xue-Jun Zhang","Journal of  Med Genet","<p class=""MsoNormal"" style=""text-align:justify;"">
	<b><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">ABSTRACT.</span><o:p></o:p></b> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">Background. Punctate palmoplantar keratoderma (PPPK) is a
rare autosomal dominant skin disorder characterized by numerous hyperkeratotic papules
irregularly distributed on the palms and soles. To date, </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">no causal gene for this disease
has been identified.</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:NSimSun;line-height:1.5;"">研究背景：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<br />
</p>
<div style=""text-align:justify;"">
	<span style=""font-family:NSimSun;font-size:14px;line-height:1.5;"">点状掌跖角化病（PPPK）是一种罕见的常染色体显性遗传皮肤病，以不规则分布在手掌和足跖的多个角化过度的丘疹为特征。目前，与这种疾病相关的基因尚未被鉴定。</span> 
</div>
<span style=""font-size:14px;font-family:NSimSun;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span> 
</div>
</span><span style=""font-size:14px;font-family:NSimSun;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';""></span><span style=""line-height:1.5;font-family:'Times New Roman';"">Methods. &nbsp;We
performed exome sequencing analysis of four affected individuals and </span><span style=""line-height:1.5;font-family:'Times New Roman';"">two
unaffected controls from one Chinese PPPK family where disease locus
was mapped at </span><span style=""line-height:1.5;font-family:'Times New Roman';"">8q24.13-8q24.21 by our previous
linkage analysis.</span> 
</div>
</span> 
<p class=""MsoNormal"" style=""text-align:justify;"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:NSimSun;line-height:1.5;"">研究方法：</span><o:p></o:p>
</p>
<span style=""font-size:14px;font-family:NSimSun;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">我们通过外显子测序技术分析一个PPPK家庭的四个受累个体和两个未受累的对照个体，通过我们先前的分析得出疾病的基因座定位在8q24.13-8q24.21之间。</span> 
</div>
</span><span style=""font-size:14px;font-family:NSimSun;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span> 
</div>
</span> 
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">Results. </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">We identified a novel heterozygous mutation in COL14A1 gene</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">(c.4505C→T ( p.Pro1502Leu)), which located within the linkage region that we
previously identified for PPPK. </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">The mutation
was shared by the four affected individuals, but not
for the two controls of the family. </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">Sanger sequencing confirmed this mutation in another four cases from this
family. </span><span style=""font-size:14px;font-family:NSimSun;line-height:1.5;""><span style=""font-family:Times New Roman;"">T</span><span style=""font-family:Times New Roman;"">his
mutation was invisible in the normal controls of this family as well as the
additional 676 unrelated normal controls and 781 patients with other disease. The shared COL14A1 mutation, </span></span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">p.Pro1502Leu,&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">is a missense
substitution at a highly conserved amino acid residue across multiple species.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:NSimSun;line-height:1.5;"">研究结果：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<br />
</p>
<div style=""text-align:justify;"">
	<span style=""font-family:NSimSun;font-size:14px;line-height:1.5;"">我们在COL14A1基因(c.4505C→T ( p.Pro1502Leu))中鉴定出了新的突变，该突变位于我们先前鉴定的PPPK基因的连锁区域处。在四个受累个体中均存在该突变，但在该家庭的两个对照个体中并未发现。Sanger测序证实了在这个家庭中的另外4个病例中也存在该突变。这个突变在这个家庭的正常对照个体中是隐性的。同样在另外不相关的676例正常对照个体和781例患有其他疾病的患者中也是如此。共有的COL14A1突变，p.Pro1502Leu，是贯穿多种物种中一个高度保守的氨基酸残基的替代。</span> 
</div>
<span style=""font-size:14px;font-family:NSimSun;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span> 
</div>
</span><span style=""font-size:14px;font-family:NSimSun;line-height:1.5;""> 
<div style=""text-align:justify;"">
	<br />
</div>
</span> 
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">Conclusions. The power of combining exome sequencing and
linkage information in the study of genetics of autosomal dominant disorders,
even in simplex cases, </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">has been demonstrated. Our results suggested
that COL14A1 would be </span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">a casual gene for PPPK,&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';line-height:1.5;"">which
was helpful for advancing us on understanding of the pathogenesis of PPPK.</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:NSimSun;line-height:1.5;"">研究结论：</span><o:p></o:p>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:NSimSun;line-height:1.5;"">在研究常染色体显性遗传疾病的遗传学，甚至在单纯的病例中，外显子测序和连接信息相结合的作用已被证实。我们的研究结果表明，COL14A1将是PPPK的一种休闲基因，这对于促进我们对PPPK发病机制的了解是很有帮助的。</span><o:p></o:p>
</p>
<o:p></o:p>
<p>
	<br />
</p>
<o:p></o:p>
<p>
	<br />
</p>","/uploadfiles/image/20131212/20131212142258_7110w.jpg","/uploadfiles/file/20131212/20131212142331_1746.pdf",,12/12/2013,12/12/2013,"medicool",14,,"Exome sequencing, Punctate palmoplantar keratoderma, COL14A1",0,"65",110,"Exome sequencing identifies a COL14A1 mutation in a large Chinese pedigree with punctuate palmoplantar keratoderma","2012",
673,,"10.1111/j.1525-1470.2009.00953.x","Victoria Woo, D.D.S.,* Julia Bonks, D.M.D.,","Pediatric Dermatology","<span style=""font-family:'Times New Roman';font-size:14px;"">Abstract:<br />
&nbsp; &nbsp; Lichenoid drug eruptions are seen most frequently on the</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">skin and seldomly affect themucosal surfaces. Oral involvement―known as</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">oral lichenoid drug eruption―is more common in the adult population and</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">has been associated with numerous medications. Pediatric-onset oral lichenoid</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">drug eruption is an exceptionally rare finding with only isolated cases</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">published in the literature. The nonspecific appearance and latent presentation</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">of pediatric oral lichenoid drug eruption can cause confusion in</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">diagnosis and treatment. We report a case of oral lichenoid drug eruption</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">occurring in a 15-year-old and explore challenges in the clinical and histologic</span>&nbsp;<span style=""font-family:'Times New Roman';font-size:14px;"">recognition of this condition.</span><br />
<span style=""font-family:'Times New Roman';font-size:14px;""></span><br />",,"/uploadfiles/file/20131217/20131217133652_1142.pdf",,12/17/2013,12/17/2013,"medicool",8,,,0,"67",112,"Oral Lichenoid Drug Eruption: A Report of a Pediatric Case and Review of the Literature","2009",
647,"缺乏瞬时自然杀伤细胞的男性儿童患有与单纯疱疹病毒相关的复发性多形红斑","10.3109/00365548.2011.560185","MARIA  FRANCESCA   MESSINA  ,  SERAFINELLA  PATRIZIA  CANNAV  ?   , SALVATORE  AVERSA    &   FILIPPO DE  LUCA","Scandinavian Journal of Infectious Diseases","<p style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:'Times New Roman';"">&nbsp; &nbsp; &nbsp; Erythema multiforme is characterized by itching macules, papules and
bullae, symmetrically distributed on the dorsum of the hands. They can follow
the administration of several drugs or infections with various agents, and in
particular with herpes simplex virus. The recurrent variant is very rare,
especially in the paediatric age group. We describe the case of a male
adolescent with recurrent erythema multiforme caused by herpes virus and
transient natural killer de?&nbsp; ciency.&nbsp;&nbsp;</span> 
</p>
<p style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:SimSun;"">&nbsp; &nbsp;多形性红斑以对称分布在手背的瘙痒斑疹、丘疹和大疱为特征。它们可能在服用一些药物或多种情况引起的感染后发生，特别是单纯疱疹病毒。多形红斑的复发性变异非常罕见，尤其是在儿科年龄组。我们描述了一例由疱疹病毒和缺乏瞬时自然杀伤细胞引起的复发性多形性红斑男性青少年病例。</span> 
</p>","/uploadfiles/image/20131212/20131212164843_7275w.jpg","/uploadfiles/file/20131212/20131212164853_2592.pdf",,12/12/2013,12/12/2013,"medicool",14,,"Erythema multiforme | herpes virus |  immunity  | natural killer",0,"85",111,"Transient natural killer de?ciency in a boy with herpes simplex virus-associated recurrent erythema multiforme","2011",
649,,"10.1007/s11739-010-0394-5","Attilio Allione, Luca Dutto , Elisabetta Castagna","CE - MEDICAL ILLUSTRATION","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; &nbsp; Since the increasing popularity of tattoos among young&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">people, numerous and variegated complications are&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">described. For several years, para-phenylenediamine&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">(PPD) has been used to darken the henna dye commonly&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">used for tattoos. PPD is a potent additive sensitizer and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">contact dermatitis is the most common reaction pattern.</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Erythema multiforme (EM)-like reaction secondary to&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">PPD henna tattoo contact is a well described but unusual&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">manifestation, and only six previous cases are reported .</span>
</div>",,"/uploadfiles/file/20131213/20131213085825_8705.pdf",,12/13/2013,12/13/2013,"medicool",6,,"tattoo| variegated complications| contact dermatitis| cases",0,"85",111,"Erythema multiforme caused by tattoo: a further case","2011",
734,"血小板凝胶治疗严重的硬皮病皮肤溃疡","DOI 10.1007/s00296-011-2038-0","Dilia Giuggioli ・ Michele Colaci ・ Andreina Manfredi ・ Mariateresa Mariano ・ Clodoveo Ferri","Rheumatol Int","<p class=""MsoNormal"" style=""text-align:justify;text-indent:21pt;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><br />
<strong style=""font-family:'Times New Roman';font-size:14px;line-height:21px;text-align:justify;text-indent:28px;white-space:normal;"">Abctract.<br />
</strong> &nbsp; &nbsp; &nbsp;Systemic sclerosis (SSc) is characterized by </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">microvascular damage and </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">fibrosis of the skin and </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">internal organs. </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Non-healing </span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">skin
ulcers, mainly non-venous leg ulcers,&nbsp;</span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">represent
one of the most challenging complications. Platelet gel (PG) is a&nbsp;</span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">hemocomponent </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">containing
numerous growth factors, </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">potentially useful
for tissue reparation. </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">This pilot open study
aimed to evaluate </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">effect of PG in 12 SSc patients </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with skin ulcers </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">resistant to
conventional therapies from at least 6 months.&nbsp;</span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">PG was
applied in the </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">wound bed twice weekly for 2 weeks, then once a week for 12 weeks; </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">in all cases, </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the
ongoing treatments remained unchanged at the time of PG applications. </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Skin ulcers were evaluated at 0, 12 and 24 weeks; </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the
patient’s quality of life was also evaluated using the visual analogical scale
(VAS) and the health assessment questionnaire (HAQ). During the 6-month
follow-up, </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the skin ulcers consistently improved in 10/12
patients, </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with complete healing in 4.
At the last evaluation, wound size reduced from 23.4 </span><u style=""text-indent:21pt;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">+</span></u><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;""> 14.9 SD to 2.3 </span><u style=""text-indent:21pt;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">+</span></u><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;""> 2.2 SD cm</span><sup style=""text-indent:21pt;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">2</span></sup><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;""> (</span><i style=""text-indent:21pt;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">p </span></i><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&lt;
0.0001). Patient’s quality of life markedly improved: </span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">VAS decreased from
87.08 </span><u style=""text-indent:21pt;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">+</span></u><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;""> 13.5 to 57.9 </span><u style=""text-indent:21pt;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">+</span></u><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;""> 12.6;</span><i style=""text-indent:21pt;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">p </span></i><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&lt; 0.0001 and HAQ from 0.73 </span><u style=""text-indent:21pt;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">+</span></u><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;""> 0.43 to 0.57 </span><u style=""text-indent:21pt;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">+</span></u><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;""> 0.22; </span><i style=""text-indent:21pt;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">p </span></i><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&lt; 0.0001.</span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">PG may
represent a novel therapeutic option for SSc skin ulcers&nbsp;</span><span style=""text-indent:21pt;line-height:1.5;font-family:'Times New Roman';font-size:14px;"">refractory to conventional treatment.</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">摘要：</span>
</p>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">&nbsp;&nbsp;&nbsp; 系统性硬化症（SSc）以微血管损坏、皮肤和内脏纤维化为特征。未愈合部分的皮肤溃疡，主要为非静脉下肢溃疡，是最具挑战性的并发症之一。血小板凝胶（PG）是含有大量生长因子的血液组成部分，对于组织修复具有潜在作用。该试点开放性研究旨在评估12位有皮肤溃疡的硬皮病患者使用PG后的效果，这些患者对抵抗常规疗法至少6个月。PG被应用于创口处，每周两次，一共两周，随后每周一次，共12周；在任何情况下，应用PG的持续治疗均保持不变。皮肤溃疡分别在0、12和21周进行评估；患者的生活质量采用视觉类比量表（VAS）和健康评估问卷（HAQ）进行评估。在6个月的随访期间，12位患者中的10位患者的皮肤溃疡得到持续改善，其中4位患者已得到全面治愈。在最后的评估中，伤口的大小从</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">23.4 </span><u><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">+</span></u><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">14.9 SD减少到</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">2.3 </span><u><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">+</span></u><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">2.2 SD cm</span><sup><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">2</span></sup><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">(p
＜</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;""> 0.0001)</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">。患者的生活质量得到明显改善：VAS测试从</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">87.08 </span><u><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">+</span></u><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">13.5下降至</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">7.9 </span><u><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">+</span></u><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">12.6；</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">p</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">＜</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">0.0001</span><span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">，HAQ测试从0.73 § 0.43下降至0.57 § 0.22；p＜0.0001。对于难以用常规疗法治愈的硬皮病皮肤溃疡，PG可能代表了一种新的治疗选择。</span>
</p>","/uploadfiles/image/20131219/20131219162456_4926w.jpg","/uploadfiles/file/20131219/20131219162513_0755.pdf",,12/19/2013,12/19/2013,"medicool",7,,"Scleroderma ・ Systemic sclerosis ・ Skin ulcers ・ Platelet gel",0,"66",114,"Platelet gel in the treatment of severe scleroderma skin ulcers","2012",
648,,,"Laura Rodr? ?guez-Pazos, Silvia G? omez-Bernal, Iria Montero","BRIEF COMMUNICATION","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; &nbsp;Erythema multiforme (EM) is a self-limited skin disease, characterized by the abrupt onset of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">symmetric red papules that may evolve into target lesions often precipitated by an infection.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Photosensitive erythema multiforme (PEM) is a rare disorder characterized by the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">distribution of the lesions on sun-exposed areas. It has been described at the sites of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">sunburn, following episodes of polymorphic light eruption or herpes labialis and in&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">association with drugs. To our knowledge, PEM photoinduced by selective serotonin&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">reuptake inhibitors has not been reported. We describe a patient who had two consecutive&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">episodes of PEM related to two different triggers: paroxetine and HSV infection. In the ?rst&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">episode, systemic photosensitivity was con?rmed with the photobiological study. UVB-MED&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">was decreased when the patient was taking paroxetine and did not change after its&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">substitution for duloxetine. However, it became normal after the withdrawal of both drugs,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">suggesting a cross-reactivity reaction. The UVB photopatch test with paroxetine was positive.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">The second episode occurred after a herpes labialis relapse. At that time, UVB-MED was&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">normal.</span>
</div>",,"/uploadfiles/file/20131213/20131213085233_6999.pdf",,12/13/2013,12/13/2013,"medicool",8,,"erythema multiforme| paroxetine;photoinduced| photopatch test| selective
serotonin reuptake inhibitors| systemic photosensitivity",0,"85",111,"Erythema multiforme photoinduced by paroxetine and herpes simplex virus","2011",
737,,,"Mei Zong,   Ingela Loell,  Eva Lindroos",,"<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Objectives</strong> &nbsp;To investigate the expression of interleukin&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">(IL)-15 and IL-15 receptor α (IL-15Rα) in muscle tissue&nbsp;</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">from patients with polymyositis or dermatomyositis&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">before and after conventional immunosuppressive (IS)&nbsp;</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">treatment.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Methods </strong>&nbsp;Muscle biopsies from 17 patients before&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and after conventional IS treatment and seven healthy&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">individuals were investigated by immunohistochemistry&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">using antibodies against IL-15 and IL-15Rα. Quanti? cation&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">was performed by computerised image analysis.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Cellular localisation of IL-15 was determined by double&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">immuno? uorescence. Clinical outcome was measured&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">by the functional index and serum creatine kinase.&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Human myotubes were cultured and IL-15 staining was&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">performed by immunocytochemistry.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Results</strong> &nbsp;IL-15 was observed in mononuclear&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">in? ammatory cells of muscle tissue while IL-15Rα was&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">localised to mononuclear in? ammatory cells, capillaries&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">and large vessels. Double staining showed localisation&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">of IL-15 to CD163+ macrophages. A signi? cantly larger&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">number of IL-15 and IL-15Rα-positive cells were seen&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">in muscle tissue of patients compared with healthy&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">individuals. Baseline IL-15 expression correlated&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">negatively with improvement in muscle function. After&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">conventional IS treatment, a signi? cantly lower number&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">of IL-15 and IL-15Rα-positive cells was found. However,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""></span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">compared with controls, eight of 17 patients still had&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">more IL-15-positive cells and less muscle function&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">improvement was shown in this group of patients,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">both in short-term and long-term observations. Human&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">differentiated myotubes were negative for IL-15 staining.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Conclusions </strong>&nbsp;IL-15 and its receptor are expressed in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">the muscle tissue of patients with myositis and IL-15&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">expression is correlated with improvement in muscle&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">function. IL-15 may play a role in the pathogenesis of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">myositis and could be a biological treatment target,&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">at least in a subgroup of patients with polymyositis or&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">dermatomyositis.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""></span> 
</div>
<br />",,"/uploadfiles/file/20131219/20131219164524_8232.pdf",,12/19/2013,12/19/2013,"medicool",2,,,0,"65",115,"Effects of immunosuppressive treatment on  interleukin-15 and interleukin-15 receptor α  expression in muscle tissue of patients with  polymyositis or dermatomyositis","2012",
738,,"10.1002/art.34657","Takahisa Gono,  Yasushi Kawaguchi,  Masataka Kuwana","ARTHRITIS & RHEUMATISM","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Objective. </strong>The complication of interstitial lung&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">disease (ILD) in polymyositis/dermatomyositis (PM/</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">DM) is associated with antiCaminoacylCtransfer RNA&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">synthetase (anti-aaRS) antibody or antiCmelanoma&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">differentiationCassociated gene 5 (antiCMDA-5) anti-</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">body positivity. AntiCMDA-5 antibody is associated with&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">clinically amyopathic DM and fatal outcome due to&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">rapidly progressive ILD in Asian populations. The&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">association between genetic factors and antiCMDA-5</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">antibodyCpositive DM is unclear. This study was under</span><span style=""line-height:1.5;"">taken to investigate the HLACDRB1 genotype in pa</span><span style=""line-height:1.5;"">tients with antiCMDA-5 antibodyCpositive DM.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Methods. </strong>We examined genetic differences among&nbsp;</span><span style=""line-height:1.5;"">17 patients with antiCMDA-5 antibodyCpositive DM, 33&nbsp;</span><span style=""line-height:1.5;"">patients with anti-aaRS antibodyCpositive PM/DM, 33&nbsp;</span><span style=""line-height:1.5;"">patients with PM/DM without anti-aaRS antibody or</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">ILD, and 265 healthy controls.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""><strong>Results. </strong>The frequencies of HLACDRB1*0101 and&nbsp;</span><span style=""line-height:1.5;"">DRB1*0405 were 29% and 71%, respectively, in patients&nbsp;</span><span style=""line-height:1.5;"">with antiCMDA-5 antibodyCpositive DM, which were&nbsp;</span><span style=""line-height:1.5;"">higher than the frequencies in healthy controls (10%&nbsp;</span><span style=""line-height:1.5;"">and 25%, respectively). Among the 17 patients with&nbsp;</span><span style=""line-height:1.5;"">antiCMDA-5 antibodyCpositive DM, 16 (94%) harbored&nbsp;</span><span style=""line-height:1.5;"">either the DRB1*0101 or DRB1*0405 allele. The com</span><span style=""line-height:1.5;"">bined frequency of the DRB1*0101 allele and the&nbsp;</span><span style=""line-height:1.5;"">DRB1*0405 allele was significantly higher in patients&nbsp;</span><span style=""line-height:1.5;"">with antiCMDA-5 antibodyCpositive DM than in pa</span><span style=""line-height:1.5;"">tients with PM/DM without anti-aaRS antibody or ILD,&nbsp;</span><span style=""line-height:1.5;"">with an odds ratio (OR) of 42.7 (95% confidence interval&nbsp;</span><span style=""line-height:1.5;"">[95% CI] 4.9C370.2) (P  1.1  105</span><span style=""line-height:1.5;"">), or in patients&nbsp;</span><span style=""line-height:1.5;"">with anti-aaRS antibodyCpositive PM/DM (OR 13.3&nbsp;</span><span style=""line-height:1.5;"">[95% CI 1.6C112.6], P  4.5  103</span><span style=""line-height:1.5;"">).</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span><span style=""line-height:1.5;""><strong>Conclusion. </strong>Our findings indicate that HLAC</span><span style=""line-height:1.5;"">DRB1*0101/*0405 is associated with susceptibility to&nbsp;</span><span style=""line-height:1.5;"">antiCMDA-5 antibodyCpositive DM in the Japanese&nbsp;</span><span style=""line-height:1.5;"">population.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span>
</div>
</span>",,"/uploadfiles/file/20131219/20131219164820_8695.pdf",,12/19/2013,12/19/2013,"medicool",5,,"The complication of interstitial lung disease| antiCMDA-5 antibodyCpositive DM  | t he HLACDRB1 genotype |",0,"65",115,"Association of HLACDRB1*0101/*0405 With Susceptibility to AntiCMelanoma DifferentiationCAssociated Gene 5 AntibodyCPositive Dermatomyositis in the Japanese Population","2012",
650,,"10.1111/j.1525-1470.2010.01217.x","Hidetaka Nakai,Ken Sugata,Chie Usui","Wiley Periodicals, Inc","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;We present a case of primary EpsteinCBarr virus (EBV)&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">infection with erythema multiforme. A 1-year-old Japanese boy presented&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with skin eruptions, including typical target lesions and a low-grade fever.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Just before the skin biopsy, 95 copies ?lg DNA of EBV genome was detected&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">in peripheral blood mononuclear cells, which subsequently increased to&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">6,834 copies?lg DNA. Skin tissue collected from the skin lesion showed the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">typical pathologic ?ndings of erythema multiforme. EBV-encoded&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">small nuclear RNA signals were not detected in the skin tissue by in situ&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">hybridization.</span>
</div>",,"/uploadfiles/file/20131213/20131213090411_9571.pdf",,12/13/2013,12/13/2013,"medicool",8,,"A Case | Erythema Multiforme |  Primary EpsteinCBarr Virus | small nuclear RNA signals",0,"85",111,"A Case of Erythema Multiforme Associated with Primary EpsteinCBarr Virus Infection","2011",
707,,"10.2340/00015555-1373","Anna CAMPANATI', Rosaria GESUITAS Melania GIANNONI', Francesca PIRACCINI^ Lucia SANDRONI^, Emanuela MARTINA', Luca CONOCCHIARI', Emanuele BENDIA\ Antonio DI SARIO^ and Annamaria OFFIDANI","Acta Derm Venereol","<div style=""text-align:justify;"">
	<span style=""font-size:16px;font-family:'Times New Roman';"">The aim of this study is to assess the associations between&nbsp;chronic spontaneous urticaria (CSU), Helicobacter pylori&nbsp;infection and small intestinal bacterial overgrowth. Fortyeight&nbsp;patients with CSU were studied by scoring the urticaria&nbsp;activity and assesing the quality of life. Patients&nbsp;with H. pylori infection (? = 11) or small intestinal bacterial&nbsp;overgrowth (? = 13) were specifically treated for&nbsp;one week and clinically evaluated both before and 4&nbsp;weeks after the eradication therapy. Eradication of H.&nbsp;pylori infection led to a significant improvement in CSU&nbsp;(p&lt; 0.002). In contrast, eradication of small intestinal&nbsp;</span><span style=""font-family:'Times New Roman';font-size:16px;"">bacterial overgrowth was not associated with any clinical&nbsp;improvement in CSU, despite the fact that these patients&nbsp;had statistically significant more urticaria activity at baseline.&nbsp;Thus there is no evidence to support the eradication&nbsp;of small intestinal bacterial overgrowth in CSU, but&nbsp;eradication of ? pylori infection may result in an improvement&nbsp;of the disease.&nbsp;</span>
</div>",,"/uploadfiles/file/20131218/20131218164229_3667.pdf",,12/18/2013,12/18/2013,"medicool",4,,"chronic spontaneous urticaria; Helicobacter pylori; small intestinal bacterial overgrowth.",0,"65",113,"Role of Small Intestinal Bacterial Overgrowth and Helicobacter pylori Infection in Chronic Spontaneous Urticaria: A Prospective Analysis ","2013",
651,,"10.1111/j.1742-6723.2010.01381.x","Hoon Kim, JinHong Min, JungSoo Park","Emergency Medicine Australasia","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; &nbsp;Alachlor and butachlor are commonly used chloroacetanilide herbicides. They are cyto</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">toxic, but there have been rare reported cases of alachlor or butachlor induced erythema&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">multiforme major. We report the case of a 38-year-old farmer with erythema multiforme&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">major due to the occupational exposure to alachlor/butachlor. The patient presented to the&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">ED because of itching. Con?uent erythematous to violaceous maculopatches with bullae&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and erosions were seen on the trunk, both upper extremities and both lower extremities. He&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">had no relevant past or family history of a similar skin disease. He had used alachlor/</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">butachlor for 3 days before he developed the itch. We performed a skin incisional biopsy&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and found diffuse hydropic degeneration with many necrotic keratinocytes in the epidermis&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">and mild to moderate super?cial perivascular lymphocytic in?ltrate admixed with neutro</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">phils and eosinophils in the upper dermis. These results con?rmed the diagnosis of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">erythema multiforme major. The patient was admitted and received systemic and topical&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">steroids. After 18 days, most lesions had healed, and he was discharged.</span> 
</div>",,"/uploadfiles/file/20131213/20131213091018_8386.pdf",,12/13/2013,12/13/2013,"medicool",9,,"acetamides| acetanilides| erythema multiforme",0,"85",111,"Erythema multiforme major due to occupational exposure to the herbicides alachlor and butachlor","2011",
742,,,"Dragana Lazarevic,   Angela Pistorio,   Elena Palmisani,","Ann Rheum Dis","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""><strong>Objectives </strong>To develop data-driven criteria for&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">clinically inactive disease on and off therapy for juvenile&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">dermatomyositis (JDM).</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Methods &nbsp;</strong>The Paediatric Rheumatology International&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Trials Organisation (PRINTO) database contains 275&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">patients with active JDM evaluated prospectively up&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">to 24 months. Thirty-eight patients off therapy at 24&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">months were de? ned as clinically inactive and included&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">in the reference group. These were compared with a&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">random sample of 76 patients who had active disease at&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">study baseline. Individual measures of muscle strength/</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">endurance, muscle enzymes, physician’s and parent’s&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">global disease activity/damage evaluations, inactive&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">disease criteria derived from the literature and other ad&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">hoc criteria were evaluated for sensitivity, speci? city and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Cohen’s κ agreement.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Results</strong> &nbsp;The individual measures that best characterised&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">inactive disease (sensitivity and speci? city &gt;0.8 and&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Cohen’s κ &gt;0.8) were manual muscle testing (MMT)&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">≥78, physician global assessment of muscle activity=0,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">physician global assessment of overall disease activity&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">(PhyGloVAS) ≤0.2, Childhood Myositis Assessment Scale&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(CMAS) ≥48, Disease Activity Score ≤3 and Myositis&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Disease Activity Assessment Visual Analogue Scale ≤0.2.</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">The best combination of variables to classify a patient as&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">being in a state of inactive disease on or off therapy is at&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">least three of four of the following criteria: creatine kinase</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">≤150, CMAS ≥48, MMT ≥78 and PhyGloVAS ≤0.2. After&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">24 months, 30/31 patients (96.8%) were inactive off&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">therapy and 69/145 (47.6%) were inactive on therapy.</span> 
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Conclusion</strong> &nbsp;PRINTO established data-driven criteria&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">with clearly evidence-based cut-off values to identify&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">JDM patients with clinically inactive disease. These&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">criteria can be used in clinical trials, in research and in&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">clinical practice.</span> 
</div>",,"/uploadfiles/file/20131219/20131219171305_1653.pdf",,12/19/2013,12/19/2013,"medicool",2,,"juvenile dermatomyositis |the PRINTO criteria | evaluated prospectively | clinical practice",0,"66",115,"The PRINTO criteria for clinically inactive  disease in juvenile dermatomyositis","2013",
747,,"10.1007/s10067-012-2044-y","Shiro Matsubara ,Koichi Kondo , Keizo Sugaya & Kazuhito Miyamoto","Clin Rheumatol","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">&nbsp; &nbsp; &nbsp;Dermatomyositis (DM) and polymyositis (PM)&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">are often refractory to conventional therapy with cortico</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">steroids sometimes combined with immune-suppressing&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">agents and can lead to severe disability if these treatments</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">are unsuccessful. In this prospective, open, non-randomized&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">study, we examined the efficacy of tacrolimus (FK506), an&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">immunosuppressant, in nine patients with DM ( 05) or PM&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">( 04) who did not respond to previous therapy. Outcomes&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">included compound muscle strength, ambulatory status, and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">serum creatine kinase activity measured at intervals after&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">starting tacrolimus. At 6 months after the introduction of&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">tacrolimus, all five patients with DM and three patients with&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">PM showed clinical improvements. Patients with a disease&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">duration of &lt;4 years and those with trough level of tacroli</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">mus &gt;5 ng/ml tended to have better outcomes than those&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">with longer disease duration or lower trough levels. There&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">were no side effects other than moderate hypertension and&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">aggravation of diabetes mellitus. Tacrolimus was beneficial&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">in the majority of patients with PM or DM refractory to&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">corticosteroid therapy. It was also effective in four patients&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">who were previously treated with other immunosuppres</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">sants or intravenous immunoglobulin combined with corti-</span>
</div>
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">costeroids. These results warrant further studies as to the&nbsp;</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">efficacy of tacrolimus compared to other immunosuppress</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">ing agents.</span>
</div>",,"/uploadfiles/file/20131219/20131219173323_2311.pdf",,12/19/2013,12/19/2013,"medicool",5,,"Creatine kinase | Dermatomyositis | Polymyositis | Tacrol imus",0,"67",115,"Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature","2012",
652,"ATF3在多形性红斑中表达增大，在人类角质细胞中受IFN-γ调节","10.1111/j.1600-0625.2009.01008.x","Brian P. Pollack, Bishu Sapkota and Paul L. Haun","John Wiley & Sons A/S, Experimental Dermatology","<p class=""MsoNormal"" style=""text-align:justify;text-indent:15.75pt;"">
	<span style=""font-size:14px;font-family:'Times New Roman';"">Activating transcription factor 3 (ATF3) is a member of the ATF ? </span><span style=""font-size:14px;font-family:'Times New Roman';"">cyclic AMP responsive element-binding protein (CREB) family of transcription
factors and is involved in the regulation of immune responses, apoptosis, DNA
repair and oncogenesis. The epidermal expression of ATF3 in the setting of cutaneous
in?ammation has not been well
characterized. To examine the expression of ATF3 in the setting
of in?ammatory skin disease, ATF3 protein expression was analysed by immunohistochemistry
(IHC). We found diffuse epidermal ATF3 protein expression in skin biopsies of
erythema multiforme (EM).</span> 
</p>
<p class=""MsoNormal"" style=""text-align:justify;text-indent:15.75pt;"">
	<span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;"">转录激活因子</span><span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;""> 3 (ATF3)</span><span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;"">是</span><span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;"">ATF/</span><span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;"">环磷酸腺苷反应元件结合蛋白</span><span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;"">(CREB)</span><span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;"">家族中转录因子的一员，参与管理免疫应答、细胞凋亡、</span><span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;"">DNA</span><span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;"">修复和癌变。在皮肤炎症的环境中</span><span style=""text-indent:15.75pt;line-height:1.5;font-size:14px;font-family:SimSun;"">表皮的ATF3表达还没有被很好地表现出来。为了调查ATF3在皮肤炎症疾病环境中的表达，我们采用免疫组化(IHC)对ATF3蛋白表达进行了分析。我们在多形红斑（EM）的皮肤活检中发现了弥漫性表皮中ATF3蛋白的表达。</span> 
</p>","/uploadfiles/image/20131213/20131213091758_1346w.jpg","/uploadfiles/file/20131213/20131213091707_4813.pdf",,12/13/2013,12/13/2013,"medicool",11,,"activating transcription factor 3 | epidermis | erythema multiforme | gene expression | interferon-gamma | keratinocyte",0,"65",111,"Activating transcription factor 3 (ATF3) expression is increased in erythema multiforme and is regulated by IFN-γ in human keratinocytes","2009",
677,,"10.1111/ijd.12197","Muhammad Hasibur Rahman, MBBS, FCPS, MRCPS, FACP, FRCP","The International Society of Dermatology","<span style=""font-size:16px;font-family:'Times New Roman';"">Abstract</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';"">Background <br />
Fixed drug eruption is designated as a typical allergic reaction occurring due</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">to exposure to a medicine. This common dermatological condition is often being ignored</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">for its causative agent as well as the patient’s sufferings sometimes become unpredictable.</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';"">Aims <br />
The objective of this large population study is to identify the causative agents</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">responsible for fixed drug eruption.</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';"">Materials &amp; Methods <br />
The study is comprised of 120 suspected patients of fixed drug</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">eruption. History, classic clinical features of well circumscribed erythema, edema, and</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">violaceous pigmentation, and the recurrence of the eruptions on the same sites upon</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';"">re-administering drug were used as diagnostic criteria. The drug(s) causing allergic</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">reactions were confirmed by provocation tests.</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';"">Results <br />
The incidence of drug eruption was found distributed in 0.62% amongst all</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">dermatology outpatient attendees. The male to female ratio recorded was 7:2. The highest</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">number of cases was observed within in the age group of 21C35 years. The provocation</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">tests were positive in 92 among 120. The genitalia and lips/face were the most commonly</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">affected site for fixed drug eruption.</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';"">Discussion<br />
The drug sulphonamide (including co-trimoxazole) accounted for the highest</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">number of cases of eruptions (28.33 %). The other drugs, in order of frequency,</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">responsible for the cause of eruptions were identified as nonsteroidal anti-inflammatory</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';"">drugs, tetracycline, metronidazole, herbal medicine, paracetamol, fluconazole, penicillin,</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">Griseofulvin, and homeopathic medicine, etc.</span><br />
<span style=""font-size:14px;font-family:'Times New Roman';"">Conclusion <br />
Drug reactions are very frequently experienced by dermatologists in their dayto-</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">day practice. The patients are often ignorant of the drugs consumed and often do not</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">accept them as an etiologic factor. A detailed drug history as well as the complaints will be</span>&nbsp;<span style=""font-size:14px;font-family:'Times New Roman';"">helpful before undertaking the provocation test.</span><br />
<br />",,"/uploadfiles/file/20131217/20131217140233_5997.pdf",,12/17/2013,12/17/2013,"medicool",7,,"Fixed drug eruption, confirmed by provocative test",0,"66",112,"Fixed drug eruption in Bangladeshi population: confirmed by provocative test","2013",
750,"多发性肌炎和皮肌炎早期的治疗效果","10.4103/0028-3886.60398","Peyman Naji, Farhad Shahram, Abdolhadi Nadji","Neurology India | Jan-Feb","<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;""><strong>Background:</strong> Idiopathic inflammatory myopathies, dermatomyositis (DM) and polymyositis&nbsp; (PM) are rare but are potentially treatable.</span> <o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:SimSun;font-size:14px;"">背景：特发性炎性肌病、皮肌炎（<span style=""font-family:Times New Roman;"">DM</span>）和多发性肌炎（<span style=""font-family:Times New Roman;"">PM</span>）罕见但是可以治愈。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<strong style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Aim:</strong><span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;""> To compare the effect of early and late treatment in patients with PM and DM.</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:SimSun;font-size:14px;"">目的：比较皮肌炎和多发性肌炎早期和晚期治疗的效果。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Patients
and Methods: </strong>The study included all the adult patients with definite diagnosis
of PM or DM treated for at least 12 months. The patients were divided into two
groups: Early Group - treatment within three months and Late Group - treatment
after three months. The number of patients with positive therapeutic response,
remission in less than one year and the mean time elapsed for reaching the
remission were assessed and compared between the two groups. Chi-square test, Fisher’s
exact test, t-test and Pearson correlation test were used for data analysis.</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:SimSun;font-size:14px;"">对象与方法：本研究包括所有已确诊为多发性肌炎（<span style=""font-family:Times New Roman;"">PM</span>）或者皮肌炎（<span style=""font-family:Times New Roman;"">DM</span>）的成年患者，他们接受过至少<span style=""font-family:Times New Roman;"">12</span>个月的治疗。将患者分为两组：早期组，三个月内治疗和晚期组，三个月后治疗。我们评估了出现积极治疗反应（一年内缓解）的患者数量和达到症状缓解的平均时间，并在两组间比较。采用卡方检验、<span style=""font-family:Times New Roman;"">Fisher</span>精确检验、<span style=""font-family:Times New Roman;"">t</span>检验、<span style=""font-family:Times New Roman;"">Pearson</span>相关检验进行数据分析。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Results: </strong>The analysis included 65 patients, 42 with DM and 23 with PM. Late Group
included 24 patients (seven PM and 17 DM), while Early Group included 41
patients (16 PM and 25 DM). Positive therapeutic response, remission rate
within one year was higher in Early</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">Group
(80% vs. 46%, P: 0.004). The mean time needed to achieve remission was much less
with early treatment (5.5 vs. 11.9 months, P: 0.003). The relapse rate was also
lower in Early Group (5% vs. 25%, P , 0.02). The comparison of treatment
outcomes showed the same results in both PM and DM, but it was statistically significant
in patients with DM.</span> <o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:SimSun;font-size:14px;"">结果：研究分析了<span style=""font-family:Times New Roman;"">65</span>例患者，其中<span style=""font-family:Times New Roman;"">42</span>例皮肌炎、<span style=""font-family:Times New Roman;"">23</span>例多发性肌炎。晚期组包括<span style=""font-family:Times New Roman;"">24</span>例患者（<span style=""font-family:Times New Roman;"">7</span>例多发性肌炎和<span style=""font-family:Times New Roman;"">17</span>例皮肌炎），而早期组包括的是<span style=""font-family:Times New Roman;"">41</span>例患者（<span style=""font-family:Times New Roman;"">16</span>例多发性肌炎和<span style=""font-family:Times New Roman;"">25</span>例皮肌炎）。在早期组中，患者在一年内的缓解率，出现积极治疗反应高于晚期组（<span style=""font-family:Times New Roman;"">80％</span>比<span style=""font-family:Times New Roman;"">46％</span>，<span style=""font-family:Times New Roman;"">P：0.004</span>）。早期治疗中达到缓解的平均时间较短（<span style=""font-family:Times New Roman;"">5.5</span>比<span style=""font-family:Times New Roman;"">11.9</span>个月，<span style=""font-family:Times New Roman;"">P：0.003</span>）。早期组的复发率也比较低（<span style=""font-family:Times New Roman;"">5％</span>比<span style=""font-family:Times New Roman;"">25％</span>，<span style=""font-family:Times New Roman;"">P：0.02</span>）。对比治疗结果显示，多发性肌炎和皮肌炎的结果相同，但在皮肌炎患者更显著。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;""><strong>Conclusions:</strong> Early treatment in patients with PM and DM is associated with higher remission rates,
shorter treatment period and low complication rates.</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""font-family:SimSun;font-size:14px;"">结论：多发性肌炎和皮肌炎患者早期治疗，和缓解率较高，治疗周期较短，并发症发生率低有关。</span><o:p></o:p>
</p>","/uploadfiles/image/20131223/20131223095138_6967w.jpg","/uploadfiles/file/20131223/20131223095253_0933.pdf",,12/23/2013,12/23/2013,"medicool",2,,"Dermatomyositis| early treatment | inflammatory myositis | polymyositis | 
relapses",0,"66",115,"Effect of early treatment in polymyositis and dermatomyositis","2010",
653,,"10.1111/j.1600-0560.2009.01287.x","Anita Sebastian,Connor Patterson,Andrea L. Zaenglein","John Wiley & Sons,Journal of Cutaneous Pathology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp; Erythema multiforme is histologically characterized by liquefactive&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">degeneration along the dermal-epidermal junction, necrotic&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">keratinocytes and a lymphocytic in?ltrate. We report a 10-year-old&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">boy with recurrent erythema multiforme major of undetermined&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">etiology with unusual histologic ?ndings. A skin biopsy taken at day 2&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">of his eruption revealed histologic features otherwise characteristic of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">erythema multiforme, but mediated instead by a CD68-positive&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">in?ltrate, resembling cutaneous Kikuchi’s disease. To the best of our&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">knowledge this is the ?rst reported case of ‘histiocytic’ erythema&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">multiforme.</span> 
</div>",,"/uploadfiles/file/20131213/20131213092312_1476.pdf",,12/13/2013,12/13/2013,"medicool",6,,"liquefactive degeneration | Erythema multiforme | cutaneous Kikuchi’s disease",0,"65",111,"Histiocytic erythema multiforme","2009",
669,"弥散性小儿带状疱疹",,"A. Ortiz-Brugués, X. Soria-Gili, J.M. Casanova-Seuma","Actas Dermosifiliogr","<p class=""MsoNormal"" style=""text-indent:21.0pt;"">
	<br />
</p>
<div style=""text-align:justify;"">
	<span style=""text-indent:21pt;""></span><span style=""text-indent:21pt;font-family:'Times New Roman';font-size:14px;line-height:2;"">&nbsp; &nbsp; Herpes
zoster (shingles) is rare in children with no history of chickenpox but can
occur when their mothers are infected with the virus during pregnancy. In such
cases, herpes zoster generally presents after the first year of life after
maternal immunoglobulin (Ig) G antibodies have disappeared from the child’s
blood. Disseminated pediatric herpes zoster is&nbsp;</span><span style=""text-indent:21pt;font-family:'Times New Roman';font-size:14px;line-height:2;"">an unusual
condition.</span> 
</div>
<p>
	<br />
</p>
<p class=""MsoNormal"" style=""text-align:justify;text-indent:21pt;"">
	<span style=""font-size:14px;line-height:2;"">带状疱疹在无水痘病史的儿童中很少发生，但是当他们的母亲在怀孕期间感染了该病毒时则可能发生。在这种情况下，带状疱疹通常出现在出生一年后，在母体免疫球蛋白后球蛋白</span><span style=""font-family:'Times New Roman';font-size:14px;line-height:2;"">（Ig）G</span><span style=""font-size:14px;line-height:2;"">抗体从孩子的血液中消失后。弥散性小儿带状疱疹是一种特殊的病症。</span> 
</p>","/uploadfiles/image/20131213/20131213151301_0016w.jpg","/uploadfiles/file/20131213/20131213151429_4850.pdf",,12/13/2013,12/13/2013,"medicool",22,,,0,"85",58,"Disseminated Pediatric Herpes Zoster",,"/uploadfiles/kejian/20131213/1213151217_4151.pdf"
654,,,"Liborija Lugovi? Mihi?, Marija Buljan, Vedrana Bulat, Mirna ?itum",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">&nbsp; &nbsp;Erythema multiforme (EM) is a skin disease caused </span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">by numerous potential triggering agents. It is characterized by&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">symmetrically distributed, round, erythematous iris lesions,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with remarkable tendency of recurrence. The purpose of&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">this randomized retrospective study was to summarize our&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">experience concerning the etiology, clinical variants and&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">management of EM. We present 12 EM patients, along&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with laboratory, clinical and histopathologic analysis, and&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">an overview of the treatment used. According to clinical&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">presentation and histopathologic analysis, there were six cases&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">of EM major, five cases of EM minor and one case of Stevens-</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">Johnson syndrome. In five patients, EM was associated with&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the use of certain drugs (terbinafine, azithromycin, diclofenac,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">piroxicam). In three patients, the disease was triggered by&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the herpes simplex virus infection. In four cases, the etiologic&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">factor (involved in the occurrence) of EM remained unknown.&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">We also present an unusual case of an HIV-positive patient&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with multiple acral target lesions without mucosal involvement,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">which developed upon antiretroviral therapy discontinuation. To&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">our knowledge, no case of such EM occurrence has yet been&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">reported. There are various etiologic factors and numerous&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">clinical presentations of EM, including acral target lesions and&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">atypical widely distributed cutaneous and mucosal lesions.&nbsp;</span>
</div>",,"/uploadfiles/file/20131213/20131213092731_4044.pdf",,12/13/2013,12/13/2013,"medicool",7,,"erythema multiforme | Stevens-Johnson syndrome | toxic epidermal necrolysis",0,"65",111,"Erythema Multiforme with Reference to Atypical  Presentation in an HIV-Positive Patient Following  Antiretroviral Therapy Discontinuation","2009",
464,"有神经性皮炎和牛皮癣的性功能障碍患者","10.1080/00926230701267951","Mercan, Sibel,Altunay, Ilknur Kivanc,Demir, Basaran, AkpInar, Abdullah1 Kayaoglu, Semra","Journal of Sex & Marital Therapy","<div style=""text-align:justify;"">
	&nbsp; <span style=""font-size:14px;font-family:'Times New Roman';"">We investigated sexual dysfunction and accompanying depression&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">in patients with neurodermatitis and psoriasis. Patients with neurodermatitis&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">(n = 31) and psoriasis (n = 24) were compared to&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">control cases (n = 33) with Beck depression scale (BDS) and Arizona&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">Sexual Experience Scale (ASEX). Beck Depression Scale and&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">ASEX scores varied between three groups. In two group comparisons,&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">the neurodermatitis group had more sexual problems than&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">the psoriasis group and the control group. Patients with neurodermatitis&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">and psoriasis have sexual dysfunction and depression in the&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">course of these chronic diseases and the higher frequency of sexual&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">problems was seen in patients with neurodermatitis.</span> 
</div>
<p class=""MsoNormal"" align=""left"">
	<span></span> 
</p>
<div style=""text-align:justify;"">
	<span style=""font-size:14px;font-family:'Times New Roman';""></span> 
</div>",,"/uploadfiles/file/20131121/20131121164931_6047.pdf",,11/21/2013,11/21/2013,"medicool",21,,,0,"85",77,"Sexual Dysfunctions in Patients with Neurodermatitis and Psoriasis","2008",
576,,,"Rémi Marty1*, Stéphane Roze1, Xavier Bresse2, Nathalie Largeron2 and Jayne Smith-Palmer3","Marty et al. BMC Cancer","<p align=""justify"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Background: HPV is related to a number of cancer types, causing a considerable burden in both genders in </span><span style=""font-family:Times New Roman;font-size:16px;"">Europe. Female vaccination programs can substantially reduce the incidence of HPV-related diseases in women </span><span style=""font-family:Times New Roman;font-size:16px;"">and, to some extent, men through herd immunity. The objective was to estimate the incremental benefit of </span><span style=""font-family:Times New Roman;font-size:16px;"">vaccinating boys and girls using the quadrivalent HPV vaccine in Europe versus girls-only vaccination. Incremental </span><span style=""font-family:Times New Roman;font-size:16px;"">benefits in terms of reduction in the incidence of HPV 6, 11, 16 and 18-related diseases (including cervical, vaginal, </span><span style=""font-family:Times New Roman;font-size:16px;"">vulvar, anal, penile, and head and neck carcinomas and genital warts) were assessed.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Methods: The analysis was performed using a model constructed in MicrosoftWExcel, based on a </span><span style=""font-family:Times New Roman;font-size:16px;"">previously-published dynamic transmission model of HPV vaccination and published European epidemiological data </span><span style=""font-family:Times New Roman;font-size:16px;"">on incidence of HPV-related diseases. The incremental benefits of vaccinating 12-year old girls and boys versus </span><span style=""font-family:Times New Roman;font-size:16px;"">girls-only vaccination was assessed (70% vaccine coverage were assumed for both). Sensitivity analyses around </span><span style=""font-family:Times New Roman;font-size:16px;"">vaccine coverage and duration of protection were performed.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Results: Compared with screening alone, girls-only vaccination led to 84% reduction in HPV 16/18-related </span><span style=""font-family:Times New Roman;font-size:16px;"">carcinomas in females and a 61% reduction in males. Vaccination of girls and boys led to a 90% reduction in HPV </span><span style=""font-family:Times New Roman;font-size:16px;"">16/18-related carcinomas in females and 86% reduction in males versus screening alone. Relative to a girls-only </span><span style=""font-family:Times New Roman;font-size:16px;"">program, vaccination of girls and boys led to a reduction in female and male HPV-related carcinomas of 40% and </span><span style=""font-family:Times New Roman;font-size:16px;"">65%, respectively and a reduction in the incidence of HPV 6/11-related genital warts of 58% for females and 71% </span><span style=""font-family:Times New Roman;font-size:16px;"">for males versus girls-only vaccination.</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""> Conclusions: In Europe, the vaccination of 12-year old boys and girls against HPV 6, 11, 16 and 18 would be </span><span style=""font-family:Times New Roman;font-size:16px;"">associated with substantial additional clinical benefits in terms of reduced incidence of HPV-related genital warts </span><span style=""font-family:Times New Roman;font-size:16px;"">and carcinomas versus girls-only vaccination. The incremental benefits of adding boys vaccination are highly </span><span style=""font-family:Times New Roman;font-size:16px;"">dependent on coverage in girls. Therefore, further analyses should be performed taking into account the </span><span style=""font-family:Times New Roman;font-size:16px;"">country-specific situation. In addition to clinical benefits, substantial economic benefits are also anticipated and </span><span style=""font-family:Times New Roman;font-size:16px;"">warrant further investigation as do the social and ethical implications of including boys in vaccination programs</span>
</p>",,"/uploadfiles/file/20131206/20131206104202_2566.pdf",,12/06/2013,12/06/2013,"medicool",18,,"Human papillomavirus, Vaccination, HPV-related cancer, Genital warts, HPV-related disease, Cervical cancer",0,"67",107,"Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe","2013",
584,,"10.4103/0378-6323.62965","Vamseedhar Annam, B. R. Yelikar , Arun C. Inamadar",,"<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Background: Itchy folliculitis are pruritic, folliculo-papular lesions seen in human&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">immunodeficiency virus (HIV)-infected patients. Previous studies have shown that it was&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">impossible to clinically differentiate between eosinophilic folliculitis (EF) and infective folliculitis&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(IF). Also, attempts to suppress the intense itch of EF were ineffective. <br />
Aims: The present&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">study is aimed at correlating clinical, histopathological and immunological features of itchy&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">folliculitis in HIV patients along with their treatment.<br />
Methods: The present prospective&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">study lasted for 36 months (September, 2005 to August, 2008) after informed consent,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">data on skin disorders, HIV status and CD4 count were obtained by physical examination,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">histopathological examination and laboratory methods. <br />
Results: Of 51 HIV-positive patients&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with itchy folliculitis, the predominant lesion was EF in 23 (45.1%) followed by bacterial&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">folliculitis in 21 (41.2%), Pityrosporum folliculitis in five (9.8%) and Demodex folliculitis in two&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(3.9%) patients. The diagnosis was based on characteristic histopathological features and was&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">also associated with microbiology confirmation wherever required. EF was associated with a&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">lower mean CD4 count (180.58 ± 48.07 cells/mm3</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">, P-value &lt; 0.05), higher mean CD8 count&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">(1675.42 ± 407.62 cells/mm3) and CD8/CD4 ratio of 9.27:1. There was significant reduction&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">in lesions following specific treatment for the specific lesion identified.<br />
Conclusion: Clinically,&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">it is impossible to differentiate itchy folliculitis and therefore it requires histopathological&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">confirmation. Appropriate antimicrobial treatment for IF can be rapidly beneficial. The highly&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">active antiretroviral therapy along with Isotretinoin therapy has shown marked reduction in&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">the lesions of EF. Familiarity with these lesions may help in improving the quality of lives of&nbsp;</span> 
</div>
<span style=""font-family:'Times New Roman';font-size:14px;""> 
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">the patients.</span> 
</div>
</span>",,"/uploadfiles/file/20131206/20131206170115_4114.pdf",,12/06/2013,12/06/2013,"medicool",14,,"Itchy folliculitis| histopathology| Infective folliculitis| HIV",0,"66",105,"Clinicopathological study of itchy folliculitis in HIV- infected patients","2009",
466,"神经性皮炎皮损处神经纤维的数量 及其与朗格汉斯细胞关系的研究","10.3760/j.issn:0412-4030.2007.09.008","崔绍山  陆洪光  王雅坤  郭哲   金光玉   陈洪铎","中华皮肤科杂志","<p>
	<span style=""font-size:14px;font-family:SimSun;"">摘要</span>
</p>
<p>
	<br />
</p>
<div>
	<span style=""font-size:14px;font-family:SimSun;"">&nbsp; &nbsp;</span>
</div>
<div>
	<span style=""font-size:14px;font-family:SimSun;"">&nbsp; &nbsp;目的探讨神经性皮炎患者皮损处神经纤维的数量变化及其与朗格汉斯细胞接触的关系。方法用辣根过氧化物酶结合的链霉亲和素一生物素技术观察24例神经性皮炎患者皮损处神经纤维的表达及数量变化。用免疫荧光双标记及共聚焦激光扫描显微镜技术观察神经f生皮炎患者皮损处神经纤维与朗格汉斯细胞接触数量关系。用实时定量PCR方法检测皮损处神经生长因子mRNA的表达情况。结果神经性皮炎患者皮损处神经纤维长度显著增加，与皮损周边对照(t=6．90。P&lt;0．001)及正常人对照(t=5．71，P&lt;0．001)比较差异有统计学意义。皮损表皮内有神经纤维接触的朗格汉斯细胞占朗格汉斯细胞总数的百分数明显增多，与皮损周边对照( =43．91，P&lt;0．001)及正常人对照( =46．11，P&lt;0．001)比较差异有统计学意义。皮损处神经生长因子mRNA高表达，与皮损周边对照(t=3．25，P&lt;0．01)及正常人对照(f=3．67，P&lt;0．01)比较差异有统计学意义。结论神经性皮炎患者皮损处存在高水平活性的NGF导致神经纤维增生。</span>
</div>
<p>
	<br />
</p>",,"/uploadfiles/file/20131121/20131121170754_6982.pdf",,11/21/2013,11/21/2013,"medicool",29,,,0,"65",77,,"2007",
467,"中西医结合治疗神经性皮炎69例","10.3969/j.issn.1671-8194.2011.06.235","赵海峰   裴贤淑","中国医药指南","<div style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">摘要</span>
</div>
<div>
</div>
<div style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">&nbsp; </span><br />
<span style=""font-family:SimSun;font-size:14px;""></span><br />
<span style=""font-family:SimSun;font-size:14px;""> &nbsp;</span><span style=""font-family:SimSun;font-size:14px;"">目的 探讨神经性皮炎的中西医治疗疗效.方法 随机将齐齐哈尔市碾子山区疾病预防控制中心门诊2008年1月至2009年11月收治的135例神经性皮炎患者分为观察组69例、对照组66例,对照组进行西医对症治疗,观察组进行中西医结合治疗,对两组临床疗效进行分析比较.结果 观察组临床治愈率为75.36%,治疗总有效率为91.30%;对照组临床治愈率为59.09%,治疗总有效率为77.27%.观察组临床治愈率、总有效率与对照组相比有显著性差异(χ2=4.07,P&lt;0.05;χ2=5.10,P&lt;0.05).治疗前后监测两组血常规、肝肾功未见明显异常.所有患者均随访8～12个月,两组复发率比较有显著性差异(χ2=4.53,P&lt;0.05).结论 中西医结合治疗神经性皮炎临床疗效显著,远期复发率低,值得临床进一步应用.</span>
</div>",,"/uploadfiles/file/20131121/20131121171101_7113.pdf",,11/21/2013,11/21/2013,"medicool",23,,,0,"85",77,,"2011",
468,"慢性外阴瘙痒的病变","62 (2), pp. 97-9.","Colden Cahill S","The Journal Of Family Practice","<p class=""MsoNormal"" align=""left"">
	<span style=""font-family:'Times New Roman';font-size:14px;"">&nbsp; DURING A ROUTINE EXAM, a 45-year-old Caucasian woman complained of intense
itching on her labia. She said that the itching had heen an issue for more than
9 months and that she found herself scratching several times a day. She denied
any vaginal discharge and said she hadn't heen sexually active in years. She
had tried over-the-counter antifungals and topical Benadryl, but they provided
only limited relief. The patient had red thickened plaques with accentuated
skin lines (furrows) covering hoth ofher labia majora (FIGURE). Throughout the
lesion, there were scattered areas of excoriation. Her labia minor were spared.
A speculum and bimanual exam.</span><o:p></o:p>
</p>
<br />",,"/uploadfiles/file/20131121/20131121172025_2779.pdf",,11/21/2013,11/21/2013,"medicool",40,,,0,"85",77,"Chronic pruritic vulva lesion","2013",
578,"毛囊单位移植后受区毛囊炎：临床特点的描述及相关因素的分析","10.1111/j.1524-4725.2010.01601.x","M.J. KRISTINE S. BUNAGAN, MD, DAMKERNG PATHOMVANICH","Wiley Periodicals","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">BACKGROUND Postoperative recipient-area folliculitis may be a cause of
less or delayed growth of transplanted hair and an obvious cause of distress to
the patient. No study has been done to elaborate on its clinical features and
assess possible factors that may correlate with its occurrence.</span>
</div>
<p class=""MsoNormal"" style=""text-align:justify;"">
	<span style=""font-family:SimSun;font-size:14px;"">背景</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<div style=""text-align:justify;"">
		<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">&nbsp; &nbsp;术后受区毛囊炎可能会导致移植头发较少或头发生长迟缓并明显给患者带来痛苦。目前，尚未有研究详细说明其临床特点并评估与其病发相关的可能因素。</span>
	</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
	<div style=""text-align:justify;"">
		<span style=""line-height:1.5;"">OBJECTIVE
To study the clinical features and possible factors that may be associated with
the development </span><span style=""font-family:'sans serif', tahoma, verdana, helvetica;font-size:12px;line-height:1.5;""><span style=""font-family:'Times New Roman';font-size:14px;"">of recipient-area folliculitis after
follicular-unit transplantation (FUT).</span></span>
	</div>
</span><span style=""line-height:1.5;"">
	<p class=""MsoNormal"" style=""text-align:justify;"">
		<span style=""font-family:SimSun;font-size:14px;"">目的</span><o:p></o:p>
	</p>
	<p class=""MsoNormal"">
		<div style=""text-align:justify;"">
			<span style=""font-family:SimSun;font-size:14px;line-height:1.5;"">&nbsp; &nbsp;旨在研究毛囊单位移植（<span style=""font-family:Times New Roman;"">FUT</span>）后受区毛囊炎形成相关的临床特征和可能因素。</span>
		</div>
		<p class=""MsoNormal"">
			<div style=""text-align:justify;"">
				<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">METHODS
Retrospective analysis of 27 patients who developed folliculitis after FUT and 28
patients without such complication.</span>
			</div>
			<p class=""MsoNormal"" style=""text-align:justify;"">
				<span style=""font-family:SimSun;font-size:14px;"">方法</span><o:p></o:p>
			</p>
			<p class=""MsoNormal"" style=""text-align:justify;"">
				<span style=""font-family:SimSun;font-size:14px;"">&nbsp; &nbsp;对毛囊单位移植后引发毛囊炎的27位患者和无此类并发症的28位患者进行了回顾性分析。</span><o:p></o:p>
			</p>
			<p class=""MsoNormal"" style=""text-align:justify;"">
				<span style=""font-family:'Times New Roman';font-size:14px;"">RESULTS
Lesion onset ranged from 2 days to 6 months after FUT (mean 1.44 months).
Lesions were mostly pustules that resolved without sequela. Statistical
analysis showed that, in terms of patient characteristics (e.g., hair features,
scalp condition) and the number of grafts transplanted, there was no statistically
significant difference in assessed parameters between those with and without
folliculitis (p＜.05).</span><o:p></o:p>
			</p>
			<p class=""MsoNormal"" style=""text-align:justify;"">
				<span style=""font-family:SimSun;font-size:14px;"">结果</span><o:p></o:p>
			</p>
			<p class=""MsoNormal"" style=""text-align:justify;"">
				<span style=""font-family:SimSun;font-size:14px;"">&nbsp; 毛囊单位移植后<span style=""font-family:Times New Roman;"">2</span>天到<span style=""font-family:Times New Roman;"">6</span>个月（平均为<span style=""font-family:Times New Roman;"">1.44</span>个月）开始出现皮损。皮损多为脓疱，恢复后无后遗症。统计分析表明，依据患者的特征（如头发特性、头皮状况）和移植的数量，在评估那些患有和未患毛囊炎患者之间的参数时，我们发现两者之间并无统计学显著差异（<span style=""font-family:Times New Roman;"">p＜.05</span>）。</span><o:p></o:p>
			</p>
			<p class=""MsoNormal"" style=""text-align:justify;"">
				<span style=""font-family:'Times New Roman';font-size:14px;"">CONCLUSION
Main clinical features of postoperative folliculitis consist mostly of few to
moderate self-limited pustules. In this study, </span><span style=""font-family:'Times New Roman';font-size:14px;"">regardless
of management, lesions healed without scarring and without affecting graft
growth. Neither patient characteristics nor number of grafts transplanted was
associated with this complication.</span><o:p></o:p>
			</p>
			<p class=""MsoNormal"" style=""text-align:justify;"">
				<span style=""font-family:SimSun;font-size:14px;"">结论</span><o:p></o:p>
			</p>
			<p class=""MsoNormal"" style=""text-align:justify;"">
				<span style=""font-family:SimSun;font-size:14px;"">&nbsp; &nbsp;术后毛囊炎的主要临床特征大多是由轻微至中度的自限性脓包组成。在这项研究中，与管理无关，皮损愈合后无瘢痕形成且不影响移植生长。病人的特征和移植的数量都与此类并发症无关。</span><o:p></o:p>
			</p>
<o:p></o:p>
		</p>
<o:p></o:p>
	</p>
<span style=""font-family:SimSun;font-size:14px;"">
	<div style=""text-align:justify;"">
		<span style=""line-height:1.5;""></span>
	</div>
</span></span>
	<p class=""MsoNormal"">
		<o:p></o:p>
	</p>
<o:p></o:p>
</p>","/uploadfiles/image/20131206/20131206133045_1612w.jpg","/uploadfiles/file/20131206/20131206133104_7548.pdf",,12/06/2013,12/06/2013,"medicool",25,,"follicular-unit transplantation|recipient area folliculitis|characterization of clinical features |analysis",0,"65",105,"Recipient Area Folliculitis After Follicular-Unit Transplantation: Characterization of Clinical Features and Analysis of Associated Factors","2010",
469,"肛门-生殖器区域神经性皮炎",,"PETER J.LYNCH","Dermatologic Therapy","<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lichen simplex chronicus (LSC) of the anogenital area is an eczematous disease characterized </span><span style=""font-size:14px;"">by unremitting itching and scratching. In most instances, it arises in individuals who are </span><span style=""font-size:14px;"">genetically atopic, and as such, LSC can be viewed as a localized variant of atopic/neurodermatitis. </span><span style=""font-size:14px;"">Common triggers for the development of the disease include psychological distress, and local environmental </span><span style=""font-size:14px;"">problems such as heat, sweating, and excess dryness. Lichen simplex chronicus may also </span><span style=""font-size:14px;"">develop as a superimposed condition in the presence of other anogenital diseases such as candidiasis, </span><span style=""font-size:14px;"">psoriasis, lichen sclerosus, tinea cruris, and neoplasia. Lichen simplex chronicus frequently persists </span><span style=""font-size:14px;"">as an itch-scratch cycle, even when environmental triggers are removed and the underlying disease is </span><span style=""font-size:14px;"">treated. For this reason, successful therapy requires attention not only to trigger factors, but also to </span><span style=""font-size:14px;"">repair of the damaged barrier layer, reduction in inflammation, and breakup of the itch-scratch cycle.</span> 
</p>",,"/uploadfiles/file/20131122/20131122111402_0343.pdf",,11/22/2013,11/22/2013,"medicool",15,,"atopic dermatitis, itch-scratch cycle, lichen simplex chronicus, neurodermatitis.",0,"67",77,"Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region","2004",
470,"一般神经性皮炎饿敏感综合症表现",,"In Young Oh, Eun Jung Ko, and Kapsok Li","Department of Dermatology","<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Autoerythrocyte sensitization syndrome (AES) was first described by Gardner and Diamond in 1955, when four women with painful </span><span style=""font-size:14px;"">bruising were depicted. Patients with AES typically present with the development of recurrent, spontaneous, painful ecchymosis, </span><span style=""font-size:14px;"">frequently preceded by a prodrome of pain or itching of the skin. The patients are sensitive to their own red blood cells injected </span><span style=""font-size:14px;"">intradermally, and underlying coagulopathies are thought to be absent. We introduce a 70-year-old woman presenting with recurrent </span><span style=""font-size:14px;"">episodes of painful bruising on the trunk and extremities.</span>
</p>",,"/uploadfiles/file/20131122/20131122111852_7252.pdf",,11/22/2013,11/22/2013,"medicool",32,,"Autoerythrocyte sensitization; Painful ecchymosis; Psychogenic purpura",0,"85",77,"Autoerythrocyte sensitization syndrome presenting with general neurodermatitis","2013",
510,"给药间隔和联合疗法对光线性角化病管理的影响：综述及临床考虑","10.3109/09546631003797072","GEORGE M. MARTIN","Journal of Dermatological Treatment","<span style=""font-family:'Times New Roman','serif';color:#231f20;""><strong>Abstract</strong></span> 
<p class=""MsoNormal"">
	<span style=""font-family:宋体;color:#231f20;""><strong>摘要</strong></span><span style=""font-family:'Times New Roman','serif';color:#231f20;""></span>
</p>
<p class=""MsoNormal"">
	<a name=""OLE_LINK4""></a><a name=""OLE_LINK3""></a><span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">An increasing body of evidence, including epidemiological data, clinical and histopathologic observations, and molecular biological </span></span></a><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">fi</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">ndings, has highlighted the underlying malignant nature of actinic keratosis (AK).</span></span></span><span style=""font-family:'Times New Roman','serif';color:#231f20;""> <a name=""OLE_LINK5""></a><span>Scienti</span></a></span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">fi</span></span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;""><span>c evidence accumulated over the past decade supports the concept that </span><a name=""OLE_LINK7""></a><a name=""OLE_LINK6""></a><span>AK should no longer be considered premalignant</span></a> <a name=""OLE_LINK9""></a><a name=""OLE_LINK8""></a><span>but instead is now thought to be the earliest stage of a biologic continuum ending in squamous cell carcinoma</span></a><span>. </span></span></span><a name=""OLE_LINK11""></a><a name=""OLE_LINK10""></a><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">This paradigm shift, coupled with a worldwide increase in the incidence of AK, has changed how dermatologists treat AK.</span></span></span><span style=""font-family:'Times New Roman','serif';color:#231f20;""> <a name=""OLE_LINK13""></a><a name=""OLE_LINK12""></a><span>These changes include </span></a><a name=""OLE_LINK21""></a><a name=""OLE_LINK20""></a><span><span><span>the development of novel topical</span></span></span></a><span><span> and procedural therapies;</span></span> <a name=""OLE_LINK15""></a><a name=""OLE_LINK14""></a><span>modi</span></a></span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">fi</span></span></span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;""><span>cation of established topical monotherapy regimens to include interval, sequential, short-course, and </span><a name=""OLE_LINK29""></a><a name=""OLE_LINK28""></a><span>short-contact therapies</span></a></span></span></span><span style=""font-family:'Times New Roman','serif';color:#231f20;""><span>; </span><a name=""OLE_LINK17""></a><a name=""OLE_LINK16""></a><a name=""OLE_LINK22""></a><span><span>combining various topical therapies</span></span></a><span><span>; and combining topical and procedural therapies.</span></span> <a name=""OLE_LINK19""></a><a name=""OLE_LINK18""></a><a name=""OLE_LINK24""></a><a name=""OLE_LINK23""></a><span><span><span>This review will examine the mechanisms of action</span></span></span></a><span><span><span> and </span><a name=""OLE_LINK25""></a><span>the safety and ef</span></a></span></span></span><span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">fi</span></span></span></span><span><span><span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">cacy data for emerging interval and combination therapies used to treat AK.</span></span></span></span>
</p>
<span></span><span></span><span></span> 
<p class=""MsoNormal"">
	<span style=""font-family:宋体;color:#231f20;"">&nbsp;&nbsp;&nbsp; 越来越多的证据包括流行病学数据、临床和组织病理学观察以及分子生物学的研究结果，强调了光线性角化病（</span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">AK</span><span style=""font-family:宋体;color:#231f20;"">）潜在的恶性本质。过去十年累积的科学证据支持这一观点，即</span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">AK</span><span style=""font-family:宋体;color:#231f20;"">不再被视为是一种癌前病变，恰恰相反，而应被认为是鳞状细胞癌中的一个生物连续体结束的最初阶段。这种模式的转变，加上</span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">AK</span><span style=""font-family:宋体;color:#231f20;"">全球发病率的增加，改变了皮肤科医生治疗</span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">AK</span><span style=""font-family:宋体;color:#231f20;"">的方式。这些改变包括新型外用药物及程序化疗法的开发，修改已制定的局部单药治疗方案，包括给药间隔、持续时间、短期疗程以及短时接触疗法，与各种外用药物治疗相结合，以及外用药物和程序化疗法相结合。本文将研究其作用机制以及探讨应用新型给药间隔和联合疗法治疗</span><span style=""font-family:'Times New Roman','serif';color:#231f20;"">AK</span><span style=""font-family:宋体;color:#231f20;"">数据的有效性和安全性。</span><span style=""font-family:'Times New Roman','serif';color:#231f20;""></span>
</p>
<p>
	&nbsp;
</p>","/uploadfiles/image/20131204/20131204105508_4609w.png","/uploadfiles/file/20131204/20131204105526_5569.pdf",,12/04/2013,12/04/2013,"medicool",19,,"actinic keratosis; combination therapy; cryotherapy, diclofenac, 5-fluorouracil, imiquimod, interval therapy; photodynamic therapy, squamous cell carcinoma",0,"67",104,"Impact of interval and combination therapies on the management of actinic keratosis: Review and clinical considerations","2011",
471,,"10.1111/j.1524-4725.2008.34129.x","ALBERTO GOLDMAN, MD, FLA?VIA ROSSATO, MD, AND CLARISSA PRATI","the American Society for Dermatologic Surgery","<span style=""font-family:Times New Roman;"">BACKGROUND <br />
&nbsp;Striae are frequent skin lesions that cause considerable aesthetic concern. The 1,064-nm </span><span style=""font-family:Times New Roman;"">long-pulsed Nd:YAG laser has been used to promote an increase in dermal collagen and is known to be a </span><span style=""font-family:Times New Roman;"">laser that has a high affinity for vascular chromophores.<br />
</span><br />
<span style=""font-family:Times New Roman;"">OBJECTIVE<br />
&nbsp; This study aims to verify the efficacy of the long-pulsed Nd:YAG laser in the treatment of </span><span style=""font-family:Times New Roman;"">immature striae.</span><br />
<span style=""font-family:Times New Roman;""><br />
MATERIALS AND METHODS<br />
&nbsp;&nbsp;Twenty patients who had immature striae, i.e., red striae, were treated </span><span style=""font-family:Times New Roman;"">using the 1,064-nm long-pulsed Nd:YAG laser. The analysis of treatment efficacy was performed by the </span><span style=""font-family:Times New Roman;"">comparison between the images taken before and after each treatment session as well as through a</span><br />
<span style=""font-family:Times New Roman;"">subjective assessment carried out by the patients themselves.<br />
</span><br />
<span style=""font-family:Times New Roman;"">RESULTS<br />
&nbsp; &nbsp;Results were considered satisfactory to both patients and doctors. A higher number of patients</span><span style=""font-family:Times New Roman;"">(55%) considered the results excellent when compared to the same assessment made by the </span><span style=""font-family:Times New Roman;"">doctor (40%).<br />
</span><br />
<span style=""font-family:Times New Roman;"">CONCLUSION <br />
&nbsp; The clinical improvement of immature striae can be obtained with the use of the 1,064-</span><span style=""font-family:Times New Roman;"">nm long-pulsed Nd:YAG laser. The low incidence of side effects makes this laser a good alternative in the </span><span style=""font-family:Times New Roman;"">treatment of these common skin lesions.</span>",,"/uploadfiles/file/20131122/20131122112543_5207.pdf",,11/22/2013,11/22/2013,"medicool",22,,,0,"66",102,"Stretch Marks: Treatment Using the 1,064-nm Nd:YAG Laser","2008",
472,"神经性皮炎","10.1007/s00347-005-1202-x","Schmack ・ F. E. Kru se ・ A. Bau er ・ H. E. V?l cker ・ S. Dith mar","Ophthalmologe","<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ein 34-j?h ri ger Pa ti ent wur de auf grund </span><span style=""font-size:14px;"">eines thera piere frak t? ren Horn hau tul kus </span><span style=""font-size:14px;"">des lin ken Au ges mit zu neh mend bren nenden </span><span style=""font-size:14px;"">Schmerzen, Pho to phobie und Epi phora </span><span style=""font-size:14px;"">in un se re Am bu lanz über wiesen. Die </span><span style=""font-size:14px;"">bisheri ge 14-t?gige Lo kal thera pie mit steroidhal </span><span style=""font-size:14px;"">tigen und an tibio tischen Au gen tropfen </span><span style=""font-size:14px;"">hat te zu keiner signifi kan ten Be fundver </span><span style=""font-size:14px;"">besse rung ge führt. </span><span style=""font-size:14px;"">In der Anamnese des Pa ti en ten fanden </span><span style=""font-size:14px;"">sich seit frühester Kind heit re zidi vierend </span><span style=""font-size:14px;"">auf tretende aller gi sche Blepha ro kon junkti</span><span style=""font-size:14px;"">vitiden. Fer ner litt er un ter ato pi scher </span><span style=""font-size:14px;"">Der ma ti tis (Syno nym: Neuro der mi tis atopi</span><span style=""font-size:14px;"">ca) so wie ex trin si schem Asth ma bronchiale.</span><span style=""font-size:14px;"">Der der ma to logische und pulmona</span><span style=""font-size:14px;"">le Be fund spra chen bis her im mer gut</span><span style=""font-size:14px;"">auf Kor ti kosteroide an.</span>
</p>",,"/uploadfiles/file/20131122/20131122112537_9203.pdf",,11/22/2013,11/22/2013,"medicool",40,,,0,"67",77,"Neurodermitis","2006",
489,,"10.1111/j.1600-0536.2012.02076.x","Audrey Nosbaum1,2,3, Catherine Dupin, Jean-Franc ?ois Nicolas and Fr ? ed? eric B? erard","Department of Allergy and Clinical Immunology","<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">&nbsp;&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">&nbsp; Allergic hypersensitivity reactions induced by hair dyes&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">mainly occur in the formof allergic contact dermatitis (1).&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">We describe a case inwhich both delayed hypersensitivity&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">(DHS) and immediate hypersensitivity (IHS) to hair dyes&nbsp;</span><span style=""font-size:14px;font-family:'Times New Roman';"">are associated.</span> 
</div>",,"/uploadfiles/file/20131128/20131128100700_5833.pdf",,11/28/2013,11/28/2013,"medicool",9,,"allergic contact dermatitis| allergic hypersensitivity| hair dyes| severe immediate hypersensitivity",0,"85",103,"Severe immediate hypersensitivity and allergic contact dermatitis caused by hair dyes","2012",
501,,"10.1111/j.1398-9995.2012.02863.x","J. P. Thyssen , J. D. Johansen , A. Linneberg, T. Menne  & K. Engkilde","european journal of allergy and clinical immunology","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';font-size:14px;line-height:1.5;"">Background:<br />
&nbsp; &nbsp;&nbsp;Experimental studies have shown that individuals with atopic der</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">matitis are likely to have suppressed contact sensitivity secondary to their disease&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">whereas some clinical and epidemiological studies have shown that individuals&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">with atopic dermatitis might have a higher prevalence of contact sensitization&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">than controls. The objective was to study the association between contact&nbsp;</span><span style=""line-height:1.5;font-family:'Times New Roman';font-size:14px;"">sensitization and, respectively, atopic dermatitis and asthma using clinical</span>
</div>
<span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">databases.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Methods:<br />
&nbsp; &nbsp;&nbsp;Record linkage of two different registers was performed: (i) a tertiary&nbsp;</span><span style=""line-height:1.5;"">hospital register of dermatitis patient’s patch tested for contact sensitivity and (ii)&nbsp;</span><span style=""line-height:1.5;"">the Danish National Patient Register containing nationwide hospital discharge&nbsp;</span><span style=""line-height:1.5;"">diagnoses and outpatient contacts.&nbsp;<br />
</span><span style=""line-height:1.5;"">Results:<br />
&nbsp; &nbsp; An inverse association was found between contact sensitization and,&nbsp;</span><span style=""line-height:1.5;"">respectively, presumed severe atopic dermatitis (OR, 0.70; 95% CI, 0.61C0.81)&nbsp;</span><span style=""line-height:1.5;"">and asthma (OR, 0.61; 95% CI, 0.42C0.90) when linkage was performed. Inverse&nbsp;</span><span style=""line-height:1.5;"">associations were found for all groups of chemicals and metals except for sensiti</span><span style=""line-height:1.5;"">zation to fragrances and topical drugs where positive associations were identi?ed.&nbsp;</span><span style=""line-height:1.5;"">A signi?cant positive association between fragrance sensitization and presumed&nbsp;</span><span style=""line-height:1.5;"">mildCmoderate atopic dermatitis was also found when data from hospital register&nbsp;</span><span style=""line-height:1.5;"">only were used, suggesting an overall higher prevalence of fragrance sensitization&nbsp;</span><span style=""line-height:1.5;"">in patients with atopic dermatitis.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;"">Conclusions: <br />
&nbsp; &nbsp;Our ?ndings support that patients with severe atopic dermatitis and&nbsp;</span><span style=""line-height:1.5;"">asthma have an overall lower prevalence of contact sensitization when compared&nbsp;</span><span style=""line-height:1.5;"">with controls, whereas mild-to-moderate disease does not suppress contact sensiti</span><span style=""line-height:1.5;"">zation. The prevalence of contact sensitization to fragrance chemicals was higher&nbsp;</span><span style=""line-height:1.5;"">in patients with atopic dermatitis. Patients should be instructed to avoid scented&nbsp;</span><span style=""line-height:1.5;"">moisturizers and products containing highly sensitizing substances.</span>
</div>
</span><span style=""font-family:'Times New Roman';font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""line-height:1.5;""></span>
</div>
</span>",,"/uploadfiles/file/20131129/20131129103603_9985.pdf",,11/29/2013,11/29/2013,"medicool",15,,"Atopic dermatitis| asthma| sensitizers|epidemiology| patch testing.",0,"66",103,"The association between contact sensitization and atopic disease by linkage of a clinical database and a nationwide patient registry","2012",
473,,"10.1111/j.1524-4725.2009.01094.x","MOHAMED L. ELSAIE MD, LESLIE S. BAUMANN MD,","American Society for Dermatologic Surgery","<span style=""font-family:Times New Roman;"">BACKGROUND<br />
&nbsp;&nbsp; &nbsp;Striae distensea (SD; stretch marks) are a well-recognized, common skin condition that </span><span style=""font-family:Times New Roman;"">rarely causes any significant medical problems but are often a significant source of distress to those </span><span style=""font-family:Times New Roman;"">affected. The origins of SD are poorly understood, and a number of treatment modalities are available </span><span style=""font-family:Times New Roman;"">for their treatment, yet none of them is consistently effective, and no single therapy is considered to </span><span style=""font-family:Times New Roman;"">be pivotal for this problem. With a high incidence and unsatisfactory treatments, stretch marks remain </span><span style=""font-family:Times New Roman;"">an important target of research for an optimum consensus of treatment.<br />
</span><br />
<span style=""font-family:Times New Roman;"">OBJECTIVE&nbsp;<br />
&nbsp;&nbsp;&nbsp; To identify the current treatment modalities and their effectiveness in the treatment of </span><span style=""font-family:Times New Roman;"">stretch marks.<br />
</span><br />
<span style=""font-family:Times New Roman;"">MATERIALS AND METHODS<br />
&nbsp;&nbsp;&nbsp; &nbsp;Review of the recent literature regarding clinical treatment of stretch marks </span><span style=""font-family:Times New Roman;"">with emphasis on the safety and efficacy of the newer optical devices and laser applications.<br />
</span><br />
<span style=""font-family:Times New Roman;"">RESULTS <br />
&nbsp;&nbsp; &nbsp;No current therapeutic option offers complete treatment, although there are a number of </span><span style=""font-family:Times New Roman;"">emerging new modalities that are encouraging.<br />
</span><br />
<span style=""font-family:Times New Roman;"">CONCLUSION <br />
&nbsp; &nbsp;The therapeutic strategies are numerous, and no single modality has been far more </span><span style=""font-family:Times New Roman;"">consistent than the rest. The long-term future of treatment strategies is encouraging with the advance in </span><span style=""font-family:Times New Roman;"">laser technologies.</span> 
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131122/20131122113219_2310.pdf",,11/22/2013,11/22/2013,"medicool",21,,,0,"66",102,"Striae Distensae (Stretch Marks) and Different Modalities of Therapy: An Update","2009",
475,,,"S. Al-Himdani, S. Ud-Din, S. Gilmore",,"<span style=""font-family:Times New Roman;"">ABSTRACT</span><br />
<span style=""font-family:Times New Roman;"">&nbsp;&nbsp; Striae distensae are an extremely common, therapeutically challenging form of dermal scarring.</span><span style=""font-family:Times New Roman;"">Risk factors have been reported but much remains to be understood about their epidemiology, </span><span style=""font-family:Times New Roman;"">diagnosis and treatment. Up-to-date knowledge of the scientific research and the evidence behind </span><span style=""font-family:Times New Roman;"">both preventative and therapeutic agents is vital in order to understand striae and to offer patients </span><span style=""font-family:Times New Roman;"">the best therapeutic alternatives. We present a clinical review of the current literature concerning </span><span style=""font-family:Times New Roman;"">striae distensae and both their prevention and treatment. A systematic review of the literature </span><span style=""font-family:Times New Roman;"">was undertaken utilising MEDLINE, EMBASE and Google scholar. Articles in English, </span><span style=""font-family:Times New Roman;"">Spanish, Portuguese, Turkish and French were included.</span>",,"/uploadfiles/file/20131122/20131122114911_1892.pdf",,11/22/2013,11/22/2013,"medicool",25,,,0,"67",102,"Striae distensae: A comprehensive review and evidencebased evaluation of prophylaxis and treatment",,
478,,"10.1684/ejd.2011.1456.","Kanata M, Oka M, Nagai H, Kunisada M, Nishigori C.","Eur J Dermatol","<p>
	<span style=""font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;"">Striae distensae (SD) or stretch marks, are linear, smooth </span><span style=""font-family:Times New Roman;"">bands of atrophic-appearing skin occurring in areas subject </span><span style=""font-family:Times New Roman;"">to stretching and observed associated with pregnancy, </span><span style=""font-family:Times New Roman;"">obesity, growth during adolescence, increased adrenocortical </span><span style=""font-family:Times New Roman;"">function, and corticosteroid therapy [1]. The cause of </span><span style=""font-family:Times New Roman;"">these lesions is unknown, a combination of hormonal factors </span><span style=""font-family:Times New Roman;"">associated with lateral stretch is thought to be important .</span><span style=""font-family:Times New Roman;"">Rare variations of striae distensae have been described: </span><span style=""font-family:Times New Roman;"">edematous, ruptured and ulcerated, keloidal and urticariform </span><span style=""font-family:Times New Roman;"">SD . Only one case of urticariform SD has been </span><span style=""font-family:Times New Roman;"">reported ,without histological findings. We describe a </span><span style=""font-family:Times New Roman;"">second case and present histological findings.</span>
</p>",,"/uploadfiles/file/20131122/20131122132458_3017.pdf",,11/22/2013,11/22/2013,"medicool",23,,,0,"85",102,"Urticariform striae distensae with severe pruritus and pain in an obese woman","2011",
716,,,,"Korean J Intern Med","<span style=""font-size:16px;font-family:Times New Roman;"">Cold urticaria is a disorder in which patients experience pruritus and urticaria within a few minutes after exposure to cold [1]. Cholinergic urticaria, which is also known as generalized heat urticaria, develops after an increase in body temperature</span>",,"/uploadfiles/file/20131219/20131219095659_4422.pdf",,12/19/2013,12/19/2013,"medicool",3,,,0,"85",113,"A Case of Combined Cholinergic and Cold Urticaria","2012",
476,,"10.1002/14651858.CD000066.","Gavin Young, David Jewell","The Cochrane Collaboration","<span style=""font-family:Times New Roman;"">Background</span><br />
<span style=""font-family:Times New Roman;"">Striae gravidarum (stretch marks developing during pregnancy) occur in over 50% of women. There is no evidence that any treatment</span><br />
<span style=""font-family:Times New Roman;"">removes striae once they have appeared. Some women are upset about the change in the appearance of their skin.<br />
</span><br />
<span style=""font-family:Times New Roman;"">Objectives</span><br />
<span style=""font-family:Times New Roman;"">To assess the effects of topical treatments in preventing the development of stretch marks.<br />
</span><br />
<span style=""font-family:Times New Roman;"">Search methods</span><br />
<span style=""font-family:Times New Roman;"">We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (April 2004). We updated this search on 1 October 2009</span><br />
<span style=""font-family:Times New Roman;"">and added the results to the awaiting classification section.<br />
</span><br />
<span style=""font-family:Times New Roman;"">Selection criteria</span><br />
<span style=""font-family:Times New Roman;"">Randomised trials comparing active creams with either no treatment or placebo for the treatment of stretch marks in pregnant women.</span><br />
<span style=""font-family:Times New Roman;"">Data collection and analysis </span><span style=""font-family:Times New Roman;"">Two review authors assessed trial quality and extracted data independently.<br />
</span><br />
<span style=""font-family:Times New Roman;"">Main results</span><br />
<span style=""font-family:Times New Roman;"">Two studies, involving 130 women in total, were included.</span><span style=""font-family:Times New Roman;"">One study, involving 80 women, indicated that, compared to placebo, massage with a cream (Trofolastin) containing Centella asiatica </span><span style=""font-family:Times New Roman;"">extract, alpha tocopherol and collagen-elastin hydrolysates was associated with less women developing stretch marks (odds ratio (OR) </span><span style=""font-family:Times New Roman;"">0.41, 95% confidence interval (CI) 0.17 to 0.99). A second study of 50 women compared massage using an ointment (Verum) </span><span style=""font-family:Times New Roman;"">containing tocopherol, panthenol, hyaluronic acid, elastin and menthol with no treatment. Massage with the ointment was associated </span><span style=""font-family:Times New Roman;"">with less women developing stretch marks (OR 0.26, 95% CI 0.08 to 0.84)</span>",,"/uploadfiles/file/20131122/20131122115407_7145.pdf",,11/22/2013,11/22/2013,"medicool",22,,,0,"67",102,"Creams for preventing stretch marks in pregnancy","2010",
575,"特应性皮炎、身材矮小、骨骼畸形、高免疫球蛋白E综合征、嗜伊红细胞增多症和复发性感染：一例病例报告",,"Salvatore Leonardi*, Martina Filippelli, Valentina Costanzo, Novella Rotolo and Mario La Rosa","Leonardi et al. Journal of Medical Case Reports","<span><span><span><span style=""font-family:&quot;""><br />
<span style=""font-family:&quot;font-size:10.5pt;""><span style=""font-family:Times New Roman;font-size:16px;"">Introduction:</span><br />
<span style=""font-family:Times New Roman;font-size:16px;""></span></span><span style=""font-family:Times New Roman;font-size:16px;""></span><span style=""font-family:Times New Roman;font-size:16px;"">We report an interesting clinical case </span></span></span></span></span><span><span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:16px;"">which could represent a new syndrome never described </span><span style=""font-family:Times New Roman;font-size:16px;"">previously in the literature</span></span></span></span> 
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:Times New Roman;font-size:16px;"">介绍：</span><span style=""font-family:&quot;""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:Times New Roman;font-size:16px;"">我们报道了一个有趣的临床案例，它代表了一个在以前的文献中从未被描述过新的临床综合征。</span><span style=""font-family:&quot;""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Case presentation: </span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:16px;"">A 15-year-old Caucasian boy presented to our institution&nbsp;</span><span style=""font-family:Times New Roman;font-size:16px;"">with recurrent respiratory infections, severe atopic dermatitis, short stature </span><span style=""font-family:Times New Roman;font-size:16px;"">and skeletal malformations. Laboratory tests showed a high level of </span><span style=""font-family:Times New Roman;font-size:16px;"">immunoglobulin E, </span><span style=""font-family:Times New Roman;font-size:16px;"">hypereosinophilia</span><span style=""font-family:Times New Roman;font-size:16px;""> with a normal white </span><span style=""font-family:Times New Roman;font-size:16px;"">blood cell count and a low level of somatomedin C. The patient had had atopic </span><span style=""font-family:Times New Roman;font-size:16px;"">dermatitis resistant to treatment since the age of 6 months. </span><span><span><span><span style=""font-family:Times New Roman;font-size:16px;"">His height did not increase </span><span style=""font-family:Times New Roman;font-size:16px;"">despite receiving cyclic therapy with</span></span></span></span></span></span><span></span><span></span><span></span><span style=""font-family:Times New Roman;font-size:16px;""><span style=""font-family:Times New Roman;font-size:16px;""><span style=""font-family:Times New Roman;font-size:16px;""> recombinant growth hormone</span></span></span><span style=""font-family:Times New Roman;font-size:16px;""><span style=""font-family:Times New Roman;font-size:16px;""><span style=""font-family:Times New Roman;font-size:16px;"">.</span></span></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:Times New Roman;font-size:16px;"">病例报告：</span><span style=""font-family:&quot;""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:Times New Roman;font-size:16px;"">一个</span><span style=""font-family:Times New Roman;font-size:16px;"">15</span><span style=""font-family:Times New Roman;font-size:16px;"">岁的白人男孩呈现给我们机构的是复发性呼吸道感染、严重的特应性皮炎、身材矮小和骨骼畸形。实验室检查显示为高水平的免疫球蛋白</span><span style=""font-family:Times New Roman;font-size:16px;"">E</span><span style=""font-family:Times New Roman;font-size:16px;"">，以及</span><span style=""font-family:Times New Roman;font-size:16px;"" class=""apple-converted-space""><b><span style=""color:#003333;font-family:Times New Roman;font-size:16px;"">&nbsp;</span></b></span><span style=""font-family:Times New Roman;font-size:16px;"">伴有正常白细胞计数和低水平生长调节素</span><span style=""font-family:Times New Roman;font-size:16px;"">C</span><span style=""font-family:Times New Roman;font-size:16px;"">的嗜伊红细胞增多症。病人从六个月大的时候就开始接受抗特应性皮炎的治疗。尽管接受了重组生长激素的循环治疗，但他的身高并没有增加。</span><span style=""font-family:&quot;""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:Times New Roman;font-size:16px;"">Conclusion:</span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:16px;"">We hypothesized the </span><span style=""font-family:Times New Roman;font-size:16px;"">presence of several diseases not confirmed by any genetic tests. Our </span></span><span style=""font-family:&quot;""><span style=""font-family:Times New Roman;font-size:16px;"">patient could have </span><span style=""font-family:Times New Roman;font-size:16px;"">an unknown disease. Further research is needed to identify this possible new </span><span style=""font-family:Times New Roman;font-size:16px;"">syndrome.</span></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:Times New Roman;font-size:16px;"">结论</span><span style=""font-family:&quot;""></span> 
</p>
<p style=""text-align:left;"" class=""MsoNormal"" align=""left"">
	<span style=""font-family:Times New Roman;font-size:16px;"">我们假设存在着多种不能通过任何基因测试来确定的疾病。我们的病人可能还有其他未知的疾病。这还需要进一步的研究来鉴别这种可能存在的新型综合征。</span><span style=""font-family:&quot;""></span> 
</p>
<br />
<br />
<p>
	&nbsp;
</p>","/uploadfiles/image/20131206/20131206103229_9072w.png","/uploadfiles/file/20131206/20131206103038_1954.pdf",,12/06/2013,12/20/2013,"medicool",6,,"Atopic dermatitis, Hypereosinophilia, Hyperimmunoglobulin E, Short stature, Skeletal malformations",0,"85",46,"Atopic dermatitis, short stature, skeletal malformations, hyperimmunoglobulin E syndrome, hypereosinophilia  and recurrent infections: a case report","2013","/uploadfiles/kejian/20131220/1220155044_0624.pdf"
477,,"10.1001/archderm.148.3.385-c.","Jacquelyn Dosal, MD; Marc Z. Handler, MD; Carlos A. Ricotti, MD; Janelle Vega, MD; Antonella Tosti, MD; Francisco A. Kerdel, MD",,"<span style=""widows:2;text-transform:none;background-color:#ffffff;text-indent:0px;letter-spacing:normal;display:inline !important;font:13px/19px Times New Roman;white-space:normal;orphans:2;float:none;color:#333333;word-spacing:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">&nbsp;&nbsp;&nbsp; A 32-year-old cushingoid man presented with a 2-month history of progressively enlarging deep tender ulcerations on his arms, abdomen, back, proximal legs, and beneath his panus. His medical history was significant for World Health Organization stage IV glioblastoma multiforme (GBM) treated with a regimen of etoposide and bevacizumab, as well as dexamethasone, 4 mg, twice daily to decrease cerebral edema. On examination, we found 35 ulcerations that were all localized on striae distensae. The ulcers had rolled violaceous borders and clean bases</span><span style=""widows:2;text-transform:none;background-color:#ffffff;text-indent:0px;letter-spacing:normal;display:inline !important;font:13px/19px Times New Roman;white-space:normal;orphans:2;float:none;color:#333333;word-spacing:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">A complete blood cell count showed leukocytosis (white blood cell count, 14.3 &nbsp; × &nbsp;10</span><sup style=""border-bottom:0px;position:relative;border-left:0px;padding-bottom:0px;widows:2;text-transform:none;background-color:#ffffff;text-indent:0px;margin:0px;padding-left:0px;letter-spacing:normal;padding-right:0px;font:0.84em/0 Georgia, Cambria, Times, 'Times New Roman', serif;white-space:normal;orphans:2;color:#333333;vertical-align:baseline;border-top:0px;border-right:0px;word-spacing:0px;padding-top:0px;top:-0.5em;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span style=""font-family:Times New Roman;"">3</span></sup><span style=""widows:2;text-transform:none;background-color:#ffffff;text-indent:0px;letter-spacing:normal;display:inline !important;font:13px/19px Times New Roman;white-space:normal;orphans:2;float:none;color:#333333;word-spacing:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">/ μL), anemia (hemoglobin level, 11.4 g/dL), a positive antinuclear antibody titer (1:40), and a positive finding for anti-Sj ?gren syndrome A (anti-SSA) antibodies. (To convert white blood cells to number of cells &nbsp; × &nbsp;10</span><sup style=""border-bottom:0px;position:relative;border-left:0px;padding-bottom:0px;widows:2;text-transform:none;background-color:#ffffff;text-indent:0px;margin:0px;padding-left:0px;letter-spacing:normal;padding-right:0px;font:0.84em/0 Georgia, Cambria, Times, 'Times New Roman', serif;white-space:normal;orphans:2;color:#333333;vertical-align:baseline;border-top:0px;border-right:0px;word-spacing:0px;padding-top:0px;top:-0.5em;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;""><span style=""font-family:Times New Roman;"">9</span></sup><span style=""widows:2;text-transform:none;background-color:#ffffff;text-indent:0px;letter-spacing:normal;display:inline !important;font:13px/19px Times New Roman;white-space:normal;orphans:2;float:none;color:#333333;word-spacing:0px;-webkit-text-size-adjust:auto;-webkit-text-stroke-width:0px;"">/L, multiply by 0.001; to convert hemoglobin to grams per liter, multiply by 10.) A biopsy specimen was obtained and submitted for histopathologic evaluation .</span>",,"/uploadfiles/file/20131122/20131122132019_8256.pdf",,11/22/2013,11/22/2013,"medicool",24,,,0,"85",102,"Ulceration of Abdominal Striae Distensae (Stretch Marks) in a Cancer Patient ―Quiz Case","2012",
479,,"org/10.5021/ad.2011.23.S2.S141","Jin Seob Jeong, M.D., Ji Yeoun Lee, M.D., Mi Kyeong Kim, M.D., Tae Young Yoon, M.D.","Departments of Dermatology and Internal Medicine","<p>
	<span style=""font-family:Times New Roman;"">&nbsp;&nbsp;&nbsp; </span><span style=""font-family:Times New Roman;"">Linear focal elastosis (LFE) is a rare dermal elastosis </span><span style=""font-family:Times New Roman;"">characterized by hypertrophic yellowish linear plaques and </span><span style=""font-family:Times New Roman;"">increased abnormal elastic tissues in the lumbosacral area. </span><span style=""font-family:Times New Roman;"">Although the pathogenesis of this disorder remains </span><span style=""font-family:Times New Roman;"">unknown, it may be associated with keloidal repair process</span><br />
<span style=""font-family:Times New Roman;"">(KRP) of elastic tissues in striae distensae (SD), because there </span><span style=""font-family:Times New Roman;"">have been some reported cases of LFE accompanied by SD.<br />
</span><span style=""font-family:Times New Roman;"">&nbsp;&nbsp; We herein report a 14-year-old boy with LFE following SD in </span><span style=""font-family:Times New Roman;"">the lumbar region. Our case supports the hypothesis of KRP </span><span style=""font-family:Times New Roman;"">in the pathogenesis of LFE. Immunohistochemical study for </span><span style=""font-family:Times New Roman;"">transforming growth factor-beta (TGF-β) was negative. </span><span style=""font-family:Times New Roman;"">Therefore, we assume that the pathogenesis of KRP in LFE is </span><span style=""font-family:Times New Roman;"">different from that of keloid development, which is the TGF- </span><span style=""font-family:Times New Roman;"">β signaling pathway.</span>
</p>",,"/uploadfiles/file/20131122/20131122134140_1822.pdf",,11/22/2013,11/22/2013,"medicool",14,,,0,"65",102,"Linear Focal Elastosis Following Striae Distensae: Further Evidence of Keloidal Repair Process in the Pathogenesis of Linear Focal Elastosis","2011",
488,,,"Paolo Pigatto , Alberto Martelli  , Chiara Marsili , Alessandro Fiocchi","Italian Journal of Pediatrics","<div style=""text-align:justify;"">
	<span style=""font-family:'Times New Roman';line-height:1.5;font-size:14px;"">&nbsp; &nbsp; Contact dermatitis in pediatric population is a common but (previously) under recognized disease. It is usually</span>
</div>
<span style=""font-size:14px;"">
<div style=""text-align:justify;"">
	<span style=""font-family:Times New Roman;"">divided into the allergic and the irritant forms.&nbsp;The diagnosis is usually obtained with the patch test technique after conducting a thorough medical history and&nbsp;</span><span style=""font-family:Times New Roman;"">careful physical examination but patch testing in infants may be particularly difficult, and false-positive reactions&nbsp;</span><span style=""font-family:Times New Roman;"">may occur.</span><span style=""font-family:Times New Roman;"">&nbsp;This study also provides an overview of the most common allergens in pediatric population and discusses various&nbsp;</span><span style=""font-family:Times New Roman;"">therapeutic modali</span><span style=""font-family:'Times New Roman';""></span><span style=""font-family:Times New Roman;"">ties.</span>
</div>
</span>",,"/uploadfiles/file/20131128/20131128092758_6604.pdf",,11/28/2013,11/28/2013,"medicool",12,,"pediatric population|common allergens|therapeutic modalitie|allergic forms|the irritant forms",0,"85",103,"Contact dermatitis in children","2010",
480,"'银屑病神经性皮炎'和典型的慢性单纯性苔藓的临床和病理检查结果","10.1111/j.1468-3083.2006.02055.x","S Gunasti, SS Marakli, I Tuncer, N Ozpoyraz,§ VL Aksungur","European Academy of Dermatology and Venereology","<p align=""justify"">
	<strong><span style=""font-size:14px;"">Background</span></strong><br />
<span style=""font-size:14px;"">We have seen several patients with itchy lichenified plaques </span><span style=""font-size:14px;"">located bilaterally on the elbows and/or knees and have named this condition </span><span style=""font-size:14px;"">‘psoriatic neurodermatitis’ (PN). </span><br />
<strong><span style=""font-size:14px;""></span></strong><strong><span style=""font-size:14px;"">Objective </span></strong><br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;"">The purpose of this study was to compare clinical and histopathological</span><br />
<span style=""font-size:14px;"">characteristics of these patients to those of patients with typical lichen </span><span style=""font-size:14px;"">simplex chronicus (LSC).</span><br />
<strong><span style=""font-size:14px;"">Methods</span></strong><br />
<span style=""font-size:14px;"">Nineteen patients with PN and 34 patients with typical LSC were </span><span style=""font-size:14px;"">included. Besides clinical dermatological evaluation, the prick test was carried </span><span style=""font-size:14px;"">out on 49 patients; the Phadiatop test on 40 patients; the patch test with </span><span style=""font-size:14px;"">European standard series on 47 patients; histopathological evaluation on 39 </span><span style=""font-size:14px;"">patients; and clinical psychiatric examination on 38 patients.</span><br />
<strong><span style=""font-size:14px;"">Results </span></strong><br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;"">Almost exclusively, PN was seen in females and was located on the </span><span style=""font-size:14px;"">extremities. It caused more plaques than typical LSC did. In PN, the plaques </span><span style=""font-size:14px;"">were smaller, sharper, more keratotic and less excoriated, and had fewer </span><span style=""font-size:14px;"">lichenoid papules around them. Itching was usually more severe in the </span><span style=""font-size:14px;"">evening, while resting and in a hot environment in typical LSC, but not in PN.</span><br />
<span style=""font-size:14px;"">In plaques of PN, microabscesses in the horny layer, hypogranulosis, regular </span><span style=""font-size:14px;"">acanthosis and thinning of the suprapapillary plates were more frequent, and </span><span style=""font-size:14px;"">hyperpigmentation in the basal layer was less. In patients with PN, depressive </span><span style=""font-size:14px;"">disorder was found more frequently; and generalized anxiety disorder or </span><span style=""font-size:14px;"">psychosomatic characteristics, less. There were no significant differences in the </span><span style=""font-size:14px;"">results of prick, Phadiatop and patch tests between patients with PN and those </span><span style=""font-size:14px;"">with typical LSC.</span><br />
<strong><span style=""font-size:14px;"">Conclusion</span></strong><br />
<span style=""font-size:14px;"">In our opinion, it is most likely that the so-called PN is itchy </span><span style=""font-size:14px;"">psoriasis superimposed by LSC.</span> 
</p>",,"/uploadfiles/file/20131122/20131122134555_9759.pdf",,11/22/2013,11/22/2013,"medicool",30,,"epidermal hyperplasia, excoriation, itching,lichen simplex chronicus, psoriasis",0,"65",77,"Clinical and histopathological findings of ‘psoriatic neurodermatitis’ and of typical lichen simplex chronicus","2007",
481,,"10.1155/2012/673706","Mariella Bleve, Priscilla Capra, Franca Pavanetto, and Paola Perugini","Dermatology Research and Practice","<span style=""font-family:Times New Roman;""><span style=""font-size:14px;"">Background.</span><br />
&nbsp;&nbsp; Over time, the striae rubra develop into striae alba that appear white, flat, and depressed. It is very important to </span><span style=""font-family:Times New Roman;"">determine the optimum striae management. In order to evaluate the effectiveness of these therapies, objective measurement tools </span><span style=""font-family:Times New Roman;"">are necessary.<br />
<br />
<span style=""font-size:14px;"">Objective. </span><br />
&nbsp;&nbsp; The aim of this study is to evaluate if ultrasonography and PRIMOS can be used to obtain an objective </span><span style=""font-family:Times New Roman;"">assessment of stretch marks type and stage; furthermore, we aim to apply these techniques to evaluate the efficacy of a topical </span><span style=""font-family:Times New Roman;"">treatment. <br />
<span style=""font-size:14px;""><br />
Methods. </span><br />
&nbsp;&nbsp; 20 volunteers were enrolled with a two-month study. Amarketed cosmetic product was used as the active over </span><span style=""font-family:Times New Roman;"">one body area. The controlateral area with stretch marks was treated with a “placebo” formulation without active, as a control. </span><span style=""font-family:Times New Roman;"">The instrumental evaluation was carried out at the beginning of the trial (baseline values or t0), after 1 month (t1), and at the </span><span style=""font-family:Times New Roman;"">end of the study (t2). <br />
<br />
<span style=""font-size:14px;"">Results.</span><br />
&nbsp;&nbsp;&nbsp; PRIMOS was able to measure and document striae distensae maturation; furthermore, ultrasound </span><span style=""font-family:Times New Roman;"">imaging permitted to visualize and diagnose the striae. Statistical analysis of skin roughness demonstrated a statistically significant </span><span style=""font-family:Times New Roman;"">reduction of Rp value only in a treated group. In fact, the Rp value represented a maximum peak height in the area selected. These </span><span style=""font-family:Times New Roman;"">results demonstrated that after two months of treatment only the striae rubra can be treated successfully. <br />
<br />
<span style=""font-size:14px;"">Conclusions.</span><br />
&nbsp; &nbsp;This work </span><span style=""font-family:Times New Roman;"">demonstrated that the 22MHz ultrasound can diagnose stretch marks; PRIMOS device can detect andmeasure striae distensae type </span><span style=""font-family:Times New Roman;"">and maturation. Furthermore, the high-frequency ultrasound and the 3D image device, described in this work, can be successfully</span><br />
<span style=""font-family:Times New Roman;"">employed in order to evaluate the efficacy of a topical treatment.</span> 
<p>
	&nbsp;
</p>",,"/uploadfiles/file/20131122/20131122135040_6140.pdf",,11/22/2013,11/22/2013,"medicool",18,,,0,"65",102,"Ultrasound and 3D Skin Imaging:Methods to Evaluate Efficacy of Striae Distensae Treatment","2012",
482,,"10.1111/j.1468-3083.2006.02055.x","S Gunasti, SS Marakli, I Tuncer, N Ozpoyraz,§ VL Aksungur","European Academy of Dermatology and Venereology","<p align=""justify"">
	<span style=""font-size:14px;"">Background</span><br />
<span style=""font-size:14px;"">We have seen several patients with itchy lichenified plaques </span><span style=""font-size:14px;"">located bilaterally on the elbows and/or knees and have named this condition </span><span style=""font-size:14px;"">‘psoriatic neurodermatitis’ (PN).</span><br />
<span style=""font-size:14px;"">Objective </span><br />
<span style=""font-size:14px;""></span><span style=""font-size:14px;"">The purpose of this study was to compare clinical and histopathological </span><span style=""font-size:14px;"">characteristics of these patients to those of patients with typical lichen </span><span style=""font-size:14px;"">simplex chronicus (LSC).</span><br />
<span style=""font-size:14px;"">Methods</span><br />
<span style=""font-size:14px;"">Nineteen patients with PN and 34 patients with typical LSC were </span><span style=""font-size:14px;"">included. Besides clinical dermatological evaluation, the prick test was carried </span><span style=""font-size:14px;"">out on 49 patients; the Phadiatop test on 40 patients; the patch test with </span><span style=""font-size:14px;"">European standard series on 47 patients; histopathological evaluation on 39 </span><span style=""font-size:14px;"">patients; and clinical psychiatric examination on 38 patients.</span><br />
<span style=""font-size:14px;"">Results</span><br />
<span style=""font-size:14px;"">Almost exclusively, PN was seen in females and was located on the </span><span style=""font-size:14px;"">extremities. It caused more plaques than typical LSC did. In PN, the plaques </span><span style=""font-size:14px;"">were smaller, sharper, more keratotic and less excoriated, and had fewer </span><span style=""font-size:14px;"">lichenoid papules around them. Itching was usually more severe in the </span><span style=""font-size:14px;"">evening, while resting and in a hot environment in typical LSC, but not in PN. </span><span style=""font-size:14px;"">In plaques of PN, microabscesses in the horny layer, hypogranulosis, regular </span><span style=""font-size:14px;"">acanthosis and thinning of the suprapapillary plates were more frequent, and </span><span style=""font-size:14px;"">hyperpigmentation in the basal layer was less. In patients with PN, depressive </span><span style=""font-size:14px;"">disorder was found more frequently; and generalized anxiety disorder or </span><span style=""font-size:14px;"">psychosomatic characteristics, less. There were no significant differences in the </span><span style=""font-size:14px;"">results of prick, Phadiatop and patch tests between patients with PN and those </span><span style=""font-size:14px;"">with typical LSC.</span><br />
<span style=""font-size:14px;"">Conclusion</span><br />
<span style=""font-size:14px;"">In our opinion, it is most likely that the so-called PN is itchy</span><span style=""font-size:14px;"">psoriasis superimposed by LSC.</span>
</p>",,"/uploadfiles/file/20131122/20131122135545_1109.pdf",,11/22/2013,11/22/2013,"medicool",33,,"epidermal hyperplasia, excoriation, itching,lichen simplex chronicus, psoriasis",0,"66",77,"Clinical and histopathological findings of ‘psoriatic neurodermatitis’ and of typical lichen simplex chronicus","2007",
484,,,"AYLIN TU¨ REL ERMERTCAN,GULSUM GENCOGLAN, GOKHAN TEMELTAS","Journal of Andrology","<p align=""justify"">
	<span style=""font-size:14px;"">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neurodermatitis is a chronic disease affecting the </span><span style=""font-size:14px;"">patient’s psychosocial status and quality of life. It is associated with a </span><span style=""font-size:14px;"">variety of psychologic problems, including demoralization, depression, </span><span style=""font-size:14px;"">anxiety, obsessive-compulsive disorder, and sleep disturbances.</span><span style=""font-size:14px;"">Coexistence of sexual dysfunction, especially in women, with </span><span style=""font-size:14px;"">several systemic diseases has gained interest in recent years. In this </span><span style=""font-size:14px;"">study, we evaluated sexual function in female patients with </span><span style=""font-size:14px;"">neurodermatitis. We enrolled 89 women (43 patients, 46 controls)</span><span style=""font-size:14px;"">in the study. Quality of life was assessed with the Dermatology Life </span><span style=""font-size:14px;"">Quality Index (DLQI), and the Female Sexual Function Index (FSFI) </span><span style=""font-size:14px;"">was used to determine sexual function. Individuals with psychiatric </span><span style=""font-size:14px;"">disorders and/or those using antidepressants were excluded. The </span><span style=""font-size:14px;"">total DLQI score was 11.95 6 5.65 in patients with neurodermatitis.</span><span style=""font-size:14px;"">The total FSFI score was significantly lower in patients compared </span><span style=""font-size:14px;"">with healthy controls (22.76 6 5.31 and 28.83 6 3.50, respectively; P </span><span style=""font-size:14px;"">5 .001). Domain scores of FSFI (desire, arousal, lubrication,</span><span style=""font-size:14px;"">orgasm, and satisfaction) except pain were significantly lower in </span><span style=""font-size:14px;"">patients with neurodermatitis (P 5 .001). The pain score was also </span><span style=""font-size:14px;"">lower in patients than controls, but the difference was not statistically </span><span style=""font-size:14px;"">significant (P 5 .073). Neurodermatitis may be associated with </span><span style=""font-size:14px;"">sexual dysfunction, and patients with neurodermatitis should be </span><span style=""font-size:14px;"">evaluated with regard to sexual function to provide a better quality of </span><span style=""font-size:14px;"">life</span>
</p>",,"/uploadfiles/file/20131122/20131122140549_6432.pdf",,11/22/2013,11/22/2013,"medicool",30,,"Lichen simplex chronicus, sex, quality of life, Female
Sexual Function Index, FSFI.",0,"66",77,"Sexual Dysfunction in Female Patients With Neurodermatitis","2011",
572,"系统性治疗皮肤疣:系统综述","10.3109/09546634.2010.500324","THIERRY SIMONART & VIVIANE DE MAERTELAER","Journal of Dermatological Treatment.","<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">Background: </span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">Systemic therapies are routinely used for the
management of cutaneous warts. However, there is a lack of evidence-based data
on their effectiveness. </span><?xml:namespace prefix = o /><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">研究背景：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">系统性疗法常用来治疗皮肤疣。但是，它们的疗效缺乏以数据为基础的证据。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">Objective:</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">To assess
the evidence for the efficacy of systemic treatments for cutaneous
warts. </span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">研究目的：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">本文旨在评估系统性疗法治疗皮肤疣有效性的证据。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">Methods: </span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">We designed
a systematic review of the randomized controlled clinical trials (1962 to
April 2010) investigating systemic therapies for the treatment of cutaneous
warts. </span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">We obtained data from MEDLINE, PubMed, Current
Contents, reference lists, and specialist textbooks, with no restriction on
language. </span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">The main
outcome measures were the total clearance of warts and the
adverse effects. </span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">研究方法：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">我们设计了一项随机的、临床对照的、系统性回顾试验（从1962年至2010年4月），研究系统性疗法治疗皮肤疣的疗效。我们从MEDLINE、PubMed、 Current Contents、，参考文献目录和专业教科书中获得数据，且对语言没有限制。主要的测量结果是疣的总清除率及不良反应。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">Results: </span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">There was substantial heterogeneity in the
design of the trials. </span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">No consistent evidence was found for the efficacy of cimetidine, levamisole or
homeopathy, and only limited evidence was found for the efficacy of zinc.</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">研究结果：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">试验的设计存在大量的异质性。没有统一的证据表明西米替丁，左旋咪唑或顺势疗法的有效性，并且仅有有限的证据表明锌的有效性。</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">Conclusions: </span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">Reviewed trials of systemic treatments for
cutaneous warts were</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">&nbsp;highly variable in
methods and quality, and&nbsp;</span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">there was a paucity of
evidence from randomized, placebo-controlled trials on which to base the
rational use of such therapies. Limited evidence is emerging that </span><span style=""line-height:1.5;font-family:&quot;font-size:14px;"">zinc
may be effective in selected populations with zinc deficiency.</span> 
</p>
<p class=""MsoNormal"">
	<o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">结论：</span><o:p></o:p>
</p>
<p class=""MsoNormal"">
	<span style=""line-height:1.5;font-family:&quot;font-size:14px;"">对于系统性治疗皮肤疣的回顾性实验在方法和质量上变化很大，并且缺乏合理使用这种疗法的随机、安慰剂对照试验的证据。有限的证据表明锌可能对于锌缺乏症的人群是有效的。</span><o:p></o:p>
</p>","/uploadfiles/image/20131205/20131205152333_0585w.png","/uploadfiles/file/20131205/20131205151037_7528.pdf",,12/05/2013,12/05/2013,"medicool",21,,"cimetidine, randomized clinical trial, wart, zinc",0,"67",107,"Systemic treatments for cutaneous warts: A systematic","2012",
485,,,"In Su Kim1, MD, Kui Young Park1, MD, Beom Joon Kim1, MD, Myeung Nam Kim1, MD,","International Journal of Dermatology","<span style=""font-family:Times New Roman;""><span style=""font-size:14px;"">Background </span><br />
&nbsp;&nbsp; Different types of laser have recently been reported as effective tools of treatment </span><span style=""font-family:Times New Roman;"">in striae distensae. Although fractional photothermolysis is effective for striae distensae, </span><span style=""font-family:Times New Roman;"">post-inflammatory hyperpigmentation is a major concern and common complication. </span><span style=""font-family:Times New Roman;"">There are no reports of the effects of using an intradermal radiofrequency (RF) device in </span><span style=""font-family:Times New Roman;"">striae distensae. Autologous platelet-rich plasma (PRP) is an effective treatment known for </span><span style=""font-family:Times New Roman;"">its wound-healing effects.<br />
</span><br />
<span style=""font-family:Times New Roman;""><span style=""font-size:14px;"">Methods</span><br />
&nbsp; &nbsp;Nineteen Asian female patients with striae distensae were enrolled in this study. </span><span style=""font-family:Times New Roman;"">Three sessions of intradermal RF (1134-kHz frequency, 12-W power, 26-G electrode size) </span><span style=""font-family:Times New Roman;"">combined with autologous PRP were performed in each patient at intervals of four weeks. </span><span style=""font-family:Times New Roman;"">Patients were evaluated subjectively by the investigators and by themselves.<br />
<br />
</span><span style=""font-family:Times New Roman;""><span style=""font-size:14px;"">Results</span><br />
&nbsp; &nbsp;Evaluation of clinical results at four weeks after treatment showed that only one </span><span style=""font-family:Times New Roman;"">(5.3%) of the 19 patients achieved excellent improvement, whereas seven (36.8%) demonstrated </span><span style=""font-family:Times New Roman;"">marked improvement, six (31.6%) showed moderate improvement, and five (26.3%) </span><span style=""font-family:Times New Roman;"">showed mild improvement. None of the patients showed worsening of striae distensae. </span><span style=""font-family:Times New Roman;"">A total of 63.2% of patients reported they were ‘‘satisfied’’ or ‘‘very satisfied’’ with the </span><span style=""font-family:Times New Roman;"">degree of overall improvement.<br />
</span><br />
<span style=""font-family:Times New Roman;""><span style=""font-size:14px;"">Conclusions </span><br />
&nbsp; &nbsp;Intradermal RF combined with autologous PRP appears to be an effective </span><span style=""font-family:Times New Roman;"">treatment for striae distensae.</span> 
<p>
	<span style=""font-family:Times New Roman;"">&nbsp;</span>
</p>",,"/uploadfiles/file/20131122/20131122141037_1361.pdf",,11/22/2013,11/22/2013,"medicool",29,,,0,"65",102,"Efficacy of intradermal radiofrequency combined with autologous platelet-rich plasma in striae distensae: a pilot study","2012",
486,,"10.1111/j.1524-4725.2012.02552.x","KUI YOUNG PARK, MD, PHD,* HYUN KYU KIM, MD,* SUNG EUN KIM, MD,?","American Society for Dermatologic Surgery","<span style=""font-family:Times New Roman;"">BACKGROUND<br />
Striae distensae are dermal scars characterized by flattening and atrophy of the epidermis. </span><span style=""font-family:Times New Roman;"">Although many treatment modalities have been attempted with variable results, there is no criterion standard </span><span style=""font-family:Times New Roman;"">treatment modality for striae distensae.<br />
</span><br />
<span style=""font-family:Times New Roman;"">OBJECTIVES <br />
To evaluate the effectiveness and safety of a disk microneedle therapy system (DTS) in the </span><span style=""font-family:Times New Roman;"">treatment of striae distensae.<br />
</span><br />
<span style=""font-family:Times New Roman;"">MATERIALS AND METHODS<br />
<div style=""text-align:justify;"">
	Sixteen Korean volunteers with striae distensae alba or rubra were enrolled. Patients received three treatments using a DTS at 4-week intervals. Clinical response to treatment was assessed by comparing pre- and post-treatment clinical photographs, skin biopsies, and patient satisfaction scores. Clinical improvement was assessed using the quartile grading scale.
</div>
</span><br />
<span style=""font-family:Times New Roman;"">RESULTS <br />
Marked to excellent improvement was noted in seven (43.8%) patients, with minimal to moderat .</span><span style=""font-family:Times New Roman;"">improvement in the remaining nine. Patient satisfaction scores showed that six (37.5%) patients were highly </span><span style=""font-family:Times New Roman;"">satisfied, eight (50.0%) were somewhat satisfied, and two (12.5%) were unsatisfied. There were no significant </span><span style=""font-family:Times New Roman;"">side effects except mild pain, erythema, and spotty bleeding.<br />
</span><br />
<span style=""font-family:Times New Roman;"">CONCLUSION <br />
Disk microneedle therapy system (DTS) can be effectively and safely used in the treatment of </span><span style=""font-family:Times New Roman;"">striae distensae.</span>",,"/uploadfiles/file/20131122/20131122141715_5764.pdf",,11/22/2013,11/28/2013,"medicool",20,,,0,"65",102,"Treatment of Striae Distensae Using Needling Therapy: A Pilot Study","2012",
748,"荨麻疹：综述",,"Tasneem Poonawalla and Brent Kelly","Adis Data Informatian BV","<p class=""MsoNormal"" align=""justify"">
	<span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">urticaria is often classified as acute, chronic, or
physical based on duration of symptoms and the presence or absence of inducing
stimuli</span></span></span><span style=""font-size:12.0pt;font-family:&quot;""><span style=""font-size:16px;font-family:Times New Roman;"">. </span><span style=""font-size:16px;font-family:Times New Roman;"">Urticarial
vasculitis, contact urticaria, and</span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""> special syndromes</span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""> are also
included under the broad heading of urticaria</span></span><span style=""font-size:16px;font-family:Times New Roman;"">. </span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">Recent
advances in our understanding of the pathogenesis of chronic urticaria include
the finding of </span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">autoantibodies
to mast cell receptors</span></span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""> in nearly half of patients with chronic idiopathic urticaria</span></span></span><span style=""font-size:16px;font-family:Times New Roman;"">.These
patients may have more severe disease and require more aggressive therapies.</span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">Extensive laboratory
evaluation for patients with chronic urticaria is typically unrevealing and
there are no compelling data that associate urticaria with chronic infections
or malignancy</span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">.</span></span> <span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">Pharmacologic therapy consists primarily of the
appropriate use of first- and second-generation histamine H1 receptor
antihistamines.</span></span> <span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">Additional
therapy may include leukotriene receptor antagonists, </span></span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">corticosteroids</span></span></span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">，</span></span></span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">and immunomodulatory agents for severe</span></span></span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;"">，</span></span></span></span></span><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""><span style=""font-size:16px;font-family:Times New Roman;""> unremitting disease.</span></span></span></span></span><span><span><span style=""font-size:12.0pt;font-family:&quot;""> </span></span></span><span style=""font-size:12.0pt;font-family:&quot;""><span style=""font-size:16px;font-family:Times New Roman;"">Despite our
greater understanding of the pathogenesis of urticaria, the </span><span style=""font-size:16px;font-family:Times New Roman;"">condition remains a frustrating
entity</span><span style=""font-size:16px;font-family:Times New Roman;""> for many patients, particularly those with chronic urticaria.</span></span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:12.0pt;font-family:&quot;"">&nbsp;</span> 
</p>
<p class=""MsoNormal"">
	<span style=""font-size:12.0pt;font-family:宋体;"">根据症状持续的时间和是否存在诱导刺激，通常将荨麻疹分为急性荨麻疹、慢性荨麻疹或物理性荨麻疹。在荨麻疹这个大类下还包含荨麻疹性血管炎、接触性荨麻疹和特殊综合征。<span>在我们了解的关于慢性荨麻疹的发病机制的最新进展中发现近一半慢性特发性荨麻疹患者体内有肥</span></span><span><span><span style=""font-size:12.0pt;font-family:宋体;"">大细胞自身抗体的受体。</span></span></span><span style=""font-size:12.0pt;font-family:宋体;"">这些患者可能患有更严重的疾病并且需要更有效的治疗。对慢性荨麻疹患者进行广泛的实验室评估，通常未见异常，并没有可信的数据证明荨麻疹与慢性传染病或恶性肿瘤之间有关联。药物治疗主要包括恰当使用第一代和第二代组胺<span>H1</span>受体抗组胺药。对于严重性，反复发作的疾病，其他的疗法可能包括应用白三烯受体抗结剂、糖皮质激素和免疫调剂剂。尽管我们对荨麻疹的发病机制有了更深入</span><span style=""font-size:12.0pt;font-family:宋体;"">的了解，但对许多患者，特别是那些患有慢性荨麻疹患者来说，情况仍然是令人沮丧的。</span><span style=""font-size:12.0pt;font-family:&quot;""></span> 
</p>","/uploadfiles/image/20131220/20131220091723_0461w.png","/uploadfiles/file/20131220/20131220091638_4613.pdf",,12/20/2013,12/20/2013,"medicool",8,,"urticaria,special syndromes,Pharmacologic therapy",0,"67",113,"Urticaria:A Review","2009",
